<SEC-DOCUMENT>0001558370-25-001438.txt : 20250225
<SEC-HEADER>0001558370-25-001438.hdr.sgml : 20250225
<ACCEPTANCE-DATETIME>20250225072753
ACCESSION NUMBER:		0001558370-25-001438
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		130
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250225
DATE AS OF CHANGE:		20250225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BICYCLE THERAPEUTICS PLC
		CENTRAL INDEX KEY:			0001761612
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38916
		FILM NUMBER:		25659404

	BUSINESS ADDRESS:	
		STREET 1:		BLOCKS A & B, PORTWAY BUILDING
		STREET 2:		GRANTA PARK, GREAT ABINGTON
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB21 6GS
		BUSINESS PHONE:		011441223261503

	MAIL ADDRESS:	
		STREET 1:		BLOCKS A & B, PORTWAY BUILDING
		STREET 2:		GRANTA PARK, GREAT ABINGTON
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB21 6GS

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BICYCLE THERAPEUTICS plc
		DATE OF NAME CHANGE:	20190530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BICYCLE THERAPEUTICS Ltd
		DATE OF NAME CHANGE:	20181212
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bcyc-20241231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 2/24/2025 9:41:19 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: f4027c54-3245-479c-9f72-ed8ea18a157d -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:bcyc="http://www.bicycletherapeutics.com/20241231" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>BICYCLE THERAPEUTICS PLC_December&#160;31, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" xs:nil="true" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_lDjarV2SKEKFeVF5ca6tnQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" xs:nil="true" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Cs-wGQgBv0KoBVquS-BRZw"></ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_qzHYc8yUfk2FxdcgIRRDwA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_eeqXDGfmiUODYVi353xFTA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityCentralIndexKey" id="Tc_82V5GHsWf0am4NT5Nc8s6A_2_1">0001761612</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:DocumentFiscalYearFocus" id="Tc_1kiYeAN46UC1mXVGrdqYOQ_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:DocumentFiscalPeriodFocus" id="Tc__9bPHJUmm0mgZiM8Y24DiQ_5_1">FY</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5MPhoYm4pEaBvoSPbVf8mQ" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_KG5Qrpf6fkO6xb-NWzVFZA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IE3SmW-yQ0GAQXZrSOSVUQ" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_A2wJE6ZI3ECm9iej_OAGQg">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityTaxIdentificationNumber" id="Hidden_eLwDL01wNUSd9XxGg7qjIA">00-0000000</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ" name="dei:NoTradingSymbolFlag" id="Hidden_5e8aMSlzvkS657lOCk_QDg">true</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_4nF_ujCUWUWXOLzbDfjUZw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_p8M7K2bjKEax4G-nyR6gbA">P3Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RLygLLyFe0W8BGYlL5x-bA" decimals="-5" name="us-gaap:MoneyMarketFundsAtCarryingValue" id="Hidden_X5wnyztC8UGUEz3EZ1OAbA">664900000</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4FpKp43eMEOYJ8Be5CBt9Q" name="bcyc:TermDepositMaturityPeriod" id="Hidden_Vut1ulUKVEGQr75nUhokTQ">P30D</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_KW1rNIXqDU6mr2igGNJAXQ">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_WTohRhZpUkiEgaVCaOLomQ">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_tsh7VRNlykaXUR1w5uepYg">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_VotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJXTy3J51UCZNJxJ1Ym8RQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_Lpo0wyq33EyQ4jsKrECq2Q">47569319</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y61uWaX9NEaChNzvdxBdnQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_isC1MjD3_kuhXs60-F47rw">21492099</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_qGTPrbV9lESEael4XrVLgA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Hidden_8SmY0G3wPEWWtHANX-xYGQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5-nN-zX1y0-eX0PVinKM1w" name="bcyc:MaterialRightsExerciseOrExpiryTerm" id="Hidden_7Ox68_7-tk2-gZ54jj6J7A">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BdeUCV5wOkyMU6qL2DhWkg" name="bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed" id="Hidden_PuaulHhMWk2PS85VLrvMLw">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BdeUCV5wOkyMU6qL2DhWkg" name="bcyc:MaterialRightsExerciseOrExpiryTerm" id="Hidden_CuyU_1zNJ0eAuH7pLi5zdQ">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_SwAG22aJtUSKIsi9PCAZJQ" name="bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed" id="Hidden_23cxoubFkkqKtXI7gxQnYw">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_89Xiz3lIwU210xUHlqxyBQ">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_SQ4PzHGMvEedzinnZFOhqA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-5" name="us-gaap:FinanceLeaseLiability" id="Hidden_o8BOhRO22E6Ob_Qt--G_Gg">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Hidden_lYaA-73yc0O8cmcTzPPaEg">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Hidden_Rcc02-kBPEezAjTVUU7wRQ">P4Y8M12D</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_u8XOnpcF106LEEpbmUkWMA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:AmendmentFlag" id="Narr_bPio0aHPH02H3kETPh3RQQ">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bcyc-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_2q8U443nOk6gQC6m8b41-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:BakerBrothersAdvisorsLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_Q3Ip6DsZDUiZokIoW7oY_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_FinancialInstrumentAxis_us-gaap_OptionOnSecuritiesMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_cVgwDI4loUexIB3GNxcfVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_M9NqLknzNU-sMVpqCl-eFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_2llzQZ6_20K-zZTfy-CSow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_2uabg4H0sUy4TlBNK2BBbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_XPuSzU4R-ki_U9PggBrUeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_9_2021_To_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_IhORSIdihkWEmJuOaow7HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:IonisSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-09</xbrli:startDate><xbrli:endDate>2021-07-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0HyqUG8pkaNcopt1SdSjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dEcOv1S1kUyL15GIo0RjgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F8DiQa_QMka5iKKuHx7img"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EwM5Itcxx0ys92D7oHiEgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W-C5t6IG6UWyCMUiL7Gv7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wdRGjbbwREGbPju45P3i5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_StHDH1DIL0imMDDzyJOvmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_McmuDya3A0yjgIlscqnbsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_opu5bUpl2UC0TqjQ2ARQ8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CUy4QtZ-V0Cj2wqjpP3QOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_17g0OGLnwUulZtNoxhH01g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6cIYOfo-dUykEJArEMVFiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_23_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_1meCJkhmuUalIyW_wBy3UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_8bqxGZ3cOEORs4A2Xq-g5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:IonisSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kkvEbVaSgkafrtITcLkMkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Zt6VhwsXG0aIIZfDEMHd7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_v3o1BPc0-02UERuTDFMLWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_JmkuGODyoEa7uHAIThFJUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uYPMjaOR30-b-lalBWgACw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_a1Oi0t48FUudnS8WN5P3Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_WCDTG0m9xUCkxUKiJgwLbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Vi_9DbVLDEiUNj4B5lOvvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_P5YoMS1KNkutLYwlGkurgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_MAFub_g2y0GAD_IA8SQX-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zpq2bppWNkmyNQUoVWcEXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:PreIpoShareOptionsAndRestrictedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YameRw5flUWof726OmcJYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_QDfyXxUou0-hgJMM6cWXtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_E1--0LWw1EmKwIGcLWnwFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Iontov7wME-Mj-R-qqxvRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_NONBGaPxIUSKmSHZSQ1OaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_cpfcqvh4YUOX2BEX6A_K5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Lhc563hBmUO8945Z0wzLwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_ATqayKrwE0yk5TqZ6Qd3VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WvZe8laaPEeAxoXCnyr6Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_ThirdAmendedIonisMember_M_GcK9lsOUqu7PozYRvR_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:ThirdAmendedIonisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_axun9IhIKEiYQ2ka_ErQBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AmendedIonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QObiLon3H06DowS0D9UT9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_6B9ln8pBckaqlZDRFLAB3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qLy1Qlk7lUqL6zN6xMcMvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_DementiaDiscoveryFundCollaborationAgreementMember_LB_cYGPJt0-dBCSytUGDoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:DementiaDiscoveryFundCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yibznVR9GEqfsVp2Udu60g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_is22NBT1Jka8Gu-uasBItg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AstrazenecaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kkZvNCSDbEyvWrxvy0J0Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_4nF_ujCUWUWXOLzbDfjUZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B4rIlVudJkC7UiJJ14Ug0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CzvZPim0k0CUHrLZ3N9Ulw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_jYlsDtcKqkiYG1N-mRdO7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LZhexdWpm0qTV2Rf8LpgSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_cyshTxnH0kyrdYWVdqiIsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xx2lOaIKTUaBAJxmtahpDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nP9jA-aiYkONgvoroTyc9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PorQ7L3GZEWmg7J9b0BaFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_8msZM6Sha0iTRy5AvtsnvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_anAvD0bAqk2fupg6zYmu5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-28</xbrli:startDate><xbrli:endDate>2024-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AM5bQ16iwE-vzlxN1fzJfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TWmLZerPx0-0_LBFph8ZLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_teqqpUcfr0ylhQrf7zeYbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_Emy5XN272EGkU-HVUNZzhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_FM8UcsJ6oE-QbWuVRXzXKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_QMFxV79NjE6OHW4kO9biSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_GB_wdbEmUAGK06mdxOOtgPJ8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DBNovfpDakCcvAVq5SANGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2JyJSn_aPkarPPFGcqtS1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNjPjZIFd06Z_lIP7g-WCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RLygLLyFe0W8BGYlL5x-bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gmBeuV6pUkqZOjdLGoLzMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_bcyc_TermLoanMember_us-gaap_TypeOfArrangementAxis_bcyc_LoanAndSecurityAgreementMember_65OBBumYj02j9k3Pn3oFYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_bMuDMhK8aEyJU12mzFiI9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:InitialTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_Ex-1F6jyfUO72vn1vcWu-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:InitialTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_X1BWRi7-lk2fvBqoP0fM9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:InitialTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_VGLTprSZ00ajPx_iwKZOCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:ConsultancyServicesWithStoneSunnyIslesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_87Upa33xjkaMN_hOb2X7Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:ConsultancyServicesWithStoneSunnyIslesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_ypWL3awvzEqfgXwFXfo9UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:ConsultancyServicesWithStoneSunnyIslesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_fLJS0eBl9EOeJzgPO_7mZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ig3SHtuCIE-Ory8Hp3Mv3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_9GER_6W-HkqnPxCUmp0fyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:UKPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_NRO15gR8R0C1PGFIWwvPqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:Plan401KMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_pS-QJkjLfUGnpbmjfIIQ7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:UKPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_arXRVu5ZWUSBIuONzGMp-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:Plan401KMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_-W-mugKxsU2yACc1ikbSBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:UKPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_PvHkFyAfO0qLp2QAqJ7T7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:Plan401KMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_olYsF14wyEW_U0xeDnkzAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_xsjVq66pdkiUGagQ0I5-lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_D3g9RlG-o0yxRqde4Bnx9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_NmP2-XzDFUGGWP4ZizBE4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_30_2020_To_9_30_2020_OY1e7NwWCUq25fNFOMQDzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-30</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ObVPQDakX0Kipqu1I4B_ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_2L8b9aOuvEGTIyzSbt8YAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_0G_PjFAo40GKFUdlMvcXrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_sWPs1iEFhUqaA2I4dkmTgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_KVWfPM5pcEK7pqypuPXWLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_5LReFI3s3U24XzqlQU2yZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_cyHRxQCIEESnLP8sT0_U6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_CLM3oWHaYEmA9xWRlsRxFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_l4IhOsVA_kaoaEarP7YyVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_-gMn9m7NtkmdLXLyH9rqdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_jkHOHVP16kyVT6B0B3UJYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_RdiH8PgdtkyqEjCC0xKdGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_YYJ26o4FAkKUoYNNZn4kKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgram4PerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_ISvkPDGZT0GtRplR-nMrEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UTg8-nc3xku3S4nBOYYTgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_tyLSGaCBcUCWHOiuJFWHhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AstrazenecaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_IbZb9vf99kediN_LZbIFuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisEvaluationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyIVXSsfEEW_9ZjaJ49EjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TZxfpEvZdUat_yMyIb9Zww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m2IV-GHD4EWsFxAP8z8-YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_VotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJXTy3J51UCZNJxJ1Ym8RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:VotingOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y61uWaX9NEaChNzvdxBdnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_y0EPkZSaVU-zndPzJODGAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:BakerBrothersAdvisorsLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_IYGnT7YWfkykLNwOFediag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_V7TD4LyjyEOPQOb-5emQbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_jjLRXKu4UkmDU29qbwfUyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_A4JYy9Ek902M2Ll6OJMTig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_llEDFF1MSUKzib9liGvGRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2025_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_3jebnT0paUKkYaQIJZSi9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_5QeHcJfW2U6x27_YDU1Ogw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_J_fXlQvUukSBnlagZHQH8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_MBs7tOGmkE641EB2R-K8nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_gQdGQPSVDUGV2TfhbI5-2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_27_2022_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_4Vyzs47cNE-kgf6kZGnMbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_hWWYIZXzx0acMJRpjAgv5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gejPkuQhakeSpM_QZlP27Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_slT9uSBHsk6jvBbMvui31g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_7Bn4AO2XvkW3epaw1AM0Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IE3SmW-yQ0GAQXZrSOSVUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5MPhoYm4pEaBvoSPbVf8mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_RMsDq0ZFvE2Wx7B1y-0u5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s2IO880e1061sN4EIeiaUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_n-D9Cq5DWkCzJZg9ZJYbnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m2jh4dTe1k6tiJLwVhJUjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_4N9eS-gJjkuSY1TcnrqmKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b9GnNZBmAkmTdN5HqzSMxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_IrNimC9diUCVSYzfxLOnXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QJYt99nJFU-BQx9iYlyOVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_MD5oMOXiBEqT_oj0JeJMKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ExXLTtPGjESDM4D_A9YCDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qLo7iHGMOUW9rHUjaCEH5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_fd4h2ljJA02Or70KQeym_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tkd3FyxzzUqahEHsT-hpIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3zI24sd1-km1PKi1awanEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_Fpz4VUhMv0GEtQ7djr-DbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0q3pUAqe0kaGx2oDa6WY6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_Kd_FmvXFs06iCWxDu-Ik9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_k7kwiL6Tv0Oaw0c1V1bDWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_hMqy_55tV0OU0RmfGW8IMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4FpKp43eMEOYJ8Be5CBt9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d2w1uOPLe0uqStZt99DW4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kKS5dyzsFEufpIX9K-WVUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_bG4-HMluqEmz8RSPzC0fGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_UuY5gYBUFEyCVoKDAuW1eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:PreIpoShareOptionsAndRestrictedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_A43fKLk6X0Wn-S-Osq4rcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_qGTPrbV9lESEael4XrVLgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcyc:ShareBasedPaymentArrangementThreeYearVestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_78XxKxfYa0e6KIo8HByUpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcyc:ShareBasedPaymentArrangementThreeYearVestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_o8DXnIN9Gka0CBw_y9jx6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2019_To_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uDaWQIIw1kGEaQUSk3pBNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VqqK4Cb9V0iqlo_bcaxLfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsForExpansionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_1eSemPD_PUGZrSIfTiqkcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qPiuB9BUQEah87FFQEHHLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:SpecifiedTargetingArmMaterialRightArmProgramOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_kzAbTqHZN0CArARXFbOtYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationTwoPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fY6J4ndKWkuZNzesRX6wQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationTwoPerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_uRCFMRtOakyg2OeSksR3_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationOnePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_YDSCq1R7SUe1ir6yappJew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_qpxzdeztD02IVOBhBuyF0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0SmQ9UkaoEyo_zuVmF9T8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_r6MfE3ksRECQo64rWUZQ_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_H7vbLohDfUqZtqXKcd9CpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_IU-HPwKXJEOuf8TPozi9MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_Dj0LVN0iZ0u9fcBupRC2Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_z9unUt1Yik6ssQwliMMpIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_o4Ynp2Df5ky0p5ZF-8lSyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_vbS2D-byxUiv2iYUzl3WkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_uCp5g8aYYkiBWHoG8i9XIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_RWvBuWuwx0SypjAqYYDYow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_7_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5spYzCTLIUOCuK3Eylw0Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2024_To_2_29_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_F9BWe4BDkEGe1GncdURkdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_1_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_DRGyMBQk30C0HCqiKdLvbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_1IrDAG-GjkaODsojD2rcmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_1_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_mZK_WLmvd0u3bkPaVSH2lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_4_2024_To_12_4_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_goSmqlBU3UOCLW6hsHOXGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-04</xbrli:startDate><xbrli:endDate>2024-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_13_2016_-ccexalN_EuXuCJAskV6sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_a9Bb03tCQUq9DG0yh6RePg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_NYezOdO0N0G3gVUx6-pWmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_gUaCXINS2kCBhTYjLBFLvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_qWduzYXktEC6ieFWheazqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_10I2hU65G06H9LVN1JzgNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_Tw08wGHpiE2_uOJjC2Yifg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_DUUmLvrM0Ua-IV4gtEO4dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_m8NGtuG9hEuc-Q3am5BHDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_uoSoJfk0zkCYReunHXtq8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_TGvFsvJDaU-Z2goQUm6szg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_EDbD_nwgWEm3h1bnui3JPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_QCbJPntYS0mr7VXNm13-GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_SE-anRzrlEiUC4bJHOOjnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_SwAG22aJtUSKIsi9PCAZJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_p4p-FG55D0eRUEKCq8P6yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_4t0N24_S70mz2Zd2yTJ85A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-13</xbrli:startDate><xbrli:endDate>2016-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_B_kz3AanWUGz-CXUrr44Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-13</xbrli:startDate><xbrli:endDate>2016-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_T4B2SYwvKkiwF5Y-H5SnKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:SpecifiedTargetingArmMaterialRightArmProgramOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_NG89CENXf0WsYpj98IPH8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_HyrRNe-YbEC-tdg9gRuhvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_7SqqxQUnTU-2GwYuJp8WsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_94phe6rJ4kWybY0cwUE7iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_eqvMYjbIIU-vjO_qsp7v0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_tnuYUMT7jkGkdVdgNaWQgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QqTrQCxSy0WuafIhqTZmRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WDczl612dESosUCoC72gug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5p4e8zASzk6UtchIaZHdrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ccXf6ptJGE-9qaLqRgb8FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsForExpansionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yFgBlbVotUajI_G7d99bBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_EZSaePc-y0-TinfVuSqYaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_Uq2YtHbmDEqFEAKHinp0mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UiXZnEQKrUaSVgTitUBvIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BdeUCV5wOkyMU6qL2DhWkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationOnePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BteqU8JwLEGuk_pXYeS0Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationOnePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5-nN-zX1y0-eX0PVinKM1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_AvjycYZCW0uI2cpw5iScdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_Jlm0mrvCf0W3IJVZZ2e3GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_SGS5MZDDqEWSBRcvMGqfGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2021_To_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_7_XmUdC8h0aJCYWeYcBvog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-06</xbrli:startDate><xbrli:endDate>2021-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_NV57yxdHsUG-EvMIcuAkLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:IonisSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PHabuvgaTkmQG0J2ns37DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_cqFl8FEbxkiSfD6iCj1uZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgram4PerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_D0rz7JpLrEi8DFIjkqRfAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_AjyoIuYKZEiR1VI--kfKQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qCp4Kues8ESQiRZdeh8N9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_9_2024_To_7_9_2024_ZJZfQXYoCEan2WXy8RfycA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-09</xbrli:startDate><xbrli:endDate>2024-07-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_DRfguGfVi0Or7GWsyp0CBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AstrazenecaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_30_2023_us-gaap_TypeOfArrangementAxis_bcyc_ThirdIonisAmendmentMember_wgyO8-AVfkC5eQxgiBeTrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:ThirdIonisAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_QA6y8ag3QEm7TEW69r2qZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AmendedIonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_4xrbU9mf7U-6_-7nZgiopA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisEvaluationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-09</xbrli:startDate><xbrli:endDate>2021-07-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-09</xbrli:startDate><xbrli:endDate>2021-07-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_95vuv8ocIUSRAGL9jhXDpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisEvaluationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-21</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_2TOiizb3YE6trqr0NK51Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TerminationIfSafetyOrRegulatoryIssueExistsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_l_SYxC8CcEy6vP73RrP97g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_k-g66Brr1Ea_7MONWi3pTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PVgTMTZKEkukeSrHzooTww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgram4PerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_ZNuFcicSUka_auEsj1BcvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentAndRegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rDEBgcbU2U6rfbdVzl6Apg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bsrGl4-r_kuiY-MRpYt5Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:MilestoneAcrossAllPotentialTargetProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xp4_gR1lU0ecKBaQ7hdhGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:AchievementOfSpecifiedLevelsOfNetSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_CompletionOfAllMilestonesForTargetsMember_WaiOPCwXwUCGOrGcdYAYvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CompletionOfAllMilestonesForTargetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_xgSdh5vtDES1WDH_f8Xs-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_RegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_m_fV9ESl1kiTO5YyS3qSDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_tki1umMlTE2iFkLuV5EjMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:DevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_LwM9FXA8rkKkuLMtRDp7wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VivFA-_htU2GU3D3QWHvWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:SpecifiedTargetingArmMaterialRightArmProgramOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationPerformanceOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_TSRQzXGT_UCdLkzF9xrWhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationPerformanceOneAndTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_AgreementWithThirdPartyMember_cjzTWIaOY0KrEHYqPIpAew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AgreementWithThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001761612</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_M_lugMOcstmECVEFUGtQg6XA"><xbrli:measure>bcyc:M</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_Im4dTiIF5UiSe0qPdBr-ew"><xbrli:measure>bcyc:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ"><xbrli:measure>bcyc:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_jurisdiction_Wo3Cb55Vx0GOZokPR6rMjw"><xbrli:measure>bcyc:jurisdiction</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg"><xbrli:measure>bcyc:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_F2iWXsaSbUSm_tPiCaeIdA"><xbrli:measure>bcyc:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4495114f_cb17_4ff2_9720_f0c4c97557dd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:DocumentType" id="Narr_fXuiG5l0iU6QV8KHo7W_Vw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 18pt;"><ix:nonNumeric format="ixt:fixed-true" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:DocumentAnnualReport" id="Narr_suWSMoOh70GCzqZYX5RQrg"><b style="font-family:'Times New Roman';font-size:7pt;font-weight:bold;">&#8999;</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:DocumentPeriodEndDate" id="Narr_BQoM0Dyb-Eeeg1kuT14UPA"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:CurrentFiscalYearEndDate" id="Narr_f0ZiEEh63EuO44tPSu-aaw"><b style="font-size:7pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 18pt;"><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:DocumentTransitionReport" id="Narr_hV1FDn89x0ixc65PaoTGBA"><b style="font-family:'Times New Roman';font-size:7pt;font-weight:bold;">&#9723;</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:7pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityFileNumber" id="Narr_utB0preXEUCAToayv86CJg"><b style="font-size:7pt;font-weight:bold;">001-38916</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityRegistrantName" id="Narr_rf1cBen0TkeKcOpq9Nn8uQ"><b style="font-weight:bold;">BICYCLE THERAPEUTICS PLC</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_1c54d4c7_3b7f_4066_8392_56c236e81be7"></a><a id="Tc_vWNKFBYKJUahXbD9Zv9P5w_2_0"></a><a id="Tc_7DYKxEVR-kWhsgpWzqQ2VQ_2_2"></a><a id="Tc_dPXhKEa1zk2wQGJgCr2sVg_4_0"></a><a id="Tc_01w32aTncESxjM4DVCkk7g_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_34dsv_L-ZEWljuiZ_AdLGg_1_0"><b style="font-size:7pt;font-weight:bold;">England and Wales</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_eLwDL01wNUSd9XxGg7qjIA;"><b style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:bold;">Not Applicable</b></span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityAddressAddressLine1" id="Narr_TAEUaDzH-k2MuPJcBerZ-A"><b style="font-size:7pt;font-weight:bold;">Blocks A &amp; B, Portway Building, Granta Park</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b><b style="font-size:7pt;font-weight:bold;"><br/></b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityAddressCityOrTown" id="Narr_01bpfWvS30OgYBIKQyRdBw"><b style="font-size:7pt;font-weight:bold;">Great Abington, Cambridge</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">,&#160;</b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityAddressCountry" id="Narr_uJ27db28_EuOWnhKDOdDcA"><b style="font-size:7pt;font-weight:bold;">United Kingdom</b><span style="font-size:7pt;"> </span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityAddressPostalZipCode" id="Narr_eiwDq5XhjkSd9iyrEsHsqw"><b style="font-size:7pt;font-weight:bold;">CB21 6GS</b></ix:nonNumeric><span style="font-size:7pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Registrant&#8217;s telephone number, including area code </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:CityAreaCode" id="Narr_KXGyt6Dgu0yg5YUM9Ms6yg"><b style="font-size:7pt;font-weight:bold;">+44</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:LocalPhoneNumber" id="Narr_UAroe5kui0-Fggwy5M4DBA"><b style="font-size:7pt;font-weight:bold;">1223 261503</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.37%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:35.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.37%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.38%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ" name="dei:Security12bTitle" id="Narr_R876U4qs1UieI-gfbiWmYQ"><span style="font-size:7pt;">Ordinary shares, nominal value &#163;0.01 per share*</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg" name="dei:Security12bTitle" id="Narr_8HajR58KkkKmQ9vfvAovHg"><span style="font-size:7pt;">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.01 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_5e8aMSlzvkS657lOCk_QDg;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">n/a</span></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg" name="dei:TradingSymbol" id="Narr_jUFmn2ruiUKCKSOpvF6pVw"><span style="font-size:7pt;">BCYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ" name="dei:SecurityExchangeName" id="Narr_fsjm6WJ1B0CKAVWdukBtrg"><span style="font-size:7pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg" name="dei:SecurityExchangeName" id="Narr_q2AyrwhP40KYcjUkCoUKBg"><span style="font-size:7pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:24pt;margin:0pt 0pt 6pt 0pt;">*&#160;Not for trading, but only in connection with the listing of the American Depositary Shares on the NASDAQ Global Select Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_18dz3XLPv0yBwspgSnURug"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;"> No </span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span><span style="font-size:7pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityVoluntaryFilers" id="Narr_fwhYrTrJ_E2bU12nRYBoAw"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityCurrentReportingStatus" id="Narr_-D2ghJ5fO0Wazo5ZsALl2w"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;"> No </span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityInteractiveDataCurrent" id="Narr_nsYQVS_rQkyRi235D7LoQA"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;"> No </span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:24pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:21.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:18.84%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.6%;margin:0pt;padding:0pt;"/></tr><tr style="height:11.35pt;"><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityFilerCategory" id="Narr__5q8yLS6XUi0nKGgSKcuVA"><span style="font-size:7pt;">Large accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:21.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:18.84%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 32.15pt;">Accelerated filer <span style="font-family:'Times New Roman';">&#9723;</span> </p></td></tr><tr style="height:11.35pt;"><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;">Non-accelerated filer <span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;">Smaller reporting company </span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntitySmallBusiness" id="Narr_NNh4DR4DWE2btiU6_CrH_A"><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.35pt;"><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Emerging growth company  </span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityEmergingGrowthCompany" id="Narr_WS9leNYseECmlAm7eZwzPA"><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:7pt;"> </span><ix:nonNumeric format="ixt:fixed-true" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_UfUQFmhQ4kqfzqECpi8wvw"><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_ZPJshysAcEansXO3YNDIRg"><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:EntityShellCompany" id="Narr_31N6BC-U20eKyJQhQjBy5A"><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></ix:nonNumeric><span style="font-size:7pt;"> No </span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;">The aggregate market value (approximate)&#160;of the registrant&#8217;s voting and non-voting common equity held by non-affiliates based on the closing price per American Depositary Share, or ADS, of the registrant&#8217;s ADSs on The Nasdaq Global Select Market on June 30, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_6_30_2024_Fpz4VUhMv0GEtQ7djr-DbQ" decimals="0" name="dei:EntityPublicFloat" id="Narr_LAvXb8TZ1UuXNSb2eMF0Tw">758,541,179</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:24pt;margin:0pt 0pt 6pt 0pt;">As of February 20, 2025, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0q3pUAqe0kaGx2oDa6WY6A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_vN-XvvWHIkWZVhcqdvWnFg">47,710,256</ix:nonFraction> ordinary shares, nominal value &#163;0.01 per share, and <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_Kd_FmvXFs06iCWxDu-Ik9Q" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_5rFqc0gkwkWUBLWn9kZRBA">21,492,099</ix:nonFraction> non-voting ordinary shares, nominal value &#163;0.01 per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:23.75pt;margin:0pt;">Portions of the registrant&#8217;s definitive proxy statement, or Proxy Statement, for its 2025 Annual General Meeting, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2024, are incorporated by reference into </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:23.75pt;margin:0pt 0pt 6pt 0pt;">Part III of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e83050c5_d747_47b5_89e7_16800c262192"></a><a id="SPECIALNOTEREGARDINGFORWARDLOOKINGSTATEM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-align:center;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, or this Annual Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements may be identified by such forward-looking terminology as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to advance our product candidates into, and successfully complete, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reliance on the success of our product candidates in our pipeline programs for our Bicycle</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Toxin Conjugate, or BTC</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">molecules, Bicycle Radionuclide Conjugates, or BRC</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> molecules, and Bicycle Tumor-Targeted Immune Cell Agonist</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, or Bicycle</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TICA</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">molecules, as well as our other pipeline programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to utilize our screening platform to identify and advance additional product candidates into clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing or likelihood of regulatory filings and approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commercialization of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop sales and marketing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the pricing, coverage and reimbursement of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the implementation of our business model, strategic plans for our business, product candidates and technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with defending intellectual property infringement, product liability and other claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States, the United Kingdom and other jurisdictions and changes to the laws and regulations of England and Wales, and other jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of strategic collaboration agreements and our ability to enter into additional strategic arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain and establish collaborations or obtain additional grant funding;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance of any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry, including competing therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to effectively manage our anticipated growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain qualified employees and key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance; </span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of adverse global economic conditions, including those arising from public health crises, on our operations and the potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers, and collaborators with whom we conduct business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse developments affecting the financial services industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential business interruptions resulting from geo-political actions, such as war and terrorism, or the perception that such hostilities may be imminent; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to data privacy and security (including our ability to identify and respond to potential future security incidents); and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking statement. These risks, uncertainties and other factors are described in greater detail under the caption &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A and elsewhere in this Annual Report.&#160;&#160;As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Undue reliance should not be placed on any forward-looking statement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, any forward-looking statement in this Annual Report represents our views only as of the date of this Annual Report and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless the context otherwise requires, the terms &#8220;Bicycle,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar references in this Annual Report refer to Bicycle Therapeutics plc and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5d7e1a3a_b202_49fe_b1e7_9aff2f6cd1c6"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:0.9pt;"><td style="vertical-align:bottom;white-space:nowrap;width:92.33%;margin:0pt;padding:0pt;"><div style="height:0.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:0.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt;"><div style="height:0.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.8pt;"><td style="vertical-align:bottom;white-space:nowrap;width:92.33%;margin:0pt;padding:0pt;"><div style="height:11.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:11.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td style="vertical-align:bottom;width:6.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:11.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SPECIALNOTEREGARDINGFORWARDLOOKINGSTATEM"><span style="font-style:normal;font-weight:normal;">Special Note Regarding Forward Looking Statements</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">i</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:bottom;white-space:nowrap;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:3.6pt;"><td style="vertical-align:bottom;white-space:nowrap;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI_197597"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUSINESS_1823"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Business</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors__090955"><span style="font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_724560"><span style="font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">105</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1C_CYBERSECURITY"><span style="font-style:normal;font-weight:normal;">Item 1C. Cybersecurity</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">105</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2PROPERTIES_952404"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Properties</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">106</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_246541"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_102091"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII_193203"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#item6"><span style="font-style:normal;font-weight:normal;">Item 6. [Reserved]</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">110</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">111</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7AQANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">128</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_11536"><span style="font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_881554"><span style="font-style:normal;font-weight:normal;">Item&#160;9B. Other Information</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM_9C_DISCLOSURE_REGARDING_FOREIGN"><span style="font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII_687409"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_896456"><span style="font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIP_194439"><span style="font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item&#160;14. Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIV_634070"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-style:normal;font-weight:normal;">Item&#160;15. Exhibit and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">133</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_15998"><span style="font-style:normal;font-weight:normal;">Item 16. Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">138</p></td></tr><tr style="height:3.6pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><div style="height:3.6pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:15.4pt;"><td style="vertical-align:top;width:92.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_280864"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6118abb3_dd46_4620_8471_5152c215dc7b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="PARTI_197597"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="ITEM1BUSINESS_1823"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;BUSINESS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage pharmaceutical company developing a novel class of medicines, which we refer to as Bicycle<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making&#160;Bicycle<i style="font-style:italic;"> </i>molecules&#160;attractive candidates for drug development.&#160;Bicycle molecules are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic, or PK, properties of a small molecule. The relatively large surface area presented by Bicycle molecules allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycle molecules are excreted by the kidney rather than the liver and have shown no signs of immunogenicity to date, qualities which we believe explain the molecules&#8217; favorable toxicological profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a novel and proprietary phage display screening platform which we use to identify Bicycle molecules in an efficient manner. The platform initially displays linear peptides on the surface of engineered bacteriophages, or phages, before &#8220;on-phage&#8221; cyclization with a range of small molecule scaffolds which can confer differentiated physicochemical and structural properties. Our platform encodes quadrillions of potential Bicycle molecules which can be screened to identify molecules for optimization to potential product candidates. We have used this powerful screening technology to identify our current portfolio of candidates in oncology and intend to use it in conjunction with our collaborators to seek to develop additional future candidates across a range of other disease areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our product candidates, zelenectide pevedotin, formerly BT8009, and BT5528, are each a Bicycle Toxin Conjugate, or a BTC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>molecule. These Bicycle molecules are chemically attached to a toxin that, when administered, is cleaved from the Bicycle molecule and kills the tumor cells. We are evaluating zelenectide pevedotin, a BTC molecule targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing company-sponsored Phase II/III registrational trial called Duravelo-2, and enrollment in both of these trials are ongoing. We are also evaluating BT5528, a BTC molecule targeting Ephrin type A receptor 2, or EphA2, in a company-sponsored Phase I/II clinical trial, for which enrollment is ongoing. Our other product candidate, BT7480, is a Bicycle Tumor-Targeted Immune Cell Agonist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, or a Bicycle TICA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>molecule. A Bicycle TICA molecule links immune cell receptor binding Bicycle molecules to tumor antigen binding Bicycle molecules. We are evaluating BT7480, a Bicycle TICA molecule targeting Nectin-4 and agonizing CD137, in a company-sponsored Phase I/II clinical trial. Our discovery pipeline in oncology includes next-generation BTC molecules and Bicycle<i style="font-style:italic;"> </i>Radionuclide Conjugates, or BRC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>molecules. <span style="background:#ffffff;">In August 2024, we focused our research and development pipeline on clinical programs and research areas that we believe have the highest potential to maximize value creation and we consolidated all discovery research activities to our headquarters in Cambridge, U.K. Moving forward, we will prioritize the clinical development of BTC molecules in multiple tumor types; focus near-term research efforts on advancing our BRC pipeline and the discovery of next-generation BTC molecules; and, except for BT7480, explore innovative ways to continue development of our immuno-oncology portfolio, including Bicycle TICA molecules, through collaboration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beyond our wholly owned oncology portfolio, we are collaborating with biopharmaceutical companies and organizations in additional therapeutic areas in which we believe our proprietary Bicycle screening platform can identify therapies to treat diseases with significant unmet medical need. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:243pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes key information about our oncology programs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><img src="bcyc-20241231x10k001.jpg" alt="Graphic" style="display:inline-block;height:242.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:496.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k002.jpg" alt="Graphic" style="display:inline-block;height:22.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:487.22pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were founded in 2009 based on innovative science conducted by Sir Greg Winter and Professor Christian Heinis. Sir Greg Winter is a pioneer in monoclonal antibodies and, in 2018, was awarded a Nobel Prize in chemistry for the invention of the technology underpinning our proprietary phage display screening platform that we use to identify Bicycle molecules. From our founding through December 31, 2024, we have generated substantial intellectual property, including 10 patent families directed to novel scaffolds, linkers and payloads, 10 patent families directed to our platform technology, 48 patent families directed to bicyclic peptides and related conjugates, and 21 patent families directed to later inventions relating to such bicyclic peptides and related conjugates, such as methods of making or using certain bicyclic peptide conjugates for treating various indications. As of December 31, 2024, our trademark portfolio consisted of 106 trademark registrations across six territories (the United Kingdom, European Union, United States, Japan, Hong Kong and Australia) as well as a number of pending applications for new trademarks. The work we have conducted in developing Bicycle molecules and our proprietary screening platform have created substantial know-how that we believe provides us with a competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management team includes veteran executives in drug development from leading pharmaceutical companies including AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer. Our board of directors, scientific advisory board and clinical advisory board include industry experts with extensive experience in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our mission is to become a leading pharmaceutical company by pioneering Bicycle molecules as a novel therapeutic modality to treat diseases that are inadequately addressed with existing treatment modalities. Specifically, we seek to execute on the following strategy to maximize the value of our novel technology and pipeline:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Progress our most advanced internal candidates, zelenectide pevedotin, BT5528, and BT7480 through clinical development.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are evaluating zelenectide pevedotin, a BTC molecule targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing Phase II/III registrational trial called Duravelo-2. In 2025, we plan to initiate additional Phase I/II clinical trials to assess zelenectide pevedotin in patients with NECTIN4 gene-amplified breast cancer, lung cancer and multiple other cancers. </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are also evaluating BT5528, another BTC molecule targeting EphA2, in a company-sponsored Phase I/II clinical trial and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BT7480, a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicycle</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> TICA molecule targeting Nectin-4 and agonizing CD137, in a company-sponsored Phase I/II clinical trial. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We intend to advance development of these candidates across oncology indications based on target expression and initial clinical activity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Advance our discovery programs into clinical development.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We intend to continue our ongoing discovery activities to screen and select candidates for oncology indications. For example, we are developing BRC molecules targeting both MT1-MMP and EphA2 in collaboration with the German Cancer Research Center, or DKFZ. We intend to advance our BRC molecule pipeline and progress our strategy for leadership in next-generation radiopharmaceuticals. We are also developing next generation BTC molecules. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Leverage our powerful proprietary screening platform and novel Bicycle modality to grow our pipeline.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our novel and proprietary phage display screening platform allows us to rapidly and efficiently identify potential candidates for development. We can incorporate a wide range of small molecule scaffolds into Bicycle molecules to increase diversity and confer differentiated physicochemical and structural properties. We have used our powerful Bicycle screening platform to identify our current pipeline of BTC, BRC and Bicycle</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TICA molecules, and we intend to use it to develop a broader pipeline of diverse product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Collaborate strategically with leading organizations to access enabling technology and expertise in order to expand the application of our novel Bicycle modality to indications beyond oncology.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are collaborating with leading biopharmaceutical companies and organizations to apply our novel Bicycle modality to other disease areas. We may opportunistically enter into additional collaborations in the future to apply our technology to areas of unmet medical need.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Maximize the commercial potential of our product candidates, if approved, by either establishing our own sales and marketing infrastructure or doing so through collaborations with others.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Subject to receiving marketing approval, we intend to pursue the commercialization of our product candidates either by building internal sales and marketing capabilities or doing so through opportunistic collaborations with others.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The</b><span style="font-style:italic;font-weight:bold;"> </span><b style="font-weight:bold;">Bicycle</b><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> Advantage</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Introduction to Bicycle</i> <i style="font-style:italic;">molecules</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Bicycle molecules are fully synthetic, short peptides consisting of nine to 20 amino acids constrained to form two loops which stabilize the structural geometry of the peptide and facilitate target binding with high affinity and selectivity. Bicycle molecules represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and PK advantages of a small molecule, with no signs of immunogenicity observed to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drugs must bind to target proteins with high affinity and selectivity to achieve a therapeutic effect, while minimizing undesired effects on other proteins and physiological functions. Peptides exist in a number of folded states, only a few of which are able to bind to target proteins, and a key challenge for peptide therapeutics is designing structures that achieve these goals. We have designed our molecules to be highly constrained by linking a chemical connector compound, also known as a scaffold, to particular amino acids in the peptide chain. The resulting cyclized molecule, which we refer to as a Bicycle molecule, is locked in the preferred state to bind to the target proteins.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:160.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Schematic of the Creation of a Cyclized Molecule Resulting in a Bicycle</span><b style="font-weight:bold;"> </b><span style="font-style:italic;font-weight:bold;">Molecule</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k003.jpg" alt="Graphic" style="display:inline-block;height:160.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:367.32pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have expanded the diversity of the chemical space we can cover from approximately 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> potential molecules in 2009 to in excess of 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">20</sup> potential molecules today. We have applied our novel Bicycle modality to a growing range of targets, from a single target in 2009 to more than 150 today. We can create a wide range of Bicycle molecules by varying four parameters:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of amino acids in the two loops;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amino acid composition at each position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the symmetry of the two loops; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the small molecule scaffold used to cyclize the Bicycle molecule.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Properties of Bicycle</i> <i style="font-style:italic;">Molecules as Therapeutic Agents</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Bicycle molecules have a large surface area available for target binding, which is designed to allow for high affinity and selectivity to the designated target. As short sequences of amino acids, or peptides, they have a low molecular weight, typically ranging from 1.5 kDa to 2.0 kDa. Bicycle molecules have a readily adjustable&#160;<span style="white-space:pre-wrap;">PK profile with good plasma stability and rapid distribution from the vasculature into the extracellular space. This PK profile enables rapid tissue penetration and a renal route of elimination that minimizes liver exposure. Toxicity issues are observed with small molecules that are metabolized and eliminated by the liver. Bicycle molecules, by contrast, are not subject to metabolism or elimination by the liver but are metabolized in the peripheral circulation or kidney with subsequent rapid excretion in the urine.  Consequently, by increasing excretion in urine, the liver exposure is minimized and the risk of liver toxicity is reduced. The modular nature of Bicycle molecules allows us to optimize therapeutic molecules for specific targets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compared to biologics, Bicycle molecules have a lower cost of production and a simpler manufacturing process, and are recognized by regulatory authorities as small molecule new chemical entities. We can readily identify Bicycle molecules that may drug a wide spectrum of targets and target classes, including many that have so far been undruggable with small molecules, such as protein-protein interactions. Our novel and proprietary screening platform allows us to screen Bicycle<i style="font-style:italic;"> </i>molecules against molecular targets rapidly and efficiently, affording potentially reduced timelines and costs compared to other high-throughput screening approaches. Leveraging our platform, we can rapidly and efficiently identify a compound for development with the historical average time being 12&#160;months after a target has been selected.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:229.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Properties of Bicycle</span><b style="font-weight:bold;"> </b><span style="font-style:italic;font-weight:bold;">Molecules May Translate into Potential Therapeutic and Other Advantages</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k004.jpg" alt="Graphic" style="display:inline-block;height:229.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:517.38pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of Bicycle</span><b style="font-weight:bold;"> </b><span style="font-style:italic;font-weight:bold;">Molecules to Other Common Classes of Therapeutics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k005.jpg" alt="Graphic" style="display:inline-block;height:171pt;width:519.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Proprietary Bicycle Screening Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We utilize our novel and proprietary phage display screening platform to identify Bicycle molecules that are potentially useful in medicine. We have used this technology to identify our current pipeline and intend to leverage it to develop a broader portfolio of product candidates to address unmet medical needs across a wide range of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Phages are bacteria-infecting viruses consisting of genetic material wrapped in a protein coat. Phages can be harnessed to identify Bicycle molecules by splicing DNA into the genome of a phage so that the linear peptides that encode Bicycle molecules are presented on the surface of the phage. One of our founders, Sir Greg Winter, a pioneer in phage display, applied this technology and added a cyclization step that forms Bicycle molecules from these linear peptides. This technology underpins our novel and proprietary screening platform.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:240pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our screening process self-selects for Bicycle molecules that are amenable to attachment, commonly referred to as conjugation, to other molecular payloads such as cytotoxins, chelated radiopharmaceutical agents, innate immune agonists or other Bicycle molecules. Bicycle molecules can be linked together with synthetic ease to create complex molecules with combinatorial pharmacology. Alternatively, Bicycle molecules in the form of multimers can also be used as standalone therapeutics, such as those that we are exploring in our systemic and tumor-targeted immune cell agonist programs. We believe that the flexibility of our Bicycle molecules and our powerful screening platform allow new therapeutics to be rapidly conceived and reduced to practice to potentially serve diverse therapeutic applications across a wide range of indications. We can readily identify Bicycle molecules&#8239;that may drug a wide spectrum of targets and target classes, including many that have so far been undruggable with small molecules, such as protein-protein interactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Schematic of our Proprietary Bicycle Screening Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k006.jpg" alt="Graphic" style="display:inline-block;height:240pt;width:156.27pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have optimized our proprietary Bicycle screening platform, enabling the technique to be applied to a diverse range of over 150 challenging targets to date, successfully identifying Bicycle molecules for over 85% of these targets since our IPO, some of which are intractable to small molecules. During these screens, Bicycle molecules with diverse pharmacologies were identified, including enzyme inhibitors, receptor antagonists, agonists (partial, full and supra) and neutral site binders. Neutral site binders often bind to entirely novel sites on target proteins, previously undescribed in the scientific literature. These binders can be useful when conjugated with therapeutic payloads since they allow antigen-targeted payload delivery without impacting target function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our portfolio of internal product candidates is directed to oncology applications where we believe they have the potential to treat a broad spectrum of cancers. We are collaborating with biopharmaceutical companies and organizations in additional therapeutic areas where we believe our proprietary Bicycle screening platform can identify therapies to treat diseases with significant unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes key information about our programs.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:28.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:27.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:11.8pt;"><td style="vertical-align:top;width:25.33%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:top;width:2.43%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:28.74%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:top;width:2.78%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:10.24%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stage</b></p></td><td style="vertical-align:top;width:2.76%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:27.7%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></td></tr><tr style="height:9.1pt;"><td colspan="7" style="color:#ffffff;vertical-align:top;width:100%;background:#0041c1;margin:0pt;padding:0pt;"><p style="color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Internal programs</b></p></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Zelenectide pevedotin (Nectin-4)</b></p></td><td style="vertical-align:top;width:2.43%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">High Nectin-4 expressing tumors (oncology) </span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Phase I/II/III</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Ongoing company-sponsored Phase I/II and Phase II/III clinical trials</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">BT5528 (EphA2)</b></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">High EphA2 expressing tumors (oncology)</span></div></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Phase I/II</span></div></div></div></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Ongoing company-sponsored Phase I/II clinical trial </span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">BT7480 (Nectin-4/CD137)</b></p></td><td style="vertical-align:top;width:2.43%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Immuno-oncology</span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Phase I/II</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Ongoing company-sponsored Phase I/II clinical trial</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">MT1-MMP</b></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Radiopharmaceutical</span></div></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Preclinical</span></div></div></div></td><td style="vertical-align:top;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">IND-enabling activities ongoing and collaborating with our academic partner DKFZ</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EphA2</b></p></td><td style="vertical-align:top;width:2.43%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Radiopharmaceutical</span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Preclinical</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Collaborating with our academic partner DKFZ</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#0099e5;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="color:#ffffff;font-weight:bold;">Partnered programs</b></p></td><td style="vertical-align:top;width:2.43%;background:#0099e5;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#0099e5;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;background:#0099e5;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#0099e5;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#ffffff;font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.76%;background:#0099e5;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#0099e5;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#ffffff;font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undisclosed</b></p></td><td style="vertical-align:top;width:2.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Immuno-oncology</span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Preclinical</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Collaborating with Genentech</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Novel CNS targets</b></p></td><td style="vertical-align:top;width:2.43%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">CNS</span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Preclinical</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Collaborating with Ionis</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Novel neuromuscular targets</b></p></td><td style="vertical-align:top;width:2.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Neuromuscular</span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Preclinical</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Collaborating with Ionis</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undisclosed</b></p></td><td style="vertical-align:top;width:2.43%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Radiopharmaceutical</span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Preclinical</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#d1cfcf;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#d1cfcf;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Collaborating with Novartis</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:25.33%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undisclosed</b></p></td><td style="vertical-align:top;width:2.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:28.74%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Radiopharmaceutical</span></div></div></div></td><td style="vertical-align:top;width:2.78%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.24%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Preclinical</span></div></div></div></td><td style="vertical-align:top;width:2.76%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;background:#ffffff;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:7.2pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">Collaborating with Bayer</span></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/></b><b style="font-weight:bold;">Our Internal Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe Bicycle molecules are an ideal vehicle to deliver small molecule payloads to tumors, each as potent cytotoxins in the case of BTC molecules, chelated radiopharmaceutical payloads and imaging agents in the case of BRC molecules, as well as small molecule agonists of the immune system in the case of our Bicycle TICA molecules. We believe that Bicycle conjugates can offer improved performance as compared to antibody-mediated delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to their use as drug conjugates, Bicycle molecules can also be configured for use as standalone therapeutics. We have identified Bicycle molecules that have been observed to directly interact with CD137, a key immune cell co-stimulatory molecule. We believe our CD137-targeting Bicycle molecules may overcome limitations inherent in antibody-mediated approaches and have the potential to be converted into simple tumor-targeted immune cell-engaging Bicycle molecules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bicycle Toxin Conjugates</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Within our BTC programs, we are evaluating zelenectide pevedotin, a BTC molecule that targets Nectin-4 and carries a monomethyl auristatin E, or MMAE, cytotoxin payload, in both an ongoing company-sponsored Phase I/II clinical trial to assess the safety, pharmacokinetics and preliminary clinical activity in patients with Nectin-4 expressing advanced malignancies, and an ongoing company-sponsored Phase II/III registrational trial, called Duravelo-2, allowing for potential accelerated approval in untreated and previously treated metastatic urothelial cancer. Zelenectide pevedotin has been granted Fast Track Designation, or FTD, by the FDA as a monotherapy for the treatment of adult patients with previously treated, locally advanced or metastatic urothelial cancer. The FDA has also granted FTD to zelenectide pevedotin for the treatment of adult patients with previously treated, NECTIN4 gene-amplified, advanced or metastatic triple-negative breast cancer and non-small cell lung cancer, and we plan to initiate additional Phase I/II clinical trials to assess zelenectide pevedotin in NECTIN4 gene-amplified breast cancer, lung cancer and multiple other cancers in 2025. Zelenectide has also been selected to participate in the Chemistry, Manufacturing and Controls, or CMC, Development </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and Readiness Pilot Program launched by the FDA to facilitate CMC development for therapies with expedited clinical development timeframes based on the anticipated clinical benefits of earlier patient access to the therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also evaluating BT5528, a BTC molecule that targets EphA2 and carries an MMAE cytotoxin payload, in an ongoing, company-sponsored Phase I/II clinical trial to assess safety, pharmacokinetics, and preliminary clinical activity in patients with solid tumors. BT5528 has been granted FTD for treatment of adult patients with previously treated, locally advanced or metastatic urothelial cancer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Background</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The discovery of monoclonal antibodies enabled the development of antibody drug conjugates, or ADCs. ADCs link antibodies that target tumor-associated antigens to potent cytotoxins through a process known as conjugation. ADCs are designed to selectively and potently destroy cancer cells by combining the targeting capability of antibodies with the cancer-killing ability of cytotoxins. Despite the growing use of ADCs in treating cancer and high interest in ADC development programs, we believe there are significant challenges to ADCs. The large molecular size of the antibody impairs the penetration of ADCs into tumors. ADCs are generally required to internalize into tumor cells after binding to internalizing tumor antigens on the surface. Finally, the relatively long systemic exposure and subsequent liver clearance generally associated with ADCs result in dose-limiting toxicities as well as other toxicities, such as hematological, liver, ocular, skin and gastrointestinal toxicities, and neuropathies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Properties of Bicycle Toxin Conjugates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe the properties of our BTC molecules may address the challenges associated with ADCs and therefore that our approach has the potential to offer substantial benefits, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Extensive and rapid tumor penetration. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicycle molecules have been observed in our preclinical studies to penetrate tumors more rapidly and exhibit increased penetration to poorly perfused regions of the tumor when compared to a comparator antibody. Early clinical data from an ongoing clinical trial has shown 10 times higher tumor cytotoxin levels than corresponding plasma levels based on clinical tumor biopsies taken 24 hours post-infusion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Retention in tumors. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In preclinical studies, following administration of a tumor antigen targeting Bicycle molecule the toxin payload was observed to be retained in the tumor for at least 120 hours after dosing. Preliminary clinical data observed to date from our ongoing clinical trials are consistent with preclinical observations of post-dose tumor retention.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Short systemic half-life and renal elimination</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicycle molecules have been observed in clinical and preclinical studies to have a short systemic half-life of approximately 20 to 30 minutes. Due to their small size, Bicycle molecules are able to exit the tissue rapidly and are excreted through the kidneys rather than the liver, which we expect will support a favorable toxicity profile.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">No requirement for internalization.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unlike ADCs, which require cellular internalization for activity, BTC molecules do not require internalization into the cell, and therefore potentially can target a wider range of tumor antigens.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Access to non-expressing tumor cells.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The toxin in our BTC molecules is liberated in the extracellular space, enabling cell-killing adjacent cells that do not express the specific target through a toxin bystander effect. In our preclinical studies, we observed activity for BTC molecules even in tumors that were heterogeneous for target expression.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Larger toxin payload.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Despite the small size of Bicycle molecules, they are able to carry a larger dose of toxin per unit mass than a comparator ADC. Therefore, we believe that Bicycle molecules can deliver a higher concentration of the linked toxin to increase the probability of tumor killing.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:213pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Manufacturing.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The fully synthetic process by which Bicycle molecules are manufactured facilitates ease and consistency of manufacturing and improved formulation compared to ADCs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to compare the ability of a Bicycle conjugate and an antibody conjugate to penetrate a tumor, using positron emission tomography, or PET, imaging, we compared a radiolabeled Bicycle molecule to an antibody directed at the same target in a preclinical rodent study. As shown in the figure below, we observed that 15% to 20% of the injected dose per gram was detected after administration of the Bicycle molecule in the tumor at 40 to 60&#160;minutes, with no antibody detectable in the tumor during this time. We also observed accumulation of the balance of the Bicycle molecules in the bladder and kidneys, indicating rapid renal excretion. In contrast, the antibody was detected in the vasculature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PET Imaging Revealing Payload Delivery in a Mouse Model</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k007.jpg" alt="Graphic" style="display:inline-block;height:213pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:248.85pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in a preclinical rodent study using photoacoustic imaging, we observed that Bicycle molecules were retained in the tumor for 24&#160;hours and at levels substantially in excess of those observed with a comparator antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:177pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The figure below summarizes the results of a preclinical rodent xenograft model that investigated payload concentrations over time in different organ systems after administration of a BTC molecule. In this model, we observed the toxin payload was retained in the target-expressing tumor over time but was rapidly eliminated from other tissues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Payload Concentrations Over Time in Different Organ Systems After Administration of a BTC Molecule</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k008.jpg" alt="Graphic" style="display:inline-block;height:176.75pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:385.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe these data demonstrate the potential of BTC molecules to have long-term sustained activity and to limit the toxicity associated with ADCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Zelenectide Pevedotin</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Zelenectide pevedotin is a BTC molecule designed to target Nectin-4, a well-validated tumor antigen. The molecule is composed of our Nectin-4 targeting <i style="font-style:italic;">Bicycle</i> molecule, a val-cit cleavable linker, and a cytotoxin MMAE payload.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Schematic of Zelenectide Pevedotin</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k009.jpg" alt="Graphic" style="display:inline-block;height:128.59pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:329.25pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nectin-4 (also known as PVRL4) is a cell adhesion molecule from the Nectin and Nectin-like family, members of which are integral to the formation of the homotypic and heterotypic cell junctions. Nectin-4 has been shown to be overexpressed in tumor cells and is believed to play a role in tumor cell growth and proliferation. High in normal embryonic and fetal tissue, Nectin-4 declines in adulthood, showing a limited distribution in healthy tissues. However, Nectin-4 is expressed on tumor cells in numerous cancer types including bladder, breast, gastric, lung and ovarian. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FDA approved enfortumab vedotin, a Nectin-4 ADC program developed jointly by Pfizer Inc., (formerly Seagen, Inc., or Seagen, acquired by Pfizer in December 2023) and Astellas Pharma, Inc., or Astellas, in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer. The FDA previously granted accelerated approval to this combination for patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy as well as to enfortumab vedotin as a monotherapy for adult patients with locally advanced or metastatic urothelial cancer following treatment with platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Additionally, in April 2022 the European Commission approved enfortumab vedotin as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Pfizer and Astellas are also pursuing additional indications for enfortumab vedotin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are advancing zelenectide pevedotin in both an ongoing company-sponsored Phase I/II clinical trial to assess the safety, pharmacokinetics and preliminary clinical activity in patients with Nectin-4 expressing advanced malignancies, and an ongoing company-sponsored Phase II/III registrational trial, called Duravelo-2, allowing for potential accelerated approval in untreated and previously treated metastatic urothelial cancer. Zelenectide pevedotin has been granted FTD by the FDA as a monotherapy for the treatment of adult patients with previously treated, locally advanced or metastatic urothelial cancer and has also been selected to participate in the Chemistry, Manufacturing and Controls, or CMC, Development and Readiness Pilot Program launched by the FDA to facilitate CMC development for therapies with expedited clinical development timeframes based on the anticipated clinical benefits of earlier patient access to the therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2024, we announced updated Phase I/II clinical results for zelenectide pevedotin used as a monotherapy in metastatic urothelial cancer at the European Society for Medical Oncology, or ESMO, Congress 2024. In the ongoing Phase I/II clinical trial evaluating 5 mg/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup><span style="white-space:pre-wrap;"> weekly of zelenectide pevedotin monotherapy in 45 metastatic urothelial cancer patients who had not previously been treated with enfortumab vedotin, updated results showed an overall response rate, or ORR, of 45% in 38 efficacy-evaluable patients, including one confirmed complete response and 16 partial responses with 13 confirmed. Stable disease was maintained in nine patients, and 12 patients experienced progressive disease.  In addition, updated results showed a median duration of response of 11.1 months among the 14 patients with confirmed responses. </span><span style="background:#ffffff;">Zelenectide pevedotin continued to show an emerging differentiated safety profile, particularly around adverse events of interest such as peripheral neuropathy, skin reactions and eye disorders. Notably, there were no treatment-related adverse events of peripheral neuropathy, skin reactions or eye disorders at or above Grade 3, and patients with pre-existing peripheral neuropathy were unlikely to develop worsening peripheral neuropathy during treatment with zelenectide pevedotin. In addition, low rates of treatment-related peripheral neuropathy, or TRPN, were observed following monotherapy treatment with zelenectide pevedotin. In 149 patients treated with zelenectide pevedotin, results showed TRPN in 28% of patients, nearly all of which were low grade. One Grade 3 event of neuralgia was reported in a patient treated with zelenectide pevedotin following prior therapy with enfortumab vedotin. Among zelenectide pevedotin patients with peripheral neuropathy at baseline, 80% did not develop TRPN during treatment. TRPN had completely resolved in 14% of zelenectide pevedotin patients and 26% had some resolution or improvement at the time of reporting, though post-treatment follow-up was limited. The median time to resolution or improvement of TRPN was 2.2 weeks for zelenectide pevedotin. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In January 2025, we also announced updated topline results from the ongoing Phase I trial evaluating 5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> weekly of zelenectide pevedotin plus 200 mg of pembrolizumab once every three weeks. In 22 previously untreated cisplatin-ineligible patients with metastatic urothelial cancer, results showed an ORR of 65% among all 20 efficacy-evaluable patients, and an ORR of 50% among patients with confirmed responses. Of the three unconfirmed responses, one patient remained on treatment. A median duration of response is not yet mature, with 12 patients still on treatment. The safety and tolerability profile continues to be broadly consistent with other Phase I zelenectide pevedotin monotherapy and combination cohorts. Adverse events of interest such as peripheral neuropathy, skin reactions and eye disorders were primarily low grade. All cases of Grade 3 treatment-related adverse events of interest were reversible, and there were no Grade 4 or Grade 5 treatment-related adverse events of interest. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our ongoing Phase II/III registrational trial, Duravelo-2, is evaluating zelenectide pevedotin plus pembrolizumab versus chemotherapy in patients with previously untreated metastatic urothelial cancer, or Cohort 1, as well as zelenectide pevedotin monotherapy and in combination with pembrolizumab in patients with previously treated metastatic urothelial cancer, or Cohort 2. In each cohort, two doses of zelenectide pevedotin, 5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> weekly and 6 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> two weeks on, one week off, are initially being assessed before an optimized dosage is selected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In addition to the above, in December 2024, we announced data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Cancer Symposium, or SABCS, and shared topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer patients with NECTIN4 gene amplification. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Gene amplification is a common mechanism by which cancer cells gain function. We have identified that the NECTIN4 gene sits on a commonly amplified chromosomal site in cancer, creating more copies of the gene and often translating to more protein expression. As zelenectide pevedotin binds to Nectin-4, it was hypothesized that NECTIN4 gene amplification may predict response and could serve as a biomarker for therapy stratification. We conducted a post-hoc analysis of 38 heavily pretreated breast cancer patients enrolled in the Phase I/II clinical trial for zelenectide pevedotin, of which 32 were confirmed to have triple-negative breast cancer. The majority were treated with zelenectide pevedotin 5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> weekly. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Of the 38 breast cancer patients enrolled, 35 patients were efficacy-evaluable. Additionally, 23 breast cancer patient samples were available for NECTIN4 testing, of which eight demonstrated NECTIN4 gene amplification or harbored NECTIN4 polysomy. Results showed an ORR of 62.5% among eight breast cancer patients with NECTIN4 gene amplification or polysomy, with five partial responses, compared to an ORR of 14.3% among all efficacy-evaluable patients. Of the five partial responses, four were confirmed and one was unconfirmed. All responses were seen in patients with NECTIN4 gene amplification and/or polysomy. Of the 32 triple-negative breast cancer patients enrolled, 30 patients were efficacy evaluable. Additionally, 19 triple-negative breast cancer patient samples were available for NECTIN4 testing, of which seven demonstrated NECTIN4 gene amplification or harbored NECTIN4 polysomy. Results showed an ORR of 57.1% among triple-negative breast cancer patients with NECTIN4 gene amplification or polysomy, with four partial responses, compared to an ORR of 13.3% among all efficacy-evaluable triple-negative breast cancer patients. Of the four partial responses, three were confirmed and one was unconfirmed. All responses were seen in patients with NECTIN4 gene amplification and/or polysomy. All three patients with NECTIN4 gene amplification who responded to zelenectide pevedotin had prior treatment with sacituzumab govitecan. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In this study of heavily pretreated breast cancer patients, zelenectide pevedotin was generally well tolerated, and its safety and tolerability profile was consistent with data from other Phase I/II clinical trial cohorts. Low rates of treatment-related adverse events at or above Grade 3 and treatment-related serious adverse events at or above Grade 3 occurred. The most common treatment-related adverse events were fever, nausea and diarrhea. Treatment-related adverse events of interest, including peripheral neuropathy and skin reactions, were low grade.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We also conducted a post-hoc analysis of 40 pretreated patients with non-small cell lung cancer enrolled in the Phase I/II clinical trial for zelenectide pevedotin. The majority of patients received zelenectide pevedotin 5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> weekly. Of the 40 patients enrolled, 34 patients were efficacy-evaluable. Additionally, 19 patient samples were available for NECTIN4 testing, of which six demonstrated NECTIN4 gene amplification. Five out of six patients with NECTIN4 gene amplification were efficacy evaluable. Results showed an ORR of 40% among patients with NECTIN4 gene amplification, with two partial responses, compared to 8.8% among all efficacy-evaluable patients, with three partial responses. Of the three partial responses, two were confirmed and one was unconfirmed. Two out of three responses were seen in patients with NECTIN4 gene amplification. The safety and tolerability profile of zelenectide pevedotin was broadly consistent with data from other Phase I/II clinical trial monotherapy cohorts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Based on the data from these studies, we plan to advance development of zelenectide pevedotin in broader indications outside of metastatic urothelial cancer utilizing a NECTIN4 gene amplification strategy to target patients who have the potential for significantly deeper responses. In January 2025, we announced that the FDA granted FTD to zelenectide pevedotin for the treatment of adult patients with previously treated, NECTIN4 gene-amplified, advanced or metastatic triple-negative breast cancer and non-small cell lung cancer. Over the course of 2025, we plan to initiate </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:141.09pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">several additional Phase I/II clinical trials to assess zelenectide pevedotin in NECTIN4 gene-amplified breast cancer, lung cancer and multiple other cancers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">BT5528</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">BT5528 is a BTC molecule designed to target EphA2. The molecule is comprised of our EphA2 targeting Bicycle molecule, a valine-citrulline, or val-cit, cleavable linker and a cytotoxin MMAE payload.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Schematic of BT5528</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k010.jpg" alt="Graphic" style="display:inline-block;height:141.09pt;width:327pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EphA2 is a member of the Ephrin superfamily of receptor tyrosine kinases regulating cell migration, adhesion, proliferation and differentiation. EphA2 is expressed at relatively low levels in normal adult tissues, but is overexpressed in numerous difficult-to-treat tumors including lung, breast, bladder, head and neck, gastric, ovarian, and pancreatic cancer. In both cell-derived and patient-derived preclinical models, we observed anti-tumor activity signals following administration of our EphA2 toxin conjugates, which correlated with EphA2 expression, as determined by FACS studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EphA2 has been pursued by other companies utilizing antibody drug conjugates, or ADCs. Significant safety concerns, including bleeding events and liver toxicity, were observed in preclinical studies and early clinical development, which resulted in the discontinuation of development. For example, in a Phase&#160;I clinical trial of MEDI-547, an EphA2-targeting ADC, an increase in the liver enzymes ALT and AST was observed in half of the dosed patients and bleeding events were observed in five out of six patients, in each case with in two to eight days following a single dose. The bleeding events observed in humans from the clinical trial were consistent with findings from the preclinical studies in other species, including primates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe EphA2 is an attractive target for our BTC molecules due to the potential of Bicycle molecules to overcome the safety concerns observed with ADCs. In our preclinical PK and toxicokinetic studies, we observed a short systemic half-life and volume of distribution approximately equal to extracellular fluid. We observed that the accumulation of MMAE in the tumor tissue led to mitotic arrest of tumor cells and tumor regression was evident within days of administration. Due to the shorter half-life, improved penetration into solid tumors and kidney elimination, we believe that BT5528 could overcome the challenges faced by ADCs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">BT5528 was evaluated in preclinical studies in multiple species, including rodents and non-human primates. In our preclinical studies, BT5528 was not observed to have a significant effect on clotting parameters and did not exhibit abnormal liver function at tolerated doses. We also observed no bleeding events in primates at toxin equivalent doses over 150-fold higher than the clinical dose of an ADC with the same amino acid sequence and with the same linker-toxin combination and average drug/antibody ratio as MEDI-547 used in patients. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Clinical Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently evaluating BT5528 in a company-sponsored Phase I/II clinical trial <span style="background:#ffffff;">to assess safety, pharmacokinetics and preliminary clinical activity </span>in patients with advanced solid tumors associated with EphA2 expression. BT5528 has been granted FTD for treatment of adult patients with previously treated, locally advanced or metastatic urothelial cancer. In September 2024, we announced updated Phase I/II clinical results for BT5528 in advanced solid tumors, including metastatic urothelial cancer and ovarian cancer, at the ESMO Congress 2024, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Updated results from the ongoing Phase I/II clinical trial evaluating 6.5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> every two weeks and 5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> weekly of BT5528 monotherapy in patients with advanced solid tumors showed an ORR of 12% among 113 efficacy-evaluable patients with advanced solid tumors. Of these, the highest anti-tumor activity was in metastatic urothelial cancer, with a 34% ORR in all efficacy-evaluable patients enrolled in the dose escalation and expansion cohorts. Among patients receiving 6.5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> every two weeks, a 31% ORR was observed in the dose escalation and expansion cohort and a 45% ORR was observed in the expansion cohort only. A lower, but acceptable ORR of 27% was observed in patients receiving 5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> weekly. There were no objective responses observed in patients with ovarian cancer who received 5 mg/m2 weekly. However, five patients maintained stable disease at the time of data cut off. In addition, the updated results suggested a correlation between EphA2 expression and response. Among 14 patients with metastatic urothelial cancer who had available immunohistochemistry and response data, a 43% ORR was observed in EphA2-positive patients compared to a 20% ORR in EphA2-negative patients. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">BT5528 showed an emerging differentiated safety profile, with none of the hemorrhage events or hematological toxicities that have been associated with other EphA2-targeting drug conjugates. Low rates of TRPN were observed following monotherapy treatment with BT228. In 74 patients treated with BT5528 at 6.5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> every two weeks, results showed TRPN in 19% of patients, nearly all of which were low grade, with no events at or above Grade 3. TRPN had completely resolved in 21% of BT5528 patients and 21% had some resolution or improvement at the time of reporting, though post-treatment follow-up was limited. The median time to resolution or improvement of TRPN was 1.7 weeks for BT5528.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We have begun assessing BT5528 at 6.5 mg/m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">2</sup><span style="background:#ffffff;"> every two weeks in combination with nivolumab and are further evaluating BT5528 in certain other tumor indications. Results from the combination cohort are expected in 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bicycle</i> <i style="font-style:italic;">Immune Cell Agonist</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Approaches that activate cytotoxic T-cells and other types of cells used in a body&#8217;s immune response have been observed to improve outcomes in cancer. However, prolonged immune activation can be toxic and lead to T-cell exhaustion, which is a challenge amplified by the long half-life of antibodies and biologics that are often used in these treatment approaches. We believe the differentiated properties of Bicycle molecules may allow us to develop molecules with a pharmacodynamically distinct and improved profile over existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are aware of anti-CD137 antibodies undergoing clinical testing, including urelumab being developed by Bristol-Myers Squibb, which produced single agent responses but also severe liver toxicity, and utomilumab being developed by Pfizer, which exhibited minimal clinical activity with less toxicity. We are developing immune cell agonists, designed to trigger an immune response to tumors. We have identified potent Bicycle<i style="font-style:italic;"> </i>agonists of CD137, a tumor necrosis factor receptor, or TNFR, family member. We believe that Bicycle molecules represent a differentiated approach to target CD137 that may confer several advantages over existing modalities due to the small size and PK characteristics of Bicycle molecules. Our Bicycle<i style="font-style:italic;"> </i>immune cell agonists are designed to circumvent the limitations of antibody and biologic therapies, such as liver toxicity and limited efficacy, and to better enable combination therapy. Bicycle<i style="font-style:italic;"> </i>immune cell agonists can be formed by conjugating multiple copies of a CD137 Bicycle molecule to form multimers or by utilizing a bi-specific format in which CD137 Bicycle molecules are linked to Bicycle molecules that bind to tumor antigens, inhibit checkpoint proteins or otherwise activate the immune system. We believe we are currently the only company that has fully chemically synthetic multivalent or tumor-targeted CD137 agonists.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:151.54pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Properties of Bicycle Immune Cell Agonists</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to agonize the CD137 receptor, cross-linking of a trimeric receptor is required. As a result, we are developing multivalent systemic and tumor-targeted molecules that cross-link the receptor into an active form in a tumor cell independent or dependent manner as shown in the image below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Schematic of Proposed CD137 Bicycle Agonists</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k011.jpg" alt="Graphic" style="display:inline-block;height:151.24pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:353.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These Bicycle<i style="font-style:italic;"> </i>CD137 agonists feature the following favorable pharmacological characteristics for immuno-oncology therapeutics. We believe these characteristics have the potential to overcome the limitations of antibodies and fusion proteins.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Simplicity and small size.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our systemic and tumor-targeted immune cell agonizing Bicycle molecules are chemically synthesized and are very small in comparison to other molecules targeting the CD137 receptor. For example, the approximate molecular weight of urelumab is 146 kDa. In contrast, the molecular weight of our multivalent and tumor-targeted </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Bicycle</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> molecules is in the range of approximately 4 kDa to 15 kDa, which is designed to facilitate the rapid penetration of the therapeutic into tumor tissue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Tunable PK.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicycle molecules are amenable to chemical modifications that allow the PK to be fine-tuned. We believe this enables the development of molecules with the optimal balance of prolonged CD137 agonism, but with rapid enough elimination from systemic circulation to avoid the undesired toxicities of CD137, as has been observed with urelumab. In addition, this tunable half-life is expected to enable different sequences of therapeutics to be evaluated in the clinic potentially reducing the risk of overlapping toxicities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Renal elimination.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rapid renal elimination may avoid liver toxicity observed with other CD137 agonists in development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">Modular.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The modular nature of Bicycle molecules permits the presentation of CD137 binders in various orientations and in combination with other Bicycle molecules allowing us to design molecules with a range of activities. We believe that we can select the optimal activity profile to avoid the weak efficacy seen with the utomilumab molecule or the overstimulation of CD137 by urelumab that resulted in systemic toxicity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Tumor targeting</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Combining CD137-binding Bicycle molecules with Bicycle molecules that bind to tumor targets potentially affords an additional level of safety as compared to systemically active agonists such as urelumab. The clustering and activation of CD137 occurs only when the tumor-targeting Bicycle molecule binds to both the tumor antigen target and CD137. Therefore, we expect the tumor targeted agonists will achieve a higher degree of activation locally in the tumor but will have significantly reduced or no activity in healthy tissues that do not express the tumor antigen.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:129.15pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bicycle</i> <i style="font-style:italic;">Tumor-Targeted Immune Cell Agonists</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our product candidate BT7480 is a Bicycle TICA molecule. A Bicycle TICA molecule links immune cell receptor binding Bicycle molecules to tumor antigen binding Bicycle molecules. We are evaluating BT7480, a Bicycle TICA molecule targeting Nectin-4 and agonizing CD137, in a company-sponsored Phase I/II clinical trial to assess the safety and tolerability of BT7480, and to determine a recommended Phase II dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Background</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have linked immune cell receptor binding Bicycle molecules to tumor antigen binding Bicycle molecules<i style="font-style:italic;"> </i>to form Bicycle<i style="font-style:italic;"> </i>TICA molecules. We have found this approach to be generalizable across tumor antigen and immune cell receptors. We constructed CD137-targeting Bicycle<i style="font-style:italic;"> </i>TICA molecules and observed that these bi-specific Bicycle molecules<i style="font-style:italic;"> </i>agonize the CD137 receptor only in the presence of cells that express the appropriate tumor antigen. Additionally, we have constructed Bicycle<i style="font-style:italic;"> </i>TICA molecules with Bicycle molecules that bind to another member of the TNF family of T-cell costimulatory receptors TNFRSF4, also known as OX40.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In pre-clinical studies, we have observed that intermittent dosing of BCY12491, an EphA2/CD137 Bicycle<i style="font-style:italic;"> </i>TICA molecule, leads to a robust anti-tumor activity in syngeneic MC38 mouse model using humanized CD137 (huCD137) C57BL/6 mice. Administration of BCY12491 in six intravenous biweekly doses over a period of 17 days at 5 mg/kg led to substantial tumor regressions, including two out of six CRs. In addition, administration of BCY13626, a non-binding analog of BCY12491 had no impact on tumor growth rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Activity of EphA2 Bicycle</span><b style="font-weight:bold;"> </b><span style="font-style:italic;font-weight:bold;">TICA Molecule in vivo</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k012.jpg" alt="Graphic" style="display:inline-block;height:129.15pt;width:311.05pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have also observed that intermittent dosing of Bicycle<i style="font-style:italic;"> </i>TICA molecule BCY12491 leads to an increase in immune cell infiltration and an increase in the expression of checkpoint inhibitor genes in tumors of a syngeneic MC38 mouse model using humanized CD137, or huCD137, C57BL/6 mice. In other pre-clinical studies, we have observed that when BCY12491 is dosed in combination with pembrolizumab, a PD1 checkpoint inhibitor, there is an increased antitumor effect as shown in the figure below. Administration of BCY12491 in eight intravenous doses at 5 mg/kg (dosed on days 0, 1, 7, 8, 14, 15, 21 and 22) in combination with 4 intraperitoneal doses of pembrolizumab at 3 mg/kg (dosed on days 0, 7, 14 and 21) lead to substantial tumor regressions, including ten out of ten CRs. We observed that dosing BCY12491 or pembrolizumab alone using the same dose and schedule led to only two and three out of ten complete regressions respectively. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:120.46pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Activity of EphA2 Bicycle TICA Molecule and PD1 Inhibitor in vivo</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k013.jpg" alt="Graphic" style="display:inline-block;height:120.46pt;width:349.5pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our ability to rapidly generate and test Bicycle<b style="font-weight:bold;"> </b>TICA molecules and their simple molecular format may form the basis of additional programs in the future. In addition to the immune cell and tumor targets that we have already investigated, we are screening for&#160;Bicycle molecules<i style="font-style:italic;"> </i>that target NK cell receptors as well as additional immune cell and tumor specific antigens.&#160;We have identified Bicycle<i style="font-style:italic;"> </i>TICA candidates that target and activate NK cells. We have observed that treatment of primary human NK cells in co-culture with target-positive tumor cells with NK TICAs results in increased NK cell mediated tumor cell killing and an increase in NK cell secreted pro-inflammatory cytokines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-style:italic;font-weight:bold;">BT7480</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">BT7480 is a Bicycle<i style="font-style:italic;"> </i>TICA molecule that targets CD137 and Nectin-4. BT7480 exhibits potent CD137 agonism in an engineered CD137 reporter assay system that correlates with Nectin-4 surface expression on the co-cultured tumor cells. In addition, BT7480 induces robust production of interleukin-2, or IL-2, and interferon gamma, or IFN&#42857;, in primary PBMC/tumor cell co-culture assays. This activity is strictly dependent on the tumor cells expressing Nectin-4 and on the ability of the Bicycle<i style="font-style:italic;"> </i>TICA molecule to bind to both of its targets, Nectin-4 and CD137. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we have observed that intermittent dosing of BT7480 leads to a robust anti-tumor activity in syngeneic MC38 mouse model, engineered to overexpress Nectin-4, using huCD137 C57BL/6 mice. Administration of BT7480 in six intravenous biweekly doses over a period of 17 days at 1.5 or 5 mg/kg led to substantial tumor regressions, including five out of six complete responses at 1.5 mg/kg and six out of six CRs at 5 mg/kg. In addition, animals that were complete responders in the experiment were subsequently re-challenged with the same tumor cell implantation and no tumor growth was observed, implying development of immunogenic memory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;background:#ffffff;">Clinical Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are evaluating BT7480 in a company-sponsored Phase I/II clinical trial. In September 2024, we announced updated Phase I/II clinical trial results for BT7480 in advanced solid tumors at the ESMO Congress 2024, as described below.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Initial data from the dose escalation portion of the Phase I/II clinical trial evaluating BT7480 in patients with advanced solid tumors showed an emerging differentiated safety and tolerability profile among 39 patients assigned to receive one of 10 different doses of BT7480, ranging from 0.002-3.5 mg/kg weekly, with a low number of severe adverse events. Low rates of adverse events at or above Grade 3 were observed, with 8% of patients experiencing treatment-related adverse events at or above Grade 3 and 5% of patients experiencing treatment-related severe adverse events at or above Grade 3. No such events were observed among those patients receiving the highest dose of 3.5 mg/kg. The best overall response observed was stable disease in 13 patients, five of whom had non-small cell lung cancer. Stable disease was prolonged in three patients, two with non-small cell lung cancer and one with anal cancer. In addition, there were two unconfirmed partial responses, both in patients with cervical cancer. Preliminary biomarker analyses that support BT7480 dual targeting of CD137 and Nectin-4 as demonstrated by enhanced immune cell activation, aligned with the proposed mechanism of action of BT7480.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:136.62pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are evaluating BT7480 in an ongoing company sponsored Phase I/II clinical trial as a monotherapy and in combination with nivolumab. Results from the combination cohort are expected in 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bicycle</i> <i style="font-style:italic;">Radionuclide Conjugates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Radiopharmaceuticals are drugs that contain medical isotopes, which are unstable elements that emit radiation and can be used to diagnose and treat cancers. To create radiopharmaceuticals, radiation emitting medical isotopes are typically attached to targeting molecules, which are then administered via intravenous injection. Once administered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle molecules for selectively delivering cytotoxic payloads are advantageous for delivering radionuclide payloads. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Schematic of Proposed Bicycle Radionuclide Conjugates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;"><img src="bcyc-20241231x10k014.jpg" alt="Graphic" style="display:inline-block;height:111.49pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:362.66pt;"/></i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Bicycle molecules have ideal properties for radioisotope delivery due to their low molecular weight, high selectivity and high affinity for their intended target and rapid systemic clearance. Our strategy for radiopharmaceuticals involves (i) partnering with industry and academic leaders in the radiopharmaceutical field to build our understanding and deepen our knowledge base, (ii) pursuing novel targets with first-in-class potential by using early human imaging agents to direct indication selection for theranostics and build programs in a data-driven manner and (iii) studying our BRC molecules with a range of isotopes to select that which best aligns with target biology and indication. We plan to partner with various isotope suppliers and have signed a letter of intent with leading isotope technology company Eckert &amp; Ziegler to put in place an agreement to supply a range of radioisotopes and develop and manufacture BRC molecules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We are developing a pipeline of novel binders with optimized properties for radioisotope delivery. In October 2024, first human imaging data for a BRC molecule targeting MT1-MMP was presented by the German Cancer Consortium, or DKTK, at the European Association for Nuclear Medicine, or EANM, 2024 Congress. During an oral presentation, DKTK focused on a case study in a 65-year old male diagnosed with advanced pulmonary adenocarcinoma, the most common type of non-small cell lung cancer, in the lung and lymph nodes confirmed by endobronchial ultrasound biopsy. The patient received fluorine-18-labelled FDG-PET/CT imaging, and two weeks later received MT1-MMP PET/CT imaging up to one hour post injection of the gallium-68-labelled BRC tracer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k015.jpg" alt="Graphic" style="display:inline-block;height:136.62pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:380.4pt;"/></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Both scans revealed multiple lymph node metastases and bone metastases in the sternum. MT1-MMP imaging demonstrated tracer uptake in the primary tumor in the lung and lymph node and bone metastases, consistent with FDG imaging. Additionally, the MT1-MMP BRC tracer showed renal excretion, with all other organs showing only negligible tracer uptake. Clear imaging contrast was also observed at early time points. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In addition, at the EANM 2024 Congress, we presented preclinical data demonstrating the suitability of Bicycle molecules to deliver indium to tumors <i style="font-style:italic;">in vivo</i> due to their favorable properties, including specific tumor uptake, rapid tumor penetration and rapid renal elimination. Imaging showed how the biodistribution profile of BRC molecules can be optimized to maintain high tumor uptake and retention while significantly reducing kidney uptake and retention. Altogether, we believe the data presented at EANM validates the potential of MT1-MMP as a novel target in the treatment of cancer, demonstrate the translatability of BRC preclinical data and highlight the potential of Bicycle molecules for targeted radionuclide therapy. We have selected tumor antigen EphA2 as our second BRC molecule target. We plan to generate additional human imaging data for BRC molecules targeting MT1-MMP and EphA2 in 2025, which we expect to further inform our drug discovery efforts, and we are targeting our first radiotherapeutic program to begin clinical trials in 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Collaborations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into several collaborations, including those briefly described below, which are predominantly focused on indications beyond our internal focus in oncology to leverage the broad applicability of Bicycle molecules. Our strategic collaborations are based on the ability of Bicycle molecules to address a wide variety of targets and we are working with collaborators with deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients. For additional information on these collaboration agreements, see Note 9. &#8220;Significant agreements&#8221; of our consolidated financial statements appearing elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bayer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">On May 4, 2023, we entered into a collaboration and license agreement with Bayer Consumer Care AG, or Bayer, pursuant to which we and Bayer will perform research and discovery activities under a mutually agreed upon research plan during a research term up to a specified number of years per target program to generate radiopharmaceutical compounds incorporating optimized Bicycle constructs directed to two specified targets, under the oversight of a joint research committee. In addition, Bayer has a one-time right to expand the collaboration to include a third target program, and with respect to each of the up to three target programs, Bayer has an option, exercisable within a specified period of time following the effective date of the agreement, to generate, develop and commercialize non-radiopharmaceutical compounds directed to the applicable target, either by itself or in collaboration with us. Bayer also has certain limited target substitution rights, in certain cases subject to specified additional payments. For each collaboration program, Bayer may elect, at its sole discretion, to progress compounds arising from activities under the research programs into further preclinical development of potential products directed to the target of such collaboration program. On a target-by-target basis, if Bayer elects to progress development candidates directed to such target into further clinical development, Bayer will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products directed to the applicable target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Novartis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">On March 27, 2023, we entered into a collaboration and license agreement with Novartis Pharma AG, or Novartis, pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term of up to a specified number of years per target program to generate compounds incorporating optimized&#160;Bicycle&#160;constructs directed to two specified targets, under the oversight of a joint steering committee. We granted Novartis a non-exclusive, worldwide, royalty-free, sublicensable (subject to certain restrictions) license under our intellectual property solely for Novartis to perform its research activities under each collaboration program during the research term. For each collaboration program, Novartis may elect to progress compounds arising from activities under the research programs, or Licensed Compounds, into further preclinical development of potential products directed to the target of such collaboration program. At a specified point, we will grant Novartis an exclusive, royalty-bearing, sublicensable, license under certain of our intellectual property to develop, manufacture, and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">commercialize such Licensed Compound, subject to certain limitations. Novartis may extend the initial research term by one year by electing to make an additional payment. On a target-by-target basis, if Novartis elects to progress development candidates directed to such target into further clinical development, Novartis will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products containing Licensed Compounds directed to the applicable target. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ionis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 9, 2021, we and Ionis entered into a collaboration and license agreement, or the Ionis Collaboration Agreement. Pursuant to the Ionis Collaboration Agreement, we granted to Ionis a worldwide exclusive license under our relevant technology to research, develop, manufacture and commercialize products incorporating Bicycle<i style="font-style:italic;"> </i>peptides directed to the protein coded by the gene TFRC1 (transferrin receptor), or TfR1 Bicycle<span style="white-space:pre-wrap;"> molecules, intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans. Ionis will maintain exclusivity to all available targets unless it fails to achieve specified development diligence milestone deadlines.  If Ionis fails to achieve one or more development diligence milestone deadlines, we have the right to limit exclusivity to certain specific collaboration targets, subject to the payment by Ionis of a low-single-digit million dollar amount per target as specified in the Ionis Collaboration Agreement.  Each party was responsible for optimization of such TfR1 </span>Bicycle molecules and other research and discovery activities related to TfR1 Bicycle molecules, as specified by a research plan which was completed as of December 31, 2024, and thereafter Ionis is responsible for all future research, development, manufacture and commercialization activities. We performed research and discovery activities including a baseline level of effort for a period of three years. We have retained certain rights, including the right to use TfR1 Bicycle molecules for all non-oligonucleotide therapeutic purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Genentech</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 21, 2020, we entered into a Discovery Collaboration and License Agreement with Genentech, or the Genentech Collaboration Agreement. The collaboration is focused on the discovery and development of Bicycle peptides directed to biological targets selected by Genentech and aimed at developing up to four potential development candidates against multiple I-O targets suitable for Genentech to advance into further development and commercialization. The initial discovery and optimization activities are focused on utilizing our phage screening technology to identify product candidates aimed at two I-O targets, or Genentech Collaboration Programs, which may also include additional discovery and optimization of Bicycle molecules as a targeting element for each Genentech Collaboration Program, or each a Targeting Arm. Genentech also had the option to nominate up to two additional I-O targets, or each an Expansion Option, which may also include an additional Targeting Arm for each Expansion Option, as additional Genentech Collaboration Programs. Genentech exercised the Expansion Options in October 2021 and June 2022, respectively. Genentech exercised its right to select a Targeting Arm for one of the initial Genentech Collaboration Programs at the inception of the arrangement and for the first Expansion Option in October 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We also granted Genentech a non-exclusive research license under our intellectual property solely to enable Genentech to perform any activities under the agreement. After we perform the initial discovery and optimization activities in accordance with an agreed research plan and achieve specified criteria, Genentech will have the option to have us perform initial pre-clinical development and optimization activities for each Genentech Collaboration Program, or the LSR Go Option.  Upon completion of such initial pre-clinical development and optimization activities for each Genentech Collaboration Program, Genentech will have the option to obtain an exclusive license to exploit any compound developed under such Genentech Collaboration Program for each of the initial two Genentech Collaboration Programs and each of the two Expansion Option Genentech Collaboration Programs, or the Dev Go Option. Genentech terminated the collaboration activities for one of the initial Genentech Collaboration Programs in June 2023. In January 2024, the joint research committee reached a decision to discontinue research activities associated with the first Expansion Option program and in January 2025, Genentech terminated the collaboration activities for the second Expansion Option program. The remaining Genentech Collaboration Program remains ongoing.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Overview</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including our Bicycle platform. This includes seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties, which are directed to the use of our Bicycle platform, composition of matter of bicyclic peptides identified through use of the platform and further chemical optimization, conjugates comprising such bicyclic peptides, methods of using our product candidates, and other inventions that are important to our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets and know-how that may be important for the development of our business. This includes aspects of our proprietary technology platform and our continuing technological innovation to develop, maintain, and strengthen our position in the field of peptide, peptidomimetic, and small molecule-based therapeutics. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions where available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our product candidates, technology and know-how, defend and enforce our patents; prevent others from infringing our proprietary rights, preserve the confidentiality of our trade secrets, and to operate without infringing the proprietary rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to stop third parties from making, having made, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade secrets that cover these activities. In some cases, these rights may need to be enforced by third-party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary position in a variety of ways, including by pursuing patent protection in certain jurisdictions where it is available. For example, we file&#160;U.S. and certain foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel products. We seek protection, in part, through confidentiality and proprietary information agreements. We are a party to various other license agreements that give us rights to use specific technologies in our research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&#160;years from the earliest date of filing a non-provisional patent application related to the patent. A U.S. patent also may be accorded a patent term adjustment, or PTA, under certain circumstances to compensate for delays in obtaining the patent caused by the United States Patent and Trademark Office, or USPTO. In some instances, such a PTA may result in a U.S. patent term extending beyond 20&#160;years from the earliest date of filing a non-provisional patent application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We own various trademark registrations and applications, and unregistered trademarks, including our name and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. Solely for convenience, the trademarks and trade names in this report may be referred to without the &#174;, &#8482; or &#169; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Company-Owned Intellectual Property</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, our patent portfolio included 10 patent families directed to novel scaffolds, linkers and payloads, 10 patent families directed to our platform technology, 48 patent families directed to bicyclic peptides and related conjugates, and 21 patent families directed to later inventions relating to such bicyclic peptides and related conjugates, such as methods of making or using certain bicyclic peptide conjugates for treating various indications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We own at least 11 patent families relating to our product candidate zelenectide pevedotin, including patent families directed to its composition of matter, methods of use for treating cancer, synthetic routes to zelenectide pevedotin and methods of identifying patients suitable to receive zelenectide pevedotin. The issued patents in these families, and the pending patent applications if issued, are expected to expire between 2039 and 2044, not including any patent term extensions and/or patent term adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We own at least eight patent families relating to our product candidate BT5528, including patent families directed to its composition of matter, methods of use for treating cancer and methods of identifying patients suitable to receive BT5528. The issued patents in these families, and the pending patent applications if issued, are expected to expire between 2038 and 2044, not including any patent term extensions and/or patent term adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We own at least 10 patent families relating to product candidate BT7480, including patent families directed to its composition of matter and the composition of matter of its constituent bicyclic peptides, methods of use for treating cancer, combinations with other active agents, and the methods of identifying patients suitable to receive BT7480. The issued patents from these families, and the pending patent applications, if issued, are expected to expire between 2038 and 2044, not including any patent term extensions and/or patent term adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In total, as of December 31, 2024, we owned about 481 patents in the United States and in foreign jurisdictions, such as Australia, Canada, China, Europe, Hong Kong, Japan, New Zealand, Russia and Singapore. In addition, as of December 31, 2024, we had about 529 patent applications pending in the United States and in foreign jurisdictions, such as Argentina, Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Korea, New Zealand, Russia, Singapore and Taiwan, as well as pending international applications under the Patent Cooperation Treaty, or PCT.  These patents, as well as any patents that may be issued from these patent applications, are generally expected to have terms that will expire at various dates between February 2029 and December&#160;2044, not including any patent term extensions and/or patent term adjustments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In total, as of December 31, 2024, we owned 106 trademark registrations across six territories (United Kingdom, European Union, United States, Japan, Hong Kong and Australia), as well as a number of pending applications for new trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Trade Secret Protection</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Finally, we may rely, in some circumstances, on trade secrets to protect our technology. We anticipate relying on trade secrets to protect the know-how behind our Bicycle platform. However, trade secrets can be difficult to protect. We seek to protect our technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For further information, please see &#8220;Risk Factors&#160;&#8212; Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are a number of currently marketed products and product candidates in preclinical research and clinical development by third parties for the various oncology applications that we are targeting. For example, a number of multinational companies as well as biotechnology companies are developing programs for the targets that we are exploring for our BTC programs, including, but not limited to, Pfizer Inc. (formerly Seagen, acquired by Pfizer Inc. in December 2023) which has a marketed Nectin-4 antibody-drug conjugate, Eli Lilly and Company, Corbus Pharmaceutical Holdings, Inc., Innate Pharma SA and Mabwell Therapeutics, Inc. Furthermore, many companies are developing programs for CD137 or CD137 bi-specific antibodies or antibody fragments as well as radiopharmaceutical therapies. In addition, we are aware that technologies for drug discovery, including peptide-based medicines, continue to advance rapidly, which may compete with our own screening technology or render it obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products. Accordingly, our competitors may be more successful than we may be in discovering product candidates, obtaining approval for drugs and achieving widespread market acceptance. Our competitors&#8217; drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our product candidates. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to receiving marketing approval, we intend to pursue the commercialization of our product candidates either by building internal sales and marketing capabilities or through opportunistic collaborations with others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to build our marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Each of our Bicycle molecules is entirely synthetic. We believe the synthetic nature of our product candidates allows for a more cost effective and scalable manufacturing process compared to biologics. In addition, this property of Bicycle molecules allows for the manufacturing of product candidates of consistent pharmaceutical quality with </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">favorable stability characteristics. Based on our experience, we believe that the manufacturing of Bicycle molecules can be made to be well controlled, reproducible and scalable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate an outsourced model for the manufacture of our product candidates, and contract with multiple good manufacturing practice, or GMP, licensed pharmaceutical contract development and manufacturing organizations, both for the synthesis of each drug substance component, and the formulation and packaging of finished drug product candidates. We selected these organizations based on their experience, capability, capacity and regulatory status. Projects are managed by a specialist team of our internal staff, which is designed to promote compliance with the technical aspects and regulatory requirements of the manufacturing process. We do not own or operate GMP manufacturing facilities, nor do we currently plan to build our own GMP manufacturing capabilities for production of clinical or commercial supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Review and Approval of Drugs in the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs and devices under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities. In addition, an applicant may need to recall a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must take effect before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent IRB representing each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation and submission to the FDA of a new drug application, or NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">review of the product by an FDA advisory committee, where appropriate or if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees and securing FDA approval of the NDA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Human Clinical Trials in Support of an NDA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA can place an IND on full or partial clinical hold at any point in development, and depending upon the scope of the hold, clinical trial(s) may not restart until resolution of the outstanding concerns to the FDA&#8217;s satisfaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct a continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Phase&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">I.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Phase&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">II.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Phase&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">III.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Phase&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">IV.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Post-approval studies may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase&#160;I, Phase&#160;II and Phase&#160;III clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Review of an NDA by the FDA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to substantial user fees, and the sponsor of an approved NDA is also subject to annual program user fees. These fees are typically increased annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of an NDA within 60&#160;days of its receipt and informs the sponsor whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within 10 months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fast Track, Breakthrough Therapy and Priority Review Designations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are Fast Track designation, Breakthrough Therapy designation and priority review designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s NDA before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing an application under rolling review does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that is expected to lead to improvement in serious outcomes, and evidence of safety and effectiveness in a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accelerated Approval Pathway</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit and to provide regular updates to the FDA on the progress of such studies. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;IV or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In October 2022, the FDA announced a two-year opportunity for a limited number of applicants to participate in the CDRP program to facilitate expedited development CMC development of products under an IND, where warranted, based on the anticipated clinical benefit of earlier patient access to the products. The FDA has implemented this pilot program to facilitate CMC readiness for selected Center for Biologics Evaluation and Research, or CBER, and Center for Drug Evaluation and Research, or CDER, regulated products with accelerated clinical development timelines. To accelerate CMC development and facilitate CMC readiness, the pilot features increased communication between the FDA and sponsors and explores the use of science- and risk-based regulatory approaches, such as those described in FDA guidance, as applicable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Project Optimus</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Project Optimus is an initiative of the Oncology Center of Excellence at the FDA.&#160;This project focuses on dose optimization and dose selection in oncology drug development, and whether the current paradigm based on cytotoxic chemotherapeutics leads to doses and schedules of molecularly targeted therapies that provide more toxicity without additional efficacy, among other things.&#160;In Project Optimus, drug developers have the opportunity to meet with the FDA&#8217;s Oncology Review Divisions early in their development programs, well before conducting trials intended for registration, to discuss dose-finding and dose optimization.&#160;The program thus allows sponsors to develop strategies for dose finding and dose optimization that leverages nonclinical and clinical data in dose selection, including randomized evaluations of a range of doses in trials, with the objective of performing these studies as early as possible in the development program to bring new therapies to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Project Frontrunner</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Project Frontrunner is an Oncology Center of Excellence initiative to encourage drug sponsors to consider when it may be appropriate to first develop and seek approval of new cancer drugs for advanced or metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a new drug for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. The goals of Project Frontrunner are to develop a framework for identifying candidate drugs that are appropriate to initially develop for the treatment of early metastatic disease (e.g., first or second line setting), taking into account clinical, scientific, regulatory and operational considerations; facilitate engagement with drug sponsors during drug development to develop and implement strategies to support approvals in early clinical setting; and to engage and collaborate with internal and external stakeholders on related research, policy and educational initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The FDA&#8217;s Decision on an NDA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&#160;IV clinical trials, be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or voluntary product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs generally may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Drug Supply Chain Security Act, which regulates the distribution of drugs at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states, which additionally limit the distribution of prescription pharmaceutical products and impose requirements to ensure accountability in distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Companion Diagnostics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may employ companion diagnostics to help us to more accurately identify patients within a particular subset, both during our clinical trials and in connection with the commercialization of our product candidates that we are developing or may in the future develop. Companion diagnostics can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA and, as such, require either clearance or approval prior to commercialization. The level of risk combined with available controls to mitigate risk determines whether a companion diagnostic device requires Premarket Approval Application, or PMA, approval or is cleared through the 510(k) premarket notification process. For a novel therapeutic product for which a companion diagnostic device is essential for the safe and effective use of the product, the companion diagnostic device should be developed and approved or 510(k)-cleared contemporaneously with the therapeutic. The use of the companion diagnostic device will be stipulated in the labeling of the therapeutic product.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Abbreviated New Drug Applications for Generic Drugs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&#160;IV certification, which states the proposed generic drug will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following the original product approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hatch-Waxman Patent Certification and the 30-Month Stay</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. An applicant who submits a section&#160;505(b)(2) NDA, which is for new or improved formulations or new uses of previously approved drug products and where at least one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted, also must certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Specifically, the applicant must certify with respect to each patent that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required patent information has not been filed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has expired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph&#160;IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the ANDA applicant is not seeking approval).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the ANDA applicant has provided a Paragraph&#160;IV certification to the FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days after the receipt of a Paragraph&#160;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months after the receipt of the Paragraph&#160;IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Designation and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Studies and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Term Restoration and Extension</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&#160;years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">European Union/Rest of World Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, there are a variety of regulations in other jurisdictions governing, among other things, clinical trials, commercial sales and distribution of medicinal products. Even if FDA approval of a particular product is obtained, it must still obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the European Union, or EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20, or CTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal", the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. For clinical trials in relation to which an application for approval was made on the basis of the CTD before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. All ongoing trials are now subject to the provisions of the CTR. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>cases,<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.05pt;"> </span>must<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>conducted<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>accordance<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>GCP<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>requirements and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>ethical<span style="letter-spacing:0.1pt;"> </span>principles<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>origin<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>Declaration<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Helsinki.<span style="letter-spacing:0.05pt;"> </span>Medicines<span style="letter-spacing:0.1pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="color:#ff0000;"> </span>must be manufactured<span style="letter-spacing:0.1pt;"> </span>in accordance<span style="letter-spacing:0.1pt;"> </span>with the guidelines<span style="letter-spacing:0.1pt;"> </span>on cGMP and in a GMP licensed facility,<span style="letter-spacing:0.1pt;"> </span>which can be subject<span style="letter-spacing:0.05pt;"> </span>to GMP inspections. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">EU Review and Approval Process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EU, medicinal products can only be commercialized after a related marketing authorization, or MA, has been granted. To obtain an MA for a product in the EU, an applicant must submit a Marketing Authorization Application, or MAA, either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by the competent authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The centralized procedure provides for the grant of a single MA by the European Commission that is valid throughout the EEA (which is comprised of the 27 EU Member States plus Norway, Iceland and Liechtenstein). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs, and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. The maximum timeframe for the evaluation of an MAA under the centralized procedure is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five-year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfils an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the MA will cease to be renewed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><span style="color:#231f20;font-style:italic;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><i style="color:#231f20;font-style:italic;">Pediatric</i><i style="color:#231f20;font-style:italic;letter-spacing:0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Development in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Regulation</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">(EC) No 1901/2006</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">provides</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">all</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MAAs for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">new medicinal</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">have</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">include the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">results</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">conducted</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">population,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">compliance</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">investigation</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">plan,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or PIP, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">agreed with the EMA&#8217;s Pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Committee,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or PDCO.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">The PIP sets out the timing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">proposed to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generate</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">support</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">indication</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">being</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sought.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">The PDCO</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">can</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">grant</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">deferral</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obligation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">implement</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">some</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">all</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">provided</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">PIP</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">until there</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sufficient</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">demonstrate</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">efficacy</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adults.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Further,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obligation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to provide</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trial</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">can</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">waived</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">PDCO</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">when</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">these</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">needed</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">appropriate</span> <span style="color:#231f20;">because</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">likely</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ineffective</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">unsafe</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">children,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">disease</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">condition</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">intended</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">occurs</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">only</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adult</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">populations,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">when</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">does</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">represent</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">significant</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">therapeutic benefit</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">over</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">existing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">treatments</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">patients.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Once</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obtained</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">all</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">States</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and study</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">results</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">included</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">information,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">even</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">when</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">negative,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eligible</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">six-month extension</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Supplementary</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Protection</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Certificate,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">SPC,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">if</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">any</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">effect</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">at</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">time</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">authorization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or, in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">case</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">orphan</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">two-year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">extension</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">orphan</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Manufacturing Regulation in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">In addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products in the EU requires a manufacturing authorization and import of medicinal products into the EU requires a manufacturing authorization allowing for import.  The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of EU Member States. Marketing authorization holders and/or manufacturing and import authorization, or MA holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><i style="color:#231f20;font-style:italic;">Data and Market</i><i style="color:#231f20;font-style:italic;letter-spacing:0.05pt;"> </i><i style="color:#231f20;font-style:italic;">Exclusivity in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 15.6pt 0pt 0pt;"><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">provides</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">opportunities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">market</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">related</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MAs.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Upon receiving</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA, innovative</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generally</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">entitled</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">receive</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eight</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">10</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">exclusivity.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Data exclusivity,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">if</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">granted,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">prevents</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">referencing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the innovator&#8217;s</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">assess</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generic</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">application</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">biosimilar</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">application</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eight</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">date</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of authorization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of the innovative</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product, after</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">which a generic</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or biosimilar</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">MAA can be submitted,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and the innovator&#8217;s</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be referenced.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">The market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">period</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">prevents</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">a successful</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">generic</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or biosimilar applicant</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">commercializing</span><span style="color:#231f20;letter-spacing:0.2pt;"> </span><span style="color:#231f20;">its</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">until</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">10 years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">have</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">elapsed</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">initial</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">overall</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ten-year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">period</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">occasionally,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">extended</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">further</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a maximum</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">11</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">if,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">during</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">first</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eight</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">those</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">10</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA holder</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obtains</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">authorization for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">one</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">more</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">new</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">therapeutic</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">indications</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">which,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">during</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">scientific</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">evaluation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">prior</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">their</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">authorization, are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">held</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">bring</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">significant</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">benefit</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">comparison</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">existing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">therapies.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">However,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">there</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">no guarantee</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">that a product will be considered</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">by the EU&#8217;s regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">to be a new chemical/biological entity,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">qualify</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">there</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">special</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regime</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">biosimilars,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">biological</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">similar</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span> <span style="color:#231f20;">reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">but that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">do not meet</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">definition</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of a generic</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">For such products, the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">results</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">appropriate</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">preclinical</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">must</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">provided</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">support</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">application</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA. Guidelines</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EMA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">detail</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">type</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">quantity</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">supplementary</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">provided</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">different</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">types</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of biological</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Orphan Designation in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In the EU, Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a medicinal product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (i) the product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii) either (a) such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or (b)  the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii) there exists no </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Regulation (EC) No 847/2000 sets out further provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product. An application for the designation of a medicinal product as an orphan medicinal product must be submitted at any stage of development of the medicinal product but before filing of an MAA. An MA for an orphan medicinal product may only include indications designated as orphan. For non-orphan indications treated with the same active pharmaceutical ingredient, a separate marketing authorization has to be sought.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Orphan medicinal product designation entitles an applicant to incentives such as fee reductions or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of 10 years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The period of market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product designation, including where it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, an MA may be granted to a similar medicinal product with the same orphan indication during the 10 year period if: (i) if the applicant consents to a second original orphan medicinal product application; (ii) if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities; or (iii) if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><span style="color:#231f20;font-style:italic;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><i style="color:#231f20;font-style:italic;">Post-Approval</i><i style="color:#231f20;font-style:italic;letter-spacing:0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Requirements in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.15pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 5.15pt 0pt 0pt;"><span style="color:#231f20;">Where</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">granted</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">relation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">holder</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">required</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">comply with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">range</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">applicable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">manufacturing,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">marketing,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sale</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Similar</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">United</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">States,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">both</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">holders</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">manufacturers</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are subject</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">comprehensive</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">oversight</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EMA,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">European</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Commission</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and/or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">competent regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">individual</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">States.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">The holder</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of an MA must</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">establish</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and maintain</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">a pharmacovigilance</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">system</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and appoint an individual</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">qualified</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">person for pharmacovigilance</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">who is responsible for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">oversight</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">system.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Key</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obligations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">include</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">expedited</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reporting</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">suspected</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">serious</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adverse</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reactions and submission</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of periodic</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">update</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reports,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or PSURs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 2.35pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 2.35pt 0pt 0pt;"><span style="color:#231f20;">All</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">new MAAs must</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">include</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">risk</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">management</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">plan,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">RMP, describing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">risk</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">management</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">system</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the company</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">will</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">put</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">place</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">documenting</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">prevent</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">minimize</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">risks</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">associated</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the product.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">The regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">also</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">impose</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">specific</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">obligations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">as a condition</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA. Such risk- minimization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or post-authorization</span><span style="color:#231f20;letter-spacing:0.2pt;"> </span><span style="color:#231f20;">obligations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">include</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">additional</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">monitoring,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">more</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">frequent submission</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">PSURs,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">conduct</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">additional</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">post-authorization</span><span style="color:#231f20;letter-spacing:0.2pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 2.4pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">EU,</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">advertising</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:-1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">subject</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">both</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;">States&#8217;</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">laws governing</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">products,</span><span style="color:#231f20;letter-spacing:-0.85pt;"> </span><span style="color:#231f20;">interactions</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">physicians</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">other</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">healthcare</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span><span style="color:#231f20;">professionals, </span><span style="color:#231f20;">misleading</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">comparative</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">advertising</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">unfair</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">commercial</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">practices.</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span>General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, which may require </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 2.4pt 0pt 0pt;">approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Regulation of Companion Diagnostics in the EU </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EEA, companion diagnostics are deemed to be <i style="font-style:italic;">in vitro</i> diagnostic medical devices, or IVDs, and are governed by Regulation 2017/746, or IVDR, which entered into application on May 26, 2022, repealing and replacing Directive 98/79/EC. The IVDR defines a companion diagnostic as a device which is essential for the safe and effective use of a corresponding medicinal product to: (a) identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or (b) identify, before and/or during treatment, patients likely to be at increased risk of serious adverse reactions as a result of treatment with the corresponding medicinal product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The IVDR and its associated guidance documents and harmonized standards govern, among other things, device design and development, preclinical and clinical or performance testing, premarket conformity assessment, registration and listing, manufacturing, labeling, storage, claims, sales and distribution, export and import and post-market surveillance, vigilance, and market surveillance. IVDs, including companion diagnostics, must conform with the general safety and performance requirements, or GSPR, of the IVDR. Compliance with these requirements is a prerequisite to be able to affix the CE mark to devices, without which they cannot be marketed or sold in the EEA. To demonstrate compliance with the GSPR laid down in Annex I to the IVDR, and obtain the right to affix the CE mark, IVD manufacturers must conduct a conformity assessment procedure, which varies according to the type of IVD and its classification. Apart from low risk IVDs (Class A which are not sterile), in relation to which the manufacturer may issue an EU Declaration of Conformity based on a self-assessment of the conformity of its products with the GSPRs, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization designated by a Competent Authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body audits and examines the technical documentation and the quality system for the manufacture, design and final inspection of the medical devices. The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the GSPRs. This Certificate and the related conformity assessment process entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Companion diagnostics must undergo a conformity assessment by a Notified Body. If the related medicinal product has, or is in the process of, been authorised through the centralized procedure for the authorization of medicinal products, the notified body will, before it can issue a CE Certificate of Conformity, be required to seek a scientific opinion from the EMA on the suitability of the companion diagnostic for use in relation to the medicinal product concerned. For medicinal products that have or are in the process of authorisation through any other route provided in EU legislation, the Notified Body must seek the opinion of the national competent authority of an EU Member State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In order to secure coverage and reimbursement for any product approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. Additionally, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Our results of operations could be adversely affected by the Affordable Care Act, the Inflation Reduction Act of 2022, or IRA, and by other healthcare legislative reforms that may be enacted or adopted in the future, particularly in light of the recent U.S. Presidential and Congressional elections. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we may develop companion diagnostic tests for use with our product candidates. Companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical products, will apply to companion diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, ensuring adequate coverage and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of our product candidates or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. The European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. In addition, some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment, or HTA, process is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Healthcare Laws and Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted regulatory approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Such restrictions under applicable federal and state healthcare laws and regulations, include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, health information privacy and security, price reporting and physician sunshine laws. Some of our pre-commercial activities are subject to some of these laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Health Care Program Anti-Kickback Statute, or Anti-Kickback Statute, prohibits any person or entity, including a prescription drug manufacturer or a party acting on its behalf, from, among other things, knowingly and willfully, directly or indirectly, soliciting, receiving, offering, or providing any remuneration that is intended to induce the referral of business, including the purchase, order or recommendation or arranging of, any good or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed. Persons and entities can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, any of our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and other third-party payor reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. Penalties for federal civil False Claims Act violations may include up to three times the actual damages sustained by the government, plus significant mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, False Claims Act violations may also implicate various federal criminal statutes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to the extent that any of our product candidates, if approved, are sold in a foreign country, we may be subject to similar foreign laws.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, including the final omnibus rule published on January&#160;25, 2013, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as independent contractors or agents of certain healthcare providers, healthcare clearinghouses and health plans, known as covered entities, that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity or another business associate, and their covered subcontractors. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain state and foreign laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For further information concerning the data privacy and security laws we may be subject to and our processing of personal data, see the risk factor titled &#8220;<i style="font-style:italic;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our (and third parties&#8217; with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse business consequences.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, ACA, including the provision commonly referred to as the Physician Payments Sunshine Act imposed, among other things, annual reporting requirements for covered manufacturers for certain payments and other transfers of value provided to physicians, as defined by such law, other healthcare professionals (such as physician assistant and nurse practitioners), and teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family members. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may be subject to certain analogous state and foreign laws of each of the above federal healthcare laws. In some instances, such laws may be broader in scope than its federal counterpart, such as certain state anti-kickback and false claims laws, which may apply to claims involving healthcare items or services reimbursed by&#160;non-governmental&#160;third-party payors, including private insurers. In addition, certain states and local jurisdictions also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices or require the tracking and reporting of gifts, compensation or other remuneration to physicians and other healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we intend to commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs, we intend to develop a comprehensive compliance program that establishes internal control to facilitate adherence to the rules and program requirements to which we will or may become subject. Although the development and implementation of compliance programs designed to establish internal control and facilitate compliance can mitigate the risk of investigation, prosecution, and penalties assessed for violations of these laws, the risks cannot be entirely eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, including Medicare and Medicaid, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Healthcare Reform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, government control and other changes to the healthcare system in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">By way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. The ACA, which was signed into law in 2010, is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been judicial, executive branch and Congressional challenges and amendments to certain aspects of the ACA. For example, on August 16, 2022, President Biden signed the IRA into law which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is unclear how any additional healthcare reform measures of the new Trump administration or future legal challenges will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year that became effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA and the Infrastructure Investment and Jobs Act, will stay in effect through 2032 unless additional Congressional action is taken. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the IRA will, among other things, (i) allow HHS to negotiate the price of certain drugs and biologics covered that have been on the market for at least seven years under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) impose rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively starting in 2023. On August 15, 2024, HHS announced the agreed-upon prices of the first 10 drugs that were subject to price negotiations, which take effect in January 2026. HHS will select up to 15 additional products covered under Part D for negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare drug price negotiation program. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in December 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA Regulation, was adopted in the EU. The HTA Regulation is intended to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The HTA Regulation has applied from January 12, 2025 although it will enter into force iteratively and initially apply to new active substances to treat cancer and to all advanced therapy medicinal products, or ATMPs, it will then be expanded to orphan medicinal products in January 2028, and to all centrally authorized medicinal products as of 2030. Selected high-risk medical devices will also be assessed under the HTA Regulation as of 2026. The HTA Regulation is intended to harmonize the clinical benefit assessment of HTA across the EU. Pricing and reimbursement decisions, based on these assessments, remain the responsibility of individual Member States.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Brexit and the Regulatory Framework in the United Kingdom</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">As a result of the United Kingdom&#8217;s,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or U.K., withdrawal</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the EU on January 31, 2020 (commonly</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">referred</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to as Brexit), the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Medicines and Healthcare</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Regulatory</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Agency, or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MHRA,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">now the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.&#8217;s standalone</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulator for medicinal products and medical devices.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">The U.K.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> no longer subject to EU regulations (Northern Ireland continues to follow certain limited EU regulatory rules, including in relation to medical devices, but not in relation to medicinal products)</span><span style="color:#231f20;">.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.25pt 0pt 0pt;"><span style="color:#231f20;letter-spacing:0.05pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The U.K. regulatory framework in relation to clinical trials is governed by the <span style="color:#040c28;">Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is </span>derived from the CTD, as implemented into U.K. national law through secondary legislation. <span style="letter-spacing:-0.25pt;">On </span>January 17, 2022, the MHRA<span style="letter-spacing:-0.25pt;"> </span>launched<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>eight-week<span style="letter-spacing:-0.2pt;"> </span>consultation<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>reframing<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>U.K.<span style="letter-spacing:-0.2pt;"> </span>legislation<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>U.K. government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation, and such changes were laid before Parliament on December 12, 2024. These resulting legislative amendments will, if implemented in their current form, bring the U.K. regulations into closer alignment with the EU CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">Marketing authorizations in the U.K. are governed by the </span><span style="color:#333333;">Human Medicines Regulations (SI 2012/1916), as amended. </span><span style="color:#231f20;">Since January 1, 2021, an applicant</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for the EU centralized</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">procedure</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">marketing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorization</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">can no longer</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be established</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> As a result, s</span><span style="color:#231f20;">ince</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">this</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">date,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">companies established</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">cannot</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">use</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> EU </span><span style="color:#231f20;">centralized</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">procedure. In order to obtain an MA to commercialize products in the U.K., an applicant must be established in the remaining post-Brexit international cooperation procedures. Applications are governed by the Human Medicines Regulations (SI 2012/1916) and are made electronically through the MHRA Submissions Portal. The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, a 150-day assessment (subject to clock-stops) and a rolling review procedure. The rolling-review procedure permits the separate or joint submission of quality, non-clinical, and clinical data to the MHRA which can be reviewed on a rolling basis. After an application under rolling-review procedure has been validated, the decision should be received within 100 days (subject to clock-stops).</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;letter-spacing:-0.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;letter-spacing:-0.05pt;">In addition, since January 1, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of MAAs. Pursuant to the IRP, the MHRA will take into account the expertise and decision-making of trusted regulatory partners (e.g., the regulatory in Australia, Canada, Switzerland, Singapore, Japan, the U.S. and the EU). The MHRA will conduct a targeted assessment of IRP applications but retain the authority to reject applications if the evidence provided is considered insufficiently robust. The IRP allows medicinal products approved by such trusted regulatory partners that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the U.K.&#160;Applications should be decided within a maximum of 60 days if there are no major objections identified that cannot be resolved within such 60 day period and the approval from the trusted regulatory partner selected has been granted within the previous 2 years or if there are such major objections identified or such approval hasn&#8217;t been granted within the previous 2 years within 110 days. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;letter-spacing:-0.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;letter-spacing:-0.05pt;">A</span>ll existing EU marketing authorizations for centrally authorized products were automatically converted<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>grandfathered<span style="letter-spacing:-0.4pt;"> </span>into<span style="letter-spacing:-0.4pt;"> </span>U.K.<span style="letter-spacing:-0.4pt;"> </span>marketing authorization, effective<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>Great Britain<span style="letter-spacing:-0.4pt;"> </span>only,<span style="letter-spacing:-0.4pt;"> </span>free<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.4pt;"> </span>charge<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:-0.4pt;"> </span>January 1,<span style="letter-spacing:-0.4pt;"> </span>2021,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.2pt;">unless </span>the marketing authorization holder opted-out of this possibility. Northern Ireland remained within the scope of EU authorizations in relation to centrally authorized medicinal products until January 1, 2025. On January 1, 2025, a new arrangement as part of the so-called &#8220;<span style="color:#0b0c0c;background:#ffffff;">Windsor Framework&#8221; came into effect and reintegrated in Northern Ireland under </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0b0c0c;background:#ffffff;">the regulatory authority of the MHRA with respect to medicinal products. Pursuant to the Windsor Framework holders of Great Britain marketing authorizations converted into U.K. marketing authorizations on January 1, 2025 unless the entities holding such marketing authorizations also held a Northern Ireland marketing authorization that they failed to cancel before December 31, 2024. The Windsor Framework removes EU licensing processes and EU labelling and serialization requirements in relation to Northern Ireland and introduces a U.K.-wide licensing process for medicines.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no pre-marketing authorization orphan designation for medicinal products in the U.K. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU, but have been tailored for the market. This includes the criterion that prevalence of the condition in the U.K., rather than the EU, must not be more than five in 10,000. Upon the grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication. The start of this market exclusivity period will be set from the date of first approval of the product in the U.K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we had 305 full-time or part-time employees, including 113 with M.D. or Ph.D. degrees. Of these employees, 235 employees are engaged in research and development activities and 70 employees are engaged in general and administrative activities. Our employees are primarily based at the locations of our office and laboratory facilities: 188 are located in the United Kingdom and 117 are located in the United States. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider the relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, developing, retaining, incentivizing and integrating our existing and additional employees to support the continued growth of our company and progress the development of our product candidates. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Compensation and Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe our employees are our most valuable assets and are key to achieving our goals. We focus our efforts on attracting and retaining a diverse, high-performing workforce through offering competitive and fair compensation packages that are based on robust industry market data. Our total compensation package includes competitive base pay, annual bonus, equity participation, and a broad range of benefits, including retirement planning, healthcare and insurance benefits, paid time off, enhanced paid family and medical leave, flexible working, and various health and wellness programs. We also run recognition programs that highlight employees who exhibit exceptional performance and demonstrate our company values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We ensure that our compensation programs are designed to be equitable and fair, and routinely analyze data to ensure that our programs are administered in a fair and equitable way.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Diversity, Equity and Inclusion (DEI)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe a diverse workforce is critical to our success and we are fundamentally committed to creating and maintaining a work environment in which employees are treated fairly, with dignity, decency, respect and in accordance with all applicable laws. We understand that varied perspectives lead to the best ideas and outcomes. We believe that by creating a workplace where every individual can feel welcome and valued, we will be better able to achieve our corporate objectives. All employees must adhere to a code of business conduct and ethics and our employee handbook, which combined, define standards for appropriate behavior and all employees are annually trained to help prevent, identify, report, and stop any type of discrimination and harassment. Our processes in recruitment, hiring, development, training, compensation, and advancement are based on qualifications, performance, skills, and experience without regard to gender, race, or ethnicity. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have formed a cross-functional DEI employee network that continues to work with human resources and our leadership to develop the DEI strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Career Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We invest heavily in our employees&#8217; personal and professional development. We offer a vast array of learning and development opportunities including online and classroom training and learning, technical training, mentoring and coaching programs, training academies and management and leadership development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We are committed to developing the next generation of talent and have active internship partnerships with local universities in both the United States and United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2009, we were incorporated as a limited liability company under the laws of England and Wales. In 2017, we effected a reorganization to create a new holding company which, in connection with our IPO, was re-registered as a public limited company named Bicycle Therapeutics&#160;plc. Bicycle Therapeutics&#160;plc is the parent company of three wholly owned subsidiaries, two of which are based in Cambridge, United Kingdom and one of which is based in Massachusetts, United States, that carry on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.K. subsidiaries are BicycleTx Limited and BicycleRD Limited, and the U.S. subsidiary is Bicycle Therapeutics&#160;Inc. Our principal executive offices are located at Blocks A &amp; B, Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, United Kingdom, and our phone number is +44 1223 261503.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our website address is http://www.bicycletherapeutics.com. We make available on our website, free of charge, our Annual Reports on Form&#160;10-K, our Quarterly Reports on Form&#160;10-Q and our Current Reports on Form&#160;8-K and any amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains a website that contains reports, proxy and information statements and other&#160;information regarding our filings at www.sec.gov. The information found on our website is not incorporated by reference into this Annual Report or any other report we file with or furnish to the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fe1b5251_786d_45b7_a6be_2f7243b574a9"></a><a id="Item1ARiskFactors__090955"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1A.</b></span><b style="font-weight:bold;">Risk Factors</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">Our operations and financial results are subject to various risks and uncertainties, including those described below.  The following information about these risks and uncertainties, together with the other information appearing elsewhere in this Annual Report on Form&#160;10-K, or this Annual Report, including our consolidated financial statements and related notes thereto, should be carefully considered before a decision to invest in our American Depositary Shares, or ADSs. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. Additional risks that are currently unknown to us or that we currently believe to be immaterial may also impair our business. In these circumstances, the market price of our ADSs could decline and holders of our ADSs may lose all or part of their investment. We cannot provide assurance that any of the events discussed below will not occur.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.15;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Summary of Selected Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Our business is subject to numerous risks and uncertainties, of which you should be aware before making a decision to invest in our ADSs. These risks and uncertainties include, among others, the following:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital may cause dilution to our existing shareholders or holders of our ADSs, restrict our operations or cause us to relinquish valuable rights.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are substantially dependent on the success of our internal development programs and of our product candidates from our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicycle</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Toxin Conjugate, or BTC</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and Bicycle Tumor-Targeted Immune Cell Agonist</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, or Bicycle</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TICA</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, programs, which may not successfully complete clinical trials, receive regulatory approval or be successfully commercialized.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are at an early stage in our development efforts, and our product candidates and those of our collaborators represent a new category of medicines and may be subject to heightened regulatory scrutiny until they are established as a therapeutic modality.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs, or IND, that could halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be delayed or not be successful in our efforts to identify or discover additional product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may expend our limited resources to pursue a particular development strategy, product candidate or indication and fail to capitalize on strategies, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">We may seek designations for our product candidates with the U.S. Food and Drug Administration, or FDA, and other comparable regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway, but there can be no assurance that we will successfully obtain such designations.  In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time consuming and uncertain and may prevent us or any collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any collaborators, will obtain marketing approval to commercialize a product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for any current or future product candidate we develop, if and when approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products, if approved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, payors and others in the medical community.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, could limit our ability to market those products and decrease our ability to generate revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our (and third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse business consequences.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties, including independent clinical investigators and clinical research organizations, or CROs, to conduct and sponsor some of the clinical trials of our product candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval for our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We intend to rely on third parties to manufacture product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent and other intellectual property protection for our products and product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products and product candidates may be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of our ADSs is highly volatile, and holders of our ADSs may not be able to resell their ADSs at or above the price at which they purchased their ADSs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As a company based outside of the United States, we are subject to economic, political, regulatory and other risks associated with international operations.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and we may never achieve or maintain profitability</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We do not expect to generate revenue or profitability that is necessary to finance our operations in the short term. Since inception, we have incurred recurring losses, including net losses of $169.0 million, $180.7 million and $112.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, we had an accumulated deficit of $680.8 million. To date, we have not commercialized any products or generated any revenues from the sale of products, and absent the realization of sufficient revenues from product sales, we may never attain profitability in the future.  We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials.  Our net losses may fluctuate significantly from quarter to quarter and year to year. </span><span style="background:#ffffff;">Net losses and negative cash flows have had, and will continue to have, an adverse effect on our shareholders&#8217; equity and working capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We anticipate that our expenses will increase substantially if and as we:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to develop and conduct clinical trials with respect to our BTC and Bicycle</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"> </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TICA</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">programs and our other pipeline programs, including for the ongoing Phase II/III Duravelo-2 registrational trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and continue research, preclinical and clinical development efforts for any future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to discover and develop additional product candidates and further expand our clinical product pipeline;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek marketing and regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our research and development infrastructure, including hiring and retaining additional personnel, such as clinical, quality control and scientific personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize products for which we obtain marketing approval, if any;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization and help us comply with our obligations as a public company; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add equipment and physical infrastructure to support our research and development.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Our ability to become and remain profitable depends on our ability to generate revenue. Generating product revenue will depend on our or any of our collaborators&#8217; ability to obtain marketing approval for, and successfully commercialize, one or more of our product candidates. Successful commercialization will require achievement of key milestones, including completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of revenues, and if or when we might achieve profitability. We </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">and any collaborators may never succeed in these activities and, even if we do, or any collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Our revenue to date has been primarily generated from our research collaborations with Bayer Consumer Care AG, or Bayer, Novartis Pharma AG, or Novartis, Ionis Pharmaceuticals, Inc., or Ionis, and Genentech Inc., or Genentech.  There can be no assurance that we will generate revenue from our collaborations in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Our failure to become and remain profitable would depress the market price of our ADSs and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.  If we continue to suffer losses, investors may not receive any return on their investment and may lose their entire investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our limited operating history may make it difficult for holders of our ADSs or ordinary shares to evaluate the success of our business to date and to assess our future viability</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Our business commenced operations in 2009. Our operations to date have been limited to financing and staffing our company, developing our technology, conducting preclinical research and early-stage clinical trials for our product candidates and pursuing strategic collaborations to advance our product candidates. We have not yet demonstrated an ability to successfully conduct late-stage clinical trials, obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, any current or prospective holder of our ADSs or ordinary shares should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development, especially clinical-stage pharmaceutical companies such as ours. Any predictions made about our future success or viability may not be as accurate as they would be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control and reliance should not be made upon the results of any quarterly or annual periods as indications of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may need substantial additional funding</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and if we are unable to raise capital when needed</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we could be forced to delay</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">reduce or eliminate our product discovery and development programs or commercialization efforts</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate new clinical trials of, initiate new research and preclinical development efforts for and seek marketing approval for, our current product candidates or any future product candidates. In addition, if we obtain marketing approval for any of our product candidates, we may incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a collaborator. Furthermore, we expect to incur significant ongoing costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We will be required to expend significant funds in order to advance the development of the product candidates in our pipeline, as well as other product candidates we may seek to develop. In addition, while we may seek one or more collaborators for future development of our product candidates, we may not be able to enter into a collaboration for any of our product candidates for such indications on suitable terms, on a timely basis or at all. In any event, our existing cash will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">any of our product candidates. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_2_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe that our existing cash and cash equivalents of $879.5 million as of December 31, 2024, will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing of this Annual Report. Our estimate may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, our current and future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into, and the terms and timing of, any collaborations, licensing or other arrangements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify one or more future product candidates for our pipeline;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and costs of seeking regulatory approvals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to receipt of marketing approval, revenue, if any, received from commercial sales of our current and future product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights including enforcing and defending intellectual property related claims; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>While the long-term economic impact of public health crises or geographical tensions and wars, such as the ongoing wars involving Ukraine and Israel, is difficult to assess or predict, these events have caused or may cause significant disruptions to the global financial markets and have contributed or may contribute to a general global economic slowdown. Furthermore, inflation rates, particularly in the United States and the United Kingdom, have increased recently to levels not seen in decades. Increased inflation may result in increased operating costs (including labor costs) and may affect our operating budgets. In addition, the U.S. Federal Reserve has raised, and may further raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets and the global banking system, may further increase economic uncertainty and heighten these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing shareholders or holders of our ADSs</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">restrict our operations or cause us to relinquish valuable rights</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, licensing arrangements or monetization transactions. To the extent that we raise </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">additional capital through the sale of equity, convertible debt securities or other equity-based derivative securities, the ownership interest of existing holders of our ADSs or ordinary shares will be diluted and the terms may include liquidation or other preferences that adversely affect existing holders&#8217; rights. Any indebtedness we incur would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline and existing shareholders may not agree with our financing plans or the terms of such financings. If we raise additional funds through strategic partnerships and alliances, licensing arrangements or monetization transactions with third parties, we may have to relinquish valuable rights to our technologies, or our product candidates, or grant licenses on terms unfavorable to us. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to the Discovery</b>, <b style="font-weight:bold;">Development and Regulatory Approval of Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are substantially dependent on the success of our internal development programs and of our product candidates from our BTC and Bicycle TICA programs, which may not successfully complete clinical trials</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">receive regulatory approval or be successfully commercialized</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our future success will depend heavily on the success of our internal development programs and of product candidates from our BTC and Bicycle TICA programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Within our BTC programs, we are evaluating zelenectide pevedotin, formerly BT8009, a BTC molecule that targets Nectin-4 and carries a monomethyl auristatin E, or MMAE, cytotoxin payload, in both an ongoing company-sponsored Phase I/II clinical trial to assess safety, pharmacokinetics and preliminary clinical activity in patients with Nectin-4 expressing advanced malignancies and an ongoing Phase II/III registrational trial called Duravelo-2, and BT5528, a BTC molecule that targets Ephrin type-A receptor 2, or EphA2 and carries a MMAE cytotoxin payload, in an ongoing, company-sponsored Phase I/II clinical trial to assess safety, pharmacokinetics and preliminary clinical activity in patients with advanced malignancies associated with EphA2 expression. We are also evaluating BT7480, a Bicycle<i style="font-style:italic;">&#160;</i>TICA molecule targeting Nectin-4 and agonizing CD137, in a company-sponsored Phase I/II clinical trial to assess the safety and tolerability of BT7480, and to determine a recommended Phase II dose. There can be no assurance our BTC molecules or Bicycle TICA molecules will ever demonstrate evidence of safety or effectiveness for any use or receive regulatory approval in the United States, the European Union, or any other country in any indication. Even if clinical trials show positive results, there can be no assurance that the FDA in the United States, or the European Commission, whose decision is based on an opinion from the European Medicines Agency, or EMA, in Europe or similar regulatory authorities will approve our BTC molecules or any of our other product candidates for any given indication for several potential reasons, including the failure to follow Good Clinical Practice, or GCP, a negative assessment of the risks and benefits, insufficient product quality control and standardization, failure to have Good Manufacturing Practices, or GMP, compliant manufacturing facilities, or the failure to agree with regulatory authorities on clinical endpoints<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our ability to successfully commercialize our BTC molecules,<i style="font-style:italic;"> </i>Bicycle TICA molecules, and our other product candidates, including our BRC molecules, will depend on, among other things, our ability to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully complete preclinical studies and clinical trials, which may be delayed;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receive regulatory approvals from the FDA, the European Commission based on an opinion from the EMA and other similar regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish and maintain collaborations with third parties for the development and/or commercialization of our product candidates, or otherwise build and maintain strong development, sales, distribution and </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing capabilities that are sufficient to develop products and launch commercial sales of any approved products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain coverage and adequate reimbursement from payors such as government health care systems and insurance companies and achieve commercially attractive levels of pricing;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">secure acceptance of our product candidates from physicians, health care payors, patients and the medical community;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">produce, through a validated process, in manufacturing facilities inspected and approved by regulatory authorities, including the FDA, sufficiently large quantities of our product candidates to permit successful commercialization;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manage our spending as expenses increase due to clinical trials and commercialization; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and enforce sufficient intellectual property rights for any approved products and product candidates and maintain freedom to operate for such products with respect to the intellectual property rights of third parties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Of the large number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a new drug application, or NDA, to the FDA or comparable foreign applications to competent regulatory authorities abroad, and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market our product candidates, any such approval may be subject to limitations on the indicated uses or patient populations for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we cannot provide assurance that our product candidates will be successfully developed or commercialized.  If we are unable to develop, or obtain regulatory approval for, or, if approved, to successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">addition,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">policies</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">FDA,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">competent</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">States,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EMA,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">European Commission</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and other</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">comparable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">responsible</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">change</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and additional government</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regulations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">enacted.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">For</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">instance,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">landscape</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">related</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU recently</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">evolved. The EU Clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Trials</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Regulation,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or CTR, which was adopted in April 2014 and repeals</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the EU Clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Trials</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Directive,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">became</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">applicable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">on January 31, 2022. The CTR allows sponsors</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to make a single submission</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">both</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">competent</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authority</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ethics</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">committee</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">each</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">State,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">leading</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a single</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">decision</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">each</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">State.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">The assessment</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">procedure</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">authorization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of clinical</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">has been harmonized</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">as well, including</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a joint assessment</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">by all EU Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">States concerned,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and a separate assessment</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">by each EU Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">State with respect</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to specific</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">related</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to its own territory,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">including ethics</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">rules.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Each</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">State&#8217;s</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">decision</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">communicated</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sponsor</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">via</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">centralized</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">portal. Once the clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trial</span><span style="color:#231f20;letter-spacing:0.1pt;"> is </span><span style="color:#231f20;">approved, clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">study development</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may proceed. The CTR</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">foresees</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">a three-year transition</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">period. The extent to which ongoing and new clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">will be governed by the CTR</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">varies.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">For clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">relation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">application</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">approval</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">was</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">made</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">basis</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Trials</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Directive before</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">January 31, 2023, the Clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Trials</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Directive</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">continued</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to apply on a transitional</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">basis until</span> January 31, 2025<span style="color:#231f20;">, by which date,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">all</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ongoing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">trials under the Clinical Trials Directive became</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">subject</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">provisions</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the CTR and all new trials since January 31, 2023 have been subject to the CTR.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Compliance</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">with the CTR</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">by us and our third-party</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">service</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">providers,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">such as CROs,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">may impact</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">our developments</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">plans. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation. The proposed revisions remain to be agreed and adopted by the European Council. Moreover, on December 1, 2024, a new European Commission took office. The proposal could, therefore, still be subject to revisions. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'TimesNewRoman';">The U.K.&#8217;s regulatory framework in relation to clinical trials is derived from existing legislation of the EU (as implemented into the law of the U.K., through secondary legislation). On January 17, 2022, the MHRA launched an eight-week consultation on reframing the U.K.&#8217;s legislation for clinical trials. The U.K.&#8217;s government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These changes were laid before parliament on December 12, 2024 and if adopted will bring the U.K. into closer alignment with the EU.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">If we are slow or unable to adapt to changes in existing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or the adoption of new requirements</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or policies,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">our development</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">plans</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are at an early stage in our development efforts</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and</span><i style="font-style:italic;"> </i><span style="font-style:italic;font-weight:bold;">our product candidates and those of our collaborators represent a new category of medicines and may be subject to heightened regulatory scrutiny until they are established as a therapeutic modality</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Bicycle<span style="background:#ffffff;"> molecules&#160;are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry.&#160;This constraint facilitates target binding with high affinity and selectivity, making&#160;</span>Bicycle<span style="background:#ffffff;"> molecules&#160;attractive candidates for drug development.&#160;</span>Bicycle<span style="background:#ffffff;"> molecules&#160;are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic, or PK, properties of a small molecule.</span> Our product candidates may not demonstrate in patients any or all of the pharmacological benefits we believe they may possess. We have not yet succeeded and may never succeed in demonstrating efficacy and safety for these or any other product candidates in clinical trials or in obtaining marketing approval thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Regulatory authorities have limited experience with Bicycle molecules and may require evidence of safety and efficacy that goes beyond what we and our collaborators have included in our development plans. In such a case, development of Bicycle product candidates may be more costly or time-consuming than expected, and our candidate products and those of our collaboration partners may not prove to be viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we are unsuccessful in our development efforts, we may not be able to advance the development of our product candidates, commercialize products, raise capital, expand our business or continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates and those of our collaborators will need to undergo preclinical and clinical trials that are time consuming and expensive</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the outcomes of which are unpredictable</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and for which there is a high risk of failure</span><i style="font-style:italic;white-space:pre-wrap;">.  </i><span style="font-style:italic;font-weight:bold;">If preclinical or clinical trials of our or their product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the EMA and the European Commission and any other comparable regulatory authority</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">additional costs may be incurred or delays experienced in completing</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the development of these product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or their development may be abandoned</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA in the United States, the European Commission based on a positive opinion from the EMA, or national competent regulatory authorities in the European Economic Area, or EEA, countries and any other comparable regulatory authorities in other jurisdictions must approve product candidates before they can be marketed, promoted or sold in those territories. We have not previously submitted an NDA to the FDA or similar drug approval filings to comparable foreign regulatory authorities for any of our product candidates. We must provide these regulatory authorities with data from preclinical studies and clinical trials that demonstrate that our product candidates are safe and effective for a specific indication before they can be approved for commercial distribution. We cannot be certain that our clinical trials for our product candidates will be successful or that any of our other product candidates will receive approval from the FDA, the European Commission based on a positive opinion from the EMA or any other comparable regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Preclinical studies and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. It may take several years and require significant expenditures to complete the preclinical studies and clinical trials necessary to commercialize a product candidate, and delays or failure are inherently unpredictable and can occur at any stage. New or ongoing public health crises may also impact our and our collaboration partners&#8217; abilities to activate trial </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">sites or enroll patients in clinical trials or to otherwise advance those clinical trials. Interruptions resulting from such crises may reduce our, or our collaboration partners&#8217;, abilities to administer the investigational product to enrolled patients, present difficulties for enrolled patients to adhere to protocol-mandated visits and laboratory/diagnostic testing, increase the possibility of patient dropouts, or impact our, and our suppliers&#8217;, abilities to provide investigational product to trial sites, all of which could negatively impact the data we are able to obtain from our clinical trials and complicate regulatory review<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may also be required to conduct additional clinical trials or other testing of our product candidates beyond the trials and testing that we contemplate, which may lead to us incurring additional unplanned costs or result in delays in clinical development. In addition, we may be required to redesign or otherwise modify our plans with respect to an ongoing or planned clinical trial, and changing the design of a clinical trial can be expensive and time consuming. An unfavorable outcome in one or more trials would be a major setback for our product candidates and for us. An unfavorable outcome in one or more trials may require us to delay, reduce the scope of or eliminate one or more product development programs, which could have a material adverse effect on our business, financial position, results of operations and future growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our product candidates. The FDA, EMA or the European Commission or any other comparable regulatory authority may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with clinical trials of our product candidates, we face a number of risks, including risks that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate is ineffective, inferior or a rigorous comparison cannot be made to existing approved products for the same indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate causes or is associated with unacceptable toxicity or has unacceptable side effects;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients may die or suffer adverse effects for reasons that may or may not be related to the product candidate being tested;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results may not confirm the positive results of earlier trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results may not meet the level of statistical significance required by the FDA, the EMA or the European Commission or other relevant regulatory authorities to establish the safety and efficacy of our product candidates for continued trial or marketing approval; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborators may be unable or unwilling to perform under their contracts.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Furthermore, we sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies, clinical trials, the submission of regulatory filings or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, the receipt of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, which may cause the timing of achievement of the milestones to vary considerably from our estimates. If we fail to achieve milestones in the timeframes we expect, the commercialization of our product candidates may be delayed, we may not be entitled to receive certain contractual payments, which could have a material adverse effect on our business, financial position, results of operations and future growth prospects<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which could delay or prevent us from proceeding with clinical trials of our product candidates</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate as well as the completion of required follow-up periods. Patients may be unwilling to participate in our clinical trials because of negative publicity from adverse events related to novel therapeutic approaches, competitive clinical trials for similar patient populations, the existence of current treatments or for other reasons. Enrollment risks are heightened with respect to certain indications that we may target for one or more of our product candidates that may be rare diseases, which may limit the pool of patients that may be enrolled in our planned clinical trials. The timeline for recruiting patients, conducting trials and obtaining regulatory approval of our product candidates may be delayed, which could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with the required or desired characteristics, to complete our clinical trials in a timely manner. For example, due to the nature of the indications that we are initially targeting, patients with advanced disease progression may not be suitable candidates for treatment with our product candidates and may be ineligible for enrollment in our clinical trials. Therefore, early diagnosis in patients with our target diseases is critical to our success. Patient enrollment and trial completion is affected by factors including the<span style="background:#ffffff;">:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size of the patient population and process for identifying subjects;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eligibility and exclusion criteria;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety profile, to date, of the product candidate under study;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of the product candidate under study;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of our approach to treatment of diseases;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of competing therapies and clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">degree of progression of the subject&#8217;s disease at the time of enrollment;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective subjects;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to obtain and maintain subject consent;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk that enrolled subjects will drop out before completion of the trial;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to monitor subjects adequately during and after treatment.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, clinical testing of zelenectide pevedotin, BT5528, and BT7480 is currently taking place outside of the United States. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in establishing or managing relationships with academic partners or contract research organizations, or CROs, and physicians;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">different standards for the conduct of clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the absence in some countries of established groups with sufficient regulatory expertise for review of protocols related to our novel approach;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to locate qualified local consultants, physicians and partners; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of clinical trials do not necessarily predict success in the results of completed clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. For example, our company-sponsored Phase I/II clinical trials of zelenectide pevedotin, BT5528 and BT7480 are ongoing, and the interim results of these trials, including specific patient responses we have observed and disclosed, may not be replicated in the completed data sets or in future trials at global clinical trial sites in a later stage clinical trial conducted by us or our collaborators. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. While we aligned with the FDA on the design of a Phase II/III registrational trial for zelenectide pevedotin, called Duravelo-2, which is currently enrolling, we otherwise have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, our ability to enroll trial participants, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Failure to successfully validate</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">develop and obtain regulatory approval for companion diagnostics could harm our drug development strategy</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may employ companion diagnostics to help us more accurately identify patients within a particular subset, both during our clinical trials and in connection with the commercialization of our product candidates that we are developing or may in the future develop. Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate regulatory approval or certification prior to commercialization. We do not develop companion diagnostics internally and thus we will be dependent on the sustained </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">cooperation and effort of our third-party collaborators in developing and obtaining approval or certification for these companion diagnostics. There can be no guarantees that we will successfully find a suitable collaborator to develop companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval or certification for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval or certification of the companion diagnostics could delay or prevent approval of our product candidates. In addition, our collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community or difficulties obtaining insurance coverage and reimbursement from private insurance or government payors. If such companion diagnostics fail to gain market acceptance, our ability to derive revenues from sales of any products, if approved, will be adversely affected. In addition, the diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">prevent their marketing approval</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">limit their commercial potential or result in significant negative consequences</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Undesirable or clinically unmanageable side effects could occur and cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If unacceptable side effect profiles arise, or side effects beyond those identified to date develop or worsen, as we continue development of our current or future product candidates, we, the FDA or comparable foreign regulatory authorities, the Institutional Review Boards, or IRBs, or independent ethics committees at the institutions in which our studies are conducted, or Safety Review Committees could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, cause delays in ongoing clinical trials, or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may be required to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Three of our product candidates are currently undergoing safety testing in the form of Phase I/II or Phase II/III clinical trials. None of our products have completed this testing to date. While our current and future product candidates will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects could arise either during clinical development or, if such side effects are rarer, after our products have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated, and we cannot predict if ongoing or future clinical trials will demonstrate, that zelenectide pevedotin, BT5528, BT7480, or any other of our product candidates are safe in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">effective than previously believed or causes undesirable side effects that were not previously identified, any of the following consequences could occur:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the product or seize the product;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any collaborators, may need to recall the product, or be required to change the way the product is administered or conduct additional clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any collaborators, may be required to create a medication guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any collaborators, could be sued and held liable for harm caused to patients;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If any of our current or future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue and our business will be harmed. Any of these events could harm our business and operations, and could negatively impact the price of our ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be delayed or may not be successful in our efforts to identify or discover additional product candidates</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Although we intend to utilize our&#160;Bicycle&#160;screening platform to explore other therapeutic opportunities in addition to the product candidates that we are currently developing, we may fail to identify other product candidates for clinical development for a number of reasons. For example, our research methodology may not be successful in identifying potential product candidates or those we identify may be shown to have harmful side effects or other characteristics that make them unmarketable or unlikely to receive regulatory approval. A key part of our strategy is to utilize our screening technology to identify product candidates to pursue in clinical development. Such product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and approval by the FDA and/or applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development. If we fail to identify and develop additional potential product candidates, we may be unable to grow our business and our results of operations could be materially harmed<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular development strategy, product candidate or indication and fail to capitalize on strategies, product candidates or indications that may be more profitable or for which there is a greater likelihood of success</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In August 2024, we focused our research and development pipeline on clinical programs and research areas that we believe have the highest potential to maximize value creation and we consolidated all discovery research activities to our headquarters in Cambridge, U.K. Moving forward, we will prioritize the clinical development of BTC molecules in multiple tumor types and focus our near-term research efforts on advancing our BRC pipeline and the discovery of next-generation BTC molecules. Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific indications that we identify as most likely to succeed, in terms of both their </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our recent resource allocation decisions, and those we may make in the future, may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face potential product liability</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">if successful claims are brought against us</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we may incur substantial liability and costs</span><i style="font-style:italic;white-space:pre-wrap;">.  </i><span style="font-style:italic;font-weight:bold;">If the use of our product candidates harms patients</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or is perceived to harm patients even when such harm is unrelated to our product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impairment of our business reputation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs due to related litigation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the distraction of management&#8217;s attention from our primary business;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our product candidates; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates, if approved for commercial sale.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage each time we commercialize an additional product; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our ADS price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Patients with the diseases targeted by certain of our product candidates, such as our lead indications in oncology, are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may seek designations for our product candidates with the FDA and other comparable regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">but there can be no assurance that we will successfully obtain such designations</span><i style="font-style:italic;white-space:pre-wrap;">.  </i><span style="font-style:italic;font-weight:bold;">In addition</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">even if one or more of our product candidates are granted such designations</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we may not be able to realize the intended benefits of such designations</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA and other comparable regulatory authorities offer certain designations for product candidates that are intended to encourage the research and development of pharmaceutical products addressing conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority review. There can be no assurance that we will successfully obtain such designation for any of our other product candidates. In addition, while such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for one or more of our product candidates, there can be no assurance that we will realize their intended benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For example, we may seek a Breakthrough Therapy Designation for one or more of our product candidates. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, if preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA are also eligible for accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may also seek Fast Track Designation for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track Designation does not provide assurance of ultimate FDA approval. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. The EMA has a similar program called PRIME.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may seek priority review designation for one or more of our product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">but we might not receive such designation</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and even if we do</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">such designation may not lead to a faster regulatory review or approval process</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, in particular if such product candidate has received a Breakthrough Therapy Designation, the FDA may decide not to grant it. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Moreover, a priority review designation does not result in expedited development and does not necessarily result in expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our current and future product candidates in other jurisdictions</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. We do not have experience in obtaining reimbursement or pricing approvals in international markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Obtaining marketing approvals and compliance with regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries outside of the United States. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The withdrawal of the U.K. from the EU, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 6.1pt 0pt 0pt;"><span style="color:#231f20;">Following</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Brexit,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">signed</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU-U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Trade and Cooperation</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Agreement,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or TCA, which became</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">provisionally</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">applicable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">on January 1, 2021, and entered into force</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">on May 1, 2021. The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">TCA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">primarily</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">focuses on ensuring</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">free</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">trade</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">between</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">relation</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">goods,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">including</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Among the changes that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">have</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">occurred</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> the U.K.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">treated</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">as</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">&#8220;third</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">country,&#8221;</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">country that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">member</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">whose</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">citizens</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">do</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">enjoy</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">right</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">free</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">movement.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Northern</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Ireland continues</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">follow</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">certain limited</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">rules,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">including</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">relation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medical devices, but not in relation to medicinal products.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">As</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">part</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of the TCA,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">the EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">and the U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">recognize</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">GMP inspections</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">carried</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">out by the other party and the acceptance</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of official</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">GMP documents</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">issued</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">other</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">party.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">TCA</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">also</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">encourages,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">although</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">it</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">does</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">oblige,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the parties</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">consult</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">one</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">another</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">proposals</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">introduce</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">significant</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">changes</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">technical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regulations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">inspection procedures.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Among</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">areas</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">absence</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">mutual</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">recognition</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">batch</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">testing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">batch</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">release.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">has unilaterally</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">agreed</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to accept</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU batch</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">testing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and batch</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">release.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">However, the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU continues</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to apply</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU laws that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">require</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">batch</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">testing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">batch</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">release</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">take</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">place</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">territory.</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">This</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">means</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products that are tested</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and released</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in the U.K. must be retested</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and re-released</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">when entering</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the EU market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for commercial</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">use.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 6.1pt 0pt 0pt;"><span style="color:#231f20;font-size:7pt;letter-spacing:0.05pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">On February 27, 2023, the U.K. government and the European Commission reached a political agreement on the so-called &#8220;Windsor Framework.&#8221; The Windsor Framework</span> <span style="color:#231f20;">is intended to revise the Northern Ireland Protocol to address some of the perceived shortcomings in its operation. The agreement was adopted at the Withdrawal Agreement Joint Committee on March 24, 2023, and the arrangements under the Windsor Framework relating to medicinal products took effect on January 1, 2025. </span>As it relates to marketing authorizations, the U.K. has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland continued, until January 1, 2025, to be covered by the marketing authorizations granted by the European Commission but the Windsor Framework </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">provides that the MHRA is the sole regulatory body responsible for granting marketing authorizations for Northern Ireland as of January 1, 2025<span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="color:#231f20;font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A significant proportion of the regulatory framework in the U.K. applicable to medicinal products is currently derived from EU Directives and Regulations. The potential for U.K. legislation to diverge from EU legislation following Brexit could materially impact the regulatory regime with respect to the development, manufacture, import, approval, and commercialization of our product candidates in the U.K. or the EU. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">All</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">these</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">changes</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">could</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">increase</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">costs</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">otherwise</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adversely affect</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">our business. Any delay in obtaining,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or an inability</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to obtain, any regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">approvals,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">as a result</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of Brexit</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">otherwise,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">would</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">prevent</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">us</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">commercializing</span><span style="color:#231f20;letter-spacing:0.2pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">candidates</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and restrict</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ability</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generate</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">revenue</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">achieve</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sustain</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">profitability.</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">addition,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">we</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">required</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to pay</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">taxes</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">duties</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">subjected</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">other</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">hurdles</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">connection</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">importation</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">candidates into</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">If</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">any</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">these</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">outcomes</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">occur,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">we</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">forced</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">restrict</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">delay</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">efforts</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">seek</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulatory approval</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">candidates,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">incur</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">significant</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">additional</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">expenses</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">operate</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">our business,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">could</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">significantly</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">materially</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">harm</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">delay</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ability</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generate</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">revenues</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">achieve profitability</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">business.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Any</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">further</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">changes</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">international</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">trade,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">tariff</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">import/export</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">regulations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">as</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a result</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Brexit</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">otherwise</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">impose</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">unexpected</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">duty</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">costs</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">other</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">non-tariff</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">barriers</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">us.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">These developments,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">perception</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">any</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">them</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">could</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">occur,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">significantly</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">reduce</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">global</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">trade</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in particular,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">trade</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">between</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">impacted</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">nations</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">U.K.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">It</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">also</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">possible</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Brexit</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">negatively</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">affect our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ability</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">attract</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">retain</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">employees,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">particularly</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">those</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Commercialization of Our Product Candidates and Other Regulatory Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we complete the necessary preclinical studies and clinical trials</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the marketing approval process is expensive</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">time consuming and uncertain and may prevent us or any collaborators from obtaining approvals for the commercialization of some or all of our product candidates</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">As a result</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we cannot predict when or if</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and in which territories</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or any collaborators</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">will obtain marketing approval to commercialize a product candidate</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. It is possible that we could experience delays in the timing of our interactions with regulatory authorities due to absenteeism by governmental employees, inability to conduct planned physical inspections related to regulatory approval, or the diversion of regulatory authority efforts, which could delay anticipated approval decisions and otherwise delay or limit our ability to make planned regulatory submissions or obtain new product approvals. Additional delays may result if an </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. Any marketing approval we ultimately obtain, if any, may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authority. The FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. For example, regulatory authorities may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. Regulators may approve a product candidate for a smaller patient population, a different drug formulation or a different manufacturing process, than we are seeking. If we are unable to obtain necessary regulatory approvals, or more limited regulatory approvals than we expect, our business, prospects, financial condition and results of operations may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any delay in obtaining or failure to obtain required approvals could negatively impact our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact the price of our ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We currently have limited marketing</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">sales or distribution infrastructure with respect to our product candidates</span><i style="font-style:italic;white-space:pre-wrap;">.  </i><span style="font-style:italic;font-weight:bold;">If we are unable to develop our sales</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">marketing and distribution capability on our own or through collaborations with marketing partners</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we will not be successful in commercializing our product candidates</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We currently have limited marketing, sales or distribution capabilities and have limited sales or marketing experience within our organization. If one or more of our product candidates is approved, we intend either to build our sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize that product candidate, or to outsource this function to a third party. There are risks involved with either building our own sales and marketing capabilities and entering into arrangements with third parties to perform these services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Recruiting and training an internal commercial organization is expensive and time consuming and could delay any product launch. Some or all of these costs may be incurred in advance of any approval of any of our product candidates. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire a sales force in the United States or other target market that is sufficient in size or has adequate expertise in the medical markets that we intend to target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or our failure to educate physicians on the benefits of prescribing our products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with expanding an independent sales and marketing organization.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability to us from these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The market opportunities for any current or future product candidate we develop</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">if and when approved</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and may be small</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cancer therapies are sometimes characterized as first-line, second-line, third-line or later-line therapies, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy, immunotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We may initially seek approval of zelenectide pevedotin, BT5528, BT7480, and any other product candidates we develop as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but there is no guarantee that product candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including use as first- or second-line therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive marketing approval of a product candidate</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we will be subject to ongoing regulatory obligations and continued regulatory review</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">if approved</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_37"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any marketing approvals that we receive for any current or future product candidate may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA or comparable foreign regulatory authorities may also require a Risk Evaluation and Mitigation Strategy, or REMS, or a comparable foreign strategy, as a condition of approval of any product candidate, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA or a comparable foreign regulatory authority approves a product candidate, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include, among others, submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Manufacturing Practice, or cGMP, and Good Clinical Practice, or GCP, for any clinical trials that we conduct post-approval, and prohibitions on the promotion of an approved product for uses not included in the product&#8217;s approved labeling. The FDA and other or comparable foreign regulatory authorities actively enforce the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products<span style="background:#ffffff;">. Similar considerations apply outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling, distribution, marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">untitled and warning letters, or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications we filed or suspension or revocation of license approvals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on coverage by third-party payors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of the product; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face significant competition and if our competitors develop and market products that are more effective</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">safer or less expensive than the product candidates we develop</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">our commercial opportunities will be negatively impacted</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The life sciences industry is highly competitive. We are currently developing therapeutics that will compete, if approved, with other products and therapies that currently exist, are being developed or will in the future be developed, some of which we may not currently be aware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering, developing and commercializing products in our field before we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, such as traditional chemotherapy, as well as novel immunotherapies. For example, a number of multinational companies as well as biotechnology companies are developing programs for the targets that we are exploring for our BTC programs, including, but not limited to, Pfizer Inc. (formerly Seagen, acquired by Pfizer Inc. in December 2023) which has a marketed Nectin-4 antibody-drug conjugate, Eli Lilly and Company, Corbus Pharmaceutical Holdings, Inc., Innate Pharma SA and Mabwell Therapeutics, Inc. Furthermore, many companies are developing programs for CD137 or CD137 bi-specific antibodies or antibody fragments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EU or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Smaller and other early-stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the pharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our product candidates obsolete, less competitive or not economical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">patients</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">payors and others in the medical community</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have never commercialized a product, and even if we obtain any regulatory approval for our product candidates, the commercial success of our product candidates will depend in part on the medical community, patients, and payors accepting products based on our&#160;Bicycle peptides in general, and our product candidates in particular, as effective, safe and cost-effective. Any product that we bring to the market may not gain market acceptance by physicians, patients, payors and others in the medical community. Physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The degree of market acceptance of these product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential efficacy and potential advantages over alternative treatments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the frequency and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the frequency and severity of any side effects resulting from follow-up requirements for the administration of our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative convenience and ease of administration;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning our products or competing products and treatments; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient third-party insurance coverage and adequate reimbursement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if a product candidate displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product, if approved for commercial sale, will not be known until after it is launched. Our efforts to educate the medical community and payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors, particularly due to the novelty of our Bicycle<i style="font-style:italic;">&#160;</i>approach. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunities for our product candidates are smaller than we believe they are</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">our product revenues may be adversely affected and our business may suffer</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We currently focus our research and product development on treatments for oncology indications and our product candidates are designed to target specific tumor antigens. Our understanding of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, is based on estimates. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases. Patient identification efforts also influence the ability to address a patient population. If efforts in patient identification are unsuccessful or less impactful than anticipated, we may not address the entirety of the opportunity we are seeking.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the tumor antigens that our product candidates target may not be expressed as broadly as we anticipate. Further, if companion diagnostics are not developed alongside our product candidates, testing patients for the tumor antigens may not be possible, which would hamper our ability to identify patients who could benefit from treatment with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result, the number of patients we are able to identify in the United States, the European Union and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products or patients may become increasingly difficult to access, all of which would adversely affect our business, financial condition, results of operations and prospects<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The insurance coverage and reimbursement status of newly approved products is uncertain</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">if approved</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">could limit our ability to market those products and decrease our ability to generate revenue</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We expect the cost of our product candidates to be substantial, when and if they achieve market approval. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by private payors, such as private health coverage insurers, health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health care programs, such as Medicare and Medicaid. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize our product candidates, even if approved. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage and reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, as the CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to coverage and reimbursement for novel products such as ours, as there is no body of established practices and precedents for these new products. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: (1)&#160;a covered benefit under its health plan; (2)&#160;safe, effective and medically necessary; (3)&#160;appropriate for the specific patient; (4)&#160;cost-effective; and (5)&#160;neither experimental nor investigational. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved drugs for a particular indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Because our product candidates may have a higher cost of goods than conventional therapies, and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.<br/><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_38"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We or our collaborators will be required to obtain coverage and reimbursement for companion diagnostic tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved. There is significant uncertainty regarding our and our collaborators&#8217; ability to obtain coverage and adequate reimbursement for any companion diagnostic test for the same reasons applicable to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Outside the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical products, or medicinal products, as they are commonly referred to in the European Union. These countries have broad discretion in setting prices and we cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product before it can be lawfully marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we, or any collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Moreover, efforts by governments and payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate reimbursement for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Our results of operations could be adversely affected by the Patent Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, the Inflation Reduction Act of 2022, or the IRA, and by other healthcare legislative reforms that may be enacted or adopted in the future, particularly in light of the recent U.S. Presidential and Congressional elections. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In December 2021, Regulation No 2021/2282 on HTA amending Directive 2011/24/EU, was adopted in the European Union. This Regulation, which entered into force in January 2022 and applies as of January 12, 2025, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the level of the European Union for joint clinical assessments in these areas. The Regulation permits Member States to use common HTA tools, methodologies, and procedures across the European Union, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual Member States continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. In light of the fact that the U.K. has left the EU, Regulation No 2021/2282 on HTA does not apply in the U.K.  However, the U.K. Medicines and Healthcare products Regulation Agency, or MHRA is working with U.K. HTA bodies and other national organizations, such as the Scottish Medicines Consortium, the National Institute for Health and Care Excellence, and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products, including, effective as of March 31, 2025, relaunching the Innovative Licensing and Access Pathway with more predicable timelines and closer involvement of the National Health Service.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product candidates that receive marketing approval</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or such authorities do not grant such products appropriate periods of data exclusivity before approving generic versions of such products</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the sales of such products could be adversely affected</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Once an NDA is approved, the product covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning, in part, that it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug may be typically lost to the generic product, and the price of the branded product may be lowered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA may not accept for review or approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">expiration of five years unless the submission is accompanied by a Paragraph&#160;IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed drug. It is unclear whether the FDA will treat the active ingredients in our product candidates as NCEs and, therefore, afford them five years of NCE data exclusivity if they are approved. If any product we develop does not receive five years of NCE exclusivity, the FDA may approve generic versions of such product three years after its date of approval, subject to the requirement that the ANDA applicant certifies to any patents listed for our products in the Orange Book. Three-year exclusivity is given to a non-NCE drug if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the NDA. Manufacturers may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Competition that our products may face from generic versions of our products could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">directly or indirectly</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">to federal and state healthcare fraud and abuse laws</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">false claims laws health information privacy and security laws</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and other health care laws and regulations</span><i style="font-style:italic;white-space:pre-wrap;">.  </i><span style="font-style:italic;font-weight:bold;">If we are unable to comply</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or have not fully complied</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">with such laws</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we could face substantial penalties</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various U.S. federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, or Anti-Kickback Statute, the federal civil and criminal False Claims Act and Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs and other interactions with healthcare professionals. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs.  &#8220;Remuneration&#8221; has been interpreted broadly to include anything of value.  A person or entity does not need to have actual knowledge of the Anti-Kickback Statute or specific intent to violate it to have committed a violation.  In addition, the government may assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA, or federal civil money penalties.  The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other.  There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_39"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal civil and criminal false claims laws</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, including the FCA, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">and civil monetary penalty law, which impose criminal and civil penalties against individuals or entities for, among other things:  knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government.  Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims.  The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the beneficiary inducement provisions of the civil monetary penalty law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their respective business associates, individuals and entities that perform services on their behalf that involve the use or disclosure of individually identifiable health information and their subcontractors that use disclose or otherwise process individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, which requires applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, we are subject to U.S. state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the Anti-Kickback Statute and FCA, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April&#160;2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable state law requirement we could be subject to significant&#160;penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For further information concerning the data privacy and security laws </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">we may be subject to and our processing of personal data, see the risk factor titled &#8220;<i style="font-style:italic;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our (and the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenues or profits, and other adverse business consequences.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, imprisonment,&#160;exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products, (iv)&#160;restriction on coverage, reimbursement, and pricing for our products, (v)&#160;transparency reporting obligations regarding transfers of value to health care professionals or (vi)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Among policy makers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, the ACA, which was signed into law in 2010, is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health care spending, enhance remedies against fraud and abuse, add new transparency requirements for the health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been executive, judicial and Congressional challenges and amendments to certain aspects of ACA. For example, on August 16, 2022, President Biden signed the IRA into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket costs and creating a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the new Trump administration will impact the ACA and our business. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, including the BBA and the Consolidated Appropriations Act of 2023, will remain in effect through 2032 unless additional Congressional action is taken. Additionally, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. The IRA, among other things, (i) allows HHS to negotiate the price of certain high-expenditure drugs and biologics that have been on the market for at least seven years and covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.  HHS has and will continue to issue and update guidance as these programs are implemented. These provisions began to take effect progressively starting in 2023. On August 15, 2024, HHS announced the agreed-upon prices of the first 10 drugs that were subject to price negotiations, which take effect in January 2026. HHS will select up to 15 additional products covered under Part D for negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare drug price negotiation program. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation, administrative or executive action. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug, which could have an adverse effect on customers for our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to the U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">K</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">Bribery Act 2010</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or the Bribery Act</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">S</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">Foreign Corrupt Practices Act of 1977</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">as amended</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or the FCPA</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and other anti-corruption laws</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">as well as export control laws</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">import and customs laws</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">trade and economic sanctions laws and other laws governing our operations</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our operations are subject to anti-corruption laws, including the Bribery Act, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us, our employees&#160;and our intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (and third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation (including class claims), fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse business consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive or confidential information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. To the extent applicable, the exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, referred to collectively as CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA allows for fines for noncompliance and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data maintained by covered entities about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future, and these developments may further complicate compliance efforts and may increase legal risk and compliance costs for us and the third parties with whom we work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Outside of the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, and the United Kingdom&#8217;s GDPR, or U.K. GDPR, impose strict requirements for processing personal data. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may be subject to new laws governing the privacy of consumer health data, including reproductive, sexual orientation, and gender identity privacy rights. For example, Washington&#8217;s My Health My Data Act, or MHMD, broadly defines consumer health data, places restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. Other states are considering and may adopt similar laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our employees and personnel may use generative artificial intelligence technologies to perform their work, and the disclosure and use of personal data in generative artificial intelligence technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative artificial intelligence. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative artificial intelligence, it could make our business less efficient and result in competitive disadvantages.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In the ordinary course of business, we transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area, or the EEA, and the U.K., have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and U.K. to the United States in compliance with law, such as the European Commission&#8217;s Standard Contractual Clauses, the U.K. International Data Transfer Agreement and the U.K. Transfer Addendum, the EU-U.S. Data Privacy Framework and the U.K.&#8217;s Extension to that Framework (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the relevant Framework and/or Extension), these mechanisms are subject to potential legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, U.K. or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors, and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and U.K. to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In addition to data privacy and security laws, we are also bound by other contractual and industry obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We publish privacy policies, marketing materials, whitepapers, and other statements concerning data privacy and security. Regulators in the United States are increasingly scrutinizing these statements, and if these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflicting among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties with whom we work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations. Such failures can subject us to potential foreign, local, state and federal action if they are found to be deceptive, unfair, misleading or misrepresentative of our actual practices, which could negatively impact our business operations and compliance posture. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy or security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our activities subject us to various laws relating to foreign investment and the export of certain technologies</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and our failure to comply with these laws or adequately monitor the compliance of our suppliers and others we do business with could subject us to substantial fines</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">penalties and even injunctions</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the imposition of which on us could have a material adverse effect on the success of our business</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to laws that regulate certain transactions and access to technology. In the United States, these laws include section&#160;721 of the Defense Production Act of 1950, as amended by the Foreign Investment Risk Review Modernization Act of 2018, and the regulations at 31&#160;C.F.R. Parts&#160;800 and 801, as amended, administered by the Committee on Foreign Investment in the United States; and the Export Control Reform Act of 2018, which is being implemented in part through Commerce Department rulemakings to impose new export control restrictions on &#8220;emerging and foundational technologies&#8221; yet to be fully identified. Application of these laws, including as they are implemented through regulations being developed, may negatively impact our business in various ways, including by restricting our access to capital and markets; limiting the collaborations we may pursue; regulating the export of our products, services, and technology from the United States and abroad; increasing our costs and the time necessary to obtain required authorizations and to ensure compliance; and threatening monetary fines and other penalties if we do not.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">health and safety laws and regulations</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products.  We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials.  In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.  In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Business and Our International Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">As a company with operations outside of the United States</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we are subject to economic</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">political</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">regulatory and other risks associated with international operations</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">As a company with operations in the U.K., our business is subject to risks associated with conducting business outside of the United States. Many of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing and changing regulatory requirements for product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potentially reduced protection for intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations, including, without limitation, restrictive regulations such as the EU GDPR and U.K. GDPR governing the use, processing, and cross-border transfer of personal data;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in non-U.S. regulations and customs, tariffs and trade barriers;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in non-U.S. currency exchange rates of the pound sterling, U.S. dollar, euro and currency controls;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in a specific country&#8217;s or region&#8217;s political or economic environment, including the implications of Brexit and the recent presidential election in the United States;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade protection measures, import or export licensing requirements or other restrictive actions by governments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing reimbursement regimes and price controls in certain non-U.S. markets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative consequences from changes in tax laws;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable tax treatment in different jurisdictions of options granted under our share option schemes or equity incentive plans;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation or administrative actions resulting from claims against us by current or former employees or consultants individually or as part of class actions, including claims of wrongful terminations, discrimination, misclassification or other violations of labor law or other alleged conduct;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties associated with staffing and managing international operations, including differing labor relations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_83"></a><a id="_cp_text_1_84"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geo-political actions, including war and terrorism, natural disasters</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including earthquakes, typhoons, floods and fires</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, or public health crises</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any or all of these factors could have a material adverse impact on our business, financial condition and results of operations. Moreover, global instability continues as a result of the Russia-Ukraine and the Hamas-Israel wars as well as the conflicts in the Middle East, including between Israel and Hezbollah. These wars could have a lasting impact on regional and global economies, any or all of which could disrupt our supply chain and increase the costs associated with or otherwise adversely affect our ability to conduct ongoing and future clinical trials of our product candidates. In addition, continued instability may adversely impact our ability to raise capital in the future on favorable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cyber-attacks, </span><span style="font-style:italic;font-weight:bold;">failures</span><span style="font-style:italic;font-weight:bold;"> in or interruptions of, or other compromise to our information technology systems, or those of third parties with whom we work, or our data could result in adverse consequences that materially affect our business, including without limitation,</span> <span style="font-style:italic;font-weight:bold;">regulatory investigations or actions, litigation, fines and penalties, information theft, data corruption, harm to our reputation and brand, significant disruption of our business operations, and other adverse consequences</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In the ordinary course of business, we and the third parties with whom we work and may process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets (collectively, sensitive information). Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability conduct our research and development programs and our clinical trials. We and the third parties with whom we work may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks and deep fakes, which may be increasingly more difficult to identify as fake), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats. In particular, severe ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, disruption of clinical trials, loss of sensitive data (including data related to clinical trials), loss of income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Remote work has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside of our premises or network, including working at home, while in transit and in public locations. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We may rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, third-party providers of information technology infrastructure, cloud-based infrastructure, encryption and authentication technology, employee email, content delivery to customers, CROs for managing clinical trial data, and other functions. We may also rely on third-party service providers to provide other products, services, parts, or otherwise operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, the liability of such third party may be limited such that any award may be insufficient to cover our damages, or we may be unable to recover any such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may expend significant resources or modify certain of our business activities (which could include our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While we have established physical, electronic and organizational security measures designed to safeguard and secure our systems against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information technology systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties with whom we work. For example, we have been the target of unsuccessful phishing attempts in the past and we expect such attempts will continue in the future. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our products or services. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences. If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may experience material adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class-action claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.  Security incidents and attendant material consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, our sensitive information, including personal data, could be leaked, disclosed or revealed as a result of, or in connection with, our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative artificial intelligence technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Social media platforms and artificial intelligence-based platforms present new risks and challenges to our business</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Social media is increasingly being used to communicate information about us, our programs and the diseases our therapeutics are being developed to treat. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product or a product candidate, which could result in reporting obligations or other consequences. Further, the accidental or intentional disclosure of non-public information by our workforce or others through media channels could lead to information loss. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us, our products, or our product candidates on any social media platform. The nature of social media prevents us from having real-time control over postings about us on social media. We may not be able to reverse damage to our reputation from negative publicity or adverse information posted on social media platforms or similar mediums. If any of these events were to occur or we otherwise fail to comply with application regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business including quick and irreversible damage to our reputation, brand image and goodwill. Additionally, artificial intelligence, or AI, based platforms are increasingly being used in the pharmaceutical industry. While we have introduced measures to restrict the internal use of public AI platforms, they may be used by our vendors, suppliers and contractors with access to our proprietary and confidential information, including trade secrets. Such use may lead to the release of our proprietary and confidential information, which may negatively impact our company, including our ability to realize the benefit of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Exchange rate fluctuations may materially affect our results of operations and financial condition</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the pound sterling and the U.S. dollar, may adversely affect us. Although we are based in the U.K., we source research and development, manufacturing, consulting and other services from the United States, European Union and Asia that are billed in U.S. dollars. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. dollar, but also the euro, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. Any fluctuation in the exchange rate of these foreign currencies may negatively impact our business, financial condition and operating results. Global economic events have and may continue to significantly impact local economies and the foreign exchange markets, which may increase the risks associated with sales denominated in foreign currencies<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">For certain product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we depend</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or will depend</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">on development and commercialization collaborators to develop and conduct clinical trials with</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">obtain regulatory approvals for</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and if approved</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">market and sell product candidates</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">If such collaborators fail to perform as expected</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">the potential for us to generate future revenue from such product candidates would be significantly reduced and our business would be harmed</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For certain products candidates, we depend, or will depend, on our development and commercial collaborators to develop, conduct clinical trials of, and, if approved, commercialize product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Under our collaborations with Genentech, Ionis, Novartis, and Bayer, we are responsible for identifying and optimizing&#160;Bicycle peptides related to collaboration targets and our collaborators are responsible for further development and product commercialization after we complete the defined research screening and compound optimization. We depend on these collaborators to develop and, where applicable, commercialize products based on Bicycle peptides, and the success of their efforts directly impacts the milestones and royalties we will receive. We cannot provide assurance that our collaborators will be successful in or that they will devote sufficient resources to the development or commercialization of their products. If our current or future collaboration and commercialization partners do not perform in the manner we expect or fail to fulfill their responsibilities in a timely manner, or at all, if our agreements with them terminate or if the quality or accuracy of the clinical data they obtain is compromised, the clinical development, regulatory approval and commercialization efforts related to their and our product candidates and products could be delayed or terminated and it could become necessary for us to assume the responsibility at our own expense for the clinical development of such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our current collaborations and any future collaborations that we enter into are subject to numerous risks, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to the collaborations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected or fail to fulfill their responsibilities in a timely manner, or at all;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay preclinical studies or clinical trials, provide insufficient funding for clinical trials, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our shareholders about the status of such product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the collaborations may not result in product candidates to develop and/or preclinical studies or clinical trials conducted as part of the collaborations may not be successful;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates developed with collaborators may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to stop commercialization of our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product candidate; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public health crises and other adverse global economic events could materially affect our operations as well as causing significant disruption in the operations and business of our collaborators and the third-party </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers, CROs and other service providers that we and/or our collaborators conduct business with; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, certain collaboration and commercialization agreements provide our collaborators with rights to terminate such agreements, which rights may or may not be subject to conditions, and which rights, if exercised, would adversely affect our product development efforts and could make it difficult for us to attract new collaborators. In that event, we would likely be required to limit the size and scope of efforts for the development and commercialization of such product candidates or products; we would likely be required to seek additional financing to fund further development or identify alternative strategic collaborations; our potential to generate future revenue from royalties and milestone payments from such product candidates or products would be significantly reduced, delayed or eliminated; and it could have an adverse effect on our business and future growth prospects. Our rights to recover tangible and intangible assets and intellectual property rights needed to advance a product candidate or product after termination of a collaboration may be limited by contract, and we may not be able to advance a program post-termination<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If conflicts arise with our development and commercialization collaborators or licensors</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">they may act in their own self-interest</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which may be adverse to the interests of our company</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may in the future experience disagreements with our development and commercialization collaborators or licensors. Conflicts may arise in our collaboration and license arrangements with third parties due to one or more of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes with respect to milestone, royalty and other payments that are believed due under the applicable agreements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with respect to the ownership of intellectual property rights or scope of licenses;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with respect to the scope of any reporting obligations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities, or to permit public disclosure of these activities; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes with respect to a collaborator&#8217;s or our development or commercialization efforts with respect to our products and product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For example, we were previously involved in litigation with Pepscan Systems&#160;B.V., and its affiliates, or Pepscan, related to a non-exclusive patent license agreement that our subsidiary, BicycleRD Limited, or BicycleRD, entered into with Pepscan in 2009.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Conflicts with our development and commercialization collaborators or licensors could materially adversely affect our business, financial condition or results of operations and future growth prospects. If we are unable to prevail against these challenges, our intellectual property estate may be materially harmed, which would impair our ability to establish competitive barriers to entry in the form of intellectual property protections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">including independent clinical investigators and CROs</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">to conduct and sponsor some of the clinical trials of our product candidates</span><i style="font-style:italic;white-space:pre-wrap;">.  </i><span style="font-style:italic;font-weight:bold;">Any failure by a third party to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval for our product candidates</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, academic partners, regulatory affairs consultants and third-party CROs, to conduct our preclinical studies </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and clinical trials, including in some instances sponsoring such clinical trials, and to engage with regulatory authorities and monitor and manage data for our ongoing preclinical and clinical programs. We also utilize CROs to perform toxicology studies related to our preclinical activities. While we will have agreements governing the activities of such third parties, we will control only certain aspects of their activities and have limited influence over their actual performance. Given the breadth of clinical therapeutic areas for which we believe Bicycle molecules&#160;may have utility, we intend to continue to rely on external service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new contract research organization begins work. As a result, delays would likely occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of EEA countries and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we fail to exercise adequate oversight over any of our academic partners or CROs or if we or any of our academic partners or CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon a regulatory inspection of us, our academic partners or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under applicable CGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If any of the third parties conducting clinical trials on our behalf, including clinical investigators, do not successfully carry out their contractual duties for any reason, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, with respect to investigator-sponsored trials that are being or may be conducted, we do not control the design or conduct of these trials, and it is possible that the FDA or EMA will not view these investigator-sponsored trials as providing adequate support for future clinical trials or market approval, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials, manufacturing issues, safety concerns or other trial results. We expect that such arrangements will provide us certain information rights with respect to the investigator-sponsored trials, including the ability to obtain a license to obtain access to use and reference the data, including for our own regulatory submissions, resulting from the investigator-sponsored trials. However, we do not have control over the timing and reporting of the data from investigator-sponsored trials, nor do we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the firsthand knowledge we might have </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. Additionally, the FDA or EMA may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored trials, or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, the FDA or EMA may require us to obtain and submit additional preclinical, manufacturing, or clinical data<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We intend to rely on third parties to manufacture product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which could delay</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">prevent or impair our development or commercialization efforts</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We do not own or operate manufacturing facilities for the production of clinical or commercial supplies of the product candidates that we are developing or evaluating in our development programs.  We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale.  We rely on third parties, including those located in China, for supply of our product candidates, and our strategy is to outsource all manufacturing of our product candidates and products to third parties. For any activities conducted in China, we are exposed to the increased possibility of supply disruptions and higher costs in the event of changes in the policies of the U.S. or Chinese governments, political unrest or unstable economic conditions including sanctions on China or any of our China-based suppliers. Our manufacturing costs could also increase as a result of future appreciation of the local currency in China or increased labor costs if the demand for skilled laborers increases and/or the availability of skilled labor declines in China. In addition, certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting the supply of material to us. Such disruption could have adverse effects on the development of our product candidates and our business operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In order to conduct clinical trials of product candidates, we will need to have them manufactured in potentially large quantities. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. For example, ongoing data on the stability of our product candidates may shorten the expiry of our product candidates and lead to clinical trial material supply shortages, and potentially clinical trial delays. Additionally, our manufacturers may experience delays as a result of impacts due to the ongoing wars involving Ukraine and Israel. If our third-party manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Our use of new third-party manufacturers increases the risk of delays in production or insufficient supplies of our product candidates as we transfer our manufacturing technology to these manufacturers and as they gain experience manufacturing our product candidates.  Even after a third-party manufacturer has gained significant experience in manufacturing our product candidates or even if we believe we have succeeded in optimizing the manufacturing process, there can be no assurance that such manufacturer will produce sufficient quantities of our product candidates in a timely manner or continuously over time, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We may be delayed if we need to change the manufacturing process used by a third party.  Further, if we change an approved manufacturing process, then we may be delayed if the FDA or a comparable foreign authority needs to review the new manufacturing process before it may be used.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">We operate an outsourced model for the manufacture of our product candidates, and contract with cGMP licensed pharmaceutical contract development and manufacturing organizations. While we have engaged several third-party vendors to provide clinical and non-clinical supplies and fill-finish services, we do not currently have any agreements with third-party manufacturers for long-term commercial supplies. In the future, we may be unable to enter into agreements with third-party manufacturers for commercial supplies of any product candidate that we develop, or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">may be unable to do so on acceptable terms. Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on third parties for manufacturing process development, regulatory compliance and quality assurance;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations on supply availability resulting from capacity and scheduling constraints of third parties;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of manufacturing agreements by third parties because of factors beyond our control; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or non-renewal of the manufacturing agreements by the third party, at a time that is costly or inconvenient to us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third-party manufacturers may not be able to comply with cGMP requirements or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and/or criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates. In addition, some of the product candidates we intend to develop, including zelenectide pevedotin and BT5528 use toxins or other substances that can be produced only in specialized facilities with specific authorizations and permits, and there can be no guarantee that we or our manufacturers can maintain such authorizations and permits. These specialized requirements may also limit the number of potential manufacturers that we can engage to produce our product candidates and impair any efforts to transition to replacement manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our future product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP requirements that might be capable of manufacturing for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the third parties that we engage to supply any materials or manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, including as a result of the impacts of public health crises on the global workforce and manufacturing operations, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because we rely on third parties to manufacture our product candidates, and because we collaborate with various organizations and academic institutions on the development of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent and other intellectual property protection for our products and product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">our competitors could develop and commercialize products similar or identical to ours</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and our ability to successfully commercialize our products and product candidates may be adversely affected</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Our ability to compete effectively will depend, in part, on our ability to maintain the proprietary nature of our technology and manufacturing processes.  We rely on research, manufacturing and other know-how, patents, trade secrets, license agreements and contractual provisions to establish our intellectual property rights and protect our products and product candidates.  These legal means, however, afford only limited protection and may not adequately protect our rights. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In certain situations and as considered appropriate, we have sought, and we intend to continue to seek to protect our proprietary position by filing patent applications in the United States and, in at least some cases, one or more countries outside the United States relating to current and future products and product candidates that are important to our business. However, we cannot predict whether the patent applications currently being pursued will issue as patents, or whether the claims of any resulting patents will provide us with a competitive advantage or whether we will be able to successfully pursue patent applications in the future relating to our current or future products and product candidates.  Moreover, the patent application and approval process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to seek additional patent protection. It is possible that defects of form in the preparation or filing of patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if they are unchallenged, our patents and patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to one or more of our product candidates but that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Other parties, many of whom have substantially greater resources and have made significant investments in competing technologies, have developed or may develop technologies that may be related or competitive with our approach, and may have filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or conflict with our patent applications, either by claiming the same compositions, formulations or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. As a result, any patents we may obtain in the future may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our products and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in which they claim that our patents are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the future, one or more of our products and product candidates may be in-licensed from third parties. Accordingly, in some cases, the availability and scope of potential patent protection is limited based on prior decisions by our licensors or the inventors, such as decisions on when to file patent applications or whether to file patent applications at all. Our failure to obtain, maintain, enforce or defend such intellectual property rights, for any reason, could allow third parties, in particular, other established and better financed competitors having established development, manufacturing and distribution capabilities, to make competing products or impact our ability to develop, manufacture and market our products and product candidates, even if approved, on a commercially viable basis, if at all, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to patent protection, we expect to rely heavily on trade secrets, know-how and other unpatented technology, which are difficult to protect. Although we seek such protection in part by entering into confidentiality agreements with our vendors, employees, consultants and others who may have access to proprietary information, we cannot be certain that these agreements will not be breached, adequate remedies for any breach would be available, or our trade secrets, know-how and other unpatented proprietary technology will not otherwise become known to or be independently developed by our competitors. If we are unsuccessful in protecting our intellectual property rights, sales of our products may suffer and our ability to generate revenue could be severely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Issued patents covering our products and product candidates could be found invalid or unenforceable if challenged in court or in administrative proceedings</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">We may not be able to protect our trade secrets in court</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we initiate legal proceedings against a third-party to enforce a patent covering one of our products or product candidates, should such a patent issue, the defendant could counterclaim that the patent covering our product or product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the United States Patent and Trademark Office (USPTO), or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <i style="font-style:italic;">inter partes</i> review and equivalent proceedings in foreign jurisdictions. An adverse determination in any of the foregoing proceedings could result in the revocation or cancellation of, or amendment to, our patents in such a way that </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">they no longer cover our products or product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our products and product candidates. Such a loss of patent protection may materially harm our intellectual property estate, which would impair our ability to establish competitive barriers to entry in the form of intellectual property protections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors and other third parties could purchase our products and product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in the patents and intellectual property that we own or that we may own or license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may be breached. We could be subject to ownership disputes arising, for example, from conflicting obligations of employees, consultants or others who are involved in developing our products or product candidates. Litigation may be necessary to defend against any claims challenging inventorship or ownership. If we fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and financial condition<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">document submission</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">fee payment and other requirements imposed by governmental patent agencies</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and our patent protection could be reduced or eliminated for non-compliance with these requirements</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the patent application process and after a patent has issued. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. The terms of one or more licenses that we enter into the future may not provide us with the ability to maintain or prosecute patents in the portfolio, and must therefore rely on third parties to do so<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension and data exclusivity for our products and product candidates</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">our business may be materially harmed</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the future, if we obtain an issued patent covering one of our present or future product candidates, depending upon the timing, duration and specifics of any FDA marketing approval of such product candidates, such patent may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. A patent may only be extended once and only based on a single approved product. However, we may not be granted an extension because of, for example, failure to obtain a granted patent before approval of a product candidate, failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents or otherwise our failure to satisfy applicable requirements. A patent licensed to us by a third party may not be available for patent term extension. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">thereby impairing our ability to protect our products and product candidates</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. When implemented, the Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also included provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allowed third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file&#160;a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&#160;16, 2013. It remains unclear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent rulings from the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We cannot provide assurance that our efforts to seek patent protection for one or more of our products and product candidates will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact courts&#8217; decisions in historical and future cases may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Filing, prosecuting, maintaining, defending and enforcing patents on products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. There can be no assurance that we will obtain or maintain patent rights in or outside the United States under any future license agreements. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Proceedings to enforce our patent rights, even if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. While we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are sued for infringing intellectual property rights of third parties</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may have U.S. and non-U.S. issued patents and pending patent applications relating to compounds, methods of manufacturing compounds and/or methods of use for the treatment of the disease indications for which we are developing our product candidates. If any third-party patents or patent applications are found to cover our product candidates or their methods of use or manufacture, we and our collaborators or sublicensees may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all. We may also be required to indemnify our collaborators or sublicensees in such an event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we were previously party to protracted litigation with Pepscan, which we settled in 2020. We may become party to, or be threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates, including interference and post-grant proceedings before the USPTO. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of our product candidates. We cannot guarantee that any of our patent searches or analyses including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents are complete or thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally, it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or claiming ownership of what we regard as our own intellectual property</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Many of our current and former employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors. Some of these employees may be subject to proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we have been in the past and may be subject in the future to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which could be expensive</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">time-consuming and unsuccessful</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. In addition, our patents may become, involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time-consuming, and our adversaries may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In an infringement proceeding, a court may decide that a patent is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating intellectual property rights we own or control. An adverse result in any litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly. Further, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if resolved in our favor, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations under any future intellectual property licenses with third parties</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we could lose license rights that are important to our business</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with our efforts to build our product candidate pipeline, we may enter into license agreements in the future. We expect that such license agreements will impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under these licenses, our licensors may have the right to terminate these license agreements, in which event we might not be able to market any product that is covered by these agreements, or our licensors may convert the license to a non-exclusive license, which could negatively impact the value of the product candidate being developed under the license agreement. Termination of these license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">then we may not be able to build name recognition in our marks of interest and our business may be adversely affected</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our trademarks or trade names may be challenged, infringed, circumvented or declared invalid, generic or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive objections. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such objections. In addition, in the USPTO and in comparable Intellectual Property Offices in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings have been and may in the future be filed against our trademarks, and our trademarks may not survive such proceedings. For example, our U.K. trademark application for &#8220;TICA&#8221; was successfully opposed in the U.K., Japan and the EU for the majority of goods and services for which we originally applied, and we have abandoned our trademark application for &#8220;TICA&#8221; in the United States as a result. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters and Managing Growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain key employees</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">consultants and advisors and to attract</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">retain and motivate qualified personnel</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are highly dependent on principal members of our executive team and key employees, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. The loss of the services of one or more of our current key employees might impede the achievement of our research, development and commercialization objectives. Furthermore, replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives and personnel in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical trials may make it more challenging to recruit and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The inability to recruit or the loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our employees</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">independent contractors</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">consultants</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">collaborators and CROs may engage in misconduct or other improper activities</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">including non-compliance with regulatory standards and requirements</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which could cause significant liability for us and harm our reputation</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are exposed to the risk that our employees, independent contractors, consultants, collaborators and contract research organizations may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (1)&#160;FDA regulations or similar regulations of comparable non-U.S. regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; (2)&#160;manufacturing standards; (3)&#160;federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities; and (4)&#160;laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, bribery and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or collaborator misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Further, because of our hybrid work environment, information that is normally protected, including company confidential information, may be less secure. We have adopted a code of conduct and business ethics to which all of our employees must adhere, but it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have recently expanded our organization significantly and we expect to continue to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have recently experienced significant growth in the number of our employees and the scope of our operations and expect to continue to expand, particularly in the areas of drug manufacturing, supply chain, clinical development, sales, marketing, as well as to support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Moreover, our expected growth could require us to relocate to geographic areas beyond those where we have been historically located. For example, we maintain office and laboratory&#160;space in Cambridge, U.K. and in Massachusetts, U.S. Due to our limited resources, we may not be able to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our ADSs is highly volatile</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">and holders of our ADSs may not be able to resell their ADSs at or above the price at which they purchased their ADSs</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The market price of our ADSs is highly volatile. Since our initial public offering, or IPO, in May&#160;2019, through February 20, 2025, the trading price of our ADSs has ranged from $6.24 to $62.08. The stock market in general, and the market for pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, holders of our ADSs may not be able to sell their ADSs at or above the price at which they purchased their ADSs. The market price for our ADSs may be influenced by many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in preclinical studies or clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reports of adverse events in products similar or perceived to be similar to those we are developing or clinical trials of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to obtain additional funding;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to successfully develop and commercialize our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to maintain our existing strategic collaborations or enter into new collaborations;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to identify additional product candidates for our pipeline;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us or our licensors and strategic partners to prosecute, maintain or enforce our intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or regulations applicable to future products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_162"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new products, services or technologies by our competitors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to meet or exceed financial projections we may provide to the public;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to meet or exceed the financial projections of the investment community;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic partners or our competitors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or shareholder litigation;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our ADSs or ordinary shares by us or our shareholders in the future; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading volume of our ADSs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. Similarly, the ongoing wars involving Ukraine and Israel have created extreme volatility in the global capital markets and are expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets continue to deteriorate, it may make any necessary debt or equity financings more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. In addition, higher inflation and macro turmoil and uncertainty could also adversely affect our buyers and sellers, which could reduce demand for our products. These factors may negatively affect the market price of our ADSs, regardless of our actual operating performance<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">The dual class structure of our shares may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background:#ffffff;">As of February 20, 2025, we had </span>47,710,256<span style="background:#ffffff;"> ordinary shares, nominal value &#163;0.01 per share, and 21,492,099 non-voting ordinary shares, nominal value &#163;0.01 per share, outstanding. The dual class structure of our shares may limit your ability to influence corporate matters. Holders of our ordinary shares are entitled to one vote per share, while holders of our non-voting ordinary shares are not entitled to any votes. Nevertheless, non-voting ordinary shares may be re-designated at any time as ordinary shares at the option of the holder by providing written notice to us, subject to certain restrictions. Such restrictions include prohibitions on a holder from re-designating the non-voting ordinary shares as ordinary shares if such re-designation would result in such holder beneficially owning (when aggregated with &#8220;affiliates&#8221; and &#8220;group&#8221; members) in excess of 9.99% of any class of our securities registered under the Exchange Act, or upon at least 61 days&#8217; notice, not in excess of 19.9%. Any re-designation of non-voting ordinary shares as ordinary shares will have the effect of increasing the relative voting power of those prior holders of our non-voting ordinary shares, and correspondingly decreasing the voting power of the holders of our ordinary shares, which may limit your ability to influence corporate matters. The ordinary shares currently have 100% of the voting power, but if the holders of non-voting ordinary shares were to re-designate all of their non-voting ordinary shares as ordinary shares (assuming, for these purposes, that they were able to do so in compliance with the beneficial ownership limitation), based on the number of ordinary shares and non-voting ordinary shares outstanding on December 31, 2024, the ordinary shares outstanding prior to the re-designation would have approximately 69% of the voting power and the former non-voting ordinary shares would represent approximately 31% of the voting power.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Substantial future sales or issuances of shares of our ordinary shares or ADSs or other equity-related securities could adversely affect the price of our ADSs and dilute shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background:#ffffff;">Sales of a substantial number of ordinary shares or ADSs, and sales by our management, our directors, their affiliates, or significant shareholders, could occur at any time. In June 2024, we registered for resale 37,656,764 ordinary shares, representing 37,656,764 ADSs that were or may become beneficially owned by selling securityholders, including certain entities affiliated with Baker Bros. Advisors LP, or the Baker Entities. The selling securityholders will determine whether and when these securities are resold in the public market. These shares represent a large number of our ordinary shares, and if sold in the market in transactions that occur at about the same time, such transactions could depress the market of our ADSs and could also affect our ability to raise equity capital through the sale of additional equity or equity-related securities, including non-voting ordinary shares, to meet our capital needs, including in connection with funding potential future acquisition or licensing opportunities, capital expenditures or product development costs. Our registration obligations pursuant to the Registration Rights Agreement with the Baker Entities also cover all shares thereafter acquired by the Baker Entities, for up to 10 years, and include our obligation to facilitate certain underwritten public offerings of our ordinary shares or ADSs by the Baker Entities in the future. In addition, ordinary shares subject to outstanding options under our equity incentive plans and the ordinary shares reserved for future issuance under our equity incentive plans will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations, which will dilute current holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Our existing shareholders may consult with our management and have various impacts on our business affairs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background:#ffffff;">Based on information available to us, the Baker Entities beneficially own approximately 22.9% of our ordinary shares. While our shareholder base and relative holdings may change over time, the Baker Entities hold the largest ownership position in our outstanding ordinary shares and non-voting ordinary shares. In addition, Felix J. Baker, a member of our board of directors, is a managing member of Baker Bros. Advisors (GP) LLC, which is the sole general partner of Baker Bros. Advisors LP. The interests of the Baker Entities and its affiliates may not always coincide with the interests of other shareholders, and any influence exerted over our business and affairs by these entities may not coincide with the wishes of other shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In addition, our executive officers and directors and holders of greater than five percent of our outstanding ordinary shares beneficially owned approximately 59% of our voting power as of February 20, 2025. As a result, these shareholders in aggregate are able to exert substantial influence over our management and affairs and matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may result in our taking corporate actions that our other shareholders may not consider to be in their best interest. For example, it may have the effect of delaying, deferring or preventing a change in control, including a merger, consolidation, takeover or other business combination involving us or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control, which might affect the market price of our ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our ADSs in the foreseeable future</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">capital appreciation</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">if any</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">will be the sole source of gains for holders of our ADSs, and they may never receive a return on their investment</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs will be a holder&#8217;s sole source of gains for the foreseeable future, and holders will suffer a loss on their investment if they are unable to sell their ADSs at or above the original purchase price<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Incorporation Under the Laws of England and Wales</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Claims of U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">S</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">civil liabilities may not be enforceable against us</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are incorporated under English law. Certain members of our board of directors and senior management are non-residents of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the United Kingdom. In addition, uncertainty exists as to whether U.K. courts would entertain original actions brought in the United Kingdom against us or our directors or senior management predicated upon the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the United Kingdom as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are a controlled foreign corporation</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">there could be adverse U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">S</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">federal income tax consequences to certain U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">S</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">holders</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation,&#8221; or a CFC, for U.S. federal income tax purposes generally is required to report annually and include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart&#160;F income,&#8221; &#8220;global intangible low-taxed income,&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation that is a Ten Percent Shareholder with respect to a CFC. Failure to comply with these reporting and tax paying obligations may subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations from starting with respect to such shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own (directly, indirectly or constructively through the application of attribution rules) more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own (directly, indirectly or constructively through the application of attribution rules) 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the total value of all classes of stock of such corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Each Ten Percent Shareholder should also be aware that because our group includes a U.S. subsidiary, certain of our non-U.S. subsidiaries will be treated as CFCs (regardless of whether or not we are treated as a CFC). We cannot provide any assurances that we will assist shareholders in determining whether we are or any of our non-U.S. subsidiaries is </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">treated as a CFC or whether any shareholder is treated as a Ten Percent Shareholder with respect to any such CFC or furnish to any shareholders information that may be necessary to comply with reporting and tax paying obligations. The Internal Revenue Service has provided limited guidance on situations in which investors may rely on publicly available information to comply with their reporting and tax paying obligations with respect to foreign-controlled CFCs. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. United States persons should consult their own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are a passive foreign investment company, there could be adverse U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">S</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">federal income tax consequences to U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">S</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">holders</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which (1)&#160;75% or more of our gross income consists of passive income or (2)&#160;50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income, including cash. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable year during which a United States person holds our shares, such U.S. shareholder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Based on our analysis of our income, assets, activities and market capitalization, we believe that we were a PFIC in the 2024 taxable year. In addition, no assurances can be provided that we will not be a PFIC for any future taxable year or that we have not been a PFIC in any prior taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. As a result, there can be no assurance regarding if we will be PFIC or will not be a PFIC in the future. In addition, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into and our corporate structure. In the event we are a PFIC, we intend to provide the information necessary for U.S. holders to make a qualified electing fund, or QEF, election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">K</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">tax legislation</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As an entity incorporated and tax resident in the United Kingdom, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception and therefore have not paid any U.K. corporation tax. Subject to numerous utilization criteria and restrictions (including the Corporate Income Loss Restriction and the Corporate Capital Loss Restriction that, broadly, restrict the amount of carried forward losses that can be utilized to 50% of group profits or gains arising above &#163;5.0 million per tax year, we expect losses to be eligible for carry forward and utilization against future operating profits. In addition, if we were to have a major change in the nature of the conduct or the conduct of our trade, loss carryforwards may be restricted or extinguished.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a group that carries out extensive research and development, or R&amp;D, activities, we seek to benefit from the U.K. R&amp;D tax credit regime. In respect of accounting periods in which we qualify as a Small and Medium-sized Enterprise, or SME, and in which our relevant R&amp;D expenditure represents 40% (or, from April 1, 2024, 30%) or more of the total relevant expenditure (meaning we also qualify as &#8220;R&amp;D intensive&#8221; during such accounting period), we may, under this regime, surrender the trading losses that arise from our R&amp;D activities for a cash rebate of up to 26.97% of qualifying R&amp;D expenditure. Accordingly, if we cease to qualify as an R&amp;D-intensive SME in the future, we will either cease to be able to claim cash rebates in respect of our R&amp;D activities, or only be able to receive cash payments or other tax relief (under other provisions of the U.K. R&amp;D tax credit regime) at a significantly lower rate than at present. Further, the regime&#8217;s rules are complex, and if a tax authority were to challenge or seek to disallow our claims (in whole </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">or in part), for example by asserting that we do not (or the relevant expenditure does not) meet the technical conditions to be granted tax credits (or cash rebates), then such challenge or disallowance, if successful, could have a material impact on our cash-flow and financial performance. In addition, future changes to the U.K. R&amp;D tax credit regime may mean that we no longer qualify for it or have a material impact on the extent to which we can make claims (or benefit from them).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may benefit in the future from the United Kingdom&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenues from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction. We are the exclusive licensee or owner of several patent applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues and royalties could be eligible for this tax deduction. When taken in combination with the enhanced relief available on our R&amp;D expenditures, we expect a long-term rate of corporation tax lower than the statutory rate to apply to us. If, however, there are unexpected adverse changes to the U.K. R&amp;D tax relief programs or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Future changes to tax laws could materially adversely affect our company and reduce net returns to our shareholders</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The tax treatment of the company is, and our ADSs and ordinary shares are, subject to changes in tax laws, regulations and treaties, or the interpretation thereof, tax policy initiatives and reforms under consideration or being implemented by tax authorities in jurisdictions in which we operate, including in connection with tax policy initiatives and reforms led by the Organization for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS, Project (including &#8220;BEPS 2.0&#8221;) and the European Commission. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid, or the stamp duty or stamp duty reserve tax treatment of our ADSs or ordinary shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the United States on August 16, 2022, President Biden signed into law the IRA, which includes a minimum tax equal to 15% of the adjusted financial statement income of certain corporations, as well as a 1% excise tax on share buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. Although Congress is considering legislation that would defer the amortization requirement to later years, we have no assurance that the provision will be repealed or otherwise modified. If the requirement is not modified or deferred, it may materially reduce our cash flows. We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders, and increase the complexity, burden and cost of tax compliance<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Tax authorities may disagree with our positions and conclusions regarding certain tax positions</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">or may apply existing rules in an unforeseen manner,</span><i style="font-style:italic;"> </i><span style="font-style:italic;font-weight:bold;">resulting in unanticipated costs</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">taxes or non-realization of expected benefits</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, while we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities. HMRC, the Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties and, such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in the U.K. City Code on Takeovers and Mergers that may have anti-takeover effects do not apply to us. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The U.K. City Code on Takeovers and Mergers, or the Takeover Code, applies to an offer for, among other things, a public company whose registered office is in the United Kingdom if the company is considered by the Panel on Takeovers and Mergers, or the Takeover Panel, to have its place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the &#8220;residency test.&#8221; The test for central management and control under the Takeover Code is different from that used by the U.K. tax authorities. Under the Takeover Code, the Takeover Panel will determine whether we have our place of central management and control in the United Kingdom by looking at various factors, primarily where the directors are resident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">In September 2019, the Takeover Panel Executive confirmed that, based on our current circumstances, we are not subject to the Takeover Code. As a result, our shareholders are not entitled to the benefit of certain takeover offer protections provided under the Takeover Code. We believe that this position is unlikely to change at any time in the near future but, in accordance with good practice, we will review the situation on a regular basis and consult with the Takeover Panel if there is any change in our circumstances which may have a bearing on whether the Takeover Panel would determine our place of central management and control to be in the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The rights of our shareholders may differ from the rights typically offered to shareholders of a U</span><i style="font-style:italic;">.</i><span style="font-style:italic;font-weight:bold;">S</span><i style="font-style:italic;">. </i><span style="font-style:italic;font-weight:bold;">corporation</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by English law, including the provisions of the U.K. Companies Act 2006, or the Companies Act, and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. The principal differences include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">under English law and our articles of association, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned.  Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">under English law, the number of shares determines the number of votes a holder may cast only on a poll.  However, that the voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">under English law and our articles of association, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the articles of association.  This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors.  Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve other significant transactions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">in the United Kingdom, takeovers may be structured as takeover offers or as schemes of arrangement.  Under English law, if we were to be subject to the Takeover Code, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs.  If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares/ADSs will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law.  By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares voting, as well as the sanction of the U.K. court; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under English law and our articles of association, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">General Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">we may not be able to accurately report our financial results or prevent fraud</span><i style="font-style:italic;white-space:pre-wrap;">.  </i><span style="font-style:italic;font-weight:bold;">As a result</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">shareholders could lose confidence in our financial and other public reporting</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">which would harm our business and the trading price of our ADSs</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Our management is required to assess the effectiveness of our controls over financial reporting annually. Pursuant to Section&#160;404, we are also required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We could be subject to securities class action litigation</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business</span><i style="font-style:italic;">, </i><span style="font-style:italic;font-weight:bold;">our ADS price and trading volume could decline</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The trading market for our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. Although we have obtained research </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">coverage from certain analysts, there can be no assurance that analysts will continue to cover us or provide favorable coverage. If one or more analysts downgrade our ADSs or change their opinion of our ADSs, our ADS price would likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our ADS price or trading volume to decline.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6e580c30_b855_4afd_8cb2_18cdfd0ac938"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_724560"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1B.&#160;&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><a id="_7e2d8179_c1fc_40ca_bd5a_80e2c7a55b95"></a><a id="ITEM1C_CYBERSECURITY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1C.&#160;&#160;&#160;&#160;&#160;CYBERSECURITY.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_9zojx7Xew0mMSuLPccLUBg" continuedAt="Tb_9zojx7Xew0mMSuLPccLUBg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk management and strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, computer hardware and software, <span style="white-space:pre-wrap;">and our critical data, which includes proprietary, confidential and sensitive data, including, without limitation, personal data (such as health-related data), intellectual property and trade secrets, referred to collectively as Information Assets.  Accordingly, we maintain certain risk assessment processes intended to identify cybersecurity threats, determine their likelihood of occurring, and assess potential material impact to our business.  Based on our assessment, </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_It_BIjO9X0-COpkmkpV6tw" escape="true">we implement and maintain risk management <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_zo2kChfUD0qrjw1irNK28w">processes</ix:nonNumeric> designed to protect the confidentiality, integrity, and availability of our Information Assets and mitigate harm to our business.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Risks from cybersecurity threats are among those that we address in our general risk management program. We rely on a multidisciplinary team (including personnel from our information security function, management and <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_ihVcTU8llkyYA1wuT0neCw">third-party service providers</ix:nonNumeric><span style="white-space:pre-wrap;">, as needed, as described further below) to help identify, assess and manage our risks. We identify and assess such threats by, among other things, monitoring and evaluating the threat environment using various methods, including, for example, manual and automated tools, information security tools and platforms to alert us to potentially unwarranted activity on our networks, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#8217;s risk profile, evaluating threats reported to us, conducting threat assessments for internal and external threats, and conducting risk and vulnerability assessments to identify vulnerabilities.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depending on the environment, we implement and maintain various technical, physical and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Assets. For example, the risk management and reduction measures we implement for certain of our Information Assets include: policies and procedures designed to address cybersecurity threats, including an incident response plan, vulnerability management, and disaster recovery/business continuity plans; incident detection and response solutions; internal and/or external audits to assess our exposure to cybersecurity threats; documented risk assessments; implementation of certain security standards/certifications; encryption of data; network security controls; data segregation; physical and electronic access controls; physical security; asset management, tracking and disposal; systems monitoring; employee security training; penetration testing; and cyber insurance. In addition to the above, management obtains a third-party review and formal certification of its information management system policies and procedures, which has been collated into an Information Security Management System (ISMS) which is maintained to ISO27001 standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_sFqayYMYDkOngS8LPsWe-Q">We work with third parties from time to time that assist us to identify, assess, and manage cybersecurity risks, including professional services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms and other vendors that help to identify, assess, or manage cybersecurity risks.</ix:nonNumeric><span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">To operate our business, we utilize certain third-party service providers to perform a variety of functions, such as outsourced business critical functions including contract research organizations, or CROs, for managing clinical trials, professional services, SaaS platforms, managed services, property management, cloud-based infrastructure, data center facilities, content delivery to customers, encryption and authentication technology, corporate productivity services, and other functions. We generally engage reliable, reputable service providers that maintain cybersecurity programs.  Depending on the nature of the services provided, the sensitivity and quantity of information processed, and the identity of the service provider, our vendor management process may include reviewing the cybersecurity practices of such provider, contractually imposing obligations on the provider related to the services they provide and/or the information </span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_9zojx7Xew0mMSuLPccLUBg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">they process, conducting security assessments, requiring their completion of written questionnaires regarding their services and data handling practices, and conducting periodic re-assessments during their engagement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">For service providers that provide particularly critical services to us or process particularly sensitive information for us, we may also require that such providers possess at least one of the following certificates, reports, or procedures: SOC 2 Type 2; ISO 27001; annual penetration tests; and/or red/blue team tests.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For a description of the risks from cybersecurity threats that may <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_v3On-tkYKEqN_6ydhPldxQ">materially affect</ix:nonNumeric> us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including the risk factor titled: <i style="font-style:italic;">Cyber-attacks, failures in or interruptions of, or other compromise of our information technology systems, or those of third parties with whom we work, or our data could result in adverse consequences that materially affect our business, including without limitation, regulatory investigations or actions, litigation, fines and penalties, information theft, data corruption, harm to our reputation and brand, significant disruption of our business operations and other adverse consequences</i>. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_hKvAQ1ld10yxQ6Dt4azAIQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Governance</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_z6OCd-SyRUqdyUSUSOEnYQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_fXDg_gFqjEWW-A-hKAqC2w" escape="true">Our cybersecurity risk management strategy relies on input from management, including our Vice President, Head of Computational &amp; Structural Science, who reports directly to our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Group_EibKFks58U2M_3p3cA2tIg" continuedAt="Group_EibKFks58U2M_3p3cA2tIg_2" escape="true">Chief Technology Officer</ix:nonNumeric>, and has over 10 years of experience in developing and implementing cybersecurity strategies for companies in the biopharmaceutical industry, as well as our Chief Financial Officer and Chief Legal Officer and General Counsel.</ix:nonNumeric> We have also formed an Information Risk Assessment Committee, or IRAC, consisting of senior members of the finance, legal, operations and information technology functions, to oversee the management of information security as a whole, including integrating cybersecurity considerations into the company&#8217;s overall risk management strategy, and for communicating key priorities to employees. The IRAC meets on a regular basis, generally quarterly, to discuss cybersecurity risk and to review our cybersecurity program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_ApklqUHSfEGPWvElSi0gBQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our incident response team, which includes, but is not limited to, our <ix:continuation id="Group_EibKFks58U2M_3p3cA2tIg_2">Vice President, Head of Computational &amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer</ix:continuation><span style="white-space:pre-wrap;">. In addition, our incident response processes include reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_oeWrQm1xWEmV-1rfLPA17g">Management, including the IRAC, is also responsible for approving budgets, helping prepare for cybersecurity incidents, responding to cybersecurity incidents</ix:nonNumeric>, approving cybersecurity policies and procedures, reviewing audit reports, and <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_NT9neWo8n02R_lSYA1li_g">reporting to the board of directors</ix:nonNumeric>.<span style="white-space:pre-wrap;">  </span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our board of directors oversees our risk management strategy with respect to cybersecurity threats.  </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_BpnZDfZsWU6rM-BMNFSLDQ" escape="true">The board, through its <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_UxZMVXk3FUCcIAueZq0VkQ" escape="true">Audit Committee</ix:nonNumeric>, holds regular meetings, at least quarterly, to discuss issues including our cybersecurity threats. The meetings involve presentations and reports from our management</ix:nonNumeric>, including our Vice President, Head of Computational &amp; Structural Science, concerning our significant cybersecurity threats and risks and the processes we have implemented to address them. </p></ix:nonNumeric><a id="_1de1c1ba_5aea_4994_ba98_746c97369162"></a><a id="ITEM2PROPERTIES_952404"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;PROPERTIES. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We occupy approximately 45,000 rentable square feet of office and laboratory space in Cambridge, United Kingdom under a lease that expires in December 2031, which may be cancelled after December 2026, and may be renewed for 10 years, also cancelable in the fifth year of the extension. We also lease an additional 11,000 rentable square feet of office and laboratory space in Lexington, Massachusetts under a lease that expires in December 2027 and approximately 23,000 rentable square feet of office and laboratory space in Cambridge, Massachusetts under a lease that expires in March 2026, which may be extended for an additional two years at our option. We believe that our office and laboratory spaces are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c272a886_bf0e_4196_93f4_cef3eb0cd3a0"></a><a id="ITEM3LEGALPROCEEDINGS_246541"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently subject to any material legal proceedings.</p><a id="_0408074d_c233_4daf_9feb_819ca8deaf5b"></a><a id="ITEM4MINESAFETYDISCLOSURES_102091"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Not Applicable.</p><a id="_ef54219e_cf01_41db_8789_4b09ecf77520"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="PARTII_193203"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Neither our ordinary shares, nominal value &#163;0.01 per share, nor our non-voting ordinary shares, nominal value &#163;0.01 per share, are publicly traded. Our American Depositary Shares, or ADSs, each represent one ordinary share of Bicycle Therapeutics plc and began trading on The Nasdaq Global Select Market on May 23, 2019 under the symbol &#8220;BCYC.&#8221;  Prior to that date, there was no public trading market for our ADSs, ordinary shares, or non-voting ordinary shares.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders of Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of February 20, 2025, there were approximately 45 holders of record of our ordinary shares, three holders of record of our non-voting ordinary shares, and one holder of record of our ADSs. The number of beneficial owners of the ADSs in the United States is likely to be much larger than the number of record holders of our ordinary shares in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Proceeds from Registered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Performance Graph</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The performance graph shown below compares the annual change in cumulative total shareholder return on our ADSs with the Nasdaq Composite Index and the Nasdaq Biotechnology Index from December 31, 2019, through the year ended December 31, 2024. The graph assumes an investment of $100 on December 31, 2019 in our ADSs, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes reinvestment of dividends, if any. All index values are weighted by the capitalization of the companies included in the index. The comparisons shown in the graph below are based upon historical data. The share price performance included in this graph is not necessarily indicative of future share price performance. The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:235.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="bcyc-20241231x10k016.jpg" alt="Graphic" style="display:inline-block;height:235.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:345.6pt;"/></p><a id="_cd3db171_746c_4f5f_9d13_00d2f140e7a1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="item6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ITEM 6. [Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_75662d62_601a_48ff_9ee4_82016bac949c"></a><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read this discussion and analysis of our financial condition and consolidated results of operations together with the consolidated financial statements, related notes and other financial information included in this Annual Report on Form 10-K, or this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including statements of our plans, objectives, expectations and intentions, contain forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Please also see the section titled &#8220;Forward-Looking Statements.&#8221;</i></p><a id="_cp_text_1_552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">For the discussion of the financial condition and results of operations for the year ended December 31, 2023 compared to the year ended December 31, 2022, refer to &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; and &#8220;Liquidity and Capital Resources&#8221; included in </i><i style="font-style:italic;">the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission, or the SEC, on February 20, 2024.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage pharmaceutical company developing a novel class of medicines, which we refer to as Bicycle<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making&#160;Bicycle molecules&#160;attractive candidates for drug development. Bicycle molecules are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic, or PK, properties of a small molecule. The relatively large surface area presented by Bicycle molecules allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycle molecules are excreted by the kidney rather than the liver and have shown no signs of immunogenicity to date, qualities which we believe explain the molecules&#8217; favorable toxicological profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a novel and proprietary phage display screening platform which we use to identify Bicycle molecules in an efficient manner. The platform initially displays linear peptides on the surface of engineered bacteriophages, or phages, before &#8220;on-phage&#8221; cyclization with a range of small molecule scaffolds which can confer differentiated physicochemical and structural properties. Our platform encodes quadrillions of potential Bicycle molecules which can be screened to identify molecules for optimization to potential product candidates. We have used this powerful screening technology to identify our current portfolio of candidates in oncology and intend to use it in conjunction with our collaborators to seek to develop additional future candidates across a range of other disease areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates zelenectide pevedotin, formerly BT8009, and BT5528, are each a Bicycle Toxin Conjugate, or BTC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>molecule. These Bicycle molecules are chemically attached to a toxin that, when administered, is cleaved from the Bicycle molecule and kills the tumor cells. We are evaluating zelenectide pevedotin, a BTC molecule targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing Phase II/III registrational trial called Duravelo-2, and enrollment in both of these trials are ongoing. We are also evaluating BT5528, a BTC molecule targeting Ephrin type A receptor 2, or EphA2, in a company-sponsored Phase I/II clinical trial, for which enrollment is ongoing. Additionally, our other product candidate, BT7480, is a Bicycle Tumor-Targeted Immune Cell Agonist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, or Bicycle TICA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>molecule. A Bicycle TICA molecule links immune cell receptor binding Bicycle molecules to tumor antigen binding Bicycle molecules. We are evaluating BT7480, a Bicycle TICA molecule targeting Nectin-4 and agonizing CD137, in a company-sponsored Phase I/II clinical trial. Our discovery pipeline in oncology includes next-generation BTC molecules and Bicycle<i style="font-style:italic;"> </i>Radionuclide Conjugates, or BRC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>molecules. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Zelenectide pevedotin has been granted Fast Track Designation, or FTD, by the FDA as a monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer as well as for the treatment of adult patients with previously treated, NECTIN4 gene-amplified, advanced or metastatic triple-negative breast cancer and non-small cell lung cancer. BT5528 has been granted FTD for the treatment of adult patients with </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">previously treated, locally advanced or metastatic urothelial cancer. Zelenectide pevedotin has also been selected to participate in the Chemistry, Manufacturing and Controls, or CMC, Development and Readiness Pilot Program launched by the FDA to facilitate CMC development for therapies with expedited clinical development timeframes based on the anticipated clinical benefits of earlier patient access to the therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beyond our wholly owned oncology portfolio, we are collaborating with biopharmaceutical companies and organizations in additional therapeutic areas in which we believe our proprietary Bicycle screening platform can identify therapies to treat diseases with significant unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have devoted substantially all of our resources to developing our Bicycle platform and our product candidates including zelenectide pevedotin, BT5528 and BT7480, conducting research and development of our product candidates and preclinical programs, raising capital and providing general and administrative support for our operations. To date, we have financed our operations primarily with proceeds from the sale of our ordinary shares, American Depositary Shares, or ADSs, non-voting ordinary shares and convertible preferred shares; proceeds received from upfront payments, research and development payments, and development milestone payments from our collaboration agreements; and borrowings pursuant to a loan and security agreement, or the Loan Agreement, with Hercules Capital, Inc., or Hercules. From our inception in 2009 through December 31, 2024, we have received gross proceeds of $1.4&#160;billion from the sale of ordinary shares, ADSs, non-voting ordinary shares and convertible preferred shares; and $236.6&#160;million of cash payments under our collaboration agreements, including $45.3 million from Bayer, $53.0 million from Novartis, $47.7 million from Ionis and $56.0 million from Genentech. We do not have any products approved for sale and have not generated any revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $169.0 million, $180.7&#160;million and $112.7 million for the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $680.8&#160;million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly as we advance our product candidates into later-stage clinical trials and continue preclinical activities and clinical trials for our pipeline programs and, if any product candidates are approved, pursue the commercialization of such product candidates by building internal sales and marketing capabilities. We expect that our expenses and capital requirements will increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our development of our product candidates, including conducting future clinical trials of zelenectide pevedotin, BT5528 and BT7480;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify and develop additional product candidates, including expanding our pipeline of BRC molecules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop the necessary processes, controls and manufacturing data to obtain marketing approval for our product candidates and to support manufacturing to commercial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek marketing approvals for our product candidates that successfully complete clinical trials, if any;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire and retain additional personnel, such as non-clinical, clinical, pharmacovigilance, quality assurance, regulatory affairs, manufacturing, distribution, legal, compliance, medical affairs, commercial and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other products and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our infrastructure and facilities to accommodate our growing employee base, including adding equipment and infrastructure to support our research and development; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our research and development programs and any future commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we expect will take many&#160;years and is subject to significant uncertainty. We have no commercial-scale manufacturing facilities of our own, and all of our manufacturing activities have been and are planned to be contracted out to third parties. Additionally, we currently utilize third-party contract research organizations, or CROs, to carry out our clinical development activities. If we seek to obtain marketing approval for any of our product candidates from which we obtain encouraging results in clinical development, we expect to incur significant commercialization expenses as we prepare for product sales, marketing, manufacturing, and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, charitable and governmental grants, monetization transactions or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of one or more of our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we had cash and cash equivalents of $879.5&#160;million. We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing of this Annual Report. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our available capital resources sooner than we expect. See &#8220;Liquidity and Capital Resources&#8221; and &#8220;Capital Resources and Funding Requirements.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue from product sales and we do not expect to generate any revenue from product sales for the foreseeable future. Our revenue primarily consists of collaboration revenue under our arrangements with our collaboration partners, including amounts that are recognized related to upfront payments, milestone payments and option exercise payments, amounts due to us for research and development services and reimbursement of certain expenses incurred. In the future, revenue may include additional milestone payments and option exercise payments, and royalties on any net product sales under our collaborations. We expect that any revenue we generate will fluctuate from period to period as a result of the timing and amount of license, research and development services, milestone and other payments, as well as the exercise or expiration of options.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research and development activities, including our discovery efforts, and the development of our product candidates, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses including salaries, benefits, and share-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with third parties that conduct research and development, preclinical activities, clinical activities and manufacturing on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of lab supplies and acquiring, developing and manufacturing preclinical study materials and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to compliance with regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and other operating costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid expenses and other current assets or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our direct external research and development expenses are tracked on a program-by-program basis and consist of costs, such as fees paid to consultants, contract research organizations, or CROs, contractors and contract manufacturing organizations, or CMOs, in connection with our preclinical and clinical development activities. Costs incurred after a product candidate has been designated and that are directly related to the product candidate are included in direct research and development expenses for that program. Costs incurred prior to designating a product candidate are included in discovery, platform and other expense. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple product development programs and, as such, are not separately classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2016, we entered into a Clinical Trial and License Agreement with Cancer Research Technology Limited, or CRTL and Cancer Research UK, or the BT1718 Cancer Research UK Agreement, pursuant to which the Cancer Research UK Centre for Drug Development sponsored and funded a Phase&#160;I/IIa clinical trial for our previous product candidate, BT1718, in patients with advanced solid tumors. The costs incurred by Cancer Research UK were recorded as a liability in accordance with ASC&#160;730,&#160;<i style="font-style:italic;">Research and Development</i> as the payments were not based solely on the results of the research and development having future economic benefit. The accrual of the liability is recorded as incremental research and development expense in our consolidated statements of operations and comprehensive loss. See &#8220;Other Income (Expense)&#8221; for additional information on our accounting for the expiration and termination of the BT1718 Cancer Research UK Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">U.K. research and development tax credits and government grants received are recorded as a reduction to research and development expenses. We receive reimbursements of certain research and development expenditures incurred by our U.K. subsidiaries from one of two U.K. research and development tax credit cash rebate regimes in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">effect for us for the year ended December 31, 2024: the Small and Medium-sized Enterprises R&amp;D Tax Relief program, or SME Program, and the Research and Development Expenditure Credit program, or RDEC Program.<span style="font-size:12pt;"> </span>Qualifying expenditures largely comprise employment costs for research staff, consumables, expenses incurred under agreements with third parties that conduct research and development, preclinical activities, clinical activities and manufacturing on our behalf and certain internal overhead costs incurred as part of research projects. Under the SME Program, the trading losses that arise from our qualifying R&amp;D activities can be surrendered for a cash rebate of up to 33.35% of qualifying expenditure incurred prior to April 1, 2023, and up to 18.6% of qualifying expenditure incurred thereafter. Amendments to the U.K. R&amp;D tax credit regime included in Finance Act 2024, which was enacted in February 2024, increase the cash rebate that may be claimed from such date to 26.97% of qualifying expenditure, if we qualify as &#8220;R&amp;D intensive&#8221; for an accounting period (broadly, a loss making SME whose relevant R&amp;D expenditure represents 40% for accounting periods beginning on or after April 1, 2023, or 30% for accounting periods beginning on or after April 1, 2024, of its total expenditure for that accounting period). We qualified as an R&amp;D intensive SME for the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Further amendments to the U.K. R&amp;D tax credit regime included in Finance Act 2024 introduce restrictions (unless limited exceptions apply) on the tax relief that can be claimed for expenditures incurred on sub-contracted R&amp;D activities or externally provided workers, where such sub-contracted activities are not carried out in the United Kingdom or such workers are not subject to U.K. payroll taxes. These amendments take effect for accounting periods beginning on or after April 1, 2024, which may limit our ability to claim R&amp;D tax credits for sub-contracted R&amp;D in the future. In addition, for accounting periods beginning on or after April 1, 2024, if we do not qualify as R&amp;D intensive for an accounting period, we will be subject to a merged scheme with a single 20% gross rate applying to all claims. If we no longer qualify for the R&amp;D intensive reimbursement the amount of research and development tax credit may be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The U.K. research and development tax credit is fully refundable to us after surrendering tax losses and is not dependent on current or future taxable income. As a result, we have recorded the entire benefit from the U.K. research and development tax credit as a reduction to research and development expenses and is not reflected as part of the income tax provision. If, in the future, any U.K. research and development tax credits generated are needed to offset a corporate income tax liability in the U.K., that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded as a reduction to research and development expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as a result of our expanded portfolio of product candidates and as we: (i)&#160;continue the clinical development and seek to obtain marketing approval for our product candidates, including zelenectide pevedotin, BT5528 and BT7480; (ii)&#160;initiate clinical trials for our other product candidates; and (iii)&#160;build our in-house process development and analytical capabilities and continue to discover and develop additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of these product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from our product candidates. This is due to the numerous risks and uncertainties associated with developing products, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying new product candidates to add to our development pipeline, including expanding our pipeline of BRC molecules;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing research and preclinical development of our product candidates;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing an appropriate safety profile with IND-enabling studies to advance our preclinical programs into clinical development;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in, and the initiation and completion of clinical trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, including conducting future clinical trials of zelenectide pevedotin, BT5528 and BT7480</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercializing the product candidates, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments, as well as any changes in governmental regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how, as well as obtaining and maintaining regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued acceptable safety profile of the drugs following approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, the FDA, the European Medicines Agency, or EMA, or another regulatory authority may require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or we may experience significant trial delays due to patient enrollment or other reasons in which case we would be required to expend significant additional financial resources and time on the completion of clinical development. In addition, we may obtain unexpected results from our clinical trials and we may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the current EU pharmaceutical legislation. The proposed revisions remain to be agreed and adopted by the European Council. Moreover, on December 1, 2024, a new European Commission took office. The proposal could, therefore, still be subject to revisions. If adopted in the form proposed, the European Commission proposals may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in our executive, finance, corporate and business development, commercial and administrative functions. General and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, insurance, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Foreign currency transactions in currencies different from the applicable functional currency are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange differences resulting from the settlement of such transactions and from the remeasurement at period-end exchange rates in foreign currencies are recorded in general and administrative expense in the consolidated statements of operations and comprehensive loss. As such, our operating expenses may be impacted by future changes in exchange rates. See &#8220;Quantitative and Qualitative Disclosures About Market Risks&#8221; for further discussion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and potential commercialization of our portfolio of product candidates. We also expect to continue to incur increased expenses associated with being a public company including costs of accounting, audit, information systems, legal, intellectual property, regulatory and tax compliance services, director and officer insurance and investor and public relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest and Other Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest and other income consists primarily of interest earned on our cash held in operating accounts and our cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists primarily of interest expense for financing arrangements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Loss on Extinguishment of Debt</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>Loss on extinguishment of debt is related to the loss recognized from the repayment and voluntary termination of the Loan Agreement on July 9, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Gain on Extinguishment of Research and Development Funding Liability</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>Gain on extinguishment of research and development funding liability is related to the gain recognized from the extinguishment of the research and development funding liability previously recognized under the BT1718 Cancer Research UK Agreement. In December 2024, we entered into an Expiry and Revenue Sharing Agreement, or the BT1718 Expiration Agreement, with CRTL and Cancer Research UK pursuant to which, among other things, the BT1718 Cancer Research UK Agreement expired and all rights and obligations (other than certain surviving provisions as outlined in the agreement) under the BT1718 Cancer Research UK Agreement expired and terminated. We accounted for the BT1718 Expiration Agreement by applying the concepts of ASC 470, <i style="font-style:italic;">Debt</i>. As all rights and obligations, including our payment obligations, under the BT1718 Cancer Research UK Agreement expire and are terminated, we concluded that the research and development funding liability recorded under the BT1718 Cancer Research UK Agreement is extinguished as we have been legally released from being the primary obligor under the BT1718 Cancer Research UK Agreement. As such, we recognized a gain on extinguishment of the research and development funding liability of $4.5 million during the year ended December 31, 2024, which is recorded within other income, net, in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(Benefit From) Provision For Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to corporate taxation in the United States and the United Kingdom. We have generated losses since inception and have therefore not paid U.K. corporation tax. The (benefit from) provision for income taxes included in the consolidated statements of operations and comprehensive loss represents the tax impact from operating activities in the United States, which has generated taxable income based on intercompany service arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">After consideration of our history of cumulative net losses in the U.K., we have concluded that it is more likely than not that we will not realize the benefits of our U.K. deferred tax assets and accordingly we have provided a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">valuation allowance for the full amount of the net deferred tax assets in the U.K. We intend to continue to maintain a full valuation allowance on our U.K. deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. The release of the valuation allowance would result in the recognition of certain deferred tax assets and an increase to the benefit from income taxes for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change on the basis of the level of profitability that we are able to actually achieve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unsurrendered U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each&#160;year is limited to &#163;5.0&#160;million plus an incremental 50% of U.K. taxable profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>The following table summarizes our results of operations for the years ended December 31, 2024, 2023 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,275</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,463</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 172,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 156,496</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 81,609</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 72,181</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 49,507</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 245,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 216,922</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 131,116</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (209,872)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (189,946)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (116,653)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest and other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,284</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,002</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,756</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,730)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,263)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,344)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (954)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain on extinguishment of research and development funding liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36,076</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,739</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,412</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (173,796)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (179,207)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (114,241)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Benefit from) provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,765)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,457</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,524)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (169,031)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (180,664)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (112,717)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:12pt 0pt 12pt 0pt;">Comparison of the Years Ended December 31, 2024 and 2023</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,275</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,299</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 172,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 156,496</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,470</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 72,181</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,755</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 245,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 216,922</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,225</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (209,872)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (189,946)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (19,926)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest and other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,284</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,002</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,282</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,730)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,263)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,533</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (954)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (954)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain on extinguishment of research and development funding liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,476</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36,076</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,739</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,337</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (173,796)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (179,207)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,411</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">(Benefit from) provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,765)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,457</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,222)</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (169,031)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (180,664)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,633</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:12pt 0pt 12pt 0pt;">Collaboration Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Collaboration revenue increased by $8.3 million in the year ended December 31, 2024, compared to the year ended December 31, 2023, primarily due to increases of $6.3 million from our collaboration with Novartis entered into in March 2023, $2.9 million from our collaboration with Genentech which was primarily<span style="color:#212529;background:#ffffff;">&#160;due to revenue recognized </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">upon the Genentech joint research committee&#8217;s decision to discontinue research activities for Collaboration Program #3 during the year ended December 31, 2024 and the resulting expiration of options that are material rights, and </span>$2.2 million from our collaboration with Bayer entered into in May 2023. These increases were offset by decreases in revenue of $1.9 million from our collaboration with Ionis due to the completion of the combined licenses and research and discovery performance obligation during the year ended December 31, 2024, and $1.2 million from our collaboration with AstraZeneca due to the termination of collaboration activities related to the fourth target and recognition of remaining deferred revenue during the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses for the years presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:59.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:59.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Zelenectide pevedotin (Nectin&#8209;4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,705</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,135</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,570</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BT5528 (EphA2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,119</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,195</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (76)</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BT1718 (MT1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 520</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (270)</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bicycle tumor-targeted immune cell agonists</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,840</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,878</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,038)</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discovery, platform and other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,043</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,252)</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee and contractor related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 58,687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,506</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,181</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Share-based compensation  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,424</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,581</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,843</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,845</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (740)</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development incentives and government grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (43,207)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,459)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,748)</span></p></td></tr><tr><td style="vertical-align:top;width:59.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 172,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 156,496</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,470</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by $16.5 million in the year ended December 31, 2024 compared to the year ended December 31, 2023, primarily due to increases of $38.6 million in clinical program expenses for <span style="color:#212529;background:#ffffff;">zelenectide pevedotin primarily due to the ongoing Phase II/III Duravelo-2 registrational trial which commenced recruiting patients in the first quarter of 2024,</span> $12.2 million in employee and contractor related expenses primarily attributable to increased headcount and $3.8 million of incremental share-based compensation expense primarily associated with equity grants issued since the prior year. These increases were offset by $18.7 million of incremental U.K. research and development tax incentives primarily associated with increased research and development spending as well as the impact of U.K. R&amp;D tax credit reimbursement rate changes enacted in February 2024, retroactively applied to April 1, 2023, as well as decreases of $11.0 million in Bicycle TICA program development expenses due to the timing of clinical program activities, $7.3 million in discovery, platform and other expenses primarily due to the reprioritization of our pipeline in August 2024, and $0.7 million in facility expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We begin to separately track program expenses at candidate nomination, at which point we accumulate all direct external program costs incurred to support that program to date. Through December&#160;31, 2024, we have incurred approximately $156.6&#160;million, $48.7&#160;million, and $15.7 million of direct external expenses for the development of zelenectide pevedotin, BT5528, and BT1718, respectively, since their candidate nominations, and an aggregate of $49.3&#160;million of direct external expenses for the development of the two named Bicycle<i style="font-style:italic;"> </i>TICA candidates since their nominations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our general and administrative expenses for the years presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel-related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,985</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,515</span></p></td></tr><tr><td style="vertical-align:top;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,258</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,814</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,444</span></p></td></tr><tr><td style="vertical-align:top;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other general and administration costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,047</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,137</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (90)</span></p></td></tr><tr><td style="vertical-align:top;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Share-based compensation  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,657</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,896</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,761</span></p></td></tr><tr><td style="vertical-align:top;width:51.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 719</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 594</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 125</span></p></td></tr><tr><td style="vertical-align:top;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 72,181</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,755</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $11.8 million in the year ended December 31, 2024 compared to the year ended December 31, 2023 primarily due to an increase of $5.4 million in professional and consulting fees primarily associated with increased legal and consulting fees to support our growth, an increase of $4.5 million increase in personnel-related costs primarily associated with increased headcount, as well as incremental share-based compensation of $1.8 million <span style="color:#212529;background:#ffffff;">primarily associated with equity grants issued since the prior year</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income, net increased by $25.3 million in the year ended December 31, 2024 compared to the year ended December 31, 2023, which was primarily due to an increase in interest and other income of $20.3 million related to higher interest rates as well as higher average interest-bearing cash and cash equivalents balances period over period, a gain on extinguishment of the research and development funding liability of $4.5 million as a result of the termination of our arrangement with Cancer Research UK for BT1718 in the fourth quarter of 2024, and a decrease in interest expense of $1.5 million due to the repayment and voluntary termination of the Loan Agreement in July 2024. These increases were offset by the loss on extinguishment of debt of $1.0 million recognized in the third quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">(Benefit From) Provision For Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>The benefit from income taxes of $4.8 million for the year ended December 31, 2024, is mainly the result of deferred tax assets benefited in the United States that do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement, including income tax benefits of approximately $3.5 million recognized during the third quarter of 2024 related to the completion of a U.S. research and development tax credit study. The provision for income taxes of $1.5 million for the year ended December 31, 2023 is primarily associated with a change in estimate that certain research and development expenses incurred by our U.S. subsidiary pursuant to an intercompany service arrangement are not required to be capitalized under IRC Section 174 because our U.S. subsidiary does not retain any ownership or rights in the underlying intellectual property resulting from the research activities, which resulted in an impact to the income tax provision of $2.4 million during the year ended December 31, 2023, offset by the impact of deferred tax assets benefited in the United States that do not have a valuation allowance against them because of profits that will be generated by the intercompany service agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From our inception in 2009 through December 31, 2024, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We do not expect to generate significant revenue from sales of any products for several&#160;years, if at all.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations primarily with proceeds from the sale of our ADSs, ordinary shares, non-voting ordinary shares and convertible preferred shares; proceeds received from upfront payments, payments for research and development services and development milestone payments pursuant to our collaboration agreements; and borrowings pursuant to our Loan Agreement with Hercules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the years ended December 31, 2024, 2023 and 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:56.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:56.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (164,724)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (60,628)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (86,111)</span></p></td></tr><tr><td style="vertical-align:top;width:56.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,235)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,929)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18,987)</span></p></td></tr><tr><td style="vertical-align:top;width:56.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 519,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 250,027</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,692</span></p></td></tr><tr><td style="vertical-align:top;width:56.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (694)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,346</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,120)</span></p></td></tr><tr><td style="vertical-align:top;width:56.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 353,097</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 187,816</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (99,526)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2024 was $164.7 million as compared to $60.6 million for the year ended December 31, 2023. The increase in cash used in operations of $104.1 million is primarily due to the timing of cash receipts in the prior year, including $95.0 million in upfront payments received pursuant to our collaboration agreements with Novartis and Bayer. In addition, during the year ended December 31, 2024, we have incurred higher cash payments associated with ongoing development activities to advance our pipeline, including the initiation of our Phase II/III Duravelo-2 registrational trial for zelenectide pevedotin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2024 and 2023, we used $1.2 million and $2.9 million, respectively, of cash in investing activities<span style="color:#212529;background:#ffffff;"> for purchases of property and equipment, consisting primarily of laboratory equipment</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, <span style="color:#212529;background:#ffffff;">net cash provided by financing activities was $519.8 million, primarily consisting of net proceeds of $544.1 million from the private placement completed in May 2024 and $7.5 million from the exercise of share options, offset by payments on debt of $31.9 million associated with the repayment and voluntary termination of the Loan Agreement</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, net cash provided by financing activities was $250.0 million, primarily consisting of net proceeds of $215.1 million from the underwritten public offering in July 2023, $34.2 million from our ATM program and $0.7 million from the exercise of share options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">At-the-Market Program</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>On June 5, 2020, we entered into a Sales Agreement with Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc., collectively, the Sales Agents, with respect to an at-the-market, or ATM, program pursuant to which we may offer and sell through the Sales Agents, from time to time at our sole discretion, ADSs. No ADSs were issued or sold pursuant to the Sales Agreement during the year ended December 31, 2024. As of December 31, 2024, we may offer and sell ADSs, representing the same number of our ordinary shares, having an aggregate offering price of up to $117.5 million under the Sales Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Loan Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 9, 2024, we repaid all amounts outstanding, including $30.0 million in outstanding borrowings, $0.1 million in accrued and unpaid interest, an end-of-term charge of $1.5 million and a prepayment charge of $0.3 million, for a total aggregate payment of $31.9 million, and terminated the Loan Agreement. Upon the termination of the Loan Agreement, all security interests granted to the secured parties thereunder were terminated and released. For additional information on the Loan Agreement, see Note 6. &#8220;Debt&#8221; of our consolidated financial statements included elsewhere in this Annual Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capital Resources and Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Our material cash requirements include expenses associated with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our development of our product candidates, including continuing current trials and conducting future clinical trials of zelenectide pevedotin, BT5528 and BT7480;</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify and develop additional product candidates, including expanding our pipeline of BRC molecules;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop the necessary processes, controls and manufacturing data to seek to obtain marketing approval for our product candidates and to support manufacturing of product to commercial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire and retain additional personnel, such as non-clinical, clinical, pharmacovigilance, quality assurance, regulatory affairs, manufacturing, distribution, legal, compliance, medical affairs, finance, commercial and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other products and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our infrastructure and facilities to accommodate our growing employee base, including adding equipment and infrastructure to support our research and development; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we obtain marketing approval for any product candidate that we identify and develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, and distribution are not the responsibility of our collaboration partners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the following table summarizes our contractual obligations as of December&#160;31, 2024 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods. For additional information, see Note 11. &#8220;Commitments and contingencies&#8221; of our consolidated financial statements.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments&#160;due&#160;by&#160;period</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less&#160;than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1&#160;to&#160;3&#160;years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">3&#160;years to&#160;5&#160;years</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:45.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease commitments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,964</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,818</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,146</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:top;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease commitments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,216</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 256</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 512</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 448</span></p></td></tr><tr><td style="vertical-align:top;width:45.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,074</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,658</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 448</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts reflect minimum payments due for our office and laboratory space leases. We have one office and laboratory lease in Cambridge, U.K. under an operating lease with a lease term through December 2026. We have two office and laboratory leases in Massachusetts, U.S. under operating leases that expire in March 2026 and December&#160;2027.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, we enter into various agreements with contract research organizations to provide clinical trial services, with contract manufacturing organizations to provide clinical trial materials, and with vendors for preclinical research studies, synthetic chemistry and other services for operating purposes. These payments are not included in the table above since the contracts are generally cancelable with advanced written notice, generally with a notice period of 90 days or less. From the time of notice until termination, we are contractually obligated to make certain minimum payments to the vendors, based on the timing of the notification and the exact terms of the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have<span style="background:#ffffff;"> also entered into separate agreements with third parties which provide for various future milestone payments upon the achievement of specified development, regulatory, commercial and sales-based milestones with an aggregate total value of $166.2 million, as well as potential future royalty and other payments at percentages ranging from very low to low single digits.</span> These additional milestone payments are contingent upon future events that are not considered probable of achievement as of December 31, 2024. As of December 31, 2024, we were unable to estimate the timing or likelihood of achieving these milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we had cash and cash equivalents of $879.5&#160;million. We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing of this Annual Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development of product candidates and programs, and because the extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise capital in light of the impacts of the unfavorable global economic and political conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results, and costs of drug discovery, preclinical development, laboratory testing, and clinical trials for the product candidates we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enroll clinical trials in a timely manner and to quickly resolve any delays or clinical holds that may be imposed on our development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with our manufacturing process development and evaluation of third-party manufacturers and suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing and submitting marketing approvals for any of our product candidates that successfully complete clinical trials, and the costs of maintaining marketing authorization and related regulatory compliance for any products for which we obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms of our current and any future license agreements and collaborations; and the extent to which we acquire or in-license other product candidates, technologies and intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our ongoing or future collaborations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain additional collaborations on favorable terms, if at all; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, monetization transactions, government contracts or other strategic transactions. To the extent that we raise additional capital through the sale of equity, ownership interests of existing holders of our ADSs and ordinary shares will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our ADSs or ordinary shares. If we raise additional funds through collaboration agreements, strategic alliances, licensing arrangements, monetization transactions, or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. Future debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt or equity financing that we raise may contain terms that are not favorable to us or our shareholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been significant disruptions to global financial markets that have contributed to a general global economic slowdown. The resulting high inflation rates may materially affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of our clinical trial materials and supplies, interest rates and overhead costs may adversely affect our operating results. High interest rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Additionally, the general consensus among economists suggests that we should expect a higher recession risk to continue over the next year, which, together with the foregoing, could result in further economic uncertainty and volatility in the capital markets in the near term, and could negatively affect our operations. Furthermore, such economic conditions have produced downward pressure on share prices. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates remain high or begin to rise again) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with geopolitical conflicts such as the ongoing wars involving Ukraine and Israel, worsening global macroeconomic conditions, and employee availability and wage increases, which may result in additional stress on our working capital resources. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in greater detail in Note&#160;2 to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The terms of these arrangements may include (i)&#160;performing research and development </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">services using our bicyclic peptide screening platform with the goal of identifying and/or optimizing compounds for further development and commercialization, (ii)&#160;the transfer of intellectual property rights (licenses), or (iii) options to obtain additional research and development services or licenses for additional targets, or to optimize product candidates, upon the payment of option fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of these arrangements typically include payment to us of one or more of the following: non-refundable upfront license fees; payments for research and development services and reimbursement of certain expenses incurred; fees upon the exercise of options to obtain additional services or licenses; payments based upon the achievement of defined collaboration objectives; future regulatory and sales-based milestone payments; and royalties on net sales of future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue in accordance with Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers,</i> or ASC 606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, and financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when, or as, we satisfy the performance obligations. We only apply the five-step model to contracts when it is probable that we will collect substantially all of the consideration we are entitled to in exchange for the goods or services we transfer to the customer. As part of the accounting for these arrangements, we must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each performance obligation based on estimated relative standalone selling prices, and measuring progress towards the satisfaction of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once a contract is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. The promised goods or services in our contracts with customers primarily consist of license rights to our intellectual property for research and development, research and development services, and options to acquire additional research and development services or options to obtain additional licenses, such as a commercialization license for a potential product candidate. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources, and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own and whether the required expertise is readily available. In addition, we consider whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We estimate the transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, we evaluate the amount of the potential payments and the likelihood that the payments will be received. We utilize either the most likely amount method or expected value method to estimate variable consideration to include in the transaction price based on which method better predicts the amount of consideration expected to be received. The amount included in the transaction price </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After determining the transaction price, we allocate it to the identified performance obligations based on the estimated standalone selling prices. We must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We utilize key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, probabilities of technical and regulatory success and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts we would expect to receive for each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We then recognize as revenue in the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of an arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property:</i> If a license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from the portion of the transaction price that is allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, such as research and development services and a research license, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services:</i> The promises under our collaboration agreements may include research and development services to be performed by us on behalf of the customer. Payments or reimbursements resulting from our research and development efforts are recognized as the services are performed and presented on a gross basis because we are the principal for such efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Customer Options:</i> A customer&#8217;s right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If we are not presently obligated to provide, and do not have a right to consideration for delivering additional goods or services, the item is considered an option. We evaluate customer options to obtain additional items (i.e.,&#160;additional license rights) for material rights, or options to acquire additional goods or services for free or at a discount. Optional future goods and services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. If optional future goods and services reflect a significant or incremental discount, they are material rights, and are accounted for as performance obligations. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Milestone Payments:</i> Our collaboration agreements may include development and regulatory milestones. We evaluate whether the milestones are considered probable of being reached and estimate the amounts to be included in the transaction price using the most likely amount method. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#8217;s control, such as marketing approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net loss in the period of adjustment. Milestone payments that may only be achieved after the exercise of a customer option are excluded from the initial determination of the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For sales-based royalties, including milestone payments based on the level of sales, we determine whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, we recognize revenue at the later of: (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any sales-based royalty revenue resulting from our collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include costs associated with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors related to product manufacturing and development and distribution of preclinical and clinical supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs, investigative sites or other service providers in connection with clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs, research institutions and vendors that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and actual results could differ from our estimates. As of December&#160;31, 2024, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</p><a id="_aef87dd4_cfaa_4d94_bc71_8b4acab4e199"></a><a id="ITEM7AQANTITATIVEANDQUALITATIVEDISCLOSUR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;7A.&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Rate Sensitivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31, 2024, we had cash and cash equivalents of $879.5 million. Our exposure to interest rate sensitivity is impacted by changes in the underlying U.K. and U.S. bank interest and treasury rates. Our surplus cash has been invested in money market funds that invest primarily in U.S. Treasury obligations and fully collateralized repurchase obligations and that maintain a constant net asset value. We have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments with short-term maturities, we do not believe an immediate one&#160;percentage point change in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interest rates would have a material effect on the fair market value of our portfolio. Our earnings would be affected by changes in interest rates due to the impact those changes have on interest income generated from our cash and cash equivalents. We believe we have minimal interest rate risk as a one&#160;percentage point change in the average interest rate on our portfolio would not have a material effect on our consolidated statements of operations and comprehensive loss for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Foreign Currency Exchange Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency is the currency of the primary economic environment in which an entity&#8217;s operations are conducted. The functional currency of Bicycle Therapeutics plc and Bicycle Therapeutics&#160;Inc. is the United States Dollar, or USD. The functional currency of Bicycle Therapeutics plc&#8217;s wholly owned non-U.S. subsidiaries, BicycleTx Limited and BicycleRD Limited, is the British Pound Sterling, and the consolidated financial statements are presented in USD. The functional currency of our subsidiaries is the same as the local currency. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in general and administrative expense in the consolidated statements of operations and comprehensive loss as incurred. We recorded foreign exchange losses of $0.7 million, $0.6 million and $0.6 million for the years ended December 31, 2024, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For financial reporting purposes, our consolidated financial statements have been translated into U.S. dollars. We translate the assets and liabilities of BicycleTx Limited and BicycleRD Limited into USD at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period and shareholders&#8217; equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining net loss but are included in our foreign currency translation adjustment included in the consolidated statements of shareholders&#8217; equity and as a component of accumulated other comprehensive income (loss) in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future.</p><a id="_62c45f3a_cf2e_47c6_90e8_25f59d6c7621"></a><a id="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The financial statements required by this item are set forth beginning on page F-1 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8780c9fe_8b0f_4a6a_8fa8_6df1ae9bb594"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_daca1a08_d4bf_4cc1_b504_eff4e11a1282"></a><a id="ITEM9ACONTROLSANDPROCEDURES_11536"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;9A.&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Control over Financial Reporting.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management conducted an assessment of our internal control over financial reporting based on the framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013). Based on the assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</b><b style="font-weight:bold;"><br/></b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their attestation report, which is included herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b29156ce_a38d_484e_afb7_94db30dfdfb3"></a><a id="ITEM9BOTHERINFORMATION_881554"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;9B.&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Insider Trading Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>During the three months ended December 31, 2024, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_e5TBDzWGQESUzP1nB09nGw">no</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_jgvjAb5Eb0mGYXYtlUXp9Q">ne</ix:nonNumeric> of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_DHt2946LgUy4cuWrZVclmQ">adopted</ix:nonNumeric> or <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_-Y_2TrBPF0OdRw6aJ7Vr9g">terminated</ix:nonNumeric> any contracts, instructions or written plans for the purchase or sale of our securities. </p><a id="ITEM_9C_DISCLOSURE_REGARDING_FOREIGN"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">ITEM 9C. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><a id="_a5bac8c9_cb81_4811_8ab0_41ade2f655c1"></a><a id="PARTIII_687409"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;10.&#160;&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</p><a id="_cp_text_1_823"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information About Our Directors and Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information required by this item will be contained in our Proxy Statement under the captions &#8220;Board of Directors and Corporate Governance&#8212;Board of Directors&#8221; and &#8220;Executive Officers of the Company&#8221; <span style="background:#ffffff;">and </span>is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Identification of Audit Committee and Financial Experts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Information regarding our Audit Committee required by this item will be contained in our Proxy Statement under the caption &#8220;Information Regarding the Board of Directors and Corporate Governance&#8212;Committees of the Board of Directors<span style="background:#ffffff;">&#8212;Audit Committee</span>,&#8221; and is hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Material Changes to Procedures for Recommending Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Information regarding procedures for recommending directors required by this item will be contained in our Proxy Statement under the caption &#8220;Information Regarding the Board of Directors and Corporate Governance&#8212;Nominating and Corporate Governance Committee&#8212;Shareholder Recommendations and Nominees,&#8221; and is hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Code of Business Conduct and Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Information regarding our Code of Business Conduct and Ethics required by this item will be contained in our Proxy Statement under the caption &#8220;Information Regarding the Board of Directors and Corporate Governance&#8212;Code of Business Conduct and Ethics,&#8221; and is hereby incorporated by reference. The full text of our Code of Business Conduct and Ethics is available at the investors section of our website at&#160;www.bicycletherapeutics.com.&#160;If we make any amendments to our Code of Business Conduct and Ethics, or grant any waiver from a provision of our Code of Business Conduct and Ethics to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Delinquent Section&#160;16(a) Reports</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Information regarding compliance with Section&#160;16(a) of the Exchange Act required by this item will be contained in our Proxy Statement under the caption &#8220;Delinquent Section&#160;16(a) Reports,&#8221; if any, and is hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Insider Trading Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_3uyC1kn92kq1g7OPB2BWgg">We adopted insider trading policies and procedures</ix:nonNumeric> governing the purchase, sale, and/or other dispositions of our ordinary shares by directors, officers, employees and consultants that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable listing standards. It is our policy to comply with all applicable laws and regulations relating to insider trading in connection with the repurchase of our securities. A copy of our Amended and Restated Insider Trading Policy, as amended, is filed as Exhibit 19.1 to this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_199e9a8c_0e6f_404a_8068_1acd93bf5df6"></a><a id="ITEM11EXECUTIVECOMPENSATION_896456"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;11.&#160;&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Information regarding our executive compensation required by this item will be contained in our Proxy Statement under the captions &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Pay Versus Performance&#8221; and &#8220;Director Remuneration,&#8221; and is hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_543876d4_a8e4_40e1_98f9_b77c89a6b419"></a><a id="ITEM12SECURITYOWNERSHIP_194439"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;12.&#160;&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</p><a id="_cp_text_1_827"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information required by this item will be contained in our Proxy Statement under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; and is hereby incorporated by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_98f76844_01b6_4b66_b642_0fc005040006"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;13.&#160;&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</p><a id="_cp_text_1_829"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information required by this item will be contained in our Proxy Statement under the captions &#8220;Board of Directors and Corporate Governance&#8212;Corporate Governance&#8212;Board Independence&#8221; and &#8220;Transactions with Related Persons&#8221; and is hereby incorporated by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cee1e007_5b82_4be4_b913_a6d27aadac44"></a><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;14.&#160;&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES.</p><a id="_cp_text_1_831"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Information regarding accounting fees and services required by this item will be contained in our Proxy Statement in the Proposal titled &#8220;Ratification of the Appointment of PricewaterhouseCoopers LLP as our U.S. Independent Registered Public Accounting Firm for the Year Ending December 31, 2025&#8221; under the captions &#8220;Independent Registered Public Accounting Firm Fees&#8221; and &#8220;Pre-Approval Policies and Procedures&#8221; and is hereby incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_41d6876e_42bb_477e_b75f_e2a0b9ffe52a"></a><a id="PARTIV_634070"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">ITEM&#160;15.&#160;&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The financial statements schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(a)(1) Financial Statements</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Report of Independent Registered Public Accounting Firm</span></a><span style="background:#ffffff;"> (PCAOB ID </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:AuditorFirmId" id="Narr_mcaVUFOT40ujPMeVOd3iyw"><span style="background:#ffffff;">876</span></ix:nonNumeric><span style="background:#ffffff;">)</span></p></td><td style="vertical-align:top;width:5.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_138799"><span style="font-style:normal;font-weight:normal;">Consolidated</span><span style="font-style:normal;font-weight:normal;"> Balance Sheets as of December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperationsandCom"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofConvertiblePrefe"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Consolidated Statements of Shareholders&#8217; Equity for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_57561"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-8</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_3"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(a)(2) Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a)(3) Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The exhibits listed below are filed as part of this Annual Report other than Exhibit 32.1, which shall be deemed furnished:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Number</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Description</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837024010949/bcyc-20240630xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Association, dated May 16, 2024 (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q (File No. 001-38916) filed with the Securities and Exchange Commission on August 6, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000104746919003038/a2238712zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Deposit Agreement (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-231076), filed with the Securities and Exchange Commission on May 13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000104746919003038/a2238712zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of American Depositary Receipt (included in Exhibit 4.1) (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-231076), filed with the Securities and Exchange Commission on May 13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837020012697/bcyc-20200930ex41acb0f9b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement, dated July 1, 2020, between Bicycle Therapeutics plc and Citibank, N.A. (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on November 5, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837021002758/bcyc-20201231ex446072044.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Letter Agreement, dated October 27, 2020, between Bicycle Therapeutics plc and Citibank, N.A. (incorporated by reference to Exhibit 4.4 to Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 11, 2021).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Number</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Description</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837021010379/bcyc-20210630xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Letter Agreement, dated May 24, 2021, between Bicycle Therapeutics plc and Citibank, N.A. (incorporated by reference to Exhibit 4.1 to Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on August 5, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex4d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.1+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000104746919002638/a2238403zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Share Option Contract of Bicycle Therapeutics Limited for employees in England (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 (File No. 333-231076), filed with the Securities and Exchange Commission on April 26, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.2+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000104746919002638/a2238403zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Share Option Contract of Bicycle Therapeutics Limited for employees in the United States (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-231076), filed with the Securities and Exchange Commission on April 26, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.3+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000155837019010277/bcyc-20190930ex1032a60cf.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Rules of the Bicycle Therapeutics Share Option Plan, as amended on September 12, 2019 (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q (File No. 001-38916) filed with the Securities and Exchange Commission on November 7, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.4+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/bcyc-20191231ex104df6dea.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Forms of award agreements under the Bicycle Therapeutics Share Option Plan, as amended (incorporated by reference to Exhibit 10.4 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 10, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000104746919003038/a2238712zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2019 Employee Share Purchase Plan (incorporated by reference to Exhibit 10.5 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-231076), filed with the Securities and Exchange Commission on May 13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.6+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023002238/bcyc-20221231xex10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bicycle Therapeutics plc 2020 Equity Incentive Plan, or the 2020 Plan and forms of awards thereunder (incorporated by reference to Exhibit 10.6 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on February 28, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.7+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Option Grant Notice and Agreement (for employees) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.8+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Option Grant Notice and Agreement (for non-employees) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.9+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Share Unit Grant Notice and Agreement (for employees) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.10+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Restricted Share Unit Grant Notice and Agreement (for employees) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.11+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Share Unit Grant Notice and Agreement (regular settlement for directors) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.12+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Restricted Share Unit Grant Notice and Agreement (regular settlement for directors) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.13+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Share Unit Grant Notice and Agreement (deferred settlement for directors) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.14+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Restricted Share Unit Grant Notice and Agreement (deferred settlement for directors) for the 2020 Plan.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.15+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000110465924086332/tm2420494d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bicycle Therapeutics plc 2024 Inducement Plan, or the 2024 Plan (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 (File No. 333-281304), filed with the Securities and Exchange Commission on August 6, 2024).</span></a></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Number</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Description</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.16+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000110465924086332/tm2420494d1_ex99-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Option Grant Notice and Option Agreement for the 2024 Plan (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-8 (File No. 333-281304), filed with the Securities and Exchange Commission on August 6, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.17+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000110465924086332/tm2420494d1_ex99-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of RSU Grant Notice and RSU Agreement for the 2024 Plan (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-8 (File No. 333-281304), filed with the Securities and Exchange Commission on August 6, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.18+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000104746919003038/a2238712zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-231076), filed with the Securities and Exchange Commission on May 13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.19+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000110465919052038/a19-19170_2ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Service Agreement, dated September 26, 2019, by and between BicycleTx Ltd. and Kevin Lee (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-38916) filed with the Securities and Exchange Commission on September 30, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.20+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023017317/bcyc-20230930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Service Agreement, dated July 24, 2023, by and between BicycleTx Limited and Kevin Lee (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-38916) filed with the Securities and Exchange Commission on November 2, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.21+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023013057/bcyc-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated June 22, 2023, by and between Bicycle Therapeutics Inc. and Alethia Young (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on August 3, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.22+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/bcyc-20191231ex1097f5a2c.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated September 26, 2019, by and between BicycleTx Ltd. and Michael Skynner, Ph.D. (incorporated by reference to Exhibit 10.9 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 10, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.23+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837022002457/bcyc-20211231xex10d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated January 6, 2022, by and between BicycleTx Ltd. And Michael Skynner, Ph.D. (incorporated by reference to Exhibit 10.11 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 1, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.24+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023007979/bcyc-20230331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2 to Service Agreement, dated February 20, 2023, by and between BicycleTx Limited and Michael Skynner (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on May 4, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.25+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837024010949/bcyc-20240630xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Service Agreement, dated March 18, 2024, by and between BicycleTx Ltd. and Michael Charles Ferguson Hannay (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on August 6, 2024).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.26+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001761612/000155837020002278/bcyc-20191231ex10116116f.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Service Agreement, dated September 26, 2019, by and between BicycleTx Ltd and Nigel Crockett, Ph.D. (incorporated by reference to Exhibit 10.11 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.27+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023007979/bcyc-20230331xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Service Agreement, dated February 20, 2023, by and between BicycleTx Limited and Nigel Crockett (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on May 4, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.28+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837020005538/bcyc-20200331ex1011f0973.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of letter agreement to amend Service Agreement by and between the BicycleTx Ltd. and its executive officers in the United Kingdom, effective January 1, 2020 (incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on May 7, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Number</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Description</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.29+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023007979/bcyc-20230331xex10d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 31, 2023, by and between Bicycle Therapeutics Inc. and Santiago Arroyo (incorporated by reference to Exhibit 10.7 to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on May 4, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.30+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837021002758/bcyc-20201231ex102755560.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of letter agreement to amend Service Agreement by and between the BicycleTx Ltd. and its executive officers in the United Kingdom, effective January 1, 2021 (incorporated by reference to Exhibit 10.27 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 11, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.31+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837022002457/bcyc-20211231xex10d17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Service Agreement, dated January 5, 2022, by and between BicycleTx Ltd. and Alistair Milnes (incorporated by reference to Exhibit 10.17 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 1, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.32+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023007979/bcyc-20230331xex10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Service Agreement, dated February 20, 2023, by and between BicycleTx Limited and Alistair Milnes (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on May 4, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.33+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000110465924048576/tm2412008d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement, dated as of April 17, 2024, by and between Bicycle Therapeutics plc and Veronica Jordan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-38916), filed with the Securities and Exchange Commission on April 18, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.34+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000110465919062674/a19-22563_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Deed of Indemnity between the Company and each of its directors (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K (File No. 001-38916), filed with the Securities and Exchange Commission on November 12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.35+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000110465919062674/a19-22563_1ex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Deed of Indemnity between the registrant and each of its executive officers (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K (File No. 001-38916), filed with the Securities and Exchange Commission on November 12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.36+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex10d36.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Policy, as amended as of December 12, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.37&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/bcyc-20191231ex1018192ea.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Discovery Collaboration and License Agreement between BicycleTx Limited and Genentech, Inc., dated February 21, 2020 (incorporated by reference to Exhibit 10.18 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 10, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.38&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837022012050/bcyc-20220630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the Discovery Collaboration and License Agreement, dated November 5, 2021, by and between Genentech, Inc. and BicycleTx Limited (incorporated by reference to Exhibit 10.1 to Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on August 4, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.39&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837022012050/bcyc-20220630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to the Discovery Collaboration and License Agreement, dated June 27, 2022, by and between Genentech, Inc. and BicycleTx Limited (incorporated by reference to Exhibit 10.2 to Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on August 4, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.40&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023002238/bcyc-20221231xex10d25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to the Discovery Collaboration and License Agreement, dated October 26, 2022, by and between Genentech, Inc. and BicycleTx Limited (incorporated by reference to Exhibit 10.25 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on February 28, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.41&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001761612/000155837021014435/bcyc-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement, dated as of July 9, 2021, between BicycleTx Limited and Ionis Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on November 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Number</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Description</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.42&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837022002457/bcyc-20211231xex10d25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Collaboration and License Agreement, dated December 17, 2021, between BicycleTx Limited and Ionis Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.25 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on March 1, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.43&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837022016140/bcyc-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2 to Collaboration and License Agreement, dated August 1, 2022, between BicycleTx Limited and Ionis Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on November 3, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.44&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023013057/bcyc-20230630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 3 to Collaboration and License Agreement, dated April 27, 2023, between BicycleTx Limited and Ionis Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on May 4, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.45&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837024006453/bcyc-20240331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 4 to Collaboration and License Agreement, dated January 17, 2024, between BicycleTx Limited and Ionis Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on May 2, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.46</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001761612/000155837021014435/bcyc-20210930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Share Purchase Agreement, dated as of July 9, 2021, between Bicycle Therapeutics plc and Ionis Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Form 10-Q (File No. 001-38916), filed with the Securities and Exchange Commission on November 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.47&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023007979/bcyc-20230331xex10d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and Licence Agreement, dated March 27, 2023, by and between BicycleTx Limited and Novartis Pharma AG (incorporated by reference to Exhibit 10.8 to the Quarterly Report on Form 10-Q (File No. 001-38916) filed with the Securities and Exchange Commission on May 4, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.48&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837023013057/bcyc-20230630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and Licence Agreement, dated May 4, 2023, by and between BicycleTx Limited and Bayer Consumer Care AG (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-38916) filed with the Securities and Exchange Commission on August 3, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.49</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000110465924048576/tm2412008d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of April 18, 2024, by and among Bicycle Therapeutics plc and 667 L.P. and Baker Brothers Life Sciences L.P. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K (File No. 001-38916) filed with the Securities and Exchange Commission on April 18, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">10.50</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000110465924064716/tm2415400d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement, dated as of May 23, 2024, by and among Bicycle Therapeutics plc and purchasers named therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-38916), filed with the Securities and Exchange Commission on May 23, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">19.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Insider Trading Policy, as amended (adopted September 26, 2019 and amended September 27, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1761612/000104746919002638/a2238403zex-21_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-231076), filed with the Securities and Exchange Commission on April 26, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#POWEROFATTORNEY_259162"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on the signature page of this report).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Number</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">Description</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:89.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bcyc-20241231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">97.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1761612/000155837024001324/bcyc-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Incentive Compensation Recoupment Policy (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K (File No. 001-38916), filed with the Securities and Exchange Commission on February 20, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Instance Document.</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents.</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="background:#ffffff;">Cover page interactive data file (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.8%;margin:0pt;padding:0pt;"/></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"><a id="_cp_text_1_849"></a><a id="_cp_text_1_850"></a></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;">*&#160;&#160;&#160;&#160;&#160;Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</p><a id="_cp_text_1_851"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">+</b>&#160;&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#8224;&#8224;&#160;&#160;&#160;&#160;Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain portions of this exhibit (marked by [***]) have been omitted because the identified information is not material and is the type that the registrant treats as private or confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7115e644_fa1e_46da_bcf6_1f9116d5977a"></a><a id="ITEM16FORM10KSUMMARY_15998"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 16. </b></span><b style="font-weight:bold;">FORM 10-K SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0a92affb_cab1_4d68_ba4d_d8ad71cadc1b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Index to Consolidated Financial Statements of </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Bicycle Therapeutics plc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Report of Independent Registered Public Accounting Firm (PCAOB ID 876)</span></a></p></td><td style="vertical-align:top;width:5.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_138799"><span style="font-style:normal;font-weight:normal;">Consolidated</span><span style="font-style:normal;font-weight:normal;"> Balance Sheets as of December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperationsandCom"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofConvertiblePrefe"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Consolidated Statements of Shareholders&#8217; Equity for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_57561"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-8</p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_3"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F<b style="font-weight:bold;">-</b>9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f5660570_8e16_4afb_96b4_fc5641a7acaf"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the Board of Directors and Shareholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of Bicycle Therapeutics plc<b style="font-weight:bold;"> </b>and its subsidiaries<b style="font-weight:bold;"> </b>(the &#8220;Company&#8221;) as of December 31, 2024 and 2023,<b style="font-weight:bold;"> </b>and the related consolidated statements of operations and comprehensive loss, of shareholders&#8217; equity and of cash flows<b style="font-weight:bold;"> </b>for each of the three years in the period ended December 31,<b style="font-weight:bold;"> </b>2024, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).<b style="font-weight:bold;"> </b>We also have audited the Company's internal control over financial reporting as of December 31,<b style="font-weight:bold;"> </b>2024, based on criteria established in <i style="font-style:italic;">Internal Control - Integrated Framework</i> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In our opinion, the consolidated<b style="font-weight:bold;"> </b>financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31,<b style="font-weight:bold;"> </b>2024 and 2023<b style="font-weight:bold;">, </b>and the results of its operations and its cash flows for each of the three years in the period ended December 31,<b style="font-weight:bold;"> </b>2024<b style="font-weight:bold;"> </b>in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31,<b style="font-weight:bold;"> </b>2024, based on criteria established in <i style="font-style:italic;">Internal Control - Integrated Framework</i> (2013) issued by the COSO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying<b style="font-weight:bold;"> </b>Management's<b style="font-weight:bold;"> </b>Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated<b style="font-weight:bold;"> </b>financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated<b style="font-weight:bold;"> </b>financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audits of the consolidated<b style="font-weight:bold;"> </b>financial statements included performing procedures to assess the risks of material misstatement of the consolidated<b style="font-weight:bold;"> </b>financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated<b style="font-weight:bold;"> </b>financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated<b style="font-weight:bold;"> </b>financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;">dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the<b style="font-weight:bold;"> </b>consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated<b style="font-weight:bold;"> </b>financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Revenue recognition - Estimating costs to complete the performance obligations in collaboration and license agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As described in Note<span style="color:#ff0000;"> </span>9 to the consolidated financial statements, the Company recorded $35.3 million of revenue for the year ended December 31, 2024, in connection with collaboration and license agreements. As disclosed by management, the Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an input method. Management evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of an arrangement. Management recognizes revenue related to amounts allocated to the performance obligations in the collaboration and license agreements as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of full-time equivalent efforts and external costs incurred to date as a percentage of total expected full-time equivalent efforts and external costs, which best reflects the progress towards satisfaction of the performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The principal considerations for our determination that performing procedures relating to estimating costs to complete the performance obligations in collaboration and license agreements is a critical audit matter are (i) the significant judgment exercised by management in determining the total costs to complete the performance obligations under such collaboration and license agreements, and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to the expected full-time equivalent efforts and external costs to complete the performance obligations under such collaboration and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to estimating costs to complete the performance obligations in collaboration and license agreements.<b style="color:#ff0000;font-weight:bold;"> </b>These procedures also<span style="color:#ff0000;"> </span>included, among others, (i) testing management&#8217;s process for determining estimated costs to complete the performance obligations under the respective collaboration and license agreements, (ii) evaluating the appropriateness of the input method used by management for the recognition of revenue, (iii) testing the completeness, accuracy, and relevance of the data used by management in determining the estimated costs, and (iv) evaluating the reasonableness of the significant assumptions used by management related to the expected full-time equivalent efforts and external costs to complete the performance obligations. Evaluating the reasonableness of significant judgments and assumptions related to the expected full-time equivalent efforts and external costs involved (i) evaluating the identification of circumstances that may warrant a change to estimated costs to complete, (ii) testing the actual costs incurred, and (iii) performing retrospective reviews of costs incurred to evaluate management&#8217;s ability to estimate future costs to complete performance obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:AuditorName" id="Narr_qgulTrCGjkWxT0Uzjt_Iuw">PricewaterhouseCoopers LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="dei:AuditorLocation" id="Narr_zV_MJq5QuUGxLa9hv5zBIA">Cambridge, United Kingdom</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">February 25, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as the Company&#8217;s auditor since 2010.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 4.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ConsolidatedBalanceSheets_138799"></a><a id="_80e30bb2_e1a8_4320_92f5_26fd859e8a60"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Bicycle Therapeutics plc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_27c56a12_c09b_478c_95b8_e980599f2e7b"></a><a id="Tc_Sq9nZMWBGUiD9wevZ7qCjA_1_2"></a><a id="Tc_aYHxu1ed9UCoKvFScEat7Q_1_5"></a><a id="Tc_KzO_0RsVLEmYPIHTiGBDnw_2_2"></a><a id="Tc_ZFjLuu5aXEuuLa5jVhu9mw_2_5"></a><a id="Tc_vAZD4Xc61kK7deVm7P2xSw_3_0"></a><a id="Tc_KfPxanE2zEqfUIriy2vCHg_4_0"></a><a id="Tc_kUYGwncHzUWT9WdilBFgwA_5_0"></a><a id="Tc_ye9ZDwO2gkKn-eZQ-nNnvQ_5_2"></a><a id="Tc_c0gyr0abiESkXjxjBSKUSg_5_5"></a><a id="Tc_he4ixzdCREW70CmwVI6_ew_6_0"></a><a id="Tc_uopdKjrgwUaU9dy8YUoe6A_7_0"></a><a id="Tc_hXkKJWbUOEyG6KPLhwwKrA_8_0"></a><a id="Tc_M0SyA4UCck21983YI0KoxA_9_0"></a><a id="Tc_jmwgieNGH0qCzSxl2oeYtA_10_0"></a><a id="Tc_Oya_xMW35kiOyhqIFvZ6Ug_11_0"></a><a id="Tc_vunczu2R20yLaSKu7R9gDw_12_0"></a><a id="Tc_eDN988G2f0iIzLGOyBYKNA_12_2"></a><a id="Tc_18nWJJdBl0aKbcfKZVWbag_12_5"></a><a id="Tc_EhQTYlL8mkGwhDgowYcZ0A_13_0"></a><a id="Tc_Wehnjgdew0ezQGifgtoTZQ_14_0"></a><a id="Tc_0z70nMaxgkKKgOGfoQw5jA_15_0"></a><a id="Tc_yH0ayo7DIU2SvrRMTyX19A_15_2"></a><a id="Tc_Pg0Dx1p0ykWakOaHNIn4Yg_15_5"></a><a id="Tc_sETH8SzGd0u_JR7fyXWDUw_16_0"></a><a id="Tc_Lfv96jfzXE6-CS5KfsZtuQ_17_0"></a><a id="Tc_Tk30J4HKgUKVRQE8UtBl6w_18_0"></a><a id="Tc_t85BRTUBN0yve_ud4JUPMQ_19_0"></a><a id="Tc_jNMM7UHN7EK33ORud58Oeg_19_3"></a><a id="Tc_JmWPYAKjxEGYiG07ImKh3A_20_0"></a><a id="Tc_feo_SjanS0CdtrrJXzwejg_21_0"></a><a id="Tc__kYun4MkYUSv5nnZQBAdDw_22_0"></a><a id="Tc_PVJoW5ZJv0a8mgn013UvVw_23_0"></a><a id="Tc_G8dfgxsBdkqfVc4wjDS68A_24_0"></a><a id="Tc_Onr83gqd8kukW3sn7nHR2g_25_0"></a><a id="Tc_NRDKS9WjGEipC-e2Sn4ajQ_26_0"></a><a id="Tc_aOx5MOo3HUug1SWbo3XWnQ_27_0"></a><a id="Tc_tpdq_3J36Ua2pwztSTZEfw_28_0"></a><a id="Tc_MKeesSZy8k6RnZ_UID73UQ_29_0"></a><a id="Tc_pCCVr7X8Y0KiehtzKNQ8HA_30_0"></a><a id="Tc_vqENQmQ6QUWzb_IozwUz8Q_31_0"></a><a id="Tc_7_nPflegcUqW_QOm87VRbA_31_2"></a><a id="Tc_8lH81YfuYEuVPEBdEfA1OA_31_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_TEPO02NCRUCMPKNRDeo3zw_5_3">879,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_4JQ0zOJ3CUuGkt5jH-qNpg_5_6">526,423</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_6R3WCQx_0Ue56YrfHlQ8Rg_6_3">13,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_tqa9W3w8L02hFSmdPPOwSw_6_6">11,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Research and development incentives receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentIncentivesReceivableCurrent" scale="3" id="Tc_-8Q5UQr0pkO1U_8a5sOQkw_7_3">35,653</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentIncentivesReceivableCurrent" scale="3" id="Tc_sCTWW-Os00OxPQrp0iKimg_7_6">24,039</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_44mVsT2ACUGk7fOorPl9Vw_8_3">928,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_hW28rEwKREOgrat_QPtoxQ_8_6">561,868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_fG3O3ARjJ0y0bg8QmG4ZrQ_9_3">9,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_jRsCeSYLike7Q1qvvB-uiQ_9_6">14,515</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_UA54MpyS106rZSXw7fbE1w_10_3">7,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_lL8Hha4z2k6C_07ckY6HXg_10_6">13,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_6NBNY0wxukihVNkofhd8RQ_11_3">11,074</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_sSm2IdHaG0alCl2E0d7YsQ_11_6">5,792</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_orSyzO6F3EKDy0wcSARtjA_12_3">956,868</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_Db_RXM5Rd0GuTzBqtTXlvA_12_6">595,344</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_1vGjzkGzD0ayINNNy5N7sw_15_3">15,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_3qYCwBAZPkuqgtMjfE26gA_15_6">13,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_7A0pG3Xg2Ead5-3M0OljQA_16_3">41,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_B6ghhvq35028VHOkOBUj_g_16_6">31,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_gpz8di5J6ECjeEp6PcYBig_17_3">10,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_4RCVnC893k-Be89VPFxT3w_17_6">24,978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_sWXrY6AJlUaLHken547h9g_18_3">67,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_U_96kKR1F0-b80nEtA1KiA_18_6">69,537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Long-term debt, net of discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_7dxhMwTVZkCQjYKFzrNWEQ_19_6">30,698</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_7PaVTIU_sUOFMLGTR-wGJw_20_3">3,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_1HUtyWelIkO3P4rS0_KP6g_20_6">9,382</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="Tc_UsLzgMmM_EemZfpgtv4ScA_21_3">91,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="Tc_mx87ZUQfmUC_jCj3vY83Eg_21_6">110,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other long&#8209;term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_Sl6Efpf7DU-VwxxQYdWoTw_22_3">1,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_A6MCfcOySESlmznAm9AT9w_22_6">4,579</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_ImeTtrHlBEu5vj7X8yBunw_23_3">163,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_QFehG46fWkOJ0HkGO5MXBQ_23_6">224,412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Commitments and contingencies (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Shareholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Ordinary shares, including non-voting ordinary shares, &#163;<ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_pGuSZkx0tUaxbcu6OqQMgA"><ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_tWtWbUyv2U6UKqL39fR2dQ">0.01</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_OcBOm7VyCkWXToG-veamJQ">155,876,645</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ZIpKHPmLIkqJLp54sZ1g9g">59,612,613</ix:nonFraction> shares authorized at December 31,&#160;2024 and December 31,&#160;2023, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_9tbUKZKU5UeNfrdJAwn6tg"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_HMrFlNJX10uf3TMmc7TK6w">69,061,418</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_eZ-VX68cL0ap56pd3ufUXw"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_ZawGuXXiq0-TG9CN9HKpew">42,431,766</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024 and December 31,&#160;2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_YM_It4MNs0ei2hxqh7prqg_26_3">890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_JQ6cuw0zdEuqNiRcWhw8OQ_26_6">550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_nf8N61aIHUCMv4MfX9Vy6w_27_3">1,472,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_gg1FFKtFFU-_jDsMZLl8cw_27_6">883,446</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_eeQZGN3S2Umjr-AxVyr4tw_28_3">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_DVG-Kj2onU-zygD8JMjzAw_28_6">1,304</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_exwNFRMaZ0KodHQ5fUdP8w_29_3">680,791</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_uMfZOPD-n0SDfkCh7TWr_g_29_6">511,760</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total shareholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AdkRNKyjE0m9K6KhQ4PqZQ_30_3">793,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VA3YmlpGF0eBXJgGmMQovQ_30_6">370,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities and shareholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_JpFHMsppaky9PC3Ievs4tw_31_3">956,868</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_fI8jU41ykk-WcATcPDNB4g_31_6">595,344</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of the consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="ConsolidatedStatementsofOperationsandCom"></a><a id="_d04be374_ddc5_4acc_9fe7_d484f70e50ae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Bicycle Therapeutics plc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b820e4af_ad35_4c41_82cb_d9d37624bc27"></a><a id="_d6d2125c_479e_4b95_b919_fe24aff2d84b"></a><a id="Tc_pOJG67f5yUWeJFrblo-I6w_1_2"></a><a id="Tc_F4UNyko_8UKTUdtbZsmnUQ_2_2"></a><a id="Tc_pDVc0tgMTEyNrMeOin8Y7g_3_2"></a><a id="Tc_YNb0wW5De0yOp1Ysho7egQ_3_5"></a><a id="Tc_n1ypewXphEu8gkFJ6sUMvw_3_8"></a><a id="Tc_rBNYyi-Ye0etd-DFHaB8Rg_4_0"></a><a id="Tc_jAemMZ6XJE2bY5zgA2Iy0w_4_2"></a><a id="Tc_6doXdxG7UkiK13IW20jB1g_4_5"></a><a id="Tc_U-gDINd0lki04mWBy_wP_A_4_8"></a><a id="Tc_DZJ12ALsq023IcMHzOlLcA_5_0"></a><a id="Tc_BnLnhGeOTkS_SwXxj9Yf1Q_6_0"></a><a id="Tc_N8R0iYeHREOwtCqOAwxsag_7_0"></a><a id="Tc_Fukrc8Ezu0am07YNmrfJ5A_8_0"></a><a id="Tc_5MmZoB-g9k21Dm_qub633Q_9_0"></a><a id="Tc_BAYIjogRvEKs10d1ftI6Ag_10_0"></a><a id="Tc_OcF7TsT2SU-KIBs_Uku1cA_11_0"></a><a id="Tc_PF-k_pYEsE2ymJV2pOB6yw_12_0"></a><a id="Tc_8wcbm0Q0KEu5Q0Nhi4w25Q_13_0"></a><a id="Tc_MDadA5HBuUuhNn0U70dOqA_13_6"></a><a id="Tc_EmcJZWVRGES8tfCdCwp8fQ_13_9"></a><a id="Tc_rpWLV0alw02-mMouGYgkng_14_0"></a><a id="Tc_evvsok6zXUO_-z7byrW0Lg_14_6"></a><a id="Tc_hK5t7uav60mqTSbJ_eXZpA_14_9"></a><a id="Tc_3FbqR2KRPUKUPtA80BSrIQ_15_0"></a><a id="Tc_gwHO6nUbGkitYVwmSjxvHg_16_0"></a><a id="Tc_Xq2bKYN4oEm0ZBre_lq1og_17_0"></a><a id="Tc_TR2PISm__kiKbcjP_tjwsA_18_0"></a><a id="Tc_5RVl0YeTYE69uCZ2l61MjQ_18_2"></a><a id="Tc_jX26wXRHtkqsTf3SKFJycA_18_5"></a><a id="Tc_hFhuqbtANk6wSSVMwnGTqQ_18_8"></a><a id="Tc_RpGjTV_hikiDn0r7WOdlOQ_19_0"></a><a id="Tc_FHXwxCf2IkKzY3rm1QYoGw_19_2"></a><a id="Tc_A9lO1CYjyEWsisu6ogcYDw_19_5"></a><a id="Tc_fZVFqr2N006F7uclOyJIYw_19_8"></a><a id="Tc_MR2EsiT5-UyabJ-wP063NQ_20_0"></a><a id="Tc_17T7NoZ3Wk6T-xbQ2IqYeg_22_0"></a><a id="Tc_KrTKewcNeE-l-Ji4bE-skQ_23_0"></a><a id="Tc_ijFprm52l02BeVS5mqx3Yw_23_2"></a><a id="Tc_9cJM-0ClGEO0E4lqJ0goGw_23_5"></a><a id="Tc_DQefqAl8CEGaFF0FjVUA-g_23_8"></a><a id="Tc_sS_HnSRHn02Dh62hKCRR4g_24_0"></a><a id="Tc_wuf0z14DjEq-VIdLaKaROQ_25_0"></a><a id="Tc_GeAQSOeHp0qp54YfMyiC7g_26_0"></a><a id="Tc_WUn1q1CfAU-QjrGfbK35Tg_26_2"></a><a id="Tc_1uewWuJPH02cT8cg7UJHeQ_26_5"></a><a id="Tc_pn97wIbTr0aieOM9cwaDUA_26_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_U_5tsnMbKU6izfmUbV31uA_4_3">35,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_GFrwoEDlK0W2XH2-f6ZqzQ_4_6">26,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_0zTWW2wotE6Nyup72CY_Wg_4_9">14,463</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_7D0xIk91JkezNOUDVVmxeg_6_3">172,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_NtjaQrF61kS1A1VlqXFcOQ_6_6">156,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_z3qGbYkGMUWhzdGZHPEwFA_6_9">81,609</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_yntlJMgFekicTYVDw8z3vg_7_3">72,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_sZLSyyaCn0erWTW88GLJzw_7_6">60,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_6KnacaCNOUKCSQd6hIordQ_7_9">49,507</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_ZPDh56JAcEOB7Kx5JN6XPA_8_3">245,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_AOqZLdDjKkeXDBKGXIIrrA_8_6">216,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_k-t6JhNuEUamFB-SwHvZoA_8_9">131,116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_cER7Y54lF0GubujtyaOGXQ_9_3">209,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_EgojgkLfR0av8PeLko-X3A_9_6">189,946</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_SiOgSwEbO0iB9ZLoxaYMaw_9_9">116,653</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="Tc_3JJShh-ldkyBUr3E4IBuJg_11_3">34,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="Tc_s1ArO5wG6Ey__JzUGEXiCA_11_6">14,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="Tc_N8zXLwcHZ0alFmcdDx1v4g_11_9">5,756</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_zgL-F9yYe0C90LG84v7PoA_12_3">1,730</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_r4hnJvcBKEOQj3QPGYjnJw_12_6">3,263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_gEx-E7eHsUGKSTvu0mL0Iw_12_9">3,344</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_12jCDkLlBU2yHp56uo0q4A_13_3">954</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain on extinguishment of research and development funding liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" scale="3" id="Tc_lL2zAjF7a0Cy8RbX-k9RPg_14_3">4,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_AALqWln6QEyZrRtmVMfoFw_15_3">36,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_xpWv84bpAkaKg18lzHIPBg_15_6">10,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_DylQ8giHA0evoz78BwT3_A_15_9">2,412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss before income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_II0rJHLDskSRc36YVVOIvw_16_3">173,796</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_kVAg-XxOd06qO6BT3ZgFZw_16_6">179,207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_xYS5lvwejkaEbZw3bt-3vA_16_9">114,241</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Benefit from) provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_OLhNfOWiRE2fYcLjlvbupg_17_3">4,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_-mghNzYsqk6v5gy4B3AwUA_17_6">1,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_Is6rA3PLf0mDSWxhmeq26g_17_9">1,524</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_dTK4b-ML00qeJSI0wVpokQ_18_3">169,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PhiAQOuix0yifdWucANaqA_18_6">180,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_AoIs33qW-kW4vzHufcG-3A_18_9">112,717</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_tN9_WG89zkOz2g1lqqzyIA_19_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_tN9_WG89zkOz2g1lqqzyIA_19_3_2">2.90</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NldJMR8JsES9oQitIlw6og_19_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_NldJMR8JsES9oQitIlw6og_19_6_2">5.08</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Oknb-ZIbL0ao1R1V--XKZw_19_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Oknb-ZIbL0ao1R1V--XKZw_19_9_2">3.80</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average ordinary shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Mx-2zMKqxU-emRj-nxEwrQ_20_3"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Mx-2zMKqxU-emRj-nxEwrQ_20_3_2">58,207,593</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_gsslnCc6T0OIQHJG9HcgXA_20_6"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_gsslnCc6T0OIQHJG9HcgXA_20_6_2">35,592,362</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_YUM9LdTjpEG9EkZHZAEHEw_20_9"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_YUM9LdTjpEG9EkZHZAEHEw_20_9_2">29,660,659</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensives loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_92hzwotLoUOhycE9Y7TvMg_23_3">169,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eGNers5R8kuB4qHhIguerQ_23_6">180,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UwOG43pZ0kWMXvyLTomjeg_23_9">112,717</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive income (loss):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_3KPyFfWzT0qLBocxzK9z4g_25_3">1,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_q0VLbCWcTk-0p7aXtlkkqg_25_6">1,691</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_2_Xxv5TbWUqYp9vwfc_IgA_25_9">3,775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_SZYZKvBV0kC-zSfDHS3mDg_26_3">167,608</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_i1CaoAlZt0a-7XNo5PqHGg_26_6">182,355</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_e2OE1c_d_U610wWW42fgrw_26_9">108,942</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of the consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2add719c_e78d_463a_b280_34026f65ae41"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Bicycle Therapeutics plc</p><a id="ConsolidatedStatementsofConvertiblePrefe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Shareholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1b5fffca_2087_4600_bd60_f5d941944c5c"></a><a id="Tc_sd7ygx6kw0eqNiTffnoo7g_1_10"></a><a id="Tc_-8SCkSy9T0GNfTeiihHz6w_2_7"></a><a id="Tc_VeGgWn3o-ESYiNMAvx5ydg_2_10"></a><a id="Tc_gwymyAHtdU6H4sWxQwyh3w_2_16"></a><a id="Tc_Ewdkx4xYMUacdbqmkD3HAg_3_2"></a><a id="Tc_wclg_4hEpE64SCO54mek1A_3_7"></a><a id="Tc_PlVTvUWbxUK44zCN8O08bA_3_10"></a><a id="Tc_ttz3P7JXwk-VkfTH24toSA_3_13"></a><a id="Tc_V_CoIsiCzUW8qZvcaJCA6g_3_16"></a><a id="Tc_kCxKh1lAqECm13Q4Oe2lNg_4_2"></a><a id="Tc_M9hG1ARqEU24tOZA7n47xQ_4_4"></a><a id="Tc_pie2tIbooUSR4BbeQclHxA_4_7"></a><a id="Tc_zgnYXTrEWUyE3H0rRE6HKA_4_10"></a><a id="Tc_uyNP5VchwE2-2ILaYe56cg_4_13"></a><a id="Tc_cfMxdjbTMEq1gVvhIq8TNw_4_16"></a><a id="Tc_B7b6qgjj9kao5_bEJeyAdg_5_0"></a><a id="Tc_IDi7gRqCTkuaYXcVwweNiQ_5_4"></a><a id="Tc_aY_Ndzjm_0mDMtqW3ta_3w_5_7"></a><a id="Tc_vWoSw1YeUEyu-ANDkELWaA_5_10"></a><a id="Tc_c7XcnCdUKkyKTCYcjHTFOQ_5_13"></a><a id="Tc_1kEPdGbXRUWmRKjuMA79ow_5_16"></a><a id="Tc_IIvjpuM6hECr2qq8pMuZ5g_6_0"></a><a id="Tc_iX3PTT7HgkajzpDOrMS02w_6_11"></a><a id="Tc_N8w7Zhf0FEuKlwISKJyPFg_6_14"></a><a id="Tc_Q3FMiYDCL0iAjp1T9YYKMQ_7_0"></a><a id="Tc_1UGt9pnxu0iQuC88_Gyy1g_7_11"></a><a id="Tc__55WTWT7REKUzy6TyI0gAQ_7_14"></a><a id="Tc_FY6s_XRgEkGycw7dwj0myA_8_0"></a><a id="Tc_yDse2Z0ZuEO8Fsn46BdoaQ_8_5"></a><a id="Tc_nS04uOkrC0eE2gkW3Ql_iw_8_8"></a><a id="Tc_w2X2nNBAj0uh8m857WWB8g_8_11"></a><a id="Tc_Ihk-KUOWpkOePC1C620P7Q_8_14"></a><a id="Tc_2pGwNPjU9Eqgmt79bItLLg_8_17"></a><a id="Tc_r4ruRnYiXk6r5-s6Yw31mw_9_0"></a><a id="Tc_Matw-OXMD0Sci3yoEmQY2Q_9_2"></a><a id="Tc_mPOu0R3EgEeWb5Nq7x_bfg_9_5"></a><a id="Tc_VCFYSA9d7UW7GhH-aYjbbQ_9_11"></a><a id="Tc_8lrVtJXR5U2_qpgonPkNOQ_9_14"></a><a id="Tc_GiWsHVUo90qqld9XxM65jA_10_0"></a><a id="Tc_Aclc_p2atEm9a8iaTRik1A_10_2"></a><a id="Tc_1ZCaFcbqjEujtVGAn0f18Q_10_5"></a><a id="Tc_6pUJlbDDB0qG5I9gtsAO4w_10_8"></a><a id="Tc_yTOl0UOVv0uQpxvR3cSX2w_10_14"></a><a id="Tc_8j6C1CDakkmSBFfuC-mIvg_11_0"></a><a id="Tc_Or_Yig0pZU6-yjlT4bLp-g_11_2"></a><a id="Tc_sSB89yY_9EmVuFckvuUrZQ_11_5"></a><a id="Tc_nDYZd0pmSky_XkzXsYt6-Q_11_8"></a><a id="Tc_6NUgD1wT-0G8AYQxTFS4QA_11_11"></a><a id="Tc_1USsqFkmOEWq6mcddzcGOg_12_0"></a><a id="Tc_K4HXLVX_B0a04HimI5pEcA_13_0"></a><a id="Tc_NiTZwoM4kky--7DCbsyrsg_13_5"></a><a id="Tc_InEHKDps0kuK5ly2JKPjkg_13_11"></a><a id="Tc_kq40binM8Eiaeu9bgQZz5w_13_14"></a><a id="Tc_1lm3kymLPEGF2N45cgvoSA_14_0"></a><a id="Tc_BUcGQGIhsky1_O1ymKB0xQ_14_11"></a><a id="Tc_OtBU54Pt3U2ujUZ0w23O2A_14_14"></a><a id="Tc_KGRq10ifP0y5uoaYeb5YpQ_15_0"></a><a id="Tc_laDWh6MS9UqVruj4vEe7ZA_15_8"></a><a id="Tc_NCMUqj06Wk6SvM-MCi3NxA_15_11"></a><a id="Tc_UWGyQaA5hU2jo4Kc-slkCQ_15_14"></a><a id="Tc_e2xdfgS5h0qo0AIbEyTo-A_16_0"></a><a id="Tc_5cF5zDjJ0kKYHe_ebOsVMw_16_2"></a><a id="Tc_q29dGU-MAk-EdB85KEetHg_16_5"></a><a id="Tc_3ohjmvWcbEaZP9WjiabhDA_16_11"></a><a id="Tc_M9FH_giVE02ZRCQZ-LKVOA_16_14"></a><a id="Tc_cewgj0Sao0ScMi4b07wLmA_17_0"></a><a id="Tc_CLrw4En5SEy1CJUtDIkoqw_17_2"></a><a id="Tc_dgzGxFXkiUC-IqsCJyTK-w_17_5"></a><a id="Tc_wz6ayj_I0Emx8Jd2T6p2mg_17_8"></a><a id="Tc_4Q8IwyyD8EqT__OUjf3w7A_17_14"></a><a id="Tc_SJUXe7k8A0Gu4z1qExIf7Q_18_0"></a><a id="Tc_TpU7pXFsWES6sWJ8lNA4dw_18_2"></a><a id="Tc_WT334erwmESaaJCnDtixTg_18_5"></a><a id="Tc_rGluyGU5kUOJy1adHVMBEw_18_8"></a><a id="Tc_eYBKt5tL-UaguVZb_cpG9A_18_11"></a><a id="Tc_W6tylzU5DkeaDirpp2jJIA_19_0"></a><a id="Tc_QBI-jrG2HkKyn0TV2YWMpQ_20_0"></a><a id="Tc_PRa5mbN5N0aizovgEZG7Mg_20_11"></a><a id="Tc_8wH3GGBc6ku0O7ZHPm3x2w_20_14"></a><a id="Tc_KXXzwMXFCES8jZ9xcCYrjQ_21_0"></a><a id="Tc_xasfRzyVEkiIkIRhDuo3sw_21_11"></a><a id="Tc_esF93gamfU2iEswBtyYPMQ_21_14"></a><a id="Tc_SYzTKmWkeUmnVfz_JNxl8w_22_0"></a><a id="Tc_Hi6gIw-lTkicdX22CMCo1A_22_8"></a><a id="Tc_5kE-wHBIqEaK7tvTygyUtw_22_11"></a><a id="Tc_zOklpT8pZ06qvNL2M3ojgQ_22_14"></a><a id="Tc_csSJdpVLUka6jOiRBt8gBA_23_0"></a><a id="Tc_p2B12h_WaUW_P869IdNOqQ_23_2"></a><a id="Tc_B50L7zHsdUa5njDik_guYw_23_5"></a><a id="Tc_bqIFYD5Y80iPD6fMtrQbtg_23_11"></a><a id="Tc_R7zUGF70fEWAnl5nGnQUiw_23_14"></a><a id="Tc_kXY7yCICS0yaFIsdsixIKw_24_0"></a><a id="Tc_82gKzcR46Eq2Qj7LVgkVEg_24_2"></a><a id="Tc_84I8n-LhgEuBz7WpRFLEig_24_5"></a><a id="Tc_E_2BoPMeukC095g3upe8PA_24_8"></a><a id="Tc_PJXhKG6yr06C_l40vAtcHw_24_14"></a><a id="Tc_-_-xxAM6tEOQGEeBDaMDBQ_25_0"></a><a id="Tc_vadXKHU3Ak2kjyTDCpo2HA_25_2"></a><a id="Tc_ny1kZ-AowUGwTQhbDQtU4A_25_5"></a><a id="Tc_0Ka0v_YlHEiZboB1t0i1JQ_25_8"></a><a id="Tc_Afy-WNvjq0Gr9kxk2JiOzg_25_11"></a><a id="Tc_Gr2JcrvN2UO3SVuM3tfUWA_26_0"></a><a id="Tc__qjRXS8SC0OZGyu3fSnuVA_26_4"></a><a id="Tc__N8yZ-GSUUmKoKMFOcxRpA_26_7"></a><a id="Tc_dgpfcGb2OEu63v69Xzrprw_26_10"></a><a id="Tc_bxY6nO1X_Ui3maYJXWqe2A_26_13"></a><a id="Tc_bvc51MeSOE-gGz3bixIf7A_26_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ordinary&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_UadjxvHA8kGgTPrfUzKVGA_5_2">29,579,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_33GOvKZNmUKwnuUuFRe4qA_5_5">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_17g0OGLnwUulZtNoxhH01g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Nw-7Mhg3HkiBHAMVSTyk1w_5_8">567,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6cIYOfo-dUykEJArEMVFiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_s4o7LTbYZkqT7BzvfYVgbQ_5_11">3,388</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CUy4QtZ-V0Cj2wqjpP3QOg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_VY7MzxBXzUiUi70TKLLmqw_5_14">218,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_7Bn4AO2XvkW3epaw1AM0Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_u2eHW47sF0G3XtiqN6YNvQ_5_17">346,254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs upon exercise of share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EJ7qvv9OGEuz-vh1pZ5l5g_6_2">78,074</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_vA_npVpam0y-pEEGNzbPig_6_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Bapl-rwA20Gpnu3sJ79HIQ_6_8">988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Ns25Wcfx9E-KNIfHjQJGMQ_6_17">989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs, net of commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_aoD3YlMiskyBN2yDn0dckg">0.2</ix:nonFraction> million</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_1m4Gh4RiOUysm_DC14Iw8Q_7_2">181,455</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_M7TgJkBumEyh5POJqXDgTg_7_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_FYDGlaXZBEubENykLANUbg_7_8">5,701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_41BqrKGjy0K2vH__HN4J_w_7_17">5,703</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs upon settlement of restricted share units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_qKn_qULDs0uhzsCjN7d3hQ_8_2">35,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_t40pPaq3IUS6oS_FBY2s8w_9_8">26,779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_9vpUSRE_JUqyk-mC443fnQ_9_17">26,779</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_teqqpUcfr0ylhQrf7zeYbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_7QAECYfjr0-1ugdf_4y7iQ_10_11">3,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_I94TPNXOS0KqVz99lLa0aw_10_17">3,775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNjPjZIFd06Z_lIP7g-WCw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GBVpGupL3kSmm_1I6sdHeg_11_14">112,717</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_t4gh-f_K9U-QIz91lD8tYw_11_17">112,717</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m2IV-GHD4EWsFxAP8z8-YA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_x2s_Qqrn-kWXDPpJDxc6XA_12_2">29,873,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m2IV-GHD4EWsFxAP8z8-YA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AEUJp48imkuJPxXJa-4bNA_12_5">387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_McmuDya3A0yjgIlscqnbsQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cw5h1wcaCECWCeyrts4H5w_12_8">601,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_opu5bUpl2UC0TqjQ2ARQ8A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_E2pD-Qz8Y0SFKphzkiKsAg_12_11">387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_StHDH1DIL0imMDDzyJOvmA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7-KdiYcpRU-_U8_oRB4Ijg_12_14">331,096</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AYiJ_hLNPkOaK2SWs9OKNw_12_17">270,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs upon exercise of share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_7wVDd1xMqU6AqDBZbxNWwQ_13_2">54,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_iroPJFsGzkShD6zMXMSQmg_13_8">681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_gCZdjVCPFEugMw82Hl_pew_13_17">681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_0pbPLS3uvkObg5DeJKMMhA">16.0</ix:nonFraction> million</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_qqbo-iMuJ06Bxaj9aUrswQ_14_2">12,384,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc__YRKY9Nq50yudGomal0lJg_14_5">162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_L4HZSeH7fUqVxr0rcXiMuQ_14_8">249,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_eAyhoCmnVEKn1f5kj9xzDA_14_17">249,345</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs upon settlement of restricted share units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_bUlhLMj-dES1Sv7J87-KcQ_15_2">119,144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_o4jIEcV5_UWocOXeJytK1g_15_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_Y5f5d-YX5UCtYnUFDeJkiQ_15_17">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_zxoOWwk7lUWFyN-3QxcBwA_16_8">32,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_1T4qPiL6MkaI6Fqwy5s_qg_16_17">32,477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TWmLZerPx0-0_LBFph8ZLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_IG_mK6thQ0uL2f_PYyyu5g_17_11">1,691</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_wDzS4A2ms0Covk5fSkkSAw_17_17">1,691</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2JyJSn_aPkarPPFGcqtS1Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tIDuIzsLY02HNadC2Jjw-w_18_14">180,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1gHi2wKdy0iw_X3FHXv2rg_18_17">180,664</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TZxfpEvZdUat_yMyIb9Zww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_jGeZ7r-sE0657VksgO2Kcg_19_2">42,431,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TZxfpEvZdUat_yMyIb9Zww" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0Wha9WvSDkWi5BnrVP6UQQ_19_5">550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W-C5t6IG6UWyCMUiL7Gv7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BjQA1zLUWUqa2kWS-ZVTKw_19_8">883,446</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wdRGjbbwREGbPju45P3i5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_AdohFCZPVUapRNDVo9TZlg_19_11">1,304</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EwM5Itcxx0ys92D7oHiEgw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_q96h7W6JxEyYue9kAL8ImQ_19_14">511,760</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_k6Oiw-0kLESQ0jlBIAvonw_19_17">370,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs upon exercise of share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_lFCNvkR2P0uhgISPpez2Ng_20_2">554,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_NMLCIWDA3kSf8KS6iGC0Pg_20_5">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_MU3w8gZ-qUiFwlj8lDs6pg_20_8">7,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ewdASPELyE2Fa4-oilIFTw_20_17">7,527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_I1pTz_ZT6kaG6PIdyDQKBw">11.4</ix:nonFraction> million</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_ue84irKu9EOBc4OUJyKCLw_21_2">25,933,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_LCBLRkzhd0ihF2wP-yx4iQ_21_5">331</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_tR2j2RML-0CFcnwodm7crg_21_8">543,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_c4hynl_B5EasMl3iucWJYw_21_17">544,127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ADSs upon settlement of restricted share units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_P9D5Z_WI_E6JpJraIVlnag_22_2">141,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_-Vhre670_UCmLiY0ZnUeEg_22_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_UwMKA0K5BkSrWfwSNdilkA_22_17">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3MvGgunkS0SuUbbei9sajA_23_8">38,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_VV2LPMqZG0CGgRdbHhLn5A_23_17">38,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AM5bQ16iwE-vzlxN1fzJfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_afXF6j4d-k6C5cZ6HDg81g_24_11">1,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_LMI4CbUD7EWSrhmCexvEaw_24_17">1,423</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DBNovfpDakCcvAVq5SANGw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3tBlu2X00ECTKkHEEdj4Og_25_14">169,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZH-77hzPxkOes6nGyVCeqA_25_17">169,031</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyIVXSsfEEW_9ZjaJ49EjA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_ig4PgRpackSteTy1a6L1DA_26_2">69,061,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyIVXSsfEEW_9ZjaJ49EjA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XdY-xUb26ES2Y4ZwvzmCNw_26_5">890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dEcOv1S1kUyL15GIo0RjgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r8saVKe6vkqfKsHmB2C1uw_26_8">1,472,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F8DiQa_QMka5iKKuHx7img" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_oJ8TEVAFAka_86WINQg1Vg_26_11">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0HyqUG8pkaNcopt1SdSjQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_nSJ3CXLPVk2d3k4OVxoAMA_26_14">680,791</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aDsu4bCwikiqMA1Oh487_Q_26_17">793,060</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of the consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9ea4f6a4_e13d_4f2d_913c_100dbd31fef3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Bicycle Therapeutics plc</b></p><a id="ConsolidatedStatementsofCashFlows_57561"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_f4c796d5_cc74_4350_b6f3_b63adf4fa847"></a><a id="Tc_fvnuCJjTLEihsmBiC5UQhg_2_2"></a><a id="Tc_ZyNlxfV870m-HIKvv6-G6A_3_2"></a><a id="Tc_YmBWr1lRiU2f93_9ggTLZw_4_2"></a><a id="Tc_xZT9nfwEOUKVKOBzCm6Kzg_4_5"></a><a id="Tc_Pg1BFpjyqU2CV03wqrcqVA_4_8"></a><a id="Tc_vmF11mjtmEGa9kVO433e3Q_5_0"></a><a id="Tc_AwjuQPbeT0W2VYb3KAzrNg_6_0"></a><a id="Tc_X3i3SimInk6N5gE0GgZFVw_6_2"></a><a id="Tc_5GZy_fGMnE6TGJK94FY8bQ_6_5"></a><a id="Tc_JQrkYOfEB02bopmUSy3KwA_6_8"></a><a id="Tc_fsSWp-4Yk0aUWQ27xF2WHg_7_0"></a><a id="Tc_jXqURZayoU-FfV52DzLv4A_8_0"></a><a id="Tc_orClo1QlB0SdY-hMCihgNw_9_0"></a><a id="Tc_3G-H8h6BsEWL_PCd2_5MVA_10_0"></a><a id="Tc_vj4uFTBmJkuQXrtVqD256A_11_0"></a><a id="Tc_9ROGXQd730-6r5HYjbYIMg_11_6"></a><a id="Tc_DcYrb4gbxkiHahHnybhdSA_11_9"></a><a id="Tc_SteXPfzNSEuUZJEL-MoYew_12_0"></a><a id="Tc_hBzVYK98lkOznL3wL-NnYw_12_6"></a><a id="Tc_lH8v7HqS5Ua-a2GtwcAG8Q_12_9"></a><a id="Tc_Ovj7WSpmZ0yeN2AjOV7z2w_13_0"></a><a id="Tc_KfLTZgbjrE-cun6IkUuq6w_14_0"></a><a id="Tc_yMQv6AWTBUWkwOfjA52zDw_14_9"></a><a id="Tc_jNEMeUcFGEitBl7wXDOk6w_15_0"></a><a id="Tc_t1LeyZjc406Pfr18j1hVcA_16_0"></a><a id="Tc_d-44zU6pU0SHyEUmteSu0Q_16_3"></a><a id="Tc_65lAdyp_-keY5EldP1eQrw_17_0"></a><a id="Tc_B6pS85jdAEKv7lysaUROPQ_18_0"></a><a id="Tc_yT6jNTf5f0yZVlNhcbI4mw_19_0"></a><a id="Tc_4WPHd2D_vkSzHd59pbnGpA_20_0"></a><a id="Tc_6QXqduRUQkqVjp4k-euQjQ_21_0"></a><a id="Tc_gy6kGeSXJES85fsQlPEX9Q_22_0"></a><a id="Tc_1K4uG4UR40GfZPjzL0HnPg_23_0"></a><a id="Tc_kpAnqR1Kl06qTuHnuV-Z9A_24_0"></a><a id="Tc_R_OL_VrTnUiDQlYqtva3ng_25_0"></a><a id="Tc_sjG08uZ6JUSHXnSvlWwVmw_26_0"></a><a id="Tc_da1akMyTwkC9WcZh0mv4Ig_27_0"></a><a id="Tc_zksBjfKhXEuIzDitrBXiag_28_0"></a><a id="Tc_EXlcTVn4Y0u92OuDcRE3mA_29_0"></a><a id="Tc_W6NKZWZ520i3yt23KF4zHw_30_0"></a><a id="Tc_eUJpwQ_QCUyq6wQvX0hQtg_30_6"></a><a id="Tc_fMgYqR65a0a6WlgcGuA8cg_30_9"></a><a id="Tc__UjitI1PRkaUOt32oR_Spg_31_0"></a><a id="Tc_0P1Bnk4_cEiXuQoCkH281w_32_0"></a><a id="Tc_FC0fhb23zEaO9GuLERqjQg_33_0"></a><a id="Tc_XVPwfqcG5keXcQLUkI--8A_33_6"></a><a id="Tc_1vm0l-TWIkiWR8X6FAz9Dg_33_9"></a><a id="Tc_uELH6KIki06LNT2Mgb7jCw_34_0"></a><a id="Tc_mcK02GQ44ESch6NZ_tqnMw_35_0"></a><a id="Tc_i4AuC9jrqUecDk5tMc9wmQ_36_0"></a><a id="Tc_n4emkwGS0kCBg8EHOT36Fw_37_0"></a><a id="Tc_A4uIk8PQzEGkgpp0Ea8Blg_38_0"></a><a id="Tc___TGVb6KQUif38XAMGOWhw_38_2"></a><a id="Tc_Rj8RDcmFSUKWYSXr8c6WvQ_38_5"></a><a id="Tc_uszpYYaLLkycCbxl-jBrKg_38_8"></a><a id="Tc_dPODXb2SakSNyCtsdadQ2A_39_0"></a><a id="Tc_MVyQ05IbzEOyLPeaMpIvhw_40_0"></a><a id="Tc_goPTXYHnhkCthJ709tiHLA_40_2"></a><a id="Tc_wb81F1WMuUy5m0GpPAs4Rw_40_5"></a><a id="Tc_PDrbUHkFzkio1mosjnYzkg_40_8"></a><a id="Tc_qJfERiRE0E2SqxExzXAqcA_41_0"></a><a id="Tc_lWGD92glQ0qQPdIYNgPKew_41_9"></a><a id="Tc_4saX9QmckkGEzUi48f1aCg_42_0"></a><a id="Tc_2oj0gVZTXkmVtoPHyaYWXw_42_2"></a><a id="Tc_nEIs5y4jEESw21KRjUrafw_42_5"></a><a id="Tc_fd4CnaaCiEWLxhXIDuYxdA_42_8"></a><a id="Tc_FefVulFn_kSJG_MBqXYX6A_43_0"></a><a id="Tc_kXQiwMkbW0-GeR58TMzPQA_44_0"></a><a id="Tc_dG8hKVUkFESBTOsACgkRfA_44_2"></a><a id="Tc_PYBYfw9PREWsStY0ak88_g_44_5"></a><a id="Tc_TNgzhajbN0Gpq5AuM9SIYQ_44_8"></a><a id="Tc_3iMhRU5loEmrAlb_zHrrsA_45_0"></a><a id="Tc_6O7UM-_tl0mTEs-LGw4Pmg_45_2"></a><a id="Tc__rZwnIK6gke16c88rBKOWg_45_5"></a><a id="Tc_I5Jzi9hKCUOD0Nhd_f1b8w_45_6"></a><a id="Tc_zM_FE6OA5k2dzw3MAQKxvw_45_8"></a><a id="Tc_SpBNwnMMukeWG4bELyVRPA_45_9"></a><a id="Tc_T4AYCSDUkU245hdvdWY0xA_46_0"></a><a id="Tc_Dz0LT18zJkGhRVsdgzohBg_46_2"></a><a id="Tc_UEWJKqoXHUOIJUuyHT8qfw_46_5"></a><a id="Tc_a_W39ZIsXkWDMD-WHR81nQ_46_8"></a><a id="Tc_j4HoxuwMm066rD1IMLL6gw_47_0"></a><a id="Tc_afPmBNW0xkazPKDIbmyvMA_47_2"></a><a id="Tc_w0vMCVYnPUOsZAHXC3eMNw_47_5"></a><a id="Tc_D6sW1Yl5GUaQ-KsfmscRGQ_47_8"></a><a id="Tc__XeOML27AkO9osgi_QtDqg_48_0"></a><a id="Tc_3is-xt_3LkO-qKvZ3pj7JQ_48_2"></a><a id="Tc_FFKZtshvlEe20VwV2rqdSA_48_5"></a><a id="Tc_cJJT77ApbUWwwPNSmRT_Hg_48_8"></a><a id="Tc_Bczv_kQNC0yUPowUl5UYJA_49_0"></a><a id="Tc_277tZ4n6MUuac1vWMkNcaw_49_2"></a><a id="Tc_AQxHKvjUSEeEu8uBt6UYOA_49_3"></a><a id="Tc_iZE-GawTQkufBK7jpvvMdw_49_5"></a><a id="Tc_TJUuGkyCEkafNsXh5p1-TA_49_8"></a><a id="Tc_43jxYBs6ykC7F7QeDtihcw_50_0"></a><a id="Tc_e-a09nGhUUu9eC2wnlOR3A_50_2"></a><a id="Tc_eFIuyzw_LUSE6gMfBJDHog_50_5"></a><a id="Tc_xfG5E1GYc0GlPAEiFGzIOw_50_6"></a><a id="Tc_rOvFvnddCE-i3sTXWMkcZg_50_8"></a><a id="Tc_wTbCNJfiwEG8ssv-LkPOfQ_50_9"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_6xk1aku2SUuXOIF-1O_UWQ_6_3">169,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_bBm4UhPFKEG9wqxtuMYo6A_6_6">180,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc__sScb7edWEepi7_Dg2iQag_6_9">112,717</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_z4q1-3t8Bk-gtc5w0a4i9Q_8_3">38,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ChhkNgjdzEyLVIJMaz2o-w_8_6">32,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_xqDr8j9Mj06uPtm4iGuf7g_8_9">26,779</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_GvpcXsZO8kK8RxOxgJOaPA_9_3">7,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_0u9Ttk9kmU6LbG6UU_BGOQ_9_6">6,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_fSY2nOmQa0eYZEc_KO5Lkg_9_9">3,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Non-cash interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:NonCashInterestExpense" scale="3" id="Tc_dHTNBgWF8E2yUnoOXCAvlw_10_3">211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:NonCashInterestExpense" scale="3" id="Tc_MCJB7mAYkEGS8yXz6rI7fA_10_6">383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:NonCashInterestExpense" scale="3" id="Tc_GNbM9FiHUECZg3Rl-lBAeQ_10_9">442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_3GelHm8K70GaMzcr1NYkCQ_11_3">954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Gain on extinguishment of research and development funding liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" scale="3" id="Tc_WT9sFKIXBEqwm_o98EZGhA_12_3">4,476</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Deferred income tax (benefit) provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_hgny9Wi7FUainjy-DYIZaQ_13_3">5,226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_QlrkP6WLpUmAbZ8xZQx65Q_13_6">3,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_BW46nZ0X0EWVFDhHlPohbg_13_9">4,976</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other non-cash charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" id="Tc_Zfs3UmVv9EymnbQYxDrNCw_14_3">1,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" id="Tc_0ntefU7CVU2TNtqbe-3SJQ_14_6">661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_2TC-hsw4XU-6UvT-J-0ETw_16_6">2,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_XKUW8YlHl0yCacK-QwBXeg_16_9">1,641</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Research and development incentives receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" scale="3" id="Tc_TezjvRLnFU-qu-q_lYrypg_17_3">11,947</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" scale="3" id="Tc_4IB9v1oud0CP2ZPyUHkA8Q_17_6">3,684</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" scale="3" id="Tc_1SIwvVVNZEaNfOJdVa0Q3g_17_9">9,707</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_UWZdXkwDeEqvItDubeiDfg_18_3">2,044</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_82McyKNIf0Szy3eRU2GE4w_18_6">2,072</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_K-FRssEG9EqbpzKA1jVr_g_18_9">2,020</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right&#8209;of&#8209;use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_ax9JK8hxI0SGYdAFN-wb2g_19_3">4,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_tKhKhyPk2kSESotWOdAaLQ_19_6">4,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_7jDRN27SD0-pj8Z_X5Fx-w_19_9">2,698</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_piQbht4Lq0-ifgFazEbGlg_20_3">3,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_6ozHOFklhEe_5ePnv0gKVA_20_6">8,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_bLaeQqx5Vkm6Ko2KfiOVjA_20_9">2,561</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_vKMTL1miJ0ePw6yr_HoceA_21_3">9,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_NeecUq61wEmnFk2nhh5usA_21_6">2,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_5vNeL20xc02WaOcwhj4QKA_21_9">12,362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_lZv1N3VrckOEewZFKhWsNQ_22_3">4,888</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_SfYm7Rq68UGAtH8K6FgxJA_22_6">4,109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_eGE-aBklnUyxzNpjZxUfgw_22_9">2,114</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_8caHU-QOjUGU-jiD9AeFeg_23_3">31,952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="Tc_EXPl3ALHeE6faj7WaHRCvA_23_6">68,951</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_ioUR7Q13f0GVLNc-NEjtAw_23_9">2,135</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_8y7Ye3Yn0kGfS6ctjjd7LQ_24_3">189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_cg5r-KJq-Ua7MrY5Ue-I3w_24_6">509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_sNaLVUY4ZU27gc-iot5Xhg_24_9">668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_tNl33O1_UUGvZRpze5Ctag_25_3">164,724</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Yek0EluU5ky86fywnSYJzw_25_6">60,628</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_HxT7YCAWI0C03xVBChC3XA_25_9">86,111</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash used in investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_OrVyUaAoCkCq21MT3X8gGA_27_3">1,235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_w_5QqFFDaEawlEh9Id9-pQ_27_6">2,929</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_x2M5DIwsQ0CiitlrUxZJ4w_27_9">18,987</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_REeC-hTYE0-si2KASMTIUg_28_3">1,235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_ySMPax6EmkKyZCvlII4Z_w_28_6">2,929</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_trKxMNsYZEmRbWNIN7AMKg_28_9">18,987</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Repayment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_vz1jVEH3dUGZGahHTLCEzA_30_3">31,863</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from the issuance of ADSs and non-voting ordinary shares, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Gah27WVyFUG8SV-EGqrkKw_31_3">544,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_yvKkEumAc0m9fzM0SCLqNA_31_6">249,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_wuEdgFKnHkGppB9jZk6Y1A_31_9">5,703</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from the exercise of share options and settlement of restricted share units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_tWXf1FYIRk67jXSqXpAEyA_32_3">7,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_ACADALAGqUGh0wlIS6vlGQ_32_6">682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_HIBa9b7xkkyyLk5nSOBxJg_32_9">989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Principal payments on finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_Mx7M6Po0pU-fPIsWgk5DwA_33_3">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_iMDSRtkC_k2CQ7zT9Oc8hw_34_3">519,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_4u3NjYoawUW5MVcsi0-cpA_34_6">250,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_qdyrDut1tkGz3VpWiuuHlQ_34_9">6,692</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_yZSCKKks7U-YIkKWezJ-dg_35_3">694</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_JRPGhwho-EGHlkhgoOBapQ_35_6">1,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_l3_Ks5u8-0qgBw3h4SDBMg_35_9">1,120</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_ICZ453GgrkO92rTdroYZJA_36_3">353,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_KNB7ydvi8k6fwrMdaSgd3w_36_6">187,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_odQV_fahlESBRe7sByt58A_36_9">99,526</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_w2WIgF33ZUuGFPP08jvPOg_37_3">526,970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_vK68RPO6oUmHhpFOwiutvw_37_6">339,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_7Bn4AO2XvkW3epaw1AM0Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Cbjhgh8dQkypxpu-Ji4C-g_37_9">438,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Uh9sprQIb0WtmVUPX9uGPQ_38_3">880,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_GiuNwWJ2aU2yEMpoqODSpQ_38_6">526,970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_cxaYMFS5LUKGWB-rM3nbPQ_38_9">339,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reconciliation of cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_dE-HrepswkWWTo5lXZomVg_40_3">879,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_BHbn4blXdECBRUb2WK-lEQ_40_6">526,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_wrLgLKtsjUGO1TZjkc2_3Q_40_9">339,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash included in other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_lMTPPbLdZkCFQewGXan4QQ_41_3">547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gkUbciRYCkuQosKnU0R1_w_41_6">547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hFguOFd7w0-CqKUAidMWBQ_42_3">880,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_2gBj7j1oaU2c0A58XKxyZQ_42_6">526,970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ysNz5FwGmkatz752BowP2g_42_9">339,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for interest on debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_vGJzJmqXTEi4AS-oi-Ja0g_44_3">1,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_buD9Mo9ae0GwBdLieUEn2g_44_6">2,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_xJHk_4f6vUGFXF4J8Tv5xA_44_9">2,793</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for interest on finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_IVp5M7d-wU6YCMYsoL1NaA_45_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_97v1F6R6XU-yecx-HI36ug_46_3">792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_MO9n_pW6uEqOQQgaPrHfWA_46_6">562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_VQhwDidIZUOegjwtsiVlNA_46_9">2,228</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_LVRxa0ijOkKmu7fo2CVbNg_47_3">5,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_Ig3KYGJ-10-bhTH5TQIMfw_47_6">5,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_2dPGDZIDq0SmeIiuOXSfcA_47_9">3,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Changes in purchases of property and equipment in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" sign="-" scale="3" id="Tc_VVQusbQoO0e3lOB1bTUc4Q_48_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" sign="-" scale="3" id="Tc_mn1lFckw602zXeQYVGLq9A_48_6">1,744</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_EiTqmOfUSkCOboQzZ4d0eA_48_9">1,564</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Non-cash impact to operating lease right-of-use assets and operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_K9tPMJeRsEm2rBaHAx7TuQ_49_6">3,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_nPzxb0ySsEKbGBPvzQ7Vng_49_9">3,120</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment obtained under finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_rRvF8K_2y0uraa1LIiQvnA_50_3">1,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of the consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_18c8d786_e202_4acd_9ba1_09f2ffe8b1b9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Bicycle Therapeutics plc</b></p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Notes to Consolidated Financial Statements<br/><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_-qAWikrN4UaJKCwpgtD9qA" continuedAt="Tb_-qAWikrN4UaJKCwpgtD9qA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">1. Nature of the business and basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Bicycle Therapeutics plc (collectively with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company developing a novel class of medicines, which the Company refers to as&#160;Bicycle<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> &#174;</sup> molecules, for diseases that are underserved by existing therapeutics.&#160;Bicycle molecules&#160;are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. The Company&#8217;s initial internal programs are focused on oncology indications with high unmet medical need. The Company is evaluating zelenectide pevedotin, formerly BT8009, a Bicycle Toxin Conjugate (a &#8220;BTC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221;<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>molecule) targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing company-sponsored Phase II/III registrational trial, called Duravelo-2, BT5528, a BTC molecule targeting Ephrin type-A receptor 2 (&#8220;EphA2&#8221;), in an ongoing company-sponsored Phase I/II clinical trial, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (a &#8220;Bicycle TICA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221; molecule) targeting Nectin-4 and agonizing CD137, in an ongoing company-sponsored Phase I/II clinical trial. The Company&#8217;s discovery pipeline in oncology includes&#160;next-generation BTC molecules and Bicycle<i style="font-style:italic;"> </i>Radionuclide Conjugates (&#8220;BRC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221;<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>molecules). Beyond the Company&#8217;s wholly owned oncology portfolio, the Company is collaborating with biopharmaceutical companies and organizations in therapeutic areas in which the Company believes its proprietary Bicycle screening platform can identify therapies to treat diseases with significant unmet medical need. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of Bicycle Therapeutics plc and its wholly owned subsidiaries, BicycleTx Limited, BicycleRD Limited and Bicycle Therapeutics&#160;Inc. All intercompany balances and transactions have been eliminated on consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>As of December 31, 2024, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_j9BIUOm9vkSQpTQXuRCezA">879.5</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital. The Company has funded its operations with proceeds from the sale of its ordinary shares, American Depositary Shares (&#8220;ADSs&#8221;), including in its offerings pursuant to its at-the-market offering program (&#8220;ATM&#8221;), and non-voting ordinary shares, as well as proceeds received from its collaboration arrangements (Note&#160;9) and proceeds from a loan agreement with Hercules Capital, Inc. (&#8220;Hercules&#8221;) (Note 6). The Company has incurred recurring losses since inception, including net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_q2aq-cNYmk-KiMUmgUKE2w">169.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_RqU8899S3kaC2GhyOWFhrg">180.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_fEX9F9HxckujokGIlrnvwg">112.7</ix:nonFraction> million for the&#160;years ended December&#160;31, 2024, 2023, and 2022, respectively. As of December&#160;31, 2024, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_y3IzUzzOt0i8Ada46Wn_kw">680.8</ix:nonFraction> million. The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash will be sufficient to fund its operating expenses and capital expenditure requirements through at least twelve&#160;months from the issuance date of these annual consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects its expenses to increase substantially in connection with ongoing activities, particularly as the Company advances its clinical trials for its product candidates in development and preclinical activities. Accordingly, the Company will need to obtain additional funding in connection with continuing operations. If the Company is unable to raise funding when needed, or on attractive terms, it could be forced to delay, reduce or eliminate its research or drug development programs or any future commercialization efforts. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-qAWikrN4UaJKCwpgtD9qA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology and pharmaceutical industries, including but not limited to, risks of delays in initiating or continuing research programs and clinical trials, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, if approved, dependence on key personnel and collaboration partners, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if the Company&#8217;s research and development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_h5E56m3mTU23hOcIRe21Dw" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">2. Summary of significant accounting policies</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:UseOfEstimates" id="Tb_j9RJzY4qgkCIvIxiUghLDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and research and development incentives receivable, share-based compensation expense, valuation of right-of-use assets and liabilities, gain on extinguishment of research and development funding liability and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:SignificantRisksAndUncertaintiesPolicyTextBlock" id="Tb_7BcIsmm0S0uxh-v_6glM0Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant risks and uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company currently operates in a period of economic uncertainty which has been significantly impacted by domestic and global monetary and fiscal policy, geopolitical conflicts such as the ongoing wars involving Ukraine and Israel, inflation and interest rates, and fluctuations in monetary exchange rates. While the Company has experienced limited financial impacts at this time, the Company continues to monitor these factors and events and the potential effects each may have on the Company&#8217;s business, financial condition, results of operations and growth prospects. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_AhsD5Ybm-EytXKASIxtYbg" continuedAt="Tb_AhsD5Ybm-EytXKASIxtYbg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The reporting currency of the Company is the U.S. Dollar (&#8220;USD&#8221;). The functional currency of Bicycle Therapeutics plc&#8217;s wholly owned non-U.S. subsidiaries, BicycleTx Limited and BicycleRD Limited, is the British Pound Sterling, and the functional currency of its U.S. subsidiary, Bicycle Therapeutics Inc., is the USD. The functional currency of the Company&#8217;s subsidiaries is the same as the local currency. Monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in general and administrative expense in the consolidated statements of operations and comprehensive loss as incurred. The Company recorded foreign exchange losses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="6" id="Narr_uRVNdsAb80OOcw5Ig3UFtA">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="6" id="Narr_CkZzqzW8RkWYXOCBcb7FaQ">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="6" id="Narr_D0XfiWtVdUGp_MJxU5n4sQ">0.6</ix:nonFraction> million for the years ended December 31, 2024, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company translates the assets and liabilities of its non-U.S. subsidiaries into USD at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a foreign currency translation adjustment, which is </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_hFKnZiGsG0Cb2AB4zByFAw_1_2"></a><a id="Tc_jQGfeNA_kkajus2WlpgoXQ_2_0"></a><a id="Tc_zYY-KsVf6EucXw8NjHRWcA_2_2"></a><a id="Tc_QPtQtAI2d0uuWmm_yzzviw_3_0"></a><a id="Tc_u0Rs0KoXoEi_IDIy2iJEzg_3_2"></a><a id="Tc_N5jF0j3JzEeyDF0RIJCgCA_4_0"></a><a id="Tc_y3s6ZcVRk0aUzgIz03FJag_5_0"></a><a id="Tc_vbNGYxWDE0-r0OtlbCqfzg_5_2"></a><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont1" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont2"><ix:continuation id="Tb_AhsD5Ybm-EytXKASIxtYbg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">included in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive income (loss).</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_7oYyEoKqFEaq02l6a81Tlg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. The Company diversifies its cash and cash equivalents in multiple financial institutions and in money market funds that are primarily invested in U.S. Treasury securities that are backed by the U.S. government and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships and investments in money market funds invested in U.S. Treasury securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Narr_dSJV7o_CDkuBlUGo--oz1g"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Narr_cp1KmJAWSk6QFql8RROFJA">no</ix:nonFraction></ix:nonFraction> accounts receivable. For the years ended December&#160;31, 2024, 2023, and 2022, the Company&#8217;s revenue has primarily been generated from collaboration agreements with Bayer Consumer Care AG (&#8220;Bayer&#8221;), Novartis Pharma AG (&#8220;Novartis&#8221;), Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;), Genentech, Inc. (&#8220;Genentech&#8221;) and AstraZeneca AB (&#8220;AstraZeneca&#8221;) (Note 9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on multiple vendors to manufacture clinical trial materials and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_uWoQccJLgk-RR5NpZ9G-Mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments that are readily convertible to known amounts of cash with original maturities of three&#160;months or less at date of purchase to be cash equivalents. The Company had cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_eOxsQPNFNUW5htG-SqCshQ">664.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_Zw1EqSggmUW8nsqp7tMVkQ">72.3</ix:nonFraction> million at December&#160;31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_AQQVIRQUfkm2FOsVScPM7w"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_3u0zJeoV3kioY4ax5oe-ug">0.5</ix:nonFraction></ix:nonFraction> million of restricted cash related to a collateralized letter of credit in connection with the Company&#8217;s lease for office and laboratory space in Cambridge, Massachusetts, which is included within other assets in the Company&#8217;s consolidated balance sheet. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_1HfjtNwyQUSYGUgUsOqWRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="Tb_DOTSTA1JHE6jzTT8YFGQIw" continuedAt="Tb_DOTSTA1JHE6jzTT8YFGQIw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the respective assets as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_A4rOo4WOVkOReKwKDydyAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p8M7K2bjKEax4G-nyR6gbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CzvZPim0k0CUHrLZ3N9Ulw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_KUkPDjU5zUmUmY7lsnDx2g">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or useful life</p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xx2lOaIKTUaBAJxmtahpDA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_dypJc4jlukOCY43A41TbzA_4_2">3 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kkZvNCSDbEyvWrxvy0J0Jg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_IArfIt_Zr0ytUbutd4kZKA">3</ix:nonNumeric> to <ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B4rIlVudJkC7UiJJ14Ug0g" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_1MdycqwAHU2ds5Kj-tFHoA">5 years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont2" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont3"><ix:continuation id="Tb_DOTSTA1JHE6jzTT8YFGQIw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for property and equipment not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. To date, there have been no significant asset retirements. Expenditures for repairs and maintenance are charged to expense as incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_UfxqvYRgQ0aBDoMhPjxzdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss may be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any material impairment losses on long-lived assets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_BQV8rCsiDECbXnjVCGHglQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company&#8217;s assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#160;&#8212; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#160;&#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash, cash equivalents and restricted cash, research and development incentives receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. As of December 31, 2023, the carrying value of the debt approximated its fair value, which was determined using unobservable Level 3 inputs, including quoted interest rates from a lender for borrowings with similar terms. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:DebtPolicyTextBlock" id="Tb_z_LdgmJZjkKDsU1Lq3euIQ" continuedAt="Tb_z_LdgmJZjkKDsU1Lq3euIQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Debt issuance costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Debt issuance costs consist of certain third-party legal expenses and payments made to secure commitments under certain debt financing arrangements. These amounts are recorded as a reduction to the carrying value of the associated debt and are recognized as interest expense over the period of the financing arrangement.</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont3" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont4"><ix:continuation id="Tb_z_LdgmJZjkKDsU1Lq3euIQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_K_0zFodpWke1LgFLhZdvXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment and geographic information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of a business for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates in <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfGeographicRegionsInWhichOperating" scale="0" id="Narr_at9EyFuNf0G4DfjNXFQP4A">two</ix:nonFraction> geographic regions: the United&#160;Kingdom and the United&#160;States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional segment information, see Note&#160;15, &#8220;Segments and geographic information.&#8221;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_OEmndfTpBEqj1Dd1qgfgYg" continuedAt="Tb_OEmndfTpBEqj1Dd1qgfgYg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases are accounted for in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, <i style="font-style:italic;">Leases </i>(&#8220;ASC 842&#8221;). The Company determines if an arrangement is or contains a lease at inception. Assets and liabilities related to operating leases are included in operating lease right of use (&#8220;ROU&#8221;) assets, other current liabilities, and operating lease liabilities in the Company&#8217;s consolidated balance sheets. Assets and liabilities related to finance leases are included in property and equipment, net, accrued expenses and other current liabilities, and other long-term liabilities in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use and control an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The ROU asset also includes lease payments made before the lease commencement date and excludes any lease incentives. The Company identifies and assesses the following significant assumptions in recognizing the ROU assets and corresponding lease liabilities: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected lease term</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; The expected lease term includes both contractual lease periods and, when applicable, periods covered by an option to extend the lease when it is reasonably certain that the Company will exercise the extension option, or cancelable option periods when it is reasonably certain that the Company would not exercise such cancelation option.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Incremental borrowing rate</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available on the commencement date in determining the present value of lease payments. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimates the incremental borrowing rate by comparing interest rates available in the market for similar borrowings and third-party quotations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Lease and non-lease components</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; The components of a lease shall be split into three categories, if applicable: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must then be allocated based on fair values to the lease components and non-lease components. The Company&#8217;s operating leases for its facilities and finance leases for property and equipment may have both lease components and non-lease components for which the Company has elected to apply the practical expedient to account for each lease component and related non-lease component as one single component. The lease component results in a ROU asset being recorded on the consolidated balance sheets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For operating leases, lease expense for lease payments is considered operating lease cost and is recognized on a straight-line basis over the lease term. Variable payments for other operating costs, which may be billed based on both usage and as a percentage of the Company&#8217;s share of total square footage, are considered variable lease cost and are recognized in the period in which the costs are incurred. For finance leases, amortization expense related to finance lease ROU assets is recognized on a straight-line basis over the earlier of the useful life of the ROU asset or the lease term and </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont4" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont5"><ix:continuation id="Tb_OEmndfTpBEqj1Dd1qgfgYg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interest expense is recognized based on the effective interest method using the Company&#8217;s incremental borrowing rate. Operating, variable and finance lease cost are recorded as a component of research and development expenses and general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_j7GeSuWS4EazPLKwXQV5YA" continuedAt="Tb_j7GeSuWS4EazPLKwXQV5YA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The terms of these arrangements may include (i)&#160;performing research and development services using the Company&#8217;s bicyclic peptide screening platform with the goal of identifying and/or optimizing compounds for further development and commercialization, (ii) the transfer of intellectual property rights (licenses), or (iii) options to obtain additional research and development services or licenses for additional targets, or to optimize product candidates, upon the payment of option fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; payments for research and development services and reimbursement of certain expenses incurred; fees upon the exercise of options to obtain additional services or licenses; payments based upon the achievement of defined collaboration objectives; future regulatory and sales-based milestone payments; and royalties on net sales of future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC&#160;606&#8221;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, and financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC&#160;606, it performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each performance obligation based on estimated relative standalone selling prices, and measuring progress towards the satisfaction of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once a contract is determined to be within the scope of ASC&#160;606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations at contract inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. The promised goods or services in the Company&#8217;s contracts with customers primarily consist of license rights to the Company&#8217;s intellectual property, research and development services, options to acquire additional research and development services, and options to obtain additional licenses, such as a commercialization license for a potential product candidate. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources, and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the collaboration partner to develop the intellectual property on their own and whether the required expertise is readily available. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont5" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont6"><ix:continuation id="Tb_j7GeSuWS4EazPLKwXQV5YA_cont1" continuedAt="Tb_j7GeSuWS4EazPLKwXQV5YA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate variable consideration to include in the transaction price based on which method better predicts the amount of consideration expected to be received. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. The initial transaction price of a contract does not include amounts associated with customer option payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the transaction price is determined, it is allocated to the identified performance obligations based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, probabilities of technical and regulatory success and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an input method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i> If a license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from portion of the transaction price allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, such as research and development services and a research license, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development services:</i> The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Customer options:</i> A customer&#8217;s right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide, and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or at a discount. Optional future goods and services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. If optional future goods and services include a material right, they are accounted for as performance obligations. The Company determines an estimated standalone selling price of any material rights for the purpose of </p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont6" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont7"><ix:continuation id="Tb_j7GeSuWS4EazPLKwXQV5YA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">allocating the transaction price. The Company considers factors such as the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone payments:</i> The Company&#8217;s collaboration agreements may include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net loss in the period of adjustment. Milestone payments that may only be achieved after the exercise of a customer option are excluded from the initial determination of the transaction price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company&#8217;s collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company receives payments from customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional, such as when the Company has a contractual right to payment per the terms of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional information regarding the Company&#8217;s accounting for collaboration revenue, see Note&#160;9, &#8220;Significant agreements.&#8221;</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_ekCYzrmLnUa1wOwKpQsfzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, facilities costs, depreciation, materials and laboratory supplies, and external costs of outside vendors engaged to conduct preclinical development and clinical development activities, as well as costs to manufacture clinical trial materials. Facilities costs primarily include the allocation of rent and utilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized until the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" id="Tb_Z9G0lXS6Z0CowCvLs1XG5g" continuedAt="Tb_Z9G0lXS6Z0CowCvLs1XG5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has entered into various research and development and manufacturing contracts, including contracts with respect to preclinical studies and clinical trials, with companies both inside and outside of the United&#160;States. These agreements are generally cancelable with 90&#160;days or less notice, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research and development and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont7" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont8"><ix:continuation id="Tb_Z9G0lXS6Z0CowCvLs1XG5g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock" id="Tb_mDOUbpUPREiF4fH7Z7cLjQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development incentives and receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company, through its subsidiaries in the U.K., receives reimbursements of certain research and development expenditures as part of a U.K. government&#8217;s research and development tax reliefs program. Under the Small and Medium-Sized Enterprises (&#8220;SME&#8221;) R&amp;D Tax Relief program, the Company is able to surrender trading losses that arise from qualifying research and development expenses incurred by the Company&#8217;s subsidiaries in the United&#160;Kingdom for a cash rebate of up to <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_3_31_2023_To_3_31_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_1IrDAG-GjkaODsojD2rcmg" decimals="4" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" scale="-2" id="Narr_ywkV-ubSxE2yJHnQPGMYBw">33.35</ix:nonFraction>% of qualifying expenditure incurred prior to April 1, 2023, and up to <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_4_1_2023_To_4_1_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_DRGyMBQk30C0HCqiKdLvbA" decimals="3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" scale="-2" id="Narr_pMettojnVkWUYPsq8h42HQ">18.6</ix:nonFraction>% of qualifying expenditure incurred thereafter. Amendments to the U.K. R&amp;D tax credit regime included in Finance Act 2024, which was enacted in February 2024, increased the cash rebate that may be claimed to <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_2_1_2024_To_2_29_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_F9BWe4BDkEGe1GncdURkdA" decimals="4" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" scale="-2" id="Narr_jdz3HqdX20aeZrAXk4bapA">26.97</ix:nonFraction>% of qualifying expenditure, retroactively applied to qualifying expenditures incurred after April 1, 2023, if the Company qualifies as &#8220;R&amp;D intensive&#8221; for an accounting period (broadly, a loss making SME whose relevant R&amp;D expenditure represents, for accounting periods beginning on or after April 1, 2023, <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_4_1_2024_To_4_1_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_mZK_WLmvd0u3bkPaVSH2lQ" decimals="2" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" scale="-2" id="Narr_0o0l-MksEUeon01v-sLoPg">40</ix:nonFraction>%, or, for accounting periods beginning on or after April 1, 2024, <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_4_1_2024_To_4_1_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_mZK_WLmvd0u3bkPaVSH2lQ" decimals="2" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" scale="-2" id="Narr_PmHpCAesE06_Sz9Ty6kAzg">30</ix:nonFraction>%, of its total expenditure for that accounting period). The Company was an R&amp;D intensive SME for the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and development incentives as a reduction to research and development expenses in the consolidated statements of operations and comprehensive loss, as the research and development tax credits are not dependent on us generating future taxable income, the Company&#8217;s ongoing tax status, or tax position. The research and development incentives receivable represent an amount due in connection with the above program. The Company recorded a reduction to research and development expense of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ReductionOfResearchAndDevelopmentExpense" scale="6" id="Narr_ET6Dh-DVcEabpK_9O5aKOQ">43.1</ix:nonFraction> million for the year ended December 31, 2024, including the impact of an increase to U.K. R&amp;D tax credit reimbursement rates enacted with Finance Act 2024 retroactively applied to qualifying expenditures incurred after April 1, 2023. The Company recorded a reduction to research and development expense of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ReductionOfResearchAndDevelopmentExpense" scale="6" id="Narr_CIAQ2chcVU6-hakYDjvbWg">23.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ReductionOfResearchAndDevelopmentExpense" scale="6" id="Narr_jk9Dw59NI0GKXIQyQ3dYJQ">19.3</ix:nonFraction>&#160;million during the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" id="Tb_BSNsdfOPL0-CGa99mg-bhw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with preparing, filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_9hHiR1q1f06qsMYvMzOvPA" continuedAt="Tb_9hHiR1q1f06qsMYvMzOvPA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures all equity awards granted to employees and directors based on the fair value on the date of grant. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with only service-based vesting conditions using the straight-line method. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For share-based awards granted to non-employee consultants, the measurement date is the date of grant. The compensation expense is then recognized over the requisite service period, which is the vesting period of the respective award, without subsequent changes in the fair value of the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The fair value of each restricted share award is based on the fair value of the Company&#8217;s shares, less any applicable purchase price. The fair value of each share option is estimated using the Black-Scholes option-pricing model, </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont8" continuedAt="Tb_h5E56m3mTU23hOcIRe21Dw_cont9"><ix:continuation id="Tb_9hHiR1q1f06qsMYvMzOvPA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which requires inputs based on certain subjective assumptions, including the fair value of shares, the expected share price volatility, the expected term of the award, the risk-free interest rate and expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to 2022, due to a lack of company-specific historical volatility data, the Company&#8217;s expected volatility was calculated based on reported volatility data for a representative group of publicly traded companies for which historical information was available. The historical volatility was calculated based on a period of time commensurate with the assumption used for the expected term. During 2022, the Company began to estimate its volatility by using a blend of its stock price history for the length of time it has market data for its stock and the historical volatility of similar public companies for the expected term of each grant. The Company continues to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its share-based awards. The Company uses the remaining contractual term for the expected life of non-employee awards. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_dYLPBxsIKE2jri5I2g5nHw">zero</ix:nonFraction> as the Company has never paid dividends and has no current plans to pay any dividends on ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll or service costs are classified.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_QsVm7HOFaEyle9eNwqLDrw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation as a component of other comprehensive loss in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="Tb_DCGB_oUWHkGDQ6TqnlsbuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential loss range is probable and reasonably estimable under the provisions of ASC Topic 450, <i style="font-style:italic;">Contingencies</i>. The Company expenses costs as incurred in relation to such loss contingencies as general and administrative expense within the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_uZEqd6HI_EiSBToZySOhng" continuedAt="Tb_uZEqd6HI_EiSBToZySOhng_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the (benefit from) provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h5E56m3mTU23hOcIRe21Dw_cont9"><ix:continuation id="Tb_uZEqd6HI_EiSBToZySOhng_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that will more likely than not be realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_KvhjuYsySU2gg5A9N_4Deg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period, including potential dilutive ordinary shares assuming the dilutive effect of ordinary share equivalents. In periods in which the Company reported a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_Dr5qV8-vJkipvs29bvOrag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2023, the FASB issued ASU No. 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures</i>, which requires disclosure of incremental segment information on an interim and annual basis. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, and requires retrospective adoption to all prior periods presented in the consolidated financial statements. The adoption of ASU 2023-07 had no impact on the Company&#8217;s reportable segments identified and additional required disclosures have been included in Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements not yet adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, <i style="font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40)</i>, which requires more detailed disclosures about specified categories of expenses included in certain expense captions presented on the face of the consolidated statements of operations and comprehensive loss, including employee compensation, depreciation and amortization. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to all prior periods presented. The Company is currently evaluating the impact of the adoption of ASU No. 2024-03 on its consolidated financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740) Improvements to Income Tax Disclosures</i>, which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 is effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its consolidated financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><a id="_2121263d_3a36_4d21_ad59_89aec6cddb86"></a><a id="_2121263d_3a36_4d21_ad59_89aec6cddb86_2"></a><a id="_2121263d_3a36_4d21_ad59_89aec6cddb86_3"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_5rd9voRKVESwpkaR3lydqA" continuedAt="Tb_5rd9voRKVESwpkaR3lydqA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">3. Fair value of financial assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December 31, <span style="-sec-ix-hidden:Hidden_X5wnyztC8UGUEz3EZ1OAbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2024</span></span>, the Company had cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gejPkuQhakeSpM_QZlP27Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_jXC6lsvfZEeuAIbVHC5qOw">664.9</ix:nonFraction> million consisting of money market funds that are primarily invested in U.S. Treasury securities, which are considered Level 1 assets. As of December 31, 2023, the Company had cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_slT9uSBHsk6jvBbMvui31g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_4rbcbE26ukqpXS_-kRuH1w">72.3</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gmBeuV6pUkqZOjdLGoLzMQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="Narr_BLX1M1xr0EmoNva4BVQVVA">22.1</ix:nonFraction> million of money market funds and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gmBeuV6pUkqZOjdLGoLzMQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TimeDepositsAtCarryingValue" scale="6" id="Narr_sEbd7WDkzEqv3oRnRdvY2w">50.2</ix:nonFraction> million in <span style="-sec-ix-hidden:Hidden_Vut1ulUKVEGQr75nUhokTQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30-day</span></span> term deposits which are considered Level 1 assets. As of December 31, 2024 and 2023, there were <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5MPhoYm4pEaBvoSPbVf8mQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="6" id="Narr_sZbYHVOncEuvSx7oijpGmQ"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IE3SmW-yQ0GAQXZrSOSVUQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="6" id="Narr_BIJtioe7_kmUoptroIlfQw">no</ix:nonFraction></ix:nonFraction> other assets or liabilities measured at fair value on a recurring basis.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_5rd9voRKVESwpkaR3lydqA_cont1"></ix:continuation><a id="_34f05070_51e4_4d4c_9fc4_c28995a2e98b"></a><a id="Tc_SRf3H28uK0mY-8J5iDIAOQ_1_2"></a><a id="Tc_Uj-MmUA7rUyh4IWhR8M3VQ_1_5"></a><a id="Tc_Cpk77IrADUae-Bz17_87RQ_2_2"></a><a id="Tc_sB5mir4BJkKVktydZpjAYA_2_5"></a><a id="Tc_S81w9q6gg02j-VfZV2QmfA_3_0"></a><a id="Tc_J02nUQMttEeFqV6luTwmjw_3_2"></a><a id="Tc_CSXLuPdPJk6pPRRIHT_0VQ_3_5"></a><a id="Tc_08RO8--zR0yN4Dw5S4XedA_4_0"></a><a id="Tc_8dr1T7iknEO-Cpo8sNdIOQ_5_0"></a><a id="Tc_bkxeDP1iwUigthQ6SffDnw_5_6"></a><a id="Tc_gcWACLkBcE6saqc213mrMQ_6_0"></a><a id="Tc_80AfLIlUfUqLq9fcUZQWmA_7_0"></a><a id="Tc_BZD6XQWvfU-opBsaO6KqZQ_9_0"></a><a id="Tc_k-L3crbPK02_JEXMe0ePLw_10_2"></a><a id="Tc_nuwxKia8P0OUKeoU7RP__g_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_pewttxbshEO_-9gZ3KijOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">4. Property and equipment, net</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_pvkHlFs84ECq5ulwvz8j8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_cyshTxnH0kyrdYWVdqiIsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_g3OB9ZN6wUutx1maFmA71A_3_3">14,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_8msZM6Sha0iTRy5AvtsnvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_r2E3a02biUmwmV9w1tQhVw_3_6">15,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_jYlsDtcKqkiYG1N-mRdO7w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_VUnVF0hyrEOkYTPFSuOyrA_4_3">10,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nP9jA-aiYkONgvoroTyc9A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_3MaGi-rPeEKHQZNGQTQGwQ_4_6">11,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="Tc_6PtWJR1_jUG29cYcz9eufA_5_3">1,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xx2lOaIKTUaBAJxmtahpDA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_GG-87_ALa0mwDblVuRcuqA_6_3">581</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_anAvD0bAqk2fupg6zYmu5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_dBRssS5ir0moFDYRqYBXDA_6_6">532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LZhexdWpm0qTV2Rf8LpgSA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_820Vw0GNKUenkqdzRrAN8Q_7_3">1,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PorQ7L3GZEWmg7J9b0BaFA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_SR6RX1C4mUCA8ZdctCRLpg_7_6">822</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_DCNQ4aNH4UW-JzsNuBuLIw_8_3">28,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_C2L11pSAhE2wpjNdgmxPzQ_8_6">27,908</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_w9AuVGY4yEisZQxQpVjV0w_9_3">18,949</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_rhGnJCOpnUumaE98JwN5qA_9_6">13,393</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_Or1LJJaP3UC2UlvjyooN2g_10_3">9,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_O2X5Ukb1FU6vcEK8EprO9A_10_6">14,515</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_U0BItUD_H0y_Szk8m1PKDw">7.2</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_P_DwUyte60m8M_ZsgBO1Uw">6.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_8kmD3fl_pkKj_11V1-jRlQ">3.7</ix:nonFraction> million for the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. Depreciation and amortization expense for the years ended December 31, 2024, 2023 and 2022 included amortization expense of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="Narr_mH-e50SGSEuotNUe3LsBAQ">0.1</ix:nonFraction> million, <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="Narr_-D-3paKqYU6klfgk9vx5lQ">zero</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="Narr_0kRa3GzKAUy4W8oYNDSxgg">zero</ix:nonFraction>, respectively, related to property and equipment obtained under finance leases. </p></ix:nonNumeric><a id="_6ace5276_1cfc_4dc3_bb29_3455465e376e"></a><a id="Tc_FUmjmBMivEaWFmNGb6zCqw_1_2"></a><a id="Tc_t-SmRHYcCEKkOUZjXsApLg_1_5"></a><a id="Tc_2IoeH23-60iXl0PodR4XaQ_2_2"></a><a id="Tc_2pV1A4Qo3Uu1RPpm_Qpc9Q_2_5"></a><a id="Tc_MjOIltICtkubT6V1DXepWg_3_0"></a><a id="Tc_O_6gLspSBkCVdDOD7IdZug_3_2"></a><a id="Tc_XZUi3QKbbEOAKOsMIRRwqQ_3_5"></a><a id="Tc_bnjh8bj4P0ydpWUsomJukg_4_0"></a><a id="Tc_K0_dilVcnEq8IZzNRF6ezA_5_0"></a><a id="Tc_3j1HWSKi40OmuhbCXIzV6w_7_6"></a><a id="Tc_5vFaKlZBskSN5d12I9koXw_8_0"></a><a id="Tc_V8euQ3bwoUGtMUnBkAPWkQ_9_2"></a><a id="Tc_JEC3Rdi6C0-0ZBJhj6ksgA_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_uBtCVy1Gr0q-O47VsKkrGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">5. Accrued expenses and other current liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb_zrHW8u09Y0u_eSDUpJtPmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_PQs20Ac_XEKCsRkH-_ZQOQ_3_3">16,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_d082mTifPEqRgRhPAN4KxA_3_6">13,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:AccruedExternalResearchAndDevelopmentExpenses" scale="3" id="Tc_Y3PfcummREmd1XWHwuWVbA_4_3">14,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:AccruedExternalResearchAndDevelopmentExpenses" scale="3" id="Tc_-iyOpAnZWEGwSLJ_Tj9qkg_4_6">11,839</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_he2ES-aPtEKY-lCgBdqz8Q_5_3">4,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_SKL7cPDzf0uSAREigJEmpw_5_6">1,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KW1rNIXqDU6mr2igGNJAXQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of operating lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_d2TopchPjE6FarcTSsn6vw_6_3">5,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_sVSaNs_l80OZy6R2S02QgA_6_6">4,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WTohRhZpUkiEgaVCaOLomQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of finance lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_1Q06UAKtJ0SZVXPcdJ5N6g_7_3">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_ToA6XmyNH0ejB_GuaaQxxw_8_3">297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_AJ2ys4AcQkmDbcQQn07hVA_8_6">257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_rtY6n9_ttUCfRaws8fNBew_9_3">41,246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_LmetBoZ8WkiKFI1VgR6P0Q_9_6">31,509</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In August 2024, the Company consolidated all discovery research activities to the Company&#8217;s headquarters in Cambridge, U.K. As a result, during the year ended December 31, 2024, the Company recognized charges of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_3bZ0WezC1ECTNMuaNEL3sQ">2.0</ix:nonFraction> million in severance and other one-time termination benefits which are included in <span style="-sec-ix-hidden:Hidden_tsh7VRNlykaXUR1w5uepYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research</span></span> and development expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss, of which $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="6" id="Narr_uMgTpcPpqEaXZ4fIbshszA">1.6</ix:nonFraction> million were paid during the year ended December 31, 2024, and the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="6" id="Narr_8Wqsobo7mEeeVZFeP96TsQ">0.4</ix:nonFraction> million in unpaid benefits are included in accrued expenses and other current liabilities in the Company&#8217;s consolidated balance sheet as of December 31, 2024.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:DebtDisclosureTextBlock" id="Tb_SpYyYCYWtESBU3_RzP9Phg" continuedAt="Tb_SpYyYCYWtESBU3_RzP9Phg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">6. Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On September 30, 2020, Bicycle Therapeutics plc and its subsidiaries (the &#8220;Borrowers&#8221;) entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Hercules, as amended from time to time, which provided for aggregate maximum borrowings of up to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_bcyc_TermLoanMember_us-gaap_TypeOfArrangementAxis_bcyc_LoanAndSecurityAgreementMember_65OBBumYj02j9k3Pn3oFYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_jYt5gWmjm06pztUAJJqfTg">75.0</ix:nonFraction> million, of which the Company had drawn down an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_NmP2-XzDFUGGWP4ZizBE4g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_Zqrm9KF-Y0uAxJznj4qIOA"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_D3g9RlG-o0yxRqde4Bnx9Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_uzoLQT8zUki2ETE2lO61qw"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_xsjVq66pdkiUGagQ0I5-lQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_0WNtuJIyUEaCW1c4a9B7xQ">30.0</ix:nonFraction></ix:nonFraction></ix:nonFraction> million in 2021 and 2020. Payments on borrowings under the Loan Agreement were interest-only until April 1, 2025 and interest was paid at an annual rate of the <i style="font-style:italic;">Wall Street Journal </i>prime rate plus <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_9_30_2020_To_9_30_2020_OY1e7NwWCUq25fNFOMQDzQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_oMIf1gb9J0yrr40ckgs7Iw">4.55</ix:nonFraction>%, with a minimum annual rate of at least <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_olYsF14wyEW_U0xeDnkzAg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_FTEgfVVbEUKiJ9W09U7SPA">8.05</ix:nonFraction>%, capped at a rate no greater than <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_NmP2-XzDFUGGWP4ZizBE4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_LKta_S5gxUKc0U2pXBORzg">9.05</ix:nonFraction>%, and the Loan Agreement included a <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_9_30_2020_DRfguGfVi0Or7GWsyp0CBw" decimals="3" format="ixt:num-dot-decimal" name="bcyc:DebtInstrumentEndOfTermChargeRate" scale="-2" id="Narr_nyiwKpjF-02CKfwatn4Qig">5.0</ix:nonFraction>% end-of-term charge payable upon maturity or repayment. The scheduled maturity date was July 1, 2025. On July 9, 2024, the Company repaid all amounts outstanding, including the outstanding borrowings of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_WnwNY1t2gkep67F-aGUgkw">30.0</ix:nonFraction> million, accrued and unpaid interest of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="6" id="Narr_PoNI65N5QEybLpsmd1fv8Q">0.1</ix:nonFraction> million, an end-of-term charge of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:DebtEndOfTermCharge" scale="6" id="Narr_Wjvd-OrWqU2rRh5a7lZUFA">1.5</ix:nonFraction> million and a prepayment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_9_2024_To_7_9_2024_ZJZfQXYoCEan2WXy8RfycA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:DebtInstrumentPrepaymentCharges" scale="6" id="Narr_LOqQSu-750SFUWHPb3gjqw">0.3</ix:nonFraction> million, for a total aggregate payment of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_9_2024_To_7_9_2024_ZJZfQXYoCEan2WXy8RfycA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="Narr_w982B3koHU6tb7naA4kKKQ">31.9</ix:nonFraction> million, and terminated the Loan Agreement. The Company recognized a loss on extinguishment of debt of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_KRaDIhn8nE-KAluNFxwSOw">1.0</ix:nonFraction> million during the year ended December 31, 2024 in connection with the repayment and termination of the Loan Agreement. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_82d4a441_091d_4377_85ec_d58d80fa2189"></a><a id="Tc_qo0Nabi67UeeWXQHKwZsOw_1_2"></a><a id="Tc_pIE7ayWhzUG-v8SdOtLk9g_1_5"></a><a id="Tc_YCdzkUo-rES_6B99v2iUrA_2_2"></a><a id="Tc_Wsb_FSWaeEC_gyGBq2OmEQ_2_5"></a><a id="Tc_fmxR6e7fgkaW3rCB3fTtMQ_3_0"></a><a id="Tc_7ghj78AmTUCOtWLVwB50Xg_3_2"></a><a id="Tc_x7QvhnDu0Uqeuy5YliT6jw_3_3"></a><a id="Tc_TQ1JOBvICEGIZMWK3onH5Q_3_5"></a><a id="Tc_u9_acp6-hEqy6RPkptFKTA_4_0"></a><a id="Tc_UuzW_2mkhUiGoJHrOl4xHA_4_3"></a><a id="Tc_3rVjWvD8Ok-sYXSKR7XOFg_5_0"></a><a id="Tc_ZIc0v-wB5UyuTEYNvjGclw_5_3"></a><a id="Tc_80189c2mGkW7TX-y7XepCw_6_0"></a><a id="Tc_xSPG5hEQqEWpO75maeuplg_6_2"></a><a id="Tc_zf9oRWUZa06OOOocPqgr3w_6_3"></a><a id="Tc_CYO8NLj1B0OAulotkZ1rAA_6_5"></a><ix:continuation id="Tb_SpYyYCYWtESBU3_RzP9Phg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense associated with the Loan Agreement for the years ended December 31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_bMuDMhK8aEyJU12mzFiI9Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseLongTermDebt" scale="6" id="Narr_MgoVZ6R9lEmRCggxP8-vAA">1.6</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_Ex-1F6jyfUO72vn1vcWu-w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseLongTermDebt" scale="6" id="Narr_KXM5Zl-oQECJ2mZGx8O41Q">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_X1BWRi7-lk2fvBqoP0fM9A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseLongTermDebt" scale="6" id="Narr_Ce4-y2xRTk6W138OBSpJBw">3.2</ix:nonFraction> million, respectively. Upon termination of the Loan Agreement, all security interests granted to the secured parties thereunder were terminated and released.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_MoofFSv1KUueGEjjy7g1IQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Debt consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term loan payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_FVtIi79SkUC_DUzvSVgKJg_3_6">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End of term charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:DebtEndOfTermCharge" scale="3" id="Tc_t_B4FXX2OUS169LrYjRBQw_4_6">946</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="Tc_wMBCRk-JI0OUBA7hnNtdng_5_6">248</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carrying value of term loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_3BLLR4Zng0qsb-QnPFNFtQ_6_6">30,698</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1.3pt;"><td style="vertical-align:top;width:29.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_CBd-HkTby028OXsii2nJdw" continuedAt="Tb_CBd-HkTby028OXsii2nJdw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">7. Ordinary shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s ordinary shares are divided into two classes: (i) ordinary shares and (ii) non-voting ordinary shares. Each holder of ordinary shares is entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_F2iWXsaSbUSm_tPiCaeIdA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfVotePerShare" scale="0" id="Narr_YNijXuKWg0OipNcynWobgA">one</ix:nonFraction> vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders. Holders of ADSs are not treated as holders of the Company&#8217;s ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of the Company&#8217;s ordinary shares, other than the rights that they have pursuant to the deposit agreement with the depositary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-voting ordinary shares have the same rights and restrictions as the ordinary shares and otherwise rank <i style="font-style:italic;">pari passu</i> in all respects with the ordinary shares except for the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a holder of non-voting ordinary shares shall, in relation to the non-voting ordinary shares held, have no right to receive notice of, or to attend or vote at, any general meeting of shareholders save in relation to a variation of class rights of the non-voting ordinary shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the non-voting ordinary shares shall be re-designated as ordinary shares by the Company&#8217;s board of directors, or a duly authorized committee or representative thereof, upon receipt of a re-designation notice and otherwise subject to the terms and conditions set out in the terms of issue. A holder of non-voting ordinary shares shall not be entitled to have any non-voting ordinary shares re-designated as ordinary shares where such re-designation would result in such holder thereof beneficially owning (for purposes of section 13(d) of the Exchange Act), when aggregated with &#8220;affiliates&#8221; and &#8220;group&#8221; members with whom such holder is required to aggregate beneficial ownership for the purposes of section 13(d) of the Exchange Act, in excess of 9.99% of any class of the Company&#8217;s securities registered under the Exchange Act (which percentage may be increased or decreased on a holder-by-holder basis subject to the provisions set out in the terms of issue); and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the non-voting ordinary shares shall be re-designated as ordinary shares automatically upon transfer of a non-voting ordinary share by its holder to any person that is not an &#8220;affiliate&#8221; or &#8220;group&#8221; member with whom such holder is required to aggregate beneficial ownership for purposes of section 13(d) of the Exchange Act. This automatic re-designation shall only be in respect of the non-voting ordinary shares that are subject to such transfer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="Narr_DmJcFT8N2E2uu6-UPK7tFQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="Narr_mU0M1rw7vk6ISTIugzyd8w">no</ix:nonFraction></ix:nonFraction>t declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31, 2024 and 2023, the Company&#8217;s authorized capital share consisted of <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_REj3b3oIlUCm8SlJVjGueg">155,876,645</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_NOUoR4rYLU-uX7ULycv37Q">59,612,613</ix:nonFraction> ordinary shares, respectively, including ordinary shares and non-voting ordinary shares, with a nominal value of &#163;<ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_RIAxj2CuckeJEm18IMVEiQ"><ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_AmI5j4n8tkyOv-r6Deq5eQ">0.01</ix:nonFraction></ix:nonFraction> per share. Authorized share capital, or shares authorized, comprises (i) the currently issued and outstanding ordinary shares and non-voting ordinary shares, (ii) the remaining ordinary shares available for allotment under the existing authority granted to the Board at the annual general meeting held on May 16, 2024, (iii) ordinary shares issuable on the exercise of outstanding options and settlement of vested restricted share units (&#8220;RSUs&#8221;), and (iv) ordinary shares </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CBd-HkTby028OXsii2nJdw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reserved for issuance under the Bicycle Therapeutics plc 2024 Inducement Plan (the &#8220;2024 Inducement Plan&#8221;), the Bicycle Therapeutics plc 2020 Equity Incentive Plan (as amended from time to time, the &#8220;2020 Plan&#8221;), and/or the Bicycle Therapeutics plc 2019 Employee Share Purchase Plan (the &#8220;ESPP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_VotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJXTy3J51UCZNJxJ1Ym8RQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_-KJkurTXaEmp_ckZj1r8FQ">47,569,319</ix:nonFraction> ordinary shares <span style="-sec-ix-hidden:Hidden_Lpo0wyq33EyQ4jsKrECq2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding and <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y61uWaX9NEaChNzvdxBdnQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_kGEOULlsl0GiwZxR8PmuIw">21,492,099</ix:nonFraction> non-voting ordinary shares <span style="-sec-ix-hidden:Hidden_isC1MjD3_kuhXs60-F47rw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 23, 2024, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with purchasers named therein (the &#8220;Investors&#8221;). Pursuant to the Purchase Agreement, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_IYGnT7YWfkykLNwOFediag" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_znsXwMH2LEKdHC8TUu7XHw">6,764,705</ix:nonFraction> ADSs, representing the same number of ordinary shares, nominal value &#163;<ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_IYGnT7YWfkykLNwOFediag" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Xpxhk5P5KUWuz7pJXlMqpw">0.01</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_V7TD4LyjyEOPQOb-5emQbg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_1rdMDHYfHkK8t28VgO5STg">19,169,001</ix:nonFraction> non-voting ordinary shares, nominal value &#163;<ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_V7TD4LyjyEOPQOb-5emQbg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_LUo5wExB00Oc_Ps-qBqMnA">0.01</ix:nonFraction> per share, each at a purchase price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_5_23_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_1meCJkhmuUalIyW_wBy3UA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_racjQtVoXEmyYtkAzkzwJg">21.42</ix:nonFraction> per share (the &#8220;Private Placement&#8221;). The Company completed the Private Placement on May 28, 2024. The transaction resulted in gross proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_yHGwA2U7FUitPPxAQFyV8g">555.5</ix:nonFraction> million, and after deducting commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_lrKTMmdy00a2dk5eblQOEA">11.4</ix:nonFraction> million, net proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_6q_uuy3JekKID4nTDE-YtQ">544.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2023, the Company completed an underwritten public offering of its securities, pursuant to which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_M9NqLknzNU-sMVpqCl-eFw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_P6QBLRdHhUSf9Q_WrbZnIQ">6,117,648</ix:nonFraction> ADSs, representing the same number of ordinary shares, nominal value &#163;<ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_jjLRXKu4UkmDU29qbwfUyg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_wEHLWSz2pECqfjBsXbvdbQ">0.01</ix:nonFraction> per share, which included <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_FinancialInstrumentAxis_us-gaap_OptionOnSecuritiesMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_cVgwDI4loUexIB3GNxcfVg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_uHpfsnKzmEqCufuQXN7VRQ">1,411,764</ix:nonFraction> ADSs sold upon the underwriters&#8217; full exercise of their option to purchase additional ADSs, and <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_2llzQZ6_20K-zZTfy-CSow" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_QU9Ch4xHREKSPN53Vr8KMA">4,705,882</ix:nonFraction> non-voting ordinary shares, nominal value &#163;<ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_A4JYy9Ek902M2Ll6OJMTig" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ixRD0U4upUKOOKpXiaRPbw">0.01</ix:nonFraction> per share, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_jjLRXKu4UkmDU29qbwfUyg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_XNF2AmaYJ0KTXL-XUByv1Q">21.25</ix:nonFraction> per ADS or non-voting ordinary share, respectively. The transaction resulted in gross proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_zitLz3sakEipy2sk2MAb1A">230.0</ix:nonFraction> million, and after deducting underwriting discounts, commissions, and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_v-EdpVPLj0eg6o8_IaxTrQ">14.9</ix:nonFraction> million, net proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_7mgFEkKsg0iGN1ULId3ICQ">215.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On June 5, 2020, the Company entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc. (the &#8220;Sales Agents&#8221;) with respect to an ATM program pursuant to which the Company may offer and sell through the Sales Agents, from time to time at the Company&#8217;s sole discretion, American Depositary Shares (&#8220;ADSs&#8221;), each ADS representing one ordinary share. <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_Q3Ip6DsZDUiZokIoW7oY_g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_LJ-gzEm1MEOGgrTPuQS6gA">No</ix:nonFraction> ADSs were issued or sold pursuant to the Sales Agreement during the year ended December 31, 2024. During the year ended December 31, 2023, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_2uabg4H0sUy4TlBNK2BBbg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_7nEN-wKvWk6gw9DP9Qzd_w">1,561,176</ix:nonFraction> ADSs, representing the same number of ordinary shares for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_04AAW9NKfkWTo21c6ZX1mQ">35.3</ix:nonFraction> million, resulting in net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_bRaQAvH3j0KEMPAZ-_Nz1Q">34.2</ix:nonFraction> million after deducting sales commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_JikYKAhCJ0a-KfWIhBxpkQ">1.1</ix:nonFraction> million. During the year ended December 31, 2022, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_XPuSzU4R-ki_U9PggBrUeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_HXOvmidqV0qj2UQXP4taCw">181,455</ix:nonFraction> ADSs, representing the same number of ordinary shares for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_lfdKNYeNEky7U9NU1xjf8A">5.9</ix:nonFraction> million, resulting in net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_jYvSwz9bM0KCS0PP4q2RWg">5.7</ix:nonFraction> million after deducting sales commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_rE6glOBXt0-FtmmWqu6Jmg">0.2</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_u4U8_1IEzUSWWKSOSzsf-w" continuedAt="Tb_u4U8_1IEzUSWWKSOSzsf-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">8. Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Employee incentive pool</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2024 Inducement Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In July 2024, the Company&#8217;s board of directors approved the 2024 Inducement Plan. </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">The 2024 Inducement Plan allows for the granting of nonqualified share options, RSUs, and other equity awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company.</span><span style="font-style:normal;font-weight:normal;"> </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">Share options granted under the 2024 Inducement Plan have a </span><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_a1Oi0t48FUudnS8WN5P3Bw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_li7JlGQl_Uy_LegMMnWSXQ"><span style="font-style:normal;font-weight:normal;background:#ffffff;">10-year</span></ix:nonNumeric><span style="font-style:normal;font-weight:normal;background:#ffffff;"> contractual life and generally vest over a </span><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_E1--0LWw1EmKwIGcLWnwFA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_raYQFuW0JEuJ1ExCAfiwBQ"><span style="font-style:normal;font-weight:normal;background:#ffffff;">four-year</span></ix:nonNumeric><span style="font-style:normal;font-weight:normal;background:#ffffff;"> service period with </span><span style="font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_MAFub_g2y0GAD_IA8SQX-A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_m5vIkXhYwE6jBDs4Epg5xA">25</ix:nonFraction>%</span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> of the award vesting on the first anniversary of the vesting commencement date and the balance thereafter in </span><span style="font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_M_lugMOcstmECVEFUGtQg6XA" contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_bG4-HMluqEmz8RSPzC0fGQ" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_CC0gjSNMwUGUIdCJf4o1ug">36</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> equal monthly installments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;background:#ffffff;"> The Company initially reserved </span><span style="font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_7_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_MBs7tOGmkE641EB2R-K8nw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_XP1Re5DXnU-CudUFik6JUQ">1,500,000</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> of its ordinary shares, or the equivalent number of ADSs, for the issuance of awards under the 2024 Inducement Plan. As of December 31, 2024, there were </span><span style="font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_J_fXlQvUukSBnlagZHQH8g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_rwy5nUnjjk-K0K62r-agRg">1,251,400</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> shares available for future issuance under the 2024 Inducement Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_v3o1BPc0-02UERuTDFMLWg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_1Caf8exPLkytuhSkjPxJlQ">248,600</ix:nonFraction> shares outstanding under the 2024 Inducement Plan.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_u4U8_1IEzUSWWKSOSzsf-w_cont1" continuedAt="Tb_u4U8_1IEzUSWWKSOSzsf-w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">2020 Equity Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2020, the Company&#8217;s shareholders first approved the 2020 Plan, under which the Company may grant market value options, market value stock appreciation rights or restricted shares, RSUs, performance RSUs and other share-based awards to the Company&#8217;s employees. The Company&#8217;s non-employee directors and consultants are eligible to receive awards under the 2020 Non-Employee Sub-Plan to the 2020 Plan. All awards under the 2020 Plan, including the 2020 Non-Employee Sub-Plan, will be set forth in award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms, change of control provisions and post-termination exercise limitations. In the event of a change of control of the Company, as defined in the 2020 Plan, any outstanding awards under the 2020 Plan will vest in full immediately prior to such change of control. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company initially reserved up to <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_hWWYIZXzx0acMJRpjAgv5w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_fMsxM-e2VE2sOyMFGiqUzw">4,773,557</ix:nonFraction> ordinary shares for future issuance under the 2020 Plan, including shares subject to options that were granted under the Company&#8217;s 2019 Share Option Plan (the &#8220;2019 Plan&#8221;) and that were granted pursuant to option contracts granted prior to the Company&#8217;s IPO, in each case that expire, terminate, are forfeited or otherwise not issued from time to time, if any. On June 27, 2022, the Company&#8217;s shareholders approved an amendment to the 2020 Plan (the &#8220;Amendment&#8221;) which increased the number of ordinary shares reserved for future issuance by <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_6_27_2022_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_4Vyzs47cNE-kgf6kZGnMbw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_Rd_KfGf9mE2GtEa-xz-KTQ">750,000</ix:nonFraction> shares. Additionally, the number of ordinary shares reserved for issuance pursuant to the 2020 Plan will automatically increase on the first day of January of each year, initially commencing on January&#160;1, 2021 and continuing up to and including January 1, 2032, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_o8DXnIN9Gka0CBw_y9jx6g" decimals="2" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" scale="-2" id="Narr_fF2WZEOhUUWfWj-hKNeMnQ">5</ix:nonFraction>% of the total number of the Company&#8217;s ordinary shares outstanding on the last day of the preceding&#160;year, or a lesser number of shares determined by the Company&#8217;s board of directors. Pursuant to this evergreen provision, on January 1, 2024, the number of shares reserved for issuance under the 2020 Plan was increased by <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_1_1_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_gQdGQPSVDUGV2TfhbI5-2w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_2kxUhQDcSkCBDrM5U9xftg">1,886,294</ix:nonFraction> shares. As of December 31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_5QeHcJfW2U6x27_YDU1Ogw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_vw1oTLI4dkud5W-BwK-FDw">463,374</ix:nonFraction> shares available for issuance under the 2020 Plan. The number of shares reserved for issuance under the 2020 Plan was increased by <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_1_1_2025_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_3jebnT0paUKkYaQIJZSi9A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_nwp4YaFPbka4RlCaKGr62A">2,378,465</ix:nonFraction> shares effective January 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options granted under the 2020 Plan have a <ix:nonNumeric contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Vi_9DbVLDEiUNj4B5lOvvQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_gQyFSHsma0-5eItKerRFDQ">10-year</ix:nonNumeric> contractual life, and generally vest over either a <ix:nonNumeric contextRef="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Lhc563hBmUO8945Z0wzLwA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_7Kh1MzmjlEyjQK0KsXY6bg">three-year</ix:nonNumeric> service period in <ix:nonFraction unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg" contextRef="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_78XxKxfYa0e6KIo8HByUpg" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" scale="0" id="Narr_KlbNzv8gnUm9YLY0UY_Edw">three</ix:nonFraction> equal annual installments for new non-employee director grants, or a <ix:nonNumeric contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_cpfcqvh4YUOX2BEX6A_K5g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_UZ7NUbKWzkqlSCJjjYBO1w">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_QDfyXxUou0-hgJMM6cWXtA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_7PgsaPEIUkKqi7VXz9sykw">25</ix:nonFraction>% of the award vesting on the first anniversary of the vesting commencement date and the balance thereafter in <ix:nonFraction unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_A43fKLk6X0Wn-S-Osq4rcQ" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_Ck3Nb58gvke10OoP3fTzvQ">36</ix:nonFraction> equal monthly installments for employees and consultants. Certain options granted to the Company&#8217;s non-employee directors vest over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kKS5dyzsFEufpIX9K-WVUQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_K39tgZduK0iOluR8fY1RHw">one-year</ix:nonNumeric> service period in <ix:nonFraction unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kKS5dyzsFEufpIX9K-WVUQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" scale="0" id="Narr_58uvwkyIm0y-WB9ivZ7U2w">four</ix:nonFraction> equal quarterly installments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants RSUs to non-employee directors, consultants and certain employees under the 2020 Plan. Each RSU represents the right to receive <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" scale="0" id="Narr_BROGknKEO0u8XxEa9KV-ng">one</ix:nonFraction> of the Company&#8217;s ordinary shares upon vesting. RSUs granted to employees and consultants vest over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Ui0BdifMukaA7zUExh2iww">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YameRw5flUWof726OmcJYQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_nuDbwjPwQkyx19KdTSsdHw">25</ix:nonFraction>% of the award vesting on the first anniversary of the vesting commencement date and the remaining RSUs vesting in <ix:nonFraction unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d2w1uOPLe0uqStZt99DW4A" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" scale="0" id="Narr_20o5292hfECcpHiHb9Zt9g">12</ix:nonFraction> equal quarterly installments. Certain RSUs granted to the Company&#8217;s non-employee directors either vest over a <span style="-sec-ix-hidden:Hidden_8SmY0G3wPEWWtHANX-xYGQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span></span> service period in <ix:nonFraction unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_qGTPrbV9lESEael4XrVLgA" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" scale="0" id="Narr_XxLEWOLGjU-uLeM7aaAQWQ">three</ix:nonFraction> equal annual installments for new non-employee director grants or over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_nzQDe9trVUK2zsTsGDudSw">one-year</ix:nonNumeric> service period in <ix:nonFraction unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_7SqqxQUnTU-2GwYuJp8WsQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfQuarterlyInstallments" scale="0" id="Narr_CF-nAjfS2kKL6NYXL0YG2A">four</ix:nonFraction> equal quarterly installments. The Company may also, in its sole discretion, provide for deferred settlement of RSUs granted to the Company&#8217;s non-employee directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kkvEbVaSgkafrtITcLkMkQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_Ao6VSqd5j02nFPUt5er61A">6,211,123</ix:nonFraction> shares and RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" scale="0" id="Narr__kc9_MdZlEOyAjB06AqEVQ">716,262</ix:nonFraction> shares outstanding under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2019 Share Option Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;<span style="white-space:pre-wrap;">2019, the Company adopted the 2019 Plan, which became effective in conjunction with the IPO.  As of December 31, 2024, there were </span><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Zt6VhwsXG0aIIZfDEMHd7w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_-O8FYm6XA06fTALwoc0OCw">1,773,816</ix:nonFraction> options to purchase ordinary shares outstanding under the 2019 Plan. In conjunction with the adoption of the 2020 Plan, all shares available for future issuance under the 2019 Plan as of June 29, 2020 became available for issuance under the 2020 Plan and the Company ceased making awards under the 2019 Plan. The 2020 Plan is the successor of the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Share options previously issued under the 2019 Plan have a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_WCDTG0m9xUCkxUKiJgwLbw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_sfZ9eVrrhU-71ip1jyGDow">10-year</ix:nonNumeric> contractual life, and generally either vest&#160;monthly over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Iontov7wME-Mj-R-qqxvRw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ekjU7gYbhkqconqTDBJ2hw">three-year</ix:nonNumeric> service period, or over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_NONBGaPxIUSKmSHZSQ1OaQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_CUeWA3k8EkWB4FNYZ6zjsQ">four-year</ix:nonNumeric> service period with <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zpq2bppWNkmyNQUoVWcEXg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_HqS1Ot1K9U2p3k_r2ioYWg">25</ix:nonFraction>% of the award vesting on the first anniversary of the commencement date and the balance thereafter in <ix:nonFraction unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_UuY5gYBUFEyCVoKDAuW1eA" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_SRKPS7U0-ketwf-bhMJZBg">36</ix:nonFraction> equal&#160;monthly installments. Certain awards </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_016256e3_b0bc_491d_8d74_c7e93056bffb"></a><a id="Tc__GYegIauoEaEd0aQZkOlpg_1_2"></a><a id="Tc_-3CfrYKV0kmoWehKvqfVgg_2_2"></a><a id="Tc_7YadU-NMOU-QglHlFnzeLg_3_2"></a><a id="Tc_ykxLxj0yLkKD4-vxYiKDjw_3_5"></a><a id="Tc_8XDmbb15IUKeAjhGC-bB-Q_3_8"></a><a id="Tc_xAcIwmPetEGDpqShJLBSjw_4_0"></a><a id="Tc_jazARnBTTE20r6qnQp-Ieg_4_2"></a><a id="Tc_6NnPzcZO1keic_y1Cznd0g_4_5"></a><a id="Tc_JIbLyRs5Nke1FS2pBm-pYg_4_8"></a><a id="Tc_ZneL3KDgFUKzHpTw7x7L0g_5_0"></a><a id="Tc_ABQGULQ3f02s5BH0sWgayg_6_2"></a><a id="Tc_upGh8EP0wkqjhaRz11dG2A_6_5"></a><a id="Tc_TEUYvowLfUysUSrTjAFfeA_6_8"></a><a id="Tc_siQp_cSXoEKBItRVmJh-tQ_1_2"></a><a id="Tc_dg2MGwFyxEimHhPhi7KA4A_1_7"></a><a id="Tc_4Z-gnrchUk2-bqrbtYihzg_2_2"></a><a id="Tc_R3mHXLRqKU-199O2BmWa2g_2_4"></a><a id="Tc_Z0lRB4gBGUidPJlbOc_tRw_2_7"></a><a id="Tc_4JmJYFW0b0OnRC3IFjRQug_2_9"></a><a id="Tc_eLfaemgm3kyTQWXJaL1xZA_3_2"></a><a id="Tc_01Pe7PDWjkaN_qppvkkb7Q_3_4"></a><a id="Tc_Xhvk2cK1gkCTdSbh00xZCA_3_7"></a><a id="Tc_Z5a3N7fgPkOWs7dyYolPug_3_9"></a><a id="Tc_CmQYFCLKd0amhN64V-g7SA_4_2"></a><a id="Tc_atCKD4wVaki5vm4Ma2u2hQ_4_4"></a><a id="Tc_c5dt_8Co4UaIz0LBgfQRgw_4_7"></a><a id="Tc_GBb4w2gOX0KNNCuGn_iYJw_4_9"></a><a id="Tc_Lk-Qjk9mxkOm8SPcYWyPEg_5_7"></a><a id="Tc_sGlWARRVC0ut5sHKhfOteA_5_9"></a><a id="Tc_8Dzott1kiUatFkTviFFeDg_6_0"></a><a id="Tc_gJo6wgCkIUW0a-6u1Ffpgw_6_4"></a><a id="Tc_d0H0vRVcmkiyxthBjwf0jA_6_9"></a><a id="Tc_bzUC_nU2aki2ADjf7kZjcA_7_0"></a><a id="Tc_fuIGJHaT7kOKOQTllLDgGw_7_7"></a><a id="Tc_Pjz05KTG50yP3pqyukth_g_7_10"></a><a id="Tc_ZCvQekaFIU62DDeCdXc8NA_8_0"></a><a id="Tc_CpyykmIYF0q8qucDx3KlCQ_8_7"></a><a id="Tc_jZd_JKGd0Uef9LPG080xJw_8_10"></a><a id="Tc_9f7E6WpVtUa5gQiNiTEWBQ_9_0"></a><a id="Tc_SkejIM6l6kqctTCZ1RM0cA_9_7"></a><a id="Tc_KH_2Mue2qUSXIPEwsKURfw_9_10"></a><a id="Tc_TAPv4WXqX0Gb-RBP5AsknA_10_0"></a><a id="Tc_cTl7EpMcVUunbtn-MWdEfA_10_4"></a><a id="Tc_hLDKqbEwMkqrh8ik5RYm8g_10_9"></a><a id="Tc_heKPNVv9UEived4fOm4RHQ_11_0"></a><a id="Tc_LdeUkxSz7062kux82WKDlw_11_4"></a><a id="Tc_9WinzoOQJ0-HjR6Jl0jEfQ_11_9"></a><a id="Tc_zytOjv_EH0G3TVt9bICFFQ_12_0"></a><a id="Tc_1VjYrZkQNk-c-Z24E1y55w_12_4"></a><a id="Tc_bSrXse2Vt0e46x64cIOG_A_12_9"></a><ix:continuation id="Tb_u4U8_1IEzUSWWKSOSzsf-w_cont2" continuedAt="Tb_u4U8_1IEzUSWWKSOSzsf-w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">granted to the Company&#8217;s non-employee directors were fully vested on the date of grant. The exercise price of share options issued under the 2019 Plan is not less than the fair value of ordinary shares as of the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Employee Share Purchase Plan (&#8220;ESPP&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Company adopted the ESPP, which became effective in conjunction with the IPO. The Company initially reserved <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uYPMjaOR30-b-lalBWgACw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_BNuGdqMCKkmT_rsDh1lxBg">215,000</ix:nonFraction> ordinary shares for future issuance under this plan. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020 and each January 1 thereafter through January 1, 2029, by the lower of (i) <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uDaWQIIw1kGEaQUSk3pBNw" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" scale="-2" id="Narr_WKezOkiNGUeiB8ri_psgng">1</ix:nonFraction>% of the outstanding number of ordinary shares on the immediately preceding December 31; (ii) <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uYPMjaOR30-b-lalBWgACw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_xZzTrZSFzUCjIz_OlRtNuA">430,000</ix:nonFraction> ordinary shares or (iii) such lesser number of shares as determined by the Compensation Committee. The number of shares reserved under the ESPP is subject to adjustment in the event of a split-up, share dividend or other change in the Company&#8217;s capitalization. As of December 31, 2024, the total number of shares available for issuance under the ESPP was <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_JmkuGODyoEa7uHAIThFJUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_VAgXyi-kM0WxxiEAT4UnTA">1,577,671</ix:nonFraction> shares. The number of shares reserved for issuance under the ESPP was increased by <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_1_1_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_llEDFF1MSUKzib9liGvGRg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_I94FshnqSUCGnJPsw7ftGw">430,000</ix:nonFraction> shares effective January 1, 2025. As of December 31, 2024, there have been no offering periods to employees under ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_XV1yR6EGv0icba-vozrO_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_IrNimC9diUCVSYzfxLOnXA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0GUlfNkZOEuXSTOlh4G2oA_4_3">19,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ExXLTtPGjESDM4D_A9YCDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DFxX_-FCwUWyj5w5crXIRQ_4_6">15,581</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tkd3FyxzzUqahEHsT-hpIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6KrJtWMSH0ORuLeUU4VSdg_4_9">10,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QJYt99nJFU-BQx9iYlyOVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0uZTdfO7AEmhNCVxRdG2YQ_5_3">18,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qLo7iHGMOUW9rHUjaCEH5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_WRFLQ69nGEyjyxRLsPX5Cw_5_6">16,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3zI24sd1-km1PKi1awanEA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cBlcGcGwUEmUbkTZ9Kjk4Q_5_9">16,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Oft1xit0AUO6Yu4mB6zH0A_6_3">38,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_eqmDkQdb3UOuFo4AlPrf8A_6_6">32,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rBCAwCpwUky5isg_BznY_g_6_9">26,779</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s option activity since December&#160;31, 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_MeQtVHrEHUuYWo7kcmaJcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December 31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_bh4of0PupEupeB-VjAm4aA_6_2">7,469,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_dWnlBYXIPUqI3VwPb_PmJw_6_5">23.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_wYa6poBIMkqE718vt6mlpQ_6_7"> 6.83</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_N4VDy42YI0mK2z11Zy1oTQ_6_10">21,920</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_dEWDmUpQj0mzKqh4A502vw_7_2">2,438,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vr_7gJ1UakKSCXKpdW_Cbw_7_5">19.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Zw2HwXbDKUigXj_XeE4JMA_8_2">554,596</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_3zIv9t9Y7EWPEcFnHcarww_8_5">13.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_kTwZ5ZFf7UCQpHDyXjrOEQ_9_2">604,561</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_-UVVR4DX5UWfAUus3eDayQ_9_5">27.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_qK2FFHL0ZUGZV4X1jzx1SA_10_2">8,748,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_s1PNF8XFyk64_GgjfwNTRg_10_5">22.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_jdU5aKW6JUC6Sw1ikvyONA_10_7"> 6.81</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_-24VnK08-kagXgtoVyfBCw_10_10">9,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested and expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_HKIbKIhcqUaopzbAem4zZw_11_2">8,748,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_cfHChGncQEe_R2dyrVGTyQ_11_5">22.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_UP52BV4aVEyMsj8TlW_WrQ_11_7"> 6.81</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="Tc_zuxMZro92ECBqvBMtyfsoQ_11_10">9,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_I2nQaqMWtUWuid3WacxnJA_12_2">5,359,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_4NeneMjNSk-pkUYVkwT2Jw_12_5">21.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_pVuhtwBYC0ybiHiAULdU_w_12_7"> 5.60</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_UgvoOhVEokOrOW-lCsB5_Q_12_10">9,559</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value of share options granted during the&#160;years ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr__NFmXwZoi0OSlOqzTEcNww">13.52</ix:nonFraction> per share, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_7oef8opr-UaGJ6CAMY0ieg">19.36</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_kiJGQCblXUuxu_kSTlYMzg">31.45</ix:nonFraction> per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ordinary shares. The aggregate intrinsic value of share options exercised during the&#160;years ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_DmuO-TnAGU2yic7F6BpFZA">5.1</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_EjjuyWEK_02irS0cj3wE6g">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_Zceoknl8E0CBaz00ClLXHA">1.5</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recorded share-based compensation expense for share options granted of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr__ECWpdh9UUug5uKM-Cw3iw">30.2</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr__PO0nf-AIkeuijxfZNhCdQ">27.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_FYZPMeZ6IkKwKbHBGhI9Mw">21.9</ix:nonFraction> million, respectively.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_toFwDAbzKUqmCzWVppekzQ_1_2"></a><a id="Tc_3UDBiwFTYEiP5Ady-6Dliw_2_2"></a><a id="Tc_yIBmf9lUEUiVnrput0ykHQ_3_2"></a><a id="Tc_fg13TlhcMEmx81W6CRCp_g_3_4"></a><a id="Tc_36wQX35uok2CuYlSWSJY3A_3_6"></a><a id="Tc_JV89QUDRDEySUXOVHp3Ayg_4_0"></a><a id="Tc_U93Vreq3q0yWaXbE3OAEJg_4_3"></a><a id="Tc_JV7WBkrBbkGW3mpISUTysg_4_5"></a><a id="Tc_lVHav9WvTU-zQB7MFnrgbQ_4_7"></a><a id="Tc_l6ykE2T5nk-OVeJug2Fg5w_5_0"></a><a id="Tc_6QvaYKUmc0i6SkIVVHAqmQ_5_3"></a><a id="Tc_6gM3cGPh3UKtfj4sc1yFNA_5_5"></a><a id="Tc_tIbN1ctFSUmYWaJuZT9ZlQ_5_7"></a><a id="Tc_NRlr7yCc0kSrZd_8DeFWGw_6_0"></a><a id="Tc_WIFHt1aPs0Ob8WPu-2GD_g_6_2"></a><a id="Tc_m-mWKkeoykeBb8Sq-GuvKg_6_4"></a><a id="Tc_9ZNNZ3xbmUmQXy5ZOin3xQ_6_6"></a><a id="Tc_JLCfOtmCB0iYK-frE2IsDA_7_0"></a><a id="_689648e8_d5e1_4f9c_874a_d41c400b632e"></a><a id="Tc_0fktsdTnrk6iZjXlSYi3CQ_1_2"></a><a id="Tc_LgZrPXZlLUeoOY0HuAQLzw_1_4"></a><a id="Tc_dlfVvuq8yEmBG8BAI_8vDg_2_2"></a><a id="Tc_QEgsYGLD0kCL2UNMHOShUg_2_4"></a><a id="Tc_NT8ZAhQElEeePrTKL11d0Q_3_0"></a><a id="Tc_kYgn4pgQ7kSJKrxhEoSCDA_3_4"></a><a id="Tc_YidjOznlP0eJsfe9j6k5IQ_4_0"></a><a id="Tc_eU6xnsJ3NEquyk-BHBrpGg_5_0"></a><a id="Tc__xvB6GdVdkinGUWBotkzNw_6_0"></a><a id="Tc_L5pSKCVcY0eKpQvby1foCA_7_0"></a><a id="Tc_9VR82at1o0ewSW2uSvXq5Q_8_0"></a><a id="Tc_4RMypXtWA0ak02ka5FVIXg_9_0"></a><a id="Tc_PZFph2u0f0WQWEtPocuJsQ_10_0"></a><a id="Tc_qQ6m76hXbk-VxtOMq5jQcQ_10_4"></a><ix:continuation id="Tb_u4U8_1IEzUSWWKSOSzsf-w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of share options granted to employees and directors:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_FHs_KDfcKUOthDg8QHFOWA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_6_yJzi25LkySNzXU0Srn2g_4_2">4.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_WJ09b9crXEK8mLXYZdFoRQ_4_4">4.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_-1hh4tmv6kKM3SqGWmICrw_4_6">2.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_b8-HY7tkMkaSBiwJjssCQg_5_2">77.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_Fl31aRoU1EWoaq3fsTKFnQ_5_4">82.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_yX38cIUg7k-1DJLDUklJlA_5_6">82.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_68gMdExs_UqFwvHdQVMrpA_7_2"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_-V7dYAHvuU2G5vnA3cJzVQ_7_4"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Dr0d2VAK8kuME3mcLUh7Yw_7_6"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, total unrecognized compensation expense related to the share options was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ig3SHtuCIE-Ory8Hp3Mv3Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_8B7QbVOGXkCBKNSGy-isQw">48.3</ix:nonFraction>&#160;million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_-T80r2p7bUiOKwBMiSPdww">2.4</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Restricted share units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s RSU activity under the 2020 Plan since December 31, 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_gndiCvCDNUWmWdnqmGlrFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_P5YoMS1KNkutLYwlGkurgg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_287jUgfsoUWjkVw6JaEaFA_3_2">326,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_P5YoMS1KNkutLYwlGkurgg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_pcmFtOB94EWeUF9JYDKsAQ_3_5">37.40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_1_f1lJQpikGdlpGwR39iHQ_4_2">617,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_KXwJHTb-a0GgIVEP0wQGMQ_4_5">18.26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested and settled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" sign="-" scale="0" id="Tc_PP1BAjxl-E62N_3-6_Nj5A_5_2">141,350</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="2" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_weAp9lqxCk6hrQ_3HLoSVg_5_5">37.76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested and deferred<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" sign="-" scale="0" id="Tc_eNe8EpG1dECfsl9feiAfEg_6_2">42,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="2" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_ErbLgeMiSUaF87WYT0cdVw_6_5">18.07</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_N-vGzDGznke58vru1EZcsw_7_2">86,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_2NVKl-C1sEe4aVL-cLTZ7g_7_5">22.15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Hmh5zSYgE06mLdAP70KuNA_8_2">674,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_VXWfTK3W2kC1DaivSj3cGQ_8_5">22.96</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested but subject to deferred settlement at December 31, 2024<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" scale="0" id="Tc_ZT5B2wsmXUu87iVbDsB0EA_9_2">42,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="2" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" scale="0" id="Tc_LKH1Ven1D0G-aW4o1BHHXw_9_5">18.07</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" scale="0" id="Tc_7DKEUgOig0CWksuqpxHgOw_10_2">716,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg" decimals="2" format="ixt:num-dot-decimal" name="bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" scale="0" id="Tc_X05sEIY73UuCYej9pzghLQ_10_5">22.67</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">The Company granted certain RSUs to the Company&#8217;s non-employee directors which provided for deferred settlement of the RSUs to a specified date following the first to occur of (i) the date of the director&#8217;s separation from service, (ii) the date of the director&#8217;s disability, (iii) the date of the director&#8217;s death or (iv) the date of a change in control event.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of RSUs that vested during the years ended December 31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_5_YVaqRN9kWPU5MB12oiPw">3.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_MD5oMOXiBEqT_oj0JeJMKQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_dqZxlB57hEScAEwOqnaDlQ">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_fd4h2ljJA02Or70KQeym_A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_DBNcsWCgP02Se7upLs-Wew">2.1</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total share-based compensation expense for RSUs granted for the years ended December 31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_tqE2N1-toUKsUNHJMCphZA">7.9</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_MD5oMOXiBEqT_oj0JeJMKQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr__5vl9gFkPkmLj7wMNtyAYQ">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_fd4h2ljJA02Or70KQeym_A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_qOjkF3xpH0a9yXrPY2yF1Q">4.9</ix:nonFraction> million, respectively. As of December 31, 2024, the total unrecognized compensation expense related to RSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_ZqAdCPkgV0WHfBI-rXVxAQ">11.4</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_lFmknT6kJUGaBg0z6v99lA">2.4</ix:nonNumeric> years. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_koEcBfr4r0eJ_a7AM2PB2Q" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">9. Significant agreements</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="Tb_jH_uEfo5lkiyFYhItrYfTg" continuedAt="Tb_jH_uEfo5lkiyFYhItrYfTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the revenue recognized from the Company&#8217;s collaboration arrangements in the consolidated statements of operations and comprehensive loss (in&#160;thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_04eb033a_5c40_4873_a193_dc835361a0a9"></a><a id="Tc_ThFKWFTm10-to7A-byQrIw_2_2"></a><a id="Tc_RLzC52T8EEuBwp0NqN9e8w_3_2"></a><a id="Tc_6l1eU-hGDESEddBbpVyLVg_4_2"></a><a id="Tc_zTX4zO5ovUKM0syTjOieeA_4_5"></a><a id="Tc_9VG4kCKLpk-l9437MU4uqg_4_8"></a><a id="Tc_gVedu95D-E6AgdFx-XlrNw_5_0"></a><a id="Tc_AtAvCZMS2U6CkuHpjruJHQ_6_0"></a><a id="Tc_YYt6Qwwc802FHL9E68rKzg_6_2"></a><a id="Tc_oGpIhPrztUm5ve2OAa4fYA_6_5"></a><a id="Tc_lflsr1e_5Uex1iNtEIZjXw_6_8"></a><a id="Tc_v_b-EfGWF0K2UVBFbGYJdg_6_9"></a><a id="Tc_swt-0Ll-G0Oh_qiLV0bfQg_7_0"></a><a id="Tc__wtKjQ0sqEiG-rSqnkdCNg_7_9"></a><a id="Tc_jbTUZ4bzY0m4F81lbvTNIw_8_0"></a><a id="Tc_ZFLWly0X70KciXvGUY_LIw_9_0"></a><a id="Tc_Zq9bQBzZok-oFj3Tbr5oJg_10_0"></a><a id="Tc_25QrjLIJ5EWcbxQ3-awhBQ_10_3"></a><a id="Tc_nTM6HxdbyUGpZP5fVfUy-g_10_6"></a><a id="Tc_i0XFN7hGhUSHae3wu7ntPw_11_0"></a><a id="Tc_96oCRKPVfk23gb_ApfaMeA_11_3"></a><a id="Tc_vuYdGHbLZUy8rK1eYQeqUw_12_0"></a><a id="Tc_GA03JfbyiEm9PYdi0eKmVw_12_2"></a><a id="Tc_Q1CJGeZTr0qkgFCjkOrC7g_12_5"></a><a id="Tc_kd2Mm2B8H0O2uvocu-UVXA_12_8"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont1" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont2"><ix:continuation id="Tb_jH_uEfo5lkiyFYhItrYfTg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Collaboration revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bayer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_hRCPME3KykmbJxyfhLjkGw_6_3">3,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_NmsOA9SdJ0yWjXQRbcseWg_6_6">1,160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_5P6iK70Gg0Gx9PNFTyvj6Q_7_3">8,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_kB_UoMqMaUOhc8VGPkfXGA_7_6">1,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ionis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Pe1KJMH8yEeijWQ2HmTmSA_8_3">8,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_BUVHY3EO9UC9xYhGHudk_g_8_6">10,734</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_6B9ln8pBckaqlZDRFLAB3A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Hcc0XZjZCEacU1r57G0H6A_8_9">9,347</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Genentech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_JwyKxtt-eEKxQ9C3IaVEhg_9_3">14,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_xnLNEonYv0WPxBQdNSgnpA_9_6">11,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qLy1Qlk7lUqL6zN6xMcMvQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_paxV88IVaUyznYnaQb_YWQ_9_9">3,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dementia Discovery Fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_DementiaDiscoveryFundCollaborationAgreementMember_LB_cYGPJt0-dBCSytUGDoA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Ibt8OwxDKkG_nNdq447wWw_10_9">386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">AstraZeneca</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_NtnMY0W9JUuIqN4XSU6R2A_11_6">1,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_is22NBT1Jka8Gu-uasBItg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_QcyvYpLrvUiQnMrE2B3U1A_11_9">1,165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_0DePMDfJ1EayyLyWt-Q6nQ_12_3">35,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_S0gj-aDXeEqJit8Xistw2A_12_6">26,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_R7Uz8x_MeUmgrqNTGI3Amw_12_9">14,463</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Bayer Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 4, 2023, the Company and Bayer entered into a collaboration and license agreement (the &#8220;Bayer Collaboration Agreement&#8221;), pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term up to a specified number of years per target program to generate radiopharmaceutical compounds incorporating optimized Bicycle constructs directed to <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_X4loeahQ60-QbvyXmAA1lQ">two</ix:nonFraction> specified targets, under the oversight of a joint research committee. In addition, Bayer has a one-time right to expand the collaboration to include a third target program, and with respect to each of the up to <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_VN5tjHEf00esfvmjE9j5aA">three</ix:nonFraction> target programs, Bayer has an option, exercisable within a specified period of time following the effective date of the Bayer Collaboration Agreement, to generate, develop and commercialize non-radiopharmaceutical compounds directed to the applicable target, either itself or in collaboration with the Company. Bayer also has certain limited target substitution rights, in certain cases subject to specified additional payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For each collaboration program, Bayer may elect, at its sole discretion, to progress compounds arising from activities under the research programs into further preclinical development of potential products directed to the target of such collaboration program. On a target-by-target basis, if Bayer elects to progress development candidates directed to such target into further clinical development, Bayer will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products directed to the applicable target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Bayer paid an upfront payment to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_msS3A3WlU0Co_cYTL5rgMg">45.0</ix:nonFraction> million in July 2023. All other payments under the Bayer Collaboration Agreement will be made in British Pound Sterling. If Bayer elects to expand the collaboration to include an additional target program, it will be required to make a one-time payment to the Company in connection with the selection of such target in the high single-digit millions. In addition, on a target-by-target basis, if Bayer elects to exercise its option to expand its rights with respect to such target to develop and commercialize non-radiopharmaceutical compounds directed to such target, Bayer will be required to pay to the Company, for each such target program for which it exercises such option, either a one-time option fee payment or quarterly payments of specified installment amounts for a specified maximum time period during which the Company is performing research activities, with the aggregate amounts receivable by the Company ranging from the high single-digit millions in the case of the one-time option fee payment, to the low single-digit millions in the case of the quarterly installments, in each case where the Company is performing specified research activities following the exercise of the option. Additionally, for each collaboration program, Bayer will reimburse the Company for certain expenses incurred in connection with specified research and discovery activities performed by a contract research organization (&#8220;CRO&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On a target-by-target basis for the up to <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_UPeOeaN4c0KbTiJigoDNoQ">three</ix:nonFraction> targets, if Bayer elects to progress <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_ZNuFcicSUka_auEsj1BcvA" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" scale="0" id="Narr_l6mq0UkjrEO6_JQ5g6JvyA">one</ix:nonFraction> or more candidate compounds into further development, Bayer will be required to pay a candidate selection fee for the first such compound progressed by Bayer directed to such target that incorporates a radionuclide, and for the first such compound directed to such target that does not incorporate a radionuclide (and for which Bayer has not paid the one-time option fee payment for non-radiopharmaceutical compounds), ranging from high single-digit millions to the mid single-digit millions. Upon declaring a candidate, Bayer will be responsible for all future development, manufacturing, and commercialization activities. On a target-by-target basis, if Bayer successfully conducts clinical development and achieves regulatory approval for compounds arising from the collaboration directed to such target in two indications, Bayer will be required </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont2" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to pay to the Company development and regulatory/first commercial sale milestones of up to &#163;<ix:nonFraction unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ" contextRef="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentAndRegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rDEBgcbU2U6rfbdVzl6Apg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable" scale="6" id="Narr_0i2NDOlFHE2ccVzgK88d5Q">178.3</ix:nonFraction> million for the first product directed to the applicable target to achieve such milestones (whether radiopharmaceutical or non-radiopharmaceutical), or &#163;<ix:nonFraction unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ" contextRef="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bsrGl4-r_kuiY-MRpYt5Sg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable" scale="6" id="Narr_G1GB_RdDYEakrbFvq2ZzTg">534.9</ix:nonFraction> million across all <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_huR3G1gtd06hy7HWTa09rw">three</ix:nonFraction> potential target programs. In addition, if Bayer successfully commercializes products arising from the collaboration, Bayer will be required to pay to the Company, on a product-by-product basis, tiered royalties on net sales of products by Bayer, its affiliates or sublicensees at percentages ranging from the mid-single digits to the very low double digits, subject to standard reductions and offsets in certain circumstances, and a royalty floor. If Bayer commercializes diagnostic products directed to a target, royalties will be payable on such diagnostic products at a specified reduced percentage of the rates for therapeutic products. Royalties will be payable under the Bayer Collaboration Agreement on a product-by-product and country-by-country basis, commencing on the first commercial sale of each product, until the latest of (a) the expiration of the last valid claim of certain patents licensed by the Company to Bayer, (b) a specified number of years following first commercial sale of such product, and (c) expiration of all data and regulatory exclusivity for such product in the applicable country. On a target-by-target basis, Bayer will also owe the Company tiered sales milestones based on the achievement of specified levels of net sales of therapeutic products directed to such target totaling up to &#163;<ix:nonFraction unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ" contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable" scale="6" id="Narr_97gbRdUQaUKMXXMDYuj9KQ">194.5</ix:nonFraction> million in the aggregate per target, or &#163;<ix:nonFraction unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ" contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_XoeOZGRs8kGew3ee8YnMHA">583.5</ix:nonFraction> million across all <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_Hl6-S_BA1kWW7CDcJkibRA">three</ix:nonFraction> potential target programs, and on diagnostic products directed to such target at a low double digit percentage of the therapeutic product milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Bayer Collaboration Agreement will remain in force on a product-by-product and country-by-country basis, unless earlier terminated by either party, until the expiration of the obligation for Bayer to make royalty payments to the Company for such product in such country, and will terminate in its entirety on the expiration of all such royalty terms in all countries. Either party may terminate the agreement upon <ix:nonNumeric contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg" format="ixt-sec:durwordsen" name="bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" id="Narr_ZMZlWTMgt0ejs-V-OHUgug">90 days</ix:nonNumeric>&#8217; written notice for the other party&#8217;s uncured material breach (or <ix:nonNumeric contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg" format="ixt-sec:durday" name="bcyc:ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" id="Narr_kI9ckzjyiEGQetSYkTG-gQ">20</ix:nonNumeric> business days in the case of non-payment by Bayer), subject to extension of such cure period in certain circumstances, or upon the other party&#8217;s insolvency. In addition, the Company has the right to terminate in the case of a patent challenge by or on behalf of Bayer (or any of its affiliates or sublicensees). In addition, Bayer may terminate the Bayer Collaboration Agreement (i) in its entirety or with respect to any product, collaboration program or target for any reason upon <ix:nonNumeric contextRef="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_k7kwiL6Tv0Oaw0c1V1bDWg" format="ixt-sec:durday" name="bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" id="Narr_4g7wBmL-xEOnyfObTdOvuw">60</ix:nonNumeric> or <ix:nonNumeric contextRef="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_hMqy_55tV0OU0RmfGW8IMg" format="ixt-sec:durwordsen" name="bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" id="Narr_BkwcuWykQ0eqLryRRukUjA">90 days</ix:nonNumeric>&#8217; written notice to the Company (depending on whether such termination is prior to or following first commercial sale of a licensed product). The closing of the Bayer Collaboration Agreement was subject to the clearance of the transaction under the U.K. National Security and Investment Act 2021, which occurred on June 22, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>At inception of the Bayer Collaboration Agreement, the Company identified the following performance obligations:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yFgBlbVotUajI_G7d99bBg" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfCombinedPerformanceObligations" scale="0" id="Narr_1AzSpmZwlE2Tk_HPPSkB3A">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> combined performance obligations comprised of the license and the related research and development services during the research term associated with radiopharmaceutical compounds for the first and second targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A material right associated with certain limited substitution rights with respect to either the first or second target;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_94phe6rJ4kWybY0cwUE7iw" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfMaterialRights" scale="0" id="Narr_OUY5O_i-IUefO7g1_oXsYQ">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_eqvMYjbIIU-vjO_qsp7v0A" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfMaterialRights" scale="0" id="Narr_d6Dv1wjqOUiJkFPPrYPWIA">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the options to generate, develop, and commercialize non-radiopharmaceutical compounds for each of the first and second targets, for which each option includes an underlying option for research and development services and an option to progress non-radiopharmaceutical candidates directed to the first and second targets into further development; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A material right related to the option to expand the collaboration to include a third target, which upon exercise includes research and development services during the research term associated with radiopharmaceutical compounds directed to the third target, as well as underlying options for: certain limited substitution rights; an option to progress a radiopharmaceutical candidate directed to the third target into further development; and an </span></td></tr></table></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_55E7kutSD0uECezDiIfGIg_1_2"></a><a id="Tc_ISie82nWUk6ajkUp9FI3Og_2_0"></a><a id="Tc_h-nwlPtJtU2Zc9Tfdhyijg_2_2"></a><a id="Tc_Oq51zoBXzE-eknyiJlHapQ_3_0"></a><a id="Tc_cOuw4ufyI06cT-eTO3vK1Q_3_2"></a><a id="Tc_yJT9LQ2BkU2ZH96FWSt_sA_4_0"></a><a id="Tc_W9SQQPhrD0ydAOf_QgIDPQ_5_0"></a><a id="Tc_MaLYTFLFQ02X4v8EjBWW1w_6_0"></a><a id="Tc_mkxvmK3sr0OZ9pYW0PJALQ_7_0"></a><a id="Tc_NCLFSW52qkWyajxXhsy4dQ_8_2"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont3" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont4"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">option to generate, develop, and commercialize non-radiopharmaceutical compounds directed to the third target, inclusive of an underlying option for research and development services and an option to progress a non-radiopharmaceutical candidate into further development.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s participation in the joint research committee was assessed as immaterial in the context of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the license granted at contract inception is not distinct from the research and development services as Bayer cannot obtain the benefit of the license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as they relate to constrained peptide technology that is not available in the marketplace. As a result, for each target, the license has been combined with the research and development services into a single performance obligation which is the combined performance obligation comprised of the license and related research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In assessing whether the various options under the Bayer Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material rights identified above, the Company concluded that each of the options provided Bayer with a discount that it otherwise would not have received. The Company exercised judgment in concluding that certain development and commercialization rights associated with progressing product candidates into further development and commercialization represent options that are material rights, as Bayer cannot benefit from the development and commercialization rights until Bayer, in its sole discretion, elects to progress candidates into further development and pays the associated candidate selection fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction price was initially determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_UJ0E6dqwr0eoDw3-Bqgafw">47.5</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_Oh9RAY1gaUiW80G-BgOOxQ">45.0</ix:nonFraction> million upfront fee and an estimated $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" scale="6" id="Narr_Z_1Zf7ckBESsKLKvhcDLQQ">2.5</ix:nonFraction> million for the reimbursement of certain external CRO costs. The Company utilized the expected value method to determine the amount of variable consideration to be received. Additional payments to the Company upon Bayer&#8217;s exercise of options are excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. The estimated $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" scale="6" id="Narr_301clj6sz0ybiFGqwIiZyA">2.5</ix:nonFraction> million in variable consideration was first allocated entirely to the first and second target combined performance obligations as the terms of the variable consideration relate specifically to the Company&#8217;s efforts in satisfying the performance obligations and allocating the variable consideration entirely to those performance obligations is consistent with the allocation objective in ASC 606. The remaining transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the combined performance obligations for the first and second targets were based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling prices for the material rights were determined based on the fees that Bayer would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Bayer would exercise the options, inclusive of the probability of technical success. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw" name="bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" id="Group_92GvSY0wwki8su7Fa3gl_g" continuedAt="Group_92GvSY0wwki8su7Fa3gl_g_2" escape="true">Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_92GvSY0wwki8su7Fa3gl_g_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocation of</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction Price</b></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_r6MfE3ksRECQo64rWUZQ_w" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_UnlosqYBikCxf42PXGImuQ_3_3">14,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Material right associated with limited substitution rights for either the first or second target</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_IU-HPwKXJEOuf8TPozi9MQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_70aUJBKFkUO83hMAnl2T1w_4_3">1,527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_qpxzdeztD02IVOBhBuyF0g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_LleZRmVTrkqzKQMC3E06Lg_5_3">14,691</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0SmQ9UkaoEyo_zuVmF9T8g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_LVZQ39w48EqEc0NHOFHjfw_6_3">8,703</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Material right for the option to expand the collaboration to include a third target and the underlying additional option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_H7vbLohDfUqZtqXKcd9CpQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_R8XpHIMF2EufT69PfutHYw_7_3">7,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_HOUkRuzQKkOlPcut7-ltmA_8_3">47,500</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont4" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is recognizing revenue related to amounts allocated to the first and second target combined performance obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of full-time equivalent efforts and external costs incurred to date as a percentage of total expected full-time equivalent efforts and external costs, which best reflects the progress towards satisfaction of the performance obligations. The amounts allocated to the material rights are recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. The first and second target combined performance obligations are expected to be satisfied over a period of approximately <ix:nonNumeric contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg" format="ixt-sec:durwordsen" name="bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed" id="Narr_uEPzRkKoiU-9hnfs4YpDMg">four years</ix:nonNumeric> and the remaining material rights are expected to be exercised or expire within approximately <ix:nonNumeric contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg" format="ixt-sec:durwordsen" name="bcyc:MaterialRightsExerciseOrExpiryTerm" id="Narr_QIpIktam1k2S75V05GhRgw">seven years</ix:nonNumeric> from contract inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-weight:normal;">During the years ended December 31, 2024 and 2023, the Company recognized revenue of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_fDJ8L3tHmki1_6Kr-2OG3w">3.4</ix:nonFraction></span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_hwkmCmbIN02x2LqKW5LKQA">1.2</ix:nonFraction></span><span style="font-weight:normal;"> million, respectively, in connection with the Bayer Collaboration Agreement. The Company did </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yibznVR9GEqfsVp2Udu60g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_u-FcWnCG3UWRv_ZxL-4O0Q">no</ix:nonFraction></span><span style="font-weight:normal;">t recognize revenue in connection with the Bayer Collaboration Agreement during the year ended December 31, 2022. As of December 31, 2024 and 2023, the Company recorded deferred revenue of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_CLM3oWHaYEmA9xWRlsRxFw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_fG5pm3iWUU2WWWW6r_cM0g">40.0</ix:nonFraction></span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_Ud59MTJ2xUqxAzQ4_r2A-g">43.6</ix:nonFraction></span><span style="font-weight:normal;"> million, respectively, in connection with the Bayer Collaboration Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"><span style="font-style:italic;">Novartis Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">On March 27, 2023, the Company and Novartis entered into a collaboration and license agreement (the &#8220;Novartis Collaboration Agreement&#8221;), pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term of up to a specified number of years per target program to generate compounds incorporating optimized&#160;Bicycle&#160;constructs directed to <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_xGEmcPczzEa1enUUII57RA">two</ix:nonFraction> specified targets, under the oversight of a joint steering committee. The Company granted Novartis a non-exclusive, worldwide, royalty-free, sublicensable (subject to certain restrictions) license under the Company&#8217;s intellectual property solely for Novartis to perform its research activities under each collaboration program during the research term (the &#8220;Novartis Research License&#8221;). For each collaboration program, Novartis may elect to progress compounds arising from activities under the research programs (&#8220;Licensed Compounds&#8221;) into further preclinical development of potential products directed to the target of such collaboration program. At a specified point, the Company will grant Novartis an exclusive, royalty-bearing, sublicensable, license under certain of the Company&#8217;s intellectual property to develop, manufacture, and commercialize such Licensed Compound, subject to certain limitations. Novartis also has certain limited substitution rights for each target, and Novartis may extend the initial research term by <ix:nonNumeric contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg" format="ixt-sec:durwordsen" name="bcyc:AdditionalResearchTerm" id="Narr_steJJ0lRREmlaJbu1uH1VQ">one year</ix:nonNumeric> by electing to make an additional payment. On a target-by-target basis, if Novartis elects to progress development candidates directed to such target into further clinical development, Novartis will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products containing Licensed Compounds directed to the applicable target. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Novartis paid a nonrefundable upfront payment to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_3h9LOsPatEqIAtZd0BH3fg">50.0</ix:nonFraction> million in April 2023. During the research term, upon achievement of a specified discovery milestone for the first target program, Novartis will make a one-time payment to the Company in the low single digit millions. On a target-by-target basis, if Novartis elects to progress one or more candidate compounds into further development and obtain an exclusive license for commercialization, Novartis will be required to pay a candidate selection fee for the first such Licensed Compound progressed by Novartis that incorporates a radionuclide, and for the first such Licensed Compound that does not incorporate a radionuclide, in each case in the mid-teen millions. Upon declaring a candidate, Novartis will be responsible for all future development, manufacturing, and commercialization activities. On a target-by-target basis, Novartis will be required to pay to the Company additional development and regulatory/first commercial sale milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable" scale="6" id="Narr_o1RjA6Ya4Ueoe80DnChxAg">210.0</ix:nonFraction> million for each of the first radionuclide product and non-radionuclide product directed to the applicable target upon the achievement of specified milestones, or $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_QOmhVFzG30KR4Jan3QJatA">840.0</ix:nonFraction> million in the aggregate if Novartis successfully achieves all such milestone events for both a radionuclide and a non-radionuclide product in each of the targets. In addition, the Company is eligible to receive tiered sales milestones based on the achievement of specified levels of net sales of such products totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xp4_gR1lU0ecKBaQ7hdhGA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable" scale="6" id="Narr_PwGxmIq6mUGTocHU-G-FZw">200.0</ix:nonFraction> million in the aggregate per product, or $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_CompletionOfAllMilestonesForTargetsMember_WaiOPCwXwUCGOrGcdYAYvw" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable" scale="6" id="Narr_uaFBKe3PLk-EPDTvnrV5Wg">800.0</ix:nonFraction> million in the aggregate if Novartis successfully commercializes both a radionuclide and a non-radionuclide product in each of the target programs. In addition, (i) the Company is eligible to receive, on a therapeutic product-by-therapeutic product basis, tiered royalties on net sales of products by Novartis, its affiliates or sublicensees at percentages ranging from the high single digits to the very low double digits, subject to standard reductions and offsets in certain circumstances, and a royalty floor, and (ii) the Company is eligible to receive low single digit royalties on net sales of diagnostic products on a diagnostic product-</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont5" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">by-diagnostic product basis and a low single digit percentage of sublicensing income on diagnostic products. Royalties will be payable under the Novartis Collaboration Agreement on a product-by-product and country-by-country basis, commencing on the first commercial sale of each product in a country, until the latest of (a) the expiration of the last valid claim of certain patents licensed by Company to Novartis, (b) a specified number of years following first commercial sale of such product, and (c) expiration of all data and regulatory exclusivity for such product in the applicable country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The Novartis Collaboration Agreement will remain in force on a product-by-product and country-by-country basis, unless earlier terminated by either party, until the expiration of the obligation for Novartis to make royalty payments to Company for such product in such country, and will terminate in its entirety on the expiration of all such royalty payment obligations in all countries. Either party may terminate the agreement upon <ix:nonNumeric contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_l_SYxC8CcEy6vP73RrP97g" format="ixt-sec:durwordsen" name="bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" id="Narr_1I4DmEwSsUGmW2m57Ak3xA">60 days</ix:nonNumeric>&#8217; written notice for the other party&#8217;s uncured material breach, or upon the other party&#8217;s insolvency. In addition, Novartis may terminate the Collaboration Agreement (i) in its entirety or on a product-by-product or target-by-target basis for any reason upon <ix:nonNumeric contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_k-g66Brr1Ea_7MONWi3pTQ" format="ixt-sec:durwordsen" name="bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" id="Narr_H8sSXrJRIE-LcaS8XQq7kg">90 days</ix:nonNumeric>&#8217; written notice to Company, and (ii) on a target-by-target basis on <ix:nonNumeric contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_2TOiizb3YE6trqr0NK51Qw" format="ixt-sec:durwordsen" name="bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" id="Narr_2GAg-Vr8VUe8yt6T8cqFvg">30 days</ix:nonNumeric>&#8217; written notice if Novartis determines that a safety or regulatory issue exists which would have a material adverse effect on the development, manufacture, or commercialization of any product with respect to a given target. The Company may terminate the Novartis Collaboration Agreement, (a) on a target-by-target basis upon <ix:nonNumeric contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg" format="ixt-sec:durwordsen" name="bcyc:MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" id="Narr__mFik9CYo0GVDK_ERxTHMA">30 days</ix:nonNumeric>&#8217; prior written notice if Novartis has not yet declared a development candidate for such target by the sixth anniversary of the commencement of research activities for such target and (b) if Novartis or any of its affiliates or sublicensees challenges the validity or enforceability of any of the patents in the Company&#8217;s licensed intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>Upon the execution of the Novartis Collaboration Agreement, the Company identified the following performance obligations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_EZSaePc-y0-TinfVuSqYaQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfCombinedPerformanceObligations" scale="0" id="Narr_UZ06X4YV7EGEmUJV5nBFnQ">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> combined performance obligations comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WDczl612dESosUCoC72gug" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfMaterialRights" scale="0" id="Narr_9YNFS76qzUC4bwCMaeBRRw">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with certain limited substitution rights with respect to the first and second targets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QqTrQCxSy0WuafIhqTZmRw" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfMaterialRights" scale="0" id="Narr_A2OvpBTFbUSdpIhlM-3piA">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the option to progress development candidates that incorporate a radionuclide with respect to the first and second target; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_tnuYUMT7jkGkdVdgNaWQgQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfMaterialRights" scale="0" id="Narr_KXJiVQzfBEe0v-DIPAix7w">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the option to progress development candidates that do not incorporate a radionuclide with respect to the first and second target.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The Company concluded that certain rights that require the payment of additional consideration, which approximates the standalone selling price of the underlying services to be provided, do not provide the customer with a material right and therefore, are not considered as performance obligations at the inception of the arrangement. The Company&#8217;s participation in the joint steering committee was assessed as immaterial in the context of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The Company has concluded that the Novartis Research License is not distinct from the research and development services as Novartis cannot obtain the benefit of the research license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as they relate to constrained peptide technology that is not available in the marketplace. As a result, for each target, the research license has been combined with the research and development services into a single performance obligation. The Company exercised judgment in concluding that Novartis&#8217; rights to obtain certain research and development services associated with compounds that do not incorporate a radionuclide during the research term are not options that are material rights as they do not represent either options for additional goods or services or options for additional services that are at a discount that it would not have otherwise received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_HU3Z-KX760qzZTpo6Hbk6g_1_2"></a><a id="Tc_VClLU7tzi0mIuzFOcnCaaQ_2_0"></a><a id="Tc_qfOtxGTaJECF4gKTfm2Xew_2_2"></a><a id="Tc_f5hxN1yjQUK8HCF0_2fppg_3_0"></a><a id="Tc_FureFHQa5kaYHqGmfGSDKQ_3_2"></a><a id="Tc_XYsaMgOyjUeIdyNifEYPPw_4_0"></a><a id="Tc_HRIvleAXOkyWFvItROCsrg_5_0"></a><a id="Tc_lhlimU4FLES4duX8iVerlg_6_0"></a><a id="Tc_4nwsghHlV0S7QlSGdz8H-A_7_2"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont6" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In assessing whether the various options under the Novartis Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material rights identified above the Company concluded that each of the options provided Novartis with a discount that it otherwise would not have received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The total transaction price was initially determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_QBJ30q7W-EqXX1nzRzdXpg">50.0</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_qN2yl9t_E0GaIuo3FZKVWw">50.0</ix:nonFraction> million upfront fee. The Company utilizes the most likely amount method to determine the amount of variable consideration to be received. Variable consideration for development milestones not subject to option exercises was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved. Additional consideration to be paid to the Company upon the exercise of options by Novartis is excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the combined performance obligations for each of the targets were based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling prices for the material rights were determined based on the fees Novartis would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Novartis would exercise the options, inclusive of the probability of technical success. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA" name="bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" id="Group_h203v0VCx0G93Xq9xbC9ew" continuedAt="Group_h203v0VCx0G93Xq9xbC9ew_2" escape="true">Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_h203v0VCx0G93Xq9xbC9ew_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_vbS2D-byxUiv2iYUzl3WkQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_-Ck_DXRS50iKTzGGx6v58Q_3_3">18,008</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with limited substitution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_o4Ynp2Df5ky0p5ZF-8lSyA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_KrL5ewlNMEu_UVQwQJpvzg_4_3">2,466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with options to progress development candidates incorporating radionuclides</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_z9unUt1Yik6ssQwliMMpIw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_SFDMLCRrhUeIMS-sFd8O8w_5_3">19,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with options to progress development candidates not incorporating radionuclides</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_Dj0LVN0iZ0u9fcBupRC2Fg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_jxRiAFlOukqKL_YcOrhspw_6_3">9,842</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_wdSgumeI6kuT0I6Odg_HJw_7_3">50,000</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">In November 2024, the Company achieved a specified discovery milestone for the first target program and therefore updated its estimate of the variable consideration to include an additional $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_AjyoIuYKZEiR1VI--kfKQQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedVariableConsiderationNoLongerConstrained" scale="6" id="Narr_2zwEvlIZAkK5XcT3bZHsAA">3.0</ix:nonFraction> million, that is no longer constrained. The arrangement consideration was increased to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_YDSCq1R7SUe1ir6yappJew" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_dYF5MZOp8k6l79_IJKTM5w">53.0</ix:nonFraction> million. The Company allocated the additional $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_AjyoIuYKZEiR1VI--kfKQQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedVariableConsiderationNoLongerConstrained" scale="6" id="Narr_qDNkYu-HvEGFf-s8ma0Cdw">3.0</ix:nonFraction> million to the performance obligations based on the relative estimated standalone selling prices of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt;">The Company is recognizing revenue related to amounts allocated to the first and second target combined performance obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligations. The amounts allocated to the material rights are recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. The first and second target combined performance obligations are expected to be satisfied over a period of approximately <ix:nonNumeric contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg" format="ixt-sec:durwordsen" name="bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed" id="Narr_YQWg5MFcYEC6wKq6Nt9usQ">three years</ix:nonNumeric> and the remaining material rights are expected to be exercised or expire within approximately <ix:nonNumeric contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg" format="ixt-sec:durwordsen" name="bcyc:MaterialRightsExerciseOrExpiryTerm" id="Narr_9Ke9DY6Ndk62e123ckmRFA">six years</ix:nonNumeric> from contract execution. During the year ended December 31, 2024, the Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WvZe8laaPEeAxoXCnyr6Mg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_PY6PDkDckUOrwzI6CljS5A">2.5</ix:nonFraction> million upon the expiration of Novartis&#8217; material rights for limited substitution rights for the first and second targets. The research and discovery activities for these targets are ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont7" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the years ended December 31, 2024 and 2023, the Company recognized revenue of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_FcF97NV59UiTO-XbTBvWUQ">8.2</ix:nonFraction></span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_VpE6_frq_k2OIgdOx3H98Q">1.9</ix:nonFraction></span><span style="font-weight:normal;"> million in connection with the Novartis Collaboration Agreement. The Company did </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QObiLon3H06DowS0D9UT9Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_sVm9m3_obUSOkhPniT8vog">no</ix:nonFraction></span><span style="font-weight:normal;">t recognize revenue in connection with the Novartis Collaboration Agreement during the year ended December 31, 2022.</span><span style="font-weight:normal;"> As of December 31, 2024 and 2023, the Company recorded deferred revenue of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_cyHRxQCIEESnLP8sT0_U6Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_jyzm-j9rw0yHR31Q69RGGA">44.1</ix:nonFraction></span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_OLqS_4w_rEqOKYp764AYNg">50.0</ix:nonFraction></span><span style="font-weight:normal;"> million, respectively, in connection with the Novartis Collaboration Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Ionis Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ionis Evaluation and Option Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On December 31, 2020, the Company entered into an Evaluation and Option Agreement (the &#8220;Evaluation and Option Agreement&#8221;) with Ionis. Under the terms of the Evaluation and Option Agreement, Ionis had the option (the &#8220;Ionis Option&#8221;) to obtain an exclusive license to the Company&#8217;s intellectual property for the purpose of continued research, development, manufacture and commercialization of products within a particular application of the Company&#8217;s platform technology.  Ionis paid the Company a nonrefundable option fee of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_95vuv8ocIUSRAGL9jhXDpw" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_u1yqWJjrIki4QUFvdDhJrw">3.0</ix:nonFraction> million in January 2021 that was fully creditable against the upfront payment to be paid upon the execution of a license agreement. On July 9, 2021, the Ionis Option was exercised upon the parties&#8217; entry into a collaboration and license agreement as contemplated by the Evaluation and Option Agreement. The Company determined that the Ionis Option exercise constituted a continuation of an existing arrangement. Therefore, the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_IbZb9vf99kediN_LZbIFuQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_7yTnU9EjF0u2Ff36TDazMA">3.0</ix:nonFraction><span style="white-space:pre-wrap;"> million paid under the Evaluation and Option Agreement was included in the transaction price of the collaboration and license agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ionis Collaboration Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Following the exercise by Ionis of the Ionis Option granted pursuant to the Evaluation and Option Agreement, on July 9, 2021, the Company and Ionis entered into a collaboration and license agreement (the &#8220;Ionis Collaboration Agreement&#8221;). Pursuant to the Ionis Collaboration Agreement, the Company granted to Ionis a worldwide exclusive license under the Company&#8217;s relevant technology to research, develop, manufacture and commercialize products incorporating Bicycle<i style="font-style:italic;"> </i>peptides directed to the protein coded by the gene TFRC1 (transferrin receptor) (&#8220;TfR1 Bicycle<span style="white-space:pre-wrap;">&#8221; molecules) intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans. Ionis will maintain exclusivity to all available targets unless it fails to achieve specified development diligence milestone deadlines.  If Ionis fails to achieve one or more development diligence milestone deadlines, the Company has the right to limit exclusivity to certain specific collaboration targets, subject to the payment by Ionis of a low-single-digit million dollar amount per target as specified in the Ionis Collaboration Agreement.  Each party was responsible for optimization of such TfR1 </span>Bicycle molecules and other research and discovery activities related to TfR1 Bicycle<span style="white-space:pre-wrap;"> molecules, as specified by a research plan which was completed during the year ended December 31, 2024, and thereafter Ionis will be responsible for all future research, development, manufacture and commercialization activities.  The Company performed research and discovery activities including a baseline level of effort for a period of </span><ix:nonNumeric contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng" format="ixt-sec:durwordsen" name="bcyc:PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" id="Narr_NPia6DEWO0ata6-zftTlaA">three years</ix:nonNumeric> for no additional consideration. The parties will negotiate a commercially reasonable rate if additional research activities are agreed to be performed. The Company has retained certain rights, including the right to use TfR1 Bicycle molecules for all non-oligonucleotide therapeutic purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The activities under the Ionis Collaboration Agreement are governed by a joint steering committee (&#8220;JSC&#8221;) with an equal number of representatives from the Company and Ionis.  The JSC will oversee the performance of the research and development activities.  Upon first commercial sales of a licensed product, the JSC will have no further responsibilities or authority under the Ionis Collaboration Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the Ionis Collaboration Agreement, Ionis made a non-refundable upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_-cwk2t0ZHUqIwHSH0W5MNQ">31.0</ix:nonFraction> million in addition to the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_4xrbU9mf7U-6_-7nZgiopA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_D-zsP3rea0-ZEu21AaKrGQ">3.0</ix:nonFraction> million already paid under the Option and Evaluation Agreement. Additionally, Ionis is obligated to reimburse the Company on a pass-through basis for expenses incurred in connection with research and discovery activities performed by a CRO. If Ionis is at risk of failing to achieve a specified development diligence milestone deadline, it can make up to <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" scale="0" id="Narr_T3OJFPrPUkSqsVcUS6yrFQ">three</ix:nonFraction><span style="white-space:pre-wrap;"> separate payments of a mid-single-digit million dollar amount to extend the development diligence milestone deadlines.  On a collaboration target-by-collaboration target basis, Ionis will be required to make a low-single-digit million dollar payment upon acceptance of an investigational new drug application (&#8220;IND&#8221;) for the first product directed to such collaboration target (provided that Ionis will have a high single-digit </span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont8" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">million dollar credit to be applied towards the IND acceptance fee for </span><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_WhxX1MyAlUCQyuTth82xTQ">four</ix:nonFraction> collaboration targets, or for exclusivity payments for certain targets if specified development diligence milestones deadlines are not achieved), and Ionis will be required to make milestone payments upon the achievement of specified development and regulatory milestones of up to a low double-digit million dollar amount per collaboration target. In addition, the Company is eligible to receive up to a low double-digit million dollar amount in cumulative sales milestone payments. The Company is also entitled to receive tiered royalty payments on net sales at percentages in the low single digits, subject to certain standard reductions and offsets. Royalties will be payable, on a product-by-product and country-by-country basis, until the latest of the expiration of specified licensed patents covering such product in such country, <ix:nonNumeric contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng" format="ixt-sec:durwordsen" name="bcyc:NumberOfYearsOverWhichRoyaltyIsPayable" id="Narr_A8BlED9zbkaDesQFmduRRg">ten years</ix:nonNumeric> from first commercial sale of such product in such country, or expiration of marketing exclusivity for such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2021, the Company and Ionis entered into the first amendment to the Ionis Collaboration Agreement (the &#8220;First Ionis Amendment&#8221;) and Ionis paid the Company $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_QA6y8ag3QEm7TEW69r2qZQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_pT1Anu759kWO5Q0sovd8tg">1.6</ix:nonFraction> million to perform additional research services utilizing its proprietary phage screening technology to identify and optimize new product candidates that target the TfR1 receptor. In April 2023, the Company and Ionis entered into the third amendment to the Ionis Collaboration Agreement (the &#8220;Third Ionis Amendment&#8221;) and Ionis paid the Company $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_TypeOfArrangementAxis_bcyc_ThirdIonisAmendmentMember_wgyO8-AVfkC5eQxgiBeTrA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_tO3oWSkJWUyIPqtcgmNPwg">0.8</ix:nonFraction> million and the Company agreed to perform additional research services to continue to evaluate and optimize the new product candidates that target the TfR1 receptor for a period of one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Either party may terminate the Ionis Collaboration Agreement for the uncured material breach of the other party or in the case of insolvency. Ionis may terminate the Ionis Collaboration Agreement for convenience on specified notice periods depending on the development stage of the applicable target, either in its entirety or on a target-by-target basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Ionis Share Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Concurrently with the execution of the Ionis Collaboration Agreement on July 9, 2021, the Company entered into the Ionis Share Purchase Agreement with Ionis, pursuant to which Ionis purchased <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_IhORSIdihkWEmJuOaow7HQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kSgdefOn9E2amLbrJ9jw6g">282,485</ix:nonFraction> of the Company&#8217;s ordinary shares (the &#8220;Ionis Shares&#8221;) at a price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_bEtM9upU1E28oKg6ENXuqw">38.94</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_IhORSIdihkWEmJuOaow7HQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_65ja8zHp20a1jtSC8pwF1Q">11.0</ix:nonFraction> million. The Share Purchase Agreement also provided that, subject to limited exceptions, Ionis could not sell any of the Ionis Shares until July 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company determined the fair value of the Ionis Shares to be $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:FairValueOfSharesHeld" scale="6" id="Narr_-oYvlU_9gUK-fmpunYeOxg">7.6</ix:nonFraction> million, based on the closing price of the Company&#8217;s ADSs of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="As_Of_7_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_8bqxGZ3cOEORs4A2Xq-g5Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_0pKXrVUVu0uE6eSJlW_d_Q">31.11</ix:nonFraction><span style="white-space:pre-wrap;"> per ADS on the date of the Ionis Share Purchase Agreement, less a discount for lack of marketability associated with resale restrictions applicable to the Ionis Shares. The Company concluded that the premium paid by Ionis under the Ionis Share Purchase Agreement represents additional consideration for the goods and services to be provided under the Ionis Collaboration Agreement.  As such, the total premium of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_j0GyHqM09kWwsmevewiQrQ">3.4</ix:nonFraction> million was included in the transaction price under the Ionis Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting Analysis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon execution of the Ionis Collaboration Agreement, the Company identified the following promises in the arrangement: (i) a worldwide exclusive license to research, develop, manufacture and commercialize products incorporating TfR1 Bicycle molecules intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans; (ii) research and discovery activities to customize and optimize such TfR1 Bicycle molecules; (iii) <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfMaterialRightsAssociatedWithFuturePayments" scale="0" id="Narr_WSSQoEwJnE667ETTgoWP1g">four</ix:nonFraction> material rights associated with options to obtain credits to be applied towards the IND acceptance fee for <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:CollaborationAgreementNumberOfTargets" scale="0" id="Narr_U0MjLO3W4UeIyWWicOOEZw">four</ix:nonFraction><span style="white-space:pre-wrap;"> collaboration targets.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company&#8217;s participation in the JSC was deemed immaterial in the context of the contract.  </span>The Company concluded that the exclusive license to research, develop, manufacture and commercialize products was not distinct from the research and discovery services as Ionis cannot obtain the intended benefit of the license without the Company performing the agreed upon research and discovery services, including the optimization of such TfR1 Bicycle molecules. The services incorporated proprietary technology, unique skills and specialized expertise to optimize Bicycle molecules that were not available in the marketplace. As a result, the exclusive license to research, develop, manufacture and commercialize products was combined with the research and discovery activities into a single performance obligation. The Company concluded that the low-single-digit million dollar payments upon acceptance of an IND (and payment to </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_coshVLyA00Gqc9qjbUra6w_1_2"></a><a id="Tc_avadHGy-eEevWQT_zF2Z5A_2_0"></a><a id="Tc_WczGQ8p21kabF9NVR5ZthQ_2_2"></a><a id="Tc_-p6Lys70_ESMYqPULaX-Ug_3_0"></a><a id="Tc_N8g576GScEKUq7RQZaF0vA_3_2"></a><a id="Tc_nY1JxNlI50GufnKtBQmoGw_4_0"></a><a id="Tc_PGE6qYMT6EW9KlYBsXhBEQ_5_2"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont9" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont10"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">extend the exclusive license to research, develop, manufacture and commercialize a product candidate for certain specific collaboration targets if Ionis fails to achieve specified development diligence milestone deadlines) is a customer option, as Ionis has the contractual right to choose to make the payment in exchange for the continued exclusive right to research, develop, manufacture and commercialize the product candidate, and the Company is not presently obligated to provide, and does not have a right to consideration, for the additional goods or services prior to Ionis&#8217;s exercise of the option. In assessing whether the options under the Ionis Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon the option exercise and the standalone selling price of the underlying goods and services. For the material rights identified as performance obligations above, the Company concluded that each of the options to obtain credits provided Ionis with a discount that it otherwise would not have received without entering into the Ionis Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The total transaction price was initially determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_18HOPz-YLk-_dsPaBhqt1g">38.0</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_zpf5oG572kqkj2beDGdOzA">31.0</ix:nonFraction> million up front payment, the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_4xrbU9mf7U-6_-7nZgiopA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_RdfOS6NAyUO0Z77WSFlX7A">3.0</ix:nonFraction> million payment under the Option and Evaluation Agreement, that was credited against the total upfront payment payable pursuant to the Ionis Collaboration Agreement, the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_HN972QzvR02BTpII9kUsWA">3.4</ix:nonFraction> million premium paid under the Ionis Share Purchase Agreement, and an estimated $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" scale="6" id="Narr_aRaakE1VrU-cxJbisG7AIw">0.6</ix:nonFraction><span style="white-space:pre-wrap;"> million for the reimbursement of CRO costs. Additional variable consideration including development diligence milestone deadline extension payments, development and regulatory milestone payments, sales milestone payments and royalty payments was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling price of the Ionis combined licenses and research and discovery performance obligation was based on the nature of the licenses to be delivered, as well as the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling price for the material rights was determined based on the estimated value of the underlying goods and services, and the probability that Ionis would exercise the option. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw" name="bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" id="Group_w9JUx3SIA0G_PhvAAlmWVw" continuedAt="Group_w9JUx3SIA0G_PhvAAlmWVw_2" escape="true">Based on the relative standalone selling price, the initial allocation of the transaction price to the separate performance obligations was as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_w9JUx3SIA0G_PhvAAlmWVw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Combined licenses and research and discovery performance obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_RWvBuWuwx0SypjAqYYDYow" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_lPaYifzJ3EG28jVZvweJVQ_3_3">34,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Four material rights associated with credits for IND Acceptance fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_uCp5g8aYYkiBWHoG8i9XIA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_ASEbVVPumEWBqgfUb1rQlA_4_3">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_9_7_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5spYzCTLIUOCuK3Eylw0Fg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc__T88XyaOh0euySO6WvbtVw_5_3">38,000</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended December 31, 2024, the Company updated its estimate of variable consideration for the reimbursement of CRO costs from $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" scale="6" id="Narr_F2iEtz5F9E-kWbeapCMM2g">0.6</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" scale="6" id="Narr_tYCQUc1dXk-9w-dAycEfKA">0.4</ix:nonFraction> million, and the transaction price decreased to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_9_A8HjW_FEORtXneZyk0Vw">37.8</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company recognized revenue related to amounts allocated to the combined licenses and research and discovery performance obligation using a proportional performance model over the period of service using input-based measurements including total full-time equivalent effort and CRO costs incurred to date as a percentage of total full-time equivalent effort and CRO costs expected, which best reflects the progress towards satisfaction of the performance obligation. The amount allocated to the material rights is recorded as deferred revenue and the Company commences revenue recognition upon exercise of or upon expiry of the respective option. As of December 31, 2024, the combined licenses and research and discovery performance obligation was completed and all revenue allocated to the combined licenses and research and discovery performance obligation was recognized. The Company anticipates the material rights may be exercisable or may expire after approximately <span style="-sec-ix-hidden:Hidden_7Ox68_7-tk2-gZ54jj6J7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_AvjycYZCW0uI2cpw5iScdQ" format="ixt-sec:durwordsen" name="bcyc:MaterialRightsExerciseOrExpiryTerm" id="Narr_mm--kN8Y00iUEsB4SPwbWw">seven years</ix:nonNumeric> from contract execution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span>The Company concluded that the First Ionis Amendment was a separate contract, as the services were distinct from the Ionis Collaboration Agreement, and the price of the contract increased by an amount of consideration that reflects the Company&#8217;s standalone selling price. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_QA6y8ag3QEm7TEW69r2qZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_Qh2eGQN1O0GiYX4htUs88w">0.8</ix:nonFraction> million associated with services for an initial six-month period as revenue as the underlying services were performed. The contract included an option to perform additional research services for an additional six months that did not contain a material right and the Company accounted for Ionis&#8217; exercise of the option in October 2022 as a separate contract. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_axun9IhIKEiYQ2ka_ErQBg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_LoArq_3uEkypf_JZN3d8gw">0.8</ix:nonFraction> million associated with the services for the additional six-month period as revenue as the underlying services were performed. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont10" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont11"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company concluded that the Third Ionis Amendment was a contract modification to the separate contract under the First Ionis Amendment, as the services were not distinct from the services provided under the First Ionis Amendment. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_ThirdAmendedIonisMember_M_GcK9lsOUqu7PozYRvR_A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_dbBVBOpDSUCcAoXZh4_rhw">0.8</ix:nonFraction> million associated with the services for the additional one-year period as revenue as the underlying services were performed. Revenue was recognized under the First Ionis Amendment and the Third Ionis Amendment using a proportional performance model over the period of service using input-based measurements of total full time equivalent efforts and external costs incurred to date as a percentage of total expected full time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2024, 2023 and 2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_PSXUyrb5dECw2y154V7uOg">8.9</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_bHrLi8MhCE-ebw2M_3VQ6A">10.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_6B9ln8pBckaqlZDRFLAB3A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_YSoZOkGAIE6l2GrhcEQ3Hw">9.3</ix:nonFraction> million in revenue, respectively, and as of December 31, 2024 and 2023, the Company recorded deferred revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_A1rEWBxMikOb21s6_Ma8tQ">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_Z-AV5JUJcUmwBHA-_NMHLQ">12.5</ix:nonFraction> million, respectively, in connection with the Ionis Collaboration Agreement, First and Third Ionis Amendments, and Ionis Evaluation and Option Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Genentech Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 21, 2020, the Company entered into a Discovery Collaboration and License Agreement, as amended from time to time (as amended, the &#8220;Genentech Collaboration Agreement&#8221;), with Genentech. The collaboration is focused on the discovery and development of Bicycle peptides directed to biological targets selected by Genentech and aimed at developing up to <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfPotentialDevelopmentCandidates" scale="0" id="Narr_6h7Rc05aGUi9P8dUAYzcFA">four</ix:nonFraction> potential development candidates against multiple immuno-oncology targets suitable for Genentech to advance into further development and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Genentech Collaboration Agreement, the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_TNyeBlXQzESHLoAfM8kvdA">30.0</ix:nonFraction> million upfront, non-refundable payment. The initial discovery and optimization activities are focused on utilizing the Company&#8217;s phage screening technology to identify product candidates aimed at <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfImmunoOncologyTargets" scale="0" id="Narr_78rb96WL0Uyp4d8v4JJ8Ew">two</ix:nonFraction> immuno-oncology targets (&#8220;Genentech Collaboration Programs&#8221;), which may also include additional discovery and optimization of Bicycle molecules<i style="font-style:italic;"> </i>as a targeting element for each Genentech Collaboration Program (each a &#8220;Targeting Arm&#8221;). Genentech also had the option to nominate up to <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:AdditionalNumberOfImmunoOncologyTargets" scale="0" id="Narr_EOqbo-_b9kWLpuOqaQgUqA">two</ix:nonFraction> additional immuno-oncology targets (each, an &#8220;Expansion Option&#8221;) as additional Genentech Collaboration Programs, which may also include an additional Targeting Arm for each Expansion Option. Genentech exercised the Expansion Options in October 2021 and June 2022, respectively. Genentech paid to the Company an expansion fee of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ExpansionFeePerAdditionalCollaborationProgram" scale="6" id="Narr_PIJkPlvZjkKu_keCf0HA-w">10.0</ix:nonFraction> million for each Expansion Option. The Genentech Collaboration Agreement included rights, under certain limited circumstances, for Genentech to select an alternative target to be the subject of a Genentech Collaboration Program, in some cases subject to payment of an additional target selection fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If Genentech elects for the Company to perform discovery and optimization services for certain Targeting Arms, the Company will be entitled to receive an additional advance payment for the additional research services.  Genentech exercised its right to select a Targeting Arm for </span><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="As_Of_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VivFA-_htU2GU3D3QWHvWQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfInitialCollaborationPrograms" scale="0" id="Narr_krrP3JuvCUeeidiNqm7qzw">one</ix:nonFraction> of the initial Genentech Collaboration Programs at the inception of the arrangement, and for the first Expansion Option in October 2021, which entitled the Company to additional payments of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_T4B2SYwvKkiwF5Y-H5SnKQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:OptionFeeForDevelopmentAndExploitationRights" scale="6" id="Narr_nWRdNhWxgUqTBZ0AgteXpg">1.0</ix:nonFraction><span style="white-space:pre-wrap;"> million each. If a Targeting Arm achieves specified criteria in accordance with the research plan, Genentech will be required to pay a further specified amount in the low single digit millions for each such Targeting Arm as consideration for the additional services to be provided.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company granted to Genentech a non-exclusive research license under the Company&#8217;s intellectual property solely to enable Genentech to perform any activities under the agreement. The activities under the Genentech Collaboration Agreement are governed by a joint research committee (&#8220;JRC&#8221;) with representatives from each of the Company and Genentech. The JRC will oversee, review and recommend direction of each Genentech Collaboration Program, achievement of development criteria, and variations of or modifications to the research plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">After the Company performs the initial discovery and optimization activities in accordance with an agreed research plan and achieves specified criteria, Genentech will have the option to have the Company perform initial pre-clinical development and optimization activities in exchange for an additional specified milestone payment in the mid-single digit millions for each Genentech Collaboration Program (the &#8220;LSR Go Option&#8221;).  Upon completion of such initial pre-clinical development and optimization activities for each Genentech Collaboration Program, Genentech will have the option to obtain an exclusive license to exploit any compound developed under such Genentech Collaboration Program in exchange for an additional specified payment in the mid to high single digit millions for each of the initial </span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont11" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont12"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UiXZnEQKrUaSVgTitUBvIQ" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfCollaborationPrograms" scale="0" id="Narr_mi6MQn2AHESZVqTTY8F4AQ">two</ix:nonFraction> Genentech Collaboration Programs and each of the <ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ccXf6ptJGE-9qaLqRgb8FA" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfExpansionOptionCollaborationProgramsDevGo" scale="0" id="Narr_OacxlxHdpUSWChUoiDJZoA">two</ix:nonFraction> Expansion Option Genentech Collaboration Programs (the &#8220;Dev Go Option&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On a Genentech Collaboration Program by Genentech Collaboration Program basis, if Genentech elects to obtain exclusive development and commercialization rights and pays the applicable LSR Go Option and Dev Go Option fees, Genentech will be required to make milestone payments to the Company upon the achievement of specified development, regulatory, and initial commercialization milestones for products arising from each collaboration program, totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_LwM9FXA8rkKkuLMtRDp7wg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_pNS2Gn90sEStpfMyuhIvbA">200.0</ix:nonFraction> million. Specifically, the Company is eligible for additional development milestones totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_tki1umMlTE2iFkLuV5EjMA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_XHoDv5RtekyECBoG-0Ks0Q">65.0</ix:nonFraction> million, as well as regulatory milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_RegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_m_fV9ESl1kiTO5YyS3qSDg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_CK9GvTSO8kS9Od5DF3INtg">135.0</ix:nonFraction> million for each collaboration program. In addition, the Company is also eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationPerformanceOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_TSRQzXGT_UCdLkzF9xrWhA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" scale="6" id="Narr_RSojqaXkh0OgEPylL6q37A">200.0</ix:nonFraction> million in sales milestone payments on a Genentech Collaboration Program-by-Genentech Collaboration Program basis. In addition, to the extent any of the product candidates covered by the licenses conveyed to Genentech are commercialized, the Company would be entitled to receive tiered royalty payments on net sales at percentages ranging from the mid-single to low double-digits, subject to certain standard reductions and offsets. Royalties will be payable, on a product by product and country by country basis, until the later of the expiration of specified licensed patents covering such product in such country, or <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_HyrRNe-YbEC-tdg9gRuhvQ" format="ixt-sec:durwordsen" name="bcyc:NumberOfYearsOverWhichRoyaltyIsPayable" id="Narr_ALctHrZ5wEW1ObWDFjRzMw">ten years</ix:nonNumeric> from first commercial sale of such product in such country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the execution of the Genentech Collaboration Agreement, the Company has identified the following performance obligations: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research license, and the related research and development and preclinical services through LSR Go for a first Genentech Collaboration Program (Genentech Collaboration Program #1); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research license, and the related research and development and preclinical services through LSR Go for a second Genentech Collaboration Program with a specified Targeting Arm (Genentech Collaboration Program #2); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Material right associated with an option to a specified Targeting Arm for Genentech Collaboration Program #1;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_Uq2YtHbmDEqFEAKHinp0mg" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfCollaborationPrograms" scale="0" id="Narr_AYIHzVq7_0GdK8derNgeAw">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the LSR Go Option for Genentech Collaboration Program #1 and Genentech Collaboration Program #2, which includes research services to be provided through the Dev Go Option and an option to receive an exclusive license; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Material rights associated with certain limited substitution rights with respect to a limited number of collaboration targets; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_Uq2YtHbmDEqFEAKHinp0mg" decimals="INF" format="ixt-sec:numwordsen" name="bcyc:NumberOfExpansionOptionCollaborationProgramsDevGo" scale="0" id="Narr_Sbh8z31DYk2dCMzs93N3_A">Two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights related to each Genentech Expansion Option, which upon exercise include the services for an additional immuno-oncology target through the LSR Go Option, an LSR Go Option which includes the services to be provided through the Dev Go Option and an option to receive an exclusive license, limited substitution rights, and an option to select a specified Targeting Arm. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company concluded that certain substitution rights that require the payment of additional consideration, which approximate the standalone selling price of the underlying services to be provided, do not provide the customer with a material right and therefore, are not considered as performance obligations and are accounted for as separate contracts upon exercise, if ever.  The Company&#8217;s participation in the JRC was assessed as immaterial in the context of the contract. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has concluded that the research license is not distinct from the research and development services as Genentech cannot obtain the benefit of the research license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as it relates to constrained peptide technology that is not available in the marketplace. As a result, for each </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_9PeI8bhdVUGhxfQbudmoPw_1_2"></a><a id="Tc_C7cTA2GqLUCzUKp_Ni0i6A_2_0"></a><a id="Tc_qP_JcBrxs0-xPGEpAVnsYQ_2_2"></a><a id="Tc_k5QIKwSZvUOoVBZcDSa0MA_3_0"></a><a id="Tc_TaT8fSnAi0WRHe-6Je0cJw_3_2"></a><a id="Tc_rvcoWk7aMUirp-fGWmWNGA_4_0"></a><a id="Tc_rAkt_UkLsUCn_p1Urwp_GA_5_0"></a><a id="Tc_2pf3eDx9KU6dpdFigxbxaQ_6_0"></a><a id="Tc_4TfZ1xp1ak-aieGB9ln9SA_7_0"></a><a id="Tc_PR1w2cN18E29jaK1-qYlAg_8_0"></a><a id="Tc_vLN_GlmHXEKT63NuUOrsWg_9_2"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont12" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont13"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">research program, the research license has been combined with the research and development services into a single performance obligation. In addition, the Company concluded that the Dev Go Option is not distinct or separately exercisable from the LSR Go Option, as the customer cannot benefit from the Dev Go Option unless and until the LSR Go Option is exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In assessing whether the various options under the Genentech Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon the option exercise, the standalone selling price of the underlying goods, services, and additional options.  For the material rights identified above the Company concluded that each of the options provided Genentech with a discount that it otherwise would not have received. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total transaction price was initially determined to be $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_4IPgN-lhdkWHWZntHonA2w">31.0</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborativeArrangementUpfrontCashPaymentReceived" scale="6" id="Narr_yhySmwBCC0WFtGJuuvQLGg">30.0</ix:nonFraction> million upfront fee and the additional $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VivFA-_htU2GU3D3QWHvWQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_kfj9GXqSMEaSHB5owogCkg">1.0</ix:nonFraction><span style="white-space:pre-wrap;"> million for Genentech&#8217;s selection of a new Targeting Arm at inception.  The Company utilizes the most likely amount method to determine the amount of research and development funding to be received. Additional consideration to be paid to the Company upon the exercise of options by Genentech and subsequent milestones are excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. In addition, other variable consideration for development milestones not subject to option exercises was fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. In March 2021, the Company achieved specified criteria in accordance with the research plan under the Genentech Collaboration Agreement and therefore updated its estimate of the variable consideration to include an additional </span>$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_xgSdh5vtDES1WDH_f8Xs-A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_kuh01Rm43EG3mFb2YQZGDg">2.0</ix:nonFraction> million, that is no longer constrained. The arrangement consideration was increased to $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_xgSdh5vtDES1WDH_f8Xs-A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_mCqgc5VVUkS5Gj21Dh0pjw">33.0</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the Genentech Collaboration Programs was based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling price for the material rights was determined based on the fees Genentech would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Genentech would exercise the option and any underlying options.  </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A" name="bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" id="Group_llnRfFzTJUSPQgI_JZqTUw" continuedAt="Group_llnRfFzTJUSPQgI_JZqTUw_2" escape="true">Based on the relative standalone selling price, the allocation of the transaction price to the separate performance obligations is as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_llnRfFzTJUSPQgI_JZqTUw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genentech Collaboration Program #1 Performance Obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_uRCFMRtOakyg2OeSksR3_Q" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_JGOq5tPQsU6ArzVNzyum7A_3_3">4,019</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genentech Collaboration Program #2 Performance Obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationTwoPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fY6J4ndKWkuZNzesRX6wQw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_okLB38mPLkaBRKgvC0DW9w_4_3">8,037</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Specified Targeting Arm Material Right Arm for Genentech Collaboration Program #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qPiuB9BUQEah87FFQEHHLw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_V0AqDk6J-kyYtVYedsvQLg_5_3">352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with the LSR Go Option for Collaboration Programs #1 and #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_1eSemPD_PUGZrSIfTiqkcQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_6QfImL2FXU-IxyqbfOYTHQ_6_3">12,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Material rights associated with limited substitution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_kzAbTqHZN0CArARXFbOtYw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_WOyh7gc6g0y9GkhvspiqdQ_7_3">1,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights for Expansion Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VqqK4Cb9V0iqlo_bcaxLfw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_RGfcdFf8o0KPEqRI20y-Wg_8_3">7,005</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="3" id="Tc_z5LRzeAs_kSSESmeCbhvXQ_9_3">33,000</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company recognizes revenue related to amounts allocated to the Genentech Collaboration Program #1 and #2 Performance Obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligation. The amount allocated to the material rights is recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. In June 2023, Genentech terminated Genentech Collaboration Program #2 and revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_l4IhOsVA_kaoaEarP7YyVg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_nMtGtotx60WVkB3ttOclxw">6.0</ix:nonFraction> million was recognized during the year ended December 31, 2023 related to the expiration of the material right associated with the LSR Go Option for Collaboration Program #2. The Company expects the remaining Genentech Collaboration Performance Program #1 performance obligations will be satisfied over the next <span style="-sec-ix-hidden:Hidden_PuaulHhMWk2PS85VLrvMLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BteqU8JwLEGuk_pXYeS0Cw" format="ixt-sec:durwordsen" name="bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed" id="Narr_Wo3wGId5FEi2_Y9qKoBbRw">two years</ix:nonNumeric>, and the remaining deferred revenue allocated to the LSR Go Option for Collaboration Program #1 will commence revenue recognition when the option is exercised or expires within approximately <span style="-sec-ix-hidden:Hidden_CuyU_1zNJ0eAuH7pLi5zdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BteqU8JwLEGuk_pXYeS0Cw" format="ixt-sec:durwordsen" name="bcyc:MaterialRightsExerciseOrExpiryTerm" id="Narr_ttcqtLxxIkKSvWqIUH_g-g">five years</ix:nonNumeric> from contract execution. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3544f8c4_ce79_466b_a239_7013641522ee"></a><a id="Tc_ztH5KPx4GEiWtHlMIz8WGg_1_2"></a><a id="Tc_dQu_3J2O-kWd3CIQxsOJsw_1_11"></a><a id="Tc_48uvOhAcKUSCaweYi20IVQ_1_14"></a><a id="Tc_75frp42cTkCHa55yQRICug_2_2"></a><a id="Tc_hYMORkaPNk-M0Oo8yCudxQ_2_11"></a><a id="Tc_T3Snk9Y2cEKOvKKmLb7FrA_2_14"></a><a id="Tc_xUpTBmLJ0UuLrXidK8vJng_3_2"></a><a id="Tc_mbRGqIJiIkuYweBA5HBMkg_3_5"></a><a id="Tc_QGQ4ndP2HU67qdlS_b3QhQ_3_8"></a><a id="Tc_vMul6Uv6aU6KGU1lrZ6exQ_3_11"></a><a id="Tc_2ee01UGzREqVuXHfjTiiog_3_14"></a><a id="Tc_owrOIfoTb06pA53JrnkVcg_4_0"></a><a id="Tc_4BJbLgwnmUOvfY0AGnshHQ_5_0"></a><a id="Tc_PvNFAW0PNUqcok2wDbUyyw_6_0"></a><a id="Tc_IfJVTtuH_EuaU3YfH1qLDg_6_2"></a><a id="Tc_cPK_48BV206dvR3t98WEcA_6_5"></a><a id="Tc_dok2YRIaR0K-oTs70k8uog_6_8"></a><a id="Tc_9r8nwrjDpkiFGVN0uh8KPw_6_11"></a><a id="Tc_S7KbmSGM2kyfTW41_SGWMQ_6_14"></a><a id="Tc_L2ppFdiqq0iyNVVhWSMD0Q_7_0"></a><a id="Tc_vFImDjDCA0mHsoyJIEHm6Q_8_0"></a><a id="Tc_ccW8IguFW066sy-YLV-0OQ_9_0"></a><a id="Tc_igeThGISHEWERm_HVTtF2w_9_6"></a><a id="Tc_pzx6Ro7FVEmoSYYIqLKi_Q_10_0"></a><a id="Tc_mcaB0ZMbOUuNEqjyOFJSlw_10_2"></a><a id="Tc_J3BZLxWwZk-DscBKP7Eu4A_10_5"></a><a id="Tc_aJIkrlJU4Ee3P5unlffqJA_10_8"></a><a id="Tc_nH93iGZRU0mq0rA4KeVEOw_10_11"></a><a id="Tc_-nq0FMnIzkeCWOV5p3ggjA_10_14"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont13" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont14"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In October 2021 and June 2022, respectively, Genentech exercised the first and second Expansion Options to add additional Genentech Collaboration Programs (Genentech Collaboration Program #3 and Genentech Collaboration Program #4) and paid to the Company an expansion fee of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_D0rz7JpLrEi8DFIjkqRfAQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ExpansionFeePerAdditionalCollaborationProgram" scale="6" id="Narr_KbDhfBIUTUS1n6FlD8BD3A"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PHabuvgaTkmQG0J2ns37DA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ExpansionFeePerAdditionalCollaborationProgram" scale="6" id="Narr_2Egg-wlR7keThxuLvQ6hSg">10.0</ix:nonFraction></ix:nonFraction> million for each option. For the first Expansion Option, Genentech also elected for the Company to perform discovery and optimization services for a Targeting Arm, and the Company received an additional payment of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable" scale="6" id="Narr_RS2SFQ7deE23l_qlOX84RA">1.0</ix:nonFraction> million for additional research services. The Company concluded that the exercise of each Expansion Option, including the option to a specified Targeting Arm for the first Expansion Option, is accounted for as a continuation of an existing contract as the customer decided to purchase additional goods and services contemplated in the original contract. For the first Expansion Option, the additional arrangement consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice" scale="6" id="Narr_oLAjxK_1UU67Cqbc5GUmNg">11.0</ix:nonFraction> million received upon the option exercises and the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationProgramAmountOfMaterialRights" scale="6" id="Narr_rlXzsLuXe0aMehwkVpAlbQ">3.5</ix:nonFraction> million originally allocated to the first Expansion Option material right is allocated to the underlying goods and services associated with the first Expansion Option on the same basis as the initial allocation of the Genentech Collaboration Agreement. In December 2022, the Targeting Arm associated with the first Expansion Option achieved specified criteria in accordance with the research plan under the Genentech Collaboration Agreement and therefore the Company updated its estimate of variable consideration to include an additional $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qCp4Kues8ESQiRZdeh8N9A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedVariableConsiderationNoLongerConstrained" scale="6" id="Narr_hThZ_5EIQUC_ZhsabPkAbw">2.0</ix:nonFraction> million, that is no longer constrained. The Company allocated the additional $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qCp4Kues8ESQiRZdeh8N9A" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:EstimatedVariableConsiderationNoLongerConstrained" scale="6" id="Narr_KPo4mOXYmkSEFGD7CM1uHg">2.0</ix:nonFraction> million entirely to the Genentech Collaboration Program #3 and Targeting Arm services as the terms of the variable consideration relate specifically to the Company&#8217;s efforts in satisfying the performance obligation and allocating the variable consideration entirely to the performance obligation is consistent with the allocation objective in ASC 606. For the second Expansion Option, the additional arrangement consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_cqFl8FEbxkiSfD6iCj1uZQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ExpansionFeePerAdditionalCollaborationProgram" scale="6" id="Narr_QKegQPeBdUGbJd9JXQZx5g">10.0</ix:nonFraction> million received pursuant to the option exercise together with the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PVgTMTZKEkukeSrHzooTww" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationProgramAmountOfMaterialRights" scale="6" id="Narr_rPpVR6mg0UyjEw-Xqstm7g">3.5</ix:nonFraction> million originally allocated to the second Expansion Option material right is allocated to the underlying goods and services associated with the second Expansion option on the same basis as the initial allocation of the Genentech Collaboration Agreement. Other variable consideration for development milestones not subject to option exercises was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved. The Company recognized the $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PHabuvgaTkmQG0J2ns37DA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_T32i_15nBUu71qiO7rxVIA">8.4</ix:nonFraction> million allocated to the Genentech Collaboration Program #3 and Targeting Arm services and is recognizing $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_cqFl8FEbxkiSfD6iCj1uZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_v9dSTZB5V0W66dTg2sWgAw">5.3</ix:nonFraction> million allocated to the Genentech Collaboration Program #4 services as the underlying services are performed using a proportional performance model over the period of service of approximately <span style="-sec-ix-hidden:Hidden_23cxoubFkkqKtXI7gxQnYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to <ix:nonNumeric contextRef="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_p4p-FG55D0eRUEKCq8P6yg" format="ixt-sec:durwordsen" name="bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed" id="Narr_lT3QwcqDQ0GmDYzlwptGwA">three years</ix:nonNumeric> for each program using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and external costs expected, which best reflects the progress towards satisfaction of the performance obligations. The amount allocated to the material rights associated with an LSR Go Options for Genentech Collaboration Program #3 and Genentech Collaboration Program #4 of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_-gMn9m7NtkmdLXLyH9rqdQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_rwXTpQ0SIkSwnERIpTh2VA">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_jkHOHVP16kyVT6B0B3UJYg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_XqQeDyRczkqMeZKwJ2en4Q">7.4</ix:nonFraction> million, respectively, limited substitution material rights of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_RdiH8PgdtkyqEjCC0xKdGw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_RR-LjfT9OkW6oDy38ntifQ">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_RdiH8PgdtkyqEjCC0xKdGw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_zwtniAgEjEOu6iZmhKX4gA">0.7</ix:nonFraction> million, respectively, and the material right associated with the option to select a Targeting Arm for Genentech Collaboration Program #4 of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_YYJ26o4FAkKUoYNNZn4kKw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_jfTbm8dpLE-Z9VyqW_ZxDQ">0.1</ix:nonFraction> million were recorded as deferred revenue. In January 2024, the JRC decided to discontinue research activities associated with Genentech Collaboration Program #3 and, as a result, the Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_2L8b9aOuvEGTIyzSbt8YAA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_d6TAKxvGhUiZKe0aP1Skww">10.4</ix:nonFraction> million during the year ended December 31, 2024, including $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_2L8b9aOuvEGTIyzSbt8YAA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_jp6q2N7alkSjRaJtuU27mw">7.5</ix:nonFraction> million related to the expiration of remaining material rights. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_xaq-E5bLUUucXbEuy_hs4g">14.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_rNYInLIoA0CQAnFsyr-jqA"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_WapKFGXK1EedLSUb7pEEcw">12.0</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qLy1Qlk7lUqL6zN6xMcMvQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_qLm3W6TeoU2SOTMlSxRJjA">3.6</ix:nonFraction> million, respectively, and as of December 31, 2024 and 2023, the Company recorded deferred revenue of <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_WYnykJwM-kSavM-sBWYqRQ">14.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_WRm-b3u0DUKBjM14IVMb4Q">29.1</ix:nonFraction> million, respectively, in connection with the Genentech Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Summary of Contract Assets and Liabilities</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="Tb_p7V5nSJD402i8G1tr0lq9g" continuedAt="Tb_p7V5nSJD402i8G1tr0lq9g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents changes in the balances of the Company&#8217;s contract liabilities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impact&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Bayer collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_zNiebIxv9k-kZeCIPNg5Tw_6_3">43,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_8Bo8k1ajoEi-MlP-H7RfwA_6_6">296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_ed6V_jUL-ECIxqt0YKlRjw_6_9">3,393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" scale="3" id="Tc_SN1569PEukeD_AxOM_BX9Q_6_12">561</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_CLM3oWHaYEmA9xWRlsRxFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_8wxlkyqfQE6iXvpyE4uoJA_6_15">39,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Novartis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_WxcNoBShQkiaLqf-u2MiuQ_7_3">50,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_hVr2modrl0O1t3-Chy9JYA_7_6">3,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_cYwswef9DUmx_n5cZTihFg_7_9">8,161</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" scale="3" id="Tc_hIU4zkLqvUq8sC92GuiQxQ_7_12">774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_cyHRxQCIEESnLP8sT0_U6Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_VpM-HTxrxUalnECPY297YQ_7_15">44,073</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Ionis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_g5r8L-r4nUOGsiznym-FXg_8_3">12,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_QTzyuaAOVUK0j3P-qQaYgw_8_6">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_uXwOQE-LtE-EQ5-n0og0-w_8_9">8,881</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" scale="3" id="Tc_MpAwKpPFbkSYVdEYf_VUvQ_8_12">86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_-QGjamG2Lk6dpj4AsZ9Utg_8_15">3,587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Genentech collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_oRgT6mQB5U-gySfW2z5cIA_9_3">29,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_j7qgKc1diEi79oul9HQRBw_9_9">14,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" scale="3" id="Tc_FHmkeiR8fEuG_mWu9i-9HA_9_12">226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_NDY7KXvevE-nBWvaIBQvLQ_9_15">14,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_6aQyv6Vdxk2cH7imnFxPAw_10_3">135,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_v3OvYpeduEeVN5-Y5gVvfA_10_6">3,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_dMMNL0QnmU-lsdPpEIVgnw_10_9">35,275</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" scale="3" id="Tc_4OWmwz1aXkmTotwFCA_kdA_10_12">1,647</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_BHbvleEXnkWXraCDdmPSMA_10_15">101,658</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9f2b207d_04e8_48f1_af73_44265826479b"></a><a id="Tc_Sf_DRVNhLk2cdItgbjeZrQ_1_2"></a><a id="Tc_VZwNb1OJ8UiG9OB2BKM1MQ_1_11"></a><a id="Tc_fxFY8vVjYEu2rKP4cx--0A_1_14"></a><a id="Tc_m_KtOvqqN0-0UpwSURspDQ_2_2"></a><a id="Tc_fQmuhy9HhkaY2PYr5SyjYQ_2_11"></a><a id="Tc_CuNs9ONTyEK00wHYgl7xEw_2_14"></a><a id="Tc_RPDQaY60KEGKwmUiz4dWmg_3_2"></a><a id="Tc_V91JQz5CUEqzJf6bL-T1gw_3_5"></a><a id="Tc_5NajPp7JcE2zL8lrSftzCg_3_8"></a><a id="Tc_62KbMFu5AU6RPhPWj34lCw_3_11"></a><a id="Tc_K3h7bwBvz06-wO6aRyW6hA_3_14"></a><a id="Tc_5QejFZmVLUWEWsOTdUnZ8g_4_0"></a><a id="Tc_dWlsdR7UhUWTehOhE6ABrw_5_0"></a><a id="Tc_w3sY9pADOUy1tWh1cHs2lw_6_0"></a><a id="Tc_vPbvGsHMp0i1ydydnMGCdw_6_2"></a><a id="Tc_hY-zA08rGE-Jz7Ee-HmLDA_6_3"></a><a id="Tc_UwsNtYVDEEG-OEUu1suljw_6_5"></a><a id="Tc_YTosZcy-S0qA-8YtTtGetQ_6_8"></a><a id="Tc_HdjiYmCx0UKqtfDMQczEPw_6_11"></a><a id="Tc_PUI0s4px6k2tEqx40gxFNQ_6_14"></a><a id="Tc_q1N0iO-0GUKdhLIuqbeOtA_7_0"></a><a id="Tc_i8yZQ-FeHEOPDTcdnD3wYA_7_3"></a><a id="Tc_xRL6JjXFtE6VeoSDaMyOug_8_0"></a><a id="Tc_zTxqn3wXgU2D2cqGc-YtEw_9_0"></a><a id="Tc_qttTz0FiDkCw85wMjjbQbQ_9_6"></a><a id="Tc_fX6Qk22F80uz8aj0VaHsdQ_10_0"></a><a id="Tc_rjdjssRQoEepAQ0vBM1DvQ_10_6"></a><a id="Tc_s3qRjS1cJ0qxffEmwlxW8g_10_15"></a><a id="Tc_3ni164QlkUaXxWRn3zbesg_11_0"></a><a id="Tc_0kajmC9Zk0ygcDzIp7-QfA_11_2"></a><a id="Tc_58M9wP98_EWsj3qkeyrDmg_11_5"></a><a id="Tc_-m98CSoYs0KqvAgsOxm51A_11_8"></a><a id="Tc_aujDL_bPQU6_BIdMmlJkUA_11_11"></a><a id="Tc_A1xKD6uzE0iz9lBo4QFgbA_11_14"></a><a id="_b8819ec8_d96a_42d6_8d6c_560b0ec8ca01"></a><a id="Tc_9I-jGVxf1E6jHbf8EgHanQ_1_2"></a><a id="Tc_N8iRk_PzBUWW2h0C-IkWVw_2_2"></a><a id="Tc_TB7wmFqeCESHWU2MdtlIUg_3_2"></a><a id="Tc_oPk-WVNewUG0f7x8X6F8xw_3_5"></a><a id="Tc_8-SJEo4EWkWuFboweDJohQ_3_8"></a><a id="Tc_i28UaEQBtE6z-9RN9Z62Fw_4_0"></a><a id="Tc_oxLMqyfjLE6ugCOcW0k5gA_5_0"></a><a id="Tc_mnoTlZ8cbkScGEYoFICLsw_5_2"></a><a id="Tc_45LspPX_RU-KP9IvVhjZLw_5_5"></a><a id="Tc_4Hvl8oV5kUuNnql9iPMCHQ_5_8"></a><a id="Tc_bntESotIDUyGowDAmQqJvA_6_0"></a><a id="Tc_CZu5mpcyLk-E0DI7H5FPsw_7_0"></a><a id="Tc_A4dJxd-Bs0anj0q4v9xaqQ_7_6"></a><a id="Tc_DShqJqHNqEOjFM9jnB6VlQ_8_0"></a><a id="Tc_StQN35Ik4Umq8m2ipYmwdg_8_2"></a><a id="Tc_SrAhFJ90k0um3FbyZCbKVQ_8_5"></a><a id="Tc_M6pIPS7rIECBe3M4gSKH9A_8_8"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont14" continuedAt="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont15"><ix:continuation id="Tb_p7V5nSJD402i8G1tr0lq9g_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Beginning&#160;Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impact&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ending Balance</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exchange</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bayer collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_A0goISth_Eu1gtIFPTOnuw_6_6">45,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_y2bfPJ9tQk6qJiolTZsMOA_6_9">1,160</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" scale="3" id="Tc_MOfZHtB8m0iJB-pCThdrxQ_6_12">222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_QUgKXSEs3UimYQu0t8Ro8A_6_15">43,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Novartis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_DJ5mOS1CtEanMB3Quk4Klw_7_6">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_Y3B5-FBgdESgnuL08bFOdg_7_9">1,909</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" sign="-" scale="3" id="Tc_OxbunQfMgUmS2bq-mxBe3Q_7_12">1,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_dmoAro6KVEG1zGDl1u6t0g_7_15">50,008</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Ionis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_ISvkPDGZT0GtRplR-nMrEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_zt7Rfej4z0ivgpolvjmxuw_8_3">21,489</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_tBE9Fmau-0GsAznA3Nplxw_8_6">960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_WUkwX25hRE-OZSQnj7u3Jg_8_9">10,734</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" sign="-" scale="3" id="Tc_yE6Gwq4jc0SmxkDOxCxISQ_8_12">749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_0nU4a9P9kUGjmiunR8QQMw_8_15">12,464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Genentech collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UTg8-nc3xku3S4nBOYYTgw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_rPnxrqaIVEq-OpZSTWSPnA_9_3">39,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_jOi55sEMhU6CrUacpRhMXA_9_9">11,969</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" sign="-" scale="3" id="Tc_Qg7yP_XUbki5TwpmE0iu4g_9_12">1,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_brgryS4kZkWX738FGFZjpA_9_15">29,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">AstraZeneca collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_tyLSGaCBcUCWHOiuJFWHhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_xh1JsSqYokiQM7z0x1ib1g_10_3">1,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_HAv9KlP9XESIREyCBaF9bQ_10_9">1,204</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" sign="-" scale="3" id="Tc_S6w-SqCfBEqnXYOmq_0Zdw_10_12">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_u3-gaUqqa0qqF6jYQxxamA_11_3">61,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_5sAA825Y0ECaxtCsfxIBmQ_11_6">95,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_g8CstDBle0-Z_RU_z7_iIg_11_9">26,976</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment" sign="-" scale="3" id="Tc_dpbo2BbVyUGqdqRjU4XuCg_11_12">4,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_gpbA45zxzUSqjUWrW_eLxw_11_15">135,194</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract assets represent research and development services which have been performed but have not yet been billed, and are reduced when they are subsequently billed. There were <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_5CPdAC1ZJ0a_nhd-9g9f_A"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_LXA_SZyYhEC2pQJQvwRUPQ">no</ix:nonFraction></ix:nonFraction> contract assets at December 31, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Bayer, Novartis, Ionis, and Genentech deferred revenue balances include $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_5LReFI3s3U24XzqlQU2yZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_wN2CxmHn7EaYo0OUAFMByg">31.9</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_0G_PjFAo40GKFUdlMvcXrw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_gRYrVi8yo0CwXWAcjusVkQ">32.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_sWPs1iEFhUqaA2I4dkmTgg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_Mi8A_RFrZk2dFwLnVWhI6g">3.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_KVWfPM5pcEK7pqypuPXWLw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_xkcXyIEEzU60Y7seJm_aHw">13.5</ix:nonFraction> million, respectively, allocated to material rights that will commence revenue recognition when the respective underlying options are exercised or when the options expires. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" id="Tb_Ush0bnPMnUCvyLFbLrtnog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue recognized in the period from:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on proportional performance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" scale="3" id="Tc_1h5YLU9390-c2C81FWncOQ_5_3">24,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" scale="3" id="Tc_DDJwLKY1SkyZgRSoI7Nv3A_5_6">19,160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" scale="3" id="Tc_5PxkLlJpq0CG89DaqiTQxg_5_9">12,358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on expiration of material rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" scale="3" id="Tc__UEUbEo7bkKkDJPEeuMZ0A_6_3">10,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" scale="3" id="Tc_0lt8LV82GkerqlzrEoctRA_6_6">7,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" scale="3" id="Tc_SRt8cRdtDE-6DIp2XtYGyA_6_9">1,433</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on changes in transaction price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" scale="3" id="Tc_ySYpg3JgekuBAQs50LzpPQ_7_3">433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" scale="3" id="Tc_M2ZL6qQ_tkCD-FYU_6q4eQ_7_9">672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" scale="3" id="Tc_iAogAmhmXkO5M8w_vQB68g_8_3">35,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" scale="3" id="Tc_o7NDHCblPU2UI5FXGKsUmg_8_6">26,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" scale="3" id="Tc_-STWnxQfekmrrG3TmpDvRw_8_9">14,463</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cancer Research UK</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">BT1718</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December 13, 2016, the Company entered into a Clinical Trial and License Agreement with Cancer Research Technology Limited (&#8220;CRTL&#8221;), a wholly owned subsidiary of Cancer Research UK that Cancer Research UK&#8217;s commercial activities operate through, and Cancer Research UK (the &#8220;BT1718 Cancer Research UK Agreement&#8221;). Pursuant to the BT1718 Cancer Research UK Agreement, as amended in March 2017 and June 2018, Cancer Research UK&#8217;s Centre for Drug Development sponsored and funded a Phase I/IIa clinical trial for BT1718, a BTC molecule, in patients with advanced solid tumors. The Company retained the right to continue the development of BT1718 during the clinical trial. Upon the completion of the Phase I/IIa clinical trial, the Company had the right to obtain a license to the results of the clinical trial upon the payment of a milestone, in cash and ordinary shares, with a combined value in the mid six-digit dollar amount. If such license was not acquired, or if it was acquired and the license was terminated and the Company decided to abandon development of all products that deliver cytotoxic payloads to the MT1 target antigen, CRTL could elect to receive an assignment and exclusive license to develop and commercialize the product on a revenue sharing basis (in which case the Company would receive tiered royalties of <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_4t0N24_S70mz2Zd2yTJ85A" decimals="2" format="ixt:num-dot-decimal" name="bcyc:PercentageOfTieredRoyaltyOnNetRevenue" scale="-2" id="Narr_8aiD-VDJk0uh3ix1qa652w">70</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_B_kz3AanWUGz-CXUrr44Qg" decimals="2" format="ixt:num-dot-decimal" name="bcyc:PercentageOfTieredRoyaltyOnNetRevenue" scale="-2" id="Narr_KZ85mO-nH0y9URB_mlvexw">90</ix:nonFraction>% of the net revenue depending on the stage of development when the license is granted). The BT1718 Cancer Research UK Agreement contained additional future milestone payments upon the achievement of development and regulatory milestones, payable in cash and shares, with an aggregate total value of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_13_2016_-ccexalN_EuXuCJAskV6sA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentArrangementObligationToRepayOtherParties" scale="6" id="Narr_F_ZTLfvqBEaewQM98ic62w">50.9</ix:nonFraction> million, as well as royalty payments based on a single digit percentage on net sales of products developed. Cancer Research UK could terminate the arrangement for safety reasons or if it was determined that the objectives of the clinical trial will not be met and either party could terminate the arrangement upon an insolvency event, material breach of the terms of the contract, or upon a change in control (and the new controlling entity develops, sells or manufactures tobacco products or generates the majority of its profits from tobacco products or </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Narr_lGArpmBYtU-oYxZvAcrqtA"></a><ix:continuation id="Tb_koEcBfr4r0eJ_a7AM2PB2Q_cont15"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is an affiliate of such party). The Company was required to reimburse Cancer Research UK for certain costs upon specified termination events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the costs incurred by Cancer Research UK was a research and development funding liability in accordance with ASC&#160;730, <i style="font-style:italic;">Research and Development</i>, as certain payments were not based solely on the results of the research and development having future economic benefit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 4, 2024, the Company, CRTL and Cancer Research UK entered into an Expiry and Revenue Sharing Agreement (the &#8220;BT1718 Expiration Agreement&#8221;) pursuant to which (i) the Company did not exercise its option to obtain a license to the results of the clinical trial, (ii) CRTL did not elect to receive an assignment and exclusive license to develop and commercialize the product, (iii) the BT1718 Cancer Research UK Agreement will expire on December 4, 2024, and (iv) all rights and obligations (other than certain surviving provisions as outlined in the agreement) under the BT1718 Cancer Research UK Agreement expired and terminated as of December 4, 2024. Under the terms of the BT1718 Expiration Agreement, the Company agreed to pay to CRTL an upfront payment of &#163;<ix:nonFraction unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ" contextRef="Duration_12_4_2024_To_12_4_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_goSmqlBU3UOCLW6hsHOXGg" decimals="0" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentArrangementUpfrontCashPayment" scale="0" id="Narr_-hvGrs9SPkuh02mV9zmVxg">50,000</ix:nonFraction>. The Company will also pay to CRTL specified royalty and other payments at percentages in the very low to low single digits related to specified products targeting the MT1 target antigen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the BT1718 Expiration Agreement by applying the concepts of ASC 470, <i style="font-style:italic;">Debt</i>. As all rights and obligations, including the Company&#8217;s payment obligations, under the BT1718 Cancer Research UK Agreement expired and terminated, the Company concluded that the liability recorded under the BT1718 Cancer Research UK Agreement is extinguished as the Company has been legally released from being the primary obligor under the BT1718 Cancer Research UK Agreement. As such, the Company recognized a gain on extinguishment of the research and development funding liability of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_NV57yxdHsUG-EvMIcuAkLA" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" scale="6" id="Narr_thIyiiOY5US92SmDjGpKlA">4.5</ix:nonFraction> million during the year ended December 31, 2024, which is recorded within other income, net, in the consolidated statements of operations and comprehensive loss. As of December 31, 2024 and 2023, the Company recorded a research and development funding liability of zero and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_a9Bb03tCQUq9DG0yh6RePg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" scale="6" id="Narr_mbzsIeCDhka8kl56RR0m3Q">4.3</ix:nonFraction> million, respectively, related to the BT1718 Cancer Research UK Agreement, which is recorded in other long-term liabilities in the consolidated balance sheets.</p></ix:continuation><a id="_6120ae41_2716_489e_adc4_3230f5db81e5"></a><a id="Tc_Y1Mkb8wEgU-B100ipe_2tQ_1_2"></a><a id="Tc_aUP_m7TQjE2dp8l7L4p-Cw_2_2"></a><a id="Tc_9chU8XHomEK23qhP7WOj_w_3_2"></a><a id="Tc_v0sTtNQ8Q0ivRPl8_hUEow_3_5"></a><a id="Tc_nKLD6od4G0-7kkyC_Vmdvw_3_8"></a><a id="Tc_CatH36-ESkGXo25ZzmS34A_4_0"></a><a id="Tc_mWe-7ODwpEOCVG2EKbUgZg_4_2"></a><a id="Tc_6BeqX32bBk-kfNThisfZ_A_4_5"></a><a id="Tc_upTxtvN980qsLoVQ-CZX6Q_4_8"></a><a id="Tc_YShWZkrYYUalnusov1GGGA_5_0"></a><a id="Tc_bMo9Jiwtok-oeDIcyAMM5A_6_0"></a><a id="Tc_pr0AAd-Z0ky6zTzwOXBDHQ_6_2"></a><a id="Tc_YUnaOhw-uEOMs0VZMsO81w_6_5"></a><a id="Tc_hTB6tu-mkEWOCm9suLdXqQ_6_8"></a><a id="_1a860abc_ad3a_420c_a20e_391e2266c66f"></a><a id="Tc_QX-PaMQ5F0-mvRTu6WSEWw_1_3"></a><a id="Tc_Y0JmLnbDx0yUDQA-Dj064A_2_3"></a><a id="Tc_7nzrSbH_L02CGPriGb0cOA_3_3"></a><a id="Tc_HM7A5YC_SkSR_3Q1QPrmdg_3_6"></a><a id="Tc_CjGIs0RjT02fdlO6CeaL4Q_3_9"></a><a id="Tc_n6whcyWkYkKXpKybrajh2Q_4_0"></a><a id="Tc_zp1IoFJ7RkuhrTCLwKO11A_5_0"></a><a id="Tc_rRmfoRpzE0aIpmeN92uXcg_5_3"></a><a id="Tc_m2DHSME-zUeSRcXZ1elZdQ_5_6"></a><a id="Tc_VA7JtDNUH0aPU2LnLrRZbQ_5_9"></a><a id="Tc_kOk72_RLtUmx4gGp4E0kNQ_6_0"></a><a id="Tc_2UFLzYJDyU2GYbHof4mhTA_7_0"></a><a id="Tc_qUW2dgMt_kKyQ3KJTbqT5Q_8_0"></a><a id="Tc_XrjxiXC-g06e5iNVjq1_KQ_9_0"></a><a id="Tc___WNsrq16EyzgoOkcMEzvw_10_0"></a><a id="Tc_GWPUlh-UIkuZMm2d3gWcNg_11_0"></a><a id="Tc_uB-_d548vUC88JPl-mQKlw_12_0"></a><a id="Tc_ebpyxbjNWUC2sGp3I7SumQ_12_3"></a><a id="Tc_6uqezoh-cEiwgRYrj-ggng_12_6"></a><a id="Tc_2AHeS4yiakugy2AYcp7YtA_12_9"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_kbxLzpIgi0G-RxnCMrMMrg" continuedAt="Tb_kbxLzpIgi0G-RxnCMrMMrg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">10. Income taxes</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="bcyc:ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock" id="Tb_9JXAqskntUqP3wtRdPYvqg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of net loss before income tax provision are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United&#160;Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_2jeZkgFG80CrLNf69xdSMg_4_3">179,610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_gJQgu9ZbHEG80A9uEHuV0Q_4_6">182,980</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_-xBHEjOaBkOZw93LPbecRQ_4_9">116,275</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United&#160;States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="Tc_Oj5HEhdbMU6tGShg2y-cVA_5_3">5,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="Tc_2egEJbXxQU-pUqHraBFgOw_5_6">3,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="Tc_v7D89GPS3Eie9cj3M1ufXA_5_9">2,034</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_3mPMn8xKmkmZ2NqjAjNlHQ_6_3">173,796</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_vQ_UJFMM_kCC3h3nLBvd5A_6_6">179,207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_AX59XZmcqkaVfalr3ERb4A_6_9">114,241</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_KdEj2ce0SUGfJvL21Itprg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the (benefit from) provision for income taxes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_u5whFZTKqEOqcCxSol3GpA_5_4">283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" sign="-" scale="3" id="Tc_e4aXQWbD6k-c5QPjfqwBoQ_5_7">1,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_rohf023qQkyZnmuz0khmvQ_5_10">2,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_1b2GdkrS2U2gVkNMb_M3tA_6_4">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" sign="-" scale="3" id="Tc_1xwvjSd2bUyb8LG0EF5ucQ_6_7">669</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_hfPfdmavakWL6CzhDaJPzg_6_10">1,404</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_MnXLra4IXkWwHNbE4YeNXw_7_4">461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_l2wUQ3feSkiWBd8Axzdm1Q_7_7">1,849</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_hr8WbpAPKkOW1KVr4wXxOA_7_10">3,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax (benefit) provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_sIQASnEcYEucSJTSquuO8g_9_4">3,772</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="Tc_I2SBvL1qqkyA9_JidWwMOw_9_7">2,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_u10lJgF4C0aKXAewyHxy_Q_9_10">4,111</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_qBIzDxx0i0iF--OG6l2Tpg_10_4">1,454</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="Tc_BWVI5pe5AU6-gNZ-KLNkOQ_10_7">793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_TwMrbI9lUkGgEoqjDZqVig_10_10">865</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred income tax (benefit) provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc__g-nUbdnBUihKebxeDPaMA_11_4">5,226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_NFPvgPFtj0episaBF2sXYg_11_7">3,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_9rQhyiOwskeJbRbWf1wwVQ_11_10">4,976</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total (benefit from) provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_ZbTjy0Osmk-9IoCXki3S_w_12_4">4,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_xdN8nf8KUUeLc8PdW0m0gw_12_7">1,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_bsalgRq-V02weu3lMuX7LA_12_10">1,524</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_6hjGLmJvsEuBWLskixGAEA_1_2"></a><a id="Tc_CVLxluiAJkiHO59Z5MH-aA_2_2"></a><a id="Tc_LG0c48tlfU65ecNBWsb4TQ_3_2"></a><a id="Tc_ElSwXRGuC0yykFgZxx5jBg_3_4"></a><a id="Tc__EsqDu3o5Uq8_laQMZ_f0w_3_6"></a><a id="Tc_SFQQMrd6wkiNyMPGnPXq4g_4_0"></a><a id="Tc_ynFQ9QCqAEOwsvs5mkYJfQ_4_3"></a><a id="Tc_Sczs-ui7B02j-vadjPm7Dw_4_5"></a><a id="Tc_OY3hhaI1mEigmrGPhtqB2w_4_7"></a><a id="Tc_M69KTwXyLEyENSpFdNZ0Ew_5_0"></a><a id="Tc_jL3szEp-x0GPD5ff7dGkkQ_6_0"></a><a id="Tc_GTbiBMCvC0qNBT7ua88hmQ_6_3"></a><a id="Tc_Ck4A7gOR6EWd4N56Xnw3DQ_6_5"></a><a id="Tc_BSdASs4_8U2lZmkfgInFuQ_6_7"></a><a id="Tc_lrbD4ako30Oq3Tjt2xYRyQ_7_0"></a><a id="Tc_9i21RYvCqU69WX8PucIuVA_7_3"></a><a id="Tc_3r64Ufd9eEGGIRy8aidxBg_7_5"></a><a id="Tc_FXaGiEt7A0uPpd64Xha-5w_7_7"></a><a id="Tc_OnX6idMjKEOa59_8t2A-iw_8_0"></a><a id="Tc_eHeQzvpfQ0Kfa1XwBoingQ_8_3"></a><a id="Tc_UwTg-4VXNEaQCeCu5d8Idg_8_5"></a><a id="Tc_t-iM5qFHNkiWV2fGxabuYw_8_7"></a><a id="Tc_jMfQreZz6U6YRIg3fP0J-A_9_0"></a><a id="Tc_YtYpgMaH9kiGak8czums7w_9_2"></a><a id="Tc_snNk4SgLf0i27fpuzS9nZQ_9_3"></a><a id="Tc_hwu-kvtRjEeMB9dXwQgJnQ_9_5"></a><a id="Tc_QYtcWhMpokK7FDofCx4CQg_9_7"></a><a id="Tc_JIHEnTuGak6HyKRp4hH07w_10_0"></a><a id="Tc_Mh4GxUxrDE6-mxGIaXBAjg_10_3"></a><a id="Tc_aoOk_l4eO06vi5c_A5eW0A_10_5"></a><a id="Tc_PBJMKojGrk2uo_Sdd4ofXA_10_7"></a><a id="Tc_9HW-AwQL8EGPM-Dnu2jE_Q_11_0"></a><a id="Tc_BX_V2to4MkGWJx7ji7Fg5Q_11_3"></a><a id="Tc__xs-kF2Ug0eoZuYVhnU3aA_11_5"></a><a id="Tc_swkjUgDb40eHKTTCgonazg_11_7"></a><a id="Tc_iYN9teEsxUycB46NLLa9CA_12_0"></a><a id="Tc_mylBdKDycUqAT0gjlmHycw_12_3"></a><a id="Tc_6thSnfuGNk2R7Z8Echd4Tg_12_5"></a><a id="Tc_iQhQ0v3btUK3Pf1kpyTYYg_12_7"></a><a id="_a01ffa67_1a45_4622_a4f8_f6917ae7d4e8"></a><a id="Tc_ZcXyv_4yoEq-5I9BXaVOOw_2_2"></a><a id="Tc_7O7MKUbOP0-Q5I5u3gNagQ_3_2"></a><a id="Tc_92t87PFTcEqUOedNBW1rDA_3_5"></a><a id="Tc_RsK5qfJExEumK0CaPSrL1Q_4_0"></a><a id="Tc_lq8AQ1YjsUuVZ1MzjemiAA_5_0"></a><a id="Tc_usMRObQ1lkSjGvMEcRGRiA_5_2"></a><a id="Tc_cieC-QzObECAyG4rleMdTQ_5_5"></a><a id="Tc_68VLYCqNqkiUSN3ugU01EQ_6_0"></a><a id="Tc_razT4cfsWUilMmMiDHjIIg_6_6"></a><a id="Tc_W32TBipd0ku3MJuDSrv0tg_7_0"></a><a id="Tc_5TpZXtt4O02ZLggFPKiquQ_8_0"></a><a id="Tc_WAj6-mhprEKaPHCCEGAUQw_9_0"></a><a id="Tc_67EkEKdViUC9Q1-9L4NYjg_9_6"></a><a id="Tc_aFsk6pLBYkyKhYQgqNG4wA_10_0"></a><a id="Tc_sahCfSfYn0i-5614H4tO8w_11_0"></a><a id="Tc_KF8XHmPjPUCHR5X8KMHY1A_12_0"></a><a id="Tc_IOspyNVhPEukqPL4e9pjRg_13_0"></a><a id="Tc_ryJZJCb4pEORRwb0gQaCRA_14_0"></a><a id="Tc_wtFcyuEnZUqbLnjfGBUgiw_15_0"></a><a id="Tc_0WvD5xKgckqjpMviQNthWw_16_0"></a><a id="Tc_-_lTNwoUTki-Zk-xZ14Hmg_16_2"></a><a id="Tc_uZuEG8PMWE2C-DKiMvnp_Q_16_5"></a><ix:continuation id="Tb_kbxLzpIgi0G-RxnCMrMMrg_cont1" continuedAt="Tb_kbxLzpIgi0G-RxnCMrMMrg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the (benefit from) provision for income taxes computed at the statutory income tax rate to the (benefit from) provision for income taxes as reflected in the financial statement is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_gdCOARDkv0iFd-99v1eGdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(Benefit from) provision for income taxes at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_43cEzrWnXkGg3ySrEJYa3w_4_2">25.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_ZSmX18lBj0exuo98oc374A_4_4">23.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_EHTXiCSLt0uq2UmLzOk5qg_4_6">19.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increases (decreases) resulting from:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" sign="-" scale="-2" id="Tc_VFHWsJIaTEG_3Sf2V6xVSg_6_2">3.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" sign="-" scale="-2" id="Tc__wbYHSb-XUmTFU6tMk564Q_6_4">0.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" sign="-" scale="-2" id="Tc_fJBSXh1xmkif8c3pZu-Vpg_6_6">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_bGVafrFGe0Cir7934vxm3Q_7_2">11.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_qM1PrgaIYEen3FuBRZXhow_7_4">14.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_agHGiLlEhESnOVzL5Mtjpw_7_6">16.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net losses surrendered for research credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" sign="-" scale="-2" id="Tc_WEs3w7mce0iJvR0Avvklqw_8_2">14.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" sign="-" scale="-2" id="Tc_ucMWeB99VkuQh7LiRV6-sg_8_4">11.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" sign="-" scale="-2" id="Tc_szFESx5APUyJUdFvRc74Sg_8_6">6.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of statutory rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" scale="-2" id="Tc_DCivsPEMpkad_4EGm_wnmQ_9_4">2.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" scale="-2" id="Tc_weYZcbJYAESald6urcsUag_9_6">11.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" sign="-" scale="-2" id="Tc_ZeixxAG_X0id0MqG1077NQ_10_2">1.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" sign="-" scale="-2" id="Tc_brCUKnnhTUmy0QbfqLAahQ_10_4">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" sign="-" scale="-2" id="Tc_6fIlYsffdU-Bg0CoQAfi5A_10_6">9.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_8naiPfD110uSFqjoQ3_g4g_11_2">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_slHNxSG_NEG83_RT7YlcTw_11_4">1.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_GU63a95DT0WK_ndwFc89cQ_11_6">3.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_EocaulyTZU2Pxk49fl970w_12_2">2.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_AalPjhtw6kKbtpRGc2vdiw_12_4">0.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_aRoa_K96V0qrnImB0M9zuA_12_6">1.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_2GrMTplUT0C3c35ZNCcH7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_6Y57PDBM0UOz_Z-xiho49A_5_3">81,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_gR6S4Exdoka89BULVy6Xsg_5_6">66,555</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_ONJlonS4306hPIaLlXNdOA_6_3">3,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="Tc_sl1bRujbXkSOLaINUuA_ag_7_3">2,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="Tc_f14dQpr5O0C7yqnAhmJ3zQ_7_6">3,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_uGFUU6hqLEaSvr8wKCW5XA_8_3">21,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_Ywf4QotnTkOFLU56y-8KZw_8_6">15,577</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation &amp; amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:DeferredTaxAssetDepreciationAndAmortization" scale="3" id="Tc_BUgqSHr9mEmG_R9JcNFySw_9_3">1,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_79mHoe6orE6WmwDnagNKwA_10_3">1,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_Bpu2NFNtwECgVGkPgROJ2g_10_6">2,742</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_-t5Yc_wmW0eC2UoH7L8Efw_11_3">111,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_3uEhXiSmUEWl2CvIUoatmg_11_6">88,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_6UZ6BNa-WkKlS-fEB-2Zdw_13_3">2,201</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_qGTrQMagOUWGvTurbHrJng_13_6">3,389</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_Tz2WxnixLky3wouvQAaw0A_14_3">2,201</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_zWWO6VnU6UeL4kYyogINKg_14_6">3,389</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_WIyXd33vuU-qScjzwF_rlg_15_3">99,672</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_sd4tsAmzR0iVjFixUFAUVg_15_6">80,274</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_LVq4AJ7goU2qdbVVC_J_RQ_16_3">10,117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_A1VrcDwTp0G-d66ul7uV9w_16_6">4,891</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the years ended December 31, 2024, 2023 and 2022, the Company recorded an income tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="6" id="Narr_Qd4IuEplNUiiB7TCIPGYfQ">4.8</ix:nonFraction> million, an income tax provision of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_aytr3POz1kqRmf8BOP_7xw">1.5</ix:nonFraction> million and an income tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="6" id="Narr_6NREiCwODk2owMWBzslohA">1.5</ix:nonFraction> million, respectively. The Company is subject to U.K. corporate taxation. Due to the nature of its business, the Company has generated losses since inception and therefore not paid U.K. corporation tax. The (benefit from) provision for income taxes included in the consolidated statements of operations and comprehensive loss represents the tax impact from operating activities in the United States, which has generated taxable income based on intercompany service arrangements. Deferred tax assets benefitted in the United States do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s income tax benefit recognized during the year ended December 31, 2024 is mainly the result of deferred tax assets in the United States that do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement, including incremental income tax benefits of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" scale="6" id="Narr_PpiD5hvFhUK34gOPc5HEwQ">3.5</ix:nonFraction> million recognized during the year ended December 31, 2024 related to the completion of a U.S. research and development tax credit study. The Company&#8217;s income tax provision recognized during the year ended December 31, 2023 is primarily related to the completion of an assessment, inclusive of an external tax analysis, during the year ended December 31, 2023, whereby the Company concluded that it is not required to capitalize certain research and development expenses incurred by its U.S. subsidiary associated with contractual research services performed on behalf of its U.K. subsidiary pursuant to an intercompany service arrangement because its U.S. subsidiary does not retain any ownership or rights in the underlying intellectual property resulting from the research services. The change in estimate </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_kbxLzpIgi0G-RxnCMrMMrg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon the completion of this analysis resulted in the recognition of an income tax provision of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInIncomeTaxes" scale="6" id="Narr_Pl6QfYxpL0-g7wlUuE-sow">2.4</ix:nonFraction> million during the year ended December 31, 2023. The Company's income tax benefit recognized during the years ended December 31, 2022 is mainly the result of deferred tax assets benefitted in the U.S. that do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighed the evidence based on its objectivity. After consideration of the evidence, including the Company's history of cumulative net losses in the U.K., the Company has concluded that it is more likely than not that the Company will not realize the benefits of its U.K. deferred tax assets and accordingly the Company has provided a valuation allowance for the full amount of the net deferred tax assets in the U.K. The Company has considered its history of cumulative net profits in the United States and estimated future taxable income and has concluded that it is more likely than not that the Company will realize the benefits of its United States deferred tax assets and has not provided a valuation allowance against the net deferred tax assets in the United States. The valuation allowance increased in the year ended December 31, 2024 by $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_-_kikkayqEyWiELYduyfOQ">19.4</ix:nonFraction> million due to the corresponding increase in U.K. deferred tax assets, primarily due to operating loss carryforwards generated during the year that were not surrendered for research credit utilization. The Company recorded a valuation allowance against all of its U.K. deferred tax assets as of December&#160;31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company intends to continue to maintain a full valuation allowance on its U.K. deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. The release of the valuation allowance would result in the recognition of certain deferred tax assets and an increase to the benefit for income taxes for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change on the basis of the level of profitability that the Company is able to actually achieve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The (benefit from) provision for income taxes shown on the consolidated statements of operations differs from amounts that would result from applying the statutory tax rates to income before taxes primarily because of certain permanent expenses that were not deductible and U.K., U.S. federal and state research and development credits, as well as the application of valuation allowances against the U.K. deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr__Sx-oX8S5ESMJhnrPYjLAg">326.0</ix:nonFraction> million of U.K. operating loss carryforwards that have an indefinite life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes, in its consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. The Company had <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_kpSi7USxAEuBjHKMxjZgwA"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_t8nnLTSubkaW0aLmdFB2rw">no</ix:nonFraction></ix:nonFraction> uncertain tax positions during the years ended December 31, 2024 and 2023. There are <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_2LA40HCXuk6S5irr4LPlEw"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_z1PP4Ecb_U21kcsOYWknwg"><ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_9DQstctoF0aISeTa9Q6ozQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> amounts of interest or penalties recognized in the consolidated statement of operations or accrued on the consolidated balance sheet for any period presented. The Company does not expect any material changes in these uncertain tax benefits within the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the United Kingdom, and in the United States for federal income taxes and in <ix:nonFraction unitRef="Unit_Standard_jurisdiction_Wo3Cb55Vx0GOZokPR6rMjw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5p4e8zASzk6UtchIaZHdrQ" decimals="INF" format="ixt:num-dot-decimal" name="bcyc:NumberOfJurisdictions" scale="0" id="Narr_Ta9ljMymL0CLYjHaXC_oJA">11</ix:nonFraction> jurisdictions for state income taxes. In the normal course of business, the Company is subject to examination by tax authorities in these jurisdictions. The 2023 and 2022 tax years remain open to examination by the HM Revenue &amp; Customs. The statute of limitations for assessment with the Internal Revenue Service is generally three years from filing the tax return. As such, all years since 2021 in the U.S. remain open to examination. The Company is currently not under examination by jurisdictions for any tax years.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_ASd2JGhsa0yCBJ0pIGlvrA" continuedAt="Tb_ASd2JGhsa0yCBJ0pIGlvrA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">11. Commitments and contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In January 2023, the Company entered into a lease agreement for office and laboratory space in Cambridge, Massachusetts. The lease has a contractual period of approximately <ix:nonNumeric contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw" format="ixt-sec:durwordsen" name="bcyc:LesseeOperatingLeaseContractualTerm" id="Narr_iYonqfjMT0q1UL1bjN1Xcg">three years</ix:nonNumeric>, which, subject to certain conditions, may be extended for an additional <ix:nonNumeric contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_DBMF7vfwL0CrLfYOrIL7-Q">two years</ix:nonNumeric> at the Company&#8217;s option. The Company concluded that the lease term is <ix:nonNumeric contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_qjl5jbAot0eKyn11RRQiow" continuedAt="Narr_qjl5jbAot0eKyn11RRQiow_cont1">three </ix:nonNumeric></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ASd2JGhsa0yCBJ0pIGlvrA_cont1" continuedAt="Tb_ASd2JGhsa0yCBJ0pIGlvrA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:continuation id="Narr_qjl5jbAot0eKyn11RRQiow_cont1">years</ix:continuation>, representing the non-cancelable lease period, as it is not reasonably certain that the lease will be extended. The annual rent is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:OperatingLeaseAnnualRent" scale="6" id="Narr_--3OOdkJXkir1RAFnw7lmQ">2.1</ix:nonFraction> million in the first year of the lease and increases annually with the last year of the lease having annual rent of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="6" id="Narr_nPIvQlBYB0C87s3d_SXj8w">2.3</ix:nonFraction> million. The annual rent is payable monthly in advance following a <ix:nonNumeric contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw" format="ixt-sec:durwordsen" name="bcyc:LesseeOperatingLeaseRentFreePeriod" id="Narr_cbbOOGubDkypYk-uLYkN9w">two-month</ix:nonNumeric> rent-free period. In connection with the lease agreement, the Company has delivered to the landlord a security deposit in the form of a letter of credit of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_76qVcDPFvE2JEjDQ5qGyvw">0.5</ix:nonFraction> million. The Company recorded a right of use asset and lease liability of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_U9GxDeemL0OJlwVcfmMpTQ">5.8</ix:nonFraction> million, respectively, at the lease commencement date, based on the present value of future lease payments, discounted at <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_sHN__CmKhkSgKltJfafIVQ">9.0</ix:nonFraction>%, the Company&#8217;s estimated incremental borrowing rate at the commencement of the lease, over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 6, 2021 the Company entered into a lease of new office and laboratory space, in Cambridge, United Kingdom. The lease has a contractual period of <ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_7_XmUdC8h0aJCYWeYcBvog" format="ixt-sec:durwordsen" name="bcyc:LesseeOperatingLeaseContractualTerm" id="Narr_XwtcRAkPBEimRfdrpEePZQ">10 years</ix:nonNumeric>, but may be cancelled by the Company on the fifth anniversary of the lease commencement date. The lease term is <ix:nonNumeric contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_hqEX00ougEqxFWq2nUNbFA">five years</ix:nonNumeric>, representing the non-cancelable lease period, as it is not reasonably certain that the lease will not be cancelled. The Company has a contractual right to renew the lease for a further <ix:nonNumeric contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_RhA9Wod-wEWLbHeDAmJc6g">ten-year</ix:nonNumeric> period, which also may be cancelled after <ix:nonNumeric contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_g-LDGDneREe4ogWdpCDvXg">five years</ix:nonNumeric>. The annual rent is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:OperatingLeaseAnnualRent" scale="6" id="Narr_Scr21G3CckO_TywS7ySuNQ">3.0</ix:nonFraction> million, payable quarterly in advance beginning in June 2022, following a <ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_7_XmUdC8h0aJCYWeYcBvog" format="ixt-sec:durwordsen" name="bcyc:LesseeOperatingLeaseRentFreePeriod" id="Narr_-MVwU4fo2EmsTLscl0VemA">six-month</ix:nonNumeric> rent-free period. There was <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:SecurityDeposit" scale="6" id="Narr_ENns996UekGwjUjmYQpc7g">no</ix:nonFraction> deposit paid in conjunction with the lease. The Company recorded a ROU asset of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_Q96Z0sIgnEaSrv9eZcAjvQ">11.6</ix:nonFraction> million and a lease liability of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_pAhaWq9mFkC9Ec8GUx24Ow">11.1</ix:nonFraction> million at the lease commencement date, based on the present value of future lease payments, discounted at <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_5ENfumMNfUWpWBX5UbTv9Q">6.9</ix:nonFraction>%, the Company&#8217;s estimated incremental borrowing rate at the commencement of the lease, over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2017, the Company entered into a lease agreement for office and laboratory space in Building 900, Babraham Research Campus, Cambridge, U.K., which was renewed in December 2021 for <ix:nonNumeric contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_ZlFOGbDJAE6FE-OQbaU4iQ">five years</ix:nonNumeric> through December 2026. The annual rent for the lease was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:OperatingLeaseAnnualRent" scale="6" id="Narr_oNVGWBRnzEyhxTw58y8Ehw">0.6</ix:nonFraction> million. Service charges were also payable based on floor area and are estimated to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:OperatingLeaseAgreementEstimatedServiceCharges" scale="6" id="Narr__RMt6ukv_0izKwLvfILAfw">0.2</ix:nonFraction> million per year. In April 2023, the Company entered into a deed of surrender related to the lease, pursuant to which the lease was terminated effective immediately. As a result of the deed, the Company derecognized the lease liability and right of use asset associated with the lease. The Company also paid termination-related fees of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_fLJS0eBl9EOeJzgPO_7mZA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="Narr_NpG5v4o6vUWOR8ys0fp3WA">0.3</ix:nonFraction> million in connection with the deed, which were recorded as a loss on lease termination and are included in operating expenses in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2017, Bicycle Therapeutics Inc. entered into a lease agreement for office and laboratory space in Lexington, Massachusetts, which commenced on January 1, 2018. In conjunction with the lease agreement, Bicycle Therapeutics Inc. paid a security deposit of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_9_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_ATqayKrwE0yk5TqZ6Qd3VA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_Dt5bM3DJ8kGRGQWRTbeMCQ">0.2</ix:nonFraction> million. The deposit is recorded in other assets in the consolidated balance sheets. In March 2022, Bicycle Therapeutics Inc. notified the landlord of its intent to exercise its option to extend the lease, originally set to expire on December 31, 2022, for a successive period through December 31, 2027, which successive period was not included in the original lease term. The Company accounted for the change in lease term as a modification of the existing lease and remeasured the ROU asset and lease liability by calculating the present value of lease payments, discounted at <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_NG89CENXf0WsYpj98IPH8w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_6fWAZXcLhUadBndMkHH9hA">7.0</ix:nonFraction>%, the Company&#8217;s incremental borrowing rate at the date of the modification of the lease, over the remaining lease term. In May 2022, the lease was extended. The payments for the extended lease are approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_SGS5MZDDqEWSBRcvMGqfGg" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" scale="6" id="Narr_j_m_3iwoPke1_lVV78fvdw">0.2</ix:nonFraction> million for the remainder of 2022, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_Jlm0mrvCf0W3IJVZZ2e3GQ" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" scale="6" id="Narr_rKj262Czu0eK4hYUYgsNdQ">0.7</ix:nonFraction> million in 2023, and increases annually pursuant to an escalation clause with the last year of the lease term having a per annum fixed rent obligation of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_NG89CENXf0WsYpj98IPH8w" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:OperatingLeaseAnnualRent" scale="6" id="Narr_oSYfbA6paE6BZ9A1zEWDNg">0.8</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Finance Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>From time to time, the Company may enter into finance lease agreements for property and equipment. As of December 31, 2024, the Company recorded finance lease right-of-use assets of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="Narr_TOAKZzLB30ihy_hzT1j3Lw">1.0</ix:nonFraction> million, which are included in <span style="-sec-ix-hidden:Hidden_89Xiz3lIwU210xUHlqxyBQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property and equipment</span></span>, net, in the consolidated balance sheets. As of December 31, 2024, the Company recorded finance lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="6" id="Narr_lhjqQqGqXECUwz0vPD7xMQ">1.0</ix:nonFraction> million, which are included in <span style="-sec-ix-hidden:Hidden_SQ4PzHGMvEedzinnZFOhqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accrued</span></span> expenses and other current liabilities and other long-term liabilities, as applicable, in the consolidated balance sheets. <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="Narr_5yIxaPLhVECaeG2X7EoHOw">No</ix:nonFraction> finance lease right-of-use assets or <span style="-sec-ix-hidden:Hidden_o8BOhRO22E6Ob_Qt--G_Gg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities</span></span> were recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9308de27_7d5e_42ae_a1d8_133324581b59"></a><a id="Tc_KaC1fcuISEm8slva0PQTGg_1_1"></a><a id="Tc_8ET7RNTwYkuw_AbGC_UC2g_2_1"></a><a id="Tc_1R517BnxMUyrmwwHvVzIAA_3_1"></a><a id="Tc_P3pU-NpvZ02tkAAkuyErhw_3_4"></a><a id="Tc_tiRKLb3ZSEqFRVmEzaLYXw_3_7"></a><a id="Tc_kDFgUwqVMkSX9UiSONBkYA_4_0"></a><a id="Tc_d3cgqqz-u0qt-F0M61qFWg_4_1"></a><a id="Tc_gDNbFAOUQUeVyAwtXe564g_4_4"></a><a id="Tc_-m0U4z4lbEe5gqvCm0GFYA_4_7"></a><a id="Tc_t66uSY3V10up39JV_mk3DA_5_0"></a><a id="Tc_gyDoSGwoHEm8XP82JxcHww_6_0"></a><a id="Tc_ZzaU0A-RCkCkhlohGbSokA_7_0"></a><a id="Tc_dkSQduKZdk2eajxzwTyoKg_7_5"></a><a id="Tc_XEGeQomCIUy27HVNyIgw9g_7_8"></a><a id="Tc_dmk8ekNdPUqY74jN7-mCCQ_8_0"></a><a id="Tc_iJOSrLhVAUCx1i0ZFWtk1g_8_5"></a><a id="Tc_X67N8Rj3AkWiMhb5ZjfZVQ_8_8"></a><a id="Tc_IEIRMymXbEu6t2bFt1c0Bw_9_0"></a><a id="Tc_FAD4t9E9KUCB9TJQJuwvWw_9_1"></a><a id="Tc_CUQRHQvxBUi-7DXwLieRpQ_9_4"></a><a id="Tc_7utIVPuh4kmjvjQ-fcYN4Q_9_5"></a><a id="Tc_ytDCDaAIO06lPD3L7lng3w_9_7"></a><a id="Tc_vtvkyzCr70qCtXdSeAAyCA_9_8"></a><a id="_18e81768_104f_4df2_bbb5_7c0e7db1af3b"></a><a id="Tc_6nlxO_Ut6Ui7DYgRkc_cUw_1_0"></a><a id="Tc_edXkTN7lakmnhWHxw9C82g_1_2"></a><a id="Tc_av4M8-pia0SPVXsle7CVaw_1_5"></a><a id="Tc_V0glKcWYQkuW6FWGB8LXDQ_2_0"></a><a id="Tc_GwA-PQX8PU-hVq4zMsONhg_2_2"></a><a id="Tc_sV74sn20H0mSBMW_NZ1GNw_2_5"></a><a id="Tc_s9wMd32gr0iwTkLqUKhFzg_3_0"></a><a id="Tc_Ia9pkuTMokGKSHGC_cttHQ_4_0"></a><a id="Tc_-RtAzbKJyECpLeSTJpboFQ_5_0"></a><a id="Tc_nJ6TozEd7k2Ei1ORM7pniA_5_3"></a><a id="Tc_w59AeV11f0-3BWnRIrbbGA_6_0"></a><a id="Tc_rYKnEL32x0mlj5ymI10nSw_6_3"></a><a id="Tc_l3s6oo7ggUyht7bFd7xQxA_7_0"></a><a id="Tc_U-EADzzPI0-uNV2lJwLUBw_8_0"></a><a id="Tc_Q1jW6qG9WEuESoxOV30_Nw_10_0"></a><a id="Tc_8ntE6vG_RU-buOFjgdg9aA_10_2"></a><a id="Tc_2qKtuyJC0Uil2F-FEsbR_g_10_5"></a><ix:continuation id="Tb_ASd2JGhsa0yCBJ0pIGlvrA_cont2" continuedAt="Tb_ASd2JGhsa0yCBJ0pIGlvrA_cont3"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:LeaseCostTableTextBlock" id="Tb_iWOZdHfoWkClhYm91SpugA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the Company&#8217;s lease expense are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_h69muI7E5E-nkiN7Us5RTg_4_2">5,299</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_2Oqev_biBUij8EH-S9cBFA_4_5">5,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_E37o8pXTAEGirE98ZygdDA_4_8">3,790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_fWOQmflCx02PMrvAVHkGeA_5_2">2,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_uTXvIk08gU-SQaPPP5MBng_5_5">2,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_CZwPg0r90UOy71ktHOQ_lw_5_8">1,643</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_CmybGp6egESQA0aA7vI3QA_7_2">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_HXCAMv2m_UWSHF6jz1rPNQ_8_2">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:FinanceLeaseCost" scale="3" id="Tc_1DD_TICX_Euyt1pg4__auQ_9_2">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining operating lease term was <span style="-sec-ix-hidden:Hidden_lYaA-73yc0O8cmcTzPPaEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.0</span></span> years and <ix:nonNumeric contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_DJugmSt9hU6Xxw-JOyFCQg">2.9</ix:nonNumeric> years as of December 31, 2024 and 2023, respectively, and the weighted average operating lease discount rate was <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_SKmccdSFGkeCGMoX8sA5Jw">7.8</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_h2rN1qIanE2Qse2d2ibHaw">7.9</ix:nonFraction>% as of December 31, 2024 and 2023, respectively. The weighted average remaining finance lease term was <span style="-sec-ix-hidden:Hidden_Rcc02-kBPEezAjTVUU7wRQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</span></span> years as of December 31, 2024, and the weighted average finance lease discount rate was <ix:nonFraction unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_TOQuLnkh_0yzUoeehbmG6A">9.5</ix:nonFraction>% as of December 31, 2024.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_80txg3OVC0i_oocQipLsMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the maturities of the Company&#8217;s lease liabilities as of December 31, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ending December 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_uUVlR9p3Z0md-goZ9jg3bQ_2_3">5,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_6RHmIkjmMkGTpmfgRIQIqg_2_6">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_YWp8lrpa6kOTW8aKQMttDA_3_3">3,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_OFnJzsF-QUaKMMeUBnkxGA_3_6">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_DcqLwWt1zU6-_JKxj3Ka2A_4_3">821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_Pm46uzU1Vk-xRSpQ9Kq_qg_4_6">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_ThOOZDUVHE-xtygiusNMlg_5_6">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_E8PbViFhJ0mDND9VKPRbyA_6_6">192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_FWTIqLlLe0Wi3Ki7rYW-lA_7_3">646</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_6u8mwBD6u0WjrPT349JA7Q_7_6">224</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_QBDxk7aTXk6zZqvUzMXQIQ_8_3">9,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_p61stqV6AUShAp-8yjG43Q_8_6">992</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_u8XOnpcF106LEEpbmUkWMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Less: current lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_sapSwDlxNk6JBudS7yfVJA_9_3">5,328</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_Yh02fTIrFEOhQudh7ZeYAw_9_6">175</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_iG2r8ypWvEClG9Pro8L6wQ_10_3">3,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_yFa8tXoOB0266TTlI2WhjQ_10_6">817</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various agreements with contract research organizations to provide clinical trial services, contract manufacturing organizations to provide clinical trial materials and with vendors for preclinical research studies, synthetic chemistry and other services for operating purposes. These contracts are generally cancelable at any time upon less than <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" format="ixt-sec:durwordsen" name="bcyc:MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" id="Narr_vvOv2Q3TlUWyBhrD2XlAPA">90&#160;days</ix:nonNumeric>&#8217; prior written notice. The Company is not contractually able to terminate for convenience and avoid any and all future obligations to these vendors. In some cases, the Company is contractually obligated to make certain minimum payments to the vendors, based on the timing of the termination notification and the exact terms of the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">T<span style="background:#ffffff;">he Company has also entered into separate agreements with third parties which provide for various future milestone payments upon the achievement of specified development, regulatory, commercial and sales-based milestones with an aggregate total value of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_AgreementWithThirdPartyMember_cjzTWIaOY0KrEHYqPIpAew" decimals="-5" format="ixt:num-dot-decimal" name="bcyc:CollaborationAgreementFutureMilestoneContingentPaymentsPayable" scale="6" id="Narr_h5jAglAhw0Or8gT7q6cS_A">166.2</ix:nonFraction></span><span style="background:#ffffff;"> million, as well as potential future royalty and other payments at percentages ranging from very low to low single digits.</span> These additional milestone payments are contingent upon future events that are not considered probable of achievement as of December 31, 2024. As of December 31, 2024, the Company was unable to estimate the timing or likelihood of achieving these milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Legal proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company or its subsidiaries may become involved in various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. The Company is not currently subject to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of ASC 450, <i style="font-style:italic;">Contingencies</i>.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ASd2JGhsa0yCBJ0pIGlvrA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Indemnification obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has indemnification obligations towards members of its board of directors and officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. In addition, the Company has agreed to indemnify certain investors in limited circumstances. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2024 and 2023.</p></ix:continuation><a id="_e46fe11e_f9d4_4fd6_b134_bbde8bcab066"></a><a id="_b3514873_1848_4d07_ab90_f2f6be120e64"></a><a id="Tc_2Y7XeSdL2EOlLvkrx3MeYw_1_2"></a><a id="Tc_pQ0neiTUoky7LIdM0hAN9w_2_2"></a><a id="Tc__p_ox8-P2UGmzWoFG2Notw_3_2"></a><a id="Tc_wwkDbR3GekSQknMCIk6rew_3_5"></a><a id="Tc_gR7n6_UWoESuIO5O6S2HGA_3_8"></a><a id="Tc_leCLAFCpe0eTkirpa1Foww_4_0"></a><a id="Tc_YYuICdOjrEKdPHcLWGa2gQ_5_0"></a><a id="Tc_SowaPvOvwUCrPJmNQGuo5A_5_2"></a><a id="Tc_sRmg3L4wWkGd4sOkTiRChQ_5_5"></a><a id="Tc_6fktFacxa0CzCcuy5kdJQg_5_8"></a><a id="Tc_A-wMP_gDrEiK_XE61kFYVw_6_0"></a><a id="Tc_Nse9o34iJkai49jr9OhWLQ_7_0"></a><a id="Tc_-nqbSNjTeEebZzQsCqITyw_8_0"></a><a id="Tc_rlGDvCsX0EW7H6pDADBtKg_8_2"></a><a id="Tc_kk-icizYckypzy5bG5yb2w_8_5"></a><a id="Tc_98X_eXy-z0-rKsK2xopduQ_8_8"></a><a id="Tc_QkOklbdkJk-bW9VwSHdsnA_1_2"></a><a id="Tc_zihmM2R8mEyZbFeSudYmyw_2_2"></a><a id="Tc_5-82OVUlgEKZNmklYDuoLQ_2_4"></a><a id="Tc_DNv0kZO7I0uFVJ7XRAsBdw_2_6"></a><a id="Tc_RkTvvh7E8kKpm14l0dDoDg_3_0"></a><a id="Tc_D7o-zIiIzk2Ru6lHEQA1dg_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_n_mli4MNJU6N_kIgTvQybg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">12. Net loss per share</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_zwAXgOZgpEmCzunjd5dINQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_CjbwmaXD50aOTuaTdVErJQ_5_3">169,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_mgMpr1udeEubUiodxr8dyw_5_6">180,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_y_Md6kJqWkWnR4a5TaTalA_5_9">112,717</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average ordinary shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_xpmLDKl_v0GeErm1A0IMPg_7_3"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_xpmLDKl_v0GeErm1A0IMPg_7_3_2">58,207,593</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ZYAUe0NBl0q37huiz2HLgg_7_6"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ZYAUe0NBl0q37huiz2HLgg_7_6_2">35,592,362</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_bvCaQSRccEWFLNRARyH7Mw_7_9"><ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_bvCaQSRccEWFLNRARyH7Mw_7_9_2">29,660,659</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_13dEY_wR6UWAW5u3s8L_1g_8_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_13dEY_wR6UWAW5u3s8L_1g_8_3_2">2.90</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_xNRtpy-pckePFATbLPf1CQ_8_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_xNRtpy-pckePFATbLPf1CQ_8_6_2">5.08</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_4ac3f-Yw5UuJCjuBB-DVXg_8_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_4ac3f-Yw5UuJCjuBB-DVXg_8_9_2">3.80</ix:nonFraction></ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potentially dilutive securities, which include options to purchase ordinary shares and restricted share units for ordinary shares, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of ordinary shares outstanding, which includes both ordinary shares and non-voting ordinary shares, used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potentially dilutive ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_n_QagbIRIU2mEmiqna4KbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_RMsDq0ZFvE2Wx7B1y-0u5w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_0Ow_ZhiZEE64d49OW1lNdA_3_2">716,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_n-D9Cq5DWkCzJZg9ZJYbnA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_OOyVUr-mZE6iCxylsranBw_3_4">326,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_4N9eS-gJjkuSY1TcnrqmKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_W2N71mCudES-oCpK7ILYPA_3_6">187,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s2IO880e1061sN4EIeiaUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8KKF4Qvw50mD1wVpQjjaKA_4_2">8,748,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m2jh4dTe1k6tiJLwVhJUjw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_dZCdiJcCCUSc1sTySq7R5A_4_4">7,469,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b9GnNZBmAkmTdN5HqzSMxQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_wEoG5ITvvE-O6VfCJYdt_A_4_6">5,898,888</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_q1lgWLINFkaxkfPqNl0Ygg_5_2">9,464,988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_rsd-pzfi6UG0xgalb-FWWw_5_4">7,796,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_95w0XlfaLUePTHahm3-e4g_5_6">6,086,613</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_2w9nCYUNMUSY4Z9cxagtvw" continuedAt="Tb_2w9nCYUNMUSY4Z9cxagtvw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">13. Benefit plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company established a defined-contribution savings plan under Section&#160;401(k)&#160;of the Code (the &#8220;401(k)&#160;Plan&#8221;). The 401(k)&#160;Plan covers all U.S. employees and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of the Company&#8217;s board of directors. During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company made contributions totaling $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_NRO15gR8R0C1PGFIWwvPqg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_EblZp2j34UCn6MUsmC0KFw">1.1</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_arXRVu5ZWUSBIuONzGMp-A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_wu8IEVj9tkyr8UhTJUpwHg">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_PvHkFyAfO0qLp2QAqJ7T7g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_vpeS0hX0lkuSTzLucFWXWA">0.5</ix:nonFraction> million, respectively, to the 401(k)&#160;Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides a pension contribution plan for its employees in the United Kingdom, pursuant to which the Company may make contributions each&#160;year (&#8220;U.K Plan&#8221;). During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company made contributions totaling $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_9GER_6W-HkqnPxCUmp0fyA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_SUnwg72mX0-F1wSygQEoDA">2.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_pS-QJkjLfUGnpbmjfIIQ7w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_8GcdW_yO1U2MRYJ7zAmMbg">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_-W-mugKxsU2yACc1ikbSBQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_U-vGO0YKaEWC42s3VT0oPg">1.4</ix:nonFraction> million, respectively, to the U.K. Plan.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2w9nCYUNMUSY4Z9cxagtvw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_Llt80H765kmxrevTpGaufw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">14. Related party transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Consulting Agreement with Stone Atlanta Estates LLC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Chairman of the Company&#8217;s board of directors is associated with Stone Atlanta Estates LLC, the successor-in-interest to Stone Sunny Isles Inc., which provided consultancy services to the Company totaling $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_VGLTprSZ00ajPx_iwKZOCQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="Narr_8w1P9OmZs0ObrLzAMzO7HA">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_87Upa33xjkaMN_hOb2X7Ag" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="Narr_mrex0tOXzki1gmFMNYUrKA">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_ypWL3awvzEqfgXwFXfo9UA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="Narr_WnLdE68emkSjKrQ8GcJ04A">0.2</ix:nonFraction> million during each of the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Related Party Participation in Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Investors in the Private Placement included certain entities affiliated with Baker Bros. Advisors LP (the &#8220;Baker Entities&#8221;), an entity which may be deemed a beneficial owner of greater than 10% of the Company&#8217;s voting securities. Felix J. Baker, one of the Company&#8217;s directors, is a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP. In the Private Placement, the Baker Entities purchased an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_y0EPkZSaVU-zndPzJODGAA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_BUTBuU2Rb0CB2KXEae1tag">17,114,846</ix:nonFraction> non-voting ordinary shares, nominal value &#163;<ix:nonFraction unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_y0EPkZSaVU-zndPzJODGAA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_o5CmUgrpD0q1xNny0kS88g">0.01</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_2q8U443nOk6gQC6m8b41-A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_e0ee5Pr-Y0SYQ9mIrgrdYg">366.6</ix:nonFraction> million. The Private Placement was approved in accordance with the Company&#8217;s related person transaction policy by the Company&#8217;s Related Parties Committee. See Note 11. &#8220;Commitments and contingencies&#8221; for additional information on indemnities provided to certain investors.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_fIJW9jVTzkacxSgKdL7Dvg" continuedAt="Tb_fIJW9jVTzkacxSgKdL7Dvg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9ce081aa_292f_4f83_a5a8_512e424266eb"></a><a id="Tc_ECXgYtB4u0-IUH8MFWhRbw_1_2"></a><a id="Tc_zjUujYFJiEqzdrR4lEwqnQ_2_2"></a><a id="Tc_Ic1Fkq5uw02dpifX9JEQ2g_3_2"></a><a id="Tc_HjF6NGchOkuJGpxu5JRglw_3_5"></a><a id="Tc_zX7AIOy_HkeqeOmrwYGFqw_3_8"></a><a id="Tc_gEaFttSQwUGe9Ji5Nzs7IQ_4_0"></a><a id="Tc_fwp51ZrdVEG0ZE3bLAc9Dw_4_2"></a><a id="Tc_96lmqCY1hUWTmWRBAF5-Sw_4_5"></a><a id="Tc_Y0GA4bvgz06-ZpjCsGGnWQ_4_8"></a><a id="Tc_c3-YYKlOBEakRamn3uNcyQ_5_0"></a><a id="Tc_2KV0KByi9EusIxIM_O2jWA_6_0"></a><a id="Tc__1Yfwl58T06D-ma8HSIFfg_7_0"></a><a id="Tc_eM8XNHyPZk2Er-U3p30H2A_8_0"></a><a id="Tc_nHRWKGJYNE--0LOAu2_sHw_9_0"></a><a id="Tc_STFS7N6MoUao5IS_rcfpLQ_10_0"></a><a id="Tc_Ie3GTNiCYkq-3BrOtposew_11_0"></a><a id="Tc_bIb6c1avYU25sfFtn9WN0g_12_0"></a><a id="Tc_EOtBgnGiYUSD3PF-fp9BrQ_13_0"></a><a id="Tc_8FojdaPAyU-Ytm_Ku3q72Q_14_0"></a><a id="Tc_XqGdv7ngPkWV0lEw4C-DQQ_15_0"></a><a id="Tc_lQQbv5FT10KhAqYhIAtPSQ_16_0"></a><a id="Tc_z46vm_NCi02eJbnrv4b29A_17_0"></a><a id="Tc_wLeD9ziyi0KoTvr9McLu4g_18_0"></a><a id="Tc_DmeA1bDXyUutHQV7_rOljg_19_0"></a><a id="Tc_mZ7o0mzP80Kcz1S04IgVFA_20_0"></a><a id="Tc_8aXNqcrOTUKo2qN5wl5t5Q_21_0"></a><a id="Tc_FZUZpbqmzU2cICoQQbSJ3Q_22_0"></a><a id="Tc_SvvajWZkWUKYFPuLFAG2lg_23_0"></a><a id="Tc_dkHZ_dlj3kGkM0xR8iEdSw_24_0"></a><a id="Tc__ep-7BJ1hUe93L2m-WHZ-g_25_0"></a><a id="Tc_0Am2lVulwUKOLXLw35djDg_26_0"></a><a id="Tc_fsuuBa0DyUmAj6H3MU2jlA_26_2"></a><a id="Tc_w5xVdRqgb02w-6Xwf_9how_26_5"></a><a id="Tc_u4LoyNqevEi5chDqTJWOQg_26_8"></a><ix:continuation id="Tb_fIJW9jVTzkacxSgKdL7Dvg_cont1" continuedAt="Tb_fIJW9jVTzkacxSgKdL7Dvg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">15. Segments and geographic information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;). The CODM reviews consolidated operating results, manages the business on a consolidated basis and utilizes consolidated net loss from the consolidated statements of operations and comprehensive loss as the primary measure of segment profit or loss in making decisions surrounding allocating resources and assessing performance of the Company. The CODM is regularly provided detailed expense information, including expenses by program and expense category, and the CODM makes decisions surrounding capital and personnel allocation using this information on a consolidated basis.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_SYKNwHkpw0yevzyxb3oepA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s single operating segment, including significant segment expenses, for the years ended December 31, 2024, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_8ANx4ISMhEu_f6cytaDtgA_4_3">35,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_jz1PsxS8Y0qLBFNyLcfRsw_4_6">26,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_RxWiSjMhvUSMo_t90M_SGQ_4_9">14,463</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Significant segment expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Zelenectide pevedotin (Nectin-4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_gUaCXINS2kCBhTYjLBFLvQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_0eI7I4REeEONbc01L5u1Iw_7_3">82,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_DUUmLvrM0Ua-IV4gtEO4dw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_8sZhCW2WmkyLrF-mobulCg_7_6">44,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_EDbD_nwgWEm3h1bnui3JPw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_GKlH3FO3gE66AGy1gTyc3A_7_9">11,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">BT5528 (EphA2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_qWduzYXktEC6ieFWheazqQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_VUxFpYUJGEexD-Psue-ThA_8_3">9,119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_m8NGtuG9hEuc-Q3am5BHDQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_kDlv7FNciUqYVgfkOcChPw_8_6">9,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_QCbJPntYS0mr7VXNm13-GA" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_kCGyyxXGeUiFo05fzCnoVg_8_9">10,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">BT1718 (MT1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_NYezOdO0N0G3gVUx6-pWmw" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_AFT3JeWMyUGUGMvm4gDDzg_9_3">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_Tw08wGHpiE2_uOJjC2Yifg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_iM2pbtifaECcliKsW0g9Mw_9_6">520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_TGvFsvJDaU-Z2goQUm6szg" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc__xT1mXyAW0arxmEYpjC6DQ_9_9">692</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bicycle tumor-targeted immune cell agonists</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_10I2hU65G06H9LVN1JzgNQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_w-2gJPXNI02HR75ioYH9nw_10_3">7,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_uoSoJfk0zkCYReunHXtq8g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_mCt08ITHikmqTFmk47vutw_10_6">18,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_SE-anRzrlEiUC4bJHOOjnQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ProjectSpecificCosts" scale="3" id="Tc_MReONNRQ0EOARBfTPtvEhQ_10_9">11,268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Discovery, platform and other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" scale="3" id="Tc_3vFisiQ5ikyUh413QzJoMw_11_3">30,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" scale="3" id="Tc_Pr6yEL7OGkiQIYWQ55RCEg_11_6">37,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" scale="3" id="Tc_-zMLES90HEK6xJZR34sGQQ_11_9">21,811</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Employee and contractor related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" scale="3" id="Tc_sgf4yikXu0OKeuM9ddh8Ug_12_3">58,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" scale="3" id="Tc_P89Vxsn3606PR_GP3VESvg_12_6">46,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" scale="3" id="Tc_zqB59uq8DU-Bga3BxelBpQ_12_9">31,346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense" scale="3" id="Tc_Vo33iTx7tEalK8Keln20jQ_13_3">19,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense" scale="3" id="Tc_imnWWPmuQ0m18qO-NVdAlg_13_6">15,581</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense" scale="3" id="Tc_ULgaHr_tXUmY-ITAZVSRSw_13_9">10,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:FacilityExpenses" scale="3" id="Tc_PrURAKUbj06wlroEfDyHUA_14_3">8,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:FacilityExpenses" scale="3" id="Tc_BjeRQSu8g02vK3IIJxlj_Q_14_6">8,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:FacilityExpenses" scale="3" id="Tc_NPV24KWpRkalehhyPk7V4g_14_9">5,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development incentives and government grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" scale="3" id="Tc_Ch8rxCBH2EiVjhfziqb23Q_15_3">43,207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" scale="3" id="Tc_dsy4X4UrYEm7pqyXywDXzA_15_6">24,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" scale="3" id="Tc_6ERsm16NpEejrNaw-1lghA_15_9">20,813</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Lxl9wrdr6k6oyqtoxOqnqQ_16_3">172,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_jlvf18-RfUCOIckA1Tft6A_16_6">156,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_KVtydc5Do0i6kffGcmRjOA_16_9">81,609</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel-related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_4azdw_UFAEuWvJVkpfJjwQ_18_3">23,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_nVSe_zYkz0agfDc0DmqXDw_18_6">18,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_CBzFp7Y5YEqUrA9Syr02cQ_18_9">13,948</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="Tc_zFx_y23YFE-hOj7Cv4UZZQ_19_3">20,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="Tc_Z5OfoZ0dGUi_CMSZqM7xJg_19_6">14,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="Tc_A6jZbFqYCU-xtuKyCGzqfw_19_9">9,836</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other general and administrative costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_RbegqlaTj0ics6BjrmMidQ_20_3">9,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_QNv2lgcF-USye7I_zNpP9g_20_6">9,137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc__PrDa4A1XECu6L-Wj-xdPg_20_9">8,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense" scale="3" id="Tc_pkQWO1F91EmY2m9EqQd50g_21_3">18,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense" scale="3" id="Tc_t_AvtFspfUKW6-fsmBDf5A_21_6">16,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense" scale="3" id="Tc_dHctzYtXg02_6kpRUloH0w_21_9">16,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Effect of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_M-ujDy6wtUaxET84NA9uyw_22_3">719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_0HReeK26_Ue94inJXFrBMA_22_6">594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="3" id="Tc_XKhSc2w9PUiY5YCZGEe_8w_22_9">555</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_VVM5FlN9OEyH16CTZJpv8g_23_3">72,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_bqeBI6aepEqC3b8S6x6yxw_23_6">60,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_OUv-k0p8fUCZceWjoW5Uwg_23_9">49,507</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total significant segment expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_-s0H6ePmbEu9sjAAQBQXCA_24_3">245,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_JSLhdv1Wkk-_KoTFD4CWhA_24_6">216,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_uZGSvXP4D0GtQ21Cb-u32A_24_9">131,116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_D3hWTFpx1UygzWGz7JxcPQ_25_3">40,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_ycRn0qfpHEqGvueJcXkpOQ_25_6">9,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_chqnIn8PWEKemMYQUGlv-g_25_9">3,936</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tVvJGFn7N0mW7kX7UJPTAg_26_3">169,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oB19mQN75ke2WWXs3vORAA_26_6">180,664</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YDjen0LSCkSHTJ2mlbQz6A_26_9">112,717</ix:nonFraction>)</p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Other segment items include interest and other income, interest expense, loss on extinguishment of debt, gain on extinguishment of research and development funding liability and (benefit from) provision for income taxes.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not regularly provide the CODM with detailed segment asset information other than what is included in the consolidated balance sheets. Please refer to the consolidated financial statements and the accompanying notes to the consolidated financial statements for segment asset information.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_iJnNjt3Ab0G9Dj_v_8tYcg_1_2"></a><a id="Tc_1WgryohjBUGhBnzr4-v5Tw_2_2"></a><a id="Tc_WYjksM64hUGZrQ1YnA9_cw_2_5"></a><a id="Tc_zjWjULr4rEGGt9AqxSYztA_3_0"></a><a id="Tc_qBRr5En4DESqr5GgaEQADg_3_2"></a><a id="Tc_QCAUXaANFUuS89FEdfsYxQ_3_5"></a><a id="Tc_5PHBx8AO5EiJNEtTrEmk7g_4_0"></a><a id="Tc_YCz1ldUpEECPGfIEU3jm9A_5_2"></a><a id="Tc_VHUtiZwSh06c37KRJuUwGw_5_5"></a><ix:continuation id="Tb_fIJW9jVTzkacxSgKdL7Dvg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company operates in <ix:nonFraction unitRef="Unit_Standard_segment_Im4dTiIF5UiSe0qPdBr-ew" contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_rBISI5BhE0iLd3fwRRVAYw">two</ix:nonFraction> geographic regions: the United States and the United Kingdom. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="Group_9M050xE47E2qkC-ZU25k0w" continuedAt="Group_9M050xE47E2qkC-ZU25k0w_2" escape="true">Information about the Company&#8217;s long-lived assets, including operating lease ROU assets, held in different geographic regions is presented in the table below (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_9M050xE47E2qkC-ZU25k0w_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_Emy5XN272EGkU-HVUNZzhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_Xl5Rl_QDsU-7091gdRq7wQ_3_3">3,037</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_QMFxV79NjE6OHW4kO9biSA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_hJ4EkOVvoEiptlPH3noYSg_3_6">7,486</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_FM8UcsJ6oE-QbWuVRXzXKA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_GzS8-529o0SRRbPWhaaZgw_4_3">14,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_GB_wdbEmUAGK06mdxOOtgPJ8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_-j2OTEZipkiN760umVITHQ_4_6">20,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc__cXx4ubPtE-lB4ZpwNBlcA_5_3">17,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="3" id="Tc_hz6yQU0BPUC0DUJLvtmV7A_5_6">27,684</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s collaboration revenue is attributed to the operations of the Company in the United Kingdom.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_RRMvW6gVQUiJLu8204yslg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">16. Subsequent events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2025, Genentech provided the Company with a notice of termination for Genentech Collaboration Program #4, effective in March 2025, and the Company expects to recognize revenue of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA" contextRef="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ObVPQDakX0Kipqu1I4B_ig" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_aOo44z4Ssku8bwnOIXZAkg">7.4</ix:nonFraction> million of deferred revenue allocated to the material right associated with the LSR Go Option for Collaboration Program #4 in the first quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bb1fad59_92d3_4f8a_b903_b78d33d5ec89"></a><a id="SIGNATURES_280864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Bicycle Therapeutics plc</b></p></td></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: February 25, 2025</p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Kevin Lee</p></td></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kevin Lee, Ph.D., MBA</p></td></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/Alethia Young</p></td></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alethia Young</p></td></tr><tr><td style="vertical-align:top;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (Principal Financial Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="POWEROFATTORNEY_259162"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Each person whose individual signature appears below hereby authorizes and appoints Kevin Lee and Alethia Young, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.15pt;"><td style="vertical-align:bottom;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:2.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:38.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:38.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Kevin Lee</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chief Executive Officer and Director </p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Kevin Lee, Ph.D., MBA</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Alethia Young</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Alethia Young</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Financial Officer)</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Travis Thompson</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chief Accounting Officer</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Travis Thompson</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Accounting Officer)</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Pierre Legault</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chairman of the Board and Director</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Pierre Legault, MBA, CPA</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Felix J. Baker</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Felix J. Baker, Ph.D</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Janice Bourque</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Janice Bourque, MBA</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Jose-Carlos Gutierrez-Ramos</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Jose-Carlos Gutierrez-Ramos, Ph.D</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Richard Kender</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Richard Kender, MBA</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Stephen Sands</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Stephen Sands, MBA</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">/s/ Sir Gregory Winter</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">February 25, 2025</p></td></tr><tr><td style="vertical-align:top;width:31.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">Sir Gregory Winter, FRS</p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:38.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:33.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A</p></div></div></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:33.97%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>bcyc-20241231xex4d6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:17 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 4.6</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#39;S SECURITIES</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The following describes certain material terms and provisions of the ordinary shares with nominal value of &#163;0.01 per share of Bicycle Therapeutics plc (&#8220;Bicycle,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) which are represented by American Depositary Shares (&#8220;ADSs&#8221;) with each ADS representing one ordinary share that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The description summarizes relevant provisions of English law, including the U.K. Companies Act 2006 (the &#8220;Companies Act&#8221;). The following summary does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the applicable provisions of English law and our articles of association, a copy of which is filed as an exhibit to the Annual Report on Form 10-K. We encourage you to read our articles of association and the applicable provisions of English law for additional information.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">General</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We were incorporated pursuant to the laws of England and Wales as Bicycle Therapeutics Limited on October 27, 2017 and re-registered as a public limited company named Bicycle Therapeutics plc on May 22, 2019. We are registered with the Registrar of Companies in England and Wales under number 11036004, and our registered office is at Blocks A &amp; B, Portway Building Granta Park, Great Abington, Cambridge, United Kingdom, CB21 6GS.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our securities include (a) ordinary shares, nominal value of &#163;0.01 per share, (b) non-voting ordinary shares, nominal value of &#163;0.01 per share, and (c) ADSs, each representing one ordinary share, nominal value $0.01 per share.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;text-indent:-10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Ordinary Shares</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following is a summary of the rights of our holders, including a summary of such rights and restrictions as specified in our articles of association:</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preemptive Rights</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">English law generally provides shareholders with preemptive rights when new shares are issued for cash;&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">however</i><font style="font-family:'Times New Roman','Times','serif';">, it is possible for the articles of association, or shareholders in general meeting, to disapply preemptive rights. Such disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder resolution, if the disapplication is by shareholder resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). On May 16, 2024, our shareholders approved the disapplication of preemptive rights for a period of five years from the date of approval in relation to the shares authorized to be allotted pursuant to such resolutions, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Shareholder Rights</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Certain rights granted under the Companies Act, including the right to requisition a general meeting or require a resolution to be put to shareholders at the annual general meeting, are only available to our members. For English law purposes, our members are the persons who are registered as the owners of the legal title to the shares and whose names are recorded in our register of members. In the case of shares held in a settlement system operated by the Depository Trust Company, or DTC, the registered member will be DTC&#39;s nominee, Cede &amp; Co. If a person who holds their ADSs in DTC wishes to exercise certain of the rights granted under the Companies Act, they may be required to withdraw their ADSs upon delivery of ordinary shares on deposit with DTC and become the registered holder of the shares in our register of members. A withdrawal of ADSs may have tax implications.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Articles of Association</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our ordinary shares have the rights and restrictions described in &#8220;Key Provisions of Our Articles of Association&#8221; below. The following summarizes the rights of holders of our ordinary shares:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">each holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally;</font></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">1</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;padding-bottom:8pt;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">the holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings; and</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">holders of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:-10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Key Provisions of Our Articles of Association</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The following is a summary of certain key provisions of our articles of association. Please note that this is only a summary and is not intended to be exhaustive. For further information please refer to the full version of our articles of association, which is included as an exhibit to our Annual Report on Form 10-K.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Purpose</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The articles of association contain no specific restrictions on our purpose and therefore, by virtue of section 31(1) of the Companies Act, our purpose is unrestricted.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Share Capital</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our share capital consists of ordinary shares and non-voting ordinary shares. We may issue shares with such rights and restrictions as may be determined by ordinary resolution, or if no ordinary resolution has been passed or so far as the resolution does not make specific provision, as the board of directors may determine, including shares which are to be redeemed, or are liable to be redeemed at our option or the option of the holder of such shares.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The holders of ordinary shares have the right to receive notice of, and to attend and vote at, our general meetings. Subject to any other provisions of our articles of association and without prejudice to any special rights, privileges or restrictions as to voting attached to any shares forming part of our share capital, each holders of ordinary shares who is present in person (or, being a corporation, by representative) or by proxy at a general meeting on a show of hands has one vote and, on a poll, every such shareholder who is present in person (or, being a corporation, by representative) or by proxy has one vote in respect of every share held by him.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;"><a name="_cp_change_247"></a></font><font style="font-family:'Times New Roman','Times','serif';">The holders of non-voting ordinary shares have the right to receive notice of, and to attend and vote at, any separate class meeting of the holders of non-voting ordinary shares and at any general meeting of shareholders in relation to a variation of class rights of the non-voting ordinary shares.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Variation of Rights</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Whenever our share capital is divided into different classes of shares, the special rights attached to any class may be varied or abrogated either (i) with the consent in writing of the holders of three-quarters in nominal value of the issued shares of that class (excluding any shares of that class held as treasury shares), (ii) with the authority of a special resolution passed at a general meeting of the holders of the shares of that class or (iii) in any other way as expressly provided for in relation to such rights, and may be so varied and abrogated whilst the company is a going concern.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We may, subject to the provisions of the Companies Act and the Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by our board of directors. Subject to the provisions of the Companies Act, in so far as, in the board of directors&#39; opinions, our profits justify such payments, the board of directors may pay interim dividends on any class of our shares.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, before a company can lawfully make a distribution or dividend, it must ensure that it has sufficient distributable reserves, as determined on a non-consolidated basis. The basic rule is that a company&#8217;s profits available for the purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution or capitalization, less its accumulated, realized losses, so far as not previously written off in a reduction or reorganization of capital duly made. The requirement to have sufficient </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">2</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">distributable reserves before a distribution or dividend can be paid applies to us and to each of our subsidiaries that has been incorporated under English law.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As a public company, it will not be sufficient that we have made a distributable profit for the purpose of making a distribution. An additional capital maintenance requirement will be imposed on us to ensure that the net worth of the company is at least equal to the amount of its capital. A public company can only make a distribution:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">if, at the time that the distribution is made, the amount of its net assets (that is, the total excess of assets over liabilities) is not less than the total of its called up share capital and undistributable reserves; and</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">if, and to the extent that, the distribution itself, at the time that it is made, does not reduce the amount of its net assets to less than that total.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as provided otherwise by the rights attached to shares, dividends may be declared or paid in any currency. The board of directors may decide the rate of exchange for any currency conversions that may be required and how any costs involved in such conversions are to be met.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Any dividend unclaimed after a period of 12 years from the date such dividend was declared or became payable shall, if the board of directors resolve, be forfeited and shall revert to us. No dividend or other moneys payable on or in respect of a share shall bear interest as against us.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Preference</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">On a distribution of assets on a liquidation, the surplus assets remaining after payment of liabilities shall be distributed among the holders of ordinary shares pro rata to the number of ordinary shares held irrespective of the amount paid or credited as paid on any share.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Transfer of Ordinary Shares</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Each member may transfer all or any of his or her shares which are in certificated form by means of an instrument of transfer in any usual form or in any other form which the board of directors may approve. Each member may transfer all or any of his or her shares which are in uncertificated form by means of a &#8220;relevant system&#8221; in such manner provided for, and subject as provided in, the uncertificated securities rules (as defined in our articles of association).</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The board of directors may, in its absolute discretion, refuse to register a transfer of certificated shares unless:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i)</font></p></td><td style="vertical-align:middle;width:92.35%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">it is for a share which is fully paid up;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii)</font></p></td><td style="vertical-align:middle;width:92.31%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">it is for a share upon which the company has no lien;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iii)</font></p></td><td style="vertical-align:middle;width:92.01%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">it is only for one class of share;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iv)</font></p></td><td style="vertical-align:middle;width:92.06%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">it is in favor of a single transferee or no more than four joint transferees;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(v)</font></p></td><td style="vertical-align:middle;width:92.35%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">it is duly stamped or is duly certificated or otherwise shown to the satisfaction of the board of directors to be exempt from stamp duty; and</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(vi)</font></p></td><td style="vertical-align:middle;width:92.06%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">it is delivered for registration to the registered office of the company (or such other place as the board of directors may determine), accompanied (except in the case of a transfer by a person to whom the company is not required by law to issue a certificate and to whom a certificate has not been issued) by the certificate for the shares to which it relates and such other evidence as the board of directors may reasonably require to prove the title of the transferor (or person renouncing) and the due execution of the transfer by him or her or, if the transfer is executed by some other person on his or her behalf, the authority of that person to do so.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The board of directors shall not refuse to register any transfer of partly paid shares in respect of which ADSs are admitted to Nasdaq on the grounds that they are partly paid shares in circumstances where such refusal would prevent dealings in such shares from taking place on an open and proper basis.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The board of directors may refuse to register a transfer of uncertificated shares in any circumstances that are allowed or required by the uncertificated securities rules and the &#8220;relevant system&#8221;.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">3</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Allotment of Shares and Preemption Rights</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Subject to the Companies Act and to any rights attached to existing shares, any share may be issued with or have attached to it such rights and restrictions as the company may by ordinary resolution determine, or if no ordinary resolution has been passed or so far as the resolution does not make specific provision, as the board of directors may determine. In accordance with section 551 of the Companies Act, the board of directors may be generally and unconditionally authorized to exercise all the powers of the company to allot shares up to an aggregate nominal amount equal to the amount stated in the relevant ordinary resolution authorizing such allotment. Specifically, o</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:0.2pt;">ur board of directors has the authority pursuant to Section&#160;551 of the Companies Act to allot new shares or to grant rights to subscribe for or to convert any security into shares in the company up to a maximum aggregate nominal amount of &#163;1,000,000.&#160;</font><font style="font-family:'Times New Roman','Times','serif';">The authorities referred to above were passed by ordinary resolution on May 16, 2024 and&#160;</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:0.2pt;">runs for five years and will expire on May 15, 2029</font><font style="font-family:'Times New Roman','Times','serif';">.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The provisions of section 561 of the Companies Act (which confer on shareholders rights of preemption in respect of the allotment of equity securities which are paid up in cash) apply to the company except to the extent disapplied by special resolution of the company. Such preemption rights have been disapplied pursuant to the special resolution passed on May 16, 2024.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Alteration of Share Capital</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In accordance with the Companies Act, the company may, by ordinary resolution, consolidate all or any of its share capital into shares of a larger nominal value than its existing shares, or sub-divide its shares, or any of them, into shares of a smaller amount than the existing shares.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The company may, in accordance with the Companies Act, reduce or cancel its share capital or any capital redemption reserve or share premium account in any manner and with and subject to any conditions, authorities and consents required by law.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Board of Directors</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The articles of association provide that our board of directors is divided into three classes, each of which will consist, as nearly as possible, of one-third of the total number of directors constituting our entire board and which will serve staggered three-year terms, with eligibility for re-appointment at the end of such term.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">At each annual general meeting, the directors of the class whose term expires shall retire from office but are eligible for re-election by ordinary resolution at such annual general meeting and, in each case, where such director is re-elected, they will be entitled to serve until the third anniversary of such annual general meeting following election, at which point such director shall retire from office but shall be eligible for re-election.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Capitalization of Profits</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The directors may, if they are so authorized by an ordinary resolution of the shareholders, decide to capitalize any undivided profits of the company not required for paying any preferential dividend (whether or not they are available for distribution), or any sum standing to the credit of any reserve or fund which is available for distribution or standing to the credit the company&#39;s share premium account, capital redemption reserve or other distributable reserve. The directors may also, subject to the aforementioned ordinary resolution, appropriate any sum which they so decide to capitalize to the persons who would have been entitled to it if it were distributed by way of dividend and in the same proportions.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:-10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Limitation on Owning Securities</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Neither English law nor our articles of association restrict in any way the ownership or voting of our shares by non-residents.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Uncertificated Shares</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Subject to the Companies Act, the board of directors may permit title to shares of any class to be issued or held otherwise than by a certificate and to be transferred by means of a &#8220;relevant system&#8221; (e.g., the CREST System or DTC) without a certificate.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">4</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The board of directors may take such steps as it sees fit in relation to the evidencing of and transfer of title to uncertificated shares, any records relating to the holding of uncertificated shares and the conversion of uncertificated shares to certificated shares, or vice-versa.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The company may by notice to the holder of an uncertificated share, require that share to be converted into certificated form.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The board of directors may take such other action that the board considers appropriate to achieve the sale, transfer, disposal, forfeiture, re-allotment or surrender of an uncertified share or otherwise to enforce a lien in respect of it.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Other Relevant United Kingdom Laws and Regulations</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Mandatory Bid</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The City Code on Takeovers and Mergers (the &#8220;Takeover Code&#8221;) does not currently apply to the company. However, if the company were to become subject to the Takeover Code in the future, the following provisions will apply. Under the Takeover Code, where:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.81%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i)</font></p></td><td style="vertical-align:middle;width:92.24%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">any person, together with persons acting in concert with him, acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting in concert with him are interested) carry 30% or more of the voting rights of a company; or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.81%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii)</font></p></td><td style="vertical-align:middle;width:92.24%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">any person who, together with persons acting in concert with him, is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person, or any person acting in concert with him, acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which he is interested;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">such person shall, except in limited circumstances, be obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non-voting, and also to the holders of any other class of transferable securities carrying voting rights. Offers for different classes of equity share capital must be comparable; the Takeover Panel should be consulted in advance in such cases.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">An offer under Rule 9 of the Takeover Code must be in cash or be accompanied by a cash alternative at not less than the highest price paid for any interest in the shares by the person required to make an offer or any person acting in concert with him during the 12 months prior to the announcement of the offer.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Takeover Code, a &#8220;concert party&#8221; arises where persons acting together pursuant to an agreement or understanding (whether formal or informal and whether or not in writing) actively cooperate, through the acquisition by them of an interest in shares in a company, to obtain or consolidate control of the company. &#8220;Control&#8221; means holding, or aggregate holdings, of an interest in shares carrying 30% or more of the voting rights of the company, irrespective of whether the holding or holdings give&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">de facto</i><font style="font-family:'Times New Roman','Times','serif';">&#160;control.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Squeeze-Out</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under sections 979 to 982 of the Companies Act, where a takeover offer has been made for us and the offeror has acquired, or unconditionally contracted to acquire, not less than 90% in value of the shares to which the offer relates and not less than 90% of the voting rights carried by those shares, it could then compulsorily acquire the remaining 10%. It would do so by sending a notice to outstanding shareholders telling them that it will compulsorily acquire their shares, provided that no such notice may be served after the end of: (a) the period of three months beginning with the day after the last day on which the offer can be accepted; or (b) if earlier, and the offer is not one to which section 943(1) of the Companies Act applies, the period of six months beginning with the date of the offer.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Six weeks following service of the notice, the offeror must send a copy of it to the company together with the consideration for the ordinary shares to which the notice relates, and an instrument of transfer executed on behalf of the outstanding shareholder(s) by a person appointed by the offeror.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The company will hold the consideration on trust for the outstanding shareholders.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">5</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Sell-Out</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sections 983 to 985 of the Companies Act also give minority shareholders in the company a right to be bought out in certain circumstances by an offeror who has made a takeover offer. If a takeover offer relating to all the ordinary shares of the company is made and the offeror has acquired or unconditionally agreed to acquire not less than 90% in value of the voting shares and not less than 90% of the voting rights carried by those shares, at any time before the end of the period within which the offer could be accepted, any holder of shares to which the offer related who had not accepted the offer could by a written communication to the offeror require it to acquire those shares. The offeror is required to give any shareholder notice of his or her right to be bought out within one month of that right arising. The offeror may impose a time limit on the rights of minority shareholders to be bought out, but that period cannot end less than three months after the end of the acceptance period, or, if longer a period of three months from the date of the notice.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If a shareholder exercises his or her rights, the offeror is bound to acquire those shares on the terms of the offer or on such other terms as may be agreed.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Differences in Corporate Law</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The applicable provisions of the Companies Act differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#39; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and English law.</i></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Number of Directors</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company&#39;s articles of association.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Removal of Directors</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has with the company, provided 28 clear days&#39; notice of the resolution has been given to the company and its shareholders. On receipt of notice of an intended resolution to remove a director, the company must forthwith send a copy of the notice to the director concerned. Certain other procedural requirements under the Companies Act must also be followed, such as allowing the director to make</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, stockholders may effect such removal only for cause, or (ii) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">6</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">representations against his or her removal either at the meeting or in writing.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Vacancies on the Board of Directors</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under English law, the procedure by which directors, other than a company&#39;s initial directors, are appointed is generally set out in a company&#39;s articles of association, provided that where two or more persons are appointed as directors of a public limited company by resolution of the shareholders, resolutions appointing each director must be voted on individually.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (i) otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Annual General Meeting</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, a public limited company must hold an annual general meeting in each six-month period following the company&#39;s annual accounting reference date.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">General Meeting</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, a general meeting of the shareholders of a public limited company may be called by the directors.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Shareholders holding at least 5% of the paid-up capital of the company carrying voting rights at general meetings (excluding any paid up capital held as treasury shares) can require the directors to call a general meeting and, if the directors fail to do so within a certain period, may themselves convene a general meeting.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Notice of General Meetings</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, at least 21 clear days&#39; notice must be given for an annual general meeting and any resolutions to be proposed at the meeting. Subject to a company&#39;s articles of association providing for a longer period, at least 14 clear days&#39; notice is required for any other general meeting of a public limited company. In addition, certain matters, such as the removal of directors or auditors, require special notice, which is 28 clear days&#39; notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders&#39; consent required being</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour and purpose or purposes of the meeting.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">7</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.73%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.28%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.28%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">100% of those entitled to attend and vote in the case of an annual general meeting and, in the case of any other general meeting, a majority in number of the members having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to attend and vote at the meeting.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Quorum</font></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Subject to the provisions of a company&#39;s articles of association, the Companies Act provides that two shareholders present at a meeting (in person or by proxy) shall constitute a quorum.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The certificate of incorporation or bylaws may specify the number of shares, the holders of which shall be present or represented by proxy at any meeting in order to constitute a quorum, but in no event shall a quorum consist of less than one third of the shares entitled to vote at the meeting. In the absence of such specification in the certificate of incorporation or bylaws, a majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at a meeting of stockholders.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Proxy</font></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the meeting on their behalf by proxy.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#39;s voting rights as a director.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Issue of New Shares</font></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, the directors of a company must not exercise any power to allot shares or grant rights to subscribe for, or to convert any security into, shares unless they are authorized to do so by the company&#39;s articles of association or by an ordinary resolution of the shareholders. Any authorization given must state the maximum amount of shares that may be allotted under it and specify the date on which it will expire, which must be not more than five years from the date the authorization was given. The authority can be renewed by a further resolution of the shareholders.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, if the company&#39;s certificate of</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">incorporation so provides, the directors have the power to authorize the issuance of additional stock. The directors may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the company or any combination thereof.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Preemptive Rights</font></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, &#8220;equity securities,&#8221; being (i) shares in the company other than shares that, with respect to dividends and capital, carry a</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">8</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.73%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.28%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.28%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">right to participate only up to a specified amount in a distribution, referred to as &#8220;ordinary shares,&#8221; or (ii) rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing equity shareholders in the company in proportion to the respective nominal value of their holdings, unless an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise in each case in accordance with the provisions of the Companies Act.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Authority to Allot</font></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, the directors of a company must not allot shares or grant rights to subscribe for or convert any security into shares unless an exception applies or an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise, in each case in accordance with the provisions of the Companies Act.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, if the corporation&#39;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. The board may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liability of Directors and Officers</font></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.73%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, any provision, whether contained in a company&#39;s articles of association or any contract or otherwise, that purports to exempt a director of a company, to any extent, from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company, is void. Any provision by which a company directly or indirectly provides an indemnity, to any extent, for a director of the company or of an associated company against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a director is also void except as permitted by the Companies Act, which provides exceptions for the company to (i) purchase and maintain insurance against such liability; (ii) provide a &#8220;qualifying third party indemnity,&#8221; or an indemnity against </font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, a corporation&#39;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director or officer to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director or officer. However, no provision can limit the liability of a director for:</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; any breach of the director&#39;s or officer&#8217;s duty of loyalty to the corporation or its stockholders;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; a director for intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; any transaction from which the director or officer derives an improper personal benefit; or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">9</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.71%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.38%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:36.71%;border-top:1.5pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">liability incurred by the director to a person other than the company or an associated company or criminal proceedings in which he is convicted; and (iii) provide a &#8220;qualifying pension scheme indemnity,&#8221; or an indemnity against liability incurred in connection with the company&#39;s activities as trustee of an occupational pension plan.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.38%;border-top:1.5pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; an officer in any action by or in the right of the corporation.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">10</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under English law, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or the company&#39;s articles of association, shareholders shall vote on all resolutions on a show of hands. Under the Companies Act, a poll may be demanded by (i) not fewer than five shareholders having the right to vote on the resolution; (ii) any shareholder(s) representing not less than 10% of the total voting rights of all the shareholders having the right to vote on the resolution (excluding any voting rights attaching to treasury shares); or (iii) any shareholder(s) holding shares in the company conferring a right to vote on the resolution (excluding any voting rights attaching to treasury shares) being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right. A company&#39;s articles of association may provide more extensive rights for shareholders to call a poll.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under English law, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in person or by proxy, who, being entitled to vote, vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present, in person or by proxy, at the meeting. If a poll is demanded, a special resolution is</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">passed if it is approved by holders representing not less than 75% of</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">the total voting rights of shareholders in person or by proxy who, being entitled to vote, vote on the resolution.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each Stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:0;margin:30pt 110.1pt 30pt 110.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">11</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Shareholder Vote on Certain Transactions</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Companies Act provides for schemes of arrangement, which are arrangements or compromises between a company and any class of shareholders or creditors and used in certain types of reconstructions, amalgamations, capital reorganizations or takeovers. These arrangements require:</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; the approval at a shareholders&#39;&#8217; or creditors&#39;&#8217; meeting convened by order of the court, of a majority in number of shareholders or creditors representing 75% in value of the capital held by, or debt owed to, the shareholders or creditors or class thereof present and voting, either in person or by proxy; and</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; the approval of the court.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Generally, under Delaware law, unless the certificate of Incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires:</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; the approval of the board of directors; and</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; the approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of the corporation entitled to vote on the matter.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Standard of Conduct for Directors</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under English law, a director owes various statutory and fiduciary duties to the company, including:</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; to act in the way he considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the company;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; to act in accordance with the company&#8217;s constitution and only exercise his or her powers for the purposes for which they are conferred;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; to exercise independent judgment;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; to exercise reasonable care, skill and diligence;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; not to accept benefits from a third party conferred by reason of his or her being a director or doing, or not doing, anything as a director; and</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; to declare any interest that he or she has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the company.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">12</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:0;margin:0pt 110.1pt 30pt 110.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:36.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">England and Wales</b></p></td><td style="vertical-align:bottom;width:2.43%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:33.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Delaware</b></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.</font></p></td></tr><tr><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Shareholder Litigation</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under English law, generally, the company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the company or where there is an irregularity in the company&#39;s internal management. Notwithstanding this general position, the Companies Act provides that (i) a court may allow a shareholder to bring a derivative claim (that is, an action in respect of and on behalf of the company) in respect of a cause of action arising from a director&#39;s negligence, default, breach of duty or breach of trust and (ii) a shareholder may bring a claim for a court order where the company&#39;s affairs have been or are being conducted in a manner that is unfairly prejudicial to some of its shareholders.</font></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff&#8217;s shares thereafter devolved on the plaintiff by operation of law; and</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#39;s failure to obtain the action; or</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; state the reasons for not making the effort.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679; Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">13</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Disclosure of Interest in Shares</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to Part 22 of the Companies Act, a company is empowered by notice in writing to require any person whom the company knows to be, or has reasonable cause to believe to be, interested in the company&#39;s shares or at any time during the three years immediately preceding the date on which the notice is issued to have been so interested, within a reasonable time to disclose to the company details of that person&#39;s interest and (so far as is within such person&#39;s knowledge) details of any other interest that subsists or subsisted in those shares.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under our articles of association, if a shareholder defaults in supplying the company with the required details in relation to the shares in question, or the default shares within the prescribed period of 14 days our board of directors may by notice direct that:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">the relevant shareholder shall not be entitled in respect of the default shares to be present or vote, either in person or by representative or proxy, at any general meeting or separate meeting of the holders of a class of shares or upon any poll or to exercise any other right conferred by the membership in relation to any such meeting;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">where the default shares represents at least 0.25% in nominal value of the issued shares of the class in question (calculated exclusive of any shares held as treasury shares), (a) any dividend or other money payable in respect of the default shares shall be retained by us without any liability to pay interest and the relevant shareholder shall not be entitled to elect to receive ordinary shares instead of any dividend, and/or (b) no transfers by the relevant shareholder of default shares (other than a transfer excepted from these provisions in accordance with the provisions of the company&#39;s articles of association) may be registered, unless the shareholder himself or herself is not in default and the shareholder proves to the satisfaction of the board of directors that no person in default as regards to supplying such information is interested in any of the default shares; and/or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">any shares held by the relevant shareholder in uncertificated form shall be converted into certificated form.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Purchase of Own Shares</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:12pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">English law permits a public limited company to purchase its own shares out of the distributable profits of the company or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, subject to complying with procedural requirements under the Companies Act and provided that its articles of association do not prohibit it from doing so. Our articles of association, a summary of which is provided below, do not prohibit us from purchasing our own shares. A public limited company must not purchase its own shares if, as a result of the purchase, there would no longer be any issued shares of the company other than redeemable shares or shares held as treasury shares. Shares must be fully paid in order to be repurchased.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:12pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Any such purchase will be either a &#8220;market purchase&#8221; or &#8220;off market purchase,&#8221; each as defined in the Companies Act. A &#8220;market purchase&#8221; is a purchase made on a &#8220;recognized investment exchange (other than an overseas exchange) as defined in the UK Financial Services and Markets Act 2000, or FSMA. An &#8220;off market purchase&#8221; is a purchase that is not made on a &#8220;recognized investment exchange.&#8221; Both &#8220;market purchases&#8221; and &#8220;off market purchases&#8221; require prior shareholder approval by way of an ordinary resolution. In the case of an &#8220;off market purchase,&#8221; a company&#39;s shareholders, other than the shareholders from whom the company is purchasing shares, must approve the terms of the contract to purchase shares and in the case of a &#8220;market purchase,&#8221; the shareholders must approve the maximum number of shares that can be purchased and the maximum and minimum prices to be paid by the company. Both resolutions authorizing &#8220;market purchases&#8221; and &#8220;off-market purchases&#8221; must specify a date, not later than five years after the passing of the resolution, on which the authority to purchase is to expire.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Nasdaq is an &#8220;overseas exchange&#8221; for the purposes of the Companies Act and does not fall within the definition of a &#8220;recognized investment exchange&#8221; for the purposes of FSMA and any purchase made by us would need to comply with the procedural requirements under the Companies Act that regulate &#8220;off market purchases.&#8221;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">A share buy-back by a company of its shares will give rise to U.K. stamp duty reserve tax and stamp duty at the rate of 0.5% of the amount or value of the consideration payable by the company (rounded up to the next &#163;5.00), and such stamp duty reserve tax or duty will be paid by the company. The charge to stamp duty reserve tax will be canceled or, if already paid, repaid (generally with interest), where a transfer instrument for stamp </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">14</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">duty purposes has been duly stamped within six years of the charge arising (either by paying the stamp duty or by claiming an appropriate relief) or if the instrument is otherwise exempt from stamp duty.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our articles of association do not have conditions governing changes to our capital which are more stringent than those required by law.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Share Register</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We are required by the Companies Act to keep a register of our shareholders. Under English law, the ordinary shares are deemed to be issued when the name of the shareholder is entered in our share register. The share register, therefore, is prima facie evidence of the identity of our shareholders, and the shares that they hold. The share register generally provides limited, or no, information regarding the ultimate beneficial owners of our ordinary shares. Our share register is maintained by our registrar, Computershare Investor Services plc.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Holders of our ADSs are not treated as one of our shareholders and their names are therefore not entered in our share register. The depositary, the custodian or their nominees will be the holder of the shares underlying our ADSs. Holders of our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see &#8220;American Depositary Shares.&#8221;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the Companies Act, we must enter an allotment of shares in our share register as soon as practicable and in any event within two months of the allotment. We also are required by the Companies Act to register a transfer of shares (or give the transferee notice of and reasons for refusal as the transferee may reasonably request) as soon as practicable and in any event within two months of receiving notice of the transfer.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We, any of our shareholders or any other affected person may apply to the court for rectification of the share register if:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">the name of any person, without sufficient cause, is wrongly entered in or omitted from our share register; or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:3.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:92.32%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">there is a default or unnecessary delay in entering on the register the fact of any person having ceased to be a member or on which we have a lien, provided that such delay does not prevent dealings in the shares taking place on an open and proper basis.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">U.K. Taxation Impacts on U.S. Holders of Our Ordinary Shares</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The discussion below is intended as a general guide to current U.K. tax law and HM Revenue &amp; Customs (&#8220;HMRC&#8221;) published practice applying as at the date of this filing (both of which are subject to change at any time, possibly with retrospective effect) which related to our ordinary shares. It does not constitute legal or tax advice and does not purport to be a complete analysis of all U.K. tax considerations relating to the holding of ordinary shares. In particular, it should be noted that special rules may apply to certain persons such as market makers, brokers, dealers or intermediaries.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dividends paid by the company are not subject to any withholding tax or deduction for or on account of U.K. tax.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Stamp Duty and Stamp Duty Reserve Tax</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">The discussion below relates to the holders of our ordinary shares or ADSs wherever resident, however it should be noted that (i) special rules may apply to certain persons such as market makers, brokers, dealers or intermediaries, and (ii) in respect of our ordinary shares, this discussion applies only to issues or transfers occurring on or before December 31, 2023 (for a discussion in respect of issues or transfers of our ordinary shares after that date, please see the paragraph below entitled &#8220;Issue or Transfers of Ordinary Shares from January 1, 2024&#8221;).</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">15</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Issue of Ordinary Shares</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">No U.K. stamp duty or stamp duty reserve tax (&#8220;SDRT&#8221;) is generally payable on the issue of ordinary shares in the company.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Transfers of Ordinary Shares</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">An unconditional agreement to transfer ordinary shares in certificated form will normally give rise to a charge to SDRT at the rate of 0.5% of the amount or value of the consideration payable for the transfer. The purchaser of the shares is liable for the SDRT. Transfers of ordinary shares in certificated form are generally also subject to stamp duty at the rate of 0.5% of the amount or value of the consideration given for the transfer (rounded up to the next &#163;5.00). Stamp duty is normally paid by the purchaser. The charge to SDRT will be canceled or, if already paid, repaid (generally with interest), where a transfer instrument has been duly stamped within six years of the charge arising (either by paying the stamp duty or by claiming an appropriate relief) or if the instrument is otherwise exempt from stamp duty.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">An unconditional agreement to transfer ordinary shares to, or to a nominee or agent for, a person whose business is or includes the issue of depositary receipts or the provision of clearance services will generally be subject to SDRT (or, where the transfer is effected by a written instrument, stamp duty) at a higher rate of 1.5% of the amount or value of the consideration given for the transfer unless the clearance service has made and maintained an election under section 97A of the U.K. Finance Act 1986, or a section 97A election. It is understood that HMRC regards the facilities of DTC as a clearance service for these purposes and we are not aware of any section 97A election having been made by DTC. However, no SDRT is generally payable where the transfer of ordinary shares to a clearance service or depositary receipt system is an integral part of an issue of share capital.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Any stamp duty or SDRT payable on a transfer of ordinary shares to a depositary receipt system or clearance service will in practice generally be paid by the transferors or participants in the clearance service or depositary receipt system.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Issue or Transfers of Ordinary Shares from January 1, 2024</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under recently enacted U.K. legislation, the U.K. stamp duty and stamp duty reserve tax treatment of the issue and transfer of ordinary shares in the company will change with effect from January 1, 2024, unless action is taken by the U.K. government or Parliament to retain the treatment set out in the preceding paragraphs.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If this change in treatment does occur (i) an unconditional agreement to transfer ordinary shares to, or to a nominee or agent for, a person whose business is or includes the issue of depositary receipts or the provision of clearance services will generally be subject to SDRT (or, where the transfer is effected by a written instrument, stamp duty) at the higher rate of 1.5%, and (ii) SDRT will also generally arise (at the same higher rate of 1.5%) on the issue of ordinary shares to such persons.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;letter-spacing:-0.1pt;">Non-Voting Ordinary Shares</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to our articles of association, the non-voting ordinary shares have the same rights and restrictions as the ordinary shares and otherwise rank&#160;pari&#160;passu&#160;in all respects with the ordinary shares except for the following:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679;</font></p></td><td style="vertical-align:middle;width:94.85%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">a holder of non-voting ordinary shares shall, in relation to the non-voting ordinary shares held by him, have no right to receive notice of, or to attend or vote at, any general meeting of shareholders save in relation to a variation of class rights of the non-voting ordinary shares;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679;</font></p></td><td style="vertical-align:middle;width:94.85%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">the non-voting ordinary shares shall be re-designated as ordinary shares by our board of directors, or a duly authorized committee or representative thereof, upon receipt of a re-designation notice and otherwise subject to the terms and conditions set out in our articles of association. A holder of non-voting ordinary shares shall not be entitled to have any non-voting ordinary shares re-designated as ordinary shares where such re-designation would result in such holder thereof beneficially owning (for purposes of section 13(d) of the Exchange Act), when aggregated with &#8220;affiliates&#8221; and &#8220;group&#8221; members with whom such holder is required to aggregate beneficial ownership for purposes of section 13(d) of the Exchange Act, in excess of 9.99&#160;percent of any class of our securities registered under the Exchange Act (which&#160;percentage may be increased or decreased on a holder-by-holder basis subject to the provisions set out in our articles of association); and</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">16</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#9679;</font></p></td><td style="vertical-align:middle;width:94.85%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">the non-voting ordinary shares shall be re-designated as ordinary shares automatically upon transfer of a non-voting ordinary share by its holder to any person that is not an &#8220;affiliate&#8221; or &#8220;group&#8221; member with whom such holder is required to aggregate beneficial ownership for purposes of section 13(d) of the Exchange Act. This automatic re-designation shall only be in respect of the non-voting ordinary shares that are subject to such transfer.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman Bold';font-size:10pt;font-variant:small-caps;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">American Depositary Shares</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Depositary</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We have appointed Citibank, N.A. (&#8220;Citibank&#8221;) as the depositary for the ADSs pursuant to a deposit agreement (the &#8220;Deposit Agreement&#8221;). Citibank&#8217;s depositary offices are located at 388 Greenwich Street, New York, New York 10013.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Provisions</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">American Depositary Shares are frequently referred to as &#8220;ADSs&#8221; and represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as &#8220;American Depositary Receipts&#8221; or &#8220;ADRs.&#8221; The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A. (London), located at Citigroup Centre, Canary Wharf, London, E14 5LB, United Kingdom.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following is a summary of the material provisions of the Deposit Agreement. For more complete information, you should read the Deposit Agreement and Form of ADR.&#160;A copy of the Deposit Agreement is on file with the SEC under cover of a Registration Statement on Form F-6 that was declared effective on May 23, 2019. You may obtain a copy of the Deposit Agreement from the SEC&#8217;s website (www.sec.gov).</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one ordinary share that is on deposit with the depositary bank and/or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary bank may agree to change the ADS-to-Share ratio by amending the Deposit Agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the Deposit Agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the Deposit Agreement.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If you become an owner of ADSs, you will become a party to the Deposit Agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The Deposit Agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary bank. As an ADS holder you appoint the depositary bank to act on your behalf in certain circumstances. The Deposit Agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of England and Wales, which may be different from the laws in the United States.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">17</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary bank only to the extent contemplated in the</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Deposit Agreement. To exercise any shareholder rights not contemplated in the Deposit Agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The manner in which you own the ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary bank&#39;s services are made available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary bank in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#8220;direct registration system&#8221; or &#8220;DRS&#8221;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and The Depository Trust Company (&#8220;DTC&#8221;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#8220;holder.&#8221; When we refer to &#8220;you,&#8221; we assume the reader owns ADSs and will own ADSs at the relevant time.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The registration of the ordinary shares in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Dividends and Distributions</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the Deposit Agreement in proportion to the number of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Distributions of Cash</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to English laws and regulations.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the Deposit Agreement. The depositary bank will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">18</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Distributions of Shares</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">either</i><font style="font-family:'Times New Roman','Times','serif';">&#160;distribute to holders new ADSs representing the ordinary shares deposited&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">or</i><font style="font-family:'Times New Roman','Times','serif';">&#160;modify the ADS-to-ordinary-share ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The distribution of new ADSs or the modification of the ADS-to-ordinary-share ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the Deposit Agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">No such distribution of new ADSs will be made if it would violate a law (</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">e.g.</i><font style="font-family:'Times New Roman','Times','serif';">, the U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the Deposit Agreement and will distribute the proceeds of the sale as in the case of a distribution of cash.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Distributions of Rights</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the Deposit Agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">not</i><font style="font-family:'Times New Roman','Times','serif';">&#160;distribute the rights to you if:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We do not timely request that the rights be distributed to you or we request that the rights not be distributed to you; or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We fail to deliver satisfactory documents to the depositary bank; or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">It is not reasonably practicable to distribute the rights.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Elective Distributions</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the Deposit Agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the Deposit Agreement.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in England and Wales would receive upon failing to make an election, as more fully described in the Deposit Agreement.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">19</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Other Distributions</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If it is reasonably practicable to distribute such property to you and if we provide to the depositary bank all of the documentation contemplated in the Deposit Agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the Deposit Agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">not</i><font style="font-family:'Times New Roman','Times','serif';">&#160;distribute the property to you and will sell the property if:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We do not request that the property be distributed to you or if we request that the property not be distributed to you; or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We do not deliver satisfactory documents to the depositary bank; or</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Redemption</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is practicable and if we provide all of the documentation contemplated in the Deposit Agreement, the depositary bank will provide notice of the redemption to the holders.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary bank will convert into U.S. dollars upon the terms of the Deposit Agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">pro rata</i><font style="font-family:'Times New Roman','Times','serif';">&#160;basis, as the depositary bank may determine.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Changes Affecting Ordinary Shares</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, split-up, cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of the company.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If any such change were to occur, your ADSs would, to the extent permitted by law and the Deposit Agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the Deposit Agreement, the ADRs and the applicable Registration Statement(s) on Form F-6, call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary bank may not lawfully distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Issuance of ADSs upon Deposit of Ordinary Shares</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary bank. As such, you will be deemed to represent and warrant that:</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">20</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained.</font></p></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">You are duly authorized to deposit the ordinary shares. The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#8220;restricted securities&#8221; (as defined in the Deposit Agreement).</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transfer, Combination and Split Up of ADRs</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary bank and also must:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">provide any transfer stamps required by the State of New York or the United States; and</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the Deposit Agreement, upon the transfer of ADRs.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">To have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the Deposit Agreement, upon a combination or split up of ADRs.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Withdrawal of Ordinary Shares Upon Cancellation of ADSs</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of underlying ordinary shares at the custodian&#39;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and English law considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the Deposit Agreement.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If you hold ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that represent a whole number of securities on deposit.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">You will have the right to withdraw the securities represented by your ADSs at any time except for:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Temporary delays that may arise because (i) the transfer books for the ordinary shares or ADSs are closed, or (ii) ordinary shares are immobilized on account of a shareholders&#39; meeting or a payment of dividends.</font></p></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Obligations to pay fees, taxes and similar charges.</font></p></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Deposit Agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">21</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Voting Rights</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As a holder, you generally have the right under the Deposit Agreement to instruct the depositary bank to exercise the voting rights for the ordinary shares represented by your ADSs. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">At our request, the depositary bank will distribute to you any notice of shareholders&#39; meeting received from us together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary bank may distribute to holders of ADSs instructions on how to retrieve such materials upon request.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If the depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#39;s ADSs as follows:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">In the event of voting by show of hands</i><font style="font-family:'Times New Roman','Times','serif';">, the depositary bank will vote (or cause the custodian to vote) all ordinary shares held on deposit at that time in accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">In the event of voting by poll</i><font style="font-family:'Times New Roman','Times','serif';">, the depositary bank will vote (or cause the Custodian to vote) the ordinary shares held on deposit in accordance with the voting instructions received from the holders of ADSs.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Securities for which no voting instructions have been received will not be voted (except (a) as set forth above in the case voting is by show of hands, (b) in the event of voting by poll, holders of ADSs in respect of which no timely voting instructions have been received shall be deemed to have instructed the depositary to give a discretionary proxy to a person designated by us to vote the ordinary shares represented by such holders&#39; ADSs; provided, however, that no such discretionary proxy shall be given with respect to any matter to be voted upon as to which we inform the depositary that (i) we do not wish such proxy to be given, (ii) substantial opposition exists, or (iii) the rights of holders of ordinary shares may be adversely affected, and (c) as otherwise contemplated in the Deposit Agreement). Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">22</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Fees and Charges</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As an ADS holder, you will be required to pay the following fees under the terms of the Deposit Agreement:</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:71.27%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Service</b></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:top;width:26.94%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Fees</b></p></td></tr><tr><td style="vertical-align:top;width:71.27%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary-share(s) ratio, or for any other reason), excluding ADS issuances as a result of distributions of shares)</font></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS issued</font></p></td></tr><tr><td style="vertical-align:top;width:71.27%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the ADS(s)-to-ordinary-share(s) ratio, or for any other reason)</font></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS cancelled</font></p></td></tr><tr><td style="vertical-align:top;width:71.27%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</font></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS held</font></p></td></tr><tr><td style="vertical-align:top;width:71.27%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) exercise of rights to purchase additional ADSs</font></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS held</font></p></td></tr><tr><td style="vertical-align:top;width:71.27%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)</font></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS held</font></p></td></tr><tr><td style="vertical-align:top;width:71.27%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">ADS Services</font></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</font></p></td></tr><tr><td style="vertical-align:top;width:71.27%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">vice versa</i><font style="font-family:'Times New Roman','Times','serif';">, or for any other reason)</font></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</font></p></td></tr><tr><td style="vertical-align:top;width:71.27%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely transferable ADSs, and&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">vice versa</i><font style="font-family:'Times New Roman','Times','serif';">).</font></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:26.94%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As an ADS holder you will also be responsible to pay certain charges such as:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">taxes (including applicable interest and penalties) and other governmental charges;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">certain cable, telex and facsimile transmission and delivery expenses;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which may be a division, branch or affiliate of the depositary bank) in the conversion of foreign currency;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">the reasonable and customary out-of-pocket expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the ADR program.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">ADS fees and charges for (i) the issuance of ADSs, and (ii) the cancellation of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">23</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i) registration of ADS transfers, the ADS transfer fee will be payable by the ADS holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the holder whose ADSs are converted or by the person to whom the converted ADSs are delivered.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In the event of refusal to pay the depositary bank fees, the depositary bank may, under the terms of the Deposit Agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Certain depositary fees and charges (such as the ADS services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Amendments and Termination</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We may agree with the depositary bank to modify the Deposit Agreement at any time without your consent. We undertake to give holders 30 days&#39; prior notice of any modifications that would materially prejudice any of their substantial rights under the Deposit Agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">You will be bound by the modifications to the Deposit Agreement if you continue to hold your ADSs after the modifications to the Deposit Agreement become effective. The Deposit Agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law).</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We have the right to direct the depositary bank to terminate the Deposit Agreement. Similarly, the depositary bank may in certain circumstances on its own initiative terminate the Deposit Agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until termination, your rights under the Deposit Agreement will be unaffected.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">After termination, the depositary bank will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses).</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In connection with any termination of the Deposit Agreement, the depositary bank may make available to owners of ADSs a means to withdraw the ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary bank. The ability to receive unsponsored American depositary shares upon termination of the Deposit Agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the payment of applicable depositary fees.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Books of Depositary</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the Deposit Agreement.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">24</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Limitations on Obligations and Liabilities</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Deposit Agreement limits our obligations and the depositary bank&#39;s obligations to you. Please note the following:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank are obligated only to take the actions specifically stated in the Deposit Agreement without negligence or bad faith.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the Deposit Agreement.</font></p></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the Deposit Agreement, for the timeliness of any of our notices or for our failure to give notice.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the Deposit Agreement.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the Deposit Agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of our articles of association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement or in our articles of association or in any provisions of or governing the securities on deposit.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.</font></p></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the Deposit Agreement, made available to you.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of the terms of the Deposit Agreement.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">No disclaimer of any Securities Act liability is intended by any provision of the Deposit Agreement.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Nothing in the Deposit Agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship, among us, the depositary bank and you as ADS holder.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Nothing in the Deposit Agreement precludes Citibank (or its affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have interests, and nothing in the Deposit Agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any payment received as part of those transactions.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Taxes</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">25</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are due.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Foreign Currency Conversion</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the Deposit Agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical.</font></p></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Distribute the foreign currency to holders for whom the distribution is lawful and practical.</font></p></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="vertical-align:middle;width:0.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88.45%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Hold the foreign currency (without liability for interest) for the applicable holders.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Governing Law/Waiver of Jury Trial</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Deposit Agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of England and Wales.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-indent:25.2pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">As a party to the deposit agreement, you irrevocably waive, to the fullest extent permitted by applicable law, your right to trial by jury in any legal proceeding arising out of the Deposit Agreement or the ADRs against us and/or the depositary bank. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed by agreeing to the terms of the deposit agreement to have waived our or the depositary&#8217;s compliance with U.S. securities laws and the rules and regulations promulgated thereunder.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">26</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>bcyc-20241231xex10d7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.1%;padding-right:12.1%;position:relative;"><div style="margin-top:28.8pt;min-height:43.2pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.7</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial Bold';font-size:10pt;font-weight:bold;line-height:1.79;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc38189872"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>OPTION GRANT NOTICE</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS PLC</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Option Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the option described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Option</b>&#8221;), subject to the terms and conditions of the Plan and the Option Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Grant date]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Exercise Price per Share:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Exercise price]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Shares Subject to the Option:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Final Expiration Date:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Expiration date]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Vesting start date]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Vesting Schedule]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Type of Option</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Incentive][Non-Qualified] Option</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:12pt 0pt 12pt 0pt;">By countersigning this Option Grant Notice, Participant agrees to be bound by the terms of this Grant Notice, the Plan, the Agreement and any Group Company policy that may be applicable to the Participant and the Option from time to time (the &#8220;<b style="font-weight:bold;">Policies</b>&#8221;). &#160;Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:12pt 0pt 12pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:0pt;line-height:1.49;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.1%;margin-right:12.1%;margin-top:30pt;page-break-after:always;width:75.8%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.79;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.79;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OPTION AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">GENERAL</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.1</font>Grant of Option. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;).</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.2</font>Incorporation of Terms of Plan. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">PERIOD OF EXERCISABILITY</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.1</font>Commencement of Exercisability. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Option will vest and become exercisable according to the vesting schedule in the Grant Notice (the &#8220;<b style="font-weight:bold;">Vesting Schedule</b>&#8221;) except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a whole Share has accumulated. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company, the Option will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#8217;s Termination of Service for any reason.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.2</font>Duration of Exercisability. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Vesting Schedule is cumulative. Any portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.3</font>Expiration of Option. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Option may not be exercised to any extent by anyone after, and will expire on, the first of the following to occur:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The final expiration date in the Grant Notice;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Except as the Administrator may otherwise approve, the expiration of twelve (12)&#160;months from the date of Participant&#8217;s Termination of Service; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Except as the Administrator may otherwise approve, Participant&#8217;s Termination of Service for Cause.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">EXERCISE OF OPTION</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.1</font>Person Eligible to Exercise. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">During Participant&#8217;s lifetime, only Participant may exercise the Option. After Participant&#8217;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by Participant&#8217;s Designated Beneficiary as provided in the Plan.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.2</font>Partial Exercise. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Tax Withholding.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax and/or social security withholding obligations that arise in connection with the Option. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax and/or social security withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#8217;s tax and/or social security liability.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"><a name="_Ref36217797"></a></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">OTHER PROVISIONS</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.1</font>Adjustments. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.2</font>Notices. </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#8217;s last known mailing address or email address in the Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i) if sent by email, when actually received; and (ii) if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.3</font>Titles. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.4</font>Conformity to Applicable Laws. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and this Option may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.5</font>Successors and Assigns. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.6</font>Limitations Applicable to Section&#160;16 Persons. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in any applicable exemptive rule&#160;under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.7</font>Entire Agreement. </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Plan, the Grant Notice and this Agreement (including any exhibit&#160;hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.8</font>Agreement Severable. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.9</font>Limitation on Participant&#8217;s Rights. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.10</font>Not a Contract of Employment. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.11</font>Counterparts. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.12</font>Incentive Options. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">If the Option is designated as an Incentive Option:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the option with respect to the shares is granted) with respect to which options intended to qualify as &#8220;incentive stock options&#8221; under Section&#160;422 of the Code, including the Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such options do not qualify or cease to qualify for treatment as &#8220;incentive stock options&#8221; under Section&#160;422 of the Code, such options (including the Option) will be treated as non-qualified options. Participant further acknowledges that the rule&#160;set forth in the preceding sentence will be applied by </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">taking the Option and other options into account in the order in which they were granted, as determined under Section&#160;422(d)&#160;of the Code. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant also acknowledges that if the Option is exercised more than three (3)&#160;months after Participant&#8217;s Termination of Service, other than by reason of death or Disability, the Option will be taxed as a Non-Qualified Option.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant will give prompt written notice to the Company of any disposition or other transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a)&#160;within two (2)&#160;years from the Grant Date or (b)&#160;within one (1)&#160;year after the transfer of such Shares to Participant. Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>4
<FILENAME>bcyc-20241231xex10d8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.1%;padding-right:12.1%;position:relative;"><div style="margin-top:28.8pt;min-height:43.2pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.8</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial Bold';font-size:10pt;font-weight:bold;line-height:1.79;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc38189872"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>OPTION GRANT NOTICE</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS PLC</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN: </b><b style="font-weight:bold;">NON-EMPLOYEE SUB-PLAN</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Option Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan: Non-Employee Sub-Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the option described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Option</b>&#8221;), subject to the terms and conditions of the Plan and the Option Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Grant date]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Exercise Price per Share:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Exercise price]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Shares Subject to the Option:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Final Expiration Date:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Expiration date]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Vesting start date]</p></td></tr><tr style="height:29.25pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">[Vesting Schedule]</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 10pt;"><b style="font-weight:bold;">Type of Option</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:64.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin:0pt 0pt 12pt 0pt;">Non-Qualified Option</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:12pt 0pt 12pt 0pt;">By countersigning this Option Grant Notice, Participant agrees to be bound by the terms of this Grant Notice, the Plan, the Agreement and any Group Company policy that may be applicable to the Participant and the Option from time to time (the &#8220;<b style="font-weight:bold;">Policies</b>&#8221;). &#160;Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:12pt 0pt 12pt 0pt;"><font style="margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:0pt;line-height:1.49;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.1%;margin-right:12.1%;margin-top:30pt;page-break-after:always;width:75.8%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.79;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.79;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OPTION AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">GENERAL</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.1</font>Grant of Option. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;).</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.2</font>Incorporation of Terms of Plan. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">PERIOD OF EXERCISABILITY</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.1</font>Commencement of Exercisability. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Option will vest and become exercisable according to the vesting schedule in the Grant Notice (the &#8220;<b style="font-weight:bold;">Vesting Schedule</b>&#8221;) except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a whole Share has accumulated. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company, the Option will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#8217;s Termination of Service for any reason.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.2</font>Duration of Exercisability. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Vesting Schedule is cumulative. Any portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.3</font>Expiration of Option. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Option may not be exercised to any extent by anyone after, and will expire on, the first of the following to occur:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The final expiration date in the Grant Notice;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Except as the Administrator may otherwise approve, the expiration of twelve (12)&#160;months from the date of Participant&#8217;s Termination of Service; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Except as the Administrator may otherwise approve, Participant&#8217;s Termination of Service for Cause.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">EXERCISE OF OPTION</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.1</font>Person Eligible to Exercise. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">During Participant&#8217;s lifetime, only Participant may exercise the Option. After Participant&#8217;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by Participant&#8217;s Designated Beneficiary as provided in the Plan.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.2</font>Partial Exercise. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Tax Withholding.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax and/or social security withholding obligations that arise in connection with the Option. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax and/or social security withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#8217;s tax and/or social security liability.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"><a name="_Ref36217797"></a></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">OTHER PROVISIONS</b></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.1</font>Adjustments. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.2</font>Notices. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#8217;s last known mailing address or email address in the Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i) if sent by email, when actually received; and (ii) if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.3</font>Titles. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.4</font>Conformity to Applicable Laws. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and this Option may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.5</font>Successors and Assigns. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.6</font>Limitations Applicable to Section&#160;16 Persons. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in any applicable exemptive rule&#160;under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.7</font>Entire Agreement. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Plan, the Grant Notice and this Agreement (including any exhibit&#160;hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.8</font>Agreement Severable. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.9</font>Limitation on Participant&#8217;s Rights. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.10</font>Not a Contract of Employment. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.11</font>Counterparts. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="line-height:1.49;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;margin-left:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.12</font>Incentive Options. </div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;text-align:justify;margin:0pt 0pt 12pt 36pt;">If the Option is designated as an Incentive Option:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the option with respect to the shares is granted) with respect to which options intended to qualify as &#8220;incentive stock options&#8221; under Section&#160;422 of the Code, including the Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such options do not qualify or cease to qualify for treatment as &#8220;incentive stock options&#8221; under Section&#160;422 of the Code, such options (including the Option) will be treated as non-qualified options. Participant further acknowledges that the rule&#160;set forth in the preceding sentence will be applied by taking the Option and other options into account in the order in which they were granted, as determined under Section&#160;422(d)&#160;of the Code. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant also acknowledges that if the Option is exercised more than three (3)&#160;months after Participant&#8217;s Termination of Service, other than by reason of death or Disability, the Option will be taxed as a Non-Qualified Option.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.49;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant will give prompt written notice to the Company of any disposition or other transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a)&#160;within two (2)&#160;years from the Grant Date or (b)&#160;within one (1)&#160;year after the transfer of such Shares to Participant. Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>5
<FILENAME>bcyc-20241231xex10d9.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:16 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;min-height:25.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.9</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS&#160;PLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Restricted Share Unit Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics&#160;Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the Restricted Share Units (the &#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Award</b>&#8221;), subject to the terms and conditions of the Plan and the Restricted Share Unit Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.714283%;padding-left:3.6pt;padding-right:3.6pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Grant Date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Number of RSUs:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Vesting start date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Vesting schedule]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Participant Acknowledgements:</b><font style="display:inline-block;width:7.07pt;"></font>By accepting this Award electronically, Participant understands and agrees that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant shall be bound by the terms of this Grant Notice, the Plan, the Agreement and any policy of the Company or any Subsidiary that may be applicable to the Participant and the Award from time to time (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Policies</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To the fullest extent permitted under the Plan and applicable law, any Withholding Taxes (as defined in the Agreement) applicable to the Award will be satisfied through the sale of a number of the Shares issuable in settlement of the Award as determined in accordance with Section 3.2 of the Agreement and the remittance of the cash proceeds to the Company. Under this Grant Notice and the Agreement, the Company or, if different, the Participant&#8217;s employer is authorized and directed by the Participant to make payment from the cash proceeds of this sale directly to the appropriate tax or social security authorities in an amount equal to the Withholding Taxes required to be remitted. The Participant further agrees that, as a result of the Participant&#8217;s authorization, the Company will have the authority to administer the Mandatory Sell to Cover (as defined in the Agreement) in connection with the Participant&#8217;s receipt of the Award.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby further agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Award of RSUs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;). Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Incorporation of Terms of Plan.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Unsecured Promise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">VESTING; FORFEITURE AND SETTLEMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Vesting; Forfeiture.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Settlement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60)&#160;days after the RSU&#8217;s vesting date (except as otherwise provided in Sections&#160;2.2(d) and (e) below). Notwithstanding the foregoing, to the extent permitted under Applicable Laws, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will not cause such a violation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">[RESERVED.]</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">When an RSU is paid in Shares, Participant may be required to pay the nominal value thereof in the same manner as provided for Withholding Taxes below.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Notwithstanding the foregoing, if (i) selling Shares in the open market pursuant to Section 2.2(a) (the &#8220;<font style="font-style:italic;font-weight:bold;">Original Issuance Date</font>&#8221;) to satisfy Participant&#8217;s tax withholding obligation in accordance with Section 3.2 below is prohibited for any reason, and (ii) the Company elects not to instead satisfy the Withholding Taxes obligations by withholding shares from Participant&#8217;s distribution, then such Shares shall not be delivered on such Original Issuance Date and shall instead be delivered to Participant on the earliest of: (1) the first date that Participant is not prohibited from selling Shares in the open market, or (2) such earlier date that the Company elects to satisfy the Withholding Taxes obligation by withholding Shares from Participant&#8217;s distribution; provided, however, that if the Company determines that Participant may be subject to taxation in the United States, then notwithstanding the foregoing, in no event will the Shares be delivered to Participant any later than: (A) December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), or (B) if and only if permitted in a manner that complies with United States Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the Shares under this Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations Section 1.409A-1(d).</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">In addition and notwithstanding the foregoing, no Shares issuable to Participant under this Section 2 as a result of the vesting of one or more RSUs will be delivered to Participant until any filings that may be required pursuant to the Hart-Scott-Rodino (&#8220;<font style="font-style:italic;font-weight:bold;">HSR</font>&#8221;) Act in connection with the issuance of such Shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#8220;<font style="font-style:italic;font-weight:bold;">HSR Requirements</font>&#8221;). If the HSR Requirements apply to the issuance of any Shares issuable to Participant under this Section 2 upon vesting of one or more RSUs, such Shares will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when Participant is permitted to sell Shares in the open market. Notwithstanding the foregoing, if the Company determines that Participant may be subject to taxation in the United States, the issuance date for any Shares delayed under this Section 2(e) shall in no event be later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), unless a later issuance date is permitted without incurring adverse tax consequences under Section 409A or other Applicable Laws.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TAXATION AND TAX WITHHOLDING</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Representation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax and/or social security consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Withholding.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges that, regardless of any action taken by the Company, or if different, the Subsidiary or affiliate employing or engaging Participant (the &#8220;<font style="font-style:italic;font-weight:bold;">Employer</font>&#8221;), the ultimate liability for all income tax (including U.S. federal, state, and local and/or non-U.S. taxes), social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to Participant&#8217;s participation in the Plan and legally applicable to Participant (the &#8220;<font style="font-style:italic;font-weight:bold;">Tax-Related Items</font>&#8221;) is and remains Participant&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer. Participant further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including, but not limited to, the grant of this Award, the vesting of this Award, the issuance of Shares in settlement of vesting of this Award, the subsequent sale of any Shares acquired pursuant to this Award and the receipt of any dividends or dividend equivalent; and (ii) do not commit to and are under no obligation to reduce or eliminate Participant&#8217;s liability for Tax-Related Items. Further, if Participant becomes subject to taxation in more than one country, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one country.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On or before the time Participant receives a distribution of the Shares underlying the RSUs, and at any other time as reasonably requested by the Company in accordance with Applicable Laws, Participant agrees to make adequate provision for any sums required to satisfy the withholding obligations of the Company or the Employer in connection with any Tax-Related Items that arise in connection with this Award (the &#8220;<font style="font-style:italic;font-weight:bold;">Withholding Taxes</font>&#8221;). The Company shall arrange a mandatory sale (on Participant&#8217;s behalf pursuant to Participant&#8217;s authorization under this section and without further consent) of the Shares issued in settlement upon the vesting of the RSUs in an amount necessary to satisfy the Withholding Taxes and shall satisfy the Withholding Taxes by withholding from the proceeds of such sale (the &#8220;<font style="font-style:italic;font-weight:bold;">Mandatory Sell to Cover</font>&#8221;). Participant hereby acknowledges and agrees that the Company shall have the authority to administer the Mandatory Sell to Cover arrangement in its sole discretion with a registered broker-dealer that is a member of the Financial Industry Regulatory Authority as the Company may select as the agent (the &#8220;<font style="font-style:italic;font-weight:bold;">Agent</font>&#8221;) who will sell on the open market at the then prevailing market price(s), as soon as practicable on or after each date on which the RSUs are settled, the number (rounded up to the next whole number) of the Shares to be delivered to Participant in connection with the settlement of the RSUs sufficient to generate proceeds to cover (i) the Withholding Taxes that Participant is required to pay pursuant to the Plan and this Agreement as a result of the settlement of the RSUs and (ii) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto, and any remaining funds shall be remitted to Participant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If, for any reason, such Mandatory Sell to Cover does not result in sufficient proceeds to satisfy the Withholding Taxes, or if such Mandatory Sell to Cover is not permitted by Applicable Laws, the Company or the Employer may, </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">in its sole discretion, satisfy all or any portion of the Withholding Taxes relating to this Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to Participant by the Company or the Employer; (ii) causing Participant to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); or (iii) withholding Shares from the Shares issued or otherwise issuable to Participant in connection with the RSUs with a fair market value (measured as of the date Shares are issued to Participant) equal to the amount of such Withholding Taxes; provided, however, that Shares shall not be withheld with a value exceeding the maximum amount of tax required to be withheld by Applicable Laws (or such lesser amount as may be necessary to avoid classification of this Award as a liability for financial accounting purposes); and to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or Remuneration Committee of the Board.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Unless the tax withholding obligations of the Company or the Employer with respect to the Tax-Related Items are satisfied, the Company shall have no obligation to deliver to Participant any Shares.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">In the event the Company&#8217;s obligation to withhold arises prior to the delivery to Participant of Shares or it is determined after the delivery of Shares to Participant that the amount of the Tax-Related Items was greater than the amount withheld, Participant agrees to indemnify and hold the Company and the Employer harmless from any failure to withhold the proper amount.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges and agrees that, as a result of Participant&#8217;s authorization under this section and without further consent, the Company will have the authority to administer the Mandatory Sell to Cover pursuant to the terms of this Award.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">OTHER PROVISIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adjustments.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Notices.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address or email address. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i)&#160;if sent by email, when actually received; and (ii)&#160;if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Titles.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Conformity to Securities Laws.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and the RSUs may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Successors and Assigns.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitations Applicable to Section&#160;16 Persons.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Entire Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Agreement Severable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font>Limitation on Participant&#8217;s Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Not a Contract of Employment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Counterparts.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>6
<FILENAME>bcyc-20241231xex10d10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:28 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;min-height:25.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.10</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED &amp; RESTATED RESTRICTED SHARE UNIT GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS&#160;PLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Amended &amp; Restated Restricted Share Unit Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics&#160;Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the Restricted Share Units (the &#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Award</b>&#8221;), subject to the terms and conditions of the Plan and the Amended &amp; Restated Restricted Share Unit Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.714283%;padding-left:3.6pt;padding-right:3.6pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Grant Date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Number of RSUs:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Vesting start date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Vesting schedule]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Participant Acknowledgements:</b><font style="display:inline-block;width:7.07pt;"></font>By accepting this Award electronically, Participant understands and agrees that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant shall be bound by the terms of this Grant Notice, the Plan, the Agreement and any policy of the Company or any Subsidiary that may be applicable to the Participant and the Award from time to time (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Policies</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To the fullest extent permitted under the Plan and applicable law, any Withholding Taxes (as defined in the Agreement) applicable to the Award will be satisfied through the sale of a number of the Shares issuable in settlement of the Award as determined in accordance with Section 3.2 of the Agreement and the remittance of the cash proceeds to the Company. Under this Grant Notice and the Agreement, the Company or, if different, the Participant&#8217;s employer is authorized and directed by the Participant to make payment from the cash proceeds of this sale directly to the appropriate tax or social security authorities in an amount equal to the Withholding Taxes required to be remitted. The Participant further agrees that, as a result of the Participant&#8217;s authorization, the Company will have the authority to administer the Mandatory Sell to Cover (as defined in the Agreement) in connection with the Participant&#8217;s receipt of the Award.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby further agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Award of RSUs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;). Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Incorporation of Terms of Plan.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Unsecured Promise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">VESTING; FORFEITURE AND SETTLEMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Vesting; Forfeiture.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Settlement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60)&#160;days after the RSU&#8217;s vesting date (except as otherwise provided in Sections&#160;2.2(d) and (e) below). Notwithstanding the foregoing, to the extent permitted under Applicable Laws, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will not cause such a violation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">[RESERVED.]</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">When an RSU is paid in Shares, Participant may be required to pay the nominal value thereof in the same manner as provided for Withholding Taxes below.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Notwithstanding the foregoing, if (i) selling Shares in the open market pursuant to Section 2.2(a) (the &#8220;<font style="font-style:italic;font-weight:bold;">Original Issuance Date</font>&#8221;) to satisfy Participant&#8217;s tax withholding obligation in accordance with Section 3.2 below is prohibited for any reason, and (ii) the Company elects not to instead satisfy the Withholding Taxes obligations by withholding shares from Participant&#8217;s distribution, then such Shares shall not be delivered on such Original Issuance Date and shall instead be delivered to Participant on the earliest of: (1) the first date that Participant is not prohibited from selling Shares in the open market, or (2) such earlier date that the Company elects to satisfy the Withholding Taxes obligation by withholding Shares from Participant&#8217;s distribution; provided, however, that if the Company determines that Participant may be subject to taxation in the United States, then notwithstanding the foregoing, in no event will the Shares be delivered to Participant any later than: (A) December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), or (B) if and only if permitted in a manner that complies with United States Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the Shares under this Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations Section 1.409A-1(d).</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">In addition and notwithstanding the foregoing, no Shares issuable to Participant under this Section 2 as a result of the vesting of one or more RSUs will be delivered to Participant until any filings that may be required pursuant to the Hart-Scott-Rodino (&#8220;<font style="font-style:italic;font-weight:bold;">HSR</font>&#8221;) Act in connection with the issuance of such Shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#8220;<font style="font-style:italic;font-weight:bold;">HSR Requirements</font>&#8221;). If the HSR Requirements apply to the issuance of any Shares issuable to Participant under this Section 2 upon vesting of one or more RSUs, such Shares will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when Participant is permitted to sell Shares in the open market. Notwithstanding the foregoing, if the Company determines that Participant may be subject to taxation in the United States, the issuance date for any Shares delayed under this Section 2(e) shall in no event be later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), unless a later issuance date is permitted without incurring adverse tax consequences under Section 409A or other Applicable Laws.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TAXATION AND TAX WITHHOLDING</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Representation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax and/or social security consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Withholding.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges that, regardless of any action taken by the Company, or if different, the Subsidiary or affiliate employing or engaging Participant (the &#8220;<font style="font-style:italic;font-weight:bold;">Employer</font>&#8221;), the ultimate liability for all income tax (including U.S. federal, state, and local and/or non-U.S. taxes), social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to Participant&#8217;s participation in the Plan and legally applicable to Participant (the &#8220;<font style="font-style:italic;font-weight:bold;">Tax-Related Items</font>&#8221;) is and remains Participant&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer. Participant further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including, but not limited to, the grant of this Award, the vesting of this Award, the issuance of Shares in settlement of vesting of this Award, the subsequent sale of any Shares acquired pursuant to this Award and the receipt of any dividends or dividend equivalent; and (ii) do not commit to and are under no obligation to reduce or eliminate Participant&#8217;s liability for Tax-Related Items. Further, if Participant becomes subject to taxation in more than one country, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one country.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On or before the time Participant receives a distribution of the Shares underlying the RSUs, and at any other time as reasonably requested by the Company in accordance with Applicable Laws, Participant agrees to make adequate provision for any sums required to satisfy the withholding obligations of the Company or the Employer in connection with any Tax-Related Items that arise in connection with this Award (the &#8220;<font style="font-style:italic;font-weight:bold;">Withholding Taxes</font>&#8221;). The Company shall arrange a mandatory sale (on Participant&#8217;s behalf pursuant to Participant&#8217;s authorization under this section and without further consent) of the Shares issued in settlement upon the vesting of the RSUs in an amount necessary to satisfy the Withholding Taxes and shall satisfy the Withholding Taxes by withholding from the proceeds of such sale (the &#8220;<font style="font-style:italic;font-weight:bold;">Mandatory Sell to Cover</font>&#8221;). Participant hereby acknowledges and agrees that the Company shall have the authority to administer the Mandatory Sell to Cover arrangement in its sole discretion with a registered broker-dealer that is a member of the Financial Industry Regulatory Authority as the Company may select as the agent (the &#8220;<font style="font-style:italic;font-weight:bold;">Agent</font>&#8221;) who will sell on the open market at the then prevailing market price(s), as soon as practicable on or after each date on which the RSUs are settled, the number (rounded up to the next whole number) of the Shares to be delivered to Participant in connection with the settlement of the RSUs sufficient to generate proceeds to cover (i) the Withholding Taxes that Participant is required to pay pursuant to the Plan and this Agreement as a result of the settlement of the RSUs and (ii) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto, and any remaining funds shall be remitted to Participant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If, for any reason, such Mandatory Sell to Cover does not result in sufficient proceeds to satisfy the Withholding Taxes, or if such Mandatory Sell to Cover is not permitted by Applicable Laws, the Company or the Employer may, </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">in its sole discretion, satisfy all or any portion of the Withholding Taxes relating to this Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to Participant by the Company or the Employer; (ii) causing Participant to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); or (iii) withholding Shares from the Shares issued or otherwise issuable to Participant in connection with the RSUs with a fair market value (measured as of the date Shares are issued to Participant) equal to the amount of such Withholding Taxes; provided, however, that Shares shall not be withheld with a value exceeding the maximum amount of tax required to be withheld by Applicable Laws (or such lesser amount as may be necessary to avoid classification of this Award as a liability for financial accounting purposes); and to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or Remuneration Committee of the Board.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Unless the tax withholding obligations of the Company or the Employer with respect to the Tax-Related Items are satisfied, the Company shall have no obligation to deliver to Participant any Shares.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">In the event the Company&#8217;s obligation to withhold arises prior to the delivery to Participant of Shares or it is determined after the delivery of Shares to Participant that the amount of the Tax-Related Items was greater than the amount withheld, Participant agrees to indemnify and hold the Company and the Employer harmless from any failure to withhold the proper amount.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges and agrees that, as a result of Participant&#8217;s authorization under this section and without further consent, the Company will have the authority to administer the Mandatory Sell to Cover pursuant to the terms of this Award.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">OTHER PROVISIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adjustments.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Notices.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address or email address. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i)&#160;if sent by email, when actually received; and (ii)&#160;if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Titles.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Conformity to Securities Laws.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and the RSUs may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Successors and Assigns.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitations Applicable to Section&#160;16 Persons.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Entire Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Agreement Severable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font>Limitation on Participant&#8217;s Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Not a Contract of Employment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Counterparts.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>7
<FILENAME>bcyc-20241231xex10d11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:28 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;min-height:25.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.11</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS&#160;PLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN: NON-EMPLOYEE SUB-PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Restricted Share Unit Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan: Non-Employee Sub-Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics&#160;Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the Restricted Share Units (the &#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Award</b>&#8221;), subject to the terms and conditions of the Plan and the Restricted Share Unit Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Grant Date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Number of RSUs:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Vesting start date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Vesting schedule]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">By accepting this Award electronically, Participant agrees to be bound by the terms of this Grant Notice, the Plan, the Agreement and any policy of the Company or any Subsidiary that may be applicable to the Participant and the Award from time to time (the &#8220;<b style="font-weight:bold;">Policies</b>&#8221;) and Participant undertakes to pay to the Company the nominal value of the Ordinary Shares underlying the RSUs in cash by way of deduction (which Participant hereby authorises) from the next instalment of cash fees that would otherwise be due to Participant. Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:-0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Award of RSUs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;). Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Incorporation of Terms of Plan.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Unsecured Promise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">VESTING; FORFEITURE AND SETTLEMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Vesting; Forfeiture.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Settlement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60)&#160;days after the RSU&#8217;s vesting date (except as otherwise provided in Sections&#160;2.2(d) and (e) below). Notwithstanding the foregoing, to the extent permitted under Applicable Laws, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will not cause such a violation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">[RESERVED]</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">When an RSU is paid in Shares, Participant may be required to pay the nominal value thereof in the same manner as provided for Withholding Taxes below.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">If the date Shares would otherwise be distributed pursuant to Section&#160;2.2(a) (the &#8220;<font style="font-style:italic;font-weight:bold;">Original Issuance Date</font>&#8221;) falls on a date that is not a business day, delivery of Shares will instead occur on the next following business day. In addition, <i style="font-style:italic;">if</i>:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the Original Issuance Date does not occur (1)&#160;during an &#8220;open window period&#8221; applicable to Participant, as determined by the Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2)&#160;on a date when Participant is otherwise permitted to sell Shares on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule&#160;10b5-1 under the Exchange Act and was entered into in compliance with the Company&#8217;s policies (a &#8220;<b style="font-weight:bold;">10b5-1 Arrangement</b>&#8221;)), and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">either (1)&#160;Withholding Taxes do not apply, or (2)&#160;the Company decides, prior to the Original Issuance Date, (A)&#160;not to satisfy Withholding Taxes by withholding Shares from the Shares otherwise due, on the Original Issuance Date, to Participant under the Award, and (B)&#160;not to permit Participant to enter into a &#8220;same day </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">sale&#8221; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C)&#160;not to permit Participant to pay the Withholding Taxes in cash,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><i style="font-style:italic;">then</i> such Shares shall not be delivered on such Original Issuance Date and shall instead be delivered to Participant on the earliest of: (1) the first date that Participant is not prohibited from selling Shares in the open market, or (2) such earlier date that the Company elects to satisfy <a name="_Hlk97019959"></a>the Withholding Taxes obligation by withholding Shares from Participant&#8217;s distribution; provided, however, that if the Company determines that Participant may be subject to taxation in the United States, then notwithstanding the foregoing, in no event will the Shares be delivered to Participant any later than: (A) December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), or (B) if and only if permitted in a manner that complies with United States Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the Shares under this Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations Section 1.409A-1(d).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">In addition and notwithstanding the foregoing, no Shares issuable to Participant under this Section 2 as a result of the vesting of one or more RSUs will be delivered to Participant until any filings that may be required pursuant to the Hart-Scott-Rodino (&#8220;<font style="font-style:italic;font-weight:bold;">HSR</font>&#8221;) Act in connection with the issuance of such Shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#8220;<font style="font-style:italic;font-weight:bold;">HSR Requirements</font>&#8221;). If the HSR Requirements apply to the issuance of any Shares issuable to Participant under this Section 2 upon vesting of one or more RSUs, such Shares will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when Participant is permitted to sell Shares in the open market. Notwithstanding the foregoing, if the Company determines that Participant may be subject to taxation in the United States, the issuance date for any Shares delayed under this Section 2(e) shall in no event be later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), unless a later issuance date is permitted without incurring adverse tax consequences under Section 409A or other Applicable Laws.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">TAXATION AND TAX WITHHOLDING</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Representation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax and/or social security consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Withholding.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On each vesting date, and on or before the time Participant receives a distribution of the shares underlying the RSUs, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, Participant hereby authorizes any required withholding from the shares issuable to Participant and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax and/or social security withholding obligations of the Company or any parent or Subsidiary that arise in connection with Participant&#8217;s RSUs (the &#8220;<b style="font-weight:bold;">Withholding Taxes</b>&#8221;). Participant hereby authorizes the Company and/or the relevant parent or Subsidiary, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following: (i)&#160;withholding from any compensation otherwise payable to Participant by the Company or any parent or Subsidiary; (ii)&#160;causing Participant to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); (iii)&#160;withholding shares from the shares issued or otherwise issuable to Participant in connection with Participant&#8217;s RSUs with a fair market value (measured as of the date shares are issued to Participant) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares so withheld will not exceed the amount necessary to satisfy the required tax and/or social security withholding obligations using the minimum statutory withholding rates for federal, state, local and, if applicable, foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and, provided, further, that to the extent necessary to qualify for an exemption from application of Section&#160;16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the prior approval of the Company&#8217;s Remuneration Committee; or (iv)&#160;by requiring Participant to </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">enter into a &#8220;same day sale&#8221; commitment with a broker-dealer in a manner satisfactory to the Company (including but not limited to a commitment under a 10b5-1 Arrangement).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax and/or social security withholding obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax and/or social security withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant&#8217;s tax and/or social security liability.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">OTHER PROVISIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adjustments.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Notices.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address or electronically via email or through the Company&#8217;s online equity administration platform. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i)&#160;if sent by email or through an online platform, when actually received; and (ii)&#160;if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Titles.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Conformity to Securities Laws.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and the RSUs may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Successors and Assigns.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitations Applicable to Section&#160;16 Persons.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Entire Agreement.</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Agreement Severable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitation on Participant&#8217;s Rights.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Not a Contract of Employment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Counterparts.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>8
<FILENAME>bcyc-20241231xex10d12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:29 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;min-height:25.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.12</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT GRANT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS&#160;PLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN: NON-EMPLOYEE SUB-PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Amended and Restated Restricted Share Unit Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan: Non-Employee Sub-Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics&#160;Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the Restricted Share Units (the &#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Award</b>&#8221;), subject to the terms and conditions of the Plan and the Amended and Restated Restricted Share Unit Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Grant Date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Number of RSUs:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Vesting start date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Vesting schedule]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">By accepting this Award electronically, Participant agrees to be bound by the terms of this Grant Notice, the Plan, the Agreement and any policy of the Company or any Subsidiary that may be applicable to the Participant and the Award from time to time (the &#8220;<b style="font-weight:bold;">Policies</b>&#8221;) and Participant undertakes to pay to the Company the nominal value of the Ordinary Shares underlying the RSUs in cash by way of deduction (which Participant hereby authorises) from the next instalment of cash fees that would otherwise be due to Participant. Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:-0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Award of RSUs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;). Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Incorporation of Terms of Plan.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Unsecured Promise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">VESTING; FORFEITURE AND SETTLEMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Vesting; Forfeiture.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Settlement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60)&#160;days after the RSU&#8217;s vesting date (except as otherwise provided in Sections&#160;2.2(d) and (e) below). Notwithstanding the foregoing, to the extent permitted under Applicable Laws, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will not cause such a violation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">[RESERVED]</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">When an RSU is paid in Shares, Participant may be required to pay the nominal value thereof in the same manner as provided for Withholding Taxes below.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">If the date Shares would otherwise be distributed pursuant to Section&#160;2.2(a) (the &#8220;<font style="font-style:italic;font-weight:bold;">Original Issuance Date</font>&#8221;) falls on a date that is not a business day, delivery of Shares will instead occur on the next following business day. In addition, <i style="font-style:italic;">if</i>:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the Original Issuance Date does not occur (1)&#160;during an &#8220;open window period&#8221; applicable to Participant, as determined by the Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2)&#160;on a date when Participant is otherwise permitted to sell Shares on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule&#160;10b5-1 under the Exchange Act and was entered into in compliance with the Company&#8217;s policies (a &#8220;<b style="font-weight:bold;">10b5-1 Arrangement</b>&#8221;)), and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">either (1)&#160;Withholding Taxes do not apply, or (2)&#160;the Company decides, prior to the Original Issuance Date, (A)&#160;not to satisfy Withholding Taxes by withholding Shares from the Shares otherwise due, on the Original </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Issuance Date, to Participant under the Award, and (B)&#160;not to permit Participant to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C)&#160;not to permit Participant to pay the Withholding Taxes in cash,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><i style="font-style:italic;">then</i> such Shares shall not be delivered on such Original Issuance Date and shall instead be delivered to Participant on the earliest of: (1) the first date that Participant is not prohibited from selling Shares in the open market, or (2) such earlier date that the Company elects to satisfy <a name="_Hlk97019959"></a>the Withholding Taxes obligation by withholding Shares from Participant&#8217;s distribution; provided, however, that if the Company determines that Participant may be subject to taxation in the United States, then notwithstanding the foregoing, in no event will the Shares be delivered to Participant any later than: (A) December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), or (B) if and only if permitted in a manner that complies with United States Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the Shares under this Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations Section 1.409A-1(d).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">In addition and notwithstanding the foregoing, no Shares issuable to Participant under this Section 2 as a result of the vesting of one or more RSUs will be delivered to Participant until any filings that may be required pursuant to the Hart-Scott-Rodino (&#8220;<font style="font-style:italic;font-weight:bold;">HSR</font>&#8221;) Act in connection with the issuance of such Shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#8220;<font style="font-style:italic;font-weight:bold;">HSR Requirements</font>&#8221;). If the HSR Requirements apply to the issuance of any Shares issuable to Participant under this Section 2 upon vesting of one or more RSUs, such Shares will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when Participant is permitted to sell Shares in the open market. Notwithstanding the foregoing, if the Company determines that Participant may be subject to taxation in the United States, the issuance date for any Shares delayed under this Section 2(e) shall in no event be later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), unless a later issuance date is permitted without incurring adverse tax consequences under Section 409A or other Applicable Laws.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">TAXATION AND TAX WITHHOLDING</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Representation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax and/or social security consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Withholding.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On each vesting date, and on or before the time Participant receives a distribution of the shares underlying the RSUs, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, Participant hereby authorizes any required withholding from the shares issuable to Participant and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax and/or social security withholding obligations of the Company or any parent or Subsidiary that arise in connection with Participant&#8217;s RSUs (the &#8220;<b style="font-weight:bold;">Withholding Taxes</b>&#8221;). Participant hereby authorizes the Company and/or the relevant parent or Subsidiary, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following: (i)&#160;withholding from any compensation otherwise payable to Participant by the Company or any parent or Subsidiary; (ii)&#160;causing Participant to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); (iii)&#160;withholding shares from the shares issued or otherwise issuable to Participant in connection with Participant&#8217;s RSUs with a fair market value (measured as of the date shares are issued to Participant) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares so withheld will not exceed the amount necessary to satisfy the required tax and/or social security withholding obligations using the minimum statutory withholding rates for federal, state, local and, if applicable, foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and, provided, further, that to the extent necessary to qualify for an exemption from application of Section&#160;16(b) of the Exchange Act, if applicable, such share withholding procedure </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">will be subject to the prior approval of the Company&#8217;s Remuneration Committee; or (iv)&#160;by requiring Participant to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer in a manner satisfactory to the Company (including but not limited to a commitment under a 10b5-1 Arrangement).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax and/or social security withholding obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax and/or social security withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant&#8217;s tax and/or social security liability.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">OTHER PROVISIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adjustments.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Notices.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address or electronically via email or through the Company&#8217;s online equity administration platform. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i)&#160;if sent by email or through an online platform, when actually received; and (ii)&#160;if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Titles.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Conformity to Securities Laws.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and the RSUs may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Successors and Assigns.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitations Applicable to Section&#160;16 Persons.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Entire Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Agreement Severable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitation on Participant&#8217;s Rights.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Not a Contract of Employment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Counterparts.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>9
<FILENAME>bcyc-20241231xex10d13.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:31 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;min-height:25.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.13</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT GRANT NOTICE (DEFERRED SETTLEMENT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS&#160;PLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN: NON-EMPLOYEE SUB-PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Restricted Share Unit Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan: Non-Employee Sub-Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics&#160;Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the Restricted Share Units (the &#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Award</b>&#8221;), subject to the terms and conditions of the Plan and the Restricted Share Unit Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Grant Date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Number of RSUs:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Vesting start date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Vesting schedule]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">By accepting this Award electronically, Participant agrees to be bound by the terms of this Grant Notice, the Plan, the Agreement and any policy of the Company or any Subsidiary that may be applicable to the Participant and the Award from time to time (the &#8220;<b style="font-weight:bold;">Policies</b>&#8221;) and Participant undertakes to pay to the Company the nominal value of the Ordinary Shares underlying the RSUs in cash by way of deduction (which Participant hereby authorises) from the next instalment of cash fees that would otherwise be due to Participant. Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:-0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT AGREEMENT </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(DEFERRED SETTLEMENT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Award of RSUs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;). Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Incorporation of Terms of Plan.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Unsecured Promise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">VESTING; FORFEITURE AND SETTLEMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Vesting; Forfeiture.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Settlement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">RSUs that have vested will be paid in Shares on the first to occur of the following (such date, the &#8220;<b style="font-weight:bold;">Settlement Date</b>&#8221;) or such later date that is not later than December 31 of the calendar year in which the Settlement Date occurs as set forth in Section 2.2(d)(ii) below, except as may be required pursuant to Section 3.3 of this Agreement:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of the Participant&#8217;s &#8220;separation from service&#8221; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definitions therein, a &#8220;<b style="font-weight:bold;">Separation from Service</b>&#8221;); </p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of the Participant&#8217;s &#8220;disability&#8221; (as defined under Treasury Regulation Section 1.409A-3(i)(4));</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of the Participant&#8217;s death; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of a Change in Control that also would constitute a &#8220;change in control event&#8221; (as defined under Treasury Regulation Section 1.409A-3(i)(5)).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">[RESERVED]</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">When an RSU is paid in Shares, Participant may be required to pay the nominal value thereof in the same manner as provided for Withholding Taxes below.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">If the date Shares would otherwise be distributed pursuant to Section&#160;2.2(a) (the &#8220;<b style="font-weight:bold;">Original Issuance Date</b>&#8221;) falls on a date that is not a business day, delivery of Shares will instead occur on the next following business day. In addition, <i style="font-style:italic;">if</i>:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the Original Issuance Date does not occur (1)&#160;during an &#8220;open window period&#8221; applicable to Participant, as determined by the Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2)&#160;on a date when Participant is otherwise permitted to sell Shares on an established stock exchange or </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 36pt;">stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule&#160;10b5-1 under the Exchange Act and was entered into in compliance with the Company&#8217;s policies (a &#8220;<b style="font-weight:bold;">10b5-1 Arrangement</b>&#8221;)), and</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">either (1)&#160;Withholding Taxes do not apply, or (2)&#160;the Company decides, prior to the Original Issuance Date, (A)&#160;not to satisfy Withholding Taxes by withholding Shares from the Shares otherwise due, on the Original Issuance Date, to Participant under the Award, and (B)&#160;not to permit Participant to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C)&#160;not to permit Participant to pay the Withholding Taxes in cash,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><i style="font-style:italic;">then</i> such Shares shall not be delivered on such Original Issuance Date and shall instead be delivered to Participant on the earliest of: (1) the first date that Participant is not prohibited from selling Shares in the open market, or (2) such earlier date that the Company elects to satisfy <a name="_Hlk97019959"></a>the Withholding Taxes obligation by withholding Shares from Participant&#8217;s distribution; provided, however, that if the Company determines that Participant may be subject to taxation in the United States, then notwithstanding the foregoing, in no event will the Shares be delivered to Participant any later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">In addition and notwithstanding the foregoing, no Shares issuable to Participant under this Section 2 as a result of the vesting of one or more RSUs will be delivered to Participant until any filings that may be required pursuant to the Hart-Scott-Rodino (&#8220;<font style="font-style:italic;font-weight:bold;">HSR</font>&#8221;) Act in connection with the issuance of such Shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#8220;<font style="font-style:italic;font-weight:bold;">HSR Requirements</font>&#8221;). If the HSR Requirements apply to the issuance of any Shares issuable to Participant under this Section 2 upon vesting of one or more RSUs, such Shares will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when Participant is permitted to sell Shares in the open market. Notwithstanding the foregoing, if the Company determines that Participant may be subject to taxation in the United States, the issuance date for any Shares delayed under this Section 2(e) shall in no event be later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), unless a later issuance date is permitted without incurring adverse tax consequences under Section 409A or other Applicable Laws.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Notwithstanding anything herein to the contrary, to the extent permitted under Applicable Laws, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will not cause such a violation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">TAXATION AND TAX WITHHOLDING</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Representation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax and/or social security consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Withholding.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On each vesting date, and on or before the time Participant receives a distribution of the Shares underlying the RSUs, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, Participant hereby authorizes any required withholding from the Shares issuable to Participant and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax and/or social security withholding obligations of the Company or any parent or Subsidiary that arise in connection with Participant&#8217;s RSUs (the &#8220;<b style="font-weight:bold;">Withholding Taxes</b>&#8221;). Participant hereby authorizes the Company and/or the relevant parent or Subsidiary, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following: (i)&#160;withholding from any compensation otherwise payable to Participant by the Company or any parent or Subsidiary; (ii)&#160;causing Participant to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); (iii)&#160;withholding Shares from the Shares issued or otherwise issuable to Participant in connection with Participant&#8217;s RSUs with a fair market value (measured as of the date Shares are issued to Participant) equal to the amount of such Withholding Taxes; provided, however, that the number of such Shares so withheld will not exceed the amount </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">necessary to satisfy the required tax and/or social security withholding obligations using the minimum statutory withholding rates for federal, state, local and, if applicable, foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and, provided, further, that to the extent necessary to qualify for an exemption from application of Section&#160;16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the prior approval of the Company&#8217;s Remuneration Committee; or (iv)&#160;by requiring Participant to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer in a manner satisfactory to the Company (including but not limited to a commitment under a 10b5-1 Arrangement).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax and/or social security withholding obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax and/or social security withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant&#8217;s tax and/or social security liability.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Consequences.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font>To the extent that Participant may be subject to taxation in the United States, this Award is intended to comply with Section 409A, and, accordingly, to the maximum extent permitted, this Agreement will be interpreted and administered to be in compliance with Section 409A. Any installment of RSUs that vests hereunder is intended to constitute a &#8220;separate payment&#8221; for purposes of Section 409A. If Participant is a &#8220;specified employee&#8221; for purposes of Section 409A upon the Separation from Service, then the issuance of any Shares or other property that would otherwise be made on the date of Separation from Service (or within the first six months thereafter as a result of the Separation from Service) will not be made on the originally scheduled date(s) and will instead be issued in a lump sum on the earlier of (i) the date that is six months and one day after the date of the Separation from Service or (ii) the date of Participant&#8217;s death, but if and only if such delay in the issuance is necessary to avoid the imposition of taxes in respect of the Shares or property under Section 409A. Notwithstanding anything to the contrary in the Plan or this Agreement, none of the Company, its Subsidiaries and affiliates, the Board or the Committee will have any obligation to take any action to prevent the assessment of any excise tax or penalty on Participant under Section 409A and none of the Company, its Subsidiaries and affiliates, the Board or the Committee will have any liability to Participant for such tax or penalty.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">OTHER PROVISIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adjustments.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Notices.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address or electronically via email or through the Company&#8217;s online equity administration platform. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i)&#160;if sent by email or through an online platform, when actually received; and (ii)&#160;if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Titles.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Conformity to Securities Laws.</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and the RSUs may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Successors and Assigns.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitations Applicable to Section&#160;16 Persons.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Entire Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Agreement Severable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font>Limitation on Participant&#8217;s Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Not a Contract of Employment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Counterparts.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>10
<FILENAME>bcyc-20241231xex10d14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:38 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:28.8pt;min-height:25.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.14</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT GRANT NOTICE (DEFERRED SETTLEMENT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BICYCLE THERAPEUTICS&#160;PLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2020 EQUITY INCENTIVE PLAN: NON-EMPLOYEE SUB-PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capitalized terms not specifically defined in this Amended and Restated Restricted Share Unit Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Notice</b>&#8221;) have the meanings given to them in the 2020 Equity Incentive Plan: Non-Employee Sub-Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) of Bicycle Therapeutics&#160;Plc (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has granted to the participant listed below (&#8220;<b style="font-weight:bold;">Participant</b>&#8221;) the Restricted Share Units (the &#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) described in this Grant Notice (the &#8220;<b style="font-weight:bold;">Award</b>&#8221;), subject to the terms and conditions of the Plan and the Amended and Restated Restricted Share Unit Agreement attached as Exhibit&#160;A (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), both of which are incorporated into this Grant Notice by reference.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:3.6pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Participant Name]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Grant Date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Number of RSUs:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Number of shares]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:bottom;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[Vesting start date]</p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Vesting schedule] </p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:26.85%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:73.14%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">By accepting this Award electronically, Participant agrees to be bound by the terms of this Grant Notice, the Plan, the Agreement and any policy of the Company or any Subsidiary that may be applicable to the Participant and the Award from time to time (the &#8220;<b style="font-weight:bold;">Policies</b>&#8221;) and Participant undertakes to pay to the Company the nominal value of the Ordinary Shares underlying the RSUs in cash by way of deduction (which Participant hereby authorises) from the next instalment of cash fees that would otherwise be due to Participant. Participant has reviewed the Plan, this Grant Notice, the Agreement and the Policies in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice, the Agreement and the Policies. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:-0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED SHARE UNIT AGREEMENT </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(DEFERRED SETTLEMENT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Award of RSUs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<b style="font-weight:bold;">Grant Date</b>&#8221;). Each RSU represents the right to receive one Share as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Incorporation of Terms of Plan.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Unsecured Promise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">VESTING; FORFEITURE AND SETTLEMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Vesting; Forfeiture.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Settlement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">RSUs that have vested will be paid in Shares on the first to occur of the following (such date, the &#8220;<b style="font-weight:bold;">Settlement Date</b>&#8221;) or such later date that is not later than December 31 of the calendar year in which the Settlement Date occurs as set forth in Section 2.2(d)(ii) below, except as may be required pursuant to Section 3.3 of this Agreement:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of the Participant&#8217;s &#8220;separation from service&#8221; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definitions therein, a &#8220;<b style="font-weight:bold;">Separation from Service</b>&#8221;); </p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of the Participant&#8217;s &#8220;disability&#8221; (as defined under Treasury Regulation Section 1.409A-3(i)(4));</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of the Participant&#8217;s death; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the date of a Change in Control that also would constitute a &#8220;change in control event&#8221; (as defined under Treasury Regulation Section 1.409A-3(i)(5)).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">[RESERVED]</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">When an RSU is paid in Shares, Participant may be required to pay the nominal value thereof in the same manner as provided for Withholding Taxes below.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">If the date Shares would otherwise be distributed pursuant to Section&#160;2.2(a) (the &#8220;<b style="font-weight:bold;">Original Issuance Date</b>&#8221;) falls on a date that is not a business day, delivery of Shares will instead occur on the next following business day. In addition, <i style="font-style:italic;">if</i>:</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">the Original Issuance Date does not occur (1)&#160;during an &#8220;open window period&#8221; applicable to Participant, as determined by the Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2)&#160;on a date when Participant is otherwise permitted to sell Shares on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule&#160;10b5-1 under the Exchange Act and was entered into in compliance with the Company&#8217;s policies (a &#8220;<b style="font-weight:bold;">10b5-1 Arrangement</b>&#8221;)), and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">either (1)&#160;Withholding Taxes do not apply, or (2)&#160;the Company decides, prior to the Original Issuance Date, (A)&#160;not to satisfy Withholding Taxes by withholding Shares from the Shares otherwise due, on the Original Issuance Date, to Participant under the Award, and (B)&#160;not to permit Participant to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C)&#160;not to permit Participant to pay the Withholding Taxes in cash,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 9pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><i style="font-style:italic;">then</i> such Shares shall not be delivered on such Original Issuance Date and shall instead be delivered to Participant on the earliest of: (1) the first date that Participant is not prohibited from selling Shares in the open market, or (2) such earlier date that the Company elects to satisfy <a name="_Hlk97019959"></a>the Withholding Taxes obligation by withholding Shares from Participant&#8217;s distribution; provided, however, that if the Company determines that Participant may be subject to taxation in the United States, then notwithstanding the foregoing, in no event will the Shares be delivered to Participant any later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">In addition and notwithstanding the foregoing, no Shares issuable to Participant under this Section 2 as a result of the vesting of one or more RSUs will be delivered to Participant until any filings that may be required pursuant to the Hart-Scott-Rodino (&#8220;<font style="font-style:italic;font-weight:bold;">HSR</font>&#8221;) Act in connection with the issuance of such Shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#8220;<font style="font-style:italic;font-weight:bold;">HSR Requirements</font>&#8221;). If the HSR Requirements apply to the issuance of any Shares issuable to Participant under this Section 2 upon vesting of one or more RSUs, such Shares will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when Participant is permitted to sell Shares in the open market. Notwithstanding the foregoing, if the Company determines that Participant may be subject to taxation in the United States, the issuance date for any Shares delayed under this Section 2(e) shall in no event be later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant&#8217;s taxable year in which the Original Issuance Date occurs), unless a later issuance date is permitted without incurring adverse tax consequences under Section 409A or other Applicable Laws.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">Notwithstanding anything herein to the contrary, to the extent permitted under Applicable Laws, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will not cause such a violation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;"><b style="font-weight:bold;">TAXATION AND TAX WITHHOLDING</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Representation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax and/or social security consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Withholding.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On each vesting date, and on or before the time Participant receives a distribution of the Shares underlying the RSUs, and at any other time as reasonably requested by the Company in accordance with applicable tax laws, Participant hereby authorizes any required withholding from the Shares issuable to Participant and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax and/or social security withholding obligations of the Company or any parent or Subsidiary that arise in connection with Participant&#8217;s RSUs (the &#8220;<b style="font-weight:bold;">Withholding Taxes</b>&#8221;). Participant hereby authorizes the Company and/or the relevant parent or Subsidiary, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following: (i)&#160;withholding from any compensation otherwise payable to Participant by the Company or any parent or Subsidiary; (ii)&#160;causing Participant to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); </p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">(iii)&#160;withholding Shares from the Shares issued or otherwise issuable to Participant in connection with Participant&#8217;s RSUs with a fair market value (measured as of the date Shares are issued to Participant) equal to the amount of such Withholding Taxes; provided, however, that the number of such Shares so withheld will not exceed the amount necessary to satisfy the required tax and/or social security withholding obligations using the minimum statutory withholding rates for federal, state, local and, if applicable, foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and, provided, further, that to the extent necessary to qualify for an exemption from application of Section&#160;16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the prior approval of the Company&#8217;s Remuneration Committee; or (iv)&#160;by requiring Participant to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer in a manner satisfactory to the Company (including but not limited to a commitment under a 10b5-1 Arrangement).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax and/or social security withholding obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax and/or social security withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant&#8217;s tax and/or social security liability.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tax Consequences.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font>To the extent that Participant may be subject to taxation in the United States, this Award is intended to comply with Section 409A, and, accordingly, to the maximum extent permitted, this Agreement will be interpreted and administered to be in compliance with Section 409A. Any installment of RSUs that vests hereunder is intended to constitute a &#8220;separate payment&#8221; for purposes of Section 409A. If Participant is a &#8220;specified employee&#8221; for purposes of Section 409A upon the Separation from Service, then the issuance of any Shares or other property that would otherwise be made on the date of Separation from Service (or within the first six months thereafter as a result of the Separation from Service) will not be made on the originally scheduled date(s) and will instead be issued in a lump sum on the earlier of (i) the date that is six months and one day after the date of the Separation from Service or (ii) the date of Participant&#8217;s death, but if and only if such delay in the issuance is necessary to avoid the imposition of taxes in respect of the Shares or property under Section 409A. Notwithstanding anything to the contrary in the Plan or this Agreement, none of the Company, its Subsidiaries and affiliates, the Board or the Committee will have any obligation to take any action to prevent the assessment of any excise tax or penalty on Participant under Section 409A and none of the Company, its Subsidiaries and affiliates, the Board or the Committee will have any liability to Participant for such tax or penalty.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">OTHER PROVISIONS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adjustments.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Notices.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address or electronically via email or through the Company&#8217;s online equity administration platform. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given: (i)&#160;if sent by email or through an online platform, when actually received; and (ii)&#160;if sent by certified mail (return receipt requested) and deposited with postage prepaid in the applicable national mail, when delivered by a nationally recognized express shipping company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Titles.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Conformity to Securities Laws.</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws, and the RSUs may be unilaterally cancelled by the Company (with the effect that all Participant&#8217;s rights hereunder lapse with immediate effect) if the Administrator determines in its reasonable discretion that such conformity is not possible or practicable.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Successors and Assigns.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitations Applicable to Section&#160;16 Persons.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Entire Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Agreement Severable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font>Limitation on Participant&#8217;s Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Not a Contract of Employment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Counterparts.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>11
<FILENAME>bcyc-20241231xex10d36.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:39 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;min-height:43.2pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.36</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:center;margin:0pt;"><a name="_Hlk163573105"></a><b style="font-family:'Times New Roman Bold';font-size:12pt;font-variant:small-caps;font-weight:bold;">Bicycle Therapeutics plc</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-size:12pt;font-variant:small-caps;font-weight:bold;">Non-Employee Director Compensation Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-size:12pt;font-variant:small-caps;font-weight:bold;">As amended through December 12, 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Non-Employee Director Compensation Policy (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) has been established in order to attract and retain non-employee directors who have the knowledge, skills and experience to serve as a member of the Board of Directors (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) of Bicycle Therapeutics plc (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). &#160;Directors who are employees of the Company or any of its subsidiaries will receive no additional compensation for their service as directors. &#160;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">All equity awards granted in accordance with this Policy shall be granted under the Company&#8217;s then-current equity incentive plan (or director equity incentive plan, if any). </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">A.</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><b style="font-family:'Times New Roman Bold';font-size:12pt;font-variant:small-caps;font-weight:bold;">Equity Awards</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Either by unanimous written resolutions or by resolutions adopted at the next scheduled meeting of the Board or the Compensation Committee, as applicable, in each case following a non-employee director&#8217;s initial election to the Company&#8217;s Board, the Board or the Compensation Committee of the Board shall grant such non-employee director an option to purchase 25,000 of the Company&#8217;s ordinary shares and a restricted stock unit award (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">RSU</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) for 12,500 ordinary shares (collectively, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Initial Grant</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). The options and RSUs comprising the Initial Grant will vest in three equal installments on the first, second and third anniversaries of the date of grant, subject to continued service by the director as of such vesting date.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">In addition, in January of each year, the Board or the Compensation Committee of the Board will grant to each non-employee director (other than the Chair) an option to purchase 12,500 ordinary shares and an RSU award for 6,250 ordinary shares, and the Chair will be granted an option to purchase 25,000 ordinary shares and an RSU award for 12,500 ordinary shares (collectively, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Annual Grant</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). If a new non-employee director joins the Board following the date of grant of the Annual Grant in any calendar year, such non-employee director will be granted a pro-rata portion of the next Annual Grant, based on the time between his or her appointment and the date of such Annual Grant. &#160;Annual Grants shall vest in four substantially equal installments on the 15</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> day of the last month of each fiscal quarter in the year in which the Annual Grant is made, in each case, subject to continued service by the director as of each applicable vesting date. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Notwithstanding anything herein to the contrary, the Compensation Committee may, in its sole discretion, provide for deferred settlement of RSUs awarded to a non-employee director as part of the Initial Grant and/or the Annual Grant.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">B.</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;&#160;&#160;&#160; </font><b style="font-family:'Times New Roman Bold';font-size:12pt;font-variant:small-caps;font-weight:bold;">Cash Fees</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Each non-employee director will receive an annual cash fee for service on the Board and for service on each committee of which the director is a member. The chairs of the Board and of each committee will receive higher fees for such service. The amounts of the fees paid to each non-employee director for service on the Board and for service on each committee of the board of directors on which the director is a member are as follows:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:88%;"><tr><td style="vertical-align:top;width:60.51%;background:#ffffff;border-bottom:1.5pt solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:3.35%;background:#ffffff;border-bottom:1.5pt solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:top;width:14.71%;background:#ffffff;border-bottom:1.5pt solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Member</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Annual</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Fee</b></p></td><td style="vertical-align:top;width:3.35%;background:#ffffff;border-bottom:1.5pt solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:top;width:14.71%;background:#ffffff;border-bottom:1.5pt solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Chair</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Annual</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Fee</b></p></td><td style="vertical-align:top;width:3.35%;background:#ffffff;border-bottom:1.5pt solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:60.51%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-right:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Board of Directors</b></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">50,000</font></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">12,000</font></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:60.51%;border-bottom:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Audit Committee</b></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">15,000</font></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">25,000</font></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:60.51%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Compensation Committee</b></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">10,000</font></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">20,000</font></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:60.51%;border-bottom:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Nominating and Corporate Governance Committee</b></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">10,000</font></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:4.07%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">15,000</font></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:top;width:60.51%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Strategic Committee</b></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.07%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">35,000</font></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.07%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">50,000</font></p></td><td style="vertical-align:top;width:3.35%;background:#dce6f2;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:60.51%;border-bottom:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Scientific Committee</b></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.07%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">10,000</font></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.07%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$</font></p></td><td style="vertical-align:top;width:10.63%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-right:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.27pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">15,000</font></p></td><td style="vertical-align:top;width:3.35%;border-bottom:1px solid #95b3d7;border-left:1px solid #95b3d7;border-top:1px solid #95b3d7;margin:0pt;padding:0pt 5.4pt 0pt 5.27pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">These fees are payable in arrears in twelve equal monthly installments, subject to deduction of applicable income tax or national insurance which the Company is required by law to deduct and any other statutory deductions, provided that the amount of such payment shall be prorated for any portion of such month during which the director was not serving.&#160; &#160;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">C. </b></font><b style="font-family:'Times New Roman Bold';font-size:12pt;font-variant:small-caps;font-weight:bold;">Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The reasonable expenses incurred by non-employee directors in connection with attendance at Board or committee meetings or other Company-related activities will be reimbursed upon submission of appropriate documentation.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">D.</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;&#160;</font></font><b style="font-family:'Times New Roman Bold';font-size:12pt;font-variant:small-caps;font-weight:bold;">Administration</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Program shall be administered by the Compensation Committee, which shall have the power to interpret these provisions and approve changes from time to time as it deems appropriate. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>12
<FILENAME>bcyc-20241231xex19d1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:40 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 19.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Bicycle Therapeutics plc</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended and Restated Insider Trading Policy, as Amended</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">(adopted September 26, 2019</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">and Amended </b></font><b style="font-variant:small-caps;font-weight:bold;">September 27, 2023)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-variant:small-caps;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:468pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><font style="font-size:11pt;font-variant:small-caps;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Introduction</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the course of your relationship with Bicycle Therapeutics plc (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), you may receive material information that is not yet publicly available (&#8220;<font style="font-style:italic;font-weight:bold;">material nonpublic information</font>&#8221;) about the Company or other publicly traded companies with which the Company has business relationships. Material nonpublic information may give you, or someone you pass that information on to, a leg up over others when deciding whether to buy, sell or otherwise transact in the Company&#8217;s securities or the securities of another publicly traded company. This Amended &amp; Restated Insider Trading Policy, as amended from time to time (the &#8220;<font style="font-style:italic;font-weight:bold;">Insider Trading Policy</font>&#8221; or this &#8220;<font style="font-style:italic;font-weight:bold;">Policy</font>&#8221;) sets forth guidelines with respect to transactions in the Company&#8217;s securities and in the securities of other applicable publicly traded companies, in each case by our employees, directors and consultants who may become aware of material nonpublic information and the other persons subject to this Policy as described below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Statement of Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is the policy of the Company that an employee, director or consultant of the Company (or any other person subject to this Policy) who is aware of material nonpublic information relating to the Company <b style="font-weight:bold;">may not</b>, directly or indirectly: &#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">engage in any transactions in the Company&#8217;s securities, except as otherwise specified under the heading &#8220;Exceptions to this Policy&#8221; below; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">recommend the purchase or sale of any the Company&#8217;s securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">disclose material nonpublic information to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons, such as family, friends, business associates and investors, unless the disclosure is made in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of information regarding the Company; or </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">assist anyone engaged in the above activities.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The prohibition against insider trading is absolute. It applies <font style="font-style:italic;font-weight:bold;">even if</font> the decision to trade is not based on such material nonpublic information. &#160;It also applies to transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) and also to very small transactions. &#160;All that matters is whether you are aware of <b style="font-weight:bold;">any</b> material nonpublic information relating to the Company at the time of the transaction. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal securities laws do not recognize any mitigating circumstances to insider trading. In addition, even the appearance of an improper transaction must be avoided to preserve the Company&#8217;s reputation for adhering to the highest standards of conduct. In some circumstances, you may need to forgo a planned transaction even if you planned it before becoming aware of the material nonpublic information. So, even if you believe you may suffer an economic loss or sacrifice an anticipated profit by waiting to trade, you must wait.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is also important to note that the laws prohibiting insider trading are not limited to trading by the insider alone; advising others to trade on the basis of material nonpublic information is illegal and squarely prohibited by this Policy. Liability in such cases can extend both to the &#8220;tippee&#8221;&#8212;the person to whom the insider disclosed material nonpublic information&#8212;and to the &#8220;tipper,&#8221; the insider himself or herself. &#160;In such cases, you can be held liable for your own transactions, as well as the transactions by a tippee and even the transactions of a tippee&#8217;s tippee. For these and other reasons, it is the policy of the Company that no employee, director or consultant of the Company (or any other person subject to this Policy) may either (a) recommend to another person that they buy, hold or sell the Company&#8217;s securities <b style="font-weight:bold;">at any time</b> or (b) disclose material nonpublic information to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons (unless the disclosure is made in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of information regarding the Company). &#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">In addition, it is the policy of the Company that no employee, director or consultant of the Company (or any other person subject to this Policy) who, in the course of his or her relationship with the Company, learns of or is otherwise aware of material nonpublic information about another publicly traded company with which the Company does business, including a supplier, partner or collaborator of the Company, may trade in that other company&#8217;s securities until the information becomes public or is no longer material to that other company. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">There are no exceptions to this Policy, except as specifically noted above or below. &#160; &#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Transactions Subject to this Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Policy applies to all transactions in securities issued by the Company, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company&#8217;s securities. Accordingly, for purposes of this Policy, the terms &#8220;<font style="font-style:italic;font-weight:bold;">trade</font>,&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">trading</font>&#8221; and &#8220;<font style="font-style:italic;font-weight:bold;">transactions</font>&#8221; include not only purchases and sales of the Company&#8217;s <font style="font-size:12pt;"><a name="_cp_text_1_2"></a><a name="_cp_text_2_3"></a><a name="_cp_text_2_4"></a><a name="_cp_text_2_5"></a><a name="_cp_text_2_6"></a><a name="_cp_text_2_1"></a></font>American Depositary Shares (&#8220;<font style="font-style:italic;font-weight:bold;">ADSs</font>&#8221;) in the public market but also any other purchases, sales, transfers, gifts or other acquisitions and dispositions of ADSs, ordinary or preferred equity, options, warrants and other securities (including debt securities) and other arrangements or transactions that affect economic exposure to changes in the prices of these securities. &#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Persons Subject to this Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;">This Policy applies to you and all other employees, directors and consultants of the Company and its subsidiaries. This Policy also applies to members of your immediate family, persons with whom you share a household, persons who are your economic dependents and any other individuals or entities whose transactions in securities you influence, direct or control (including, e.g., a venture or other investment fund, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">if</u> you influence, direct or control transactions by the fund)<font style="font-size:12pt;"><a name="_cp_text_2_9"></a><a name="_cp_text_1_10"></a></font>. However, this Policy does not apply to any entity that invests in securities in the ordinary course of its business (e.g., a venture or other investment fund) if (and only if) such entity has established its own insider trading controls and procedures in compliance with applicable securities laws with respect to trading in the Company&#8217;s securities.<font style="font-size:12pt;"> &#160;</font>The foregoing persons who are deemed subject to this Policy are referred to in this Policy as &#8220;<font style="font-style:italic;font-weight:bold;">Related Persons</font>.&#8221; You are responsible for making sure that your Related Persons comply with this Policy. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Material Nonpublic Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Material information</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is not always easy to figure out whether you are aware of material nonpublic information. But there is one important factor to determine whether nonpublic information you know about a public company is material: &#160;whether the information could be expected to affect the market price of that company&#8217;s securities or to be considered important by investors who are considering trading that company&#8217;s securities. If the information makes you want to trade, it would probably have the same effect on others. Remember, both positive and negative information can be material. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by relevant enforcement authorities with the benefit of hindsight. If you possess inside information, you may not trade in a company&#8217;s shares, advise anyone else to do so or communicate the information to anyone else until you know that the information has been publicly disseminated. <font style="font-size:12pt;"><a name="_cp_text_2_24"></a></font>This means that in some circumstances, you may have to forego a proposed transaction in a company&#8217;s securities even if you planned to execute the transaction prior to learning of the inside information and even though you believe you may suffer an economic loss or sacrifice an anticipated profit by waiting. &#8220;<font style="font-style:italic;font-weight:bold;">Trading</font>&#8221; includes engaging in short sales, transactions in put or call options, hedging transactions and other inherently speculative transactions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You may not participate in &#8220;chat rooms&#8221; or other electronic discussion groups or contribute to blogs, bulletin boards or social media forums on the internet concerning the activities of the Company or other companies with which the Company does business, even if you do so anonymously, unless doing so is part of your job responsibilities and you have explicit authorization from the Company&#8217;s Chief Financial Officer, or if no individual currently holds such position, then our General Counsel (the &#8220;<font style="font-style:italic;font-weight:bold;">Clearing Officer</font>&#8221;). &#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending on the specific details, the following items may be considered material nonpublic information until publicly disclosed within the meaning of this Policy. There may be other types of information that would qualify as material information as well; use this list merely as a non-exhaustive guide: </p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">financial results or forecasts;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">status of product or product candidate development or regulatory approvals;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">clinical data relating to products or product candidates;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">timelines for pre-clinical studies or clinical trials; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">communications with government agencies, including, but not limited to, the U.S. Food and Drug Administration; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">strategic plans; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">acquisitions or dispositions of assets, divisions or companies;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">public or private sales of debt or equity securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">share splits, dividends or changes in dividend policy;</font></td></tr></table><div style="margin-top:3pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">the establishment of a repurchase program for the Company&#8217;s securities;</font></td></tr></table><div style="margin-top:3pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">gain or loss of a significant licensor, licensee or supplier; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">changes or new corporate partner relationships or collaborations;</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">notice of issuance or denial of patents; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">regulatory developments;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">management or control changes;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">employee layoffs; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">a disruption in the Company&#8217;s operations, supply chain or breach or unauthorized access of its property or assets, including its facilities and information technology infrastructure; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">tender offers or proxy fights;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">accounting restatements;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">litigation or settlements; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">impending bankruptcy.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">When information is considered public</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The prohibition on trading when you have material nonpublic information lifts once that information becomes publicly disseminated. But for information to be considered publicly disseminated, it must be widely disseminated through a press release, a filing with the Securities and Exchange Commission (the &#8220;<font style="font-style:italic;font-weight:bold;">SEC</font>&#8221;), or other widely disseminated announcement. Once information is publicly disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information. Generally speaking, information will be considered publicly disseminated for purposes of this Policy only after two (2) full trading days have elapsed since the information was publicly disclosed. For example, if we announce material nonpublic information before trading begins on Wednesday, then you may execute a transaction in our securities on Friday; if we announce material nonpublic information after trading ends on Wednesday, then you may execute a transaction in our securities on Monday. Depending on the particular circumstances, the Company may determine that a longer or shorter waiting period should apply to the release of specific material nonpublic information. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Quarterly Trading Blackout Periods</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because our workplace culture tends to be open, odds are that the vast majority of our employees, directors and consultants (&#8220;Covered Insiders&#8221;) will possess material nonpublic information at certain points during the year. To minimize even the appearance of insider trading among our Covered Insiders, we have established &#8220;quarterly trading blackout periods&#8221; during which our Covered Insiders and their Related Persons&#8212;regardless of whether they are aware of material nonpublic information or not&#8212;may not conduct any trades in the Company&#8217;s securities. That means that, except as described in this Policy, Covered Insiders and their Related Persons will be able to trade in the Company&#8217;s securities <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">only</u> during limited open trading window periods that generally will begin after two (2) full trading days have elapsed since the public dissemination of the Company&#8217;s annual or quarterly financial results and end at the beginning of the next quarterly trading blackout period (as defined below). &#160;Of course, even during an open trading window period, you may not (unless an exception applies) conduct any trades in the Company&#8217;s securities if you are otherwise in possession of material nonpublic information. &#160; </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt;">For purposes of this Policy, each &#8220;<font style="font-style:italic;font-weight:bold;">quarterly trading blackout period</font>&#8221; will generally begin at the close of business on the day that immediately precedes the date of the first Disclosure Committee meeting for each fiscal quarter and end after two full trading days have elapsed since the public dissemination of the Company&#8217;s financial results for that quarter. Please note that the quarterly trading blackout period may commence early or may be extended if, in the judgment of </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Chief Executive Officer, Chief Financial Officer or General Counsel, there exists undisclosed information that would make trades by Covered Insiders inappropriate. It is important to note that the fact that the quarterly trading blackout period has commenced early or has been extended should be considered material nonpublic information that should not be communicated to any other person. &#160; </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A Covered Insider who believes that special circumstances require him or her to trade during a quarterly trading blackout period should consult the Clearing Officer. Permission to trade during a quarterly trading blackout period will be granted only where the circumstances are extenuating, the Clearing Officer concludes that the person is not in fact aware of any material nonpublic information relating to the Company or its securities, and there appears to be no significant risk that the trade may subsequently be questioned. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Event-Specific Trading Blackouts</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, an event may occur that is material to the Company and is known by only a few directors, officers and/or employees. So long as the event remains material and nonpublic, the persons designated by the Chief Executive Officer, Chief Financial Officer or General Counsel may not trade in the Company&#8217;s securities. &#160;In that situation, the Company will notify the designated individuals that neither they nor their Related Persons may trade in the Company&#8217;s securities. The existence of an event-specific trading blackout should also be considered material nonpublic information and should not be communicated to any other person. &#160;Even if you have not been designated as a person who should not trade due to an event-specific trading blackout, you should not trade while aware of material nonpublic information. &#160;Exceptions will not be granted during an event-specific trading blackout.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The quarterly and event-driven trading blackouts do not apply to those transactions to which this Policy does not apply, as described under the heading &#8220;Exceptions to this Policy&#8221; below. &#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Exceptions to this Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Policy includes limited exceptions in the case of the following transactions:</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:18pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Option Exercises</font><font style="font-size:11pt;">. </font><a name="_cp_text_1_21"></a><a name="_cp_text_1_14"></a><font style="font-size:11pt;">This Policy </font><a name="_cp_text_1_23"></a><font style="font-size:11pt;">shall </font><font style="font-size:11pt;">apply to any sale of shares as part of a broker-assisted cashless exercise or any other market sale. &#160;This </font><font style="font-size:11pt;">Policy </font><a name="_cp_text_1_16"></a><font style="font-size:11pt;">does not apply to an </font><font style="font-size:11pt;">exercise </font><a name="_cp_text_1_17"></a><font style="font-size:11pt;">of </font><font style="font-size:11pt;">options granted under the Company&#8217;s equity compensation plans for cash in which the optionholder (a) pays cash, (b) if permitted under the option, exercises the options through </font><a name="_cp_text_1_18"></a><font style="font-size:11pt;">a </font><font style="font-size:11pt;">net exercise </font><a name="_cp_text_1_19"></a><font style="font-size:11pt;">transaction with the Company </font><font style="font-size:11pt;">or (c) if permitted under the option, exercises the options by delivering to the Company already-owned Company shares. &#160;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:18pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Tax Withholding</font><a name="_cp_text_1_26"></a><font style="font-size:11pt;font-style:italic;font-weight:bold;"> Transactions</font><font style="font-size:11pt;">. This Policy does not apply to the surrender of shares directly to the Company to satisfy tax withholding obligations as a result of the issuance of shares upon vesting or exercise of restricted share units, options or other equity awards granted under the Company&#8217;s equity compensation plans. &#160;Of course, any market sale of the shares received upon exercise or vesting of any such equity awards remains subject to all provisions of this Policy whether or not for the purpose of generating the cash needed to pay the exercise price or pay taxes. </font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:18pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">ESPP</font><i style="font-size:11pt;font-style:italic;">.</i><font style="font-size:11pt;font-style:italic;font-weight:bold;"> </font><a name="_cp_text_1_28"></a><font style="font-size:11pt;">This Policy does not apply to the </font><font style="font-size:11pt;">purchase </font><a name="_cp_text_1_29"></a><font style="font-size:11pt;">of </font><a name="_cp_text_1_30"></a><font style="font-size:11pt;">ordinary shares by employees </font><font style="font-size:11pt;">under the Company&#8217;s Employee Share Purchase Plan (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">ESPP</font><font style="font-size:11pt;">&#8221;) on periodic designated dates in </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">4</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">accordance with the ESPP</font><a name="_cp_text_1_37"></a><font style="font-size:11pt;">. &#160;This Policy does, however, </font><font style="font-size:11pt;">apply to any sale of ordinary shares acquired pursuant to the ESPP. </font><a name="_cp_text_2_33"></a><a name="_cp_text_1_34"></a><a name="_cp_text_2_35"></a><a name="_cp_text_1_36"></a><font style="font-size:11pt;"> &#160;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:18pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">10b5-1 Automatic Trading Programs</font><i style="font-size:11pt;font-style:italic;">. </i><font style="font-size:11pt;">Under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-size:11pt;">&#8221;), and as permitted or required by the Company, employees, directors and consultants may establish a trading plan under which a broker is instructed to buy and sell the Company&#8217;s securities based on pre-determined criteria (a &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">10b5-1 Trading Plan</font><font style="font-size:11pt;">&#8221;). So long as a 10b5-1 Trading Plan is properly established, purchases and sales of the Company&#8217;s securities pursuant to that </font><a name="_cp_text_1_39"></a><font style="font-size:11pt;">10b5-1 Trading Plan are not subject to this Policy. To be properly established, a</font><font style="font-size:11pt;"> 10b5-1 Trading Plan must be established in compliance with the requirements of Rule 10b5-1 of the Exchange Act and any applicable 10b5-1 trading plan guidelines of the Company at a time when the Company was not in a trading blackout period and they were not otherwise aware of any material nonpublic information relating to the Company . &#160;Moreover, all 10b5-1 Trading Plans must be reviewed and approved by the Clearing Officer before being established to confirm that the 10b5-1 Trading Plan complies with all pertinent company policies and </font><a name="_cp_text_1_41"></a><font style="font-size:11pt;">applicable </font><font style="font-size:11pt;">securities laws. </font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:10pt;font-weight:bold;min-width:18pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">5.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">401(k) Plan</font><font style="font-size:11pt;">. This Policy does not apply to purchases of the Company&#8217;s securities in the Company&#8217;s 401(k) plan, if permitted, resulting from your periodic contribution of money to the plan pursuant to your payroll deduction election. This Policy does apply, however, to certain elections you may make under the 401(k) plan, including: (a) an election to increase or decrease the percentage of your periodic contributions that will be allocated to the Company&#8217;s share fund; (b) an election to make an intra-plan transfer of an existing account balance into or out of the Company&#8217;s share fund; (c) an election to borrow money against your 401(k) plan account if the loan will result in a liquidation of some or all of your Company share fund balance; and (d) </font><a name="_9kR3WTr5DA459ki"></a><font style="font-size:11pt;">an</font><font style="font-size:11pt;"> election to pre-pay </font><a name="_9kR3WTr5DA458j"></a><font style="font-size:11pt;">a</font><font style="font-size:11pt;"> plan loan if </font><a name="_9kR3WTr5DA45A4vh"></a><font style="font-size:11pt;">the</font><font style="font-size:11pt;"> pre-payment will result in allocation of loan proceeds to the Company&#8217;s share fund.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Special and Prohibited Transactions</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Inherently Speculative Transactions</font><b style="font-size:11pt;font-weight:bold;">. &#160;</b><font style="font-size:11pt;">No Company employee, director or consultant may engage in short sales, transactions in put options, call options or other derivative securities on an exchange or in any other organized market, or in any other inherently speculative transactions with respect to the Company&#8217;s shares.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Hedging Transactions. &#160;</font><font style="font-size:11pt;">The purchase of or the entry into other transactions that are designed to offset or &#8220;hedge&#8221; decreases in the market value of the Company&#8217;s securities may permit a Company employee, director or consultant to continue to own the Company&#8217;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the Company&#8217;s employee, director or consultant may no longer have the same objectives as the Company&#8217;s other shareholders. Therefore, the Company&#8217;s employees, directors and consultants are prohibited from engaging in any such transactions. </font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Hedging can be accomplished through any number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. &#160;Other examples include borrowing or other arrangements involving a non-recourse pledge of the Company&#8217;s securities and selling a security future that establishes a position that increases in value as the value of the underlying equity security decreases. &#160;</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Margin Accounts and Pledged Securities</font><font style="font-size:11pt;">. Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&#8217;s consent if the </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">5</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in the Company&#8217;s securities, the Company&#8217;s employees, directors and consultants are prohibited from holding Company securities in a margin account or otherwise pledging the Company&#8217;s securities as collateral for a loan. &#160;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Standing and Limit Orders</font><font style="font-size:11pt;">. Standing and limit orders (except standing and limit orders under approved 10b5-1 Trading Plans, as discussed above) create heightened risks for insider trading violations similar to the use of margin accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when a Company employee, director or consultant is in possession of material nonpublic information. The Company therefore discourages placing standing or limit orders on the Company&#8217;s securities. If a person subject to this Policy determines that they must use a standing order or limit order (other than under an approved 10b5-1 Trading Plan as discussed above), the order should be limited to short duration and the person using such standing order or limit order is required to cancel such instructions immediately in the event restrictions are imposed on their ability to trade pursuant to the &#8220;Quarterly Trading Blackouts&#8221; and &#8220;Event-Specific Trading Blackouts&#8221; provisions above. </font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Pre-Clearance and Advance Notice of Transactions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;text-align:justify;text-indent:18pt;margin:0pt;">In addition to the requirements listed above, employees, directors and consultants face a further restriction: Even during an open trading window, they may not engage in any transaction in the Company&#8217;s securities without first obtaining pre-clearance of the transaction from <font style="font-size:12pt;"><a name="OLE_LINK1"></a></font>the Clearing Officer or his or her designee at least two (2)<b style="font-weight:bold;"> </b>business days in advance of the proposed transaction. The Clearing Officer or his or her designee will then determine whether the transaction may proceed and, if so, will direct the Compliance Coordinator (as identified in the Company&#8217;s Section 16 Compliance Program) to help assist, if applicable, in complying with the required reporting requirements under Section 16(a) of the Exchange Act. Pre-cleared transactions not completed within five (5) business days will require new pre-clearance. The Company may, at its discretion, choose to shorten or extend this period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">Persons subject to pre-clearance must also give advance notice of their plans to exercise an outstanding stock option to the Clearing Officer. Upon completion of any transaction, the director or Section 16 officer must immediately notify the Compliance Coordinator and any other individual(s) identified in the Company&#8217;s Section 16 Compliance Program so that the Company may assist in any Section 16 reporting obligations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company is required to disclose certain information on a quarterly basis on Forms 10-Q and 10-K with respect to the adoption, material modification or termination of 10b5-1 Trading Plans and Non-10b5-1 Trading Plans by any director or Section 16 officer. By entering into a 10b5-1 Trading Plan or Non-10b5-1 Trading Plan, the Company&#8217;s directors and Section 16 officers are deemed to understand, and agree to cooperate with the Company with respect to, such disclosure obligations, including by notifying the Compliance Coordinator of information relevant to the preparation of such disclosure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Short-Swing Trading, Control Shares and Section 16 Reports &#160;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt;">Officers and directors subject to the reporting obligations under Section 16 of the Exchange Act should take care to avoid short-swing transactions (within the meaning of Section 16(b) of the </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">6</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Exchange Act) and the restrictions on sales by control persons (Rule&#160;144 under the Securities Act of 1933, as amended), and should file all appropriate Section 16(a) reports (Forms&#160;3, 4 and 5), which are described in the Company&#8217;s Section 16 Compliance Program, and any notices of sale required by Rule 144.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Prohibition of Trading During Pension Plan Blackouts </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No director or executive officer of the Company may, directly or indirectly, purchase, sell or otherwise transfer any equity security of the Company (other than an exempt security) during any &#8220;blackout period<font style="font-size:12pt;"><a name="_9kR3WTr5A7457"></a></font>&#8221; (as defined in Regulation BTR under the Exchange Act) if a director or executive officer acquires or previously acquired such equity security in connection with his or her service or employment as a director or executive officer. This prohibition does not apply to any transactions that are specifically exempted, including but not limited to, purchases or sales of the Company&#8217;s securities made pursuant to, and in compliance with, a 10b5-1 Trading Plan; compensatory grants or awards of equity securities pursuant to a plan that, by its terms, permits executive officers and directors to receive automatic grants or awards and specifies the terms of the grants and awards; or acquisitions or dispositions of equity securities involving a bona fide gift or by will or the laws of descent or pursuant to a domestic relations order. The Company will notify each director and executive officer of any blackout periods in accordance with the provisions of Regulation BTR. &#160;Because Regulation BTR is very complex, no director or executive officer of the Company should engage in any transactions in the Company&#8217;s securities, even if believed to be exempt from Regulation BTR, without first consulting with the Clearing Officer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Policy&#8217;s Duration</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Policy continues to apply to your transactions in the Company&#8217;s securities or the securities of other public companies engaged in business transactions with the Company even after your relationship with the Company has ended. If you are aware of material nonpublic information when your relationship with the Company ends, you may not trade the Company&#8217;s securities or the securities of other applicable companies until the material nonpublic information has been publicly disseminated or is no longer material. &#160;Further, if you leave the Company during a trading blackout period, then you may not trade the Company&#8217;s securities or the securities of other applicable companies until the trading blackout period has ended. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Individual Responsibility </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">Persons subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage in transactions in the Company&#8217;s securities while aware of material nonpublic information. Each individual is responsible for making sure that he or she complies with this Policy, and that any family member, household member or other person or entity whose transactions are subject to this Policy, as discussed under the heading &#8220;Persons Subject to this Policy&#8221; above, also comply with this Policy. In all cases, the responsibility for determining whether an individual is aware of material nonpublic information rests with that individual, and any action on the part of the Company or any employee or director of the Company pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. You could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws. See &#8220;Penalties&#8221; below. &#160;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">7</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Penalties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Anyone who engages in insider trading or otherwise violates this Policy may be subject to both civil liability and criminal penalties. Violators also risk disciplinary action by the Company, including termination of employment. Anyone who has questions about this Policy should contact their own attorney or the Clearing Officer. Please also see Frequently Asked Questions, which are attached as <b style="font-variant:small-caps;font-weight:bold;">Exhibit A</b>. &#160; </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amendments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is committed to continuously reviewing and updating its policies and procedures. The Company therefore reserves the right to amend, alter or terminate this Policy at any time and for any reason. A current copy of the Company&#8217;s policies regarding insider trading may be obtained by contacting the Clearing Officer.</p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">8</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Exhibit A</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Insider Trading Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Frequently Asked Questions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">1.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What is insider trading?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Generally speaking, insider trading is the buying or selling of shares, bonds, futures or other securities by someone who possesses or is otherwise aware of material nonpublic information about the securities or the issuer of the securities. Insider trading also includes trading in related financial instruments, including derivatives (such as put or call options) where the price is linked to the underlying price of a company&#8217;s shares. It does not matter whether the decision to buy or sell was influenced by the material nonpublic information, how many shares you buy or sell, or whether it has an effect on the share price. Bottom line: If, during the course of your relationship with the Company, you are aware of material nonpublic information about the Company or another publicly traded company that the Company has business relationships with and you trade in the Company&#8217;s securities or such other company&#8217;s securities, you have broken the law and violated our insider trading policy. In addition, our insider trading policy provides that if in the course of your relationship with the Company, you learn of any confidential information that is material to another publicly traded company with which the Company does business, including a supplier, partner or collaborator of the Company, you may not trade in that other company&#8217;s securities until the information becomes public or is no longer material to that other company.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">2.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Why is insider trading illegal?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>If company insiders are able to use their confidential knowledge to their financial advantage, other investors would not have confidence in the fairness and integrity of the market. This ensures that there is an even playing field by requiring those who are aware of material nonpublic information to refrain from trading.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">3.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What is material nonpublic information?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Information is material if it would influence a reasonable investor to buy or sell a share, bond future or other security. This could mean many things: financial results or forecasts, the status of product or product candidate development, results or regulatory approvals, clinical data relating to products or product candidates, timelines for pre-clinical studies or clinical trials, potential acquisitions or major partnerships or contracts to name just a few. Information is nonpublic if it has not yet been publicly disseminated within the meaning of our Insider Trading Policy.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">4.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Who can be guilty of insider trading?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Anyone who buys or sells a security or related financial instrument while aware of material nonpublic information, or provides material nonpublic information that someone else uses to buy or sell a security or related financial instrument, may be guilty of insider trading. This applies to all individuals, including officers, directors and others who don&#8217;t even work at the Company. Regardless of who you are, if you know something material about the value of a security that not everyone knows and you trade (or convince someone else to trade) in that security or related financial instrument, you may be found guilty of insider trading. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="display:inline-block;width:227.33pt;"></font>9</p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:0%;position:absolute;top:0pt;width:202.5pt;z-index:-9223372036603117568;"><div style="height:20.15pt;left:0pt;padding-bottom:0.85pt;position:relative;top:0pt;width:201.6pt;"><div style="height:20.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">289693501 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">5.</font><a name="_Hlk111565280"></a><font style="font-size:11pt;font-style:italic;font-weight:bold;">Does the Company have an Insider Trading Policy?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Yes, the Insider Trading Policy is available to read in our Human Resources Portal. &#160;</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">6.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I work in a foreign office?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>The same rules apply to U.S. and foreign employees and consultants. The Securities and Exchange Commission (the U.S. government agency in charge of investor protection) and the Financial Industry Regulatory Authority (a private regulator that oversees U.S. securities exchanges) routinely investigate trading in a company&#8217;s securities conducted by individuals and firms based abroad. In addition, as a Company director, employee or consultant, our policies apply to you no matter where you work.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">7.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I don&#8217;t buy or sell anything, but I tell someone else material nonpublic information and they buy or sell?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>That is called &#8220;tipping.&#8221; You are the &#8220;tipper&#8221; and the other person is called the &#8220;tippee.&#8221; If the tippee buys or sells based on that material nonpublic information, both you and the &#8220;tippee&#8221; could be found guilty of insider trading. In fact, if you tell family members who tell others and those people then trade on the information, those family members and the &#8220;tippee&#8221; might be found guilty of insider trading too. To prevent this, you may not discuss material nonpublic information about the Company with anyone outside the Company, including spouses, family members, friends or business associates (unless the disclosure is made in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of information regarding the Company). This includes anonymous discussions on the internet about the Company or companies with which the Company does business.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">8.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I don&#8217;t tell them the information itself; I just tell them whether they should buy or sell? </font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>That is still tipping, and you can still be responsible for insider trading. You may never recommend to another person that they buy, hold or sell the Company&#8217;s securities or any derivative security or related financial instruments related to the Company&#8217;s securities, since that could be a form of tipping.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">9.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What are the sanctions if I trade on material nonpublic information or tip off someone else?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>In addition to disciplinary action by the Company&#8212;which may include termination of employment&#8212;you may be liable for civil sanctions for trading on material nonpublic information. The sanctions may include return of any profit made or loss avoided as well as penalties of up to three times any profit made or any loss avoided. Persons found liable for tipping material nonpublic information, even if they did not trade themselves, may be liable for the amount of any profit gained or loss avoided by everyone in the chain of tippees as well as a penalty of up to three times that amount. In addition, anyone convicted of criminal insider trading could face prison and additional fines.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="display:inline-block;width:227.33pt;"></font>10</p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:0%;position:absolute;top:0pt;width:202.5pt;z-index:-9223372036603117568;"><div style="height:20.15pt;left:0pt;padding-bottom:0.85pt;position:relative;top:0pt;width:201.6pt;"><div style="height:20.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">289693501 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">10.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What is &#8220;loss avoided&#8221;?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>If you sell Company securities or a related financial instrument before negative news is publicly announced, and as a result of the announcement the share price declines, you have avoided the loss caused by the negative news.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">11.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Am I restricted from trading securities of any companies other than the Company, for example, a partner or competitor of the Company?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Possibly. U.S. insider trading laws generally restrict everyone aware of material nonpublic information about a company from trading in that company&#8217;s securities, regardless of whether the person is directly connected with that company, except in limited circumstances. Therefore, if you have material nonpublic information about another company, you should not trade in that company&#8217;s securities. You should be particularly conscious of this restriction if, through your position at the Company, you sometimes obtain sensitive, material information about other companies and their business dealings with the Company.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">12.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">So if I do not trade Company securities when I have material nonpublic information, and I don&#8217;t &#8220;tip&#8221; other people, I am in the clear, right?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Not necessarily. Even if you do not violate U.S. law, you may still violate our policies. For example, employees and consultants may violate our policies by breaching their confidentiality obligations or by recommending Company securities as an investment, even if these actions do not violate securities laws. Our policies are stricter than the law requires so that we and our employees and consultants can avoid even the appearance of wrongdoing. Therefore, please review the entire Insider Trading Policy carefully. </p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">13.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">So when can I buy or sell my Company securities?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>If you are aware of material nonpublic information, you may not buy or sell our securities until two (2) full trading days have elapsed since the information was publicly disclosed. At that point, the information is considered publicly disseminated for purposes of our Insider Trading Policy. For example, if we announce material nonpublic information before trading begins on Wednesday, then you may execute a transaction in our securities on Friday; if we announce material nonpublic information after trading ends on Wednesday, then you may execute a transaction in our securities on Monday. <b style="font-weight:bold;">Even if you are not aware of any material nonpublic information, you may not trade our securities during any trading &#8220;blackout&#8221; period</b>. Our Insider Trading Policy describes the quarterly trading blackout period, and additional event-driven trading blackout periods may be announced by email. </p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">14.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">If I have an open order to buy or sell Company securities on the date a blackout period commences, can I leave it to my broker to cancel the open order and avoid executing the trade?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>No, unless it is in connection with a 10b5-1 Trading Plan (see Question 27 below). If you have any open orders when a blackout period commences other than in connection with a 10b5-1 Trading Plan, it is your responsibility to cancel these orders with your broker. If you have an open order and it executes after a blackout period commences not in connection with a 10b5-1 trading plan, you will have violated our Insider Trading Policy and may also have violated insider trading laws. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="display:inline-block;width:227.33pt;"></font>11</p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:0%;position:absolute;top:0pt;width:202.5pt;z-index:-9223372036603117568;"><div style="height:20.15pt;left:0pt;padding-bottom:0.85pt;position:relative;top:0pt;width:201.6pt;"><div style="height:20.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">289693501 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">15.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Am I allowed to trade derivative securities of the Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;)?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>No. Under our policies, you may not trade in derivative securities related to our ADSs, which include publicly traded call and put options. In addition, under our policies, you may not engage in short selling of our ADSs at any time.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Derivative securities&#8221; are securities other than ADSs or ordinary shares that are speculative in nature because they permit a person to leverage their investment using a relatively small amount of money. Examples of derivative securities include &#8220;put options&#8221; and &#8220;call options.&#8221; These are different from employee options and other equity awards granted under our equity compensation plans, which are not derivative securities for purposes of our Policy. &#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Short selling&#8221; is profiting when you expect the price of the share to decline, and includes transactions in which you borrow shares from a broker, sell it, and eventually buy it back on the market to return the borrowed shares to the broker. Profit is realized if the share price decreases during the period of borrowing. </p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">16.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Why does the Company prohibit trading in derivative securities and short selling?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Many companies with volatile share prices have adopted similar policies because of the temptation it represents to try to benefit from a relatively low-cost method of trading on short-term swings in share prices, without actually holding the underlying ADSs, and encourages speculative trading. We are dedicated to building shareholder value, short selling our ADSs conflicts with our values and would not be well received by our shareholders.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">17.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I purchase the Company&#8217;s securities on margin or hold them in a margin account?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Under our policies, you may not purchase our securities on margin or hold it in a margin account at any time.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Purchasing on margin&#8221; is the use of borrowed money from a brokerage firm to purchase our securities. Holding our securities in a margin account includes holding the securities in an account in which the shares can be sold to pay a loan to the brokerage firm.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">18.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Why does the Company prohibit me from purchasing the Company&#8217;s securities on margin or holding them in a margin account?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Margin loans are subject to a margin call whether or not you possess material nonpublic information at the time of the call. If a margin call were to be made at a time when you were aware of material nonpublic information and you could not or did not supply other collateral, you may be liable under insider trading laws because of the sale of the securities (through the margin call). The sale would be attributed to you even though the lender made the ultimate determination to sell. The U.S. Securities and Exchange Commission takes the view that you made the determination to not supply the additional collateral and you are therefore responsible for the sale.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="display:inline-block;width:227.33pt;"></font>12</p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:0%;position:absolute;top:0pt;width:202.5pt;z-index:-9223372036603117568;"><div style="height:20.15pt;left:0pt;padding-bottom:0.85pt;position:relative;top:0pt;width:201.6pt;"><div style="height:20.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">289693501 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">19.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I pledge my Company securities as collateral for a personal loan?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A:</b> No. Pledging your shares as collateral for a personal loan could cause the pledgee to transfer your shares during a trading blackout period or when you are otherwise aware of material nonpublic information. As a result, you may not pledge your shares as collateral for a loan. </p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">20.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I hedge my ownership position in the Company? &#160;</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A:</b> &#160;The purchase of financial instruments or the entry into other transactions that are designed to offset or &#8220;hedge&#8221; decreases in the market value of the Company&#8217;s securities are prohibited by our Insider Trading Policy. Since such hedging transactions allow you to continue to own the Company&#8217;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership, you may no longer have the same objectives as the Company&#8217;s other shareholders. Therefore, our Insider Trading Policy prohibits you from engaging in any such transactions.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">21.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What are examples of prohibited hedging transactions?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A:</b> &#160;Hedging can be accomplished through any number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. &#160;Other examples include borrowing or other arrangements involving a non-recourse pledge of the Company&#8217;s securities and selling a security future that establishes a position that increases in value as the value of the underlying equity security decreases.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">22.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I exercise options granted to me under the Company&#8217;s equity compensation plans during a trading blackout period or when I possess material nonpublic information?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>It depends on the method through which you will exercise. You may <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</u> effect a broker-assisted cashless exercise (these cashless exercise transactions include a market sale) during a trading blackout period or any time that you are aware of material nonpublic information. &#160;You may, however, exercise the options <font style="font-size:12pt;"><a name="_cp_text_1_47"></a></font>by paying cash (or via net exercise transaction with the Company or as otherwise permitted by the relevant plan under which the options were granted) and receive shares, but you may not sell the shares (even to pay the exercise price or any taxes due) during a trading blackout period or any time that you are aware of material nonpublic information. <font style="font-size:12pt;"><a name="_cp_text_1_48"></a></font> </p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">23.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Am I subject to trading blackout periods if I am no longer an employee or consultant of the Company?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>It depends. If your employment with the Company ends during a trading blackout period, you will be subject to the remainder of that trading blackout period. If your employment with the Company ends on a day that the trading window is open, you will not be subject to the next trading blackout period. However, even if you are not subject to our trading blackout period after you leave the Company, you should not trade in the Company&#8217;s securities if you are aware of material nonpublic information. That restriction stays with you as long as the information you possess is material and not publicly disseminated within the meaning of our Insider Trading Policy. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="display:inline-block;width:227.33pt;"></font>13</p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:0%;position:absolute;top:0pt;width:202.5pt;z-index:-9223372036603117568;"><div style="height:20.15pt;left:0pt;padding-bottom:0.85pt;position:relative;top:0pt;width:201.6pt;"><div style="height:20.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">289693501 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">24.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I purchased publicly traded options or other derivative securities before I became a Company employee or consultant?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>The same rules apply as for employee share options. You may exercise the publicly traded options at any time, but you may not sell the securities during a trading blackout period or at any time that you are aware of material nonpublic information. </p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">25.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">May I own shares of a mutual fund that invests in the Company? </font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Yes.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">26.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Are mutual fund shares holding the Company&#8217;s ADSs subject to the trading blackout periods? </font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>No. You may trade in mutual funds holding the Company&#8217;s ADSs at any time.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">27.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">May I use a &#8220;routine trading program&#8221; or &#8220;10b5-1 plan&#8221;?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Yes, subject to the requirements discussed in our Insider Trading Policy and any 10b5-1 trading plan guidelines. A routine trading program, also known as a 10b5-1 plan, allows you to set up a highly structured program with your stock broker where you specify ahead of time the date, price, and amount of securities to be traded. If you wish to create a 10b5-1 plan, please contact the Clearing Officer for approval.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">28.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What happens if I violate our Insider Trading Policy?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>Violating our policies may result in disciplinary action, which may include termination of your employment or other relationship with the Company. In addition, you may be subject to criminal and civil sanctions.</p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;font-weight:bold;min-width:36pt;text-decoration-line:none;white-space:nowrap;">29.</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Who should I contact if I have questions about our Insider Trading Policy or specific trades?</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A: &#160;</b>You should contact the Clearing Officer at clearing@bicycletx.com.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="display:inline-block;width:227.33pt;"></font>14</p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:0%;position:absolute;top:0pt;width:202.5pt;z-index:-9223372036603117568;"><div style="height:20.15pt;left:0pt;padding-bottom:0.85pt;position:relative;top:0pt;width:201.6pt;"><div style="height:20.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">289693501 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="_cp_text_2_592"></a></font><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Bicycle Therapeutics plc</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="_cp_text_2_593"></a></font><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Insider Trading Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="_cp_text_2_594"></a></font><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Certification</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:35.3pt;margin:0pt 0pt 12pt 0.7pt;"><a name="_cp_text_2_595"></a><a name="_Hlk111565305"></a>After carefully reviewing this Insider Trading Policy (this &#8220;<b style="font-weight:bold;">Policy</b>&#8221;), please accept and acknowledge that you have read this Policy in accordance with Bicycle Therapeutics plc&#8217;s (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;) documentation requirements. You understand and agree that it is your responsibility to read and familiarize yourself with the provisions in this Policy, and to abide by the rules, policies, and standards set forth. You further acknowledge that the terms and conditions set forth in this Policy or any other Company policy may be modified, changed, or deleted at any time without prior notice to you and other personnel, provided such changes are in writing and approved by an authorized officer of the Company.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="display:inline-block;width:234pt;"></font><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:0%;position:absolute;top:0pt;width:202.5pt;z-index:-9223372036603115520;"><div style="height:20.15pt;left:0pt;padding-bottom:0.85pt;position:relative;top:0pt;width:201.6pt;"><div style="height:20.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;">289693501 v3</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>13
<FILENAME>bcyc-20241231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:41 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-272248) and S-8 (Nos. 333-231718, 333-237054, 333-240993, 333-254163, 333-263156, 333-270091, 333-277171, 333-281304) of Bicycle Therapeutics plc of our report dated February 25, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a name="_2et92p0"></a>/s/ PricewaterhouseCoopers LLP <br>Cambridge, United Kingdom<br>February 25, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>14
<FILENAME>bcyc-20241231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:47 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">I, Kevin Lee, certify that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Bicycle Therapeutics plc;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:34.55pt;text-align:justify;text-indent:-34.55pt;margin:0pt 0pt 12pt 37.45pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1</font></p></div></div></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date: February 25, 2025</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By</font><font style="font-size:12pt;">:</font></p></td><td style="vertical-align:bottom;width:45.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Kevin Lee</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Kevin Lee, Ph.D., MBA</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>15
<FILENAME>bcyc-20241231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:49 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">I, Alethia Young, certify that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Bicycle Therapeutics plc;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:34.6pt;text-align:justify;text-indent:-34.6pt;margin:0pt 0pt 12pt 37.4pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1</font></p></div></div></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date: February 25, 2025</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By</font><font style="font-size:12pt;">:</font></p></td><td style="vertical-align:bottom;width:45.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Alethia Young</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Alethia Young</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>16
<FILENAME>bcyc-20241231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 09:41:51 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Kevin Lee, Chief Executive Officer of Bicycle Therapeutics plc (the &#8220;Company&#8221;), and Alethia Young, Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><font style="font-size:12pt;">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><font style="font-size:12pt;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Dated: February 25, 2025</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:12pt;">, the undersigned have set their hands hereto as of the 25</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> day of February, 2025.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Kevin Lee</font></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Alethia Young</font></p></td></tr><tr><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Kevin Lee, Ph.D., MBA</font></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Alethia Young</font></p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Bicycle Therapeutics plc under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>bcyc-20241231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'H ^@# 2(  A$! Q$!_\0
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MDF?QGXE+R,7;&HN.2<GO4?\ 8&J_]#GXF_\ !B_^-;M%?U%_JSD__0-'\?\
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M_P#C1_8&J_\ 0Y^)O_!B_P#C6[11_JSD_P#T#1_'_,/[6QW_ #]9A?V!JO\
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M%_\ &MVBC_5G)_\ H&C^/^8O[6QW_/UF%_8&J_\ 0Y^)O_!B_P#C1_8&J_\
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MLY/_ - T?Q_S#^UL=_S]9A_V!JO_ $.?B;_P8O\ XT?V!JO_ $.?B;_P8O\
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M7_H<_$W_ (,7_P :W:*/]6<G_P"@:/X_YA_:V._Y^LPO[ U7_H<_$W_@Q?\
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M>""#@@UC5X=R:C3E4>&CHF^O3YFD,SQTYJ"JO4\K_L#5?^AS\3?^#%_\:/[
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M8O\ XUNT4?ZLY/\ ] T?Q_S#^UL=_P _687]@:K_ -#GXF_\&+_XT?V!JO\
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M]C*Z&.H1FL=44VWI;\>BM?MJD<&,J8>HXO#QMW_K]0HHHKW#S@HHHH ****
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M>/F.*PE@\XITFW6;FVDK.Z2;=V[I;1::?==>NBKX&4[<GNZMWT;LE9+5[O\
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M/_B*^_\ ]:*?_/I_>1_JC4_Y_+[C\J,CU'YT9'J/SK]5_P#A6?@__H4]"_\
M!9!_\11_PK/P?_T*>A?^"R#_ .(H_P!:*?\ SZ?WA_JC4_Y_+[C\J,CU'YT9
M'J/SK]5_^%9^#_\ H4]"_P#!9!_\11_PK/P?_P!"GH7_ (+(/_B*/]:*?_/I
M_>'^J-3_ )_+[C\J,CU'YT9'J/SK]5_^%9^#_P#H4]"_\%D'_P 11_PK/P?_
M -"GH7_@L@_^(H_UHI_\^G]X?ZHU/^?R^X_*C(]1^=&1ZC\Z_5?_ (5GX/\
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M+_Y<O[U_D'^JM3_GZON/QIR/4?G1D>H_.OV4D^%7@2)&=_!OAM$4%F9M)MP
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M=ZO8P7MCX4\+WMG.GF17%OIEL\<B^JL$P1[BK/\ PJ;P-_T)?AS_ ,%%O_\
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M.?\ A/+_ /&:/]8,5_T U/N?^0?ZGXG^?_R5GY7Y'J/SHR/4?G7ZH?\ "7?
M;_H%>'/_  GE_P#C-'_"7? ;_H%>'/\ PGE_^,T?ZP8K_H!J?<_\@_U/Q/\
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MR/4?G1D>H_.OU0_X2[X#?] KPY_X3R__ !FC_A+O@-_T"O#G_A/+_P#&:/\
M6#%?] -3[G_D'^I^)_G_ /)6?E?D>H_.C(]1^=?JA_PEWP&_Z!7AS_PGE_\
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M"N'R"?F;+>]?J?\ \*F\#?\ 0E^'/_!1;_\ Q%'_  J;P-_T)?AS_P %%O\
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M $+6D?\ @#%_\31_KK0_Y\O[T']H1_E/@/</44;AZBOOS_A7OA;_ *%K2/\
MP!B_^)H_X5[X6_Z%K2/_  !B_P#B:/\ 76A_SY?WH/[0C_*? >X>HHW#U%??
MG_"O?"W_ $+6D?\ @#%_\31_PKWPM_T+6D?^ ,7_ ,31_KK0_P"?+^]!_:$?
MY3X#W#U%&X>HK[\_X5[X6_Z%K2/_  !B_P#B:/\ A7OA;_H6M(_\ 8O_ (FC
M_76A_P ^7]Z#^T(_RGP'N'J*-P]17WY_PKWPM_T+6D?^ ,7_ ,31_P *]\+?
M]"UI'_@#%_\ $T?ZZT/^?+^]!_:$?Y3X#W#U%&X>HK[\_P"%>^%O^A:TC_P!
MB_\ B:/^%>^%O^A:TC_P!B_^)H_UUH?\^7]Z#^T(_P I\I_L]Z1XGOO',-UX
M>E^RVUOC[?<2@F#RB>48?Q$]AU!YXQ7V8>O'2JFF:18:+;&WTZRM["W+%S%;
M1+&I8]3A0.:MU\)G.:?VMB/;*'*DK+O\WU_0\W$5O;SYK6"BBBO!.4**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH N:/_R$[7_KH**-'_Y"
M=K_UT%%>1C?C7H<]3<\MHHHK[\],**** "BBB@ HHHH **** "BBB@ HHHH
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M"BBB@ HHHH **** "BBB@ HHHH *!UYX%%(<XXQGWH \4U7X\^(?#"7DFO\
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M_&CV7#G_ $Z^]?YA;">1I?\ #5?C3_GAI'_@*_\ \71_PU7XT_YX:1_X"O\
M_%UF_P##-7C[_H&6O_@=%_C1_P ,U>/O^@9:_P#@=%_C1[+AS_IU]Z_S"V$\
MC2_X:K\:?\\-(_\  5__ (NC_AJOQI_SPTC_ ,!7_P#BZS?^&:O'W_0,M?\
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M** "BBB@"YH__(3M?^N@HHT?_D)VO_7045Y&-^->ASU-SRVBBBOOSTPHHHH
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MZ<FFWFKVE]<:<Z0:E:VHW3R6K'_6;000"%+ @C(YKT>WOH;G3X;U7"6TL*W
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MX9@\"?\ /OJ7_@<?_B:/^&8/ G_/OJ7_ (''_P")KAO^&OYO^A5C_P# X_\
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M[ZE_X''_ .)KAO\ AK^;_H58_P#P./\ \11_PU_-_P!"K'_X''_XBCZCQ/\
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M[PUKWAF'POIVGZ[);ZW''\0#>1K-<M=M(8V 3,Q+B15D$HVH$^7<0M97AO\
M9\UN^\2Z-?:MX=%OI$&K:7-=:;J#Z;Y;I;0W>Z3R+.)(F"M-$BLV9&'55517
MUO\ V1_TU_\ ':/[(_Z:_P#CM'+3[AH9B*$15      & *=6C_9'_37_ ,=H
M_LC_ *:_^.UT>UAW*NC.HK1_LC_IK_X[1_9'_37_ ,=H]K#N%T9U%:/]D?\
M37_QVC^R/^FO_CM'M8=PNC.HK1_LC_IK_P".T?V1_P!-?_':/:P[A=&=7DO[
M3FG76I_#6.&SMIKN4:C WEP1L[8"R9. "<5[7_9'_37_ ,=I1I)4Y$Q!]A_]
M>NW!8Z.#Q$,0E?E=[&E.I[.:EV/SI_X1#7O^@)J7_@')_P#$T?\ "(:]_P!
M34O_  #D_P#B:_1?^S7_ .?AOU_QH_LU_P#GX;]?\:^\_P!>I_\ /E?>_P#(
M]/\ M)_RGYT?\(AKW_0$U+_P#D_^)H_X1#7O^@)J7_@')_\ $U^B_P#9K_\
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MZG_SY7WO_(/[2?\ *?G1_P (AKW_ $!-2_\  .3_ .)H_P"$0U[_ * FI?\
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M\<Q6T4LBJT[A2Q5 3EB%4L0.P)IUU?VUBL1N;B*W$LJP1F5PN^1CA4&>K$\
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M\ ?_ ,B'UG">7W?\ \5_X7'XY_Z&W6/_  +:C_A<?CG_ *&W6/\ P+:O:O\
MABJ7_H;HO_ !O_BZ/^&*I?\ H;HO_ !O_BZ/[<X<[Q_\ ?\ \B'UG">7W?\
M /%?^%Q^.?\ H;=8_P# MJ/^%Q^.?^AMUC_P+:O:O^&*I?\ H;HO_ !O_BZ/
M^&*I?^ANB_\  !O_ (NC^W.'.\?_  !__(A]9PGE]W_ /%?^%Q^.?^AMUC_P
M+:C_ (7'XY_Z&W6/_ MJ]J_X8JE_Z&Z+_P  &_\ BZ/^&*I?^ANB_P# !O\
MXNC^W.'.\?\ P!__ "(?6<)Y?=_P#Q7_ (7'XY_Z&W6/_ MJ/^%Q^.?^AMUC
M_P "VKVK_ABJ7_H;HO\ P ;_ .+H_P"&*I?^ANB_\ &_^+H_MSASO'_P!_\
MR(?6<)Y?=_P#Q7_A<?CG_H;=8_\  MJ/^%Q^.?\ H;=8_P# MJ]J_P"&*I?^
MANB_\ &_^+H_X8JE_P"ANB_\ &_^+H_MSASO'_P!_P#R(?6<)Y?=_P  \5_X
M7'XY_P"AMUC_ ,"VH_X7'XY_Z&W6/_ MJ]J_X8JE_P"ANB_\ &_^+H_X8JE_
MZ&Z+_P  &_\ BZ/[<X<[Q_\  '_\B'UG">7W?\ \5_X7'XY_Z&W6/_ MJ/\
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M;H678V]BVQMP;=Q/M/(5SVBB@=**U*"BBB@ HHHH **** "BBB@ HHHH *4
MGH,TE>$_M>ZI>Z5X'T.2RN[BSD;4BK/;RM&2/*8X)4CBO1R_!O,,53PL96<G
M:_RN:TJ?M9J'<]XV-_=/Y4;&_NG\J_-C_A,M?_Z#FI_^!LO_ ,51_P )EK__
M $'-3_\  V7_ .*K]!_U$K?]!"_\!?\ F>K_ &9+^;\#])]C?W3^5&QO[I_*
MOS8_X3+7_P#H.:G_ .!LO_Q5'_"9:_\ ]!S4_P#P-E_^*H_U$K?]!"_\!?\
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M]JS>B?E1_:LWHGY4?ZP9S_S_ ']T?\@^M8C^;\CPS_AC#1/^AEU#_P !8_\
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MX_:J^(T>A^)M5-AX2M;9?&ESX-T&*5;V>YN989W#RM!"K-(?+481""3N.0,
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MK_\ $5X;_P *]\4?]"YJO_@')_A1_P *]\4?]"YJO_@')_A1_8.1_P J_P#
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MJ_\  W_\D'U7#=OQ_P"">Y?\-?0?]"M-_P"!J_\ Q%'_  U]!_T*TW_@:O\
M\17AO_"O?%'_ $+FJ_\ @')_A1_PKWQ1_P!"YJO_ (!R?X4?V#D?\J_\#?\
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M?^">Y?\ #7T'_0K3?^!J_P#Q%'_#7T'_ $*TW_@:O_Q%>&_\*]\4?]"YJO\
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MF( R>*R-+^)GA#6Q$=.\4Z-?"6=+6,VU_%)OF<,4C&&Y9@K$+U.T^E)R2T;
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M[4]%LKO4]-?1M0GB$EQI\DJRM;.>L9=?E;'J.*OT45Z25E8U"D=2R, Q1B"
MPZ@^M+13 ^>=!_8YL+#P]XK\/ZOXWUSQ%H7B?S9=2M;NVMTEFN6966Y,ZJ9"
MZ,H*@DJ.1C%6O#_['WA_0XK!GUR]N[VVURQUMK@6-K;)(;0.(X?*A15"GS&W
M-RQ/->+_  O_ &F_'VI#PA=Q^*;+QYJVJV^L?VAX1M].2*:P^S13/!*73YOG
M9$7D $-A<GFJ?PZ_:&^,/C[PSXI_L[7+'4-6B\,'Q!$([>U9[&YBE5GM/+C9
MB$>/>@$H$@8 UX,:N&TM!_UKW\S"\.Q[)H_[#_@_0FU:*TU;4(]/NK._L[.T
M%K:@V0NT=)&\X1B6;:)&V"1B%]ZV?$G[(_A;Q7:R0ZEJ5_(G_".:?X?C8)&#
M$+*3S(;@9!!?/52-I!([UX?XF_:C^(6K>'K'Q5H]\-$\'^*O$=Q9:=J,]O;*
M=/L[:!?XIRD8::;S.96X$9 Y-5-5_:,\;^*/"6G6?B7Q3I7@>UNO!VH:A]O:
MR6:+Q!<K/-;B",YPF8U5L1DMELC(Q1[7"I-* <T-K'N>F_LBZ)I6DV,FF^)M
M3L/$]EJ3:I:^([*TM(9(7:+R618$C$/EF,D%<=3G/:NCG^ <"ZIX!U@>,=>_
MM?PE]H0:E>21W$NH17#*9XYBXP VT*-N-HX'0&OEC3_V@/&?@CX>Z#9V/B.S
M\._\(_X,T"\T;0KNP%Q+XIFG0":-7)W#:1LQ'R#R:?\ $37M;TE?VBK76/%G
M]JW4.IZ/-!X>U*V0A8Y);0^:JYR%C#^5\ORDX8_-1[:BH^[#\>VOZ!S12T1[
MM9_L:Z1H^C:?9:-XR\0:)-#I%SH-[=V0A#W]E-/)/Y;AE(4J\SX9<''''6H=
M0_8>\(7T^DR+J]_;BWTNRTF^VVEK(U]':H$B;=)&S0.5 #&,C( KE-%^,/Q%
M_P"%DV5U<>)(+KPY<?$^]\%_V*=.C7;:JC,DGG#YMRXP!CZDU];CD"NJE2P]
M9.T=BTHRZ#8XUAC2-%"HBA54=@!@"G445ZAH%%%% !1110 5M^$_^0A+_P!<
MC_,5B5M>%.-0E_ZY'^8KGQ'\*1,MF<[XS^ >B>-]!\=Z9>WMW$?%5['J!NH0
MHET^X2VCMT>$^H6/G/4.ZG@T:1\'=3\+:]>ZAX>\;7FD07L.GPW-F=-@G5_L
MELMNA#,05W(@SZ$\5@1_$"_F^)>KPWWC6UT$Z?XCCTFU\*RV:2-?VIAC<2C'
M[[?)O=E=?D41X(.&->06_P"T5XTO;:Y&F^(EN)=3T2/4[2YNK>R9;5SJ=G I
M6"%V>-#'=.#'.=X*@Y!R!\DW3;O8Y+I'T!-\%"MQ?6EAXLUC2O"U]?MJ-QH-
MHL:CS'D\V5([C'FQ12299D4_Q. RAL#J9/!%M)XI\0:X;F43ZSI<&E2Q!1LC
M2(SD.ON?M#<'CY17C&J>//$VB_$&^\#:GXV.F:5!J[0MXLN+2VCG1&TZ*ZCM
MCN7R59G>3#%<E8R.O-<MXP^._C*PNRNG:]9W-O8Z%8ZA9:B@M;2UUN25Y5:1
MH[AO-,9,:1[;?+ L2"<H*:J070+I'L6E_L^:#8Z!J.CW%W=WMI>^']+\/L7"
MH\:V*R""X1A]V4-('S_"R*163=_LG^!=2^&UMX6O[(7M[!HT6BCQ!(FV\:*/
M.QB%8*2"S$ C +&NA^"FK:_XDTS7]7UW56O-^N:C96MB((XTLX;>[EB1=RC<
M[84 EC_", <Y]&K90A);#LF</KWP9\):UX?U+3(=(MM(FO=.?2_[3T^)4O88
M&39A)B"_"\8)((X/%<MX._9LTKPEXF@UU=6>:\2^L[]HK73;:QMRUO!=0HHB
MA4!05NV)/)RHYQP/8:*ITXMWL%D>->/_ ( 1ZS\.;_1]+OII=0B&O7-FLQ6-
M9)]1BN$9';^%5-P<$<_*,UH6?P(2>\AU+6_$NHZWJL)TQ+>>>&%/L\%G<K=)
M" @ ;?*HWR'DX& ,5ZK12]G&]PLCR2+]G/2(=.:T75[[:UC'8[_+3(5-4;40
MWU\QMG^Z/6LY?V4?"QN]3C>YD&C78OMEA!8VT,L1NM^_-T$\Z0(9'*!C\IVY
M+;17ME%+V4.P61YG8_!B9O\ A*)=;\7:GX@O=?T(:!-<3VT,(AA'G8=$C &\
M^>Q)/4@'CH,Z+]G>VN$A.K^*-5UN>TMK&PL9KF&%#;6UM=0W.S"@!VD>WC#R
M-SA1@#OZ[13]G$+(\GO_ -G30[SQ_>>)8[QK5+W4EU>ZM(["V,KW(4 E+ID,
MT:,55BBGJ#@@$BL#0/V3]-\.L9;3Q1?P72:6VDP7-OIUI$_E&:&4-/A/])<F
M *YER) [9 )S7N]%+V4.P61Y5X6^ 5IX1NM O+'7;F.\TS4KS4',=G#';S+<
MQQQS6Z0+A8(]L49&SD$,>2QKU6BBKC!0V&E8****L I"=O.<8YSZ4M% 'QQ/
MJ/A'QSX>\9R^&8;?1].T3PCKND>']$BM9%OM0$D#&XN9RR[MK&,>6C$LV6D;
MEE%>PS?%5?$_PCU%?AW<V>M:UINB?Z1'+--:M;?Z(P#H?*8M('7A<=1U%>T&
M:1NLCGORQH:61\;I';'3<Q.*YE2:ZBL<;\*9]<USP#H+^+M/LH[Z2TM6=$G-
MT)1Y,9WR;XUPY8L2N#@]Z^?Y/AA:^,_@K\!O#UY82Z>LVL%IKBUM_+GLY%M+
M]HKC( *O')Y;*3W '>OK G)R>32[CS\QYZ\]:MT[VN%KGQ+J^H^(;W6=<U+Q
M-#%H.LV/C?PU;ZEJ%SI[7-F)+?3IXY+I8P1OA?*N.1CS "<BMOP9LLO%O_"3
M:TL>N^!+?Q5?7=QK-KI#P64EQ-IMO'!<_9<-MCA>.:$R?,/,<.3G./K\2.N,
M.PQTPQ&*4R.6W%VW?WMQS^=9*A9WN+E.%^%EYX=U6'Q!J7AC1YM,TR]U(RFZ
M: P0:C*(D5[B&,XPAP%+!5#LC-S]X]Q0S%CEB6/J3DT5TQ5E8H****H HHHH
M **** "BBB@ HHHH *\F_::U.\TGX;1SV-W/93'48%\RWD:-L%7R,@@XX%>L
MUQGQ8^'S_$SPJNCI?+I[+=1W'G/&7'RAAC (_O?I7J975I4,;2J5G[J:OUT-
MJ,E&I%RV/C#_ (37Q%_T']5_\#9?_BJ/^$U\1?\ 0?U7_P #9?\ XJO;O^&0
M;G_H:(/_  #;_P"*H_X9!N?^AH@_\ V_^*K]?_MW)/YU_P" O_Y$][ZUAN_X
M'B/_  FOB+_H/ZK_ .!LO_Q5'_":^(O^@_JO_@;+_P#%5[=_PR#<_P#0T0?^
M ;?_ !5'_#(-S_T-$'_@&W_Q5']NY)_.O_ 7_P#(A]:PW?\  \1_X37Q%_T'
M]5_\#9?_ (JC_A-?$7_0?U7_ ,#9?_BJ]N_X9!N?^AH@_P# -O\ XJC_ (9!
MN?\ H:(/_ -O_BJ/[=R3^=?^ O\ ^1#ZUAN_X'B/_":^(O\ H/ZK_P"!LO\
M\51_PFOB+_H/ZK_X&R__ !5>W?\ #(-S_P!#1!_X!M_\51_PR#<_]#1!_P"
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M *&B#_P#;_XJC_AD&Y_Z&B#_ , V_P#BJ/[=R3^=?^ O_P"1#ZUAN_X'B/\
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M?\,@W/\ T-$'_@&W_P 51_;N2?SK_P !?_R(?6L-W_ \1_X37Q%_T']5_P#
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MY/\ @.*2XT;3[R626>PM)Y9%"/)+;H[,H((!)&2 0" >X%7**.5=@*HTJQ#
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MNKE(\12LRQ/R>C,K!3W*G'2N:^)OQT\.?#'P)I?C"Y:;6-!U"^MK..YTC;.
MDQ;]_P 'YHT569MN3@' -#KV#F.I^PS_ //-ORH^PS_\\V_*N-\6?'W0O"VK
MZCI@M;O4[R :2MJMHT>R^DU!IUMDC=G"C_CW<EG*J 1R<U8N/C*EAH\,EYX6
MURTUZYU+^R;30'BC-Q=W'E&7,4@?RGC$89S+OVJ$8,01BE]9%SG5?89_^>;?
ME1]AG_YYM^5<GI?QKMKGQ!I.@ZCX?U;0]<OM3;2S9WJ1D1-]DENEE$B,R21M
M'"P#(6PW! (-:/BGXF/HOB7_ (1W1O#FI^*];CLUO[FUTUH8Q:P.S)&SO,Z+
MN=D<*@)8[&.,#-'UC2X^8V_L,_\ SS;\J/L,_P#SS;\JE\)>)K7QEX<L-:LH
M[F&VO(]ZPWD+0S1$$JR.C<JRL""/45K57MFPYC$^PS_\\V_*C[#/_P \V_*M
MNBG[:0<QB?89_P#GFWY4?89_^>;?E6W7GGQL^*TOPD\/Z?J46FIJ;75T;8QO
M,8POR%LY .>F*Z<-"MC*T:%&-Y2V6WYEP4JDE&*U9U'V&?\ YYM^5'V&?_GF
MWY5\Y_\ #:MW_P!"G!_X'-_\11_PVK=_]"G!_P"!S?\ Q%?3?ZLYU_SY7_@4
M?\SL^IXC^7\4?1GV&?\ YYM^5'V&?_GFWY5\Y_\ #:MW_P!"G!_X'-_\11_P
MVK=_]"G!_P"!S?\ Q%'^K.=?\^5_X%'_ ##ZGB/Y?Q1]&?89_P#GFWY4?89_
M^>;?E7SG_P -JW?_ $*<'_@<W_Q%'_#:MW_T*<'_ ('-_P#$4?ZLYU_SY7_@
M4?\ ,/J>(_E_%'T9]AG_ .>;?E1]AG_YYM^5?.?_  VK=_\ 0IP?^!S?_$4?
M\-JW?_0IP?\ @<W_ ,11_JSG7_/E?^!1_P P^IXC^7\4?1GV&?\ YYM^5'V&
M?_GFWY5\Y_\ #:MW_P!"G!_X'-_\11_PVK=_]"G!_P"!S?\ Q%'^K.=?\^5_
MX%'_ ##ZGB/Y?Q1]&?89_P#GFWY4?89_^>;?E7SG_P -JW?_ $*<'_@<W_Q%
M'_#:MW_T*<'_ ('-_P#$4?ZLYU_SY7_@4?\ ,/J>(_E_%'T9]AG_ .>;?E1]
MAG_YYM^5?.?_  VK=_\ 0IP?^!S?_$4?\-JW?_0IP?\ @<W_ ,11_JSG7_/E
M?^!1_P P^IXC^7\4?1GV&?\ YYM^5'V&?_GFWY5\Y_\ #:MW_P!"G!_X'-_\
M11_PVK=_]"G!_P"!S?\ Q%'^K.=?\^5_X%'_ ##ZGB/Y?Q1]&?89_P#GFWY4
M?89_^>;?E7SG_P -JW?_ $*<'_@<W_Q%'_#:MW_T*<'_ ('-_P#$4?ZLYU_S
MY7_@4?\ ,/J>(_E_%'T9]AG_ .>;?E1]AG_YYM^5?.?_  VK=_\ 0IP?^!S?
M_$4?\-JW?_0IP?\ @<W_ ,11_JSG7_/E?^!1_P P^IXC^7\4?1GV&?\ YYM^
M5'V&?_GFWY5\Y_\ #:MW_P!"G!_X'-_\11_PVK=_]"G!_P"!S?\ Q%'^K.=?
M\^5_X%'_ ##ZGB/Y?Q1]&?89_P#GFWY4?89_^>;?E7SG_P -JW?_ $*<'_@<
MW_Q%'_#:MW_T*<'_ ('-_P#$4?ZLYU_SY7_@4?\ ,/J>(_E_%'T9]AG_ .>;
M?E1]AG_YYM^5?.?_  VK=_\ 0IP?^!S?_$4?\-JW?_0IP?\ @<W_ ,11_JSG
M7_/E?^!1_P P^IXC^7\4?1GV&?\ YYM^5'V&?_GFWY5\Y_\ #:MW_P!"G!_X
M'-_\11_PVK=_]"G!_P"!S?\ Q%'^K.=?\^5_X%'_ ##ZGB/Y?Q1]&?89_P#G
MFWY4?89_^>;?E7SG_P -JW?_ $*<'_@<W_Q%'_#:MW_T*<'_ ('-_P#$4?ZL
MYU_SY7_@4?\ ,/J>(_E_%'T9]AG_ .>;?E1]AG_YYM^5?.?_  VK=_\ 0IP?
M^!S?_$4?\-JW?_0IP?\ @<W_ ,11_JSG7_/E?^!1_P P^IXC^7\4?1GV&?\
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MU/\ \!)/\*/^%?\ B;_H7]3_ / 23_"OT@\Q_P"^WYFCS'_OM^9H_P!>Z_\
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MY!_:<OY3\W_^%?\ B;_H7]3_ / 23_"C_A7_ (F_Z%_4_P#P$D_PK](/,?\
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M%%?HYZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV<#!Q9\)_%JYU_QAIWAK4?#5[H&J3Z;?7UQ'=NI$36US# 50CB1'\\.LBG!
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M_$#_ )\K+_P-C_QH_P"&4?B!_P ^5E_X&Q_XT<_#7_3G_P E"^#_ +OX%/\
MX:?^(G_09A_\ XO\*/\ AI_XB?\ 09A_\ XO\*N?\,H_$#_GRLO_  -C_P :
M/^&4?B!_SY67_@;'_C1S\-?].?\ R4+X/^[^!3_X:?\ B)_T&8?_  #B_P *
M/^&G_B)_T&8?_ .+_"KG_#*/Q _Y\K+_ ,#8_P#&C_AE'X@?\^5E_P"!L?\
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M02H[?WY"."!V7N>O'7Z4K\KXC>6O%_\ ";M;6WPW_N_KT_$\7%^Q]I^Y_P"
M%%%%?*'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 3V7_
M !]Q?[PHHLO^/N+_ 'A17'7W1E+<\0HHHK]'/5"BBB@ HHHH **** "BBB@
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M"OJ/_?JC_A2_CG_H5]1_[]5]S8HQ1_KGB_\ GU'\?\P_M"IV1\,_\*7\<_\
M0KZC_P!^J/\ A2_CG_H5]1_[]5]S8HQ1_KGB_P#GU'\?\P_M"IV1\,_\*7\<
M_P#0KZC_ -^J/^%+^.?^A7U'_OU7W-BC%'^N>+_Y]1_'_,/[0J=D?#/_  I?
MQS_T*^H_]^J/^%+^.?\ H5]1_P"_5?<V*,4?ZYXO_GU'\?\ ,/[0J=D?#/\
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MHKQ"V_:*N-=\4:+::#X;O]82XM=52[TNU\E[F.ZM)K52!+YGE;-DY((8[MR
M'/%6;W]JOP?;V]M>6\=W>Z<=/MM3O;I#%&;&"8G;OC=U=G 5RR(K%0IR.E+V
ML>X71[-17)?#'Q5=^,?#]_?7@A$D.LZE8(8 0IB@NY(HSU/)5!D]S76UHG=7
M&% X/'6BD(!!!&0>U,#Y)U*RL)-!^(6K>#]8O)](T?PGK=E?Z]<ZB\DWB#4#
M"29$7=MVV[(_[U HW,43A37N'B/XAOX;^$;:MHUM/XAO[;1A+LTTQSM"PM2X
MED!<?(&7GG-=!I_PM\&:0[O8^$="LF>)X'-OIT*;HW!5T.%^ZP)!'0@U8T/X
M?^%_#,=W'H_AO2-)CNT\JY2QL8H1,F"-KA5&X<G@^IKGC3DMF*S/-?$/QDU^
MQ_9_M?%\.@WEAK,XTVW*WT"  W+P(]RJ>8%,8\UF 9U' !('-<%+\:OB WVC
M3?MUM:S6%S="6X:VM)-0FC2""49M1<[,1F5O,V.7V^60HW&OIV73+.?3FT^2
MT@DL&B\AK5XE:(QXQL*$8*XXQC&*QY?AUX3FT>#29/"^BR:5!(9HK%M/A,,<
MAZNJ;<!CW.,GO0Z<GU%9GBD/QSU_53/K]GK.E?V?9ZKHVFQ>'Q:,)M4BO([5
MFG1F8.A;[4QC781B$AN2<<;K/QD\6:U\'H[R[\1:7K#>*/#&OM+9:;;F"73)
M+6VE9)A(KEL90(^0,-(NT^OU6_A?19=:M-7DT?3Y-5M%$=O?/:1F>%1D!4?&
MY1@G@'N:P_!_PF\+>"-!CTJPT>SD06?V&>YN+:-I[J')^29PHWCGH>*GV<[[
MA9GD7B#XG^,O!-]<>&;O7+:_U.ZAT>:PNK;2QYJFY^U"6W2-I0C$"T++)(ZC
M!;=D@ Y7AGX[>+?%^EO&WB#2O#,^EZ9J][-?:A9HXU&2TO9+=4VB7;& L:M)
ML9CEUV\5]&:KX4T37HIHM3T;3]1CF2..5+NU24.B$M&I# Y"EF('8DXZUQ_C
MKX%>&_'-MIUNPDT:WL?.\N'3(+98_P![CS"$>)PKG'WT 89/-#IR6S"S/&8_
MVA_'5Y=6MQ!;Q"&RM-">> P0)#?M>V\$LC&6297C!:9DCV(PW)SG) Q_&_QV
M\1ZWI'B:P:_^T:+K>@Z_-8S0VBVHB%H/W;PN)3*W&58R(G/*\<5]26_@'PW;
MMH\@T+3Y+C1X([;3[F:V22:UCC4*BI(P+# '8^]*G@#PO'<W5POAO2%GN]_V
MB5;"(/-O&'WG;EMPX.>O>CV4^K"S[FW%_JH_]T?RI](!BEKJ*"BBB@ HHHH
M**** "O(OVH+N>R^&<<EO/+;R?VE -\+E&QMDXR#7KM<M\1O %I\2?#RZ1>7
M4UI"+A+CS(%!;*A@!SV^:O3RRO3PV-I5JOPQ:;-J,E"I&4MD?#G_  D&J?\
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M[GKVKT.OSC/\=A,?BO:82%E;5[7^7E^)Y.*J4ZL[P04445\R<84444 %%%%
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MO+?B/;W_ (,U_P#:"\;V(N)]-N&DT37;1,L!;OHL'V:[1?[T,TA5L=8Y6/\
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MBR?MFF207!N5"]Y(MB3)W/ELO\=8/B>?Q3K'[)OA/3H] UB?P99>#H=1FO\
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M79+>,N57RF&2!VS7KY31HXC'4J6(^!O76W1]3>A&,ZBC+8Y[_AKVV_Z%F?\
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M .2#ZKAOZ9[I_P ->VW_ $+,_P#X%+_A1_PU[;?]"S/_ .!2_P"%>%_\*_\
M$W_0OZG_ . C_P"%'_"O_$W_ $+^I_\ @(_^%']@Y'_*O_ W_P#)!]5PW],]
MT_X:]MO^A9G_ / I?\*/^&O;;_H69_\ P*7_  KPO_A7_B;_ *%_4_\ P$?_
M  H_X5_XF_Z%_4__  $?_"C^P<C_ )5_X&__ )(/JN&_IGNG_#7MM_T+,_\
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M/B84Z<[4V%%%%?.'(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 7-'_P"0G:_]=!11H_\ R$[7_KH**\C&_&O0YZFYY;1117WYZ84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5M
M^$_^0A+_ -<C_,5B5M^$_P#D(2_]<C_,5SXC^%(F6S.G:WB=95:*-EE_U@*
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MV?4[H^Y_,;^\WYT>8W]YOSKX8_X73XY_Z&>^_-/_ (FC_A=/CG_H9[[\T_\
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MXJU&5"7+(6BBBO(.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7AGQG' ]!79@\56I8B$\/&\T[I;Z^A=.<HR3@M3Y+_X9.\5?]!'2_P#OX_\
M\31_PR=XJ_Z".E_]_'_^)KZ,_P"%_?#K_H9;+_OAO\*/^%_?#K_H9;+_ +X;
M_"ON?[?XB_Y\O_P!_P"1Z7UK%_R_@?.?_#)WBK_H(Z7_ -_'_P#B:/\ AD[Q
M5_T$=+_[^/\ _$U]&?\ "_OAU_T,ME_WPW^%'_"_OAU_T,ME_P!\-_A1_;_$
M7_/E_P#@#_R#ZUB_Y?P/G/\ X9.\5?\ 01TO_OX__P 31_PR=XJ_Z".E_P#?
MQ_\ XFOHS_A?WPZ_Z&6R_P"^&_PH_P"%_?#K_H9;+_OAO\*/[?XB_P"?+_\
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M_P#P!_Y!]:Q?\OX'SG_PR=XJ_P"@CI?_ '\?_P")H_X9.\5?]!'2_P#OX_\
M\37T9_PO[X=?]#+9?]\-_A1_PO[X=?\ 0RV7_?#?X4?V_P 1?\^7_P" /_(/
MK6+_ )?P/,_A)^SDGA#53JWB&2WU&\A8&U@ART49_OMD#+>@Z#K7M^#4WA;Q
M?H/C:RDN]#O[?48(W\MVB_A;K@@\BMKRT_N+^0KXW,<QQ6,KN>,OS+2STMY6
MZ'!5JSJ2O4W.?Q1BN@\M/[B_D*/+3^XOY"O,]MY&/,<_BC%=!Y:?W%_(4>6G
M]Q?R%'MO(.8Y_%&*Z#RT_N+^0H\M/[B_D*/;>0<QS^*,5T'EI_<7\A1Y:?W%
M_(4>V\@YCG\48KH/+3^XOY"CRT_N+^0H]MY!S'/XHQ70>6G]Q?R%'EI_<7\A
M1[;R#F.?Q1BN@\M/[B_D*/+3^XOY"CVWD',<_BC%=!Y:?W%_(4>6G]Q?R%'M
MO(.8Y_%&*Z#RT_N+^0H\M/[B_D*/;>0<QS^*,5T'EI_<7\A1Y:?W%_(4>V\@
MYC+T<?\ $SMO^N@HK;LHT%W%A5'S#M17FXJ?/),PF[L\2HKSF3XE^*E=E7X6
M^('4$@,+NQP??_7TG_"S?%?_ $2OQ#_X&6/_ ,?K[WVL?/[G_D/^T\%_S^C]
MZ/1Z*\X_X6;XK_Z)7XA_\#+'_P"/T?\ "S?%?_1*_$/_ (&6/_Q^CVL?/[G_
M )!_:>"_Y_1^]'H]%><?\+-\5_\ 1*_$/_@98_\ Q^C_ (6;XK_Z)7XA_P#
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M#_PJSQ%D=#]LL>/_ "/42PM.5O>?W/\ R!X_ O\ Y?Q^]'R5\*O"&K?#O4M
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M\-W.D-;PS1V<]S_9]DMV9@H$9 Q*)?,X4#Y<&O>_^%V>+?\ HC_BK_P-T_\
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MCL?!FC>+](^$GQ.&AV5[9^(I=,T86 $6V9G31;..7R@PP9%VR*/1P!UKO/\
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M2,6E:PUB:/\ .OO/7:*\B_X75XL_Z(]XI_\  W3_ /Y(H_X75XL_Z(]XI_\
M W3_ /Y(JM>P_K-'^=?>>NT5Y%_PNKQ9_P!$>\4_^!NG_P#R11_PNKQ9_P!$
M>\4_^!NG_P#R11KV#ZS1_G7WGKM%>1?\+J\6?]$>\4_^!NG_ /R11_PNKQ9_
MT1[Q3_X&Z?\ _)%&O8/K-'^=?>>NT5Y%_P +J\6?]$>\4_\ @;I__P D4?\
M"ZO%G_1'O%/_ (&Z?_\ )%&O8/K-'^=?>>NT5Y%_PNKQ9_T1[Q3_ .!NG_\
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M\ _MO#=_Q1\G9/O1D^]?6/VVU_Z-SU3_ +_:?_\ )-'VVU_Z-SU3_O\ :?\
M_)-'^O6%_P"?$_P#^V\-W_%'R=D^]&3[U]8_;;7_ *-SU3_O]I__ ,DT?;;7
M_HW/5/\ O]I__P DT?Z]87_GQ/\  /[;PW?\4?)V3[T9/O7UC]MM?^C<]4_[
M_:?_ /)-'VVU_P"C<]4_[_:?_P#)-'^O6%_Y\3_ /[;PW?\ %'R=D^]&3[U]
M8_;;7_HW/5/^_P!I_P#\DT?;;7_HW/5/^_VG_P#R31_KUA?^?$_P#^V\-W_%
M'R=D^]&3[U]8_;;7_HW/5/\ O]I__P DT?;;7_HW/5/^_P!I_P#\DT?Z]87_
M )\3_ /[;PW?\4?)V3[T9/O7UC]MM?\ HW/5/^_VG_\ R31]MM?^C<]4_P"_
MVG__ "31_KUA?^?$_P  _MO#=_Q1\G9/O1D^]?6/VVU_Z-SU3_O]I_\ \DT?
M;;7_ *-SU3_O]I__ ,DT?Z]87_GQ/\ _MO#=_P 4?)V3[T9/O7UC]MM?^C<]
M4_[_ &G_ /R31]MM?^C<]4_[_:?_ /)-'^O6%_Y\3_ /[;PW?\4?)V3[T9/O
M7UC]MM?^C<]4_P"_VG__ "31]MM?^C<]4_[_ &G_ /R31_KUA?\ GQ/\ _MO
M#=_Q1\G9/O1D^]?6/VVU_P"C<]4_[_:?_P#)-'VVU_Z-SU3_ +_:?_\ )-'^
MO6%_Y\3_  #^V\-W_%'R=D^]&3[U]8_;;7_HW/5/^_VG_P#R31]MM?\ HW/5
M/^_VG_\ R31_KUA?^?$_P#^V\-W_ !1\G9/O1D^]?6/VVU_Z-SU3_O\ :?\
M_)-'VVU_Z-SU3_O]I_\ \DT?Z]87_GQ/\ _MO#=_Q1\G9/O1D^]?6/VVU_Z-
MSU3_ +_:?_\ )-'VVU_Z-SU3_O\ :?\ _)-'^O6%_P"?$_P#^V\-W_%'R=D^
M]&3[U]8_;;7_ *-SU3_O]I__ ,DT?;;7_HW/5/\ O]I__P DT?Z]87_GQ/\
M /[;PW?\4>3_ +-EKXLF^(,$GAMO+MDQ_:+S9\CR<\A_5O[N.<_C7W(>O'2O
M$-#^(^K^&+5[;2/@;X@TVW=_,:.VN=.4,V,9/^D<FM'_ (75XL_Z(]XI_P#
MW3__ )(K\[SW-5G&*]O&GRI*RTU?J_ZLCRL3F%"O/F4DOF>NT5Y%_P +J\6?
M]$>\4_\ @;I__P D4?\ "ZO%G_1'O%/_ (&Z?_\ )%?.Z]CD^LT?YU]YZ[17
MD7_"ZO%G_1'O%/\ X&Z?_P#)%'_"ZO%G_1'O%/\ X&Z?_P#)%&O8/K-'^=?>
M>NT5Y%_PNKQ9_P!$>\4_^!NG_P#R11_PNKQ9_P!$>\4_^!NG_P#R11KV#ZS1
M_G7WGKM%>1?\+J\6?]$>\4_^!NG_ /R11_PNKQ9_T1[Q3_X&Z?\ _)%&O8/K
M-'^=?>>NT5Y%_P +J\6?]$>\4_\ @;I__P D4?\ "ZO%G_1'O%/_ (&Z?_\
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M^HWR6=OU/2\#THP/04M%=1@)@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4
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M -#->?DG_P 31_PO'QW_ -#->?DG_P 37<_\,C^*_P#H(Z7_ -_6_P#B:/\
MAD?Q7_T$=+_[^M_\31];R7O#[E_D'U'B'M4_\"?^9PW_  O'QW_T,UY^2?\
MQ-'_  O'QW_T,UY^2?\ Q-=S_P ,C^*_^@CI?_?UO_B:/^&1_%?_ $$=+_[^
MM_\ $T?6\E[P^Y?Y!]1XA[5/_ G_ )G#?\+Q\=_]#->?DG_Q-'_"\?'?_0S7
MGY)_\37<_P##(_BO_H(Z7_W];_XFC_AD?Q7_ -!'2_\ OZW_ ,31];R7O#[E
M_D'U'B'M4_\  G_F<-_PO'QW_P!#->?DG_Q-'_"\?'?_ $,UY^2?_$UW/_#(
M_BO_ *".E_\ ?UO_ (FC_AD?Q7_T$=+_ ._K?_$T?6\E[P^Y?Y!]1XA[5/\
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M_$T?\+Q\=_\ 0S7GY)_\37<_\,C^*_\ H(Z7_P!_6_\ B:/^&1_%?_01TO\
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M9>>1\K<CT-%XC]XN7VBZ?J=Q9SWEC;74]E)YUK)/"KM ^,;D)&5..,BL_3O
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M-_\ $T?\-B:E_P!"U:_^!3?_ !-']D9QY_\ @?\ P0_M[A_R_P# '_D>Z_\
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M_P *E\&?]"SIW_?H_P"-=;12^M8C_GY+[V/ZEA?^?4?_  %?Y')?\*E\&?\
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MO_P#NZ/^$"^+W_0=\%_^ =W1_;>#[O[@_LK$>7WG345S/_"!?%[_ *#O@O\
M\ [NC_A OB]_T'?!?_@'=T?VW@^[^X/[*Q'E]YTU%<S_ ,(%\7O^@[X+_P#
M.[H_X0+XO?\ 0=\%_P#@'=T?VW@^[^X/[*Q'E]YTU%<S_P (%\7O^@[X+_\
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MOM#M[6:"]\$2Z%$9YUC)NFU"&< YZ+L1CNZ9XKW#_A OB]_T'?!?_@'=T?\
M"!?%[_H/>"__  #NZS^O9?:4>9Z_\'_,U]GCN:,K1]W];?Y'S9XI_9*O9=;^
M(%]H?AW2+-KW5?#MYH4D#1Q-;I:[#>%/^>18J<XP7]ZQ_P#AFCXCW/Q=/B*X
MMM.TJV74=:EFU/2YX@\D-U;RI$ZHJ^:Q!925=CST KZK_P"$"^+W_0=\%_\
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M#;AI%VY8DD#%;VB_L8_$"S\#^*-,>SL;:_D\-MHD+1ZA"4U*4W,4GF,%C7
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M1?XU?]!OP-_X!W?^->+]9H-WNSZI4:R[?>>3Z5\"/%&D:5H4TNCV.J7FE?\
M"*R?8VGBS*UA#-'<JK-\H(\T$$X#8KIO@EX8=OBAXPU&*1)_"N@7=Q8>'=B$
M"-KMUN;\+D8PDN(@1Q@,/6NR_P"$7^-7_0;\#?\ @'=_XTO_  C'QJ/_ #&_
M _\ X!WG^-)8B@G=,;HUI)IV^\\HN?@3XFO=0\4V$.BZ;8:9J%AKEOY]Q-#<
M)+)=JYA:$[1,A,CAI%EW*-OR]%-6-6^&?CFXT;7]/L?"]C!%XCAT)YE:^A5;
M!K)HEFB*CARRQ;E*\?-@XQ7IW_"+_&K_ *#?@;_P#O/\:/\ A%_C5_T&_ W_
M (!WG^-3[>AW8_95O+[SS71O@YJEAK?ABWUOPOI T;0K_69]4\1&XC:74K6[
M@NEW%,;R6$PWA^A7C(YKI/V7= U"'PC>>(-7N/MUW?NFG6%VRD-)I5EN@LW(
M/(,@WS'U,N:Z;_A%_C5_T&_ W_@'=_XTI\,?&HGG6_ Y_P"W.\_QJHXBA%WN
M3*C5DK.WWGH5%>>?\(O\:O\ H-^!O_ .\_QH_P"$7^-7_0;\#?\ @'>?XUO]
M>I&/U2IY?>>AT5YY_P (O\:O^@WX&_\  .\_QH_X1?XU?]!OP-_X!WG^-'UZ
MD'U2IY?>>AT5YY_PB_QJ_P"@WX&_\ [S_&C_ (1?XU?]!OP-_P" =Y_C1]>I
M!]4J>7WGH=%>>?\ "+_&K_H-^!O_  #O/\:/^$7^-7_0;\#?^ =Y_C1]>I!]
M4J>7WGH=%>>?\(O\:O\ H-^!O_ .\_QH_P"$7^-7_0;\#?\ @'>?XT?7J0?5
M*GE]YZ'17GG_  B_QJ_Z#?@;_P  [S_&C_A%_C5_T&_ W_@'>?XT?7J0?5*G
ME]YZ'2,Q52P7>0,[,XW>WXUY[_PB_P :O^@WX&_\ [S_ !H_X1?XU?\ 0;\#
M?^ =Y_C1]>I#^J5/+[SRJP^ ?CW38M.UQ]<M[_6+V357U?2?(CB5%U*)_/47
M&XF012K;;00,B+BNATSX,>(F^%WC_P .RR065]KFGZ;;6L@FRA:#3;:"17*\
MA6DA="?[K9KM/^$7^-7_ $&_ W_@'=_XT?\ "+_&K_H-^!O_  #N_P#&N=5Z
M"[FSI5GV.*U/X>:[J]_IWB"/X?:)I8T[5X;R3PY'=0_\3%%M)H-[D#R0T;3*
MT8/4)R0=M<S:_LWZM<Z-XV^WZ+I7VK6/#&H66FV:NCQZ?/<WUU<);QD\*J"6
M+YUP <[>!7K?_"+_ !J_Z#?@;_P#O/\ &C_A%_C5_P!!OP-_X!WG^-'MZ >R
MK=+?>>9^/O@#K=]X@:_T"U@L]-MWT:Z.G6+P0_;)+>WO(9^)%,>]?/A92XPW
MECD$ BIX<_9PU6*TUQ]3T:QNY;[PY?V-O:WUXC>3-<7KS&+S(D C!0KEHUVJ
M6(&1G/J__"+_ !J_Z#?@;_P#O/\ &C_A%_C5_P!!OP-_X!WG^-'MZ'F/V5>U
MM/O*/P-\(:]X57Q&^LZ?#IMO>W$#VD!-NUSA8MKF9[<"-N<!2 &VK\W:O4:\
M\_X1?XU?]!OP-_X!WG^-'_"+_&K_ *#?@;_P#O/\:UCC*,59&,L-5D[NWWGH
M=%>>?\(O\:O^@WX&_P# .\_QH_X1?XU?]!OP-_X!WG^-7]>I$_5*GE]YZ'17
MGG_"+_&K_H-^!O\ P#O/\:/^$7^-7_0;\#?^ =Y_C1]>I!]4J>7WGH=%>>?\
M(O\ &K_H-^!O_ .\_P :/^$7^-7_ $&_ W_@'>?XT?7J0?5*GE]YZ'17GG_"
M+_&K_H-^!O\ P#O/\:/^$7^-7_0;\#?^ =Y_C1]>I!]4J>7WGH=%>>?\(O\
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MX?\ SZ7WL/\ B'M+_G\_P/CK_A77BC_H7]2_\!G_ ,*/^%=>*/\ H7]2_P#
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M [S_ !H_X1?XU?\ 0;\#?^ =Y_C1]>I!]4J>7WGH=%>>?\(O\:O^@WX&_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME/N#7Q%=7/CC0/"_@RUTW3==L]3TG0="^QH#=!6;S5-QY<4:^6=H)63SCT'
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MN_\ 1M7B[_OX/_B:**/91[!]4I=@_P"&K_B[_P!&U>+O^_@_^)H_X:O^+O\
MT;5XN_[^#_XFBBCV4>P?5*787_AK'XO8 _X9K\7X'3]YT_\ ':/^&LOB^?\
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M0_MD?%XC!_9H\7D>AE'^%%%'*@]E'L'_  V1\7CC_C&GQ?Q_TU_^M1_PV/\
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/ZNW'04444TK%QBH['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>bcyc-20241231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  P!!T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**\HL?
MC+JU[\7?%'@^?PG=Z-9:1H8U6WU#4)86^WGS63,:Q2.1'\O\>ULY^44 >KT5
MR'PW\</XO^&&B>*]1BCM'O+!;V>. ,RQ_+DA1R3T]S63X_\ BZWAWX07?CKP
MSX>U+QC$+)KRWM+01VSE A;S)!<O$508RPY?'12: /1:*\CN?C?J%K!X2;_A
M'X'&MZ;!>275Q>M;01RRX"PHQC92VXCAV0D?=#G*U2T?XW:[=_"SX3>)K[2=
M.M=0\8WEA;W5M;SR2Q01W$+R;D8A3G"KP0<9(RV,D ]IHKR33OVD?!MIHNA-
MJ6O-JNIZGIS:G!'H6A7\S7-NLA1I8[=(Y)0JG@YR1U.!6SJ7Q\\#Z;I^CWHU
M6XU*'5K7[=9KHVF7>HRO;]YFCMXG=(P3@LX !X)S0!Z%16#HGCC1_$DUBNE3
MS:A!?6?V^WO;>TF>T>+<%_X^ GE!\G_5E@^ 3MP"1Y9XY^+?CWP6\^O7NB:/
M8>&$UN+2+;2[II&U/4(WE6(7$;HVQ"Q8LL11B57)92<  ]QHKAOA3X^N_']M
MXHDN[:&V.D^(;[1XA#GYXX'"J[9/WCGG'%=%+XLTJ'Q5!X;>ZQK4]H]]';>6
M_P T*L%9MV-HPS 8SGGI0!KT5RLOCZ#4/"WB'5/#EE=>(+S26N;8:<D36\EQ
M=0@@PJ90HY; #_=YR"17ELGQQ\9>"O$]YH?BO2=%U;4/^$>;7X[?09)(C:LL
M\4/V>=I"P.XS?)(-N[RI/D&* /?**\-USX]^(%M]2TZP\,VD6OZ9;W-QJ6_5
M-T%M'%*(U:%C"#.S$D[6$8 4Y8$J&UOB1\9;GP+K_A_3Y9K"PLM0T.^U.XU*
M\MY9Q \#VJK^[B(9E/VAL@<\#WH ]<HKS/5_VCOA_P"']=U'1=0UR9-1TN:W
MM]1,6EW<D-D\\:21&:58C'$CK*F'=@N21G((%[Q+\=O!/A#79])U75YK>XMC
M&+NX33[F6SLM_*?:;I(S#!D$']ZZ\$>HH [ZBN-\<?%[PO\ #N\MK/6;R[:^
MN(FGCL],TRZU&X\I?O2M%;1R,L8[NP"^]4X?CMX'O/$&BZ)9:RVIZGK%G'J-
ME#IME<78EMGD,8F+11LJ1AQAF8@+QN(R* .^HKRO_A>=CHWBWQWI^OC[+8Z#
M?V5C9?8;6>[NKQY[59MBPQ*[R-DM@(I.%)[$U%KO[3'A#2M'\.ZI:1ZSK-GK
M6J'24^P:)?2RVTRG:ZSQ+"9(G4\>6ZJQYP#@T >LT5Y^_P >/!$?B9M";5IQ
M=K=+8/<?V==?8DNC@"W:[\OR%ER0/+,@;)QC/%2:'\;_  EXFU#4;/2+G4]4
MET[4FTB[>ST2^EB@NEE,+QM(L)0;7!W-G:JX8D*0U '>45P6J?$Q='^+UIX3
MO&L[6PGT5]3%U/+L?S%F$>P9.,8.?6O+_$W[2.N#7M5TG0_[ A$/C"S\-0:E
M?;YH%BFLC<-*X21,L&&T ,!@T ?1M%>3?"WXIZWX@^(OBCP9KIT;4[C1K&SU
M%-9\/!UMG6=IE\F1'=RDB^3NP';*L#QWZR'XJ^&+CP?I_BB'4))M#U"9(+:Y
MBLYV+N\GEJ-@3>!NXR0 .I('- '6T5Y9\0/CC9_#GXGZ'X=U.*5M/U+2KJ^#
M6-C<WMXTD4D2A8X8$=V&)"3A3C&>!5V^_:%\!66BZ)JL>LSZI:ZU:F]L%T;3
M+O49YH!]Z7R;>)Y%1>A9E !X.#Q0!Z-17ELG[3GPU5[T1>(VO8[+3?[8NKBQ
MT^ZN8+>S\IY?.DECB9$4K&^,D$L-H^8@5&_[47PXC-VG]KZ@]Q;0I=/:QZ#J
M#W#V[9Q<QQ" O)!P<S(&C'=A0!ZM17FFJ?M'_#O2+F&&;7WF5X(;J2YLM/NK
MJVM8I0#$]S/%$T=N&!!'G,G'/2DUK]I'X>:!KVJ:->:[*+[2I8(=0\C3;N>&
MR,\:20M--'$T<<;+(A$C,$R2,Y!  /3**X!OCQX'3Q.=!.KRF[%V+!KE=/N3
M8K=' %N;P1_9Q+D@>69-V>,9XK1\0_%?PSX6\8:7X6U"]N!X@U./S[6QM;"X
MN6:+>$,C&*-@B*S#<S$!0<L0.: .NHK@/#OQX\#^*=:CTO3]8E-Q.)3:S76G
MW-M;7@C!,GV:XEC6*XVA68^4S8 )Z#-5M&_:)^'VO7%S%;:Z\20VTMZMS>V%
MS:6UQ!&<22V\TL:QW"KD9,3.!D>HH ](HKRQ_P!IWX;P64US=Z[<Z8L7DGRM
M3TB]LYI$ED$<<D<4L*O)&SLJ^8BE,D#-4O$?[4O@K0_#5[JUNNM:E)97MO8W
M6FQ:%?I?6[3,!&\ENT E1&!)5B@5\84D\4 >P45YQJ_[0W@+0-573]1U>YM)
MPL#7#R:5>>38^< T2W<WE>7:LP9?EG9&Y&16UHOQ5\,^(O&NL>$]-O;B\US2
M&"7\4=A<>3;,41PKS^7Y08JZD#?D\XS@X .MHKA_&?QI\(^ M=31-7OKPZP]
MI]O6PT_2[N^G:WWE#($MXG)4$')Q\HY.!S6/>?M,?#>T\AAXB:\@D@CNI+K3
M]/NKNWM8G.$>YFBB9+8'_ILR=#Z&@#U"BO/K[X]^!]/\1-HLFKS/=)+%;RW,
M&G74UC!+(JM''+=I$8(W970A7D!PZ\?,,X&G?M%:*NH>"-+F^W:Y<^*/M'D:
MGHV@WWV-?+=U^8^6^S!0@[F&,;CA2#0![!17EWA/]H#PCJ?@G5=<O?$MI<Q:
M)8?VGJEY;Z==6T26Y,A61(Y 788C884L=RD=2!5_6_C[X&\.ZN^G:AJUQ;RQ
M>7]IN?[,NFM+(R %!<W(B,5N2".)74\CUH ]"HKB_&OQ"&A?#;Q9XFTZVF>;
M1+2ZE6+4;2:V622%">DBJ60D<.N5(Y!-<QXV^.47A[PUX(OM.ETR_O=>UC3-
M-GMQ.&\I+E@'90K9RN>,_C0!ZW17AWPM^)'C?XC6UIJK:[X,L;&:\GB.E"RG
M:\$<<SQXW_:@-Q"9SLQSTKD[#]HSQG%X"TOQQ=W'A"]TZ\U!+1O#UG'-'J(5
MKLVXV.9G#N/O;?+&>1D=: /IVBO#/$OQ>\>>%=4T_5-3T+2M.\-WWB2'0+32
M)V=M5N8Y)A"MVC*QC /,OE%21&"2P/ ];\6^+-+\#>'KO6]9FDM]-M=OFR16
M\D[#<P082-68\L.@/KTH V**\N^)OQLMOAE\0_!6BZA&6TW7K;496>WM9[J[
M:2W6%DCAAA5GD+"5R556.$ST!K>\/?&+PAXJN_#]KI>L"ZN->M[JZT^+[-,C
M2);-&MQN#(/+9&EC!1]K9/3@X .SHKRF]_:C^&EC-/"^O7,TMO:F^FCM=(O9
MVBMQ/+ TS".%ML:R02JS'A=H)(#*3L>'OCMX'\4ZG/8Z?K1:2*R;45GN+.XM
M[:XM5QNG@GDC6.>,9&6B9@,\F@#OJ*\KD_:@^&UKIM_?WNNW6E6=E#'<R3:I
MI%[9J\$DJQ)-%YT*^;$7=1YD>Y0&!) YKJ/!7Q2\-_$&\U&TT:[N6O=.*?:;
M6^T^XL9D5\['$<\:,R-@X=05..": .LHK@(/COX(N/$R:$FK3"[>[-A'<R:=
M<I8R7(./(2\,8@:7.1Y:R%B01C(K)C_:9^'NH#R[/7Y$,KS6T%_<Z1>K8FXC
MW!H?M!B6(R H?W0?><<#D4 >JT5Y?>?'_P *:%H^CF_UD7VJ:CI@U.-=+TN[
ME7R".+B1$1VMX2P(#S%1P1NR#65X2_:9\.7/P[\&ZWXCGEM=5UW1+?69K/2-
M-N[];:*1 3))Y,<ABB!R-\A"\'G@T >RT5Y9>_M/_#.P;5S)XE\RVTE;9KZ]
MM["ZFM+=;@1- 6N$B,>'$\14[L$,3T5L1W?[4GPXL$U W.K:E ^G$?;H)- U
M$36D9&1--'Y&Z. CD3,!&?[U 'J]%>?ZE\>?!&DZ_%I%SJMP)GGBMC>1:;=2
MV$<TN/+CDO%B,$;-N7"O("=R^HJ/P=\6(=3T;QKJVOO::1IOAW6+RP>Y+$((
M8",2.3W.>WX4 >B45Y0W[4OPTAAO)+K7KG3C9Z<VK3Q:CH][:2QV8D2/SS'+
M"K;"TB!6QAN2N0K$6M4_:/\  6C06LMYJ&IP_:+=KORO[!U!I8+<.4\^>,0%
MH(25;$LH5& W D<T >FT5Y_X@^/OP_\ "VE:IJ>J>);:VT_3([.:YNO+D>,1
MW1 MW4JI#JY/WDR!R20 :R/%W[2?A/PEX]TGPB8=9U35+R]^PS'2]%O;J.U<
MV[SKN>*%E8E4^ZI)4'<<*K$ 'J]%>+_"_P#:;\.^,C9Z?JUP=.UR\U6[TJW6
M.QN?L<DT,LJK"+HH8?.*1%O+\S=P<+3;K]HBWT_XQ^*?#E^LNF>'?#FG6T]S
M=3:'?O)<SS,X58I5C\O'RJ%4;VE+'9G:U 'M5%>>VOQ\\#77AK5-<.KSVEGI
MERMG>6]]IMU:WD,[!2D1M)8EGWN&4JH3+9&W-8&J_M3>#+&314M8/$&HOJ.I
M_P!E200^'=1%Q92["_[^ V_F1DC! 9064[AE030![#17GZ?'KP-)XN'AL:S)
M_:)O#IHF-A<BR-V.#;"[\OR#-GCRQ)NR,8S5_P (_%SPMX[DUI=#OKB]CT::
M6VOISI]S'#'+$[))&)7C".RLC95"2.#T() .QHKR^R_:7^'NI^'=.UNRU34+
MZPU*0QV M="OY9[["!V:"%8#),B@_,Z*RJ>"0>*O:A\?? NG:'I.JG6)KR#5
M6E2RM]-TZZO+N8Q\2@6T,3S#RSP^4&P\-@T >A45YSJ/[0O@+3;33;DZQ<7L
M6H6OVZ$:9I=W>NEON*F:58(G:% P(+2!0"K G@XIWG[3GPUL;V[MG\1M,MF8
M/M=W:Z?=3VEJL\,<T,DMQ'$T4<;1RQL)'8)SC.00 #U*BO+$_:.\)0^)?&6E
M:E_:6CV_A9(I+O4]0TNZAM'#\#9*T01R3@*%8F3(V;J;-^U#\-[2TBFNM:O;
M&66^BTY+&]T6^@O3<2H[Q)]E> 3?.L;[3LPQ& 22 0#U6BN"\9>)?&%Q<:!:
M>"])M1%J,4EU=ZUKT4B6^GQ*JE$>WW)*TKEL!25VA7+'("E?@G\1+KXH> H-
M;O;:WM[I;JYLY&LV9K>9H9GB,L);DQOLW#/8]3UH [RBO-8?VC/A]<Z^^CQ:
MW,]W%J<FBS2#3;O[-!>H^PV\EQY7E1N3]T,XW @KD$&KDGQV\$Q>*6T!M6F^
MVK=C3VN!I]R;%;HD 6YO/+^SB7) \LR;L\8SQ0!WU%>::C^T?\/=*UPZ3<ZY
M,EP-3AT43KIMV]J]])*L26RW*Q&)I-[ ,H<E>2V "1+>?M!>"+'7I-'DU"^:
M\$LMO&\>C7KV\\\:,[P0W"PF*68!6_=([.2I 4D8H ]&HKQ#2?VI_"VK:-X<
M\07%Y=>'-)U!;UI+/5M!OTN9! 4!>-O+4*B[P68JP(. 05;'>:]\8?!_AJ_U
M:RU'65AN=*L[:^NXT@EDV17#R)!C8I#N[12!8URYQ]W!&0#LZ*XK0/C%X7\3
MV=W/IL^I3RV<\5M=6#Z->QWULTA_=F6U>$31HW4.R!< G. 354?$^.V^+FJ^
M$K^2QLK.UTBWU&*XFE"2.\DLB,O)Q@! >/6@#OZ*^6/%7[7>OZ#?M-8^';+6
MM'LO%-_IFH&R9Y+@:;:P12RW$(!(>15D9RO0JA YQ75_$[]I>?P5<>(I-*L+
M/5]+LM%TO4[6_P![>4!>73P>?,RYQ!&H61BHSM#?4 'OE%>):9\;=9\/^%O$
MGB+Q*_A_Q)X<T[3EO[77?"5Q^ZN')*FV,+R.ROG:0X8J0Q^Z1@R:C\1_B+X!
MT6V\4^+M&T:]\-,AFU&UT%)C>:3%L+>8S.Q6X5<8;:L9'49Z4 >TT5XUI'CO
MXHW6BZ1XKF\.Z/=Z%J,D,C:#8>:VIVEK*1MD,Q;RY'56#.@1?X@&; ST?C3X
MMV>E_"WXA>*-!_T^Z\*6FH&2"[MY84-U:PLYC.Y5++D ;DR#G@F@#T*BO-?
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M4:^DU(PE8KR*2:3S8WE$6\DQ2<$KPRCMS73?'[XXZ]\(/&7@.&PTJUU+P[J
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M.KWMU=ZT'MWC6<PR1)';,68,8E,@&3A\* ?J:B@# \"ZWJWB/PM9:CKFB?\
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M(Z5[S10!\I:O\._%?P>^S>,[NZL=6U]O%FH:LRVEE=26:07D2(8W$2O*A78
M'"/GC(&>.G_9]F\:V+:QJ=UH4=U:>*_%UY?SW;))9?9K/[+&L<J0R N07BV
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M ^:_ _[+>J^%KO1YA+H&FVUGXV'BG^SM)ADC@A@_L^:V\B/(Y8/*&W' (!.
M>*Z;6?@CK\/B.?Q1H=_IIUVV\32Z[8V]]Y@MY89;)+62&5E!*,0"P=5;! X.
M37MU% 'SAXW_ &=/$?Q U?0_%7B6U\'^+/$%FMY;R:-J4$D>G16\[1,JQ2JC
M.9$,(_>,GSAV&%XQT7PK_9_NOASKGA*]%QI"PZ3IFHVL]MI5B+.'SKJZ6?\
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-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>bcyc-20241231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %" N(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBFR2)$I9V"*.[' H =15-[XS96U42M_?;A1_C2K8K+&OVG][
M(.Y[?3TH MT54^P+'S')(A'8,<?D:SX=>^S:E#879+/.2(I0O!(YVGT- &W1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7\3:OX>LM2M[K6M(C@EU"RB;=):K,&,7F#^$L$8@'D@9Z5S&@?'?P?XHU?\
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MGPSTWQ_8>";CQCIB>);XP"WL5<MN:92T"F0 HK2*,HK,"P^Z#Q0!XE^S_P#
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M %%%% !1110 5QOQ1\#6WC;PZ4=2+RS?[3:RH<,KKVSZ$9!^M=E3)76.-F?
M4 DYH \'\ VUAHU]MAS#'<CSA$XP0>_'UKS3XW_ 30_"CCXA^#_"\6N:A8W?
M]H:EH=TQGCODSN<JCY^8<MM'7\J^AD\'Q:DJW"Q;1EG3'! )R*R-5T_4--^6
M!RXZ -UKMPN+JX23E2>CT:Z-=F3**EN<]HGQ/T/XO^ +/5O#L@ELKV+RO(*X
M:!@,-$R]BO3TQ6KX.N_$'@9-/T?%O?:2(MD<MP[":'GA2>0R^F<$5PW@#0[?
M1_B7>_V--&-+9&GU*W3!AAF). F.C,V25[8)KU;5O$MGX?T#5M=NHC<6VGVS
MW#1)C+!!G KR<-B%C'*5.-ES-+6][.VCLK]MM[]-3247#1G8V\4?RW5Q.'E(
MY"\ ?2N5^)-YX*AT>:X\80:1+8!>4U*V2=F^BD$YKXOUC]M3Q+XE+2V5K9:+
M8GF*VMQO;';=(>2?I@5XY\0/BOJOBV0SZMJ+W&W.U7.$3Z*.!7Z5@^$ZLFJF
M+J*,?[NK_P OS.*5=;11)^T1=^"]<\374W@VT;2M(ACVV]L=RH7YW,%9FV \
M?*,#VK[$_9:U.ZG^ /@NR8L]PUJ[,2?X3(V*^,_AM^SGX[^.%VEQ:V,ND^&M
MV9M9OD*(R]Q"IYD;Z<>IK]"_@9X5L_#GA:STZW;$5B/LJ"1OF 4XY]^_XUY_
M$%>C>.&H2O&/G?;3<NDGNSTK1]/BFM1%,,@+C:PZU=M;6>T40VDH-O'P!*-V
M/8'-7)/*AMB"0!BL.S\0I;JT+%=RD]37QQT&C'JY@N5@O=D3.VV-U/RL?3GH
M:TZ\Y\4:XMP]M#$^)Y9T5".H)/%>BCIZT +1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?&OQ\^"WQ'^)7[4?BQ?"@L-*T+7_A:/#-YK6M6$L]L!
M->S^:D+1LO[]4<.%;*D'D=#56S_X)_WV@_$^TOK#Q#8:AX->]T:_N[;5/MOV
MQ9-/MXX5$:13I Q?RD822(S1DMC(K[4HH ^%OV?_ -FCX@Z]K&DWWBF>TT#P
MOX=^(6M^*+;3I=.EBU.XE>2:.',A;9Y#+(7W;<D8'3!JUX7_ & _$R>#-$\*
M>(/%VDMIFC^'O$7AJ"XTVTF$TD&HLKQRN';;O1MV5'!& .YK[?HH ^&?$/[!
MGCSXA6VJW/B?QEX>AU=_#>E:)8_V187,4"2:?=K/$\O[P,5<*0VPJ5+?+]T9
M^A?V:/@I??!CPUKJ:Q/I]QK>N:K+JEX^F-=/$"55%!DN99)9&"H,NQ!/IQ7L
M-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1SSI;QEG.!V
M'K0 YW6-2S$*!W-9=WJC/E8OE7^]W-5KJ[>Z;+<+V45!0 I.3D\FDHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH E@N9+=LHW'<'H:U[2_2Y&/NO_=-8=*"
M0<@X- '2T5G6.I;\1RG#=F]:T: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"M>7HM/+78TCR-M51_,^U<)\0[VZDU31+%IVBM9;
M@-.D9*AP!D*<=LUKW&K&X\;2V8=MEM;JY!' 9B>GJ<"O._VB_'I^'>FZ#JMQ
M:QR6MW?K;3.V=R @D;<'@DC'-)WVBFWV2N]>R1I3A[27+=+U=E][/4M0\4Z?
MX:\.W6IWLOE6MG"TTK 9PH&37A.K?%7QQ\3K0GP9X2&C:9< B/7=?F$2LIXW
MQ1C+-[$ CWKS_P"._P <+?7/#2^$_"VH0:K/JRB.2:-@"J'DJ ?XL=<=*Z'2
M/V4O"]OI-A=6-YK27IMTV:E'JTLA4E1DHK90#.>-M>)7G6KXF>&I.W)\2ORN
M[Z7Y6]/*WJ?34*%# X2GBL3'WJC?*VN9)*VMN:*U??FT6QU?@WX=0_#?P;!I
M=K="XOY7:XO;SH;F=OO.<]NP] *\W\6_$[Q!XZ&J>!?AO96OB6ZDA>WU/6)"
M?L-@K A@9!D,_H!GZ&O8;[X.:YXC\-CP[<:U"=)GC\B[O0CK>O%C!5>2H8_W
M\\>E>@^"?AMX<^''A&VT+0--ATK3+93MAB'5N[,3RS'NQY->YEU>%*#<Z#4H
MZ13M;UT;OY)V\[['S6(E*M4<Y2NV[M]S\<M+\/Z[X<UF[T35[:33+FRE:"1+
ME2AX. 0#U!'(/<&O4?AY>Z7X+\1V>K36UKJDT#!@NH0).@]PC#;GWZ^]?:MY
MX<L=8^+6LVWBC1[+5/#]_;(EO#>PB1=R'DC/0G/!&#Q7#?%;]BGPSJ]O->^!
M]7D\,78!86%V6N+-SZ D[X_P+#VK[_+,^H6]ECTVGIW7W'GSI/>!ZQ\.?CSX
M;\?R6L8U"VM;ID"&!FV!3Z;3T'T)'TKK=$LVT#Q/J%D<-'?O]I@XX5@/G7\<
M _@:_)[QE9^*?A+XE.G^(+.73KG<1!/$^^&?'>.0<-].".XK[E^!?QP_X2#X
M>^ +_6+IGO!>-8M.S9+!#M#,?3! )]J\[.<MPE"E'%X*I>,G:W;?9_(NG.3?
M+)'TQJL]Q;@)C=NZ 5YUXEE:&>21-0$$ZC+*WW178^,/$ATZW$OECSI (X2S
M *S-P.:M1?!_PW=0P/JU@NJW:L)'DN9&96?K]W.TC/0$5\B=!R7PC\(7VKZJ
MWB;5[PW5K'E=/MQ'MC)[R\\MZ ].IKV6FI&L2*B*%11@*HP /2G4 %%%% !1
M110 4444 %%%% !1110 4444 >?ZM\:M#T;Q1-X:N+741XB^V6]K::8L ,M\
MDHR+B#YL-"@67>Y(V>2^X#Y=W?\ 6O(/$/PKU?5_B(/&0\30VWBC3YEAT2V
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M4UW$:EF. .2: &SSK;QEV/T'K6%<7#W,A9C]!Z4Z\NC=2D\A!]T5!0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J:=?YQ%(?]UC_*LN
MB@#IJ*I:=>>>FQS^\'ZBKM !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %,FE$,+R'.$4L<>U/ILB"1&4]&&#0!YYX+>'6O$NK:P[EWE*0JK'A
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M \-_$?1DU;PQK=EKFGMQY]E,) I]& Y4^Q -=!7P1\3OV/\ QG^SGK<WQ"^
MNKWYCA^>[\.NWFR&(<E5!XN$_P"F;?./X237N_[+G[7.@_M#:9_9]PB:)XUM
M(\WFD.WRR8X:2 GEDSU4_,O0YZGKQN3P5!X[+JGM:*WTM*'^)?JM#&AC6ZGL
M,3'EGT[/T?Z;GT!116'XYEM(/!VM27VK2Z#9I:2M+JD$OEO:*%),JMV*]><]
M.AKY@]4W**\4_9O\9>(?&\6M7OC*YN;/Q1%Y$3:%+&;=(+3:3;W0A/(:X!:1
MLD["/*X,39]KH *9+*D,;/(P1%!9F8X  ZDFLCQAXQTCP'H%UK.MWL=C86XR
MTC]2>RJ.K,>P')KY0NM;\>_M@:Y/8:29?#'P\@DV2S.#^] /1\']XYZ^6#M7
MN3W[\-A)5TYR?+!;M_IW?D>K@LOGBDZLY<E..\GMZ+N_(]>\>_M<_#[P1+);
M17\FOWJ$J8M*42(K>AE)"?D37YU_\%0_VBX_C+\-O!MK;>&[K2[>TUMIQ<W$
MH?S"(&&SA< _-GJ>E?IA\//V<O OPYM(EM-&AU&_50'U#44$TS'U&1M0>R@5
MP_[9/[(-M^UWX/\ #V@S^)Y/"L>CZC_:"S0V(N?,_=LFS:73'WLYYZ=*TJSP
M<8.%&#;_ )F_T1K7JY="FZ>'IRE+^:3M_P"2K3[SA?V,?VTO$/[0?B9_">J_
M"?5? ]KIVCK=1ZI>RRO'.4,:!%#0H!D-N'S'@=^M?8-5-*L/[+TRTL_,,OV>
M%(MY&-VU0,X_"K=>8>*%%%% !1110 4444 %%%% !1110 5DZI=;V\E3\H^]
M[FK]Y<?9H&;^+H/K6"2222<D]Z $HHHH **** "BBB@ HHHH **** "BBB@
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M*** "BBB@ HHHH **** $ Q2T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6?K$NV!8QU=N?H*T*QM7?==*O95_F?_K4 4J*** "BBB@ HHHH *_.
MG]MS]I2_^(GBA_ACX.EEETF"<6]\UIDMJ%SNP(1CJBM@8_B;Z5]:_M8_%IO@
M]\%-:U:UE$6KW8&GZ>>XFDR-P_W5W-_P&OE__@G3\$(]9U2_^)>LPF=;*5K7
M2A*,YG(S)-SU*@@ ^K$]17Z%P[AZ& PM7/<7&ZIZ07>7?Y?AJ^A\WF=2IB*L
M,OHNSEK)]D>M?LJ_L7:3\*K*S\2>+[6'5?&;J)$AF DATWN H/#2#NQZ'@>M
M?5!.223DGN:2BOCL?F&)S.N\1B97D_N2[)=$>UAL-2PE-4J2LOZW"BBBO..H
M^$/^"@W_  3^G^/M\_Q"\%WEM9>++>U$=]8WC;(;^.,':ROCY) ..>&&.1CG
MXB^ 7_!-_P"(_P 7?&0L-7-GX5T:VVRWE[/.LLGE[@"(HT)W,>V2![U^W/BC
M_D6]5_Z]9?\ T$UX9^S)_P A[6/^O1/_ $,4 >R?#KP%I'PN\#:)X3T&$P:1
MI%JEK;JQRQ ZLQ[LQ)8GU)KHJ** "L3QAX+T;QYHLNEZY8QWUH_0.,-&W]Y&
MZJWN*VZ*J,I0:E%V:+A.5.2G!V:ZGPC\0? /B+]FGQW9:QHUY(]@TA-E?8^\
M/XH91T)QU'0CFOK_ .%?Q(L/BEX0MM9LP(I3^[NK;.3!*!ROT[@^E6OB-X'L
MOB)X/U#0[U1MN(SY4F,F*0<HX^AKY+_9F\47GPW^+EQX6U,F&.^E:PGC)X6=
M2=C?GQ]&KZ>4EFN$<Y?Q:?XK^OQ]3[6<EGF E4DOW]);_P T?Z_'U/MFBBBO
MECX<**** "BBB@"2"7R9XW]#S]*Z*N989!KH+23S;:)_510!-1110 4444 %
M%%% !1110 4444 %%%% !1110 5R_BJ<V.JZ;<MD1'=%G/ 8X(_E7453U72;
M76[)[6\B$L+=LX(/8@]B* *2:T)HPJD<]Q4NLVUW=Z'=PZ3<Q6FH/$P@GD7<
MJ/C@D>F:Y*]\&:UHO[[2[I=3C7D6UP=DF/9^A/U ^M1:!XY$D\]M=Q3:??1'
M:]M<H4<>XSPP]P2*:=G<#SFV_9IL$$FN>.YT\9^(I#YC)=;FLX3Z*A^__O/G
MV KO/#'B_2-%T^WLK"TBBGDRD=E80!3D=E1 .E2^+_&5M9Z?-)+,JJ!U8U+\
M&_ TWAO3K[5=0+G4]6E,YC< ?9XOX(QZ?WC[GVKHKXFMB9<U:5_T]%LEZ"24
M=AM[XCUJ-G=O#VJ-["(/_P"@DUR-YHGCOQ9XCM)+?1$T[250N;K4;L1N6_NB
M)0S?BV*]UQ2US#/ M3TSXEW%Y+80>&HHK5#M%^U]&ZN/[RH"#^#8KIOA[\#[
M31KJXU;Q!C5=4N4">5.YEAA7OA>%R?4#\37J]% ' WWP6\/$R2Z3%)X>N9&W
M-)IQVJQ]T.5/Y UG3_"_7=.ADDTWQ$MS*HRL%[; "0^A=3Q]<&O3Z* /'/!_
MC*+[;<:=J-K_ &7K$!_?V4_#+Z,.S*>S#@UUMW)::HA'RB3&0U:GBCX?Z#XQ
MEMY]4L5ENK;/D74;M'-'GJ ZD''MT]JYM/@^;?4A+!XDU..T[V[+&Y_!RN:
M*5]XFFT1&2=3@#AQT-0?"JZU#Q3XLU37)(F328(1:VTC@CS9"<N5]0 ,9]37
M>V_@O2XD EB>](_BNG+_ *=/TK:AACMXECB18XU&%1!@ >PH ?1110 4444
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M'+74-,G\V+:$=#P\3@#*L.Q%=#0 4444 %%%% !1110 4444 %%%% !1110
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MXL?!OX*:5XKN/BMI?CR3PAXKC@\13Z%'$QN]+:0(T-X #LG0XR5VX!.<D9H
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M,7XEV+6?PS2Y62]ET:X6XCFF_@$S+@JOL0#C..:^F=3^(6D#PW'?V=W;'2#
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M<211F/"AAOB4N&4"+(!8,3]Y") ,;%QC;C';TIBV<"W#3K!&)F #2!!N(&<
MGKQD_G0!\_:-\1O%<7[+7C+6+CQ- OB?09=;TZ'Q'J-CN0FTNYX(KB:*&,C.
MV-2Q5"H(+;<9%>/^$OVAO$.M^']*TC5_B'>^&]*;Q*^GZMXUDN-+OHK:,V'G
MP6\%_%$+9UDD!'F/$KKD(5!937W*$4 @  'J,55&D6*V+60L[<6;9S;B)?+.
M3D_+C'7F@#X&^*7[5?B+04LY_#7Q*NM<DTG3],N1/<6=AI5MJZRW#!YA:RQO
M<70DB7!, BC0*6#<\4(_ .HP_$N#6K?4[K7-1'Q&\37::;<:=8R+>36EA/)
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M -V-0U:2T "K:_:ML:CTX&[]:])HH JZ=IMKI%G':V<"6UO&,+'&, 5:HHH
M*Y;Q)\--!\3W;WL]JUMJ3)L^W6CF*8CL"1PP]F!KJ:* /(;?X3>*-"=XM/\
M$=OJ-F6)0:C"8Y4'H63(;Z[15BQ^$6M7UX9]:\0K'%C'V;38<'\9'S^BBO5J
M* ,GP[X7T[PO:M!80E-YS)+(Q>20^K,>36M110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>bcyc-20241231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '-! X# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#X[_L#3/\
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MG_P._H?-?B3X&+IFM>'](TG1;G7-4U72X-0^Q)H$T$Z/(&+1I&Z;I57:?WB
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M_P!^%_PJYYJ?WU_.CS4_OK^='U?#?R1^Y![6K_,_O93_ + TO_H&VG_?A?\
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MH_L#2_\ H&VG_?A?\*N>:G]]?SH\U/[Z_G1]7PW\D?N0>UJ_S/[V4_[ TO\
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M+_Z!MI_WX7_"C^P-+_Z!MI_WX7_"KGFI_?7\Z/-3^^OYT?5\-_)'[D'M:O\
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MNC_X9!^"_P#T37P]_P" @K%O_P!GRXOO%OC[^T+&UU[POXOO+>^FA.N7=A)
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M.\*+-$V-LB$MAE.1AAP<UF>*/@[^SAX6U+4-(G\%^$#KUIIKZG_9LWDV[/$
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M<E/&_P %_%/B-/B@MHVCJ/$^IZ3>V)GNY5\M+46P?S<0G:Q^SG;MW?>&2,4
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M=\MR]^%NJVVC?"/2[*ZMK^+P=>V\MY<WTKQR7$<>GW%IN0!'RY:8/@D#@\T
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MUGX*7\6E>'Y_#VF6%AJ=GXPC\4W]I=ZS<W"73^2\,A$[QLRN0ZG 3;E3W)-
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MX>_\!!1_PR#\%_\ HFOA[_P$%>OT4 >0?\,@_!?_ *)KX>_\!!1_PR#\%_\
MHFOA[_P$%>OT4 >0?\,@_!?_ *)KX>_\!!1_PR#\%_\ HFOA[_P$%>OT4 >0
M?\,@_!?_ *)KX>_\!!1_PR#\%_\ HFOA[_P$%>OT4 >0?\,@_!?_ *)KX>_\
M!!1_PR#\%_\ HFOA[_P$%>OT4 >0?\,@_!?_ *)KX>_\!!1_PR#\%_\ HFOA
M[_P$%>OT4 >0?\,@_!?_ *)KX>_\!!1_PR#\%_\ HFOA[_P$%>OT4 >0?\,@
M_!?_ *)KX>_\!!1_PR#\%_\ HFOA[_P$%>OT4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117
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MW+]XC QN(!U0^)?A _:,>*M$/V<[9O\ B8P_NCYACPWS<'>"G/\ $".M6_\
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M/V9=0NM UC2-!BT[0M.DM-&-E9G5+JX!N+/4KJ^ECED:,.(I#<X#@DKC(7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'&*Y&+X;^)3\0$UR1-*2S/BX:^R)>2M((/[#_LXH!Y(!?S/GQD#;WSQ7$MX
MU7P3\ /#G@O4+G2X/&^ASQW/AF2UN))A>7=O,&C^4QH5#A_+=1NQ')(2< D
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M=V\RE<8&T 'FJ?B/X%:AX@/C,CQ);6__  D6NZ5K7.F,WV?[$;4B+_7C?O\
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MXN-.ET_5+*&!A#?ED"1S'GY9$4NH;DE6 /W15'PE^SUK&@W'P^COM0EU#3_
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M*'F7\B:7X[T];2Y@73'\ZUD%G]E+I)YF"NT!MI7.?XJP-8_9A\7^(KZ*^O\
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ML4-2^.&BQGQ[;6@N(KOPE9_:;NYOK*X6S4F#SAETC8[0I5C@$D$E0V#1X?\
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M?S!_HJO_  _>(YZUY*G[(T\&C>+M.T_Q%I_AJT\1>%[WP]<:9H&E36^EF>Y
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MYQDFN5T+]G?6_"?B_3/%6D>+;!=;MGUV*<7>C/);3VNIZE_:#1A!<JRR12@
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M/M;]VYQA20V/]HOP2ND6M]<W>H6LDND#79;,Z1=R7%I9G(\Z:-(F,:95P&;
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M?Q\&B#Q_X8M_$@T69[BP\^66/R7;;N_U;+N!V)E6R#M'% 'HM>(?%7XYZQX
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M_%?P^\7-X#TW60=-M?AI8^&!XHN?#\Q@E=+J]+; )@@D6.9&P78$L/0B@#Z
MOOC1X;T?4-9EO]9L8]&L=-TR_CGA$TLLHO9IXH"@6,K*)6B58Q$7=FW J/EW
M9OPP^+5[XY\>_$K2+BW$>F^&KBS2S?\ LZXM;ETFMA,PDBE^8L"< A5R.@YK
MDM:_902XM;6VTGQ,--@TG3?#-GHOGV!N&MI=%N9KBWDF/FJ)E<SE70!#@9#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JM>ZE::=Y/VNZ@M?.D$4?G2!-[GHJY/)/H*L
MUYU\8/V>/AW\?!H@\?\ ABW\2#19GN+#SY98_)=MN[_5LNX'8F5;(.T<4 >B
MUYM?_$K5-:^*^I^ O"]K9BYT;3;;4]6U742[16XN7E6WACB3!D=A;RLQ+J%
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MUU6XT#Q=<>)X+Z\TB274+B*1;I19R3FZP$C2Z"+L15 A3Y.M7_!/[-&H^&/
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M#8UOXU>#?#NI:C97^KM$VFW$%K?W"6<\EM933!#&D\ZH8HF(DC.'88$B$X#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKO@G5O&7B#5]*U;29-&DN+A+%+F*"2,QLRNELH+E21N8,.^,\U6O/V?=+O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHNHWEN($M[>[OC;B!6WR"1E N[<LR1O@/P&*L GB/]FG1?%$'CB*\\1:^O\
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MVO1/'7CV'P);6\]QIMW?Q2AR7MY[6%8]H!PS7$T2Y;.  23@]@369;_">/\
MX3;PYXKO?$>KZCJNAV5[80B5+6.*:.Z:!I?,6.!3D&UBVE2N,'.<U'XR^#UE
MXN^(/A_QFNLZIH^M:-976G1&R%O)')!.\3R!DGBD"MN@3#IM;&X9(- '#Q?M
M@>%]1\.MK>C^'?$FN:>OA6'QD[VD5JC+ITAE!;;+<(2Z&&3<@R>/EW9%3_%;
MX_0P^#_&5MX-BU2^U[2_"9\1F_L(;;RM/CEBF>U>7[0X#%_(D.Q5<[4.0,KF
M#PO^Q]X8\)>&KC0K+Q'XD>QF\(+X)_?2VA=+ -*P8$6X_>CSY!N.1C'RY&:U
M-0_9CT:Z34$L_$OB#25U7PY!X8U;[(UH?[1M(4E2)I/,MV"RJL\HWQA,AN0<
M+@ ]#^'VJW6O> O#6IWL@EO+W3+:YGD"A=TCQ*S' X&23P*Z"LOPOH$7A7PW
MI6BP3S74&G6L5I'-<E3(ZQJ%!;:JKG &< #VK4H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!RR\I=?MD:!%X-M?$<?A/Q&MEJ/AO4/$NE-<BT5;V*SC62>+Y;AFC<*P/SJ
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M=#(W +1E<;05VM\U &3XB_:%EMI?C39)H>HZ9%\/=.^T2ZTJV]TK,;/[5N6
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M4$QOC<I]#@D9'L2*\5B^"C7WB?X?6>H1:G?67@-C):^(-0N+97U&,PH$MC'
MJ?*LR0RL61?FM(B-^X[?;: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.\2_&/P-X-\9Z+X2UWQ
M;H^D^)]:V_V=I-Y>)'<76YBB;$)R=S JO]Y@0,D8KL:PM6\!^&=?U_3M=U/P
M[I.HZWIO_'CJ5W8Q2W-KSG]U(REDYY^4B@#=KPVP^+>H0_'3XE>$]3O=5;2M
M)L-,FT[^RM#EO'A>Y28R%VA@?[IB78']6SN[>Y5P^C_"FUT/X@>,/%]KK>JC
M4O$]M:VUQ$_V<PVXMPXB:$>3N# 2O]]G!SR.* /)OA3^TA-)\(O ?C'QQJ$B
MC4? -_XRU0VVGH8MML;-I2A5]R^6MQA8]C;P^2X*8:'XR_M+:I8:!K%EH&E:
MOX8\0Z;;:%K >_6SE%Q:7VII:B-0KRKDJLX.XH5(0@D$D;=]^S,O@_X4V>A^
M#]:U:]U/P]X-U+PIHD>IW%O&LD5TL',KI IWJUK#M9=HX.0<DUQ_AG]E[6;P
M2>&+C5-<TCP%<6=N]\+RQT&VU"2\M;FWFLO):PMMIC412A_.W'YD"8^8T >\
M^ OBA:>/-9\4:/\ V3J>AZOX<NHK:^LM3$);]["LT4B-#+(C*R-_>R"""!7*
M:?\ M+Z'>7UJD_A_7M/TRX\23>$AJ]REL;9-1CF> 1,$G:0!Y$*J^S;EER1F
MNO\ "OPULO"?C7Q=XG@U'4+N]\326TEW#=&+R8C!"(D\H)&K#*@9W,W/I7E/
MPN^ E_=?VD_C,ZE:6MMX\U'Q9IVC^=:M;2L]Y+/:RNT8:0E=ZOL+@!U&00,4
M =KKW[0&B^&?&^D>%]0TK4X;_5]1ETNP826C">=(99E&P3^:BNL+A7=%7.,E
M0P)Y'QG^T='X@^ OB'Q/X/M]6TO4SX1U?7K2XN8+9FTZ6S5T\NYC+N%D\Y2N
MS# ^7(,@J<64_9:T?P_%IUS8:WXBO4T'Q)=>,=-TD262AKZ87)>)I6M][HQN
MYE!D<D K\V%J[H'P!T[4_!_Q0L;^"_\ #J?$26Z^V6MO<123V%O-&4>-&P\:
ML[R7$[8# 274F"V : -7Q)^T3X=\,GQ5<3:?JMUHOA6]BT_7-:MHX3:V,SI%
M(P8-*)'$:3PLYC1@ _<JP$^K?'S0] \?:'X3U/3]0L;W6M3DTFQN'>U=))EA
MDE!,:3&9$987VLT8&0,XW FEK_[.&@^(8?%%E/JVL1:+XJO(;_7=)A> 07\R
M1PQLS$Q%T$J6\2R"-E!V\;2S$Y>E_LIZ#I-WHKP^)?$/V31O%-QXNL;-C9E4
MO)S<F17D^S^;(A^US ;W+ ;0&^44 9'C'X_WFM:IX!N/!T>IV^@7WC@>'+O5
M98;4VFH)']HCG2,,S3 ":!E#A%!V-@D$$]W=?&5;3XW77P_DT*[$%IH":_<Z
MV9X1!%$\LD8RI</@&%\D G..,?-6):_LQ:-82:7!:>)?$%MHFD^(W\4:?HJ-
M:&WMKMY)99%5FMS*8B\\QV%SC>0" % ZG5/A#IVJ?%+_ (3DZC?P7LNC#0;S
M3T\EK2\M1*\JK('C+@AI7Y1ER#@]* ,SPC^T!H7BZ]\'1)IFKZ9:>,;62\\/
MW]_%$L.H1K$)OE"2LZ%H3YH$BH2H/0@K7$_%[XL^(_"7Q=O] L-4OK;3XO"3
MZY!#8^'I=6<W2SM$%984+B,@ G)7G^(5V?A#]GW1?"-[X+D&K:OJEIX+M9+/
MP_8WTD)BL8WB$ .4B5Y&6',2M(S?*3G+$M6AKWP@75_B._C6T\5Z[H>KMI0T
M?98+9O"(/-\W(6:WD.[<<Y)Q[4 </X:_:5MH?#UKJOB5TDO9_#_AR[_LS0DB
MN89K_4YKB!(K2<3$3;YXC& VU5$88NP8E>SUGXT0^&;G1HM;\*>(-(35=;@T
M&*>X6U:))IDW12.R3L/+9OW0(R?,PNWE<\O#^R-X-M=%DTNVU#6[:W%EI=M:
MO'<1>99S:?=SWEM=QN8B?/\ /N978ON1MV-FWBM3XG_#K6/%?P\O/!-Q<ZMX
MG_MH;3K]Q)9VSZ/*CQO#< 1)&2T;KYJ;58^9&H.U3E0"33OVAM.U[5M6TO1/
M"_B'7-2TJU:]N[:R2US'"9IH87#/<*K><;:9HPI)*J&(4,N<&7]H2S\!:[XQ
MM_%5Y<70?QE!H&@V2I!%*!)H]E>M&78QH%0RW#EY'X&%R3M!ZM?@9INE>*T\
M0>&=:U;PE>-I5KHUS%IGV>2&ZMK8O]F#I/#)AHQ+(%9=IPY#;L#&?XA_9PT3
MQ%JUWJ\FN:W:ZT_B*+Q/:ZC;O;"2QO$L8[$B(&$H8WMX@C)(KYR2,'! !T/P
MP^+VA_%S0M7U+0$N';2=1GTJ\M)#$9([F(*Q0,CM&P*NC*RN5(<<CG'-:#^T
M=8>(O!6D>*[;PEX@@T35K.*_L[B]DT^W66&2(2*=SW84'G;M)#9!.-OS5Z3H
MVCW.EZ2;2?5[O4K@[O\ 3;B.!)03Z+'&J<=LJ??->6Z%^R]HOAC_ (5^^E>)
M?$%M<^"]%E\/V-P_V.9IK.0PDK(KVY0./L\8\R-4;&X$D&@".Q_:<T[Q)J7P
MJC\->'M3UK3OB#IESJUG>*T$+6\,,<3,'221<L#,F0#C ."QXI?#/[26EZCX
M1T^ZMM/UKQ5>P>%-/\4:I+I]I;P-!;W,+O$SQO< !W$,S"*-I"H3&3E2S_#?
M[+VB>#]+^&=GHWB3Q!92> +2YT_2[LM:R2RVTZHLD<P: HW$4>&55(V]>32Z
M3^S!HGAW0UTW1O$GB#2UD\-VGA6]N8'M3+>V5JDB6YD+0%5E1)I%WQJN0W()
M"E0#U3P[K]AXL\/Z9K>E7"W>EZE:Q7MI<*"!+#(@=& //*L#SZUHUF^&_#UA
MX2\.Z7H6E6XM-+TRUBLK2W4DB*&- B+D\G"J!SZ5I4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?$3XQ
M^!OA(-,_X37Q;H_A;^TY6ALO[5O$@\]EQNV[B,A=RY/0;ADC(KL:PO%'@/PS
MXX%E_P )'X=TGQ!]AE\^U_M2QBN?L\G'SQ[U.UN!R,'B@#=KS+_A+M9/[2!\
M)_;<:"OA@:Q]F\I-QG-R8<;\;MNWG&<Y[XXKTVN UOX1IJOQ(;QM:^*-<T;5
MFTH:/Y5DMFT(@$IE^[+;R'=N.<Y_"@"/Q7\:M,\,Z]KVCV^CZOX@OM TN/6-
M532DA(L[>0R^5N\V6/<["WF(1-QPG(&Y=V1J/[3_ ('T9-0N]1N+JQT*U\.6
MOBI-<EB4VMU83OL1X0K&1F#;0RE!C>G]X9GO?V?=-F>^EL_$FOZ9=ZGH-MX>
MU2[MY;=Y=0MX%D6*20R0L!,!--^\0+GS#D<+MM:K^SYX+U>;P3YVG,MIX2L)
MM*L+%7S!)9R0I$;>93GS$'E0N 3P\2-U% %GQ3\8+3P[X&^('B:+2+Z_M?"$
M$\THC>$+>^5;+.YA;>05"L 2V""&&"1BN?N?VEM#T:P\$1ZSIEY8:_XJT^34
M;;2&N;16CAC6,R2/+).D07,L87Y]S;Q\O#;>@T;X)Z!HOP3?X71S7T_AZ729
M](FGGGW74L<R.LKM)C_6-YC'.,9/3M6,?V>+(/X+OH_%6O0^(?"EC+IEEK:+
M9^=-:2+&'@FC-N8G0F&)LA P* AADY .<LOVR_">M^'[S6=$\/\ B/7;&S\/
MMXEN6LX[13%:)-<03<27";GCDM9U95SG;\I;(JY\5OC]##X/\96W@V+5+[7M
M+\)GQ&;^PAMO*T^.6*9[5Y?M#@,7\B0[%5SM0Y RN=W7_P!GW3?$VI^(M0U#
MQ'KLMWKOAC_A%+QT^R(/LN^5C(H%O@2YGDY^[R/EXK/U#]F/1KI-02S\2^(-
M)75?#D'AC5OLC6A_M&TA25(FD\RW8+*JSRC?&$R&Y!PN #E[;]L_P9X=\,O+
MKUQ=7,^B6FFC7]0@-LD=O/<P0R'$32I)(%69'?RHV"AL#)! ZWQ1^TKHOA/5
MO$UI=^'M?EM?#6IV.EZKJ4"6I@MFNQ"89<&<2-'_ *1'G:A8<_+Q4O@S]G;3
MOAWJ]Y>^'/$^O:;'J"VO]H6F+.6*[E@@2W68A[<E)&BBC5O+*J=H.T')IOBK
M]FW0_%H\>+=:]KL"^,KZPU"_%N]L/)>S$(B6'= <*1!'NW;B<'!&: -CPW\9
M;7QFSSZ!X;UW5]'&HW>F+K%NEL+:2:W:2.4J'F638)87B#E I8#G:=U'PX^-
MFD_%"U\/W&DZ9JD,>KV-Q?'[6D*M8B&80/%<!9&*2>9N4*-W,<G(VG$7A/X3
M?\*LBU-O#6M:U/I+7-WJD7A=FM/LQN)W>:2..1H1(BO,[O@R85G.,+\M'P>^
M&L/@N[\7Z[_9\NDWGBC57U)].EG64V:$9\O*$H"TK3W#!20)+F0!F !(!S%Q
M\;9_#OCOQ]/KR:I'HFB:GI_A[3=.M8K5UO[N[CM&A"'=YGFM)<[1N98@C M@
MJ2-#4OVEM'TOQ*OAJ7PSXA?Q.=1BTS^QT6T,WF2V=Q=P/O-P(]DD=I< -OX:
M,A@O6M37_@+HGB27Q-+>:GJIDUO5['75>-X5.GWMFL MY;<^5QM^S1$B3>#@
M@@AB*H-^SCHUQXWM/%]WKVMW7B.#5K?5WO':V7SF@M+BTA@9!"%$2QW=P0%"
ML6D)+'C !W'B#QDOAWP]:ZM-I=[*LYC#VP>"*2#<N29&EE2-0N,'Y^N ,YKS
M[PU^U%X9\9_V+!H.E:QJVJZK+JL,6F0+;"6,Z=,L%V6D:<0D"22,*4D;=O!&
M0&(ZKXF?":P^)M[X5OKC5-0TC4/#6I'4["XL/)?$I@D@8/'-')&PV3/@E<J<
M$$$5XAXR_93GL=7T:WTF^\1:GH"7NMZW=2P)HUU=C4+^:.1AY-];>1Y.#<88
M*9%W!00I- 'I?AG]I+1O%NA> +W3-#U>_O\ QMI=QK6F:7;B 3):0^5O:5I9
M$C5AY\*E0Q^9^"RJ6JM\.OVG]'^)7]D'3?#>N+'J&C6/B![AA;^59V-V]PD4
MDQ,P;*FVD#A%;:>067YJ\ZU_X&^/?%>D_#ZW\42W5S%H,&JIN\/VNBR7"+),
MBV4<L%Y ;3*VJE'>%!A\A $))]&^"OP<U?PX\WB'QAJDM]X@O-+709+!(K6.
MU338+JZDLD9(8443+%<E9/+Q&6R%7 !(!'X!_:T\#?$77?"NFZ8UY'_PE4-S
M/HUS,UN5NEA0R-E(YFEB+1!I%$J)E5.<-\M2^&/VG-'\87_A*+3/#NMFQ\4Z
M/>Z]I-].MNJ7=K;"+=L196<.WVB$JLBIPQR0PVUO?#+X.K\(/#]GHFA>(M6O
MM#TRW:WTS2-3-LT5O& ?+B\Y8!,50852SL0!R6KYZ\(_LG^)[CPY8>%M2N]7
ML-*UG3;G3/%\EU!HL>^":"3S%L;BU@%TS_:6C<-<.045BX9CB@#V*_\ VI=
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M3D$&I=)_9PT;2DLU_P"$AU^Y^S>([_Q.6EDME:6ZO(+B"96*0+B/;=S$!=K
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M: .GHKF/^%BZ-_?F_P"_9H_X6+HW]^;_ +]F@#IZ*YC_ (6+HW]^;_OV:/\
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MT =/17,?\+%T;^_-_P!^S1_PL71O[\W_ '[- '3T5S'_  L71O[\W_?LT?\
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M6VWO)X8U2RF,]HJHCA5$<C%@ !G/.1Q0!Y_IOQ>\0R>+?"&@Z?IEK=QZQ?\
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M@"O0]"^%^@^&M4N=0TU+VSFNKE[VXA@U"X2VEN'Y>4VX<1!F.2V% )))!/-
M&/\ "'XA:QX\@\67&KV-AI]OI6NWNE0-:W+N66WD,9+AD4#[N<@\YZ#'.9X:
M^.P\0>.-"\/#3+26/7--O-1L-2T^^DN+>06[0@J7,"*P83J0T;2#@^Q/9Z#\
M.]!\,S:Z^GVLL2:W<RW=];R74LD$DLO,K")F*(6.2=H&236-X>^!O@_PM=:%
M<:?9WT<VA6DMCIAEU:[E%I;R!%>) \I 7$48 QQL7&,4 >=/^UC_ &1X2T/Q
M1KGA=;/1=8T&]UJV-EJ)N+@-;*C-"Z-#&HW>8 K!SR.0!S72>%];\1W'[0E[
M8ZPHT^!_"D%W_9EKJ<MW;I*;J1"X#(@5L *2J\@=:W/^% > VT?2-*DT-I]-
MTFRN=.L[6>^N)8TM[A=LT9#2'>&  ^;)&!C&*UO#GPM\/^%=<76;*._DU060
MTX75]JEU=M]G#;A'^]D88#9.>O)YY- 'E7QG^*>K:OX/\;CP[!)I]MX9UJQT
MN;5TU*2WN&N#+:O*L<:(=R!+A4.YQDEN, $ZEQ\>)O"VE6,MYI4ILKG4=;MY
M]9U2ZD^Q6;VE_) L<D\-LVP.%8IO155(R"[,/F[/7_@EX/\ $MWJ]Q?:?=?\
M3>2*?4(;;4KJWAN98]@CD>..14+@1QC=C)V+DG:,6(?A'X<M;9H+9=3M8G>Z
M=U@UB\3S#<2M-.6Q+SND9FS_  ECMQDT 9>G?%#5=<\9KH.EZ)IU[$NC:?K4
ME\FKDQF*Z>X0>7MA82!6MR=V0&5LCG@\A=_M.O;^!?#/B5?#*O%K?A?4?$BV
MYU##0_9(4E:$GRCG<)  _'(^[7I_ASX:^&_".IQW^CZ<;">+3+;1HUBN)?*2
MT@+F&(1EM@"^8^"!GYCDUPOBS]FWPW<>!=2TGP]:2VFHKI&H:7I+7FJWCV]B
MMW$8W"QEV4)]T[0N!M &* *_B#X]:MH.G^(4N?#EG!JEKX2G\6:<(]1>>"XA
MB \R.0F%&C<%X^ &#!OO#!K=UKXI:KX5^#>E^,-0TBTN]0N/[/26SM[QDBS=
M310A@YB)X,P8KM[$9/4W] ^$.AVVB30:K8?;KZ^TA=&OY)[V>Y#VVTAH4:0Y
M1#N8D*%SP3R :SOB)\(VUKX1KX*\.RF&*.XL7B?4[^XD*16]U#,5\T[Y,D1;
M1SQG/:@#-U;X[W^@MXFL;_PW;C6]#O\ 2+62W@U-G@FAU&X6"&593"I!5B^Y
M"@^YP3D5#>_'_4-*T#QAK=[X8MTTWPA?+8:RT.J%Y X2&25K=3 /,5$G0C<8
MRQ## P">PF^#_A>^T^_MKRPGG;4;NUO[R9]0N&FFGMV1X"9MX<K&T:%5R%&/
MN\FI=6^$GA;6[R_N+S3I)!J$T-S?6ZW<R6]W+$$$;S0JX20@1H#N4[@BALA1
M@ \\\2?M#ZEX/\0?$./4-#MKK3?#VH:9I5@EI<R&XN;B\6$QAAY9 7,XR1DJ
M%.%<D5J7/Q>U*]M]0BN_#FI:,;#6]$M%O(VEB@O([N\ABS%)/;H6VLQ62/8/
ME/#@L".HUSX+>#_$FH:_>:CIDMQ)KJP#44%[.D<[0A1#)L5PJR)L3;(H##:I
M!R*T)_AOHMWHZZ7=G4KZT6ZM[U?M6K74KB:"5986#M(6^5T1L9P2HR#0!PMA
M\>=0N-3TY;CPU;0Z5=^*[KPFUS'J;/-'/$9@LOE&!048PG/S@C<.#BM'QG\?
MM$T#0M1N]&"Z[?V%U:VT]DYEM0OG745MN\QHB#M:4' !R :VX_@UX2A6W5=/
MN +?6G\0Q@ZC<G%^Y8M-_K.<EV^4_+\QXJ/XU>!K_P"(_P /KG0-.DMX;B:\
MLK@R7,SQ*%@NHIV 9%+ D1;01T)SGB@#DKWX]:Q8>-1X/D\*V9\1'4K>P"KJ
M[?92D]G=7,,HE^S[N?L<R,NS*G!&X&I]:^/D^CZ/XPUIO#R/HWA&\BL=7E-_
MB<2>5!+.88_*(D6-;A>6="Q5L <$]5#\'O"PU*UU66PGDU:"_35!>/J-P\IN
M5@:!69R^758Y)$"-\H#MA1DU-J_PE\+:[>ZA<WFG/)_:,\5S?6Z74R6]W+$$
M"/+"KA)"!&@.Y3N"*&R%& #SNW_:'U+2O!/B_P 1ZYH=LZZ;XHD\-Z=::=<R
M.]Q+]K6U0/F/Y1N8,6 8X)PF0 =.S^+VJZQXWT?1;KPWJ.D$ZN+2.[\R6*SO
M0^FWEPN&FMD:0*UNRLJA2K>4VY@2IZF7X+>#[C3O$.GS:9++I^O79O[ZU>]G
M,1N"XD,T:[\1/O4/NCVD, 00:O#X::(7TN29M4NY=,N3>6DMUJ]W*\4IADA+
M9:4Y_=RR+@Y'S$]>: .)^'GQYO?&E]X%6\\.0:;8^+]-N;^RF@U)KB2)X/++
MQR(84 !$G#*Q^[R!G-6/B!\6;CX?:[XIE&GR:FNG66ANMN]\(HB+R]N;;<H$
M1*L&0%LE@RA<;2#NZ30?@[X3\,OX9;3M.GMSX;AFM]*!O[AQ;QRX\Q<-(0^<
M#[^[&!C%2^)_A/X8\8W6HW&KV,]S+J,5I#<E+^XB#I:S--;C"2 +LD=VX R6
M.<T >>>-OCWK_ASPQX\>/P]I\.O^&-2TZQ:,Z@\UM-'>- $E#^2C9 FY0KP5
M^\:FU;]HJ]L=3\4VECX,O=;?PS<V]GJ$>FFXGEEF>..25;=4MBKA$E4_.T98
M@\ 8)[;5_@WX2UV'Q-'?:=-./$;6\FIDWUP#*\&WR64^9^[9-B8*;?NBI+7X
M2^'+#7+C6+2/4;34;H1"ZFM]6NX_M9C4*C3 2@2.% 7>P+$  D@ 4 <]?_&.
M^LM9\76[:1I5MI_AW48=,DOK_63 )99K>WFAPOD'[WVD)@%FW !0V[C+C_:.
MC6Q\3+/H$B:OI.OV'AZ&T6=Q'=7%X(#;MODB1HU_TA=Q,? 4D;LC/9:Q\'/"
M>NC6OMFGSN^L7]MJEW(E_<(_VNW$8@FC82 Q,@AB ,>W[@J(_!+P<]KK]O+I
MD]RFO307&HO<ZA<RR330JBPRAVD+)(@BCPZ%6!13G(S0!A:M\2O&.E_%;P?X
M4G\/:1;VNLB^E>X75))2T5O' 25_<+M.Z8\$<[.HSFH?"_Q<O-3U:R\-Z=IA
MU#7+F;7;F0ZEJ&R*&"RU-K0XD2 DY=T"+L^5 =S$KENKD^$OAZ?4=&U"8:I<
M:AH\DLEE=S:Q=O+'YBJLBES+ED8(F4.5.T'&:2+X0^%[=K=[>SNK6XMYKR>*
MZ@U&Y2=&NI?.N1YHDW;9)/G*9V[@" "!@ \VM_VG[W6-)U:^TCPG!.-+\/2:
M]<Q7FK&!OW-Q<V\\"[8'!97M)-K<!@5/RUN^)OV@8O#NJ:?#-I4.GZ9?Z9;:
MA;ZQKEW)9V<KS,P\A9EADC610%)$CIGS%QD9(Z*#X%^";6WNH(-'>"&ZTC^P
MIHX;ZX17LMSL8\"3J6DD)?[Y+L2QR:GU+X.^%]7TI]+N[:]FTJ6SCL)K ZI=
M>1-!&,*CIYF&XX)/+#AB1Q0!VM%"J%    '  [44 %%%% !1110 4444 %<!
M\6/CGX2^"@T4^*;F\M_[8N#;6OV2PFNLN-N<^6K8^\.#R>< X.._HH *\B_:
M)\5Z[H^@16/A6ZN[;Q L,^K1"TM)+CSQ;!2MLP1&*B:1XTR0!M$G->NUEQ^&
MK"+7KW652<:A>6\=I-)]IEVF-"Q4*F[:I!=SE0#\QYH \BU7X@:GXC^)OPJU
M3P?*M_IOB'PQJFH"QO-1EM;6=0VGM"[A$D&]1.X!V9^8C-8WC3XSW'C#X7ZC
MJNFIJ.A7-SX)\2W\8@OMIM;NQD@A;E5#,RR,=DBNHV[LJ=PV^FZ;\#/!VC6N
MCP:?97MBNCI<Q6#P:M=K);QW#(TR*_F[MK&-#MS@;1MQ4MY\$_!E[I%OI;Z0
M\>GP:5<Z)';P7MQ"OV.X*&>,[)!N+F-"SG+$C.>30!QGBOXN:[X=\1R:=I6G
MP7LMSXXMO#K_ -I7I$<:2:9#=9BV0Y0$$@AMY#%CDA@%Z&3XMWL/C;6?"LFA
M0)J]I=6"641OS_I]K<ARUPO[KY1&(;C<O/\ J6Y&5SJZG\&_"FKF=KFSNVFF
MU2'6FG74KE95O(H5@297$F5(B14(4@$#D&G67@B2[^($7BC5K2Q6ZTVTFTW3
M9+>1Y)6@DD5F>4N!AL1HH W8S*=QWX !DWOQ,U6R^-5]X5>QLAH%CX=36Y[T
MSO\ :/FFECX0(0<>4>,CKG/\-5?"?QLGU^X\ />Z"NG:?XXM'NM)FCO?.E3%
MO]I1)T\M0A:$,?E9P&7;SP:[*[\ Z)>^,H?%4EO,NMQ6?V#SXKJ6-)(-Y<1R
M1JP20!F8C<#C<:I>'_A/X7\,7NF76GZ?)&^E0O;Z='+=S316,;@!E@C=RL8P
M HV@87Y1A>* //\ 4O%FLV?C3QC>7;7'V+3_ !'HFB6J6FJ.@6*YDL,YA,1C
M/S7!+'[Y5G0,O#5=L/CSJ%QJ>G+<>&K:'2KOQ7=>$VN8]39YHYXC,%E\HP*"
MC&$Y^<$;AP<5VU_\+O#FISZG-<6ER[ZE?VNIW6V_N$#W-L8S!( ) %VF&+A<
M [!D&JL?P:\)0K;JNGW %OK3^(8P=1N3B_<L6F_UG.2[?*?E^8\4 >9^(?BG
MJWC27P!K.D02:3X?N/&YTA+B/4I%FO8HFN89!) J!?+:2!B SL<!3@$D#N+W
MXF:K9?&J^\*O8V0T"Q\.IK<]Z9W^T?--+'P@0@X\H\9'7.?X:O+\$/!Z7\5T
MEA=Q>3J9UF&VBU.Z2VBO"S,TR0B01J69W) 7!+,2,L<[5WX!T2]\90^*I+>9
M=;BL_L'GQ74L:20;RXCDC5@D@#,Q&X'&XT <;X3^-D^OW'@![W05T[3_ !Q:
M/=:3-'>^=*F+?[2B3IY:A"T(8_*S@,NWG@TNE_%C4W\:_$^RU.UTFQT+P@L!
M2]FOS$6WVJW&Z4LFQ%P^"V?EV_Q=:Z3P_P#"?POX8O=,NM/T^2-]*A>WTZ.6
M[FFBL8W #+!&[E8Q@!1M PORC"\5#K/P<\)>(+SQ/<:AILEQ_P )-:K::O";
MR=8;M%C\M2T8<*&" *' ## YXH X+4/VE9]-U/5--D\-137MG%H\\;17TJP3
MQ7]\;-6#R6R-\C_-PI5EZ,#Q5KX@_'[4OA^=5L[OP[IRZSIWA]M<-M<:R8H[
MQA)*@MK1_()GD_=#(VJ1YT0QEN.EN_@'X+U"\>[O+/4;V\DAM()+FYUJ]DD=
M+:X^T6X+&;)V3?./?VXK'\>_"'4/$_CNY\00S32*^F06%NMKXCU#1W@*22NQ
M<VI_?@F12 V-NT@?>)H RKS]I"\AN?$4%AX-U'7&\.36MKJ$=G#<&XEFDBBE
ME6"%(9%/EI,IVO(I)##H QZWP5X_UKQ+\4O'_AZYT^Q@TGP[-:P0W$5P[32-
M+;I-EE* ='QP>-N/FSFCPC\&=.\/PV=[>W^HW_B9K2UAU75[>^N+3^U)H8UC
M$\T4<@1G(7J06P "2!71:?X#T;2O%^J^)K2">#5]56-;UTNI?*G,:!$9HMWE
M[@H"[MN< <T <]8?$34O%NN^)]-T+0H;RPT+4H]'O+JXU)K:5I3%#+,8D6-L
MA(YT()=2S!@,8#'SW3/CU<^"/@5X;UBXA@\2ZA8^"++7]2CEU&3[=(/LP=G9
M5AD(W;'/F2,JEL\\,1ZS+\,M ;Q'?:Y#%>V.HW[(]XUAJ5S;1W+HH57DCCD5
M&8*JKN(R0H!)  K!?]G?P&VGS6*Z5=Q64^CQZ!<6\.K7D:7%C&KI'#*%E'F!
M5ED4,V6 8C/2@#.\7_'N/PIKEI:3Z7#8:;=Z?;WUOK.MW4EG9S/*S#R%F6&2
M-9% 4D2.F?,7&1DA^K_':+0OB!>>&]2TZ#18H;J&"WN]7NI;;^T4>-7:2U_<
M&*4@LR",2ART;#:/EST>K_"#PSKNG3:=?6]]/IL]I'8SV+:I=>1/"@PJ.GF8
M;@X)/+#AB1Q4^I?"WP[K%Z+B^MKJ[47L6HBTFOYVMA<1E6CD$)?8-K(K!=NW
M<-V,\T <1\.OV@KOX@R>%;B#P;J46C>([6:ZMKZ))I/LRK'YD0N"T"1)YB @
M%9'&_"Y.<UJ_"?XU#XEWQLKC3[;0M32S^U7&C7-W*NI6AW!=LMO+!&0 3@R(
M73(P"003T/A;X6>'?!=H;/1H;VRTX(\<>GC4KE[6%7SN6.%I"B+R<!0 O\.*
MFT/X;:%X?UFWU:WAN[C4[:S;3X+J_OY[IXK=F1FC4RNV 3&A)ZG:N2<"@#C_
M !)\=)/#L7CASH*3_P#"+ZQIVER 7I7[0MVML5E'[L[2OVI<ISG:?FJ3PS\;
MG\0^-KCPS<:5:Z'J275W;PV&K7DMO>W"0E]DT4;0!)8W"A\Q2/M5P3R& VO$
M/P4\(^*-1U:]U&QNWEU9[>6^C@U.Z@BN)("GDNT<<BJ67RX_FQG"*#TJ]:?"
M_P /6FKZ=J1@N[JZTV:6XL?MFH7%PEM)(K*[(DCE02LCJ./E#$+@'% '*>"_
MCL/%W_"N';15L8/&.CW.JAVO-YLS"L3,A&P!P1*/FR.AXKB/B7^T%->^$-?T
MNTMTM)M2\'ZUK.E:YHFI2R(KVD2$%9?*C!_UJ,&B=QE2#P03Z?H?P+\&>'I]
M+ELM.N@-+BN+>QAFU.ZFAMXIP!+$D3R% A"J-N,  8 Q5#_AF[P VEV6G2:9
M?S65CIMQH]K#+K5\P@LIT1);=,S<(4C1<#H%&,4 8Q^)-_X)\3^+&N;>34]%
M?QO9Z/)<7%ZX&EQ7&FV!1E4JV8S<38V@J 9L],XZ+Q-X]NA\$O%'BTV;VBVV
MF7U[;"RO ));>-)&CFCD:(A&=%#KE& W+G/-'BWX46VL:3KVBV-G =,\5.3K
ML]]>W$DV?*BA$D*L6&_RHE4<IM*HWS%2#UVN^%-*\2>%KWPY?VN_1;RT:QGM
M(9&A#0,NQHPR%64%3C@CB@#S3Q7\>=0\,ZCXO4>&K:ZTWPQJ>GV%[<?VFR3.
MEV("LD<?D$$KYXRI<9VG#53TOXZZ^/"?BC7;_P /Z?+'IOBX>&K>"WU!U+@W
M\=D'8F(]&D#\=1D87 SVVI?!?PCK$6O1WFGW,ZZ[-;7&HYU*Z!GDMP@A;(DR
MNT1I]W&=HSFFO\%/",EIJUJ;&[%IJFIIK%U;KJ=TL;7:3+,)542 (?-17.W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 ?%CX
MY^$O@H-%/BFYO+?^V+@VUK]DL)KK+C;G/EJV/O#@\GG .#COZ* "O(/$?BC5
M]+_:-TW2[6#5=6TR;PQ<7SZ;8W$:()UN8HUE(EE1>%=A@'J0<9&1Z_6#)X%T
M:7QK%XL:WF_MZ*S;3TN1=S!! S!F3R@_E\LJG.W.0#F@#R#X4>.M5N;;13J<
MVIS27_CS7='"7%XK/!#;KJ!AAD&'#JJ6P7Y7!+JK%FY#:WP_^/-Q\3-?\,Z=
M!HUM:V.MZ9=ZA<&WU%IKS3O*:-%@N8UC3[/(QE/\9(:)U&<;AV6G?![PSHD=
ML=-M+BWFM-4N=;MGEU"ZE"7TZRK+,0TOS;O/ERI^7YVX&:X3X=? C6O!EUX6
M5-9O;"VTM&74%B\1ZA>PZD# \91;68B*V4R.LH,>2NP*N <T 4/V??BMKL_A
MGX7Z-X@M!?GQ'H]Q<0ZVVI//<R20;"PFC>,8RK\,)&.5Y'.:ZZ\^-O\ 9_Q*
MF\)WNF6^C_Z;!:6ESK%W):_VD)$1B]J3"8I2"S((_-#EHV&!QG>T+X/>$_#3
M>&3IVG3V_P#PC<,T&E W]PXMXY0!(N&D(?.!]_=C QBK&I?##P_K&H"[OH+N
M[Q?1:D+:;4+AK87,95HY!"7V#:R*P&-NX;L9YH X70_VB)O$FIP'3/".HWVB
MR>(9= -Y;I/)+'Y<K0-=.H@\L0B5""?-R%^8@<J,KPW\:;CPY)I?AD6EUK^L
MZCJOB65);J:=U@M+359H4#,D4TAP'B11MP%4Y(P ?4-&^&.@>'=8O-2TN&\T
M^6[NGOI[>WU&X2UDG<Y>0P"3R\L>6PN"22<GFJ4OP7\).;%TLKNWN;&ZN[RV
MO+?4KF.XBDNI#)<XE60/MD=BS(3LSCC@8 .7\&?'/6?B#/=6&C^"IK/6=/TR
M*_U"PUZ[>Q:&266>.*%<PLS;OLTC;V5!M:,_Q$"A?_%[7Y/&'B[2KG38+72]
M"U[0--2>RORMRQO)K7.X-"RLO^D ,H*G:& .2&'H%W\*_#UWJ\&JE-0@U2*V
M6R-[;:K=0S30JQ94E=) 90&9B-Y8KN;!&34&H_!OPIJNN:AJ]Q9W?VW4)K.Y
MNC%J5S$DTUJR-;R,B2!2R&./G'.P9S0!C>&/B_?>)=4DT3^P8+3Q!;:O=Z;?
M6)U M]FAAC61;K=Y(W)(LML0,#_CX3G@XP/AE\7M?\5^)/#6BV^FVTNFW7@?
M3_$9N;^_8W;23[E"NRPA6.4P2%7.XL /N5ZE!X*T6V\3:IXAAL4AUK4[6*SN
M[R-F5Y(HR^P9!X(WGYA@G"Y)VKC!L/A#X>\,3Z;J&@6$EKJNCZ0NC:=YFHW(
MB^S1Y,,,OSGS$5CP7#$9.* *7PR^+-Q\1TTX#18]/G^S7#:M;F\,CZ9<17#6
M_P!G8>6-Y9XIOF^7_5'@@@GT:N5\!^"H_"\FNZE+:VEMJ^O7QU"_6R):(/Y:
M1JJLP!8!4!)P-SL[;1NQ754 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 45V?_  J^_P#^?NV_\>_PH_X5??\ _/W;?^/?X4 <9179_P#"
MK[__ )^[;_Q[_"C_ (5??_\ /W;?^/?X4 <9179_\*OO_P#G[MO_ ![_  H_
MX5??_P#/W;?^/?X4 <9179_\*OO_ /G[MO\ Q[_"C_A5]_\ \_=M_P"/?X4
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MW^% '&45V?\ PJ^__P"?NV_\>_PH_P"%7W__ #]VW_CW^% '&45V?_"K[_\
MY^[;_P >_P */^%7W_\ S]VW_CW^% '&45V?_"K[_P#Y^[;_ ,>_PH_X5??_
M //W;?\ CW^% '&45V?_  J^_P#^?NV_\>_PH_X5??\ _/W;?^/?X4 <9179
M_P#"K[__ )^[;_Q[_"C_ (5??_\ /W;?^/?X4 <9179_\*OO_P#G[MO_ ![_
M  H_X5??_P#/W;?^/?X4 <9179_\*OO_ /G[MO\ Q[_"C_A5]_\ \_=M_P"/
M?X4 <9179_\ "K[_ /Y^[;_Q[_"C_A5]_P#\_=M_X]_A0!QE%=G_ ,*OO_\
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MI(0-RJVX ]P#@9^N!3J[/_A5]_\ \_=M_P"/?X4?\*OO_P#G[MO_ ![_  H
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M\>_PH XRBNS_ .%7W_\ S]VW_CW^%'_"K[__ )^[;_Q[_"@#C**[/_A5]_\
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M ,_=M_X]_A1_PJ^__P"?NV_\>_PH XRBNS_X5??_ //W;?\ CW^%'_"K[_\
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MY.3S5?1?@SX \-W%K/I/@?PYID]HLB6\MII4$3PK( )%0J@*A@ "!P0 #TH
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M+G(;&*K7W[0FO>$_%&OZ)XDU'0X]^D:#J.BW=KI%R6,^I7EQ:I:/ +AVF??
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M2 ZZ=$=+@*V8;&\1#;\@.U<XQG:/04 ?*GPV^+7BGQ]XHU;XGZ*= \/ZK?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$[FYY-.B^'OA:'7_ .W8_#>DIK7FM/\ VBME$+CS&78S^9MW;BORELY(XZ4
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MBS_9RB)YG5\DG;@[]M\'? =EH-_H=OX+\/P:+?QK%=:=%ID*V\Z*<JKQA=I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+
M_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z
M!S_]_1_A0!W=%<)_PM2+_H'/_P!_1_A1_P +4B_Z!S_]_1_A0!W=>8_&SXS:
ME\(1X>.G_#CQ;\0?[5NFMY?^$6M$G^PJ-OSS;G7:#NX/W?E;++QG3_X6I%_T
M#G_[^C_"C_A:D7_0.?\ [^C_  H [NOF#X[Z]>?##XZZ=\28[Z>W\/:!8:?;
M^)+5)&$#Z=>7%U!)<N@X+02):R[L$B..0=#7LG_"U(O^@<__ ']'^%8]WXB\
M-W^H7E_=>$K"YOKRV^Q7-S-#&\L]OS^Z=BF63D_*>.3Q0!XGI'C?Q/X2\3_M
M%^/9B9=:L/!.F^)-/TO5A(\-BNS4Y$MO*#*8RT=M;B4*1F16;GBMWXM?$W5=
M?\3Z3X8N[>P.G ^"O$<$T43B>.>?Q';PR)N+D%=J'&%!PY!)KTL:SX5&JZIJ
M@\&Z:-3U6 6NH7OV>+SKR$9 CF?9F1.3\K$CDUB66@_#/3A$+7X7^&[?REB2
M/R],M@46*021 'R^ C@.OHP!&#0!RGASXF^+M:\%>*=4U^]T[58[#XI6OAVU
MMXK2:U,5NNNVUH#OCG!8@.K@'()!#B16(J>U^/7C*2*TU#4X/#]_H5S\0KGP
M)/I<&GS1W#Q?;);5+A96G=20$5W0QX*A\$8KLF7P*]QJ$[^ -%>;4;N._O)&
MLX";BY1@R32$I\TBLJL&/((!SFN6^&GA3P]X%GUJ\U#1=-U_5-0UK4-92_DL
M(XYH#>2O))&&8N2 )&3.02O!S0!P_P (_C5XY'@OP1X$\%:#;7U_I/PMT+6U
MDO(5F-Y// R1QC==0;(P8,,XWG,@X&WYO?O&GC+QOI?P@L==TCPK$_C2>.Q>
MX\/3W,4C6[2-']JC0^;&D\D2&4JHE02,@ 89KG;JT^'][;Z5;S_#K0I8-)A^
MS:?$UA 5LX>/W<0\OY$X'RK@<#BMK6/%6@>(=)32]4\,6FHZ:C(RV=TB21*4
M(*$*5(!4@$$="!B@#BM,_:*U/4)?!\5O+9W4]_XV/A36+2[T6YTZZT_.GRW8
M1HI)FVR#RXSN!='252N*S/#7QZ\?>,/B'IOA.UD\.:=)=ZGXHT\WLVEW$X4:
M7<V\43>6+I/OK.2PW=5&,=*[.Y'@:\T(Z)<> ='GT<W0OC826D+0FX!R)BA3
M!DX^_P!?>N+UOX?>$-1\?>%]=L_#.BZ;I.C1:BLVB0Z7$(;R2\,'F2L5V@/_
M *.O)4D[FSG- $G@S]H#QM\1I/A;::?'H.B77BK3]=DO)[FQGO(HY].N8H \
M*K<1$Q2[V< DD*5^8UQ'@SXN7_C;4M0\97.F6=M?ZA%X(L;VWA>98)'_ .$I
MU.P>>)D=6VG:)$W%@5"*X=<@^@^+/#6A>*O'/@C6)-)T^/1/"UA>Z?#H#V*/
M \=P( =O(6,(+= H"$89ATZ=/(/ LI4O\/\ 1'VQVT*[K& X2W;?;*/W?2)C
MN0=$/*X- '*^ _CO\2OB-J)U'1/!MM=>'8/&-UX>O;<B..:ULH+A[:2Z:9KH
M$R*R"4Q>1DJ=H).&,47QE^*U]H[:SI>D:-K=A%XIU;0KNTTS3W>^M[:SO+JW
M%U'%)>(+@L880T:E67>S /\ ='9Q77@R#Q)-XAC\#:3'KTT@FEU-+6$7,D@&
M [2;-Q;  W$YQQ43#P,]HMK_ ,(#HRVZ7<E^L2V<*JMS)N\R< )Q(VYMS]3N
M.2<F@"MK_P 2I_&O[)WC+Q;HFLPR:@FA:N4OX-/GLC#/;K/&ZFWE?S(I$:,J
M59CM=2<D8SA6'CWQ!X4/BGPCX;@\-:+;^"O"=IK\LEQILJP7LMT;QR(XTG7R
M8U-JVYR7):4\#;ANW3Q#X:C\,/X;7PE8+X=>%K=M($,?V1HVSN0Q;-A4Y.1C
M!R:I:M/X*UZ.VCU+P)I&H1VL'V6!+FTAD6*'@^4H*<)D [>G XXH S_@'\8?
M%7QGU/6-0F@TO2O#]B]CC3VM)?MNVZTBROU#2F7;NC>[9"/+^8*#\I&#SWC_
M ..WCOP[K/Q!;3G\.C3/"OB70]&$%UIL\DUS#J'V)2WF+<J%>,WA(^0A@@&%
MSD>A:5XJT#0K_4;[3?"]GI][J4BRWUS:QQQ273JH16E95!<A5"@MG  ':LS4
M'\#ZL^I/?> =%O'U*XBNKYKBR@D-U-%CRI)<Q_.Z;5VLV2N!C&* .;L_CWXA
MLO$_B/P9J]_HS^*K/Q5%H6EOI^C7#+J4;Z5#J+ 6YN3L=$D<%WF"8CSP2%.9
MH/[1OC+Q!X3\)SBST?3]8U'X@ZAX(OC/:221*MN]ZJSI&MQ\K'[*N5\QQ\S8
M;H:[#4K/X?:Q+=2WWPZT&\ENKM+^XDGL('::Y1-B3.3'EI A*ACR%)&<<5);
M)X#LXK:*W^'NAP16U\VJ0)%8P*(KQL[KA0(_EE.3EQ\W)YH Y?X;?'_QAXG^
M)&D^$-5BT/S);KQ/IUQ>VEG-&'ETRXMHX941IVVJZ7.6C+,<IPX!XR/"'C[4
M_C!?? OQ3XB.D6UE>>']4U^^LC9N\$<]O+9;)H]TOR,@=MK'<5R_7=QW,^G_
M  \NA&)OAQH$@CO)-00-I]N<7,@Q)-_J_P#6,/O-U/<FKNF77@S13I9T_P "
MZ18'2XY(;#[-:0Q_8XY"#(D6U!Y:L0"P7 .!F@#R7Q9^V3K_ (*T^PU[^R;3
MQ-X:U;P7J_BS3+BWL)=/:X%HML\6WS)Y',3I<@EGCC8 !@#DJ.X^._C7XE?#
MSX+:MXCMO$/AN2ZWZ3#;7=AI,H"-<7L4$Q >X<,I292AX(PV0<@C3T?2_ASX
M>FMIM+^&OA[3IK9)8X)+73K>-H4D $BH1'E58  @<$  ]*?;6'P^LM!O]#M_
MAUH4&BW\:Q76G16,"V\Z*<JKQA-I /(!& >10!SOBOX_>+_"FF_%$O'HEY>>
M#O$.AZ5%(MG-''<PWJ6)D9D\\E6!O'VD,1\@R#S1\1?B=XOG\/?M!$?V$^B>
M![6[A2T>UNDN+M3HL%\NZ:.Y4I\T[(2@4XP05(YW;S1OAOJ%PT]W\,_#MU,T
M44#23Z=;N3'$<Q*28^B$#:.V.*TY=0\'SP:Y#+X(TJ2'7>-6C>UA*ZC\@3_2
M!L_>_* OSYX '2@#B?B%\?O&WA75/B;<60T"32O!6N:-8FUGL)S/>6]ZMH7'
MFBX"QR+]I;#>6P.T97FKFB?&+XB>+?&^GV&GZ5!'IL?C._T75((=(N&^S:;;
M"?9=?V@7^SLTC10!HU4L//9!AXV8=%=)X$OHM2CN?A[H=Q'J3Q2WR2V,#"Z>
M( 1-*#'\Y0*NTMG;@8QBO)8_@;X5_P"$ACU632M'6_37_P"WVUZUT:*#7I)!
M=_:A$U^K9V9Q$0L:DQ#9QG- 'U]17"?\+4B_Z!S_ /?T?X4?\+4B_P"@<_\
MW]'^% '=T5PG_"U(O^@<_P#W]'^%'_"U(O\ H'/_ -_1_A0!W=%<)_PM2+_H
M'/\ ]_1_A1_PM2+_ *!S_P#?T?X4 =W17"?\+4B_Z!S_ /?T?X4?\+4B_P"@
M<_\ W]'^% '=T5PG_"U(O^@<_P#W]'^%'_"U(O\ H'/_ -_1_A0!W=%<)_PM
M2+_H'/\ ]_1_A1_PM2+_ *!S_P#?T?X4 =W17"?\+4B_Z!S_ /?T?X4?\+4B
M_P"@<_\ W]'^% '=T5PG_"U(O^@<_P#W]'^%'_"U(O\ H'/_ -_1_A0!W=%<
M)_PM2+_H'/\ ]_1_A1_PM2+_ *!S_P#?T?X4 =W17"?\+4B_Z!S_ /?T?X4?
M\+4B_P"@<_\ W]'^% '=T5PG_"U(O^@<_P#W]'^%'_"U(O\ H'/_ -_1_A0!
MW=%<)_PM2+_H'/\ ]_1_A1_PM2+_ *!S_P#?T?X4 =W17"?\+4B_Z!S_ /?T
M?X4?\+4B_P"@<_\ W]'^% 'SW\9_-UC0+;PM;Q:A-)KLAAG_ +)D6.YBM47?
M+(K,Z  D1QD[ACSABO'V\3ZOXT\(? FXNI(;/QEI_B^31=2DO(?-\J\M].U&
M*?>JNI(=HA)@/@AD.3Q7TI+HFG3ZM!JLEA:R:G!&T,5ZT*F:.-B"R*^-P4D#
M(!P<5D-\-/"+I<(?"VC;;BZ^W38T^(>9<;2OG-\O,FUF&_K@D9YH \UT/XC:
MIXHUO0]-UFST^XGL_&M_X;N+BV2:."Y6/2[J<31QF0@<#RV20R*#OQR%(\VL
M?B%X@\'? ^QFT.>VL[^T\%>"WCO)HI)FVW5Q-;NI0R;,@*6#!03N(;.%*_3B
M^!O#:6MA;+X?TM;:PD>:SA%E'LMI'#!WC&W",P=P2,$[FSU-5?\ A6/@_P#L
M^>P'A31!97%K'8RVXTZ$1R6\9)CA9=N"BDDJO0$G % '#GXD>*;#XCWW@B^;
M26U69[&YTB>.RE2.YLF#_;'93,</&890,' WPYSOJ?XF>-O$/A[XM> M(TR[
M@CTC4++5+R]MFLS-+/\ 9DA945@ZX)$IQZ$ G<.*ZW0O R:7KXU.>2TE-I;R
MV.EPVMDMNME:R2*[Q\,=Q)CB!/RC$2X4'<6U=9\*Z+XBNK"YU72+'4KC3Y#+
M:2W=NDKV[D8+1E@2I([B@#RSP3\8M?UF7X57.I0Z9-9>/;"2\2WL89$ET\BU
M%TH9VD82J%S&QVI\Q4\9Q6_>^-_$.M?$_P 1>#]!?2],?1M(M-0^T:I;23FZ
MDN'G50JI+'MC3[/\S?,27 XQSU^E>"O#VA7[7VFZ%INGWK*RFXM;2..3:S;F
M&X '!89([GD\TFN^"/#OBB\M[O6-!TW5;JV4I#/>VD<KQJ3DJK,"0#@9 X.*
M /*/%/QM\0Z-H_Q&UZWM=-&G^"M3AT^739H9&N;[]S;2R,D@D C+"YVQ@HV2
M@)SNP(=.^,_BQ]2TJ>Y&C2:7<>-[SPE+;16<J3[(VG6.=93,R@_N5RI0@Y."
M*]<O/ _AS4-334;K0=,N;]#&RW4MI&T@,9S&=Q&<J?N^G;%5Y/ASX8\C9!X=
MT>!TNVU&%QIT)\J\;.;D#;_K<G)?J?6@#SGP9\1]7;Q=H'AU(;"*UU:Y\4F2
M39,[I+9:EY2,"\I^5Q*69.@(PNU< <CI_P"T+X\\3>#X+O2=(L?[:N/"*ZY:
M0V^E75\EY?-+/&MOMCE!@3,4?SR$AO-)!Q&U>R:3\*-!BT6TL]:T[3_$,]O?
M7FI)<7MDCB.XN9Y)Y3&K;B@W2L ,D[0 2>M<GXE_9J\+ZWK1O(=$\+FU6PCL
M+:PU/P[#=PV"H\KEK90R",L926X.2J^F* */Q3^,NM^"-"\2MI#6FH:WX7\-
M#6]3T^XL6E*'9*R^9,LT2('\B0 (';@G;C .3'\</$FDK\9_$=X+;4='\)Z=
M;7UCH\-N4D._3TNMIFW'C+D,=IX&1C&#Z5I7P4\'66@Z3IM_H5CXBDT[2XM'
M6_UJUBNKF>W1=NV1V7Y@<L2.GS-@#-;EGX#\-:=J$M_:^'M+MKV6W6TDN(;.
M-'>%1M6,D#)4#@+TQQ0!R?PY\5^.M<UV!-=T.V7P_<:3'>1ZO;+'"!=%AF$(
M+F9G5D;<K_*!L(/45Z36+X=\$>'?" 8:%H6FZ,&7:186D< *]A\H''MTK:H
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M#1@"-I 5^<J -I.<8&.E20^ ?#-OKDFLQ>'M*BU>1Q(]\EE&)V<# 8N!DD
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M=RP.>] 'A/PGEU30/&_@*.^4:7;>(O"+I;6]E?RWD%Y=1K!*]Q<(XC\J14)
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M,=* .)^$OQ$UCQCK_CO1=;LX;:Z\-ZG#9I)#%Y1ECEM(;A2R>;* P\TCASD
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MTU[!9XN TS!E_?APP://ELIQ]X=/KWQ*^(?AG0]<N]2T*QLD@U71K/3;ZYB
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M9(Q:S21KF161/,E2./<P(^; ^9E(^#/^'M?BW_H0M%_\"YJ&_P""M/BQ@0?
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MGA@9DO"TBLJ"!$9T("-L.YN.",U\N#_@K3XL7./ .B#)SQ=RTO\ P]K\6_\
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M 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\
M#VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<
MU'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_
M^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17Y
MC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_
M .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T
M(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?I
MQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0
MA:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VO
MQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S
M4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6
M_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'
M_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_
M (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P
M]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^
M!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"
M%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8
M_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(
M6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;
M_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<
M45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ
M;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#
MVOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U
M 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\
M#VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<
MU'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_
M^!<U 'Z<45^8_P#P]K\6_P#0A:+_ .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17Y
MC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T(6B_^!<U 'Z<45^8_P#P]K\6_P#0A:+_
M .!<U'_#VOQ;_P!"%HO_ (%S4 ?IQ17YC_\ #VOQ;_T(6B_^!<U'_#VOQ;_T
*(6B_^!<U '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>bcyc-20241231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %9!!4# 2(  A$! Q$!_\0
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M'Q _\-QXA_\ D&C_ (:6\(_] CX@?^&X\0__ "#0!ZK17E7_  TMX1_Z!'Q
M_P##<>(?_D&C_AI;PC_T"/B!_P"&X\0__(- 'JM%>5?\-+>$?^@1\0/_  W'
MB'_Y!H_X:6\(_P#0(^('_AN/$/\ \@T >JT5Y5_PTMX1_P"@1\0/_#<>(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S\_;-3_Z&#Q!_P"#
MN\_^.T?;-3_Z&#Q!_P"#N\_^.TVBOZO_ +%RO_H%I_\ @$?\C\;^OXO_ )_2
M_P# G_F.^V:G_P!#!X@_\'=Y_P#':/MFI_\ 0P>(/_!W>?\ QVFT4?V+E?\
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M_0+3_P# (_Y!]?Q?_/Z7_@3_ ,QWVS4_^A@\0?\ @[O/_CM'VS4_^A@\0?\
M@[O/_CM-HH_L7*_^@6G_ . 1_P @^OXO_G]+_P "?^8[[9J?_0P>(/\ P=WG
M_P =H^V:G_T,'B#_ ,'=Y_\ ':;11_8N5_\ 0+3_ / (_P"0?7\7_P _I?\
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M_P QWVS4_P#H8/$'_@[O/_CM'VS4_P#H8/$'_@[O/_CM-HH_L7*_^@6G_P"
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MZ7_@3_S'?;-3_P"A@\0?^#N\_P#CM'VS4_\ H8/$'_@[O/\ X[3:*/[%RO\
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M_P# G_F.^V:G_P!#!X@_\'=Y_P#':/MFI_\ 0P>(/_!W>?\ QVFT4?V+E?\
MT"T__ (_Y!]?Q?\ S^E_X$_\QWVS4_\ H8/$'_@[O/\ X[1]LU/_ *&#Q!_X
M.[S_ ..TVBC^Q<K_ .@6G_X!'_(/K^+_ .?TO_ G_F.^V:G_ -#!X@_\'=Y_
M\=H^V:G_ -#!X@_\'=Y_\=IM%']BY7_T"T__  "/^0?7\7_S^E_X$_\ ,=]L
MU/\ Z&#Q!_X.[S_X[1]LU/\ Z&#Q!_X.[S_X[3:*/[%RO_H%I_\ @$?\@^OX
MO_G]+_P)_P"9-!<:C+-&C>)=>A5F"F1];O2J GJ<2$X'L"?:O;]0_9)^)%KK
M4&AVOB^35?$%QHXUZVTBT\2:@)[BS.<.ADV(3\K?)NW<=*\,A022HC2+$K,
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MVL^#;SQ+K>HZCIDPADDLM:OF20E%;*@R ]&]*Y!KK5%8@Z_XA!'!!UN\X_\
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MV:G_ -#!X@_\'=Y_\=IM%']BY7_T"T__  "/^0?7\7_S^E_X$_\ ,=]LU/\
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M>P0*/W6,-]I8G(SE%QCG/W57GFN?\G"^"O\ L5M>_P#2O2*3S7,):/$3_P#
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MC+'C#_:E']KYC_T$S_\  Y?YA]2PO_/J/W+_ "/D'_AW!X=_Z*'XK_[YM/\
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M.X']KYC_ -!,_P#P.7^8?4L+_P ^H_<O\CY:D_X)Q^&XD9W^(OBE$4$LS"T
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M_OFT_P#C-?7U%5_:^8_]!,__  .7^9/U+"_\^H_<O\CY!_X=P>'?^BA^*_\
MOFT_^,T?\.X/#O\ T4/Q7_WS:?\ QFOKZBC^U\Q_Z"9_^!R_S#ZEA?\ GU'[
ME_D?(/\ P[@\._\ 10_%?_?-I_\ &:/^'<'AW_HH?BO_ +YM/_C-?7U%']KY
MC_T$S_\  Y?YA]2PO_/J/W+_ "/D'_AW!X=_Z*'XK_[YM/\ XS1_P[@\._\
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MP[@\._\ 10_%?_?-I_\ &:/^'<'AW_HH?BO_ +YM/_C-?7U%']KYC_T$S_\
M Y?YA]2PO_/J/W+_ "/D'_AW!X=_Z*'XK_[YM/\ XS1_P[@\._\ 10_%?_?-
MI_\ &:^OJ*/[7S'_ *"9_P#@<O\ ,/J6%_Y]1^Y?Y'R#_P .X/#O_10_%?\
MWS:?_&:/^'<'AW_HH?BO_OFT_P#C-?7U%']KYC_T$S_\#E_F'U+"_P#/J/W+
M_(^0?^'<'AW_ **'XK_[YM/_ (S1_P .X/#O_10_%?\ WS:?_&:^OJ*/[7S'
M_H)G_P"!R_S#ZEA?^?4?N7^1\@_\.X/#O_10_%?_ 'S:?_&:/^'<'AW_ **'
MXK_[YM/_ (S7U]11_:^8_P#03/\ \#E_F'U+"_\ /J/W+_(^0?\ AW!X=_Z*
M'XK_ .^;3_XS1_P[@\._]%#\5_\ ?-I_\9KZ^HH_M?,?^@F?_@<O\P^I87_G
MU'[E_D?(/_#N#P[_ -%#\5_]\VG_ ,9H_P"'<'AW_HH?BO\ [YM/_C-?7U%'
M]KYC_P!!,_\ P.7^8?4L+_SZC]R_R/D'_AW!X=_Z*'XK_P"^;3_XS1_P[@\.
M_P#10_%?_?-I_P#&:^OJ*/[7S'_H)G_X'+_,/J6%_P"?4?N7^1\@_P##N#P[
M_P!%#\5_]\VG_P 9HKZ^HH_M?,?^@F?_ ('+_,/J6%_Y]1^Y?Y!17<_\*LN/
M^?\ B_[]G_&C_A5EQ_S_ ,7_ '[/^->2=IPH4 D@ $]3ZT,BOC<H;!R,C.#7
M=?\ "K+C_G_B_P"_9_QH_P"%67'_ #_Q?]^S_C0!PK(K@;@&P<C([T;1NW8&
M[&,]Z[K_ (59<?\ /_%_W[/^-'_"K+C_ )_XO^_9_P : .%90XPP##T(I:[G
M_A5EQ_S_ ,7_ '[/^-'_  JRX_Y_XO\ OV?\: .&(!ZC/UH  S@8SS7<_P#"
MK+C_ )_XO^_9_P :/^%67'_/_%_W[/\ C0!PJ(L:[54*OH!BO/I_@GI%YI\F
MEW6I:G=:%+J)U23297A,3S&X^T_-)Y?G%?-^;!DZ *<KQ7O?_"K+C_G_ (O^
M_9_QH_X59<?\_P#%_P!^S_C0!PU(%4,2  3U('6NZ_X59<?\_P#%_P!^S_C1
M_P *LN/^?^+_ +]G_&@#AJ*[G_A5EQ_S_P 7_?L_XT?\*LN/^?\ B_[]G_&@
M#AJ*[G_A5EQ_S_Q?]^S_ (T?\*LN/^?^+_OV?\: .&HKN?\ A5EQ_P _\7_?
ML_XT?\*LN/\ G_B_[]G_ !H X:O/-<_Y.%\%?]BMKW_I7I%>^?\ "K+C_G_B
M_P"_9_QKS37_ (;3I^TEX$MOML9,GA+Q#)NV'C;>:*,=?]O]* -*BNY_X59<
M?\_\7_?L_P"-'_"K+C_G_B_[]G_&@#A&B1UVLBLN<X(XS3J[G_A5EQ_S_P 7
M_?L_XT?\*LN/^?\ B_[]G_&@#AJ*[G_A5EQ_S_Q?]^S_ (T?\*LN/^?^+_OV
M?\: .&HKN?\ A5EQ_P _\7_?L_XT?\*LN/\ G_B_[]G_ !H X:BNY_X59<?\
M_P#%_P!^S_C1_P *LN/^?^+_ +]G_&@#AJ*[G_A5EQ_S_P 7_?L_XT?\*LN/
M^?\ B_[]G_&@#AJ*[G_A5EQ_S_Q?]^S_ (T?\*LN/^?^+_OV?\: .&HKN?\
MA5EQ_P _\7_?L_XT?\*LN/\ G_B_[]G_ !H X:BNY_X59<?\_P#%_P!^S_C1
M_P *LN/^?^+_ +]G_&@#AJ*[G_A5EQ_S_P 7_?L_XT?\*LN/^?\ B_[]G_&@
M#AJ\\US_ ).%\%?]BMKW_I7I%>^?\*LN/^?^+_OV?\:\TU_X;3I^TEX$MOML
M9,GA+Q#)NV'C;>:*,=?]O]* -*BNY_X59<?\_P#%_P!^S_C1_P *LN/^?^+_
M +]G_&@#A!&@<N%&\C!;'.*78N_=M&[&-V.<5W7_  JRX_Y_XO\ OV?\:/\
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M .&HKN?^%67'_/\ Q?\ ?L_XT?\ "K+C_G_B_P"_9_QH X:BNY_X59<?\_\
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M9_QH_P"%67'_ #_Q?]^S_C0!PU%=S_PJRX_Y_P"+_OV?\:/^%67'_/\ Q?\
M?L_XT <-17<_\*LN/^?^+_OV?\:/^%67'_/_ !?]^S_C0!PU%=S_ ,*LN/\
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M_C1_PJRX_P"?^+_OV?\ &@#AJ*[G_A5EQ_S_ ,7_ '[/^-'_  JRX_Y_XO\
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M#+#X=>"-!\+:5YAT[1K&&P@:8[I&2- H9CW8XR3W)- &]1110 4444 %%%%
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MJ]Q^SWX&G73673KZUNM-O[W4K._M=7O(KNWGO)&DNRLZRAPDKL6:/=L)Q\O
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MU.<$'/ (!KI?A1KFJ>+SXOO=3-[ BZO=Z;;PO+'Y<<<$TD0,80DJQ &XD\D
MB@#ZG_X371/^?]/^^6_PH_X371/^?]/^^6_PKXC\(_%S63\([O59I[G4M=L/
MAYI?B%A+%"(I)YH+IFE# @DL\!W*0  B[<EB*CM?VG?#W@K0-4@U=M1OKCPY
M%"^LS7-U:FX1YE$Q6- ZF;8DBL0B\+@#<P*T ?<'_":Z)_S_ *?]\M_A1_PF
MNB?\_P"G_?+?X5XW%(LT:2(P9' 96'0@]#3J /8O^$UT3_G_ $_[Y;_"C_A-
M=$_Y_P!/^^6_PKQVB@#V+_A-=$_Y_P!/^^6_PH_X371/^?\ 3_OEO\*\=HH
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M $_[Y;_"C_A-=$_Y_P!/^^6_PKQVB@#V+_A-=$_Y_P!/^^6_PH_X371/^?\
M3_OEO\*\=HH ]B_X371/^?\ 3_OEO\*/^$UT3_G_ $_[Y;_"O':* /8O^$UT
M3_G_ $_[Y;_"C_A-=$_Y_P!/^^6_PKQVB@#V+_A-=$_Y_P!/^^6_PH_X371/
M^?\ 3_OEO\*\=K"\>7MUIG@C7[VRN&M+RUL)YX9D56*.D98'# @\CN* /?\
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M@'"[B"  ?5G_  FNB?\ /^G_ 'RW^%'_  FNB?\ /^G_ 'RW^%?*.O?'G2=
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MO8U@"K"5CP?]8(I&W(HS;)C.>-;QA\&-.\=W\,VM:KJ%Y:V^I6^J6]HR6_\
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MD"G#$'(J#Q1\%+#QK<6C:[K6IZG;VNH6VI00S1VH:&6%D=1'*L(D12\89@K
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MQN5N-H*[2,UWM% $=M;I:6\4$>?+B0(NYBQP!@9)Y/U-2444 %%%% !1110
M4444 %8OB/PNGB2XTB5[^[LFTR\%[&+7R\2,$9-K[T;Y<.WW<'WK:HH \QM/
MV>O#.E6F@VNDSW^CVNCZ_-XCAAM'B(EN9!*NU]\;'RU29D55*X55&?E!JQI?
MP0TW2?$&C:Q'K>L27.E76JW<"2-;["^H2F6<,!""0')VX(QWS7HU% 'EFD?L
M^Z9X?M?"::9XBURSNO#37WV2]!M7E>.[<//'(&@*%2P4@A0PVCGKE-,_9XT?
M1K?P='9ZWK,<GA=KT6DSFW=IHKHYFBE!AVE3Q@@!ACK7JE% '"_#_P"%*?#?
M1K;0]+\2:S)X?LXV@L]-N3;LMM$<[4600B0A,_+N<D8 )-1Z#\'=.TCQO9^+
MKK4K[5]>M-/DTU+NYCMXGDB=HV8RF&)#*V8EP6R!S@ DD]]10!YUJ_P-T/7=
M7\;W-]=W\]AXRLX[35]*+1_9Y D/DJZML\Q&V8Z/C(!Q6IH?PSMM+\5VWB2^
MU?4M>UBUTYM+MI]0,(\F%W1Y,"*- 6=HX]S'/W!C SGL:* /,_$OP$TCQ3%X
MZCNM9UB)/&#6S7ZP/;CRO(14019A./E10=V[\*?KOP(T;7H?%-I)JFJVVE>*
M9$FUK3K=X1%>.(HXG))C+IYD<2(^QER%R-I))])HH \M\6?L^Z3XKN_%;MKN
MM:99^)A:MJ-C8FV\II+=42-U,D+LIVQQ@@-@[>G7.WH?PLC\.>'M0TK3_$6L
M0&]U6?5WO#]F,HEFG::5 /)V&-F9@5*DX. 1P1V]% '(?#WX8:3\-CKKZ8TK
MS:U??VA>,Z1QH9?+2/Y(XD1$&V-<X7).2Q).:Z^BB@ HHHH **** "BBB@ K
ME)_AU:7'Q/M/'!U*_74;;3)=)6S4Q?9FADD21L@Q[]VZ)#D..G3FNKHH \OL
M/V?]'TY_M$6M:P=1CU^?Q);7[M;^;;74Z/',$ A"F-TD=2K*W!X((!#[KX!Z
M1<6>4U?5H-8/B!?$K:TC0&Y>\6+R02K1&+8(?W879C: ?O?-7IM% 'F5A\!=
M,L+FUN/[?UN::W\1R>*-TC6WSW;PO"P8" #RRLC<#!R>M7)O@QIVH>+M"\1:
MIJNH:K?Z'=S7E@UPENKQM(DB;&E2)9&C596 0M@X4MN(!KT&B@#S_6?AHNJ^
M*?%K3AI=#\7:*FEZBL3A)8'C69-ZYZAXYROJIB7@AB5KQ?!.&%/!LD?BG7(]
M1\*P2VEGJ"K:>;)!(D:/%(I@*$8BC.0H;*]>37I%% 'F7AGX":3X4F\(26>M
MZS(?#"7T=D)FMR'%TP:7S,0C."!MQC'?-5-!_9UTKPO<^&+K2_$6NVUYH$-]
M;6]RQM9&DANIEFE1U: J/G48955L9!)%>L44 >/>%?V9M(\$V26VB>)O$-EC
M1UT)I=]JTAM5FGF7!,& X:XD^8#ICN,U=U+]G#PKJ.D7.E+-J-GIKZ5IFDVU
MM:RHHLDT^5Y;26%BA;S$>1CEBP/&017JE% '!>+?!&M:M\/-=\-KKUYK%SK=
MJ^G-?:@EO']DBE1DDE BB3<0K$A<'+!1\H)([>RM(M/LX+6!=D$$:Q1KZ*HP
M!^0J:B@ HHHH **** "BBB@ HHHH **** "BNG_X5UK/]R'_ +^"C_A76L_W
M(?\ OX* .8HKI_\ A76L_P!R'_OX*/\ A76L_P!R'_OX* .8HKI_^%=:S_<A
M_P"_@H_X5UK/]R'_ +^"@#F**Z?_ (5UK/\ <A_[^"C_ (5UK/\ <A_[^"@#
MF**Z?_A76L_W(?\ OX*/^%=:S_<A_P"_@H YBBNG_P"%=:S_ '(?^_@H_P"%
M=:S_ '(?^_@H YBBNG_X5UK/]R'_ +^"C_A76L_W(?\ OX* .8HKI_\ A76L
M_P!R'_OX*/\ A76L_P!R'_OX* .8HKI_^%=:S_<A_P"_@H_X5UK/]R'_ +^"
M@#F**Z?_ (5UK/\ <A_[^"C_ (5UK/\ <A_[^"@#F*\\US_DX7P5_P!BMKW_
M *5Z17M7_"NM9_N0_P#?P5YOKW@+5E_:.\#0%(O,?PIX@<?O!C"WFC _^A"@
M#SO5?A3K&JVOCGP_::I-H::KKUOX@L]1CC:6&:,"W,UK,JNC$,\,BLH9=T<J
MX)PX&;+^S'+--XJNDU^PL+S5]3TG6K0:=HWDV]C=V'EF,^5YY\Q&,8W+E3\Q
MPPX(^GO^%=:S_<A_[^"C_A76L_W(?^_@H ^89_ACKUE\:]&\07=\FK3ZAJ5M
M>7@LM*DM[:TBMM.U" -YK2R EFN8UVG!^8$9 ;%SP7^S_K/A(^ HCXKLKFR\
M&QWD%BB:0R2RQ31E%\QS<$;E&.0H!P>!GCZ2_P"%=:S_ '(?^_@H_P"%=:S_
M '(?^_@H ^9[/]F=(3K(CU6RT2WU;0KW1[VR\.Z<]E:74MPJ@W<D!F>/>F'*
MA0I_>-EB, :0^"WB"7_A"C=^)M,OXO#^FR:;-IUUI$DEA=Y$02?R?M/$J"(@
M,Q88D; '4_0W_"NM9_N0_P#?P4?\*ZUG^Y#_ -_!0!\V>"/V>=2\ :?\/8]/
M\36D]WX/L-1TZ*2XTMO+N8[J2%\E%G!5D\D=&(.3TJ-_V8+6Z\.+H=WKS36-
MQI&N:=J+K:;)KB;5+B*XFG1MY$>V2+Y4*MP<$G&:^E_^%=:S_<A_[^"C_A76
ML_W(?^_@H \*\'?#N3X;Z>-1N--\/:SJMC8&T@GT/P^MC>W'W?E+F5P Y5=P
MX7.&) '&I\(O ^K_  ^\'Z%H=[J-K=6MAI%K:M##;D,+M=YGD$A;YD8LH5=H
M(VDY.[ ]A_X5UK/]R'_OX*/^%=:S_<A_[^"@#Y[@^#'B.WTKQII,?B^R@T[Q
M5J-S>W3P:.PNH$G18W2*1KAE#!5X=D;!.=IKG/%'[*\VNZ7X@T:W\1V<6CWT
MU@^G"^TI[NYTF*U%N%MX)#<*%B/V?. H.9'R2>:^I_\ A76L_P!R'_OX*/\
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M\%'_  KK6?[D/_?P4 ?,FO?LOVM_X5TG0-/U"QL4T?18-'TK6VT]_P"V-/\
M+7;YL5U'-&<GY6"$;0P)(8';6KXE^ DGB/Q7!KHU:RTW4X+VUN%UO3]/:#57
M@A*$V\LZ3!9E<*RDO&0%D(VY -?0W_"NM9_N0_\ ?P4?\*ZUG^Y#_P!_!0!\
M^:?\$M6T?Q!H>MVGB.R:_P!+N==F19M+<Q2+J=VERRD"<$&-DP#GY@>@K+?]
MF"UNO#BZ'=Z\TUC<:1KFG:BZVFR:XFU2XBN)IT;>1'MDB^5"K<'!)QFOI?\
MX5UK/]R'_OX*/^%=:S_<A_[^"@#Q;X;?"P^"GM9[Z#PS=7]K9_8TU'2M %C<
MNORY+/YK\-M!*C ) /;%-UI0G[0?@E5 51X6UX  <#_2](KVO_A76L_W(?\
MOX*\WU[P%JR_M'>!H"D7F/X4\0./W@QA;S1@?_0A0!T-%=/_ ,*ZUG^Y#_W\
M%'_"NM9_N0_]_!0!S%%=/_PKK6?[D/\ W\%'_"NM9_N0_P#?P4 <Q173_P#"
MNM9_N0_]_!1_PKK6?[D/_?P4 <Q173_\*ZUG^Y#_ -_!1_PKK6?[D/\ W\%
M',45T_\ PKK6?[D/_?P4?\*ZUG^Y#_W\% ',45T__"NM9_N0_P#?P4?\*ZUG
M^Y#_ -_!0!S%%=/_ ,*ZUG^Y#_W\%'_"NM9_N0_]_!0!S%%=/_PKK6?[D/\
MW\%'_"NM9_N0_P#?P4 <Q173_P#"NM9_N0_]_!1_PKK6?[D/_?P4 <Q173_\
M*ZUG^Y#_ -_!1_PKK6?[D/\ W\% ',45T_\ PKK6?[D/_?P4?\*ZUG^Y#_W\
M% ',45T__"NM9_N0_P#?P4?\*ZUG^Y#_ -_!0!S%%=/_ ,*ZUG^Y#_W\%'_"
MNM9_N0_]_!0!S%%=/_PKK6?[D/\ W\%'_"NM9_N0_P#?P4 <Q173_P#"NM9_
MN0_]_!1_PKK6?[D/_?P4 <Q173_\*ZUG^Y#_ -_!1_PKK6?[D/\ W\% ',45
MT_\ PKK6?[D/_?P4?\*ZUG^Y#_W\% ',45T__"NM9_N0_P#?P4?\*ZUG^Y#_
M -_!0!S%%=/_ ,*ZUG^Y#_W\%'_"NM9_N0_]_!0!S%%=/_PKK6?[D/\ W\%'
M_"NM9_N0_P#?P4 <Q173_P#"NM9_N0_]_!1_PKK6?[D/_?P4 <Q173_\*ZUG
M^Y#_ -_!1_PKK6?[D/\ W\% ',45T_\ PKK6?[D/_?P4?\*ZUG^Y#_W\% ',
M45T__"NM9_N0_P#?P4?\*ZUG^Y#_ -_!0!S%%=/_ ,*ZUG^Y#_W\%'_"NM9_
MN0_]_!0!S%%=/_PKK6?[D/\ W\%'_"NM9_N0_P#?P4 <Q173_P#"NM9_N0_]
M_!1_PKK6?[D/_?P4 <Q173_\*ZUG^Y#_ -_!1_PKK6?[D/\ W\% ',45T_\
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MB3_PE'@+PQ'>+XNOM36;Q+X=MX);F"WCFCBGU:VM[F)C%&B.CQ2D#*[AD\Y
M(Z[QK\,-.\9Z[H.OB\O=&\1Z'YRV&K::R":.*8*)H661'1XWV(2K*>45@58
MUF:U\'/^$FL;F#5_%_B"]>:_TV_67_1$\EK&Z6ZA2-!!M"F507)!=@ -P
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M()!!KL:J:59S:?I\-O<7]QJ<T8PUW=+&LDG.<L(T1/;A1TJW0 4444 %%%%
M!1110 4444 %%%% !7EGB+_DZ/X??]B;XE_]+="KU.O+/$7_ "='\/O^Q-\2
M_P#I;H5 'CWQ7^.'BSPE\0/BAI6E^*KLZQI8TF/PIX?;3();;4;ZZC<BTED$
M.\!W4*#YJ%02V2!7?>/?VPO!?P_U7QC9WD<]RG@\P+K4D-Q;J\;21K(5AB>1
M9)RD;H[[%Z'"[F!4=!XC_9R\.^+;_P"(%QJFI:O<Q^,[>UAN[<20HMF]L/\
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M >/(SM8#.".AJ>F0H8XD1I&E95 ,CXW,?4X &3[ "GT %%%% !1110 4444
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M_=6\\$JL5MN(BMS*0 ,@D'/ % '4?'+5;W0?@MX\U73;N6QU+3]"OKVUN82
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M((GU"*VC91CH!!%&/?D'GTZ5L4 %%%% !1110 4444 %%%% !7S9\<_B_?\
M@#XNW>G7GCB_\*^'(O"$NLH;73(+H"[6Y6% VZ"1MC;@-NY<D@!AFOI.O/\
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M."#6SI7[0NDZ_P"!]'\3:?IMPEM?W%U9S0ZG=VMDUC<6\KPS03&27;O$L;H
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M1;K5+ZWT^W:18EDN) @=VX5%SU8GH!R>U 'T'_:EE_S]P?\ ?U?\:/[4LO\
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MJ_XUX763XNUR3PSX6U?6([=;M]/M);KR'D\L2!%+$;MK8R >QH ^BO[4LO\
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M$E1E; RKQ2QN#@?>P>0: /I/^U++_G[@_P"_J_XT?VI9?\_<'_?U?\:\+HH
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MX$4LK%U& K[2%;O@D;@IK7\"?$S0?'MI;+8:K83ZJ;*"\NM/M[E9)+<2+D9
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M^U++_G[@_P"_J_XT?VI9?\_<'_?U?\:\+HH ]T_M2R_Y^X/^_J_XT?VI9?\
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MJ\7B"](+&-XA(+1D\N-G1RK*"P&XD9XKWBB@#Y>U7]F#Q9K_ ,+?!'A"YO\
M2+)])TO5]-OKRVNIG(^UV\D2-$IA7> 7!8,5X! -==;? V^U?PGJEOJNDV&G
M^)I?"]WX<M]5B\0WU_&JS1JK 13(H2,LB-W(V@#UKW.B@#R+PU\.O%,6O?#2
M_P!4MM'AA\.:%>:1?107TLQD:5;0*T>8%##_ $9LAMOWAUKF-6^#WQ$U_4]
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MO_A%](_Z!UM_W[%'_"+Z1_T#K;_OV*U** ,O_A%](_Z!UM_W[%'_  B^D?\
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MCVLGBR#3EU33[N5$%O:I=VCG[1&6R7>5,YBC;S'8FJ?C[X/?$?Q]J^BZG9>
M[_3+:U\+Z1I^IZ?J%]8(=4^RZG;W%S8L8[AQME@CD0%L(<[6*JQ- 'UW#I7A
MRXMGN(H-/E@3.Z5-I5<=<GH*='HWA^6T^U);6+VV-WG*%*8]=W2O#_B)\/\
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M'7AZ.+1]0LY;,1/<G2S;R0EI)$="9P&RRA2,,3FM'5/@5XC;2?BMIW@S0(_
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MO&MI<3QR7"6D=ND[S[T+ O'Y<\08$C-]&?2@#Z<F\.Z7]E>6WTNTN'V%HUP
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MCUKY3;X#:]:VZ:C)\/XH=2A^+$WB)KQI; 2)HSSNSN9/.X0Q.P,>=Q#$%:]
M_9M^&%QX2U_6]-N8+27P]X'O+S1/"EQ%AF^RW#I=2@\=80T-J#U!MY<_>- '
MN7_"+Z1_T#K;_OV*/^$7TC_H'6W_ '[%:E% &7_PB^D?] ZV_P"_8H_X1?2/
M^@=;?]^Q6I10!E_\(OI'_0.MO^_8H_X1?2/^@=;?]^Q6I10!E_\ "+Z1_P!
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M(OI'_0.MO^_8H_X1?2/^@=;?]^Q6I10!E_\ "+Z1_P! ZV_[]BC_ (1?2/\
MH'6W_?L5J44 9?\ PB^D?] ZV_[]BC_A%](_Z!UM_P!^Q6I10!E_\(OI'_0.
MMO\ OV*/^$7TC_H'6W_?L5J44 9?_"+Z1_T#K;_OV*/^$7TC_H'6W_?L5J44
M 9?_  B^D?\ 0.MO^_8H_P"$7TC_ *!UM_W[%:E% &7_ ,(OI'_0.MO^_8HK
M4HH **** "N?C^'OA6+6O[83PUHZ:OYIG^WK81"?S#U?S-N[<<GG.>:Z"B@
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M@&[7RYX"U7Q?)KO@^"]\-:OI,-GXZFBN+[3%U)M/U"R;1+@>?Y,Z[[>W^T-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU@Z'^T)X9UF^FMG@U.R_XJ"3PU!-<6$HCFNTSE=VW"9*N!N(Z#H2!0!]=?\
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M_+_C7QOXW^-D]CXI^'.F>&$LM1L?$UW +G4)@SK!;3P3RV[(H9<M(+>7!)P
MAR.172-\:?"2W_V<W\IA_M4:']N%K*;7[>6VBW\[;MW;_DSG;O\ DSNXH ^I
M/^$DTG_H)6O_ '^7_&C_ (232?\ H)6O_?Y?\:^,?'_QQ2SGT#_A%Y)+Z&3Q
M3;Z!?7!LG>V;=+Y<Z))P&=""N5) 8,IR00.J\,_%32=5LO!L,]XMQJGB31_[
M6LS:6DRPW*)'&\K)N&4'[U"$<AL,.^: /J3_ (232?\ H)6O_?Y?\:/^$DTG
M_H)6O_?Y?\:^0Q^TEX&?3Y;V&ZU*Y@AT\ZK(;?2+J4I:"22-I6"QG 5H9 <\
M_+TZ9Z3PQ\4?#_B[7IM&T^:[%_'9QZBB75C-;B:V=BJRQF1%#KN&,CV[$9 /
MIC_A)-)_Z"5K_P!_E_QH_P"$DTG_ *"5K_W^7_&O$Z* /;/^$DTG_H)6O_?Y
M?\:/^$DTG_H)6O\ W^7_ !KQ.B@#VS_A)-)_Z"5K_P!_E_QH_P"$DTG_ *"5
MK_W^7_&O$Z* /;/^$DTG_H)6O_?Y?\:/^$DTG_H)6O\ W^7_ !KQ.B@#VS_A
M)-)_Z"5K_P!_E_QH_P"$DTG_ *"5K_W^7_&O$Z* /;/^$DTG_H)6O_?Y?\:/
M^$DTG_H)6O\ W^7_ !KQ.B@#VS_A)-)_Z"5K_P!_E_QH_P"$DTG_ *"5K_W^
M7_&O$Z* /;/^$DTG_H)6O_?Y?\:/^$DTG_H)6O\ W^7_ !KQ.O*O''Q"\1Z3
M\7]#\(Z;=:+96.HZ+>ZJ]YJ5I)*83;R0)M)69!M;SLY[;>^: /L'_A)-)_Z"
M5K_W^7_&C_A)-)_Z"5K_ -_E_P :^-?AU^T=H_C#P/INL7]I<VNIRZ>^I7EA
MIUO->"WMEFEB6?<B9,<AA=H^-S+R <&NJNOC%X6@"&WO9M5!TR/66.EVLMT$
MLI,^7.WEJ<*VUMH^\VUL X. #Z@_X232?^@E:_\ ?Y?\:/\ A)-)_P"@E:_]
M_E_QKY@M_B_X8OM<LM*LKJYU"YO+2TOX'LK&:>%[:Y9EAF,J(45&*-\S$8Q]
M*[.@#VS_ (232?\ H)6O_?Y?\:/^$DTG_H)6O_?Y?\:\3HH ]L_X232?^@E:
M_P#?Y?\ &C_A)-)_Z"5K_P!_E_QKQ.B@#VS_ (232?\ H)6O_?Y?\:/^$DTG
M_H)6O_?Y?\:\3HH ]L_X232?^@E:_P#?Y?\ &C_A)-)_Z"5K_P!_E_QKQ.B@
M#VS_ (232?\ H)6O_?Y?\:/^$DTG_H)6O_?Y?\:\3HH ]L_X232?^@E:_P#?
MY?\ &C_A)-)_Z"5K_P!_E_QKQ.B@#VS_ (232?\ H)6O_?Y?\:/^$DTG_H)6
MO_?Y?\:\3HH ]L_X232?^@E:_P#?Y?\ &C_A)-)_Z"5K_P!_E_QKQ.B@#VS_
M (232?\ H)6O_?Y?\:*\3HH P/$>E:]>ZE87&D:O9V=K%%-%=6-]8M<1W.\Q
ME&!61"A38X_B!$AR. :\LNOV7;%O"ND6%KJ%E%J6F>))_$T1ETM9-.,TWF"2
M#[)Y@Q"4E("A\@@-N)SGW*B@#S,?!M"_AYX_[!TK^S]7DU6\BT?1?LL=]OLI
M[0J0)B0VR<GS#N^XHP *Q_AE^SK9?#_1M+T6Z3P[K.G:5#);6=ZV@K%J:QLC
M(NZX$I&\(Q4NJ#<,\#)KV2B@#RO0?@]K.E_"FX^'-UXDM+SPZNB2Z%:3KIC1
MWD<!A,,9=_.*.R(1DA%W8Z+4&A? J9]+U?3?%.KV>MZ?JGABS\,3P6FG/:GR
M[?[1B4,TTGS$7+=A@JI!KUNB@#S71OA'?:9IG@2*;Q#_ &AJ/A_4GU;4=0N;
M3=)JD[VL]NYXD'E\7#$??P$1>0*XSQ1\);W1O"WC/P[#?3ZC-XGUFXU[1)K/
M29-^F:B9HYHGEG#L@2.55<%E3*JPR3P??:* ,[PYH</AK0;#2[=FDBM(5B\V
M3[\A Y=CW9CEB>Y)-:-%% !1110 4444 %%%% !1110 4444 %>>:Y_R<+X*
M_P"Q6U[_ -*](KT.O/-<_P"3A?!7_8K:]_Z5Z10!9T/X=:AHGQ-\9>+EUBVE
M7Q!9V=K'9&Q8&V-L)MC%_-^<'SFR-J]!@BO-IO@-K'@?X7Q65OJ4'BB71/"V
MM:-#81:2%:_-XT4@^5YF7AH%&TA@P8BOH.B@#YB\*?#CQ3>-J7AII;34+/6?
M#$^C7?B:XT'4[2XT]0@2",?;;N0S*WFS,4CV %<L>0#ZOX8^%%YH'CC0O$$N
MMP72:9X:7P\;5+$QF7$B/YV_S6V\Q@;<'KUKT:B@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O/-<_P"3A?!7_8K:]_Z5Z17H=>>:Y_R<+X*_
M[%;7O_2O2* +.A_#K4-$^)OC+Q<NL6TJ^(+.SM8[(V+ VQMA-L8OYOS@^<V1
MM7H,$5YM-\!M8\#_  OBLK?4H/%$NB>%M:T:&PBTD*U^;QHI!\KS,O#0*-I#
M!@Q%?0=% 'S%X4^''BF\;4O#32VFH6>L^&)]&N_$UQH.IVEQIZA D$8^VW<A
MF5O-F8I'L *Y8\@'U?PQ\*+S0/'&A>()=;@NDTSPTOAXVJ6)C,N)$?SM_FMM
MYC VX/7K7HU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB
M?29M>\.:GID%PEI+>6TENL\D1E6/>I7)4,N<9Z9%:=% 'DC_  /U$^ OA?X;
M3Q':J_@FYL;C[4VF,1>_983$@V>>/+RI))W-STQ7.?%WX9ZY]J>ZL+P2'5O%
MUOKGVN+2+BX.E"'3A;C<MO.L[[S!&N^)HR/-8-\A(/OU% 'SYX+^&GB/Q+96
M-K>_8-%L_#WBM-=M=0CTBZ@?628F,S20W%R\T;>9-(OF2.Q;8"%QC/J/PY\
MW'@2?Q7)/J<>H_VYK4VL 1VIA\CS$C7R^7;=CRQ\W'7I7944 %%%% !1110
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M#<7AXVT=BT1DV2!_.WF5L9QC;@_6O1J* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KS7Q?\&T\8_%KP[XQOKK3KJQTC3[FP&DWNE_:/,\Z2)VD$AD
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MC^Q[#_GQMO\ ORO^%7** *?]CV'_ #XVW_?E?\*/['L/^?&V_P"_*_X5<HH
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M_?E?\*/['L/^?&V_[\K_ (5<HH I_P!CV'_/C;?]^5_PH_L>P_Y\;;_ORO\
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MH_L>P_Y\;;_ORO\ A5RB@"G_ &/8?\^-M_WY7_"C^Q[#_GQMO^_*_P"%7**
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MLS,3@  $DFIO^%D:QZP?]^__ *] 'J-M;16=O%!!$D$$2A(XHU"JB@8  '
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M!ZK17E7_  LC6/6#_OW_ /7H_P"%D:QZP?\ ?O\ ^O0!ZK17E7_"R-8]8/\
MOW_]>C_A9&L>L'_?O_Z] 'JM%>5?\+(UCU@_[]__ %Z/^%D:QZP?]^__ *]
M'JM%>5?\+(UCU@_[]_\ UZ/^%D:QZP?]^_\ Z] 'JM%>5?\ "R-8]8/^_?\
M]>C_ (61K'K!_P!^_P#Z] 'JM%>5?\+(UCU@_P"_?_UZ/^%D:QZP?]^__KT
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M 'JM%>5?\+(UCU@_[]__ %Z/^%D:QZP?]^__ *] 'JM%>5?\+(UCU@_[]_\
MUZK:E\6[O1K*2\U"\L;&TBP7N+G$<:9.!EF( Y- 'KU<_J/P]\*ZQJIU2_\
M#6CWVI%D<WES8123$IC8=Y4G*X&.>,<5YI8?'>'5;)KRRUO1[RS6=;5KBWGC
M>,3,RJL98-C>2Z +U)8#N*UO^%D:QZP?]^__ *] 'JM%>5?\+(UCU@_[]_\
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M"R]"1R*6@#Y4\;_$7Q!X63XJ/:_$2]F_X12_TN6P2?[$1(LXA,L4N(063)<
M @C<>>!BSI_Q/\12/]HLO&,VJZY'\0I="BT BV=;C31?&)\HL8<>7!NE\W/'
MEY)(R#]15S'@3X?V7@"'5H[*\O+P:EJ-QJ<IO#&2LTTADD"E$7Y2Q. <XH ^
M>+3XEZIHNI^&-)L=7L=*\+ZGX@\6M>:E-?):Q27*:K,T%N;@Q2",LLCR 8!?
M8,' (;W[X2RZ_-X#T]O$NL:;K^J;Y@=2TF4207$7FOY3;@B*7$>P,54#<&P
M*Z]T612K*&4]01D4M !1110 4444 %%%% !1110 4444 %%%% !1110 5YYK
MG_)PO@K_ +%;7O\ TKTBO0Z\\US_ ).%\%?]BMKW_I7I% '*_#[5K+PG\7OB
MJ?%MW;:9K%_J5O/IMUJ$JQ"XTM;2%8UA9L K'*+C<J]&8DCY@3D7GQ*M+GQ5
MXFM;;Q4GA#PA9Z"NH:'=VGD)%?W#7%VMU,C2*PE$;1181?E(F#$,'7'T$\:2
M##J' .<,,TI4-C(!P<C/:@#Y3O\ XI>,=4T^^?4_$]SX2U>#X9VOB6;3K=+9
M#!J9\XN"LL;,!E8\QD^W>K>H?%/Q#I]OXE-MXRFOII_AI)XG@#BV8VE\@8AH
M@D8^7&,JP8?*/?/U%6/XQ\,6WC;PGK/AZ\FGM[/5;26RGDMBHD$<B%'VEE8
M[21D@T ?,OCGQYJ=WX/\7V$7BE_$^AW_ ,,M2U+5'F,#+I]\8D6$!XD7;YPD
MF'EMG_5 KCG.OXD^)/C36O'GQ"T73?%FA^%KS3VL_P#A&TU?4([:">%X(Y/M
M!0P.;E))&DC)5QM"X&UOF/T9X?T:/P]HMEID,TMQ%:0K"LLVW>P48!;:JC.
M.@%7BBLRL5!9>A(Y% '@WA3X@ZA'\8AH6J^*WNO#FH7%Q+H=Z/)V7MQ&L:W&
MG[PHW"%B[*P 9\LN?W+;[7QC-M'\=_AB]YKDGARU_L?7E;4(YHH=I+6!"[Y%
M*C."?7Y3VS7N%(R*XPRAAUP1F@#Y0\&_&'QQ-X+^).I0SKKWB;3?"JWND(UK
M&)KP)>ZK'!<F-%!;S(8K:38/E._*A?,YL?$7X@.GB+PYI%AXO7Q7X8N6T34+
MZ]GD@86MRNNZ=Y+>9&JA?-C:=C&>,0DJ% ;/U12*H7. !DY.* /F_P"(7Q2\
M1Z3;_%JY77WTCQ'X?O(HO#/A]4B(U",VT$D1\ME+S^?,\L7RGC9A=K*36/IO
MQ<U'Q#\1K?0;SQS8Z=K5IXTF@N].?6K*VB?3HR_E6R6^];EI,^4N=F'</\S1
MD _5!4%@2 2.A]*\^G^">D7FGR:7=:EJ=UH4NHG5)-)E>$Q/,;C[3\TGE^<5
M\WYL&3H IRO% 'ENA?%.[D\1Z#I>J>)XM#\)W.H>)DFUB-H(1/=6^J-':VC2
M[=J$P,\G&'D,8.3\V[Z \+E3H%F4U?\ MY"F4U(E#YZY.&S& IXP,@ '%:;*
MKJ58!E/4$9%+0 4444 %%%% !1110 5P7Q\L-?U3X)^.;/PMYQ\0SZ/<QV0M
MSB5I#&0%0CHYY"^Y%=[10!YOX:\:_#N3PCX7L-.O=+2S+6D&G:5&Z>=#*"HC
MC$/WE=#]X8!7:V[&#7F<'Q4\3/I]A?'7'_X3.7QLVCS>$=D6%L/[0:$KY>WS
M !: 7/G9_P!K.P[:^DA&@<N% <C!;')I=HW;L#=C&>] 'RQ'\2=?N)=/NA\0
M;N(2_$2\\,F!/L1C^PAYU3[T).Y0L9#$GMG.>8?#OQ1UB^^(>G^&]2^(=Q;Z
M,FK>(M/FOC):1RR1VWV5[;=(8\!E\Z09 &X 9SBOJZN8USX?V6O^-O#WB>>\
MO(KW1(KB&W@B,?DNL^SS-X9"Q_U28PPQB@#YSB^)WBQM!T7Q$A36?&-MX.\7
MR:5YD*K)J20WUD+2?R4 W&6*)9,( &Y*@ \=?X!\8ZQK5H=6NOB7HDGA5_#C
M2WUS;ZK!<7MK=Y0K=*OV9%B7!=6C8%0VP!1\V?H2D5%3.U0N3DX'4T >/_L_
M>-M7\2'6=,\5ZJ[>+M)$$%SI;I'&/),:M%>!1D_OP=S#.$;,>,H6;RWPKXEU
M+PO%=MH'B*9M>N?B?J%F_AG]S(EQ:2ZM()V,>SS%"PL\WF!AC8,_+P?K.DV*
M&+;1N(P3CF@#YP\,_$F_OO$NC:5?^)$T?PM->>*/-U: P1>?<V^JF.VMFD*[
M5/D,\O&&DV9)(#9YFX^*?BQM TKQ+ $U;QA;>$/%[Z3NA42:A'%?V*VEQY*@
M;C)%$LF% #X)4 ' ^M64.,, 1Z&EH ^>-5^)&LZ=JNK6WA+QA%XHT]/!%_K$
MFI7HBGAL;^/R_LLCM"@PLH:4F+!XARJC!!XRV^+DGB3PCX]US3?'EM?VUCX!
MEG2PN=9TZ]G340CO)*8+=W39Q$I$@QD[54 MGZE\3^&K/Q;X;U30[[S4LM2M
MY+:<V\AC?:ZE6PPZ'!K&T_X;6=OXGT_7[_4;[6=2TVWEMK%[P0(MLDNSS=JP
MQ1@EA&@RV< <8R<@'GFC^/9/$?CWQIIFM^-E\*SV-_;1Z%8K+;Q+<V;6\,BW
M*^8I,XEE>5#@D#RP!ALD^XTA16() )'0D=*6@ HHHH **** "BBB@ KS'X^:
M3I>L:%X=COO%?_"%ZA#K<-SI.KR)&\,=ZD4S(LJ281D9!(-I(RVW!#8KTZAE
M#*00"#U!H ^;;3XDZV/#'B%M9N-!:]TWQ?H5DWB;1(@ECJZ275FLAVREP)8X
MF*/AVV%058%>,F/XDZ_<2Z?=#X@W<0E^(EYX9,"?8C']A#SJGWH2=RA8R&)/
M;.<\_5 4*    . !VHH ^7%^*.N1Z;IUH_C>98(/B1/X;N-48VHD>P\B:15D
M;R]@(*J X4'Y>N<UB2?$_P 3VOBKQ1=Z9?#Q7J&@Z)XIC\,7<R1M)J*(-'E4
M;8PHFV3>?&"H^?R2.2&-?2_C;P!9^.I_#\MY>7EHVB:BNJ6XM#& \RQO&-^]
M&RNV1^!CK[5TX    P!VH \2^"GB;Q#XHUS3;X>--#\1^'I]$#W=K#J<=U>"
M\W(5G"I;Q>4I!D5T)P#LP 0<^VTBHJ9VJ%R<G ZFEH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O#?BO;"P^*8U[P]\0M(\(^,;70DBFT[Q)"DMA>V
M1FE9"?GC="'23<\;' V[E/RU[E2,BOC<H;!R,CH: /D:^^,VKVW@K4-3M9H/
M ^H+X?\ "]Q%ID*P_P"B&;4KF"94\Q,F-H0C*KCY0P( +'-_QO\ $7Q!X63X
MJ/:_$2]F_P"$4O\ 2Y;!)_L1$BSB$RQ2XA!9,EP ""-QYX&/JNB@#Y?^(WQ.
M\0:5J/QA?3?&<\&J^'I[%_#>BHMLXO));2&46_EF,O*LLCE>#D;OE((S3/&G
MQ'U?PEXD\3_V3?6FF6M]\0;*SUK4)+A42QMVT.S.'E*2"(/+&L7F%3C) P2"
M/?/#WP_LO#?B[Q-XA@O+R>[U^6*:YBG,9BC:.)8D\O"!A\B*.6.>M=.0&!!&
M0>H- ' _!ZZUZ\TK69-:U[2?$5J=2D.F7.EW8NC%;%$(AFD6.,,ZN7Y"YVE,
MDG)/?4BJ$4*H"J. !T%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ';_\*MNO^?Z'_ODT?\*MNO\ G^A_[Y-9?Q(OK^W^.OPKM+2_NX+>\AU8
MSVD=W+';W#101M%YB*=K;68GD'K7%>"/VE_&?CE?AP]MX-T*V3QUI=Y>V!EU
MR8FVDM@A=90+7E6#G&WNO/7( /2?^%6W7_/]#_WR:/\ A5MU_P _T/\ WR:X
M/PQ^TIXA\;6OPRCTCPKID>H^---U.Y,=]JLB164UD\:2+N6!C(C%S@[5.!R.
M>%^&O[2?B#QS>?#8WGA73=,L?'.GWTUH\&JR7$MM<VJ!F213 @*-\X#*<C:.
M.> #N_\ A5MU_P _T/\ WR:/^%6W7_/]#_WR:\MN?VOM1C^&7@/Q=%X3M6'B
MCP[JNN&T?46'V9[*U:X,6[ROF#A=N[ QUP:O:K^UC=^"[36[_P 5>&+>#3[/
MP-_PG%M_9.H-<221*P5K=P\485\NF&!(Y.<8R0#T3_A5MU_S_0_]\FC_ (5;
M=?\ /]#_ -\FN;\0_'O6_ 6M7NC^(O"B7>J?\(E?^*K*VT"[>Z:Y-F8Q-9@-
M&I\PF>((X!#Y;Y5( ;E[;]K.>TM?%.O7]EI.J>%/#_@M?%=Q>>&KIKT&5BY%
MF92%59 L9(R,L'#$1A?F /3/^%6W7_/]#_WR:/\ A5MU_P _T/\ WR:X+_AI
M3Q/::-K%_>^ +I+>T\(W/B>.^6*]BLTF@57:PDFFMHQO96RDB@A@K_*-HW9N
MM_M%ZX^LZ%HVJ^'8+"/5K?P_KEI/I.M2^8(;G5[2T>*4F!>AN$8J,K(F]"5S
MD@'I_P#PJVZ_Y_H?^^31_P *MNO^?Z'_ +Y-4M)^*VO>-/%/C?3O"VA6-Q9^
M$M4CT>YFU&^:&2[N#!#<2B-5C8(J1W$8#,?F;<,* &/GVF?&SQ<WCKP#X:T;
M3[%[?7M8\6PWDFK:A+-)G3KZ:(*C^7E8R2&5<':H5.B[F /3O^%6W7_/]#_W
MR:/^%6W7_/\ 0_\ ?)K&^#WQPU+XJ-H\,FAVVFWZ0WP\0V:W;2/I%U;W1MEM
MS\@WEW28JQ"Y6%F Y%>P4 ><?\*MNO\ G^A_[Y-'_"K;K_G^A_[Y->CT4 ><
M?\*MNO\ G^A_[Y-'_"K;K_G^A_[Y->CT4 ><?\*MNO\ G^A_[Y-'_"K;K_G^
MA_[Y->CT4 ><?\*MNO\ G^A_[Y->:Z_\-[E/VDO MM]LBW2>$O$,@;:<#;>:
M*,?^/_I7TC7EGB+_ ).C^'W_ &)OB7_TMT*@"Y_PJVZ_Y_H?^^31_P *MNO^
M?Z'_ +Y->3_$/Q-XL^&'Q8\6>/;+4M5UGP-HK6MOXC\,F:2=8+&6!7>_M4R2
MDD#9=T7AXC)@;E6M7X6_&*XO+GP_X3\-NOB6_P!=/B'6XM7U75)IH(].M=4^
MS0[)#YC2;A- J@$ *K,23@, >A_\*MNO^?Z'_ODT?\*MNO\ G^A_[Y-<)X?_
M &FM8\9WO@?3M%\+V,>I>(GUVSG2_P!3=8[*[TN?R)E#I"QEC9]Q5L*2 ,@$
MD"CHO[7,WB*R^&UK:^&'CU[Q;9ZE>3Q(;B[@L$L9A!*1Y$#22[I64+\B#:26
M(("L >D_\*MNO^?Z'_ODT?\ "K;K_G^A_P"^360W[0#Z'^SMK?Q1\4^$]4\.
M2Z+9WMS>:%<QNDY:W=T'EF1$)278K(S*ORR*2!R*\<^)WQO\0_!7XW+X@\1Z
M7'-/<^#88XO#^D7TTL$M[<:M:VT6]C'R5,N#(L98J#A22%(![U_PJVZ_Y_H?
M^^31_P *MNO^?Z'_ +Y->6_$S]I7QMX6\ ^/;VU\&M8W^A-I0L=7U"VO(+"]
M6\N5@?8)H$8RPL?F3D8=&SR4KIO&/[0VL:#\0M0\#Z9X7&K:_I7AZ+7+UH5O
M)H6>625(;:/R+:1AN,$F9'"A?EPK$D* =9_PJVZ_Y_H?^^31_P *MNO^?Z'_
M +Y-<[X6^.VN_$77VT/P_P"$CI6K6?AO3M?U.U\3326DMI+>^=Y-F8UC9MZ_
M9Y0[G 7"X#9..'\2?M5>)O >O_%-];\.6-Q8>&+K0]+L=/LKJ1IY;S4$BV!W
M$1RN^<;BJD@)\JN3R >M?\*MNO\ G^A_[Y-'_"K;K_G^A_[Y-<+J_P"TWK/A
MJ+6H-3\"WPNX]0T?2]%NY(KJRL=5N-0N/LZ)YEQ K1F&3F3"O\A5ADMM%SX,
M7NM-^T)\9K'5YH\00:'+':VL\CVT320W!=D5\;2Q +8') - '7?\*MNO^?Z'
M_ODT?\*MNO\ G^A_[Y->:Z#^TMXCMO"WC/6=;T33KF6U\>GP5HME9W3H))GO
M8K.+SI&C.U-TF]G )QNPO0'T[P1\3KS6_B1XK\"ZSIL%GK.A6=CJ0N+*=I8+
MJVNC,J$;E4HZO;2J5.>-I!Y(4 C_ .%6W7_/]#_WR:/^%6W7_/\ 0_\ ?)KQ
MCQU\6]9^)FD_#_Q/I5K'HWAP_$RUT6VG2]D%Y=10ZA):S-(JJ%6.1X9!Y9+9
M4*3R=H[3Q'^TS+H?BW0+"TT[3==TS6?%+>%8KJPNIV6"?RYB&DF\@PEA)"4>
M)7+)DGYBI6@#L_\ A5MU_P _T/\ WR:/^%6W7_/]#_WR:\D\&_M7Z^_P5^&7
MB77="M;WQ#X\U=M-L+;33.\4*_OY&DD5(GD.R.!@%16+';DKEBOLWPE^(6K?
M$"RUTZSX8OO#=SI6IR6$;75O/%%J$01'2Y@\Z.-]C!]I!7Y61QE@ 2 5/^%6
MW7_/]#_WR:/^%6W7_/\ 0_\ ?)KT>B@#SC_A5MU_S_0_]\FO-=?^&]RG[27@
M6V^V1;I/"7B&0-M.!MO-%&/_ !_]*^D:\L\1?\G1_#[_ +$WQ+_Z6Z%0!<_X
M5;=?\_T/_?)H_P"%6W7_ #_0_P#?)KPGXE:UKLW[07Q8\/Z5?^-+N_@\'Z;?
M>'M.T&]NO+@U*5[U?,(W_9T#&*'(GQ'A3Q]ZNJM?VD/%?ASX8^,]?UK0+'4G
M^&T-O9^*I4O3#+>7L=C;W-^UJ@C*A4%Q\@8CS""/D&&(!Z9_PJVZ_P"?Z'_O
MDT?\*MNO^?Z'_ODURNJ?M&R:5\4Y/"VHZ=:^&[)[^RM--O\ 7VN+>+68YTC9
MI+:<0F#>I=T6 R;W>/!";@:7PM^T-=:_\2IO"&J:99^$]3.HWUE;:7KDEQ;7
M=Y#")/*N;9VA$-RL@1'V1.Q1')+$H5H ZG_A5MU_S_0_]\FC_A5MU_S_ $/_
M 'R:\&^&_P 0_%NH>/H-:\-6<>H+>?"3P]KTFE:]K<VUIGEO<DRB)M\S*D:-
M,4!.P$@]!?E_:AL]$&M_$^TTR_O=.UWP=X-O-.T)Y64_:M1OM1A0-M5]IYA#
MNBL2L0P&(44 >U?\*MNO^?Z'_ODT?\*MNO\ G^A_[Y-'PR^)NM>,O%'B31=7
M\*WVD1:7%:SVNL/:74-IJ"RA]Z)]HAC821-'AA\PPZ'/) ]'H \X_P"%6W7_
M #_0_P#?)H_X5;=?\_T/_?)KT>B@#SC_ (5;=?\ /]#_ -\FC_A5MU_S_0_]
M\FO1Z* /./\ A5MU_P _T/\ WR:/^%6W7_/]#_WR:]'HH \X_P"%6W7_ #_0
M_P#?)H_X5;=?\_T/_?)KT>B@#SC_ (5;=?\ /]#_ -\FC_A5MU_S_0_]\FO1
MZ* /./\ A5MU_P _T/\ WR:/^%6W7_/]#_WR:]'HH \X_P"%6W7_ #_0_P#?
M)H_X5;=?\_T/_?)KT>N;^)321_#SQ-)%-/;31Z;<21S6TS12(RQLRLKJ0000
M.AH YS_A5MU_S_0_]\FC_A5MU_S_ $/_ 'R:\3^%WCG5/#O[/.D_$BYL/%]W
MJ^C_  ^C\1WDFNZ[-+8ZU+]B$L@ ,TRQL64N#L4KO'RXR!WFN_M#:[H'BGPA
MX7N_#%L-=\36UYJ<+6,UU?P6UC D'SN(K;S&D9[A5VA J@$E^@8 [#_A5MU_
MS_0_]\FC_A5MU_S_ $/_ 'R:Y'PI^T/K_C36?"/AJ'P3-X>\5ZOI^I:I?6>O
MR2VZ6-O9W4=L74-$LDOG/-&T>53]VVXX("F'X:?M):GX[O?AU:3^'[2TD\7V
MFNS[X[QF%K)IURL(7!3YU<.ISD$8/!H [3_A5MU_S_0_]\FC_A5MU_S_ $/_
M 'R:\B\)?MF:EX\\NRT7P4\NLPZ VMW4"F[N8]QNKBWAMT:"V<Y<VKL9'50N
M5 #G..@U+]I/Q3)+<0Z9X&AL[N'P-#XTELO$-]+97-ON:19+.6,0.5D4Q$9Z
M9/3CD [W_A5MU_S_ $/_ 'R:/^%6W7_/]#_WR:Y'P5\<O$/CSXU:#H=GIMA:
M^%M1\#V?BLF:9C=*;F4J%X3;\NW&,X.2<] /=: /./\ A5MU_P _T/\ WR:/
M^%6W7_/]#_WR:]'HH \X_P"%6W7_ #_0_P#?)H_X5;=?\_T/_?)KT>B@#SC_
M (5;=?\ /]#_ -\FC_A5MU_S_0_]\FO1Z* /./\ A5MU_P _T/\ WR:/^%6W
M7_/]#_WR:]'HH \X_P"%6W7_ #_0_P#?)H_X5;=?\_T/_?)KT>B@#SC_ (5;
M=?\ /]#_ -\FC_A5MU_S_0_]\FO1Z* /./\ A5MU_P _T/\ WR:/^%6W7_/]
M#_WR:]'KP;]L[7;[PQ\*=)U+3M3U72YQXGT6UEETBYGBF>WFU""*:/$)#/NC
M=EP,GGY><4 =E_PJVZ_Y_H?^^31_PJVZ_P"?Z'_ODUY?IWQ&\5_"=_&VK7NG
MZSJ/@_4=<T31?!6G^([ETNWNKMTMYFDEE#SQV_G21L#,"XVR87!0'2\9?M-Z
MYX'\7ZIX5OO!SWFH:;)I\UYJFE?:+VUM;"[2ZVW<D44+3#;+:-$R!2!YB.7
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MY->CT4 ><?\ "K;K_G^A_P"^31_PJVZ_Y_H?^^37H]% 'G'_  JVZ_Y_H?\
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MF#@+@T?^&WO#7_1.?BQ_X0E__P#$4?\ #;WAK_HG/Q8_\(2__P#B* /3-/\
M@?X5T[PA?^%E76;GP_>V#:7+8WFOW]PBVK+M,2%YB4&WY<J00. <<52U+]G+
MP#JU]I5Y=:5>O<Z79VMA:2+K-ZGEP6UQ'<P)\LP#;9H8GRV22@R37 ?\-O>&
MO^B<_%C_ ,(2_P#_ (BC_AM[PU_T3GXL?^$)?_\ Q% 'J\WPA\,OXOOO$T$-
M_IVL:@T3WTFFZK=6D=XT:A4::**14D8*%7<RDE5"DD "L;4/@%X4BCT^]TO3
M;A-:T:[U'5-*F?6;V+9=WC-)<[Y%D+^7+(VYDY7G(6N!_P"&WO#7_1.?BQ_X
M0E__ /$4?\-O>&O^B<_%C_PA+_\ ^(H ]2^&OP]C\(WOBC7+FRL;/Q!XHU :
MCJ2Z<S/"K+#'#&BNRJ6 2,,6*KEWD; W5W%?.O\ PV]X:_Z)S\6/_"$O_P#X
MBC_AM[PU_P!$Y^+'_A"7_P#\10!]%45\Z_\ #;WAK_HG/Q8_\(2__P#B*/\
MAM[PU_T3GXL?^$)?_P#Q% 'T517SK_PV]X:_Z)S\6/\ PA+_ /\ B*/^&WO#
M7_1.?BQ_X0E__P#$4 ?15%?.O_#;WAK_ *)S\6/_  A+_P#^(H_X;>\-?]$Y
M^+'_ (0E_P#_ !% 'T57EGB+_DZ/X??]B;XE_P#2W0JXC_AM[PU_T3GXL?\
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M?4K5M6T.\MI+.YMM2GDNC/#("'1WD9F8$,1R3Q]*X.\_9;^&^J1/'J>D:AK
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M\.6'V2VFO;B/<7+W]]-=R$G'\<K,V..F<#TKP?\ X;>\-?\ 1.?BQ_X0E_\
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M(Y3M1%.Y3N5%5MP  \R_X;>\-?\ 1.?BQ_X0E_\ _$4?\-O>&O\ HG/Q8_\
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M\(V?A&VD@L[G5+I7VY;5-4N;Y^,XPT\CD=><8SWS6W7SK_PV]X:_Z)S\6/\
MPA+_ /\ B*/^&WO#7_1.?BQ_X0E__P#$4 ?15%?.O_#;WAK_ *)S\6/_  A+
M_P#^(H_X;>\-?]$Y^+'_ (0E_P#_ !% 'T517SK_ ,-O>&O^B<_%C_PA+_\
M^(H_X;>\-?\ 1.?BQ_X0E_\ _$4 ?15%?.O_  V]X:_Z)S\6/_"$O_\ XBC_
M (;>\-?]$Y^+'_A"7_\ \10!]%45\Z_\-O>&O^B<_%C_ ,(2_P#_ (BC_AM[
MPU_T3GXL?^$)?_\ Q% 'T517SK_PV]X:_P"B<_%C_P (2_\ _B*/^&WO#7_1
M.?BQ_P"$)?\ _P 10!]%45\Z_P##;WAK_HG/Q8_\(2__ /B*/^&WO#7_ $3G
MXL?^$)?_ /Q% 'T55'7-%M/$>C7NE7Z226-["UO.D4SQ,R,,, Z$,N03R"#7
M@?\ PV]X:_Z)S\6/_"$O_P#XBC_AM[PU_P!$Y^+'_A"7_P#\10!ZS!\(_"UO
M\+6^'*6%P?!S::='.GO?W#,+,Q^5Y(F,AE"[/EX?.*B\1?!OPKXG'AQ[VTO$
MO/#JNFE:A::E<V]Y:JZ!'03QR+(RLJJ&5F(;:,@D"O*_^&WO#7_1.?BQ_P"$
M)?\ _P 11_PV]X:_Z)S\6/\ PA+_ /\ B* /4M>^#OAK7IM$O+F#4'U70XYH
M]/U&/6;R&[1)<>9&UPDGF.CE4RKEA\JG&57'!_"C]FJST'X=^#=*\7)YOB'P
MQ<ZC+9:CH6KWD#1I=7$DCIYJ&)V#*R!E;()0'D@&LG_AM[PU_P!$Y^+'_A"7
M_P#\11_PV]X:_P"B<_%C_P (2_\ _B* .XTC]F;X?>'9M-FT;3-1T:YT^VDL
MH;G3];OH)C;O,TS0R2+,&D3S'=PKDA2S%<9-;FJ?!GPGK.M7^K7ME>3ZC?Z+
M_P (_<SG5+L&6QRQ\H@2XSEF._[Y+$[J\K_X;>\-?]$Y^+'_ (0E_P#_ !%'
M_#;WAK_HG/Q8_P#"$O\ _P"(H ].T?X'^#_#^O:!K.FV%W9:CH>DIH=E+%J=
MT!]A1MT<$H\S$RJ>1YFXC)YKO*^=?^&WO#7_ $3GXL?^$)?_ /Q%'_#;WAK_
M *)S\6/_  A+_P#^(H ^BJ*^=?\ AM[PU_T3GXL?^$)?_P#Q%'_#;WAK_HG/
MQ8_\(2__ /B* /HJBOG7_AM[PU_T3GXL?^$)?_\ Q%'_  V]X:_Z)S\6/_"$
MO_\ XB@#Z*HKYU_X;>\-?]$Y^+'_ (0E_P#_ !%'_#;WAK_HG/Q8_P#"$O\
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M .(H ^BJ*^=?^&WO#7_1.?BQ_P"$)?\ _P 11_PV]X:_Z)S\6/\ PA+_ /\
MB* /HJBOG7_AM[PU_P!$Y^+'_A"7_P#\11_PV]X:_P"B<_%C_P (2_\ _B*
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M+'_A"7__ ,10!]%45\Z_\-O>&O\ HG/Q8_\ "$O_ /XBC_AM[PU_T3GXL?\
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M_P IJ]5HH \J_P"$C^-__1//A_\ ^%Y??_*:C_A(_C?_ -$\^'__ (7E]_\
M*:O5:* /*O\ A(_C?_T3SX?_ /A>7W_RFH_X2/XW_P#1//A__P"%Y??_ "FK
MU6B@#RK_ (2/XW_]$\^'_P#X7E]_\IJK>&O#GQ$U[XR:)XN\7Z'X8\/Z=I&@
M:GI446B>(+C4Y;B6[N-/E#,)+&V"*HL6'!8DN.!BO7J* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(>HH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI.YH 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI!T% "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(>E+0 4444 %%
K%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%,D[44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>bcyc-20241231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '9 30# 2(  A$! Q$!_\0
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M6VN8TR3L\R)E++DDA6R 22 ": /SB_9X\(>(_P!H;]NGX^:-XXU?2;_5]?\
M!%]INJZIX9)EL+225+.%4A8GYO)XCY)R86Y/)K*T3]B;XV?#[PO>_#]?V<O!
M?C'6OM;"R^(=U?Q.BPL^2S1O*N[ W8WHI (&UL#/ZA_ W]FGX;?LX:5>6'P]
M\,6^@K>LK7=QYLD]Q<%<[=\LC,Y R<+G:,G &37I] 'FO[.'PNN?@O\ !'PI
MX-OFTYK_ $VV8W7]D6X@M!/)(\L@B0 84/(P!P"<9(!.*_/7P+\'_P!L3]G7
MXX?&'Q'\-OA;H>JZ=XSUNXN%NM:U.S<>0+F>2&1%6]C925F)(8$].!S7ZJ44
M ?"/[*G[&7Q0M?C]K'Q\^.FMV%[XYNK62"QTG36#K:EXO)RS* BA8LQJB;AA
MBQ;/7R+X)?L>?M$?#K]C?Q;X1M?#7A^T\4W7B<ZB_AGQ*FGZG;:M9?9H4PK%
MI(HY!(F5W%?NGD?*:_4NB@#\H/@S^QU\6M:_:@^'OC>S^#NG_L_Z/X?NXKK6
MY]-UPSQZB$<-)%'#YTA59%!CVJ F'.XGBN3_ &*/'?QQ\!^+/CW=_"/P)IGQ
M#M)-?\N^T^\OEMIK6<RW/DS)N90Z8#AU!SPF,#)K]BZ\X^$?[._P^^!-[XDN
M_ WA_P#L.X\1W*W>J/\ ;;BX^T2J7(;$LCA.9'X7 YZ<"@#\ZK;_ ()]?&"R
M_8O^(>G7.CPZI\4_'/B.QU:YT6"^MD%O#"[M\TKR+%OW2RL0K$8*@$G(&I\?
M_P!D?XOZAX]^"/B*Y^&R?%WP?X;\'Z?I%_X)DUR.S2VO([8QRJS;\8\PH_F)
MO#>6%;Y0,_J110!^<'[%?[+_ ,1_@?\ M;>-OB-XP^'NC?#?P%?^')X88]-U
M>VFLK M):2B$_O#)\JQ2!W*A2RL0=I7/B/[/G[.EAXG_ ."D&J^$-#U6WUWX
M6>!=:N/&%NEA,LUE$\BP-#$K+E2ZR?9XV'.1;,.QK]=?&/A'2?'_ (3UCPUK
MUI]OT35[26QO;7S'C\V&12CIN0AERI(RI!'8BN/^"O[.?PX_9VTN^T_X>>%;
M7PW!?.LET\<LL\TY7.W?+*SNP7<V 6P-QP.30!Z11110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7"?'K_DAGQ%_[%S4?_262N[KD_BYH=]X
MG^%/C31M,@^TZEJ.BWMI:P[U3S)9('1%W,0!EB!DD#U- 'Y5_L$?\$]_AA^U
M'^S;=>*/%$VMV/B(ZM=6,=YIEXJ+&B)&4/ELC*<%SGUK \!?$KQ!X7_9S_:I
M^#/CR;_A8>B^ +FUCL8-2N9UC_<ZJD#H'1UD6,O'%(J!P%(8=&(KT+]G?X>?
MMU_LZ_#.7X?>$/AGX;T[3+B[EO!JVIZA93W%O)(JJ6&V\*D#8" 8F_&NTT?_
M ()U>/? 7[)'QJLKB[@\;_&/XA?9))H;6Y5(E\N\29D$TQ0,[%I'=FV@D*!G
M&6 ,N;]N?6OV>O@;^S[X*^'G@[PWIVH>*M"2^CNO$FH2QZ1IZ/.Z[#))*K?>
M#,S/*-H*]<\>Z? []LSXB/HGCR_^-7P_M-&TCPQI<VK)XM\(R_:](OTC56,$
M3^9(ID8,"N)"#\P(4CGR?Q_^S=\==-_9[^">C6/P_P#"GQ!L/#FD)::_X#\0
M0V<EQ%.&8M);W9;Y=R$*?*E!!12 V2!QW[._[ /Q#\1^,/BG>ZYX2C^!W@3Q
M1X<N-'M_#-MJYU',\BH(Y"#(Y*)(ID^<@Y(50%)( .X\._MT?M2>.?!*?%?P
MO\"]%UOX62WC0P:?923W&LSQ+*8F9-DA+ ."I80'!!.-H)KT+XY?MY>+[#QO
M\.OAM\(OA\=5^)GB_3(M6?3O%B26HTN-T=_)GBW(WF*L4K/EE"A 1NW<>2_"
M[0OVU_@;\)=/^"?A+X>Z%!_9MW(ECX\;4;:6"*V>X:9R8I&.1EW&6CW!3@)N
M -=;\>/V9?CCX*^/7PS^/G@.+3_B?XUT71X],\1Z=.\5A]MF$4D4L\2DH@1D
MF8!0=RE$.'R0 #:^&G[</Q9U;Q=\1_A)XU\!Z)H?QLT#19]6T:WLGDETW4VC
MB658-HD9@71E*L)"#DYVE<'*LO\ @II>S_L*7OQBETC1U\=V^N#P\-''FBS:
MZ+B1>-_F8^RDO][ED/..FE^S%^SW\6_&?[7/B#]HGXPZ!9>"+I['[!I/ARUN
MTN9%!B6$.S(S *(U;J0S,Y.%  /B6L?\$W/B-=_M?3Z=#I /[/=YXLC\332_
M;K80A0C2-#]G\SS<Y=[<$)T(/3F@#V#XM?\ !0?X@> X/A=X%TKPEX=O/C-X
MLTB#5]1@U*Y:TTK25F#.D3[Y5.\(K%MTJ@;>,[@!/\'/^"AOB[5]<^)'@/XB
M^'/#NF_$+PWX>O-=TVZ\/7ANM*U#R+<S>7E99#G;ALK(<@.#L9<')_;P_8R\
M8^-OCYX:^,G@GP=I'Q-M[:S2QUGP9J\ZPK<A!(JR*S,@(VR#@-N5HU(#@D#F
M_@;^R%\2M0U7XC>+=6^$OA+X56EQX9U+3/#_ (9TOR9KZ6YGM'A7-SO;8AW-
MDNRY+#@+S0!-\"O^"B?Q^_:$L"_A7X0Z9=0V5MJ#:AKB6]T]@+J.UEFMK9?W
MHPSLD2$ER?WP^4<%N@N?^"GFH+^P_8_%J'1M'D^(%QX@/APZ*!*;07 8RD[0
M_F8^S;6^]]]QVXKUW_@G3\'O%7[.?[,1T#XAZ7%X8U:#4[R_N(Y;R"5$A(0B
M1I(G9 ,*<Y;@#G%?#?PY_9WTWQK_ ,%,=2\$^'M7M==^%V@ZV_CB2'3IUFLX
MB4BE6+Y<J2)GBA(R?E4^XH _6_X?7GB#4? OA^[\5VUK9>)KBPAFU*ULE80P
M7#(#)&FYF.%8E<DG.,UT%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJN]"1D=QFC3O%NAZOK>I:-8:SI][J^F[/MVGV]U')<6NX93S8P2R9'(W 9H
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M?%FUB\2^)=7B%WI^CWH\VPT:T?YHH8H6^4OM*EF8$Y]P6;I/VP(DUOX ^,M
MM[J!=9O-.>XM;-I )KA8&6:41IU8A(V.!7HWPW\36'C/X?\ AW7-,9#87]A#
M/$(SP@*#Y/8J<J1V((KVZ52>%P+JT':4I.+:W2232OTYKN_?EMM<X)Q57$<E
M35))I=W=Z_*R^_T/&_VM_P!F'P5\7O@U?Z?-86^@7>GNE[::AI=I$DL;J"NT
M_*-R$.<KD= <\"NA_9T_9W\&_";X,^'?#MIIEOJR?9A<SWNI6T4DT\DO[QBW
MRXP"V .P ZG).;\;?BA=:M:7?ASPQ:RZ@A/EWMY#&70?["D<9XY/M6K\%OBE
M/<6=EX<\1V\FG:@B"&RGFC,:W"J  G/&X< >OU^]XSG)N[9Z$7R_#H4?B#X&
M'P:E;Q]X'A.GVUJRMK6@VYVVU[;[OF94Z(Z9)&  !GW#;?P[_9Y^%/A?Q-?>
M/O"WA'3[/5_$,/G2WR!V#QRD2'9&Q*1AC@D(JYKH/C;K=IH/PF\57%XRB.33
MYK9%;^.213&B_BS"K_PNTBYT#X;>%].O RW5KIMO%*K#!5A&N5_#I^%=E23J
MT(U)[IVOW5E^7Z^AZ5:4JV&C5J.\DVK]6K)_.WY.VR1@?%/X-Z;X\T@FTAAL
M-6@7]Q-&@56_V'QV]^U5?V<8'MOAR(I/OI=RJ<'_ ':ZSXE^,'^'WP[\3>)X
MM.FU>31].N+];"W^_<&.-G" X.,XQG!QZ&OC;]B/]ML>-O!_B&T\0>$K^VGL
M;T/;SZ) ]Q%<"0$F/!/RNNT9YP0P.!WXXQE.2C%79P0IRJR4(*[/K;XWS6<'
MP@\8-?A3;G3)U&[_ )Z%2(\>^\KCWQ7DO@;3-0^.=MINB:G=7%KX+\-6%G9:
MA:PNT;:I?+"AD1V'(2,X!&>3@CJ"O23Z9XD^/>J60UK1I_"_@"SG6Y:POOEO
M-4=3E!(@_P!7&#R1W[$\%;O[.1&GVWC?1)V U.P\173W"'J5DP4D^C!3CZ5Z
M\/\ 9Z$DG>:U_P -]/O_ "NNNWOP?U3"R46G4B[Z:\M[*]^^G3:ZZK3K;KX,
M>![KP_<Z,?"NDQV5Q UNX2SC#[64J3OQG=@_>SG/-?,7['O[#'@CX2>*/'&J
MWLJ^,9X;Z32;./5[&)H[:%&5MP!W R'@;AMX!P.37TY\3?B;9_#S2\[1=ZM.
MI^RV8ZM_M-Z*/UZ#N1XE\)?C)>^&]>U!=?A+:=JERUU/<1Q_-#*W5\#JIXR/
MQ'H?*]I/FYN9W]3YZI*57^([^NIW'Q)_98\*>)HO[5\)6T'@#QM:#S-.U[0H
MA;,D@Y E1,+*C=&# G'&>U;G[/7Q0OOBAX$EDURW2R\5Z)>S:-KEM'PJ7D)
M=E_V6!5A_O$#.,UZ5!/'=01S0R++#(H=)$8,K*>001U%?/\ ^R]-'K7C'XT>
M*;1E_L/4_$[0V<H/R3?9XPDLJ^JEC][O@U[$:M3%X*JJ[O[.SBWNKNSC?LU=
MVZ<MUN[^:X1HUX>S5N:]UZ*]_5;7\_0^A**0$, 0<@]Q2UX9Z 4444 %%%%
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ME%1;T6WYG=?'1[^/X)^/VTO(U(>'[\VQ7.?,^SOMQCG.<5S7[(]GH]G^S/\
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M'XTL[!I5X8V=Z&AN(\^C#9^5?2=?.'[=7_)-O!?_ &/&B?\ I17T?0 4444
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M"/WL^D0:C<OU+SW"^?*Q/4G=(1D]@*G_ &M/^38OBI_V+5__ .B&K?\ @/\
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MGP+#&^G'7)/LPL_MS$2^9LSOWY7;C& #FH;/Q3\=!^V1KMW_ ,(+X3_X2UO
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M^*NAR26'A_PWJ][HJZI,+._UZWN[N:YBV6QBBR\,4T:,9+G,DJML:,C>5VY
M/JBBOF'6_BE\<M+M(GC\,Q3K=1_:?/CT:X8V;;KM4MFC5V:3>8;;+C&T3'(
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M1I,;B%GP"<=Z^GZZZ<7&$8OHCR<1-5*TYQV;;_$**SO$7B"P\)Z!J6MZK/\
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M]*HHH \F_:T_Y-B^*G_8M7__ *(:J_A?P3%\2OV1M$\)SR>3'K?@FWT\R_\
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MSX3^(?Q?\.W'B3XJ6W@?2+GPCJNDW%K9:I;VU]?V]P\+R8,T;IY!B@F#-PW
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M^'__ $/7AK_P;V__ ,71]5K_ //M_<P]M3_F7WG8T5QW_"YOA_\ ]#UX:_\
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MX5?]$S\'?^""T_\ C='_  SQ\*O^B9^#O_!!:?\ QNO0:*\_Z[BO^?LOO?\
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MO_!!:?\ QNO0:*/KN*_Y^R^]_P"8>PH_R+[D>??\,\?"K_HF?@[_ ,$%I_\
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M>X(/ID8..:Z.N>47"3C+=').$J<G":LUHPHHHJ2 HHHH **** "BN>\=>/\
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M?7<-_P _%]Z/<J*\-_X;*^'7]WQ+_P"$W??_ !JC_ALKX=?W?$O_ (3=]_\
M&J/[)S#_ )\2_P# 6'UW#?\ /Q?>CW*BO#?^&ROAU_=\2_\ A-WW_P :H_X;
M*^'7]WQ+_P"$W??_ !JC^R<P_P"?$O\ P%A]=PW_ #\7WH[GXV_!KPW\?_AE
MK7@7Q9%/)HNJ(JR/:R".:%U8.DD;$$!E901D$<8(()!C^!OP3\,_L\_#+2/
MOA*&>/1].#$2W<@DGGD=BSRRL  78DDX  X    '%?\ #97PZ_N^)?\ PF[[
M_P"-4?\ #97PZ_N^)?\ PF[[_P"-4?V3F'_/B7_@+#Z[AO\ GXOO1[BRAU*L
M RD8(/0UX7^SW^Q?\-/V9/%7BSQ!X)L[V&^\12?O%O+@2I9P[BXM[<!05CW8
M/S%F^5<L<"G_ /#97PZ_N^)?_";OO_C5'_#97PZ_N^)?_";OO_C5']DYA_SX
ME_X"P^NX;_GXOO1[E7EO[1W[.'@_]J/X<MX-\9I>)8+=1WMO=Z=*L5S:SH"
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M_$E$U>[UF[\1SZ98:>B6<1CMI;J*"XG"D./E0 R/O=B3T /T\\2?$CPSX/\
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MIH(9B!M7='(&VY7!&XY /M>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &B-!(7"J'(P6QR1]:=110 V.-(E"HH11V4
M8%$D:2@!U5P"#AAGD=#3J* "BBB@ HHHH *1E#J58!E(P01D&EHH :B+&H50
M%4#  & *=110 QHD:17**77.UB.1GK@TYE#J58!E(P0>AI:* &A%5 @4! ,!
M0. /2DCB2% D:*B#HJC %/HH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>bcyc-20241231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &K ?,# 2(  A$! Q$!_\0
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M[!GA=?@[XOT7X1>&[/1/%'B"6R^T37FH7!BECBNTG8$NSA3\I(P.O%</X_\
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M5O8\U>KYL_8"\&7VA? 2'Q/K,3)K_CG4+GQ3?,X^=C<ONCS_ -L]A_&OI.F
M4444 %%%% !1110 4444 %%%% %>]T^UU*(1W=M#=1@[@DT8< ^N#3++2+'3
M=_V2RM[7?][R8E3/UP*MT4 54TNRCM'M4LX%MGSNA6)0C9ZY7&*X/XU?":]^
M*O@!O"FC^*[[P+:SR;;JYT>",R36Q5E> ;AA V[)(&>/K7HU% '-?#GX=Z'\
M*O NB^$?#MH+31=)MEM;>(G<Q4#EF/\ $S'))[DFMF/1["*VDMDL;9+>0Y>%
M8E"/]1C!JY10!5GTJRNH(X9K.WFACQLCDB5E7'3 (XJR%"XP ,<<4M% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^)NCZAN_L<7?B( XWZ3;F:+/IYO$?_CU1I?>,]9G(@T[3_#UD>DU_,;JY/\
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MIY&0>17SU\'3DH-P X)KV2;09].E?6M CM;6_:1&OTDC;;>PKG<#MR0X!)#
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MR*,YD192&*Y&.0,]LBM71O&L&IZI>:;/9WNEWMLX4+?0[$G!W;6B?)5P0K'
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MS[G^#GCYFACC>0E<C.2?5O>OK3P)K"7%FK*W)YY^@K\^?AA<+#=Q('"DL/\
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M'7>']3N6B4;L#UQ[FO:?AMXHO;&:-5D&TD=5_P!VO*/#VE+* @7:?8?6O5/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M(WW3]*YS6HC(K'K712?=-8EZ&D8C'%/H-'@GQ+T426<VU.2IY_X#7S-KOAJ,
M7SF1 Q+'K]?K7V_XHT5+BUERN?E/\J^?_$G@\3:I+\I4;F]?7Z5S25F=$7<\
M"O?!,5P^Z./;CTY_K61J_@V,VK!UP5XSC_Z]>X76@FUF*!"?P_\ K5S.OZ6J
ML0ZG![#CO4E'R]<>%HEU0%_F (X(]OK7K/@?PNC6R,HV*!Z9[#WJW?\ A&U,
M_F*&#=>3_P#6KI?"^GSP*%&T1CCH?04Q6)[/1B'(0X)[XKI_#&G/;W7[QB1G
M/(]Q4^G6().S'U-=#9Z4^U#&-SEAT!Z4AGLGPA+&^4 ?+D?R:O>$^XOTKQOX
M0:7)%LD=2#QV/^U7LJ_='TKHAL<\]Q:***H@**** "BBB@"-OO&C/-/*@FFD
M '\* &]R/2N?\22*%"YKH <DUR7B-B;@CBA[#CN<]<_O/E''I7F/Q7T*2^\/
M38&>#7JK[&=01^(K%\3Z?'=V#Q 94C%8O4U3/RM^+'A&=-5F8Q?*">U>8W7A
M&.<Q'RB3NYK[[^)_PH.HR2M#&.N<D5X?J_PX@TB4F=E3;U)Z5-RFKG*?"#P8
M\5W"V D8/0U]?:+96<6B+'*RE]N,5\<:W\9=)\"-Y4$@>[C."L?-8EK^V-J"
M72F6W<PYZYZ"BS872T/HGXL^ _[1TV:2%%R<]J^.M4^'[V>K2DH  Q[5](>"
MOVE=(\8H;6YDVR-QM<XJY?> HO$6^XM@K*Y)R*2T&TF>#>%O";F2,D;TSR!7
MVY^R[X7%@RR(A4'GFO(/ _PNN?MYB,9"*<YQUK['^$OA1=!L$)0 X':GN&R/
M:-+AWPQ <;:Z^ 8B4>U<EI0)=/Z5UZ#$:_2MUL82)%.%-,)R<TJ\\=J<4&*9
M(RGJ.,TU5S4@&!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ,?GBJ-S&%!P :MOP>M12?,/<U0'-WMOYH8,
M!@UYYXF\-"6Z+HBC.>F/6O5+R @\?RK,N;'S@!C\36;C<T3/!-1T-8G;=&I8
M]#^%<K?>#OM]RQ<#;DX'![U] ZEH4,K8V9/U-8USX8."4&/P-9.)I<^8O%?A
M(:=*2B@#T&!V%8NF^:DFS>0/0&O:_&^C;V*$98?X"N*@\%EW,I!'/O4%$WAR
MQ,RX8GGC^==[X=TC;=1C[P)'!^HK$\/Z,T#98$ 'CK[UZ3X2T9YKA' _SQ32
MN)GJW@[2TM;5'50N>P'N:ZBJ6D6[6]E&K=0/ZU=KI.=ZL****!!1110 4444
M ,+$&@FG%0:93 3. :X/Q/>$7+J<5W-PX2%C[5YCXA5YM0. 2M3+8J)##>-(
M,%@*=/(#"P8Y7!JO#8@84D@FI-1A%M:.,\[>]9FAY!\3/$$>C6$\K[<!2:_.
MO]H3XVW%]?2Z=I\FUB3N=>PKZI_:F\;?V%I5T&8KA#7YIZQJ+ZIJ5Q=.Q9I'
M)YJ8J[N$G96*TL\D\ADD<N[<ECR:9BBBM3$EM+J:RG2:"0QRKR&!Q7UO^S%\
M7VU2=-+OF#3 @<GK7R'7:?"#67T/QYILRD@%\'!J6KHJ+LS]=?!&AV=W'&^P
M!R 3@5ZQI]E]F2-57 KR#X+7#:KI=M-DG(!/Y5[O:0;HU!&,"IB:R-/36VRH
M!771_P"K'TKB[1BEPG2NRA;=$I]16RV,I$R#O3J:G2G4$AC%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113
M)G\N,F@"J\N)""1FE.2ON:P;W5/+ER.N:T-/O/M,()Z\4TPL69%#@@U3EAZX
M%796"\]:KRL6''RTV",A[10S,P!..]9-VCDL%^5>>E;E\PAC)SDUES-OMF;'
M-9LT1Y7XOL?.N@ !U_H*BB\.%[--H&< G\JOZI</<:CL XR/Y5O:';M*53&!
MBLK:FFQ@6/ATE5"C![UZ/X/T/[,!E1ZY_*FVND"*3@<FNMTJW$$.<<__ *JT
MC$SDS4C&U OI3JCB.:DK0S"BBBD 4444 %%%% !3&X:D)^:E;J: *FH<0&N7
MN+(3.[ 8;Z5TFI9\H5F*N,T/4:,5+$&0;@..]97B*V(B< \8-=7Y&\UD:[!F
MUD 7)Q4-%IGYO?MSL8M&N @^8=37P >U?IE^V=X%FU'0;J14+9&37YHSQ-;S
M/$XVLC$&IB$]R.BBBK,PKJ/AE8/J7C?3($!),F:Y>O>_V2_AW<^*/&\-^T3&
MVA( ;'&<U+V'%79^EO[/FG-;:+;PG.0H_E7O$7F)%MVY]ZX?X7>&O[.M5&,?
M**](%NN!D\BB*T-9/4Q \B78ZXKO-+E\VT0\DBN/N;7S+D$<<]JZS1(MEN!5
MQ(D:*=*=113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K-UJ9HX"%ZX_K6E6?JT7F1'Z4 <9*K3GKS6GI$
MWDC8V<BF16&)"<U.(5@?H#4HTN:DLH '=JJ-<$/AJ5YAW'XU5N"#\V<FJ9*0
M^^&8RW4"L2[O0D#9P!5U[\("C_,#QS7+:W>B(R'^').*ALI(Y2><R:C(^!Q@
MCCVKL/"TN]=S+QZX]A7G]G=&YU%L#"Y'&:[[3+A+:S&T8/?\JS1;.MM\2RJ5
MSBMZW0+&!7.^&\W$>X]?_P!=:U]>&T08%;KN9/>QK6[C.,U8KFM+OWGN!S@>
ME=(O(%/<FUA:***0!1110 4444 ,*DDTF*D-,))/H* *6I?ZKI^%8[/AADX]
MJVM20F XZUS$S,Q8$].U#*1H!LBJ][#YT!(&34$-R^,$&K".S#CBD/8\5^+G
M@=-?TJXCDB# @\&ORP_:(^!MYX6U^XOM/MF:W=B61%Z5^T>MZ:E[:R1L <UX
M3\1?@U::XLC2Q*P;U'%9--.YII)69^+#QM$Y5U*L#@AA@BDS7Z"^-OV.M*UK
M4GDBM%C;/+)QFH?#7[$6DB='DM00#R'R<T^9$<C/COX9?"35_B+JT4-O"\5K
MD;IF4XQ[5^FG[.?P-M_"5C:PK&(F7&YL?>]ZZGX8?L^Z?X6B40V:JH P0*]Z
M\/\ A^'3HU C"D#%+612M$T=&T\64*!.W&:UF3<V:CB1E0\X%21\5J0,6%#)
M[UT%E'Y4*BL>VC\R;@9K>4848["FB629HIB @T^@04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S(&'-24U
M^:8&085\_ !I)X #P#4\F$G^M/*[SR,TP,2^B?;\O;VK/>Z\A,-^==#=[0""
MH_*L'5D2*$OM!^HJ'H6F8D^HM*Y P![USVMQ"56Y)/L:DOKAI'Q$Q0G^[Q1$
MT>S;-^\;U89K+<T,31+(I*6=3CCM7:Z79K<8_NCMFL.95ME+( %'(Q5C0]8<
MS[!P,]L^U"T!ZGI&F*EG!L0<_P#ZZI:U<D$<9_R:FL)BX!J.\B^T28VC\JUZ
M&749H:M),&''U_&NNC^X*P],L?LX!'%;D?W:?03W'4444""BBB@ HHHH :YX
MQ312LI)--Q0!%=C]P^>F*YFR N+]UXP372ZBX2T;GM7.Z#$QORQ' H&MBY?Z
M25&]3QCM5.WRH*GH*ZJ1-ZXQQ6#J%FT3DKT/6BP)E"9D96!.:Q+ZV2="K 8]
MZO7)*2'!XJA>L=N!U-0V6CEIM BN+EO+0 9[5L6.@6\:8:(9]<5.MLR@8'S'
MFKT>?+  YJ2KERSM52WVJH %6@!%'SSVS4.GLY5ESCVJ=@) W&?>K1#*EQ.Z
MN%#_ )58MI6D'+5GR95B2,$5KZ+8F<;L<4+<;-C2H<C=C\:TONG%1PQ")0J\
M5*%YR15F8ZBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %(W2EI",B@"C+&'<-T.:E *BFN"'HE8A<"K$
M5KN R+E>HK$U6W=K<J#\W':M\2<>]8NJ2L';&,5#*1Q<&E&%V>7H.>14<MM
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M<^M8RC?4UC*VA\>S"ZMH0CC<?4FN^^%4=Q/=J&'R\]_85ZKJGPJBG((C(/\
MP*M[P=\/UTMU.P\?7T%9J+-+H[G0M-"V\>!QZ?C76VD CC'&.*KZ=9B*(9'2
MK^,"NA:'.W<BDDVL%J1#E:K.Q:;%6E&%%,D6BBBD,**** "BBB@ HHHH *#R
M*** *SQDN.XI4BVMGI4Y&:-HIW %/%+2!0.E+2 *QO$AQ;8Q6R:Q?$.&@(-
M+<QO#H\VZ#$#CBNR P*Y+PX@%QQ77=J2V&]Q%YYH^\*4#%'2F(*:ZAA3J",B
M@#-N[<-VJ6P78-I%3RQY-)#&0Q)J@)Z***D HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1NE+37^Z<=: *N
M?GXQUZU;7[H^E5H0"WO5JFQ!5.ZL8Y3N('Y5<J.<XC)H&<M=PIYI 4?E6GI-
MDA4$J/RJH\*M-GWK=L8PD"TALG50HP*&. :6FOTH$5H_FE!%6ZAB4!N*FIL0
M4444AA1110 4444 %%%% !1110 4444 %%%% !FL#Q5-Y-N,=ZWC],US'BZ0
M[ #TH>PUN5O",IEF)/I78UQ'@SF<XZ5VP! I+8);BT4@.:6F(**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>bcyc-20241231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %C P0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]Y!:QQ32YSO<* 3^=:E><U9V.U:H****0PHHHH **** "BBB@ HHHH ****
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M:*0&EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#6N5;3%X.C47^#E?WIGQ_!^W1KFF((-9^'MY]I3AWCWHN?IM-:UC^WWH'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)5W(RNOJIR*=SZ5\<?\ #,_QL\*PLF@?$3=:J?E@6XD4D#IVQ4$>C_M/>&W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT445P'8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]H2R7\6PYVQN1@'\J]S$PA+"TZB>JT_KT/)H2DJ\H6T>I]!4445XIZ@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !11D"@'- !1110 44F\>M&X>M "T4F\>M&X9ZT +12;AG&:
M6@ HHI"P'4T +12 @FEH **** "BBB@ HHHH **** "BBB@#$\67%E9>&-7N
M-27S=.BM)7N8_P"]&%)8?EFORAMOV,O!7CWX9:Y\9M%\0:_:> X'N+DZ6R+]
MI^SJY\Q8STV]<>U?JUXST%_$_A+7-'1]C7]G-;!ST!="N?UK\V=&\,_M4?#S
MX-:E\#=,^&L.H>'G6?3X==!7'D2,<MG=[GG%2QH^[_V6=6\)ZU\ _!UQX(MY
M+3PT+)8[6"8YD0#@ASW;U^M>K5Y#^R?\(K[X&_ ?PSX1U.5)=3M(=]UY9RJR
M-R5![@5Z]5(04444 %%%% !1110 4444 %9GB/Q%IGA32)]4UB_M],TZ#!EN
MKIPD:#.!DFM.H+VPMM3MFM[NWBNK=_O13('5OJ#Q0!\;?LJ^(-,\4_MK?M"Z
MIH]_!J6G7$&GF*ZMGWQOA<'!'7FO<?VJ-)74?@SJ\IY:T*S+_P!] ?UKQG]F
MBRM]/_;D_:)M[6"*UMT@TX+%"@15^7L!Q7T/\=;+^T/A+XD@ R3;$_D0?Z5P
M8^//A*L7_*_R.W 3Y,52DOYE^97_ &?M3;5O@]X;N&)+& H<^S$?TKT4=*\9
M_9,OOMGP<L(L\V\KQ_KG^M>SCI2R^7/A*4O[J_(K,(<F+JQ_O/\ ,\*_;;T@
MZS^SAXGB"[O+$<W_ 'RP-2?L7:R-9_9T\)G.3;1&W_[Y)_QKM/CUHQU_X,^,
M;%5WR2Z;-L'^T%R*\0_X)RZXE[\#9]*=O],T[49ED7T!QC^1KZ%>]@VNTOS1
MX;TQ*\T?5E%%%><=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 444C' H 6BO#OCK\1_BOX0UVQM/ '@(^)[!
MX?,GO-X^5\_<P2*\S_X7G^TK_P!$@_\ 'E_^*KKAAISBI)K[T<TJZB[6?W'U
ME?ZC::8BR7EU#:HQVAIG"@GT&:L0R+*@=&#H>C*<@U^4O[6/C?XM>)-<TR[^
M(&C7?A.U$>RSM(V*Q,<\MD'EJ]4_9W^*G[0'ASX9V5IH7@.Z\4Z,)':VOKPX
M?;_=^8@D#M79++Y*FIJ2OZZ?><ZQ:<W'E9^A-9_B+5U\/Z!J>J/&TR65M)<M
M&IP6"*6('UQ7RD?CG^TKC_DD'_CR_P#Q5>S:;XD\3>*O@-K]_P"+_#Y\,ZVV
MF7BRV)?=@")L-[9]*X:E"5)7;7R:9TPK*;LD_N/E*U_X*YZ!/:_;6^%GBA-*
M639+?K)$T4?."21_*O9/B5^W/H/@[X8>%?'GA[PKK/C;1M?#>6-,4*]O@<B0
M-TKX#^&/A#XS^)_V*_$XT)O"\7PXB:XN+IKF/&HD(=SA7QCZ5]R?L ^(-%\8
M_L;:8+'2%LX=.BN+-TGQ(9)$7YI,D=\UR79TZ'FFD?\ !6S2?$%T8-/^$GBJ
M]='"2""2)_+)./FQTKWW]H+]L[PA^S[HFBOJ5E>ZOXDUB!9[/P[8 -<E2 3N
M/1<9QSUQ7S%_P2QLK>Y^('Q@$T$4@6^;&] <?O.U3>&7CNO^"JFNP^-1 46P
M9-#CNP"I&U?+V \9^]BBX6/H+]G/]N;PS\?O%C^%W\.:UX1\2",S)8ZK%_K$
M'4AAP*^F9)%B0N[*BCJS' %<K<P^$;3Q9ID4\>EP^(VW&T151;G&/F( YQCU
MXKS?]N"YFL_V4?B-/!+)!,FFL5DB<HRG<O0CD50CVX7MN651<1%F^Z-XR?I7
M@/[1O[4$WP.^)/PY\+QZ,NI)XJNS;O.7VF  @9'KUK\\-<^"NO>%OV0_#_QV
MC^)NMC7[$PO9V$URP3'F!0JC/S8Z]^E>R_M+>)[[QSXO_9/UW45/]H:A*DLV
M1@ESMR?QZU#>A21^DOVN"W"^;+'#N .'<#^=6$=9%#(P=3T*G(-?EO\ M5Z:
MW[1/[0OB72/ VK^(_$FL:%:JMWI-E<FSL].V<.V\'YB6QD8KH?V.?B)\5?$W
M[)/Q.T+0]6DO/%FBW,EEI$MU,&EC/0QH[<$CG&:?,*Q^D:W<#RF)9HVD'5 X
M)_*C[5#N=?.CW(,L-XRH]_2OQC^&<.J?#GXN>'S\4?$_CWX?>/[C586:XF1I
M[6]S(,JV3M ;H<>M>K6?P^UWXV_MH?&SPW9^.=7\,Z9]G#S"QF8^='M^X,GY
M1],4<P6/U&-U"(?.,T8B_P">F\;?SI_FH(_,WKLQG=D8Q]:_'WX*>"_&7QL^
M _Q.\/W_ ,1M8L="\ 32/:VT#MNN6PS#S'SNP-N ,]Z]/T'XP/J__!-?2/\
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M;+U+X\>+O$?@CQCX7/A/QAHB;Y+7S,EP/O KV(X_.N1^)/\ P45ATGXW>&?
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MZU5;..YRAXV%7! R2.17HL8VJ  % X %<=\8M/U[5/A[JMMX9&CG6G5?L_\
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MTOXF_%/0,X%O<F39Z8D*U]P5ZV.5L1)]]?P/-PKO204445P'8%%%% !1110
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M?11BI**!B-G'6F\X[FGT4 >.VG[+7@2R^/=Q\88[6]'C6>,Q/.;MC!MV;/\
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M&O\ P8Q_XTG_  U3\'O^BE>&O_!C'_C0!ZI17EG_  U/\'\9_P"%D^&L>O\
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M^O69C*F[B*$*H'.<-@]J^PJ*!G@B_L)?L_Y/_%IO#G_@,?\ &@_L)?L_D?\
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M/PF%OX7_ .$6^$VB^9_;MK_:'V:WQ_H>3YN[)^[TS7UBQ(QR>:,DD4 >%_\
M#"/[/N3_ ,6G\.'_ +=C_C2_\,(_L_#_ )I-X<_\!?\ Z]>Z<_G2J"&Y- 'S
MIXL_8(^"%_X6UBVT?X6^'+35IK.:.SG-N5$<Q0A&SGC#8-<]\'?^"?/PH\._
M#70-.\;_  Z\-:QXJ@MPM_?+$7$LG=LG&?RKZPI"H/84#/!U_80_9^(!_P"%
M3^'/_ 8_XTR3]A']GX8Q\)_#G_@,?\:]\HH ^.]+_P""=OPYA^/&L:W=> ?#
M4OP^FTN&"STGRR3%= GS)-O09&.<UZ7_ ,,(_L_?]$F\.?\ @+_]>O>:,4 >
M#?\ #"'[/W_1)_#?_@-_]>O*/CG_ ,$Z/ ?B:_\  S^ ? WAK0[>PUJ.YUQ&
M0Q_:[(?>B&,YSZ<5]H44"/!1^PE^S]V^$WAS'_7L?\:4?L)?L_'_ )I-X<_\
M!C_C7O--?H*8'RW\6OV$?@Y_PK+Q/_PB_P )M#_X2+[!+]@^S6^)/.V_+M).
M,YJK\%/V$?A#_P *E\)?\)?\)]$_X2C^SHO[2^UV^9?/Q\^X@XSFOJSD]^#2
M\@4AGA/_  PA^S]_T2?PY_X#'_&F/^PE^S\#_P DG\.?A;'_ !KW8DY.21WJ
M1<,N:!'Q]X4_X)V_#JS^-7B_6-7\!>&KKP)=V5O'I&F>62;>92?-8KVR"._:
MO2O^&$/V?A_S2?PY_P" W_UZ]YQ10,\&_P"&$?V?O^B3^'/_  &/^-<?XX_X
M)^?"/4M7\*2Z#\-_#=C9VFIB?58S"5^T6OEL"@'?YBIQQTKZIHQ0(\%7]A+]
MGXC_ ))-X<_\!C_C2_\ #"/[/W_1)O#G_@*?\:]YHH&>"2?L(?L_F-MOPG\.
M!L'!^S=_SKD_A;_P3]^$.A^!M-LO%OPX\-ZKX@C#_:;I82XD)<E>>.BD#\*^
MIZ0@8H$>#_\ #"'[/W_1)_#?_@-_]>FM^PE^S\#_ ,DG\.9_Z]C_ (U[MGU)
MH()]30,^)/ _["/@'_AI#X@_VS\)M+_X0#[):?V*9H0;;S=O[[8,Y!SUS7LH
M_81_9^_Z)-X</_;L?\:]VR6QS1T!P2/>@#PK_AA+]G\_\TF\._\ @,?\:\X^
M*7_!/'X;:WXA\#3^$_ 'AK2M,L=62?7(6C*?:[0?>C YSGTXKZ\5CNJ3 ]*
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M <#\13N<9S0!)14/7'4T4")J***!A1110 4444 %%%% !1110 4444 %>/\
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M4(3TW;0<#WH [G(-%8_A+Q/IGC7P_8:]HMVE]I6H0K/;7$?1T/0UL4 %%%%
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MIO[1O[*,O@[3]2@MO&-II#:1J6GW(*R6<P!0;UZXP!R*.H'PQ\#]3^.O@_\
M90U#QCX"\36>@>$M#U":::!5!GNFWC<&R#Q]*_17]G_Q^O[5'[*VG:UXJTRV
MF;6;"6&]M&7=$[*"N0#ZXS7F?PZ_8M\5>#OV/_%/PDN=;TJ;6]6FDEBOHP_V
M= S C=D9[>E;G@I[']@?]CRVTWQUK%G=WFF0RQ0_82?]+F?.R.,$9)Y%"T#<
MX'_@EIXGU%=(^)/@:YN))]/\,ZPT=D'?<(T<D[5] *^[:^.?^":_P<UGP+\/
M-?\ &FOP-9ZCXUO3J26C_?CAR?++>A(-?8U-;"84444P"BBB@ HHHH ****
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>bcyc-20241231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $# I8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBO+_ (M_M+?#OX)AHO$_B&"'40NX
M:9:_OKH@]#Y:\J#V+8%=%##UL3-4J$'*3Z)79G4J0I1YZCLO,]0HK\[/B1_P
M5+U&XN)K?P+X3AM+89"7^M2&25O?RDPJ_BS5\_>+OVW?C1XP\U)?&MUI<$@Q
MY.D1I:;?HZ ./^^J^YPG ^:XA*53EIKS>OW*_P"-CY^MG^#I.T;R]%_G8_92
MBOPBO?BWXYU*3?=^-/$-T_7=-JL[G\R]0Q?$[QC#('C\6:Y&Z]&74I@1^.ZO
M;7A[7MKB%_X"_P#,\_\ UFI_\^G]Y^\=%?B9X7_:I^+O@^0-IWQ"UU@,8COK
MHWD8^BS;P/P%>S>&/^"H_P 0/!]LUQXJTW2/$5C"-TK[#:2D>S)E<_\  :\G
M&<#9CAHNI3G&26N]OST_$[*'$.%JM1DFF_*_Y:_@?J3-/';1/+-(L42#<SNP
M"J/4DUPUQ\??AG:7?V6;X@^&(KG(7RGU> -D]!C?7X6_M9_M[?$+]J76IH)K
MR?PUX+CDS:>';"X81D#HT[C'G/\ 48'8"OF:OSD^H/ZGM-U2SUFSCN["[@OK
M60;DGMI!(C#U# D&K5?S=_LY_M9?$3]F/Q1#J?A/6IFTYF7[9HEU(SV5V@_A
M9#PIQT=<,/7M7Z@Z3_P4FUCXI^&+?5O">AV.BPRC9(MS(;J6&4?>4\*.,\<=
M"#79A<)5QD_9TM_4]#!8&MF%3V5"U]]78_0.BOS*\0_M'?$GQ,6%UXMO[>,_
M\L[!Q:@#T_=A2?Q-<E/XZ\2W4F^;Q#JLS_WI+V5C^9:OH8<.UFO?J)?>_P#(
M^LI\)5VOWE5)^2;_ ,C]8J*_)V'QUXDMGWP^(=5B?^\E[*#^C5UOA[]HWXD^
M&BOV;Q=J%P@/W+]Q= ^W[P,1^%$^':J7N5$_O7^83X2KI>Y53?FFO\S]-:*^
M(/"7[=WB33Y(T\0Z)9:O!D!Y+5C;R@=R/O*?I@?45]%_#S]I?P'\1Y8;:SU3
M^SM1EP%L=2 AD9O13DJQ]@:\?$99BL,KSA==UJ?/XO)<=@US5*=UW6J_X'S/
M5****\H\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDLJ01/)
M(P2- 69F.  .I-/K+\5?\BQK'_7G-_Z : +>F:G::UIUM?Z?=0WMC=1K-!<V
M[AXY4895E8<$$$$$59KR7]D?_DUCX0_]BGI?_I+'7K5 !17F/QS^'_Q$\?Z5
MIEO\//BDWPNO+>9GNKM=!M]5^U(5P$VS,H3!YR.M?$'[-NL?M-?M"^/OBUX9
M_P"&DY= _P"$"UDZ1]J_X0K3KG[=B29/,V_)Y?\ J<[<M][KQR+5M?/Y:?Y@
M[12;]/GK_D?I;17SI\7OVS?!G[/&LZ)X&UH>(/B#\09;..232?"6E+<WLV%^
M:9H@ZJF[#/MW9 Z#&*L>"OVV_ GQ)^$WBGQSX5TWQ#KQ\+C.K^&[>R1-7M"
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MGAGX>^-/AS^QO\'?BWX;\.Z@OC;P1XLOE:T-E()Y+6=\%63&[82N,XZ2&OU
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MS3"V5MHO<="[=6/KQT K!^#?P<\1_''QM:^&_#=MYD\GSSW,@(AM8L\R2$=
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MY88..^Q  JCT&>I-3?LA> ?#?@+X06EOX=T.PT:*6>4R_8X%C:4AB 78#+'
M R237MU !1110 4444 %%%% ',_$#X=:%\3- ETG7K);J!@3')TDA?'#HW8C
M\CWR*_._XW?!'5_@QXB^RW6;S2;@DV>HJN%D']UO1QW'XBOTVKG_ !WX'TKX
MB^&+S0M9@\ZSN5QD?>C8?==3V8'D5[679E/!3L]8/=?JOZU/HLHSBIEM3EEK
M3>Z_5>?YGY?^"/&NJ_#[Q+9ZYHUPUO>6S@\'Y9%_B1AW4C@BOTN^$WQ.TWXM
M>#;37=//ENP\NYMB?F@E'WE/MW![@BOS@^*/PXU+X5^,KW0-2&]X3OAN N%G
MB/W7'UQ^!!':NP_9H^,4OPG\?0"[N&3P]J3+!?HQ^1.?EEQZJ3U]":^LS3!0
MQ]!5Z.LDKKS7;_(^[SK+J>:898FAK-*Z?==O\O,_2&BFHZR(K*P96&0P.013
MJ_.3\B"BBB@ HHHH **** "BBB@ HHHH **** "LOQ5_R+&L?]><W_H!K4K+
M\5?\BQK'_7G-_P"@&@#SG]D?_DUCX0_]BGI?_I+'7K5>2_LC_P#)K'PA_P"Q
M3TO_ -)8Z]:H \8_:?\ VIO#/[+/A72]5UW3]1UF^U>\%AINE:5&K37,Q&<9
M8@ =.>3R, UR'P,_;3B^+/CJ7P1XD^&_BSX9^*&MVN;6#7;0F"X0#.%E &&Q
MDX( (!P<\5F_\%"/A_XA\?\ POT>+1OAEIGQ3L[/4!/?Z5-)+%J$46,>;9O'
M(A$F,@@[LY'RG&*\"_97T7XO']H?0YO"/A[XJ>#/@_#9LNM:;\4;AY 90C;5
MM4F.X#)0!D'.WGTJ8^\I)^?Y?Y^O8=3W8IK^M?\ +T.4_95_X*%^*_ WP=\9
M:AXKT#QK\6[[3O$-Q+=ZA;JSP:3IXBB"^9.P*CYA(0@]"21D9]=_:9_:8B\<
M>'/V<?%O@?QCXG\,Z-XUUM;7R](9(VEW20HT5R"W.Q@ZD*3U;!Z5QG[('PF\
M:^&/V$OV@M!U?P9KVD^(-4O=6:QTR]TN>&ZNU>RB6,Q1,@:0,P(&T')R!7 C
MX*_$+_AG/]CO3?\ A _$W]HZ%XOEN=6L_P"Q[CSM/A-\&$EPFS,2[>=S@#'-
M=$4G."?1TOQ6OY:E5E;G:Z^T7W)V_P" ?87QM_;QT;X:?$NX^'?A#P1XB^*G
MC2QA%QJ>G^'(LK8(1G$CX/S8*G ! ##)!XKQ_P#:9_;;B^)W[$OB7QS\+]6U
MGP=XCTG6+;3K^VD/V>_T^4R8:-]I/##/.>>1P017G?Q4^ _CCX%?M7?$/QS)
MX3^)_B_P7XP?[3:WOPIU:YMK^"9B&,5Q' 0S(#N )X'RD')Q7(>*OV8/B/'^
MR-\7=8;X:ZY8>(_&&O:?<6^@I/=ZSK,\,4TC&>Z)9RTA\TY(52<$D#( YE[U
M*[WT?H^9:?=?\]BU:-6RV_-6>OW_ .6Y]>^//VY--^"/A7X7>'7\/ZY\1_B/
MXFT2UO8M&T<!IY%,2EI9&.3EB'( !)VMG YKRWX)?M3^)OBQ_P %"M1TN6Z\
M2^&?"$7AEI[CPCKZM;_8KE$3>7B/&>20PX(.:QO'/P^^)'P)_: ^$/QST;X=
MZ[X_T:#P;::%K&BZ1:M+J-C(("AVPXW _,IZ8!#@XSFG?#_PS\1_C'^WWXE\
M8>(OAEXD^'_A[6O!D^F6UUJ%FY2(/"$3S)E'EK,<DF,,2,8/(KID_P!Y*45?
MX_E92LOFK/YZ;'.O@Y7HK0\[ZQN_EJO^'/1]<_X*B^'(M0UN^\,_#+QGXR\"
M:%<-;ZGXOTRV46L17JR ]5[Y9DXYQ7H7Q?\ V^?A_P##3X>^"/$NCVVH>.+O
MQL!_PC^C:/'_ *3=] =P;E,,P0C!.XXP>:^!O"'P1^)WP1\ >)?A7JWPO^+_
M (BUNYN+B/39_">OW</A>]BD&W==+$XC4''S X+ X.W&:]-\3?LP?$W]GU/V
M=OB;H'@.3Q1>>!X9XM;\'Z%++=R6Z2RR2?N S.\C!9I 2,_,J<8K-*-HW>C:
MN_5.^GK;IIU&[WE9:V=EZ;:_U<ZNS_:Z\7_$[]N[X1>'X+7Q;\/=+N;"9=:\
M':W&T :8+*RN5Z2*0%PP_N\@5]8?M6_M*VW[*_P_L?%^H>';KQ!IDVHQ6%Q]
MEG6(VPD!Q(<@Y&5QCU(KY+:^^)7QN_;^^#GQ!OO@[XM\%>$['3YH5N=6L'+Q
MJ4F.ZY* K 26 ".P;IZU]??M<_"<?&[]G#Q[X02W:YO+S37ELHT&6-U%B6'
M'?>BC\:B;<*2E;5-Z>5_\ATTI5G%O1I?E^C.)UC]N?PII7[3_A;X,C3)[B\U
MZSANH]86X00Q-+&TD<93&264+SG^(5\]?M/?MT:Q\0?V;?BWJOP]AU?P7<>#
M?$EGHL?B"WO &NV,Y63R]H!4;0,@D\.*^?/#/[+?Q>U/]G77?C%J'A7Q)%\;
M-%\0:5)HEO/I<ZZD+.RA6 !+<IO93E#PIW>2#ZUZIXJ_9G\8>%_^"4\?AJS\
M):YJ7CS7-7@US4])MM/FFO\ S7N5)WPA2X*Q)'NR.,'-%2-HOR<?QE%K[E=,
M=-NZ\T_P33^]VL>Y>"_^"CVC6GB/X<^&?$7@CQ;IVC^)XK2QL/&NJ6QAM;^Y
M9$4NJN Q0NP^?KSG;CFNM^,'[?FC>!/B;J/P_P#!7@3Q)\5O%&D()=8@\.PY
MBT]<9*L^#N<97( P,XW9! \P_;2^&7BSQ+X)_9;M=!\)ZSJLFBZ[ILFHPZ=I
MTLQL(TBA#-,J*?*5<$$M@#!KR?QK\"_'7[/?[2OQ,\277A#XJ^+?"/B^[:^T
M_4/A/J]S;7*R,S/Y=U' 0Q4%F&YN!@$9W8K2=G-K^])>ME%K\WZV,J=^1/RC
M\KMI_DOO/J'6/^"BG@B/]F:^^,>BZ-J6J6FGZBFE7VA7#);7EI<,V"LGW@,
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M.TM5\_\ @GS.?8-8/'245[LO>7SW_&X4445XQ\Z%%%% !1110 4444 %%%%
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M44 %%%% '/\ Q!_Y$7Q!_P!>$_\ Z :^#Z^\/B#_ ,B+X@_Z\)__ $ U\'T
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M YW KCD$$X(K]%**4DIRDWU33]'9_FD*/N1C%=&FOEI^3/RO\.^$?VD?AO\
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MXFF:D[3:#,_(ZFV8G[Z^WJ/Q^H!]=T5%;7,-[;QSP2I-!(H=)$.58'H0:EH
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M&T9L'#$@LW\)XQS7T'\-OC=JVM_MO?$[P)>>/]4O-$\/Z4+T>&[OP[96UE9
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MO1/!MK:ZK??V9/Y.GS"W8&.=]NV)P3@JY!S7D&@_ CXA_LT^)?B-X:U/P/\
M&;Q+:ZMJ,MSH>I_#/6[FWT^]#Y"_;5A.%X(R[<_>&,<U^O=%5)\S;[\W_DSO
M^!G"/(K=E'_R56_4^;/V ?@UK7P4^ 4&F>(- B\+:KJ%]-J$FD1W;W+6X?:
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M!'Q!3Q?\.7OO%SZE!/I<_P#9][)&JKM*NR-\A.<\<XKTOQ%_P3ATJ^^$NO\
M@/2_BUX_2SUR\MKB]NM<OTU%VCA#XA4!8\(Q<,P.<E%HJ?W>R_%*_P!VOW%T
M]7:3ZO\ !NWWGR-\>OVU_B5\9/CI\/\ 6/ ^J:YX3^#G_"5V^B6%S874EF=;
ME66+SVEV,"Z;6 "'Y0#R,DX_7NOR6_:)_P""=OQ)\!0?"30O"'CCQCX^T6TU
ME8TBBLL1>'8]T9^TQJKD*>2<\?<ZU^GWPM\':EX \ :-X?U?Q+?^,=1L8C'-
MKFI_\?%V2[-N?D\@$#KT IQLJ5ET;]7HOU^6MELR7=U+OJEZ+5_I^5WNCJZ*
M**@L*0C(I:* /S[_ &LO^"2WA?XO:K?^*?AMJ,'@KQ+=.T]QIT\1.G74AY+
M+\T))Y)4,/\ 9'6OC*X_X)"_M!0ZI]E2QT">WW ?;%U51'CUP5#?IFOW1HH
M_-/]F'_@CMI/@S5[3Q#\7-9MO$UW;N)(O#^F*PL@P.09I& :7M\H51UR6%?I
M1;V\5K!'##&L,,:A$C10%50,  #H!4E% !1110 4444 %%%% !1110 4444
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MM(\97MEXCN[K5/"/BVVE@OFMG*@2V<BS1&.3&X9Y/(P#C!YX:T[O^Z_O>O\
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M!)<@G. !@5ZY6E114VH[$0;<4Y;A1116984444 %%%% !1110 4444 %%%%
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>bcyc-20241231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $2 GL# 2(  A$! Q$!_\0
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M.ZJ2^]F"Q^+3NJTO_ G_ )GS-XG_ &$/".HQLVAZSJ>C3GH)MMS$/^ X5O\
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M% 'AG[77[)?A?]KCX<?\(_K;G3-9LF:?2-;AC#2V<Q&""#]Z-L*'3(S@$$$
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MHHH **** "BBB@ HHHH **** "O%/V:/^0C\9?\ LH&H?^D]K7M=>*?LT?\
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MBZK978LKRV4ML+-;P7,;H&&Y0T-S"Q1N48LI+;=Q]?H **** "BBB@ HHHH
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M^R?J6H:KX1AU/4==O8?LLFK:W<I-<+"6#&--B(BJ2JDX7)VC)XH ^9_VU_\
ME)?^S)_VZ_\ I;)4W_!:^WU)_@Y\/)U69_#\7B!A?"/IYI@;R2??:)P"?6OJ
M[XH?LE^$/BU\<O OQ5U?4M;MO$/@[R_L%M93PI:2[)6E'FJT3.?F8_==>/SK
MT7XE?#3PU\7_  5J?A+Q=I,.M:!J,?EW%I-D9P<JRL""K*0"&4@@@$&@#BO&
M'BGX1+^S1>ZKK-QI$WP>?0]K",@VLEB8]JQ1A>=Q&%55^;=@#YL5YA\%/@[\
M /CI\%?#E_\ #72-1TCPKI>I7,^BW]M-=6MS;3EE$YB:5BQ1GC7*G*%HP<;E
M!'F-O_P1F^#46MK/+XD\9W&C+-YPT=[Z 1G_ &2XA#8[<$-C^+O7V_X,\&Z)
M\//"NE^&_#FFP:1H>F0+;6EE;C"1(.W/)/4DG)))))))H S/A?\ "SPU\'?"
M4'AOPK8?8-,CD>9M\C2RS2N<O))(Q+.QXY)X  &  !UM%% !117E'BCXF?$G
M2/$%]9Z3\'+W7M-ADVP:E'XAL(%N%_O"-W#+]",T >KT5XI_PMWXM?\ 1!=0
M_P#"ITW_ .+H_P"%N_%K_H@NH?\ A4Z;_P#%T >UT5XI_P +=^+7_1!=0_\
M"ITW_P"+H_X6[\6O^B"ZA_X5.F__ != 'M=%>*?\+=^+7_1!=0_\*G3?_BZ/
M^%N_%K_H@NH?^%3IO_Q= 'M=%>*?\+=^+7_1!=0_\*G3?_BZ/^%N_%K_ *(+
MJ'_A4Z;_ /%T >UT5XI_PMWXM?\ 1!=0_P#"ITW_ .+H_P"%N_%K_H@NH?\
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M'^UG^U_]MO'$%MKERX$TAVQHM_>Y(ST &*^*M!O;B^_X)D^-'N;B6X<?$FS
M:5RQ ^P].: /W=\)^($\6>%=&UR*%K>+4[*&]6)SDH)$#A2>Y&[%:U?C=^TU
MXQ\5?%OX_P#PN^#]SIWB;Q#X(T[PGIES_P (GX7O$M;C59&L!,\FY\JQ'"\@
MX6-]N"Q->M?\$\H_'GPH_:@\4?#\:/K_ (=^&=[I[W-MX;\3ZK;W5YI=PJQ.
MK;4;*A@SCA!N5HRV2H- 'Z;T444 %%%% !1110 4444 %5M0U&TTBRFO+ZZA
MLK.%=\MQ<2"..-?5F. !]:LU^>7_  5]\$^._%'A7X=7^CZ1JWB+X?Z5?3S^
M)-+T=FWMS%Y3N%#$*$$ZB3:0A?)ZB@#[M\+_ !"\*^.&G'ASQ+H_B P?ZT:7
M?Q7/E_[VQCC\:Z"OQP^!>H_LI>)OCEX!USX:>*/%WP#\5V%U&AT[5D:ZM-2E
MWK^Y:X:9PBN-R,'*JP8#:#U^E?C%_P %!?'U_P#'WQ)\+O@KX<\)7L_AC?'J
MNM>-=1%K;/,A"R1Q S0\JYV?>))#':%7<0#[MUC6].\.Z?)?ZK?VNF6,9 >Y
MO)EBC4DX&68@#)('XU-97MOJ5G!=VEQ%=6DZ++%/ X=)$(RK*PX((.017Y8_
M'G]L5OVJ_P#@G_\ %RTUK18/#OC;PKJFEVFKV-I-YUL^Z^0)+$V3P6BD4C+8
MV@[B&%=[JG[<.J? /X(?LY?#3P%H&F^(?B'XA\%Z/<H=;NA;V%E"ULB(TK;T
MR6,<AY= H3))R!0!^C%%?"WP!_X*&:Y>?%'Q%\.?C9HWAW0=<TW2;C6H-8\)
MWGVK3[B""$SRJ,22_,(D=\AS_JV!"D#/&Z!^WA^TQ\6?#&K_ !+^&GP4T35_
MAA87K6T=I-)-/K%VJL QC6.4;B-RYVQ, <@;]IH _1NLG6/%NA^';JTM=5UK
M3],N;L[;:&\NHXGF.0,(&(+<D#CU%?E;_P %*_C1\4O%W@_X1>(;?0;KP)X6
MU.19X+2]DGL]7CU'!6>VN8R5_=+M&UMHW [NA%=K^UWX@\0/\0/V53\8? 'A
MJX\<ZKK]Q:S#3;^\%O8(+^S$;P[)@&8K(K'S-PRN,8R" ?IG17R'\+?VSM?G
M_:F^+7PE^)6FZ-H-OX3L9]7TW4;%94-S91[9-\F]V!8P2QR?+C&V3TX\J\&?
M\%/?$</[-'B_XQ^,_".F0V)UU/#_ (3TK3C+%)?7'EM)(T\CLXV(FW+*HY1Q
MU(P ?HC574],L]:L)['4+2"_LIU*36US&LD<BGJ&5@01[&OSDT'_ (*4_%3X
M?>)_!5U\8O"/@JV\$>*I4B2Z\*:H)KS3 ^TA[A!<2_=# E2J' ;!RI6OTEH
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M3Q=JZ&*\\0^(;D7%TT98,R*550JEE4G@L2HR3@8^@J* "BBB@ HHHH ****
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MWACQ#/AQB.ROI&^]Z1N3W[ _AZ9^AJ "BBB@ HHHH ***:[K&C.[!449+,<
M#UH ^*/V^/$BW?B[PSH229^PV<EU(H/ :5PHS[XBS_P+WKYU\!^'F\6>-M!T
M9%+F_OH;<@=E9P"?P&3^%:OQB\<-\1OB7X@U_>S6]S<LML&[0+\D8QV^503[
MDUZ;^Q3X+;Q'\71JTB$VNAVSW!)&097!C13^#.P_W*_4::_L_+M=XQ_%_P#!
M9^TTE_964^]HXQO\WK^;L?H   ,#@4M%%?EQ^+!1110 4444 %%%% !1110
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M*CT>WKV^?];GVI1117XB??A116/XL\6:;X*T2?5-4G$-O'P%'+R-V11W)_\
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M_KO2-S_?]#WZ=>O$_'+X*MX,N'UK18GDT.5OWL0Y-HQ/3_</8]NA[9\>5BK
M@D$<@CM0!^B%%>'_  )^-H\110^'M?N0-57Y;6ZD./M(_NL?[_\ Z%]>ON%
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M;X T";4]1D' *PP X>=\<(O^/8<U^</QULK[QSXHU#Q<EO&+B[;=<V]NF H
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MHH *^*_^"C7[._Q!^/.L?!J?P+X?_MR+P_K4MWJ;?;;>W^SQ%K<AOWTB;O\
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M_D*C_AL+X:_WO&'_ (06O?\ R%7M=%40>*?\-A?#7^]XP_\ ""U[_P"0J/\
MAL+X:_WO&'_A!:]_\A5[710!XI_PV%\-?[WC#_P@M>_^0J/^&POAK_>\8?\
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MG 0AN>G7[IH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>bcyc-20241231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O L0# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB9XE^/=W\*_A9_PC6D7.CZ'%KFJZSXHMY[E&\Z1HX;>&*)T/.TLSDG X SU
M/I&BOBRY^/'[2'B+XL>'_A]I&B^ O#'BH>$I/$&JV>LM/>VTLL=ZUOM@GMY/
MD61=C@."4R0<D"H? _[<'C[X@:U\$1%X&TK1="\8:M=Z/JM]+J!N)!=VPG66
M&",!=B[HE82L6R&V[<C) /MFBOBG2/VC/C</V@K;X3ZPW@FV\3:QI.H7BV\6
MGWHMM%ECC$EJ/M,CJ-1#JR[UA52GS<_*:UO@S^U!XOLOB1\2;+XN^+? -IX'
M\(2V^CMXDL8I=-MY-7D&][57GF8,8T#!AQ\Q'O0!]@45\M>-?^"BWPI\&_$,
M>&OM%QJUA";(7OB#3Y[9K.V^UA3 RAI1+.NUT9FA1P@8$TNE_P#!03P7<^)%
MLM0\,^)M%T5KW5M-7Q%>6\)LGN=/1Y)T79(7/R1L0=N"2!US@ ^I**^8O"W[
M=VA^(;B&.Z^'WC711=>&KGQ;8&]M+<_;]/CV;6A"3'+.'4A6VX!!8@$&L[2?
M^"B7@K6-!OI+;PWKUUXFAUFRT&W\-V+VEW/>75W&\D BFAG: C9&Y8F0;"I!
MYH ^KJ*^-[_]OR"\\8Z(MGH>I:'I%G?^(M/\0:5K6GJ=0,NF:='=LL+)/L3_
M %@&6W;L<8'-;-K_ ,%$O!W]CZA>ZCX-\7Z1<#2-.UK2M/N;2!KC6+>]E$-L
M;=4E(RTAQARO&30!]7T5Y+\$?VAK/XT:_P",M!_X1?7?"6N>$Y;2#4]/UZ.%
M9$>>$RH%\J1P1M&<YP001UKUJ@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***ANYQ;P.['  S0!SWCGQ?;
M^%=)EN97 (' /K7SSK6K:EXOG,^HW#I;-RMJAQD?[1_H*T?'WB!O&'BB>$R$
MV-DX^0='?L#[=_RKCO'=]J6G>''N-)61[U;FU 6*/S&*&XC$G&#QL+Y/89/:
MNIOV*Y8_%U-+\BLMSAO%?C+Q?X>\9WKZ7H%Y>>&K6U^PQ1K; Q-=E/-\[Y3Y
MI1?]6=J[3SSNJO?>._&D>K)+:VB:K8K#'<1QVNF75NMPJ_:_-.9,L-PBAVH<
M'<Z8)!YGM?'WQ =+;SM T]9+EK:)?+M;H"%I8H)"SY;[L?FR(1Q\T?4<BFCX
MJ>+M,M_,U;PZK^;;O+&UG:71_??OA'$1\QRS0@YX $JCT)Y3,SM9^*OCIYGM
M;+P[]A:2Q%V)I=-N9C;Y591N .'.P["HP0X8#.,5#J/Q;\=366KI'X=32W07
M"07(L;NX:.15E\J'8H^9W*(5<90;L$<KFWJGQ8\?:5:VKGPI;S-<KYZLD-T%
MA^:=5@<<DR-Y*$,!@>8,J?ESM^(?%.OZ;X@U5XWU:2ZM2C:;H=I8^9;W\/V?
M>^^79\I\S<I;>"FU<*V[D [ZUAN;<VU]:7#VE_Y2%\#"NVT9W#USGD5[%\,?
MBE_:[G3M1/E7T?RD'O[BODOP5X[\9^)_&.C_ &_3I+'29$=9O(M9%@D(CG(;
M,B[E.X1KC)&5'][%>JWMS)I<UMJ4(_>6T@9R.IC[_P!#753ESVIS^7D:)\WN
MR/K=&#J".E.K!\'ZU'K>C6]Q&P8,@-;U<S33LS,****0!1110 4444 %>1_$
M[_D9_P#MW3^;5ZY7SK\=OBSX5\&>.QIVL:F;2\^QQ2^6+>1_E)< Y52.QH =
M17G/_#0O@'_H.-_X!S?_ !%'_#0O@'_H.-_X!S?_ !% 'HU%><_\-"^ <X_M
MQL^GV.;_ .(I?^&A/ /_ $&V_P# .;_XB@#T6BO.1^T+X!(R-<8CU%G-_P#$
M4?\ #0O@'_H.-_X!S?\ Q% 'HU>>_%T'[#9GM\XS^51_\-"^ ?\ H.-_X!S?
M_$4H^,W@CQ&KVMM<?VQ*JF3[,UJXR!U.74#BNW!5'2Q$))7\CT<NJNABH3C'
MF=]O70^8O&I^9ZZ[]DD9U/Q_CG_B70=/]^2M76/B'X2T3Q[J.JWWAC[=H\UF
MD*6'DPMY<JD9<*WRC(STYKN_!GQU^&%KHD<UA''X=^U9>:RCT\JP8$CYC&I5
MCQU!/!KZS-<7-45&5-J]M=/6Q]UGF/G'#QA.DU?EUNM]';\+'FGCCH]>-3<>
M)])_Z_[?_P!&K7U7XF\:^!Q;K>+X9CU>UF02QS8\L2 \YVGD?B*\R^%7Q ^'
M>C:K';^)- CCU19I+J'5I(?.2,@@H@09(P.AP>?2NR6,E]4=1TVE\O\ /H>C
M/,)_4)571DE;RUNM]^G7U/4/C)_R'[W\/Y5\T^,OO/7U9<_%'X?>+I&6/;K=
MU&A;RC;2(VP'D[F '?UKR#5/%7@;1?%^LWNJ^$WU'1IXHUM;$!<P.N-[<L!@
M_6N?+<6Y8;EC3;Y5Y:VLN_S.7)\?*>#Y84I/E5M+:VLM-?F=M^QPC+\,]38@
MA6U:7!]<1IFO>:\?\&?'GX:6/AFPBT^3^P+;86&G"SD_<DDY!**5)SSD$Y]:
MVO\ AH7P#_T'&_\  .;_ .(KXO$S]I6G*UKL_.<;4]KB:DVK7;T-3XT<?!WQ
MRW\(T6[R>P_=-UKTCP2,>)-)&,?O%_\ 037SSX\^.?PAO8].G\0B36;6TF,R
M2MI<T\-HPQ^]D7'08'.UL8S@=:]0^&OQM\&>(?'^AZ=8:NUQ>W5R(XHS;2KN
M;:QZE<=CUKF.,^IQTHQ0.@I: "BBB@ K#\<?\B9KW_7A<?\ HMJW*P_''_(F
M:]_UX7'_ *+:@#(^"_\ R2#P1_V [#_TFCKLZXSX+_\ )(/!'_8#L/\ TFCK
MLZ "BBB@ HHHH *\3^*?[.7A3XP>-+3Q79>*_$/@SQ?;63:;)K/@W5EM+FXL
M]V[R)LJZLH8D@XRI/!KVINE?BO\ LWVUE8_$WX0W&D0:7=^+HO'%PNIZ;HFD
MZA!KOV.2>=6DN[ILV[VR*48H%4[,#/#&@#]!KK_@G[\.+Q] NO#_ (F\:>%/
M[*TEM%67PUKYMGO(&G>>7SY=C/(TDCL6.X X' P*]!T_]E'X?Z)IOPUT[2+.
MZTC3O %W->Z3:VMQE7EEC=)#.7#-)N\QV)R#DYSVKX)^$WQJ\6^$/AC\/-$U
M#Q[=_!CPG_PCVHZGINIZ7X:6\&K:N-7N$^RM"T;;ML85O)38S[\[J]OU;XQ_
M&RW_ &A$^&-C=7U\;DQ>.;6_?3X[<R:.EBWFZ<8V!:/??*D7)+JLF-V: /9/
M!7[&7@WX=^+]$\2?\)1XMU5/#27:>'[#7-8%S::)]I4I*8-R;B=IVCS6? Q[
M5W7PR_9^\%?"CX<1^#;6R_MG2ENIM1N9]>V7<]W<RN7DGF9E 9R3C=@8  [5
M^>/CCXP^(_BG^R[XZBU;XH:KXSUR[T"SO=>\)S>%3;IH%]_:=N#$ES&B>7M^
M9/(<.S!=X(%=YX:_:,^,VM?M8/X3U/4XK>T?QA-H<W@>XA^4Z&$^6Y6-;4R9
M*?O!<M.(S]W:!0!] G]EKX2?%[QUJ'C?P[XAU*W@N;FT&KZ5X=OHXK"^DM0!
M#YJ^670;54'RG0.H&<CFMJY_8J\"'2K"UBEU"X.GZMJ^MV\5_,DL$ESJ$<D<
MZ3(J*7BQ(V$4J?\ :KFOVF=(F_99_94\=:U\+);G1=?%Q8O%>;?M<B%[R&(@
M*X8$!)'XQ_$2>>:\4UCXI_&SP'\0O$<!^)&K>(=/\*?$#1-!CL[O2+1%U.UO
MU5YQ,Z1 @)N*H4*[>^>, &A\+_\ @G=K]YJ6H6WQ2UB%/"T'A2;PM;V^D>(+
MR]E\IIXY5>)KA +6*,1*%A ?_:+"NX^('[ MG;^#-6N? NL76L>,K_4]+U8:
MCXBU(VK))9(\<;VLUG$GV:7RY"H8(Z^J]Z\"F_:#^*'C?1?$&CZEXHO_ !#J
M>L^&O%Z>-/!4FCK#%X2%O;SBR,<BQJ^6(1?F9]^_/6L[2_VD/C1X0\1>"/#.
MDZLNAVFG:/X7M] \.7,&$UVWFM(?M#E/LLLLQ+%U+1R1B$KR#S0!]&_!S_@G
MY:6GARZN/B-J]W<>)+S5M>U,QZ1J<EQ' FJ6<=I+&\\\?F3NL<>[S6"_.Q."
M.*WOC%^P[X=UGP%<Q^&[K_BH;7PKIOA336U^]=+5(;*X6:"0O"%D2?<#B520
M"?N$9!\=T/\ :'^(NL:SXU$_Q+U6S^(L*^(XC\,8O"HGBL(K:*4V4J7"H#$?
MEB<2R-(LI;:%R:\U^)_[1FO?'?P7::6FOSZ_HL'A3PA?:BD=D8U76O[8@6\;
M=Y8.X @,JY4$' X- 'V1^Q[^SQXH^"]Y\0?$'C'4HKO7?%U]:W#V\>ISZFT"
M00&)3)=3(CRNQ+$_*%48 X&!])5^=GP@_:5^,WB/]K.#P]K&LQ"*;Q+J.FZA
MX+EA&;'38@WE3JB6N^/ "N)WG*2YP ,U^B0Z"@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^(=Z]CX9O
M94.U@AP1745Y_P#&>[-KX-O2O4J16M)<TXKS*CK)(\&TG:]A'*IW&;,C,>I8
MGG_/M5NH-/B$-A;1C^&-1^E3U,WS2;$W=W,_Q!KD7A[1[F_GW,D2Y" \LQX
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M+NVDDA%4-ANF.H'I4<)5O&HWRK>__#=3U\/@:]XU6^2-N;F[+Y:W[(U_AO\
ML\>"?C#XS\?R3Q7T_A;3;]+#3)H+QE\QE3]\=X'SC=C'H"*^K? W@C2/ASX3
MTWPWH5L;32=/C\N")G+D DL26/))8DD^II/ W@?1_AWX9L]"T.U%II]LN%7.
M6=CRSL?XF)Y)K?J<9BYXF?Q/E6U_)6OZO=BS#'U,;4^)N"M9/R5K^KW?J?-W
M[4OP=\.VW@'Q;XT4WD>JQ1"X5%E!A,A=5R5(SSGUK5^!7[+G@WP!?Z+XWLQJ
M$^OR:<O-U<AXHFEC7S"BA1ZD<DX!KJ/VHM.N=4^ ?C*"TB::;[&)-B#)*I(C
M-_XZI/X5U?PNUVP\2?#SP[?Z;.EQ:2V,(5D;."$ 93[@@@CU%=,L16>!2YG;
MF:^5E9?F=D\7B)99&/.[<S3].6-E^9>\7^#],\<:+)I>JQ-+:LP?]VY1E8="
M"/J?SKY3;]FWP7XG_:'USPA=PWW]BV>APWRHEXRR><\F"=W4C';UK[&/3BOS
MP\;?%OXB?"+]H--=\3Q'^W R6K6-O&D-OJEB6.V*%\$8&=V\\@KAL&GEU2M:
MI3ISMH[*_70>4U<1:K2I3M>+LK]=-ON/O;P9X.TKP!X6TWP]HEM]DTK3X1#;
MPERY51SR3R22223U)K9Q7Q5\)?VT?$WQ&^-.GZ=J@T?P[X:>:2UFA+^9&KA3
MM4W+ 9E+E   %.2.M?:HZ5YM>E4I2_>;O4\?$T*M"=JN[U.:\;_#W2/B):6]
MGK8O)]/B<M)907LT$%T#_!.D;*)4X^X^5/<'-=+@"L'Q?X[T#P#9V]YXBU6W
MT>SGF$"7-VVR(.02 SXPO3JQ ]ZWE8.H92&4C(([USG(+1110 4444 %8?CC
M_D3->_Z\+C_T6U;E8?CC_D3->_Z\+C_T6U &1\%_^20>"/\ L!V'_I-'79UQ
MGP7_ .20>"/^P'8?^DT==G0 4444 %%%% !1110 445'/,EM"\LCK'&BEF=C
M@*!R2: ,3QQX]\/_  V\.W&N^)M6MM&TF# >YN6P,GHJCJS'LH!)]*^9S^WA
MJ/C2ZE3X8?"+Q1XXL4.W^TBAMX2<]L*W'U(/M7*^ /"[_MT?%[5_'/BHR3?"
MOPS>-8:#HNXK%?2*<M-(.X(*LWKN5.BMG[8T_3;32K*&SLK:&SLX%"16\$82
M.-1T"J. /85]75HX'*+4L33]K6WDKM1A?6VFLI=]4EMJ>1"=?&>_2ER0Z.UV
M_/71+MU/A'XQ_P#!37Q'\"O#RR>,/@CK6AZU>EETV*]O/+MYR/O%G,><*".%
MR3D=.M:'[.O_  4IU']H?0;R/0OA1J=YXETXK]NM;"[\VW1&SL=7V;N=K##
M=.":]I_;2_9K\*_M)?!R\TWQ&UU9W&C[]2T^_LF E@F5"",'AD8'#*?8@@@&
ML?\ 80_9A\)_LY?"17T"2[OM3\0^7=ZEJ%Z5WRE-PC15485%!; Y.6))/&/$
MJXBA.O[6%%1C_+>5OO;O^)[&$?L&G7_>>NG_ *3;8N/^U?J_A>1'\;_#'Q!X
M<L"<&^C'G1K]<JH_7\*]K\%^.]"^(6BQZKX?U*'4K)CM+Q'YD;^ZRGE6]B*V
MY[>*YA>*6-98G4JR.,JP/4$'J*^7?BAX3?\ 9F\9V7Q%\(1-!X7NYUMM>T6(
MGR55CQ(B] .N/[K8 X8BMX0P^,?LZ<>2?36Z?EKJGVU/=IPPN8/V5*'LZG35
MN,GVUU3?36Q]3457L+Z#4[&WN[:036UQ&LL4B]'1AD$?4$58KR-M&>$U;1A1
M110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $8A023@"OC?]HCXJVWQ]O+#X>> FN=2O5OF>7E(K>\\M&.$
M=F&X*06YP#MR,X%?7VK:<NKZ7>6+N\27,+PET.&4,I&1[\UX5\"_V3+#X1>)
MWU^]U@ZYJ$2-%9XM_)2!6&"Q&X[G(X[ 9/'->OE]7#X?FKU'[\?A71OS_I'O
MY76PN%Y\35?[R/P+HWKOZ>J,WP%^S?<^#?A"^EZE*DNNW$[7LWV=MR0L0 J*
MW? 49/J37,P7$D$QLKT&&^C^4JXQYF.X]:^MF0.,$<5P7CSX6:?XKMV;RQ'<
M#E9%X(/K7-/$/$R;K/5N]^W_  #RZ^(GBJLJM;>3O_7D>(@9('J:I:1&4L59
ME*R2N\K@C!R6/7]*;\2?!OB_P[X4UA+6W>\=;=]EQ#GS0,<D =3C/O7@'@R^
MUI/ASXK2V-VT+A/*9%9L'/[W:>WR]:[</ELJ]&4U-;I??I?\?P/4P>6/%8>5
M55$K2BOO=K_C^#/H/2[=HM,MH9@"PC"N,Y'O]:32(WATRVCD&UD79CV!('Z
M5X3X.OM7C^$GB*"W6[(9LVSQHQ 3CS=K=N/3WKL?V>=&\3:UX9O(K&WD:T>Y
M M[F4$HG'S[0>O./;.:UKY9.G"K/G7NR2[7\_P ?P9T8O*94*5>HZB?)-+U\
M]_/;R>NAZ/>ZA#8*ID8EWX2-!EW/H!7<?"SP!=:KJRZUJ<'E*JXAB;G:,Y_.
MMWP/\&A9WBZAJ[B[NMH +* %'H!7KEM:QVL82-0J@8 %>3S1I*T-7W_R/F[I
M*R'0Q"&,*!@"GXI:*Y2 HHHH **** "BBB@ HHHH **** "BBB@ KSWX\>/]
M'^'OPQUZ]U:]%KYUG-;V\:3+'--(R%0L6>K#.>,XQFO0J^$_V\/BI!+\3?#?
M@F!(+Q[2U:[F0J0RRR' C+^A0(VT#NI/:N[!8=XFO&F>A@,/]9Q$:;=D?.NA
M6 >P$4T4?D")(9'Q@G[Q)![!B,D^YKZQ_P""?7V'1X_&6BV&BB.,3177]K(2
M^5882V=CUV_,ZX[.Q//)^2-3U>6T']IP&W:&&1DGB (#9P'!.3PA*\@=S7?_
M +-O[0NK_"3XF:CI;:7:0Z;J=W:IJ<,LF0L88(LT#J1R%D)(88(7J,5]AF.'
MG4P[4%=_Y;GW>:T75PKA%7E_7]6/T]HI <C-+7P)^:#9$66-D=0Z,""I&01Z
M5\;Z9\4?#W[/_P"T5XDT6P-[9>"Y@!=V C,BP7A ;S(8Q\P3G;[YXR ,?67C
M#Q39>"/"^J:]J)<6.G6[W,HC&78*,[5'=CT ]2*_-?XV?$J]^+/BZ\\2WEK+
MI4+6_D1VT>V8P0@82-F&-S%F9CZ%N.@KV\LI.JYQE\#5G^GS7X'TF3495G4A
M+^&U9_I\UNNQ^D/@;QOI7Q$\-6NN:+,TUC<%U'F(4=&5BK*RGD$$'BOAS]MN
MVU9OC:T^M(T6B#1D71YI(LQ':P:X QU<.5SGL5[5O_L/^./&5CXKD\$F.WU'
M0%@.HWL\AQ);,RXW(<Y;+!%*8..N1W\O_:V\?:E\0OCK?:3?7#R:'H-\VFVE
MG;*L;+E(S(S/]X[I ,Y.,  =\[X3#2HXUPCJDGOV_P SJP&#GA\RE3@DTDWK
MNET^9G?LX:?IWQ!_:"\.>'WL+J73&BEN]4LE_=Q'RT#PR-WVE@N1QG@'W_4,
M=*_'3P/XXU[P+XYOO$7AW4Y[?4=-.4D\I6$BGY7@.00RMCA3GYE'?I^N/@FY
MU:\\(:-/KJPIK,MG$]VMN"(Q*5!8 'IS66:QG[12D]-O\SGSV%3VJG)Z;6_/
M0QOC6 WP<\=@C(_L&_X/?_1Y*W?"/_(K:/\ ]></_HM:ROBVML_PJ\9+>O+%
M9G1;T3O;H'D5/(?<54D MC. 2!FL_P""-QXONOAOH[^-K#1M.UGR(\0Z'=RW
M,/E^6NTEI(T(?KE1N [,W6O"/F3O**PO'5YJ]AX/UBYT&W%UK$5L[6L6W>6<
M#C"Y&X]PN1D@#(S7C.K>)OB@NI[M";5M2T:)8P+S4='2VE9FE<-NM_*#R !5
M4%?**[@Y5ER2 ?0=%?/-OXW^+(L]+%AHNI:O8G4-.:[U*^TZ.UNA"WE"Z@%N
M_EG +-^^VX50_P!X@-7T+0 M8?CC_D3->_Z\+C_T6U;E8?CC_D3->_Z\+C_T
M6U &1\%_^20>"/\ L!V'_I-'79UQGP7_ .20>"/^P'8?^DT==G0 4444 %%%
M% !1110 5Y_^T%?W.E_ SQ_=6F\7,6A7K(T?WE/DMR/IU_"O0*SO$6B6WB;0
M-2TB]4O9ZA;2VDZCO&Z%6'Y$UT8><:5:%22NDT_N9E5BYPE%;M'C/[#FG6NG
M?LL^ A:HJK-:27$A7^*1II"Y/X\?A7N]?'_[$?C>7X;ZCX@^ OBR46GB/P[>
M32:5YS8%[:.2_P"[SUQG>!W5_P#9./H3XB?%G3?!FB1RV;Q:KJEVQBLK.W</
MYKYQD[<\ ]>Y/ YKUL\HSI9C6<M5-N2?>,G=-?)G)@)QGAH)=%9KLUHT4?CI
MX]TSPKX.OM.N'\W4=2MW@@MD/S888+MZ*/U/ K/_ &>/'FF:YX-LM"23R=4T
MR+RY('/,B9.'7U'//H?PK@[C]G?Q=XWD.MZYKEM!J=X/,EAEC9VB]$X.!@=A
MP*2#]FKQ5X8E&JZ/K]JVIVG[V!8HVC9F'\.2<<].>#WKP3T#Z7KS[]H"QM]1
M^"WC.&ZV^4-,FDRW0,HW*?P8 TWX;?%NT\6:7<Q:N8]'US3ODOK6X;RPI!QO
M&[H">W8\>A/GW[5?CI]0T>R^&OAYUO/$WB>6.$PQ'/DVY;)=L= V,?[H8]J[
M<%3E4Q$%'HT_1+5OY'I9=2E5Q=-1Z--OLEJW\CN_V;[N>^^!O@R6X+&7^ST3
M+==JDJOZ 5Z36-X.\-P>#_"ND:';',&GVL=LK?WMJ@9_'!/XULUC7FJE6<X[
M-M_B<V)J1JUYU([-M_>PHHHK Y@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 0G S7#7/Q,EATFYU>/0[F?2%
M64P7*S)F0H<#<O5%8@[3SVR!D5W/6N0N?A?I5U!<VS7.H+92B799I=%8H&D.
M69%QP<DD9R!DX K>DZ:_B'50=%/]ZOZZ]4,_X6.(-3ATV[TBZ@OVNXK615='
MCC$BLT<F[(RK;&' SD'( YJI_P +.F-OK+-HZQS:2B37<<E]'^YC97;#L 0)
M $Y3G[PP36S!X TV-A+,]S=W9N8[I[J>8M([H"J D8&T!CA0 .2>IJ"#X:Z8
M@<7$]]?[C ";NX,A\N%R\<9..5#')SDMW)K92P_;MW^?4W4L+UCV[_/KZ_@8
MWQ7AUGQ#\%=??2;.>TURZTIFCM5.9D9E!:,$?QXW#CO7R#\)/"/BF[^ /Q/G
ML[&[$#I!]D7RV5G*M_I'EYY_U?!Q].M?77[1DFHQ?!/Q:=*G-O??8SM=9 C;
M=P\P DCDIO'KZ5\B?#FR\5WO[*OQ!ETYKB729+VV>$1.6WQ#!N2F.=I79G'7
M!]Z]_+'_ ++*S2O.._JOZ^\^IR?_ '&5G%7J0W]5_7WFY\*?"'B>Z_99\?SV
MUG<9GD$FG#81(\0"_:#'WP0"..I#8KTS]A;2M7M_ &LS7\,T>ES7RM8"92 <
M)B1D!_A)V\C@D&O,? %GXIU']CKQA%ISSW,1U$/#! ^^3[*&3[0% R0I*OQ[
M-7KO[#HU./X6WL=_*QMCJ#M90R/EECVKN(&<A2^<?B>];X^3^K8C5:S7Y+^O
MO.G-'_LF*UCK47KLOQ_^V/HP*!T%+117QA^>!1110 4444 %%%% !1110 44
M44 %%%% !1110 5\.?M>_L]ZEXW^,$&H>'O"FHZG->V(N&G@9C ;I0R[BQ(6
M,A$C7!(W9'!K[CIDI*QL0I<@'"CJ?:NK#8B6%J>TAN=F$Q,L)4]I%7]3\@K'
MPPVG76JZ9=:?-'!;,1<P7"&.ZCD((*.IQT(.<=P!69>6DJ7YO% (D@-NL]P6
M# ! IB;CJ,L1_6M[XG^,KWQO\5-=UVXLFT&"\-Q)+86\K-/&PD"LO3A\J"W?
M)/ S7(PM<>)+F**/5KQ1;E;EOML6V96&Y<.HX.,9!Q7Z!S5)13ENU?\  _3(
MSE*$=/>:OT['ZD_LO^.]7^(/PFL;_6HXC=VT\MBMS FR.Z2(A5D"Y.#_  G_
M &E;'%>M5\D?L$_%);_PQ)X$O_L4%]86RZA:>2A22Y21F,S/R0S!RIXQPXXP
M*^MZ_/L3#V=:4;6/S/&4_95YQM;71>3V/-_VAO&FE>!OA/KEYK%G/?V=S']@
M$%O$LC,\WR+PW& 3G\*_*>YU6\;5+JUCE2Z@M5BFNK11Y8E=AT+DYX]1R3@5
M]Y?M^:O?)X2\.Z)E4TG4;EY)&B8I,T\6UHE#@_*OS,21D\ <5\)^0UYX5U&6
M>U2YNHA\\[$-)E"J\'@@D*Q!'J*^CRNGRT>;O^A]=DM+DP[GUDW^&AUOA#XF
M:YX5GN#9:C)H%U=Z9B*>VN-LUQ%O#>2D@!VNQ"<':3MX/6N3U:WU'4M8O-1:
M*>&:42>9)=.7D'[LD.9"3NYP3_%SUIUSX9NI&TY[N&73]-OK>.YA2:(I'-;Y
MRK+(<%AD'GGD8J'7F=]/AWQ3Z8L_[Q+D.6#C@?,O) / &>#7L1@D^==?ZW/H
M8TE%^T6M[:Z?F?4/_!/'1K&V\=>*H&CCO'FTR*6263$H9EG&",_=Y)/'4C/:
MOOROS:_8W^,FI_#3QO9>%6\.QW\/BC4(;5;I'VM" S\H<?,@#%L$\;#CK7Z2
M Y%?&Y@G[=MJU[?D?GN;*7UER:M=+\CC?C3S\'?'0ZG^P;__ -)WK<\(_P#(
MK:/_ -></_HM:X7]HBV1_A_=7E]H,WB/0;!9+O5;"#6Y=.:2U2-C(,)Q<#;G
M,+LJMW/:O2K%H6LH#;H(X#&IC4# "X&!CMQBO-/&)Z3%+10 F*6BB@ K#\<?
M\B9KW_7A<?\ HMJW*P_''_(F:]_UX7'_ *+:@#(^"_\ R2#P1_V [#_TFCKL
MZXSX+_\ )(/!'_8#L/\ TFCKLZ "BBB@ HHHH **** "BBB@#XT_X*<?L^ZA
M\4O@A<^)/!NAW%_X[T5XV233-PNYK+<?.B4+S)@'<%ZX#8ZD'Y;_ ."/OP@^
M(6B_%3Q+X@UOP_J.E^#X=-:$/JUK)"KWQD3885<#+JGF;F X#8)Y%?K?2 8K
M6=6I448SDVHJR\EO9?-D1A&+;BK7W%HHHK(L_+?_ (+'_"CQWXBU7P7KWAO0
MM0U3PP()8-0.E0/*5NMX\MYT0$D%/E5B.,$9Y%>R?\$JO@=XB\!_!1_$7CS1
M[JR\17UW(NE#5 PN;?3=D84;'YC#.)" 1DKM[$5]QD9HZ5<9RC?E=KZ%QG.%
MU%VOH_-=A:***@@**** "BH;R\@T^TFNKF9+>V@1I)99&VJB@9+$GH !G-/A
MFCN84EB=98G4,CH<JP/(((ZB@!]%%% !1110 4F0.]?./QS_ &MV\'>+T^'W
MPYT"3Q[\1I1AK& G[/8G .9F'< Y*Y  ^\RUR47PH_:J\:Q+?ZS\5]&\'22?
M,NEZ38K*(?\ 9+!1G_OIOK7T%+)ZCI1K8JK&E&6JYF[M=U%)NWFTD>=+&QYW
M"E%S:WMLOF[(^NR0.XHR/6OQW_;O^/G[3G[-_B30_!6I_$N62QN[7^TK;6M&
MMDM9;G#LAC:0(&RFT$J"?OKDG(Q])_L>>)?VA?VF?@5I'BS5/B!!H<?FRV<$
MQTY/-O4B8+YS;5 Y.Y<@\E#Q7FO#05:5+VL6E]K6S]-+_@>MA(+$V]I)4_\
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MT,J3Q))&RO&ZAE93D$'H0>]'M962OL/VT[)7V'T445D8!1110 4444 %%%%
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M%R7:1U"S2M%'.,Y5UVMMXP550W(Q7/6=UY<-K9S12B2>W2>XN-N]9!C)^;/
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MK5!,K;56(M%-Y)^7/G@_,3G:PR*;KFF>+#?W$9GU+4;9(IX8-R1".4D6KJ9
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MFGN)0.CN@4*#]-[&OGC2/%^J6GP5\1Z#%)(-,N-5LW<9^4924LO_  (Q(?\
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MX9IFO+:UG06HFF+L&V\X7^+G)W'UXK6\57GVIM4U:88G>X::&R,^Z.%9&9U
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M:?X@UL1JSWNF:<UC"5*C"^69).1S\V1G^ZO2JOQYE2'X(?$!Y'6-!X?O\LY
M _T=^YKKM%&-(L@>#Y$?_H(KY,^$,/XDSZW;>&&?0A<?:?M, G:S19+A;;S5
M\]HE8$%Q'NP"#[ G KQC6KKXN)/<W.FR:XVD%/+A:>"W^VLGE,V3 L>T,3C$
M@?(*A3'\_'T?UHVC'04 >)>"M7\>7/Q"T^TOW\0)H*M/()]2TZ!8IK;#B%)"
MB;EG+#<6)0*D: J6E8CVZDV@=A2T %8?CC_D3->_Z\+C_P!%M6Y6'XX_Y$S7
MO^O"X_\ 1;4 9'P7_P"20>"/^P'8?^DT==G7&?!?_DD'@C_L!V'_ *31UV=
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M?M._!RYTS6;RXTN^T4OJ>G:A;*':*58V#*RGAD9>",@\ @\5R/\ P3Q_9/\
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MO0[OP]=:=>7J>8TGVF*6&(&W$\8R"&)9=W&T8*<\%<^GT %8?CC_ )$S7O\
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MX;O[C0/,M8%OAHUV]OO@B4;A+Y#<H%'.[  ]:FCN?!4,48CFT%(Y-/DN4"M
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M?VL-)N=?_:DUG2[-5:[OI-/MH5=MJEW@B503V&2.: .$_P"%\_$C_H?/$/\
MX,'_ ,:])^&6I_%3XC^$O%6LP^/_ !/&VEPD6<4=XS"ZN!$\S1DD_P!Q.V3N
M=!WKB8/V=/&-V8#;#2+F.XF6WMY8M3C*3R%I%*H3]XJ89=WIL)JU:_ #XAQ^
M5'9-;.T5ZD<$5GJRD^9(B$2H%/R@JZY?@X!]#0!Z?:^'OBG'+=K??%_5#Y$3
M'997-U(QE1[8/$V4&,+=Q'< 1D^@) _A'XSSW<R6OQ1U!(TE.4N-0N T<)-Q
MM=G";&.VV<E4)(R 0,\>=V_P5^(D=X7DURWM?WC#[0-<)+HRP>9(FTY=0DD6
M[N0 "/E%=%J7@7XE7'AVS\/:?XELKNQL;R0(\=TEL\EQ'<7,<:QRYWR,6CG(
M!P0202>M #_%R?&'P;H&HZI=_%&]N/L0:5[:WU&X,CPBX2W\U25"XWR)P3GD
M\<5YE_POGXD?]#YXA_\ !@_^-7]7^%GCF._TW3KJ^CO+G5[F:S\D:J90DJ*E
MQ,D^3A-H=';.>>>2*F\._L\>)=?^RW2SZ9_8\]VEN+^VO8Y@Z%D5I8E!!D53
M(N<8/7C@T 97_"^?B1_T/GB'_P &#_XTH^//Q(R/^*\\0]?^@@_^-8OC_P '
MMX%\2R:0UT+TI!!/YRIL!\R)9,8R>F['X5SJ_>'UH ]I^(]Q+<^9--(\LSC>
M\CL69F/)))ZFO+O _CGQ'X/\62#0M=U'1Q=-&LXLKEHA* XP&P><9/YFO3?B
M!_J3_N#^5>+:5_R-L/\ UT3_ -#6OW;.TO[):]/S1_,O#C?]N1=^_P"3/;_B
M9KFI27 E?4;R26!R\+O<N6C;U4D_*?<5YQX8^+WCG1]8N8;'QCKMK%*\9=$U
M"7#?-CN3VKN?B3]^;ZFO&-*_Y#\G^]'_ .A5AQ%3@LK>G;\T=/"-6H\Z2<GK
M?K_=9[Q\2]=U*>022ZE>2O"_FQ-)<NQC?^\N3\I]QS7F.A_%[QSHFI7R6'C'
M7;1) I=8]1EP2"<=6/J:] ^(_P#RT_&O$;?_ )"UU_NC^='$=."RF32[?FBN
M$JM1Y[%.3UOU_NL])_X7S\2/^A\\0_\ @P?_ !H_X7S\2/\ H?/$/_@P?_&N
M$HK\0/Z/.[_X7S\2/^A\\0_^#!_\:]<_91^+/C7Q1\=M TW6/%FL:II\T5T9
M+6[O&DC<K Y7*GK@@'\*^:*]K_8S_P"3BO#7_7&\_P#29Z /TMHHHH ****
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M<D#:V=N 0.<U*G[+OPABUVUUE/AKX775;06XM[L:7%YD/D!1 4./E*!$ (Y
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M'E[%8]V*L>OJ<WOAC^PEX1\ >+_#?B/5O%WC3X@W_AB,1Z#%XLU87%MI8"[
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M0>"/^P'8?^DT==G7&?!?_DD'@C_L!V'_ *31UV= !1110 4444 %)@'M2T4
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M^D:<;.WMK6%0%4!G9F=]J%V)YV+B@#QWQM\:OB_X0_;)^(>G6VIZ)=^#= \
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M )&?_MW3^;5ZY7D?Q._Y&?\ [=T_FU ')T444 %%%% !1110!SOCW_D6Y?\
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ML$WAG1Y8;Z[&H74<FGQ,L]R"")G!7YI 0/G.3P.:Z*@ HHHH **** "BBB@
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M.Y8'$./,H^>Z]=M]M;;V/,C^U?XBT3PH+](=$O?LEJMJ-*NKB1M2FD&C"_\
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MNK0O;R1Q?:)03M,)WF5N$V1M&=[;N.>U_P#:G\6W/AKQ#9>9X;\-W]AI^L7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>bcyc-20241231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $# F\# 2(  A$! Q$!_\0
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M$L<%K%G9$OE)PH["K,SZ,C.<T^D5=M+0,**** "BBB@ HHHH **** "BBB@
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M_125[^.M> ?LP_\ (]_'?_L<IO\ T4E,1[_12+]T4M(84444 %%%% !1110
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M 4444 %%%% !1110 4444 %%0,P169V"*,DECP!ZUGQ^)-'"X_MBP)]KE/\
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M+=![50\#?LQ_#?X=>+;KQ)H7AJUM-6G);SMN=F?[H_AKU>C%.PAD9.33Z**
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M?*SZ.&2P&<<UX%^S!_R/7QV_['*;_P!%)7OH<*P!('XUX#^S$V/'/QV.,_\
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M0:ZGHOPM^,5C\1?#FI:A=VTGA^\TFXDM=0M;XA3$R'!?/]T]0:Z/PSX_\/\
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M*D9!'X$5\B?M4_VO+XWT3P'\-M,\+:!XAU:*2[N-;UFUCVJJ]ER.2:&!E?\
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ML K-= _Z/:=LLW0D?W:^0?V*OVA?%O[3V@P_#W4+A=%LM%MU6XO;0_O;N(8
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MUB/'.*?3(Q@X'2GU1(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  H\P9(QTKC.4?C-)@4@D!&>U+N]J %(SUI-H]*6B@ HP*** "BBB@ HHHH
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MU ,C>IQU-7C7G'QS^(>J_#+X>:GK.A:#/XCU=8F%M8VYQ\^.&)]!UHV J_M
M?#'4OBMX/TW2M,N(+2>VU6UOV>X!P4BD#,..Y KTFYMTN8)8IAF*52C*>X(P
M17S_ /LP?&C6/$7[/5QXU\?7$::A;2SO=B,?*@3G8HK#_9,^-_C#XQ?$/XC+
MXB@-EIEI+$^EV3#!6!AE6/H2.:5PL?0_A'P5I/@/P_;Z+H=HMCIMN6,4"DD*
M6))Z^Y-:::;;Q7<EVD$2W4BA'G"@.RCH">XJT.E%,"O=6,-] \-Q$D\+C#1R
M+N4CW%210+"JJ@"JHP% P *DHH YWPKX"T7P0NJ#1+-;(:G>R:C=A23YD[XW
MN?K@5L'3;9KI+IH(GNHU*I,5&]0>H!]*M44 4=0LH-2L+NSNE\VVN8FAEC/=
M&&&'X@FJ?A3PKIG@KPW8:%HUL+32M/B$-M AR$0=JU']OSKPS]H0^,=!MM9\
M3IXUM/"WA'1].-S;1(-DLUTH)VR,>"AP %'-(#J/ WPSU#PU\9/'WBZXN();
M#Q ELMO#'GS$\M<-NKT:\T^WU& V]W!'<PL03%*H93CID&OE'XJ_M/>-?#W[
M->A>)M$\.R:CXBU335NI[V(;(+5>-TIS^8%?0WP?UZ[\3_#'PYJU_+YUY=V:
M32R#^)B,FA/H%K'7^7\A4<#H/I6'X/\  NC> M,GL-#LUL;6>YDNY(U)(,LA
MR[<^IK?6EIB*@TRW%[]L\B+[5MV>?M&_;Z9]*DFM([F&2&9%EBD!5T<9# ]0
M14]% RO;V<=I#'#"B0PH JH@P% [ =JQ]!\"Z-X7U36=1TNS6UO-8F%Q>R@D
MF5P, G\*Z"B@13N-/MIKB"XEMXI+B#/E3,H+1Y&#@]LT7MLUQ8W,0X:6)D!(
MX!((J:Z+B%_+QYF#MSTSVKY4\4^//'GP>^(OA*WUGQ3!XBU7Q+JQM9-"MT/E
MV]J3\KJO4%1U-)NP[7/9_@'\-]0^%/PSM/#VJ7$-U=0W$\S26X.PAY"PZ^QK
MT4*6'!Z?RKX>\=_M#^-='^+FNZ?;:J\>KV>LQ6&F:"BYM+BW8#<TC]%;'K7V
M_9O));1/*H61D4L!V..:$[CM8\X^+GP+L/BQ?Z)J$VI7.EZCH\AEM;FVQN4_
MC2>%/@)HV@W^JZIJ5S/K^N:G;M:7&HWA^<PL,% .@'->GT4[(5V?.UI^Q1X/
MM+OP_.]_?3+H%W]JTR*1\K;9.2H'I63:?!K6/'W[7"_$G5="CT?1=%M7LH#<
M#,U[)T63Z#M7TZ_09II;IUXJ;(=V29S1115""BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:Y('%.IK
MCIZT <-\:OA__P +3^%OB'PJ)O(;4;?RUD/0,"&'Z@5Y-\&/A]X\OOB=I_BO
MQE9V>EVFDZ$FD6T%I/YOG2(W^L)]"O:O9?BAK=WX<\":O>V-I)?WPBV16T7W
MW+$*<?@2?PKC/@#HM]X"@U3PA?W-Q=)"_P!ML&N"69(),$J6/4AB14O<:V/7
MHFW%O6I*9&,"GU0B,DYZ\TD,JR;MKJ^TX.TYP?2L_P 0:@^D:'J%]&AFE@@>
M2.-1R[ $@?B>*\:^!%KJWAGQ!=2:G]JBM_%$8U.*SN"6-O.3^\7)Z#VI7L"5
MSWD'-+2;A^=+3 ***.M 'C'[5O@;7OB7\)9?#/AY87O;V^MBZS2;-T22J[X]
M>!TKUW3+--.T^VM8XUBCAB6-47@#  Q7@?QDM_%.M>/$U?1H7>V\)QQW-FJL
MRK+<.X64.!]Y1'D_6O?M/NEOK*"Y0Y65 _YBDG=C:L6***3<*8AD\JPJ&>18
MQG&6.,GTI"6/&<"O%OV@M.UWQ??:9HVCI)]FLE?49WC8J?-09A7(Z@GJ*].\
M%:I<:[X3TN\OE$=])"OVA ,!9,?,/SI7UL%M+G044=**8!6;K=NU[HVHV\0'
MFS6TD:9Z9*D"M(UR7Q.\0OX5\#ZG?PVLUW,5$"QP#+Y<[,CZ9S^% 'C'PH_9
MOFNO@+=>!?&4TEH)]1DNV?39\$KOW*-P^G(J+]G[]F_5?A+\:_&_B":^N9M$
MO8XH=/66?>74#G</;M7=? C2]1\$?VIX*U2\N=4NK,"]%]/DAED/" GTKUOR
MSQSBI2*>C)*;)G'!Q3JS/$VJG0O#^HZB(7N#:P/*(HQEG(&<"J)+JR*_W'#X
MX^4YQ4U>$_!*'4_#'B>>'4KF[O%\31G5(%G!Q:#KY?MUKW:DMAM6"BBBF(@)
M&23S7R9^U=\)?B+\9?BGX8TY-(BU;X6::%O+NR%UY37EP.BN.ZBOK?RN* K*
MN,T/4#R7XK>"M4\;_L\ZUX8TK3(--U.[T[[+;V"M^[B/&%!]!BNJ^$/AV]\(
M?#/PYHNHA5OK*SCAF5#D!@ #78>7[TH7F@ 0<FG4@&*6@ HHHH **** (+V2
M2.UF:%!),J$HA.-S8X%?'?P;^$_Q,L?CUKGC_P ?^'K?5-2O+AK>PN5NLI86
MA/&U/[V.]?93+NQ32A/>DU<+V/CCQA^SIX^U+Q!XHT.TL[&31O$&M1:E_P )
M"9,7%HB8)4+U).,5]A6,!MK6&'=O\N-4+>N!C-2A#SS2JFVA*P-W'4444P @
M'K1@9S110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4UNE%%  55CR >,\BF[%\PMM&[INQS
MBBBA"'+UIU%%,!@4,V" 0>QI"BD@[5RHX..E%%(!<=*?110,**** (]JC<-J
MX/7CK2Q *@P !Z"BB@!],]NU%%  %7EMHSCKBD"A1P .>PQ110!)1110 5&4
M60$.H89Z$9HHH (D7+-M&[.-V.<5)110(*:ZAA@@$'J#110!&L2'#;%W+P#C
MD#TJ:BBA#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>bcyc-20241231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #S K\# 2(  A$! Q$!_\0
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M"@#))[4 .HK@M&^.W@'Q#XLN/#6G^*M-NM:@X:TCG!;/H#T)^E=[1N 4444
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M_G,HLX,Y\J+/W5KV2BBR"[*NH@C3[HY(Q$_0X_A->&_L/@_\,]:,3_S]7?\
MZ.:O=-2_Y!UU_P!<G_\ 037AO[#_ /R;QHO_ %]7?_HYJ.H=#WJBBBF(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF[\]!FEW<
MCB@!:*"<5PNM_'3X?^'-3FT[5/%NEV-_"=LEO/.%=3Z$4 =U7F/[2BZC)\#O
M&J:1??V=J)TZ00W(;;L;'K[]*[?0?%VC^*-'75=)U"WO]-8$BZA?*$#KS7C5
MR\_[1?C,V\9>'X=Z+<9D<<#5+E>P/>-?UJ6QI:GX]_ CX<>/-<^-F@VVAZ=J
M*:U%?)+)<B)QY:ALL[$]J_??3HYX;"VCN7\VX6-5D<?Q-CDU'9Z/9V#![>T@
M@<*$W1QA3@=LBKM-( HHHIB"BBB@ HHHH **** "BBB@ HHHH *3=SBFR2K$
MI9R%4#)8G %<%\2OCAX0^%_@_4?$>K:O;-:62%F2"57=CV4 'UH [_<,TM?&
MGP%_X*6>"_C'X[/AJ^TZ7PU).Y2QN;F4%)SV!/\ "37UY9:]IVI2-':7]M<R
M+]Y895<C\ :+A8ODX&:;Y@YZ\4K#*D>U?,7PA^(VJ_#[Q;\8O#'BK4+G4(O#
MTS:MI]Q=MEI+:1"^U?8'BDW8:5SZ<#@G'>C>!ZU\?^ _C?XH\$>"?#[3I+XI
M\9>.[V?4]/L+^X\I+6SSPNX] !CBL+QM^U1KOBO5/!!\/64T7B2SUR;2M6T"
M&7,;3*!C+CJG/6IYD5RL^W2X% <&OD?7OVH[K5O#>IV.LZ+<Z+XCT/Q+::5>
M6EG=<?O&!#!^ZX/2N[O/V@O$>J^)]4M_"?@Y]?\ #VDW"V=[J,<X$GF8&[8G
M?;W^E/F0N5GON\4NX5\7?![]HW7?#WPWEMYQ)XH\4ZIXJU"SL(;R81JD2R<!
MF/15Z5[[\#/C8GQ9M=9M+NR&E^(-$NS9:A9K)YBJX[JPZ@T*28.+1ZK1115$
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M+_%W]H/P[X5MM7T+3_$^G:=XKBB(B^U@O'')C@''5O\ 9KYW\*?LM>(OCWID
M?B34?C_KFJ7>[YUTQC$D#]=A3((QZ&O=8?V2_#<OQ&\1^(]28:E9:K?QZM%8
MW$8;[->+_P M5/I[=*^>/#7[3.@_L\>./'6B:/X5\2>/]5N=6>XU75;*VQ"9
MNRHJC "CBLWOJ::6T/H;X*?"CXJ?"S7Q9ZWX^'C/PIY>U1J$?^E1$=,-W%>]
MC.>:\R^ ?QF;XW^$GUMO#NH^&RLIC^RZDA1S[CVKT/4M2M=&LY+N]N8K2UB&
M7FG<(BCW)XJU:VA#\RW16-I?BW2-<L)+[3M4L[VRB)$EQ!,K(I'7)!P*-&\8
M:+XBMY[C2]5LM0@@)662VG618R/[Q!XIB-FBL71?&&C>)(YY-)U6RU)+<[96
MM9U<1G_:P>*71?%^C^(Y9X]*U6RU*2W;;,EK.LAC/H<'B@#1U+_D'77_ %R?
M_P!!->&?L/\ _)O&B_\ 7U=_^CFKW/4O^0==?]<G_P#037AG[#__ ";QHO\
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MPN_9K\(_"?7)-6TF*>>^6(V]L]W(9/LD'_/*//1::BQ.2L<IJ?[6,B07L/\
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MY^Q\$WVK?!R_TSX<:Y:>+_$&JZDD_B>]9]C7*,<R(A_A&.!7D=S8^*/^$?\
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M%% !1110 4444 %%%% !1110 4444 %%%% '#_%/XLZ5\)]-AOM6MKZXAE)
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MWUJ4H$M6SN)<X4?4UV88<>],#AO 'PDT3X>6>KVMC&9K;4KMKR6&90R*Q.<
M>@KLQ:0+,)1"@DQMWA1G'IGTJ8L!UXK#L/%VEZCXDOM"MYV?4K%%DGB,; (K
M?=^;&#^%&P;AXQ\)6/C?P_<Z3J",8)@,,OWD8'(93V(-2Q^&[!K33X+JUBU
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M0 4444 %%%% !1110 4444 %(3BEJGJ^I6^CZ;<WUW*(;6VC:661C@*H&2:
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MP_X(N[*XN6>&6]F43,O^T/6HD7$^NOV3;66T^'\BR?$4?$DF<_\ $S#;MO\
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M** "BBB@ HHHH **** "BBB@ H)P**HZXMZVCW@TUXX]0,3"!Y1E0^."?;-
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MR#Q3$;=%8FB^,=$\1I.^E:O9ZBL'$IMIU<1_[V#Q1HGC#1?$LL\>E:O9ZE)
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MN^KHK+WEZ(YL-\+]6%-<96G4C?=-<YUG ^& &^)_B0'H((C^M=\!BN"\+_\
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MCPWE\L2IYP7[H  P !VKZ[I+75C?9&.GA'0TF$JZ+IZR Y#BU3(_2M=5"C
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M;<>5H5CI<++#+#C*N".&-1(J)]Y? 'XMZE\8O"4FL:IX4OO"-PLIC%GJ P[
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MY5YGZI2>-M%L]!75I[^*"P*[A+(^T'CMZUY-\1/%FK?&CPIK/AOP;I4SVMY
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MF&&KQIJ'M7MY?Y'G5,;A)UG6^K*U[VO+_.Q\G>#OC7XTM?'D-_\ VA=7QFF
MDLBQ(D!/W0*^H]7_ &@CX>U+0]-U3PIJEM?ZTYAL8?E/G.J[F Y[#FNATGX%
M>$=%\53>(+73%6]D&0K,2B'/51V-:OBCX:Z-XP\1>&=;U*&22_\ #MP]S8.L
MFT*[KM;<._%<> P&*PZE[2KN^G_!/6SG.,OQ]2$J.&2LK/=?DT8&J?%S4M*T
MVZO;OP5JT-K;QM++(2GRJ!DGKZ5S4WQ[O=:\ -XBT3PMJ3V-Q;&>VNWV["O9
MB,YKV/6]*M]>T>]TV[4M:W<+P2JK$$JPP>?H:RO"/@?2_!?A'3_#6FP%=)L8
M!;0PRMO.P=B3UKTIT*THM*J_P_R/ IXK#1FI/#JR\Y?YGP_X-^-7C&T\=0WH
MOKJ]DFF >S+$JX)^Z!VKZ=U?X^/H&JZ'IFJ>%M4M[_6F:.QB4K^^90"P'/8'
M-='HOP(\(Z!XIFU^UTQ1?2\X9B40^JCM6OXH^&VC>+_$GAG7=1B=]1\.S23V
M#(^T*SKM;([\ 5YV"P.)P\9*=7?Y_F?09SG&7X^I"5##)65G>Z_)G,ZG\7M2
MT33KF_O?!FK0VEM&TDTFY#M11DGKZ5SNJ?'6\UOX=OK^C^$;Z;3[JU%Q;7,X
M4QLIZ,1G->P:YHEOXCT6^TJ\5GM+R%K>8 X)1A@\_2J/A7P;I7@WPCI_AG3H
M"-*L8!;0PRMO.P#@$GK7H3H5I)J-5K[O\CP88K"1DI2PZ:3VO+_,^%/A[\1]
M;L_B';7P6.ZFN;@+) 8@0V3T [8K]!+9B]O$S#8Q4$KZ5\^^!?A6VD?M,^,K
MI]!\GPO'IUK+IMPP_=_:23YH7W%?0P(P >M<V6X7$X:,OK$^:[/1S[,,%F%2
MG+!T>1):Z)7^[L?#GP3\>Z/\.OVLOCU=>(+AM.AFFB>)I(SB0!>=I[UXV9M?
MT7PUXN\70V4NGZ-XX\:1K;WUU:&3[#"A/[\1D=\]Z_2Z_P# GA_5+MKJ[T2P
MN+ER"TLD"LS$=,G'-7[C1+&[LOL<]G;S6F /(>,%,?3I7K<K9\US)'Y8_"[X
M8_\ "7K^T;I5C<W.M36GV75-,U"6W\AKB:(EC(JXP,X[5]!?L!OJ7Q@\5^,O
MC'KL$D-W<"+1+**3^"*%0&(_X%FOIWX@?"*R\9>%[S1]/N&\-->*L,UYIB+'
M*8AG* @=\FK_ ,)OA;HGP:\#:?X4\/1/%IED#M,K;G=B269CW))H4=0;T.O7
M..:6BBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/$?VJOC#K'P>\!Z=-X>AA?7M9U*#2K.6X7='"\K;?,8=\9SBLK]G7XL>+M<\
M>^-/ 'CB:SU'6O#KQM'J5A%Y4=Q&ZYY7L0:V?VIO@_JGQ?\  ^EQ:),D>KZ+
MJ<&K6R2\+,T1W;">V>E9'[//PN\3:5\0?&GQ!\76\6FZIXA:-(M-A;<((T&.
M3W)-1KS%:6/H&BBBK)"BBB@ HHHH *JZI#/<:;<QVLRV]RT;"*5ER$;'!Q]:
MM4V7/E-CDXXS0!\B>'_&OQ?NOVFK;P';^+=,UK1M,@^VZY*EEL,*$X6('^\>
M*^ND'7TKPG]FOX3:_P"!_$GQ%\0^*$B.K>(M6-Q'(C;CY"C"+["O>%7!-3'8
M;%HHHJA!32ISGBG44 -P?;%*1FEHH Y/XI>-Q\.? ^HZ^;"XU1[51Y=G:KND
ME<G 4?C7SO\ LC?M/>(/BIH'Q,USQ^D&CVWAZ_V1P!0AMH@NXJWJ:^KKJ)9H
MBCJ&'8$9Y[5\C?"C]DW4KO0_C+X>\9M-8:9XLUP7UM/8R@2&,'(.?KBI=[W&
MK=23]E/]J/Q-\>/C7X[TJ_M$L/#FGPK+IL#1[9"A;"N3[CFOKF-=J]:^0?V?
M_P!D[Q%\)_VD?$WB:?6KJY\-M91V]FSL-T^!C:X'85]?K]T417<'N+1115"$
MQ@<&D8$K@'!IU%%A#-I)YQ4=P"L;$<M@X'3FIZANRZPNT:[Y I*J>A..!189
M\?>./C/\6OA-\3/",7B35="O;3Q+K)TZW\,VD7^D1VQ/$^_VXS53QK^U]XR_
MX:G\'>!-(T5M)\*7=Y)9SWE_%\U\Z8W>7Z ?K6;\,?@_\2HOVEM8^(OQ$\)?
M\)#<S3>1I$PN5\G38,_>5#WQ7IOQ]^"'B/QY^T+\'_%>D01G1_#LL[W[%@I7
M?@@@=^E9ZFFA]++]T4M(.@I:T,P--"X[TZB@!N#ZYI"AW;AC/O3Z*-@(]C9)
MR.G2OG_]I7Q'\4/"IN-6\,:WH?A?PGIFGO=7=_J<7FO-,.5B4=@<8_&OH2OC
M[]LKX6_$OXP^//#&F:?I!U3X;:<ZW6H6$%P(GOI1R%;_ &1TI2V''<X?X@?M
MD>/9/"'PVU.QN=,\'6VOZ1<W]SJ-[;F9))HONHB]@Q'ZU]6?L\>/-9^)OP?\
M-^)?$%M%::M?P;YD@^X?F(# =L@9Q7@WQ'^"'BS4/%OAKQIHGA2PNK.'0I-'
M?PG>,K)8E@0LB<;3CJ>_%>X_LT?#35?A'\'M#\,ZW>)>:E;>8\KQDE5+N6"C
M/8 X_"HC>Y3M;0]5HHHK0@**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@",]&^E("0X^N/THHH EHHHH **** "BBB@ I
M&Z444 ,CZU)110 4444 %%%% !1110 U_NU$2>/H:** 0-QC'O4J?=HHH =1
M110 4444 %-?M110!&W8=B#2GM113$/0Y04ZBBD,**** "BBB@ J*0D9HHH
M ,$CT%.51112$/HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>bcyc-20241231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #A MH# 2(  A$! Q$!_\0
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MP B(JJJ@*H  JG#EOS/T^]I_EIY6[Z3S*5N7OK]R:^>MG_5^SHHHK,H****
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M#?\ !0C3/%&E_#?X1:IH'BG4?$]Q&;.7Q#=E9;>1T1W+M(SESD)CD=37U?\
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M>,(H=%=V=FLX"9V1025^;@$@8SSC-?MA??\ 'E<?]<V_E7R)^SW_ ,E<L/\
M<G_] :@#Z6^%GPO\._!KP'I/A#PM8KI^BZ;%Y<,0Y9CG+.Q[L222?4UUE%%
M!1UHHH ^8?VG_P!F:V\26%UXJ\+VJP:O"IDNK.%<+<J.K =G'ZUQ7['?QSGT
MO5H_ VMW!:RN"1I\DIYAD_YY\]CV]_K7VD0""",@]J_/C]J;X?-\+/BO'JVE
M VUGJ3?;K<Q\".4,-X'XX/XU]5EU98ZE+ UW?3W7V/N<IQ"S.A++,4[Z7B^J
M:_R_*Z/T(HKDOA3XS3X@?#W0]=# R75NOG =I!P_Z@_G76U\Q.#IR<);H^*J
M4Y4ING+=.P4445!F<C\8/^22^-O^P'??^B'J?X7_ /)-/"7_ &"+3_T2E-^*
M<0N/AKXI@;A)M,N(FQUPT;*?T-7O ]JECX+T"VCSY<.GV\:YZX$:@?RH VZ*
M** "BBB@ HHHH **** "BBB@ HHHH **** &R.L2,[D*J@DD]A6!X)^('AWX
MCZ5-J7AG5[;6K"&XDM)+BU;<JS(<.A]P>#7F'[5S?&Q?!MC_ ,*3716U;SF_
MM#^VMNS[/L/W=W?.*^-_^";[?M&YA$*>'?\ A5W_  D5[_;!.S[7]HW_ +[R
M^^-W3VJJ2]I*4=K?YK\/U%5_=QC+>_\ P?QT^X_3BBBBI&%%%% !1110 444
M4 5=2U.ST:REO-0NX+&TBQYEQ<R+'&F2 ,LQ ') _&L+_A:/@S_H;M"_\&4/
M_P 57%?M9?!6^_:)_9]\6?#S3=2M](O=:6V6.\ND9XX_*N8ICD+R<B,CZFOS
M;_X<A^.O^BE>'O\ P#GH _5G_A:/@S_H;M"_\&4/_P 51_PM'P9_T-VA?^#*
M'_XJORF_X<A^.O\ HI7A[_P#GH_X<A^.O^BE>'O_  #GH _5G_A:/@S_ *&[
M0O\ P90__%4?\+1\&?\ 0W:%_P"#*'_XJORF_P"'(?CK_HI7A[_P#GH_X<A^
M.O\ HI7A[_P#GH _5G_A:/@S_H;M"_\ !E#_ /%5Y+\*/VYOA+\6O%FK>%['
MQ'!IOB'3KZ>Q-EJ#B/SS'(4WQ/G:ZG&1@]Z^ /\ AR'XZ_Z*5X>_\ YZ\&^$
MO_!.+XP?$SX@:KI>FV)TG2-(U*>Q?Q)>AH(7,4K(9(@?F;.W(QZT ?OPK!@"
M""#R".]+7DO[-7P2U3X$?#VW\/:OXUU7QM=(!_I.I/D1<?=C'7;]237K5 %'
M6I/*TJZ;_IF:Q;0;;6$?[ _E6IXF8KHMSCK@#]:SHQB- >" * '4444 %%%%
M !67XJUE?#GAC6-6?[EA9S739]$0L?Y5J5R?Q;LI=3^%/C.SA&9KC1;V) .[
M- X'ZFMZ$8SJPC+9M?F9U&XP;6]C\^/^">.A?\))^T'JFM7,?GC3].GG69SD
MK-)(J _4J9*_3.OSG_X)E:A%;?$OQ?I[G%S-IJ2HOJJ2X;]76OT8K[;C:4GF
M\HO91BEZ6O\ FV>!D"2P2:ZMA1117P1]&%%%<5\2_B79^ =-_AN-3E!$%N#_
M ./-Z"@#Q[]H8C_A8MISTM(O_0WKZ,TDAM+LR""#"F"/]T5\5:WK=[XAU.:_
MOYVGN93EF/;T ] *]5^#WQC?1GAT36Y2]BQ"P7+GF'V/^S_*@#Z*HIJ.LB*Z
M,&5AD,#D$4Z@ HHHH \P_:3T>+6/@WK_ )B;VMHUN(\=F5A_B:\T_8DUHS:#
MX@TIG+>3.DZ*3PJL,''XBO8/CE=+9?"3Q1,XRHLV&/J0/ZUX/^P_92"^\47>
M/W1CBBS_ +0)/]:^CP_O9563Z-6_ ^PPGOY'B%+I)6_ ^LJ***^</CPHHHH
M**** +FD<74OH4'Z$_XUKUC:8?\ 3,>J-_,5^./_  [F_;"_Z&-__"MD_P#B
MJ /VGHK\6/\ AW-^V%_T,;_^%;)_\51_P[F_;"_Z&-__  K9/_BJ /VGHK\6
M/^'<W[87_0QO_P"%;)_\51_P[F_;"_Z&-_\ PK9/_BJ /VGKBM?^,W@OPKXX
ML/"&L^(;/2]?OX3<6MI=R",S(#@[2>"<]J_(W_AW-^V%_P!#&_\ X5LG_P 5
M7@/QU_9C^-WPW^(F@>&_%Z7WB+Q3J$)FT^.ROWU"0(& X;DKR10!_1(K!U#*
M0RD9!!R#2U\/_P#!/KX2?M'_  _TF!_B;XG1/"YC_<:#J'^D7L?''[S^ >QR
M:^X* /@C]MK69-4^+T&G+EULK.-$ ]7Y(_.OM'X9Z#%X9^'_ (?TV%-B0640
MV^Y4$_SKX>_:]!LOCY<RR A/)MI,CN,5]Z^&YDN?#VERH<H]K$P/ML%?39C[
MN!PT5M:_Y'V>;^[EN#A':U_G9?YLTJ***^9/C HHIKNL2,[L%11DLQP * (=
M08)87+,0JB)B23P.#7R)^SXZK\6]/RP&5F R>OR-73?''XX-KCS:!H,Q73U.
MVXND.#,?[H_V?YUXE97L^G7<5U;2O!<1,'21#AE([B@#]"J*\I^"_P 9X/'=
MHFFZDZ0:[$O3H+@#^)??U%>K4 %%%% !7SA^W)X?34/AA9:I@"73[U#NQR5<
M%2/S(/X5]'UX/^VE,D?P2NT9@&DNX H]3O!_D*]++6XXRDUW1Z^42<<PHN/\
MR_$ROV&]9>^^%U_8NQ;['?MMSV#*#C]#7T;7R[^P7;/'X*\1SDMLDO(U4'IP
MISC\Q7U%59HDL;42[FF=Q4<QK)=_T"BBBO+/$/'?VN/%/BKP5\ ?%>L^$=(@
MUS4K6V+26,Q8%X3PY3:,E@#D"NB^ 6L^(O$/P<\):EXKTZ#2-;N=/BDFLK=B
MRP@J-HR>^,9KO)Q$T3+,$:(C#!QD$>]47UW3[;$8F4!1@!!P!2;2W+C"4OA5
MS2HJE;ZQ9W1Q'.I/H>*N=:$T]A.+CHT+1113)"BBB@ HHHH **** "BBB@ H
MHHH ;(BRHR.-RL""#W%<_P"!_A[X<^&VE3:9X8TBWT6PFN)+N2"V!"M-(<NY
MR>I-=%11L&X4444 %%%% !1110 4444 %%%% !1110 4444 %-5%084!1Z 8
MIU% !1110!E>)P3HESCT!_6L^(YB0YSD#FM;78S+H]VHZ^636+9-OLX&ZY1?
MY4 34444 %%%% !3)HDGB>*10R.I5E/<'K3Z* /RT^!&I2?LX_MC/HVK2&&U
M:]GT6XF=<;HY6_=/[*7$1SZ&OU+!R,BO@[_@HO\  NX>>T^)VCPLRJJ6FJK&
M.5(XBF_DA/;"U[/^QM^TA;?&GP+#I6ISHGB[2(EBNHV;YKJ,#"SKZYQ\WH?J
M*_2N(*?]L8"AG5#5I*-3R:Z_>_NL?*Y9/ZCB*F J:7=X^:?]?F?15%%<5\3/
MB99^ --_AN-3F'[BVS_X\WH/YU^:GU0?$OXEV?@#3#R)]3F4^1;@_P#CS>@%
M?*NM:U>>(=3GO[^9I[F8Y9CV]AZ >E>@^!? NJ_%O7YM8UB:3[!YF9IVX,A_
MN)Z#^5>XK\)_"*J%_L&T.!C)4Y/ZT ?']%?8/_"J?"/_ $ +/_OD_P"-'_"J
M?"/_ $ +/_OD_P"- 'D/P=^,3:*\6BZU*6L"=L%PW)A/H?\ 9_E7T2CK(BLK
M!E89!!R"*\@^)7P,L+_33=>';6.RO(5R;=.%E'^-<S\)/BW-X<N5\/\ B!G6
MV5O+CFE^] ?[K>W\J /H:BFHZRHKHP9&&0P.015/7-;LO#FE7.HZA.MM9VZ%
MY)'.  /ZTTFW9#C%R:C%:L\5_:_\9QZ%\.TT:.3%WJLH7:/^>:\MG]*E_9!\
M*/H/PR;4)E9)-4N#. W]P#:I'L0,UX%KFHZG^TU\9(8;5'CL-WEQCM!;J>6/
MN?YFON/1=)M]!TFSTZU01V]K$L2*!C@#%?1XQ?4L%#"?:E[TOZ_K8^QS%++<
MNIX!_'-\TO+LOZ[%VBBBOFSXT**** "BBB@"UI8_TX'_ &&_F*V:QM'YO9O1
M8U_4G_"MF@ HHHH **** "J+:'ISZLNJ-8V[:DL?E+=M&#*J9SM#=0/:KU%
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ML1PZAE.0>0:=67HLI3S[5CDP-@?3M6I7>G=7/GYQY)6"BBBJ("BBB@ HHHH
M**** "BBB@ HKG/B+?W&F>!=<N[29H+F&U=XY4.&4@=17/\ P)UR_P#$/P^M
M[S4KN6]NFF=3+*<L0,8H ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*K_6:\ZS5N9WLC^@#]E#P'I7Q%\&Z%\1;AEN;'485N;*U/.W/=_<'M7U*
M , 5\Y?\$]/AQJWPL_9)\#:)K<<T&I/%+>R03C#P^=(TH0CM@,!BOHZN<Y0H
MHHH *JZGIEKK%A/97L"7%K,I22-QD,#5JB@#\WOVZ/%[_L;6UAJFCRBXOM6E
M<:,C/AXF3!<OW(7<O/?(%?!TG_!1W]H63Q)'K!^(E^I0@_8E51:M]8\8-?9W
M_!;;X=:QJ.C?#KQI;123Z-IC76GWA4$B!YC$T;'T#>6RY]=M?DW0!^EWPX_:
ME\<_MNW5IHM_!YFMV.Q186*E87SP9L=O?/ S7Z4? +X(V7P;\,>2=EQK=V U
MY= =3V1?]D?K7YN_\$4OACK#^/\ QIX]E@>+0H=,_LJ*5EP)9WE1R%/?:L9S
M_O"OUTKTJN/J5,/'#)6BM[=?4]FMFE:KA(8-)1C'>W7U_K5ZA1117FGC!7)W
M'$L_][[4,Y_2NLK U*T"7TBGA+@ JWHXZ5E45T=>'DE)IGXL_&+]A[7_ !E\
M5/%FN2^*[.)[_4IYS'+;.S+ES@$YYK U;X1>//V<?!UDG@BYCU+6;^Z8W]W;
M(%8Q@#8H5ST'.:_2KX\_#JYTK5I_$-K"S6$YW7(49\A^Y/L>N:_(+]J3XUW'
MQ$^(L\.F7DL6CZ7NMK?RG*B1@?F?CU-?/TGBJU=T*GPKNM+=#]#Q4<IP6!CC
ML.FJD]%:3NG]K>]ONZ^9ZWXK_8NU;XC:E'XB36[#1KB_MXI;JU\AG G*CS""
M#CD\U]=_\$U_V=M:^!FL>-I+K7H-5L=0BM%6&&%DV2*[_-R3V-?/'[#_ ,5;
MGXA>'O\ A#;EI+S7=.P+9?O/-">GUV]*_4OX-?#_ /X0O0$2[P+EF^T73#H&
MQPGX"JH3Q?MW0F_=CY?<98^CE/U"..HQ_>3\W>_6ZV\MNIZ/8X_MN[Q_<7/U
MK6K,T6(LLUTXPT[;AGT[5IU]!#8_/*OQ6[!1115F(4444 %%%% !1110 444
M4 <K\5/^2<^(?^O-_P"5<Q^SA_R3&U_Z[R?TI?CSX_TWPWX1O=*D?S=1U"%H
MHX$/*@_Q'T%<O^S3X_TUM$'AJ9_(OTD:2+>>)0>P]QZ4 >\4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5S7B6+[+J5E>CA&)AD/L>GZUT
MM4=:T\:GIL\'1BN5/H1TH RJ*J:9=&ZLU+C$J_)(/1AP:MT %%%% !1110 4
M444 >?>+OV?/AKX]UN'6/$/@?1-7U2)MZ7=U9HT@;.<YQR<^M=SI^G6NDV<5
MI96T5G:Q#;'# @1%'L!P*L44 %%%% !1110 4444 <%XT^ ?PY^(NIPZCXF\
M%:+K=]"=R7%W:*S@^N<<_C78Z3H]CH-A%8Z;9P6%G$,)!;QA$4>P%7** "BB
MB@ HHHH **** "HYD,YC@'65@GX=_P!,U)4^CP_:+R2<\I$/+3Z_Q'^0H VU
M4*H Z 8I:** "BBB@ HHHH **** "BBB@ HHHH \F^/G[+?PY_:3TF&S\<:#
M'?RP BWOHF,5S!GKMD'('M7E?PF_X)F_ [X1^*K?Q#9:%<:OJ-LP>W.JW#3Q
MPL.C!#QGW-?5M% "*H10J@ #@ =J6BB@ HHHH **** ,GQ5X3T?QQH%YHFO:
M=;ZMI-XACGM+J,/'(ON#7YJ_'_\ X)O?"CP-XU@NM-TV_M](OE,RVHO'**X8
M[D'.0.5P*_4"N&^,7@(>/_!T]K$H^WVY\^U8_P!\#[OXC(H I?L^:3X;T/X2
MZ!8>%=,M=(TRW@$1M+1 JI(.')]R><GUKT:OD7X*_$V3X:Z_/I>K"2/3+A]D
MR,.8)!QNQ^AKZUMKF*\MXYX)%FAD4,CH<A@>A!H EHHHH *@N[5+R$QO^![@
MU/4-W=PV-M)<7$J0P1KN>1S@*/4FC<:;3NCS_P")VI#0/"6HR72!I7B:&)N,
M2EAC!!KXE\$?L*?##XO>);^[U_PM''$@\R1K6X:U\R0GU0C/O7LOQE^),_Q+
M\2P:9I(=]/@D\N!$ZS2'C=_A7OWPQ^&MOX3\)6MK>1K-?R#S)W//S'M^'2LG
M!K8ZE6B_B_X!Y_\ "']F/X8_ IVF\)^'=.T>[==CW-NIEN77T,AR<5[';6CW
MRJIB-O9J<[#]Y_K6A;Z;:VO^J@13Z@5:I1AW"==/2(BJ$4 # '04M%%;'(%%
M%% !1110 4444 %%%% !7!?%;XK6/PYTH@%;C59E(@M@>G^TWH*7XH?%73_A
M[I3[72ZU63*06BMD[O5O0#(K@OAO\(KCQA=R^*O'"-=W%W\T5E,. IZ%AV]A
M0!\[Z[KM[XDU2?4-0G:XNIFW,[']!Z"JMI=S6%S'<6\C0S1L&1T.""*^U_\
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MU@\O5M/CN& PLP&V1?HPYH Y#P[^T7X1UJ)/M5S)I,YZI<(2N?9ESG]*Z?\
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M **** "BBB@ HHKD?BI\3M(^#_@N[\3ZY'=2Z=;/&CK9QJ\F78*,!F4=2.]
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M+R?P]/PK4HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>bcyc-20241231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $3 OT# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MY_Q8N;>,]LX->.^)LQ2J57<"3N^E>U>)X/,TUFZ[3G%>+^*89&0>6,$?C0!S
MX=DMYF3[WW@.M9NCRN9KXLY 9@X7NI(J7[8;;._@CY>,8K(MK@6_B.:%V7]X
MG&"/F]* .JM/$CV?^CNP&!Q7:^#_ (B&WE"22[H,_,K'I]*\6O-2$<[&5R,,
M1\W'7I3OM3V3)(&PPYVANWO0!].>-M0M+[P+J,^Y9(# 3Q]*^+FT2"6[DN!+
M^\*D&-3UX[BO2=2\;3)HRVLLCBTF/SA3U/I7B6AZZ^N>,3>V-K#8Q?/#-;3D
M^=*RG@H>F/6@#RSXL>&9O'&F:K:37/DVT44@".>#QQGVKR/1K-+_ .!E^;?4
M0+JTBDA5$_U<K < 5Z7^UQJ<_@[P'XBO;.7[-)>(ML ?E^\<$CWQFN9^ _@.
MPOO@OHXO=S>?'YK$YP"6)!QW]* '?LJ^#+[P]IUCK.J2R07DH.R)2-I0]R.Q
MKZVO?A_:^)+[2M<6XEC\D8,:M\K ]<CO7A.K7!\':=I<,;%()+N.VB<#[V??
MM7T9I]Q;_P!A$@M%'"H#3-PH/]: /I/X4?9?#O@5;EF"Q;BV?6L3Q7XW.I2'
MS25@!^6)3^IKS73?'=_=^'K:W.?L47RA(AS]359M6W0([L2[MM"'J30!U.I:
MK'<0,"Q50,!16*\ICGM8E'+>_-1?;#G?P0.N>E5;&\-[KR.A5UC7D@< ^E '
M:1#=T.UE 'K72Z*,Q"3)^5N,5REO-YDP(*L2<8'%=5X>C9H,[B!NP![T >LZ
M6<V,)]5%6ZK:<ABLH4/4**LT %%%% !1110 4TGFG4T]: #)HR:2B@!<FDR:
M** #)]:R_$?B2R\+Z3/J&H3K!;Q#))[^PK3)KY<_:6\52ZKXA314=A:6JAG0
M' 9C_A0!%XK_ &E_$&MW#Q:$J:59AL+/(-TC#UQVK'B^-WC>U7S?[;,XX(#Q
M*0?:O/;*+SR$$6 !@;JZFWT07%DP&U6& ,#C- 'M7PY_:+CUBYAT_7XA:W#D
M(ER@Q&Q]_2O;DE\Q0RD%2,@CO7Q!)H[6Y/F 9XP5-?3GP2UR?5/"@@N9#++:
M-Y89NI7M0!Z*6- )HI* %R:7)I.M% "[J4'--IR]* %I"<4M-/6@ W4;C244
M &XT;S0:,4 &X^E8GBOQCIW@[3'OM1F6*)1PO\3'T K8E<1HS'@*,FOD#XP^
M+;CQ9XJF+N6L;:0Q0Q@\>A- ';:O^T[JEU=$:/ID$5N#P]T26;\!4-G^TUKM
MI.KZAIMI+;9P1!D/7EMC8L2/D(3Z\"M"719%*EHPQ89&#TH ^IO _P 3](\=
MVV;*39<J/GMY.&7_ !KK@Y-?&7A^6X\/:K;WUE*T5U&P)P>"/0U]=>'=4_MG
M1K2\Z&6,,0/7O0!I;FS2[C2$4G:@!^ZC=244 +NIU,IPZ4 +3=U*>E-H 7=1
MN-)10 ;CBC<:0TM !N(K'\3>++#PGI[7E_.L,8Z ]6/H!6I+((XV=C\JC)KY
M-^*WBNY\5^(YV:0FTMW*0Q#IQWH [F__ &C-1N=0(TS3XQ9@X#3_ 'C[TV#]
MH36XY5>YT^V: 'YQ&3GK7EM@&QN7&.Y)K1:PWQ\G<#U7T]Z /IGPA\0M,\80
M@VLH2X ^:!^&%=/O)%?)NBR7.C:C#=6;&*>(]2>"/2OI[PUJW]M:-;7?0R*"
MP]Z -3>?2C>:0]:* %#'TI0U-I: %W4ZF4X=* %I"<4M-;K0 NZC<*;10 NX
M4;Q3:,4 .WBC>*:<"N.^)OC$^$= >2'!NYLI$#Z^M %OQ/\ $W0/"+;+^Z)E
M_P">4*[W_(5BK\=O#+)NQ?*/1K?!_G7SK]JEOKDW%T3).[;]['G-7OLKRAI0
M-QZ@CF@#Z1T'XJ^'O$-QY%O<O%+V6X39FNL$BMC!R#7R/:6V]G=%((.5.>0:
M]S^%?BZXU6!M/O3OGA *R>HH ]&W"C>*;C- % #MPI=PIM% #MU .:;2K0!%
M=P+<P/$>0PQ7E?B7356>:$KM?!QCO7K1YKEO%FC>>5N%7.!@^U '@NK:<L;,
MI3(;L2*Y'5+,1QBZ&(KE?NN>1D=*]9\1:8%AD;&S:,^QKAPBZG;+ 0!@\@CK
MCGB@#G$L(-;M8;F0%GC.Z1<X"./6HUD_>.SPN,C:&'0CUJCXLT+4=,FO+O3)
MUBCNDVM [;=[X[>]7O",[7]O]BD"JR(,\<Y[B@!L,3ZE');NX5=^ H[KZBL3
M6_A_</?PW>G7XT][7<RLD8;+$<Y_SVK8OO&>GZ=XGNO#^R2&\2 2K(\3+#[#
M?TIK^);5I_LT=RHN)$ <;SM!^I^M 'RW^TYX9N/&/P\BL)E;4=0$\;L\#@))
M\P!.[_/6NKT?P.?#FC6EC'#);P6EM'';VRR$IPO.1]375?%RWALH+6!+*+[2
MUW$0ZD8.2,G';UI;R]-WJUI&%D\U"48!<JWR]1[<4 >0_'6]DT3PWX?V6KRE
M-3BD"[&8C##)(%?3FDSSZWHL+! UH\:R[2N >.E>::UX,/B[Q%9+/.!!$?,$
M*]1QTSCKFO4M!FT[1_#ZPO*QAMEP2225'U/6@#<LWCBL@L \ME ^4=3[8IU[
M;7,MJKQ^6L"L-QD;YS^(K'TCQ?HVHZE#%:VMZQF!*S& JJX]S5K6 VH:BNG(
MR+%M#2..W- %A[I+R]M+6R<&XD&UR&R(U[G'>MNRT4Z?>32"8,A7C [^]0>"
M_"D&D7<QC_?JP^^>WH :Z>YMXX+;&#YDG&T'(_"@"32;9YO*15&&R25KU#P]
MI9?[/%CC(9\US7AG2V2W1V3)7L!UKU#0M.^R0"1Q^\<?D* -10 H Z"G4E+0
M 4444 %%%% !33UIU-/6@!**** "@44G>@".>5+>)Y)&VHH))/85\6?$R_76
M/&6LW<;>9%YY4.#V &*^PO%<OD^'M0?.,0MS^%?(EUHD=Y)<;Y,N6+@'HQH
MY>TE2)E8JQ'J>AK>TO6MUL8VB=2"0 W%4KS4(T@F$+)!(/X" 0/?Z5C:/XA&
MH3%8;B&78=CD@9)]>* .JFU%=VTJP;N:]K_9_P!3C1-0BDE1=Q0@,V"2<\5Y
M'HS)J,$T<R#"KN,F  #VKJ? ,1BOX5C?]X9U&5_2@#Z>!H'6D3(09.3CF@4
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M.#F@#T&E%0QW44W*2*X]0<U*&!Z&@!V:6FBG 8H *<.E-IPZ4 !Z4VG'I3:
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MVI;$CF;8IMS@18[MF@#V>6XE$+JLJJY' S4>@ZA?V*,99"'ST5JP(;R3[*#
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M;B"2V$94X$<A#.HYZ$@&H_#?PK\)^#FMFT;0[:Q>VE>>)TW%ED=-CMDDDDJ
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MU[7\9[=+OP^L+HKC<&R_.W\*^//%&L>*/#<<3^'=*AOK%[B0W5Q*V"B#I@4
M>WZ5XJL[?QK#8W+B*.\;YIAV'2O;CX'T^5-L0*NPXD)YKX%\!>+M0^(/C/0[
M/4[5M/E%X#$[/@, <G./Y5^CMD%VQC>#M 7/X4 <E;>%ET*]D<222)*07RWW
M3TR!71Z5K2V]RVFW$IDD #1L.I%:3VD37'SC*D8([5R]A8D2SW22K<-!.RKY
M9SMP>AH [%&N)'C6.,LN>2P[5L6\YC?()!!K$\-^(H=0=H V)$[$5NNG ?\
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MMX)N4(*+T(R#7R[\#9E/AY$W&41' 8\?A7T?X-N64PG R>#0!Z$!2T@Y%+0
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MQG6)#-*!%%E51^A[=^]>\>!BL&G.;N(-$ZA2AY*FJ>J> -'\1RM):W4<4,9
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MN0<;>1F@#\Z?VT-!FU7X43WL:NXM+E'/&0!G!KX ZU^P'C[PM;>.?"FIZ+,
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M5U%]J-A??#V>^L[J*"0QD(A;&6QZ5Q7P4\.3^*M<@^V#[1#$WG2EE)4'L :
M/4?A=\/YQ+:W%Y'MCC **!C)KWBU0/-'$%/&,_2LJT"6JQJB[5QC"]!6OIH+
M2!E&6)P >] '0>/]/%G96=VJ_+A0<5FVCJS(P(RPR*[SQ5IWVOP>4D4!DC!(
M/TKS[3QLMH"!VP30!W7@67=/*,YXKMQTK@_ "%;F7([5W@Z4 +36ZTZFMUH
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M#B+9O[,O;J.1=MNWS#:O!^M9-SH-AXFL+@3RH1DMOW$$;>AQ^5=UJ6DK<,K
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M"MZUQ9^6YR5KA=<BC7Q5J2X^\@;/O77^$T,3$'N.M<%)(-2\=:Z YVQE4P:
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M);K6M\-KQKS2RY8G+<9':L:">/4M-DCPQ*IM(SU-;'@G3VT^Q2 ;D^;KC&:
M/<-*7;I\(Z?**MU7L4\NTA7T458H **** "BBB@ HHHH *8_>GU%,=J,1Z4
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MR8(48 ].*[W22#(N!C!H ]0@_P!2GT%25';G,*'V%24 %%%% !1110 4444
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MU[3;FYEN(;JP?&(XR%(^]D9'6OTXU+QAIUGINH75M/'JDEE'YDMK8R+)+[#
M/&?>I[?Q/IDSVT+WUM;WEPH9;.69!-DC.-N<YYH ^'O#_B:9M1MML<DL4G[G
MF+ X]\?K47QKE0>"Y8X;.6YFAD25(MOH><9K[Z9@BEF(50,DGH*I6&O:9JL\
ML-EJ-I>31 -)'!.KL@/0D \9H ^./!6HQW?ANUN3;M:R+%B160ELCCGBO2/#
M6H*]O%)&KGN24(XKW?3_ ! M_KFHZ:+2XB:R5"9W4".3=GA3[8K6H \ALKEY
M?.,B,8DY)(P*N1623LH\@MGH1WKU*B@#G]"T7[&!)(H!Q\JCM6^O2EHH *HZ
MG;&ZA(4X8=*O4F!Z4 >6^*K"2)6D0$,.H R37/6 >_N40,(R/[_%>W2V<$_^
ML@CD_P!Y :@&BZ>K;A86P;U$*Y_E0!X^FHO%+)%P(^AP>K5Q^O:W]FWE@6B.
M1O'\/M7T@=$TYEVFPM2N<X,*X_E6-XHLM)T;19[O_A&4U@I@"SM+))))"?08
M_6@#Y0\2ZQ EOYPE14(QECD&N \$:[;K#JDHN%=Y+GY&YR?H:^HX_B=\/[OP
MY;W%OX*-U?SWDM@-"328S<K/$NZ12N,852#GIBNL\':1\._&?AJ#7+#POHL-
MFQ;<+C3(8VA=3A@P*_*0:=@/DC6M1C-B?G,CC)S)QCW->(^#O#=AIWQ5U/Q!
M+>%HV4;8#SUX)W#MFOTTDTOX<WJHCVGA>=2_EJK16S O_= QU]JS;#PY\/!/
MJT<W@[0=)ALI_*>>ZTZVBCF.T-N4XY'/>D!\J>'/$-MJ;WEG%<8)'_++.4'I
MFL7XB:S9:3XJ\.SL2&'R-(YZ+VSFON?2_!7@Z6W6YT[0=#>"8;A-:V<)5QZ@
MJ,&JNJ^&? $-Y"NI:3X;2Z+ 1K=6UN'+'H%W#.?I0!\\Z3J$*)%-"?W4@# J
MP .:[*SU1(X5?(8OT4&O5M=TWP[X;M[0CPQ:7*3SI $M;*,[,_Q'CH*W%\-Z
M0@PNEV2CT%N@_I0!Y5'(ETT>]=K8R%'I6A8Z:MY,IB5RXXP.GXUZ8-)L5QBR
MMQC@8B7C]*EBLX("3'!'&3U*H!0!GZ%I@TVU"GF1N6K5'2C ]!2T (>E4YH]
MQ.1UJ[32@;K0!QFKZ/M=I4&5ZE<5@&+<^%&1_*O37LXI!AER*KC0[)<XA SU
MH \QUE3Y43$C*'\*X_4]3@C&T81LY*K7N5WX.TR]3;+"V/9R*Y7Q?X$\'Z!H
ME]J^J0RQVMK$9)&64Y('0 =R>U ;GS_XNO5NRJL040?,WM[UY_X.UVUT6YOK
MZ%&E59RFR+DU[BUWX%U/0/#NH:;X3UW5WUY9##90G$JJGWBX8\5V&F_LY^ ;
M;2H[J6PN]-1R)WCN+PJ8V/9CG%.P'SUXLU^+588IMIB+#JPZU\Z_#C3=;B^,
M?B"6_,8T]?G$D<F01_#@=CZU^B4WPB^&&L"&(7MO,TQ,<0BU%27/<+@\D5SN
MA_ +X56]QJU[+I]SHWDW+6LDE_>^4DQCQ\ZY.".>M(#R+P[XG,]B8K9MX4[6
MA4 $^X)Z5@>*HET_QEI$LLCJMUU#')#?6OJ[2/V?? <,J:A8VK3"105D2XWH
MP[$$<'ZU4U[X)_#>^OH(-1F6*\WXBB?4 LA;T )S^% 'F&@7K6ZF -OC/(ST
M%=?IMP''+#;CKGK77:C\.O"_ARYTVT33+ZX^W2^2&AD+"/ SN;T%='#\,]"@
M'RP2?C(: .4L[7S8D*\!1P*T[33VGDV!<>K5U]KX<L+.+RXXCM]SFK46FV\'
MW$Q0!3TBQ6V08&/>M4=*0(%' Q3J "FMUIU)0 TG%,/S?2I< ]J3:#VH QM8
MMD^R2/\ >55)P:\2US4$>>5BJG!ZBOH1X(Y%*L@92,$'O60W@K0F+$Z7;DL<
MGY>M 'S5>^(D9'B65 ZG!&?F'TKS+QI?(MU9JI>:*6<;MH&1SV-?6OCK3?!'
M@BQCOK[P]'>7-Q*(;>UM8#)-/(>BJM<EXAU7P+HMGI[W?P]O9=6N8FN?[)BL
M]]Q#$GWI& . !^M '@LWBR72W:R9!;6X!)Z@X/3 [_6O"_COI\GB31&^RRI%
M/%)OC8$8*G ))QUK](=(\-?#[Q5X>L_$,.E6#:?<Q+(EQ.NS"GH#D\<\54/P
MY^$^JO&G]F^'[IKDLB*LJ,93GY@ &Y_"CR%?J?#?@'Q5#X8T+1H+B[62:&)$
MD\MBQW8["O3/$%^VLZ#?!KM9(C#F.)2-P[Y/O7T'8?#3X47*W=Y>^$-+T<6U
MP]OYNH*L0?;P64EN17:V7PU\'-;*UKHE@\$B !HE#*R]L$'D4#/D[X?:NESH
MUI<$&*?;Y; $<8X[=Z[NQUN&Y18P264]&&3]*]L7P?X!TF\BLOL>D6MTY*QV
M[2*KL>X"DY-/U+0_#N@ZII-LOAY97OYFA66"(%8L*3N<YX'&* .0\%7*W&HQ
M!@%#< &O6((1$H[GUJ"W\.:9:.&ALHHV'0JO2M (H[4 (.:5:7:/2B@!:*3I
M29^M "GBO-O&N&OIB>Q!S7I!/M7G'C*TNY=1F,-E<3#.=T<+,.!TX'\J .1O
MR6BDVX)?(4'\A7,V^FR6EH;9 %4,68+V^E;5S9:Q.5"Z/?IE@=WV60C\!CC\
M:YB[M/$8O D6E:JL8E955M/F(; SG<%X'UH R?$8CN[B>)9F54@(D53GGM6Q
MX.8#1;<-+M$7+ GK527PUJLD5[-_8.JQRSD[C)8R,>!QP%/%0^"O#WB06C6U
MUI>J1D2Y4S:=*N%] =M %/XF^)VM]!FU2WMRUO:-AP/O$'C/YU\K:AXVG\3Z
MSYC7;"&*8HL0^X%SWQU-?<H\,S:A:3VMYHE[<V,C&.4M9R#/0C"E<]>XXKYD
M^*O[+?BK0M;>;P[H-]>P,[2*UO$Q R1U '6@#L?#BQZ[91R*#+"T6W='D$#%
M6K+X16/VV"_DG"(&W&%N3U[U?^"/PL\4^'O#2MKNDZD+]09$@\B3!S^&!]#7
M?:AHNKW,# Z#J$4D(#%5M)&W''3(&#0!R4L=G=ZZ8H7'E6\.W8G!0@]*[:.Y
M\B$B50S!3MV<@^_UKSG1M'\1ZUXCUNYE\+Z[;VJIY*++82QF4<8()49'\N]=
MS8:7KD$8A.B:G+Y9*Y:RD X (QD<CGKZT ;6ES[[=' !,GS9/&!75Z.Y,AYY
M&#Q7&V=IJ_[I4T+40",8>UD7YO\ OGBNJT2WOUE0RV%[&6.%W6SC\SCB@#UR
MS?=:Q'U45/5:S5EM8@00=HZCFIQG- #J*04M !1110 4444 %%%% !1110 5
MXY\9_P#A)KGQSX#DT;PG=ZU8Z3J)OKFZAG1%"M#+%M ;G(+@_2O8Z*.J8[G@
M7B#X=:GJ7Q=LM7\/^%)O#=^-4@O-2\1KJ1,5Y;)M$D9A!PS.BA.@QP<\5TWQ
M0^%J^//&5A>7>E6^IV%MIEU"%N &597 "_*>/Q[5ZO11TL%];GS;:_ K4M$T
MV"'2M(@LWE\/265WY3 &6?.5WGJQ]S6@OP0N7N=7U231[=M:?5M-N+6\)!E2
M*)8A)M;JOW6X'6OH*BJYOZ^=R;'-WFH7M_X:\0?;-.;3C"D\46Z4/YR!.)!C
MIG)X/I7S[\!_".MV<'@[Q+8>"H=&@T_PXL<K072;]8>2-2F2!V^]ELX/ KZE
M*A@00"#P0:2.-(HU1%"(HPJJ, #T I+0?D>;Z-9Z_H?BKQ)K8T-KA=4-D$MU
MN%5DPK"3)QSMW?C7I5%% !1112 **** "BBB@ HHHH *YGXC17-QX0OX+72[
MG5VF7RWMK.Z%M,5/4HYZ$5TU%+<:T/EKP=\,/'7@7^QM?@T-K^.PU*]D@T2:
M]5KN.VGBV O,1AW#9)SVXS7HVB_#?6+7X(:YH=W!&-8U4W-P]K&^5C:4Y";N
M^!CFO7Z*J_0E:'S5K'[.,2VNO'3O#5C%</HEI#9,BJ"EVF-[#T;C[W7WK8D^
M#FI:SJL0U?3(;S3SXA2_ECF8,KQ"!5R1W^8'@U[[13YA]+'G'PXT34_ 5NVC
M1:*!I<^JW3Q-#*JQV=N0&3">A;(P.F:\F^*'A.^\6_%/Q986'A*WUVZN;"WB
MAU&:=4-@^3^\ (/3KE>:^H*8L2+(T@10[<%@.3^-*^J?;_*P=_/_ #N>7:_H
M/B'6=(T;2FTUBVD75H3>/."+E44;W ZCD=Z]#T+4+S4K$S7VG-I<XD9?(>42
M$J#@-D>HYQ6C11< HHHI %%%% !1110 4444 %>??&+P#K?C_2M.MM'U>WTS
M[+<BYEBNK?SH[C:/E5AGH#S7H-% 'S)%\*-?M_A9HVD^)_":^+]<MY;@V]SI
M]X;(V3.Q*MD$$CD'^E>B:G\/]=U+X%VWAG4W&J:QY,<=P6DSOPP)!;O@<9[U
MZO13#8^<]3_9YCMI=?N-)\.V5M<M=64]A)"JJ8BF/,9/[IZYQUK3C^#5YK'B
M*R;6])@OM+C\1:CJ,D5P0Z&.2-1&Q4\')!X->\T4[_U]W^0'GOPOTK5?!FE6
M'A^71REBKW#"X28;+==V8T"]<$'C'2O&_&G@S4/&'Q)\9V>F^$[?4;N:ZMO*
MUV6=5:PV@$L 1D<?W>M?4U,6)$=F5%5F^\P&"?K2OJF*VYYMJ^E:]K>N>&I'
MTEHH]%NW#3/.K>>GE@"0>F3V-=YH5_=ZEI<-Q?:>VEW3YWVKR"0IS_>'!]:T
M**+A8****0PHHHH **** "BBB@ HHHH \C_:$^'EWXXL?#US;:6VN1Z5>FXG
MTR.Z-NUPA7:0K@C!'6O//"_PZ\?_  _O;+7X-$.L-+8SV":1)J :2Q1G+1 R
M-G<!G!KZ?HH6F@[GBVH?"/4?^&=K3P2T4=Y? VGGQ!\(P6ZCDD&?0*&KGM<_
M9^6WU#Q5>:+X>LK6XDUG3;K3)(55#%%&(O.*?W,D/G&,]Z^BJ*KF=[_UT_R)
M2LK'@\?P:NM8UC3?[;TBWOM.BU:]NY(KC#H4DSL)4\'\:[CX8:=JWA+2;#0+
MC2"EI&LK_:EF&R(;SLC"]?NX^E>@44KZ6 ^5/%O@G4O&GQ'\:6.F>%+>[O)=
M6L9(O$<DZJ]@(S&[X!&X952/E/.[FO8M<TW7?$7B#PO>-I#6T>C:I.7+SJQF
MB$;*DHQTW$CCJ,UZ,D21LS*BJSG+$#!/UI]"=DE_70IO6YGZ%?7>I:5;W-]I
M[:7=2+E[1Y!(8SZ;AP:T***0@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>bcyc-20241231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bcyc-20241231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &( D # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]*/B%\3M
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M_P#R#7JM% 'E7_#2OA'_ *!'Q _\-SXA_P#D&C_AI7PC_P! CX@?^&Y\0_\
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M?$#_ ,-SXA_^0:/^&E?"/_0(^('_ (;GQ#_\@UZK10!Y5_PTKX1_Z!'Q _\
M#<^(?_D&C_AI7PC_ - CX@?^&Y\0_P#R#7JM% 'E7_#2OA'_ *!'Q _\-SXA
M_P#D&C_AI7PC_P! CX@?^&Y\0_\ R#7JM% 'E7_#2OA'_H$?$#_PW/B'_P"0
M:/\ AI7PC_T"/B!_X;GQ#_\ (->JT4 >5?\ #2OA'_H$?$#_ ,-SXA_^0:/^
M&E?"/_0(^('_ (;GQ#_\@UZK10!Y5_PTKX1_Z!'Q _\ #<^(?_D&C_AI7PC_
M - CX@?^&Y\0_P#R#7JM% 'E7_#2OA'_ *!'Q _\-SXA_P#D&C_AI7PC_P!
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MH> ;?3['PF_A&[@DOO$@B41SP:<\ E+H_E[K@1A=P1RY$19/I/\ 9*\!PO\
ML7>%/"#Z)?>#+Z;P^VFZE;76DR:=<PW;1&.>5HI$1F8N2V_&'ZY.<T .^'7[
M4?B#XYR:YK/PP^'\'B/X?Z3>-8C7]3UT:?<:M+&3YW]GVWD2+(H 3:\\MNKL
MX!*A69?8/AGXV;XB^"--\0OI-WH3WGF;M-OROVBW*2NA27:2 XV_, 2 <@$X
MR?E+]BB_U[]E7X4W'PB^(G@SQ3%K&@ZG<_V=J?A_P]>ZMIVKVTTK/'+'<6T3
MI$=Q;*S&,J"A;'S!<;]J?P!J>K?M,_"?Q_??#?5K_2+OPGKFE:U!IVBMJ\D,
MLMG*EO;77V99 <M<;,L3$"7PY4,U 'W=17Y2>'/A3JMS\#?V/M(USX<>+_[1
M\-^)[O\ X2!%\+:DMQ8637;NXD=(=ZQL)(S@'#<]=K8Y;PG\-_$7A_2?"=W;
M?#;QY8ZOI'QO.KV31>#]64Z?X7PKMY(%OB&%G=BT*!6<@94[!@ _82O&-!_:
M#N]5_:L\1_!FY\-PVL>F>'8_$5OKD6I&4W$;2QQ>6\!A7RV#._(D<84?WB%_
M/[]J_P"!7B2'Q-^UCIVF?#'Q!JTGBV^\.:MX;FT;PS<7<$\L;EKV:.6&)D20
M>=,'RP=O,<X(+5[?KW]I#]K+XE>+7^'GCCQ#X9NOA$--BAL]%U*P;4+G,<[6
M<5QY:&.5HR1\I#JV5 \P;* /O*]O;?3;.>[NYXK6TMXVEFGG<)'&BC+,S'@
M $DGIBO/K/XLW_B_2/ FO>!/#$GBWPOXCN?]*U7[?%:?V?9$-MN_+?YI@Q"X
M1<-ALG&,5\ ?!;X5^(K_ %;X]Z);?"C4_"?A;QA\.(QHN@+X:OK&Q2_AMR([
M9WN5 ENHI"4:XEV-.ZM*JA7&9O"/PM?0_#O['<EC\(_$&BZIH>LF7Q/<0^#+
MF*52888Y9[DI!N +@*6EP6$6X90*Y /U!HKXL^#G[+<'@?\ :%^(O@R;P#IK
M?"@ZW8^/M$O9M,C:".[:":$V<;,F 8I?WB*C#RD&,!9\'@/V7?A+\1=/_:$;
M7/&;ZQHGC73_ !-JK:E>#P?=/_PD.FSQ((Q-K9N/LTEJ@2'RK<*7C:(;4X)
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M?46_9R^&$>LV^I6FM6_AK3[74(-8MIK>[2ZCMTCF$J3*'W>8K<D?-]X$@@D
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M<MNVDL;>:!5C&G1QBZ6, 8EE,C%I9HUS& #[%N+B*T@DGGD2&&)2[R2,%5%
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M9/;R1RIRHSM89&0<@D&[ING6NCZ=:V%E EM9VL20001C"QQJ JJ!Z  "K-%
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M\9>(/".E:9K/PXEG\0-X1TO2O#GB22ZL&N/!&J6\31O<%A<;T42B&</:&5I
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M1?CK_P!CG;?^H]HU>JUY5\&_^2B_'7_L<[;_ -1[1J #XR?\E%^!7_8YW/\
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M%K_WY7_"KM% %+^Q=._Y\+7_ +\K_A1_8NG?\^%K_P!^5_PJ[10!2_L73O\
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M_P#:_P#?Y?\ &C^VM._Y_P"U_P"_R_XT 7:*I?VUIW_/_:_]_E_QH_MK3O\
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M)?\ XF@"[15+^UH/^>=U_P" DO\ \31_:T'_ #SNO_ 27_XF@"[15+^UH/\
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MOK+_ (]9-0[QALY>LMH^5V=T?]GI\_VI;>2[_/H=915+^UH/^>=U_P" DO\
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MH_M:#_GG=?\ @)+_ /$T 7:*I?VM!_SSNO\ P$E_^)H_M:#_ )YW7_@)+_\
M$T 7:*I?VM!_SSNO_ 27_P")H_M:#_GG=?\ @)+_ /$T 7:*I?VM!_SSNO\
MP$E_^)H_M:#_ )YW7_@)+_\ $T 7:*I?VM!_SSNO_ 27_P")H_M:#_GG=?\
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MEYNH_P#/K:_^!+?_ !NCS=1_Y];7_P "6_\ C= %VBJ7FZC_ ,^MK_X$M_\
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MH\W4?^?6U_\  EO_ (W0!=HJEYNH_P#/K:_^!+?_ !NCS=1_Y];7_P "6_\
MC= %VBJ7FZC_ ,^MK_X$M_\ &ZFMWN68^?#%&.QCE+Y_-10!/1110 5Y5\&_
M^2B_'7_L<[;_ -1[1J]5KRKX-_\ )1?CK_V.=M_ZCVC4 'QD_P"2B_ K_L<[
MG_U'M9KU6O*OC)_R47X%?]CG<_\ J/:S7JM '+:?\+/!VD^/]2\<67AC2K7Q
MAJ5NEI>:Y%:(MW/$O16D R>B@]R$C!R$7%W5O WAO7M/UFPU/P_I6HV.M,KZ
MG;7=E'+'?,J(BF=64B0A8XU!;. BCH!6Y10!SU[\//"NI?V!]K\,Z/=?\(^Z
MR:/YUA$_]FLH"JUOE?W) 50"F, #TJ'5_A?X-U^PO+'5/"6A:E97E\-3N;:[
MTV&6.>[  %PZLI#2@*HWGYL*.>*Z>B@#&N_!GA^_\3V/B2YT+3;GQ%80O;VF
MKRV<;7=O$^=Z1S$;T5LG(! .36S110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #)94@B>21UCC0%F=S@*!U)/85\R:+')^T[\8GUBX5V^'_AB
M3R[6)C\MW/G.<=]V Q_V0@/WC6_^T?XWU'7M1L/A9X5)DUO6B!?NO2"V/)#'
MMD LW^P/]H5Z[X \#Z?\.O"6GZ!IJ_N+5,-*0 TSGEI&]R>?;@=!7UN'_P"$
M?!?6G_'K)J'>,-G/UEM'RNSNC_L]/G^U+;R7?Y]#HJ***^2.$**** "BBB@
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MP\F:]%%%>"<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y5\&_\ DHOQU_['.V_]1[1J]5KRKX-_\E%^.O\ V.=M
M_P"H]HU !\9/^2B_ K_L<[G_ -1[6:]5KRKXR?\ )1?@5_V.=S_ZCVLUZK0!
MS-A\3?"6J>/]4\#V?B33+GQAI=K'>WNAQ72-=V\+XVN\8.0/F0GT$D9.!(FZ
M+3_BSX'U;PE?>*K'QGX?O?#%@SI=ZW;ZI!)96[+C<))@^Q"-PR"1C(]:^8-,
M\1>%O!G[77BK0HM9T?Q%X7UFVEO]>TO62HO?"URD>I//>98 Q6;(9$<R@?\
M(1@:.0Q2!2ZR\2QS7U]XPU#7O"NN^ +?X@V&J7GC#P^ODZ;/9KIK00^:QEEC
M_P!%NELPTJR;!Y89MA1E !]4WGQ \+Z<F@O=^)-(M4U]TBTAIK^)!J+NH9%M
M\M^]+*00$SD'(J?Q3XPT'P/I8U+Q'K>G>'].,J0"\U2[CMH?,<X1-[D#<QX
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M /[0_A?X@^5%:^(+/3=0?C[#J5L89,^BDR;6^BDGVKTWRM1_Y^K7_P !F_\
MCE>#B<)B,'/V>)@X2[-6.:=.5-VFK,NT52\K4?\ GZM?_ 9O_CE'E:C_ ,_5
MK_X#-_\ '*Y#,NT52\K4?^?JU_\  9O_ (Y1Y6H_\_5K_P" S?\ QR@"[15+
MRM1_Y^K7_P !F_\ CE'E:C_S]6O_ (#-_P#'* +M%4O*U'_GZM?_  &;_P".
M4>5J/_/U:_\ @,W_ ,<H NT52\K4?^?JU_\  9O_ (Y1Y6H_\_5K_P" S?\
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M!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^8O\ XB@"[15+[!/_ -!*Z_[YB_\
MB*/L$_\ T$KK_OF+_P"(H NT52^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XB
M@"[15+[!/_T$KK_OF+_XBC[!/_T$KK_OF+_XB@"[15+[!/\ ]!*Z_P"^8O\
MXBC[!/\ ]!*Z_P"^8O\ XB@"[15+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK_OF+
M_P"(H NT52^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XB@"[15+[!/_T$KK_O
MF+_XBC[!/_T$KK_OF+_XB@"[15+[!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^
M8O\ XB@"[15+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK_OF+_P"(H NT52^P3_\
M02NO^^8O_B*/L$__ $$KK_OF+_XB@"YUKR[Q[^S;X&\?&2>72QI.HMD_;=,Q
M"V?5EQM;ZD9]Z]%^P3_]!*Z_[YB_^(H^P3_]!*Z_[YB_^(KLPN,Q&"G[3#5'
M"7D[?\.:0J3IN\'9GSY_PA?QF^#HW>&]:B\=:'&>-/U ?OU7T&YL\#LK_P#
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M?-O1?>;0HU*OP1N>Z5#=WD%A;O<7,\=O @R\LKA54>Y/ KYZ'BKX\?$CC2-
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M,A'_  T[_P#I4G^1\Z?\-+>/M4XTGX-:TRG[LMRTH4_^00/UH_X63^T#J_\
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M_P#4>T:@ ^,G_)1?@5_V.=S_ .H]K->JUY5\9/\ DHOP*_['.Y_]1[6:]5H
M\8^'GQVU?X@?'+QSX1M?#]D/#GAEX;.:]343_:,%RWG'?/:LBJL#B$["DCN0
MT+[2LK>1'H7[1%_XA^'T6L1>#GT[Q-?>)KSPMIWAS4M2C4M<P7$\9,\\*RK&
M!';RROY8F"A&"F3 )RE^$/C+5?VLK;X@W]EH6F:3I6G?8HM;TV\F^VZK:-]L
MQ83VQ0*JJ\]O*SF1P7LXF0+YKI%5\,_!SX@6'@UI;VS\,P>+=+\<7WB_2;:W
MUBXFLIUNI;@R033&T1XSY5Y/&&6*3!"/C^$ &E??M0M'I;WEGX96Z_L2QNM2
M\71/J01M&@MKF:UN/*Q$WVF026MV47]T'2W8A@2JMW?Q&^(VH^&+W0]'\,Z'
M;^)_$FL+<7%M8W&H?8H?LT"JTTIF\N3&#)"BC;@O*@+(N6'D5Y^S/XJ@T;5;
M/3[[2'F\;:7>Z5XON)YY4-JMU>W-V\MDHB82E/M]Y&J2>5N!B8L"I4^@^.O!
MOC:^\0:-XF\,V/A^'7-!-[I=E;ZCJ<_D7&G7,<),LC+;,8YEEMX6\L*ZE8R/
M,7?E0#,T_P#:;LM?O-,U'1=(%[X'E.E07^NS7GE3VEQJ2Q&SC6V\L[Q_I%MY
MA,B&,3J0' ;;[97SAH7[,6K>$(].\):5>V%QX#EFT&_U.\NII$U'[3I:6ZHL
M<0C*,D_V&TW$R(8\285]PV_1] !7&^*/C%X,\&^8NJ>(K*.>,D-;0R>=,".Q
MC3+#\170>(="M_$NC7NFW3S1P74$D#M!(48*ZE3CL>#W!'M7EEI^RIX-MI-T
MEQJUT/[DMP@'_CJ TN;EDO<YE_BY?_;9'F8NKC8-+"TU+NW*UOE9G'>+/VTK
M&VWQ>&O#&H:F_1;F^'D1_4* Q(^I6O(?$?[1/Q*\82F.34IM!LG!S%HT"QLO
MI\S.'_)Z^J[;]G7P!;@9T,S,/XI+N8_H'Q6C!\$? MO]WPW9G_?W/_,FO<P^
M<SPBOA\'23[RYIO\;+[DCSG+/Y?!*C3\TI2?_DUU^!\-V=UID-R;N^\,W/B.
M_8Y:XUK5VV.?4I$H;\#(:['3/C1X[TV$VOAC2O#7AF,C&W1],RY_WB^[<?<U
M]CVOPY\-6&/LVD6]OCIY65_D:U8]$M84"QFX11V6YE _]"IXGB#-,9_&E"W;
ME;7W2DU^!YU?*L[QG^\YE+TBDO\ TGE/B.ZU/XT>*TR^O^)Y&;JNG63PJ?QB
M"_RJ ? ?Q;XA=)-3T3Q/JDV<[KZ[V@GWWIG]:^Y?[)@_YZ77_@7+_P#%4?V3
M!_STNO\ P+E_^*KD6;9HE:&(Y%_=A"/Y1N><^"Z-5WQ.(G/U=_\ TIR/D'1_
MV;?$$.TK\/-(5ATEOK]Y#^*_:"O_ ([7<:/\%/']A@V%GX.T(C^.+3H"_P#W
MUY+']:^AO[)@_P">EU_X%R__ !5']DP?\]+K_P "Y?\ XJN"M6QF(_C8FI+U
MFSTZ'"F P_\ #<EZ6C_Z3%'CZ?"SXG7BA;OXABV7&,6<; #Z8"4O_#/FNWG_
M "$OB1K5V#U4;P/UE->O_P!DP?\ /2Z_\"Y?_BJ/[)@_YZ77_@7+_P#%5P?4
MZ3^*[]6_\SU/[#P;^/FEZSF_U/(?^&5= N>;[7=;NW_O>=&/YHU'_#)GA#_H
M(ZW_ -_X?_C5>O?V3!_STNO_  +E_P#BJ/[)@_YZ77_@7+_\51]2P_\ (@_L
M'+/^?"_$\A_X9,\(?]!'6_\ O_#_ /&J/^&3/"'_ $$=;_[_ ,/_ ,:KU[^R
M8/\ GI=?^!<O_P 51_9,'_/2Z_\  N7_ .*H^I8?^1!_8.6?\^(GD/\ PR9X
M0_Z".M_]_P"'_P"-4?\ #)GA#_H(ZW_W_A_^-5Z]_9,'_/2Z_P# N7_XJC^R
M8/\ GI=?^!<O_P 51]2P_P#(@_L'+/\ GQ$\A_X9,\(?]!'6_P#O_#_\:H_X
M9,\(?]!'6_\ O_#_ /&J]>_LF#_GI=?^!<O_ ,51_9,'_/2Z_P# N7_XJCZE
MA_Y$']@Y9_SXB>0_\,F>$/\ H(ZW_P!_X?\ XU1_PR9X0_Z".M_]_P"'_P"-
M5Z]_9,'_ #TNO_ N7_XJC^R8/^>EU_X%R_\ Q5'U+#_R(/[!RS_GQ$\A_P"&
M3/"'_01UO_O_  __ !JC_ADSPA_T$=;_ ._\/_QJO7O[)@_YZ77_ (%R_P#Q
M5']DP?\ /2Z_\"Y?_BJ/J6'_ )$']@Y9_P ^(GD/_#*'AB/F#5];B;U\Z(_R
MC%'_  S);0_\>WB[6X/3YP?Y8KU[^R8/^>EU_P"!<O\ \51_9,'_ #TNO_ N
M7_XJCZEA_P"4/[!RWI12]&U^3/(?^&>=8A_X]OB-K<'IRY_E**/^%'^-;?\
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M_P#;.)*[_1+:X\/[3IWP&LX77I++ 99!_P "="?UKZ2_LF#_ )Z77_@7+_\
M%4?V3!_STNO_  +E_P#BJRK8W,\1_%Q<W\]/NV-\/PM1PO\ !J6??DIW^_EN
M>/0_%/XB01+%!\,WAC485%9@!]!@4_\ X6G\3F^[\.B/K(U>O?V3!_STNO\
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M,J_>\#Z:?I*/_CU>O?V3!_STNO\ P+E_^*H_LF#_ )Z77_@7+_\ %4?5I?\
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MJ #XR?\ )1?@5_V.=S_ZCVLUZK7E7QD_Y*+\"O\ L<[G_P!1[6:]5H ****
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MK_A0!=HJE_8NG?\ /A:_]^5_PH_L73O^?"U_[\K_ (4 7:*I?V+IW_/A:_\
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MJ^#?_)1?CK_V.=M_ZCVC5ZK7E7P;_P"2B_'7_L<[;_U'M&H /C)_R47X%?\
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MI37LD,*70\ZQN+836[DB*YA:6-1-!)AMD\9:-]K;6;:< ':T5X3X;^)/Q/\
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M%U#6[T6-HT@A60HSY<@D !03T!/3M4RDHJ\G9&=2I"E%SJ-)+=O1&S17F_\
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M-[6."2<O(\ 1$5;JV(=F"/Y\04L74'TZ@ HHHH *\J^#?_)1?CK_ -CG;?\
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M ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\
MY5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_
M  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T
M77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /
MA[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\
M*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U
M^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^
M'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y544
M4 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IO
MQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@
M?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y
M54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7
M?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_
M ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\
MY5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_
M  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T
M77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /
MA[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\
M*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U
M^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^
M'O\ Y5444 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y544
M4 '_  IOQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IO
MQ=_T77X@?^ /A[_Y54?\*;\7?]%U^('_ ( ^'O\ Y5444 '_  IOQ=_T77X@
M?^ /A[_Y55T'PQ^&*_#6/Q'))XCUCQ5J6OZF-5O]2UL6JS/*+6WM54+;00QJ
/HBM8A@)G.22<T44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>33
<FILENAME>bcyc-20241231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 9:41:43 PM-->
<!--Modified on: 2/24/2025 9:41:43 PM-->
<xsd:schema targetNamespace="http://www.bicycletherapeutics.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:bcyc="http://www.bicycletherapeutics.com/20241231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>99940401 - Disclosure - Property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>99940501 - Disclosure - Accrued expenses and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails" id="DisclosureDebtDebtDetails">
        <link:definition>99940602 - Disclosure - Debt - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails" id="DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails">
        <link:definition>99940912 - Disclosure - Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails">
        <link:definition>99941001 - Disclosure - Income taxes - Components of net loss before tax provision from income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails">
        <link:definition>99941002 - Disclosure - Income taxes - Components of benefit for income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails" id="DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails">
        <link:definition>99941003 - Disclosure - Income taxes - Reconciliation of benefit for income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails">
        <link:definition>99941004 - Disclosure - Income taxes - Components of the company's current and deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" id="DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails">
        <link:definition>99941102 - Disclosure - Commitments and contingencies - Components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfLeaseLiabilitiesCalc2" id="DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfLeaseLiabilitiesCalc2">
        <link:definition>41103 - Disclosure - Commitments and contingencies - Leases, Maturities of Lease Liabilities Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails">
        <link:definition>99941103 - Disclosure - Commitments and contingencies - Leases, Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" id="DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails">
        <link:definition>99941501 - Disclosure - Segments and geographic information - Significant segment expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>995200300 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>99930803 - Disclosure - Share-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables" id="DisclosureSignificantAgreementsTables">
        <link:definition>99930903 - Disclosure - Significant agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails">
        <link:definition>99940101 - Disclosure - Nature of the business and basis of presentation - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails">
        <link:definition>99940204 - Disclosure - Summary of significant accounting policies - Property and equipment, Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails">
        <link:definition>99940205 - Disclosure - Summary of significant accounting policies - Research and development incentives and receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>99940301 - Disclosure - Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>99940601 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails" id="DisclosureOrdinarySharesSharePurchaseAgreementDetails">
        <link:definition>99940702 - Disclosure - Ordinary shares - Share Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>99940801 - Disclosure - Share-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>99940802 - Disclosure - Share-based compensation - Share based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails" id="DisclosureShareBasedCompensationShareOptionsDetails">
        <link:definition>99940803 - Disclosure - Share-based compensation - Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails" id="DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails">
        <link:definition>99940804 - Disclosure - Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails" id="DisclosureShareBasedCompensationRestrictedShareUnitsDetails">
        <link:definition>99940805 - Disclosure - Share-based compensation - Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails" id="DisclosureSignificantAgreementsCollaborationRevenuesDetails">
        <link:definition>99940901 - Disclosure - Significant agreements - Collaboration revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails" id="DisclosureSignificantAgreementsBayerCollaborationAgreementDetails">
        <link:definition>99940902 - Disclosure - Significant agreements - Bayer Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails" id="DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails">
        <link:definition>99940903 - Disclosure - Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails" id="DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails">
        <link:definition>99940904 - Disclosure - Significant agreements - Novartis Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails" id="DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails">
        <link:definition>99940905 - Disclosure - Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails" id="DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails">
        <link:definition>99940906 - Disclosure - Significant agreements - Ionis Evaluation and Option Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails" id="DisclosureSignificantAgreementsIonisCollaborationAgreementDetails">
        <link:definition>99940907 - Disclosure - Significant agreements - Ionis Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails" id="DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails">
        <link:definition>99940908 - Disclosure - Significant agreements - Ionis Share Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails" id="DisclosureSignificantAgreementsIonisAccountingAnalysisDetails">
        <link:definition>99940909 - Disclosure - Significant agreements - Ionis Accounting Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails" id="DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails">
        <link:definition>99940910 - Disclosure - Significant agreements - Genentech Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails" id="DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails">
        <link:definition>99940911 - Disclosure - Significant agreements - Summary of Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails" id="DisclosureSignificantAgreementsCancerResearchUkDetails">
        <link:definition>99940913 - Disclosure - Significant agreements - Cancer Research UK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>99941005 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails">
        <link:definition>99941101 - Disclosure - Commitments and contingencies - Operating Leases and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails" id="DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails">
        <link:definition>99941202 - Disclosure - Net loss per share - Securities excluded from the diluted per share calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails" id="DisclosureBenefitPlansDetails">
        <link:definition>99941301 - Disclosure - Benefit plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>99941401 - Disclosure - Related party transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails" id="DisclosureSegmentsAndGeographicInformationDetails">
        <link:definition>99941502 - Disclosure - Segments and geographic information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941601 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" id="StatementConsolidatedStatementsOfShareholdersEquityParenthetical">
        <link:definition>995200305 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>995210101 - Disclosure - Nature of the business and basis of presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" id="DisclosureFairValueOfFinancialAssetsAndLiabilities">
        <link:definition>995210301 - Disclosure - Fair value of financial assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>995210401 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995210501 - Disclosure - Accrued expenses and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>995210601 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureOrdinaryShares" id="DisclosureOrdinaryShares">
        <link:definition>995210701 - Disclosure - Ordinary shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>995210801 - Disclosure - Share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreements" id="DisclosureSignificantAgreements">
        <link:definition>995210901 - Disclosure - Significant agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211001 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211101 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211201 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlans" id="DisclosureBenefitPlans">
        <link:definition>995211301 - Disclosure - Benefit plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995211401 - Disclosure - Related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformation" id="DisclosureSegmentsAndGeographicInformation">
        <link:definition>995211501 - Disclosure - Segments and geographic information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211601 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>99930203 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>99930403 - Disclosure - Property and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>99930503 - Disclosure - Accrued expenses and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>99930603 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931003 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>99931103 - Disclosure - Commitments and contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931203 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables" id="DisclosureSegmentsAndGeographicInformationTables">
        <link:definition>99931503 - Disclosure - Segments and geographic information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails">
        <link:definition>99940201 - Disclosure - Summary of significant accounting policies - Foreign currency and currency translation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails">
        <link:definition>99940202 - Disclosure - Summary of significant accounting policies - Concentrations of credit risk and of significant suppliers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
        <link:definition>99940203 - Disclosure - Summary of significant accounting policies - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails">
        <link:definition>99940206 - Disclosure - Summary of significant accounting policies - Share based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails" id="DisclosureOrdinarySharesDetails">
        <link:definition>99940701 - Disclosure - Ordinary shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>99941201 - Disclosure - Net loss per share - Basic and diluted net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="bcyc-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bcyc-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bcyc-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bcyc-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <element id="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent" name="ResearchAndDevelopmentIncentivesReceivableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" name="IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" name="AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AccruedExternalResearchAndDevelopmentExpenses" name="AccruedExternalResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" name="RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" name="RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AstrazenecaCollaborationAgreementMember" name="AstrazenecaCollaborationAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_DementiaDiscoveryFundCollaborationAgreementMember" name="DementiaDiscoveryFundCollaborationAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AchievementOfMilestoneAxis" name="AchievementOfMilestoneAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AchievementOfMilestoneDomain" name="AchievementOfMilestoneDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_DevelopmentMilestoneMember" name="DevelopmentMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_RegulatoryMilestoneMember" name="RegulatoryMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_PerformanceObligationAxis" name="PerformanceObligationAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_PerformanceObligationDomain" name="PerformanceObligationDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" name="CollaborativeArrangementUpfrontCashPaymentReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" name="CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" name="ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ContractWithCustomerLiabilityDeductions" name="ContractWithCustomerLiabilityDeductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" name="ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" name="EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" name="OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" name="OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" name="MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ShareOptionPlan2019Member" name="ShareOptionPlan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_PreIpoShareOptionsAndRestrictedSharesMember" name="PreIpoShareOptionsAndRestrictedSharesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_EmployeeAndDirectorMember" name="EmployeeAndDirectorMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_Plan401KMember" name="Plan401KMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_UKPlanMember" name="UKPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_OperatingLeaseAnnualRent" name="OperatingLeaseAnnualRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_OperatingLeaseAgreementEstimatedServiceCharges" name="OperatingLeaseAgreementEstimatedServiceCharges" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" name="RevenueRecognitionAllocatedDeterminedTransactionPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_OptionFeeForDevelopmentAndExploitationRights" name="OptionFeeForDevelopmentAndExploitationRights" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" name="ResearchAndDevelopmentArrangementObligationToRepayOtherParties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" name="ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" name="ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock" name="ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" name="ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock" name="ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" name="ConsultancyServicesWithStoneSunnyIslesInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ReductionOfResearchAndDevelopmentExpense" name="ReductionOfResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_PercentageOfTieredRoyaltyOnNetRevenue" name="PercentageOfTieredRoyaltyOnNetRevenue" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_NumberOfPotentialDevelopmentCandidates" name="NumberOfPotentialDevelopmentCandidates" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_NumberOfImmunoOncologyTargets" name="NumberOfImmunoOncologyTargets" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AdditionalNumberOfImmunoOncologyTargets" name="AdditionalNumberOfImmunoOncologyTargets" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ExpansionFeePerAdditionalCollaborationProgram" name="ExpansionFeePerAdditionalCollaborationProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" name="CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" name="CollaborationAgreementSalesMilestonePaymentsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" abstract="false" />
  <element id="bcyc_CancerResearchUkBtOneSevenOneEightMember" name="CancerResearchUkBtOneSevenOneEightMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_NumberOfInitialCollaborationPrograms" name="NumberOfInitialCollaborationPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_CollaborationOnePerformanceObligationMember" name="CollaborationOnePerformanceObligationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_CollaborationTwoPerformanceObligationMember" name="CollaborationTwoPerformanceObligationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" name="SpecifiedTargetingArmMaterialRightArmProgramOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" name="TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" name="FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_TwoMaterialRightsForExpansionOptionsMember" name="TwoMaterialRightsForExpansionOptionsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" name="NumberOfExpansionOptionCollaborationProgramsDevGo" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_NumberOfCollaborationPrograms" name="NumberOfCollaborationPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_CollaborationPerformanceOneAndTwoMember" name="CollaborationPerformanceOneAndTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock" name="SignificantRisksAndUncertaintiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" name="NumberOfYearsOverWhichRoyaltyIsPayable" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_MaterialRightsExerciseOrExpiryTerm" name="MaterialRightsExerciseOrExpiryTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" name="PeriodOverWhichPerformanceObligationsWillBePerformed" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_ShareOptionPlan2020Member" name="ShareOptionPlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_TermLoanMember" name="TermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_InitialTermLoanMember" name="InitialTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_DebtInstrumentEndOfTermChargeRate" name="DebtInstrumentEndOfTermChargeRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_DebtEndOfTermCharge" name="DebtEndOfTermCharge" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" name="EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" name="TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_NonCashInterestExpense" name="NonCashInterestExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_GenentechMember" name="GenentechMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="bcyc_DeferredRevenueMaterialRightsOptionMember" name="DeferredRevenueMaterialRightsOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="IonisCollaborationAgreementMember" id="bcyc_IonisCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationAgreementNumberOfTargets" id="bcyc_CollaborationAgreementNumberOfTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IonisEvaluationAndOptionAgreementMember" id="bcyc_IonisEvaluationAndOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" id="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" id="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UnderwrittenPublicOfferingMember" id="bcyc_UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueOfSharesHeld" id="bcyc_FairValueOfSharesHeld" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" id="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" id="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IonisSharePurchaseAgreementMember" id="bcyc_IonisSharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" id="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmendedIonisCollaborationAgreementMember" id="bcyc_AmendedIonisCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationProgramThreePerformanceObligationMember" id="bcyc_CollaborationProgramThreePerformanceObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationProgramAmountOfMaterialRights" id="bcyc_CollaborationProgramAmountOfMaterialRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" id="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseContractualTerm" id="bcyc_LesseeOperatingLeaseContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LesseeOperatingLeaseRentFreePeriod" id="bcyc_LesseeOperatingLeaseRentFreePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" id="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" id="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationProgram4PerformanceObligationMember" id="bcyc_CollaborationProgram4PerformanceObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" id="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalResearchTerm" id="bcyc_AdditionalResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfMaterialRightsAssociatedWithFuturePayments" id="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContractWithCustomerLiabilityForeignCurrencyAdjustment" id="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" id="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" id="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" id="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfJurisdictions" id="bcyc_NumberOfJurisdictions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EstimatedVariableConsiderationNoLongerConstrained" id="bcyc_EstimatedVariableConsiderationNoLongerConstrained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" id="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TermDepositMaturityPeriod" id="bcyc_TermDepositMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NovartisCollaborationAgreementMember" id="bcyc_NovartisCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationAgreementTieredSalesMilestonePaymentsReceivable" id="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AchievementOfSpecifiedLevelsOfNetSalesMember" id="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CompletionOfAllMilestonesForTargetsMember" id="bcyc_CompletionOfAllMilestonesForTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" id="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" id="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TerminationIfSafetyOrRegulatoryIssueExistsMember" id="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfCombinedPerformanceObligations" id="bcyc_NumberOfCombinedPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" id="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" id="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" id="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" id="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" id="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AgreementWithThirdPartyMember" id="bcyc_AgreementWithThirdPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" id="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" id="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ThirdAmendedIonisMember" id="bcyc_ThirdAmendedIonisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BayerMember" id="bcyc_BayerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DevelopmentAndRegulatoryMilestoneMember" id="bcyc_DevelopmentAndRegulatoryMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThirdIonisAmendmentMember" id="bcyc_ThirdIonisAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationAgreementFutureMilestoneContingentPaymentsPayable" id="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MilestoneAcrossAllPotentialTargetProgramsMember" id="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" id="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" id="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" id="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" id="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" id="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" id="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" id="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" id="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonVotingOrdinarySharesMember" id="bcyc_NonVotingOrdinarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfMaterialRights" id="bcyc_NumberOfMaterialRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="VotingOrdinarySharesMember" id="bcyc_VotingOrdinarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" id="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfQuarterlyInstallments" id="bcyc_NumberOfQuarterlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" id="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" id="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" id="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" id="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" id="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" id="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedPaymentArrangementThreeYearVestMember" id="bcyc_ShareBasedPaymentArrangementThreeYearVestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfVotePerShare" id="bcyc_NumberOfVotePerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BakerBrothersAdvisorsLpMember" id="bcyc_BakerBrothersAdvisorsLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentPrepaymentCharges" id="bcyc_DebtInstrumentPrepaymentCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InducementPlan2024Member" id="bcyc_InducementPlan2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" id="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" id="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfGeographicRegionsInWhichOperating" id="bcyc_NumberOfGeographicRegionsInWhichOperating" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InvestorsPurchaseAgreementMember" id="bcyc_InvestorsPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" id="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FinanceLeaseCost" id="bcyc_FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetDepreciationAndAmortization" id="bcyc_DeferredTaxAssetDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentArrangementUpfrontCashPayment" id="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SingleReportableSegmentMember" id="bcyc_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" id="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" id="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" id="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" id="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProjectSpecificCosts" id="bcyc_ProjectSpecificCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" id="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" id="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentShareBasedPaymentArrangementExpense" id="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FacilityExpenses" id="bcyc_FacilityExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" id="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GeneralAndAdministrativeShareBasedPaymentArrangementExpense" id="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" id="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>34
<FILENAME>bcyc-20241231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 9:41:43 PM-->
<!--Modified on: 2/24/2025 9:41:43 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureDebtDebtDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfLeaseLiabilitiesCalc2" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfLeaseLiabilitiesCalc2" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638760300981787296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638760300981787296" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300981787296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638760300981787296" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300981787296" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638760300981787296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638760300981787296" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638760300981787296" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent" xlink:label="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_638760300981787296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638760300981787296" xlink:to="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_638760300981787296" order="3" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638760300981787296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638760300981787296" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638760300981787296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638760300981787296" order="3" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638760300981787296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638760300981787296" order="4" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638760300981797298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638760300981797298" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638760300981797298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638760300981797298" xlink:to="us-gaap_LiabilitiesCurrent_638760300981797298" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638760300981797298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638760300981797298" xlink:to="us-gaap_AccountsPayableCurrent_638760300981797298" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638760300981797298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638760300981797298" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638760300981797298" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638760300981797298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638760300981797298" xlink:to="us-gaap_DeferredRevenueCurrent_638760300981797298" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent_638760300981797298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638760300981797298" xlink:to="us-gaap_DeferredRevenueNoncurrent_638760300981797298" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638760300981797298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638760300981797298" xlink:to="us-gaap_LongTermDebtNoncurrent_638760300981797298" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300981807295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638760300981797298" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300981807295" order="4" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638760300981807295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638760300981797298" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638760300981807295" order="5" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638760300981807295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638760300981807295" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638760300981807295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638760300981807295" xlink:to="us-gaap_CommonStockValue_638760300981807295" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638760300981807295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638760300981807295" xlink:to="us-gaap_AdditionalPaidInCapital_638760300981807295" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638760300981807295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638760300981807295" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638760300981807295" order="3" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638760300981817301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638760300981807295" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638760300981817301" order="4" use="optional" weight="1" priority="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638760300981817301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638760300981817301" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300981817301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638760300981817301" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300981817301" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638760300981817301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300981817301" xlink:to="us-gaap_OperatingIncomeLoss_638760300981817301" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300981817301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638760300981817301" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300981817301" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638760300981817301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638760300981817301" xlink:to="us-gaap_OperatingExpenses_638760300981817301" order="2" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638760300981817301" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638760300981827297" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638760300981817301" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638760300981827297" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300981817301" xlink:to="us-gaap_NonoperatingIncomeExpense_638760300981827297" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638760300981827297" xlink:to="us-gaap_InterestAndOtherIncome_638760300981827297" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638760300981827297" xlink:to="us-gaap_InterestExpenseNonoperating_638760300981827297" order="2" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638760300981827297" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300981827297" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638760300981827297" xlink:to="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300981827297" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638760300981827297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638760300981817301" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638760300981827297" order="2" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638760300981837311" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638760300981837311" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300981837311" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300981837311" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638760300981837311" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638760300981837311" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638760300981837311" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_ProfitLoss_638760300981837311" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_ShareBasedCompensation_638760300981847297" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638760300981847297" order="3" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300981847297" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_OtherNoncashExpense_638760300981847297" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638760300981847297" order="6" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonCashInterestExpense" xlink:label="bcyc_NonCashInterestExpense_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="bcyc_NonCashInterestExpense_638760300981847297" order="7" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300981847297" order="8" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300981847297" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300981847297" order="9" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638760300981857293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638760300981857293" order="10" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:label="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_638760300981857293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_638760300981857293" order="11" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638760300981857293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638760300981857293" order="12" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_638760300981857293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_638760300981857293" order="13" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638760300981857293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638760300981857293" order="14" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638760300981857293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638760300981857293" order="15" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638760300981867295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638760300981867295" order="16" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638760300981867295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300981837311" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638760300981867295" order="17" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638760300981867295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638760300981867295" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638760300981867295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638760300981867295" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638760300981867295" order="1" use="optional" weight="-1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300981867295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300981867295" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638760300981867295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300981867295" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638760300981867295" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638760300981877295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300981867295" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638760300981877295" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638760300981877295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300981867295" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638760300981877295" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638760300981877295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300981867295" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638760300981877295" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638760300981877295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638760300981877295" order="4" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property and equipment, net (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638760300981877295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638760300981877295" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638760300981887298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638760300981887298" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued expenses and other current liabilities (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638760300981887298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638760300981887298" order="1" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="bcyc_AccruedExternalResearchAndDevelopmentExpenses_638760300981887298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bcyc_AccruedExternalResearchAndDevelopmentExpenses_638760300981887298" order="2" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638760300981887298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638760300981887298" order="3" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638760300981887298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638760300981887298" order="4" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638760300981887298" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638760300981887298" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638760300981897296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_638760300981897296" order="6" use="optional" weight="1" priority="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Debt - Debt (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638760300981897296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_2" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638760300981897296" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtEndOfTermCharge" xlink:label="bcyc_DebtEndOfTermCharge_638760300981897296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_2" xlink:to="bcyc_DebtEndOfTermCharge_638760300981897296" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638760300981897296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_2" xlink:to="us-gaap_DeferredFinanceCostsNet_638760300981897296" order="3" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940912 - Disclosure - Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details)">
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xlink:label="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_638760300981897296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_638760300981897296" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_638760300981897296" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_638760300981897296" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_638760300981907295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_638760300981907295" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Income taxes - Components of net loss before tax provision from income taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638760300981907295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638760300981907295" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638760300981907295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638760300981907295" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Income taxes - Components of benefit for income taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300981907295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300981907295" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638760300981907295" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300981907295" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638760300981907295" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638760300981917302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300981907295" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638760300981917302" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638760300981917302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638760300981917302" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638760300981917302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638760300981917302" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638760300981917302" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638760300981917302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638760300981917302" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638760300981917302" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Income taxes - Reconciliation of benefit for income taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638760300981917302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638760300981917302" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638760300981917302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638760300981917302" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638760300981917302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638760300981917302" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_638760300981927301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_638760300981927301" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_638760300981927301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_638760300981927301" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_638760300981927301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_638760300981927301" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638760300981927301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638760300981927301" order="7" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941004 - Disclosure - Income taxes - Components of the company's current and deferred tax assets (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638760300981927301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638760300981927301" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638760300981927301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638760300981927301" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638760300981927301" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638760300981937323" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638760300981937323" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638760300981937323" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638760300981937323" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredTaxAssetDepreciationAndAmortization" xlink:label="bcyc_DeferredTaxAssetDepreciationAndAmortization_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638760300981937323" xlink:to="bcyc_DeferredTaxAssetDepreciationAndAmortization_638760300981937323" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638760300981937323" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638760300981937323" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="bcyc_DeferredTaxAssetsOperatingLeaseLiability_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638760300981937323" xlink:to="bcyc_DeferredTaxAssetsOperatingLeaseLiability_638760300981937323" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638760300981937323" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638760300981937323" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638760300981937323" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638760300981937323" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638760300981937323" order="6" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Commitments and contingencies - Components of lease expense (Details)">
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FinanceLeaseCost" xlink:label="bcyc_FinanceLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638760300981947301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="bcyc_FinanceLeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638760300981947301" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638760300981947301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="bcyc_FinanceLeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense_638760300981947301" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfLeaseLiabilitiesCalc2" xlink:type="extended" xlink:title="41103 - Disclosure - Commitments and contingencies - Leases, Maturities of Lease Liabilities Calc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638760300981947301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638760300981947301" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638760300981947301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638760300981947301" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638760300981957301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638760300981957301" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300981957301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_1" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300981957301" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Commitments and contingencies - Leases, Maturities of Operating Leases (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638760300981957301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability_1" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638760300981957301" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638760300981957301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability_1" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638760300981957301" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638760300981957301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability_1" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638760300981957301" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638760300981957301" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability_1" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638760300981957301" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638760300981967300" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability_1" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638760300981967300" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638760300981967300" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability_1" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638760300981967300" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638760300981967300" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638760300981967300" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638760300981967300" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638760300981967300" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638760300981967300" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638760300981967300" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638760300981967300" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638760300981967300" order="4" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Segments and geographic information - Significant segment expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638760300981977314" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638760300981977314" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" xlink:label="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_638760300981977314" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_638760300981977314" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_638760300981977314" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_638760300981977314" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_638760300981977314" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_ProfessionalFees_638760300981977314" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638760300981977314" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_LaborAndRelatedExpense_638760300981977314" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" xlink:label="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_638760300981987302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_638760300981987302" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FacilityExpenses" xlink:label="bcyc_FacilityExpenses_638760300981987302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="bcyc_FacilityExpenses_638760300981987302" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" xlink:label="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_638760300981987302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_638760300981987302" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" xlink:label="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_638760300981987302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_638760300981987302" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" xlink:label="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_638760300981987302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_638760300981987302" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ProjectSpecificCosts" xlink:label="bcyc_ProjectSpecificCosts_638760300981987302" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="bcyc_ProjectSpecificCosts_638760300981987302" order="6" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>35
<FILENAME>bcyc-20241231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 9:41:43 PM-->
<!--Modified on: 2/24/2025 9:41:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedStatementsOfShareholdersEquity" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureDebtDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureOrdinarySharesSharePurchaseAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationShareOptionsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationRestrictedShareUnitsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsCollaborationRevenuesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsBayerCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisAccountingAnalysisDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsCancerResearchUkDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureBenefitPlansDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSegmentsAndGeographicInformationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.bicycletherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="bcyc-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" xlink:title="us-gaap_AccruedLiabilitiesCurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_AccruedLiabilitiesCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To us-gaap_AccruedLiabilitiesCurrent_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1" xlink:title="us-gaap_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract_1 To us-gaap_PropertyPlantAndEquipmentNet_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2" xlink:title="us-gaap_AccruedLiabilitiesCurrent_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_AccruedLiabilitiesCurrent_2" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_1" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OtherLiabilitiesNoncurrent_1" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_ResearchAndDevelopmentExpense" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneAxis" xlink:label="bcyc_AchievementOfMilestoneAxis_1" xlink:title="bcyc_AchievementOfMilestoneAxis_1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneDomain" xlink:label="bcyc_AchievementOfMilestoneDomain_1" xlink:title="bcyc_AchievementOfMilestoneDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="bcyc_AchievementOfMilestoneAxis_1" xlink:to="bcyc_AchievementOfMilestoneDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:bcyc_AchievementOfMilestoneAxis_1 To bcyc_AchievementOfMilestoneDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:title="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_1" xlink:title="us-gaap_ProjectMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:to="us-gaap_ProjectMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1 To us-gaap_ProjectMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="us-gaap_GainContingenciesByNatureAxis_1" xlink:title="us-gaap_GainContingenciesByNatureAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="us-gaap_GainContingencyNatureDomain_1" xlink:title="us-gaap_GainContingencyNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GainContingenciesByNatureAxis_1" xlink:to="us-gaap_GainContingencyNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GainContingenciesByNatureAxis_1 To us-gaap_GainContingencyNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PerformanceObligationAxis" xlink:label="bcyc_PerformanceObligationAxis_1" xlink:title="bcyc_PerformanceObligationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PerformanceObligationDomain" xlink:label="bcyc_PerformanceObligationDomain_1" xlink:title="bcyc_PerformanceObligationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="bcyc_PerformanceObligationAxis_1" xlink:to="bcyc_PerformanceObligationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:bcyc_PerformanceObligationAxis_1 To bcyc_PerformanceObligationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis_1" xlink:title="us-gaap_RetirementPlanSponsorLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain_1" xlink:title="us-gaap_RetirementPlanSponsorLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis_1" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanSponsorLocationAxis_1 To us-gaap_RetirementPlanSponsorLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis_1" xlink:title="us-gaap_RetirementPlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_1" xlink:title="us-gaap_RetirementPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanNameAxis_1" xlink:to="us-gaap_RetirementPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanNameAxis_1 To us-gaap_RetirementPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis_1" xlink:title="us-gaap_ShareRepurchaseProgramAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain_1" xlink:title="us-gaap_ShareRepurchaseProgramDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ShareRepurchaseProgramAxis_1" xlink:to="srt_ShareRepurchaseProgramDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareRepurchaseProgramAxis_1 To us-gaap_ShareRepurchaseProgramDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals" />
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonVotingOrdinarySharesMember" xlink:label="bcyc_NonVotingOrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcyc_NonVotingOrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisSharePurchaseAgreementMember" xlink:label="bcyc_IonisSharePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcyc_IonisSharePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Significant agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_BayerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_GenentechMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_NovartisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" xlink:label="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails" xlink:type="extended" xlink:title="99940204 - Disclosure - Summary of significant accounting policies - Property and equipment, Geographic (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfGeographicRegionsInWhichOperating" xlink:label="bcyc_NumberOfGeographicRegionsInWhichOperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="bcyc_NumberOfGeographicRegionsInWhichOperating" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails" xlink:type="extended" xlink:title="99940205 - Disclosure - Summary of significant accounting policies - Research and development incentives and receivable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" xlink:label="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" xlink:label="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ReductionOfResearchAndDevelopmentExpense" xlink:label="bcyc_ReductionOfResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ReductionOfResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_TimeDepositsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TermDepositMaturityPeriod" xlink:label="bcyc_TermDepositMaturityPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bcyc_TermDepositMaturityPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LoanAndSecurityAgreementMember" xlink:label="bcyc_LoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_LoanAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TermLoanMember" xlink:label="bcyc_TermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcyc_TermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InitialTermLoanMember" xlink:label="bcyc_InitialTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="bcyc_TermLoanMember" xlink:to="bcyc_InitialTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtInstrumentEndOfTermChargeRate" xlink:label="bcyc_DebtInstrumentEndOfTermChargeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bcyc_DebtInstrumentEndOfTermChargeRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtEndOfTermCharge" xlink:label="bcyc_DebtEndOfTermCharge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bcyc_DebtEndOfTermCharge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtInstrumentPrepaymentCharges" xlink:label="bcyc_DebtInstrumentPrepaymentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bcyc_DebtInstrumentPrepaymentCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseLongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Ordinary shares - Share Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AtMarketOfferingMember" xlink:label="bcyc_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcyc_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_UnderwrittenPublicOfferingMember" xlink:label="bcyc_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcyc_UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InvestorsPurchaseAgreementMember" xlink:label="bcyc_InvestorsPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcyc_InvestorsPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonVotingOrdinarySharesMember" xlink:label="bcyc_NonVotingOrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcyc_NonVotingOrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_VotingOrdinarySharesMember" xlink:label="bcyc_VotingOrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcyc_VotingOrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionOnSecuritiesMember" xlink:label="us-gaap_OptionOnSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OptionOnSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Share-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2020Member" xlink:label="bcyc_ShareOptionPlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcyc_ShareOptionPlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2019Member" xlink:label="bcyc_ShareOptionPlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcyc_ShareOptionPlan2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InducementPlan2024Member" xlink:label="bcyc_InducementPlan2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcyc_InducementPlan2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PreIpoShareOptionsAndRestrictedSharesMember" xlink:label="bcyc_PreIpoShareOptionsAndRestrictedSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcyc_PreIpoShareOptionsAndRestrictedSharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedPaymentArrangementThreeYearVestMember" xlink:label="bcyc_ShareBasedPaymentArrangementThreeYearVestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="bcyc_ShareBasedPaymentArrangementThreeYearVestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfQuarterlyInstallments" xlink:label="bcyc_NumberOfQuarterlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_NumberOfQuarterlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Share-based compensation - Share based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Share-based compensation - Share Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EmployeeAndDirectorMember" xlink:label="bcyc_EmployeeAndDirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcyc_EmployeeAndDirectorMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Share-based compensation - Restricted Share Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2020Member" xlink:label="bcyc_ShareOptionPlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcyc_ShareOptionPlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Significant agreements - Collaboration revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_BayerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_NovartisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DementiaDiscoveryFundCollaborationAgreementMember" xlink:label="bcyc_DementiaDiscoveryFundCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_DementiaDiscoveryFundCollaborationAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_GenentechMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AstrazenecaCollaborationAgreementMember" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_AstrazenecaCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Significant agreements - Bayer Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_BayerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneAxis" xlink:label="bcyc_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="bcyc_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneDomain" xlink:label="bcyc_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="bcyc_AchievementOfMilestoneAxis" xlink:to="bcyc_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DevelopmentAndRegulatoryMilestoneMember" xlink:label="bcyc_DevelopmentAndRegulatoryMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="bcyc_AchievementOfMilestoneDomain" xlink:to="bcyc_DevelopmentAndRegulatoryMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" xlink:label="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="bcyc_AchievementOfMilestoneDomain" xlink:to="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementNumberOfTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" xlink:label="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" xlink:label="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_BayerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" xlink:label="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" xlink:label="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" xlink:label="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCombinedPerformanceObligations" xlink:label="bcyc_NumberOfCombinedPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfCombinedPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRights" xlink:label="bcyc_NumberOfMaterialRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfMaterialRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Significant agreements - Novartis Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_NovartisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CompletionOfAllMilestonesForTargetsMember" xlink:label="bcyc_CompletionOfAllMilestonesForTargetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcyc_CompletionOfAllMilestonesForTargetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" xlink:label="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" xlink:label="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" xlink:label="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" xlink:label="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" xlink:label="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementNumberOfTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AdditionalResearchTerm" xlink:label="bcyc_AdditionalResearchTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_AdditionalResearchTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" xlink:label="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" xlink:label="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_NovartisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCombinedPerformanceObligations" xlink:label="bcyc_NumberOfCombinedPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfCombinedPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRights" xlink:label="bcyc_NumberOfMaterialRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfMaterialRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedVariableConsiderationNoLongerConstrained" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_EstimatedVariableConsiderationNoLongerConstrained" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Significant agreements - Ionis Evaluation and Option Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisEvaluationAndOptionAgreementMember" xlink:label="bcyc_IonisEvaluationAndOptionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisEvaluationAndOptionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940907 - Disclosure - Significant agreements - Ionis Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AmendedIonisCollaborationAgreementMember" xlink:label="bcyc_AmendedIonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_AmendedIonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThirdIonisAmendmentMember" xlink:label="bcyc_ThirdIonisAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_ThirdIonisAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" xlink:label="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" xlink:label="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementNumberOfTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails" xlink:type="extended" xlink:title="99940908 - Disclosure - Significant agreements - Ionis Share Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisSharePurchaseAgreementMember" xlink:label="bcyc_IonisSharePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcyc_IonisSharePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FairValueOfSharesHeld" xlink:label="bcyc_FairValueOfSharesHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_FairValueOfSharesHeld" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails" xlink:type="extended" xlink:title="99940909 - Disclosure - Significant agreements - Ionis Accounting Analysis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisEvaluationAndOptionAgreementMember" xlink:label="bcyc_IonisEvaluationAndOptionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisEvaluationAndOptionAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AmendedIonisCollaborationAgreementMember" xlink:label="bcyc_AmendedIonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_AmendedIonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThirdAmendedIonisMember" xlink:label="bcyc_ThirdAmendedIonisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_ThirdAmendedIonisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" xlink:label="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" xlink:label="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisSharePurchaseAgreementMember" xlink:label="bcyc_IonisSharePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcyc_IonisSharePurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" xlink:label="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementNumberOfTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940910 - Disclosure - Significant agreements - Genentech Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_GenentechMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationOnePerformanceObligationMember" xlink:label="bcyc_CollaborationOnePerformanceObligationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_CollaborationOnePerformanceObligationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationTwoPerformanceObligationMember" xlink:label="bcyc_CollaborationTwoPerformanceObligationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_CollaborationTwoPerformanceObligationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" xlink:label="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" xlink:label="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsForExpansionOptionsMember" xlink:label="bcyc_TwoMaterialRightsForExpansionOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_TwoMaterialRightsForExpansionOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationPerformanceOneAndTwoMember" xlink:label="bcyc_CollaborationPerformanceOneAndTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_CollaborationPerformanceOneAndTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgramThreePerformanceObligationMember" xlink:label="bcyc_CollaborationProgramThreePerformanceObligationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_CollaborationProgramThreePerformanceObligationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgram4PerformanceObligationMember" xlink:label="bcyc_CollaborationProgram4PerformanceObligationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_CollaborationProgram4PerformanceObligationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneAxis" xlink:label="bcyc_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="bcyc_AchievementOfMilestoneAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneDomain" xlink:label="bcyc_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="bcyc_AchievementOfMilestoneAxis" xlink:to="bcyc_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DevelopmentMilestoneMember" xlink:label="bcyc_DevelopmentMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="bcyc_AchievementOfMilestoneDomain" xlink:to="bcyc_DevelopmentMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RegulatoryMilestoneMember" xlink:label="bcyc_RegulatoryMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="bcyc_AchievementOfMilestoneDomain" xlink:to="bcyc_RegulatoryMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfPotentialDevelopmentCandidates" xlink:label="bcyc_NumberOfPotentialDevelopmentCandidates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfPotentialDevelopmentCandidates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfImmunoOncologyTargets" xlink:label="bcyc_NumberOfImmunoOncologyTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfImmunoOncologyTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AdditionalNumberOfImmunoOncologyTargets" xlink:label="bcyc_AdditionalNumberOfImmunoOncologyTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_AdditionalNumberOfImmunoOncologyTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ExpansionFeePerAdditionalCollaborationProgram" xlink:label="bcyc_ExpansionFeePerAdditionalCollaborationProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_ExpansionFeePerAdditionalCollaborationProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfInitialCollaborationPrograms" xlink:label="bcyc_NumberOfInitialCollaborationPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfInitialCollaborationPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OptionFeeForDevelopmentAndExploitationRights" xlink:label="bcyc_OptionFeeForDevelopmentAndExploitationRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_OptionFeeForDevelopmentAndExploitationRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCollaborationPrograms" xlink:label="bcyc_NumberOfCollaborationPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfCollaborationPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" xlink:label="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" xlink:label="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgramAmountOfMaterialRights" xlink:label="bcyc_CollaborationProgramAmountOfMaterialRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationProgramAmountOfMaterialRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedVariableConsiderationNoLongerConstrained" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_EstimatedVariableConsiderationNoLongerConstrained" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940911 - Disclosure - Significant agreements - Summary of Contract Assets and Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_BayerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_NovartisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_IonisCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_GenentechMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AstrazenecaCollaborationAgreementMember" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_AstrazenecaCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredRevenueMaterialRightsOptionMember" xlink:label="bcyc_DeferredRevenueMaterialRightsOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bcyc_DeferredRevenueMaterialRightsOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityAdditions" xlink:label="bcyc_ContractWithCustomerLiabilityAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="bcyc_ContractWithCustomerLiabilityAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityDeductions" xlink:label="bcyc_ContractWithCustomerLiabilityDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="bcyc_ContractWithCustomerLiabilityDeductions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" xlink:label="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInContractWithCustomerAssetAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails" xlink:type="extended" xlink:title="99940913 - Disclosure - Significant agreements - Cancer Research UK (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CancerResearchUkBtOneSevenOneEightMember" xlink:label="bcyc_CancerResearchUkBtOneSevenOneEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_CancerResearchUkBtOneSevenOneEightMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PercentageOfTieredRoyaltyOnNetRevenue" xlink:label="bcyc_PercentageOfTieredRoyaltyOnNetRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:to="bcyc_PercentageOfTieredRoyaltyOnNetRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:to="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" xlink:label="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:to="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" xlink:label="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:to="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:to="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99941005 - Disclosure - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" xlink:label="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfJurisdictions" xlink:label="bcyc_NumberOfJurisdictions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="bcyc_NumberOfJurisdictions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Commitments and contingencies - Operating Leases and Finance Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" xlink:label="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseContractualTerm" xlink:label="bcyc_LesseeOperatingLeaseContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bcyc_LesseeOperatingLeaseContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OperatingLeaseAnnualRent" xlink:label="bcyc_OperatingLeaseAnnualRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bcyc_OperatingLeaseAnnualRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseRentFreePeriod" xlink:label="bcyc_LesseeOperatingLeaseRentFreePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bcyc_LesseeOperatingLeaseRentFreePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OperatingLeaseAgreementEstimatedServiceCharges" xlink:label="bcyc_OperatingLeaseAgreementEstimatedServiceCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bcyc_OperatingLeaseAgreementEstimatedServiceCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" xlink:label="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Commitments and contingencies - Leases, Maturities of Operating Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AgreementWithThirdPartyMember" xlink:label="bcyc_AgreementWithThirdPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_AgreementWithThirdPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" xlink:label="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Net loss per share - Securities excluded from the diluted per share calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Benefit plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanSponsorLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember" xlink:label="us-gaap_DomesticPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="us-gaap_DomesticPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DomesticPlanMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember" xlink:label="us-gaap_ForeignPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="us-gaap_ForeignPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_Plan401KMember" xlink:label="bcyc_Plan401KMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="bcyc_Plan401KMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_UKPlanMember" xlink:label="bcyc_UKPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="bcyc_UKPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Related party transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" xlink:label="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BakerBrothersAdvisorsLpMember" xlink:label="bcyc_BakerBrothersAdvisorsLpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcyc_BakerBrothersAdvisorsLpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonVotingOrdinarySharesMember" xlink:label="bcyc_NonVotingOrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcyc_NonVotingOrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Segments and geographic information - Significant segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SingleReportableSegmentMember" xlink:label="bcyc_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="bcyc_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProjectMember" xlink:to="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProjectMember" xlink:to="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" xlink:label="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ProjectMember" xlink:to="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" xlink:label="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ProjectMember" xlink:to="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ProjectSpecificCosts" xlink:label="bcyc_ProjectSpecificCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ProjectSpecificCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" xlink:label="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" xlink:label="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" xlink:label="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FacilityExpenses" xlink:label="bcyc_FacilityExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_FacilityExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" xlink:label="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_ProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" xlink:label="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails" xlink:type="extended" xlink:title="99941502 - Disclosure - Segments and geographic information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcyc_GenentechMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>36
<FILENAME>bcyc-20241231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 9:41:43 PM-->
<!--Modified on: 2/24/2025 9:41:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember" xlink:label="dei_AdrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">American Depositary Shares</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonVotingOrdinarySharesMember" xlink:label="bcyc_NonVotingOrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NonVotingOrdinarySharesMember" xlink:to="bcyc_NonVotingOrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NonVotingOrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to non-voting ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NonVotingOrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non voting ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NonVotingOrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-voting ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No Trading Symbol Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No Trading Symbol Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent" xlink:label="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent" xlink:to="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of research and development incentives receivables, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Incentives Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development incentives receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, net of discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 11)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, including non-voting ordinary shares, &#xA3;0.01 nominal value; 155,876,645 and 59,612,613 shares authorized at December 31, 2024 and December 31, 2023, respectively; 69,061,418 and 42,431,766 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, nominal value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from collaborative arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant segment expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:to="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference between the amount paid to settle and carrying amount of research and development funding liability which is extinguished.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Research and Development Funding Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on extinguishment of research and development funding liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on extinguishment of research and development funding liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Benefit from) provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total (benefit from) provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average ordinary shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average ordinary shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensives loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisSharePurchaseAgreementMember" xlink:label="bcyc_IonisSharePurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_IonisSharePurchaseAgreementMember" xlink:to="bcyc_IonisSharePurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_IonisSharePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ionis Share Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_IonisSharePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ionis Share Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in shareholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ADSs upon exercise of share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ADSs upon exercise of share options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds before discounts and commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate purchase price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ADSs upon settlement of restricted share units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ADSs upon settlement of restricted share units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commissions and offering expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonCashInterestExpense" xlink:label="bcyc_NonCashInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NonCashInterestExpense" xlink:to="bcyc_NonCashInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NonCashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the cost of borrowed funds accounted for as non cash interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NonCashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NonCashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax (benefit) provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred income tax (benefit) provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:label="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:to="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in amount due within one year (or one business cycle) for research and development incentives receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Research and Development Incentives Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development incentives receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the period in the carrying value of operating lease right-of-use assets reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Right-of-use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash used in investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total aggregate payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of ADSs and non-voting ordinary shares, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of share options and settlement of restricted share units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payments on finance lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash included in other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest on debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Payment on Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest on finance lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" xlink:label="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" xlink:to="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase or decrease in future cash outflow to pay for purchases of fixed assets that have occurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in purchases of property and equipment in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash impact to operating lease right-of-use assets and operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment obtained under finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the business and basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the business and basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for accrued expenses and other liabilities that are classified as current at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments and geographic information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments and geographic information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock" xlink:label="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock" xlink:to="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of policy for significant risks and uncertainties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Risks And Uncertainties Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant risks and uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency and currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of credit risk and of significant suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Impairment [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment and geographic information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:label="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:to="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy Research and manufacturing contract costs and accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Manufacturing Contract Costs And Accruals [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and manufacturing contract costs and accruals</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock" xlink:label="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock" xlink:to="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy Research and development incentives and receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Incentives And Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development incentives and receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful lives of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long term debt instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used to determine the fair value of share options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted ordinary share award activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_BayerMember" xlink:to="bcyc_BayerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_BayerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Bayer collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_BayerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_BayerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bcyc_BayerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer collaboration deferred revenue</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NovartisCollaborationAgreementMember" xlink:to="bcyc_NovartisCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NovartisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Novartis Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NovartisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NovartisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bcyc_NovartisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis collaboration deferred revenue</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_IonisCollaborationAgreementMember" xlink:to="bcyc_IonisCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_IonisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Ionis Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_IonisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ionis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_IonisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ionis collaboration deferred revenue</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_GenentechMember" xlink:to="bcyc_GenentechMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_GenentechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Genentech collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_GenentechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genentech</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_GenentechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genentech collaboration deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant agreements.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of revenue recognized from collaboration arrangements</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" xlink:label="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" xlink:to="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the tabular disclosure of allocation of transaction price to separate performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Performance Obligation, Allocation Of Transaction Price [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of allocation of transaction price to separate performance obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of changes in the balances of the Company's contract assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the tabular disclosure of recognition of revenues as a result of changes in contract asset and contract liability balances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Change In Contract with Customer, Asset and Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of recognition of revenues as a result of changes in contract asset and contract liability balances</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock" xlink:label="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock" xlink:to="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of components of net income (loss) before tax provision from income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Components Of Net Income (Loss) Before Income Tax Provision [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of net loss before tax provision from income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the benefit for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant components of the Company's current and deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss attributable to ordinary shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of company's single operating segment including significant segment expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets by Geographic Areas [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long-lived assets, including operating lease right-of-use assets, held in different geographic regions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of foreign exchange rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and office equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Useful Life</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfGeographicRegionsInWhichOperating" xlink:label="bcyc_NumberOfGeographicRegionsInWhichOperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfGeographicRegionsInWhichOperating" xlink:to="bcyc_NumberOfGeographicRegionsInWhichOperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfGeographicRegionsInWhichOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of geographic regions in which the entity operates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfGeographicRegionsInWhichOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Geographic Regions In Which Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfGeographicRegionsInWhichOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of geographic regions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to certain research and development expenditures incurred prior to April 1, 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain Research and Development Expenditures Incurred Prior to April 1, 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain research and development expenditures incurred prior to April 1, 2023</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to certain research and development expenditures incurred thereafter April 1, 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain Research and Development Expenditures Incurred, Thereafter April 1, 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain research and development expenditures incurred thereafter April 1, 2023</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to certain research and development expenditures incurred thereafter April 1, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain Research and Development Expenditures Incurred, Thereafter April 1, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain research and development expenditures incurred April 1, 2024 and thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development incentives and receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development:</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" xlink:label="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" xlink:to="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of tax credit on surrenderable trading losses that arise from qualifying research and development expenses incurred by the Company's subsidiaries in the United Kingdom.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Tax Reliefs Program, Percentage Of Tax Credit on Surrenderable Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of surrenderable losses</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" xlink:label="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" xlink:to="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of tax credit on total expenditure during the period that arise from qualifying research and development expenses incurred by the Company's subsidiaries in the United Kingdom.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Percentage Of Tax Credit on Total Expenditure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total expenditure</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ReductionOfResearchAndDevelopmentExpense" xlink:label="bcyc_ReductionOfResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ReductionOfResearchAndDevelopmentExpense" xlink:to="bcyc_ReductionOfResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ReductionOfResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reduction of research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ReductionOfResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction Of Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ReductionOfResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtCarryingValue" xlink:to="us-gaap_TimeDepositsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimeDepositsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time Deposits, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TimeDepositsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term deposits</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TermDepositMaturityPeriod" xlink:label="bcyc_TermDepositMaturityPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TermDepositMaturityPeriod" xlink:to="bcyc_TermDepositMaturityPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TermDepositMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maturity period of term deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TermDepositMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Deposit Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TermDepositMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term deposit maturity period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense of property and equipment under finance leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of finance lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued employee compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="bcyc_AccruedExternalResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="bcyc_AccruedExternalResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through and payable for external research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued External Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued external research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued restructuring costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LoanAndSecurityAgreementMember" xlink:label="bcyc_LoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_LoanAndSecurityAgreementMember" xlink:to="bcyc_LoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Loan and Security agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan and Security Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TermLoanMember" xlink:label="bcyc_TermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TermLoanMember" xlink:to="bcyc_TermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to  term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InitialTermLoanMember" xlink:label="bcyc_InitialTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_InitialTermLoanMember" xlink:to="bcyc_InitialTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_InitialTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to initial term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_InitialTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis spread variable rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument stated percentage</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtInstrumentEndOfTermChargeRate" xlink:label="bcyc_DebtInstrumentEndOfTermChargeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DebtInstrumentEndOfTermChargeRate" xlink:to="bcyc_DebtInstrumentEndOfTermChargeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DebtInstrumentEndOfTermChargeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The rate at which entity has to pay end term charge on the principle amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DebtInstrumentEndOfTermChargeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument End of Term Charge Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_DebtInstrumentEndOfTermChargeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">End term charge rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and unpaid interest</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtEndOfTermCharge" xlink:label="bcyc_DebtEndOfTermCharge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DebtEndOfTermCharge" xlink:to="bcyc_DebtEndOfTermCharge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DebtEndOfTermCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents an end of term charge related to debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DebtEndOfTermCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt End Of Term Charge</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_DebtEndOfTermCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">End-of-term charge</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bcyc_DebtEndOfTermCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">End of term charge</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtInstrumentPrepaymentCharges" xlink:label="bcyc_DebtInstrumentPrepaymentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DebtInstrumentPrepaymentCharges" xlink:to="bcyc_DebtInstrumentPrepaymentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DebtInstrumentPrepaymentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expenses for prepayment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DebtInstrumentPrepaymentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Prepayment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_DebtInstrumentPrepaymentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment charge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLongTermDebt" xlink:to="us-gaap_InterestExpenseLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value of term loan</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfVotePerShare" xlink:label="bcyc_NumberOfVotePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfVotePerShare" xlink:to="bcyc_NumberOfVotePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfVotePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfVotePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Vote Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfVotePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vote per ordinary share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Dividends, Per Share, Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AtMarketOfferingMember" xlink:label="bcyc_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AtMarketOfferingMember" xlink:to="bcyc_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to sale of stock at the market.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the market offering</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_UnderwrittenPublicOfferingMember" xlink:label="bcyc_UnderwrittenPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_UnderwrittenPublicOfferingMember" xlink:to="bcyc_UnderwrittenPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the sale of stock by a company to the public through under-writing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwritten Public Offering</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InvestorsPurchaseAgreementMember" xlink:label="bcyc_InvestorsPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_InvestorsPurchaseAgreementMember" xlink:to="bcyc_InvestorsPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_InvestorsPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Investors Share Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_InvestorsPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_InvestorsPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_VotingOrdinarySharesMember" xlink:label="bcyc_VotingOrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_VotingOrdinarySharesMember" xlink:to="bcyc_VotingOrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_VotingOrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to voting ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_VotingOrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionOnSecuritiesMember" xlink:label="us-gaap_OptionOnSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionOnSecuritiesMember" xlink:to="us-gaap_OptionOnSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionOnSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option on Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionOnSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option on securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InducementPlan2024Member" xlink:label="bcyc_InducementPlan2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_InducementPlan2024Member" xlink:to="bcyc_InducementPlan2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_InducementPlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2024 Inducement Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_InducementPlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Plan, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_InducementPlan2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2020Member" xlink:label="bcyc_ShareOptionPlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareOptionPlan2020Member" xlink:to="bcyc_ShareOptionPlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareOptionPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents 2020 share option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareOptionPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareOptionPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Plan</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2019Member" xlink:label="bcyc_ShareOptionPlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareOptionPlan2019Member" xlink:to="bcyc_ShareOptionPlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareOptionPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents 2019 share option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareOptionPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareOptionPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PreIpoShareOptionsAndRestrictedSharesMember" xlink:label="bcyc_PreIpoShareOptionsAndRestrictedSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_PreIpoShareOptionsAndRestrictedSharesMember" xlink:to="bcyc_PreIpoShareOptionsAndRestrictedSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_PreIpoShareOptionsAndRestrictedSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents Pre-IPO share options and restricted shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_PreIpoShareOptionsAndRestrictedSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-IPO Share Options and restricted shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_PreIpoShareOptionsAndRestrictedSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-IPO Share Options and restricted shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedPaymentArrangementThreeYearVestMember" xlink:label="bcyc_ShareBasedPaymentArrangementThreeYearVestMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedPaymentArrangementThreeYearVestMember" xlink:to="bcyc_ShareBasedPaymentArrangementThreeYearVestMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedPaymentArrangementThreeYearVestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement in which award of equity shares are granted with three year vesting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedPaymentArrangementThreeYearVestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement Three Year Vest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedPaymentArrangementThreeYearVestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option three year vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Share Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First anniversary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining equal installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-employee Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Percentage</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equal monthly installments for remaining awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment, Award Vesting, Number Of Equal Monthly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal monthly installments for vesting remaining awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding number of shares at end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding number of shares at beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost expected to be recognized over a weighted average period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service period</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equal quarterly installments for remaining awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment, Award Vesting, Number Of Equal Quarterly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal quarterly installments for vesting remaining awards</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon conversion of restricted share units under share based compensation arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Awards, Share Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to receive upon vesting</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfQuarterlyInstallments" xlink:label="bcyc_NumberOfQuarterlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfQuarterlyInstallments" xlink:to="bcyc_NumberOfQuarterlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This is representing number of quarterly installments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Quarterly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of quarterly installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of ordinary shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual increase in reserves on total number of ordinary shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual increase in reserves on total number of ordinary shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equal annual installments for remaining awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment, Award Vesting, Number Of Equal Annual Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal annual installments</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of vested and non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding restricted ordinary shares at ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price at ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price at beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price, vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price, options exercisable</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average contractual term, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average contractual term, vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average contractual term ,options exercisable</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value, vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value, options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EmployeeAndDirectorMember" xlink:label="bcyc_EmployeeAndDirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_EmployeeAndDirectorMember" xlink:to="bcyc_EmployeeAndDirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_EmployeeAndDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to employee and director.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_EmployeeAndDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees and directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_EmployeeAndDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees and directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation expense related to the unvested employee and director</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Underlying RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted ordinary shares at ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted ordinary shares at beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equity-based payment instruments, excluding stock (or unit) options, that vested and settled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Settled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and settled</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equity-based payment instruments, excluding stock (or unit) options, that vested and deferred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Deferred in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period, subject to deferred settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Subject to Deferred Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted ordinary shares, Vested but subject to deferred settlement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value unvested, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value unvested, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee vested and settled during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Settled in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and settled</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee vested and deferred during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Deferred in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right, subject to deferred settlement during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Subject To Deferred Settlement, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value, Vested but subject to deferred settlement</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value, Outstanding at Ending Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of employee restricted share awards vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average Period</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DementiaDiscoveryFundCollaborationAgreementMember" xlink:label="bcyc_DementiaDiscoveryFundCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DementiaDiscoveryFundCollaborationAgreementMember" xlink:to="bcyc_DementiaDiscoveryFundCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DementiaDiscoveryFundCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Dementia Discovery Fund collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DementiaDiscoveryFundCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dementia Discovery Fund</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AstrazenecaCollaborationAgreementMember" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AstrazenecaCollaborationAgreementMember" xlink:to="bcyc_AstrazenecaCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to AstraZeneca collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AstraZeneca</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AstraZeneca collaboration deferred revenue</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneAxis" xlink:label="bcyc_AchievementOfMilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AchievementOfMilestoneAxis" xlink:to="bcyc_AchievementOfMilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneDomain" xlink:label="bcyc_AchievementOfMilestoneDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AchievementOfMilestoneDomain" xlink:to="bcyc_AchievementOfMilestoneDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of milestone, including but not limited to development, sales, commercial and regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of Milestone [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DevelopmentAndRegulatoryMilestoneMember" xlink:label="bcyc_DevelopmentAndRegulatoryMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DevelopmentAndRegulatoryMilestoneMember" xlink:to="bcyc_DevelopmentAndRegulatoryMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DevelopmentAndRegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of development and regulatory first commercial sale milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DevelopmentAndRegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" xlink:label="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" xlink:to="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of sales milestone resulting in receivable across all potential target programs and/or on diagnostic products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Across all three potential target programs</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationAgreementNumberOfTargets" xlink:to="bcyc_CollaborationAgreementNumberOfTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationAgreementNumberOfTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration targets under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationAgreementNumberOfTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Number of Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborationAgreementNumberOfTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration targets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront cash payment received from collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Upfront Cash Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payment</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" xlink:label="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" xlink:to="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of candidate compounds into further development under the collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreement, Number of candidate compounds into further development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of candidate compounds into further development</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" xlink:to="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of tiered sales milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Tiered Sales Milestone Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:to="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of regulatory, development, commercialization or sales milestone payments, receivable by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Sales Milestone Payments, Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments, receivable</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" xlink:to="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period to terminate agreement upon written notice for uncured material breach.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period to Terminate Agreement upon Written Notice for Uncured Material Breach</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period to terminate agreement upon written notice for uncured material breach</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" xlink:label="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" xlink:to="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of business days to terminate agreement upon non payment by Bayer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Business Days to Terminate Agreement upon Non Payment by Bayer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of business days to terminate agreement upon non payment by Bayer</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" xlink:to="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period to terminate agreement upon written notice by Bayer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period to Terminate Agreement upon Written Notice by Bayer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period to terminate agreement upon written notice by Bayer</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" xlink:to="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated amount of reimbursement payable for services provided by Contract Research Organizations (CROs).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Amount Of Reimbursement Payable To Contract Research Organizations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated amount payable to CROs</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allocated determined transaction price under revenue recognition arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Allocated Determined Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction price</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:to="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents period over which performance obligations will be performed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Over Which Performance Obligations Will Be Performed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period over which performance obligations will be performed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected period for satisfaction of performance obligations</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The duration of material rights exercised or expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material Rights Exercise or Expiry Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material rights exercise period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" xlink:label="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" xlink:to="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" xlink:label="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" xlink:to="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to material right associated with limited substitution rights for either the first or second target.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material right associated with limited substitution rights for either the first or second target [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material right associated with limited substitution rights for either the first or second target</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" xlink:label="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" xlink:to="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to material right for the option to expand the collaboration to include a third target and the underlying additional option rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material right for the option to expand the collaboration to include a third target and the underlying additional option rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material right for the option to expand the collaboration to include a third target and the underlying additional option rights</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCombinedPerformanceObligations" xlink:label="bcyc_NumberOfCombinedPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfCombinedPerformanceObligations" xlink:to="bcyc_NumberOfCombinedPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfCombinedPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of combined performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfCombinedPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Combined Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfCombinedPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Combined performance obligations</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRights" xlink:label="bcyc_NumberOfMaterialRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfMaterialRights" xlink:to="bcyc_NumberOfMaterialRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of material rights usually associated with an option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Material Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of material rights</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" xlink:label="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" xlink:to="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to achievement of specified levels of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of Specified Levels of Net Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of specified levels of net sales</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CompletionOfAllMilestonesForTargetsMember" xlink:label="bcyc_CompletionOfAllMilestonesForTargetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CompletionOfAllMilestonesForTargetsMember" xlink:to="bcyc_CompletionOfAllMilestonesForTargetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CompletionOfAllMilestonesForTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to completion of first milestone for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CompletionOfAllMilestonesForTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Completion of All Milestones For Targets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CompletionOfAllMilestonesForTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Completion of all milestones for targets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" xlink:label="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" xlink:to="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to termination based on other party's uncured material breach or insolvency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination Based On Other Party's Uncured Material Breach Or Insolvency [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination based on other party's uncured material breach or insolvency</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" xlink:label="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" xlink:to="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to termination in  entirety or on a product-by-product or target-by-target basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination In Entirety Or Product By Product Or Target By Target Basis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination in entirety or product by product or target by target basis</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" xlink:label="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" xlink:to="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to termination of contract if safety or regulatory issue exists.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination If Safety Or Regulatory Issue Exists [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination if safety or regulatory issue exists</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" xlink:label="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" xlink:to="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the expiration of two material rights associated with limited substitution rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of Two Material Rights Associate With Limited Substitution Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of two material rights associated with limited substitution rights</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AdditionalResearchTerm" xlink:label="bcyc_AdditionalResearchTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AdditionalResearchTerm" xlink:to="bcyc_AdditionalResearchTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AdditionalResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional research term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AdditionalResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Research Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_AdditionalResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional research term</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" xlink:label="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" xlink:to="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold period of notice required for termination of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Notice Required For Termination Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period of notice required for termination of agreement</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" xlink:to="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum days allowed for cancellation of contracts prior written notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Days Allowed for Cancellation of Contracts Prior Written Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum days allowed for cancellation of contracts prior written notice</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" xlink:label="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" xlink:to="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two combined performance obligations for the first and second targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Combined Performance Obligations For First And Second Targets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" xlink:to="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two material rights associated with limited substitution rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Material Rights Associated With Limited Substitution Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with limited substitution rights</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two material rights associated with options to progress development candidates incorporating radionuclides</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Material Rights Associated With Options To Progress Development Candidates Incorporating Radionuclides [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with options to progress development candidates incorporating radionuclides</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two material rights associated with options to progress development candidates  not incorporating radionuclides.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Material Rights Associated With Options To Progress Development Candidates Not Incorporating Radionuclides [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with options to progress development candidates not incorporating radionuclides</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedVariableConsiderationNoLongerConstrained" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_EstimatedVariableConsiderationNoLongerConstrained" xlink:to="bcyc_EstimatedVariableConsiderationNoLongerConstrained_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of estimated variable consideration no longer constrained.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Variable Consideration No Longer Constrained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of estimate of variable consideration</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisEvaluationAndOptionAgreementMember" xlink:label="bcyc_IonisEvaluationAndOptionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_IonisEvaluationAndOptionAgreementMember" xlink:to="bcyc_IonisEvaluationAndOptionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_IonisEvaluationAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ionis Evaluation and Option Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_IonisEvaluationAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ionis Evaluation and Option Agreement</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AmendedIonisCollaborationAgreementMember" xlink:label="bcyc_AmendedIonisCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AmendedIonisCollaborationAgreementMember" xlink:to="bcyc_AmendedIonisCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AmendedIonisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Amended Ionis Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AmendedIonisCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Ionis</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThirdIonisAmendmentMember" xlink:label="bcyc_ThirdIonisAmendmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ThirdIonisAmendmentMember" xlink:to="bcyc_ThirdIonisAmendmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ThirdIonisAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the third Ionis Amended Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ThirdIonisAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Ionis Amendment</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" xlink:label="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" xlink:to="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the company will perform research and discovery activities including a baseline level of effort for no additional consideration, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period For Which Research And Discovery Activities Will Be Performed With No Additional Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which research and discovery activities will be performed with no additional consideration</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" xlink:label="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" xlink:to="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of payments of a mid-single-digit million dollar, failing to achieve the specified development diligence.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Payments Of Mid-single-digit Million Dollar, Failing to Achieve Specified Development Diligence Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of payments of a mid-single-digit million dollar, failing to achieve the specified development diligence</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" xlink:to="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of years over which royalty is payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Years Over Which Royalty Is Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of years over which royalty is payable</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FairValueOfSharesHeld" xlink:label="bcyc_FairValueOfSharesHeld" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_FairValueOfSharesHeld" xlink:to="bcyc_FairValueOfSharesHeld_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_FairValueOfSharesHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_FairValueOfSharesHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Of Shares Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_FairValueOfSharesHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares held</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThirdAmendedIonisMember" xlink:label="bcyc_ThirdAmendedIonisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ThirdAmendedIonisMember" xlink:to="bcyc_ThirdAmendedIonisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ThirdAmendedIonisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the Third Amended Ionis Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ThirdAmendedIonisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Amended Ionis</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" xlink:label="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" xlink:to="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to combined licenses and research and discovery performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Combined licenses and research and discovery performance obligation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" xlink:label="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" xlink:to="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to four material rights associated with credits for IND acceptance fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Four material rights associated with credits for IND Acceptance fees</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" xlink:label="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" xlink:to="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of material rights associated with future payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Material Rights Associated with Future Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of material rights associated with future payments</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationOnePerformanceObligationMember" xlink:label="bcyc_CollaborationOnePerformanceObligationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationOnePerformanceObligationMember" xlink:to="bcyc_CollaborationOnePerformanceObligationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationOnePerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Collaboration 1 performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationOnePerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Program 1 Performance Obligation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationTwoPerformanceObligationMember" xlink:label="bcyc_CollaborationTwoPerformanceObligationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationTwoPerformanceObligationMember" xlink:to="bcyc_CollaborationTwoPerformanceObligationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationTwoPerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Collaboration 2 performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationTwoPerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Program 2 Performance Obligation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" xlink:label="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" xlink:to="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to specified targeting arm material right arm.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specified Targeting Arm Material Right Arm Program One</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" xlink:to="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two material rights associated with the LSR Go Option For Collaboration Programs One and Two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights associated with the LSR Go Option for Collaboration Programs One And Two</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" xlink:label="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" xlink:to="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Four Material rights for substitution rights for technical failure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material rights for associated and limited substitution rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material rights associated with limited substitution rights</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsForExpansionOptionsMember" xlink:label="bcyc_TwoMaterialRightsForExpansionOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TwoMaterialRightsForExpansionOptionsMember" xlink:to="bcyc_TwoMaterialRightsForExpansionOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TwoMaterialRightsForExpansionOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two material right for expansion options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TwoMaterialRightsForExpansionOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two material rights for Expansion Options</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationPerformanceOneAndTwoMember" xlink:label="bcyc_CollaborationPerformanceOneAndTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationPerformanceOneAndTwoMember" xlink:to="bcyc_CollaborationPerformanceOneAndTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationPerformanceOneAndTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Collaboration One and Two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationPerformanceOneAndTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Program One and Two Performance Obligation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to material rights associated with the LSR Go Option For Collaboration Programs one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material Rights Associated With Lsr Go Option For Collaboration Programs One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material rights associated with the LSR Go Option for Collaboration Programs One</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgramThreePerformanceObligationMember" xlink:label="bcyc_CollaborationProgramThreePerformanceObligationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationProgramThreePerformanceObligationMember" xlink:to="bcyc_CollaborationProgramThreePerformanceObligationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationProgramThreePerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Collaboration 3 performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationProgramThreePerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Program 3 Performance Obligation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgram4PerformanceObligationMember" xlink:label="bcyc_CollaborationProgram4PerformanceObligationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationProgram4PerformanceObligationMember" xlink:to="bcyc_CollaborationProgram4PerformanceObligationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationProgram4PerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Collaboration 4 performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationProgram4PerformanceObligationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Program 4 Performance Obligation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to material rights associated with the LSR Go Option For Collaboration Programs Three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material rights associated with the LSR Go Option for Collaboration Programs Three</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to material rights associated with the LSR Go Option For Collaboration Program Four.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material rights associated with the LSR Go Option for Collaboration Programs Four</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DevelopmentMilestoneMember" xlink:label="bcyc_DevelopmentMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DevelopmentMilestoneMember" xlink:to="bcyc_DevelopmentMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DevelopmentMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of development milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DevelopmentMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RegulatoryMilestoneMember" xlink:label="bcyc_RegulatoryMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_RegulatoryMilestoneMember" xlink:to="bcyc_RegulatoryMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_RegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to achievement of regulatory milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_RegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory milestone</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfPotentialDevelopmentCandidates" xlink:label="bcyc_NumberOfPotentialDevelopmentCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfPotentialDevelopmentCandidates" xlink:to="bcyc_NumberOfPotentialDevelopmentCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfPotentialDevelopmentCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Potential development candidates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfPotentialDevelopmentCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Potential Development Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfPotentialDevelopmentCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of potential development candidates</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfImmunoOncologyTargets" xlink:label="bcyc_NumberOfImmunoOncologyTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfImmunoOncologyTargets" xlink:to="bcyc_NumberOfImmunoOncologyTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfImmunoOncologyTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of immuno oncology targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfImmunoOncologyTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Immuno Oncology Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfImmunoOncologyTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of immuno oncology targets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AdditionalNumberOfImmunoOncologyTargets" xlink:label="bcyc_AdditionalNumberOfImmunoOncologyTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AdditionalNumberOfImmunoOncologyTargets" xlink:to="bcyc_AdditionalNumberOfImmunoOncologyTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AdditionalNumberOfImmunoOncologyTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of immuno oncology targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AdditionalNumberOfImmunoOncologyTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Number Of Immuno Oncology Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_AdditionalNumberOfImmunoOncologyTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of immuno oncology targets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ExpansionFeePerAdditionalCollaborationProgram" xlink:label="bcyc_ExpansionFeePerAdditionalCollaborationProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ExpansionFeePerAdditionalCollaborationProgram" xlink:to="bcyc_ExpansionFeePerAdditionalCollaborationProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ExpansionFeePerAdditionalCollaborationProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expansion fee to per additional collaboration program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ExpansionFeePerAdditionalCollaborationProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expansion Fee Per Additional Collaboration Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ExpansionFeePerAdditionalCollaborationProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expansion fee</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfInitialCollaborationPrograms" xlink:label="bcyc_NumberOfInitialCollaborationPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfInitialCollaborationPrograms" xlink:to="bcyc_NumberOfInitialCollaborationPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfInitialCollaborationPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of initial Genentech Collaboration Programs exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfInitialCollaborationPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Initial Collaboration Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfInitialCollaborationPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of initial collaboration programs exercised</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OptionFeeForDevelopmentAndExploitationRights" xlink:label="bcyc_OptionFeeForDevelopmentAndExploitationRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_OptionFeeForDevelopmentAndExploitationRights" xlink:to="bcyc_OptionFeeForDevelopmentAndExploitationRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_OptionFeeForDevelopmentAndExploitationRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount to be paid upon exercise of an option by the customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_OptionFeeForDevelopmentAndExploitationRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Fee for Development and Exploitation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_OptionFeeForDevelopmentAndExploitationRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option fee for development and exploitation rights</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCollaborationPrograms" xlink:label="bcyc_NumberOfCollaborationPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfCollaborationPrograms" xlink:to="bcyc_NumberOfCollaborationPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfCollaborationPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of collaboration programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfCollaborationPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Collaboration programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfCollaborationPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration programs</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" xlink:label="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" xlink:to="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of expansion option programs (Dev Go option).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Expansion Option Collaboration Programs Dev Go</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of expansion option collaboration programs</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" xlink:label="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" xlink:to="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Regulatory, and initial commercialization milestones payments receivable by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Regulatory, And Initial Commercialization Milestones, Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory, and initial commercialization milestones, payments receivable</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgramAmountOfMaterialRights" xlink:label="bcyc_CollaborationProgramAmountOfMaterialRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationProgramAmountOfMaterialRights" xlink:to="bcyc_CollaborationProgramAmountOfMaterialRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationProgramAmountOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of material rights under collaboration program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationProgramAmountOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Program Amount of Material Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborationProgramAmountOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredRevenueMaterialRightsOptionMember" xlink:label="bcyc_DeferredRevenueMaterialRightsOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DeferredRevenueMaterialRightsOptionMember" xlink:to="bcyc_DeferredRevenueMaterialRightsOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DeferredRevenueMaterialRightsOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents deferred revenue allocated to material rights that will commence revenue recognition when the respective option is exercised or when the option expires.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DeferredRevenueMaterialRightsOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue material rights option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Contract with Customer, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities:</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityAdditions" xlink:label="bcyc_ContractWithCustomerLiabilityAdditions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ContractWithCustomerLiabilityAdditions" xlink:to="bcyc_ContractWithCustomerLiabilityAdditions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in contract with customer, liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityDeductions" xlink:label="bcyc_ContractWithCustomerLiabilityDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ContractWithCustomerLiabilityDeductions" xlink:to="bcyc_ContractWithCustomerLiabilityDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ContractWithCustomerLiabilityDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in contract with customer, liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ContractWithCustomerLiabilityDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bcyc_ContractWithCustomerLiabilityDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deductions</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" xlink:label="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" xlink:to="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of adjustment in contract with customer, liability due to change in foreign exchange.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Foreign Currency Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact of Exchange Rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInContractWithCustomerAssetAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAbstract" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Contract with Customer, Asset [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Asset, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue recognized based on proportional performance that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized, Proportional Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized based on proportional performance</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue recognized based on expiration of material rights that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized, Expiration of Material Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized based on expiration of material rights</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue recognized based on changes in transaction price that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized, Changes In Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized based on changes in transaction price</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xlink:label="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xlink:to="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue recognized from both the beginning balance and current period increase in contract liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Revenue Recognized From Both The Beginning Balance And Current Period Increase In Contract Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Contract to Perform for Others [Table]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CancerResearchUkBtOneSevenOneEightMember" xlink:label="bcyc_CancerResearchUkBtOneSevenOneEightMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CancerResearchUkBtOneSevenOneEightMember" xlink:to="bcyc_CancerResearchUkBtOneSevenOneEightMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CancerResearchUkBtOneSevenOneEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to BT 1718.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CancerResearchUkBtOneSevenOneEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BT1718</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancer Research UK</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:to="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement Obligation to Repay Other Parties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development arrangement obligation to repay other parties</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PercentageOfTieredRoyaltyOnNetRevenue" xlink:label="bcyc_PercentageOfTieredRoyaltyOnNetRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_PercentageOfTieredRoyaltyOnNetRevenue" xlink:to="bcyc_PercentageOfTieredRoyaltyOnNetRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_PercentageOfTieredRoyaltyOnNetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of tiered royalty on net revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_PercentageOfTieredRoyaltyOnNetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Tiered Royalty On Net Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_PercentageOfTieredRoyaltyOnNetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tiered royalties (percentage)</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" xlink:to="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents payments due upon achievement of milestones under a Research and Development arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement Obligation to Repay Other Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent future milestones payments under research and development arrangement</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" xlink:label="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" xlink:to="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the liability recorded for research and development arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement Liability to Repay Other Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability from research and development</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" xlink:label="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" xlink:to="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront cash payment made on research and development arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Upfront Cash Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Upfront Cash Payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United Kingdom</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax (benefit) provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Benefit from) provision for income taxes at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases (decreases) resulting from:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net losses surrendered for research credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Net Losses Surrendered for Research Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net losses surrendered for research credit</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic feieral statutory income tax rates to pretax income (loss) from continuing operations attributable to Impact of statutory rate change.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Impact Of Statutory Rate Change, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact of statutory rate change</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign exchange rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Exchange Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact of foreign exchange rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="bcyc_DeferredTaxAssetsOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="bcyc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredTaxAssetDepreciationAndAmortization" xlink:label="bcyc_DeferredTaxAssetDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_DeferredTaxAssetDepreciationAndAmortization" xlink:to="bcyc_DeferredTaxAssetDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_DeferredTaxAssetDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from depreciation and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_DeferredTaxAssetDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset, Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_DeferredTaxAssetDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation &amp; amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes.</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" xlink:label="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" xlink:to="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of incremental income tax benefits due to completion of research and development tax credit study during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Income Tax Benefit on Completion of Research and Development Tax Credit Study</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental income tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases recorded to income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.K. operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and penalties accrued</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfJurisdictions" xlink:label="bcyc_NumberOfJurisdictions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NumberOfJurisdictions" xlink:to="bcyc_NumberOfJurisdictions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NumberOfJurisdictions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of Jurisdictions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NumberOfJurisdictions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Jurisdictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NumberOfJurisdictions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of jurisdictions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:to="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by type of long-lived, physical assets used to produce goods and services and not intended for resale related to office and laboratory space in Cambridge, Massachusetts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space in Cambridge Massachusetts</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" xlink:label="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" xlink:to="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to lease agreement for new office and laboratory space in Cambridge, U.K.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Office and laboratory space in Cambridge, United Kingdom [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Office and laboratory space in Cambridge, United Kingdom</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" xlink:to="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to lease agreement for office and laboratory space in Building 900, Babraham Research Campus, Cambridge, U.K.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space in Building 900, Babraham Research Campus, Cambridge</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" xlink:to="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to lease agreement for office and laboratory space in Lexington, Massachusetts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space in Lexington, Massachusetts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseContractualTerm" xlink:label="bcyc_LesseeOperatingLeaseContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_LesseeOperatingLeaseContractualTerm" xlink:to="bcyc_LesseeOperatingLeaseContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_LesseeOperatingLeaseContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total contractual term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_LesseeOperatingLeaseContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_LesseeOperatingLeaseContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease total contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, term of contract</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OperatingLeaseAnnualRent" xlink:label="bcyc_OperatingLeaseAnnualRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_OperatingLeaseAnnualRent" xlink:to="bcyc_OperatingLeaseAnnualRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_OperatingLeaseAnnualRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual rental of an operating lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_OperatingLeaseAnnualRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Annual Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_OperatingLeaseAnnualRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental payment</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseRentFreePeriod" xlink:label="bcyc_LesseeOperatingLeaseRentFreePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_LesseeOperatingLeaseRentFreePeriod" xlink:to="bcyc_LesseeOperatingLeaseRentFreePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_LesseeOperatingLeaseRentFreePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the rent free period lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_LesseeOperatingLeaseRentFreePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Rent Free Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_LesseeOperatingLeaseRentFreePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent free period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discounted percentage for present value of lease payments</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OperatingLeaseAgreementEstimatedServiceCharges" xlink:label="bcyc_OperatingLeaseAgreementEstimatedServiceCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_OperatingLeaseAgreementEstimatedServiceCharges" xlink:to="bcyc_OperatingLeaseAgreementEstimatedServiceCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_OperatingLeaseAgreementEstimatedServiceCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated service charges pertaining to operating lease per operating lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_OperatingLeaseAgreementEstimatedServiceCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Agreement, Estimated Service Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_OperatingLeaseAgreementEstimatedServiceCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated service charges payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Termination of Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on lease termination</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" xlink:label="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" xlink:to="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payment for operating lease through remaining of December.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Remaining Through December</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for the extended lease remaining</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease cost:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FinanceLeaseCost" xlink:label="bcyc_FinanceLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_FinanceLeaseCost" xlink:to="bcyc_FinanceLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lease cost incurred by the lessee over the term of finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="bcyc_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total finance lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining operating lease term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">weighted average operating lease discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining finance lease term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average finance lease discount rate</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AgreementWithThirdPartyMember" xlink:label="bcyc_AgreementWithThirdPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_AgreementWithThirdPartyMember" xlink:to="bcyc_AgreementWithThirdPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_AgreementWithThirdPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to agreement with third party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_AgreementWithThirdPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement With Third Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term lease liabilities</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" xlink:label="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" xlink:to="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of future milestone payment payable upon the achievement of development, regulatory and commercial milestones,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Future Milestone Contingent Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future milestone payment payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="us-gaap_RetirementPlanSponsorLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Sponsor Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Sponsor Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember" xlink:label="us-gaap_DomesticPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticPlanMember" xlink:to="us-gaap_DomesticPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember" xlink:label="us-gaap_ForeignPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignPlanMember" xlink:to="us-gaap_ForeignPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_Plan401KMember" xlink:label="bcyc_Plan401KMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_Plan401KMember" xlink:to="bcyc_Plan401KMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_Plan401KMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 401(k) Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_Plan401KMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_UKPlanMember" xlink:label="bcyc_UKPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_UKPlanMember" xlink:to="bcyc_UKPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_UKPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to U.K. Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_UKPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.K. Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contributions made</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affiliated Entity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affiliated Entity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" xlink:label="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" xlink:to="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to consultancy services with Stone Atlanta Estates LLC, successor-in-interest to Stone Sunny Isles Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consultancy services with Stone Sunny Isles Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consultancy services with Stone Atlanta Estates LLC</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BakerBrothersAdvisorsLpMember" xlink:label="bcyc_BakerBrothersAdvisorsLpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_BakerBrothersAdvisorsLpMember" xlink:to="bcyc_BakerBrothersAdvisorsLpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_BakerBrothersAdvisorsLpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Baker Brothers Advisors LP and/or Felix J. Baker.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_BakerBrothersAdvisorsLpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baker Brothers Advisors LP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_BakerBrothersAdvisorsLpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baker Bros. Advisors LP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SingleReportableSegmentMember" xlink:label="bcyc_SingleReportableSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_SingleReportableSegmentMember" xlink:to="bcyc_SingleReportableSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to single reportable segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project [Domain]</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" xlink:to="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to internal program for clinical trial of product candidate, a Bicycle Toxin Conjugate molecule BT8009 for tumors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal Program, Product Candidate, Bicycle Toxin Conjugate Molecule, B T 8009 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Zelenectide pevedotin (Nectin-4)</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" xlink:to="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to internal program for clinical trial of product candidate, a Bicycle Toxin Conjugate molecule BT5528 for tumors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal Program, Product Candidate, Bicycle Toxin Conjugate Molecule, B T 5528 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BT5528 (EphA2)</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" xlink:label="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" xlink:to="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to clinical trial of out product candidate BT1718, for advanced solid tumors which has been sponsored by Cancer Research Technology Limited and cancer research UK.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Candidate, B T 1718, Sponsored By Cancer Research UK Centre [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BT1718 (MT1)</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" xlink:label="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" xlink:to="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to internal program for clinical trial of Bicycle tumor-targeted immune cell agonists molecule, a BT7480 for immune.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal Program, Bicycle Tumor-Targeted Immune Cell Agonists, B T 7480 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bicycle tumor-targeted immune cell agonists</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments and geographic information</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ProjectSpecificCosts" xlink:label="bcyc_ProjectSpecificCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ProjectSpecificCosts" xlink:to="bcyc_ProjectSpecificCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ProjectSpecificCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cost incurred for specific project including but not limited to its clinical trials, program related costs and registration trails etc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ProjectSpecificCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project Specific Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ProjectSpecificCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project specific costs</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" xlink:label="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" xlink:to="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses for discovery, platform and other pursuant to research and development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development, Discovery, Platform And Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discovery, platform and other expense</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" xlink:label="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" xlink:to="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for salary, wage, profit sharing and other employee benefit and contractor related expenses pursuant to research and development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development, Employee And Contractor Related Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee and contractor related expenses</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" xlink:label="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" xlink:to="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for award under share-based payment arrangement. Excludes amount capitalized, allocated to research and development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development, Share Based Payment Arrangement Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FacilityExpenses" xlink:label="bcyc_FacilityExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_FacilityExpenses" xlink:to="bcyc_FacilityExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_FacilityExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses for utilizing the facility for clinical trials categorized as research and development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_FacilityExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_FacilityExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility expenses</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" xlink:label="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" xlink:to="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income recognized relating to tax credits, incentives and grants from government relating to research and development of the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development, Tax Credits, Incentives And Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development incentives and government grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel-related costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional and consulting fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other general and administrative costs</label>
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" xlink:label="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" xlink:to="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for award under share-based payment arrangement. Excludes amount capitalized, allocated to general and administration activities of the company as a whole.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative, Share Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_GB_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED KINGDOM</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_GB_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United Kingdom</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments and geographic information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of geographic regions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long lived assets, including operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>37
<FILENAME>bcyc-20241231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 9:41:43 PM-->
<!--Modified on: 2/24/2025 9:41:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedStatementsOfShareholdersEquity" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedStatementsOfShareholdersEquityParenthetical" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentation" roleURI="http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilities" roleURI="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureDebt" roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureOrdinaryShares" roleURI="http://www.bicycletherapeutics.com/role/DisclosureOrdinaryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreements" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxes" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureNetLossPerShare" roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureBenefitPlans" roleURI="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSegmentsAndGeographicInformation" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSubsequentEvents" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureDebtTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSegmentsAndGeographicInformationTables" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureDebtDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureDebtDebtDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureOrdinarySharesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureOrdinarySharesSharePurchaseAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationShareOptionsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureShareBasedCompensationRestrictedShareUnitsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsCollaborationRevenuesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsBayerCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsIonisAccountingAnalysisDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSignificantAgreementsCancerResearchUkDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureBenefitPlansDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSegmentsAndGeographicInformationDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="bcyc-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638760300983507324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable_638760300983507324" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638760300983507324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638760300983507324" xlink:to="us-gaap_StatementClassOfStockAxis_638760300983507324" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638760300983507324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638760300983507324" xlink:to="us-gaap_ClassOfStockDomain_638760300983507324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638760300983507324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300983507324" xlink:to="us-gaap_CommonStockMember_638760300983507324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300983507324" xlink:to="dei_AdrMember_638760300983517316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonVotingOrdinarySharesMember" xlink:label="bcyc_NonVotingOrdinarySharesMember_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300983507324" xlink:to="bcyc_NonVotingOrdinarySharesMember_638760300983517316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638760300983507324" xlink:to="dei_DocumentInformationLineItems_638760300983517316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_DocumentType_638760300983517316" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_DocumentAnnualReport_638760300983517316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_DocumentPeriodEndDate_638760300983517316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_DocumentTransitionReport_638760300983517316" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityFileNumber_638760300983517316" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityRegistrantName_638760300983517316" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638760300983517316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityIncorporationStateCountryCode_638760300983517316" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityTaxIdentificationNumber_638760300983527316" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityAddressAddressLine1_638760300983527316" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityAddressCityOrTown_638760300983527316" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityAddressCountry_638760300983527316" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityAddressPostalZipCode_638760300983527316" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_CityAreaCode_638760300983527316" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_LocalPhoneNumber_638760300983527316" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638760300983527316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_Security12bTitle_638760300983527316" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_NoTradingSymbolFlag_638760300983537314" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_TradingSymbol_638760300983537314" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_SecurityExchangeName_638760300983537314" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityWellKnownSeasonedIssuer_638760300983537314" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityVoluntaryFilers_638760300983537314" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityCurrentReportingStatus_638760300983537314" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityInteractiveDataCurrent_638760300983537314" order="22" use="optional" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638760300983537314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityFilerCategory_638760300983537314" order="23" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638760300983547333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntitySmallBusiness_638760300983547333" order="24" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638760300983547333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityEmergingGrowthCompany_638760300983547333" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638760300983547333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_IcfrAuditorAttestationFlag_638760300983547333" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638760300983547333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638760300983547333" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638760300983547333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityShellCompany_638760300983547333" order="28" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638760300983547333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityPublicFloat_638760300983547333" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638760300983557321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityCommonStockSharesOutstanding_638760300983557321" order="30" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638760300983557321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_CurrentFiscalYearEndDate_638760300983557321" order="31" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638760300983557321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_DocumentFiscalYearFocus_638760300983557321" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638760300983557321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_DocumentFiscalPeriodFocus_638760300983557321" order="33" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638760300983557321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_EntityCentralIndexKey_638760300983557321" order="34" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638760300983557321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_AmendmentFlag_638760300983557321" order="35" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638760300983567328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_AuditorName_638760300983567328" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638760300983567328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_AuditorLocation_638760300983567328" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638760300983567328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638760300983517316" xlink:to="dei_AuditorFirmId_638760300983567328" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638760300983567328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638760300983567328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638760300983567328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638760300983567328" xlink:to="us-gaap_AssetsCurrentAbstract_638760300983567328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638760300983567328" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300983577327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638760300983567328" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638760300983577327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent" xlink:label="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638760300983567328" xlink:to="bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent_638760300983577327" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638760300983567328" xlink:to="us-gaap_AssetsCurrent_638760300983577327" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638760300983567328" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638760300983577327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638760300983567328" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638760300983577327" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638760300983567328" xlink:to="us-gaap_OtherAssetsNoncurrent_638760300983577327" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638760300983567328" xlink:to="us-gaap_Assets_638760300983577327" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638760300983577327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638760300983577327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638760300983577327" xlink:to="us-gaap_AccountsPayableCurrent_638760300983587412" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638760300983577327" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638760300983587412" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638760300983577327" xlink:to="us-gaap_DeferredRevenueCurrent_638760300983587412" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638760300983577327" xlink:to="us-gaap_LiabilitiesCurrent_638760300983587412" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_LongTermDebtNoncurrent_638760300983587412" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300983587412" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_DeferredRevenueNoncurrent_638760300983587412" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638760300983587412" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638760300983587412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_Liabilities_638760300983587412" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_CommitmentsAndContingencies_638760300983597326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_StockholdersEquityAbstract_638760300983597326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638760300983597326" xlink:to="us-gaap_CommonStockValue_638760300983597326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638760300983597326" xlink:to="us-gaap_AdditionalPaidInCapital_638760300983597326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638760300983597326" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638760300983597326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638760300983597326" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638760300983597326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638760300983597326" xlink:to="us-gaap_StockholdersEquity_638760300983597326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638760300983597326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638760300983577327" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638760300983597326" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638760300983607332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638760300983607332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638760300983607332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638760300983607332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638760300983607332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638760300983607332" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638760300983607332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638760300983607332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300983607332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300983607332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638760300983607332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638760300983607332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638760300983607332" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638760300983617325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638760300983607332" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638760300983617325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638760300983607332" xlink:to="us-gaap_OperatingExpenses_638760300983617325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638760300983617325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638760300983617325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638760300983617325" xlink:to="us-gaap_InterestAndOtherIncome_638760300983617325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638760300983617325" xlink:to="us-gaap_InterestExpenseNonoperating_638760300983617325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638760300983617325" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300983617325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638760300983617325" xlink:to="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300983617325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638760300983617325" xlink:to="us-gaap_NonoperatingIncomeExpense_638760300983617325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300983617325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300983617325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638760300983627324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638760300983627324" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638760300983627324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638760300983627324" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638760300983627324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638760300983627324" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638760300983627324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638760300983627324" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638760300983627324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638760300983627324" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638760300983627324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638760300983627324" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638760300983627324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638760300983627324" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6387603009836273241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638760300983627324" xlink:to="us-gaap_NetIncomeLoss_6387603009836273241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638760300983637374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638760300983627324" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638760300983637374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638760300983637374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638760300983637374" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638760300983637374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638760300983637374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638760300983627324" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638760300983637374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638760300983637374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638760300983637374" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638760300983637374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638760300983637374" xlink:to="us-gaap_StatementEquityComponentsAxis_638760300983637374" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638760300983637374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638760300983637374" xlink:to="us-gaap_CommonStockMember_638760300983637374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638760300983637374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638760300983637374" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638760300983637374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638760300983637374" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638760300983647335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638760300983637374" xlink:to="us-gaap_RetainedEarningsMember_638760300983647335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638760300983637374" xlink:to="us-gaap_EquityComponentDomain_638760300983647335" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638760300983637374" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638760300983647335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisSharePurchaseAgreementMember" xlink:label="bcyc_IonisSharePurchaseAgreementMember_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638760300983647335" xlink:to="bcyc_IonisSharePurchaseAgreementMember_638760300983647335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638760300983647335" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638760300983647335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638760300983637374" xlink:to="us-gaap_StatementLineItems_638760300983647335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638760300983647335" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockholdersEquity_638760300983647335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_CommonStockSharesOutstanding_638760300983647335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638760300983647335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638760300983647335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638760300983657323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300983657323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638760300983657323" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638760300983657323" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638760300983657323" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638760300983657323" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638760300983657323" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638760300983657323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_NetIncomeLoss_638760300983657323" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638760300983667333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_StockholdersEquity_638760300983667333" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638760300983667333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638760300983647335" xlink:to="us-gaap_CommonStockSharesOutstanding_638760300983667333" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638760300983667333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638760300983667333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638760300983667333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638760300983667333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638760300983667333" xlink:to="us-gaap_ProfitLoss_638760300983677326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638760300983667333" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="us-gaap_ShareBasedCompensation_638760300983677326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638760300983677326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonCashInterestExpense" xlink:label="bcyc_NonCashInterestExpense_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="bcyc_NonCashInterestExpense_638760300983677326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300983677326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300983677326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300983677326" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="us-gaap_OtherNoncashExpense_638760300983677326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638760300983677326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638760300983677326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:label="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_638760300983687334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638760300983687334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_638760300983687334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638760300983687334" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638760300983687334" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638760300983687334" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638760300983687334" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638760300983677326" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638760300983687334" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300983687334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638760300983667333" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638760300983687334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638760300983697341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638760300983697341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638760300983697341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638760300983697341" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638760300983697341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638760300983697341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638760300983697341" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638760300983697341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638760300983697341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638760300983697341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638760300983697341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638760300983697341" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638760300983697341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638760300983697341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638760300983697341" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638760300983697341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638760300983697341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638760300983697341" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638760300983697341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638760300983707338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638760300983697341" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638760300983707338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300983707338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638760300983697341" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638760300983707338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638760300983707338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638760300983707338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638760300983707338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638760300983707338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638760300983707338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638760300983707338" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387603009837073381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387603009837073381" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638760300983707338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638760300983707338" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300983717323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638760300983707338" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300983717323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638760300983717323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638760300983707338" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638760300983717323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638760300983717323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638760300983707338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638760300983717323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638760300983717323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" xlink:to="us-gaap_InterestPaidNet_638760300983717323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_638760300983717323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_638760300983717323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638760300983727321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" xlink:to="us-gaap_IncomeTaxesPaidNet_638760300983727321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638760300983727321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" xlink:to="us-gaap_OperatingLeasePayments_638760300983727321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid" xlink:label="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid_638760300983727321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" xlink:to="bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid_638760300983727321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638760300983727321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638760300983727321" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638760300983727321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638760300983717323" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638760300983727321" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of the business and basis of presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637000995572191374" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638760300983737324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637000995572191374" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638760300983737324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637000995572347375" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638760300983737324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637000995572347375" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638760300983737324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:type="extended" xlink:title="995210301 - Disclosure - Fair value of financial assets and liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637000995572347375" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638760300983737324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637000995572347375" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638760300983737324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="995210401 - Disclosure - Property and equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638760300983747334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638760300983747334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="995210501 - Disclosure - Accrued expenses and other current liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_636999977174783218" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638760300983747334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_636999977174783218" xlink:to="bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638760300983747334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureDebt" xlink:type="extended" xlink:title="995210601 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638760300983747334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638760300983747334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureOrdinaryShares" xlink:type="extended" xlink:title="995210701 - Disclosure - Ordinary shares" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638760300983757342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638760300983757342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="995210801 - Disclosure - Share-based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903194874" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638760300983757342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903194874" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638760300983757342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreements" xlink:type="extended" xlink:title="995210901 - Disclosure - Significant agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638760300983757342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638760300983757342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211001 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637000961816319190" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638760300983767327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637000961816319190" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638760300983767327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211101 - Disclosure - Commitments and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638760300983767327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638760300983767327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211201 - Disclosure - Net loss per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638760300983767327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638760300983767327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlans" xlink:type="extended" xlink:title="995211301 - Disclosure - Benefit plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638760300983777325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638760300983777325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="995211401 - Disclosure - Related party transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638760300983787325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638760300983787325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformation" xlink:type="extended" xlink:title="995211501 - Disclosure - Segments and geographic information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638760300983787325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638760300983787325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211601 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638760300983787325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638760300983787325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638760300983797349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock" xlink:label="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock_638760300983797349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638760300983797349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638760300983797349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638760300983797349" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_638760300983797349" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_638760300983797349" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638760300983797349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638760300983797349" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638760300983807323" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638760300983807323" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638760300983807323" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638760300983807323" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638760300983807323" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638760300983807323" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:label="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_638760300983807323" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock" xlink:label="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock_638760300983807323" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_638760300983807323" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638760300983807323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638760300983807323" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638760300983817317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638760300983817317" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_638760300983817317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_638760300983817317" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638760300983817317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638760300983817317" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638760300983817317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638760300983817317" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638760300983817317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638760300983817317" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Summary of significant accounting policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_638760300983827320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_638760300983827320" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Property and equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638760300983827320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638760300983827320" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Accrued expenses and other current liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_638760300983827320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_638760300983827320" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638760300983837319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638760300983837319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Share-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903350873" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638760300983837319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903350873" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638760300983837319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638760300983887329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903350873" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638760300983887329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638760300983887329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903350873" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638760300983887329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638760300983887329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903350873" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638760300983887329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Significant agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300983887329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300983887329" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300983887329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300983887329" xlink:to="us-gaap_TypeOfArrangementAxis_638760300983887329" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300983887329" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300983897322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300983897322" xlink:to="bcyc_BayerMember_638760300983897322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300983897322" xlink:to="bcyc_NovartisCollaborationAgreementMember_638760300983897322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300983897322" xlink:to="bcyc_IonisCollaborationAgreementMember_638760300983897322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300983897322" xlink:to="bcyc_GenentechMember_638760300983897322" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300983887329" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300983897322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300983897322" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_638760300983897322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock" xlink:label="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300983897322" xlink:to="bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock_638760300983897322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300983897322" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_638760300983897322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_638760300983897322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300983897322" xlink:to="bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_638760300983897322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Income taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock" xlink:label="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock_638760300983907321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock_638760300983907321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638760300983907321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638760300983907321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638760300983907321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638760300983907321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638760300983907321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638760300983907321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Commitments and contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638760300983907321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638760300983907321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638760300983907321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638760300983907321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Net loss per share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638760300983917347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638760300983917347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638760300983917347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638760300983917347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables" xlink:type="extended" xlink:title="99931503 - Disclosure - Segments and geographic information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638760300983917347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638760300983917347" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_638760300983917347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_638760300983917347" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of the business and basis of presentation - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300983927326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638760300983927326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638760300983927326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss_638760300983927326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638760300983927326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638760300983927326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of significant accounting policies - Foreign currency and currency translation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637000937044877674" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638760300983927326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637000937044877674" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638760300983927326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Summary of significant accounting policies - Concentrations of credit risk and of significant suppliers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637000995572347375_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638760300983937325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637000995572347375_1" xlink:to="us-gaap_AccountsReceivableNetCurrent_638760300983937325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - Summary of significant accounting policies - Cash and cash equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638760300983937325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638760300983937325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638760300983937325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638760300983937325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails" xlink:type="extended" xlink:title="99940204 - Disclosure - Summary of significant accounting policies - Property and equipment, Geographic (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983937325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983937325" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638760300983937325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983937325" xlink:to="srt_RangeAxis_638760300983937325" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638760300983937325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638760300983937325" xlink:to="srt_RangeMember_638760300983937325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300983937325" xlink:to="srt_MinimumMember_638760300983947349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300983937325" xlink:to="srt_MaximumMember_638760300983947349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983937325" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300983947349" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300983947349" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983947349" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983947349" xlink:to="us-gaap_EquipmentMember_638760300983947349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983947349" xlink:to="us-gaap_ComputerEquipmentMember_638760300983947349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983947349" xlink:to="us-gaap_FurnitureAndFixturesMember_638760300983947349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983937325" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983947349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983947349" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638760300983947349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfGeographicRegionsInWhichOperating" xlink:label="bcyc_NumberOfGeographicRegionsInWhichOperating_638760300983947349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983947349" xlink:to="bcyc_NumberOfGeographicRegionsInWhichOperating_638760300983947349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails" xlink:type="extended" xlink:title="99940205 - Disclosure - Summary of significant accounting policies - Research and development incentives and receivable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638760300983957326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638760300983957326" xlink:to="srt_StatementScenarioAxis_638760300983957326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638760300983957326" xlink:to="srt_ScenarioUnspecifiedDomain_638760300983957326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638760300983957326" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_638760300983957326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638760300983957326" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_638760300983957326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member" xlink:label="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638760300983957326" xlink:to="bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_638760300983957326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638760300983957326" xlink:to="us-gaap_StatementLineItems_638760300983957326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638760300983957326" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300983957326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses" xlink:label="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300983957326" xlink:to="bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses_638760300983957326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure" xlink:label="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure_638760300983957326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300983957326" xlink:to="bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure_638760300983957326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ReductionOfResearchAndDevelopmentExpense" xlink:label="bcyc_ReductionOfResearchAndDevelopmentExpense_638760300983967322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300983957326" xlink:to="bcyc_ReductionOfResearchAndDevelopmentExpense_638760300983967322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails" xlink:type="extended" xlink:title="99940206 - Disclosure - Summary of significant accounting policies - Share based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638760300983967322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638760300983967322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637000995575779397" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638760300983967322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637000995575779397" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638760300983967322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638760300983967322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638760300983967322" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638760300983967322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638760300983967322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638760300983967322" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638760300983967322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638760300983967322" xlink:to="us-gaap_FairValueInputsLevel1Member_638760300983977335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638760300983967322" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638760300983977335" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638760300983977335" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638760300983977335" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638760300983977335" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638760300983977335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638760300983967322" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638760300983977335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638760300983977335" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638760300983977335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638760300983977335" xlink:to="us-gaap_CashEquivalentsMember_638760300983977335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638760300983967322" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638760300983977335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_638760300983977335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue_638760300983977335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" xlink:to="us-gaap_TimeDepositsAtCarryingValue_638760300983977335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TermDepositMaturityPeriod" xlink:label="bcyc_TermDepositMaturityPeriod_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" xlink:to="bcyc_TermDepositMaturityPeriod_638760300983987332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_638760300983987332" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638760300983977335" xlink:to="us-gaap_AssetsFairValueDisclosure_638760300983987332" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983987332" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983987332" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300983987332" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300983987332" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983987332" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983987332" xlink:to="us-gaap_EquipmentMember_638760300983987332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638760300983987332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983987332" xlink:to="us-gaap_LeaseholdImprovementsMember_638760300983987332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983987332" xlink:to="us-gaap_ComputerEquipmentMember_638760300983997333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300983987332" xlink:to="us-gaap_FurnitureAndFixturesMember_638760300983997333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638760300983987332" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638760300983997333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_638760300983997333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638760300983997333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638760300983997333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638760300983997333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" xlink:to="us-gaap_DepreciationAndAmortization_638760300983997333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638760300983997333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638760300983997333" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638760300983997333" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued expenses and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638760300984007329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="bcyc_AccruedExternalResearchAndDevelopmentExpenses_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="bcyc_AccruedExternalResearchAndDevelopmentExpenses_638760300984007329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638760300984007329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638760300984007329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638760300984007329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638760300984007329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638760300984007329" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_638760300984007329" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638760300984007329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638760300984007329" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_RestructuringCharges_638760300984017343" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638760300984017343" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_PaymentsForRestructuring_638760300984017343" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_RestructuringReserveCurrent_638760300984017343" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638760300984017343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638760300984017343" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984017343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984017343" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984017343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LoanAndSecurityAgreementMember" xlink:label="bcyc_LoanAndSecurityAgreementMember_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984017343" xlink:to="bcyc_LoanAndSecurityAgreementMember_638760300984017343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638760300984017343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638760300984017343" xlink:to="us-gaap_LongtermDebtTypeAxis_638760300984017343" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638760300984017343" xlink:to="us-gaap_LongtermDebtTypeDomain_638760300984027351" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TermLoanMember" xlink:label="bcyc_TermLoanMember_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638760300984027351" xlink:to="bcyc_TermLoanMember_638760300984027351" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InitialTermLoanMember" xlink:label="bcyc_InitialTermLoanMember_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_TermLoanMember_638760300984027351" xlink:to="bcyc_InitialTermLoanMember_638760300984027351" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638760300984017343" xlink:to="srt_RangeAxis_638760300984027351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638760300984027351" xlink:to="srt_RangeMember_638760300984027351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984027351" xlink:to="srt_MinimumMember_638760300984027351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984027351" xlink:to="srt_MaximumMember_638760300984027351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638760300984017343" xlink:to="us-gaap_DebtInstrumentLineItems_638760300984027351" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638760300984027351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638760300984027351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_DebtInstrumentFaceAmount_638760300984027351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638760300984037334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638760300984037334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtInstrumentEndOfTermChargeRate" xlink:label="bcyc_DebtInstrumentEndOfTermChargeRate_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="bcyc_DebtInstrumentEndOfTermChargeRate_638760300984037334" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_InterestPayableCurrent_638760300984037334" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtEndOfTermCharge" xlink:label="bcyc_DebtEndOfTermCharge_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="bcyc_DebtEndOfTermCharge_638760300984037334" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtInstrumentPrepaymentCharges" xlink:label="bcyc_DebtInstrumentPrepaymentCharges_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="bcyc_DebtInstrumentPrepaymentCharges_638760300984037334" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638760300984037334" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638760300984037334" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLongTermDebt" xlink:label="us-gaap_InterestExpenseLongTermDebt_638760300984037334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638760300984027351" xlink:to="us-gaap_InterestExpenseLongTermDebt_638760300984037334" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Debt - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638760300984047349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638760300984047349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DebtEndOfTermCharge" xlink:label="bcyc_DebtEndOfTermCharge_638760300984047349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="bcyc_DebtEndOfTermCharge_638760300984047349" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638760300984047349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet_638760300984047349" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638760300984047349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt_638760300984047349" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Ordinary shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfVotePerShare" xlink:label="bcyc_NumberOfVotePerShare_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="bcyc_NumberOfVotePerShare_638760300984057326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_638760300984057326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638760300984057326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638760300984057326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Ordinary shares - Share Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638760300984057326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638760300984057326" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638760300984057326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638760300984057326" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984057326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AtMarketOfferingMember" xlink:label="bcyc_AtMarketOfferingMember_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984057326" xlink:to="bcyc_AtMarketOfferingMember_638760300984057326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_UnderwrittenPublicOfferingMember" xlink:label="bcyc_UnderwrittenPublicOfferingMember_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984057326" xlink:to="bcyc_UnderwrittenPublicOfferingMember_638760300984057326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InvestorsPurchaseAgreementMember" xlink:label="bcyc_InvestorsPurchaseAgreementMember_638760300984057326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984057326" xlink:to="bcyc_InvestorsPurchaseAgreementMember_638760300984057326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638760300984057326" xlink:to="us-gaap_StatementClassOfStockAxis_638760300984067326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638760300984067326" xlink:to="us-gaap_ClassOfStockDomain_638760300984067326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300984067326" xlink:to="dei_AdrMember_638760300984067326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonVotingOrdinarySharesMember" xlink:label="bcyc_NonVotingOrdinarySharesMember_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300984067326" xlink:to="bcyc_NonVotingOrdinarySharesMember_638760300984067326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_VotingOrdinarySharesMember" xlink:label="bcyc_VotingOrdinarySharesMember_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300984067326" xlink:to="bcyc_VotingOrdinarySharesMember_638760300984067326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638760300984057326" xlink:to="us-gaap_FinancialInstrumentAxis_638760300984067326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638760300984067326" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638760300984067326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionOnSecuritiesMember" xlink:label="us-gaap_OptionOnSecuritiesMember_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638760300984067326" xlink:to="us-gaap_OptionOnSecuritiesMember_638760300984067326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638760300984057326" xlink:to="us-gaap_StatementEquityComponentsAxis_638760300984067326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638760300984067326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638760300984067326" xlink:to="us-gaap_EquityComponentDomain_638760300984067326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638760300984067326" xlink:to="us-gaap_CommonStockMember_638760300984077328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638760300984057326" xlink:to="us-gaap_ClassOfStockLineItems_638760300984077328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_CommonStockSharesIssued_638760300984077328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_CommonStockSharesOutstanding_638760300984077328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638760300984077328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300984077328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638760300984077328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638760300984077328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638760300984077328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638760300984087327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638760300984087327" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638760300984087327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638760300984077328" xlink:to="us-gaap_SharePrice_638760300984087327" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Share-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903662871" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903662871" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638760300984087327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" xlink:to="us-gaap_PlanNameAxis_638760300984087327" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638760300984087327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638760300984087327" xlink:to="us-gaap_PlanNameDomain_638760300984087327" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InducementPlan2024Member" xlink:label="bcyc_InducementPlan2024Member_638760300984087327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638760300984087327" xlink:to="bcyc_InducementPlan2024Member_638760300984087327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2020Member" xlink:label="bcyc_ShareOptionPlan2020Member_638760300984087327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638760300984087327" xlink:to="bcyc_ShareOptionPlan2020Member_638760300984087327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2019Member" xlink:label="bcyc_ShareOptionPlan2019Member_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638760300984087327" xlink:to="bcyc_ShareOptionPlan2019Member_638760300984097328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PreIpoShareOptionsAndRestrictedSharesMember" xlink:label="bcyc_PreIpoShareOptionsAndRestrictedSharesMember_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638760300984087327" xlink:to="bcyc_PreIpoShareOptionsAndRestrictedSharesMember_638760300984097328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" xlink:to="srt_RangeAxis_638760300984097328" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638760300984097328" xlink:to="srt_RangeMember_638760300984097328" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984097328" xlink:to="srt_MinimumMember_638760300984097328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984097328" xlink:to="srt_MaximumMember_638760300984097328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" xlink:to="us-gaap_AwardTypeAxis_638760300984097328" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638760300984097328" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984097328" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984097328" xlink:to="us-gaap_StockCompensationPlanMember_638760300984097328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedPaymentArrangementThreeYearVestMember" xlink:label="bcyc_ShareBasedPaymentArrangementThreeYearVestMember_638760300984097328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockCompensationPlanMember_638760300984097328" xlink:to="bcyc_ShareBasedPaymentArrangementThreeYearVestMember_638760300984097328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984097328" xlink:to="us-gaap_RestrictedStockMember_638760300984107333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984097328" xlink:to="us-gaap_EmployeeStockMember_638760300984107333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" xlink:to="us-gaap_GranteeStatusAxis_638760300984107333" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638760300984107333" xlink:to="us-gaap_GranteeStatusDomain_638760300984107333" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638760300984107333" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638760300984107333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" xlink:to="us-gaap_VestingAxis_638760300984107333" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638760300984107333" xlink:to="us-gaap_VestingDomain_638760300984107333" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638760300984107333" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638760300984107333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638760300984107333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638760300984107333" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638760300984107333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638760300984117357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" xlink:to="srt_TitleOfIndividualAxis_638760300984117357" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638760300984117357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638760300984117357" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638760300984117357" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638760300984117357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638760300984117357" xlink:to="srt_DirectorMember_638760300984117357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984087327" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638760300984117357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638760300984117357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638760300984117357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638760300984117357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638760300984117357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638760300984117357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638760300984127329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638760300984127329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638760300984127329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638760300984127329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638760300984127329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638760300984127329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638760300984127329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638760300984127329" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638760300984127329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638760300984127329" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio_638760300984127329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio_638760300984127329" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfQuarterlyInstallments" xlink:label="bcyc_NumberOfQuarterlyInstallments_638760300984127329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="bcyc_NumberOfQuarterlyInstallments_638760300984127329" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638760300984137373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638760300984137373" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_638760300984137373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_638760300984137373" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638760300984137373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638760300984137373" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments" xlink:label="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments_638760300984137373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments_638760300984137373" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_638760300984137373" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984117357" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_638760300984137373" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Share-based compensation - Share based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903818870" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638760300984147346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903818870" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638760300984147346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638760300984147346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638760300984147346" xlink:to="us-gaap_IncomeStatementLocationAxis_638760300984147346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638760300984147346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638760300984147346" xlink:to="us-gaap_IncomeStatementLocationDomain_638760300984147346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638760300984147346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638760300984147346" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638760300984147346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638760300984147346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638760300984147346" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638760300984147346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638760300984147346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638760300984147346" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638760300984147346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638760300984147346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638760300984147346" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638760300984147346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Share-based compensation - Share Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903818870" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903818870" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984157326" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984157326" xlink:to="us-gaap_AwardTypeAxis_638760300984157326" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984157326" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984157326" xlink:to="us-gaap_StockCompensationPlanMember_638760300984157326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984157326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638760300984157326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638760300984157326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638760300984157326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638760300984157326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638760300984157326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638760300984167333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638760300984167333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638760300984167333" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638760300984167333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638760300984167333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638760300984167333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638760300984167333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638760300984167333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387603009841673331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387603009841673331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638760300984177336" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638760300984167333" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638760300984177336" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984157326" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_638760300984177336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_638760300984177336" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638760300984177336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_638760300984177336" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638760300984177336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract_638760300984177336" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638760300984177336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984157326" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638760300984177336" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638760300984177336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638760300984177336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638760300984177336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638760300984187333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638760300984177336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638760300984187333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638760300984187333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_638760300984177336" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638760300984187333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638760300984187333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984157326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638760300984187333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638760300984187333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638760300984187333" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638760300984187333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638760300984187333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638760300984187333" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638760300984187333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638760300984187333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638760300984187333" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638760300984187333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903818870" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903818870" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984197328" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984197328" xlink:to="us-gaap_AwardTypeAxis_638760300984197328" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638760300984197328" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984197328" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984197328" xlink:to="us-gaap_StockCompensationPlanMember_638760300984197328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984197328" xlink:to="srt_TitleOfIndividualAxis_638760300984197328" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638760300984197328" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638760300984197328" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EmployeeAndDirectorMember" xlink:label="bcyc_EmployeeAndDirectorMember_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638760300984197328" xlink:to="bcyc_EmployeeAndDirectorMember_638760300984197328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984197328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984197328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638760300984197328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984197328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638760300984197328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638760300984207363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984197328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638760300984207363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638760300984207363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984197328" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638760300984207363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638760300984207363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984197328" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638760300984207363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638760300984207363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638760300984207363" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638760300984207363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638760300984207363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638760300984207363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638760300984207363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Share-based compensation - Restricted Share Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903974869" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984207363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637002864903974869" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984207363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638760300984207363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984207363" xlink:to="us-gaap_AwardTypeAxis_638760300984207363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638760300984207363" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984217345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638760300984217345" xlink:to="us-gaap_RestrictedStockMember_638760300984217345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984207363" xlink:to="us-gaap_PlanNameAxis_638760300984217345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638760300984217345" xlink:to="us-gaap_PlanNameDomain_638760300984217345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareOptionPlan2020Member" xlink:label="bcyc_ShareOptionPlan2020Member_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638760300984217345" xlink:to="bcyc_ShareOptionPlan2020Member_638760300984217345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638760300984207363" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984217345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984217345" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638760300984217345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638760300984217345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod_638760300984217345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_638760300984217345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod_638760300984217345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638760300984227361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638760300984227361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement_638760300984227361" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638760300984217345" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber_638760300984227361" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984217345" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638760300984227361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638760300984227361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue_638760300984227361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_638760300984227361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue_638760300984227361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638760300984237331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638760300984237331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638760300984237331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638760300984237331" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue_638760300984237331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue_638760300984237331" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_638760300984237331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638760300984227361" xlink:to="bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue_638760300984237331" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638760300984237331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638760300984217345" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638760300984237331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638760300984237331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638760300984237331" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638760300984237331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638760300984237331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638760300984237331" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638760300984237331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638760300984247343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638760300984237331" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638760300984247343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638760300984247343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638760300984237331" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638760300984247343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Significant agreements - Collaboration revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984247343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984247343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984247343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984247343" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984247343" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984247343" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember_638760300984247343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" xlink:to="bcyc_BayerMember_638760300984247343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember_638760300984247343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" xlink:to="bcyc_NovartisCollaborationAgreementMember_638760300984247343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" xlink:to="bcyc_IonisCollaborationAgreementMember_638760300984257364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" xlink:to="bcyc_GenentechMember_638760300984257364" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DementiaDiscoveryFundCollaborationAgreementMember" xlink:label="bcyc_DementiaDiscoveryFundCollaborationAgreementMember_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" xlink:to="bcyc_DementiaDiscoveryFundCollaborationAgreementMember_638760300984257364" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AstrazenecaCollaborationAgreementMember" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984247343" xlink:to="bcyc_AstrazenecaCollaborationAgreementMember_638760300984257364" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984247343" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984257364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984257364" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984257364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Significant agreements - Bayer Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984257364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984257364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984257364" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984257364" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984257364" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984267350" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984267350" xlink:to="bcyc_BayerMember_638760300984267350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneAxis" xlink:label="bcyc_AchievementOfMilestoneAxis_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984257364" xlink:to="bcyc_AchievementOfMilestoneAxis_638760300984267350" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneDomain" xlink:label="bcyc_AchievementOfMilestoneDomain_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AchievementOfMilestoneAxis_638760300984267350" xlink:to="bcyc_AchievementOfMilestoneDomain_638760300984267350" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DevelopmentAndRegulatoryMilestoneMember" xlink:label="bcyc_DevelopmentAndRegulatoryMilestoneMember_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AchievementOfMilestoneDomain_638760300984267350" xlink:to="bcyc_DevelopmentAndRegulatoryMilestoneMember_638760300984267350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MilestoneAcrossAllPotentialTargetProgramsMember" xlink:label="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AchievementOfMilestoneDomain_638760300984267350" xlink:to="bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_638760300984267350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984257364" xlink:to="srt_RangeAxis_638760300984267350" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638760300984267350" xlink:to="srt_RangeMember_638760300984267350" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984267350" xlink:to="srt_MinimumMember_638760300984267350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984267350" xlink:to="srt_MaximumMember_638760300984267350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984257364" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets_638760300984267350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_CollaborationAgreementNumberOfTargets_638760300984267350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984277340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment" xlink:label="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment_638760300984277340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_638760300984277340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_638760300984277340" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach_638760300984277340" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer" xlink:label="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer_638760300984277340" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer" xlink:label="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer_638760300984277340" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_638760300984277340" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984277340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984277340" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_638760300984287332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_638760300984287332" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984287332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984287332" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984287332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984287332" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638760300984287332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984267350" xlink:to="us-gaap_ContractWithCustomerLiability_638760300984287332" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984287332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_7" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984287332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984287332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984287332" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984287332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984287332" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984297341" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984297341" xlink:to="bcyc_BayerMember_638760300984297341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984287332" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984297341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984297341" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984297341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember" xlink:label="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984297341" xlink:to="bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_638760300984297341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember" xlink:label="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984297341" xlink:to="bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_638760300984297341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984297341" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_638760300984297341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984297341" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_638760300984297341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember" xlink:label="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984297341" xlink:to="bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_638760300984297341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984287332" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984297341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCombinedPerformanceObligations" xlink:label="bcyc_NumberOfCombinedPerformanceObligations_638760300984297341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984297341" xlink:to="bcyc_NumberOfCombinedPerformanceObligations_638760300984297341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRights" xlink:label="bcyc_NumberOfMaterialRights_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984297341" xlink:to="bcyc_NumberOfMaterialRights_638760300984307352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984297341" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984307352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Significant agreements - Novartis Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_5" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984307352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984307352" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984307352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984307352" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984307352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984307352" xlink:to="bcyc_NovartisCollaborationAgreementMember_638760300984307352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984307352" xlink:to="srt_StatementScenarioAxis_638760300984307352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638760300984307352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638760300984307352" xlink:to="srt_ScenarioUnspecifiedDomain_638760300984307352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember" xlink:label="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638760300984307352" xlink:to="bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_638760300984317350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CompletionOfAllMilestonesForTargetsMember" xlink:label="bcyc_CompletionOfAllMilestonesForTargetsMember_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638760300984307352" xlink:to="bcyc_CompletionOfAllMilestonesForTargetsMember_638760300984317350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984307352" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984317350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984317350" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984317350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember" xlink:label="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984317350" xlink:to="bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_638760300984317350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember" xlink:label="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984317350" xlink:to="bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_638760300984317350" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember" xlink:label="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984317350" xlink:to="bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_638760300984317350" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember" xlink:label="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984317350" xlink:to="bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_638760300984317350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984307352" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets_638760300984317350" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_CollaborationAgreementNumberOfTargets_638760300984317350" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AdditionalResearchTerm" xlink:label="bcyc_AdditionalResearchTerm_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_AdditionalResearchTerm_638760300984327342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984327342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable_638760300984327342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_638760300984327342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement" xlink:label="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement_638760300984327342" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_638760300984327342" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_638760300984327342" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984327342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984327342" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984337405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984337405" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638760300984337405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984317350" xlink:to="us-gaap_ContractWithCustomerLiability_638760300984337405" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984337405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_6" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984337405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984337405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984337405" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984337405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984337405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984337405" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984337405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember_638760300984337405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984337405" xlink:to="bcyc_NovartisCollaborationAgreementMember_638760300984337405" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984337405" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984347361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984347361" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984347361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember" xlink:label="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984347361" xlink:to="bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_638760300984347361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984347361" xlink:to="bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_638760300984347361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984347361" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_638760300984347361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984347361" xlink:to="bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_638760300984347361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984337405" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984347361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCombinedPerformanceObligations" xlink:label="bcyc_NumberOfCombinedPerformanceObligations_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984347361" xlink:to="bcyc_NumberOfCombinedPerformanceObligations_638760300984347361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRights" xlink:label="bcyc_NumberOfMaterialRights_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984347361" xlink:to="bcyc_NumberOfMaterialRights_638760300984347361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984347361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984347361" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984347361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedVariableConsiderationNoLongerConstrained" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984347361" xlink:to="bcyc_EstimatedVariableConsiderationNoLongerConstrained_638760300984357353" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Significant agreements - Ionis Evaluation and Option Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984357353" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984357353" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984357353" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984357353" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984357353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisEvaluationAndOptionAgreementMember" xlink:label="bcyc_IonisEvaluationAndOptionAgreementMember_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984357353" xlink:to="bcyc_IonisEvaluationAndOptionAgreementMember_638760300984357353" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984357353" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984357353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984357353" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984357353" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638760300984357353" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984357353" xlink:to="us-gaap_ContractWithCustomerLiability_638760300984357353" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940907 - Disclosure - Significant agreements - Ionis Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984367334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984367334" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984367334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984367334" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984367334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984367334" xlink:to="bcyc_IonisCollaborationAgreementMember_638760300984367334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AmendedIonisCollaborationAgreementMember" xlink:label="bcyc_AmendedIonisCollaborationAgreementMember_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984367334" xlink:to="bcyc_AmendedIonisCollaborationAgreementMember_638760300984367334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThirdIonisAmendmentMember" xlink:label="bcyc_ThirdIonisAmendmentMember_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984367334" xlink:to="bcyc_ThirdIonisAmendmentMember_638760300984367334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984367334" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984367334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration" xlink:label="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984367334" xlink:to="bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration_638760300984367334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984367334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984367334" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984367334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone" xlink:label="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone_638760300984377375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984367334" xlink:to="bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone_638760300984377375" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets_638760300984377375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984367334" xlink:to="bcyc_CollaborationAgreementNumberOfTargets_638760300984377375" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_638760300984377375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984367334" xlink:to="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_638760300984377375" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails" xlink:type="extended" xlink:title="99940908 - Disclosure - Significant agreements - Ionis Share Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984377375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_2" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984377375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984377375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984377375" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984377375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984377375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984377375" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984377375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember_638760300984377375" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984377375" xlink:to="bcyc_IonisCollaborationAgreementMember_638760300984377375" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984377375" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638760300984387345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638760300984387345" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984387345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisSharePurchaseAgreementMember" xlink:label="bcyc_IonisSharePurchaseAgreementMember_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984387345" xlink:to="bcyc_IonisSharePurchaseAgreementMember_638760300984387345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984377375" xlink:to="us-gaap_StatementClassOfStockAxis_638760300984387345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638760300984387345" xlink:to="us-gaap_ClassOfStockDomain_638760300984387345" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300984387345" xlink:to="dei_AdrMember_638760300984387345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984377375" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984387345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984387345" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638760300984387345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984387345" xlink:to="us-gaap_SharePrice_638760300984387345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300984387345" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984387345" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300984387345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FairValueOfSharesHeld" xlink:label="bcyc_FairValueOfSharesHeld_638760300984397328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984387345" xlink:to="bcyc_FairValueOfSharesHeld_638760300984397328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984397328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984387345" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984397328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails" xlink:type="extended" xlink:title="99940909 - Disclosure - Significant agreements - Ionis Accounting Analysis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984467309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_3" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984467309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984467309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984467309" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984467309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984467309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984467309" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984467309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember_638760300984467309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984467309" xlink:to="bcyc_IonisCollaborationAgreementMember_638760300984467309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisEvaluationAndOptionAgreementMember" xlink:label="bcyc_IonisEvaluationAndOptionAgreementMember_638760300984467309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984467309" xlink:to="bcyc_IonisEvaluationAndOptionAgreementMember_638760300984467309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AmendedIonisCollaborationAgreementMember" xlink:label="bcyc_AmendedIonisCollaborationAgreementMember_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984467309" xlink:to="bcyc_AmendedIonisCollaborationAgreementMember_638760300984477310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ThirdAmendedIonisMember" xlink:label="bcyc_ThirdAmendedIonisMember_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984467309" xlink:to="bcyc_ThirdAmendedIonisMember_638760300984477310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984467309" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638760300984477310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638760300984477310" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984477310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisSharePurchaseAgreementMember" xlink:label="bcyc_IonisSharePurchaseAgreementMember_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638760300984477310" xlink:to="bcyc_IonisSharePurchaseAgreementMember_638760300984477310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984467309" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984477310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984477310" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984477310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember" xlink:label="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984477310" xlink:to="bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_638760300984477310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember" xlink:label="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984477310" xlink:to="bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_638760300984477310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638760300984477310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984467309" xlink:to="srt_RangeAxis_638760300984477310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638760300984477310" xlink:to="srt_RangeMember_638760300984487335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984487335" xlink:to="srt_MinimumMember_638760300984487335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984487335" xlink:to="srt_MaximumMember_638760300984487335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984467309" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments" xlink:label="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments_638760300984487335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementNumberOfTargets" xlink:label="bcyc_CollaborationAgreementNumberOfTargets_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="bcyc_CollaborationAgreementNumberOfTargets_638760300984487335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984487335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984487335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations" xlink:label="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_638760300984487335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations_638760300984487335" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984497335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984497335" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984497335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984497335" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638760300984497335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984487335" xlink:to="us-gaap_ContractWithCustomerLiability_638760300984497335" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails" xlink:type="extended" xlink:title="99940910 - Disclosure - Significant agreements - Genentech Collaboration Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_637235881354495056" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637235881354495056" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984507329" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984507329" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984507329" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984507329" xlink:to="bcyc_GenentechMember_638760300984507329" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984507329" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984507329" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationOnePerformanceObligationMember" xlink:label="bcyc_CollaborationOnePerformanceObligationMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_CollaborationOnePerformanceObligationMember_638760300984507329" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationTwoPerformanceObligationMember" xlink:label="bcyc_CollaborationTwoPerformanceObligationMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_CollaborationTwoPerformanceObligationMember_638760300984507329" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember" xlink:label="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_638760300984507329" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember" xlink:label="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_638760300984507329" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember" xlink:label="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_638760300984507329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TwoMaterialRightsForExpansionOptionsMember" xlink:label="bcyc_TwoMaterialRightsForExpansionOptionsMember_638760300984507329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_TwoMaterialRightsForExpansionOptionsMember_638760300984507329" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationPerformanceOneAndTwoMember" xlink:label="bcyc_CollaborationPerformanceOneAndTwoMember_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_CollaborationPerformanceOneAndTwoMember_638760300984517336" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_638760300984517336" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgramThreePerformanceObligationMember" xlink:label="bcyc_CollaborationProgramThreePerformanceObligationMember_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_CollaborationProgramThreePerformanceObligationMember_638760300984517336" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgram4PerformanceObligationMember" xlink:label="bcyc_CollaborationProgram4PerformanceObligationMember_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_CollaborationProgram4PerformanceObligationMember_638760300984517336" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_638760300984517336" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984507329" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_638760300984517336" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneAxis" xlink:label="bcyc_AchievementOfMilestoneAxis_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" xlink:to="bcyc_AchievementOfMilestoneAxis_638760300984517336" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AchievementOfMilestoneDomain" xlink:label="bcyc_AchievementOfMilestoneDomain_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AchievementOfMilestoneAxis_638760300984517336" xlink:to="bcyc_AchievementOfMilestoneDomain_638760300984517336" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DevelopmentMilestoneMember" xlink:label="bcyc_DevelopmentMilestoneMember_638760300984517336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AchievementOfMilestoneDomain_638760300984517336" xlink:to="bcyc_DevelopmentMilestoneMember_638760300984517336" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RegulatoryMilestoneMember" xlink:label="bcyc_RegulatoryMilestoneMember_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_AchievementOfMilestoneDomain_638760300984517336" xlink:to="bcyc_RegulatoryMilestoneMember_638760300984527328" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" xlink:to="srt_RangeAxis_638760300984527328" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638760300984527328" xlink:to="srt_RangeMember_638760300984527328" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984527328" xlink:to="srt_MaximumMember_638760300984527328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984527328" xlink:to="srt_MinimumMember_638760300984527328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" xlink:to="srt_ProductOrServiceAxis_638760300984527328" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638760300984527328" xlink:to="srt_ProductsAndServicesDomain_638760300984527328" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember_638760300984527328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638760300984527328" xlink:to="us-gaap_RoyaltyMember_638760300984527328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638760300984537325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" xlink:to="srt_StatementScenarioAxis_638760300984537325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638760300984537325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638760300984537325" xlink:to="srt_ScenarioUnspecifiedDomain_638760300984537325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638760300984537325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638760300984537325" xlink:to="srt_ScenarioForecastMember_638760300984537325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984497335" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfPotentialDevelopmentCandidates" xlink:label="bcyc_NumberOfPotentialDevelopmentCandidates_638760300984537325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_NumberOfPotentialDevelopmentCandidates_638760300984537325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984537325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_CollaborativeArrangementUpfrontCashPaymentReceived_638760300984537325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfImmunoOncologyTargets" xlink:label="bcyc_NumberOfImmunoOncologyTargets_638760300984537325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_NumberOfImmunoOncologyTargets_638760300984537325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AdditionalNumberOfImmunoOncologyTargets" xlink:label="bcyc_AdditionalNumberOfImmunoOncologyTargets_638760300984547329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_AdditionalNumberOfImmunoOncologyTargets_638760300984547329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ExpansionFeePerAdditionalCollaborationProgram" xlink:label="bcyc_ExpansionFeePerAdditionalCollaborationProgram_638760300984547329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_ExpansionFeePerAdditionalCollaborationProgram_638760300984547329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfInitialCollaborationPrograms" xlink:label="bcyc_NumberOfInitialCollaborationPrograms_638760300984547329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_NumberOfInitialCollaborationPrograms_638760300984547329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OptionFeeForDevelopmentAndExploitationRights" xlink:label="bcyc_OptionFeeForDevelopmentAndExploitationRights_638760300984547329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_OptionFeeForDevelopmentAndExploitationRights_638760300984547329" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfCollaborationPrograms" xlink:label="bcyc_NumberOfCollaborationPrograms_638760300984547329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_NumberOfCollaborationPrograms_638760300984547329" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo" xlink:label="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo_638760300984547329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo_638760300984547329" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable" xlink:label="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_638760300984557336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable_638760300984557336" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable" xlink:label="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable_638760300984557336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable_638760300984557336" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfYearsOverWhichRoyaltyIsPayable" xlink:label="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_638760300984557336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_NumberOfYearsOverWhichRoyaltyIsPayable_638760300984557336" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice" xlink:label="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984557336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice_638760300984557336" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed" xlink:label="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_638760300984557336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed_638760300984557336" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsExerciseOrExpiryTerm" xlink:label="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984557336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_MaterialRightsExerciseOrExpiryTerm_638760300984557336" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638760300984567330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="us-gaap_ContractWithCustomerLiability_638760300984567330" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationProgramAmountOfMaterialRights" xlink:label="bcyc_CollaborationProgramAmountOfMaterialRights_638760300984567330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_CollaborationProgramAmountOfMaterialRights_638760300984567330" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EstimatedVariableConsiderationNoLongerConstrained" xlink:label="bcyc_EstimatedVariableConsiderationNoLongerConstrained_638760300984567330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="bcyc_EstimatedVariableConsiderationNoLongerConstrained_638760300984567330" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984567330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984567330" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638760300984567330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984537325" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638760300984567330" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940911 - Disclosure - Significant agreements - Summary of Contract Assets and Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984577348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984577348" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984577348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984577348" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984577348" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984577348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984577348" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984577348" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BayerMember" xlink:label="bcyc_BayerMember_638760300984577348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984577348" xlink:to="bcyc_BayerMember_638760300984577348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NovartisCollaborationAgreementMember" xlink:label="bcyc_NovartisCollaborationAgreementMember_638760300984577348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984577348" xlink:to="bcyc_NovartisCollaborationAgreementMember_638760300984577348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IonisCollaborationAgreementMember" xlink:label="bcyc_IonisCollaborationAgreementMember_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984577348" xlink:to="bcyc_IonisCollaborationAgreementMember_638760300984587341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984577348" xlink:to="bcyc_GenentechMember_638760300984587341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AstrazenecaCollaborationAgreementMember" xlink:label="bcyc_AstrazenecaCollaborationAgreementMember_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984577348" xlink:to="bcyc_AstrazenecaCollaborationAgreementMember_638760300984587341" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984577348" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638760300984587341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638760300984587341" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638760300984587341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredRevenueMaterialRightsOptionMember" xlink:label="bcyc_DeferredRevenueMaterialRightsOptionMember_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638760300984587341" xlink:to="bcyc_DeferredRevenueMaterialRightsOptionMember_638760300984587341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984577348" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984587341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984587341" xlink:to="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_638760300984587341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_638760300984587341" xlink:to="us-gaap_ContractWithCustomerLiability_638760300984587341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityAdditions" xlink:label="bcyc_ContractWithCustomerLiabilityAdditions_638760300984587341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_638760300984587341" xlink:to="bcyc_ContractWithCustomerLiabilityAdditions_638760300984587341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityDeductions" xlink:label="bcyc_ContractWithCustomerLiabilityDeductions_638760300984597329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_638760300984587341" xlink:to="bcyc_ContractWithCustomerLiabilityDeductions_638760300984597329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment" xlink:label="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment_638760300984597329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_638760300984587341" xlink:to="bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment_638760300984597329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638760300984597329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerLiabilityAbstract_638760300984587341" xlink:to="us-gaap_ContractWithCustomerLiability_638760300984597329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInContractWithCustomerAssetAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAbstract_638760300984597329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984587341" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAbstract_638760300984597329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638760300984597329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAbstract_638760300984597329" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638760300984597329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940912 - Disclosure - Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_638760300984597329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation_638760300984597329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights_638760300984607334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice" xlink:label="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice_638760300984607334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability" xlink:label="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability_638760300984607334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails" xlink:type="extended" xlink:title="99940913 - Disclosure - Significant agreements - Cancer Research UK (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638760300984607334" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638760300984607334" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984607334" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984607334" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984607334" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CancerResearchUkBtOneSevenOneEightMember" xlink:label="bcyc_CancerResearchUkBtOneSevenOneEightMember_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984607334" xlink:to="bcyc_CancerResearchUkBtOneSevenOneEightMember_638760300984607334" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638760300984607334" xlink:to="srt_RangeAxis_638760300984607334" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638760300984607334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638760300984607334" xlink:to="srt_RangeMember_638760300984607334" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984607334" xlink:to="srt_MinimumMember_638760300984617342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638760300984607334" xlink:to="srt_MaximumMember_638760300984617342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638760300984607334" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_638760300984617342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_638760300984617342" xlink:to="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_638760300984617342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_PercentageOfTieredRoyaltyOnNetRevenue" xlink:label="bcyc_PercentageOfTieredRoyaltyOnNetRevenue_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_638760300984617342" xlink:to="bcyc_PercentageOfTieredRoyaltyOnNetRevenue_638760300984617342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties" xlink:label="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_638760300984617342" xlink:to="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties_638760300984617342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties" xlink:label="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_638760300984617342" xlink:to="bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties_638760300984617342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment" xlink:label="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_638760300984617342" xlink:to="bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment_638760300984617342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability" xlink:label="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300984617342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract_638760300984617342" xlink:to="bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability_638760300984617342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Income taxes - Components of net loss before tax provision from income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638760300984627343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638760300984627343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638760300984627343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638760300984627343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300984627343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638760300984627343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Income taxes - Components of benefit for income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984627343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984627343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638760300984627343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984627343" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638760300984627343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638760300984627343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984627343" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638760300984627343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638760300984627343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984627343" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638760300984627343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984637341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984637341" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638760300984637341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984637341" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638760300984637341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638760300984637341" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638760300984637341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638760300984637341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Income taxes - Reconciliation of benefit for income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638760300984637341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638760300984637341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638760300984637341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638760300984647368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit_638760300984647368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage_638760300984647368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent" xlink:label="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" xlink:to="bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent_638760300984647368" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638760300984637341" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638760300984647368" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638760300984647368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941004 - Disclosure - Income taxes - Components of the company's current and deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638760300984647368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638760300984647368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638760300984657386" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="bcyc_DeferredTaxAssetsOperatingLeaseLiability_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" xlink:to="bcyc_DeferredTaxAssetsOperatingLeaseLiability_638760300984657386" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638760300984657386" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_DeferredTaxAssetDepreciationAndAmortization" xlink:label="bcyc_DeferredTaxAssetDepreciationAndAmortization_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" xlink:to="bcyc_DeferredTaxAssetDepreciationAndAmortization_638760300984657386" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638760300984657386" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638760300984647368" xlink:to="us-gaap_DeferredTaxAssetsGross_638760300984657386" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638760300984657386" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638760300984657386" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638760300984657386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638760300984657386" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638760300984657386" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638760300984657386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638760300984657386" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638760300984657386" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638760300984657386" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638760300984667335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99941005 - Disclosure - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638760300984667335" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638760300984667335" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638760300984667335" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638760300984667335" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638760300984667335" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638760300984667335" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638760300984667335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638760300984667335" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638760300984667335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy" xlink:label="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy_638760300984667335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy_638760300984667335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_638760300984677366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes_638760300984677366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638760300984677366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638760300984677366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638760300984677366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638760300984677366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638760300984677366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="us-gaap_UnrecognizedTaxBenefits_638760300984677366" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638760300984677366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638760300984677366" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NumberOfJurisdictions" xlink:label="bcyc_NumberOfJurisdictions_638760300984677366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638760300984667335" xlink:to="bcyc_NumberOfJurisdictions_638760300984677366" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Commitments and contingencies - Operating Leases and Finance Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638760300984687379" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638760300984687379" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300984687379" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638760300984687379" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300984687379" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300984687379" xlink:to="bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_638760300984687379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember" xlink:label="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300984687379" xlink:to="bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_638760300984687379" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300984687379" xlink:to="bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_638760300984687379" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember" xlink:label="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638760300984687379" xlink:to="bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_638760300984687379" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638760300984687379" xlink:to="us-gaap_IncomeStatementLocationAxis_638760300984687379" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638760300984687379" xlink:to="us-gaap_IncomeStatementLocationDomain_638760300984687379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638760300984687379" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638760300984687379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638760300984687379" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseContractualTerm" xlink:label="bcyc_LesseeOperatingLeaseContractualTerm_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="bcyc_LesseeOperatingLeaseContractualTerm_638760300984697337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638760300984697337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638760300984697337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OperatingLeaseAnnualRent" xlink:label="bcyc_OperatingLeaseAnnualRent_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="bcyc_OperatingLeaseAnnualRent_638760300984697337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_PaymentsForRent_638760300984697337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseRentFreePeriod" xlink:label="bcyc_LesseeOperatingLeaseRentFreePeriod_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="bcyc_LesseeOperatingLeaseRentFreePeriod_638760300984697337" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_SecurityDeposit_638760300984697337" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638760300984697337" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638760300984697337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_OperatingLeaseLiability_638760300984697337" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638760300984707337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638760300984707337" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_OperatingLeaseAgreementEstimatedServiceCharges" xlink:label="bcyc_OperatingLeaseAgreementEstimatedServiceCharges_638760300984707337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="bcyc_OperatingLeaseAgreementEstimatedServiceCharges_638760300984707337" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_638760300984707337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_GainLossOnTerminationOfLease_638760300984707337" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember" xlink:label="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember_638760300984707337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember_638760300984707337" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638760300984707337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638760300984707337" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638760300984707337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset_638760300984707337" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638760300984707337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638760300984707337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638760300984687379" xlink:to="us-gaap_FinanceLeaseLiability_638760300984707337" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_638760300984717371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiability_638760300984707337" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_638760300984717371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Commitments and contingencies - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638760300984717371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638760300984717371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638760300984717371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost_638760300984717371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638760300984717371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638760300984717371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638760300984717371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638760300984717371" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638760300984717371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638760300984717371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638760300984717371" xlink:to="us-gaap_FinanceLeaseInterestExpense_638760300984717371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FinanceLeaseCost" xlink:label="bcyc_FinanceLeaseCost_638760300984717371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638760300984717371" xlink:to="bcyc_FinanceLeaseCost_638760300984717371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638760300984727355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638760300984727355" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638760300984727355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638760300984727355" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638760300984727355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638760300984727355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638760300984727355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638760300984727355" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Commitments and contingencies - Leases, Maturities of Operating Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984727355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984727355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984727355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984727355" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984727355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984727355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984727355" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984727355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_AgreementWithThirdPartyMember" xlink:label="bcyc_AgreementWithThirdPartyMember_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984727355" xlink:to="bcyc_AgreementWithThirdPartyMember_638760300984737362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638760300984727355" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984737362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984737362" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638760300984737362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638760300984737362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638760300984737362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638760300984737362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" xlink:to="us-gaap_OperatingLeaseLiability_638760300984737362" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638760300984737362" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300984737362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638760300984737362" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300984737362" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent_638760300984737362" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638760300984747348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984737362" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638760300984747348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638760300984747348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638760300984747348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_638760300984747348" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_638760300984747348" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638760300984747348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638760300984747348" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638760300984757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiability_638760300984757362" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638760300984757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638760300984757362" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638760300984757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638760300984747348" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638760300984757362" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice" xlink:label="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_638760300984757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984737362" xlink:to="bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice_638760300984757362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable" xlink:label="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable_638760300984757362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638760300984737362" xlink:to="bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable_638760300984757362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Net loss per share - Basic and diluted net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638760300984767352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638760300984767352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638760300984767352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638760300984767352" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638760300984767352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638760300984767352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638760300984767352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638760300984767352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638760300984767352" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638760300984767352" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638760300984767352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638760300984767352" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638760300984767352" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638760300984767352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638760300984767352" xlink:to="us-gaap_EarningsPerShareBasic_638760300984767352" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638760300984767352" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638760300984767352" xlink:to="us-gaap_EarningsPerShareDiluted_638760300984767352" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Net loss per share - Securities excluded from the diluted per share calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638760300984777380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638760300984777380" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638760300984777380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638760300984777380" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638760300984777380" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638760300984777380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638760300984777380" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638760300984777380" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638760300984777380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638760300984777380" xlink:to="us-gaap_RestrictedStockMember_638760300984777380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638760300984777380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638760300984777380" xlink:to="us-gaap_EmployeeStockOptionMember_638760300984777380" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638760300984777380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638760300984777380" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638760300984777380" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638760300984777380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638760300984777380" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638760300984777380" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Benefit plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638760300984787342" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="us-gaap_RetirementPlanSponsorLocationAxis_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638760300984787342" xlink:to="us-gaap_RetirementPlanSponsorLocationAxis_638760300984787342" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="us-gaap_RetirementPlanSponsorLocationDomain_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanSponsorLocationAxis_638760300984787342" xlink:to="us-gaap_RetirementPlanSponsorLocationDomain_638760300984787342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember" xlink:label="us-gaap_DomesticPlanMember_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain_638760300984787342" xlink:to="us-gaap_DomesticPlanMember_638760300984787342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DomesticPlanMember_638760300984787342" xlink:to="country_US_638760300984787342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember" xlink:label="us-gaap_ForeignPlanMember_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanSponsorLocationDomain_638760300984787342" xlink:to="us-gaap_ForeignPlanMember_638760300984787342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638760300984787342" xlink:to="us-gaap_RetirementPlanNameAxis_638760300984787342" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis_638760300984787342" xlink:to="us-gaap_RetirementPlanNameDomain_638760300984787342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_Plan401KMember" xlink:label="bcyc_Plan401KMember_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain_638760300984787342" xlink:to="bcyc_Plan401KMember_638760300984787342" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_UKPlanMember" xlink:label="bcyc_UKPlanMember_638760300984787342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain_638760300984787342" xlink:to="bcyc_UKPlanMember_638760300984787342" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638760300984787342" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638760300984797340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638760300984797340" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638760300984797340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Related party transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638760300984797340" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638760300984797340" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638760300984797340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638760300984797340" xlink:to="us-gaap_RelatedPartyDomain_638760300984797340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638760300984797340" xlink:to="srt_AffiliatedEntityMember_638760300984797340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638760300984797340" xlink:to="srt_CounterpartyNameAxis_638760300984797340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638760300984797340" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638760300984797340" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638760300984797340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member" xlink:label="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638760300984797340" xlink:to="bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member_638760300984807336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_BakerBrothersAdvisorsLpMember" xlink:label="bcyc_BakerBrothersAdvisorsLpMember_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638760300984797340" xlink:to="bcyc_BakerBrothersAdvisorsLpMember_638760300984807336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638760300984797340" xlink:to="us-gaap_StatementClassOfStockAxis_638760300984807336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638760300984807336" xlink:to="us-gaap_ClassOfStockDomain_638760300984807336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_NonVotingOrdinarySharesMember" xlink:label="bcyc_NonVotingOrdinarySharesMember_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638760300984807336" xlink:to="bcyc_NonVotingOrdinarySharesMember_638760300984807336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638760300984797340" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638760300984807336" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638760300984807336" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638760300984807336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638760300984807336" xlink:to="us-gaap_CommonStockSharesIssued_638760300984807336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638760300984807336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638760300984807336" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638760300984807336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638760300984807336" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638760300984817342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Segments and geographic information - Significant segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638760300984817342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638760300984817342" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638760300984817342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638760300984817342" xlink:to="us-gaap_SegmentDomain_638760300984817342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_SingleReportableSegmentMember" xlink:label="bcyc_SingleReportableSegmentMember_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638760300984817342" xlink:to="bcyc_SingleReportableSegmentMember_638760300984817342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638760300984817342" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638760300984817342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638760300984817342" xlink:to="us-gaap_ProjectMember_638760300984817342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_638760300984817342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638760300984817342" xlink:to="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_638760300984817342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member" xlink:label="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638760300984817342" xlink:to="bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_638760300984827361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember" xlink:label="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638760300984817342" xlink:to="bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_638760300984827361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member" xlink:label="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638760300984817342" xlink:to="bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_638760300984827361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638760300984817342" xlink:to="us-gaap_SegmentReportingInformationLineItems_638760300984827361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638760300984827361" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638760300984827361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638760300984827361" xlink:to="us-gaap_OperatingExpensesAbstract_638760300984827361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638760300984827361" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ProjectSpecificCosts" xlink:label="bcyc_ProjectSpecificCosts_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" xlink:to="bcyc_ProjectSpecificCosts_638760300984827361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses" xlink:label="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" xlink:to="bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses_638760300984827361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses" xlink:label="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_638760300984827361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" xlink:to="bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses_638760300984827361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense" xlink:label="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" xlink:to="bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense_638760300984837337" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_FacilityExpenses" xlink:label="bcyc_FacilityExpenses_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" xlink:to="bcyc_FacilityExpenses_638760300984837337" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants" xlink:label="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" xlink:to="bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants_638760300984837337" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638760300984827361" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638760300984837337" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638760300984827361" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" xlink:to="us-gaap_LaborAndRelatedExpense_638760300984837337" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" xlink:to="us-gaap_ProfessionalFees_638760300984837337" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_638760300984837337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_638760300984837337" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense" xlink:label="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_638760300984847333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" xlink:to="bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense_638760300984847333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638760300984847333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638760300984847333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638760300984847333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_638760300984837337" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638760300984847333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638760300984847333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638760300984827361" xlink:to="us-gaap_OperatingExpenses_638760300984847333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638760300984847333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638760300984827361" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638760300984847333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638760300984847333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638760300984827361" xlink:to="us-gaap_NetIncomeLoss_638760300984847333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails" xlink:type="extended" xlink:title="99941502 - Disclosure - Segments and geographic information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638760300984857338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638760300984857338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638760300984857338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638760300984857338" xlink:to="srt_StatementGeographicalAxis_638760300984857338" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638760300984857338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638760300984857338" xlink:to="srt_SegmentGeographicalDomain_638760300984857338" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US_638760300984857338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638760300984857338" xlink:to="country_US_638760300984857338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB_638760300984857338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638760300984857338" xlink:to="country_GB_638760300984857338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638760300984857338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638760300984857338" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638760300984857338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638760300984857338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638760300984857338" xlink:to="us-gaap_NumberOfOperatingSegments_638760300984857338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638760300984857338" xlink:to="us-gaap_NoncurrentAssets_638760300984867362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638760300984867362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638760300984867362" xlink:to="us-gaap_SubsequentEventTypeAxis_638760300984867362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638760300984867362" xlink:to="us-gaap_SubsequentEventTypeDomain_638760300984867362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638760300984867362" xlink:to="us-gaap_SubsequentEventMember_638760300984867362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638760300984867362" xlink:to="us-gaap_TypeOfArrangementAxis_638760300984867362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638760300984867362" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984867362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_GenentechMember" xlink:label="bcyc_GenentechMember_638760300984867362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638760300984867362" xlink:to="bcyc_GenentechMember_638760300984867362" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638760300984867362" xlink:to="srt_StatementScenarioAxis_638760300984877348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638760300984877348" xlink:to="srt_ScenarioUnspecifiedDomain_638760300984877348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638760300984877348" xlink:to="srt_ScenarioForecastMember_638760300984877348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638760300984867362" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984877348" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638760300984877348" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984877348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="bcyc-20241231.xsd#bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember" xlink:label="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638760300984877348" xlink:to="bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_638760300984877348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638760300984867362" xlink:to="us-gaap_SubsequentEventLineItems_638760300984877348" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638760300984877348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638760300984877348" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638760300984877348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241641050144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 20, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-38916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BICYCLE THERAPEUTICS PLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Blocks A & B, Portway Building, Granta Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Great Abington, Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">CB21 6GS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1223 261503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758,541,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001761612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Cambridge, United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.01 per share*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,710,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCYC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember', window );">Non-voting ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,492,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642183920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 879,520<span></span>
</td>
<td class="nump">$ 526,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">13,432<span></span>
</td>
<td class="nump">11,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent', window );">Research and development incentives receivable</a></td>
<td class="nump">35,653<span></span>
</td>
<td class="nump">24,039<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">928,605<span></span>
</td>
<td class="nump">561,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,516<span></span>
</td>
<td class="nump">14,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">7,673<span></span>
</td>
<td class="nump">13,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">11,074<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">956,868<span></span>
</td>
<td class="nump">595,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,793<span></span>
</td>
<td class="nump">13,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">41,246<span></span>
</td>
<td class="nump">31,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">10,191<span></span>
</td>
<td class="nump">24,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">67,230<span></span>
</td>
<td class="nump">69,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">3,990<span></span>
</td>
<td class="nump">9,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">91,467<span></span>
</td>
<td class="nump">110,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">4,579<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">163,808<span></span>
</td>
<td class="nump">224,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, including non-voting ordinary shares, &#163;0.01 nominal value; 155,876,645 and 59,612,613 shares authorized at December 31, 2024 and December 31, 2023, respectively; 69,061,418 and 42,431,766 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,472,842<span></span>
</td>
<td class="nump">883,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">119<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(680,791)<span></span>
</td>
<td class="num">(511,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">793,060<span></span>
</td>
<td class="nump">370,932<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 956,868<span></span>
</td>
<td class="nump">$ 595,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development incentives receivables, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639606496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value</a></td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">155,876,645<span></span>
</td>
<td class="nump">59,612,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">69,061,418<span></span>
</td>
<td class="nump">42,431,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">69,061,418<span></span>
</td>
<td class="nump">42,431,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726393040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 35,275<span></span>
</td>
<td class="nump">$ 26,976<span></span>
</td>
<td class="nump">$ 14,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">172,966<span></span>
</td>
<td class="nump">156,496<span></span>
</td>
<td class="nump">81,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">72,181<span></span>
</td>
<td class="nump">60,426<span></span>
</td>
<td class="nump">49,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">245,147<span></span>
</td>
<td class="nump">216,922<span></span>
</td>
<td class="nump">131,116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(209,872)<span></span>
</td>
<td class="num">(189,946)<span></span>
</td>
<td class="num">(116,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">34,284<span></span>
</td>
<td class="nump">14,002<span></span>
</td>
<td class="nump">5,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,730)<span></span>
</td>
<td class="num">(3,263)<span></span>
</td>
<td class="num">(3,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability', window );">Gain on extinguishment of research and development funding liability</a></td>
<td class="nump">4,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">36,076<span></span>
</td>
<td class="nump">10,739<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax provision</a></td>
<td class="num">(173,796)<span></span>
</td>
<td class="num">(179,207)<span></span>
</td>
<td class="num">(114,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income taxes</a></td>
<td class="num">(4,765)<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
<td class="num">(1,524)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (169,031)<span></span>
</td>
<td class="num">$ (180,664)<span></span>
</td>
<td class="num">$ (112,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.9)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
<td class="num">$ (3.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.9)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
<td class="num">$ (3.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding, basic</a></td>
<td class="nump">58,207,593<span></span>
</td>
<td class="nump">35,592,362<span></span>
</td>
<td class="nump">29,660,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding, diluted</a></td>
<td class="nump">58,207,593<span></span>
</td>
<td class="nump">35,592,362<span></span>
</td>
<td class="nump">29,660,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensives loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (169,031)<span></span>
</td>
<td class="num">$ (180,664)<span></span>
</td>
<td class="num">$ (112,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="num">(1,691)<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (167,608)<span></span>
</td>
<td class="num">$ (182,355)<span></span>
</td>
<td class="num">$ (108,942)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the amount paid to settle and carrying amount of research and development funding liability which is extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241644152960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 567,637<span></span>
</td>
<td class="num">$ (3,388)<span></span>
</td>
<td class="num">$ (218,379)<span></span>
</td>
<td class="nump">$ 346,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">29,579,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of ADSs upon exercise of share options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of ADSs upon exercise of share options (in shares)</a></td>
<td class="nump">78,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">5,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses (in shares)</a></td>
<td class="nump">181,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of ADSs upon settlement of restricted share units (in shares)</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,717)<span></span>
</td>
<td class="num">(112,717)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">601,105<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="num">(331,096)<span></span>
</td>
<td class="nump">270,783<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">29,873,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of ADSs upon exercise of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of ADSs upon exercise of share options (in shares)</a></td>
<td class="nump">54,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">249,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses (in shares)</a></td>
<td class="nump">12,384,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of ADSs upon settlement of restricted share units</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of ADSs upon settlement of restricted share units (in shares)</a></td>
<td class="nump">119,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,664)<span></span>
</td>
<td class="num">(180,664)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">883,446<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(511,760)<span></span>
</td>
<td class="nump">$ 370,932<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">42,431,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,431,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in shareholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of ADSs upon exercise of share options</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">7,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of ADSs upon exercise of share options (in shares)</a></td>
<td class="nump">554,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses</a></td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">543,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses (in shares)</a></td>
<td class="nump">25,933,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of ADSs upon settlement of restricted share units</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of ADSs upon settlement of restricted share units (in shares)</a></td>
<td class="nump">141,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,031)<span></span>
</td>
<td class="num">(169,031)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 890<span></span>
</td>
<td class="nump">$ 1,472,842<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="num">$ (680,791)<span></span>
</td>
<td class="nump">$ 793,060<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">69,061,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,061,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642536816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Consolidated Statements of Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and offering expenses</a></td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642692480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (169,031)<span></span>
</td>
<td class="num">$ (180,664)<span></span>
</td>
<td class="num">$ (112,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">38,081<span></span>
</td>
<td class="nump">32,477<span></span>
</td>
<td class="nump">26,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,174<span></span>
</td>
<td class="nump">6,546<span></span>
</td>
<td class="nump">3,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NonCashInterestExpense', window );">Non-cash interest</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability', window );">Gain on extinguishment of research and development funding liability</a></td>
<td class="num">(4,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax (benefit) provision</a></td>
<td class="num">(5,226)<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="num">(4,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Other non-cash charges</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,482<span></span>
</td>
<td class="num">(1,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable', window );">Research and development incentives receivable</a></td>
<td class="num">(11,947)<span></span>
</td>
<td class="num">(3,684)<span></span>
</td>
<td class="num">(9,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,044)<span></span>
</td>
<td class="num">(2,072)<span></span>
</td>
<td class="num">(2,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,402<span></span>
</td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">2,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,698<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
<td class="nump">12,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(4,888)<span></span>
</td>
<td class="num">(4,109)<span></span>
</td>
<td class="num">(2,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(31,952)<span></span>
</td>
<td class="nump">68,951<span></span>
</td>
<td class="num">(2,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(164,724)<span></span>
</td>
<td class="num">(60,628)<span></span>
</td>
<td class="num">(86,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(2,929)<span></span>
</td>
<td class="num">(18,987)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(2,929)<span></span>
</td>
<td class="num">(18,987)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(31,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of ADSs and non-voting ordinary shares, net of issuance costs</a></td>
<td class="nump">544,127<span></span>
</td>
<td class="nump">249,345<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of share options and settlement of restricted share units</a></td>
<td class="nump">7,528<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligations</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">519,750<span></span>
</td>
<td class="nump">250,027<span></span>
</td>
<td class="nump">6,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(694)<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="num">(1,120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">353,097<span></span>
</td>
<td class="nump">187,816<span></span>
</td>
<td class="num">(99,526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">526,970<span></span>
</td>
<td class="nump">339,154<span></span>
</td>
<td class="nump">438,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">880,067<span></span>
</td>
<td class="nump">526,970<span></span>
</td>
<td class="nump">339,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">879,520<span></span>
</td>
<td class="nump">526,423<span></span>
</td>
<td class="nump">339,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash included in other assets</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">880,067<span></span>
</td>
<td class="nump">526,970<span></span>
</td>
<td class="nump">339,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on debt</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">2,753<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for interest on finance lease obligations</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="nump">2,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">5,785<span></span>
</td>
<td class="nump">5,595<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid', window );">Changes in purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1,744)<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Non-cash impact to operating lease right-of-use assets and operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,898<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Property and equipment obtained under finance leases</a></td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the amount paid to settle and carrying amount of research and development funding liability which is extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase or decrease in future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of operating lease right-of-use assets reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) for research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726207120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and basis of presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the business and basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the business and basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">1. Nature of the business and basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Bicycle Therapeutics plc (collectively with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company developing a novel class of medicines, which the Company refers to as&#160;Bicycle<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> &#174;</sup> molecules, for diseases that are underserved by existing therapeutics.&#160;Bicycle molecules&#160;are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. The Company&#8217;s initial internal programs are focused on oncology indications with high unmet medical need. The Company is evaluating zelenectide pevedotin, formerly BT8009, a Bicycle Toxin Conjugate (a &#8220;BTC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221;<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>molecule) targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing company-sponsored Phase II/III registrational trial, called Duravelo-2, BT5528, a BTC molecule targeting Ephrin type-A receptor 2 (&#8220;EphA2&#8221;), in an ongoing company-sponsored Phase I/II clinical trial, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (a &#8220;Bicycle TICA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221; molecule) targeting Nectin-4 and agonizing CD137, in an ongoing company-sponsored Phase I/II clinical trial. The Company&#8217;s discovery pipeline in oncology includes&#160;next-generation BTC molecules and Bicycle<i style="font-style:italic;"> </i>Radionuclide Conjugates (&#8220;BRC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221;<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>molecules). Beyond the Company&#8217;s wholly owned oncology portfolio, the Company is collaborating with biopharmaceutical companies and organizations in therapeutic areas in which the Company believes its proprietary Bicycle screening platform can identify therapies to treat diseases with significant unmet medical need. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of Bicycle Therapeutics plc and its wholly owned subsidiaries, BicycleTx Limited, BicycleRD Limited and Bicycle Therapeutics&#160;Inc. All intercompany balances and transactions have been eliminated on consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>As of December 31, 2024, the Company had cash and cash equivalents of $879.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital. The Company has funded its operations with proceeds from the sale of its ordinary shares, American Depositary Shares (&#8220;ADSs&#8221;), including in its offerings pursuant to its at-the-market offering program (&#8220;ATM&#8221;), and non-voting ordinary shares, as well as proceeds received from its collaboration arrangements (Note&#160;9) and proceeds from a loan agreement with Hercules Capital, Inc. (&#8220;Hercules&#8221;) (Note 6). The Company has incurred recurring losses since inception, including net losses of $169.0 million, $180.7 million, and $112.7 million for the&#160;years ended December&#160;31, 2024, 2023, and 2022, respectively. As of December&#160;31, 2024, the Company had an accumulated deficit of $680.8 million. The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash will be sufficient to fund its operating expenses and capital expenditure requirements through at least twelve&#160;months from the issuance date of these annual consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expects its expenses to increase substantially in connection with ongoing activities, particularly as the Company advances its clinical trials for its product candidates in development and preclinical activities. Accordingly, the Company will need to obtain additional funding in connection with continuing operations. If the Company is unable to raise funding when needed, or on attractive terms, it could be forced to delay, reduce or eliminate its research or drug development programs or any future commercialization efforts. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology and pharmaceutical industries, including but not limited to, risks of delays in initiating or continuing research programs and clinical trials, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, if approved, dependence on key personnel and collaboration partners, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if the Company&#8217;s research and development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726233216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">2. Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and research and development incentives receivable, share-based compensation expense, valuation of right-of-use assets and liabilities, gain on extinguishment of research and development funding liability and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant risks and uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company currently operates in a period of economic uncertainty which has been significantly impacted by domestic and global monetary and fiscal policy, geopolitical conflicts such as the ongoing wars involving Ukraine and Israel, inflation and interest rates, and fluctuations in monetary exchange rates. While the Company has experienced limited financial impacts at this time, the Company continues to monitor these factors and events and the potential effects each may have on the Company&#8217;s business, financial condition, results of operations and growth prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The reporting currency of the Company is the U.S. Dollar (&#8220;USD&#8221;). The functional currency of Bicycle Therapeutics plc&#8217;s wholly owned non-U.S. subsidiaries, BicycleTx Limited and BicycleRD Limited, is the British Pound Sterling, and the functional currency of its U.S. subsidiary, Bicycle Therapeutics Inc., is the USD. The functional currency of the Company&#8217;s subsidiaries is the same as the local currency. Monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in general and administrative expense in the consolidated statements of operations and comprehensive loss as incurred. The Company recorded foreign exchange losses of $0.7 million, $0.6 million and $0.6 million for the years ended December 31, 2024, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company translates the assets and liabilities of its non-U.S. subsidiaries into USD at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a foreign currency translation adjustment, which is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">included in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive income (loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. The Company diversifies its cash and cash equivalents in multiple financial institutions and in money market funds that are primarily invested in U.S. Treasury securities that are backed by the U.S. government and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships and investments in money market funds invested in U.S. Treasury securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had no accounts receivable. For the years ended December&#160;31, 2024, 2023, and 2022, the Company&#8217;s revenue has primarily been generated from collaboration agreements with Bayer Consumer Care AG (&#8220;Bayer&#8221;), Novartis Pharma AG (&#8220;Novartis&#8221;), Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;), Genentech, Inc. (&#8220;Genentech&#8221;) and AstraZeneca AB (&#8220;AstraZeneca&#8221;) (Note 9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on multiple vendors to manufacture clinical trial materials and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments that are readily convertible to known amounts of cash with original maturities of three&#160;months or less at date of purchase to be cash equivalents. The Company had cash equivalents of $664.9 million and $72.3 million at December&#160;31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had $0.5 million of restricted cash related to a collateralized letter of credit in connection with the Company&#8217;s lease for office and laboratory space in Cambridge, Massachusetts, which is included within other assets in the Company&#8217;s consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the respective assets as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p8M7K2bjKEax4G-nyR6gbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span> to 5 years</p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or useful life</p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 to 5 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for property and equipment not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. To date, there have been no significant asset retirements. Expenditures for repairs and maintenance are charged to expense as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss may be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any material impairment losses on long-lived assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company&#8217;s assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#160;&#8212; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#160;&#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash, cash equivalents and restricted cash, research and development incentives receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. As of December 31, 2023, the carrying value of the debt approximated its fair value, which was determined using unobservable Level 3 inputs, including quoted interest rates from a lender for borrowings with similar terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Debt issuance costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Debt issuance costs consist of certain third-party legal expenses and payments made to secure commitments under certain debt financing arrangements. These amounts are recorded as a reduction to the carrying value of the associated debt and are recognized as interest expense over the period of the financing arrangement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment and geographic information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of a business for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates in two geographic regions: the United&#160;Kingdom and the United&#160;States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional segment information, see Note&#160;15, &#8220;Segments and geographic information.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases are accounted for in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, <i style="font-style:italic;">Leases </i>(&#8220;ASC 842&#8221;). The Company determines if an arrangement is or contains a lease at inception. Assets and liabilities related to operating leases are included in operating lease right of use (&#8220;ROU&#8221;) assets, other current liabilities, and operating lease liabilities in the Company&#8217;s consolidated balance sheets. Assets and liabilities related to finance leases are included in property and equipment, net, accrued expenses and other current liabilities, and other long-term liabilities in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use and control an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The ROU asset also includes lease payments made before the lease commencement date and excludes any lease incentives. The Company identifies and assesses the following significant assumptions in recognizing the ROU assets and corresponding lease liabilities: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected lease term</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; The expected lease term includes both contractual lease periods and, when applicable, periods covered by an option to extend the lease when it is reasonably certain that the Company will exercise the extension option, or cancelable option periods when it is reasonably certain that the Company would not exercise such cancelation option.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Incremental borrowing rate</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available on the commencement date in determining the present value of lease payments. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimates the incremental borrowing rate by comparing interest rates available in the market for similar borrowings and third-party quotations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Lease and non-lease components</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; The components of a lease shall be split into three categories, if applicable: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must then be allocated based on fair values to the lease components and non-lease components. The Company&#8217;s operating leases for its facilities and finance leases for property and equipment may have both lease components and non-lease components for which the Company has elected to apply the practical expedient to account for each lease component and related non-lease component as one single component. The lease component results in a ROU asset being recorded on the consolidated balance sheets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For operating leases, lease expense for lease payments is considered operating lease cost and is recognized on a straight-line basis over the lease term. Variable payments for other operating costs, which may be billed based on both usage and as a percentage of the Company&#8217;s share of total square footage, are considered variable lease cost and are recognized in the period in which the costs are incurred. For finance leases, amortization expense related to finance lease ROU assets is recognized on a straight-line basis over the earlier of the useful life of the ROU asset or the lease term and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interest expense is recognized based on the effective interest method using the Company&#8217;s incremental borrowing rate. Operating, variable and finance lease cost are recorded as a component of research and development expenses and general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The terms of these arrangements may include (i)&#160;performing research and development services using the Company&#8217;s bicyclic peptide screening platform with the goal of identifying and/or optimizing compounds for further development and commercialization, (ii) the transfer of intellectual property rights (licenses), or (iii) options to obtain additional research and development services or licenses for additional targets, or to optimize product candidates, upon the payment of option fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; payments for research and development services and reimbursement of certain expenses incurred; fees upon the exercise of options to obtain additional services or licenses; payments based upon the achievement of defined collaboration objectives; future regulatory and sales-based milestone payments; and royalties on net sales of future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC&#160;606&#8221;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, and financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC&#160;606, it performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each performance obligation based on estimated relative standalone selling prices, and measuring progress towards the satisfaction of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once a contract is determined to be within the scope of ASC&#160;606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations at contract inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. The promised goods or services in the Company&#8217;s contracts with customers primarily consist of license rights to the Company&#8217;s intellectual property, research and development services, options to acquire additional research and development services, and options to obtain additional licenses, such as a commercialization license for a potential product candidate. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources, and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the collaboration partner to develop the intellectual property on their own and whether the required expertise is readily available. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate variable consideration to include in the transaction price based on which method better predicts the amount of consideration expected to be received. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. The initial transaction price of a contract does not include amounts associated with customer option payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the transaction price is determined, it is allocated to the identified performance obligations based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, probabilities of technical and regulatory success and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an input method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i> If a license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from portion of the transaction price allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, such as research and development services and a research license, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development services:</i> The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Customer options:</i> A customer&#8217;s right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide, and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or at a discount. Optional future goods and services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. If optional future goods and services include a material right, they are accounted for as performance obligations. The Company determines an estimated standalone selling price of any material rights for the purpose of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">allocating the transaction price. The Company considers factors such as the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone payments:</i> The Company&#8217;s collaboration agreements may include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net loss in the period of adjustment. Milestone payments that may only be achieved after the exercise of a customer option are excluded from the initial determination of the transaction price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company&#8217;s collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company receives payments from customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional, such as when the Company has a contractual right to payment per the terms of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional information regarding the Company&#8217;s accounting for collaboration revenue, see Note&#160;9, &#8220;Significant agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, facilities costs, depreciation, materials and laboratory supplies, and external costs of outside vendors engaged to conduct preclinical development and clinical development activities, as well as costs to manufacture clinical trial materials. Facilities costs primarily include the allocation of rent and utilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized until the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has entered into various research and development and manufacturing contracts, including contracts with respect to preclinical studies and clinical trials, with companies both inside and outside of the United&#160;States. These agreements are generally cancelable with 90&#160;days or less notice, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research and development and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development incentives and receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company, through its subsidiaries in the U.K., receives reimbursements of certain research and development expenditures as part of a U.K. government&#8217;s research and development tax reliefs program. Under the Small and Medium-Sized Enterprises (&#8220;SME&#8221;) R&amp;D Tax Relief program, the Company is able to surrender trading losses that arise from qualifying research and development expenses incurred by the Company&#8217;s subsidiaries in the United&#160;Kingdom for a cash rebate of up to 33.35% of qualifying expenditure incurred prior to April 1, 2023, and up to 18.6% of qualifying expenditure incurred thereafter. Amendments to the U.K. R&amp;D tax credit regime included in Finance Act 2024, which was enacted in February 2024, increased the cash rebate that may be claimed to 26.97% of qualifying expenditure, retroactively applied to qualifying expenditures incurred after April 1, 2023, if the Company qualifies as &#8220;R&amp;D intensive&#8221; for an accounting period (broadly, a loss making SME whose relevant R&amp;D expenditure represents, for accounting periods beginning on or after April 1, 2023, 40%, or, for accounting periods beginning on or after April 1, 2024, 30%, of its total expenditure for that accounting period). The Company was an R&amp;D intensive SME for the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and development incentives as a reduction to research and development expenses in the consolidated statements of operations and comprehensive loss, as the research and development tax credits are not dependent on us generating future taxable income, the Company&#8217;s ongoing tax status, or tax position. The research and development incentives receivable represent an amount due in connection with the above program. The Company recorded a reduction to research and development expense of $43.1 million for the year ended December 31, 2024, including the impact of an increase to U.K. R&amp;D tax credit reimbursement rates enacted with Finance Act 2024 retroactively applied to qualifying expenditures incurred after April 1, 2023. The Company recorded a reduction to research and development expense of $23.5 million and $19.3&#160;million during the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with preparing, filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures all equity awards granted to employees and directors based on the fair value on the date of grant. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with only service-based vesting conditions using the straight-line method. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For share-based awards granted to non-employee consultants, the measurement date is the date of grant. The compensation expense is then recognized over the requisite service period, which is the vesting period of the respective award, without subsequent changes in the fair value of the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The fair value of each restricted share award is based on the fair value of the Company&#8217;s shares, less any applicable purchase price. The fair value of each share option is estimated using the Black-Scholes option-pricing model, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which requires inputs based on certain subjective assumptions, including the fair value of shares, the expected share price volatility, the expected term of the award, the risk-free interest rate and expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to 2022, due to a lack of company-specific historical volatility data, the Company&#8217;s expected volatility was calculated based on reported volatility data for a representative group of publicly traded companies for which historical information was available. The historical volatility was calculated based on a period of time commensurate with the assumption used for the expected term. During 2022, the Company began to estimate its volatility by using a blend of its stock price history for the length of time it has market data for its stock and the historical volatility of similar public companies for the expected term of each grant. The Company continues to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its share-based awards. The Company uses the remaining contractual term for the expected life of non-employee awards. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll or service costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation as a component of other comprehensive loss in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential loss range is probable and reasonably estimable under the provisions of ASC Topic 450, <i style="font-style:italic;">Contingencies</i>. The Company expenses costs as incurred in relation to such loss contingencies as general and administrative expense within the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the (benefit from) provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that will more likely than not be realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period, including potential dilutive ordinary shares assuming the dilutive effect of ordinary share equivalents. In periods in which the Company reported a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2023, the FASB issued ASU No. 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures</i>, which requires disclosure of incremental segment information on an interim and annual basis. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, and requires retrospective adoption to all prior periods presented in the consolidated financial statements. The adoption of ASU 2023-07 had no impact on the Company&#8217;s reportable segments identified and additional required disclosures have been included in Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements not yet adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, <i style="font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40)</i>, which requires more detailed disclosures about specified categories of expenses included in certain expense captions presented on the face of the consolidated statements of operations and comprehensive loss, including employee compensation, depreciation and amortization. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to all prior periods presented. The Company is currently evaluating the impact of the adoption of ASU No. 2024-03 on its consolidated financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740) Improvements to Income Tax Disclosures</i>, which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 is effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its consolidated financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642265728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value of financial assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">3. Fair value of financial assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December 31, <span style="-sec-ix-hidden:Hidden_X5wnyztC8UGUEz3EZ1OAbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2024</span></span>, the Company had cash equivalents of $664.9 million consisting of money market funds that are primarily invested in U.S. Treasury securities, which are considered Level 1 assets. As of December 31, 2023, the Company had cash equivalents of $72.3 million, consisting of $22.1 million of money market funds and $50.2 million in <span style="-sec-ix-hidden:Hidden_Vut1ulUKVEGQr75nUhokTQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30-day</span></span> term deposits which are considered Level 1 assets. As of December 31, 2024 and 2023, there were no other assets or liabilities measured at fair value on a recurring basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726310960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">4. Property and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,554</p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 532</p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 822</p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,908</p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,393)</p></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,515</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was $7.2 million, $6.5&#160;million and $3.7 million for the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. Depreciation and amortization expense for the years ended December 31, 2024, 2023 and 2022 included amortization expense of $0.1 million, zero and zero, respectively, related to property and equipment obtained under finance leases. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639664208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">5. Accrued expenses and other current liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,394</p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,839</p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,143</p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KW1rNIXqDU6mr2igGNJAXQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of operating lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,876</p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WTohRhZpUkiEgaVCaOLomQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of finance lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 257</p></td></tr><tr><td style="vertical-align:bottom;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 31,509</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In August 2024, the Company consolidated all discovery research activities to the Company&#8217;s headquarters in Cambridge, U.K. As a result, during the year ended December 31, 2024, the Company recognized charges of $2.0 million in severance and other one-time termination benefits which are included in <span style="-sec-ix-hidden:Hidden_tsh7VRNlykaXUR1w5uepYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research</span></span> and development expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss, of which $1.6 million were paid during the year ended December 31, 2024, and the remaining $0.4 million in unpaid benefits are included in accrued expenses and other current liabilities in the Company&#8217;s consolidated balance sheet as of December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241734082960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">6. Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On September 30, 2020, Bicycle Therapeutics plc and its subsidiaries (the &#8220;Borrowers&#8221;) entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Hercules, as amended from time to time, which provided for aggregate maximum borrowings of up to $75.0 million, of which the Company had drawn down an aggregate of $30.0 million in 2021 and 2020. Payments on borrowings under the Loan Agreement were interest-only until April 1, 2025 and interest was paid at an annual rate of the <i style="font-style:italic;">Wall Street Journal </i>prime rate plus 4.55%, with a minimum annual rate of at least 8.05%, capped at a rate no greater than 9.05%, and the Loan Agreement included a 5.0% end-of-term charge payable upon maturity or repayment. The scheduled maturity date was July 1, 2025. On July 9, 2024, the Company repaid all amounts outstanding, including the outstanding borrowings of $30.0 million, accrued and unpaid interest of $0.1 million, an end-of-term charge of $1.5 million and a prepayment charge of $0.3 million, for a total aggregate payment of $31.9 million, and terminated the Loan Agreement. The Company recognized a loss on extinguishment of debt of $1.0 million during the year ended December 31, 2024 in connection with the repayment and termination of the Loan Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense associated with the Loan Agreement for the years ended December 31, 2024, 2023 and 2022 was $1.6 million, $3.1 million and $3.2 million, respectively. Upon termination of the Loan Agreement, all security interests granted to the secured parties thereunder were terminated and released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Debt consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term loan payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End of term charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 946</p></td></tr><tr><td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (248)</p></td></tr><tr><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carrying value of term loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,698</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:53.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1.3pt;"><td style="vertical-align:top;width:29.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:53.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639600416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Ordinary shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">7. Ordinary shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s ordinary shares are divided into two classes: (i) ordinary shares and (ii) non-voting ordinary shares. Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders. Holders of ADSs are not treated as holders of the Company&#8217;s ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of the Company&#8217;s ordinary shares, other than the rights that they have pursuant to the deposit agreement with the depositary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-voting ordinary shares have the same rights and restrictions as the ordinary shares and otherwise rank <i style="font-style:italic;">pari passu</i> in all respects with the ordinary shares except for the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a holder of non-voting ordinary shares shall, in relation to the non-voting ordinary shares held, have no right to receive notice of, or to attend or vote at, any general meeting of shareholders save in relation to a variation of class rights of the non-voting ordinary shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the non-voting ordinary shares shall be re-designated as ordinary shares by the Company&#8217;s board of directors, or a duly authorized committee or representative thereof, upon receipt of a re-designation notice and otherwise subject to the terms and conditions set out in the terms of issue. A holder of non-voting ordinary shares shall not be entitled to have any non-voting ordinary shares re-designated as ordinary shares where such re-designation would result in such holder thereof beneficially owning (for purposes of section 13(d) of the Exchange Act), when aggregated with &#8220;affiliates&#8221; and &#8220;group&#8221; members with whom such holder is required to aggregate beneficial ownership for the purposes of section 13(d) of the Exchange Act, in excess of 9.99% of any class of the Company&#8217;s securities registered under the Exchange Act (which percentage may be increased or decreased on a holder-by-holder basis subject to the provisions set out in the terms of issue); and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the non-voting ordinary shares shall be re-designated as ordinary shares automatically upon transfer of a non-voting ordinary share by its holder to any person that is not an &#8220;affiliate&#8221; or &#8220;group&#8221; member with whom such holder is required to aggregate beneficial ownership for purposes of section 13(d) of the Exchange Act. This automatic re-designation shall only be in respect of the non-voting ordinary shares that are subject to such transfer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had not declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31, 2024 and 2023, the Company&#8217;s authorized capital share consisted of 155,876,645 and 59,612,613 ordinary shares, respectively, including ordinary shares and non-voting ordinary shares, with a nominal value of &#163;0.01 per share. Authorized share capital, or shares authorized, comprises (i) the currently issued and outstanding ordinary shares and non-voting ordinary shares, (ii) the remaining ordinary shares available for allotment under the existing authority granted to the Board at the annual general meeting held on May 16, 2024, (iii) ordinary shares issuable on the exercise of outstanding options and settlement of vested restricted share units (&#8220;RSUs&#8221;), and (iv) ordinary shares </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reserved for issuance under the Bicycle Therapeutics plc 2024 Inducement Plan (the &#8220;2024 Inducement Plan&#8221;), the Bicycle Therapeutics plc 2020 Equity Incentive Plan (as amended from time to time, the &#8220;2020 Plan&#8221;), and/or the Bicycle Therapeutics plc 2019 Employee Share Purchase Plan (the &#8220;ESPP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were 47,569,319 ordinary shares <span style="-sec-ix-hidden:Hidden_Lpo0wyq33EyQ4jsKrECq2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding and 21,492,099 non-voting ordinary shares <span style="-sec-ix-hidden:Hidden_isC1MjD3_kuhXs60-F47rw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 23, 2024, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with purchasers named therein (the &#8220;Investors&#8221;). Pursuant to the Purchase Agreement, the Company sold 6,764,705 ADSs, representing the same number of ordinary shares, nominal value &#163;0.01 per share, and 19,169,001 non-voting ordinary shares, nominal value &#163;0.01 per share, each at a purchase price equal to $21.42 per share (the &#8220;Private Placement&#8221;). The Company completed the Private Placement on May 28, 2024. The transaction resulted in gross proceeds to the Company of $555.5 million, and after deducting commissions and offering expenses of $11.4 million, net proceeds to the Company of $544.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 17, 2023, the Company completed an underwritten public offering of its securities, pursuant to which the Company issued and sold 6,117,648 ADSs, representing the same number of ordinary shares, nominal value &#163;0.01 per share, which included 1,411,764 ADSs sold upon the underwriters&#8217; full exercise of their option to purchase additional ADSs, and 4,705,882 non-voting ordinary shares, nominal value &#163;0.01 per share, at a public offering price of $21.25 per ADS or non-voting ordinary share, respectively. The transaction resulted in gross proceeds to the Company of $230.0 million, and after deducting underwriting discounts, commissions, and offering expenses of $14.9 million, net proceeds to the Company of $215.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On June 5, 2020, the Company entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc. (the &#8220;Sales Agents&#8221;) with respect to an ATM program pursuant to which the Company may offer and sell through the Sales Agents, from time to time at the Company&#8217;s sole discretion, American Depositary Shares (&#8220;ADSs&#8221;), each ADS representing one ordinary share. No ADSs were issued or sold pursuant to the Sales Agreement during the year ended December 31, 2024. During the year ended December 31, 2023, the Company issued and sold 1,561,176 ADSs, representing the same number of ordinary shares for gross proceeds of $35.3 million, resulting in net proceeds of $34.2 million after deducting sales commissions and offering expenses of $1.1 million. During the year ended December 31, 2022, the Company issued and sold 181,455 ADSs, representing the same number of ordinary shares for gross proceeds of $5.9 million, resulting in net proceeds of $5.7 million after deducting sales commissions and offering expenses of $0.2 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241732311088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">8. Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Employee incentive pool</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2024 Inducement Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In July 2024, the Company&#8217;s board of directors approved the 2024 Inducement Plan. </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">The 2024 Inducement Plan allows for the granting of nonqualified share options, RSUs, and other equity awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company.</span><span style="font-style:normal;font-weight:normal;"> </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">Share options granted under the 2024 Inducement Plan have a </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">10-year</span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> contractual life and generally vest over a </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">four-year</span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> service period with </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">25%</span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> of the award vesting on the first anniversary of the vesting commencement date and the balance thereafter in </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">36</span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> equal monthly installments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;background:#ffffff;"> The Company initially reserved </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">1,500,000</span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> of its ordinary shares, or the equivalent number of ADSs, for the issuance of awards under the 2024 Inducement Plan. As of December 31, 2024, there were </span><span style="font-style:normal;font-weight:normal;background:#ffffff;">1,251,400</span><span style="font-style:normal;font-weight:normal;background:#ffffff;"> shares available for future issuance under the 2024 Inducement Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were options to purchase 248,600 shares outstanding under the 2024 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">2020 Equity Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2020, the Company&#8217;s shareholders first approved the 2020 Plan, under which the Company may grant market value options, market value stock appreciation rights or restricted shares, RSUs, performance RSUs and other share-based awards to the Company&#8217;s employees. The Company&#8217;s non-employee directors and consultants are eligible to receive awards under the 2020 Non-Employee Sub-Plan to the 2020 Plan. All awards under the 2020 Plan, including the 2020 Non-Employee Sub-Plan, will be set forth in award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms, change of control provisions and post-termination exercise limitations. In the event of a change of control of the Company, as defined in the 2020 Plan, any outstanding awards under the 2020 Plan will vest in full immediately prior to such change of control. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company initially reserved up to 4,773,557 ordinary shares for future issuance under the 2020 Plan, including shares subject to options that were granted under the Company&#8217;s 2019 Share Option Plan (the &#8220;2019 Plan&#8221;) and that were granted pursuant to option contracts granted prior to the Company&#8217;s IPO, in each case that expire, terminate, are forfeited or otherwise not issued from time to time, if any. On June 27, 2022, the Company&#8217;s shareholders approved an amendment to the 2020 Plan (the &#8220;Amendment&#8221;) which increased the number of ordinary shares reserved for future issuance by 750,000 shares. Additionally, the number of ordinary shares reserved for issuance pursuant to the 2020 Plan will automatically increase on the first day of January of each year, initially commencing on January&#160;1, 2021 and continuing up to and including January 1, 2032, in an amount equal to 5% of the total number of the Company&#8217;s ordinary shares outstanding on the last day of the preceding&#160;year, or a lesser number of shares determined by the Company&#8217;s board of directors. Pursuant to this evergreen provision, on January 1, 2024, the number of shares reserved for issuance under the 2020 Plan was increased by 1,886,294 shares. As of December 31, 2024, there were 463,374 shares available for issuance under the 2020 Plan. The number of shares reserved for issuance under the 2020 Plan was increased by 2,378,465 shares effective January 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options granted under the 2020 Plan have a 10-year contractual life, and generally vest over either a three-year service period in three equal annual installments for new non-employee director grants, or a four-year service period with 25% of the award vesting on the first anniversary of the vesting commencement date and the balance thereafter in 36 equal monthly installments for employees and consultants. Certain options granted to the Company&#8217;s non-employee directors vest over a one-year service period in four equal quarterly installments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants RSUs to non-employee directors, consultants and certain employees under the 2020 Plan. Each RSU represents the right to receive one of the Company&#8217;s ordinary shares upon vesting. RSUs granted to employees and consultants vest over a four-year service period with 25% of the award vesting on the first anniversary of the vesting commencement date and the remaining RSUs vesting in 12 equal quarterly installments. Certain RSUs granted to the Company&#8217;s non-employee directors either vest over a <span style="-sec-ix-hidden:Hidden_8SmY0G3wPEWWtHANX-xYGQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span></span> service period in three equal annual installments for new non-employee director grants or over a one-year service period in four equal quarterly installments. The Company may also, in its sole discretion, provide for deferred settlement of RSUs granted to the Company&#8217;s non-employee directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there were options to purchase 6,211,123 shares and RSUs for 716,262 shares outstanding under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2019 Share Option Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;<span style="white-space:pre-wrap;">2019, the Company adopted the 2019 Plan, which became effective in conjunction with the IPO.  As of December 31, 2024, there were </span>1,773,816 options to purchase ordinary shares outstanding under the 2019 Plan. In conjunction with the adoption of the 2020 Plan, all shares available for future issuance under the 2019 Plan as of June 29, 2020 became available for issuance under the 2020 Plan and the Company ceased making awards under the 2019 Plan. The 2020 Plan is the successor of the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Share options previously issued under the 2019 Plan have a 10-year contractual life, and generally either vest&#160;monthly over a three-year service period, or over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and the balance thereafter in 36 equal&#160;monthly installments. Certain awards </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">granted to the Company&#8217;s non-employee directors were fully vested on the date of grant. The exercise price of share options issued under the 2019 Plan is not less than the fair value of ordinary shares as of the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Employee Share Purchase Plan (&#8220;ESPP&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Company adopted the ESPP, which became effective in conjunction with the IPO. The Company initially reserved 215,000 ordinary shares for future issuance under this plan. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020 and each January 1 thereafter through January 1, 2029, by the lower of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31; (ii) 430,000 ordinary shares or (iii) such lesser number of shares as determined by the Compensation Committee. The number of shares reserved under the ESPP is subject to adjustment in the event of a split-up, share dividend or other change in the Company&#8217;s capitalization. As of December 31, 2024, the total number of shares available for issuance under the ESPP was 1,577,671 shares. The number of shares reserved for issuance under the ESPP was increased by 430,000 shares effective January 1, 2025. As of December 31, 2024, there have been no offering periods to employees under ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,394</p></td></tr><tr><td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,385</p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 32,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,779</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s option activity since December&#160;31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December 31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,469,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,920</p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,438,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (554,596)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (604,561)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,748,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,559</p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested and expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,748,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,559</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,359,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,559</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value of share options granted during the&#160;years ended December&#160;31, 2024, 2023 and 2022 was $13.52 per share, $19.36 per share and $31.45 per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s ordinary shares. The aggregate intrinsic value of share options exercised during the&#160;years ended December&#160;31, 2024, 2023 and 2022 was $5.1 million, $0.5 million and $1.5 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recorded share-based compensation expense for share options granted of $30.2 million, $27.0&#160;million and $21.9 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of share options granted to employees and directors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 77.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 82.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 82.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, total unrecognized compensation expense related to the share options was $48.3&#160;million, which is expected to be recognized over a weighted average period of 2.4 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Restricted share units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s RSU activity under the 2020 Plan since December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 326,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37.40</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 617,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.26</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested and settled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (141,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37.76</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested and deferred<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.15</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 674,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.96</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested but subject to deferred settlement at December 31, 2024<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.67</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">The Company granted certain RSUs to the Company&#8217;s non-employee directors which provided for deferred settlement of the RSUs to a specified date following the first to occur of (i) the date of the director&#8217;s separation from service, (ii) the date of the director&#8217;s disability, (iii) the date of the director&#8217;s death or (iv) the date of a change in control event.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of RSUs that vested during the years ended December 31, 2024, 2023 and 2022 was $3.8 million, $3.0 million and $2.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total share-based compensation expense for RSUs granted for the years ended December 31, 2024, 2023 and 2022 was $7.9 million, $5.5 million and $4.9 million, respectively. As of December 31, 2024, the total unrecognized compensation expense related to RSUs was $11.4 million, which is expected to be recognized over a weighted-average period of 2.4 years. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726251152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Significant agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Significant agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">9. Significant agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the revenue recognized from the Company&#8217;s collaboration arrangements in the consolidated statements of operations and comprehensive loss (in&#160;thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Collaboration revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bayer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ionis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,734</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,347</p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Genentech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,565</p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dementia Discovery Fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 386</p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">AstraZeneca</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,165</p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,463</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Bayer Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 4, 2023, the Company and Bayer entered into a collaboration and license agreement (the &#8220;Bayer Collaboration Agreement&#8221;), pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term up to a specified number of years per target program to generate radiopharmaceutical compounds incorporating optimized Bicycle constructs directed to two specified targets, under the oversight of a joint research committee. In addition, Bayer has a one-time right to expand the collaboration to include a third target program, and with respect to each of the up to three target programs, Bayer has an option, exercisable within a specified period of time following the effective date of the Bayer Collaboration Agreement, to generate, develop and commercialize non-radiopharmaceutical compounds directed to the applicable target, either itself or in collaboration with the Company. Bayer also has certain limited target substitution rights, in certain cases subject to specified additional payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For each collaboration program, Bayer may elect, at its sole discretion, to progress compounds arising from activities under the research programs into further preclinical development of potential products directed to the target of such collaboration program. On a target-by-target basis, if Bayer elects to progress development candidates directed to such target into further clinical development, Bayer will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products directed to the applicable target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Bayer paid an upfront payment to the Company of $45.0 million in July 2023. All other payments under the Bayer Collaboration Agreement will be made in British Pound Sterling. If Bayer elects to expand the collaboration to include an additional target program, it will be required to make a one-time payment to the Company in connection with the selection of such target in the high single-digit millions. In addition, on a target-by-target basis, if Bayer elects to exercise its option to expand its rights with respect to such target to develop and commercialize non-radiopharmaceutical compounds directed to such target, Bayer will be required to pay to the Company, for each such target program for which it exercises such option, either a one-time option fee payment or quarterly payments of specified installment amounts for a specified maximum time period during which the Company is performing research activities, with the aggregate amounts receivable by the Company ranging from the high single-digit millions in the case of the one-time option fee payment, to the low single-digit millions in the case of the quarterly installments, in each case where the Company is performing specified research activities following the exercise of the option. Additionally, for each collaboration program, Bayer will reimburse the Company for certain expenses incurred in connection with specified research and discovery activities performed by a contract research organization (&#8220;CRO&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On a target-by-target basis for the up to three targets, if Bayer elects to progress one or more candidate compounds into further development, Bayer will be required to pay a candidate selection fee for the first such compound progressed by Bayer directed to such target that incorporates a radionuclide, and for the first such compound directed to such target that does not incorporate a radionuclide (and for which Bayer has not paid the one-time option fee payment for non-radiopharmaceutical compounds), ranging from high single-digit millions to the mid single-digit millions. Upon declaring a candidate, Bayer will be responsible for all future development, manufacturing, and commercialization activities. On a target-by-target basis, if Bayer successfully conducts clinical development and achieves regulatory approval for compounds arising from the collaboration directed to such target in two indications, Bayer will be required </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to pay to the Company development and regulatory/first commercial sale milestones of up to &#163;178.3 million for the first product directed to the applicable target to achieve such milestones (whether radiopharmaceutical or non-radiopharmaceutical), or &#163;534.9 million across all three potential target programs. In addition, if Bayer successfully commercializes products arising from the collaboration, Bayer will be required to pay to the Company, on a product-by-product basis, tiered royalties on net sales of products by Bayer, its affiliates or sublicensees at percentages ranging from the mid-single digits to the very low double digits, subject to standard reductions and offsets in certain circumstances, and a royalty floor. If Bayer commercializes diagnostic products directed to a target, royalties will be payable on such diagnostic products at a specified reduced percentage of the rates for therapeutic products. Royalties will be payable under the Bayer Collaboration Agreement on a product-by-product and country-by-country basis, commencing on the first commercial sale of each product, until the latest of (a) the expiration of the last valid claim of certain patents licensed by the Company to Bayer, (b) a specified number of years following first commercial sale of such product, and (c) expiration of all data and regulatory exclusivity for such product in the applicable country. On a target-by-target basis, Bayer will also owe the Company tiered sales milestones based on the achievement of specified levels of net sales of therapeutic products directed to such target totaling up to &#163;194.5 million in the aggregate per target, or &#163;583.5 million across all three potential target programs, and on diagnostic products directed to such target at a low double digit percentage of the therapeutic product milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Bayer Collaboration Agreement will remain in force on a product-by-product and country-by-country basis, unless earlier terminated by either party, until the expiration of the obligation for Bayer to make royalty payments to the Company for such product in such country, and will terminate in its entirety on the expiration of all such royalty terms in all countries. Either party may terminate the agreement upon 90 days&#8217; written notice for the other party&#8217;s uncured material breach (or 20 business days in the case of non-payment by Bayer), subject to extension of such cure period in certain circumstances, or upon the other party&#8217;s insolvency. In addition, the Company has the right to terminate in the case of a patent challenge by or on behalf of Bayer (or any of its affiliates or sublicensees). In addition, Bayer may terminate the Bayer Collaboration Agreement (i) in its entirety or with respect to any product, collaboration program or target for any reason upon 60 or 90 days&#8217; written notice to the Company (depending on whether such termination is prior to or following first commercial sale of a licensed product). The closing of the Bayer Collaboration Agreement was subject to the clearance of the transaction under the U.K. National Security and Investment Act 2021, which occurred on June 22, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>At inception of the Bayer Collaboration Agreement, the Company identified the following performance obligations:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> combined performance obligations comprised of the license and the related research and development services during the research term associated with radiopharmaceutical compounds for the first and second targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A material right associated with certain limited substitution rights with respect to either the first or second target;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the options to generate, develop, and commercialize non-radiopharmaceutical compounds for each of the first and second targets, for which each option includes an underlying option for research and development services and an option to progress non-radiopharmaceutical candidates directed to the first and second targets into further development; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A material right related to the option to expand the collaboration to include a third target, which upon exercise includes research and development services during the research term associated with radiopharmaceutical compounds directed to the third target, as well as underlying options for: certain limited substitution rights; an option to progress a radiopharmaceutical candidate directed to the third target into further development; and an </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">option to generate, develop, and commercialize non-radiopharmaceutical compounds directed to the third target, inclusive of an underlying option for research and development services and an option to progress a non-radiopharmaceutical candidate into further development.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s participation in the joint research committee was assessed as immaterial in the context of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the license granted at contract inception is not distinct from the research and development services as Bayer cannot obtain the benefit of the license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as they relate to constrained peptide technology that is not available in the marketplace. As a result, for each target, the license has been combined with the research and development services into a single performance obligation which is the combined performance obligation comprised of the license and related research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In assessing whether the various options under the Bayer Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material rights identified above, the Company concluded that each of the options provided Bayer with a discount that it otherwise would not have received. The Company exercised judgment in concluding that certain development and commercialization rights associated with progressing product candidates into further development and commercialization represent options that are material rights, as Bayer cannot benefit from the development and commercialization rights until Bayer, in its sole discretion, elects to progress candidates into further development and pays the associated candidate selection fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction price was initially determined to be $47.5 million, consisting of the $45.0 million upfront fee and an estimated $2.5 million for the reimbursement of certain external CRO costs. The Company utilized the expected value method to determine the amount of variable consideration to be received. Additional payments to the Company upon Bayer&#8217;s exercise of options are excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. The estimated $2.5 million in variable consideration was first allocated entirely to the first and second target combined performance obligations as the terms of the variable consideration relate specifically to the Company&#8217;s efforts in satisfying the performance obligations and allocating the variable consideration entirely to those performance obligations is consistent with the allocation objective in ASC 606. The remaining transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the combined performance obligations for the first and second targets were based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling prices for the material rights were determined based on the fees that Bayer would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Bayer would exercise the options, inclusive of the probability of technical success. Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocation of</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction Price</b></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,976</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Material right associated with limited substitution rights for either the first or second target</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,527</p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,691</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,703</p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Material right for the option to expand the collaboration to include a third target and the underlying additional option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,603</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,500</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is recognizing revenue related to amounts allocated to the first and second target combined performance obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of full-time equivalent efforts and external costs incurred to date as a percentage of total expected full-time equivalent efforts and external costs, which best reflects the progress towards satisfaction of the performance obligations. The amounts allocated to the material rights are recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. The first and second target combined performance obligations are expected to be satisfied over a period of approximately four years and the remaining material rights are expected to be exercised or expire within approximately seven years from contract inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-weight:normal;">During the years ended December 31, 2024 and 2023, the Company recognized revenue of </span><span style="font-weight:normal;">$3.4</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$1.2</span><span style="font-weight:normal;"> million, respectively, in connection with the Bayer Collaboration Agreement. The Company did </span><span style="font-weight:normal;">no</span><span style="font-weight:normal;">t recognize revenue in connection with the Bayer Collaboration Agreement during the year ended December 31, 2022. As of December 31, 2024 and 2023, the Company recorded deferred revenue of </span><span style="font-weight:normal;">$40.0</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$43.6</span><span style="font-weight:normal;"> million, respectively, in connection with the Bayer Collaboration Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"><span style="font-style:italic;">Novartis Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">On March 27, 2023, the Company and Novartis entered into a collaboration and license agreement (the &#8220;Novartis Collaboration Agreement&#8221;), pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term of up to a specified number of years per target program to generate compounds incorporating optimized&#160;Bicycle&#160;constructs directed to two specified targets, under the oversight of a joint steering committee. The Company granted Novartis a non-exclusive, worldwide, royalty-free, sublicensable (subject to certain restrictions) license under the Company&#8217;s intellectual property solely for Novartis to perform its research activities under each collaboration program during the research term (the &#8220;Novartis Research License&#8221;). For each collaboration program, Novartis may elect to progress compounds arising from activities under the research programs (&#8220;Licensed Compounds&#8221;) into further preclinical development of potential products directed to the target of such collaboration program. At a specified point, the Company will grant Novartis an exclusive, royalty-bearing, sublicensable, license under certain of the Company&#8217;s intellectual property to develop, manufacture, and commercialize such Licensed Compound, subject to certain limitations. Novartis also has certain limited substitution rights for each target, and Novartis may extend the initial research term by one year by electing to make an additional payment. On a target-by-target basis, if Novartis elects to progress development candidates directed to such target into further clinical development, Novartis will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products containing Licensed Compounds directed to the applicable target. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Novartis paid a nonrefundable upfront payment to the Company of $50.0 million in April 2023. During the research term, upon achievement of a specified discovery milestone for the first target program, Novartis will make a one-time payment to the Company in the low single digit millions. On a target-by-target basis, if Novartis elects to progress one or more candidate compounds into further development and obtain an exclusive license for commercialization, Novartis will be required to pay a candidate selection fee for the first such Licensed Compound progressed by Novartis that incorporates a radionuclide, and for the first such Licensed Compound that does not incorporate a radionuclide, in each case in the mid-teen millions. Upon declaring a candidate, Novartis will be responsible for all future development, manufacturing, and commercialization activities. On a target-by-target basis, Novartis will be required to pay to the Company additional development and regulatory/first commercial sale milestones of up to $210.0 million for each of the first radionuclide product and non-radionuclide product directed to the applicable target upon the achievement of specified milestones, or $840.0 million in the aggregate if Novartis successfully achieves all such milestone events for both a radionuclide and a non-radionuclide product in each of the targets. In addition, the Company is eligible to receive tiered sales milestones based on the achievement of specified levels of net sales of such products totaling up to $200.0 million in the aggregate per product, or $800.0 million in the aggregate if Novartis successfully commercializes both a radionuclide and a non-radionuclide product in each of the target programs. In addition, (i) the Company is eligible to receive, on a therapeutic product-by-therapeutic product basis, tiered royalties on net sales of products by Novartis, its affiliates or sublicensees at percentages ranging from the high single digits to the very low double digits, subject to standard reductions and offsets in certain circumstances, and a royalty floor, and (ii) the Company is eligible to receive low single digit royalties on net sales of diagnostic products on a diagnostic product-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">by-diagnostic product basis and a low single digit percentage of sublicensing income on diagnostic products. Royalties will be payable under the Novartis Collaboration Agreement on a product-by-product and country-by-country basis, commencing on the first commercial sale of each product in a country, until the latest of (a) the expiration of the last valid claim of certain patents licensed by Company to Novartis, (b) a specified number of years following first commercial sale of such product, and (c) expiration of all data and regulatory exclusivity for such product in the applicable country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The Novartis Collaboration Agreement will remain in force on a product-by-product and country-by-country basis, unless earlier terminated by either party, until the expiration of the obligation for Novartis to make royalty payments to Company for such product in such country, and will terminate in its entirety on the expiration of all such royalty payment obligations in all countries. Either party may terminate the agreement upon 60 days&#8217; written notice for the other party&#8217;s uncured material breach, or upon the other party&#8217;s insolvency. In addition, Novartis may terminate the Collaboration Agreement (i) in its entirety or on a product-by-product or target-by-target basis for any reason upon 90 days&#8217; written notice to Company, and (ii) on a target-by-target basis on 30 days&#8217; written notice if Novartis determines that a safety or regulatory issue exists which would have a material adverse effect on the development, manufacture, or commercialization of any product with respect to a given target. The Company may terminate the Novartis Collaboration Agreement, (a) on a target-by-target basis upon 30 days&#8217; prior written notice if Novartis has not yet declared a development candidate for such target by the sixth anniversary of the commencement of research activities for such target and (b) if Novartis or any of its affiliates or sublicensees challenges the validity or enforceability of any of the patents in the Company&#8217;s licensed intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>Upon the execution of the Novartis Collaboration Agreement, the Company identified the following performance obligations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> combined performance obligations comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with certain limited substitution rights with respect to the first and second targets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the option to progress development candidates that incorporate a radionuclide with respect to the first and second target; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the option to progress development candidates that do not incorporate a radionuclide with respect to the first and second target.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The Company concluded that certain rights that require the payment of additional consideration, which approximates the standalone selling price of the underlying services to be provided, do not provide the customer with a material right and therefore, are not considered as performance obligations at the inception of the arrangement. The Company&#8217;s participation in the joint steering committee was assessed as immaterial in the context of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The Company has concluded that the Novartis Research License is not distinct from the research and development services as Novartis cannot obtain the benefit of the research license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as they relate to constrained peptide technology that is not available in the marketplace. As a result, for each target, the research license has been combined with the research and development services into a single performance obligation. The Company exercised judgment in concluding that Novartis&#8217; rights to obtain certain research and development services associated with compounds that do not incorporate a radionuclide during the research term are not options that are material rights as they do not represent either options for additional goods or services or options for additional services that are at a discount that it would not have otherwise received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In assessing whether the various options under the Novartis Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material rights identified above the Company concluded that each of the options provided Novartis with a discount that it otherwise would not have received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The total transaction price was initially determined to be $50.0 million, consisting of the $50.0 million upfront fee. The Company utilizes the most likely amount method to determine the amount of variable consideration to be received. Variable consideration for development milestones not subject to option exercises was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved. Additional consideration to be paid to the Company upon the exercise of options by Novartis is excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the combined performance obligations for each of the targets were based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling prices for the material rights were determined based on the fees Novartis would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Novartis would exercise the options, inclusive of the probability of technical success. Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,008</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with limited substitution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,466</p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with options to progress development candidates incorporating radionuclides</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,684</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with options to progress development candidates not incorporating radionuclides</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,842</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">In November 2024, the Company achieved a specified discovery milestone for the first target program and therefore updated its estimate of the variable consideration to include an additional $3.0 million, that is no longer constrained. The arrangement consideration was increased to $53.0 million. The Company allocated the additional $3.0 million to the performance obligations based on the relative estimated standalone selling prices of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt;">The Company is recognizing revenue related to amounts allocated to the first and second target combined performance obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligations. The amounts allocated to the material rights are recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. The first and second target combined performance obligations are expected to be satisfied over a period of approximately three years and the remaining material rights are expected to be exercised or expire within approximately six years from contract execution. During the year ended December 31, 2024, the Company recognized revenue of $2.5 million upon the expiration of Novartis&#8217; material rights for limited substitution rights for the first and second targets. The research and discovery activities for these targets are ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the years ended December 31, 2024 and 2023, the Company recognized revenue of </span><span style="font-weight:normal;">$8.2</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$1.9</span><span style="font-weight:normal;"> million in connection with the Novartis Collaboration Agreement. The Company did </span><span style="font-weight:normal;">no</span><span style="font-weight:normal;">t recognize revenue in connection with the Novartis Collaboration Agreement during the year ended December 31, 2022.</span><span style="font-weight:normal;"> As of December 31, 2024 and 2023, the Company recorded deferred revenue of </span><span style="font-weight:normal;">$44.1</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$50.0</span><span style="font-weight:normal;"> million, respectively, in connection with the Novartis Collaboration Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Ionis Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ionis Evaluation and Option Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On December 31, 2020, the Company entered into an Evaluation and Option Agreement (the &#8220;Evaluation and Option Agreement&#8221;) with Ionis. Under the terms of the Evaluation and Option Agreement, Ionis had the option (the &#8220;Ionis Option&#8221;) to obtain an exclusive license to the Company&#8217;s intellectual property for the purpose of continued research, development, manufacture and commercialization of products within a particular application of the Company&#8217;s platform technology.  Ionis paid the Company a nonrefundable option fee of </span>$3.0 million in January 2021 that was fully creditable against the upfront payment to be paid upon the execution of a license agreement. On July 9, 2021, the Ionis Option was exercised upon the parties&#8217; entry into a collaboration and license agreement as contemplated by the Evaluation and Option Agreement. The Company determined that the Ionis Option exercise constituted a continuation of an existing arrangement. Therefore, the $3.0<span style="white-space:pre-wrap;"> million paid under the Evaluation and Option Agreement was included in the transaction price of the collaboration and license agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ionis Collaboration Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Following the exercise by Ionis of the Ionis Option granted pursuant to the Evaluation and Option Agreement, on July 9, 2021, the Company and Ionis entered into a collaboration and license agreement (the &#8220;Ionis Collaboration Agreement&#8221;). Pursuant to the Ionis Collaboration Agreement, the Company granted to Ionis a worldwide exclusive license under the Company&#8217;s relevant technology to research, develop, manufacture and commercialize products incorporating Bicycle<i style="font-style:italic;"> </i>peptides directed to the protein coded by the gene TFRC1 (transferrin receptor) (&#8220;TfR1 Bicycle<span style="white-space:pre-wrap;">&#8221; molecules) intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans. Ionis will maintain exclusivity to all available targets unless it fails to achieve specified development diligence milestone deadlines.  If Ionis fails to achieve one or more development diligence milestone deadlines, the Company has the right to limit exclusivity to certain specific collaboration targets, subject to the payment by Ionis of a low-single-digit million dollar amount per target as specified in the Ionis Collaboration Agreement.  Each party was responsible for optimization of such TfR1 </span>Bicycle molecules and other research and discovery activities related to TfR1 Bicycle<span style="white-space:pre-wrap;"> molecules, as specified by a research plan which was completed during the year ended December 31, 2024, and thereafter Ionis will be responsible for all future research, development, manufacture and commercialization activities.  The Company performed research and discovery activities including a baseline level of effort for a period of </span>three years for no additional consideration. The parties will negotiate a commercially reasonable rate if additional research activities are agreed to be performed. The Company has retained certain rights, including the right to use TfR1 Bicycle molecules for all non-oligonucleotide therapeutic purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The activities under the Ionis Collaboration Agreement are governed by a joint steering committee (&#8220;JSC&#8221;) with an equal number of representatives from the Company and Ionis.  The JSC will oversee the performance of the research and development activities.  Upon first commercial sales of a licensed product, the JSC will have no further responsibilities or authority under the Ionis Collaboration Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the Ionis Collaboration Agreement, Ionis made a non-refundable upfront payment of $31.0 million in addition to the $3.0 million already paid under the Option and Evaluation Agreement. Additionally, Ionis is obligated to reimburse the Company on a pass-through basis for expenses incurred in connection with research and discovery activities performed by a CRO. If Ionis is at risk of failing to achieve a specified development diligence milestone deadline, it can make up to three<span style="white-space:pre-wrap;"> separate payments of a mid-single-digit million dollar amount to extend the development diligence milestone deadlines.  On a collaboration target-by-collaboration target basis, Ionis will be required to make a low-single-digit million dollar payment upon acceptance of an investigational new drug application (&#8220;IND&#8221;) for the first product directed to such collaboration target (provided that Ionis will have a high single-digit </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">million dollar credit to be applied towards the IND acceptance fee for </span>four collaboration targets, or for exclusivity payments for certain targets if specified development diligence milestones deadlines are not achieved), and Ionis will be required to make milestone payments upon the achievement of specified development and regulatory milestones of up to a low double-digit million dollar amount per collaboration target. In addition, the Company is eligible to receive up to a low double-digit million dollar amount in cumulative sales milestone payments. The Company is also entitled to receive tiered royalty payments on net sales at percentages in the low single digits, subject to certain standard reductions and offsets. Royalties will be payable, on a product-by-product and country-by-country basis, until the latest of the expiration of specified licensed patents covering such product in such country, ten years from first commercial sale of such product in such country, or expiration of marketing exclusivity for such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2021, the Company and Ionis entered into the first amendment to the Ionis Collaboration Agreement (the &#8220;First Ionis Amendment&#8221;) and Ionis paid the Company $1.6 million to perform additional research services utilizing its proprietary phage screening technology to identify and optimize new product candidates that target the TfR1 receptor. In April 2023, the Company and Ionis entered into the third amendment to the Ionis Collaboration Agreement (the &#8220;Third Ionis Amendment&#8221;) and Ionis paid the Company $0.8 million and the Company agreed to perform additional research services to continue to evaluate and optimize the new product candidates that target the TfR1 receptor for a period of one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Either party may terminate the Ionis Collaboration Agreement for the uncured material breach of the other party or in the case of insolvency. Ionis may terminate the Ionis Collaboration Agreement for convenience on specified notice periods depending on the development stage of the applicable target, either in its entirety or on a target-by-target basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Ionis Share Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Concurrently with the execution of the Ionis Collaboration Agreement on July 9, 2021, the Company entered into the Ionis Share Purchase Agreement with Ionis, pursuant to which Ionis purchased 282,485 of the Company&#8217;s ordinary shares (the &#8220;Ionis Shares&#8221;) at a price per share of $38.94, for an aggregate purchase price of approximately $11.0 million. The Share Purchase Agreement also provided that, subject to limited exceptions, Ionis could not sell any of the Ionis Shares until July 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company determined the fair value of the Ionis Shares to be $7.6 million, based on the closing price of the Company&#8217;s ADSs of $31.11<span style="white-space:pre-wrap;"> per ADS on the date of the Ionis Share Purchase Agreement, less a discount for lack of marketability associated with resale restrictions applicable to the Ionis Shares. The Company concluded that the premium paid by Ionis under the Ionis Share Purchase Agreement represents additional consideration for the goods and services to be provided under the Ionis Collaboration Agreement.  As such, the total premium of </span>$3.4 million was included in the transaction price under the Ionis Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting Analysis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon execution of the Ionis Collaboration Agreement, the Company identified the following promises in the arrangement: (i) a worldwide exclusive license to research, develop, manufacture and commercialize products incorporating TfR1 Bicycle molecules intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans; (ii) research and discovery activities to customize and optimize such TfR1 Bicycle molecules; (iii) four material rights associated with options to obtain credits to be applied towards the IND acceptance fee for four<span style="white-space:pre-wrap;"> collaboration targets.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company&#8217;s participation in the JSC was deemed immaterial in the context of the contract.  </span>The Company concluded that the exclusive license to research, develop, manufacture and commercialize products was not distinct from the research and discovery services as Ionis cannot obtain the intended benefit of the license without the Company performing the agreed upon research and discovery services, including the optimization of such TfR1 Bicycle molecules. The services incorporated proprietary technology, unique skills and specialized expertise to optimize Bicycle molecules that were not available in the marketplace. As a result, the exclusive license to research, develop, manufacture and commercialize products was combined with the research and discovery activities into a single performance obligation. The Company concluded that the low-single-digit million dollar payments upon acceptance of an IND (and payment to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">extend the exclusive license to research, develop, manufacture and commercialize a product candidate for certain specific collaboration targets if Ionis fails to achieve specified development diligence milestone deadlines) is a customer option, as Ionis has the contractual right to choose to make the payment in exchange for the continued exclusive right to research, develop, manufacture and commercialize the product candidate, and the Company is not presently obligated to provide, and does not have a right to consideration, for the additional goods or services prior to Ionis&#8217;s exercise of the option. In assessing whether the options under the Ionis Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon the option exercise and the standalone selling price of the underlying goods and services. For the material rights identified as performance obligations above, the Company concluded that each of the options to obtain credits provided Ionis with a discount that it otherwise would not have received without entering into the Ionis Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The total transaction price was initially determined to be $38.0 million, consisting of the $31.0 million up front payment, the $3.0 million payment under the Option and Evaluation Agreement, that was credited against the total upfront payment payable pursuant to the Ionis Collaboration Agreement, the $3.4 million premium paid under the Ionis Share Purchase Agreement, and an estimated $0.6<span style="white-space:pre-wrap;"> million for the reimbursement of CRO costs. Additional variable consideration including development diligence milestone deadline extension payments, development and regulatory milestone payments, sales milestone payments and royalty payments was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling price of the Ionis combined licenses and research and discovery performance obligation was based on the nature of the licenses to be delivered, as well as the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling price for the material rights was determined based on the estimated value of the underlying goods and services, and the probability that Ionis would exercise the option. Based on the relative standalone selling price, the initial allocation of the transaction price to the separate performance obligations was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Combined licenses and research and discovery performance obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,100</p></td></tr><tr><td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Four material rights associated with credits for IND Acceptance fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:bottom;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended December 31, 2024, the Company updated its estimate of variable consideration for the reimbursement of CRO costs from $0.6 million to $0.4 million, and the transaction price decreased to $37.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company recognized revenue related to amounts allocated to the combined licenses and research and discovery performance obligation using a proportional performance model over the period of service using input-based measurements including total full-time equivalent effort and CRO costs incurred to date as a percentage of total full-time equivalent effort and CRO costs expected, which best reflects the progress towards satisfaction of the performance obligation. The amount allocated to the material rights is recorded as deferred revenue and the Company commences revenue recognition upon exercise of or upon expiry of the respective option. As of December 31, 2024, the combined licenses and research and discovery performance obligation was completed and all revenue allocated to the combined licenses and research and discovery performance obligation was recognized. The Company anticipates the material rights may be exercisable or may expire after approximately <span style="-sec-ix-hidden:Hidden_7Ox68_7-tk2-gZ54jj6J7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span> to seven years from contract execution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span>The Company concluded that the First Ionis Amendment was a separate contract, as the services were distinct from the Ionis Collaboration Agreement, and the price of the contract increased by an amount of consideration that reflects the Company&#8217;s standalone selling price. The Company recognized $0.8 million associated with services for an initial six-month period as revenue as the underlying services were performed. The contract included an option to perform additional research services for an additional six months that did not contain a material right and the Company accounted for Ionis&#8217; exercise of the option in October 2022 as a separate contract. The Company recognized $0.8 million associated with the services for the additional six-month period as revenue as the underlying services were performed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company concluded that the Third Ionis Amendment was a contract modification to the separate contract under the First Ionis Amendment, as the services were not distinct from the services provided under the First Ionis Amendment. The Company recognized $0.8 million associated with the services for the additional one-year period as revenue as the underlying services were performed. Revenue was recognized under the First Ionis Amendment and the Third Ionis Amendment using a proportional performance model over the period of service using input-based measurements of total full time equivalent efforts and external costs incurred to date as a percentage of total expected full time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2024, 2023 and 2022, the Company recognized $8.9 million, $10.7 million and $9.3 million in revenue, respectively, and as of December 31, 2024 and 2023, the Company recorded deferred revenue of $3.6 million and $12.5 million, respectively, in connection with the Ionis Collaboration Agreement, First and Third Ionis Amendments, and Ionis Evaluation and Option Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Genentech Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 21, 2020, the Company entered into a Discovery Collaboration and License Agreement, as amended from time to time (as amended, the &#8220;Genentech Collaboration Agreement&#8221;), with Genentech. The collaboration is focused on the discovery and development of Bicycle peptides directed to biological targets selected by Genentech and aimed at developing up to four potential development candidates against multiple immuno-oncology targets suitable for Genentech to advance into further development and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Genentech Collaboration Agreement, the Company received a $30.0 million upfront, non-refundable payment. The initial discovery and optimization activities are focused on utilizing the Company&#8217;s phage screening technology to identify product candidates aimed at two immuno-oncology targets (&#8220;Genentech Collaboration Programs&#8221;), which may also include additional discovery and optimization of Bicycle molecules<i style="font-style:italic;"> </i>as a targeting element for each Genentech Collaboration Program (each a &#8220;Targeting Arm&#8221;). Genentech also had the option to nominate up to two additional immuno-oncology targets (each, an &#8220;Expansion Option&#8221;) as additional Genentech Collaboration Programs, which may also include an additional Targeting Arm for each Expansion Option. Genentech exercised the Expansion Options in October 2021 and June 2022, respectively. Genentech paid to the Company an expansion fee of $10.0 million for each Expansion Option. The Genentech Collaboration Agreement included rights, under certain limited circumstances, for Genentech to select an alternative target to be the subject of a Genentech Collaboration Program, in some cases subject to payment of an additional target selection fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If Genentech elects for the Company to perform discovery and optimization services for certain Targeting Arms, the Company will be entitled to receive an additional advance payment for the additional research services.  Genentech exercised its right to select a Targeting Arm for </span>one of the initial Genentech Collaboration Programs at the inception of the arrangement, and for the first Expansion Option in October 2021, which entitled the Company to additional payments of $1.0<span style="white-space:pre-wrap;"> million each. If a Targeting Arm achieves specified criteria in accordance with the research plan, Genentech will be required to pay a further specified amount in the low single digit millions for each such Targeting Arm as consideration for the additional services to be provided.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company granted to Genentech a non-exclusive research license under the Company&#8217;s intellectual property solely to enable Genentech to perform any activities under the agreement. The activities under the Genentech Collaboration Agreement are governed by a joint research committee (&#8220;JRC&#8221;) with representatives from each of the Company and Genentech. The JRC will oversee, review and recommend direction of each Genentech Collaboration Program, achievement of development criteria, and variations of or modifications to the research plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">After the Company performs the initial discovery and optimization activities in accordance with an agreed research plan and achieves specified criteria, Genentech will have the option to have the Company perform initial pre-clinical development and optimization activities in exchange for an additional specified milestone payment in the mid-single digit millions for each Genentech Collaboration Program (the &#8220;LSR Go Option&#8221;).  Upon completion of such initial pre-clinical development and optimization activities for each Genentech Collaboration Program, Genentech will have the option to obtain an exclusive license to exploit any compound developed under such Genentech Collaboration Program in exchange for an additional specified payment in the mid to high single digit millions for each of the initial </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">two Genentech Collaboration Programs and each of the two Expansion Option Genentech Collaboration Programs (the &#8220;Dev Go Option&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On a Genentech Collaboration Program by Genentech Collaboration Program basis, if Genentech elects to obtain exclusive development and commercialization rights and pays the applicable LSR Go Option and Dev Go Option fees, Genentech will be required to make milestone payments to the Company upon the achievement of specified development, regulatory, and initial commercialization milestones for products arising from each collaboration program, totaling up to $200.0 million. Specifically, the Company is eligible for additional development milestones totaling up to $65.0 million, as well as regulatory milestones of up to $135.0 million for each collaboration program. In addition, the Company is also eligible to receive up to $200.0 million in sales milestone payments on a Genentech Collaboration Program-by-Genentech Collaboration Program basis. In addition, to the extent any of the product candidates covered by the licenses conveyed to Genentech are commercialized, the Company would be entitled to receive tiered royalty payments on net sales at percentages ranging from the mid-single to low double-digits, subject to certain standard reductions and offsets. Royalties will be payable, on a product by product and country by country basis, until the later of the expiration of specified licensed patents covering such product in such country, or ten years from first commercial sale of such product in such country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the execution of the Genentech Collaboration Agreement, the Company has identified the following performance obligations: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research license, and the related research and development and preclinical services through LSR Go for a first Genentech Collaboration Program (Genentech Collaboration Program #1); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research license, and the related research and development and preclinical services through LSR Go for a second Genentech Collaboration Program with a specified Targeting Arm (Genentech Collaboration Program #2); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Material right associated with an option to a specified Targeting Arm for Genentech Collaboration Program #1;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights associated with the LSR Go Option for Genentech Collaboration Program #1 and Genentech Collaboration Program #2, which includes research services to be provided through the Dev Go Option and an option to receive an exclusive license; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Material rights associated with certain limited substitution rights with respect to a limited number of collaboration targets; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> material rights related to each Genentech Expansion Option, which upon exercise include the services for an additional immuno-oncology target through the LSR Go Option, an LSR Go Option which includes the services to be provided through the Dev Go Option and an option to receive an exclusive license, limited substitution rights, and an option to select a specified Targeting Arm. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company concluded that certain substitution rights that require the payment of additional consideration, which approximate the standalone selling price of the underlying services to be provided, do not provide the customer with a material right and therefore, are not considered as performance obligations and are accounted for as separate contracts upon exercise, if ever.  The Company&#8217;s participation in the JRC was assessed as immaterial in the context of the contract. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has concluded that the research license is not distinct from the research and development services as Genentech cannot obtain the benefit of the research license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as it relates to constrained peptide technology that is not available in the marketplace. As a result, for each </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">research program, the research license has been combined with the research and development services into a single performance obligation. In addition, the Company concluded that the Dev Go Option is not distinct or separately exercisable from the LSR Go Option, as the customer cannot benefit from the Dev Go Option unless and until the LSR Go Option is exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In assessing whether the various options under the Genentech Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon the option exercise, the standalone selling price of the underlying goods, services, and additional options.  For the material rights identified above the Company concluded that each of the options provided Genentech with a discount that it otherwise would not have received. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total transaction price was initially determined to be $31.0 million, consisting of the $30.0 million upfront fee and the additional $1.0<span style="white-space:pre-wrap;"> million for Genentech&#8217;s selection of a new Targeting Arm at inception.  The Company utilizes the most likely amount method to determine the amount of research and development funding to be received. Additional consideration to be paid to the Company upon the exercise of options by Genentech and subsequent milestones are excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. In addition, other variable consideration for development milestones not subject to option exercises was fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. In March 2021, the Company achieved specified criteria in accordance with the research plan under the Genentech Collaboration Agreement and therefore updated its estimate of the variable consideration to include an additional </span>$2.0 million, that is no longer constrained. The arrangement consideration was increased to $33.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the Genentech Collaboration Programs was based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling price for the material rights was determined based on the fees Genentech would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Genentech would exercise the option and any underlying options.  </span>Based on the relative standalone selling price, the allocation of the transaction price to the separate performance obligations is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genentech Collaboration Program #1 Performance Obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,019</p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genentech Collaboration Program #2 Performance Obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,037</p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Specified Targeting Arm Material Right Arm for Genentech Collaboration Program #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 352</p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with the LSR Go Option for Collaboration Programs #1 and #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,400</p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Material rights associated with limited substitution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,187</p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights for Expansion Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,005</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company recognizes revenue related to amounts allocated to the Genentech Collaboration Program #1 and #2 Performance Obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligation. The amount allocated to the material rights is recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. In June 2023, Genentech terminated Genentech Collaboration Program #2 and revenue of $6.0 million was recognized during the year ended December 31, 2023 related to the expiration of the material right associated with the LSR Go Option for Collaboration Program #2. The Company expects the remaining Genentech Collaboration Performance Program #1 performance obligations will be satisfied over the next <span style="-sec-ix-hidden:Hidden_PuaulHhMWk2PS85VLrvMLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to two years, and the remaining deferred revenue allocated to the LSR Go Option for Collaboration Program #1 will commence revenue recognition when the option is exercised or expires within approximately <span style="-sec-ix-hidden:Hidden_CuyU_1zNJ0eAuH7pLi5zdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span> to five years from contract execution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In October 2021 and June 2022, respectively, Genentech exercised the first and second Expansion Options to add additional Genentech Collaboration Programs (Genentech Collaboration Program #3 and Genentech Collaboration Program #4) and paid to the Company an expansion fee of $10.0 million for each option. For the first Expansion Option, Genentech also elected for the Company to perform discovery and optimization services for a Targeting Arm, and the Company received an additional payment of $1.0 million for additional research services. The Company concluded that the exercise of each Expansion Option, including the option to a specified Targeting Arm for the first Expansion Option, is accounted for as a continuation of an existing contract as the customer decided to purchase additional goods and services contemplated in the original contract. For the first Expansion Option, the additional arrangement consideration of $11.0 million received upon the option exercises and the $3.5 million originally allocated to the first Expansion Option material right is allocated to the underlying goods and services associated with the first Expansion Option on the same basis as the initial allocation of the Genentech Collaboration Agreement. In December 2022, the Targeting Arm associated with the first Expansion Option achieved specified criteria in accordance with the research plan under the Genentech Collaboration Agreement and therefore the Company updated its estimate of variable consideration to include an additional $2.0 million, that is no longer constrained. The Company allocated the additional $2.0 million entirely to the Genentech Collaboration Program #3 and Targeting Arm services as the terms of the variable consideration relate specifically to the Company&#8217;s efforts in satisfying the performance obligation and allocating the variable consideration entirely to the performance obligation is consistent with the allocation objective in ASC 606. For the second Expansion Option, the additional arrangement consideration of $10.0 million received pursuant to the option exercise together with the $3.5 million originally allocated to the second Expansion Option material right is allocated to the underlying goods and services associated with the second Expansion option on the same basis as the initial allocation of the Genentech Collaboration Agreement. Other variable consideration for development milestones not subject to option exercises was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved. The Company recognized the $8.4 million allocated to the Genentech Collaboration Program #3 and Targeting Arm services and is recognizing $5.3 million allocated to the Genentech Collaboration Program #4 services as the underlying services are performed using a proportional performance model over the period of service of approximately <span style="-sec-ix-hidden:Hidden_23cxoubFkkqKtXI7gxQnYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to three years for each program using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and external costs expected, which best reflects the progress towards satisfaction of the performance obligations. The amount allocated to the material rights associated with an LSR Go Options for Genentech Collaboration Program #3 and Genentech Collaboration Program #4 of $7.4 million and $7.4 million, respectively, limited substitution material rights of $0.7 million and $0.7 million, respectively, and the material right associated with the option to select a Targeting Arm for Genentech Collaboration Program #4 of $0.1 million were recorded as deferred revenue. In January 2024, the JRC decided to discontinue research activities associated with Genentech Collaboration Program #3 and, as a result, the Company recognized revenue of $10.4 million during the year ended December 31, 2024, including $7.5 million related to the expiration of remaining material rights. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized revenue of $14.8 million, $12.0 million and $3.6 million, respectively, and as of December 31, 2024 and 2023, the Company recorded deferred revenue of 14.0 million and $29.1 million, respectively, in connection with the Genentech Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Summary of Contract Assets and Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents changes in the balances of the Company&#8217;s contract liabilities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impact&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Bayer collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (561)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39,960</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Novartis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 50,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 44,073</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Ionis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,881)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,587</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Genentech collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,840)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,038</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 135,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 101,658</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Beginning&#160;Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impact&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ending Balance</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exchange</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bayer collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,160)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43,618</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Novartis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,909)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 50,008</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Ionis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,734)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,464</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Genentech collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,969)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,104</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">AstraZeneca collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 61,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 135,194</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract assets represent research and development services which have been performed but have not yet been billed, and are reduced when they are subsequently billed. There were no contract assets at December 31, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Bayer, Novartis, Ionis, and Genentech deferred revenue balances include $31.9 million, $32.0 million, $3.6 million, and $13.5 million, respectively, allocated to material rights that will commence revenue recognition when the respective underlying options are exercised or when the options expires. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue recognized in the period from:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on proportional performance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,358</p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on expiration of material rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,433</p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on changes in transaction price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 672</p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,463</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cancer Research UK</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">BT1718</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December 13, 2016, the Company entered into a Clinical Trial and License Agreement with Cancer Research Technology Limited (&#8220;CRTL&#8221;), a wholly owned subsidiary of Cancer Research UK that Cancer Research UK&#8217;s commercial activities operate through, and Cancer Research UK (the &#8220;BT1718 Cancer Research UK Agreement&#8221;). Pursuant to the BT1718 Cancer Research UK Agreement, as amended in March 2017 and June 2018, Cancer Research UK&#8217;s Centre for Drug Development sponsored and funded a Phase I/IIa clinical trial for BT1718, a BTC molecule, in patients with advanced solid tumors. The Company retained the right to continue the development of BT1718 during the clinical trial. Upon the completion of the Phase I/IIa clinical trial, the Company had the right to obtain a license to the results of the clinical trial upon the payment of a milestone, in cash and ordinary shares, with a combined value in the mid six-digit dollar amount. If such license was not acquired, or if it was acquired and the license was terminated and the Company decided to abandon development of all products that deliver cytotoxic payloads to the MT1 target antigen, CRTL could elect to receive an assignment and exclusive license to develop and commercialize the product on a revenue sharing basis (in which case the Company would receive tiered royalties of 70% to 90% of the net revenue depending on the stage of development when the license is granted). The BT1718 Cancer Research UK Agreement contained additional future milestone payments upon the achievement of development and regulatory milestones, payable in cash and shares, with an aggregate total value of $50.9 million, as well as royalty payments based on a single digit percentage on net sales of products developed. Cancer Research UK could terminate the arrangement for safety reasons or if it was determined that the objectives of the clinical trial will not be met and either party could terminate the arrangement upon an insolvency event, material breach of the terms of the contract, or upon a change in control (and the new controlling entity develops, sells or manufactures tobacco products or generates the majority of its profits from tobacco products or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is an affiliate of such party). The Company was required to reimburse Cancer Research UK for certain costs upon specified termination events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the costs incurred by Cancer Research UK was a research and development funding liability in accordance with ASC&#160;730, <i style="font-style:italic;">Research and Development</i>, as certain payments were not based solely on the results of the research and development having future economic benefit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 4, 2024, the Company, CRTL and Cancer Research UK entered into an Expiry and Revenue Sharing Agreement (the &#8220;BT1718 Expiration Agreement&#8221;) pursuant to which (i) the Company did not exercise its option to obtain a license to the results of the clinical trial, (ii) CRTL did not elect to receive an assignment and exclusive license to develop and commercialize the product, (iii) the BT1718 Cancer Research UK Agreement will expire on December 4, 2024, and (iv) all rights and obligations (other than certain surviving provisions as outlined in the agreement) under the BT1718 Cancer Research UK Agreement expired and terminated as of December 4, 2024. Under the terms of the BT1718 Expiration Agreement, the Company agreed to pay to CRTL an upfront payment of &#163;50,000. The Company will also pay to CRTL specified royalty and other payments at percentages in the very low to low single digits related to specified products targeting the MT1 target antigen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the BT1718 Expiration Agreement by applying the concepts of ASC 470, <i style="font-style:italic;">Debt</i>. As all rights and obligations, including the Company&#8217;s payment obligations, under the BT1718 Cancer Research UK Agreement expired and terminated, the Company concluded that the liability recorded under the BT1718 Cancer Research UK Agreement is extinguished as the Company has been legally released from being the primary obligor under the BT1718 Cancer Research UK Agreement. As such, the Company recognized a gain on extinguishment of the research and development funding liability of $4.5 million during the year ended December 31, 2024, which is recorded within other income, net, in the consolidated statements of operations and comprehensive loss. As of December 31, 2024 and 2023, the Company recorded a research and development funding liability of zero and $4.3 million, respectively, related to the BT1718 Cancer Research UK Agreement, which is recorded in other long-term liabilities in the consolidated balance sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241738784688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">10. Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of net loss before income tax provision are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United&#160;Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (182,980)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (116,275)</p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United&#160;States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,034</p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (173,796)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,241)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the (benefit from) provision for income taxes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,048</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (669)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,404</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,452</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax (benefit) provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,772)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,111)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,454)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (865)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred income tax (benefit) provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,976)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total (benefit from) provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,524)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the (benefit from) provision for income taxes computed at the statutory income tax rate to the (benefit from) provision for income taxes as reflected in the financial statement is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(Benefit from) provision for income taxes at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increases (decreases) resulting from:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net losses surrendered for research credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of statutory rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 81,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 66,555</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,680</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,577</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation &amp; amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,742</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 111,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88,554</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,389)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,389)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (99,672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (80,274)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,891</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the years ended December 31, 2024, 2023 and 2022, the Company recorded an income tax benefit of $4.8 million, an income tax provision of $1.5 million and an income tax benefit of $1.5 million, respectively. The Company is subject to U.K. corporate taxation. Due to the nature of its business, the Company has generated losses since inception and therefore not paid U.K. corporation tax. The (benefit from) provision for income taxes included in the consolidated statements of operations and comprehensive loss represents the tax impact from operating activities in the United States, which has generated taxable income based on intercompany service arrangements. Deferred tax assets benefitted in the United States do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s income tax benefit recognized during the year ended December 31, 2024 is mainly the result of deferred tax assets in the United States that do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement, including incremental income tax benefits of approximately $3.5 million recognized during the year ended December 31, 2024 related to the completion of a U.S. research and development tax credit study. The Company&#8217;s income tax provision recognized during the year ended December 31, 2023 is primarily related to the completion of an assessment, inclusive of an external tax analysis, during the year ended December 31, 2023, whereby the Company concluded that it is not required to capitalize certain research and development expenses incurred by its U.S. subsidiary associated with contractual research services performed on behalf of its U.K. subsidiary pursuant to an intercompany service arrangement because its U.S. subsidiary does not retain any ownership or rights in the underlying intellectual property resulting from the research services. The change in estimate </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon the completion of this analysis resulted in the recognition of an income tax provision of $2.4 million during the year ended December 31, 2023. The Company's income tax benefit recognized during the years ended December 31, 2022 is mainly the result of deferred tax assets benefitted in the U.S. that do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighed the evidence based on its objectivity. After consideration of the evidence, including the Company's history of cumulative net losses in the U.K., the Company has concluded that it is more likely than not that the Company will not realize the benefits of its U.K. deferred tax assets and accordingly the Company has provided a valuation allowance for the full amount of the net deferred tax assets in the U.K. The Company has considered its history of cumulative net profits in the United States and estimated future taxable income and has concluded that it is more likely than not that the Company will realize the benefits of its United States deferred tax assets and has not provided a valuation allowance against the net deferred tax assets in the United States. The valuation allowance increased in the year ended December 31, 2024 by $19.4 million due to the corresponding increase in U.K. deferred tax assets, primarily due to operating loss carryforwards generated during the year that were not surrendered for research credit utilization. The Company recorded a valuation allowance against all of its U.K. deferred tax assets as of December&#160;31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company intends to continue to maintain a full valuation allowance on its U.K. deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. The release of the valuation allowance would result in the recognition of certain deferred tax assets and an increase to the benefit for income taxes for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change on the basis of the level of profitability that the Company is able to actually achieve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The (benefit from) provision for income taxes shown on the consolidated statements of operations differs from amounts that would result from applying the statutory tax rates to income before taxes primarily because of certain permanent expenses that were not deductible and U.K., U.S. federal and state research and development credits, as well as the application of valuation allowances against the U.K. deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had $326.0 million of U.K. operating loss carryforwards that have an indefinite life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes, in its consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. The Company had no uncertain tax positions during the years ended December 31, 2024 and 2023. There are no amounts of interest or penalties recognized in the consolidated statement of operations or accrued on the consolidated balance sheet for any period presented. The Company does not expect any material changes in these uncertain tax benefits within the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the United Kingdom, and in the United States for federal income taxes and in 11 jurisdictions for state income taxes. In the normal course of business, the Company is subject to examination by tax authorities in these jurisdictions. The 2023 and 2022 tax years remain open to examination by the HM Revenue &amp; Customs. The statute of limitations for assessment with the Internal Revenue Service is generally three years from filing the tax return. As such, all years since 2021 in the U.S. remain open to examination. The Company is currently not under examination by jurisdictions for any tax years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241734004096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">11. Commitments and contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In January 2023, the Company entered into a lease agreement for office and laboratory space in Cambridge, Massachusetts. The lease has a contractual period of approximately three years, which, subject to certain conditions, may be extended for an additional two years at the Company&#8217;s option. The Company concluded that the lease term is three </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">years, representing the non-cancelable lease period, as it is not reasonably certain that the lease will be extended. The annual rent is approximately $2.1 million in the first year of the lease and increases annually with the last year of the lease having annual rent of approximately $2.3 million. The annual rent is payable monthly in advance following a two-month rent-free period. In connection with the lease agreement, the Company has delivered to the landlord a security deposit in the form of a letter of credit of approximately $0.5 million. The Company recorded a right of use asset and lease liability of approximately $5.8 million, respectively, at the lease commencement date, based on the present value of future lease payments, discounted at 9.0%, the Company&#8217;s estimated incremental borrowing rate at the commencement of the lease, over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 6, 2021 the Company entered into a lease of new office and laboratory space, in Cambridge, United Kingdom. The lease has a contractual period of 10 years, but may be cancelled by the Company on the fifth anniversary of the lease commencement date. The lease term is five years, representing the non-cancelable lease period, as it is not reasonably certain that the lease will not be cancelled. The Company has a contractual right to renew the lease for a further ten-year period, which also may be cancelled after five years. The annual rent is approximately $3.0 million, payable quarterly in advance beginning in June 2022, following a six-month rent-free period. There was no deposit paid in conjunction with the lease. The Company recorded a ROU asset of approximately $11.6 million and a lease liability of approximately $11.1 million at the lease commencement date, based on the present value of future lease payments, discounted at 6.9%, the Company&#8217;s estimated incremental borrowing rate at the commencement of the lease, over the lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2017, the Company entered into a lease agreement for office and laboratory space in Building 900, Babraham Research Campus, Cambridge, U.K., which was renewed in December 2021 for five years through December 2026. The annual rent for the lease was approximately $0.6 million. Service charges were also payable based on floor area and are estimated to be approximately $0.2 million per year. In April 2023, the Company entered into a deed of surrender related to the lease, pursuant to which the lease was terminated effective immediately. As a result of the deed, the Company derecognized the lease liability and right of use asset associated with the lease. The Company also paid termination-related fees of $0.3 million in connection with the deed, which were recorded as a loss on lease termination and are included in operating expenses in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2017, Bicycle Therapeutics Inc. entered into a lease agreement for office and laboratory space in Lexington, Massachusetts, which commenced on January 1, 2018. In conjunction with the lease agreement, Bicycle Therapeutics Inc. paid a security deposit of $0.2 million. The deposit is recorded in other assets in the consolidated balance sheets. In March 2022, Bicycle Therapeutics Inc. notified the landlord of its intent to exercise its option to extend the lease, originally set to expire on December 31, 2022, for a successive period through December 31, 2027, which successive period was not included in the original lease term. The Company accounted for the change in lease term as a modification of the existing lease and remeasured the ROU asset and lease liability by calculating the present value of lease payments, discounted at 7.0%, the Company&#8217;s incremental borrowing rate at the date of the modification of the lease, over the remaining lease term. In May 2022, the lease was extended. The payments for the extended lease are approximately $0.2 million for the remainder of 2022, $0.7 million in 2023, and increases annually pursuant to an escalation clause with the last year of the lease term having a per annum fixed rent obligation of $0.8 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Finance Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>From time to time, the Company may enter into finance lease agreements for property and equipment. As of December 31, 2024, the Company recorded finance lease right-of-use assets of $1.0 million, which are included in <span style="-sec-ix-hidden:Hidden_89Xiz3lIwU210xUHlqxyBQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">property and equipment</span></span>, net, in the consolidated balance sheets. As of December 31, 2024, the Company recorded finance lease liabilities of $1.0 million, which are included in <span style="-sec-ix-hidden:Hidden_SQ4PzHGMvEedzinnZFOhqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accrued</span></span> expenses and other current liabilities and other long-term liabilities, as applicable, in the consolidated balance sheets. No finance lease right-of-use assets or <span style="-sec-ix-hidden:Hidden_o8BOhRO22E6Ob_Qt--G_Gg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities</span></span> were recorded as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the Company&#8217;s lease expense are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,790</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,643</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining operating lease term was <span style="-sec-ix-hidden:Hidden_lYaA-73yc0O8cmcTzPPaEg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.0</span></span> years and 2.9 years as of December 31, 2024 and 2023, respectively, and the weighted average operating lease discount rate was 7.8% and 7.9% as of December 31, 2024 and 2023, respectively. The weighted average remaining finance lease term was <span style="-sec-ix-hidden:Hidden_Rcc02-kBPEezAjTVUU7wRQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</span></span> years as of December 31, 2024, and the weighted average finance lease discount rate was 9.5% as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the maturities of the Company&#8217;s lease liabilities as of December 31, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ending December 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 192</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (646)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (224)</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 992</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_u8XOnpcF106LEEpbmUkWMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Less: current lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (175)</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various agreements with contract research organizations to provide clinical trial services, contract manufacturing organizations to provide clinical trial materials and with vendors for preclinical research studies, synthetic chemistry and other services for operating purposes. These contracts are generally cancelable at any time upon less than 90&#160;days&#8217; prior written notice. The Company is not contractually able to terminate for convenience and avoid any and all future obligations to these vendors. In some cases, the Company is contractually obligated to make certain minimum payments to the vendors, based on the timing of the termination notification and the exact terms of the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">T<span style="background:#ffffff;">he Company has also entered into separate agreements with third parties which provide for various future milestone payments upon the achievement of specified development, regulatory, commercial and sales-based milestones with an aggregate total value of </span><span style="background:#ffffff;">$166.2</span><span style="background:#ffffff;"> million, as well as potential future royalty and other payments at percentages ranging from very low to low single digits.</span> These additional milestone payments are contingent upon future events that are not considered probable of achievement as of December 31, 2024. As of December 31, 2024, the Company was unable to estimate the timing or likelihood of achieving these milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Legal proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company or its subsidiaries may become involved in various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. The Company is not currently subject to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of ASC 450, <i style="font-style:italic;">Contingencies</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Indemnification obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has indemnification obligations towards members of its board of directors and officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. In addition, the Company has agreed to indemnify certain investors in limited circumstances. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241638777696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">12. Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169,031)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (180,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (112,717)</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average ordinary shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 58,207,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,592,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,660,659</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.80)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potentially dilutive securities, which include options to purchase ordinary shares and restricted share units for ordinary shares, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of ordinary shares outstanding, which includes both ordinary shares and non-voting ordinary shares, used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potentially dilutive ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 716,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 326,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 187,725</p></td></tr><tr><td style="vertical-align:top;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,748,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,469,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,898,888</p></td></tr><tr><td style="vertical-align:bottom;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,464,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,796,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,086,613</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726263440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">13. Benefit plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company established a defined-contribution savings plan under Section&#160;401(k)&#160;of the Code (the &#8220;401(k)&#160;Plan&#8221;). The 401(k)&#160;Plan covers all U.S. employees and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of the Company&#8217;s board of directors. During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company made contributions totaling $1.1 million, $0.8&#160;million and $0.5 million, respectively, to the 401(k)&#160;Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides a pension contribution plan for its employees in the United Kingdom, pursuant to which the Company may make contributions each&#160;year (&#8220;U.K Plan&#8221;). During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company made contributions totaling $2.9&#160;million, $2.2&#160;million and $1.4 million, respectively, to the U.K. Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726342160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">14. Related party transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Consulting Agreement with Stone Atlanta Estates LLC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Chairman of the Company&#8217;s board of directors is associated with Stone Atlanta Estates LLC, the successor-in-interest to Stone Sunny Isles Inc., which provided consultancy services to the Company totaling $0.3 million, $0.2 million and $0.2 million during each of the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Related Party Participation in Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Investors in the Private Placement included certain entities affiliated with Baker Bros. Advisors LP (the &#8220;Baker Entities&#8221;), an entity which may be deemed a beneficial owner of greater than 10% of the Company&#8217;s voting securities. Felix J. Baker, one of the Company&#8217;s directors, is a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP. In the Private Placement, the Baker Entities purchased an aggregate of 17,114,846 non-voting ordinary shares, nominal value &#163;0.01 per share, for an aggregate purchase price of $366.6 million. The Private Placement was approved in accordance with the Company&#8217;s related person transaction policy by the Company&#8217;s Related Parties Committee. See Note 11. &#8220;Commitments and contingencies&#8221; for additional information on indemnities provided to certain investors.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726328608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and geographic information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments and geographic information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">15. Segments and geographic information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;). The CODM reviews consolidated operating results, manages the business on a consolidated basis and utilizes consolidated net loss from the consolidated statements of operations and comprehensive loss as the primary measure of segment profit or loss in making decisions surrounding allocating resources and assessing performance of the Company. The CODM is regularly provided detailed expense information, including expenses by program and expense category, and the CODM makes decisions surrounding capital and personnel allocation using this information on a consolidated basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s single operating segment, including significant segment expenses, for the years ended December 31, 2024, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,463</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Significant segment expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Zelenectide pevedotin (Nectin-4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 82,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,054</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">BT5528 (EphA2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,702</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">BT1718 (MT1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 692</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bicycle tumor-targeted immune cell agonists</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,268</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Discovery, platform and other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,811</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Employee and contractor related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 58,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 31,346</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,394</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,155</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development incentives and government grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,459)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,813)</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 156,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 81,609</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel-related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,948</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,836</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other general and administrative costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,783</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,385</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Effect of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 555</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 72,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 60,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 49,507</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total significant segment expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 245,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 216,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 131,116</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,936</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (169,031)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (180,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (112,717)</p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Other segment items include interest and other income, interest expense, loss on extinguishment of debt, gain on extinguishment of research and development funding liability and (benefit from) provision for income taxes.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not regularly provide the CODM with detailed segment asset information other than what is included in the consolidated balance sheets. Please refer to the consolidated financial statements and the accompanying notes to the consolidated financial statements for segment asset information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company operates in two geographic regions: the United States and the United Kingdom. Information about the Company&#8217;s long-lived assets, including operating lease ROU assets, held in different geographic regions is presented in the table below (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,486</p></td></tr><tr><td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,198</p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,684</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s collaboration revenue is attributed to the operations of the Company in the United Kingdom.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726313840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">16. Subsequent events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2025, Genentech provided the Company with a notice of termination for Genentech Collaboration Program #4, effective in March 2025, and the Company expects to recognize revenue of approximately $7.4 million of deferred revenue allocated to the material right associated with the LSR Go Option for Collaboration Program #4 in the first quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726309088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (169,031)<span></span>
</td>
<td class="num">$ (180,664)<span></span>
</td>
<td class="num">$ (112,717)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241643289456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639882512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241643081840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk management and strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, computer hardware and software, <span style="white-space:pre-wrap;">and our critical data, which includes proprietary, confidential and sensitive data, including, without limitation, personal data (such as health-related data), intellectual property and trade secrets, referred to collectively as Information Assets.  Accordingly, we maintain certain risk assessment processes intended to identify cybersecurity threats, determine their likelihood of occurring, and assess potential material impact to our business.  Based on our assessment, </span>we implement and maintain risk management processes designed to protect the confidentiality, integrity, and availability of our Information Assets and mitigate harm to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Risks from cybersecurity threats are among those that we address in our general risk management program. We rely on a multidisciplinary team (including personnel from our information security function, management and third-party service providers<span style="white-space:pre-wrap;">, as needed, as described further below) to help identify, assess and manage our risks. We identify and assess such threats by, among other things, monitoring and evaluating the threat environment using various methods, including, for example, manual and automated tools, information security tools and platforms to alert us to potentially unwarranted activity on our networks, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#8217;s risk profile, evaluating threats reported to us, conducting threat assessments for internal and external threats, and conducting risk and vulnerability assessments to identify vulnerabilities.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depending on the environment, we implement and maintain various technical, physical and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Assets. For example, the risk management and reduction measures we implement for certain of our Information Assets include: policies and procedures designed to address cybersecurity threats, including an incident response plan, vulnerability management, and disaster recovery/business continuity plans; incident detection and response solutions; internal and/or external audits to assess our exposure to cybersecurity threats; documented risk assessments; implementation of certain security standards/certifications; encryption of data; network security controls; data segregation; physical and electronic access controls; physical security; asset management, tracking and disposal; systems monitoring; employee security training; penetration testing; and cyber insurance. In addition to the above, management obtains a third-party review and formal certification of its information management system policies and procedures, which has been collated into an Information Security Management System (ISMS) which is maintained to ISO27001 standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We work with third parties from time to time that assist us to identify, assess, and manage cybersecurity risks, including professional services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms and other vendors that help to identify, assess, or manage cybersecurity risks.<span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">To operate our business, we utilize certain third-party service providers to perform a variety of functions, such as outsourced business critical functions including contract research organizations, or CROs, for managing clinical trials, professional services, SaaS platforms, managed services, property management, cloud-based infrastructure, data center facilities, content delivery to customers, encryption and authentication technology, corporate productivity services, and other functions. We generally engage reliable, reputable service providers that maintain cybersecurity programs.  Depending on the nature of the services provided, the sensitivity and quantity of information processed, and the identity of the service provider, our vendor management process may include reviewing the cybersecurity practices of such provider, contractually imposing obligations on the provider related to the services they provide and/or the information </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">they process, conducting security assessments, requiring their completion of written questionnaires regarding their services and data handling practices, and conducting periodic re-assessments during their engagement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">For service providers that provide particularly critical services to us or process particularly sensitive information for us, we may also require that such providers possess at least one of the following certificates, reports, or procedures: SOC 2 Type 2; ISO 27001; annual penetration tests; and/or red/blue team tests.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including the risk factor titled: <i style="font-style:italic;">Cyber-attacks, failures in or interruptions of, or other compromise of our information technology systems, or those of third parties with whom we work, or our data could result in adverse consequences that materially affect our business, including without limitation, regulatory investigations or actions, litigation, fines and penalties, information theft, data corruption, harm to our reputation and brand, significant disruption of our business operations and other adverse consequences</i>. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">we implement and maintain risk management processes designed to protect the confidentiality, integrity, and availability of our Information Assets and mitigate harm to our business.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Governance</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our cybersecurity risk management strategy relies on input from management, including our Vice President, Head of Computational &amp; Structural Science, who reports directly to our Chief Technology Officer, and has over 10 years of experience in developing and implementing cybersecurity strategies for companies in the biopharmaceutical industry, as well as our Chief Financial Officer and Chief Legal Officer and General Counsel. We have also formed an Information Risk Assessment Committee, or IRAC, consisting of senior members of the finance, legal, operations and information technology functions, to oversee the management of information security as a whole, including integrating cybersecurity considerations into the company&#8217;s overall risk management strategy, and for communicating key priorities to employees. The IRAC meets on a regular basis, generally quarterly, to discuss cybersecurity risk and to review our cybersecurity program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our incident response team, which includes, but is not limited to, our Vice President, Head of Computational &amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer<span style="white-space:pre-wrap;">. In addition, our incident response processes include reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management, including the IRAC, is also responsible for approving budgets, helping prepare for cybersecurity incidents, responding to cybersecurity incidents, approving cybersecurity policies and procedures, reviewing audit reports, and reporting to the board of directors.<span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our board of directors oversees our risk management strategy with respect to cybersecurity threats.  </span>The board, through its Audit Committee, holds regular meetings, at least quarterly, to discuss issues including our cybersecurity threats. The meetings involve presentations and reports from our management, including our Vice President, Head of Computational &amp; Structural Science, concerning our significant cybersecurity threats and risks and the processes we have implemented to address them. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Audit Committee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The board, through its Audit Committee, holds regular meetings, at least quarterly, to discuss issues including our cybersecurity threats. The meetings involve presentations and reports from our management<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our cybersecurity risk management strategy relies on input from management, including our Vice President, Head of Computational &amp; Structural Science, who reports directly to our Chief Technology Officer, and has over 10 years of experience in developing and implementing cybersecurity strategies for companies in the biopharmaceutical industry, as well as our Chief Financial Officer and Chief Legal Officer and General Counsel. We have also formed an Information Risk Assessment Committee, or IRAC, consisting of senior members of the finance, legal, operations and information technology functions, to oversee the management of information security as a whole, including integrating cybersecurity considerations into the company&#8217;s overall risk management strategy, and for communicating key priorities to employees. The IRAC meets on a regular basis, generally quarterly, to discuss cybersecurity risk and to review our cybersecurity program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our incident response team, which includes, but is not limited to, our Vice President, Head of Computational &amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer<span style="white-space:pre-wrap;">. In addition, our incident response processes include reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management, including the IRAC, is also responsible for approving budgets, helping prepare for cybersecurity incidents, responding to cybersecurity incidents, approving cybersecurity policies and procedures, reviewing audit reports, and reporting to the board of directors.<span style="white-space:pre-wrap;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Chief Technology OfficerVice President, Head of Computational &amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity risk management strategy relies on input from management, including our Vice President, Head of Computational &amp; Structural Science, who reports directly to our Chief Technology Officer, and has over 10 years of experience in developing and implementing cybersecurity strategies for companies in the biopharmaceutical industry, as well as our Chief Financial Officer and Chief Legal Officer and General Counsel.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our incident response team, which includes, but is not limited to, our Vice President, Head of Computational &amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer<span style="white-space:pre-wrap;">. In addition, our incident response processes include reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management, including the IRAC, is also responsible for approving budgets, helping prepare for cybersecurity incidents, responding to cybersecurity incidents, approving cybersecurity policies and procedures, reviewing audit reports, and reporting to the board of directors.<span style="white-space:pre-wrap;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642170912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and research and development incentives receivable, share-based compensation expense, valuation of right-of-use assets and liabilities, gain on extinguishment of research and development funding liability and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock', window );">Significant risks and uncertainties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant risks and uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company currently operates in a period of economic uncertainty which has been significantly impacted by domestic and global monetary and fiscal policy, geopolitical conflicts such as the ongoing wars involving Ukraine and Israel, inflation and interest rates, and fluctuations in monetary exchange rates. While the Company has experienced limited financial impacts at this time, the Company continues to monitor these factors and events and the potential effects each may have on the Company&#8217;s business, financial condition, results of operations and growth prospects. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency and currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The reporting currency of the Company is the U.S. Dollar (&#8220;USD&#8221;). The functional currency of Bicycle Therapeutics plc&#8217;s wholly owned non-U.S. subsidiaries, BicycleTx Limited and BicycleRD Limited, is the British Pound Sterling, and the functional currency of its U.S. subsidiary, Bicycle Therapeutics Inc., is the USD. The functional currency of the Company&#8217;s subsidiaries is the same as the local currency. Monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in general and administrative expense in the consolidated statements of operations and comprehensive loss as incurred. The Company recorded foreign exchange losses of $0.7 million, $0.6 million and $0.6 million for the years ended December 31, 2024, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company translates the assets and liabilities of its non-U.S. subsidiaries into USD at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a foreign currency translation adjustment, which is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">included in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive income (loss).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk and of significant suppliers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. The Company diversifies its cash and cash equivalents in multiple financial institutions and in money market funds that are primarily invested in U.S. Treasury securities that are backed by the U.S. government and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships and investments in money market funds invested in U.S. Treasury securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had no accounts receivable. For the years ended December&#160;31, 2024, 2023, and 2022, the Company&#8217;s revenue has primarily been generated from collaboration agreements with Bayer Consumer Care AG (&#8220;Bayer&#8221;), Novartis Pharma AG (&#8220;Novartis&#8221;), Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;), Genentech, Inc. (&#8220;Genentech&#8221;) and AstraZeneca AB (&#8220;AstraZeneca&#8221;) (Note 9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on multiple vendors to manufacture clinical trial materials and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments that are readily convertible to known amounts of cash with original maturities of three&#160;months or less at date of purchase to be cash equivalents. The Company had cash equivalents of $664.9 million and $72.3 million at December&#160;31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company had $0.5 million of restricted cash related to a collateralized letter of credit in connection with the Company&#8217;s lease for office and laboratory space in Cambridge, Massachusetts, which is included within other assets in the Company&#8217;s consolidated balance sheet. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred offering costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders&#8217; equity as a reduction of proceeds generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the respective assets as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p8M7K2bjKEax4G-nyR6gbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span> to 5 years</p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or useful life</p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 to 5 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for property and equipment not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. To date, there have been no significant asset retirements. Expenditures for repairs and maintenance are charged to expense as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss may be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any material impairment losses on long-lived assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company&#8217;s assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#160;&#8212; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#160;&#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash, cash equivalents and restricted cash, research and development incentives receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. As of December 31, 2023, the carrying value of the debt approximated its fair value, which was determined using unobservable Level 3 inputs, including quoted interest rates from a lender for borrowings with similar terms. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt issuance costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Debt issuance costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Debt issuance costs consist of certain third-party legal expenses and payments made to secure commitments under certain debt financing arrangements. These amounts are recorded as a reduction to the carrying value of the associated debt and are recognized as interest expense over the period of the financing arrangement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and geographic information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment and geographic information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of a business for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates in two geographic regions: the United&#160;Kingdom and the United&#160;States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional segment information, see Note&#160;15, &#8220;Segments and geographic information.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases are accounted for in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, <i style="font-style:italic;">Leases </i>(&#8220;ASC 842&#8221;). The Company determines if an arrangement is or contains a lease at inception. Assets and liabilities related to operating leases are included in operating lease right of use (&#8220;ROU&#8221;) assets, other current liabilities, and operating lease liabilities in the Company&#8217;s consolidated balance sheets. Assets and liabilities related to finance leases are included in property and equipment, net, accrued expenses and other current liabilities, and other long-term liabilities in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use and control an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The ROU asset also includes lease payments made before the lease commencement date and excludes any lease incentives. The Company identifies and assesses the following significant assumptions in recognizing the ROU assets and corresponding lease liabilities: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected lease term</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; The expected lease term includes both contractual lease periods and, when applicable, periods covered by an option to extend the lease when it is reasonably certain that the Company will exercise the extension option, or cancelable option periods when it is reasonably certain that the Company would not exercise such cancelation option.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Incremental borrowing rate</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available on the commencement date in determining the present value of lease payments. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimates the incremental borrowing rate by comparing interest rates available in the market for similar borrowings and third-party quotations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Lease and non-lease components</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; The components of a lease shall be split into three categories, if applicable: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must then be allocated based on fair values to the lease components and non-lease components. The Company&#8217;s operating leases for its facilities and finance leases for property and equipment may have both lease components and non-lease components for which the Company has elected to apply the practical expedient to account for each lease component and related non-lease component as one single component. The lease component results in a ROU asset being recorded on the consolidated balance sheets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For operating leases, lease expense for lease payments is considered operating lease cost and is recognized on a straight-line basis over the lease term. Variable payments for other operating costs, which may be billed based on both usage and as a percentage of the Company&#8217;s share of total square footage, are considered variable lease cost and are recognized in the period in which the costs are incurred. For finance leases, amortization expense related to finance lease ROU assets is recognized on a straight-line basis over the earlier of the useful life of the ROU asset or the lease term and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interest expense is recognized based on the effective interest method using the Company&#8217;s incremental borrowing rate. Operating, variable and finance lease cost are recorded as a component of research and development expenses and general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The terms of these arrangements may include (i)&#160;performing research and development services using the Company&#8217;s bicyclic peptide screening platform with the goal of identifying and/or optimizing compounds for further development and commercialization, (ii) the transfer of intellectual property rights (licenses), or (iii) options to obtain additional research and development services or licenses for additional targets, or to optimize product candidates, upon the payment of option fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; payments for research and development services and reimbursement of certain expenses incurred; fees upon the exercise of options to obtain additional services or licenses; payments based upon the achievement of defined collaboration objectives; future regulatory and sales-based milestone payments; and royalties on net sales of future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with ASC Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC&#160;606&#8221;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, and financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC&#160;606, it performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each performance obligation based on estimated relative standalone selling prices, and measuring progress towards the satisfaction of each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once a contract is determined to be within the scope of ASC&#160;606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations at contract inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. The promised goods or services in the Company&#8217;s contracts with customers primarily consist of license rights to the Company&#8217;s intellectual property, research and development services, options to acquire additional research and development services, and options to obtain additional licenses, such as a commercialization license for a potential product candidate. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources, and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the collaboration partner to develop the intellectual property on their own and whether the required expertise is readily available. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate variable consideration to include in the transaction price based on which method better predicts the amount of consideration expected to be received. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. The initial transaction price of a contract does not include amounts associated with customer option payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the transaction price is determined, it is allocated to the identified performance obligations based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, probabilities of technical and regulatory success and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an input method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i> If a license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from portion of the transaction price allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, such as research and development services and a research license, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development services:</i> The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Customer options:</i> A customer&#8217;s right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide, and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or at a discount. Optional future goods and services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. If optional future goods and services include a material right, they are accounted for as performance obligations. The Company determines an estimated standalone selling price of any material rights for the purpose of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">allocating the transaction price. The Company considers factors such as the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone payments:</i> The Company&#8217;s collaboration agreements may include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net loss in the period of adjustment. Milestone payments that may only be achieved after the exercise of a customer option are excluded from the initial determination of the transaction price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company&#8217;s collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company receives payments from customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional, such as when the Company has a contractual right to payment per the terms of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional information regarding the Company&#8217;s accounting for collaboration revenue, see Note&#160;9, &#8220;Significant agreements.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, facilities costs, depreciation, materials and laboratory supplies, and external costs of outside vendors engaged to conduct preclinical development and clinical development activities, as well as costs to manufacture clinical trial materials. Facilities costs primarily include the allocation of rent and utilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized until the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock', window );">Research and manufacturing contract costs and accruals</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has entered into various research and development and manufacturing contracts, including contracts with respect to preclinical studies and clinical trials, with companies both inside and outside of the United&#160;States. These agreements are generally cancelable with 90&#160;days or less notice, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research and development and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock', window );">Research and development incentives and receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development incentives and receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company, through its subsidiaries in the U.K., receives reimbursements of certain research and development expenditures as part of a U.K. government&#8217;s research and development tax reliefs program. Under the Small and Medium-Sized Enterprises (&#8220;SME&#8221;) R&amp;D Tax Relief program, the Company is able to surrender trading losses that arise from qualifying research and development expenses incurred by the Company&#8217;s subsidiaries in the United&#160;Kingdom for a cash rebate of up to 33.35% of qualifying expenditure incurred prior to April 1, 2023, and up to 18.6% of qualifying expenditure incurred thereafter. Amendments to the U.K. R&amp;D tax credit regime included in Finance Act 2024, which was enacted in February 2024, increased the cash rebate that may be claimed to 26.97% of qualifying expenditure, retroactively applied to qualifying expenditures incurred after April 1, 2023, if the Company qualifies as &#8220;R&amp;D intensive&#8221; for an accounting period (broadly, a loss making SME whose relevant R&amp;D expenditure represents, for accounting periods beginning on or after April 1, 2023, 40%, or, for accounting periods beginning on or after April 1, 2024, 30%, of its total expenditure for that accounting period). The Company was an R&amp;D intensive SME for the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and development incentives as a reduction to research and development expenses in the consolidated statements of operations and comprehensive loss, as the research and development tax credits are not dependent on us generating future taxable income, the Company&#8217;s ongoing tax status, or tax position. The research and development incentives receivable represent an amount due in connection with the above program. The Company recorded a reduction to research and development expense of $43.1 million for the year ended December 31, 2024, including the impact of an increase to U.K. R&amp;D tax credit reimbursement rates enacted with Finance Act 2024 retroactively applied to qualifying expenditures incurred after April 1, 2023. The Company recorded a reduction to research and development expense of $23.5 million and $19.3&#160;million during the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend', window );">Patent costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with preparing, filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures all equity awards granted to employees and directors based on the fair value on the date of grant. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with only service-based vesting conditions using the straight-line method. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For share-based awards granted to non-employee consultants, the measurement date is the date of grant. The compensation expense is then recognized over the requisite service period, which is the vesting period of the respective award, without subsequent changes in the fair value of the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The fair value of each restricted share award is based on the fair value of the Company&#8217;s shares, less any applicable purchase price. The fair value of each share option is estimated using the Black-Scholes option-pricing model, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which requires inputs based on certain subjective assumptions, including the fair value of shares, the expected share price volatility, the expected term of the award, the risk-free interest rate and expected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to 2022, due to a lack of company-specific historical volatility data, the Company&#8217;s expected volatility was calculated based on reported volatility data for a representative group of publicly traded companies for which historical information was available. The historical volatility was calculated based on a period of time commensurate with the assumption used for the expected term. During 2022, the Company began to estimate its volatility by using a blend of its stock price history for the length of time it has market data for its stock and the historical volatility of similar public companies for the expected term of each grant. The Company continues to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its share-based awards. The Company uses the remaining contractual term for the expected life of non-employee awards. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll or service costs are classified.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; equity that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation as a component of other comprehensive loss in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential loss range is probable and reasonably estimable under the provisions of ASC Topic 450, <i style="font-style:italic;">Contingencies</i>. The Company expenses costs as incurred in relation to such loss contingencies as general and administrative expense within the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the (benefit from) provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that will more likely than not be realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period, including potential dilutive ordinary shares assuming the dilutive effect of ordinary share equivalents. In periods in which the Company reported a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently adopted accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2023, the FASB issued ASU No. 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures</i>, which requires disclosure of incremental segment information on an interim and annual basis. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, and requires retrospective adoption to all prior periods presented in the consolidated financial statements. The adoption of ASU 2023-07 had no impact on the Company&#8217;s reportable segments identified and additional required disclosures have been included in Note 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements not yet adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, <i style="font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40)</i>, which requires more detailed disclosures about specified categories of expenses included in certain expense captions presented on the face of the consolidated statements of operations and comprehensive loss, including employee compensation, depreciation and amortization. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to all prior periods presented. The Company is currently evaluating the impact of the adoption of ASU No. 2024-03 on its consolidated financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740) Improvements to Income Tax Disclosures</i>, which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 is effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its consolidated financial statement disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy Research and development incentives and receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy Research and manufacturing contract costs and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of policy for significant risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241637986256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of estimated useful lives of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p8M7K2bjKEax4G-nyR6gbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span> to 5 years</p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or useful life</p></td></tr><tr><td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 years</p></td></tr><tr><td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 to 5 years</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241637941904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,554</p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,000</p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 532</p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 822</p></td></tr><tr><td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 28,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,908</p></td></tr><tr><td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,393)</p></td></tr><tr><td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,515</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241637978848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,394</p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,839</p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,143</p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KW1rNIXqDU6mr2igGNJAXQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of operating lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,876</p></td></tr><tr><td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WTohRhZpUkiEgaVCaOLomQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of finance lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 257</p></td></tr><tr><td style="vertical-align:bottom;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 31,509</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639729232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long term debt instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Debt consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term loan payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End of term charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 946</p></td></tr><tr><td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (248)</p></td></tr><tr><td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carrying value of term loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,698</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241637976512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,394</p></td></tr><tr><td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,385</p></td></tr><tr><td style="vertical-align:bottom;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 32,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,779</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of share option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December 31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,469,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,920</p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,438,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (554,596)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (604,561)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,748,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,559</p></td></tr><tr><td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested and expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,748,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,559</p></td></tr><tr><td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,359,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,559</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to determine the fair value of share options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 77.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 82.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 82.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of restricted ordinary share award activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 326,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37.40</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 617,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.26</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested and settled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (141,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37.76</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested and deferred<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.15</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 674,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.96</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested but subject to deferred settlement at December 31, 2024<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18.07</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.67</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">The Company granted certain RSUs to the Company&#8217;s non-employee directors which provided for deferred settlement of the RSUs to a specified date following the first to occur of (i) the date of the director&#8217;s separation from service, (ii) the date of the director&#8217;s disability, (iii) the date of the director&#8217;s death or (iv) the date of a change in control event.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241643276960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of revenue recognized from collaboration arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the revenue recognized from the Company&#8217;s collaboration arrangements in the consolidated statements of operations and comprehensive loss (in&#160;thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Collaboration revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bayer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ionis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,734</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,347</p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Genentech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,565</p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dementia Discovery Fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 386</p></td></tr><tr><td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">AstraZeneca</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,165</p></td></tr><tr><td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,463</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of changes in the balances of the Company's contract assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents changes in the balances of the Company&#8217;s contract liabilities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impact&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Bayer collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (561)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39,960</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Novartis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 50,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 44,073</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Ionis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,881)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,587</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Genentech collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,840)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,038</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 135,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 101,658</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Beginning&#160;Balance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impact&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ending Balance</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exchange</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bayer collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,160)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43,618</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Novartis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,909)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 50,008</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Ionis collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,734)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,464</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Genentech collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 39,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,969)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,104</p></td></tr><tr><td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">AstraZeneca collaboration deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 61,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 135,194</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of recognition of revenues as a result of changes in contract asset and contract liability balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue recognized in the period from:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on proportional performance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,358</p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on expiration of material rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,433</p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue recognized based on changes in transaction price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 672</p></td></tr><tr><td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,463</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock', window );">Summary of allocation of transaction price to separate performance obligations</a></td>
<td class="text">Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Allocation of</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Transaction Price</b></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,976</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Material right associated with limited substitution rights for either the first or second target</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,527</p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,691</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,703</p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Material right for the option to expand the collaboration to include a third target and the underlying additional option rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,603</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,500</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock', window );">Summary of allocation of transaction price to separate performance obligations</a></td>
<td class="text">Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,008</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with limited substitution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,466</p></td></tr><tr><td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with options to progress development candidates incorporating radionuclides</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,684</p></td></tr><tr><td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with options to progress development candidates not incorporating radionuclides</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,842</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock', window );">Summary of allocation of transaction price to separate performance obligations</a></td>
<td class="text">Based on the relative standalone selling price, the initial allocation of the transaction price to the separate performance obligations was as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Combined licenses and research and discovery performance obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,100</p></td></tr><tr><td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Four material rights associated with credits for IND Acceptance fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:bottom;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock', window );">Summary of allocation of transaction price to separate performance obligations</a></td>
<td class="text">Based on the relative standalone selling price, the allocation of the transaction price to the separate performance obligations is as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Allocation&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction&#160;Price</b></p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genentech Collaboration Program #1 Performance Obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,019</p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genentech Collaboration Program #2 Performance Obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,037</p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Specified Targeting Arm Material Right Arm for Genentech Collaboration Program #1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 352</p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights associated with the LSR Go Option for Collaboration Programs #1 and #2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,400</p></td></tr><tr><td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Material rights associated with limited substitution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,187</p></td></tr><tr><td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two material rights for Expansion Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,005</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the tabular disclosure of recognition of revenues as a result of changes in contract asset and contract liability balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the tabular disclosure of allocation of transaction price to separate performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_BayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726194176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock', window );">Schedule of components of net loss before tax provision from income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of net loss before income tax provision are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United&#160;Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (182,980)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (116,275)</p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United&#160;States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,034</p></td></tr><tr><td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (173,796)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,241)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the benefit for income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the (benefit from) provision for income taxes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,048</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (669)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,404</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,452</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income tax (benefit) provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,772)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,111)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,454)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (865)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred income tax (benefit) provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,976)</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total (benefit from) provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,524)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the provision (benefit) for income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(Benefit from) provision for income taxes at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increases (decreases) resulting from:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net losses surrendered for research credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of statutory rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impact of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the Company's current and deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 81,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 66,555</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,680</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,577</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation &amp; amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,742</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 111,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88,554</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,389)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,201)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,389)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (99,672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (80,274)</p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,891</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of net income (loss) before tax provision from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726234528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the Company&#8217;s lease expense are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,790</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,643</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the maturities of the Company&#8217;s lease liabilities as of December 31, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ending December 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 192</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (646)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (224)</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 992</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_u8XOnpcF106LEEpbmUkWMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Less: current lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (175)</p></td></tr><tr><td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long term lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241637923728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss attributable to ordinary shareholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169,031)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (180,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (112,717)</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average ordinary shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 58,207,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,592,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,660,659</p></td></tr><tr><td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.80)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 716,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 326,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 187,725</p></td></tr><tr><td style="vertical-align:top;width:66.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,748,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,469,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,898,888</p></td></tr><tr><td style="vertical-align:bottom;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,464,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,796,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,086,613</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726189488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and geographic information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of company's single operating segment including significant segment expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents information about the Company&#8217;s single operating segment, including significant segment expenses, for the years ended December 31, 2024, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,463</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Significant segment expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Zelenectide pevedotin (Nectin-4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 82,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44,135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,054</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">BT5528 (EphA2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,702</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">BT1718 (MT1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 692</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bicycle tumor-targeted immune cell agonists</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,268</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Discovery, platform and other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 37,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,811</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Employee and contractor related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 58,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 31,346</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,394</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,155</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development incentives and government grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,459)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,813)</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 172,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 156,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 81,609</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel-related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,948</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,836</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other general and administrative costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,783</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,385</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Effect of foreign exchange rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 555</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 72,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 60,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 49,507</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total significant segment expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 245,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 216,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 131,116</p></td></tr><tr><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,936</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (169,031)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (180,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (112,717)</p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Other segment items include interest and other income, interest expense, loss on extinguishment of debt, gain on extinguishment of research and development funding liability and (benefit from) provision for income taxes.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of long-lived assets, including operating lease right-of-use assets, held in different geographic regions</a></td>
<td class="text">Information about the Company&#8217;s long-lived assets, including operating lease ROU assets, held in different geographic regions is presented in the table below (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,486</p></td></tr><tr><td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,198</p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,684</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639644096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and basis of presentation - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the business and basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 879,520<span></span>
</td>
<td class="nump">$ 526,423<span></span>
</td>
<td class="nump">$ 339,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">169,031<span></span>
</td>
<td class="nump">180,664<span></span>
</td>
<td class="nump">$ 112,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (680,791)<span></span>
</td>
<td class="num">$ (511,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241738787120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Foreign currency and currency translation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="num">$ (0.7)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639613984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Concentrations of credit risk and of significant suppliers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726071168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Cash and cash equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 664,900<span></span>
</td>
<td class="nump">$ 72,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash included in other assets</a></td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241640051920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Property and equipment, Geographic (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfGeographicRegionsInWhichOperating', window );">Number of geographic regions</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfGeographicRegionsInWhichOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of geographic regions in which the entity operates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfGeographicRegionsInWhichOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639904640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Research and development incentives and receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development incentives and receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ReductionOfResearchAndDevelopmentExpense', window );">Reduction of research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.1<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 19.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member', window );">Certain research and development expenditures incurred prior to April 1, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development incentives and receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses', window );">Percentage of surrenderable losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member', window );">Certain research and development expenditures incurred thereafter April 1, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development incentives and receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses', window );">Percentage of surrenderable losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member', window );">Certain research and development expenditures incurred April 1, 2024 and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development incentives and receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses', window );">Percentage of surrenderable losses</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure', window );">Percentage of total expenditure</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ReductionOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction of research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ReductionOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tax credit on total expenditure during the period that arise from qualifying research and development expenses incurred by the Company's subsidiaries in the United Kingdom.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tax credit on surrenderable trading losses that arise from qualifying research and development expenses incurred by the Company's subsidiaries in the United Kingdom.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642092336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Share based compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639927440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 72.3<span></span>
</td>
<td class="nump">$ 664.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities at fair value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">72.3<span></span>
</td>
<td class="nump">664.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Market funds</a></td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">$ 664.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDepositsAtCarryingValue', window );">Term deposits</a></td>
<td class="nump">$ 50.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_TermDepositMaturityPeriod', window );">Term deposit maturity period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_TermDepositMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity period of term deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_TermDepositMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241643107888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">28,465<span></span>
</td>
<td class="nump">$ 27,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(18,949)<span></span>
</td>
<td class="num">(13,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">9,516<span></span>
</td>
<td class="nump">14,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization expense of property and equipment under finance leases</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">14,658<span></span>
</td>
<td class="nump">15,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">10,903<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 1,290<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639613456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 16,272<span></span>
</td>
<td class="nump">$ 13,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">14,978<span></span>
</td>
<td class="nump">11,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">4,196<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">$ 5,328<span></span>
</td>
<td class="nump">$ 4,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">41,246<span></span>
</td>
<td class="nump">$ 31,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and Development Expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring costs</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through and payable for external research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642136272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 09, 2024</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_DebtInstrumentEndOfTermChargeRate', window );">End term charge rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued and unpaid interest</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_DebtEndOfTermCharge', window );">End-of-term charge</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_DebtInstrumentPrepaymentCharges', window );">Prepayment charge</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Total aggregate payment</a></td>
<td class="nump">$ 31,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bcyc_InitialTermLoanMember', window );">Initial Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_DebtEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents an end of term charge related to debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_DebtEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_DebtInstrumentEndOfTermChargeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate at which entity has to pay end term charge on the principle amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_DebtInstrumentEndOfTermChargeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_DebtInstrumentPrepaymentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses for prepayment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_DebtInstrumentPrepaymentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcyc_InitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcyc_InitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcyc_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcyc_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241637903136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_DebtEndOfTermCharge', window );">End of term charge</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_DebtEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents an end of term charge related to debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_DebtEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241732253872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary shares (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Ordinary shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfVotePerShare', window );">Vote per ordinary share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="nump">155,876,645<span></span>
</td>
<td class="nump">59,612,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vote per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241638206432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary shares - Share Purchase Agreement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 28, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 17, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2024 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 17, 2023 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Jul. 17, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,061,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,431,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,061,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,431,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds before discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544,127<span></span>
</td>
<td class="nump">$ 249,345<span></span>
</td>
<td class="nump">$ 5,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,127<span></span>
</td>
<td class="nump">249,345<span></span>
</td>
<td class="nump">$ 5,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,873,893<span></span>
</td>
<td class="nump">69,061,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,431,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,579,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds before discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,933,706<span></span>
</td>
<td class="nump">12,384,706<span></span>
</td>
<td class="nump">181,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember', window );">Non voting ordinary shares | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,492,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,492,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcyc_VotingOrdinarySharesMember', window );">Voting ordinary shares | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,569,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,569,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_AtMarketOfferingMember', window );">At the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds before discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,300<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,200<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_AtMarketOfferingMember', window );">At the market offering | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,176<span></span>
</td>
<td class="nump">181,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds before discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,117,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | American Depositary Shares | Option on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Non voting ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,705,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_InvestorsPurchaseAgreementMember', window );">Investors Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds before discounts and commissions | $</a></td>
<td class="nump">$ 555,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and offering expenses | $</a></td>
<td class="nump">11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance, net of issuance costs | $</a></td>
<td class="nump">$ 544,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_InvestorsPurchaseAgreementMember', window );">Investors Purchase Agreement | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764,705<span></span>
</td>
<td class="nump">6,764,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_InvestorsPurchaseAgreementMember', window );">Investors Purchase Agreement | Non voting ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,169,001<span></span>
</td>
<td class="nump">19,169,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcyc_VotingOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcyc_VotingOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcyc_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcyc_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_InvestorsPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcyc_InvestorsPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241643246192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>M </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,748,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,469,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">1,577,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Percentage of annual increase in reserves on total number of ordinary shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_InducementPlan2024Member', window );">2024 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_InducementPlan2024Member', window );">2024 Inducement Plan | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_InducementPlan2024Member', window );">2024 Inducement Plan | Stock option | First anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_InducementPlan2024Member', window );">2024 Inducement Plan | Stock option | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_InducementPlan2024Member', window );">2024 Inducement Plan | Stock option | Employee | Remaining equal installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of equal monthly installments for vesting remaining awards | M</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,773,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,374<span></span>
</td>
<td class="nump">2,378,465<span></span>
</td>
<td class="nump">1,886,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Percentage of annual increase in reserves on total number of ordinary shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,211,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Stock option | Non-employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments', window );">Number of equal quarterly installments for vesting remaining awards | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Stock option | First anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Stock option | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Stock option | Employee | Remaining equal installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of equal monthly installments for vesting remaining awards | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Stock option three year vest | Non-employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments', window );">Number of equal annual installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Restricted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio', window );">Right to receive upon vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber', window );">RSUs outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Restricted ordinary shares | Non-employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfQuarterlyInstallments', window );">Number of quarterly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Restricted ordinary shares | First anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member', window );">2020 Plan | Restricted ordinary shares | Remaining equal installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments', window );">Number of equal quarterly installments for vesting remaining awards | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2019Member', window );">2019 Plan | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,773,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2019Member', window );">2019 Plan | Minimum | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2019Member', window );">2019 Plan | Maximum | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_PreIpoShareOptionsAndRestrictedSharesMember', window );">Pre-IPO Share Options and restricted shares | Stock option | First anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcyc_PreIpoShareOptionsAndRestrictedSharesMember', window );">Pre-IPO Share Options and restricted shares | Stock option | Employee | Remaining equal installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of equal monthly installments for vesting remaining awards | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is representing number of quarterly installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual increase in reserves on total number of ordinary shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of vested and non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued upon conversion of restricted share units under share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equal annual installments for remaining awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equal monthly installments for remaining awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equal quarterly installments for remaining awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcyc_InducementPlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcyc_InducementPlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcyc_ShareBasedPaymentArrangementThreeYearVestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcyc_ShareBasedPaymentArrangementThreeYearVestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcyc_PreIpoShareOptionsAndRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcyc_PreIpoShareOptionsAndRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241643881648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Share based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 38,081<span></span>
</td>
<td class="nump">$ 32,477<span></span>
</td>
<td class="nump">$ 26,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">19,424<span></span>
</td>
<td class="nump">15,581<span></span>
</td>
<td class="nump">10,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 18,657<span></span>
</td>
<td class="nump">$ 16,896<span></span>
</td>
<td class="nump">$ 16,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241641054880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Share Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 38,081<span></span>
</td>
<td class="nump">$ 32,477<span></span>
</td>
<td class="nump">$ 26,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding number of shares at beginning</a></td>
<td class="nump">7,469,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,438,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(554,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(604,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding number of shares at end</a></td>
<td class="nump">8,748,726<span></span>
</td>
<td class="nump">7,469,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, vested and expected to vest</a></td>
<td class="nump">8,748,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, options exercisable</a></td>
<td class="nump">5,359,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price at beginning</a></td>
<td class="nump">$ 23.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">19.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">13.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">27.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price at ending</a></td>
<td class="nump">22.41<span></span>
</td>
<td class="nump">$ 23.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest</a></td>
<td class="nump">22.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercisable</a></td>
<td class="nump">$ 21.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract', window );"><strong>Weighted Average Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term, outstanding</a></td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
<td class="text">6 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term, vested and expected to vest</a></td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term ,options exercisable</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding</a></td>
<td class="nump">$ 9,559<span></span>
</td>
<td class="nump">$ 21,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">9,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable</a></td>
<td class="nump">$ 9,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 13.52<span></span>
</td>
<td class="nump">$ 19.36<span></span>
</td>
<td class="nump">$ 31.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 30,200<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639766480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details) - Stock option - Employees and directors - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">82.90%<span></span>
</td>
<td class="nump">82.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense related to the unvested employee and director</a></td>
<td class="nump">$ 48.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Unrecognized compensation cost expected to be recognized over a weighted average period</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bcyc_EmployeeAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bcyc_EmployeeAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241644309280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Restricted Share Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 38,081<span></span>
</td>
<td class="nump">$ 32,477<span></span>
</td>
<td class="nump">$ 26,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted ordinary shares | 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Underlying RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted ordinary shares at beginning</a></td>
<td class="nump">326,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">617,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod', window );">Vested and settled</a></td>
<td class="num">(141,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod', window );">Vested and deferred</a></td>
<td class="num">(42,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(86,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted ordinary shares at ending</a></td>
<td class="nump">674,262<span></span>
</td>
<td class="nump">326,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement', window );">Unvested restricted ordinary shares, Vested but subject to deferred settlement</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber', window );">Outstanding restricted ordinary shares at ending</a></td>
<td class="nump">716,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value unvested, Beginning Balance</a></td>
<td class="nump">$ 37.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">18.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue', window );">Vested and settled</a></td>
<td class="nump">37.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue', window );">Vested and deferred</a></td>
<td class="nump">18.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">22.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value unvested, Ending Balance</a></td>
<td class="nump">22.96<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested but subject to deferred settlement</a></td>
<td class="nump">18.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding at Ending Balance</a></td>
<td class="nump">$ 22.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of employee restricted share awards vested</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average Period</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of vested and non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested and deferred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee vested and deferred during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested and settled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee vested and settled during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period, subject to deferred settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right, subject to deferred settlement during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcyc_ShareOptionPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241641114288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Collaboration revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 35,275<span></span>
</td>
<td class="nump">$ 26,976<span></span>
</td>
<td class="nump">$ 14,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">8,161<span></span>
</td>
<td class="nump">1,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">8,881<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">9,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 14,840<span></span>
</td>
<td class="nump">11,969<span></span>
</td>
<td class="nump">3,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_DementiaDiscoveryFundCollaborationAgreementMember', window );">Dementia Discovery Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">$ 1,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_BayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_DementiaDiscoveryFundCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_DementiaDiscoveryFundCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241644156544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Bayer Collaboration Agreement (Details)<br> $ in Thousands, &#163; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 04, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 04, 2023 </div>
<div>GBP (&#163;) </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,275<span></span>
</td>
<td class="nump">$ 26,976<span></span>
</td>
<td class="nump">$ 14,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,658<span></span>
</td>
<td class="nump">135,194<span></span>
</td>
<td class="nump">61,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementNumberOfTargets', window );">Number of collaboration targets | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 583.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach', window );">Period to terminate agreement upon written notice for uncured material breach</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer', window );">Number of business days to terminate agreement upon non payment by Bayer</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations', window );">Estimated amount payable to CROs</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed', window );">Expected period for satisfaction of performance obligations</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaterialRightsExerciseOrExpiryTerm', window );">Material rights exercise period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,960<span></span>
</td>
<td class="nump">$ 43,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment', window );">Number of candidate compounds into further development | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer', window );">Threshold period to terminate agreement upon written notice by Bayer</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementNumberOfTargets', window );">Number of collaboration targets | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable', window );">Milestone payments receivable | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 194.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer', window );">Threshold period to terminate agreement upon written notice by Bayer</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer Collaboration Agreement | Development and regulatory milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable', window );">Milestone payments receivable | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer Collaboration Agreement | Across all three potential target programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable', window );">Milestone payments receivable | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 534.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementNumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration targets under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementNumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory, development, commercialization or sales milestone payments, receivable by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tiered sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of candidate compounds into further development under the collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront cash payment received from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of reimbursement payable for services provided by Contract Research Organizations (CROs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_MaterialRightsExerciseOrExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of material rights exercised or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_MaterialRightsExerciseOrExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents period over which performance obligations will be performed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allocated determined transaction price under revenue recognition arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days to terminate agreement upon non payment by Bayer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period to terminate agreement upon written notice by Bayer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period to terminate agreement upon written notice for uncured material breach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_BayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AchievementOfMilestoneAxis=bcyc_MilestoneAcrossAllPotentialTargetProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AchievementOfMilestoneAxis=bcyc_MilestoneAcrossAllPotentialTargetProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241641991552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details) - Bayer Collaboration Agreement<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 04, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 47,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfCombinedPerformanceObligations', window );">Combined performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 14,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Material right associated with limited substitution rights for either the first or second target</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 1,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfMaterialRights', window );">Number of material rights | item</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 14,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfMaterialRights', window );">Number of material rights | item</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 8,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Material right for the option to expand the collaboration to include a third target and the underlying additional option rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 7,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfCombinedPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of combined performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfCombinedPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfMaterialRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of material rights usually associated with an option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfMaterialRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allocated determined transaction price under revenue recognition arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_BayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642817520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Novartis Collaboration Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 27, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice', window );">Maximum days allowed for cancellation of contracts prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,275<span></span>
</td>
<td class="nump">$ 26,976<span></span>
</td>
<td class="nump">$ 14,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,658<span></span>
</td>
<td class="nump">135,194<span></span>
</td>
<td class="nump">61,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember', window );">Termination in entirety or product by product or target by target basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement', window );">Threshold period of notice required for termination of agreement</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=bcyc_CompletionOfAllMilestonesForTargetsMember', window );">Completion of all milestones for targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementNumberOfTargets', window );">Number of collaboration targets | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AdditionalResearchTerm', window );">Additional research term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable</a></td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice', window );">Maximum days allowed for cancellation of contracts prior written notice</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed', window );">Expected period for satisfaction of performance obligations</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaterialRightsExerciseOrExpiryTerm', window );">Material rights exercise period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,161<span></span>
</td>
<td class="nump">1,909<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,073<span></span>
</td>
<td class="nump">$ 50,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis | Termination based on other party's uncured material breach or insolvency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement', window );">Threshold period of notice required for termination of agreement</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis | Termination if safety or regulatory issue exists</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement', window );">Threshold period of notice required for termination of agreement</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis | Expiration of two material rights associated with limited substitution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis | Achievement of specified levels of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AdditionalResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional research term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AdditionalResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementNumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration targets under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementNumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory, development, commercialization or sales milestone payments, receivable by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tiered sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold period of notice required for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront cash payment received from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_MaterialRightsExerciseOrExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of material rights exercised or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_MaterialRightsExerciseOrExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum days allowed for cancellation of contracts prior written notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents period over which performance obligations will be performed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcyc_CompletionOfAllMilestonesForTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcyc_CompletionOfAllMilestonesForTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642741328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details) - Novartis<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 27, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_EstimatedVariableConsiderationNoLongerConstrained', window );">Amount of estimate of variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfCombinedPerformanceObligations', window );">Combined performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 18,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Two material rights associated with limited substitution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfMaterialRights', window );">Number of material rights | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 2,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Two material rights associated with options to progress development candidates incorporating radionuclides</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfMaterialRights', window );">Number of material rights | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 19,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Two material rights associated with options to progress development candidates not incorporating radionuclides</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfMaterialRights', window );">Number of material rights | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 9,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_EstimatedVariableConsiderationNoLongerConstrained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated variable consideration no longer constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_EstimatedVariableConsiderationNoLongerConstrained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfCombinedPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of combined performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfCombinedPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfMaterialRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of material rights usually associated with an option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfMaterialRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allocated determined transaction price under revenue recognition arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642809568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Ionis Evaluation and Option Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 09, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,658<span></span>
</td>
<td class="nump">$ 135,194<span></span>
</td>
<td class="nump">$ 61,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisEvaluationAndOptionAgreementMember', window );">Ionis Evaluation and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront cash payment received from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisEvaluationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisEvaluationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241640338400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Ionis Collaboration Agreement (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 09, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration', window );">Period for which research and discovery activities will be performed with no additional consideration</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="nump">$ 31.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone', window );">Number of payments of a mid-single-digit million dollar, failing to achieve the specified development diligence | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementNumberOfTargets', window );">Number of collaboration targets | item</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfYearsOverWhichRoyaltyIsPayable', window );">Number of years over which royalty is payable</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_AmendedIonisCollaborationAgreementMember', window );">Amended Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_ThirdIonisAmendmentMember', window );">Third Ionis Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementNumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration targets under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementNumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront cash payment received from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of payments of a mid-single-digit million dollar, failing to achieve the specified development diligence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfYearsOverWhichRoyaltyIsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of years over which royalty is payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfYearsOverWhichRoyaltyIsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which the company will perform research and discovery activities including a baseline level of effort for no additional consideration, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_AmendedIonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_AmendedIonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_ThirdIonisAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_ThirdIonisAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642315600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Ionis Share Purchase Agreement (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544,127<span></span>
</td>
<td class="nump">$ 249,345<span></span>
</td>
<td class="nump">$ 5,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 37,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis | Ionis Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">282,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price per share</a></td>
<td class="nump">$ 38.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_FairValueOfSharesHeld', window );">Fair value of shares held</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis | Ionis Share Purchase Agreement | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price per share</a></td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_FairValueOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_FairValueOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allocated determined transaction price under revenue recognition arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_IonisSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcyc_IonisSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642899072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Ionis Accounting Analysis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 09, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,275<span></span>
</td>
<td class="nump">$ 26,976<span></span>
</td>
<td class="nump">$ 14,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,658<span></span>
</td>
<td class="nump">135,194<span></span>
</td>
<td class="nump">61,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments', window );">Number of material rights associated with future payments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementNumberOfTargets', window );">Number of collaboration targets | item</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations', window );">Estimated amount payable to CROs</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,881<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">9,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,587<span></span>
</td>
<td class="nump">$ 12,464<span></span>
</td>
<td class="nump">$ 21,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaterialRightsExerciseOrExpiryTerm', window );">Material rights exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaterialRightsExerciseOrExpiryTerm', window );">Material rights exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis | Combined licenses and research and discovery performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis | Four material rights associated with credits for IND Acceptance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis | Ionis Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisEvaluationAndOptionAgreementMember', window );">Ionis Evaluation and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_AmendedIonisCollaborationAgreementMember', window );">Amended Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_ThirdAmendedIonisMember', window );">Third Amended Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementNumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration targets under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementNumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront cash payment received from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of reimbursement payable for services provided by Contract Research Organizations (CROs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_MaterialRightsExerciseOrExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of material rights exercised or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_MaterialRightsExerciseOrExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of material rights associated with future payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allocated determined transaction price under revenue recognition arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcyc_IonisSharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcyc_IonisSharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisEvaluationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisEvaluationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_AmendedIonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_AmendedIonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_ThirdAmendedIonisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_ThirdAmendedIonisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241633770000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Genentech Collaboration Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 21, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,658<span></span>
</td>
<td class="nump">$ 135,194<span></span>
</td>
<td class="nump">$ 61,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,275<span></span>
</td>
<td class="nump">26,976<span></span>
</td>
<td class="nump">14,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfPotentialDevelopmentCandidates', window );">Number of potential development candidates | item</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfImmunoOncologyTargets', window );">Number of immuno oncology targets | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_AdditionalNumberOfImmunoOncologyTargets', window );">Additional number of immuno oncology targets | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ExpansionFeePerAdditionalCollaborationProgram', window );">Expansion fee</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
<td class="nump">29,104<span></span>
</td>
<td class="nump">39,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,840<span></span>
</td>
<td class="nump">11,969<span></span>
</td>
<td class="nump">3,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfYearsOverWhichRoyaltyIsPayable', window );">Number of years over which royalty is payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Development milestone | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Regulatory milestone | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable</a></td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 1 Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 1 Performance Obligation | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed', window );">Period over which performance obligations will be performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaterialRightsExerciseOrExpiryTerm', window );">Material rights exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 1 Performance Obligation | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed', window );">Period over which performance obligations will be performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaterialRightsExerciseOrExpiryTerm', window );">Material rights exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 2 Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Specified Targeting Arm Material Right Arm Program One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfInitialCollaborationPrograms', window );">Number of initial collaboration programs exercised | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_OptionFeeForDevelopmentAndExploitationRights', window );">Option fee for development and exploitation rights</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Two material rights associated with the LSR Go Option for Collaboration Programs One And Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfCollaborationPrograms', window );">Number of collaboration programs | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo', window );">Number of expansion option collaboration programs | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Material rights associated with limited substitution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Two material rights for Expansion Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo', window );">Number of expansion option collaboration programs | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program One and Two Performance Obligation | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable', window );">Regulatory, and initial commercialization milestones, payments receivable</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Material rights associated with the LSR Go Option for Collaboration Programs One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 3 Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ExpansionFeePerAdditionalCollaborationProgram', window );">Expansion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable', window );">Milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationProgramAmountOfMaterialRights', window );">Material rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_EstimatedVariableConsiderationNoLongerConstrained', window );">Amount of estimate of variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 3 Performance Obligation | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed', window );">Period over which performance obligations will be performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 3 Performance Obligation | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed', window );">Period over which performance obligations will be performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Collaboration Program 4 Performance Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ExpansionFeePerAdditionalCollaborationProgram', window );">Expansion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationProgramAmountOfMaterialRights', window );">Material rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Significant agreements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AdditionalNumberOfImmunoOncologyTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of immuno oncology targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AdditionalNumberOfImmunoOncologyTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Regulatory, and initial commercialization milestones payments receivable by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory, development, commercialization or sales milestone payments, receivable by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationProgramAmountOfMaterialRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of material rights under collaboration program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationProgramAmountOfMaterialRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront cash payment received from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_EstimatedVariableConsiderationNoLongerConstrained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated variable consideration no longer constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_EstimatedVariableConsiderationNoLongerConstrained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ExpansionFeePerAdditionalCollaborationProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expansion fee to per additional collaboration program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ExpansionFeePerAdditionalCollaborationProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_MaterialRightsExerciseOrExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of material rights exercised or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_MaterialRightsExerciseOrExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of collaboration programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of expansion option programs (Dev Go option).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfImmunoOncologyTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of immuno oncology targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfImmunoOncologyTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfInitialCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of initial Genentech Collaboration Programs exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfInitialCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfPotentialDevelopmentCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Potential development candidates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfPotentialDevelopmentCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfYearsOverWhichRoyaltyIsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of years over which royalty is payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfYearsOverWhichRoyaltyIsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_OptionFeeForDevelopmentAndExploitationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid upon exercise of an option by the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_OptionFeeForDevelopmentAndExploitationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents period over which performance obligations will be performed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allocated determined transaction price under revenue recognition arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_AchievementOfMilestoneAxis=bcyc_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_AchievementOfMilestoneAxis=bcyc_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationOnePerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationOnePerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationTwoPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationTwoPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsForExpansionOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsForExpansionOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationPerformanceOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationPerformanceOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgramThreePerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgramThreePerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgram4PerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgram4PerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241635017968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Summary of Contract Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning Balance</a></td>
<td class="nump">$ 135,194,000<span></span>
</td>
<td class="nump">$ 61,873,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">3,386,000<span></span>
</td>
<td class="nump">95,960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(35,275,000)<span></span>
</td>
<td class="num">(26,976,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment', window );">Impact of Exchange Rates</a></td>
<td class="num">(1,647,000)<span></span>
</td>
<td class="nump">4,337,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">101,658,000<span></span>
</td>
<td class="nump">135,194,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerAssetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer collaboration deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning Balance</a></td>
<td class="nump">43,618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">296,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(3,393,000)<span></span>
</td>
<td class="num">(1,160,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment', window );">Impact of Exchange Rates</a></td>
<td class="num">(561,000)<span></span>
</td>
<td class="num">(222,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">39,960,000<span></span>
</td>
<td class="nump">43,618,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember', window );">Bayer collaboration deferred revenue | Deferred revenue material rights option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">31,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis collaboration deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning Balance</a></td>
<td class="nump">50,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(8,161,000)<span></span>
</td>
<td class="num">(1,909,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment', window );">Impact of Exchange Rates</a></td>
<td class="num">(774,000)<span></span>
</td>
<td class="nump">1,917,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">44,073,000<span></span>
</td>
<td class="nump">50,008,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember', window );">Novartis collaboration deferred revenue | Deferred revenue material rights option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis collaboration deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning Balance</a></td>
<td class="nump">12,464,000<span></span>
</td>
<td class="nump">21,489,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(8,881,000)<span></span>
</td>
<td class="num">(10,734,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment', window );">Impact of Exchange Rates</a></td>
<td class="num">(86,000)<span></span>
</td>
<td class="nump">749,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">3,587,000<span></span>
</td>
<td class="nump">12,464,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember', window );">Ionis collaboration deferred revenue | Deferred revenue material rights option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech collaboration deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning Balance</a></td>
<td class="nump">29,104,000<span></span>
</td>
<td class="nump">39,308,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(14,840,000)<span></span>
</td>
<td class="num">(11,969,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment', window );">Impact of Exchange Rates</a></td>
<td class="num">(226,000)<span></span>
</td>
<td class="nump">1,765,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">14,038,000<span></span>
</td>
<td class="nump">29,104,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember', window );">Genentech collaboration deferred revenue | Deferred revenue material rights option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember', window );">AstraZeneca collaboration deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,204,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment', window );">Impact of Exchange Rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in contract with customer, liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in contract with customer, liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of adjustment in contract with customer, liability due to change in foreign exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_BayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_BayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bcyc_DeferredRevenueMaterialRightsOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bcyc_DeferredRevenueMaterialRightsOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241640954384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Significant agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation', window );">Revenue recognized based on proportional performance</a></td>
<td class="nump">$ 24,266<span></span>
</td>
<td class="nump">$ 19,160<span></span>
</td>
<td class="nump">$ 12,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights', window );">Revenue recognized based on expiration of material rights</a></td>
<td class="nump">10,576<span></span>
</td>
<td class="nump">7,816<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice', window );">Revenue recognized based on changes in transaction price</a></td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability', window );">Total</a></td>
<td class="nump">$ 35,275<span></span>
</td>
<td class="nump">$ 26,976<span></span>
</td>
<td class="nump">$ 14,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized based on changes in transaction price that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized based on expiration of material rights that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized based on proportional performance that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from both the beginning balance and current period increase in contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241644151168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements - Cancer Research UK (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 04, 2024 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 13, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract', window );"><strong>Research and development arrangement obligation to repay other parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties', window );">Contingent future milestones payments under research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability', window );">Gain on extinguishment of research and development funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CancerResearchUkBtOneSevenOneEightMember', window );">BT1718</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract', window );"><strong>Research and development arrangement obligation to repay other parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties', window );">Liability from research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment', window );">Research and Development Arrangement, Upfront Cash Payment | &#163;</a></td>
<td class="nump">&#163; 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability', window );">Gain on extinguishment of research and development funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CancerResearchUkBtOneSevenOneEightMember', window );">BT1718 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract', window );"><strong>Research and development arrangement obligation to repay other parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PercentageOfTieredRoyaltyOnNetRevenue', window );">Tiered royalties (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CancerResearchUkBtOneSevenOneEightMember', window );">BT1718 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract', window );"><strong>Research and development arrangement obligation to repay other parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_PercentageOfTieredRoyaltyOnNetRevenue', window );">Tiered royalties (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the amount paid to settle and carrying amount of research and development funding liability which is extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_PercentageOfTieredRoyaltyOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tiered royalty on net revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_PercentageOfTieredRoyaltyOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the liability recorded for research and development arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents payments due upon achievement of milestones under a Research and Development arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront cash payment made on research and development arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CancerResearchUkBtOneSevenOneEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CancerResearchUkBtOneSevenOneEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241726397744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Components of net loss before tax provision from income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">United Kingdom</a></td>
<td class="num">$ (179,610)<span></span>
</td>
<td class="num">$ (182,980)<span></span>
</td>
<td class="num">$ (116,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax provision</a></td>
<td class="num">$ (173,796)<span></span>
</td>
<td class="num">$ (179,207)<span></span>
</td>
<td class="num">$ (114,241)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639765168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Components of benefit for income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax provision (benefit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="num">$ (1,180)<span></span>
</td>
<td class="nump">$ 2,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">178<span></span>
</td>
<td class="num">(669)<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision (benefit)</a></td>
<td class="nump">461<span></span>
</td>
<td class="num">(1,849)<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax (benefit) provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(3,772)<span></span>
</td>
<td class="nump">2,513<span></span>
</td>
<td class="num">(4,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,454)<span></span>
</td>
<td class="nump">793<span></span>
</td>
<td class="num">(865)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax (benefit) provision</a></td>
<td class="num">(5,226)<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="num">(4,976)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total (benefit from) provision for income taxes</a></td>
<td class="num">$ (4,765)<span></span>
</td>
<td class="nump">$ 1,457<span></span>
</td>
<td class="num">$ (1,524)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642228416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Reconciliation of benefit for income taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">(Benefit from) provision for income taxes at statutory rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Increases (decreases) resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(11.20%)<span></span>
</td>
<td class="num">(14.80%)<span></span>
</td>
<td class="num">(16.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit', window );">Net losses surrendered for research credit</a></td>
<td class="num">(14.20%)<span></span>
</td>
<td class="num">(11.10%)<span></span>
</td>
<td class="num">(6.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage', window );">Impact of statutory rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent', window );">Impact of foreign exchange rates</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic feieral statutory income tax rates to pretax income (loss) from continuing operations attributable to Impact of statutory rate change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net losses surrendered for research credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642276336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Components of the company's current and deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 81,492<span></span>
</td>
<td class="nump">$ 66,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">3,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">21,035<span></span>
</td>
<td class="nump">15,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_DeferredTaxAssetDepreciationAndAmortization', window );">Depreciation &amp; amortization</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">111,990<span></span>
</td>
<td class="nump">88,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use asset</a></td>
<td class="num">(2,201)<span></span>
</td>
<td class="num">(3,389)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,201)<span></span>
</td>
<td class="num">(3,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(99,672)<span></span>
</td>
<td class="num">(80,274)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 10,117<span></span>
</td>
<td class="nump">$ 4,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_DeferredTaxAssetDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_DeferredTaxAssetDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241639284144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>jurisdiction</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income taxes</a></td>
<td class="num">$ (4,765)<span></span>
</td>
<td class="nump">$ 1,457<span></span>
</td>
<td class="num">$ (1,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy', window );">Incremental income tax benefits</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Increase (decrease) in income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">U.K. operating loss carryforwards</a></td>
<td class="nump">326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_NumberOfJurisdictions', window );">Number of jurisdictions | jurisdiction</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incremental income tax benefits due to completion of research and development tax credit study during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_NumberOfJurisdictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of Jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_NumberOfJurisdictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241634574592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Operating Leases and Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 06, 2021</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,169<span></span>
</td>
<td class="nump">$ 7,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued Liabilities, Current, Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember', window );">Office and laboratory space in Cambridge Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_LesseeOperatingLeaseContractualTerm', window );">Lease total contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_OperatingLeaseAnnualRent', window );">Annual rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_LesseeOperatingLeaseRentFreePeriod', window );">Rent free period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discounted percentage for present value of lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember', window );">New Office and laboratory space in Cambridge, United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_LesseeOperatingLeaseContractualTerm', window );">Lease total contractual Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases, term of contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_OperatingLeaseAnnualRent', window );">Annual rent</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_LesseeOperatingLeaseRentFreePeriod', window );">Rent free period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discounted percentage for present value of lease payments</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember', window );">Office and laboratory space in Building 900, Babraham Research Campus, Cambridge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_OperatingLeaseAnnualRent', window );">Annual rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_OperatingLeaseAgreementEstimatedServiceCharges', window );">Estimated service charges payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember', window );">Office and laboratory space in Building 900, Babraham Research Campus, Cambridge | General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Loss on lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember', window );">Office and laboratory space in Lexington, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_OperatingLeaseAnnualRent', window );">Annual rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discounted percentage for present value of lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember', window );">Payments for the extended lease remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_LesseeOperatingLeaseContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total contractual term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_LesseeOperatingLeaseContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease through remaining of December.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_LesseeOperatingLeaseRentFreePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the rent free period lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_LesseeOperatingLeaseRentFreePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_OperatingLeaseAgreementEstimatedServiceCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated service charges pertaining to operating lease per operating lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_OperatingLeaseAgreementEstimatedServiceCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_OperatingLeaseAnnualRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rental of an operating lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_OperatingLeaseAnnualRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642180336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Components of lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,299<span></span>
</td>
<td class="nump">$ 5,408<span></span>
</td>
<td class="nump">$ 3,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining operating lease term (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">weighted average operating lease discount rate</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining finance lease term (years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average finance lease discount rate</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost incurred by the lessee over the term of finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241638464176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Leases, Maturities of Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 5,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">3,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">9,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liabilities</a></td>
<td class="num">(5,328)<span></span>
</td>
<td class="num">$ (4,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term lease liabilities</a></td>
<td class="nump">$ 3,990<span></span>
</td>
<td class="nump">$ 9,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current lease liabilities</a></td>
<td class="num">(175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long term lease liabilities</a></td>
<td class="nump">$ 817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice', window );">Maximum days allowed for cancellation of contracts prior written notice</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcyc_AgreementWithThirdPartyMember', window );">Agreement With Third Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable', window );">Future milestone payment payable</a></td>
<td class="nump">$ 166,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of future milestone payment payable upon the achievement of development, regulatory and commercial milestones,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum days allowed for cancellation of contracts prior written notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_AgreementWithThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_AgreementWithThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241734138416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Basic and diluted net loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (169,031)<span></span>
</td>
<td class="num">$ (180,664)<span></span>
</td>
<td class="num">$ (112,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding, basic</a></td>
<td class="nump">58,207,593<span></span>
</td>
<td class="nump">35,592,362<span></span>
</td>
<td class="nump">29,660,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding, diluted</a></td>
<td class="nump">58,207,593<span></span>
</td>
<td class="nump">35,592,362<span></span>
</td>
<td class="nump">29,660,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.9)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
<td class="num">$ (3.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.9)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
<td class="num">$ (3.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241640228544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Securities excluded from the diluted per share calculation (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">9,464,988<span></span>
</td>
<td class="nump">7,796,375<span></span>
</td>
<td class="nump">6,086,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">716,262<span></span>
</td>
<td class="nump">326,848<span></span>
</td>
<td class="nump">187,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">8,748,726<span></span>
</td>
<td class="nump">7,469,527<span></span>
</td>
<td class="nump">5,898,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241640142704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">UNITED STATES | 401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions made</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan | U.K. Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions made</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=bcyc_Plan401KMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=bcyc_Plan401KMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=bcyc_UKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=bcyc_UKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241642126416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 72,181<span></span>
</td>
<td class="nump">$ 60,426<span></span>
</td>
<td class="nump">$ 49,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,061,418<span></span>
</td>
<td class="nump">42,431,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="nump">544,127<span></span>
</td>
<td class="nump">249,345<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Consultancy services with Stone Atlanta Estates LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Baker Bros. Advisors LP | Non voting ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,114,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="nump">$ 366,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcyc_BakerBrothersAdvisorsLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcyc_BakerBrothersAdvisorsLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcyc_NonVotingOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241638828480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and geographic information - Significant segment expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segments and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 35,275<span></span>
</td>
<td class="nump">$ 26,976<span></span>
</td>
<td class="nump">$ 14,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">172,966<span></span>
</td>
<td class="nump">156,496<span></span>
</td>
<td class="nump">81,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Effect of foreign exchange rates</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
<td class="nump">72,181<span></span>
</td>
<td class="nump">60,426<span></span>
</td>
<td class="nump">49,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">245,147<span></span>
</td>
<td class="nump">216,922<span></span>
</td>
<td class="nump">131,116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(169,031)<span></span>
</td>
<td class="num">(180,664)<span></span>
</td>
<td class="num">(112,717)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcyc_SingleReportableSegmentMember', window );">Single reportable segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segments and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">35,275<span></span>
</td>
<td class="nump">26,976<span></span>
</td>
<td class="nump">14,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses', window );">Discovery, platform and other expense</a></td>
<td class="nump">30,043<span></span>
</td>
<td class="nump">37,295<span></span>
</td>
<td class="nump">21,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses', window );">Employee and contractor related expenses</a></td>
<td class="nump">58,687<span></span>
</td>
<td class="nump">46,506<span></span>
</td>
<td class="nump">31,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense', window );">Share-based compensation</a></td>
<td class="nump">19,424<span></span>
</td>
<td class="nump">15,581<span></span>
</td>
<td class="nump">10,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_FacilityExpenses', window );">Facility expenses</a></td>
<td class="nump">8,105<span></span>
</td>
<td class="nump">8,845<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants', window );">Research and development incentives and government grants</a></td>
<td class="num">(43,207)<span></span>
</td>
<td class="num">(24,459)<span></span>
</td>
<td class="num">(20,813)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">172,966<span></span>
</td>
<td class="nump">156,496<span></span>
</td>
<td class="nump">81,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel-related costs</a></td>
<td class="nump">23,500<span></span>
</td>
<td class="nump">18,985<span></span>
</td>
<td class="nump">13,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional and consulting fees</a></td>
<td class="nump">20,258<span></span>
</td>
<td class="nump">14,814<span></span>
</td>
<td class="nump">9,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative costs</a></td>
<td class="nump">9,047<span></span>
</td>
<td class="nump">9,137<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense', window );">Share-based compensation</a></td>
<td class="nump">18,657<span></span>
</td>
<td class="nump">16,896<span></span>
</td>
<td class="nump">16,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Effect of foreign exchange rates</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
<td class="nump">72,181<span></span>
</td>
<td class="nump">60,426<span></span>
</td>
<td class="nump">49,507<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">245,147<span></span>
</td>
<td class="nump">216,922<span></span>
</td>
<td class="nump">131,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">40,841<span></span>
</td>
<td class="nump">9,282<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(169,031)<span></span>
</td>
<td class="num">(180,664)<span></span>
</td>
<td class="num">(112,717)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcyc_SingleReportableSegmentMember', window );">Single reportable segment | Zelenectide pevedotin (Nectin-4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ProjectSpecificCosts', window );">Project specific costs</a></td>
<td class="nump">82,705<span></span>
</td>
<td class="nump">44,135<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcyc_SingleReportableSegmentMember', window );">Single reportable segment | BT5528 (EphA2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ProjectSpecificCosts', window );">Project specific costs</a></td>
<td class="nump">9,119<span></span>
</td>
<td class="nump">9,195<span></span>
</td>
<td class="nump">10,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcyc_SingleReportableSegmentMember', window );">Single reportable segment | BT1718 (MT1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ProjectSpecificCosts', window );">Project specific costs</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bcyc_SingleReportableSegmentMember', window );">Single reportable segment | Bicycle tumor-targeted immune cell agonists</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcyc_ProjectSpecificCosts', window );">Project specific costs</a></td>
<td class="nump">$ 7,840<span></span>
</td>
<td class="nump">$ 18,878<span></span>
</td>
<td class="nump">$ 11,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_FacilityExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for utilizing the facility for clinical trials categorized as research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_FacilityExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized, allocated to general and administration activities of the company as a whole.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ProjectSpecificCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost incurred for specific project including but not limited to its clinical trials, program related costs and registration trails etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ProjectSpecificCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for discovery, platform and other pursuant to research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing and other employee benefit and contractor related expenses pursuant to research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized, allocated to research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income recognized relating to tax credits, incentives and grants from government relating to research and development of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bcyc_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bcyc_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241633761664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments and geographic information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Segments and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of geographic regions | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets, including operating lease right of use assets</a></td>
<td class="nump">$ 17,189<span></span>
</td>
<td class="nump">$ 27,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Segments and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets, including operating lease right of use assets</a></td>
<td class="nump">3,037<span></span>
</td>
<td class="nump">7,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Segments and geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets, including operating lease right of use assets</a></td>
<td class="nump">$ 14,152<span></span>
</td>
<td class="nump">$ 20,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45241644162752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Genentech | Forecast | Material rights associated with the LSR Go Option for Collaboration Programs Four</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MR.J$>E(OHFE1_8]>ZVU[?@=%9<%IMBH61Y E>?T7OZU ;!6<.0T%WJK ^Z;
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MJUXN"(X)DQN([Y\HY>LW<@>;1^"O_@=02P,$%     @ =SM96F/C@/,*!@
M/!@  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RU66UOVS80_BN$5VPM
M8,<B)5%27@RT"8H-V-:@:;?/C$3'1"71%2FGV:_?458D1Z04M\L^)-'+W>DY
M\GC/0^;\7E9?U(9SC;X5>:DN9ANMMZ?+I4HWO&#J1&YY"6_6LBJ8AMOJ;JFV
M%6=9XU3D2^)Y=%DP4<Y6Y\VSZVIU+FN=BY)?5TC51<&JAW<\E_<7,SQ[?/!1
MW&VT>;!<G6_9';_A^O/VNH*[91<E$P4OE9 EJOCZ8O86GUZ2V#@T%G\)?J\.
MKI%)Y5;*+^;FM^QBYAE$/.>I-B$8_-GQ2Y[G)A+@^-H&G77?-(Z'UX_1WS?)
M0S*W3/%+F?\M,KVYF,4SE/$UJW/]4=[_RMN$0A,OE;EJ?J/[UM:;H;166A:M
M,R H1+G_R[ZU W'@@(,1!](ZD&,=_-;!;Q+=(VO2NF*:K<XK>8\J8PW1S$4S
M-HTW9"-*,XTWNH*W OSTZE*62N8B8YIGZ!W+69ER=&/"*;1 GV^NT.M7;] K
M)$KT:2-KQ<I,G2\U?-GX+]/V*^_V7R$C7[GBZ0GR\1P1CP0.]\OCW?VG[DO(
MMTN:=$F3)IX_EG1=5;S4B"D%>9ZZ\MD'"-P!S-HZ55N6\HL9+![%JQV?K7[^
M"5/OS)7="P5[DJO?Y>I/15]=,K5!,&LH-1?\:RUV+(?DG;.X#Q4VH4P#V*WB
M* F)=[[<'>9CFX6$!F9J=@ZD08<TF$1Z7?$M$QGBWZ!'*:X:U%)O> 4+X7#"
M7,CWH>D!).P'/AD =UCAP*-NW&&'.YS$_1'FC%7I?I0SOH/6N"T,6@%KJ31=
M2D'#2SD,_&W.7>!#"Y8?TM ?@+>M2.#YB1L\[<#32?"?I&;Y$>-+K8\G)*9>
M.,!HFX44QS1V@XPZD-$SE0&T5>F'9H1-"3?C.T<EURZLD8TUQ'2 U#;"08A#
M-]"X QI/ OT ,)D6Y1W*.7 +J@R)+.1Z4</-^.#&%I:(1L/IMXVPC^G(]"<=
MX&0:<+.\QI$EC@7C1<$ FFT51@EQ(\->STS>$:4YCJUU?SK/]+#86FZQ[<(D
M](-@!. !=>*C:"07[%;D0@ONYI(VS N1R4M%>YIT3YUXDJU6;]-4UD ?:,L>
MQOI9&^))V4!%#"O:9>9[H3<R+SWCX6G* XA5S2>)Y&#*G GX%K( DV#80QQF
M/@Z]D36)>R+$TTQXQ=<<<&9 &SM>UGS>X=[*RJA?)V8'N7DXP4/,MAD)DFBD
M0^.>!/$T"SXEDN?&U^8R&A%_J#-<9K!RHQ&L/>?A:=+[799W"\VK NCZ=L\C
M2*Y1)E13VT[$DQ&_>PW;/.E[-!F;A)XG\311#OGG8!JZ+(\I)9L<_22Q9L?!
MLWX\UO9["L73'&H7_W< MTDRP0&-AL@=7(H]@D>$(.[9%!]#IWE77L\M Q>]
M$FO%VE8!=%,W5M+3*SF&7I]!2&SNQ-2/O2''.NP(":!GCJ#L.99,TAGL3XM"
M:"/W]FT\E:6I;UZF@!B]_E-JCC!^X\3^ T2)G-NW_Q[H:?8'^]3IC>K-AE5\
M(_.,5^J71OGJ!_=V]67WJ__'AI7T_$VF^?M#E8F250](F?2A<\%&*J\ST]9*
M62YVLNEP<FAE$/AGWHF'P:R =SF"K6[-SQ .PWD<T3D-PJ:(PF1.,8$?OW5&
MK-8;68E_H.TPC:Y@MU;<PDI^/+)HO(9/_3FT*+7ES4%4_G"&:#+W*)X'.&[L
M S(/P#2B]/$K0BFC2QHY4FNEX<)D\J-?=!:"+4EBJW,[C,(QV45ZU4*F5<O;
M+!.F,<.XFWW\0I0H95L!7<8)U"%7@HC$P7#/[C",8U#O(\V:](J%3"L6D(EU
M4>?-R5>K#F4!!;TQAY0[;JI.%AR]SJ52[@9CRQ.,DR%\VV@!*G=D\T%Z#4.F
M-<PA^HRO12J<NH782F-!8R^R=*'+,,0XHF-UT8L2,BU*]D2C'*W,"=A6%;!S
M\*A5PPZ-$GF)/\8XO?X@T_K#XL5F*1X-/[;.QIR;4H>=<U.Z/#C:->?J?[#J
M3I0*]-T:'+V3"")4^Z/J_8V6V^:T]U9J+8OF<L,9P#8&\'XM@3+;&W. W/W#
M8/4O4$L#!!0    ( '<[65J'@8 C>0(  # '   8    >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&ULK95=;],P%(;_BA4D!-*H\^GN(XW$.B&X0%2;@&LO.6VL
M.7:PG7;CUV,[6=2M&6P3-XT=G_?U\SK-2;Z3ZD;7  ;=-ESH15 ;TYYBK,L:
M&JIGL@5A5]92-=38J=I@W2J@E1<U',=A2'!#F0B*W-];J2*7G>%,P$HAW34-
M57?GP.5N$43!_8U+MJF-NX&+O*4;N +SO5TI.\.C2\4:$)I)@12L%\''Z'1)
M7+TO^,%@I_?&R"6YEO+&3;Y4BR!T0,"A-,Z!VLL6EL"Y,[(8OP;/8-S2"??'
M]^Z??':;Y9IJ6$K^DU6F7@3' :I@33MN+N7N,PQY,N=72J[]+]KUM=D\0&6G
MC6P&L25HF.BO]'8XASU!E#XAB =!_%Q!,@@2'[0G\[$NJ*%%KN0.*5=MW=S
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MKL"NKZ4T]Q/7-<>/9/$'4$L#!!0    ( '<[65K+'F*P* 8  )<<   8
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M;"]W;W)K<VAE971S+W-H965T-BYX;6RM55U/VS 4_2M6AC:0MN:3#K$V$FU
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M2->31>9&%Y&B46#6"50J&=F%\8$QN9LQQXVZ: /";?HS*]V=>R87!\/_Y9[
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M,#<[DW7Y-QR6T:@D#&#E%6A$P+HA-($F,6V+B,V_"81+VDI7L+J\/I#N 9H
MX(',,,K6@HYH@?X5+;VU!D9<9%_KYA8HW9JZY)4V,'D+^Z;]:KI3MS<%,DT&
M$_.-%O3D#?+0&O1DT\H6LEVV,I4UB'W8=2LD=>Z:&FF0P=+A16)TVQ;]#C@'
MI@:H?PIL"$S#G(H 5@?D&-"KS(85TH2QZ\<LMCGL,A8'\: +@HM7$I:YS*["
M\R:9%5FR+3V_"Q3XZW9K@9!P#5!JB$Z$JV5V673(LT!KT.@.N*JO@-@6I$B;
MK=MF!^\T+I8Z@+QHCZ5;L;7N*X/; Z!M!ZQ%8B*F:-$#P>L.T (V5DM# GRY
MPHHR #9ILP,ZA4$.LH!M[@!^4\?R&4:R,#3M\]4A*V%Q &Q!8&RJ9@6KVS6U
MZ5"RX[4UR#BX1J+\ /QO&ORS(V9":0R7 1&N1\9WA,:FWC3(R;=YB\#>--4-
M_OSRM078# WZWK6YJ9#MUY4P.FV)S@!F 3&XS@5/7_6(<I90L'(/F_G&?, /
M+[-_;2WP1A>A#E<?^*#T4BG(,4:$R&4+T(,IN4C&8)G>,VO#W!;X7F2C;@)B
MMYM$5.^;#N41;C?2+P!'#OC9Y0C4#6(HGN0O?_KQ_.R'ET"JW@&"'#*R!Q$
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M'I/@!!7;TWXO"8,TIX')6C^0'(? :$8^,3EG=KUYZ7/ARK.^?&_8CL%'>J2
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M$JQ";NN84!ZEOYFV4?\S:0Y,+<*I7:.7S;1.[ASL&RYB8VLGV?A,/C<E3U.
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M*=/P1'F/H!IHF*2R8I0#-0:M 2IKX(SN&6>6H<DCZW)Z9%1-_-N1/WF#?YG
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M+>DQA98-:'YMC-]U>('A>;;X"U!+ P04    " !W.UE:W)&K >,)   I'@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RU66MSVS86_2L8M=M)9AA9
MU,MVG'C&>72:G<G6$Z>[GV$2DK E 18 K:B_?L^]("GJ83E)NQ]LD01P'P?G
M/D"^6EOWNU\I%<27LC#^]6 50O7R[,QG*U5*/[25,AA96%?*@%NW//.54S+G
M165Q-AZ-YF>EU&9P_8J?W;KK5[8.A3;JU@E?EZ5TFS>JL.O7@W30/OBDEZM
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M-R(NW_*6OWS>U->LP=E #7^0J+0:F),5&N6R;>"NA'7MR\LU;\0IRE6PO-Z
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MM^%F+@]&,2E7  <-#2+WSU)#HEF+ZKW6VSI+! 7!+;!/ ^+CL3\>\V"-P0-
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MF-D+VZ 3R19P9?'%^^TC_.C=L<9/U^FG+?H!)S83R408LT?\=L*D3<2>!7-
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MX<%M33.C&R-T*7\C[W9:9.O.D/!_Z\ SVP]X JF44]0LEK_C1R(7OPY^&*"
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M4\W;)KF4?-:D:OKB9 9/H>&!9I73IHMWLQEUG0U_Z'M?A#D8[5BA8.%:V?X
ML._4-](N]]/ 5BDT8]C#[MOIPB( ,*=RR^1.9P5S7:QXVYN7;BYQ5S'@Z['$
M1"3HWHI@5'_#7-;8(,EA]Z/7=JC@>=[(1+J!1#3^?2\&Z>BH7.?#(SQ)M%'=
MJ1\JI$GFPAWZM99TW)/=S?L=ZC_ 8Z$P9?_V7:-'J>K%68F8;R8[FG#W,\=^
M(&G4]_GAZ^ZKI2B=Z@N)3*5=7>VQ2V9J1Z&]G9H):487D'_9!#(X3NS'B$,%
M[@,U0C1/.N\3+\[2-XKM5J$@"3OH:'7[M0K#Q@2Y<]HAA!-T9OO$/'@;,CCB
MT(6"M5K.UL1/ZX&=NX'#(7RK[S=^,73W->[<6%8"W3/=RQ(7Z]HVEY<[ZN[J
M]T-SX[G_O+DW_H3F6X*74LRQU3^?)".FF[O8YL6JE;O_G"EK5>4>EX(70M,'
M6)\KQ%?[0@?L+L1O_@102P,$%     @ =SM96L^K0_6N @  "08  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&ULI51=;]LP#/PKA#OTJ8@=)_U EP1H
MVJUKL6)!@VW/BDW'0F71E>0DW:\?)2=>BK7!@+W8DD@>[V0?1VLR3[9$=+"I
ME+;CJ'2NOHQCFY58"=NC&C5'"C*5<+PUR]C6!D4>BBH5ITER%E="ZF@R"F<S
M,QE1XY34.#-@FZH2YF6*BM;CJ!_M#A[ELG3^()Z,:K'$.;KO]<SP+NY0<EFA
MMI(T&"S&T57_<CKT^2'AA\2UW5N#5[(@>O*;NWP<)9X0*LR<1Q#\6N$U*N6!
MF,;S%C/J6OK"_?4._7/0SEH6PN(UJ9\R=^4XNH@@QT(TRCW2^@MN]9QZO(R4
M#4]8M[E]3LX:ZZC:%C.#2NKV+3;;>]@KN$C>*4BW!6G@W38*+&^$$Y.1H348
MG\UH?A&DAFHF)[7_*'-G."JYSDWFS<+B<X/: :[X:4>Q8U@?C+,MQ+2%2-^!
MZ*?P0-J5%C[I'//7 #'SZ4BE.U+3]"#B#68]&/1/($W2X0&\02=R$/ &_R.R
MA1B^#>&]<6EKD>$XXI_?HEEA-#D^ZI\E'P\0''8$AX?0_XW@88C^60_^@H$[
M#?="-VPW?Y>G)W"+F@.8E5 ;6DG^7N!*A&NJ:J%?^.=S)0C0Y&2&0 4X-/S7
MB> @'@%[]>P#)19DVMC,T-*("HZ&)X!%@<%L(#4\",/);7.A7W?#3<V)%ARQ
MOS-::OD+><74F]!<U$QR(]E[J%[@PWEOR!90RO?C*'L/C6$!NPJA%&6<FWM
MW\<7&BD4&.]-$-92)D-"T.E3OLX?X9;@6]TI?$^7%^,K"FFL@V>^4P;W/+RV
M'AP?7:3)X,V?(=ZS9X5F&8:0A8P:[5JG=J?=G+MJ[?TGO1V2?)M+J2TH++@T
MZ9V?1JVXW<91'<R^(,>C(RQ+GM5H? +'"R*WV_@&W?2?_ 902P,$%     @
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M;9$[?-S^"\C.]68$"._I FJG/^P-%N(-'K4)DI&LJI'C/7CHMD-M/:* _)W
MVP><S5$_$K_*C(6]X&NQ.+W\/JN69W0+RWT3'ESGBC(\#2S:$7;!"O)V)MH7
M"R5GXJ8MR^]G\&>"X@Q,J,.$I( -8H-ND2&[_$1HE+M[Y*]"KF2IEW$RE+(<
M [9^D^[%5^$ZE8 "^DX9$(L44Z67E(>@ZL9CT#C1YMN/M2Q+W_%&KM\JL@ -
M60/3S('_[#>@[O[S7\+ESX5N4/W*XW2/RNB4TB/?H_92)3O7>7M]!HU7!/(E
M Y'+J_,+[AIHN,+&FA$>5M0>R8I$3QB6.<6NDM@:;5?G PBIT^Z3M;AV\Q5<
M;P+6[^LZC0O@*BQ/S6CK3BH4M%WKL!A%8HN'6;[:D)G:2P5B ZGAH'./XMBM
M>YN+TSYRIP7=</=. L4Q(4#V#0XB;4)O5)KX^LVC+OY&B8(&VEX;+:U!@J(K
M3U"A"[IF9Q:=;A[X]H:G@7HG/M.UW^$0WIU>[UYG["W>-+;J%G#T#1GUJ6D"
MM/\<5DS'>3JTB^UY0*Y,WE0T'\REW<X9NXQ34[-])SY"L7<T?*QU@+S,[>B;
MI)W/#,1.T.X&=&\,/#H@6?=2.XX?*-N%VSO2U3F-]]OPC7$YC76C2'6C>UUR
MP$:MP[S;F[-=\.81:3;TOLRJHGD0'9 MN??%VFE3S/GJG\:/?@8@E^0\S,?^
M\T>!7A$$/+BL/6;+\0^-MMNQ#=^'M#VVOT_94NJN]OJAM$>[(8G9MK7=5Q^Y
M[R,9I?^ZP-Z^^E@,H8G.M[LF7X8F.LYBQ'4SS=/[JRUKW@%J#/.RY:5#\IVV
M\IW>5;Z 4YEW7^W(J/^@U,,<WD17XAL$W<P7?#NSI0Q$B"X+F\H"50K_E80T
M--I?&)2UC;1;Z?& 1Q$KD3#U^KI<47H!Z@MW>+83";;]UD?KQ$,V:[]H-QG\
MSML^FUVAD%,H=;JG6]7^!5^LNP>Q]R#V'L3>@]A[$'L/8O]_0>Q0$6^_63[Y
MJJ^6:ZO2'4(RJ>VAK,.CMEN.OF6,.&D'^Y.OFNQ_C@RW@91;&#A0V>\0UO]D
M: \IN;V+F'S-9<3/!%1<N$[K/+^3DH<9^)\ ??? [T[ ;\CSVLN9R9UO9_;W
MAAV_^XI0'V3F<_N1>S!S#V;NP<PW C/MK>CDSM>B=P0"X7LH8-0/F@; S9?=
MD8X[/_&LI)GS#UGI:\Y-[?RO/=/3]&/9<_\3T7:Y_Z7MN\S,Z5O%I9QAZ\GQ
M4X 4XW^\ZM\XO>0?C$ZU<[KBEPO$HC2T )_/M';Q#1V0?D+\ZK]02P,$%
M  @ =SM96M6KIV>!+   5)X  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&ULS7UID]M&EN!?06AV.J0(%E55NBS)5H0.NU<QMENKDKHC]AL(),EL@0"-
M!*K$_O7[SCQP5<EVS^P'6T42R./ENZ_\_J9IO[B],5WV]5#5[H=[^ZX[OGCX
MT!5[<\C=NCF:&G[9-NTA[^!CNWOHCJW)2WKI4#V\/#]_^O"0V_K>J^_INP_M
MJ^^;OJML;3ZTF>L/A[P]O3%5<_/#O8M[^L5'N]MW^,7#5]\?\YVY,MWGXX<6
M/CWTHY3V8&IGFSIKS?:'>Z\O7KRY?(HOT!-_M^;&17]GN)5-TWS!#^_+'^Z=
MXXI,98H.A\CAGVOSUE05C@3K^$T&O>?GQ!?COW7TGVCSL)E-[LS;IOJ'+;O]
M#_>^NY>59IOW5?>QN?G?1C;T!,<KFLK1_[,;>?;\7E;TKFL.\C*LX&!K_C?_
M*H"XRPN7\L(EK9LGHE6^R[O\U?=M<Y.U^#2,AG_05NEM6)RM\52NNA9^M?!>
M]^J*3R-KMIFSN]IN;9'7'0"K:/JZL_4N.S:5+:QQV?T/\M>#[Q]V,#4.\+"0
M:=[P-)<STUQ<9K\T=;=WV8]U:<IT@(>P9K_P2UWXF\O%$=^98IT]NEAEE^>7
MCQ?&>^0!\8C&>_2' 3&U>Q[[\?382%DOW#$OS _W@'2<::_-O5=_^8^+I^<O
M%U;^V*_\\=+HKSX[@ZLVKK. I=/K^[81LD][D\%*CWF;$^W CT53.P! ";^7
MV=;6>5W8O,I<!U\ E78NLS4^A(S"=B= XVZ?_?7UZP] N[_U%K8-:%L#H>/#
M6=? IR\FFC*ORRQWP!R..*/+NGT.T-]N@7KA;P.C')L6Y\X/>" .UP3/FXY?
MK6R^L97MK R%KY36%57C^M;(!O 8<?:Y]W@FW"*^@'_?OFN=;&I]YBLP3P<C
MEWV+&!2>(WPRK6U*M\ZN(GR;!PAP*V1E, , &D9R=UF=K8NJ+\TJV_2P;0!$
MW72P9S@A>*-K5C#JM:E[7%;1P"IPJA6M$Q"_[6$P.,\,<39OBSVMJ80WJN9(
MQ^@WB#_,/@6+@'^ ^>(F"F.O\TT%2W)[6- 9LM02=G+ D1C;9-15=IU7O4?
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MWJ 7EEPOC>LFE;[?-5!*'OG1=G0>L"_V8 )\=WFU0F:U!90E0WH5A_6"9QU
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MH;0QZ$5:7!1G6L@8E"!%#P9-+*5&5L*W-N$YDA\9K*J!S]A7=9%GC\&ERNP
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MSJ;IRH4:4:3Y=EGH_2^> F)T\E>N*='*Q8PA8..=.BYJ4!FY4&OA>4G]*XW
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MGD1)/K\GO;,J.(*"*HS7S9A2DLYLJUM%OQ& ZDP'723PT!_T\K;.GIA-@7D
M97.4NV5]CE;;U$TO?=!9/?2/RR+GG]9;>&7<2;;QIRT-SOE7O* 8439<DO33
MZZLWNM#75Y_AD37]>G;^;)7I_2\?O75ZGPW R^_.'V3OXQN/X73X*=*%],5W
M?&,<!0OUNJ#?#9[A#AXO[N#QV3EL46S"*Q6AOJEZV%+J<I(7]+$?Q;$'&\EW
MN]9(M6F\K_M7_:9CJ%R>GST&P.A.8;T^\^(N$'_NU_N))*@ ^]GC"6"'!Z>
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;.5:;6_;.!+^*X2[V&L
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MHX(5?QU:PN>OX.:9.+$;;"^C6IHV%O!Q35AB<S2\HT6:KS*P7'A->;URF_8
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M:#+ ]TNE[%:@ -UP.O\'4$L#!!0    ( '<[65JO^(PC>P,  $X)   9
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M0#L%7-\I94\3M\%XA5K_!U!+ P04    " !W.UE:!;;9S!\&  "%$@  &0
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M[WR@+8JFW343Q5>V <RYTNW$#DO]A0#"!.C]!>=J.S$)NF^.]"]02P,$%
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MWB\K.Y)!NP1[7BJ%N\!U_3#D\[]02P,$%     @ =SM96C"/^\8] P  ? X
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M64SBCKS_B[S5 ]#5^6M.HO5V$I=6+_$^YP-DF'\@R["<C@&MKH_;'7&W/_Z
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M"2_5BF1Y.7WBA4G)TG)Q2["Z)Q8-U/XU8_)MI>B@F7:T^ ]02P,$%     @
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M,T8U-'3/[9,:OL&8SZWGJQ0WX8N&T3?!J-H;J\0(=@H$D_%/CV,=S@#IXA5
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M<FUF>)#6P-S/A- /&_N ]E^!^']02P,$%     @ =SM96FS\]FV0!   R1D
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M_+ =W^ST"UF0&,:.WLH2Q J<R:^_X+[W>YOXGP2V%XJP"478A;X-15YD_!$
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M:M(6UV]Q?>L7].!V0=2JL%ME;M)$ECB%J:.OB@2Q R=Y_VX8>1^[D/Z3V0O
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M]U=Y7CW]L.W@(2^^[7;S_']02P,$%     @ =SM96ILODYD/#P  ,.H  !D
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M1-RG@,H ,;\FA!\Z\@'-#2WX!U!+ P04    " !W.UE:&!;/9S@&   /*
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M@\H:T/I22O,YL!O47TBS_P!02P,$%     @ =SM96MVJAO3A!0  KR(  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULM9I=<YLX%(;_BL;;V6EGTH!D
M#';6\4P2FNY>=#>3-.FU;&2;+2"O)-O-SO[X%1\!!+)JI^I- UCGE<[CP^DK
MPW1/V5>^)D2 ;VF2\<O!6HC-A>/PQ9JDF)_3#<GD)TO*4BSD*5LY?,,(CHJ@
M-'&0Z_I.BN-L,)L6U^[8;$JW(HDS<L< WZ8I9L_7)*'[RP$<O%RXCU=KD5]P
M9M,-7I$'(AXW=TR>.;5*%*<DXS'- "/+R\$5O C1. \H1CS%9,];QR!/94[I
MU_SDC^ARX.8K(@E9B%P"RS\[<D.2)%>2Z_BG$AW4<^:![>,7]=LB>9G,''-R
M0Y,O<236EX/Q $1DB;>)N*?[WTF5T"C76]"$%_^"?376'8#%E@N:5L%R!6F<
ME7_QMPI$*P"-#@2@*@!U J!W(&!8!0R/#?"J *\@4Z92< BQP+,IHWO \M%2
M+3\H8!;1,OTXR[_W!\'DI[&,$[.'-6;D?4XN @N:RG+BN/A"WH-[P@6+%T)^
M4HP"CUDL.'@;$H'CA+^30QX?0O#VS3OP!CB YV,XB+-RW)F\*(\_K^F6XRSB
M4T?(Y>:3.HMJ:=?ETM"!I4$$/M%,K#GXD$4D4@4<F6>=+'I)]AH9%4.R. =#
M> :0BSS-@FZ.#Q]JPL/CPY$AFV']U0T+O>$!O=;W4[+7(2XE/+U$WE0N^ 8O
MR.5 =@U.V(X,9K_^ GWW-QT>FV*A)3$%G5>C\TSJL\]4X*2DIJM]\BT_)CJ>
MI>ZHT,U[ZFXV'+MC.'5V;5":4<@+ G54V!^%_""8U*.4U$9U:B-C:JVJH"R*
M,]G,7V[-__+*<\%=@C-=:D;=4TO%IEAH24SAZ=<\?>-=]N<VG1,&Z+)L@EQV
MMXBPY#G.5N#^X5%[T_DV2=H4"RV)*22#FF1@K,S';"=K4]8E.URB6( Y6<59
M)O'JR)8S^,J-Y8^]<>?^,R[D5&:6Q!1FXYK9V,CL(\.9Z/[?5Z(8]U#X,/ F
M?@>%4?]4%);$%!23&L7$B.*I+![I)0 G0B1Z*I,>E??0@\.1V\%BG.M4+);$
M%"S0;1R<>RP8:7@)8WHRE8J"QI/;@RX9\VRGHK&EIK)IN5MH9"/W!DL2'[B#
MJEB%R-@/AJA+Q#C'R40LJ:E$4$,$V>C")(L.M.!*7VD\@8?\'K7^.%VO#LWK
M?2V/QD1#H]$\AL<9J&ZQ^5;(#?+\;[EG!8+6=UO5C^1N6&B!#7L@M/>=57=M
M2TVEVOAK:#;8?VT%%[BHH=<7FM?C%D!?4VC&I9P,SI*:"JYQ[W!DM)M?BA\J
M)*JK'6%X14#A (#<VQ-PBV,&GG"RU>Y,H%7_;E4MM*6F0FTL/#3ZV@8JKJ"N
M"JA1#G690]WE4,&V:@5GX/K%@X)K+'=+"SWP<M)QN\$%YUZW.JWZ=UMJ*LC&
MP4.SA3?8T2H2#ELXX/@<=?VH>8:3>?P,<PX;=P[-]OPX3UJ)*&ADI00]-%:]
MNBTU%4WCUN'1=MWH2B?:LG&#+ANKAMV6FOHK9./8D=FQ&UUI%:L00>@<CCI$
MS'.<2L26FDJD\>G([--/[M ?2F]A:,_5C%V.O0UR-<[<QD/S^E_+IW'MR.S:
MC^/S@T:U6L-W[T7S6D^NO)_A_U'C_Y'9_Q]+MNUHI6T]HO[*>2=J^?D]F%9M
MORTU%69C^Y'WXX\DD$V_?F-5+;2EIO)KW#\R_WA_V[0ZN@0DW23TF9#V#JK
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M,H'^?LGU)-"\*0O87=F>_PM02P,$%     @ =SM96HVB/&XH!   51$  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C N>&ULM5C;;N,V$/T50ET4NT WNL37
MU#:0"XKM0XI@L]L^T]+8(I8B59*R8Z ?WR$E2W:MR*[CO$0BQ9DYG#F<$WJR
MENJ'3@$,><FXT%,O-2:_\7T=IY!1?25S$/AE(55&#0[5TM>Y IHXHXS[41 ,
M_(PRX<TF;NY)S2:R,)P)>%)$%UE&U>8.N%Q/O=#;3GQER]38"7\VR>D2GL%\
MSY\4COS:2\(R$)I)010LIMYM>',7.0.WXD\&:[WS3NQ6YE+^L(/?DZD76$3
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M,7_W7-!GYW/,H2OHH'88E$:@:/8N56N(L=\0O^(Z_S,MAT^O7OAK7JH7*(U
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MS;5GFAQ[YJ>@QAF41J!HME"M<<9^X_Q$,N0K,TM=U8\62+;>&6,AY %QI<P
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M2&. [Q="Z&W##%#?/4]_ %!+ P04    " !W.UE:[GCB#$D#  #<$0  &0
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M@9Z+5(I/ZJ(Z_IZPG2!%+.:F5(VNJC:CMH&KIH'V&PW$-OK*"ID(%!0QC76
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M?#(_#57S8</Q9'R:J7]%&Q/:.B;T[BNW'6+]:?5S_B-953]:$X66,:@6HYI
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M9)D6NP?4_WZ;Y]7S-[L!'O/BC_W3N?I_4$L#!!0    ( '<[65KZ&F: M@8
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M&LCW*TK%_D8Y:$[2O/\!4$L#!!0    ( '<[65IC3R7+S (  $X(   9
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M7,7R+GOFHCJALH+3+"[*O\ES=>R@1Z:K0F9)%:QJD$3I^M_PI;H06P'.<$^
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M&H/2.(IF2K3.]KON.ZTE%YK7A])\*"V TBB4QJ TCJ*98JMS_:X]O=[56CJ
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M)Z%W;R6$W4L(NYD0=C<A['9"V/V$L!L*_1DF@5>;!-['3 )[>&?)07T#*"V
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MPQ' UA) NR=0W",C]ZX!@!':YGX, P!;!P#M%N ]?@9V3< ITO]5-@4=PP7
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M\JKA6MU(MBQ[E@],2I:5EPN"$\+U /5^QIA\N=$3-&WO\7]02P,$%     @
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M3B^(_)U+LF_H!T'D^:&W<TOV#;TH#)TPB-JO2:\1W#NCX+K>MTGNG2IYW_"
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M)2FOD(#EW#GWSU+?,P!K\9O"6FY\(Q/*'>?WIO$]GSN>\0@89,I0$/WW )?
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M2V0U$8-*Q,"P=RZYQ4VR!6W*UB99U!)93;9N)5OW[-V;J,3D9+'1%5BHJI)
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MVU;5-9W[8/ZR<G/\3=OQ]WAO_@502P,$%     @ =SM96B 5OA"$ @  )C(
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:36ZC0!"&X:M8'"#M
MKNJJ[HSBK&:3[2@70$[[1[&-!8PFN?U8SL+^T"QF$_&M4(,HW@V/$/#TJQ[:
M<=^=AMW^/"P^CH?3L&IVXWC^$<*PWM5C.SQTYWJZ'-ET_;$=+\M^&\[M^KW=
MUB#+I8?^?D;S_'0_<_'Z>:[_,[';;/;K^K-;_S[6T_B/P>%/U[\/NUK'9O':
M]MLZKIKP<;CM'L)U$Q\NDYO%R]NJZ5_>8A/F#A((DOF#%()T_J $06G^((,@
MFS_((<CG#\H0E.</*A!4Y@]ZA*#'^8/B$F5<$B1-L";0.B+7D<#KB&!' K$C
MDAT)S(Z(=B10.R+;D<#MB'!' KDCTAT)[(Z(=R306U!O(=!;4&\AT%LF#]L$
M>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z*^JM!'HKZJT$
M>BOJK01ZZ^1E"8'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>"?5.
M!'HGU#L1Z)U0[T2@=T*]$X'>:?*RFT#OA'HG KT3ZIT(]$ZH=R+0.Z'>B4#O
MA'HG KT-]38"O0WU-@*]#?4V KT-]38"O0WU-@*];?*QDD!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&^?_&Q"
MH+>CWDZ@MZ/>3J"WH]Y.H'=&O3.!WAGUS@1Z9]0[$^B=4>],H'=&O3.!WAGU
MS@1Z9]0[$^B=)S\+$NB=4>],H'=&O3.!W@7U+@1Z%]2[$.A=4.]"H'=!O0N!
MW@7U+@1Z%]2[?*?>P_AYJ,.MYVN-U_].JL?+N?5V^>OR:^?DAKKB'.XKAN>_
M4$L#!!0    ( '<[65J);LQ^*P(  +LP   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W;36[;,!"&X:L8V@:6+%*DU"+.INVVS:(78"4Z%JP_D$SJW+Z4G 1H
MD1H)7*#OQH)-<KX1!WAVOO[^.%F_.O;=X+?)/H3I8Y;Y>F][X]-QLD-<V8VN
M-R%^=7?99.J#N;.9V&QT5H]#L$-8A[E&<G/]V>[,?1=67X[Q9]^.PS9QMO/)
MZM-IXYRU3<PT=6UM0ES/'H;FCY3U4T(:3RY[_+Z=_%7<D&2O)LPK?P]X.O?M
MP3K7-G9U:USX:OJX*SMVF0^/G?7I^1*O]#CN=FUMF[&^[^.1U$_.FL;OK0U]
MEYZ*7IU/#O&&[>DSOSA_*7,N,.Z\=>/DX\2<?7_<\TCFT^LI%K(NM.=?\24Q
MEK[X_>P\[<8V;\R.U_MS=(=E'CY;'I??\>\S?JG_SCX$I \)Z:. ]*$@?6A(
M'R6DCPK2QP=('_F&T@A%U)Q":DXQ-:>@FE-4S2FLYA17<PJL.45609%54&05
M%%D%159!D5509!44605%5D&155!DE119)45629%54F25%%DE159)D5529)44
M625%UH(B:T&1M:#(6E!D+2BR%A19"XJL!476@B)K09%54615%%D5159%D551
M9%44615%5D6155%D5119-45639%54V35%%DU159-D5539-44635%5DV1M:3(
M6E)D+2FREA192XJL)476DB)K29&UI,A:4F2M*+)6%%DKBJP51=:*(FOU/V7]
M,8Z'?QR_/-/>M,-S?K;\9^'F%U!+ 0(4 Q0    ( '<[65H'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ =SM96@GJF7/O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ =SM96IE<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !W.UE:
M?E#9+N (   ./P  &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ =SM96F/C@/,*!@  /!@  !@
M     ("!)!$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M '<[65J'@8 C>0(  # '   8              " @607  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " !W.UE:RQYBL"@&  "7'   &
M            @($3&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ =SM96HKP%N)<"   8$,  !@              ("!<2   'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( '<[65J,XYA;?0(  ,(&
M   8              " @0,I  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " !W.UE:L9O2G<T)   W,P  &               @(&V*P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ =SM96L0@TM(E
M"   U10  !@              ("!N34  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( '<[65K/M",P "@  *:&   8              "
M@10^  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !W.UE:
MXI/K4!("   F!0  &0              @(%*9@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( '<[65J<I1NV=0,  .\(   9
M      " @9-H  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ =SM96BJ.R"2' P  XP@  !D              ("!/VP  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !W.UE:AS@'XA $  "J"0
M&0              @('];P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( '<[65K<D:L!XPD  "D>   9              " @41T  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ =SM96CT?*IL2
M#@  %3(  !D              ("!7GX  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " !W.UE:JG$$ZW(=  !DB   &0
M@(&GC   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( '<[
M65HU?N'9L P  )(J   9              " @5"J  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ =SM96AMQU1)I#0  C"<  !D
M         ("!-[<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " !W.UE:W/-@P#8$  !5"P  &0              @('7Q   >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( '<[65H%KZ$X6 ,   \(
M   9              " @43)  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ =SM96HR#JKQ7!   ] D  !D              ("!T\P
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !W.UE:Q?-.
M%^<'   <%P  &0              @(%AT0  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( '<[65K/JT/UK@(   D&   9
M  " @7_9  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M=SM96I*H1[EE @  BP8  !D              ("!9-P  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " !W.UE:+'5HOD,"  "*!@  &0
M            @($ WP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( '<[65H\I3,X$0(  -T$   9              " @7KA  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ =SM96LHU8[\;#P
M3CP  !D              ("!PN,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " !W.UE:U:NG9X$L  !4G@  &0              @($4
M\P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '<[65I[
M#FISB@(  ,L%   9              " @<P? 0!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ =SM96I !Q$T" P  10<  !D
M     ("!C2(! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '<[65H%!5X3M 4  %T3   9              "
M@6@[ 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ =SM9
M6N#*Q$RW P  J H  !D              ("!4T$! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " !W.UE:K_B,(WL#  !."0  &0
M        @(%!10$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( '<[65H%MMG,'P8  (42   9              " @?-( 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ =SM96JIQ0LO: @  ?P@
M !D              ("!24\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " !W.UE:US:KR7T"  #<!@  &0              @(%:4@$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( '<[65H8>"4
M- (  %@%   9              " @0Y5 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ =SM96NK>TY]4 @  \ 4  !D
M ("!>5<! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !W
M.UE:,(_[QCT#  !\#@  &0              @($$6@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( '<[65JB;497IP0  ((D   9
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M970T."YX;6Q02P$"% ,4    " !W.UE:+P1!E@T&  !*.0  &0
M    @(&3<0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M '<[65J!1F:-@ (  $8'   9              " @==W 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ =SM96B"2$Z.V @  % @  !D
M             ("!CGH! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " !W.UE:H1',T4D/  #A]   &0              @(%[?0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( '<[65J;+Y.9#P\
M ##J   9              " @?N, 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ =SM96@6#LH\G P  K0T  !D              ("!
M09P! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !W.UE:
M&!;/9S@&   /*   &0              @(&?GP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( '<[65IQD[5[MP,  "T-   9
M      " @0ZF 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ =SM96MVJAO3A!0  KR(  !D              ("!_*D! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !W.UE:@G0#DS $  "^&@
M&0              @($4L $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( '<[65IC#N;0D@<  +X]   9              " @7NT 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ =SM96HVB/&XH
M!   51$  !D              ("!1+P! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " !W.UE:Y?<-9WP'  "#.0  &0
M@(&CP $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( '<[
M65IPH7"@E@0  (<6   9              " @5;( 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ =SM96NYXX@Q) P  W!$  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( '<[65KZ&F: M@8  *LN   9
M  " @3_U 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
M=SM96J1R<78> P  H@D  !D              ("!+/P! 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " !W.UE:Z4(\UV\$  !5&P  &0
M            @(&!_P$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( '<[65IC3R7+S (  $X(   9              " @2<$ @!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ =SM96CUN:;1L P
MR0P  !D              ("!*@<" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6Q02P$"% ,4    " !W.UE:P[+&U<$#  "S#@  &0              @('-
M"@( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( '<[65J)
M8[GBM ,  "L-   9              " @<4. @!X;"]W;W)K<VAE971S+W-H
M965T-S0N>&UL4$L! A0#%     @ =SM96IDNKQ[' P  BQ   !D
M     ("!L!(" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '<[65J!LSAU/0,  )4-   9              "
M@9\M @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ =SM9
M6E>(U_O9 @  Z H  !D              ("!$S$" 'AL+W=O<FMS:&5E=',O
M<VAE970X,2YX;6Q02P$"% ,4    " !W.UE:GK9[9IX$   ['   &0
M        @($C- ( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0
M   ( '<[65K4)5 &M@<  -HM   9              " @?@X @!X;"]W;W)K
M<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ =SM96FE7R_(: P  +PP
M !D              ("!Y4 " 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q0
M2P$"% ,4    " !W.UE:ARP;H&L"  "@!0  &0              @($V1 (
M>&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( '<[65HGN,!Q
M:0,  ,86   -              "  =A& @!X;"]S='EL97,N>&UL4$L! A0#
M%     @ =SM96I>*NQS     $P(   L              ( !;$H" %]R96QS
M+RYR96QS4$L! A0#%     @ =SM96GLU-L(O!@  $S@   \
M ( !54L" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( '<[65H@%;X0A (
M "8R   :              "  ;%1 @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( '<[65J);LQ^*P(  +LP   3              "
M 6U4 @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    != %T @AD  ,E6 @
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>319</ContextCount>
  <ElementCount>441</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>113</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200305 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of the business and basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the business and basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Fair value of financial assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair value of financial assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Accrued expenses and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued expenses and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Ordinary shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureOrdinaryShares</Role>
      <ShortName>Ordinary shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Significant agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreements</Role>
      <ShortName>Significant agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Benefit plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureBenefitPlans</Role>
      <ShortName>Benefit plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Segments and geographic information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformation</Role>
      <ShortName>Segments and geographic information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Accrued expenses and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued expenses and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Share-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Significant agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables</Role>
      <ShortName>Significant agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99931503 - Disclosure - Segments and geographic information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables</Role>
      <ShortName>Segments and geographic information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Nature of the business and basis of presentation - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails</Role>
      <ShortName>Nature of the business and basis of presentation - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of significant accounting policies - Foreign currency and currency translation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails</Role>
      <ShortName>Summary of significant accounting policies - Foreign currency and currency translation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940202 - Disclosure - Summary of significant accounting policies - Concentrations of credit risk and of significant suppliers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails</Role>
      <ShortName>Summary of significant accounting policies - Concentrations of credit risk and of significant suppliers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940203 - Disclosure - Summary of significant accounting policies - Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails</Role>
      <ShortName>Summary of significant accounting policies - Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940204 - Disclosure - Summary of significant accounting policies - Property and equipment, Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails</Role>
      <ShortName>Summary of significant accounting policies - Property and equipment, Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940205 - Disclosure - Summary of significant accounting policies - Research and development incentives and receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails</Role>
      <ShortName>Summary of significant accounting policies - Research and development incentives and receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940206 - Disclosure - Summary of significant accounting policies - Share based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails</Role>
      <ShortName>Summary of significant accounting policies - Share based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Accrued expenses and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued expenses and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureDebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureDebtTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - Debt - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails</Role>
      <ShortName>Debt - Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Ordinary shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails</Role>
      <ShortName>Ordinary shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureOrdinaryShares</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - Ordinary shares - Share Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails</Role>
      <ShortName>Ordinary shares - Share Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Share-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>Share-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Share-based compensation - Share based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-based compensation - Share based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Share-based compensation - Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails</Role>
      <ShortName>Share-based compensation - Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails</Role>
      <ShortName>Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99940805 - Disclosure - Share-based compensation - Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails</Role>
      <ShortName>Share-based compensation - Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Significant agreements - Collaboration revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails</Role>
      <ShortName>Significant agreements - Collaboration revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Significant agreements - Bayer Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails</Role>
      <ShortName>Significant agreements - Bayer Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails</Role>
      <ShortName>Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99940904 - Disclosure - Significant agreements - Novartis Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails</Role>
      <ShortName>Significant agreements - Novartis Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99940905 - Disclosure - Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails</Role>
      <ShortName>Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99940906 - Disclosure - Significant agreements - Ionis Evaluation and Option Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails</Role>
      <ShortName>Significant agreements - Ionis Evaluation and Option Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99940907 - Disclosure - Significant agreements - Ionis Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails</Role>
      <ShortName>Significant agreements - Ionis Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99940908 - Disclosure - Significant agreements - Ionis Share Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails</Role>
      <ShortName>Significant agreements - Ionis Share Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99940909 - Disclosure - Significant agreements - Ionis Accounting Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails</Role>
      <ShortName>Significant agreements - Ionis Accounting Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99940910 - Disclosure - Significant agreements - Genentech Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails</Role>
      <ShortName>Significant agreements - Genentech Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>99940911 - Disclosure - Significant agreements - Summary of Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails</Role>
      <ShortName>Significant agreements - Summary of Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>99940912 - Disclosure - Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails</Role>
      <ShortName>Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>99940913 - Disclosure - Significant agreements - Cancer Research UK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails</Role>
      <ShortName>Significant agreements - Cancer Research UK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Income taxes - Components of net loss before tax provision from income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Components of net loss before tax provision from income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Income taxes - Components of benefit for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Components of benefit for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>99941003 - Disclosure - Income taxes - Reconciliation of benefit for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Reconciliation of benefit for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>99941004 - Disclosure - Income taxes - Components of the company's current and deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails</Role>
      <ShortName>Income taxes - Components of the company's current and deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>99941005 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Commitments and contingencies - Operating Leases and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails</Role>
      <ShortName>Commitments and contingencies - Operating Leases and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Commitments and contingencies - Components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Commitments and contingencies - Components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>99941103 - Disclosure - Commitments and contingencies - Leases, Maturities of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails</Role>
      <ShortName>Commitments and contingencies - Leases, Maturities of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Net loss per share - Basic and diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net loss per share - Basic and diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Net loss per share - Securities excluded from the diluted per share calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails</Role>
      <ShortName>Net loss per share - Securities excluded from the diluted per share calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Benefit plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails</Role>
      <ShortName>Benefit plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureBenefitPlans</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Related party transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related party transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>99941501 - Disclosure - Segments and geographic information - Significant segment expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails</Role>
      <ShortName>Segments and geographic information - Significant segment expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>99941502 - Disclosure - Segments and geographic information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails</Role>
      <ShortName>Segments and geographic information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="bcyc-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bicycletherapeutics.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcyc-20241231.xsd</File>
    <File>bcyc-20241231_cal.xml</File>
    <File>bcyc-20241231_def.xml</File>
    <File>bcyc-20241231_lab.xml</File>
    <File>bcyc-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="bcyc-20241231x10k.htm">bcyc-20241231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bcyc-20241231x10k001.jpg</File>
    <File>bcyc-20241231x10k002.jpg</File>
    <File>bcyc-20241231x10k003.jpg</File>
    <File>bcyc-20241231x10k004.jpg</File>
    <File>bcyc-20241231x10k005.jpg</File>
    <File>bcyc-20241231x10k006.jpg</File>
    <File>bcyc-20241231x10k007.jpg</File>
    <File>bcyc-20241231x10k008.jpg</File>
    <File>bcyc-20241231x10k009.jpg</File>
    <File>bcyc-20241231x10k010.jpg</File>
    <File>bcyc-20241231x10k011.jpg</File>
    <File>bcyc-20241231x10k012.jpg</File>
    <File>bcyc-20241231x10k013.jpg</File>
    <File>bcyc-20241231x10k014.jpg</File>
    <File>bcyc-20241231x10k015.jpg</File>
    <File>bcyc-20241231x10k016.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="824">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>131
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcyc-20241231x10k.htm": {
   "nsprefix": "bcyc",
   "nsuri": "http://www.bicycletherapeutics.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "bcyc-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bcyc-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcyc-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcyc-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcyc-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "bcyc-20241231x10k.htm"
     ]
    }
   },
   "keyStandard": 337,
   "keyCustom": 104,
   "axisStandard": 31,
   "axisCustom": 1,
   "memberStandard": 33,
   "memberCustom": 77,
   "hidden": {
    "total": 31,
    "http://fasb.org/us-gaap/2024": 20,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://www.bicycletherapeutics.com/20241231": 5
   },
   "contextCount": 319,
   "entityCount": 1,
   "segmentCount": 113,
   "elementCount": 818,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 824,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "longName": "995200300 - Statement - Consolidated Statements of Shareholders' Equity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical",
     "longName": "995200305 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "longName": "995210101 - Disclosure - Nature of the business and basis of presentation",
     "shortName": "Nature of the business and basis of presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities",
     "longName": "995210301 - Disclosure - Fair value of financial assets and liabilities",
     "shortName": "Fair value of financial assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNet",
     "longName": "995210401 - Disclosure - Property and equipment, net",
     "shortName": "Property and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995210501 - Disclosure - Accrued expenses and other current liabilities",
     "shortName": "Accrued expenses and other current liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureDebt",
     "longName": "995210601 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureOrdinaryShares",
     "longName": "995210701 - Disclosure - Ordinary shares",
     "shortName": "Ordinary shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensation",
     "longName": "995210801 - Disclosure - Share-based compensation",
     "shortName": "Share-based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreements",
     "longName": "995210901 - Disclosure - Significant agreements",
     "shortName": "Significant agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxes",
     "longName": "995211001 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211101 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShare",
     "longName": "995211201 - Disclosure - Net loss per share",
     "shortName": "Net loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlans",
     "longName": "995211301 - Disclosure - Benefit plans",
     "shortName": "Benefit plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactions",
     "longName": "995211401 - Disclosure - Related party transactions",
     "shortName": "Related party transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformation",
     "longName": "995211501 - Disclosure - Segments and geographic information",
     "shortName": "Segments and geographic information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEvents",
     "longName": "995211601 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "99930203 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentImpairment",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentImpairment",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "99930403 - Disclosure - Property and equipment, net (Tables)",
     "shortName": "Property and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "99930503 - Disclosure - Accrued expenses and other current liabilities (Tables)",
     "shortName": "Accrued expenses and other current liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureDebtTables",
     "longName": "99930603 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables",
     "longName": "99930803 - Disclosure - Share-based compensation (Tables)",
     "shortName": "Share-based compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables",
     "longName": "99930903 - Disclosure - Significant agreements (Tables)",
     "shortName": "Significant agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931003 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "99931103 - Disclosure - Commitments and contingencies (Tables)",
     "shortName": "Commitments and contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931203 - Disclosure - Net loss per share (Tables)",
     "shortName": "Net loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables",
     "longName": "99931503 - Disclosure - Segments and geographic information (Tables)",
     "shortName": "Segments and geographic information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails",
     "longName": "99940101 - Disclosure - Nature of the business and basis of presentation - Liquidity (Details)",
     "shortName": "Nature of the business and basis of presentation - Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails",
     "longName": "99940201 - Disclosure - Summary of significant accounting policies - Foreign currency and currency translation (Details)",
     "shortName": "Summary of significant accounting policies - Foreign currency and currency translation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails",
     "longName": "99940202 - Disclosure - Summary of significant accounting policies - Concentrations of credit risk and of significant suppliers (Details)",
     "shortName": "Summary of significant accounting policies - Concentrations of credit risk and of significant suppliers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:AccountsReceivableNetCurrent",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:AccountsReceivableNetCurrent",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
     "longName": "99940203 - Disclosure - Summary of significant accounting policies - Cash and cash equivalents (Details)",
     "shortName": "Summary of significant accounting policies - Cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails",
     "longName": "99940204 - Disclosure - Summary of significant accounting policies - Property and equipment, Geographic (Details)",
     "shortName": "Summary of significant accounting policies - Property and equipment, Geographic (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:NumberOfGeographicRegionsInWhichOperating",
      "unitRef": "Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:NumberOfGeographicRegionsInWhichOperating",
      "unitRef": "Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails",
     "longName": "99940205 - Disclosure - Summary of significant accounting policies - Research and development incentives and receivable (Details)",
     "shortName": "Summary of significant accounting policies - Research and development incentives and receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ReductionOfResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "bcyc:ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ReductionOfResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "bcyc:ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails",
     "longName": "99940206 - Disclosure - Summary of significant accounting policies - Share based compensation (Details)",
     "shortName": "Summary of significant accounting policies - Share based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "longName": "99940301 - Disclosure - Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details)",
     "shortName": "Fair value of financial assets and liabilities - Financial assets and liabilities measured at fair value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5MPhoYm4pEaBvoSPbVf8mQ",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "longName": "99940401 - Disclosure - Property and equipment, net (Details)",
     "shortName": "Property and equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "99940501 - Disclosure - Accrued expenses and other current liabilities (Details)",
     "shortName": "Accrued expenses and other current liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "bcyc:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "bcyc:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
     "longName": "99940601 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails",
     "longName": "99940602 - Disclosure - Debt - Debt (Details)",
     "shortName": "Debt - Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails",
     "longName": "99940701 - Disclosure - Ordinary shares (Details)",
     "shortName": "Ordinary shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:NumberOfVotePerShare",
      "unitRef": "Unit_Standard_Vote_F2iWXsaSbUSm_tPiCaeIdA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:NumberOfVotePerShare",
      "unitRef": "Unit_Standard_Vote_F2iWXsaSbUSm_tPiCaeIdA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
     "longName": "99940702 - Disclosure - Ordinary shares - Share Purchase Agreement (Details)",
     "shortName": "Ordinary shares - Share Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y61uWaX9NEaChNzvdxBdnQ",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
     "longName": "99940801 - Disclosure - Share-based compensation (Details)",
     "shortName": "Share-based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_1_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_llEDFF1MSUKzib9liGvGRg",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "99940802 - Disclosure - Share-based compensation - Share based compensation expense (Details)",
     "shortName": "Share-based compensation - Share based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_IrNimC9diUCVSYzfxLOnXA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails",
     "longName": "99940803 - Disclosure - Share-based compensation - Share Options (Details)",
     "shortName": "Share-based compensation - Share Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
     "longName": "99940804 - Disclosure - Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details)",
     "shortName": "Share-based compensation - Assumptions used in the Black Scholes option pricing model to determine the fair value of share options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails",
     "longName": "99940805 - Disclosure - Share-based compensation - Restricted Share Units (Details)",
     "shortName": "Share-based compensation - Restricted Share Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
     "longName": "99940901 - Disclosure - Significant agreements - Collaboration revenues (Details)",
     "shortName": "Significant agreements - Collaboration revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_DementiaDiscoveryFundCollaborationAgreementMember_LB_cYGPJt0-dBCSytUGDoA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
     "longName": "99940902 - Disclosure - Significant agreements - Bayer Collaboration Agreement (Details)",
     "shortName": "Significant agreements - Bayer Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg",
      "name": "bcyc:CollaborativeArrangementUpfrontCashPaymentReceived",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
     "longName": "99940903 - Disclosure - Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details)",
     "shortName": "Significant agreements - Bayer Collaboration Agreement - Accounting Analysis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A",
      "name": "bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yFgBlbVotUajI_G7d99bBg",
      "name": "bcyc:NumberOfCombinedPerformanceObligations",
      "unitRef": "Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
     "longName": "99940904 - Disclosure - Significant agreements - Novartis Collaboration Agreement (Details)",
     "shortName": "Significant agreements - Novartis Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_k-g66Brr1Ea_7MONWi3pTQ",
      "name": "bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
     "longName": "99940905 - Disclosure - Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details)",
     "shortName": "Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w",
      "name": "bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w",
      "name": "bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails",
     "longName": "99940906 - Disclosure - Significant agreements - Ionis Evaluation and Option Agreement (Details)",
     "shortName": "Significant agreements - Ionis Evaluation and Option Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
     "longName": "99940907 - Disclosure - Significant agreements - Ionis Collaboration Agreement (Details)",
     "shortName": "Significant agreements - Ionis Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng",
      "name": "bcyc:PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng",
      "name": "bcyc:PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
     "longName": "99940908 - Disclosure - Significant agreements - Ionis Share Purchase Agreement (Details)",
     "shortName": "Significant agreements - Ionis Share Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_9_2021_To_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_IhORSIdihkWEmJuOaow7HQ",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
     "longName": "99940909 - Disclosure - Significant agreements - Ionis Accounting Analysis (Details)",
     "shortName": "Significant agreements - Ionis Accounting Analysis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw",
      "name": "bcyc:NumberOfMaterialRightsAssociatedWithFuturePayments",
      "unitRef": "Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
     "longName": "99940910 - Disclosure - Significant agreements - Genentech Collaboration Agreement (Details)",
     "shortName": "Significant agreements - Genentech Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ",
      "name": "bcyc:NumberOfPotentialDevelopmentCandidates",
      "unitRef": "Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
     "longName": "99940911 - Disclosure - Significant agreements - Summary of Contract Assets and Liabilities (Details)",
     "shortName": "Significant agreements - Summary of Contract Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ContractWithCustomerLiabilityAdditions",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails",
     "longName": "99940912 - Disclosure - Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details)",
     "shortName": "Significant agreements - Revenue recognition due to changes in contract assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "bcyc:RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "bcyc:RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
     "longName": "99940913 - Disclosure - Significant agreements - Cancer Research UK (Details)",
     "shortName": "Significant agreements - Cancer Research UK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_12_13_2016_-ccexalN_EuXuCJAskV6sA",
      "name": "bcyc:ResearchAndDevelopmentArrangementObligationToRepayOtherParties",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_13_2016_-ccexalN_EuXuCJAskV6sA",
      "name": "bcyc:ResearchAndDevelopmentArrangementObligationToRepayOtherParties",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails",
     "longName": "99941001 - Disclosure - Income taxes - Components of net loss before tax provision from income taxes (Details)",
     "shortName": "Income taxes - Components of net loss before tax provision from income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "bcyc:ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "bcyc:ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails",
     "longName": "99941002 - Disclosure - Income taxes - Components of benefit for income taxes (Details)",
     "shortName": "Income taxes - Components of benefit for income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails",
     "longName": "99941003 - Disclosure - Income taxes - Reconciliation of benefit for income taxes (Details)",
     "shortName": "Income taxes - Reconciliation of benefit for income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails",
     "longName": "99941004 - Disclosure - Income taxes - Components of the company's current and deferred tax assets (Details)",
     "shortName": "Income taxes - Components of the company's current and deferred tax assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails",
     "longName": "99941005 - Disclosure - Income taxes (Details)",
     "shortName": "Income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "bcyc:IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails",
     "longName": "99941101 - Disclosure - Commitments and contingencies - Operating Leases and Finance Leases (Details)",
     "shortName": "Commitments and contingencies - Operating Leases and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails",
     "longName": "99941102 - Disclosure - Commitments and contingencies - Components of lease expense (Details)",
     "shortName": "Commitments and contingencies - Components of lease expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
     "longName": "99941103 - Disclosure - Commitments and contingencies - Leases, Maturities of Operating Leases (Details)",
     "shortName": "Commitments and contingencies - Leases, Maturities of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "longName": "99941201 - Disclosure - Net loss per share - Basic and diluted net loss per share (Details)",
     "shortName": "Net loss per share - Basic and diluted net loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails",
     "longName": "99941202 - Disclosure - Net loss per share - Securities excluded from the diluted per share calculation (Details)",
     "shortName": "Net loss per share - Securities excluded from the diluted per share calculation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails",
     "longName": "99941301 - Disclosure - Benefit plans (Details)",
     "shortName": "Benefit plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_NRO15gR8R0C1PGFIWwvPqg",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_NRO15gR8R0C1PGFIWwvPqg",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "99941401 - Disclosure - Related party transactions (Details)",
     "shortName": "Related party transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_VGLTprSZ00ajPx_iwKZOCQ",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
     "longName": "99941501 - Disclosure - Segments and geographic information - Significant segment expenses (Details)",
     "shortName": "Segments and geographic information - Significant segment expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails",
     "longName": "99941502 - Disclosure - Segments and geographic information (Details)",
     "shortName": "Segments and geographic information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_Im4dTiIF5UiSe0qPdBr-ew",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_Im4dTiIF5UiSe0qPdBr-ew",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941601 - Disclosure - Subsequent events (Details)",
     "shortName": "Subsequent events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ObVPQDakX0Kipqu1I4B_ig",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ObVPQDakX0Kipqu1I4B_ig",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "Unit_Standard_USD_AdbFks_By0OXtvDENytjjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcyc-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r957"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskAndOfSignificantSuppliersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "bcyc_AccruedExternalResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through and payable for external research and development expenses.",
        "label": "Accrued External Research and Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued expenses and other current liabilities.",
        "label": "Accrued Liabilities and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accrued expenses and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accrued Liabilities and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r74",
      "r143",
      "r735",
      "r775",
      "r776"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r18",
      "r581",
      "r584",
      "r648",
      "r771",
      "r772",
      "r1122",
      "r1123",
      "r1124",
      "r1135",
      "r1136",
      "r1137",
      "r1139"
     ]
    },
    "bcyc_AchievementOfMilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AchievementOfMilestoneAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by achievement of milestone.",
        "label": "Achievement Of Milestone [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_AchievementOfMilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AchievementOfMilestoneDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of milestone, including but not limited to development, sales, commercial and regulatory milestones.",
        "label": "Achievement Of Milestone [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AchievementOfSpecifiedLevelsOfNetSalesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to achievement of specified levels of net sales.",
        "label": "Achievement of Specified Levels of Net Sales [Member]",
        "terseLabel": "Achievement of specified levels of net sales"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "bcyc_AdditionalNumberOfImmunoOncologyTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AdditionalNumberOfImmunoOncologyTargets",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of immuno oncology targets.",
        "label": "Additional Number Of Immuno Oncology Targets",
        "terseLabel": "Additional number of immuno oncology targets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r957",
      "r1342"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r1135",
      "r1136",
      "r1137",
      "r1139",
      "r1277",
      "r1345"
     ]
    },
    "bcyc_AdditionalResearchTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AdditionalResearchTerm",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional research term.",
        "label": "Additional Research Term",
        "terseLabel": "Additional research term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r480"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdrMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADR [Member]",
        "terseLabel": "American Depositary Shares",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r889",
      "r977",
      "r1223",
      "r1294",
      "r1295",
      "r1297"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1017",
      "r1027",
      "r1060"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1020",
      "r1030",
      "r1063"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "bcyc_AgreementWithThirdPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AgreementWithThirdPartyMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to agreement with third party.",
        "label": "Agreement With Third Party"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1055",
      "r1064",
      "r1068",
      "r1076"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r521"
     ]
    },
    "bcyc_AmendedIonisCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AmendedIonisCollaborationAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Amended Ionis Collaboration Agreement.",
        "label": "Amended Ionis"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r115",
      "r138",
      "r166",
      "r203",
      "r211",
      "r236",
      "r240",
      "r280",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r574",
      "r578",
      "r611",
      "r731",
      "r827",
      "r915",
      "r916",
      "r957",
      "r984",
      "r1171",
      "r1172",
      "r1298"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r144",
      "r166",
      "r280",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r574",
      "r578",
      "r611",
      "r957",
      "r1171",
      "r1172",
      "r1298"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r944"
     ]
    },
    "bcyc_AstrazenecaCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AstrazenecaCollaborationAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AstraZeneca collaboration agreement.",
        "label": "AstraZeneca",
        "terseLabel": "AstraZeneca collaboration deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to sale of stock at the market.",
        "label": "At the market offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990",
      "r1013"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990",
      "r1013"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990",
      "r1013"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "bcyc_BakerBrothersAdvisorsLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "BakerBrothersAdvisorsLpMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Baker Brothers Advisors LP and/or Felix J. Baker.",
        "label": "Baker Brothers Advisors LP [Member]",
        "terseLabel": "Baker Bros. Advisors LP"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_BayerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "BayerMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Bayer collaboration agreements.",
        "label": "Bayer",
        "terseLabel": "Bayer Collaboration Agreement",
        "verboseLabel": "Bayer collaboration deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of the business and basis of presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r85",
      "r86"
     ]
    },
    "bcyc_CancerResearchUkBtOneSevenOneEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CancerResearchUkBtOneSevenOneEightMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to BT 1718.",
        "label": "BT1718"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r724",
      "r1307"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r135",
      "r902"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r103"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r82",
      "r162"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r82"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1116",
      "r1309"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to certain research and development expenditures incurred prior to April 1, 2023.",
        "label": "Certain Research and Development Expenditures Incurred Prior to April 1, 2023 [Member]",
        "terseLabel": "Certain research and development expenditures incurred prior to April 1, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to certain research and development expenditures incurred thereafter April 1, 2023.",
        "label": "Certain Research and Development Expenditures Incurred, Thereafter April 1, 2023 [Member]",
        "terseLabel": "Certain research and development expenditures incurred thereafter April 1, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to certain research and development expenditures incurred thereafter April 1, 2024.",
        "label": "Certain Research and Development Expenditures Incurred, Thereafter April 1, 2024 [Member]",
        "terseLabel": "Certain research and development expenditures incurred April 1, 2024 and thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInContractWithCustomerAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInContractWithCustomerAssetAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Asset [Abstract]",
        "terseLabel": "Contract assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r140",
      "r141",
      "r142",
      "r166",
      "r191",
      "r192",
      "r195",
      "r197",
      "r205",
      "r206",
      "r280",
      "r327",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r366",
      "r367",
      "r370",
      "r373",
      "r380",
      "r611",
      "r780",
      "r781",
      "r782",
      "r783",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r815",
      "r836",
      "r859",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r1098",
      "r1129",
      "r1140"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r205",
      "r366",
      "r367",
      "r368",
      "r370",
      "r373",
      "r378",
      "r380",
      "r780",
      "r781",
      "r782",
      "r783",
      "r930",
      "r1098",
      "r1129"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "bcyc_CollaborationAgreementFutureMilestoneContingentPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationAgreementFutureMilestoneContingentPaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of future milestone payment payable upon the achievement of development, regulatory and commercial milestones,",
        "label": "Collaboration Agreement Future Milestone Contingent Payments Payable",
        "terseLabel": "Future milestone payment payable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationAgreementNumberOfTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationAgreementNumberOfTargets",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration targets under the collaboration agreement.",
        "label": "Collaboration Agreement , Number of Targets",
        "terseLabel": "Number of collaboration targets"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Regulatory, and initial commercialization milestones payments receivable by the entity.",
        "label": "Collaboration Agreement, Regulatory, And Initial Commercialization Milestones, Receivable",
        "terseLabel": "Regulatory, and initial commercialization milestones, payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationAgreementSalesMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of regulatory, development, commercialization or sales milestone payments, receivable by the entity.",
        "label": "Collaboration Agreement, Sales Milestone Payments, Receivable",
        "terseLabel": "Milestone payments, receivable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationAgreementTieredSalesMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationAgreementTieredSalesMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of tiered sales milestone payments.",
        "label": "Collaboration Agreement, Tiered Sales Milestone Payments Receivable",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of candidate compounds into further development under the collaboration and license agreement.",
        "label": "Collaboration and License Agreement, Number of candidate compounds into further development",
        "terseLabel": "Number of candidate compounds into further development"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationOnePerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationOnePerformanceObligationMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Collaboration 1 performance obligation.",
        "label": "Collaboration Program 1 Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationPerformanceOneAndTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationPerformanceOneAndTwoMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Collaboration One and Two.",
        "label": "Collaboration Program One and Two Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationProgram4PerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationProgram4PerformanceObligationMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Collaboration 4 performance obligation.",
        "label": "Collaboration Program 4 Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationProgramAmountOfMaterialRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationProgramAmountOfMaterialRights",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of material rights under collaboration program.",
        "label": "Collaboration Program Amount of Material Rights",
        "terseLabel": "Material rights"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationProgramThreePerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationProgramThreePerformanceObligationMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Collaboration 3 performance obligation.",
        "label": "Collaboration Program 3 Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborationTwoPerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborationTwoPerformanceObligationMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Collaboration 2 performance obligation.",
        "label": "Collaboration Program 2 Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborativeArrangementNoticeRequiredForTerminationOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborativeArrangementNoticeRequiredForTerminationOfAgreement",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold period of notice required for termination of agreement.",
        "label": "Collaborative Arrangement, Notice Required For Termination Of Agreement",
        "terseLabel": "Threshold period of notice required for termination of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CollaborativeArrangementUpfrontCashPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CollaborativeArrangementUpfrontCashPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront cash payment received from collaborative arrangement.",
        "label": "Collaborative Arrangement, Upfront Cash Payment Received",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Significant agreements.",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to combined licenses and research and discovery performance obligation.",
        "label": "Combined licenses and research and discovery performance obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r107",
      "r733",
      "r814"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r319",
      "r320",
      "r883",
      "r1160",
      "r1168"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r884"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Number of shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r975",
      "r976",
      "r978",
      "r979",
      "r980",
      "r981",
      "r1135",
      "r1136",
      "r1139",
      "r1277",
      "r1340",
      "r1345"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, nominal value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r815"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Ordinary shares, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r68",
      "r815",
      "r833",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares, including non-voting ordinary shares, \u00a30.01 nominal value; 155,876,645 and 59,612,613 shares authorized at December 31, 2024 and December 31, 2023, respectively; 69,061,418 and 42,431,766 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r734",
      "r957"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Benefit plans"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_CompletionOfAllMilestonesForTargetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "CompletionOfAllMilestonesForTargetsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to completion of first milestone for",
        "label": "Completion of All Milestones For Targets [Member]",
        "terseLabel": "Completion of all milestones for targets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r146",
      "r148",
      "r153",
      "r726",
      "r745",
      "r746"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensives loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and of significant suppliers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r119"
     ]
    },
    "bcyc_ConsultancyServicesWithStoneSunnyIslesInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ConsultancyServicesWithStoneSunnyIslesInc.Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to consultancy services with Stone Atlanta Estates LLC, successor-in-interest to Stone Sunny Isles Inc.",
        "label": "Consultancy services with Stone Sunny Isles Inc.",
        "terseLabel": "Consultancy services with Stone Atlanta Estates LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of changes in the balances of the Company's contract assets and liabilities",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Contract assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r384",
      "r395"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r395"
     ]
    },
    "bcyc_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in contract with customer, liability.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ContractWithCustomerLiabilityDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in contract with customer, liability.",
        "label": "Contract with Customer, Liability, Deductions",
        "negatedLabel": "Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityForeignCurrencyAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of adjustment in contract with customer, liability due to change in foreign exchange.",
        "label": "Contract with Customer, Liability, Foreign Currency Adjustment",
        "negatedTerseLabel": "Impact of Exchange Rates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "bcyc_ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized based on changes in transaction price that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized, Changes In Transaction Price",
        "terseLabel": "Revenue recognized based on changes in transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized based on expiration of material rights that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized, Expiration of Material Rights",
        "verboseLabel": "Revenue recognized based on expiration of material rights"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized based on proportional performance that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized, Proportional Performance Obligation",
        "terseLabel": "Revenue recognized based on proportional performance"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r340",
      "r368",
      "r654",
      "r675",
      "r730",
      "r903",
      "r905"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1132",
      "r1275"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax provision (benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r1132"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income tax provision (benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1132",
      "r1275"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1087"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1087"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1089"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1089"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1091"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1089"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r993",
      "r1082"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1083"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1083"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1081"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1081"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1081"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r995",
      "r1084"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r997",
      "r1086"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r997",
      "r1086"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1087"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1090"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1088"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1085"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r164",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r325",
      "r326",
      "r336",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r352",
      "r359",
      "r360",
      "r362",
      "r624"
     ]
    },
    "bcyc_DebtEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DebtEndOfTermCharge",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents an end of term charge related to debt.",
        "label": "Debt End Of Term Charge",
        "terseLabel": "End-of-term charge",
        "verboseLabel": "End of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Term loan payable",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r106",
      "r363"
     ]
    },
    "bcyc_DebtInstrumentEndOfTermChargeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DebtInstrumentEndOfTermChargeRate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate at which entity has to pay end term charge on the principle amount.",
        "label": "Debt Instrument End of Term Charge Rate",
        "terseLabel": "End term charge rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r624",
      "r625",
      "r926",
      "r927",
      "r954"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument stated percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r338"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r954",
      "r1130",
      "r1289",
      "r1290"
     ]
    },
    "bcyc_DebtInstrumentPrepaymentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DebtInstrumentPrepaymentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses for prepayment of debt.",
        "label": "Debt Instrument, Prepayment Charges",
        "terseLabel": "Prepayment charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r44",
      "r51",
      "r96",
      "r97",
      "r171",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r954",
      "r1130",
      "r1289",
      "r1290"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt issuance costs",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "verboseLabel": "Deferred offering costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1274",
      "r1275"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1288",
      "r1289",
      "r1290"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax (benefit) provision",
        "totalLabel": "Total deferred income tax (benefit) provision",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r125",
      "r1132"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred income tax (benefit) provision"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r105",
      "r547"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "bcyc_DeferredRevenueMaterialRightsOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DeferredRevenueMaterialRightsOptionMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents deferred revenue allocated to material rights that will commence revenue recognition when the respective option is exercised or when the option expires.",
        "label": "Deferred revenue material rights option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1274",
      "r1275"
     ]
    },
    "bcyc_DeferredTaxAssetDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DeferredTaxAssetDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from depreciation and amortization.",
        "label": "Deferred Tax Asset, Depreciation and Amortization",
        "terseLabel": "Depreciation &amp; amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1270"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "U.K. operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfCompanySCurrentAndDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contributions made",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Benefit plans",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "bcyc_DementiaDiscoveryFundCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DementiaDiscoveryFundCollaborationAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Dementia Discovery Fund collaboration agreement.",
        "label": "Dementia Discovery Fund"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r33"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r203",
      "r216",
      "r240",
      "r915",
      "r916"
     ]
    },
    "bcyc_DevelopmentAndRegulatoryMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of development and regulatory first commercial sale milestone.",
        "label": "Development and regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_DevelopmentMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "DevelopmentMilestoneMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of development milestone.",
        "label": "Development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Non-employee Director"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1341"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r482",
      "r513",
      "r514",
      "r516",
      "r937"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990",
      "r1013"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990",
      "r1013",
      "r1056"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticPlanMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1238",
      "r1239",
      "r1240"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r188",
      "r191",
      "r195",
      "r196",
      "r197",
      "r202",
      "r568",
      "r571",
      "r589",
      "r590",
      "r727",
      "r747",
      "r907"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r191",
      "r195",
      "r196",
      "r197",
      "r202",
      "r568",
      "r571",
      "r589",
      "r590",
      "r727",
      "r747",
      "r907"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r199"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r198",
      "r200",
      "r201"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r941"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Increases (decreases) resulting from:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "(Benefit from) provision for income taxes at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r532",
      "r559",
      "r941"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r941",
      "r1133",
      "r1268"
     ]
    },
    "bcyc_EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign exchange rates.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Exchange Rate Differential, Percent",
        "terseLabel": "Impact of foreign exchange rates"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic feieral statutory income tax rates to pretax income (loss) from continuing operations attributable to Impact of statutory rate change.",
        "label": "Effective Income Tax Rate Reconciliation, Impact Of Statutory Rate Change, Percentage",
        "terseLabel": "Impact of statutory rate change"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net losses surrendered for research credit.",
        "label": "Effective Income Tax Rate Reconciliation, Net Losses Surrendered for Research Credit",
        "terseLabel": "Net losses surrendered for research credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1133",
      "r1268",
      "r1269"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesReconciliationOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r537",
      "r1133",
      "r1268"
     ]
    },
    "bcyc_EmployeeAndDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "EmployeeAndDirectorMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employee and director.",
        "label": "Employees and directors",
        "terseLabel": "Employees and directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share based compensation expense",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense related to the unvested employee and director",
        "verboseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average Period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Share Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase ordinary shares",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r130",
      "r150",
      "r151",
      "r152",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r204",
      "r281",
      "r282",
      "r304",
      "r381",
      "r557",
      "r558",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r626",
      "r627",
      "r648",
      "r743",
      "r771",
      "r772",
      "r773",
      "r790",
      "r859"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1017",
      "r1027",
      "r1060"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1014",
      "r1024",
      "r1057"
     ]
    },
    "bcyc_EstimatedAmountOfReimbursementPayableToContractResearchOrganizations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "EstimatedAmountOfReimbursementPayableToContractResearchOrganizations",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of reimbursement payable for services provided by Contract Research Organizations (CROs).",
        "label": "Estimated Amount Of Reimbursement Payable To Contract Research Organizations",
        "terseLabel": "Estimated amount payable to CROs"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_EstimatedVariableConsiderationNoLongerConstrained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "EstimatedVariableConsiderationNoLongerConstrained",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated variable consideration no longer constrained.",
        "label": "Estimated Variable Consideration No Longer Constrained",
        "terseLabel": "Amount of estimate of variable consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "bcyc_ExpansionFeePerAdditionalCollaborationProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ExpansionFeePerAdditionalCollaborationProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expansion fee to per additional collaboration program.",
        "label": "Expansion Fee Per Additional Collaboration Program",
        "terseLabel": "Expansion fee"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the expiration of two material rights associated with limited substitution rights.",
        "label": "Expiration of Two Material Rights Associate With Limited Substitution Rights [Member]",
        "terseLabel": "Expiration of two material rights associated with limited substitution rights"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_FacilityExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "FacilityExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for utilizing the facility for clinical trials categorized as research and development activities.",
        "label": "Facility Expenses",
        "terseLabel": "Facility expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value of financial assets and liabilities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r603",
      "r944"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r603",
      "r944"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r602",
      "r603",
      "r605",
      "r662",
      "r663",
      "r664",
      "r926",
      "r927",
      "r933",
      "r934",
      "r935",
      "r944",
      "r947"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r594",
      "r596",
      "r944",
      "r1282",
      "r1285"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value of financial assets and liabilities",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r600",
      "r601",
      "r602",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r725",
      "r944",
      "r948"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r423",
      "r428",
      "r593",
      "r603",
      "r662",
      "r933",
      "r934",
      "r935",
      "r944"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r594",
      "r596",
      "r944",
      "r1282",
      "r1285"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r602",
      "r603",
      "r605",
      "r662",
      "r663",
      "r664",
      "r926",
      "r927",
      "r933",
      "r934",
      "r935",
      "r944",
      "r947"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1285"
     ]
    },
    "bcyc_FairValueOfSharesHeld": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "FairValueOfSharesHeld",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of shares held.",
        "label": "Fair Value Of Shares Held",
        "terseLabel": "Fair value of shares held"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost incurred by the lessee over the term of finance lease.",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on finance lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r638",
      "r956"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Cash paid for interest on finance lease obligations",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r641"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liabilities",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r645"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: current lease liabilities",
        "terseLabel": "Current portion of finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long term lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance lease obligations",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r641"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails",
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization expense of property and equipment under finance leases",
        "verboseLabel": "Amortization of finance lease right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r638",
      "r956"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average finance lease discount rate",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r956"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining finance lease term (years)",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r956"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r361",
      "r378",
      "r586",
      "r610",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r744",
      "r922",
      "r944",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r958",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1278",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure",
        "verboseLabel": "Liabilities at fair value",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1279",
      "r1280",
      "r1284"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyAndCurrencyTranslationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Effect of foreign exchange rates",
        "terseLabel": "Foreign exchange gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614",
      "r615",
      "r616",
      "r856"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency and currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_ForeignPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignPlanMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1238",
      "r1239",
      "r1240"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1064"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1064"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1064"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1064"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1064"
     ]
    },
    "bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to four material rights associated with credits for IND acceptance fees.",
        "label": "Four material rights associated with credits for IND Acceptance fees"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Four Material rights for substitution rights for technical failure.",
        "label": "Material rights for associated and limited substitution rights",
        "terseLabel": "Material rights associated with limited substitution rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and office equipment",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the amount paid to settle and carrying amount of research and development funding liability which is extinguished.",
        "label": "Gain (Loss) on Extinguishment of Research and Development Funding Liability",
        "negatedLabel": "Gain on extinguishment of research and development funding liability",
        "terseLabel": "Gain on extinguishment of research and development funding liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Termination of Lease",
        "terseLabel": "Loss on lease termination",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37",
      "r38"
     ]
    },
    "bcyc_GenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "GenentechMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Genentech collaboration agreement.",
        "label": "Genentech",
        "terseLabel": "Genentech collaboration deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "Total general and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r838"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "bcyc_GeneralAndAdministrativeShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "GeneralAndAdministrativeShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized, allocated to general and administration activities of the company as a whole.",
        "label": "General And Administrative, Share Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r481",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r481",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990",
      "r1013"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r91"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r531"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income tax provision",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r109",
      "r114",
      "r728",
      "r740",
      "r909",
      "r915",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "United Kingdom",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r531"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r312",
      "r314",
      "r597",
      "r599",
      "r604",
      "r768",
      "r770",
      "r843",
      "r897",
      "r946",
      "r1311"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r314",
      "r597",
      "r599",
      "r604",
      "r768",
      "r770",
      "r843",
      "r897",
      "r946",
      "r1311"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r532",
      "r533",
      "r542",
      "r553",
      "r941",
      "r1271"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r532",
      "r533",
      "r542",
      "r553",
      "r941",
      "r1271"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r526",
      "r532",
      "r538",
      "r539",
      "r540",
      "r544",
      "r551",
      "r560",
      "r562",
      "r563",
      "r564",
      "r785",
      "r941"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesComponentsOfBenefitForIncomeTaxesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "(Benefit from) provision for income taxes",
        "totalLabel": "Total (benefit from) provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r126",
      "r184",
      "r185",
      "r203",
      "r219",
      "r240",
      "r530",
      "r532",
      "r561",
      "r748",
      "r941"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r528",
      "r529",
      "r544",
      "r545",
      "r550",
      "r555",
      "r779"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r161",
      "r552",
      "r553"
     ]
    },
    "bcyc_IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase or decrease in future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Increase Decrease Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Changes in purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes",
        "terseLabel": "Increase (decrease) in income taxes",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1128"
     ]
    },
    "bcyc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of operating lease right-of-use assets reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Operating Lease Right-of-use Assets",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "bcyc_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) for research and development incentives receivable.",
        "label": "Increase (Decrease) in Research and Development Incentives Receivable",
        "negatedLabel": "Research and development incentives receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (decrease) in shareholders' equity (deficit)",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incremental income tax benefits due to completion of research and development tax credit study during the period.",
        "label": "Incremental Income Tax Benefit on Completion of Research and Development Tax Credit Study",
        "terseLabel": "Incremental income tax benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r924"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r924"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1055",
      "r1064",
      "r1068",
      "r1076"
     ]
    },
    "bcyc_InducementPlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "InducementPlan2024Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2024 Inducement Plan.",
        "label": "Inducement Plan, 2024 [Member]",
        "terseLabel": "2024 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_InitialTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "InitialTermLoanMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to initial term loan.",
        "label": "Initial Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1080"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1080"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1080"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Costs Incurred to Renew or Extend, Policy [Policy Text Block]",
        "terseLabel": "Patent costs",
        "documentation": "Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r1156"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Long-Term Debt",
        "terseLabel": "Interest expense",
        "documentation": "Aggregate amount of interest paid or due on all long-term debt."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r128",
      "r129"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r1126"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest on debt",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r159",
      "r160"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued and unpaid interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to internal program for clinical trial of Bicycle tumor-targeted immune cell agonists molecule, a BT7480 for immune.",
        "label": "Internal Program, Bicycle Tumor-Targeted Immune Cell Agonists, B T 7480 [Member]",
        "terseLabel": "Bicycle tumor-targeted immune cell agonists"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to internal program for clinical trial of product candidate, a Bicycle Toxin Conjugate molecule BT5528 for tumors.",
        "label": "Internal Program, Product Candidate, Bicycle Toxin Conjugate Molecule, B T 5528 [Member]",
        "terseLabel": "BT5528 (EphA2)"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to internal program for clinical trial of product candidate, a Bicycle Toxin Conjugate molecule BT8009 for tumors.",
        "label": "Internal Program, Product Candidate, Bicycle Toxin Conjugate Molecule, B T 8009 [Member]",
        "terseLabel": "Zelenectide pevedotin (Nectin-4)"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_InvestorsPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "InvestorsPurchaseAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Investors Share Purchase Agreement.",
        "label": "Investors Purchase Agreement [Member]",
        "terseLabel": "Investors Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_IonisCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "IonisCollaborationAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Ionis Collaboration Agreement.",
        "label": "Ionis",
        "terseLabel": "Ionis collaboration deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_IonisEvaluationAndOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "IonisEvaluationAndOptionAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ionis Evaluation and Option Agreement.",
        "label": "Ionis Evaluation and Option Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_IonisSharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "IonisSharePurchaseAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ionis Share Purchase Agreement.",
        "label": "Ionis Share Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Personnel-related costs",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r646"
     ]
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Description [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r647"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "bcyc_LesseeOperatingLeaseContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseContractualTerm",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total contractual term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Contractual Term",
        "terseLabel": "Lease total contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discounted percentage for present value of lease payments",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1293"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "bcyc_LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease through remaining of December.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remaining Through December",
        "terseLabel": "Payments for the extended lease remaining"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "bcyc_LesseeOperatingLeaseRentFreePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseRentFreePeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rent free period lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Rent Free Period",
        "terseLabel": "Rent free period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Leases, term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r56",
      "r57",
      "r58",
      "r61",
      "r62",
      "r63",
      "r66",
      "r166",
      "r280",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r575",
      "r578",
      "r579",
      "r611",
      "r813",
      "r908",
      "r984",
      "r1171",
      "r1298",
      "r1299"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r108",
      "r737",
      "r957",
      "r1131",
      "r1155",
      "r1286"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r134",
      "r166",
      "r280",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r575",
      "r578",
      "r579",
      "r611",
      "r957",
      "r1171",
      "r1298",
      "r1299"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r60"
     ]
    },
    "bcyc_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Loan and Security agreement",
        "label": "Loan and Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of long-lived assets, including operating lease right-of-use assets, held in different geographic regions",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "totalLabel": "Carrying value of term loan",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r106",
      "r349",
      "r364",
      "r926",
      "r927",
      "r954",
      "r1308"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of discount",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r36",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to material right associated with limited substitution rights for either the first or second target.",
        "label": "Material right associated with limited substitution rights for either the first or second target [Member]",
        "terseLabel": "Material right associated with limited substitution rights for either the first or second target"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to material right for the option to expand the collaboration to include a third target and the underlying additional option rights.",
        "label": "Material right for the option to expand the collaboration to include a third target and the underlying additional option rights [Member]",
        "terseLabel": "Material right for the option to expand the collaboration to include a third target and the underlying additional option rights"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to material rights associated with the LSR Go Option For Collaboration Program Four.",
        "label": "Material rights associated with the LSR Go Option for Collaboration Programs Four"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to material rights associated with the LSR Go Option For Collaboration Programs one.",
        "label": "Material Rights Associated With Lsr Go Option For Collaboration Programs One [Member]",
        "terseLabel": "Material rights associated with the LSR Go Option for Collaboration Programs One"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to material rights associated with the LSR Go Option For Collaboration Programs Three.",
        "label": "Material rights associated with the LSR Go Option for Collaboration Programs Three"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_MaterialRightsExerciseOrExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MaterialRightsExerciseOrExpiryTerm",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of material rights exercised or expired.",
        "label": "Material Rights Exercise or Expiry Term",
        "terseLabel": "Material rights exercise period"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum days allowed for cancellation of contracts prior written notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Days Allowed for Cancellation of Contracts Prior Written Notice",
        "terseLabel": "Maximum days allowed for cancellation of contracts prior written notice"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r472",
      "r522",
      "r596",
      "r691",
      "r767",
      "r769",
      "r777",
      "r805",
      "r806",
      "r867",
      "r869",
      "r871",
      "r872",
      "r874",
      "r895",
      "r896",
      "r921",
      "r930",
      "r936",
      "r947",
      "r948",
      "r952",
      "r953",
      "r968",
      "r1173",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "bcyc_MilestoneAcrossAllPotentialTargetProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "MilestoneAcrossAllPotentialTargetProgramsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of sales milestone resulting in receivable across all potential target programs and/or on diagnostic products.",
        "label": "Across all three potential target programs"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r472",
      "r522",
      "r596",
      "r691",
      "r767",
      "r769",
      "r777",
      "r805",
      "r806",
      "r867",
      "r869",
      "r871",
      "r872",
      "r874",
      "r895",
      "r896",
      "r921",
      "r930",
      "r936",
      "r947",
      "r948",
      "r952",
      "r968",
      "r1173",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Market funds",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash used in investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r84",
      "r110",
      "r132",
      "r145",
      "r147",
      "r152",
      "r166",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r193",
      "r280",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r568",
      "r571",
      "r590",
      "r611",
      "r742",
      "r835",
      "r857",
      "r858",
      "r982",
      "r1171"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net loss",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r177",
      "r178",
      "r179",
      "r180",
      "r188",
      "r189",
      "r194",
      "r197",
      "r571"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to lease agreement for new office and laboratory space in Cambridge, U.K.",
        "label": "New Office and laboratory space in Cambridge, United Kingdom [Member]",
        "terseLabel": "New Office and laboratory space in Cambridge, United Kingdom"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NonCashInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as non cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1021",
      "r1031",
      "r1055",
      "r1064"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "bcyc_NonVotingOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NonVotingOrdinarySharesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to non-voting ordinary shares.",
        "label": "Non voting ordinary shares",
        "terseLabel": "Non-voting ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "terseLabel": "Long lived assets, including operating lease right of use assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted ordinary share award activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "bcyc_NovartisCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NovartisCollaborationAgreementMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Novartis Collaboration Agreement.",
        "label": "Novartis",
        "terseLabel": "Novartis",
        "verboseLabel": "Novartis collaboration deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfCollaborationPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfCollaborationPrograms",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of collaboration programs.",
        "label": "Number of Collaboration programs",
        "terseLabel": "Number of collaboration programs"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfCombinedPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfCombinedPerformanceObligations",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of combined performance obligations.",
        "label": "Number Of Combined Performance Obligations",
        "terseLabel": "Combined performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfExpansionOptionCollaborationProgramsDevGo",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of expansion option programs (Dev Go option).",
        "label": "Number Of Expansion Option Collaboration Programs Dev Go",
        "terseLabel": "Number of expansion option collaboration programs"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfGeographicRegionsInWhichOperating": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfGeographicRegionsInWhichOperating",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of geographic regions in which the entity operates.",
        "label": "Number Of Geographic Regions In Which Operating",
        "terseLabel": "Number of geographic regions"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfImmunoOncologyTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfImmunoOncologyTargets",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of immuno oncology targets.",
        "label": "Number Of Immuno Oncology Targets",
        "terseLabel": "Number of immuno oncology targets"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfInitialCollaborationPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfInitialCollaborationPrograms",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of initial Genentech Collaboration Programs exercised.",
        "label": "Number Of Initial Collaboration Programs",
        "terseLabel": "Number of initial collaboration programs exercised"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfJurisdictions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfJurisdictions",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of Jurisdictions.",
        "label": "Number of Jurisdictions",
        "terseLabel": "Number of jurisdictions"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfMaterialRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfMaterialRights",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of material rights usually associated with an option.",
        "label": "Number Of Material Rights",
        "terseLabel": "Number of material rights"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfMaterialRightsAssociatedWithFuturePayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfMaterialRightsAssociatedWithFuturePayments",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of material rights associated with future payments.",
        "label": "Number of Material Rights Associated with Future Payments",
        "terseLabel": "Number of material rights associated with future payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of geographic regions",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r1144"
     ]
    },
    "bcyc_NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of payments of a mid-single-digit million dollar, failing to achieve the specified development diligence.",
        "label": "Number Of Payments Of Mid-single-digit Million Dollar, Failing to Achieve Specified Development Diligence Milestone",
        "terseLabel": "Number of payments of a mid-single-digit million dollar, failing to achieve the specified development diligence"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfPotentialDevelopmentCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfPotentialDevelopmentCandidates",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Potential development candidates.",
        "label": "Number Of Potential Development Candidates",
        "terseLabel": "Number of potential development candidates"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfQuarterlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfQuarterlyInstallments",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is representing number of quarterly installments.",
        "label": "Number Of Quarterly Installments",
        "terseLabel": "Number of quarterly installments"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfVotePerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfVotePerShare",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vote per share.",
        "label": "Number of Vote Per Share",
        "terseLabel": "Vote per ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_NumberOfYearsOverWhichRoyaltyIsPayable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "NumberOfYearsOverWhichRoyaltyIsPayable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of years over which royalty is payable.",
        "label": "Number Of Years Over Which Royalty Is Payable",
        "terseLabel": "Number of years over which royalty is payable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to lease agreement for office and laboratory space in Building 900, Babraham Research Campus, Cambridge, U.K.",
        "label": "Office and laboratory space in Building 900, Babraham Research Campus, Cambridge"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "OfficeAndLaboratorySpaceInCambridgeMassachusettsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale related to office and laboratory space in Cambridge, Massachusetts.",
        "label": "Office and laboratory space in Cambridge Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "OfficeAndLaboratorySpaceInLexingtonMassachusettsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to lease agreement for office and laboratory space in Lexington, Massachusetts.",
        "label": "Office and laboratory space in Lexington, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:",
        "verboseLabel": "Significant segment expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r909",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "bcyc_OperatingLeaseAgreementEstimatedServiceCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "OperatingLeaseAgreementEstimatedServiceCharges",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated service charges pertaining to operating lease per operating lease agreement.",
        "label": "Operating Lease Agreement, Estimated Service Charges",
        "terseLabel": "Estimated service charges payable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_OperatingLeaseAnnualRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "OperatingLeaseAnnualRent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rental of an operating lease agreement.",
        "label": "Operating Lease, Annual Rent",
        "terseLabel": "Annual rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r956"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current lease liabilities",
        "verboseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long term lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r641"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "weighted average operating lease discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r956"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining operating lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r956"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "verboseLabel": "Income taxes.",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "bcyc_OptionFeeForDevelopmentAndExploitationRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "OptionFeeForDevelopmentAndExploitationRights",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be paid upon exercise of an option by the customer.",
        "label": "Option Fee for Development and Exploitation Rights",
        "terseLabel": "Option fee for development and exploitation rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionOnSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionOnSecuritiesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option on Securities [Member]",
        "terseLabel": "Option on securities",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the business and basis of presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r10",
      "r102"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other general and administrative costs",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r1344"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r957"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Expense",
        "terseLabel": "Other non-cash charges",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1019",
      "r1029",
      "r1062"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1022",
      "r1032",
      "r1065"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1022",
      "r1032",
      "r1065"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Rent",
        "terseLabel": "Rental payment",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Payments for restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r1127"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Commissions and offering expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Benefit plans",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r420",
      "r422",
      "r428",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r466",
      "r467",
      "r468",
      "r935"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "bcyc_PercentageOfTieredRoyaltyOnNetRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "PercentageOfTieredRoyaltyOnNetRevenue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tiered royalty on net revenue.",
        "label": "Percentage Of Tiered Royalty On Net Revenue",
        "terseLabel": "Tiered royalties (percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which the company will perform research and discovery activities including a baseline level of effort for no additional consideration, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Period For Which Research And Discovery Activities Will Be Performed With No Additional Consideration",
        "terseLabel": "Period for which research and discovery activities will be performed with no additional consideration"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "PeriodOverWhichPerformanceObligationsWillBePerformed",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents period over which performance obligations will be performed.",
        "label": "Period Over Which Performance Obligations Will Be Performed",
        "terseLabel": "Period over which performance obligations will be performed",
        "verboseLabel": "Expected period for satisfaction of performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_Plan401KMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "Plan401KMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 401(k) Plan.",
        "label": "401(k) Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "bcyc_PreIpoShareOptionsAndRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "PreIpoShareOptionsAndRestrictedSharesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents Pre-IPO share options and restricted shares.",
        "label": "Pre-IPO Share Options and restricted shares",
        "terseLabel": "Pre-IPO Share Options and restricted shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of ADSs and non-voting ordinary shares, net of issuance costs",
        "verboseLabel": "Proceeds from the issuance, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of share options and settlement of restricted share units",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14"
     ]
    },
    "bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to clinical trial of out product candidate BT1718, for advanced solid tumors which has been sponsored by Cancer Research Technology Limited and cancer research UK.",
        "label": "Product Candidate, B T 1718, Sponsored By Cancer Research UK Centre [Member]",
        "terseLabel": "BT1718 (MT1)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r692",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r900",
      "r931",
      "r967",
      "r968",
      "r969",
      "r972",
      "r973",
      "r1169",
      "r1170",
      "r1176",
      "r1310",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r692",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r900",
      "r931",
      "r967",
      "r968",
      "r969",
      "r972",
      "r973",
      "r1169",
      "r1170",
      "r1176",
      "r1310",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Professional and consulting fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r982",
      "r1343",
      "r1344"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r145",
      "r147",
      "r157",
      "r166",
      "r175",
      "r181",
      "r184",
      "r185",
      "r280",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r568",
      "r571",
      "r573",
      "r576",
      "r577",
      "r590",
      "r611",
      "r728",
      "r741",
      "r789",
      "r835",
      "r857",
      "r858",
      "r942",
      "r943",
      "r983",
      "r1124",
      "r1171"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProjectMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r724",
      "r1307"
     ]
    },
    "bcyc_ProjectSpecificCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ProjectSpecificCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost incurred for specific project including but not limited to its clinical trials, program related costs and registration trails etc.",
        "label": "Project Specific Costs",
        "terseLabel": "Project specific costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1104",
      "r1106",
      "r1159"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1157"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1118",
      "r1158"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r646"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r120",
      "r123",
      "r124"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r136",
      "r739"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r646",
      "r729",
      "r739",
      "r957"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r646"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r420",
      "r472",
      "r508",
      "r509",
      "r510",
      "r522",
      "r596",
      "r665",
      "r674",
      "r691",
      "r767",
      "r769",
      "r777",
      "r805",
      "r806",
      "r867",
      "r869",
      "r871",
      "r872",
      "r874",
      "r895",
      "r896",
      "r921",
      "r930",
      "r936",
      "r947",
      "r948",
      "r952",
      "r953",
      "r968",
      "r976",
      "r1164",
      "r1173",
      "r1282",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r420",
      "r472",
      "r508",
      "r509",
      "r510",
      "r522",
      "r596",
      "r665",
      "r674",
      "r691",
      "r767",
      "r769",
      "r777",
      "r805",
      "r806",
      "r867",
      "r869",
      "r871",
      "r872",
      "r874",
      "r895",
      "r896",
      "r921",
      "r930",
      "r936",
      "r947",
      "r948",
      "r952",
      "r953",
      "r968",
      "r976",
      "r1164",
      "r1173",
      "r1282",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1014",
      "r1024",
      "r1057"
     ]
    },
    "bcyc_ReductionOfResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ReductionOfResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction of research and development expense.",
        "label": "Reduction Of Research And Development Expense",
        "terseLabel": "Reduction of research and development"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_RegulatoryMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "RegulatoryMilestoneMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to achievement of regulatory milestone.",
        "label": "Regulatory milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r447",
      "r652",
      "r653",
      "r732",
      "r738",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r832",
      "r834",
      "r866"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related party transactions",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r839",
      "r840",
      "r843"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r447",
      "r652",
      "r653",
      "r732",
      "r738",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r832",
      "r834",
      "r866",
      "r1297"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r653",
      "r655",
      "r786",
      "r787",
      "r788",
      "r841",
      "r842",
      "r843",
      "r863",
      "r865"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of debt",
        "terseLabel": "Total aggregate payment",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r783"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r340",
      "r368",
      "r654",
      "r675",
      "r730",
      "r904",
      "r905"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r1267"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Cancer Research UK",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r1267"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r1267"
     ]
    },
    "bcyc_ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the liability recorded for research and development arrangement.",
        "label": "Research and Development Arrangement Liability to Repay Other Parties",
        "terseLabel": "Liability from research and development"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementObligationToRepayOtherParties",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payments due upon achievement of milestones under a Research and Development arrangement.",
        "label": "Research and Development Arrangement Obligation to Repay Other Parties",
        "terseLabel": "Contingent future milestones payments under research and development arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementObligationToRepayOtherPartiesAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Research and Development Arrangement Obligation to Repay Other Parties [Abstract]",
        "terseLabel": "Research and development arrangement obligation to repay other parties"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentArrangementUpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentArrangementUpfrontCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront cash payment made on research and development arrangement.",
        "label": "Research and Development Arrangement, Upfront Cash Payment",
        "terseLabel": "Research and Development Arrangement, Upfront Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for discovery, platform and other pursuant to research and development activities.",
        "label": "Research And Development, Discovery, Platform And Other expenses",
        "terseLabel": "Discovery, platform and other expense"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing and other employee benefit and contractor related expenses pursuant to research and development activities.",
        "label": "Research And Development, Employee And Contractor Related Expenses",
        "terseLabel": "Employee and contractor related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r897",
      "r915",
      "r1306"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development incentives and receivable",
        "verboseLabel": "Research and development:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "bcyc_ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy Research and development incentives and receivable.",
        "label": "Research And Development Incentives And Receivable [Policy Text Block]",
        "terseLabel": "Research and development incentives and receivable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentIncentivesReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentIncentivesReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development incentives receivables, classified as current.",
        "label": "Research and Development Incentives Receivable, Current",
        "terseLabel": "Research and development incentives receivable"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tax credit on total expenditure during the period that arise from qualifying research and development expenses incurred by the Company's subsidiaries in the United Kingdom.",
        "label": "Research and Development, Percentage Of Tax Credit on Total Expenditure",
        "terseLabel": "Percentage of total expenditure"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized, allocated to research and development activities.",
        "label": "Research And Development, Share Based Payment Arrangement Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income recognized relating to tax credits, incentives and grants from government relating to research and development of the company.",
        "label": "Research And Development, Tax Credits, Incentives And Government Grants",
        "negatedLabel": "Research and development incentives and government grants"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tax credit on surrenderable trading losses that arise from qualifying research and development expenses incurred by the Company's subsidiaries in the United Kingdom.",
        "label": "Research and Development Tax Reliefs Program, Percentage Of Tax Credit on Surrenderable Losses",
        "terseLabel": "Percentage of surrenderable losses"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy Research and manufacturing contract costs and accruals.",
        "label": "Research And Manufacturing Contract Costs And Accruals [Policy Text Block]",
        "verboseLabel": "Research and manufacturing contract costs and accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1015",
      "r1025",
      "r1058"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1016",
      "r1026",
      "r1059"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1023",
      "r1033",
      "r1066"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash included in other assets",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r135",
      "r162"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted ordinary shares",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r316",
      "r317",
      "r1165"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Accrued restructuring costs",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r98",
      "r736",
      "r774",
      "r776",
      "r784",
      "r816",
      "r957"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r281",
      "r282",
      "r304",
      "r557",
      "r558",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r580",
      "r582",
      "r583",
      "r585",
      "r588",
      "r626",
      "r627",
      "r771",
      "r773",
      "r790",
      "r1345"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r936",
      "r1105",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r936",
      "r1105",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r1238",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r1238",
      "r1239",
      "r1240"
     ]
    },
    "bcyc_RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tabular disclosure of recognition of revenues as a result of changes in contract asset and contract liability balances.",
        "label": "Revenue, Change In Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Summary of recognition of revenues as a result of changes in contract asset and contract liability balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Revenue from collaborative arrangement",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r203",
      "r212",
      "r213",
      "r234",
      "r240",
      "r244",
      "r246",
      "r248",
      "r393",
      "r394",
      "r692"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Significant agreements",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r397"
     ]
    },
    "bcyc_RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tabular disclosure of allocation of transaction price to separate performance obligations.",
        "label": "Revenue, Performance Obligation, Allocation Of Transaction Price [Table Text Block]",
        "terseLabel": "Summary of allocation of transaction price to separate performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "RevenueRecognitionAllocatedDeterminedTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allocated determined transaction price under revenue recognition arrangement.",
        "label": "Revenue Recognition, Allocated Determined Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r899",
      "r906"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Segments and geographic information",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Property and equipment obtained under finance leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r956"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Non-cash impact to operating lease right-of-use assets and operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r956"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "terseLabel": "Royalty",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r477",
      "r1138"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r477",
      "r1101",
      "r1138"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareSecuritiesExcludedFromDilutedPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of antidilutive securities excluded from computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Summary of revenue recognized from collaboration arrangements",
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of share based compensation expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of the benefit for income taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "bcyc_ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of net income (loss) before tax provision from income taxes.",
        "label": "Schedule Of Components Of Net Income (Loss) Before Income Tax Provision [Table Text Block]",
        "terseLabel": "Schedule of components of net loss before tax provision from income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of long term debt instruments",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r41",
      "r44",
      "r51",
      "r96",
      "r97",
      "r926",
      "r928",
      "r1134",
      "r1289"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of the Company's current and deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1270"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of basic and diluted net loss attributable to ordinary shareholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the provision (benefit) for income taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r941",
      "r1268"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r646"
     ]
    },
    "bcyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r839",
      "r840",
      "r843"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCancerResearchUkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r1267"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of company's single operating segment including significant segment expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r481",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of share option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r99"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to determine the fair value of share options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r94",
      "r96",
      "r97",
      "r98",
      "r140",
      "r141",
      "r142",
      "r205",
      "r366",
      "r367",
      "r368",
      "r370",
      "r373",
      "r378",
      "r380",
      "r780",
      "r781",
      "r782",
      "r783",
      "r930",
      "r1098",
      "r1129"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r203",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r248",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r303",
      "r315",
      "r318",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r912",
      "r915",
      "r916",
      "r923",
      "r971",
      "r1310",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r802",
      "r803",
      "r804",
      "r868",
      "r870",
      "r873",
      "r875",
      "r882",
      "r885",
      "r886",
      "r887",
      "r888",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r901",
      "r932",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r970",
      "r976",
      "r1176",
      "r1310",
      "r1312",
      "r1313",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments and geographic information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments and geographic information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r203",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r223",
      "r225",
      "r226",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r248",
      "r910",
      "r913",
      "r914",
      "r915",
      "r917",
      "r919",
      "r920"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segments and geographic information",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r225",
      "r226",
      "r240",
      "r915"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and geographic information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r243",
      "r246",
      "r911",
      "r912",
      "r918"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual increase in reserves on total number of ordinary shares outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage",
        "terseLabel": "Percentage of annual increase in reserves on total number of ordinary shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Unrecognized compensation cost expected to be recognized over a weighted average period",
        "verboseLabel": "Service period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Restricted shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested restricted ordinary shares at ending",
        "periodStartLabel": "Unvested restricted ordinary shares at beginning",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares Underlying RSUs",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value unvested, Ending Balance",
        "periodStartLabel": "Weighted average grant date fair value unvested, Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of vested and non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Number",
        "periodEndLabel": "Outstanding restricted ordinary shares at ending",
        "terseLabel": "RSUs outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, Outstanding at Ending Balance"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested and deferred during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Deferred in Period",
        "terseLabel": "Vested and deferred"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee vested and deferred during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Deferred in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and deferred"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested and settled during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Settled in Period",
        "terseLabel": "Vested and settled"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee vested and settled during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested And Settled in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and settled"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period, subject to deferred settlement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Subject to Deferred Settlement",
        "terseLabel": "Unvested restricted ordinary shares, Vested but subject to deferred settlement"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right, subject to deferred settlement during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Subject To Deferred Settlement, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Vested but subject to deferred settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of employee restricted share awards vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation.",
        "verboseLabel": "Share options",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r481",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of ordinary shares reserved for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding number of shares at end",
        "periodStartLabel": "Outstanding number of shares at beginning",
        "terseLabel": "Shares outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price at ending",
        "periodStartLabel": "Weighted average exercise price at beginning",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares, vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "bcyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued upon conversion of restricted share units under share based compensation arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards, Share Conversion Ratio",
        "terseLabel": "Right to receive upon vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equal annual installments for remaining awards.",
        "label": "Share Based Compensation Arrangements By Share Based Payment, Award Vesting, Number Of Equal Annual Installments",
        "terseLabel": "Number of equal annual installments"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equal monthly installments for remaining awards.",
        "label": "Share Based Compensation Arrangements By Share Based Payment, Award Vesting, Number Of Equal Monthly Installments",
        "terseLabel": "Number of equal monthly installments for vesting remaining awards"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equal quarterly installments for remaining awards.",
        "label": "Share Based Compensation Arrangements By Share Based Payment, Award Vesting, Number Of Equal Quarterly Installments",
        "terseLabel": "Number of equal quarterly installments for vesting remaining awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First anniversary",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Remaining equal installments",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r486",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employee",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "bcyc_ShareBasedPaymentArrangementThreeYearVestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareBasedPaymentArrangementThreeYearVestMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted with three year vesting period.",
        "label": "Share-Based Payment Arrangement Three Year Vest [Member]",
        "terseLabel": "Stock option three year vest"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareOptionPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareOptionPlan2019Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents 2019 share option plan.",
        "label": "2019 Plan",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ShareOptionPlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ShareOptionPlan2020Member",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents 2020 share option plan.",
        "label": "2020 Plan",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Price per share",
        "verboseLabel": "Purchase price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1241"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Contractual life",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term ,options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term, vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r163"
     ]
    },
    "bcyc_SignificantRisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "SignificantRisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of policy for significant risks and uncertainties.",
        "label": "Significant Risks And Uncertainties Policy Text Block",
        "terseLabel": "Significant risks and uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "SpecifiedTargetingArmMaterialRightArmProgramOneMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to specified targeting arm material right arm.",
        "label": "Specified Targeting Arm Material Right Arm Program One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r131",
      "r203",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r248",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r303",
      "r306",
      "r315",
      "r318",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r912",
      "r915",
      "r916",
      "r923",
      "r971",
      "r1310",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r140",
      "r141",
      "r142",
      "r166",
      "r191",
      "r192",
      "r195",
      "r197",
      "r205",
      "r206",
      "r280",
      "r327",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r366",
      "r367",
      "r370",
      "r373",
      "r380",
      "r611",
      "r780",
      "r781",
      "r782",
      "r783",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r815",
      "r836",
      "r859",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r1098",
      "r1129",
      "r1140"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r68",
      "r71",
      "r72",
      "r130",
      "r150",
      "r151",
      "r152",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r204",
      "r281",
      "r282",
      "r304",
      "r381",
      "r557",
      "r558",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r626",
      "r627",
      "r648",
      "r743",
      "r771",
      "r772",
      "r773",
      "r790",
      "r859"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r802",
      "r803",
      "r804",
      "r868",
      "r870",
      "r873",
      "r875",
      "r882",
      "r885",
      "r886",
      "r887",
      "r888",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r901",
      "r932",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r970",
      "r976",
      "r1176",
      "r1310",
      "r1312",
      "r1313",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r204",
      "r627",
      "r692",
      "r778",
      "r801",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r815",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r834",
      "r837",
      "r838",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r859",
      "r977"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Shareholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r477",
      "r1101",
      "r1102",
      "r1138"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentIncentivesAndReceivableDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r204",
      "r249",
      "r627",
      "r692",
      "r778",
      "r801",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r815",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r834",
      "r837",
      "r838",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r859",
      "r977"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1018",
      "r1028",
      "r1061"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock option",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses (in shares)",
        "verboseLabel": "Shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r67",
      "r68",
      "r98",
      "r780",
      "r859",
      "r877"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of ADSs upon settlement of restricted share units (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r98"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Issuance of ADSs upon exercise of share options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r67",
      "r68",
      "r98",
      "r492"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "netLabel": "Gross proceeds before discounts and commissions",
        "terseLabel": "Issuance of ADSs and non-voting ordinary shares, net of commissions and offering expenses",
        "verboseLabel": "Aggregate purchase price",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r67",
      "r68",
      "r98",
      "r790",
      "r859",
      "r877",
      "r983"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of ADSs upon settlement of restricted share units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r67",
      "r68",
      "r98"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of ADSs upon exercise of share options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r68",
      "r71",
      "r72",
      "r98"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r88",
      "r817",
      "r833",
      "r860",
      "r861",
      "r957",
      "r984",
      "r1131",
      "r1155",
      "r1286",
      "r1345"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinaryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Ordinary shares",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r165",
      "r365",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r381",
      "r587",
      "r862",
      "r864",
      "r881"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r657"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r657"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r657"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r657"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r657"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r658"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "bcyc_TermDepositMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TermDepositMaturityPeriod",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maturity period of term deposit.",
        "label": "Term Deposit Maturity Period",
        "terseLabel": "Term deposit maturity period"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to  term loan.",
        "label": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to termination based on other party's uncured material breach or insolvency.",
        "label": "Termination Based On Other Party's Uncured Material Breach Or Insolvency [Member]",
        "terseLabel": "Termination based on other party's uncured material breach or insolvency"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TerminationIfSafetyOrRegulatoryIssueExistsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to termination of contract if safety or regulatory issue exists.",
        "label": "Termination If Safety Or Regulatory Issue Exists [Member]",
        "terseLabel": "Termination if safety or regulatory issue exists"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to termination in  entirety or on a product-by-product or target-by-target basis.",
        "label": "Termination In Entirety Or Product By Product Or Target By Target Basis [Member]",
        "terseLabel": "Termination in entirety or product by product or target by target basis"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ThirdAmendedIonisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ThirdAmendedIonisMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the Third Amended Ionis Collaboration Agreement.",
        "label": "Third Amended Ionis"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ThirdIonisAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ThirdIonisAmendmentMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the third Ionis Amended Collaboration Agreement.",
        "label": "Third Ionis Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business days to terminate agreement upon non payment by Bayer.",
        "label": "Threshold Business Days to Terminate Agreement upon Non Payment by Bayer",
        "terseLabel": "Number of business days to terminate agreement upon non payment by Bayer"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period to terminate agreement upon written notice by Bayer.",
        "label": "Threshold Period to Terminate Agreement upon Written Notice by Bayer",
        "terseLabel": "Threshold period to terminate agreement upon written notice by Bayer"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period to terminate agreement upon written notice for uncured material breach.",
        "label": "Threshold Period to Terminate Agreement upon Written Notice for Uncured Material Breach",
        "terseLabel": "Period to terminate agreement upon written notice for uncured material breach"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimeDepositsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimeDepositsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time Deposits, at Carrying Value",
        "terseLabel": "Term deposits",
        "documentation": "Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1296"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfShareOptionsDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsRevenueRecognitionDueToChangesInContractAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from both the beginning balance and current period increase in contract liability.",
        "label": "Total Revenue Recognized From Both The Beginning Balance And Current Period Increase In Contract Liability",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r361",
      "r378",
      "r586",
      "r610",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r744",
      "r944",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r958",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1278",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two combined performance obligations for the first and second targets.",
        "label": "Two Combined Performance Obligations For First And Second Targets [Member]",
        "terseLabel": "Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets.",
        "label": "Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets [Member]",
        "terseLabel": "Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two material rights associated with limited substitution rights.",
        "label": "Two Material Rights Associated With Limited Substitution Rights [Member]",
        "terseLabel": "Two material rights associated with limited substitution rights"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two material rights associated with the LSR Go Option For Collaboration Programs One and Two.",
        "label": "Two material rights associated with the LSR Go Option for Collaboration Programs One And Two"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets.",
        "label": "Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets [Member]",
        "terseLabel": "Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development.",
        "label": "Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development [Member]",
        "terseLabel": "Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two material rights associated with options to progress development candidates incorporating radionuclides",
        "label": "Two Material Rights Associated With Options To Progress Development Candidates Incorporating Radionuclides [Member]",
        "terseLabel": "Two material rights associated with options to progress development candidates incorporating radionuclides"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two material rights associated with options to progress development candidates  not incorporating radionuclides.",
        "label": "Two Material Rights Associated With Options To Progress Development Candidates Not Incorporating Radionuclides [Member]",
        "terseLabel": "Two material rights associated with options to progress development candidates not incorporating radionuclides"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_TwoMaterialRightsForExpansionOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "TwoMaterialRightsForExpansionOptionsMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to two material right for expansion options.",
        "label": "Two material rights for Expansion Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeasesMaturitiesOfOperatingLeasesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureDebtDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsBayerCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsCollaborationRevenuesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsGenentechCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisEvaluationAndOptionAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsIonisSharePurchaseAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementAccountingAnalysisDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsNovartisCollaborationAgreementDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsSummaryOfContractAssetsAndLiabilitiesDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSignificantAgreementsTables",
      "http://www.bicycletherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "bcyc_UKPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "UKPlanMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to U.K. Plan.",
        "label": "U.K. Plan"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureBenefitPlansDetails",
      "http://www.bicycletherapeutics.com/role/DisclosureSegmentsAndGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "bcyc_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the sale of stock by a company to the public through under-writing.",
        "label": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r543",
      "r940"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r940"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r117",
      "r118",
      "r121",
      "r122"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increases recorded to income tax provision",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r956"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "bcyc_VotingOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bicycletherapeutics.com/20241231",
     "localname": "VotingOrdinarySharesMember",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureOrdinarySharesSharePurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to voting ordinary shares.",
        "label": "Voting ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average ordinary shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r197"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.bicycletherapeutics.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.bicycletherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average ordinary shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r197"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>132
<FILENAME>0001558370-25-001438-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-001438-xbrl.zip
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M94UA&!6+[N7@(\7+NU1?M]\T*H)2RL5I-B%ID5R$78Z;QY[D(XP4["I?4RV
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MK)@F$1W;S>TGNB4[&=^&F:I9-!%;0QFVE+5#/ZW<=09MF(J;$OTH7JN%0"J
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M$K;YBC9"AAC=@.LWG>ZL&]#).'5V,_[(;4P^-MWY/V8^RZ=^TB$@ LN*3!?
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MW:HEG!Y2)L7V@,WN)D@U0XV[S<:UZ!4US<D*;V(Y8CK__N+]B4J$FL#J(84
M&SS<]I,/Z:A7B*1(Y!0/94O)WR^CAT],XN!5'WRB"P];_'<'U5$C%2 ,FT0W
M8&7:.RK?J/1C^&SN7X&J3*5J0(9-J++3U? 92P6=*L$8"IENB2Y-KAPIR18-
M!2G%20NZL^!O]BIO!7[$E<'""M(=6"D&K1J<WI!+9<3B"Z<</2O&Q-@PW @1
M\BNM-UM:0>D-K516S]Z<V#/709O5"/U=7\5UGM/K7D./ZJ>"^"JX]R..H=Z
MOD*D0BFW?CA&9@GYLNY/_P]02P,$%     @ =SM96F)ZK4Q*%0  *SP! !4
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M]MC:>VA*>/C33/4QB#>HD15L4+_2#[+5QKLNO&10 O(U_$+ NM:G@%&+_]7
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M8]M-N*I^4<(O6V^?TF"*]\[RU+$T%*9-TNDH9(5?LODNJ(M8]A**4R=?&DY
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M3'K!;#]-N@V2E73I]LA9]U+>41*D?C*E#X@^8U^6.2%J)O3>R1K:18>71R@
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M".IJV^4V<NSJK7I7U=8D,E' 8'])J(&NK(HZL([K$L2\9AS_AS]U^.R%#6M
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MQSR,D%+TP"0M*SH;)=M 4)S%)W8.;G7.Y><?3CZ?_,#?$-L.RO,O=^-.O.W
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MUY5[NB@"\ !>>9AFM5*FLRL<>9&/O3!+YXQ+^9P8Q<J/7Y''QPI.D^UPK=V
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M*5^"<AU4;P% YZA%HI(R6X;< /FN.06\L)F*DH8.B:E@_Y:"$JC=O%4'\3U
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MLRJ'/R#6D';O6.N$W@Z+*- Z9YJ9"L9I52CK>WZ^P9%W[U8O8\.A4V8F*7L
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M!"[[WSWZ,\4Q3E!>PA"9M.2D<P&X@ ],\-3T.JSM]?^D'DT0M;W!2J8%4&$
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MYJV1XJ6>RF< Q_V.@K7UU5;P,4#.6_+LT017]\;MEBFGLUX_ $??O@S00]0
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MX66<KY#J%90!!@5@*)MYWF0 VABY;Y-7ZK[!/ELQB&M.T>U$82%ON1P,,2H
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MQ^^D#Q.;N@.(JEI@8A,5##!Q^TI$'N7CKB"ZK'@1V>]WE,RIMV0R)F=GQX$
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M1I5*>F [G5P?JEH[C!EIB\V6SBI$C-S2F:<A;[W6(+*BL<.03GL:*_ 8*Q9
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MM0EAO"S3)B7U*DMWVL$EBG.+6-IR  #YOF8++;4CAS75RFDM!D*M897] "0
MVU&T2BJ8YF&1>H(0.]*54UZB@ E;2'#B[:X)B'C9KC^ S%ZC/&U'#5OKL_7"
M!+ B+5<YTD'?%KMJ%SF$T##A^D)4+&PQ"(0472M\;4$3-\6%^>L7\3879%/J
M.#\K"6HG]1H)0CZN@_K#S81QP_I=+A##?6L2+)>\UJ(7%E4RMW!WDHD>4T#(
MS74@+#TH9FNS^"?R:#Q]1O2W!?871=#P.BZ*KJIVB*:>5GGNPENE2XBQ0OF
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M+VV,Q^N\XW7>8[G.VU\>%QR=ZTCILCY]BK./,H%K-P: (ZOQ $ [BAQ(2.@
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M#N\M^IY]D=OM6GT!7(CNM$/J80<@EO60;[?\=O<71.:L[0+[U]&,T&66$/6
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M@_*L)&QJV=54@X%-I2K2(6L-YS2D(']E[Y-AXM;QMP^5N@J'O#V,>^4-XM7
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M5-./?LEH%-"@T!!8ME 6$@D_!L) .O9K]$* IC@Y-EA:>'E*_>]>XK?O \H
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M/_WHO/'7R?DN8)S.>9;15.9GT1SWM#;&.S:[=2R&IKXESI%I(._0@7ES<?U
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M5]D'^<@=H#6(U;5%[K1M&M:<M:DA8B=M%7?P,*UMV56$W7CDA"JZ<SFI4&N
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M!1W<(K];R[-J<5']Z 2[\P)W7RJX<7R@5>J'1;U(X$7[H8H,GP"B- Y9(/9
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MM]B42I&0W"+C0PB>FF<Q$0R)$B#!?O)+0J57S/L.PJ;R@M;\+Q.LJZ#Z/^P
M%I_&174/^\K5QUU UU1DF4YD 39[(/<Q?O.2C*4U8Y:VU*.?83_$L-A'\Q(O
M33HA!])>*EA 6-A.UJ-L(8W.F^?%V5EL4S"9'X,7KUX7#L^JX&P8?1-'_0':
MI!-B=#;6N83FSA[(<=E<_LE!68B" Y&GMXK@,#\6SZ38;"#U,XVXZ-1_U4/2
M<1/$ *31IX2;@]^1@XM.VDE7T  R)6/=2GI>.+%MAY+>_  RF2KV(6/TCK6%
M4ZS;CM=]EEG@1+8I[5E/Z&^//MY=\DFT=+F%?NOX&2 J@SZREXBMF2_R;&GW
M?1=Z^:3/:S?[''&#XPS6GO9>R@*NY,VAM/.;*LYO]&&V\N-NLX$+?N+>GP@L
MH71MS#'W[Y 4EGODX8I!D=IF77+!^YXF8A7#P>'N.60O<D&NO,]3+'&?,-\@
M[;,URCC1<@+K*57+;9!%OB2WK*2E3<&L.4=@*8_('UU)1+8@$BSV4[KUN*=2
MV ,H%")QJ=',!^9HC"O$6!%%$%))LB*5+.1N311IB!#']42"R9;*A&%A.+K9
MQ8BXK'[V*\M>+W9I%F]H(BHQ\TFXR,MH]GAE&"6<$XD%Z]2W'GJ3P1LFCU%F
M>/@K>9+/G"DIN*Y(^>]" .7OI2"KLH '>Q.PA20,=F%%!:W\5XA;TZ)RPK,7
M ABE124&>"OM1?O_!D<UN47SP@M@S7%I4MN#W@LAV$TT'I?L4<6)49:M=ACH
MCB"YC"#7AH*3!KCYTK,(*?(5*7=!_G_P+FT79@>N7'=6X:OE/Q5.NR^=W4GT
MZ];J>>0KA2 W$=%-+.>E 4MA7,\<6*Q8VR29=H1.43X+IK883A73N_5'FLE2
MH+=QFKZG/":G5<W1)'YC*=>L3S&M\<01SS76;=A0:&LD9>0SCWT][99=\$NI
MX&\1A:S8HE+N-U!H\UOR+(2#NKE0X40*)K=%F5)1UU7)+-<V+9^-WZU))0O\
M#4J5YC6'O[D5EI0BD:KX,BFE0C'/(+1JX_@4!6#-AJ7K0]+*C*7-KF0NN_<T
MHFN6#4CYV9<BSMG%HK7TZ3=[D<.[^V)#*1NN>%%S107'<@G(-[D,W[K&,VR6
MJX.8V'V1/$7523R(=;5>4TAN4D'\@Y?1!PJ.S,-T$>3TA*Q!))>"6</MU0Q:
M_>DM ;5&:&7#^4KV*F2!!*0N C[0<FRXI&Z>'+FJ<.N;YP+N<:'897Y3F-M+
M;(RDRLY(5UW$\=26@EV#K*0KQ-6#U!(0:YA"-GRNX"Q ZKPZ?T%4X ^3N5+E
M<NQQD*4<:>75_L"4Y4,"6#S*(RX7>'5+N3:06-T(C_2M<>--AY8JGFB:XL6+
M+H&'#G!!-R\R@,37IU)5OT@*@:/+S/^WE$,#O=M2N/<9O0@+E.<K'[QLEYC>
MDAE&";M?#[9.W>=[D\&,!\.5&8X5P!.R\N=<28X>RFV8+";/E-Q[+%B10@P\
MP#*_S530V4@6C"J@@Z8D\)67P!O6])Z6!5R8SV.K2Q;N,AKTW8GI20TW (VT
MDF;_I0\IO$ T5B$KNRXY9[AR+#--KXC@+F+PG/],*&12Y@Z!R9Y+\P2Y><KC
M+B_+$O:\RX2U.)[7\U*_QF' @=8M6)U'&1-RLS?Z2/T<5:^^^.$NH,$U=UY8
MCNVR_);VH9G-<<PBHZ5 G&W;-J.?+2Y+ $;KNMH  %4H4DE%"K'D ;<B6#/0
M8D15E/;V5'NGE;UIS=Y^W=Y'V,QC5PG#CJL[T1>XB/1 MW$"H?1-E0_E_3[_
ML4<9IY[4EH*D@ZRD*<S4A]02,'&80E9*+4GBI&1-%-XK430Z;X%DV8K!:'ZY
MNYUROO!OY1Y FEN+10!DXE^4C?+BUWQSS<WN=\P7^QQV WE@\'[_,XU?$F_[
MRF/MA*_"S3;6^A+!C5+#;%+;3NM% 2\F#=1C\"8:9W<F^!5';AQQ*I9$\,0"
M/3/;1D6<$.P4"CO)<[.5@C 5^LA=M(2]O&9G\?ILQ_]2-'^E80!O @*V7E-Q
M(O=2F3FA+ZZ>Q%['">4(>2&."?V]\H3X9X]%U=77)^^+YK/THX ;B 980T6A
M'MWQ0M 0)0:GO.,4\UOB*Y(S)@5G]37^JKCWS+E:!9^?I$$B^N+QM4T;_,QI
M%WG_"9!GG1N%K\SD.RYX4S]OME07!K@^5/M%C!3Q,L-)Q1[?CW=1EE9OJS_2
M3%HBTYBKHPMN(#31MU9XIZ4]7J@SDGKH$"Z(*^_Q5\1;<S<324<^BX08<'_P
M(J$!RP@XT"H'OTEJ:'0Z^#SF2$KJ3E* >.GKU=]V7(!09-_*+KPDV?/@#2H
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M@<"M"1S%CY=\ KKV6#+E-DM_*4X;I0=^E>FJ,G>*<+I(/M00&+#=( NM:$)
M!0(ZN([$%_2A,">D[9O,\2G.O'"6'75#UJ>-[WWL/T$6D%:^IXODO;3' -^-
MV65GV#3AD/D<SY+Y8]IO,2:+K.96Y=5F&\9[2L^CX)(EU.?]/M"&FJ&=C7$"
MG)F.Y15#;4OD-P*[Y1XZY![HEDM,9=15K@S)EB99?J$ZBPG-V8NCE" 7X+M9
MK_M-9X&"<EK3+IW_WIQK%7%'@F4<?)ZFNXT$Y0>6_O4ZH;"13?GWR!YXO&P;
M_WOPQ0F1LUO>2@!HRO0$H[_>JCL,_:HE.%&D71&0EX# I)"8@,C+6J?/]B&
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M4P+L$"+(\7642A;>7><K4\A9F-<<5>M_QI4,Y#,7@CS3XG<:S NG3@R5[W0
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MPBV7XJ6?IH7: 75Q<L H!(J-+=6*R+>M!ILQ\8D<F;<<SO:ZXIAOM&DZ\YO
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M]U3YB,E9K87Y=;/5G3Y=K[(@?VY17/?='QP+9IJ-A3M-2-;-VF\P/,$^= M
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M6HTM;$"T+WKM)VX0)5G_0;9! G#ZX7@L%'90&VKCC:)&V*!_=[5LS?YI,8.
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MCT]20?[K;<:._+]7GG/G13!:/W@S/U@F,/XTPNU_>WDH]><=HL9<$"U 8*U
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M3B<B)*6UJ_FD(D"\BM8,.[4($)*A=0-., ($);1HXOY8Q-!D_(2YEP^/$&T
M'!BM;T%D0;>E\AM^TMR-YKT? /1[NC6P\88I_V-R_G,3@41 )Z,[YL**)D ;
MT2&[QY[.;@* "/$"P^]X,U:L^QJO5BX$0:@.Y#:=,QAR*UQ@OJ#_X#W_A^7B
MB4LAJO3OFPM<U6%I.]FK Y"Q'^8"^8*6 "NP,0MNP0=P_42$AV2PP8_D'/8"
M;("H@19-=;@VZY:Y,%<?C-3A6?-]DV_BJ3]^!19NR[F*-LV) %5ZWPPR78G
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M\FY\+V'6[S!:W,1AY"]!4#-1,==6_025VJVZ>8:UNFD3"J<NRV](6XC<(YM
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M#^B@<13FXM\"VT7_<0B$8ZG:'1*TEJI?$6T+,*03[U4<+5!G_F*APVZ-3K.
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M='[7>[=<N?X:@'K25)0\4(8;'=V&WM:$^8+ C$"2U3NF/2O>*V<<610?E]@
MH5B!M1V92CVGGG@J2IJF=C8UU*B/(IHI9P[*GBB?J^A'$.8&C-8P15.T@VDC
MF3N_A\1[9)S3CSRK%TJ8IG;5\WD=%)1W'-IF\JS/U#F\5,8T)=>!3E13EV;L
M$FL36B+F(G9//=8IN[8%0_7:<+9N)F[GI^MZ -Y^^"T9LVEA&(RABVOF:;_F
MAO(-/X"8SAX\!R<[BRV7X*Y16:X,P_%D?#8,?V0^0"@O\92Z<>SU^'<8+1('
M?NR.M("K-__.BU!_*C< #5HPA1Y\ZJI1<P.1-;J/W,( V*@IH@="N8#1&FN
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M<>4$E1-]Z3?3%,((Z%83]=+HCCD^;-<U_932MB)(![7S$7"38?X0AC%P;N,
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M33U1JPC$4W_H1&J-E5$1CVMF(NXIZ##W4.8>[DE'Y-,\X9-.+M7.X^5*(=%
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M8V54B%LI$U:"P1.(THF<R+CZFL9QK97BV28N%@BD^ H9Y<B^'[+@-@9O?JJ
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M<BWE.7E2I\S'CH\\+"T.CF"-01'EL":$A(03XE.,[6336=%V5ID\O+)@_[C
M*6NFXHL>Y+I%)]$E3,,'('ZGS\/GP+,1W\L/:/#/]]##F\/T[]QWNL?[:6X+
M7T]>/=O%[Z/?-UT8I=],"F6]R/_)^*M@"L3,E\.<;:A=J!X!VLREK+@%H1W
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M// ^X7W@74Z'[>*OCT#Z^</#;NT/NW?]NHA3T'Y!TV:5UL^X&47L5^+BWZP
M8I?0.OWOE>N=^MDD[*.G6G%-+6SZ:N8UIKJ]8TESJ8WR5I-Y'*>D=^6L;1I[
MFBN?ZW!="X&@)8@4O5HKF?( 7-D6E8% .S6&0AH6L8T*($RX?"C*5+$!J2S3
M1QVS"RIJ):G,(*79T>5W@.="X%RAR<F:@\V=R,8G_)CI@%+?3!G9D\GX3&]0
M<L''EX8 2'6UUNQJMP-)T17D&00VV1>;MYEA48L5 *F.W,JI59RH&\]9?(WT
MCE8"Q.^77S@%$/;9BJ^1(9&*<Z:2XV]NS*5 &ESUJQ5A_WL<#':V$PZVP>W
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M .?>#VZPJ*Z;1=_/DT2&S_CCOZ//1\![\B-H[^Z2!;1H&I$4VL1EH6>438!
MPP+,2+7Y*Y?[.(H#\!6Z((Q\#VS><D;Y.$;_K7CK*J#%H=-0 GI*[ AJGOT_
M@0AG*7D&P>L"J>[:"J&-%'$+W1@M\3N_<K_S/SDZWGWGCYH<H;^$HQ4(1B%N
M%?UC\MGDV;^3?GCD[1<S_FG_G17@0"0;N&IN5\G%U>ZBD$8>T+!; JSJJP\$
M,2;^FX]?G_O>:^3;WQ>^BQ@?INR@2]6PM?(X.Y^,S_3.4G6Z+&ZH1(HL^8&.
M\JC!G-B((95I9!))D-;T&P3M=N+Y/,7X5?%TE@SE<!I'8806&S2^:R8SWF9,
M(Q[/+"9$5D%7P20>*0_>Q@H*;?+B:L,T!@EA17.R29^Q#+EX(>"1;</W8.%C
M&JF587.-"Y5^N;CL+@NTV:NR[$"8PRZ[488IX?S(A@HC0[+2 ^4(3?K^VHU>
M@9U%9;S[M-W8 <X] C_#(B]T8[EVG)I^&UB2]O))55J2MAT9@:PG(\R#$1)H
M8US:5K"W73K8EZ0'A+SR(ICH 'X0&(-S@,51=CNP*P!;,$@1'RF/WLED?''4
MF7.< B0H>^]\-CI1S;*6PEZOJQN@1(.4^$73^*> 4_M$5HUO=UC]9"W!K8_C
MGG-1<UO--'ZI5C4KV6H0(S)&+4E> %H-H(T/L]C82PT\6EFV&W2H4<:^3MEE
ME6!,4GQB6ZY<?PU (N@TZ3Z5!L3R/:4"G[Q2K-@F+!S,,^IC3;!14<V;1K<N
M;G3H8/8K#6E+J*@/%X2T;1JAI7)+.)4I&$J^H3Y5:CV[!AZ8P>C9M3S^Y"GC
M?:>JK+W1"C=HOB$+<P!X83H./.<%1#!(O/)X,J"PMZ!VBKI%FO! DJTC@.\Q
M[B'6,\UX1:M2'@P7D_&I;O=-;MT5)PAN44T\E6^%QGU_7?E>Z >/^%,8%++%
MJ+:>:<KFUE;5(:R)S)W3.M4<PU#3-,TW4QNG^BFB&V):03T$(5K%<>>I!^K]
M@IW2*$43%7,XFZP25!@"^Y>Y__%K\G8V6*<:S/ZR55[V#W]\>]U1UO8'TY3#
M".E6%S6B&#)\[OT P+E7.WKVRIFF'W&#ATU4":=VG8LEMM<Q[XORPJ9Q0/AF
MB"HHA0&&[(!J;Z%(Q4U3+(=66%0J?5=#>'B(OW]Z=/P/<LZQ<@GSU< TL;)*
M)A7[;_\@KG%[O_<)]UJYB-.8$4:9K<VB[L*#O8$R#)<(!KT68 '+5DOAI3K'
M*K^"((!QXX?1"[#]N0?_(KK*,M7M"(%8M<],)P84I#[Z&"N] G@!+@ZBDB2]
M++YMY[X..-V_#LC:'JUPXZ.HT+KY=P,D7&HN!.JKZ7)Z)?7L>EWZA<FWE:,M
MTV815KU6N[*V%=Q,>S*+3-1C,VL#II%!G&*K#F2M4.EREN&B@#4G\]V"IC&D
MI1;IM*"(;)SZPR JJ![];:MV])<_KF8SZ$(LV9V'=@75"<?)!4U6.T5+6_5R
MBF:FHV>-CF^22*%!LILC6%))Q4S3KXR)GTMVX_)MU^C^!:SBP%Z@;?@F=-6N
MK)4S/5==4UC"I<DR =K)JG'6)T:1\\+8C2S/7K^"X /:(/P=1HM7'*SL-?:\
M]4/H@O#!LW\A&QUYVRA!<W$T&8_/M=&@G3YWK)1"@-"]=!"(<FU]!\%UX&-[
M0WCE?,#0#\+'%9D5U J]I0"_U)V_@MVD0;MQK3"<SI*W#Y3C)+&\*:10<7KD
M T&095O+8;$H(/6PN%_0.$)P*6U?Z8P2FK=+>/*]WWP<N'0:.-"S@G4:S8(\
M^5,KF*961K7LS/3\(AIWYF]O1*R[SJRK9AH5-!@,Z5A(#>6B_$[S"_! 8+E7
MGG/E+*$'L4D>/^&Y^\2^_J1[B9I:IG&HD9[WZ=)$ZGX%JRL$%DWGUH<PC(EW
MWH32/64'C[3]"BI7D!R!. V239GSF^7&('_>5\\04LW^LX5+\GZ%FTOD3\?)
M;1R@G1N2'?HI#$_@1_(+^=#*4+>,X;$!'G="V--<=D&[%])C6K6AZ%[!/,\?
M\07X<U1V >T';^8'R^03KW#NP1FT+2_*BF9+-;^OS=F^KTW^]21[P7SS_1'<
M=@"7VO9A%*8U1B#KA?D^.9F,+V#E!U%]U&QR<5T^.+L]*K#C>IW]R.:!P]R2
M:7-.G0ZK_6[:B=OE@_7&IG0=AVA>#L/--,-@0:VJ8QPA!"F98D-EAJ'31$F%
MHYI02V6,(P*WNBI47BN@><;35T1U%Z2LQ^S.9" ;3ZD5C--JK49V[*;\TNF^
M$6U_9+56,+)<[&Z.G<_#Z>R;MPK\#[0U#_P5"'9CUUPM\03Y5S8S9F76TP#]
MZ5_ CB@K@X0O&4<X:>N)*O",\PWBH'(F&_65=:F,:?11I>1]>M7#8M[:]8#=
M(% 74-_1@7.)_N/$=G2#(]@[:#6_3D_.;_XG]&Y\[U\Q3MC[%?7!1@/T^NT"
M24=>YD2U;1K#ZO6\LR)*!4+WXBF%6&=G)Q>RB+5MNXSGR61\?CPD8M4 H=MO
MB?0Z?5?(M^/)\44620,XU^LD,W#P@K2'D%]\^WZ#4 \ Y3%[FP8[3R'QTDNX
M4Y P(>5C(T;+_YL5S$$$G(?E,O; _V_O:GO;MH'P7_$O6(O9CCM@&!![BU'
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M<Q._[)CA?LU.V2-@0;O7'>01VYHS49%W^(HR68PY69Z=::J.>S&^'N@U#5_
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M.)*.JOQT>F\QYZ?C]!9+(CLX)0DR=B9.EY>&R<MQ^L8\X[([#Y(<*.]$QN_
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M[036"3M$F$V%M1W*7 [&4R?D3]/T1J@C/[J.YG$4<CIR$%#WP-@ONYGRJ)@
MK%<0*5I;9!$7W%I;)Z!T<'K?,OA_*P38.4%E8V-O(/)Q>JI34ZGE$O>H33X6
M D$.\=\*@3:5;M51G% 5>C!-3XPJ.2@']WA&8" 0Q,TX?EZ?\;/=T#+Q<+S=
M'@B,H=NNBFV0Y G0FB()VG[Q7<$Q="BXNNYQM@IM3I?V?)4Z7*X55_TG^@T
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M:\W0EP7!UAR6/:[9%NP!R[9ZR>X8%"))=AS8#>-G-O5Z,<V[75A^+UL;W?G
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MFB@H83-=">RAK\_I-;[-=2JYW/EV#M=7E][4H!P^F[_E=3+X*1:0G(91A=;
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M&QWN77J%&DY4V*_5%>L1D@3G0*WT6+?M,H64K31C]LU]J#=%2%3,GST5OE8
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MYM3_3M':G8/\EYZ2>%HINT)_@.V5M&[%S4I($D0%](#+VF,J+4T#EP;]W$X
M-UJCVSF'M;/L=C6PK)9.I!'"$NR/BQ^4D0IMQ]"W=-^V>/M=83<ATM.E:ZA<
MH07 SNZX#)L>2GV1%F/6H"\W%VHL90;.0UZMQ!REX!HA9Y+P_3#]W)X#7UP
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M*LFZA<]TS2B3&:]/L! .*<5M4!&QFCHI2P<&?_UQ,ZYEX6%GE^3M8-J\'/J
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M3-0):QRBOO*/BY-^Z=7COY<V'+V@NFA@/_V "IRS-@'"O'H##L:E*I 0:.L
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MSOL?3LX_G8$UVVJVFWL/%K:=AO71]:5U+H8RGEG[V$$UB+ !:25R*Y'[HPN
MJE#GNX!X)7*K0IV'EL=B?>P6'/.G^]7'5@6R&RU+JP+9[U\*5'*WDKN5W%V_
MW%UBZG8_]L[>'UP<GIR=';P[.K\XZQU?G&/&\<GQP6^?CB[^/#OX\%"+MPL6
MKPBO9$R3EL[DR(WB4/@Q0K.U\R:B[./ MPZ^)C1RZ$Q-8#N/ _MJ##)=AK!
M#/H"ST4YBJ($/CI-0GLL(DF35OBWUCDG8%5QXLU7 %K-W4JHOT!O:B74*__U
MBQ3J/X;_&G!DLOV 7.;MAO5_SR1.EY;._ZN$Z*8+T5:S$J(OD*570K02HI40
MW5@ABI;QSL?><>_= 97>8A3XT_GYT<EQ[W@?/O[PY_G1^<GAX4,MXQVTC'TQ
MHE[PJ3F,(>$DBMR 9_[V?.'-<$XQF+F'KB]\ZC#?#WP>BTK/G.EYL4/K9"I#
M'F5>2>^-E]ZM2GJ_0%E22>]*>E?2>[.E=^^WWO'%T47OXNCW Q#:OWWJ?5!_
MI2E=#Y;>O8;U6X*SO&-""9+$\(&G_S9RNZS>($AB[0?'5E>5=-YTZ=RN'-0O
M4594TKF2SI5TWFCIO'MX!)8TSF'C86MH8X.0/O]T>OJ!_NJ=/: ?!TOGW89A
M+6<#UTA(GR?3J4=_BW!F[8M85-)XXZ7Q7B6-7Z!LJ*1Q)8TK:;S1TGBO_VOO
M^-W!.<KD?;".>^_.#E@F?SZZ^+77[Y]\.GZH--YK6/VQ\$>P9Y==UF <BU$H
ME52^<>.QU;/M( &9C!\$OOX3!Z;B#S)IGMG5E=BNQ'8E1"JQ_1U O!+;E=B^
MF]CN]4^.+\Y./J#I3$U!]KE,N=7=>D &F)+7O0:&F.,P\-ADIM8@3E6F7,G<
M2@)4,O<[@7@E<RN9>S>9^_;DXM>#LZ/CPY.SC[V+HY/CR]W=5K?[X!Z7>V\;
MUDD\EJ%UY _Q:[SJ2M)NNJ3=JA*X7B+?KR1M)6DK2;O1DO9RKW^9-=^Z/#MX
MUSO#GI>7('D/CMX]P"%M[?4;A@L9"Y)%B&>S#H,0GO>M_R2A&SFN35G45CP6
M,9B_\EKZ,4CG:"KM*KVZDLZ5K*C:AGPO$*^D<]4VY,'MNHXNMW=W.LV]G^[9
MKZMJV+71TK1JV/7]RX%*\E:2MY*\ZY>\2^SB5G/_Z.R@?W%R=G[PQT'_$U8T
MG1P>'O4/SC .W#\Y.SUYJ#.ZU40#.00[-PBCFG7P3=H)%32=#(>NK=MP]8-P
M&H0BEM8[Q"Y,SJKRL39=BE<V\<OTGU:2N?)8OTC)_.-XK%NM5"#W3SZ>'AR?
MJP#QWG:G^^"$K%:K80CB?C"92C^JHL0O0^:V*YG[ B5 )7,KF5O)W,V6N>US
M$+EG1Q=_GGP^!@OXUZ/3R]9>I[.U]V!YVV[H;M(SZ^3&!ZMW[$ZQP58?P"%<
MWWHK?0GF,!8D\?=D%6?]O%1CKH6]K"NY7<GM2HI4<OL[@'@EMRNY?3>YO=4_
M.+OH'1V?'7P@*QDE-_JOZ>^#?9Q#\6 )OM5(936)84S: AD>Y03S12C CN:,
MKIHJ3&;/MW7D.Q*L;+B#RK%=">M*=%3"^KN >"6L*V%]-V'=.3T[.NX?G?8^
M<#.0BZ/C=X<'!]2RZ^#L]Z/^P?F#A76G89V&KF^[4["GLT8@UJ&4JF>7#*]=
MNRH_KB1Q)1>JY*_O N*5)*Z2OQZ:=OW[Y?96I[G3O&?6]>]5TO4FR](JZ?K[
MEP*5W*WD;B5WUR]WEUG W8,_?CUZ>W1Q7M*XNO_KP?ZG#P</MH"[F. U!FC&
MA7:7:?-JZ]P>2R?Q*B-XXP5W:VNK$L8OT#E:">/*'?TBA?$/Y([>QN9;K>;[
M\T\?/_;._KQL=??V=N\O?JW6=@-;?\ _FO7WUGDR@9?/*@F[\1*V&L_T$OE]
M)6$K"?NC2M@"&,'DZSP>@WI2P7M^].ZX=T']I=N[S=WM>S:\/(<SB;CJ(OT"
MY.O#7,^_Q&+@R4?=J8N9>,![ME?DI:WTN;IB,*WVZB0L+-?YWY\NMUNM73$8
M;%TZ3F?[LK/=;E[N=G9:E]U6MVVW6UW'WAG\Q%C\.$>=B]0L"P=9^!\\E;4(
M$GD"7/'LFT)#!A<UI(7M21$B"8T+U[OU5))[X16T.^H.FND5M(I;_Z^<I!/V
MU2@,$M^IVX$7A*__T:3_>V,<2@F'-I']2-99D(HAO/>U\&[$+%*'W-EK@$ 8
M@(2%;YIZ3UN$$\W&5O>?EO%OA,8<*"?B6]T F.(R=4\.03CQS_1G(4LL]>$M
M EW="VI3[1;I"A/X4QVLTVKL=)]<QZ(KV<XH(Y5D%R?]^\FN"^1H5  $W^+0
MHCD1=CNF$F3K ,5LLPJRV8?Y*YF#-'\)LL1^A4]8_V.UZ9<_%Y7;_&5F0B2]
M2E/=*BRO;X6Y( 6:+UM[.]V]G<UA=K@K=IT?&1R;/ 1O/YT?'1^<GU^V=MM;
M3[OC')B[G8*PJM,GB\^ NU7N_P;_[RK_K8_7>$1NO43$%C?]65HBA/]8MN?Z
MI-5$,3 J:SH60"JV3$C5L>Q@ N0QLQQY+;U@2F.\+!^,!/C*$U&$I#21CFN[
MOHQJ%BA#]MBZD1:0J0RM.+!$9+UU[1E0T;^B9#HOX'<:R$9@#U*S%D);;<.5
MJ) H9EH['90RR?3?UB3PI(WAE)HU#$++<2,I(JDZON(1@4_+$.!U+1UK,+/D
M-S>B<638J%U,Z:!10V\R6XY^.TP\;V9%,Q\>AN>L:!R$L365T]AUX!$[\*,X
M%+!Y!\^*/=^M^":PO""81@H8 %84DW]+?*&+UD.8V* ] W!',IC(.)PUK(NQ
M:ZP66T-ANS2!' \"=RAC:P#WBMNF(6MC@)0EAD.XNGA&D:9(>MC2]AK^KED3
M<06/*CQ3T'=+."6\P7-M@*CUKU_<?Z='YQ^*&#9C4Z<"&][@.K0;@G&8C#1&
M8$BKD7M3 80"+L#]FD@3WO"((U!U0/R"@ZGKT,@'0G4TLY(H$0A]P++ =JG.
M@\XN !3X!"Q#?^,/@3@2@!F 50^:TTL!(/#F:A;L^_1]S9J&P11Q2A+J"BL"
MN>"E6\:;0.1E/@HO]Q#X5I2$L#I1C( 59(1LC;"IY,P>6,_ZUB)$BX$DB(T0
M21 IQP) "A<>!R&B-KQE(*5OP;TCO$E P:_\ '0B=5# %3&%G0M[+!?BJOQF
MAU)M"V%RY3J^G%FAH(D$\&:?/O;@8"&!B/8!&'WCP\NL".B+8.).)HD?C"1P
M!;PAV K>?,WZFN"5(>!2*A](SP4T@%=//:S0H:O(L&BWW=IY [A\'83J5-]<
M.ST1G&?H LC7QO_H_)J;$<X ;H2NI'G"@#]P\<!-X&3  0"TDM 4_HR)SE,@
M)!'=EXMO=8=E*$'#$BV)?;=<C ##47P9,JZEZR$INX0-ZJ61A5Q1A!F["1C"
M&AOAKJ0/QY,RQ%L'W &@!+3QB/!=_W,@X0W2P@MI-]\ 7M$7]&?KC86[=?^F
MRBI-8"$.><3U\]0!8 "> P)3HP#P!>1:R.H==PC_@R @2IV.9Q'<->#KA-$7
M653&^3(J;%@G29A!0?IV@$<%9'-"U_.H>3=L9!K$M+97 MYL+P.I;HKY<7HE
MV;/(O@( YT2?&![+UH9M.;!%@]\U+(TH<,U(O\"GI\&-#$$R&%@12WOL,]LR
MWQO T>PD1+# KT(X(AP(CV,P5$".P%<L#Z'DHEY*VT?$<F-\ &#\)?'M[(IH
MX<#SQ ";MP4A\9E(RBLB5^;,%BHU^!,XV#!!?XWY6F&' 8AOXZX#XA-*?A*K
MBYZ)-H$<"0GFH%^S_@:QYJ-@<X!4X%Q. +*;)/U$AD K;R]VF\T]KOE[>]'M
MMG=KS R!5<+A-+)< .?Q4>?_DHR(F0$:P+<7_<=62BS62G+R!*!9SK$U=:"0
MBV-D[G3O@ABE3\("52J0#<(!VPLD!E)ZS4)= :P25&B&83 AIE!\ T'D"B@H
MHJ_C9 )'MB7\32A-,+H67B)(%UH 9@)1MB3+-'S^&)_UZYT:8B?:1LC@ G\4
MX)=*9ZQ'4R#> 'G3Z1A1ZNB7HZ-4W;3BT%5\896?XF^/0#"/7%21%%;S$@A
M>' ?& OB?;W-V"#]$ B$,F[T'@')8[H.^B'?@7IS"A3X/# ADR+5(E <3,<A
M7M9L*JT>[- &;@V@;A..P9>]-@%)W 4LK,HR7S//$67;18)ABITCFQIL=:>S
MVR1$,6@ 4:!^01N'EQ^AF)=6'U#"ZHT"Q*ZGT= UL>EM'/5[3TYUO=SKLFN#
MQ:\BUG D44-V85J_GB=5($DF'P%<'?2BQ8^6D9:^"[%@2_-$Q42!5_(W?MS?
M;VWMW!V'&$6 G=L8T@&%QIU*A&U.X+B^[24H;WWDSG VR<250W8NW5K=CC@3
M#BR1P'8<F?%<5DG>GCTZR^6[?[Q5"\@$EYIS-&7>O]?_&-+_H0O MWK)*(EB
MJ]UL U<$M7 8V*0RH*A&BT&$*)$ D(;AE%T*@#R]/B#H42@F#/;LIRB0V8 P
M-&]239#!HT4HH]A09@!M)^(;:CK20G0$A(<EZ'9Q85@$#4[02!S2V%#1R[ E
M>RT;E2[3 1YF+(4#ZEF([6\0F?IB,@A=9P1\YU/C?</Z&%PCV@('NQ&A0["X
M 3D$QW+!X(F5)9P=UX0'<.@\YL'ZD\2+W:FG91@RVN@-@]="_;@.&YED&P8U
M&S0M4I:%<XW9E[ 9W#>@7@9OA #N(CLQO'HI$;S!W]30R@)^0?Q94S9:/ZA?
MNSZ8$F0X6NC@17@!A(&D ?2%0^)^V,ZJI[28*H@U198FB\GQ#""E> PH.!H;
M2B!LN/'X_O\[!&V>-2YQ!TOOK9P%/M/AS3A 90LL7B3,$L#?,/LVH*H]+@.R
MK.9=8ZYBCT$X@C_8J&"++].^3<\'DS%\/V=$!ZP"IQ:HOOH2VQ-MG=3(X-45
M@<9(XID3C+:.EKT+MB=6XB;^1,;LL8.-@>GH 'NKPD4/"Q>UJW!1%2Y:3[C(
M@'&[LS67ZO,H\:-GY]CH%P.&[ 4WY%NA.X@HHQ-6BZPKB8IK.F#5 DZ=Q,0^
M,Y:N5*C7CRUR<ASA%N'H3D96%-K  8"1UU$Q;+6W6M]:S:MFL]7X,AW]!$I7
M_+\_O0/V#<+@)[U+Y?][[?JDN Z\P+Y*.42G3>E&=*$&^>KL*R*\^0O-I\1U
M]K8Y9^F71Q?)J\)G+NEA&;#:]P56N]%>!JNM56"UN]-HMY\&6"M[JF\DQJ)0
MA$AT$ +U-_>L@2#SPC?US@@=S#9I]N@3X&# N1M:[T(YLCZC;Y%]_Z=A,)01
MF)!6?QQB0 Q8XZ\2?4R-N>?)BS %&$G\ Q3RP ]LCS0;M(@'@:.4H!KOK;4+
MBA0H.0+U?[0LK., E!QL#?(WF9_D]XIBT'%0C48UW/5Q,",2,_MH3(<JQ>^F
M<$BMR-_)3:\-IEN]] WK$'UI^ *"-,>D6,O>E[:<#.#T6ZU:9N&1[:7,!3AF
ME PB[':"MA<"SL. 7)(YNV>F7M]J6E.!$L4B#$( .M2RC%V ')-(W>TU<ESH
M[J13,?,"@9_>LDI@>M8SB-:LSN[2WPT(-J"LII$'MD2YV9IM6/3X>;NU=#'\
M49A=<*2B:PC= &!FC^_P.GH<, MTV''@</"90IWH6D@B\B"J9G'%18UU&.O(
M%H8?7(-4"1)4R5$GIBTVK!ZM77+M"-(X%(X$>KTR?/IH2J-_UL'?M9K;QD.F
MTS+UNT?N-[B1$.QAL(EA2Z\0Z3_Y+J[P'K;E!).:=9 @Y@!EPA>!7]/?4RDA
M0.,_ E21FO5K *=X'ZBX9R_!=WFN^!D!=8,N+B1%RT_H)!A*D8S<8CKU](D)
M)#YPKW3;$8>G;@(X@<;UC*L @(V,@!+OMC*X3%(M(4Y>%6^B0#]7?G!3'P<W
M<_X.6/":4"2)=+ *[3 9N\3_R.+'/(8U1171Y3;)F@?'4DPR']NUA!O'0*">
M $!V8#&8SBY]T"+IDA;:G!DKZ>&%_X7N>U&SWB(S#[SZQQERB_.OB3L8U*QW
MGO@6G$\ 7N]3[\?I$ X8LI=P$ "G1MQPLH%!)$IBM!L1JBZ(BIEZ#G^=>F\*
MWZG#(C4EQ.'E-^1]ZK( D!+HA"/& &N2524P>,S;6Z)SY'MMY#MK(%C.D6KE
M:,;M-=:&3VX4H61T53(!X "&K9=BR SEOA+9"R@T2D/?I8D9\[Z$-*'&]8%'
M?$T -!BX<IP0% F=G)%EU^"/"9_5DA3K/9]*FUP1GC<C&:ICEDP34H>X,^T_
M4G>0<V?B(^S25+XT=9!,:2 YJ9Q]; 0H,T(7*Z !72<_SS22K_4_WCP"JN42
ME0VKF*X>-U$'504LEM=#]YMT3%M+F_6JG"!7R\>/$;J@)II]\: =%QW@B)F4
MIK\HJ;VU.Y?(_M__V-O>V7M3S)8O9+O/&=\/2M[+A1WFJ-?<_3245,J"N89H
M%$K,64.J"J)8.8@E!]U#GX*)M\:>TX@@A9S1!9QY8TM\V@W+TDZ#IX#!,N_%
MYL9Y[Q'5;5A':%RTN\0W0(6@W W.FHFEZ6Y=N(N($Q(CQ(%22. I09=%P:<D
MUO%!_^+HN$-J?EU,0&,:NFA5H1>70JZ@;X)VGB XZ \Z:1JRX @M?X.!).T]
MFBNQ>)%^SZW*[UGY/;^;-/E*07@:!>&79]8*5I"("Y-\?&;8BU-][I/-0R)A
M73I EGZRMAVHQ)$UO?[9TFW6J.5E.:-*HRWF&W#:VWSZIY$(E'J_,L>RJCP
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M#KKCPXO]FC68T4T<[O>0ZS)2,,.=T3GP2]K0!!D4R#WA)%Y<@/W\YFL6Z$X
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MR-(K5^HX@@E=Z<*X#=A!'3"'JFVN25^@T(FJZ!=&&C052NJ U8OAQN<VE?6
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MQZTF6FZ/\"W;XUUWV"8UAD;NL1P#=?HFH&*V:*&Z5-MD'0]AN+V!VT.PLOU
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M$3#ZA&8"Q_38*Y+'V"7&/:*L-MQ0GS _ G03? TOJK9)Z"%0P6'QQE%F3$2
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MN=2INUY(C0IXN#.T%0:#9$&_ 7+.^$AJ@+<?^UO8-2&))+<&M1+:'G45HV0
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MQP$$MQ2XJ**LNXHB(P!?CA\_Z_=]53?\FJIW5)G8 VYZON3RV5;\<)4"YWS
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MN;2S;KA AF'Q1'*>Y(71+&BA%ZB"\S9:P)\X>2/,/-XDM@HZ!6=]20#E<-;
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MJ6"-4_H]SA#7G2EU!Y(:98@F1!TBSBYVX:E1>9"+-1A1L$!*/,-N;5#ODZA
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M.OL0NM$)?@:-#T9682D@N0 ;LEYN[Y!77M-[4I$9'O;8J$%9$J<A4W:"1Z^
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MWMH;K4N5KEY-S&)TO\SJNTL%P:57I]>S>/I6FSO2_F-\5% R&W,J@V,7"S,
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MU4 $F-JX_>CM0HWYT@6IS!!)HS,F*W>M!1!YHW29G'P2H+"@V6D(3K%MZ\-
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M,=F)R65B@DI%1"4FID$*S/)OF'O+5%&FFI"T#?\-DTURL[U+26B@>=>VLY/
M[1)(G-H4J8_#.#VC(DB*@! /.4O@8AWH0OM:Q$?5T7,4IDQ\48.9TWWE1ZCZ
M%DQ8\M^OR/40C&IHZ+H8[?P,'Z+#'H[*EP)PK\W6@(R '-(W>Q$RJ16Q?K@$
MJ[S<F (@2J<6Q=B *&SG\7TE6.$# X+P35HR>F+R&L%PW.,8D(@!=4,@T)N&
MHY[>+_)I;Y"<697DP)7B80(RH_X017 :A,?!2F[/5WW-QRILL]YE#E9;>L)H
M["YER@D""?Z _8R+;+CS*(J_Y8F8%&P)$I]1N#,GC^YL4A 9ZRFZ7 !73%?"
M67:S"?)@9(Q&^L??)OTK+U[RP])DTQC<&P*R7PO-Z54+FW1P0R9:;"/XHTTO
MT4*"J4?%%"I0>EG ^^%MSP_X)0)&/#JB\;7@M8I[N6H?](XY>J_I%0W:!8LC
MJ5UIXDO.JYKQ^*L1J7X(B95W]1JU"=4GO3:5-2B-;WRBZ!X3*:Z>Q0[U2)L=
MM(Y%JX*R?A:2J;.E4*KB1RAD,-9)Y0NY ARSB_;S$+5)G3DR@LJ@^T9/3(=J
MEI2YLD=C2:OT&BVR"U76SPX.XH.# U+*H,,Z@?G'"7PJB2/Q@W0#:F@]UZH,
M2P?,Y-5EY9FH&19TWO:N\SGS.-N>+D8Z9Q7?6R&7Q!T;TI"T@C*58VNB;1T(
MD7I.Y.=T<)ND<-05^M*GBN5.L)ZHDPF5BE@>:(MT<+;:2Y*4G!41,#8NGY%+
M0Y\QA@5&@T.HK:*2X@LN1/58R+:2+%DJ\R%5]CF()X)A>[=]B-X*J<KS;,-%
M5$@_TF(BGJII.><J-(A]0N8 5FN I.IZC>[M:DZ,E8CUM+P2E*EOE+N$]39S
M=@3X?9K]&!4>;Z/D?-V3X1@4^TD5LC 4&0M'<SMR(W$!Z[:3&[SH(O$%A2HM
M.D-_PHU@PP2Y0S(0 9-2'XB'3;>CJC!H?^-%>%H8EO1[&5PZJ-]&2+\TR\'M
MCPBK3U4V+G6)2D4*,97K=9[7\V[%M6#21)BU.?4I<Y4\;6E@$VN]<-MC-C\;
MC,';G+WUXBB17Q>E8>AW$HS.&D,%4F[B1F*+5DA,2<-)P?7@I'(G)%5K!L,R
M9 ).ECU&5S JXHMSDYW559*JLK^@,J) L+1$N/>^H,E!,/W%>R#55/!M9*7K
M 9@,IUD*MBB6LWQ0XJZ'9RSX02IG+A59,RX 2C%<R<]C4Y4QK,GPF)HHDU0Z
MXWF.4KAJA.3(<!$H_8#MTRR%9=W5^_1/+[F /0P+/ 2@<VK0='AY1&LW';C]
MUM5:4_JQ4@)I'TQ:.?B-L,Z+7L<)G_%G]4ZL*00:]I[N1Q^T5,4X5%R^:!X/
MXK%!F(]26:RT1HY6;*55ONAVX*7,GPQ6'<\HT[D8 X)K.OOOP3T4>0Q=/GZL
M)W>WP)GR5:6G8U'F<QL+,"P6W7-=[462GQ,R)%D9LO:LJVW"Q"539@XQQ?E6
M;E3.,/%=*K;(W;$XB16@C"P9+P\YA?(G<4'<Z\4\PML,"]>QTYWN:MI[&JU@
MCBRQ#).J-!+LVD'S E;*EY4-:C"4* =-+*P=TI)RQZI=X&];QKH%D7[,)0G/
M=R4)NY*$74G"7X6. I418RZ'C)^+D&.W5LP=Y_KU8KHQ>W%.!RN;@R6):JH5
M/ZHHS(U E[7$70-BC %FJG@.>-6DV"G$F,==P8T4F'_".C52_(VM'0O>%.*@
M?^*.!E*U%WF3;;D0XJN>I"U[":$;$<N&[1_36(;WD.[)+?2F5E#*CW>IQ*N%
M_LLT]WBK.OC.6/R!4$GRA??H@\8"$IBVA;M-PQ-):1E]#"T9$AR[UTJ!O8GJ
M8J.GPL%G7W(E^''^>% T'O+RF8F12< [$SB%5/D/@]FCP81.(2-WR?QPJF*5
M:D&MEH'V9(6,T462U^2NX(>Y-3"ZJ/'^+]VY<F)+L51Z(+K68GEE_#01MC)C
MGX/Z1.U)X2Y CSZB_%]N3,:29#LL?274J;'V=80H1B@B:9:MA-EK,)&^3233
MD8B^WV*SE3[P0VZ@:1V1+P_L1G)??%!)NBN9DY'#]J9OR\07?',"6CKL3A.8
M%X@!&HG^[P05Y*2(NSP&C2^NIMC.QI=Q.X>QEEK0E ?FI5LD3)(Y+G!/0DW?
MX'8W])W!1G?;B*VM]#QM2.\-5#&HO%] 1:[()6%#%H. Q8/P4WD)/N(2@!/8
M5K4-;<N2W)^O>J1[Y%* IKE1-UQT0P96:^[;;#1X,[K)!KIA:P<H;R?#GS9>
M6FJS2IA87#/KLNO5\Z7O_,X"P\RI8PV0&(NGP#6>S3"RR;K'OE)$SBG"QG2V
M5&6V=Y84$JG%(S?+VHM,PJA>+;D6FC)Z^\=KCP#@C0;S"2J?7Q==,_[4K5]R
MC]6 D;<O\(/[VJ%"BV1G* =G1DA)$MMI,WD8PDMQ/ZN[BIQ2P,I[T/A5RR;,
MX0M.6LFV.+.DEY+OC>I=R0NI3S7=O:3TQKL "(_*RA\MN%<INA9ARV+O8^RV
MSJR>#2("VU)N>,V0XB8/^L@6J[)ZQ'@!;,*Z4"IJ@[(UK!1"D#H"$)T9/3J"
MHU?Y>(.#F&9Y_;3_P6TOSOQCG:0$"Q:]6RP8@ R%N[&H6LWH^OCV@/X!9G Y
M)S0\/G3DAQTQ=Z1GM[A9HFJMFS6KBA2^\:9#O%+XTB>$ /ONO9CW_ZCJ(@5E
MK#:P<[WN&9-4R)=<H\QX;HXS<!3^B\Z3FOJTR;0(OLAWX9^@%9M4^1Z6**KE
M5K+! >VIX5+F[-D8F10A^=G^WT:X=,':"O(NHDE<+9TYV-HRP^%GPN5I,=DA
M@7CUSG)P+\U18(UCR=09DT@XL5"\01I0;,$'J_&7P6&GV97S3"WV/KAEU6,:
M#<*1RIKLGKU/C8#$3.1>5W4MP3[*ET.'@DIJ$ (%)(Q78\[QVZ3U\($]_4]+
MV#-?[8%>H45-G:;X1;QY+IWQ68<W<F_>^]$#,)J.=4P?>2]$"-Y\NCM#B8\F
MO370(N2:O_DT."YT(OF$>7.]/P^O<Z(G;SX]C?ZHHI?/O__NV<'A"WKN\<?W
M:A91;)#N!<;5<IL,__>WI.R03N7Y81P].WCV#%V,+'$DG_"O(IFK6X@Q63CE
M_:&\SFLQ5IX='!S"$&0 7Q7Q*5C.0'\C\@7WPO]\EJ>P 52T^>.S@^>O[E0=
M2Y0(%KY??8'P%54)SQ#NK3I+5I0"Z!] 04+35$B#G'#8YR)T6'M,8^RYV^BH
M@[U*%-3<(2D''=EC<SWIXV"[## +OTM*6*6:$<B&K3?O38#'=6:FM.5% *@B
M*9XWGZ*3;#4#.=%K)D<P5%!V!)3B9Y\&LNBF$BE2*6JT<EG K.'[8%I4N689
M_@/>@4N0%/\1CQZ.MR9]\&$#7O)*1/+MAU?NN8B#3>E?(;]K)"2PAO4EH% F
MU5;SKM?"R079AJU5-@L[1<<VB$D'P_W6]F@T!)V,I&8IW#M]?HF[Z<,\>G]_
M7:F>6WF>#&T<EQR2+D"F>[Q&&[0 ZS9Z:U\$'RZ\^IE3'IV,1',UTBWB.U+M
MODM1@W]",&51+H)A7@T. G5T&;@_17CB\X1F]SPG"&7QILSJ)?.Z@MNO+X82
M3P@G2&FG(%)R^5R+0OMAX=/!XX.R)A\.XL&&$'LM<6&JS\@+_S9R8R-V.]@5
M3MM?NOSD^(/--6^PSH'S:3022HWYD?;6 B%RM&QKL$XP,&<IK2LJ^*H\1*,,
MIN2.^Q%+IY3IP8U38]7%1HR QYDT>[%+FNV29KNDV0TM(&WNKT0C5N7>LF*R
M]5!;:!G:P-8%$XK+&S/B?*W&:PM]\6GOR8R4UG\;%9,7KO!=8BKE,([AT!P0
M73Y),WW_+&ER5_D"YJW6;_9LZ.>Q^P!-PI+8<NJ+*A3([M*0/S^:$WR]Q[T$
MZP =V)+7T+@(9771IP\9XMK"6D[DA]VK'7Y9%"08%?/_4:\7M6OM'[RDCT4R
M)KC3;_1Y*F*.;_85$<3+OW08?(>W^4:OP6C'C;XPRVXV#;5B;O2M_(;;X4B.
M;O0U#"'>Z N_'9]>]OF]X<#*F\T;SM[-)NX<J9N(B0]9W>Q;(1WTI!/+T$"]
MF?"O:_!.,01^Q0'H'1EP%FXT,HR;W73J>7VC;S#0V90'YJ;;\3J;%PG?HS=9
MW&IQH[?\GA7@9'_.]V_TK1,. -]LVS'Q-.4"?R7M+1["8D$>0JBUT08R>.Y7
M3.>P-YOHNCKS<* RR4)8=N!9%S===DS^_79RZLCI(OP':+"L1 \69D*6P!47
M96]$@B5:&MZWFYV%BD:1EQ0^0"OHJYH^QG4D:J/%IF<-71J(!D?[O>^ <1P^
MIQRMGR(:?=E0+T^ /:"0JD;./\4C^:$@_VD9FS .Q'5R$F5*;=^##;-28!!Y
MD_J0P $31 D?4=S7$.$,![:=#"(Z<6\]LF\=4#>=',$0!(Q;"!8BC$_4,AL?
M$]0J^*SV#I/+*S@-&AT1I02G&'!Z\+]54'2N<<FQYVV-@ VB14_2;'28<<0E
M?-KCE0IU[:IK.ZH"GU?+,@\COT\),?#DJ%] 1AOL$OJRS%F#N 0!)N.;3W?D
MZ3SH X,>^+CD#.H,N1J5@K@2$H?%[XL4118Y::AMP(QW('%Z19A_\^8H>N(2
M!"A!==YDJ4K<LQ^&PD.5*G]4]046U;Z=PT$M.5#]]SR;GV'U0)OE)8C%:5<W
M7<(QA2#Q=4R)KQ^>8>+KX(70A8U.7L;4%0WF=ZEH4%(=3IO8*DC\P)/\Z9C.
M@<.9GVLOZ"S'ZK:STF&32_85\QY/\ORI_9KMU9*2RN'CZ6OP/6JRG#-R<)VL
M-Z,?11Z9CR>GTKGQ)#\W[Q/B/JS $E!BAY'N("-\5B-HB/W][?_^[NCMZP\Q
MZM<YUCN6&8A#FG$'(=<E<2LBO#K-DUE&B1[L>M_+5ZNNS&PK"?\BW30+QS2,
M?SW/L0U%G\,QFZ\Q>GZK/E>)>WM<O6?Y\@Q)+)G(1,JW T*[OA0U#:?U)/2$
M^I)K0)3#,0XOEL@R[FV5R6HM6K(JW4WE 50G4AJ7:[<1H*D'I-Y\1]R6>X=T
MT8FOLG69$=K>$W>*3FVOY^]4O_ )<5 P3_C[R6FL:8Y&-CQO.3,59.)"[&K\
M'B5RF-TD9#; _E44^'75@&D62 IWBU+&F 2<))[N7 ^ /DP#KJK4 4XT3/0N
M!5>-W):NZOM$8#E6R1<B_<7*P$6-/:BNL,V1M$A5(!@DIO!RJ_P^.SR($"@C
MYNK?E,.\""K>M-6:.!B"\G7;V(6G32J[T3K!Q<F^8,^5PSW7A*S@I S =WOX
M(%I8YX.?L"%@5,SA:D&]1:K7+6'/RM#8,^UA*1W&/&B.^<E<AHHX:D% ,^W?
M[\I5UCI64BH_SQM!-7#I2RK=_Y/ >T21^)I'S'/C!\A70/U"-#S**,/= Z4I
M?XK]=_$K[ONM:?]7/6>0AFBB7!3.'+)26X]&[NB"Q;ZHE/F<L>E4MM]TE'.Z
M&:9Y^%+^]F14-)Z:,P.;"09X=8%'!(E:$;?+X04+0;5]L^LT'1=+0L#0E'$/
M%BDJJG*I#31@HDC/J^8TDW++['?*>%09NQ(QNQ6A=NOIYM!A.#DR&^>*U1*7
M @^R,P@KC[JRR)*4E(/]%+O3LXWGC!WU8"@UWK-$P^2]J2;DP\J>(S/_Y"&8
M^QC]6S!B:IU7=HE!I<$;]2IO9CAHI;G67?2G(Q4L3/4#?K#5>E1XB;]T2M([
MR*"*)"]';2&'S^0 LRL= ""Q"]#C LF$GHHTH7\EE\,(V7V_U&)+C0(Q;<<Z
MDI]D(%2<2J.(V<]&Z*(T\QQHGC>R=U_*&'S9B9FO("QL'4N_/>0&CX[23M4+
M/KN1#&2Y%/X3A\.BY-Y$$HVM<5;IHXW=K#M\<E9(V%YN+\NA1AT2=#1@G7J1
M )!^L8C (*KJ5/E1?@-16[-EQ)[Y>^.9XY1>N^.*SMRICQO0XPY?L>G$9M/)
M:QCJHO+%+1^YZ+3!NZ5L/="42-Z8CTE$@25=%M5X0=E.$V_Q^B^+K>!*5A>-
MLE@K6*"4#@]-&H>.Z,E9L12\'"H;E]7F2SEO^MJL4@BE)1=H71IC<O7FPUW_
MNUXU6T-.[56+@,*54%""W3@V?\CFOBKRQ0&FGHZ2WX,6)Z4X7,:KGNKF^HB+
MI%[NBJ1V15*[(JGML>-!'6HF@)BL-5R@7"+?AD@ZL'VW:)*-..Q]O2P.G0/R
MLZJYW7B%K!H,<X#GER<!Y%6C"GIW*X_<RIS..$L:=MFUK"%FM"V.*)$E+6OK
M6U-93'PN! S][,)EM2S':*\V#3WYO3":0T8^V)5[,WC( D1KEA3VSD,O!%D$
M+]WVD?LO=)L<IQL\#2OG;!I-P9QZ[E&LLB?'@4QZB?;8D6T;E@2)T=.O8!')
M]%9B;HT @64)__J(,7IRTEY+M;^\!X]'MP:]O4<=L80<8"B/\!'_!'N",!)"
M,"QXVMRMS%KY"GT& 4U7;*ISC72N%+_)%5@W7*K8DU*5V!TB, ]292B?GW-4
MFZTJDAT6E3%;>NO276;3,/@HN57P",X>8U,#7^*A!Z/$K.>P]212L<!ZS#'L
MY3I/%UU-*L.3%I(XHYW$'=(:S\$XY3NBL'1.0T&05718SAG'C@Z"$YT&T;'=
M6BB475>ZEG)Z V86-SW#U.6JT+=C(E(38YR3&:G=3[)80P.OTM2C1 FB)YPE
M#F,<3SG]RL_@SVDWK@P)7](_7@Z=P=.+2E([F,=0(J(G%#BK]@1^O.E*['69
M%TG78)9UIZE'R@Q<(BA,%G%L=TM@UY&F;HGNAJ%;%^L=!T$H.]I[ M) 3 ^B
MHN^!#PA$VMJ1B=OTP"EV:*)>=+X_N>6G[]^>O(%/(B=TYJ 2-!>,NJADJ#AM
M(!53@ZQP$XNB+*3%+]6F8NH@QY<PN_1Y571EBQ7,_,J(T0!A+;/R#)2$ZE6;
MI-$+PB&JFGF/=@8'FS/<&>P<UM5U7V&D.?Z*@T_M@<FSDSB^VT]:@UC,E*R@
M)C"=[+'KTSQ9EF!B-K&B?JLB=BE*5ZT OU8D&7HLZS1,>0[U#,?7:T;58.&R
M\7T'R?M4X0LV&B"#6X0@$S/)+FC$"?WV-*T5Z7%DOK.-N[7PO3PP1PNI$N'(
M&1G\2#).H/9A#WYA@X.XKVN.A#E*4.)KY,G-8<QT?4O>EX7)B)J]5Q'Q!36V
M*G@,"B-:^D8SO9(O-MW<L"E%M>PRCS1 )3&+6N-2>3/O&BF;[[<QRS@:D]&V
MTBE'T07F.$+MEAF'9?()F%6S63S*]B'&98-@[ZX$R<5)=[KZ\I*P1('0W7E.
M"@5"'Q82Y2$SO#)8.#BS,0./+,)$:#TWF4$7WVYWX6NYMB:)S,!\#=GP?#O4
M=G-@4RE7*!S*FZ=+GX.BQQ S#0U.Y<]4K4)JF\_<'D62U=+?:K\@MRUYQ. (
M<\$*#P/S.EAUI<C.AIQ3,GT*LZ+V.E7\9&>8@3X70WJ8ZGXEU2WC@UETQ2(O
MMJC?5[[&Q4S3]0*M5@2#Y2B\F1P=QR?E&9>NP1*UL^(=J[\$\G*F:,R\_(FR
M@)N,MA,0!II086+IZ.T^IT"T8<?<06PW\/P+*6S18ANY+DFXX&=Z'V;[RX:!
MBK23V\GO"OZ%(?K]Z*TIUUI(!2#9WU1Q()7'SK4LRXX4EN=WT7R&&2E%C)DZ
M3T<K-COAOV2E@Z%5)#)-WVMB+E@1J?8E=/FZ=2 %V!UE/K8?_:[)845>\R/2
MP^E7S\":^4H'M("-PVO@;(9EE/XL.S^#6[FX8[XRR[;3T%OC'J@&J13&J&!1
MUUQ9$M186-QV5>&LIT/]@Q(C8'XNK=^5U]!&H)B=5J?6?CXM/!2.>5JQ$B(B
M0IWWG"L6\)W9<'R"1/ "]'C;^D)-FLTR/K$:"R M@> O=O:\<%@]&19Z< &*
MEI\)U).'V,9S $=DPU0!6B<B)12,]N6[YJ//974!9V69,6@I_E>.[H&GCUJC
M57+ILIIB'O(T:'Q&;=&RRQV,79 U.@7P-$]$X$ )I4O(Q\@TX=._06,IQC9W
M^E8Q8CYU$.!S=LU&W @+TS'+[&X.:$(L T/#;%\#MV,KI;?CT<!0%TUJ!9/4
MB!/J)BVN==;(6)6NUL($*K$S51C#M>I1E0>A@ZL6CWBT;"C&LM/;0)V]G+!?
M%5ZB%0RP5S<[]![S,HC\Q-OCF)?=[.PQF^O- [RI5I^Q8Y#6R46I]TOP'FJ7
M"LN''!/2W7681'N'0>)MK+WHV?/#!:STL$ ]R+P<W,MM<>UYY=>=E('JI?Z9
M:W]Q>R/239[R'__]VCB"DP)+7;>5YYYZL/O#P'*5(MG\G)?85[8WPZJ_@7%C
M*3__6T>W7::IL_O*3UW5(G;I"V#_)GX#^*PW?L.P%_G25PS!"">:BW9?'/Y$
MH%\'WT_\/@U93BX$23OQ*Q!S8-HWG!P=D2TR\6N"6.7TVT\FV\2OH:;PB26L
MFO@%'"PERVSB-W&]YVWVY/#Z+ZD64V\(MVM/.@F/GC'UWC_Z2W+MC;HI=\3C
M^]_\3GY@>T+>9$X( ),N&<&L3'PW?AO"E9?G6'RUO*TA=GB3*8$7/+4(8Q[Y
M[6GL/OMXRU6_WY6K[LI5=^6JMT'*'^AJ9-Q+@ZRZJ^@XO1L]Z[I[;Z, ;V*#
M@OY[??QN?VKO'9.&H&@Q(DRH[YK$@D=-.T'*"$KB<&*[2PDO)_>#)!4QM;V*
M0>_'[C)* =;.N+N><:=9M\?N^$[NR_V5Z-#-= IZUQ-/9OJ &J4.)X\-3NWN
M3AVCHRSZU J1")9N?M_?XKH'NV)JLV*>3!V"H)3M([\^E)=UI]6OFL*L^ NA
MC0=D]B!G!]7M3CL/)/6=/$#SZ)-6W\#!N#,/BBHJ'WO8>OK] %=ZXC=PL2RU
M<$Q] "=_0]-A?61^2W7X;^8QFT+]B2_!R4^)EL5.'F&:6GZIHG=W2ST,;WGR
MZR-)L?9@:A?M5VY>GCK!]BT9[5H:_&U$^QP!P+2KAC4HT[[B#F[=Z>,,LZFE
MZB)!=.>I9S'U+74'IO4=A*VPH63ZA6J^@031],Y!64UM,& 'S>0G;_HXB0>6
ME8]'5RBT.<)R/'I]<$=&Y=2Y!6Y\?NS.Z>2W9%Z"T\BLWQ/'"B8_L%V)?N-C
M=X;F9WF1UMFM"@$?5#!".BP?^S7@.C$G?L^WD9.^L^LIFOP"T8[BJ05X/N_J
MJ>>"S$N/73%2E&AJX7*M!,WD=8B3G_:[<+F^"5L4>_H?O=-59VN$2)@Z SZU
M_XL07<2&,WGNRL*N"4# U%KX/)OZU"MNV]0G7_$T;I4@?U!6T5TUJ0EZU6VR
M'#=XS;O;M8X]+*W_^ L;F6[T\1=V3%\KA# ;-WS!#6//#,4[\308<WGJW4!<
MJK9+IS;E[Z09?/I MW3//_I#^*V8V19E;&*S <'>'K]_569+:A5\_"4+WTA.
M08&^I]6,T]N\TSMQ7_:(],!3F4XMPE,G8J8_(Q^ZM=2P)_7$%7RG-9)=3U]!
M=)S5+5/;WJZM]R'E 3Z<'D\.^95/79*8E).'@:</RT^MY"D?.K'Q._55.+VZ
M0I39J;WHR8^#!5&=7$$AC.^CW_;Y':1TI][VJEZ?35[?>+<-T[=*5STDD[&]
MJ(A1:O+X^-W8H]^(#!/%U;0"3)SR37Z>MQL7&[\+T-V?!HA2'C!X#"+X)"D[
MY(U@K@8/SCHM7O (,O_WPX';];TXR]N,MB+[>5UG>Q=ULGY%7"O*=4&,027!
MBB.O';)5,QV.@((S+S5S 0N%U"J8/!'C**%:GS=ME.6)233"IXS307E2)4,B
MWWM] 'V.@\E71#JU[8E*TG[]9RH[RX))D>#A^]'(%,)O6?)# O(38D-=Y&!Y
M$2D>88%DO@+NCKA7,,PBN6AB)3YB3@"8Y;++4^;F\R1*\.'Y;R>GD0+*PTI_
M8/8O!5I/\Z:M\UFG))(C*V1H-N!Y?6X3123T\%#7'6Q6,'>9'ZYAZ2&L;7@!
MX^C[6MMP41F(/YB#8LI?1<D\))X^(0G=MG$T[N_@;4-A%_D*OD5$"8[RTGTY
M&.KX:X1(P2XRJ+\B1BZ@%>T,XONG\&-.;8G(T-# #G!9BEG-IFO6?)LQ4]U6
MT8R5,0D_5U;EWMBN$H_98-64;'Z@&T0 1A7$N [X^MI].W!Y>,L,]?FW@9K_
MFBB+0$!/Y*+^2]CYWC*X&7C^&W^#_QN"YU]"H!,=OMS__KI4#X0A\^B3K7>$
M[5X1R%E7DK)_[-'XN^@JFKQE^]:NPLV\-Z=IIMUTX4M[[$F+DZ/)NZH_K<'Z
MJ+-YEI_?KNSL1L #DZ\76DI*(/QM!8BFUC"3EW,XLK&IE4S9YFWQ^ \_'\K)
M(4<0XGCB=Q!E^F,/V-W!+7]GU^/TYL3AP3<A4]%]15"G>1/YF^9U$_?(3)X.
MEU#2U+D3(9"?V%'Q/.D3'WX?9IMX^\L[(#Z:WB5>U-5J\JM^@?S6\\DM<.:L
M)0.YJI4B8-I7?@L0<TG39,WD%OA=V-^W:I.Y(>I&<3>8[%.'=69YU7 JYC83
M>8A+-GTH[%OQ)NY Y]\!@,/TC!M(AGV7-5B+R-Q@MX0\N7'H)6;:^6G?Q5SE
M270W6KJJHSM3;R='1]$<_LPI4R()NI7%?D,.G6_3U%DE4X?/9ICA9W,T2R?V
M1[DBXTX][(DU!IS=:NK8RMVXHPF<UOD<S-Y%-W&$^_8J[V:\85[C:0'$Y$09
M=V!'S*O5*JOG>5+D_[J=__CL!B[]Y'F(;P02^5L(?!"B_N1QXN@N[/D[(!//
MBF3=3)YU^B8<DQSK/B;GJ3\YBNX"(MY;2W?BC.P4X]6*\2[(0:=VT,XI5S[U
M9F3E731MW(E5#)[1Y-S;\WF"U;I8Q#"Q!SLY;BPUTDP/KO'X>^$73#MQ!T'-
M1Y\E 5_^2[[JIC90)K_5#P^_@1!VOIA:':;4+/#H[85%7C>3%[Y^(WF1.S"H
MJ\G[D^^F-NGQ@_ZXYJBIA8K ]J8'7YOZ!4&SV/2&3U4^>FSV534]6TIV,?U!
M5!S::7T"SW8_<>B?<I$[Z^%:;VB(IA-!DFZS)S<Q(<Z3HKN#(I$U^.J/WA6!
M?<\G=SS##MWI&RC.LN+1-S7,[N#0?SL0YW?#>'A[\/0;75X3[PJVQ"=UWDRM
M'['??O+8W*U!X&]6"PQV2YY-#6G^>W61G=\);^OTB,33TTQ$RRZAKH;)R:R3
M-DH4W"&ZR(L"*[3F8%SFX/+=*C!\$YVS$9P!K<R*'DG[PXTN4US1) (7))J?
M92O4Y-_-<OC4$G^,J%%Q\J0%@?W<30_I],5IT].P_+-+BGPQ]3R^"5"":9&_
M'CX\2']<_?5Y^RWDTG?7]D/P.-;9?')6<KB ;P<)^Z Z4'R1Y^T8X!Y2>-3;
M"M/NRK>%9(&6[=3G?7*5]1=:,QY0M$?UXN7$VW=40'>W4CZU:NC:Z X$/:TB
M,+FC538Y--0=M,-E"RH\G;PQ=?&7VK@>K$1/C43U:U5CR\F9\U;C.X /N!.J
MK.EQ\#W\ZM2BD/V5F/1#,J[N)K;>PJ84$XL7 A9/?=W< <$4XDX^>JZWIB-D
MRXG?,KU"F;Q8YMO!/#@YVH]^<VC94P<.OX7^GS>3$\2F69M,WKMV!QP]F_6C
M)VOY9Y=0GN.QSZ.Y.WJW;P$RZ5NQ&.X@4Y,O*/XQ<0$&ZI([ $R\JYAEWRF]
M)ZCZA\Q,\.HJ2IQWQ$$4O<ZPHND.R'!NC_\_2^:?EW75E>G/_[F _QP<3+ZJ
MU\OY;6?KX66,+=/0DS?'3Z,_JOWH\,7A=\\.#@[B*&F0G(3O%>9$&?O\CR]^
MH,]'"L\?2?G&@*5#D792V5-X9H+<)A'S38U\02LQNKI:9_")XVJURALB)<D7
M48Y4-^NJ;*J:'ITU;3(K\N:,1O!S]"1_2E_7I^7$UT.=A<3\P@PVR;*LFKR)
M(X$N(<83^&.=)2WQR(#B*/)%MM>>X:^R,D<2$GCC65V1DUYL8$8D$@GQO\RK
MDKF0FE<P!!A#EA,#TI/D*<>0_ >BA/@@.8Y9U1D.O(Q>HJ0?'L2TJ%G=X <]
MA0YR0UNF'#X:R/R29L0;\V3V- KFC55A%<5DLTCJZ1H8<IV?XT* T:X; .O7
M=K 2%U57I#0HQL5N$1UIL<BIG#BJL[:KS6E$FA8Y-_2;,D-D%C!$X"/GL">T
MB/#I%):WJ-:Y4/4,=OL5L8W BO&VP6I0K5D# XGL.?HNS<_UO^&_G!(NLJ3^
M>5:U9W(D]N#GMEK]_!R/QD6>MF=P@@[^"T_)5]<;<SPBM9[%9R\&-%K/?^B/
M_?^R@_<Z9$\NDP/ZSRLSJS-JU/H9$5'6R3+;FX$X?MXC^*^?D^(BV30RRQ]^
MVG_^7Z]F50U[_/.!#NHYD88<[#]_^5^1^1F78["6J^3+GEFQ-;)[E<N](ENT
M/\O7]'<U#4I_"2<)Y?%GXC@ ^<*G!\^EC6FK]<_/#O=)>\$_96(O#O=_>#G1
M5AG>%/S_[SUI2A+!L5[\?__QGQ_?'6^_/TLDER_XJ1<\7/G5?_SW1^(J BUQ
M7*%V\0';[Q(KL)>**JWL'JRB'ZRLK/]EN"6#E>8_@CZ:/\%/1/]/](R^^;2W
M![W-)&D*MQ)_M>7Q4^W*-:^N!L;2(!54!=I%:]Q!B:TR^#'%/1C5Y_% H3.Y
M5ZF<=7AAG<%=-,NRTCXW]U<E/ $?A_<.*7%Y):NHN*=ON5X1WF/*L57U,JM5
MU62B_)5M+&G]B/Y=2Y:&]H4W+YH,K@*\QJ3IG>V-QO&X.5,E438ZVN0:!*G.
M$Z9Z,\8D9<*&%L?E!LE^=%0&]ZXS(_[JDYG9S\(01FA$E1N\E)<D2W)_6A$>
ML9@Z?,H";8D%["GSI25(R'A$@S\YHC%?.I)D$U5EL1$R.$0J=+U=/=N-G[$?
M87H,J=_DF?8+=.S@TXX*KDE6(/IS8IZ#3X,2G5-_&HP AEO#<&""8'S"AJ\3
MLCU6VZCU8 1<Q]I4':BN_7^WX_)NVQ9:<13*$9(^!RV'ZP;;BW\#$XTU&JSF
M(D/(('P$[1WL*O[F(H$/U:11J[8"^P0^"AJV9;Y(--H2 N-3OCY\;(V0;ZB9
MM^P=/&H.+ZJS_8A8?@@M7X[.^%?BK1+;8'^3SC,E!M)(T6,BQG>)'%V"I1AP
MQY=RE&@-FWY)(\5@$1,"Z@I\$'%OZ%HX(?!0M)-Q =9X7IGL=-NLK>K 4ZC?
M"OX XV< %#ZID>(".D4B *)C7I$,AU=SZU*Z>=-9]/.4%_HE4P0TIEB]="G!
M U'8%KK/+BK^*CUS^\[)U0NZ("D:9015=8$+ QH!_GGZ]G0?;P-'L<P\LZ =
M;>23!#0CX04AK*GS$16(^)U*[BFTLK,$A!AGLX9A)6T-6]ZT78H,GV;,1I?M
M1]<Z<&F5->0\P75^GFUHF$EZ#N]&19ZS-=+ ;K3BR,$QT)LC%A93;3> '\]S
MT!9TR$A(^:5XW/[MU-V5,H@P2]&9M/1$,]%EK!*:_(L(9 ZK+"<8#YE<I8M\
M 1*'GXBCG&(%+IQ >D&^H1L./FE1E4L\ZUE&<FQLC;Z L?;(6^$R0Q&\AB!9
M-M8+\H=S$T)9@4 B@>N(/"?G"2@,=$HR#,@@$:L;/^B I=# ;AD!4?2JLU_0
MF0*KE1Z'0FV<_55"X11B>AW?$!!T'CDO';8)9_+IT +'JQQF"[9"@Y;%#)0Q
M?0)C+@T"/8#Q(@S3!'#%)HVRW>K!)LVOZG(XL] $&9SOB+N^Z1.B^%3<\@5'
MD_*%C;R4=,0;8JWE5V?_/WMOVARWE6R+_A5$]WD==KPB+5*2+=OOG@AJ<+=.
M7[5U)?GY8P>J"D6BA0*J,9"J_O4W5PY[0*$XV:!(&1UQCBFR"MC8R)WCRI5X
MHFOL<:#N-4>D5_:C;DFR=)>N]<JZTB;FLD;<A@D;K7*18ON1\T-Y<$-=<O!$
M.XDTSK-YNO$"R:33,]OG&0M,NL*)XQ16QE$-O#LH49C#BYR"'8.T\-)X6VOS
M%ZY\0'KY;!F@2?'*SZNB@\(G'4-':@UA\=UBG-!2+4I.BNRC7CD8%_R9!O#N
M+QOL)L&C/ "^?W_2][]EL/#;JFD/3M28_<:QPJXH<[.IPN_"@=.?I:R0/&7$
MV3[1N >O?L_8X<O7W:^$_7H''31W,+ES;.37V+5/-9 /'< FR<BQ45EWUGDP
MUO6_J&:"+X+T]^;=7C<D_1W_(>Z&;>T..+$G8W&EEF7G:&22A=&U+*>2MLD=
M4**,K<_)>)\^>*CE75%HU(%K?YL[W1PG3G'W S\JXVM%G]>@[X[=^^RRWB/S
MH),#M*[&]T?''XC=I+<2X1NB+^^XDWOLEL#W7T07]/A'_Y<R'S_T?-^F;38Z
MK3$0.P_=?10_?GQ"X_%':OA,^=B&?G3GZ,LBN4 UONGF_\I&3P[<21!19V>H
M.8\]T/6N'&1,[VEN2?E_(Q*]!V^Y7KTY>?A$^882&?DV'H,RNC/\S?@4T*._
M%>B5K!4T_8.@EKR1IW\74_J6^7F^[,:VF.,/LGR3K>=CS^\6[_@.YB7?49+8
MT!_C<TLX),3H6DW0-.FMRATWFIRLF-OJ/#^E^/66S%8W22YLFS8;FQ= \7%5
M7C*<\J[4@Q"RYF/GRJ4)C%&)=_WV+LXJ 'SJC!OM<F",[F!ZS-VXJ'=0;1J=
M!$U.U]BYKK]GHU,DD)8]O8OY,=K4,+;=^ 10\?AYKSH#HT\^-AW_'1!8@$9V
M_/T"WJGJ1D^ +*' QJ>'2[5/ ]:/^X9N&X#=T/T25.RM& 1O5I989:-SLW2;
MY>V8Z6Y^3$?/3Y-_\/;]+^^:4=L'D^/#QP\2N7CYNOM[>3+Z@&N,7GAS<M+<
M11QS-U9O="!$WGP<OZR0GC)Z8&27GISW\=7!R#=X]^;M#!TKBYI.^!<P+^\+
MDJ\[B;KO(+Z1-B%N_1CY3NC:'_D6F^[!HV5);]TJYW"_BL?+:M'A#(X>.*VS
MM.GJL5/NHY=!E4KCH=NK=5[F:_(51WX;=V*G1H]AFZ9:@+1[Y-SF'>!S@[[=
M.ZB!?'$%O?$GIZ'U?VS#N-Y4M\K(W,3GPB2D6PY;OH>94A#6^!;ML1.,=U T
M!AGV>S"=0'\>)&H-;MU1=B-\UUVX 2@/H;<VXOJXQ2V/[Z$PCJ^$;I\BN<F9
M<B0&(ZNBVZ9.;_)*JC(G,S<^SAZT B.__!7:1@#'^4UI]/M44>%$\.A]AU\$
M%*N\@S;6\:=BW)%F^7)&TXPNNW=MC.^D7J8466.7F)X\S K3)<ON;^0M)O >
MW$@<;J,Z#QYQD>RZM[AE9_M-;G$'3\'E^I:$Z!;9P(/16_EN^#"W;TH\&-=]
MN9GPWKXCAN[S_<WVZW8],72?9S=X\[=P8?'F;P*AN5W'#=WEVW%;;F[VYF_5
M9$>W>#(VJOL&[^(.SOGHSW!+8/K-CH4@TV&LC[[[\3;W^N[Z]RK2BR8Y!;:T
MO*6F__Y.U/#-]-<M-?&=-"?>4A7?RJ=X=J-4#WU9P7.WLO@W*BO?4IW=9./.
MM@V]HO1V3W.35W1+Q78#W<R,D;>YQTUZH#.P6"YN:9-OI@56&6>3*)J=7;-&
MV119NOPB?%$&;M0\/V+LA_F27/BN7*7YK<[ MS=Z-^NL)J5Q*[5^HZ9S:-K%
M;?K/=@[;7WD<49&$)#]"6N[?/Z.AG?E-0N*18'JW,=XOZ3*+]J"M#D#EV]&6
M1-<"V+EF@-N&K[:/>SZ@BLY+S$0B9^,P^9M14<N("(S]E,^+%R),Z;6;><%4
MI+YU"9<1)RP1-XF?#/R\,I5/1S>5 $AU95MOA1.=%:B,9,@^I1B*,4L\4U'"
M7I#NG]#[NKVB6Z[I/IQZ$\;Q8"=H:4:_B/L,;$1 N!529:MSUR3ON_4:).VT
MIV^5J_?%60KIH%LV)"(-,Z._7[]]X0CWTZU;ZP.>_?1LFOTTS7[:*ZI_]-E/
M.VE3-^A Q__Y9GDAQJ>_!. 7:";2W:7.?;#!$2CV XX#=8(.1E;!"OMS>D_F
M%>;E"N_35)OWIG'=A82+RAN_RE@Q>H[SKG%L]HZL_&V@4'G0#:CP^9;!:(A8
M5]HJ881H3358_5>K@R*=9P7?,6<*]K-\CJ8R3UE]9T3F_6SV=6:+?H;!F+<>
M-QI,GN+3#,0Q_O%2YHG!.@43#S_G -+=U8>::5X5RWM3$/G1#QM]=3)3'#=/
M6@AV%?[0,B-?;JG#G"Y_4?02Z#S5%5Y!<!UQ2.C +;-S.)OL2KS^_U\V.J"H
MYW0%K_OXT=%WWWSWY%O[QCMS/MBL\V&#7Q5.[B'M0H[),7WE^-'Q\8Q<E U%
ME.9[TK\*]E])>&I5$]\_^^:[[[]Y]4)T$NY""UWE9288J]U]X7%A^C V/P0C
M23!M@ORS8(+//I6$Z];2M\TC1';'1K35#SR4%#-"('0SFQPF)"MN'H8-SILE
M&]H ]KG1%HX]7=-BDR+_F!5;>7LRXL[-8+AB"3_:O-);+"&\*^:Y^/$A@'?Q
M\#UI]DRT'3,)&B:QN;2PKI!1:FXTH%/(5RS\=]>[UYOH>X\.MI-CMDZ(@QQ@
M.#GM\B5/A3&#*^$$J NJDL>"87C8,JV7EI"E4TI_.I5Y(?0":-.;F8F_S,3A
M2P0S\'C HZ$1)#2R?U0\N(6-.@^_H? ,*"5\08?4D)W%GV&8:=UTK.2*,C)$
MIS'ADD6N7XT)3!,VS/Q3TU8U>>2DW8HT7R.R3 L-U9:X5C[O9)A/]@D]H+)=
M:_<C8P1T44U7GV=Y4<A<-<?P(!ILX#.'JN#\F*!!#3N3V8+ZR%[$3S68%MB
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M"#NM];O@,E]J<I.2)./HXRT8X8\!O;POK)WFJ[819OVL;!PZ2RD,(Z1,U3]
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MI,]E\?S,0FAUHMEM/JWJ4VV5)P&DUU5IO3H,.=SW!OSG9<XK.!-VO95Q82O
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MB41NW%L!?N!"G9%W#^56C\P=.?8K[RB@_RVYCVB:W36"53S68NR' E_RR+=
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M525,9R'C=G 5F:,37V-3Y[1UF(8A7?':>8K1!M&PF@JY:$G@D[D#>S0CPX7
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M".2#5_KB^?%1\NU?W_=?[LSYI9LSO&,=5DK/\O\^>4(;=_PX.?[VZ.FCQ_<
M?G(BC-?%9U)@6JF_R.B-MSR5DLO9M%5G;;OYX9MO+BXN#N<B 6T@ (=T/MF-
M6J-[,G4/H0="KS=+T##!$[.XL6'&?SR1VM4[3@QQT>XG>G 1J:-'!W^73_V?
MCJQF5M.1W_?!_^->\POEK!K\Y+.#OTOV!S7[WJ@YF4,E7UHQ[I+'#-8V>CT
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M-M%/AJ0%H_:0(-RT,@MEFVS.M@UIZ)1YPS6LP4];G"27QW3C]VP6"A8*Z9Y
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MTO;1G9[1_0?O80*.CB? T00X^F( 1Y-A&<6P?'./K(GO:PX;]OT<Z)BTW
M-E-$B##3KF0^@MUV9^2X-%FV=%^:O*WI4#P8;TN9LAF.@0&)7*<PF%&=Y>LY
M # R50ZAQX;>2>W')09-'M;PQ*>*FS7D^"#%*HEQ/VV1[Z)3U/VY B;13^_0
MMAPNYR*Q?3J=J^E</9ASQ4C-S%!WI0=4[L,F;,ZV#8EYBC)(>)3DP,U\W=,
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MG]LU-[Q96*SK&AG/32]G9BJ;Q\8O*+1C02*EB5I@B3,>7LQ6M&?>>*!R..>
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M'&>FM]!4<54$&-WX^PXOK*]O&#WHA3.CWV=:FF&)"T_&S,"<+!X>?NGY2L(
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MGIG_._60S WT J'WHR_U  5[7<R^?CVO<X9(=?:W3W%<R[)\K-50[4=4,AZ
M@3-C!G4EKYXYV6C,V"FD0QZJY=:SO,^]?#@/(=3=,Z^<M3I0LZ^.A]K8<[^:
MZP<X,U0<8>:[]'.;<W;<9S^5O!-^OQ+'T_?ID-708>Y).] DGL>X? !5]H>
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MH1^:;%5DAN:6OQ7;;5_9=P69229\450A@+S-05;A)]/EXCG80I81>&@\@C1
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M!?17,E&:Y\9%U](H.+1]J.9HG3K'XQLU<QM"]4#XX+$V!CS4J8264ZA5+6$
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MX8DS_H#6:-'6+#9->REGL@1EZEF2/]QJSX):CT<,___3"?Y_@O^?X/_3'LW
MDK$)B$]Q]2?-N/G^97!;(*[Q1Z'X=:P,2F]$!3(!1?;2>9Z.87!TGR<7W'2G
M-^"T1:C&L18]@/3@P!>=.;*MTB7ECT@&:0NA0J=ZJ_1PG]7-:)+$H\<%E.I]
M8CE=8H8O=W#IV;(N<I!Z0#Y4/(&/S0/UJCH9'=;L!/D7[8_'8%ZC%Q&PI'+#
MA5!RQ#XI$BGLF-ZX8MWMS*4)KHY>!CJ7X1QS;R*O2EK%94X>62ZZC?9V?8MJ
MQRQ"1JD2$0\%38ER+(?D0L6!4&86S$KL8 <NB+_DQ'-AFH.I=)PAUOXIOHX_
M\C.0P>[HA+,F45ZUW[QYYKX:S+7THG!@Y3G%TN35FA9"D[RLEN?))]ROB?:=
MUSD=B=QOL%05P\4^^B3MC^?Y,L<C/_W\Z1>?:O0&413?#?Y/WJ#5V1\3;J]8
MU*O]&5X$O:Q?^PVZ,EZ41?*/HE35F&?27I32#\VB;Y-7\9+XKH9V$ST4#X+_
MMV*O2SZ5O);>R.^S!:;Y31#SRA>2;_N&7R#;ME16WNVF_MGS)U]\E;@?%L49
MXAXH2,N#*=K+'C-9-]E&VVL_-H/QPU0N:*^^+%2N:2-*')"7*$M '/9X#BY6
MA#E,Q2$_E@XR<AJ*.35:Y,[0X&,?:E.?R*.%28=?@>@#W\L2Y*KS1AH;]*.V
MO.-;<; -];&\V"Z86M3%.6,)NZ!]OXW2QOK(Y\D/@[E ^,&?4,Z?;Y]?T/[Y
MR:L73=#JQ UB>K*3$5N5>Q?&!9>-OLL4J3&G@/<3AN_*)0P*\0NZIG8!K5<7
M]8<ISA1-O0LMK6_M\!Q'-R8V72K]\/'1UK^W<@OD2U="O1VF@ED)J^BW0I$:
M<G)[;T#8%D8"68%=0]&YA=GGKG>WO(.+L>CNQ\!,='Q<K]57]%D@$ .>(0$P
M%FU'Q' CZ7NXE^H,1+RVFMJ4=$#?REN)Q.A$BH?_]:^>3 JY>BM)MG9JV)%?
MR10-%I"Y1^M\1!1>XNT!N84G!1L@@B-7 SHH?.+"=S(/P9XG()^O4<;RK+QT
M8<>\C'-K0&F,710?IF$^.2:4I$4-^Q", ,D05.*L;&?L1#09>]Y32._2SE[3
MKA=4Q<B7TX#YR-?Z[%U%Q,!OHJ^K-%\;='RU09IYL1\-'QIN$6XF*9<U3Y**
M?0YW/L\MTS#2>5!O>0 ?H-O_.W#W!L>\,B<;,<VMB'NY,"!]W$F_T_[!5;YI
M\MP#U)!=VW4@ EGL@[[K6>M9EF6=^2;[N@DRXBXM9QWMV@O>[4]ELIOJ(\(_
M&'F(*P^/D%1R?L":*.J8'N0Q\'Q&C$8ZU/D,UOV$F0F7N58)K%GVX$4[3B0E
M7+ E@CT0)2@6&?Q+>&'__5]/_O3YU]\4R_V2&0[XHRM!3(B4O++63*D#QY6+
MK V=9[ ZB?/==F<!+>U%P#YEWNM"CJTZ\.-<+6_#\WW#E@Z?_O:;XYSB/T?&
MD$$(F3F,F[RDL;&OP(<4N0%"7%8$7+8 MCA0B2]O8J& %I.!)'@/ 359[/0K
MHYE&#6%&XM"EU?#3/Z;1+2_))]@J!3'"?&7>Q<3"A8TKNUWVUHDP"'/^=?R@
M?84C39_73P^S2M'2908U?#!:4A(J[#6&T;@_FCR=GU6/D9HNCHMWX"B!@OQ@
M3C_ \_/F^OVQL\SE/\=L3%".%Y<QL#<9IYM"F\+YSR#[Y/*I+N]S8H@XH5/_
M0^C4F$G8T3%&)C5QNE>MA.!9J0B&JS##>VI..*W[1[7N'7.0ZA(9IY $2.!8
M<@G(@)N(_A:1LC;&"]$:<ZJ*U=_,&7C:,J<M\X%NF2#?*O!T6@[U]5F_.^2Z
M%7"XQZDKO=UH,'3:,:<=\ZAVC%,*=3'H4N+U/!-VP'CE/_+U_3BA:E^=H&HG
MJ-H' U4[G3$?VQG#R28:0J5I;H]#&I,]X@QFLQ\(QR&+&Y'F<E.V8^GMM'ZK
M'W_DA]1I@WQL&X3UBJN-X X#$,J!1'*_<_(.'8.>-D%JN&"97HY&K&U[!(=R
MVABGC?%H-L:N7W##-5!_#/JM!@K*K?%4YG%A$[O#9WU/?!RG9?^8EKU7+XTH
M\@H624+ASY'H"56$:L]&-=03+P>/RP"@(W)-?*[N:#5#VS6[JH7I-BHOJ381
M.!5*=!J2O^F@=T;0"63#$(\W5:SU:)+;U6=54UXT"ICIN4P0LB<%I#/*K*^6
MERSGR4!?&CQK(P$+2S<QS8D#M$,("U$4B6CD=L<P* *&$ZVR$$;I&WRLB5.
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M:SXC]?(S9A?LMYXULN5ZD7W8\ZE;[;MO0^=Y0"KD00B*![2IUP41Y=O80:0
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M 8/_H.>2M3O%Y;6XV1]2KVC*!<ZNAU!\:N6E3&<+V)FA(>O0W;5U@@:+OI$
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M*+3@7*L/F^[<Z.82ZJFR :O,K*E]:S 7+8$@1!_SNY:7#.QG%C/)T8>D8\;
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M:XSOL[F%VA19.TDS2N3RQ7GR@P_[OA3+DF+,&5FF'@$;/Q5JD:NS?B<2.LN
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MSP$3M?!NY$URT+@>3,K$K/HUY _%Z&"W">1XC,&(9E1L0>G3,:-XVRI3QIN
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M?JC_G[UO;9+;N++\*Q7V[H04@6Z)M*P79S>"EF0/9T<C!26//SI0A:PNF%5
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M>A2[C%O4 2)F7_<[2+3N3CVLGX)8EKR_[.<*#V4J84DR;#H7E8-US3GI<NO
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MS8 D_?U-"[[Y%#:O7]#3<O?[QY!0J-RA,3WM8?,^"W5PJK;Z^7DVK;4_@VV
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M2,\8D#C36CS;"V^>_Y:^^,*V_CB8(&S]>1;W_C"I3:#DY.753$F/^&% R6#
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M@UVA@GVDDTF J'<4R"$)-E7A<F=LT\XV_AOG?*GJ+AOD(6V0]* QNP2K/3?
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M@F1CZA@?G!LD_A71">]Q#F-&N3 $V2A>"KI(_@7N(<G2KJ^AT;Y!792;KAY
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MN=X<>&-[R"U"^HWD_KS]D1_,U1-.A==C!F/+0B_.-/F]41(UGSN%2GJ-G1=
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M,5L%ALGM!C_#5U_ZA<[J)*OG1)#QY*LO/\-\YW^4PV9W\;?R%S]1J^<"4.<
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MB=5/Y4HBGOW>7VY#999U%P8D2&5LZC/OT4\<DD[YH_*QA1\AF:9QKV[EB+2
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M5P0 6@S%BH74*6U;#V9$D%A/VK\LWG!)O\ZG3-+@-2'K68_UOLJ#5E?'^NA
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M7N>.(Q$&+QG.6S*<H.C:!Z*#T-.4T$S,[-DHUU"LIJM?/AN<EK:[\F[NO[@
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MX2C&+E\6 23.I0-I%B,T]LB)K"1$PQ9#HNZZ=MX),:3O\O;+6>W%X!Q%$9[
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M[H62]7$ZQ$E!8 ^9DZLOK1B+')AA<=+*,H^,)99=HD5- .6D_"ZT:<4D+;W
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M+[(22?F+N67X&?BNN2?LE@->]]YQSR183ZA@GAD 'SH\N+"<T\4#0!E3M\P
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MM)P4R)F77]C?H2V@ LA!@]!"V2SP&^ S;)1?E78RE%<B%-62%UG[V448_;A
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M _$"J9Q=#)X>1HPX(KJ(L7X0*]% 0M>]=]0&DIPT>H8!TF&>"6]V3DD9=NF
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MFLL+:6&9:\U&.G^?_F"A>HGS9W%<X6(LSF?&71)J0PN7G2967R(+3Y1/IH7
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MY8R5,V:VWA:^%TII.*"=ARHB,1E):2>+/XV)7V5<< : ]8DVVU1TL1YSFAQ
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M27JE,JWR':EPT$WN>UUR!+![]-I%*7;WM+H4?(*$59YQG[BQ,() (ESC/Y@
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M55XY9OHQB[I'MO0(5N@E[.M+%(1YP46LJ#*!S1\NM_CZ5G"7)+B"VC Q%<=
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MJ*F]2>UC,2Y\2+]@&DO7WXB?I^4GG6#[-/V9H/#T]>"- WVVHR#V<&=R'Y_
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MO)=WX'8-P+'C(-^NM_\2TJ)E=TP Q/#/5D*$N][^BR3..AO/_QK^>=W\LS#
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MHT@T7OLTE*8"_\"'](U@&C,XN3Y_=3*%_P%!*%Q7>(O\%PF^Q;CG7,M'<W^
M(P<C-/!9^B#=>,3M$>HFR %AA$@[ 1:)#X,_A 0(.O_%&;>93O)7L#R2\6:A
MO-<)<!VC*CI#5518#%5=6V:@4A=ZDN1TX&7 /ZJ'C:/:+'=V"41D<%079#]M
M T)4O'L!4ZAJ[J6 ]U(I=PQJ5P$OQ@BR8MZ+$63%O)=.N=8R]U*\>S%RK)CW
M8N18,>^E0W%'<R\O="_K@MP\Y>2_3I";I1)](Q@O2T]D&:++ @C0#6#;5,JU
M@\*S6Q=(U;#.JV"=/&#(1<ST/3!MK4/BI<UB0QH:(1JQRY6YII\])Y(-HD"^
M+)'L.0HDD,ZAR9=J$3$@C8Y_I:SYO6;T_K#>9B$B.<,4;)K'!8MYJC^)>#5H
M6D.75K-NC#4*MOF==*M6"W<,&^I/[1S,&&2[62^UJO7Y6<B&_ WY+TE!'0;U
M-RNE9K5MB-\0_UIYB\,@_G:S9-OV=T[!W[UK-&?6>?X]MGF]C%GW&OGX4&;+
M+2\!*RR?VJ5JK;%Q'64(>4\)^:D2H,+2<;74J78,'1LZ7JT$I+!T3"#SK8W8
M306SD)4I13W:?=[ S#NV3)3L%7E*FS:Z"N8O/7O@M=TIM1H5$RTP/+#O\;)G
M ]@W*J5*=;- 6H8%7@$+%"]J]NQ)MJ5FI[KO0;,442B#)"0F)='L-#0$C9?V
M/=S\2B ;.G/#>HN%S_!,-Z_9V7Q6U+#!@;*!,/(*S 7/Q]2KU3<[M]WPP4'S
MP1R01['XX+E!OY)=_5[$\(+%_'!(C@CZJ0G+;^1PW[>82443L#0_\A@'W^#0
MW]!S:5+X)@W%PIQ.X3S!G>,A[*ZN;N=;?PG%6FO42I6.":48!GKQRKR=[_Q%
M#--VJ]2V-VZ:&OYYS?RS"OIQP?CGF09MIU-J5)L++-J7@R+*WN/L:OE?E..
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MCO%;TL$1M J52(Z$2]=T<WJ<SMN@(Z)T8X#U0#3GO/HV8Y!*T#;>3L#W&F2
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M"&2:B%@$,YIOG+=BY4;B+I:XLV6J.8>85^_Q4@)XI>M48M.C8N#2+BR&S=/
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MP#_A7WLED8U +IA WG-@P)8!!C3 @ MI]46! ;4SMNUR@^_;0 4:J,#G[=U
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MZE!D]!\KNJ]JI8_Z3[C$8;? [[!';TC&$2C"&DEVB*(CD0^7.%PR(-50E;&
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M_G('Z',^ZL'"5E3S:>#[M8;G *('[I\0"E0JDK;]:CV>*YCZIID*I15J5T#
M0D&;@E<\^BX>S4 W"GS[A^3B\)J2<(\';X9N5'CA"$2D[4&[?0-Q!OGH8Z](
M[F5D H/)>Y>RN_?/[\7<LX,P821"GR0?.QA>6:'/J8K_G*AO+?4SINXO'V^1
M/T0V]^)\B$.&9NP"["?A#(><>CI_('(U0BWN$:\7TP@BX^.TI@<!!'7],.WH
M*(!_T)N!K %1U6/;#GSW8; '9302XX\-(<HG#&/([QE*\LDJD!(S(!9''H=P
M7& =#ET_L@F N$1_&:$(=O[TLKP(JS^-]]'_=CQ)T VX6$8#.2+#,!OT-\%\
MJ8F[!IQOREK/*(ISE'&Q%_]'T_)=XA AYS%1YX0V=WA&:"7N<UG>L!9/>V>A
MEN"J)Q.(#ND?)Q..'SUYGTDN1T?$3I#Y"?LW-CB86?(N[?TP"TFH;L!)A@H3
MH(20O_83<P*QAWCXU':>4=9!35)^"WDO5./WD5=(7"^SJI9077%TT)/#0H:7
M2ATIM5&.U7/^/1@<Q\;EDSV2C (8S^3E,#@K4CC#B+2\YT4@,:!;^X#V_D8U
MZ=1K3]#^BWD\4/0Z-M*G ,KQ0%\CU!,O_V2._9'@?S6 4UMF],I+[ V/;/57
M7(P.EY =N;:.$ZPB701J_T&HX4/C:V\''%D,)Z"P%]IC00+ZHQ_3;Q]W9M#X
MB$P=%5#2(TJ =.IJL">KE]KQP5H[A>%#0LI17P]!COB2OKJ<UST5!/\V_?XH
MP1=-_2!1Z@=*_4"I'Q\BBW^[_T[\5]_ J]T:?GAR-=3EP%]UX)+E_4BM$''P
M'^A(%'NVB!,BN?]-LUNYDC>D2YCOSFK]EB9XI57[(6%)"]!S1=7_R42F40-\
M\!"6HFF 34!<:;[9<W+%N3'8]#!A-_?$LA\\_&Q!AV   SHS&^S".1NF$[N)
M6JWUWW\_Z^6GQ@$_87YJ=K1['LW1KB_6*RNZ[0O%34U*S];T+EO.//S,28N)
MHRL:V!_WA[FJ0+04>W'%*2JH$\>'^3L$'3J<Z6\1D'EO"17HXHL2G4Z=0SPX
M#X"!"+0& @-L]%_77\9W</8'Y.YGEXU#KCC<>W2B9F%DP/C+LWJFCJ[U)GZ\
M8'[J!WNK63<W(C/?M0X?A90SI)S=C7(65=5[QU4Y3R7X1 Y326PR(405ESB1
M(@E,3!-36B28J<+1:963&.QJ]?=^57+ODZZN/&>7G]4 ?GYOT WW^J\R]-4"
MY5>R%'@T<P.3F*-B88<SH?O?H)_L[RN/Y,T"3L_W(5C<\;T[_AXQ!"O3C 34
M:1E+3T2*Y60Q34\X44US&)U.3PF5G3S#6$\6NZNT-:X/LD5!SZ<#=3UF5[EY
M!FKG+UM*H]+&QU4E+>3LZKK0E7G)8]N@)?VR9777%+&.VZ_QBU&K7.KIQ6S>
M"D0B_LQQ85[S?5H:\KY?D^AY?^:G%[!E[)GKS#A/#64&-ZJLHO87;(O8= .1
M%+'8VZ>MC63QQ(Y?386RHV^)=:ZDB52\I2&,BH$EEW;"H)<>*+J9+6A!1J3C
M+;=J>IP/FH1F5*V4.FZGK(:U;H.6L1')F+9U,&FB\UUC.-_,L]VJT-5 R]B(
M9BJE;W9*KL,/6"RW"/IE1E0#D8F_W;>72G7N:($@"6EERXT$6V4R(AMO.1L:
MU<I@(C3Y;9&IMFJS(*@Z&9&+MZQCW6V&$G*R0>!ICAR5L:J]R8CI>,OY(M!T
MM5$L8:O<KKLQ"5L=>4!"L'C3YE82-_4!21MZ<SM;E0OK,2-H(H['FZY]2][Y
M1(? MC6I6_793EK+!] 6C#55\XTTQQ6)*::7=[5B<YL=51L9V#0V^SAG#2H5
M)6MB4G4B3ZOC_F B:;!I;/KY6;LW,FO<PB@&L[QF!R-YC(&GGI"H@3JSYIJB
M!IBZ:Q?UJ>;9O3&0_!,BA>U8S*I+&R H5:U9G-KM@(9P.B53)4S:VFR^+!#=
MM=.I][9#/!TVC0VKI6'Y#;[$ML9 ,II2J5&VJ)$&F\:&Y?*]$M?=%17,%RL=
M=KH=#O("F-<38E6;KM/,?+H;\DPJUZ6K4W?L^6!8)^2J9Y!8A2I5-:':[[1Y
M3O"R)@.>>D*P/([.=GI"MH%MUZKH*U1%:-7!4T])5J->9X52@^6K)-GL^ K-
M-54--B5?-JTL!JU1ICK?\,617L38\J(Z(S,B<4((IZHM=N>2U<5RBN<XE>$N
M4.>:2)P00M$8^195-T9"=TU;UKB=S2A "(D30MCJ5^P!/:ZL,8E;:!:&D\*Z
M#YJ>$)<BITRUC9M5C-6T+U/!/-]E.-#7$^+2M!R.U%8*9_C&@'0MUBIU"-#7
M$^+2Z.2KW?1@7N3U92ZE$EV+DN9MH W%FTK-#5UOVF1)\#6\.YC8Y'!@@:8G
M%M9;*BN1K)",(!'+8.=U>V-^"H9UBC&JJNIVQUO.8#K66!3*>984P%-/+.PR
ME^L[[) ;855=G7F[:J/-E3(B>6*UUBN^T5ZTF;8PV$W$LKT+A!W7A@ZA6%-6
MM%I34]5D8340V\T%Q_8[DTSH.WK9E#-+'#Z:^B/>[[?XK,)/,W@S;'H S+GN
M[#Y6R"7?LY]KX^$GGWFM-Y/^P::_X373D>W\ Z/?.D=QL5N^#S?=S71/38$'
MR- "A%.W'S7Q@R"ON"A[C?*9H?:X/M]Y7? ?%('6Y0;7!2P,C1;F]A8&$=EM
MK@LBLAM=%[ P"#"76YA?W^WV[!+B7VK'5YL$;OG[]VY=EM(O'/SZ[$D"IAW\
M\'\?B(??Q33Q@V,/\;)';^URDPB]YXE#).Z",\I]?$+?<J$?3K]%-31(/'FH
ML#E!\G4E^:+O4;["NOK/A K1]^W#Z\S"$'%+_-\8VR"BCLU=>$G'%V'EKRTV
M=\6_X:TT'^3=F$?Y^/Y@65;5Z?22,Y#^%0V_-=Y,6'?KK$"YK=$?54 _A]O@
M<P?WNUOL1\YCG,/Y^/E+_L8MUJ_)P-DD 8GY=Q3SJRSY&<3\-_:O*\IQ;E\S
M+*H'^<]7T-X^&9K?'8=OQKIN!71(6I&T_CJ@<2O2^H5-'";:->#5G^%]R/"'
MIU/G[A?5]FY?M*^@)?Z*N?YUK_8,^7*DAU.U!6=?\\JW].C,*#RT*7;W-ZF)
M0C<O9I1)P7#%[!9K#KUUGF]LO?D\\_#LI&G&%9O3XZ.ECJ^NK 4F]P1]1*P)
M6\'J^17X(T65]85DNO_[D"(?PJHPDO>_#_K&^\?R%RG%]E+[%H=3J+Z;TB1I
M^0\$:,92X/_Q3^C,>#G)<6#IL[YD^NI#P@4K!?Z*?'C,I>5;38QHY#I"KMZJ
M-CIYU29W@4C#I%>.32=I CN<3#U,QE=U9"#,7Q'S-V?<?3;F29%V4Z03I*:<
MT!R-%XW^<CAIS[0K8)ZJM+%=LT+F!+]H>/2\E%HUEO!4"//PDR:8) 4]M*]B
M_JN8NY'BTH(74>C[FR'<?6FNZ-8Q^9DE_!5,BR_"8'=A7%W=$+X#I60//C["
M'J"J)@1>%!'9^Z%.T!/3(0>Y]D;$!)5F1LZT9+:YCB8R4"7!R21%$I?32!!X
M[P6\U_4+W(%V\7O@]592>D &7 TC9H7N0FFUFD$7GB,%N@6.)RF,.:]J<2O:
M<J1M=%17E1PY<I4HZEHU[>6^_"&,F^OKL(*OK )=;6*JR([Z9#OJBED4GZVX
MW-[H;XDNSZCK3.2M_,\!]X E\T^H+S^"OO.(^=>9,\6U::'M8$NCB0LB)]%N
MLVT$(@O5'I).,O1;1ADB$$0@YU6>;F_TMT0@9]2WSD8@;JXW&*2:+H8U-ZVV
ML\3TJK[0 ($ U8N@DAB9O@.O3EB(YN%G+[HR 'EPD!&(/#@7].#\RMRCJ$7?
M[1&9G% TV&G3=EIFNA^('%1:T@279# :.6L03I&SYL+.FE_A=#8@.(</JAV^
MJ3F2)[9;GKUI YS"D ^#)SF&NT^_#+:/ L%2U-XVNAQAY>O+Z*(?2_60#?5]
M@MF?X&3Y1C1VD8!1A-.6*5D>L(7X U0;ZBE6FQ;))IGIS"O8%IMH7'M1I,9.
M6PPKMJ63-/Z6KQFA':$=Y:]<.<+T(;3/.VY.[8YJNJ&R;7RU7F=3O@[1#D-+
M%(#[6Z;&5_%O1&]H+L,;(BTM8:J2JR;"U4_9TQ2\O!9Y.Y 5A;P=EU _'F%7
M@ZCKP!$VIX*KAM;5"482,C157VZ[.,8XX^XP8*<3'@]@,6*@@+!)AKU@R ;!
M]EY@BYP??ZA'?!2V9HTKS21J1QA,3L18V1@QI:$&8<N$&68X<^9(R6WIQ6$>
MS[FU"&0/H0@R2D&YLOKRE*#7L"WY]03;1K8QPH*-;^BS?L.PIS.%Z[3AQ0AD
MF*2'L11RG""B0*DF-T$4EU"8WDD4;G=!E)625,0D,V<2/*:P(S<D"A@V2K+I
MMS+QOXK'A3E**$&NE7,3VS,<DP#'BNW#NRYN@,;.>9SYRL.\);ZZ6!;*"8*R
MG>YVUV0*)%_-;[% [F8ZWCR\C E&@&CF%W%M!&\$[W<I* C>ET]>.0'O_$3L
M#.MT1\&*?F^777F]H;D.X0WUCS2=)*FW+)4O[ZEYL[!D39="E.O[0\WAO9(S
M\)WJN/OKJ<-4%V_[A8M/?A4>O"FQN>\TEU>&^Z6+3R(QO[:8WUQ^QSO%_*M8
MV=$;#L4GS:>]ZTM4H/PB^+P7,%XVD>'E%1V_AMZU5Q?)]WW)]^=>0?-I\OV%
M[:W("9R19= 5STTLI2TJT/"]M$E4W/*&_;][7+8B6+Y^S E?%^<[H[C+8]*V
MW&@TMG2#=0-X-3V,;,.(%2JB@$!^A];B/7B!WPMR<C7*!=G,N&7X*\VKSZ<\
MP6@9"/(H?0^CWRI9^U4,YD>-!+#IF^4KCVQI9&H@4P.="3B[[@$1>!1M>9V9
MV RV+))#C> EA4Z1=:QISMN F<+2E12>)*@+GDA$F+T7S*(# 7^N2KP;LUE&
MF\W6*Y+&"*Y?:AK-K# 7-8A9H$V0>)+&[O0P0*1@Y-6I"J9&23CJ6K5\-?FH
M5RQM!PX6F4<H\1>=$+@39>: ]DX$]M=945ON.$6G*PR?FZO\DFG)HZP.6#&L
M1HEC23R-(T<*8@IT1. FF.("*M2[F8+JY/I6CDN31BJK<NE^J[#ID0%DBJCL
M9)H]<V6IJTCUR;*3R/."K#CD>;F8LO(N\\T=#)T1DZF8@E0K&:I%4^PL#125
ML (EPR8)\H+WER&PW@M8D<OE#_6%=X%5$-.,4>W@!2PUX3"+]S)X5<] L )=
M@4DG:9*]9U]+S;:TE*<Z"S#-DZCZ9,*>)A3=#2-?R'ZZGT#T[4_*UTA5"0^R
M$"BM'T'CTV\5OW5H?#T5 6Q_/;#[Y<'F]V;9 5;9S.I!KS\V<NWYJ%K8.8T!
MWQ;QL-(CB269]#VX%"*=X&6EQR.?PJ."<*F(S+<&^5V9+\C7<-;*CP=C9OLV
M3;6D?J\LB*[0+-1KQ5XG%10K >A@>&-7,IU&G@<$7>1Y^-SJC^^#+EX2O.U
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M"H9>Q<GR@,#F61P^,]9/(:7ERPT%,PT=HQ:#[%8,6F(&M(SU,S^NX$2FYJZ
M3E^6ZZ5=TZS)&9&.]S-KU:Q946WVC*[8#8:;>7HTQ=LB$V_9X#J8/E)+';X9
M>+E5,Q-L7$D3V7C+@F\X,L?O?$Q:8.RHL7"F%3HC<O&6='TQMK,I+6T0>'XA
MKOP)0Y)M,7VBGYE1>6YKG35?=7%,P:=>F<EH(H[%FS;E MMS>T172%7+65<4
M#!\'@\?Q>--6(66(RQ'O\L1V4>D3RV:6V0;0((HUY0)YLL#:6)7WZ3;6F.E4
M0-!M$2?C3>MY2<G0I:PO^+.&A0DLIC17&=B4>=F47\B5\:#?*?)=SIOFE%RP
MY*;A4],QV5L.:GT,Z&X8D5K4;;\XT@P+S, )X5/7:]<VF-U0:(JI'3O9.@.L
M%C:-=6!6I3W6E]8,MECUNI.*J ['RPQL&NL 69BL.D2UTQ*J0LO+<%BVZY1!
M7T](E1:4FHPE3(J&[HWZP:([WZQ+H ,GQ&JX(B;548.R^04VSCJJ:*YP&S0]
M(5>]#M$J=Q>B") RD><MT9L'+NCK*<'J]$ULI/9&/)/V<V/"9/#ZO V;QO W
M'Q),,.R4/&/E]J9DMUJH;.7PJ3$ S@HS?S7Q,@V#";K=?CVPBKU5^-08 CO+
MXKS7%V>ZH><MS&$'3<5LAE>TQ^%2&@:;W)0H&]7=B'06>'MD%P/8--;73-IL
MXKG1?,L/7-WU&5N31_FP::ROTW&_L'*(!H8Q!=:7S>:V4AZ%36-]K7<(WM5[
M=$K82I-**FAA#-EHP\M>8WW%V1[;L,?DP&!ZJ<VD3917(U6#%X/$FE:=7E4-
MY(;*I\Q41:<F?,HUPD+9L:;ZO+!T%C1A8D16[7?IQ6I#CL*:^[$92,N5>@K+
MF46^B?&4N:I@&IPLX@2MY]OJ=)4QN1Q?E H%K##O"YF4!IO&9L#MBB6KVRE9
M&)&?,<2LFNMT*-#T!+8"?XKM<"H_YU>I?EFI256I \]3GT!!4<VTNTVUM,16
M2YH:3>M;/<>&)1)B30>"A:_PW#0CI-ISISB=5$FZ%S:-S0#NJ\' K[1*&"'W
M.%ECA4I)#0]TQV9@::79H#SI.9BDJ\UZ6@ZDO)"!30\S$+I)'NW*R!4&;$I3
M6KKJ/X<?CG49:(;M33!H9,B1%?/<Z(N;"7&KVG,.;]T_#8_TGE]Z^**X&+ @
MWXQ\'YDP1\^WP3.GIAT<5*3#[RGH*?PG,I$#, F_-$WWFM<SXT>: ,79]UX:
M/Y=VA!PU_( 7^<@M\J<>989""W$3"X$A1-S$0F _:+02-[$2B)MN92$0-]W&
M0B!NNI650-QT*PN!H86XB85 W'3>E?AUHNG';.K/&S7W>?E0;[/P'P^9>SGB
M$_G@LFW"\?SO _?PF\,@N1\8?O%QO)K"\([XVTB5G 1O*:J2> RL(2']CD)Z
MQ0,,?RK$AVK4T?0\EJ1& OU%!#K^[VD1)WY7Q''\!\U^:1&':>//Y1FM\EVN
M,HE6^=>KS'WU52;.L3==]0Q%F))FFA)8AS#W+.&H:]7RU;.)[K5']UM9S6?P
MQEY[W&<YU1&Y#*XPE#=/;?Q@GJ5SG_O01MZ/H"#BXOZ<5\\^/O6EV:U<R1O2
M)<QW9[5^2Q.\TJK]1T4^0L@5''L!LY;A, :Z-\OY+E@=U>$W^TOR,JZK@O\J
MIZLC"B+MN59]4A48?3=="),^B?LP>XU\^$G228*-W_J%0(Y CD"^/YIU#')2
M;-<:6*>GK!;"BF\44OZ(R,C>G]4".P?(BP4GL/F\6<4&Q+!$I*;,>+5KBV'B
M(<$DT^Q;!9L1R'\K=G'M<2.0GPODQ#.0$^*6Z0;=Q;PM\44G6QCVB>:V7;H^
MR+%=;S @ MOCF<;67[)$;B0.8,9Z^N$G3B4I)GY%Y9?RC^T/NEA:0MTL50M,
MQ3GNI[^XI7PCC/39JW6^"CN_"D!>G'!>>#>0T"&A0T)WNT+WV8/\#D+W!5V4
MCZ?WHZKI'=55)4>>A>=*%:!PF?82GJ%%=LX7=V:<&W[?W-CY!+=E!,2,I>2?
M8,A'*OT)LX;-8YNRD<8KAKIK-(5\O[_8J)H87FB+LT0R??*F:P1J!&H$ZD]T
M4WX,U UO+K6= H,;73R#]\W5L" WX?EV>(,+S22I- +UW7DD$:B_FEOR8Z#>
MD:OB9&04Z\)@ME.*XU*+#PH9 .KTPT\.3S+86U>MW;H#\H4Y450M%99@@]:$
MI"QT2W<])\Q?1Y;ZAQ2-ZR7R? )!77EPM\16%[<K]H@$9)5YAL?7^6IK>6:E
MKA540Y=[HWX^X';D&I;.@=<#$$F<B]^3A,"-P(W _?GVQ<?![8YKW>U6REF8
MZ@QZ XXKUBJ[0 POJ6:P)$5<T,"X?W!3UY=_!.Y[L3,^#FZF:DFRE&LTA6JN
MVU:861FL5QN &U@:5#I)8^S9+8W;B&4\N^K#CB5$(!?)^?V>UZ:"SW:A7'N\
MMT1]%S=:'G.:]ESGGB"[<2L_HYE*1N:;6;:ZH2L-9MB"=3N!F4)0=!*GWF([
M1 2("! 1W+R!\QXBR#17XYJ2GU<-=9C/5HO#<MEQ(!' +&Z<2::)MRXX0T1P
MKJ#)M8&!B.".C:'W$(&1\IC*K.'S@K0H9%/=H+0>VY (8*8WB2=Q_"WGQJU'
M6L SX;4%B:EC+PXVCFV=S[:Y?]JZ 0?&=_7._.<"]\5?SRHI6[*]4"$:W[HO
M7N8[[(BFS )6]"?^W-M*S>(07A< #10LG>38N%[R-X(S@C."\^?:%N^#,Z_9
M<\VH33N8M.9::LVP4T,R ^ ,<[.X=#)-Q;4+!&<4.T%P_F0+X7UP[NI-K1OP
MDR:F9]/CFKV11G4I '"&Q@+.)!DZ?B[T[R\=+8%G1;V9ZB3T<((2?^W#(W^?
M[[SHM<=W0V[1K\U5-Y5">JDS?]=>-22M2%J1M*+T_)N4UEMWA[Y(/"_#<H.J
MZX69Y_:1FH,L,%26X X#+A=W=AX E;&4T&J(K*H3AA19J71GLY2I&-NLX) \
M5<[Z%0U>8 I+Y5%)@J-02BD"Y7< Y<5=EN\&I8MGG"8=%!E^*XJ5G5#DAWHN
MO%68":M>8=@%<R+N'Y2HELK7 >7%'8_O!F6#VPUK@5P:8Y)96,A*?H.OJ7"G
M3#_\I),L??[TA-M(SWZAHN_]CL@R_N)^G"N,^T9-Z*^?VW  YSZ]JF%;C\<H
M3AUIUVJI0GH[4K%<&JL5.6K-MNQ,V$&@7B19$KM@*/0;BCV"^_>"^Z<9$N^#
MNT/-K,I:SE;Y9GM.MEO%T=RJ!+"#P)H@D\2)$KH([E_=[XW@?C^Y$1^#N\9O
M4CRKEERA6.WVUCZVJ&'E$.YI"'>2BCOT_C@SXFI629A3#984K UXJ:^[,UC-
M)V%/P6Q/SE<&\]ZA^_F.RJOQTYV3T>4KTDBZY4+8J6[3XI_!KCG- ]"]E;:%
M$_-<WJB968'8EI8TX]O8B@*6!PDMCS3])C,A"",(7QW"<?\G'"1.H%+FM^M^
M1W)Z4DZ_ODL:;D6GE3_GE;KHB2GH.*PM8NI2) 7(T+WSF@*W9 A?>V)N*;!W
M,45U(F_E4$N%2FI<13U=_[40\4+M0 LG=%>S1NPR\P(K8;DMUYD,4T:ZT])$
M/+Q4DDI2Z+HY1"Z(7*ZD-7]+@'R!0AX((-=5UZ^@FS^OYG>4RYU,6"IRR:(3
M\E_@2.W]:,,'M^UQT"A*<7N]$&DF4UL-3(MI\]NQT_$6_?K4+@0B3H<YX4P2
MNZ2JBW"-<'T_N+YX*LA'<+U9#M8<-5EF#*FJX9RY*Y5;60WB&J:58TF6?.LN
M$X1K5 (#X?JS<CX^@NO\UFQSFE[*8.K:WK%<-NB18@;B.OWPDTA2^%NG1;Y@
M&  \LZ%Z"1/F?DQ4,*GJH2B&)VT22\>&B+<MY%SXXBFK=W]V^^MG@SQ5ZRDX
M]B('NJ);/IC%YF.%RVP(T*A=3]JH+K_Q' EL);HE.=NRIRY<P'5P$(YMFB';
M1=EN;^61E,N84RG5\J[1[<@D,^KWF^4UL%#V]Z>22?;$58LHJ141PG<GA$](
M3;\*(1C]C)8:;IH*QJR:3+9'CK7"."0$:-JPZ21QXO841 A?/<L=$<+-&S)7
M(H3-J$N;ZT"=&Q(_&0?DQ$N1ZPPDA+!"()4DJ/A%B%\W#_ZOK&JI4]T+ZXO_
M_60#P94Z,H[.>)G2_?/;#;@\OJL_YXYL(\!H>\_-'J)OL5:S-FM,FP.]PQ/3
MD5R;F^N)O]1$G(URC%B&1AGR"-%?$='W%WEY'=XO49U::+/&;N2N#&9-:ULJ
M2V8"(0-1#8V3)$5?\*JS^P<U"KO<]3;]20;*A[;ILLLX&;)5FV*+?'>PF2W4
M%<&$VS0T+I(T<8$CMM<VM0\1%^0SN71.,PD@KMC^Q%2O0V#_^L0LS"N,]=[-
M#@#4]]VAH/2JU"15KV'82JUTRUC07]I&6\3#.UAQ)IW$R#==) C_"/\(_S=G
ME[P;_ZV9GFDW?7V#;?6I,O#E3$-:92#^PSN1L"3#7/) _K?$_WN.;"#\WS/^
M+Y\Y]E[\9^RR2Y*K0<H84.M=R9_*Q109XC\,D1!)%G\S9GKK(9+C-+&EZB3<
MF>2HR<1$<G4Y.ABNF[ZG*LC7\OL.U'OBJFL/[,^(*:^O=44-:2D4=%>DV&R[
M0[7*(B8M>ZI*Y]*9P&R?VSHA/D1.O.188.+<ENIT82^S$(QQDL(>2<IKI,5!
MD4OOC.:.T'!SM=IMRX"DPGM8[W%&\A$I_>:<B,3#3^)'.E[ %<6-$.TAVCN?
M479AVFN82J7>X2HNWTW;;=TKFP%C:Q#BS.?0WF?/R#MH[XTY@;1'_\ X1'L7
MC:PAVKLOVONX+7IAVFL:UB0U+D]JF&3C';R?2@VK,(TWO-?W'F?D';3WQIQ
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M(\..QH<O3^L;93[IU?D5KO77L_**ZS4"V#0V_"P[85;:?)XV))L6)WQ%W6:
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MN([9&X^1E-;Y.99HHQ"O&DT%N10+GF=\[-.MFK?/Q]@=SVB#A:LRVF"T<1M
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M]5K>\%C.\NEQ<K=8[/?515SI-+*[IRGP!JQ:I:^VU?H"OC=)$:05+P?LZ)$
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MB,6NP@^!.F]8/6[@(A];4".VKC$ B\86N^!Z:\'DO!ARNM!+Q!7X"]]O,A*
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M_ZPU8SS%4">U.^GB9OAH, "6R*"GCR=1$!*/W@?HA3:\;-)@DP.2D0+(*F*
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MLVJ^]9Y /G+K^<!^&:0]Z@Q ]A8^3ZNE;A+'Y_$:SSD, D,+<%?"P\%U:K-
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M@8@P&Y9=!-MPX9GN4JSJ^5!EB&,A;_M!T*HW0M6-6PW:"\YJF(#T6: )YO5
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M=O@(B?4($3ELI:/O]A_>10'.6@N"6 *!!BL<!2#PIJ$>1Q^0;XXB!OP! VZ
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MH5TGM=S(- 2-1*+8<2F>)&-R3KZ#O_Y.=2Q+4R<.$F0V:PK'G'34,M5YXT/
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M>GD>;\EI_A22G7PR0*>]=:. &5FPHC)$"=%(0<L^1ITGO.!;@!7@1D_@S#K
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MW<RQ'OX0:%X&^0G6.D<)]ZQ'!CK"?%K$2,$JGJ?"Z.G96XECZE:AAH(I(FH
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M"52XR1_WT0YD\:O$?@J=,E_(!Z?H*2P.+.O4%&<T!8X)2<??>\-,;J\8#+"
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MU@SS:S#:'V[EA>FKMYS-?TMU>X>$>3BQCP-R#W0YZQ+?FC 7#@@\$G_^&&O
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M$2L$RYQI.L8 !L:1#$Z'1* P(.*K:J+0%M;<\! AS QTN%9HE+C@71<\".3
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MB(^CCC"8"1W0"O!0F;@-7 (6&)"$1,V5"'M))2L 'BX,ML!DHY<<*Y(1 &0
M7JJI2#8<W$9".LC.&SA; ID9T)M8[LT6;X<2_@J3U.?F=#F_%%P9\X K>\"5
MG676GP97=@;<Z6*5R97VTN-<PO"RO@%"!XI4IU/<E:@9>;P'M(?9:%U821;P
MU8W02AECR[NHBM882[*Z KC@3_@3(K&"+G EV&OWID.XF ?< 8H*&/W&3Q"
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M[W4I7N1%OY2>95]H@2I-NL599K=:0)?BDNWZ1DW&WEJ3L;[-8K]9D_7J5NO
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M(W-II+;IE<"7%GVA47P9M.345X$9?F*#U>TJVA?R]=%"B#:5K% JZ'$6EN"
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MM#;;Q;ZXI/=4-Y.2-X,$SQ)#ZIPP6=MW/VZGN'7N'QOLN&X&2*E@B13V%[E
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MTFVS$ZO*/8P]$\E+VL0[3*I/I8>\U9'0JD%CYX(L:+J*(G+7MZ!^!H.[GT/
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M^5+ [.%XS_O4GZ_#?1Y%&SKD/>]1B<K]=:G0&0=I+#\I=LD&MF[FJTUKSCS
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MB8*9&TR+NCK@.Q,O+$^ONRDLKSO$6;6PW,T?D9_RE+O5=9]06W+=-_0HPE^
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M;K!>H"8&L'R3&-"M3,VA;?MV4/E$./YO8&V]!D9XP'MV;A5E?_'V2IAXA'8
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MC$/3$:;6;5I5%B['WCGQ>>XE.WS9.4GA+FG5<^W/'O[J,-4=BW[UF:SZ$Z?
M63[=UOA$R[37GG,!,^<18N\O[TPKKGN6!KF35"W"@")?D 7=ZC/,<E:ZK45J
M@/*NW4_WD0H%[:DF+8Y1)C+B1BE)4A@(N^SN'CK[&VO "SM9)TB5,#+&+M?
M<%*R:R*87DYH?OWT-Q*_4";X;'$^37>E(?OMB]_:OK@^3;92@_"$IH1> LL'
MTY-Z?=-\J7VQTT@:-H6SC0<. &*.Z/8[XSSIG#*%.LK6^9;3Y13NH&$U%^@H
M3C33"7O677U'M9-P&(["0S[.B&FRK94KY=64R5::L-SH4J&LDZ2GNC?A;@(
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M,_%C#BV4_^^_PC'LW[0 V('$6?^PA@X8T.7C3NZ\]BQ0BV$1(SS^:G[E@/(
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M8!.CPUK<'BW4&YEU?TUE\G4US["#U&#U.*++H'/I,D<T*F*0;&0[*UGM1GM
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MS\+1Q#2X3OSX%:& JMIXJD](FM^W4B"^18(1=EA19[(*6>)A @)TO+16+=
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M"3.*IEIC.8@)1"@0&# ABFU/SH]'ZL^;\$-]Z3?F?8\[W6",-(:=C@58&6A
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MZ$"I%E(9+<(RB^ZP*5-JC1]*YX(N,S+&7-I!:\8R)<Q5<F$OH35>D:UF1@Z
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MSUA8!XF4@2V0ZHZ\71/@?/L[ZZ[Q4_]P-:4UZCW77N17N6:.ZH;+E?J/7\'
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M778K! -F.C!P?G8.*S13,TY@CX*<PJEP#_R#U]2H69)9-063&!W@3]61V]I
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M9"&,UZ; H >* %Z3X\4E#R<"7PDL&;_WO><LW%45^>UD)7;^E(&- G_XOS^
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M\$U^5DOW:^WLN]+,CUK"8CJ\>QPC4A_E9R4Z\];VY]>;Q6!4[;5RL/ 5:.T
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MM^NX J%2;?^[WNT(3&30D+/]TK0JZ+?'D]9;VXW.)JJ==I'Z"-;\BSK;&Z^
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M1F!%K%C=#854E<-3F5E9F4!&?7-I?RQI*#B5;&DJR_=7O;9!OHTD&XS%CV>
MJ?Q4SV>'*K:6A<);>99.M&"T]@2>I3*U[+*9S7! 1Z;D7)765D%'3SV:0$+/
M9O(=<V!C+_,%+=N-E9["T5./I(IWIX4J-VJV6(K+E<6:KE54%@T]%BL:7[T4
M*/>-P92WK)8SDZVB//+&[LL5-\ID\*PD9#@Q2_%<DA"!/(L46 .%C3#PN<!C
M1T_/EA/3TNMJC#/4]'DTSC#R,V^<1/9Z1FFK7/,MQ_9ZQ 3+)\IJ[W5Y"H.[
MN?12+\ZE/--Y[K%$372T,GL2+<VFFNB] I. +6'C]"K3IXJ9U4FTS"0Z%<9,
M,CVUYQ9'YE(J5,Q)ZQ1:*D2&Y9E6#NC!6R+;KF>'%%%<GL(U<U6MS=?C:96A
M7#G?$'J8FI+I4[BF&V97&V:$D=H12LS +);S51LBX-&*DJFJ/6OVN3:;>&EF
MRXO7R718A2./5I1\7F@9\S6ELF[=F&M9I5G+/[? R*,5C0R'Z9A.N<"N2^:R
M0.NM>65!GT+5_-!-Z3-A7543#%8HIY]3Q2:8YPE<H9-B924F<C;&&U-LGEQD
M5_R\Y54AWA]9Z$SFE?ES?<XTIL5:=FKDJ%>M=0I7.DZK3J;*:I+5YQF=4&8#
M?2E"!#JB4L>B)\5*%E,Q5R>+H_4P/WIYA<\\HE*-FI6;G;159O(YB:PEY<[+
M<Y8&(P,J'3@;WN]&G&HR0FYL)2U,JG!\FJX1S1S1XN!0H#8Q_R>22#L?#H=S
M>N<ML_1KRNA4"DF,4#(EW+$P;9Z5O9^!7R$_;>,N>)XXNJ<VLZ6?P5]VS5YH
M7?N6-;0=!<\XW3,X>=<Q]ZU-],F>A7AL(!X[5(X53,Q_(>[9UI>X];=CN>X\
MW 0/'&OF,G F@W\G8!SCI^<9+0&1/O1(-M_S(]O47$?Z#W1.KN4S'EX^?,)2
M6T_DV/5 OP-??M9YWG&-KYLA>66F^*[[GB.RX<_WYLOY%B417V[$EX^ZJD2,
MB8 LXLOG*ZM'?+D-7SXJ!A_Q)<*QB"\1CH6=+Q&.A9,O$8Z%E2\1CH61+Q&.
MA9,O$8Z%E2_GV_-$?+D-7S[J*!3QY1_QY>,KS@&#;EEJ\1-$R( O=Y.L1J8F
M?IHJ=U44XDM)(I@:_/!_?Q __I0\Y!-^W;[A<)WG*MF>(-AH[YV[]/GQ*R>!
MWQE@@O_WOW$*^T^.UWA#D/[GWZ-(6*XN+-FO[C'_&6&) ">2H2OBC0<S$;Y$
MLG$L&V4=K,'Q),0<1S+R)08+_H23]R0DC %G%SMIJ$3V?:0ND7V_IRX5WG!Y
M:QW#XQ&>/L2>&]GTD0Q%,A3)T*UEZ-)FW4J8P!*;T2X56?TGQ*,@":C(:HP\
M-&0BFS_\RI+YB"(?1XR._W^$%!>S[F]8"/G":@,K>-X+HMZ+D&1OW:GJPC*R
MJ;$8"4HD*.?WX* &7R0ID:2<(UV;=Z1(2*YCLS^.E!P;)_?6@N!XP4%QLICF
M5R13)/OG8]03_,"1N6U_@EN285_OK]B8(,01P2_T4T/&_1"5WWT@)7BW[FZD
M Y$.1#H0Z4#HF!_I0*0#D0Z$IM[X ^G NX7&'T0'_L#KOPUW*?2*PK7:#7X[
MS3U;H^ONU/3#XE9WI921+%^P+,#=R?)']^DC48Y$.1+E2)0C48Y$.1+EKW)S
M'TB4/RIT<5>B?,_'UCB!WI'CUY(50_711Z;7Z2\F7LO1#<WB;^O[AHP,E^B)
M%XJSZ_=ZWNTN-@9YBA,7\?LCF0[M:<156\"&3:2OW/&5W.OX2G)^/T:NNYY)
MC3%M6?#Z#FS#2J\4FX-M7#FTJ]30Q0UNU)49I_&:XYAU<CY@UX6W=&JX_/*N
M\30FF^6.,^$8%Y>=<K'9;1@N;"Y%_?B53,4Q#'O0KO$11GPWC#A:Z=6;0M\/
M1)SM)[\F1N-F)>NT5&I>44RM.[1K#=C\*0M;1@,/Z%%;1D<8$6%$A!%_TF>^
MUA@/GYU<1L>42BXQRW<GHK5"C2B)'[\(@H@0XYOE@%RUP_R#>QX'/>1_&R,2
MZEO*%6KU#*;D"A6EH6/TFFM]8<OY%BN_]#N,3;**/FBYF)-IFQEH0,#&ADDR
M3N$?-IR_AWP8/W98-Q<\F)[]5>'#;X=N-\Z3N<&:OSR5YB8QPV_&U)L?QW[]
MFK_\Q/9. X7!%I+?W4%HV9+0.'];SUKN;-WM=4:,7NT2!66B)3K&GVSK_RR"
M6*BD]$8'SSL,;]1R9,M5DR_:TFOCG,*N&T'\7MH3(484$K@3P#@;3QR0N52B
MF)-%IB,;;A7+C(H-40:(@>*)62Q[Q>C ]]*>"#$B&^->(.-<>!%\#MYT DH:
MJY%KM,8UF=4[Q&B>T%<YB6P!*(%Q1H E>#HR/AXEY>[KU_SE67GW$EW\%':L
M7DQCEBP+;RK?,!,3\VW<<(FO##N*NDE;)O7RRI3PMU)!PUW*P:"= <..R#6Y
M<-@Q-#%W/Q)9-HVO"T.&9O&WC4Q&9+B;G,?K BGQ&2!%&GH61<N=A=HLE(9=
MK.2T9UH[8=0LYD\.>/\41=^<='LL39-OF+*09Z:VF.HK=\EE./+'+P*/)S/'
M[EJ$*0^=_7$KG^[[0<H%W+R/$::;<0?#D9)06$FQU\;8P"<V)7]Y'-G),=FB
MSKL)K&33;P9-UF?:"N(,]>-7]D2.600R$<@\/LC<1?0Y5!AS-O3<8]5EGTA-
MVDRB,>RTC&G:)2LR !D8>L;B:3(99:9%0/,=@2:R9KXF8KUFJ-)RGIP*6$=?
MJ87&*K\J=UH @6#$.IV,G*EOEAA[JZCV]X.?/PET?XPWJ^IBW'->UH1*50MT
M=Z%;U-3XRO@,9K!)/MO,JFQIJBNNT<ZT6C7H-\$H-T[$D]2Q37._R;4ER8"5
M"X1)E%T;9=<^='9M"*+3&V7SL8[MRIF$(9 KU24[22/7& RZ\E=BG=4T5M:<
M+[\R\T1C-NQT>YVF07-9&(LFLW'R[(%>! 11YM =9@Y%6?:1'-^;'-]%U/)P
M=QLWQ402,Z>NZB[J3LI\2Q'SQ0UBE-.&DDK93&W"4GF+Y859>U+KPTT.QBCQ
M>):*\F,C=+AG=+B/4.,-X>&/ HLM.;UN<GUVI"JI[G*F,YCB)F4 &UXJ;)I*
M1;9QE H;I<)>.$)X"!/9)BM,ZNU,!:,6KX[1-@=%T_X3F/A3'WEDR=:ZDU2'
M:J^?)C/%4G$XG4'S <8#B6P<QRX<#PQ-0-T/$=(VH-<0L$7@OVGNZ^5Z.+R7
MTGK#KJLA!,?W4UYO3:=P >JG@HY(?=^0^IX]>''6U4Z)S^<$-M][;BANI=A[
MGGPET*XF>,7NS >FJK1JZ3=LA2LC7.9P#$8C\3B6IK[-6>X% >>=#)%;*U*X
M .?=#));D^G6P<U(+R*]"".9[CY8^ME=6:Z/,NP06\Q4I91U-'I88*;E&]08
M>*87V1>MF>TSG7*;6>=S?#$[:L'-&149($XX00^;Z!FA4(1"8? &'A.&_BA8
MVZ&6B<X\/\XQ<Z,_:.AS#AN*2PA/*%I+7#&/X7'!Z9WLSEMK7;C Z=WLSUN3
MZ1^[#G>3RNB]HFLZO!;E+5[T[OV>")- A$73'6E2*%3]DOV$;KW.L(45FT6\
M-%.G8H_E"XM,)3O2DLO25\8"71+\CIW/>6P^+U+306NUXG6:PW$8"Z3P>"9-
M1J>O%[U$=FL5N+:J^T[$K9<9<I>A5:UC[:XXU]DY4R\FW %!"P[]Y7?74S9-
M9XC4 &/R_,K)V^-5.:>WH/K#R^NI^%7OKT?J'ZG_]XQ;?J'VGPTVRIF\[11R
MFH0EAER;Y=[2G%*6H?IG?_PBJ'CVQ%%@E+(9Z?]]Z__WVO[_*,PGSD8FD1N]
MKMG27)RWIVRR[^81,, P7S).DE%]TLM>[KZUPEP;%_SPW:V7&:X   D,\ 1I
M+1/C#-L8#/7ZZZP_:GUI,I \&]')U-OJC>W,IVS/ZG%2=;5$F@ZO89.I.)[]
M,._RWPX/F/@+#8/+50R7]\9=D&N* 330^;DOK(<JZWVS"0;#Q,I/:O'E9TI2
MQWH%9^3+5L"I&&_;DF/'+&EF23;X80S^P5O") :D"TC"0M+,&43L&'CG0A'
MA(":@:\G_$**C23)B,TD"\J(),9&KN-];IA.;"TYWO=@_9HDQM$#>4L";P!6
M(1B]G( OG8FT1I_:[LB6YBYXD[;V?_(4ZTXD\-42_N_VRH#MZ4+"E@2H#TN
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M%!/6CNF8*T6 M-%,7K0#DM:Z>,P!H(2Z@3B*+!E O@$B $*XFAB3@+@AEE@
MJ&#S#X#WO U[XJ*7PCE**T%S;?C=#K?\F:$!6P@ N.@QR)LDS*7@-]UL(".@
MD(UX6_&:BW@-' 4H1+N$6**9!1,"*H":S)EK7O.P9?Q9LVGF6A+W8BQ$)[%(
MV$R/(Z<ULC?HB0GY/;N)X'"2@SCM6T[!OVS+X=HP>HVZ%<%_U8!LZJY^T-TH
MP Q@[>Q PTZWH\#8Z9K^W8BB:37 ZBT[MX:MD;;=D#P4"A[(JCFG84@=2$SP
M)P-5R7]WTL'J1)+KI#']C1B*Q+I;R:3VK#KB\T8=F!6\^\W+4F/<1:1O(\JO
M&T9=<GQK;V.@)8B=7DD97BDD7@L5%7,GI++"YSR5(I8_?J6/;VC]"\I0*+C(
MKT+"Q1RGOI$T;_38TELBWV<M*YELR5_/Q9=A)J4W$L8SMLZR[1RG:PMI!;B8
M/<5%'Z@-R=FHN2C-P!:+>E)YV&K#:<"1NVBV:4L58 J !!F0%P#CW]Z>]HD=
M'7'?V_"@,^??U!^[#I"8[;X0;!?V=@/AA8D")A/@ZN[$(*!9DNQJO&."W6/S
M%+"#@.>@[D>[V\S^[@+@3@:3DY'I [TC?Y<![[A:&[= MA/ !U[Q6IUCW+Z;
MK]"V^DK9]!\T2_-;=WV@ =OK7%VS+0'2(/%OPIZ*DGVRE5J1&W:KX\4\Q_#2
MLE7+9A2!@O"0PL[VI 2;YE("&Q_XT]L#UEN&;C+V>+![&S+@C;>!SS;B#[^$
MTFF#Z:"M8[-_^DR'W7U/R)BW.VYV:T]JMJM'EIO-CR4'&EV\#1NK[1D!HN3]
M%MEB8*-&'=A&4Z_#UGL&#NH"!RV+$1!?OWV7I$"Z@B5;X%4?S0H).)!"!=BA
M0&T- 7@8"V3Z;BZ-P0+B8(G^!."CMK/Q00W9,]ZC_%1()/+P6U.+_178+0;P
MDOP/-:CNX#VPL9A/5Z 3-F ;(@OPI-PQ>#!02VB7C'A!,+>,  . 58+\!=LS
MQF"?0?@H$Y+3AB/'\$]84.WDSSU/_ZCM]F[%\)VZZ((&N QC3)/_[/OB)/3:
MKE$8_=VZ*D0R")%MG-AB@LP>UCO_K[VR[INP%VR\9EH_@]C6SKK\<O($"G/)
M4L*K&L^/P:M_\MJ27]O^.M/9)S)(F?BY"8^1R+'&GLC4OV([?X<$.:(F;.JV
M0[.]IFW^S_;[M@4??E"]WF<-[(-&X$_(M0;_]!>6Q)_2J2LQZR"^0&W#"WQL
M8D'H_>]N(W^R1"\*.!@08;6],KW^1S]^H>:&R-$V41L\>Q,NX7_M,/VLL"+*
M)@ 5MY/U*;O]<)\E1Y3VO@2X(_P%1\3^'_![X2__/N#! 3.W0=,-*V?.NX\/
MN,)O=P"M1%LS/3=PV(0Y6 T7M&#-'=A3'"[_0'V#QH^JR0BYL96T,*G"\6FZ
M1C1S1(N#0_'4M9B^$U0"=@G<UL=C15,@Y)J^,X@ ^>]]]QL"OR7YWA_RJ11]
MY%K NCFQP\ =!'R&'&'!M /S!'9A5,:*M(5Y2 R$XO:->H7O+A'0'?7VWMG6
MO,DKAN"B;N"C]:G5+H.^E=XG< _9M;I@L 3N(=O^E# \ '#>$N&S//.*[N2]
M2SMI$HO'SD?[VKMOVK%@8/P/V10!Z3>VQ!)8R=[FBXP*L(%*,$IFG I,O+N.
M";^ R_!-4 E0R]2!4SX"^QO8POR>JU_.P-TX9'*WT;O/53\B\$Z,;C]&:<30
MI9(U&AU<HNCXKOW6,C\1V-M>1CD.Z,5F._$\+RSPE_+W?GA$$1%[@NZVR#3P
MFMK^<4@I#MX"7H-6OWG^-2,BZ(7^PC[CX""+T.O8"T7QF(OP;7\IB[]1;,CO
M*(S"7QOSW([]92(3$BBLL1%[V[46"I)5,#-X_H":!P,RN8Z&K%8_,,8'4_G;
MZS;\Z9E[D_:C7#M!+\2)PW4\Q=C-P_=,TC.BLQ]B1/-$H L4&O[A2S0 56 V
M@OGLQ PAB)#_^:0_5LHU.<O \HDD62/4SL*<&&^)U)CLM]X//B1W\XF2^UVV
M;Q%:D,V./M=R+,DV\M4>-;&?&_W27F@!NZ!GR'H4SP,7N>D1?>,.8CON8&*R
M*%EVMM-4W0E&Z*_9-_UU)4-W, ZLV2.'\&"GA7H!9K[/[NW>&7B*2!5\!\K'
M>7[7/=RT/UY( -(T<PF?!?_8=2?AIJX%[;NW[]A&8E%X-8B?'P=<0[!MPZW4
MA<$59'9\H%EP"^=G,Z^QN.\8"M+, U&P"<>2Z0_WWX(T0GOM4XRVSV 3C-E#
M>R)XDS_?S7'+1FMW?W()(-I'CQ-6S=82@3<$+?C=[[U7@:W6H52XBCWQD&__
M3,0&9H%DQ#1)YN%Y') Q"5D>R,T=20%)9A9007@\!TD '?/?F04B/[17WVTS
MSL=DN!^@*C/!; .@/&OJ')ML5XAR?92D>4M4K;^FTNN5^&RSI02SJ)4%EU:K
M?QQP*P$N5$W;;AC,'A\:X]-K*WKD/\Z9V VY.9/R6E$:@Q3;R1(=O3 MS5XT
MX' EGXY30(.(V^Y9(.QF?]#,/K;M8^_9:8J]U1!HID-A0H@+--O4I3@,O\5W
M^M.CTTN$IK8#_O! &8B.=V3LV2&>"36SI FPKI"=!2B#9'G7> AF@L;#3+IC
M(;>\(]C?$^(WR3+1R*O%;(/,OUN*+Y_-C3#2R;?8>;90PM83JBTUY:O%BS>"
M^MEPL3YZL\M2OC!1^8RJI:AV&]/)%I3=XU2?;;08<'KF!5FU=7QWW_YTDL"Q
M5&\D6C,-.0'WD(V\*%L+8D^T1U[.4PP@OQ3X[<<!2B\TPE$X@?%2$LA$&J>X
M9"8K<;PH)#F2(+%Q2AQE<"GE!TGX(!]J@-?446;)R&PBAV.8,I,XPFE!D#P<
MR;--3D]W6U.&$&<9+5U-SA+Y)4<<C\P"><GTGTV=>2'(^:29[C6FW)(CCT<N
M,+OKU%N9%J8LVDTMPTU8QH0CC^9IO%0+E"DF2U@BK:KK//>JBPLX,G,X,L\[
MSR258#IJJ6\2J>&;WB&3-#"?L<.1>D]*I!N%Y8QIY%]+!/,R8N6A# WMPY%4
M3IKW26*44Q/JN-Z=*/9XR,%G'LW3G757SJ*>S6!SNVJ^MA+Y89]J@9%'\QQT
M)KVA:@T&+*\9KFTN\%*I!.M1'LUS5#.S%67IF&K"E IE84W7:BE84.%HY,S"
M:%I,##%U3;UUWY:-?J[PW (CCU8T8 V^,5DF7*91L['78<UN9/ E&'FTHDDW
M1SEN0E>97B.O9VVW*O;G\)G[*^)P/D-A_ @(BDCR7)+ P-\(3.+(+"X1!$4)
M%#4^?':KGVCRM5:JB"7T1;OK4KT.TUL"Z2./YHM5]*HQ*JRP-5MHT8G"%*,
M5XGCD6GCS>J,GKDJ1N1+34LIC3"A00-).1KY7$O3J4&>ZZB=-D>V\%;3TD49
MC*2.9&I:*MM8>]K%B+&H-:B\Q%>3+3 R>R2GU'(BK'OJ0'WISU[6(XN?3HC6
M*>E[F^%ELUA)MX'?8G7SU>5+ \=/\M]JZV.S/7MC,+X,X+">)=R^('OEB0\D
MFB@\=VI,XHV5.FVA/\0E;2BVO!JG^R-?Z73%*=399XQOLD35J%KMX:CE%4K<
M'ZDVU#3!M:L.JZ^2<FF69#"UWCHE?01;K+X-*H4U2Y0&HV=SG-0G79I+'X^<
MLSU"E&L.I[ZL6^1+I3N:=U,M+G,\LF]-5TH_GY Q2DHI]=?I'.=>6ESV>"3'
M]>JV-<<I9OTFFPU5J#%O "%P['AHJ==DM4F"+:ONL*83(BGWA+K,X?CQ4#>7
MX,14,K-@\YE,I:DE]-:+MH1[[]%0:31;KT;3>H_-$W9I1I;3'5=OH6WZ"$_<
MN?1F3A("HRSE]L":)F39D.'0(T81]+/42:X57G7E-4$/A%EZX-!P:,"IO3S4
MBUQ-\O9CWZCX64;V5Y=?%11;  :4:TE=\(:<9@KJCTUX?;2JOLW*LH*5$NV5
MD:]9M9KEYU7 G#&1=LZ,\\+P/V(2V+]GX-6.Y4H7B\D?Y9ON'4>DD@?>< )]
M\KX[C&-/,8\DP#U?25[=S&OQ -E$'0'X?:XF-<;0)#4-:.DVQG7)\:8!K?V<
M! PL:<.I9A"+0P=%Q]S*5OKTW%8-AYTWR:73%IN#Q5R^$OU_,]0@;-8(;6AX
MY@Z-=N#(PA7ZS@"D_#;@&./!%\ -'IN:9BZ]E#!G8KHV,*OMOW\B!J&D[<W1
MIY?>+\#TO)DM_0S^LCMS.%'_E!">@PG>0=O>X1GO.N;^R1GZ9$^\C@^[MH?#
M&>P))]'9EF,%4]MIX/WCLS>/4^FGJ&_[NYGFM^O;3H")17P)'U\^JD\>\>5&
M?,&>TD3$F/ Q)@*R</(E K*0\B4"LG R)@*R</(E K*0\B4"LJLRYC=+C'WD
MZ-^,!IG?H,%5 ?R>*""8&OSP?W]D?OPA-9)> .F*Y,B<NW5PFC[G>MT/8!X
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M.EVW:,-*9C6#-<]S7DW[=RH5O8C,E! DK,.6QI5%E<#+SLP*9:4B6+OQ+[]
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M;07L )^<!]PJP,8X6N_MJD 6_6T-:12@")@NU$U+FKN*Y<U4X&<*$!FPZI@
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MK![O&?#O ,C!EJ-Y3UUZT_4_ N8'LCZ!>N;A3F? (QS?_N%_[3#]K+ BRB8
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M-(;KF61^E$J]KK!28VBJS39EU:;+WPM-^2K!;62?=IV)"<R5-;U2[,W7:!5
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M$^B3]Z$7QY]B.T3R4WYWR'2E'>'\R?__*">2-E 6E[!7?Q;6GX-35+XN.Q6
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ML5$:%2HT0Q691*,UXMFDTCKG \$4:].5)WL$IHX]H^#6N1\IX+_,40HS"[_
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M"#8C-N[CG;K+'+FXGL-G!/;:D@1^%=CB\_Q,KA;[3V):!CGF.2':#VB+1OG
M_JA/S 7.9\3-YE.5?KW",")7Z4HU+Q+)23GM'.*V(1T[(K<7?#X 6R?+__X%
MR^*3M35OIS@:2Q)HD 0:-Y- 0\9(+"59BE<!DY 2:AQ(,48&DDRKO$2S+,O$
MXCS=C2=_!80(GF@JTJ.<IGN*GV^()N\:$YFJUIHY#2UZ[K;DQ6:B7FY..T-_
M*@G=7%IJI1E-8O9;TO4XG4A9LU)K[IC3Z</D:9$7!(G=;UEE1ZU(>31YH1AO
M* A#?RXZ_2EL&=MMZ>GUQV*7?6F(XVS]R107<K'SC%HF=EL.,UFM-1T_E8:-
MYV1+;U3*J6%'D&(2M=M2915M/%Y$?&KL1;)4B:/'V;8&6^[U4\N@XSZ55JT%
MGN;"U'L&<2Z&6N[U,V)2K=@B9G1%$-?&D[1)Y;+XZWO]]#C.;W38)YKR1VRR
M\"290S8C2/']?FKSC-W(3>T'R*/G*L\49LK#="IQ^RU?%G*+$B+U]# ][!MV
M/]=MV$-!2AP8^[!14_W'%W7( 'DP6TR;<_M1@RWCNRV?Q1RHV68ZWYHSB8>G
M\CRO39.H);_W3G/(@V%9K;;&G41L4$Y$S'2Z)O'[7]<+E88#S06AE9[1.O62
M;7M#6H,M][_.)<I\?< *P[9>ZG?C+X/>RQ-ZY][7\V*^7IJ;SUW1YSRFF_5H
MA4I-I>3^U[-")N8EQ>1C*YU*-@NU@C^=M%'+/;ZG6[7Z0VTR2[7T2"+S/"WJ
MH#ZJP99[?$_X7OZIZO=C0W,P&=0B/:53CJ&6>R.:>YET1A;R%8HSJAFVF# L
MC45?WY.0B3<9SA=I)T&-T]ZSV@"",$\+L.7VV"6:!SR=X*"B4[&>%%-[C-3M
M=N-20J% 0NW2<H_M[KZ;LXQ916IY7$M/9#I:?:A(2FL*]7Z/6D!]'C;+"4,>
MFE:__3";)M,\@Q""V6TI3V(E/C+29:I1?7IV#9!(/\GHG7LT>*(TXU%I=VI#
MO\UEV[D47WS.U""6['T]-Q4BU=HS7VU%^D_CV*+D5LI]A#I[7W>?$C'78J@'
MRFRD2FVI_$+GRE/8<N_K;G):4EE&<RA]VAP6QZW'?G:A02S9^WI>3HZ&?K-D
M#W./C0<(>8KG/=0.84FD[@F+[F-A+J9'1=!H%D9=.UL[I,U6@6O:"U%-#!E1
MIROU4F)DZ4COV=V6TWA2 $\TW:,B;*IMU?-.MYL3#NF]TWFTQ"++S"C3&,3G
M9IZFK 9"B+UW&JS+V79"TUKSOI?H9M7$K#8[B!"MB"AD%HMJGHKXY2?&*$R+
M+:A/![2Y1@_:W#B7;(N^V+!GE2>6DB#E:6J_*6]Y(C?)2?56I.M7L@--U9*R
M@)KN\9,9/WK^O)"F6KK!9"-9T>W6)0TU73'TZWFCF"_EC6)_G3[]Z_)TL.MA
MNV4_SZO>KKRH#SV[/4P;_8Z9I!LC7Q-.E+GUBPFQT:X6VUIM>3FT_!?X>$O'
M.UA;<Y?'OMS07]ASMGT7>K_NW[^Q<>9AZVUEAF.;&9G@ACQRP>_5+YO=1KU<
M6JS()E,"HV_;1MZWJO:]$,]9?77Y-CHP2#UU[2,!QT.5.Y9>1N#0K&Q\.LHR
M_]I,P[K\WC(EZZ;%M_%^M*C9@[18.5VKOR-3!XI&X%$@#_U#2W[I76W9BG+7
MM0W?V[453V+!0],V?MBSW'@.WORLG[GA5?[;4S_!A;[N@0C>4 35%5%O->HH
MFR1\N3R^)*))FO#E\OC"1"F.\.7R^$)P[#+YPD49EO#E\OA"<.PR^4)P[#+Y
M0G#LI'SYM^<@%_-H[N39B,"/#M1W^2Q5EA(*W7AT\?_]XG]]%]WY*)<X*7WX
M]Y84#Q.LN_7-3?K\^J>#=B>*>)OQ__V[NT$.(ABG$(QEX&B)*O1H%L);,T*K
M9=SK$9R]TO'!+T2(/A8BYKM"M+%>?PLBA(+1V_)R,JOZ*$/_]D #U=C_=V_P
M?RXBB2C'W)B,L$1&B(Q\("/,,>:=U\U5O_];40#H]<XZ%;V6ZENEBG*](ZA!
MX.A>V%C_YP@#"R+W9QC8ABCC1;S-D;)1;G>LQ]YS^]WEWHTMN%\[L[F;0-I]
MW7K+_EHMDO>YI.GG$V)<C%A#O9QHN?%Z$VU,8G[]$P\SR?V\64>#^ N3[>/
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M>HA"-^&8''EO(\E3>6#JON"LE'M4"OUU=2CV[I)!RUJEJP"J.%-@4\%$?QV
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M_XE%E0,6<&1#L%1!A5.=[GH.AE-QAMQ@<-CRG=+59,5\<:E*URDNA-*BDGC
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M!T TU  @5+9AUV@ZNK(H@MNHF\&FH""H!J=:Y=7 "&1?57$<#Z*A;@5,6&X
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M@4T/B,GS.*=.$M!T'+:?*"CUL70D4X--#W#*J-6ZDWBV25./?6'<Z><%K]J
M30^P:A'C)J943NL4 PI=RYG$NDQ2D.@#O)H602:YT.<Z]6@W)TZRI!3]&*3
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M#+_>6NYU#F.W/62CK%(H#N+K;A^_T>Y!'>AZX9 FZ];A^_ ]0':4/OZ,"B;
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M9GZKIR86R_*,AQHK@$;. :-ICEB040OH($[>U61BS1K=/SA[IX@B"5F66,7
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MY&]]J*8G'A, 7R[<4[L+K:?Z+-'%%Z1(.VDV#+("D4+T.T ,<&F+1T=K;3Q
M![*/Y<GW*X=RXTJR3$!^[C*\]P(^RIV.18"5<WEY"[4Z!EP:JR*TUJCY"8"
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M&=)5T\KWE^8Z!\<_F:!:6B8C*-D5>>24'#Q_YI.-2]=']X>)+_RI!5*)%@A
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M:P8)F,A]%IX3W@G;:?M1LXR(-61-%L]1V#6S2U-)?&$9T1F+?0P'0K]*( D
MTDP"@%,IF0XZ!&^$OC&C_&X';3/ #N$AQ+)!1=QB6P!_BM0$\9M0I*!MTI!C
M?$ 2 GN.#3NP7N.&3_-;P[5^T^'5_"D*8B,64HC)PZ&)I86%N,&NZR.^8(\Y
M."$5@:(5Q#!9/P5ITP;;7=L"+[*V>G'^?^-+RD>4FP#( WL3 %>KF+H'?PX$
MA"K V1$ BE*QN--0O&@Y%)72X$< 7.\%X^@B<4]^"G/LV=*)PC'R,/ACNEKR
M3W$0JRZMT;S.(8K890@3 !CW5.+>;&1^ZXC<E "8?0Z>5_]MG#R]H: 5Y#3B
MLTC0MA3BMV'$_J1JT<Q/LH%^&^:^N3P!H-VTAW_X5" NYZ= GO\DZV,"X#?"
M_1SFO_Q%_5][_==>O[?7&I@"^B1@_ISZ,; ]TM'JPYV9Y816*A79$\GS"96-
M\BTK2'B-43^4 FK+L>MXSQXO&L*:--52.31X0XB5.YP[AHY>=>_[/LNN@"EN
M2"GFE%Q5V<'F7G4;5&P5^6U;7"@>MEE%+-9-S[[_80G_Z10E4KC-1-2UY&6$
M%/20<IP 0-Y0]6*?B?;FWI-5K(H0A".4_C"]_Z>S&$%) '3?!!]]A[XINC..
MAN&"^(E3J!]&++5#J6[U/G;E.8]MR<#ZM/M?KH.U*$3MI[/5Q)P#MX_N)SU-
MRGD?8R4@03FF)Z_O8L!'LW>J3HS>]SH:'"OM4,\'T_1SG9[;'*@X'B*UE)C0
M'F@(H+SR:#HU8+=EKK97Y\4H9W\TSJ\0DB;J7+'A;%!=7SUD-2)@)H^*&9P&
M[4;:/(CR[38+H3@OZBI7)*(RZU'SG!JRNRQE+!TWU^=F[A.90\^EZDF[Z\(!
M,&_R'P! "("Z;+>(0V?_8^Z4]#BV6$62_"<*B>M$OX8X/3?3:&Y*<RI.'[_\
M!K/X;H-.Y^9D@MX,I+=YW.-M3K]7,<1U0GO$FO&;AG1'79OGA?.A80F5$WR^
MO0D)HPT46EB2^?8&F%Y#:75-$I>(D+"FG3MV=(ZCV*:&?V,A9%PN0ZB<7L3B
MG'BM,4T4)VQ]9_XXTKK.MK*N%C&P6>%3K-RO_[+SVO/X3:]7GUI'XOUZY)C8
MXR6^I+Z0[XZU$P:_%CT&W@)#0N^&SK%&HPZ+HNI&IH)',QR>/U3;S@JYK8OT
M.DP,3WM&04$+\Z?7PZ[,]EH #5(L6'VB)?IUAO?:JKZ01RP*"^=4)]W7>_9Y
M6^;>*PD2OAB)+59?!<Q]SIAP/]3;#=,##;0[/M#9S?W9)\/-Q^4,FMU\!6%\
MKCKR!MQ)?8]\;V$I\\'+9<O3'&;WA]YCH7XHS1MN,IV2/2+UM\P"MQ.#>V4_
MK/29OZN[L$HD-$SQ809$;7Q\WF*TXH21*Y2A[5*6^[FZ;NR7$5$U[6M414T2
MZ-RW11T9HM59)JO53,RQ6F;Y5BD:=T+/JYWACRBKOOOJQI:Y<SN4;.W 4N(C
MAB<Z<X5'H#/0/4,S=_7@YM2%G6SUG<0H)P[MOGA14I:)E\]4O2B"FJBPF<)@
M5NRE<Y*:=97XX:\/8!V>>E*R9R.%A<GM'D:_JFAH[V4PXC).FZ+3T-98OS2V
MFTIT11OEAU4%!TBLAH6*5G")F"/MKJ5CD3V);9RL#?,I2CX:Z\=9.F'^//5?
MW?O =T>*]NHM."];-^ _$[<J45T<<:\VGI*/R_T_[+UW6%-+US<<!4%$0'H3
M4 %!JG2I49 N(DAO4>E$B'2D14%Z$Q 0$"+2N_1>I/=> U)"[PDU0$A>/.<^
M]_%X/\_[/>6]KN_YOO?\L:]KDKUGUEJ_63-KK=FS9A-2[R7GG@J@FT[:]0;A
MSK6EH*W.O!V[,K_=3(^);6K:S0V D^EA4C$]NW.3&0&[R\E2>]/4A#.(H3-S
M:@*NOSY#6C:0;QH8V Y_8=AZ_(&4B@AQH6J.')[P:?9^C<26$$+,OXP[GZ$#
MK$,#+\^W)EDJB+%W9C"N=5!<YM^NL /RN>,-+-S+2;Z +IJ/"&+0+IN)S($G
MQMO2G!B+JGZL'P=3.@FVY:EXJ5\_**2!S4$BTE"BP0N;=S+UUZM)/^].V9#+
M,<I;,A6K%,L?.O*4^%+5F GZ<6H![CY(,3\5<VLW0$,_NRE@Q^60%8>WW^9:
M=^>MN2I8\YO7!K91?0[39\7?>1\U%:]KE7T87?_-Q:,=PPLCGBZ(.C')MRZ4
MR[897,T6C79D:I)_A:IY>U/G6&&BOX$U>!I%&^P$N6P]"V?8SC?],K%#?I;Y
MI$J)==J=;_F&V1QJRX1XOM#'A*\,I9"(D%:XY _FE5.+V=IV3J^+G"L+WW$9
M9JI5 H#]M(S3435L5WF=ZR4',*8H2EDT-&_M1'/UZ.MV[8C3>*T_\89B+"#E
M5E44$;5+5/>-R_1O >0^&3'*^N4!+LYBLW3"DOR4AJLY)=^[[443J71%IY@)
M3UUABW=MIPMXIZ.D=>G[F2Z-APHS\GJ/RU:-E6YXV6VY3JT5?V^K$ Q_K"/H
MRE+M3MH^5$LY/[YYAIB].H66%Z$=GE'CW:=\-6@,H2N)>V)=CDD%\HY(NM$?
M5](5P-4#3L[B(IPG;PT(DT 4QYV[I<T/;!]#]\.DY*@X3?5<:%SE"%;UC;4?
MO2N_*\<NOCU@G(3PE$/F1:^_YPAR<DE4H1]A-42'&'A.0=W%/&$">,OM4LY9
MF]ZWW>2>UI24E:!T@IP=/;B_V5YE".7;ZX!YD<N9?W3%2S@^U3G[Y&E8@&94
M0>:=@ *VGB.QD:_36[-:7:L.&F24BLW4>>@^Y-FR!O 8R JT]YKX(J"^8G$G
M1^'.)!+MC]X>>$&:X6$?<HO%:21IWW1'T2X]8_5*K?>P\-.$?#9.#I2YB=::
ML2GW;:D6KQYZTIEUGQ\Q:_'YC8%&#:?@_6[3:&5S%&.3>W*F90;<#:90/<+_
MI-O6F@2CSK,J9AXI9Q[0-1VQ#5,Y_@*=-&T3DV&H1FZU%($,)ZU/8I*2EF:^
MYE-/5MD-\%P9M-,T4!>9ML.S6]@C4T$1-A52L(1 X=7,2>GZ5B7KY;1'M+?7
M##C"\1]"!/N4/H:\B=P,UV,+!6A][4IJRA8;T+6L&)3'RVHW6.,TSF_O>KW6
M;J!RK*@S'"K!TL(+:C)8+O1(6YVA'ML2@5#,V#A4C3L+D9O?S=@*.;10["FZ
M]*1_*4-65+JF548R\=LL$;0\+X^_K'M"V)XK W:YRLS>QDB9<UKF?O?>]:,\
M:L/U5L<! ,?G7NJYAFOUK.L)1YM+IHAS<X9LRSA*H"RMKK48DNYWM3)1C^G<
M)3UD4M"],0)%ED@Y<[30>1*1%GTQ!G$$#JO!6LC7 KK!KX4[^5T"\5MX4,67
M@.*7C(D GS2VGA@=K7,O&7,<)J/LAPD#G26YC2451EZ6W=D:?E)$+O\,:4?^
MELV53&2\AYI-@^):CT"I=C<PG.5:(7\9D"3+7]JN7;/<;Q&F[,/[8#ZV3_]0
M_AE$5/56J=P-M4J%UG**TKI:^9Z(S*Q"$O2#!2]H>P.5_&(]9UGM %\M^W/W
M:MLRWV9:.,/Z.CV;'.OK8%=9!SK*0<==?XL)#&A<5[D!Y9*.(+MJG4#1G==4
M3;TOJ.C\DJ<6F6>N8!'9'EFOU&+Z8TVM*VQTZ\FV1SKU+C8:-8X@F2FOIX_<
MG!M=:1@DAXA(TQD</S%)3.$XD3#J,&2Q( WMR7-]'N ^->S-C1XW&G-F(0YS
M;88SIZ=DY/..U619;]KNM*9WM;R17^&/JC&2RF,*#K6]/G38P>=%+.\Y#VP_
M]VY[%\#II<-S<7+#96&22@GW>!? X!1[IAKASM?L31(K6XQ?-(@AEU.C< #^
M+$]B%&V@ISFR6QY%&V2W6<!?YD:#>O&U[*[B1>:+#IM&J,H*%@^ZQIPP>0XS
MVJK9\T ZJ^F/M;ILF^J9I)2FJ'7=0[CGXRGR[0R]T43Z1AZ%QUQ;;J MAPM(
M';](&#J>N>&@-7>H^U5D^XNU^;3-M*-C1HV T@3?=?=,# \_,72@,^TW[Q:C
MS8+\6LN+ \C=CO[-OT5I(YE'L:N8+'C#=Y88[PAL^A,< -:_K9A_EL2R+/-C
M;=-O'G)"+PP[]V!Q@.!4+ VM7\.JV= /3QO+58_W6SU&W=/4W=0SE10<  B;
M]CV5 /;\6)@F)FZ:W1>T!IX''C@ M>(OG'@2ED&K@5RBA4>*2XHG,7)8*+"*
M\- )^O%T[Z]$(M!Z)C\6D*.5?XL[T#EH,AL<P,E;RQ:T'=$5<< 5@,%"'<@V
MS\,7@:.5_XR\+.O:9,<8["++Y"#6=*?_5SK ^>=NAEA_-8[?W7E$[IQT[MG@
ML<9O? -'<ECVCL\Z@"6IF/99V"]DM*!-3<B*LZL)ZN?AS7G8H=OH\1M&OS,.
MS=8"KNR=OH=:*AY'-/Q*)NM7T O?'/X 2>$WQG$ S2QH_\K1#6Q?Q!Z+]R]T
M-'Y%'71AZP=*8;\Q_D?O/OB[<_^_T+E?#%RR+?,,0A*)*_EM@[AN5[Q7>A>>
M>@.1K]LV6S(;+*68BAXCD7Q882O;APJ8X@FQ#;VQP>=^4V.VX;%;8;&Z ?K1
M"O?KQZP3>XZW"VHPX^HC>_947N^.(:_^Y[PHP)SC<I,(NA&)?5&%8FF*%)Q,
M,J;2 ,DX7J+2N/_;A1\=&F4_]+^),M-NW+T1ZON-JO1"=#!@P:G05P8P %<8
M/G>H3O%X* R!DZ43J=\ILW5#WS0XO[U1*$N4F\R$?CZW<UG.B]1OWIA1(?B$
M__:Z)#'=O&$@4J']"L%2\]UO!R+=AMA!&<KDH>W]]MRIM<Z,&9O#N'$&QS2&
MF/RL[U*Q>= Q6_QKES4;?03%"Q4KZOU7U/T/C-A+O^8WOI8QNOFD\=/^W-Z:
MOGR3(;%LW4I :9VBLC'?CEI)]3"50JZY\!7DFW=4C)?;J'(6PN]*<V6$S460
MHEW@?;,J TZ]@C-]EE7EP4-#]V+IC55J ZFN"MVY\7711U'%-:A6/Q/]5,[8
MX/A[7@+8C7IKO(=GN"=204'"9XA?YM/HFC.8[H6^R<GHBQ?S9D)9.I-):/%O
M4[ZP1]='3ROHHUF:"Z_(9ZTG^+B9*AANZ8@&8Q?UY)>-4[V68LJ7FI^9,5>N
MB#SR9$7>'6(?"O 5OI#Q"-7)_G'X^6Y2M"1=P31%32)AUK07^-5YP /F3AS,
MF4B4M!3H=^!+W9U_'II;_BK-[)72A@[K2-YR:=2Z9,UK7M/.UV/: @422R5O
MP[$?\FDN<4,OK^K$C=%^M:KVI$WP*BHN2>;64BROD'X1^G8W$V_INH?6G3D0
M27N!R0;W_-8=9X^)!,9<E#D+3.HEP-QU*A8?<%GZ/GT?UT@R^^#\T,+(XNC^
M_K"9I.9!P<(U@;Z[;-]+=\F\1]FJEQ,O3>L4KXO:&S_Z9OIV^YK2IL)];0ZV
MR Z\,N95>@;^9N!EMY<*PK KJ]66L6M<7N%-G.75-)S--N%:-7.'T_9C:6,R
M3&C=EKN!9>I7UQ@^R*[MR!I/M'*>RBUX5IH#)9^9'=RC[P7+Y>I-@_I-J;=*
M*P8XK?,US:U-"5/,"+G(*G/6$%X,AARU:J;J'@\=*:=YIRU$7@EJE6]>!+"%
MKER,<+IR9'(9N744F.]\FH2G6CENJ\7#\*G<OJSG_D6 _N7INT1M9/3W-@P,
M7)*LT_0,)_6FY,PM[7SNV6X-L-EGK>:DOI'VT],A3?G@KREX61Q?<Y0MMI%*
M0_[N/Y=UEC'.R%-%=$BFH3[XCN0WB!B,KN)CFZLM=^>W?OQQ92-(*S10#=G?
MU)G'^V9$U5@1LEA:#YJYZOB).1%JL/FMK;;H6C@U/-5=?PKT5,7FL;*<XT<<
MP/\9D@-SN@Y"7X?^>)'[48H(!Y YB<,2LF!O5T+0X..&5>V(\ZDNXK<-G2*8
MV7VN<W_I;?N/+8L5)Q&4.(!P U($!^ADCBAI<X5",915_ZU&4]>EU#%#YU/Z
M. [ QMQ/__T,!T ^7L'2^S;"]G:RH7/VO[\ _@N)^8;YPN5S6Z #Q) "?^1P
MC>]!!W)9?M"[%9&% NZIGA,#8=Y[2%FZ'N$ WR1A: NRB]#^^O3?J0:E_K5]
ML/\Y@89$K)_>.?%[OVU$; ;UX@"R>= ?]()E4EMP@%Y^# ET]\$F*FEV%@?
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M*.(1_ATN5H#]4G1XEB-(DX0M%'M:2+B$ VP,./FX]\*:<8#"IS:N=:TINSA
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M4278NQBUN)*UUNI>V-+/W-#<3Z9O<W=-:"..UCTI-H8DIC:74CA.Z/*';3O
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M![V%T&(FR,.R_ DP2CEC]>M9[I/W[6RVMC1-")VP#S)#P3UT5Z^1$GW+-,&
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MABQLKK,[;?%F&\<X.J;-S&Q(/&0@GEP=[.)MS;,5DA12W1.J,0+2-7$"**/
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M\_[./?>N]=[W??[XKI6=[,R>^>S9>\\D>V;D$HY?>/*>*2D%JQY14@F]86-
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M[\6,KCGH[<KP&A,V&[EI^#=B:;O*;CZN+QFW,:P?%N3LE?KF;-L)Y9_NI'6
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MFWW/0S1MEJY')OG>.]J^(NWY%](01S5W<QR^X".J2\!:HM>K?WQJ/0BN?.]
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M?+N]BT9NDC.W!#7>YOFP??)&0*R3(E1FY/RQU4&-AQKNQC%%),QX6O%!XIT
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MS3!DU:-9]>6^,UN38ZO$]C^TA>+</KPFDU46?6BXGGOOR$Q='-Q.3X/.*++
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MHE*=,.28WM6._TD]YD3^C_ / N-%^.D-<_T/J>=JP!_.AC^SS%V3.L1M@)>
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M$N!W17 2K^.(:=%3:.'+H.#4TQXLFU,NH$F=#.;@H9Q:R9C(U>D(R/' @V;
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MJ44!X829:9(O"2UTM@J?%+E(0E5LRBBUN)?T);3$J^,_$K(0VH7W*&<19O/
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MN%Z*  @=] 71^D>6*&P@4;W2F_P-;>.Q"H?Y+D<)47G6$'V.^=D?=YGRK+$
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M!@C)%_#<>]7SC.>YSW>_=WSC'>/\N7?V7FN6WUQKSITYYVJD!O&S,,!.^3R
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M'::K\UP2G>8X,G1$YG15...=TJJ^J<J^Z?ZU HACHD92TMNR%[;<2ZK]9TL
MDM9._O9#U43E$@"3XL?J_?@.M?O2;(,=/!495 JG';./!XZH*S1G.N1IVU-N
M9N8ARN:NT:W23'TZKRH[%<AFD^BP^QEVQLZ"O5=<+HGUE?BJE%;2[3+MDD\/
M@HPYHVHMO]Q#-]=5T</O'<M6YWLV4<YT%=.X5"C7%Q\%-+BAE@U#Y[6EF6.Q
M+. A,K)[I\9V-MKR\4!=$A?3QKL"4C+ED$4?T>E0:K*%Q<S%J&H#6_'-P*BV
MY(UOFS>=US9$=SH$2G\>>D97=/AT!Q&>E=1"1+-Z?0S\V2N'B-=[$;_?Y=N9
M4/KFC$VG[_H3V4? N:16MD%U9(<% 3\>^J_0=4GMR'1;=5:K XCV9 9LC@1,
MXM30=K:R/I^4GB"<S!S+N87[*<Y,<?A96E0<4T;_"H5D>F1!5A2T;EX3K%66
MJ'U%AL>"&?/NB<)IMWL8_9S[E^3E(>)K<?O[C%I/PV+\^_9$\,QR3>"M\ST$
MP/H, 8 1AS;P>N3B_67!AS@HT5D+(\:XA^AE?)"IR,'T41$R>)(*N6!=1 #4
MLN($UJ (;"C>!XD[00!$+?K:,^*0SS=A.#'W$.0"%S& GFPA %!']==:&,/#
M4R[( RP!@-/T928 R ^F!P\IRL"[#4?M_Y"U[-"N-FOB:B%%#,N1C>#-[\2
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M9:5RWXJ26JNSM7H>K2MFW,(M*4#<':9=L0C\R]T0*%I*FP"8#0']N$$ A-2
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M;30-[QB(FW0MW!C$B0#9"8"N=L\]WN,LC5\NS3MQ8J"COZ^.TS8&_DP-4<.
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M$J2WA!I(N\&SS[T']SG//O>KYWN^\T?^>&<F:_UFK35KUGIGWAD?-K89Q)^
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M,VTRX ]XFS9N6 3^6O$'0,*9(QHE_O\MJ!"" RABF(["B6PE\("]^Z@ #PU
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M3[LOI@$E%5,+SY:9U\<F_([HF&U$'&O34"^_/'93?Z+[H;*;F)%3,#Z9$EB
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M[S3E;6$)"HBS8VAOT5'8,I,5O"Y%NJ6*D3$2L*VV833*\B@N8S=@[MB GCL
MQ9%@U6G6:%-G2TQIXOCK::%&YJ1G02?5M' /T0'9=D#GJ2Y;XBHQ DL45V "
M$BS?]>__YI_P60:<UK^0OK@I$A.GQLRG_MCF:S3I %KT*7YG :+VECX[,0&]
MQK)SB;L23 P/=K!S.&,V.3RL90TPR++M?=@^M"@8$JM+D],W8WIT(((BY]?
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MN/UI3LWT,:9E-[+P47N@'2$;R/[D']\:"A EYV>%.*"=.*:SPU.\Z:SDTOG
M*VX1R>\N]UW\)V=$TT"],E\#*[TS5\B([F!4IRR4K5_FVYE,$-Q4LRKKC<FA
MP*'@08V@$7-IF!^G\9]X>X<"1WRY3,!162W_I[,\'!A4LK:VNM=L:I#]661Y
M6+*\R'*QLINK\J$.??:#BSIZ;U;[@,]$!,DO:@J[K6@04EBBOV_@DS6'IN>Z
MS\ZRS X4T /V1K\&J<>9Q#BM43.TTNN9@+VG-?<H$V])6K"BSEJ5KX56]Q<T
M/'FR/=)%S<.3G@B3V1)EO& U'3).5A?EYU%$.J$.\^3:Y8-411%S$U;+._25
MMFZ<RTQL<(9T3O:GP5YL?H/X*4JLE6I^@7\&[P /G$T5$B&G*8$5+C+6,QL6
MPMKM:; PZ984:I9JE  )I<B;;N9Z<@>H]ME7S._QWBZBO2#.'#,+(XM)P=.O
M52<)DH<WX((4/%&MS<$GL>P>4D,O,7[_>FO]O[82<*5W+?8=;#Z,MA)=TC)S
M[.QH_MZ6.;7B1J"#!_H8/1CUJ._]83>9GIJKAN_56YCT=QVEY5WD9\I2ZK-M
MK@D):HDB>WL=\2#U[77.%#$\QMO3_XSRG\N,P5P"H,RUJ=JOR@\\?N@FJ11@
M\]L%#?&6XXU4K.US];'6#[7LO!Z7L4G=:W1/9DX@3+O(*R20"1+E'3=*W"KP
MDL2:\^$+^5\!031XVY^-/DL=:&.F&"!<;?,U7AM.I9+5<J:)20%  1];U:1Q
MD=$'33U3[(8#S*FM#_I,9Q6=[P!XSA.FHWYE+A]N"E9JKFOW692+PY9?Z"E
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MI0Z,_)K7;)ZQ;<G43Y4=%H@>'1X *$%/\RAN8R_L^JT:5[ORUN!S"BSU<_
M89JUG<S0>J?4=6#3=S6!9JH033]:>R?^B0JJ%_W>P8^Z@'[7M.[H9^*5I/)6
MVO637AVZ<W>  #\E2PLY5MC/UC[J,A.&LE\3:_IX1Y^-8H"YS-ZYE#BSOAP.
M+#\NN"_G\33\=U?C/(S;_:HRBJN\Z3DB<>0"J1+)I\+6IDZ6F=07'-V)-PE&
MO$,?,*MW8*:?9+UIG'AKYU?4_[WYR\]]0Y01 [B2D47=7Y\8/FDI400]0B?,
MQ15!:R 4V^?^=(5<HI+A-EM-I4#0,V9[,;KC36]#LFWJX&@B5[*3('%<LU/Q
MM2 N IU ?*.PUY.>&9I*VNYGH^(-(GT1?V@@T IP>QV><S^/\F4!8O[''0!.
M'(YP<O@\VSGJ39'>UMC=WM#2&+)T0+@5:9+RUOGS::JD RO\0/8L!D-1# S\
MT-8_5F!J1CIGH?$*T9#J3,IWWUJKP#";5.:I<WC8KSR/'U3_^>G;Z8WQ,"&$
M5!4HH6+9>-'YN(@>ZV(*GLV>>:@@!Y><5FUP"^QU)M&V!X_97BOB3ATVCF)R
M)"8.,O;_35$G@5)OI*3F&A8M.)?E%U)X8KW5X_F6.,E'*![G*-/@[;TW^@9<
M@PN'2HC/9$MH+]E_G_X]:P^Z83V;T 8RC([CI=->O<3[M=V<J%'V,^?Q31Z,
M$/W5R8S%:_"Q(;$!O=2<$9W/7Y,04G,U\<D";08"APU'_-9_S<S+* D7?!8[
M)0?"ZO4&,6$PZ7]T9T[:5UYJ_[.)NR-O.9P)(%39CW[&(.8N9D2_D3'-3=X!
MG->BD&==P,)%D.<_30@4RB 8+[$8=#E/R:!T%3)]0IDIU]P7<$[5"H@%G%3P
MA]3CCM:S5?I2MI-W&VXJS-+K8W=U9'9E&6N(B1B.F$3PAY/5^Y.;B1/);?;^
M5:8Y?'U:8K)P]Z'EKJ%/1BI22S+;FR5B<P[; ']C ;=E- :_,-[DC3R1!IRV
M\<=@*/OE>0?B;*PS-&_9P4)K;SL:FA(U$F=>A50@OO!]W$0Q-E.)A1&Y=,9@
MY[LM.;"*9^21E7+-U7)S=:\OO6=\/,?N<QBCVIS['K;16ANP1/.M1H;([O(/
M"P6[K$6<N<<X81]/FDFW.@LM:75<R4\M=0O\13R\D.4U2&1D@#M$C0"XDBE!
M?EC>7M.@/($:;]7F%IEW>]!4*0.Z5R/5SVS;E0CGPWP]IT)D7/A',\Z^X'R:
MI.9]9<96,]/5EWXEO9L\<MU:<N?-((CY-VXAW.X 3U-H:@)F5,X*<)"OLXU9
M"T5-;6:R0XZ3PAOI/>I+WU<XE9@6F?W34JVC?VR*Y%$:%B"N^KK8Y$A1;%3:
MA2Z9,\DK2Q<O=XU=A9P:ZT6M!X3<.!,*FI=).,>\A]A/.&ISXUFI+#BOWC2F
MZ2A>V9S@RRH_?0-K$">G'L$0Q(YV';IG+VR%R/+Q1V!X!\:)K[6ZZ/R)"CWE
MCB!G0PKS)18FU3.,^+]"MV+HH!=L<@X9*>,<!3.=LCA.3:PV+NB/X3<KC0_I
MGGJLV=[<V8BC<X[T [OGJG_8"?UH-D,3U95D+_E#ZOXC@W:?5L'2;D-6N1O3
M+^:OXDME^TXMYEO_D8$@U9ZZSEZP>R/</.K'6I),:;\B=8+,'4"WH3[NEGH4
M# ILA5VDKEHJO4L-TF\:"?081(;(M\7^K68["\=0=%0,VP%K7B!Y[#MR>K:8
M&?M,1"^D($S=DA,4L&97ZTNFV-&S. SM67:U5;#+*M(,R.2:V3_MPB1_D ]Z
M.M.P_+*^IP3Z@^ P6EK.[@7C?^3]Z7A3A,"GR+6!MD66>K)<Z[B#:4M"R\SU
M!![@2=UC6'<Z?L&0!4D/$"G8V#@*/XD+]#69@;TKO0/TO+#.#+B8,/EERM:8
M_#WC X.TCP.^;0+B\ QPLLL_#E90P-$=O9QKM*O2 8(+=5@ZKJ4NO6>K9T0U
M\6*"Q@5 _(RBDF"5+D4AE[#;:3:*>&HQD)2[A9;?&5[)6.'J8!EIDF"Q,7(R
M_U&E*+_H;Z)U!?,)XK))2[O\VZE<BFN-@!+3G<O-OUIERXWQNDB+37<-K^)P
M,QU.U8?WNPU97Q>S);6;6C+C-M;'Z7")\I2O9VH<.KZ\FIO2+EE1 4,YI9.7
MEK4>]G^@[_I\H,3RFU9#;4[P]$:4^<KXL"#,_$![Z078@8$+-OFJ8F^Z+3Z>
MNIO6/^3!WPYMU&JQ'Q;T'OM2ST7\JI:,G);3"2*N\V>8!RVYX?C8\]L?.:,"
MHS%%VG\:TO48]QI$#06I34F KA09D-O/3<TUGH+BG!I!,4K\['V#P/>N8(+X
M\CTE%JON,6;T49B<? '.RAAS!PA[IS7MFKGHS<]&O:HG6Y]_/!Q:Q6E.M]3B
M]^V>YK(ZI6^UL^D=(/:6QL5?LO(F"X+6T=;*G+)SXHH<XTWEL4K[ZKM/<,K_
MS:>6&WM^(!4,%,IR1TG#][+%]#'JE6AC^ZXPC10A<&E#HO2R0-QQ$GR(!>I:
MUBM$X4\*88,I86ANZ5JPC?-1<EH%T+!#4K9&9R:+@:^"'Z>%#T<'!<>&TDAM
MM,@^VC^6 /B8$O=T\ B2]DSN^0=6G]46+"B[".G764Q6G.RT^I(E]":VT*9M
ML'VD7@$&$4_+B9#GI)7@@JW"#4! EEG5I_61FC_(?]DS6!+))CZ#!6/=3Y+"
M9,X3$8JN8Q*?'R*H7.;JU=*U7CO!["OMV%.&AKH?,X6;W!3!&%$W$,.IHY(9
M J3$6$=)N2==KMB2,6*'><#AL]#L6VZ]+&G&%SM*CX^Z<T-ECGH[-'K.F;+G
MLF1V@NC %)#Z84ZZ+\OP]@P/RD] ?%YB^?9YRK*@D: G=> 'MU.CO;=<'5%:
M8)[#WC=S$*\%COZ^^GXYT6[2C!]?TPJA Q^>[X7G>G?@QE"!,N/Z+3F[7E<4
MC42A HI.GL\0F9H;,;0BZ60.*BWNS;QY$NJ*29W4@3[R+THZ8^]#@AML9QWJ
MTERYVE;@+YL)7 7,^(C\.%F<[U%&7"HT8):AGC^T\Y?T\A>WD]S=:Q?;5<A\
M;1WNK;#S01V</JS:<#KQ_\4W?WU+@FL,P,;^Z9<9C((QHN5%1]8'43A'K,Y*
MV30XB5QX<2"+HV.4[/?/+_@/VM6U#N#C2/J>RYEZ[H3.A@_59']-7XNW?I1"
M/SZB.P;W?;3&R&S$CF""#PA+<2/C/?Y]2;P1)P>&/9=G%K(FT]R/VI3J&C0_
M'1FH*EUP%4+&"7V^A3CB'O6LT06QX)+Z#)O\*<,E%,EW;[G:9F]7%*-K4(A$
MQDVRWB$ZLH@9)_RQ;OE^*:.;-+D7%==.4?WU)N$E$A^QRVHWA5X-$M,_ZXGU
MF?&>,X=H<+E;2"9<:4"E3&;%K\@OBS\B$Q#GZ7IEP$]*&9*8DO,TQ@Q"R6-*
MV!Q;W!W 98T<:M9C>EC?)ASM)B0^]J)1>I]G:JLY]1#O#B#(*=3E66+6]&^8
M6ANY?<'Z"$N=N-;[IR^T1CTZ$NT-M^^^$FD%1\R<K%(;^SLBEM:;>R%,VZ R
M).Z\EY6N[9,Q:U!=[2(N=>MV]^R#>O\QFU[HVR>_9A_"0@#X]ID[72BH\Z7K
MY<%M0WFP(] _,*%X%#AO^GK"T@Q^.!3[T_PB@1-LD&!G2)!H]J%?MA89]P,9
MO(CN_&0P??KLE,2K;ZH&WIJ*&1=X.TIR['.(W"/+,LOGC__7DL@A**./" WW
MQY?I$2!O42VN_ 4J;:TD,6G.#[85FB\8\1/YQSOE851SG;R[F5Z7$K^R080U
M465 !V$N;P7[8Z2</5C]0JD9EH.HP?O#8E [J$>VBG/4<228Y3X^^I5^Z;(S
MS?R[#9^'DVBEN^ZOOUWFT*2"C KZ#A##^F@2KOJNR,7'M"JCX RI"1&L 7,U
MZ3VMI&ZX"7 C*\K-(/ %#,S>$H+\(Y.P.9-"7FM2 ZFFG3GCG.@GM!&-K7\[
M=16@Y@GM+>P8#^)'6+8SG=GK-^@C1OGLW"AO<L[^YON>[N4@I@CT>,DG,O=7
ME?;1-FUOZ\+R-^,($WWQ8G<ZF8(F3;>ZL,2#J\Q8GBP;._+TPC)E5.62:C+W
MID^\H7')\N#YB$_7:(A!"Z"\6@_O=MK4K10SV&VZV@7VEFRMA'J,6LRL3W@M
M'K+7F>0;.;FZB0RF+BSWH?3,'4,D8$[K$,;M6P5608P $T6E_*_/;6ISV6C2
MQ:I4"76G1.??L8PQW;9,HB%2Q-!^QVMF'&DY3 @;T53J7K:X*SF,ZI_F3N5R
MW@25=&1N&1IC7O9?3=!O\29J^*_.WP& PE&W3!/>+"[GYOBOZR05'/KTVRNK
MM]8:VJQAN]VA M( $6G ;-)CF&FX'D:JCT6[MU[-NQ)JB'R+WJ4'!<N]Y#:0
MYN_X,)I=)2]*#O [ZA,.51"=O;9 @STU6J9J!4[E74;U90172]VM,^:PQLQ.
ML:#H_!0TQTLN9H->5\"&G!-.\<P/VQP&HQ:LSH+Z;!@E#:QA/B$7&D^G3$EM
M4\I#?DUJL;LWWH+C*8GCDV4J(=&*5 ABMHA&-F8+**0ODZ[+%V0[ST21X5ZB
M4ZHMW?=Z^)_ ?R5-+HJ,CP^/W&H3OG\[L4J)K<K4.[//C DW; ]@9OYZ<F$;
MB;8WT:X0 U"L<1_[XR>]46)5=+KBVCUC%<IYXH!:&B."4'=%JS?[EJW*GVAS
M3[8%!->Y'K-\C!]I\(N+0+YVB-0KPZGTWG+C_A6Z/0#,,=_GZS\8?R3,*FM6
M&@/>/X*LJHB)1/\NB#D7M;[W/N3F_OQ,D!Q.3R]V[Y'EZHIRY5A^'#/_,YZ6
M]$-N<@X-IOCO!M;:%/*[?\*#GF^S*HK> 6QY"GW89^RG:HP7AL+FT-)S&B:^
M>-\!/^RQ[;& 02RDVT)Q4)&^"J9=NV.JT%Q@NET/W .5_>!-<0*&1QG8\Q%-
MJ'OFNOR-Z;)O5'C2J>EU1#Z(TLYE,L%%7;&KJJK/\=.%3O3_=EVU?Q*RDZB-
MWQ^@F*C MVU%>:K#]GJF<TFAN++JP,[)!LC=UW#!5\UNH.2'%SH8%,B?C?ES
MP+V>2^MBREW\\3+4PA:U7RVT-?T[<7F%HUV^0=.(]"EUUY#?2(H2PRKU3;8K
M3*P,NJ8D$_0EE\*[LLP;Q,S,R-78VHC@I*=.87CS^V'9KLHFG3=_"%]S]WA(
MVS]/&>5OD!M5#?\*,RQF[\H\O-PY8,47 9+9,5)088]#S,H'):J+KZWF($%X
MH%7I !!UI;%&$/9E75?RZX>:Y2V0E2'E;\^/X@T=,[!2@[FT$BM&.AB!3M9)
M=LR)S\1N9GI'Z;)E]=A^T^1R8 Y)0<O' BZ/@==5!Z/K3Y!:@(-3X7M6EM=.
M$PC+>C-RF5Z-MNG-A*^(#:[ZOMWWX(%E=0\/2EUROZB(6U+<'0#E=*9;B8)>
MBU6[3"Y:[,QG!E4&NSNY<08,NW&D/IM:-1RY"!%E^"'_Q2[W#<:ICUSE;9SZ
M-$(G;WE;@1>AG2LSQPT\>/_CBG'N0YZK>Y3.@FV5J"A)E=[#VZD<8DQB=>7"
M;H;OW$[A:J]-N17I?=.Y$1,#IB<"^3YE$ F O*B[$BL8I;=H9H5I#E%XMFV%
M1%H<G,?!C>"1?T"]3"N:G[Z2LALN4J4&?[XWZ+SIV,$A',$4'TP=C&+_*Q T
M>@<@^8 YG!C;\NNQN!A8]H,>??N#<W&X*4"P"Q[]''S?U EOC9V^$@J4_&?5
MM=[#;9^^.DP6K7S.;O=@L*YJ[6'0M Q17,'"&M+Y\K!2 /F327 L7@96Z>D@
M7A7B-YDV\DVF/OR\H1_P@4EC_P9+W]U)/7_-6:"# HVQ]1M.\A0'!GM^R&"R
M[W)*1+XCLR4R*WK&X& $]?D6GS)=V'R3XPU6[%VCAU<&C-Y_UP]RHOO*]>M"
M+5RWN?'G'> )4KOGI^3A>N(%?O-,IQS43G-.+0+MTH0E_=CPZ>TGG2\F*K)X
MT3G@=H-Z)86/Z I@%UPQ4J(26/(=/G=H)YFZ:C)\DR9:DL\4N.'6[\[[&+N4
M"< >,)^]G(5;/0I,-H7Z7RDI< 13D7L<Z2- FY1>;IEK^[)RD3:<HE6KSCT'
M"B8VGPXN!WOC.JS0N]"O6\T63W'^8)8),=*0HZ>!(Y(;;I/S/I[(UNI'9Z68
MU>+U!-Y_VB <O<^!F"Z<Y0T!/AIQ77<@W](<:3F^1%U2%27R#<8$.^LHZF$I
M.O)-D5:F<<(4P[4:Z!=>BV[PDWCU7S4&C&2Q]_[@S32O$+ ZXX]VL@0-,95&
M'<DIEKHTY; U3\'D0>X@HD:',DL+JUV\@Z*FA)\/*P8=N[FX8^7:$Y46[M<D
M'JTG]5DQ7K^ 1.5PMF)JOJ+:!5E.1L':K\665ZV>*R4/81'N<4KWPD927YEQ
M$>F_. 0K.B<]J)I+_V1AN29U*2[EWYB3)OT]S,_@55727Y)FB%7:EX-E//F]
MAJQ!?_FNV%J8S-^668&3_MFM>/5^M0;9/.N5^RO,[O.Q@ O*0:N&/['7LDZE
MN(@3*S+G2S@]TC'7B>BK7T#EQ4](7JK6[W2OA(+XBU=R18:#JZ*2 -9:-&6X
M(I6<"\P";6%T2UTMV^__D<FA)+O(9'59QS9YT;SCAYB%.,GO3:"Y@TT/H/#/
MYCP8?*6!X_EK,GTR)%3KV(J8XIQ/2QUX]]A0Z)@]QVB 6D5U<5Q7'MC$!G>*
M\%;];&:VIQ!@,ASL0'!I/BE9_,!C#-RJD14:/FA+^0J DC/#Z*'IFDMP?WM]
M>'N?0WW1I*0)EL=;QWY")S%<3;&DGYN3AI9\6I)$&A#,GB/)(A;CD0JD:F"I
M/GX+WQ'$E)Q&A8H?@<_Y0ZZ"IP?K\?<9")\TO]0;T>Q^?*SF=_XQV'64W-.P
MM64&SF*F,Z$1625Q$N-5&>.&,HDO,>'B[XXPH*>@<?HT#GDS_X_@1B\SN8QF
M).Q!TJ>,/%.NW.V)JXL#;X$F>"3%'NH!]YSQ?PI?/T'KX0=-B*AA_FA.U52O
M8Z ?D7OGS<]?]M>:;UH(>'YWV/N>OTPA^F7, :=]!L'%8 9[69]BYJ..8")5
MQM!1[X'J,A=/<[/1DN61=AY)3-5;TB]GQ]''*F$ON%AE@0J*$H-]S[R&O,$\
M\TH!!SS\I./[%S7(6]EVH.-31IXWC-8A5<4F[^\]$&%/.+O)$V=1EB#5D1%\
MN?:."3Q76,KR3C=SE?1WA,?8H^_WE.Z_56)?WPJ1^_/N)AOF4 (26<+96E!,
MC64.!?=HMD7,YN23Z0\RB6HYILA).7QTHIA25[(FD566)XY0(,-U=6=J]&P?
M6*G."%U+>?I+,&RU9]) A9CT<NBIZIST=WU$R^02>JN]D;X# 2RRJ."/,&TT
MMWL9: [C9RAC ?^D)=^7<B322[4\"!#9_8 W7"HU.$[6F0 ,!D.JK4;=N2:#
MG4QVW@W[D?:Y/TVE:O_DINZY*_)M@CC%^':$E3/J%0Y<JE!9S)V34S+=[[,]
M5;\K&>,Q_UR#3M_^HEW%C?0X_?&Y4Q_;HJ(1EBU>SG+.T)*E:_+: -KLN>O?
MF0\5$M\OX"IKTHQDSE,-%KK@['93P0O?,PJ&6X7;6.#OI^[*]"$/<RYS<B'%
M.W_-M<5)1FI\*C9I!?"("3QW='//HC&^9[HQP:6C9:#**I/LEW-KFM._6W/W
MUU%%T%F/D,?EOUX0>.<1@S+=.K J**D$F*)GH3)J;VD( H^C;6D%VF8*EDB7
MVOVN?.JZ63,W:+L"2L9J[+?GCQ="Z6^INRAP(/6Y$WFGUS-"M05P8PMT:.C7
M-U/R_5F/\4,"4BP<[@ 'U.M[JHF:W#/>VL'UQ0?] UFE.NXLWX1$:V7Y;H]"
M=)F3\= EF*/!+C+HP)YA5"]VMPT)3+V0HI=D\JI7V7)43#,G$^FK6 ZFT+-3
M8@5B*M>;8V]97>B [IAQ5,=5;[#<G[Z=&MVV&"T>7PH.&9N+GB;)BX6-HW=>
M5HMJ"&&4,*$54,8W,@\7AUIY4ULT$\]MBXC5*OIKYZ=J-BRBU<W?^_1@S&N-
MK5-Z;XU$SF%=VE6\TD*[MRVDHV7^ZR1R=W6.FN2O#?('K 3\D^%QQ3?K.>%^
M2J2B.2:Q STJR#/].E?G.WS2J6GV\$FF,YCN]% U0XJ4>4LSQ?HEK23;E]\A
MFP =N_6NN%28-0)KV8'J(@3-?5\19^)GHUGYX=7^\(,)^ [08&&*RDBW$[I_
MH6RPU4%TA6J^YGBSE[D6LB^@$7?T:QVY<C ,]Y@B"NS6IMUP9S:J(7ZU[C6>
MA/P5OBX8T,=4?11QR[YDUE$EHUNX_D>R;FUY69,C%JG)"D02K>YDB#Y_TA :
MSVS)C\T=$(Y48)PY'?-9Z^GDANN('F__\XW&YL@[@(,>+2)U<.NK$-O!\W2E
MB)F7/Y)]UK/S6 9C$/C!U=>6&.%8=/JLJSBSH.XJ^@4C8BX@!:#"@%3&'X%M
M)A8R_F']!^.!RL J/98R J:#&L"<Y5=LGV<BATM=C#R7S$9!93HT67/VD>H/
MU:WUD@<,FI\O/R?WCVS&\E'>A[%F#)HBN-&-4_3O6B(7[-Q%(I]^Y2V79I08
M7H#&H0\CVQQ;T:3"%" FEHW:)7$PQ0B:_X9/BO&AWY%L]>HO_*>QCV9JW.$A
M[FRDP8ZU=#BUZW>2S67.&;XR@Q'%DP952/T"U%$C:5B?J#OK4DO46X_J 0!O
M52>.$\V(D$=ILR@:U4\)PY,>6#BK7U+]LFE))=G0LGM;Z%'Y1"Y-7OKDX%H9
M&]Z;0X<1RD6OO-4>E>>XU'SR4<N)-[?3D93I2UW+PSXRZGX'E:N7./F30--+
MH 3ILY/VEBHAK]%J!>,CU>,RYQ1K3D_ZMP_6/<?S\RCOS=P![)-8H*FWR,N
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M+E0H)?9-251S(2[CZK45D.ZL>97V=C17NP,#/H]>;YVQ21G1(>\OTJRA4[T
MM 2.=H\D?;'>Q ]6P93V7^E(:6&^749%[I\(2J 3$&\<O&5=C-(GJ3]*@@&)
M]-YX)GV',LF%[!1)@ZPT6*<^R@@V:H1(&0O3O[':I&'&:X5#&^@H0L(=41A:
M0\IC<+RF\..'SYB?6]:5UF[.H_DT.2WT&A'TK[H,RU:#IV*X*W=CKB[=]N,8
MZEJAM-X_SA>%3Z)4<F3E'_5U,9@NJ6-Y"DMP;G]59XH_CJ&R99#>,UY[?II]
MD=@MD64YFU O*G5I<-4'*8 A+OQ*8?GZY93UY"&D>M^5"P/^$^G&&U*7QO75
MUL#+'*#ORIM*J?MB8\SN)ET.(M$XNR]Y2XOYU0BQH_W&MHCLN)D_2Z;7UY%.
M11N'+P[R*=DM/1PQ"CH8@^.?&)SW93%#'D"C+")[W[?'J:5#'9L21Y3%:ZE[
M_9S5+0(9[*D_(5O&*8*F%5BP$J51*&URQUZS.3CT]$L5]]162O7!\L%?^Q_X
MHX:<@BDI__@M]T?EGXFS -+'UX9BSN+*7*0NA6J+@>F7$2LW<"DZH</)?QZN
ML/X%GU0%F=,A+(]UO%?QP2W[*G0<#8F5N!HC5IZ1,T#=*&I]3U+) 8WO7X!O
M%]-]TY\B)K,^6R^]/[4H='9LS+^=L7P4R'53<7ENBJAK;&Z=.1+/?K E"^5,
M%^%X/?0ZDHO/<[3IN0>T7'P-R3&B2(-#3K]=]"P%(A,2$F,S=>"?5JSN[W.T
M2JL)(JX//?( A3E?\RB%FF_2$>YE%N8K*[VH#B:T'MFN/TV7T[QP(QTB![VL
MP3**^,X>[T;LY1*OH3\^X2^5= =P:N^*5G@\+<Z?\!+9,PGC]$.U5T:KB*<@
M,(,,T'F :-C'];1Q5H1_<.AU8.'URVDAB'B, \\4JNKPH,;&V:DQ^V5=K/'"
MO83&S^MGU@'SG+6WDZNDF+5H[VR.,["2=L&*LE.%>7_IR-F<L*@ZEM&!M/%]
MS+NM7T2Z_OI$E!%R^%C>-[AJ%(06VJ/X8&%QVU]^*]UZXO"0-Q6M97JO@5*4
MH<]%54,$MN3Q_"B'L11&.@>&$>=MIR[O#.SV#BABDD<Y-*_(V%Q3;2M\G'XN
MX+H!3HJ2+VH:^G)9$;PH'<O+@5LS%,6W'=;\<A4[@71#@1]4/-_(R[O?>D"'
M?O$EC!\\6\^R4&=VRGUS+"1A#-<.5/;:22CNWTR-_OCF)SV(Z@_!'WSBG*?X
MP]?"5UR[;5+1XJ/,<6R46GD[R$H7_MKL5V>@BXV_3*IQ^Z_#&(H(HXX^5B>T
M4H<%6:;.H]CZMN7PA7N_WU+KD9D:KYB:[@D*'%NN5/;M/9!O_<C=2CBP8VBB
MM=1#ONSKNP:GCW3UYJD'60#CA@7HYCE?9>V??U*O&B,3!?=V4G\GMBBE#<V[
MG9+QZ2B @OH\N;="2W:9O,_R)3\%%HYQ+T\N%;F.TX3.\)4%>3(?C8\8 8?N
MP0AQE&4PPK;;\:F:@S^87_D.9,@TQ-]A+NQNS&-W^*2LD.4+6J+U3=JG)&PB
M^*2JN$<;.HIHFG?\V_Z*449OVA'MG9.GI)^SWL7:""T432.%>7B)E%Z7B]F7
MO!3:2-+"L@U:$>,LP0K,[1<E+3,"1OKPR*F5+3^TXWN=?.51D0_W3J45(AL1
MC%@V3>RR?RP0O8N\TG70[E!\TQ0 RO+H?=8I!0CY8<]Z@G?<E:1P'WH)H;SF
MQ5E4=D:P1>UGZ6-.<QI+&/^T9/),'%6C6UIB"@V:V6F7*[GROV!&)R[IKY^-
MQZYRSPB?LEC> 7H5F#OO !^%@LD6)6-\W;W>HDIBYM;AR1H1-HPC(:\>6W>]
MZ<"HG.5,W7+@I+I]9?8]@9F'':5Q(3LVXI*/?M5]Y8Z]S_8DMJ)NJ>7;L[W8
MI:D[ #"8&-3).N6=("GO<DMN_JFD&U+T:YX^NH)Q,U&^_2O]!\*V>TJ[:@ H
M0K'>-P%R#63MDF-EG,@'F9$X3E=[9QVHPM,OXZ6$GV0Z/_+9WK"FX3BP)3)^
MV#N+4,9H&\U"%$1TR) N=X >QR:.H?:69YMF5> _-M*_=24/-Z:+O::NO3&#
M9Q39%28)>H;TQSHTDJ8^V0+GRFCI+W*OVI/S4<UV!*$FP9CI(.+//\ \,XU<
M(,W:&JZZ:<>OKODI*]0UDK6']9-#S_TN*(L![CE".,:-RFBY8%3U@V"*8905
MZQ#WC#?+*[_T*VVGIEBD.QG_(^XA?A+[-2XS4CLR0%6KHE-MM"&&-Z*J!B$J
MQPG9T,.]LIVI<<K1WN$(*&E)73FXSA40;?A.N96\#C 0U?%?BU007<05HB'1
M"!:ZN$HSA00(8:^+$5U-^K1 .[8Q^@<;+[&BE/2V2U/$E2I4K$]*NJFE,W%
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M%XDU#1;34]+U2TF.FZ8TLD"VD%M>QX61T5GE:2\W<J %3 R>OT/10!X-XX^
MFNZZVIRVESIFH6UWXH.N3:)J$LT-I?P&S%OY,[QJ6^5QY@&UE)501Z9GP1_9
MDU7X6^.+;6Y[G1(;&*ZUBX73M'ADBBA6\%EY<:*PZ)]D?))YW ]R!]&44 >#
MZQ^SIJ&H^ O%FGP:K;6?B6Y\2WWB30]316*V<LK[D608R5*ED<#JK''.*\^L
M_P!B^]T?1/#\1TWP7XJU.#PKIOA^[G\16\SI:SVL/E"> *I\Q#DDQ-LS@?,,
MFOKFB@#YZU3]E&'4O%O@V:6]LI/#6D:#_9E_IZ6BP?;+B.WDM[>940;$54N)
MCL& #LQ]VM7PC\!=8\._LZ:YX$N]7M-1\2ZK:W4=QJK*RQ2S2*41VX)X4(#@
M=C@5[A10!XRGPU\;>-%\*V'C";0M+T/0+JWOOLNB3SW,M_- /W0>22.,1QA\
M,5"L6V@9'.<RT^!7B;P[\/\ X<V6D7VDW'B#P?J$EZ$O3*EI="19D92ZJ70[
M9L@[3R.E>\T4 ?*6K_#OQ7\'OLWC.[NK'5M?;Q9J&K,MI974EFD%Y$B&-Q$K
MRH5V !PCYXR!GCI_V?9O&MBVL:G=:%'=6GBOQ=>7\]VR267V:S^RQK'*D,@+
MD%XM@#[6(^<@9VCZ&HH XCQ-X#NM<^*7@KQ1'<0QVN@V^H0S0N#YDAN$B52O
M&./+.<^HKDM)^!^HZ=X=\-Z<U]9M)I?BZ3Q%(ZAL/$SSML7C[^)1[<'FO9**
M /!KGX.>.;3PMKG@/2[_ $ >#=4N+AAJ-SYWV^UMYY&>2(1!=DC#<P60NO!&
M5..=>#X6>*/AMXLUS5?A[+H]S8>(%MY-0TS7Y9HQ#=0P);K<121HY(:*.(-&
MP',8(89(KV*B@#AO!/AWQEX9AT>SU37[7Q'"5N9]6O[J)TN'N))"Z+;J#L2%
M-Q0*V2%5.2<D\3XO^ FI^(] ^*&GQZA9(_BS6;+4K=I Q$*0K:AE?CJ?L[8Q
MG[PKV^B@#Y^^-/[,TWQ1\8-XBSH]\]K<V5W:Z7K,3R6ER8HIX98Y]HR R7#%
M77<595.T@8,6E?LZ:OH/@:\M]'L_"FAZS+XCL=?BTW3+9H;!!;R1GR7F5!)(
MS+&?WC)P2 %P*^AJ* /ECQI^RKXE\9:G?371\,7%]+K::O!XEOO/N-0@C\Y)
M/LJ1E=D:J%**RMC &4!8FNG\#? /Q)X>\6V5Y)+H6@Z=;0W,=W_PCDEQ"FL-
M(A57FLB!!$P)WEEWL2, @$U] 44 ?(][^RCXUUWPO%HFNCP?KB0^'(/#UG)J
M$EU-%II@C=%NX8-@5GDW*64D;2@P[#BNYNO@)XG30(](M;_298+GP#_PB-Y-
M.TJO'.L!1)HP%(9"QY!VD#GD\5[_ $4 >#>#OA#\0OAU8S>'_#VK^'TT&^N8
M;N?4+R&62[M3L03I'$5V2ABAVL[+MW<JV #N^/OAMXNN?B1/XI\*7>C?\3'0
M/[ O8-8\U3"JRO)'/$8P=Y!E<%&VYPN&'->N44 ?/O@[]F6_TN"\M=9U>UGM
M[SP):>$I9+1&#B:*:Z=YE!_A(N%P,YRIS6MHOPF\::SKOAB?Q?J&B1V7A>SG
MM[+^QA*TE[+)$8?-E#JHB 3GRU+Y8_>P.?;** / ?A/\"/%'A/3]4AUZ\T>2
M:7PG9>%K=M/>5U86RS(LSAT&W<)5)4;L$'DURFJ?L@7(:RGCTGP;XFO9/#UA
MHUQ/XDMY7^QS6T/E"> *I\Q#U\IMF2!\PSQ]4T4 ?-]]^RSJPU73Y-.URQL[
M>RN](FBDAMO)9%L[.:W8I&B[$):5651\H Q6'X<_9*UZP\3^'-7N%\+V%UI>
MEZCIMY?V7VB:]U=[BV\E+B:6100=V6,?S=20QP!7U910!X[>?!_7]/\ "7PU
M.BWNG/XF\%(JHM]Y@M+M6MS!*A9063(.0VTD%>F":YWQ;\#_ !QXXOM*U+Q+
M-X6\4;1=+<^'[U9X=-MO-:,QR)L4M</&L9&90N[>V"E?0E% '@WP+_9XU;X4
MMX)^W:EIUX- T6^TN46431J[3WGGJ8U/W5"\8SQVR.:B\+_!+QI\,I--U+PO
M>:#?ZHMC<:=>VNJO-% R-=2W$4D;HC,"OFX*%0&]1BO?J* /ESQ/^R=JFLZ]
MJ>KWEEX*\8:KK=G#%>ZCK^GNALKA$*&2") RR1XP1$Q7E>7.3COO 'P\U_X$
M> -?M=&L[+Q+J%QJWVJUM(<6<9B<QH<A4*H54,V%&. !7LM% '#^*?A]+XE^
M)'A+Q"\ENVGZ39:C:W-I*"QF^TK"!@8P0/*;.?45Y!X+_9H\<?#G7_%]WH/C
M*S73Y6L(- L[N RC[!;FX;[#>$@DH/M+(CH=P2-,Y(.?I>B@#YUN?V9M0\<:
MGXIU3Q#_ &'X3O-3LK:VM(_"B/((;B"=;B&[E>1(_-=9$3"[ -H().>-KQ?\
M/?BI\3/#EYHVO:WH&B6C:;>6S+H3SL-2GEMI(8S-YB Q0J9-YC4N257YL AO
M<** /'-.^'WC3Q=X!OO GCRT\.P>'+G1CIAN=#O[B6YW!516VR0HH& 6SD\@
M<&I;;PM\6KZWTC2]1U_0=/L=,D2274M+\\W6J",?)')&RA8$<A3)M9R1D+MS
MD>O44 ><>-_ 6O\ Q \$^'+'4KK38=;L]3L=1O7MED%LQAE#NL8;+8..-WXU
MSOC;X'ZSK7C36O%6DZC80:H;W3-0TV*[1S$9+:.6-TFV\A7$N RY*XS@]*]I
MHH \$T/X#^)KOXU:?\3?$>H:5'JBNZ3:;IOF/## (&CB5)&53(^79F9E7J !
MQD]/I_P \.:I:ZM!XPT;2_$B3ZW=ZK:"XAWB 3;>.1][Y><5ZI10!\X>*_V<
M?$NK>([F32)M \/P37Z71UW2WN+.^DMUQ_HL]O$!#< J/++R,<*<[-P%==X6
M^">H:#J7PCN9;ZTD'@S1[S3;H(&S.\T4*!H\CH#$<YQU%>PT4 ?.FL?LX:Y<
MZ9X5LW.A>)-/TQ=1CNM$UF2=+*1KFX$L=P BG?)&H*A7&/G;#*>:YSX?_L?>
M(/!W_",B?6M(E7238;UM8I(T807]]<D(N#M!6[10,\%3VP3]744 >2>)OA_X
MWTKQSXAU_P #WNA*/$5I!;W:ZXLI-G+$&59XP@(E&U^8F* E1\PR:\Q\0_L=
MSZEKFON+#P9K(UZYBNKCQ#K>F^;?VC[$2;R[?:8I VS*!F4(6Y#@8/U310!X
M?X6^ 6I^'_C-!XQ?4;-["*[U><6R!A)MNTM%C'3&5^S-G_>&*S5^ OB[PYX^
MMO&6@:AHMSJ4&K:S/]BU$S)"UK?FW8_.BDB1#;)Q@J0S#(X-?05% 'AGPJ^
MVN^"-5\#7^JZK87T^A6FM0736L;H)GO;N.=&0'H%"$$$]2,9KC-4\+:Y^S]J
M/A'6+1K>_NEBU6PNF>QNY[40W%\UVAS;QR.CKN P4VM@C<O!KZFHH ^;_A?\
M(?$/B#]F'3-%U&==&\4C6KCQ':375H519O[5DO;<RP;LJK@INCW$J&(SD5K^
M-_A=\2_B/96LVN7OAK9:ZA#<GPO;RW"V%]"L<B-'<7002D%I%D"^64S$H(8$
MFO>:* /FOP/^RWJOA:[T>82Z!IMM9^-AXI_L[289(X(8/[/FMO(CR.6#RAMQ
MP" 3@'BNFUGX(Z_#XCG\4:'?Z:==MO$TNNV-O?>8+>6&6R2UDAE902C$ L'5
M6P0.#DU[=10!\X>-_P!G3Q'\0-7T/Q5XEM?!_BSQ!9K>6\FC:E!)'IT5O.T3
M*L4JHSF1#"/WC)\X=AA>,=%\*_V?[KX<ZYX2O1<:0L.DZ9J-K/;:58BSA\ZZ
MNEG_ '4:C 1<%<L2S8#'))KVVB@#P'X\+XN\=?LSW@GT/^QO%%SJ>G[+"W#7
MPA":K!LD*@*6'EJ)&7C R">,U0^(G[-WB+XTKKU]XON]!MM2DMK&WTVSLTEN
M+,_9;M;M3<[PC.LCJ%9 /E4G#$\U]&T4 ?-.G?LLWD>CZXL.F>$/"=UJ-]H\
MRV7A^U;RECLKQ;AS).T:R2,^& 4J%7CKDFNZUWX,W^JWOQ8GCO;1!XQM[.&V
M#!LPF& QDR<=R<C&:]<HH ^;;+]GSQW!X7\0>#)M6\//X7UWQ#/K$]VJ3"\M
MH7N%F\E%QMD8E?OEEV[B,-@&M?PU\!_$O@/P-\,8=$O])NO$O@RUDLWCO3*E
MG>12KAQO52T9X4AMAZ$$<U[W10!Y9\./A_XN\%7,UY<WVC75WK^L3ZMX@6..
M4)$&A5(HK0\9V^7&"\@RWS' ) '%WWAWX@7'QM^)[^&8=)BL=3T_3[7[1K<<
MZ(K>5(&EB9%(EVYP8_EYQ\XKZ'HH ^3[[]BJ/3);F#3-,\(^)8+W3K2R;4/%
M-H[W-C)#"L)DC15994955O*8H V?F(/'>2?L\WT?ASXGZ3!?V(3Q3#8P6;>3
MY:PB"SBMSO15PH)C) 7@ BO=** /!_BS\!/$7C3Q-I&M:'JVF6-SIUMIL:"^
MB=U9[:Y>9LA<<,&VCG(/-1:=\"O%6L?'+2OB?XDOM&M[^U'V9M,TMI9(H[=8
MI%3$CJI=R\S$DJH   SU/OM% 'S\OP"\5-8VG@Q]3TA?A_:^(U\0)<H)3J;*
MM[]M2U*D; /-PIEWEB@^Z"<TWPY\!/&/@B]US5M#U?2/[:GTW5+;3VN1)Y44
M]S?/<Q.^%)*J& ('4CTYKZ#HH ^;=*^!7CK3O"7A:T@M_#%IK'AG6X]>AN7U
M*YN?[7N6BGBN&NG-NC(SBX9@RAL$ ;<"MCPS\!_$]MK5AJ^M:II4MXGC:X\5
M31V22!!%)8FW6%-PR65B#N. 0,\'BO>J* /%H_@7J<?AS7M.74;2.;4/&3^)
MHY55L1Q-,KA""/O@+],UY!J_[%OB;7-&L[2:7PM!JUIIVH:?/XDS<SZAJ[7%
MI- LT[NO[L[I [(I<=0I  %?9%% 'AVD_#GQYI^HZ!KFO2Z'J4W@W1+BUTNV
MTGSD?4[AX47?+O&(0?* "+YG+9SQBO5;=-1\0^"8UU&TCTO5K[3P+BU67S4M
MYGC^9-^!N"L2,X&<=*W** /(;3X+ZE;^!?A-H37]JT_@Z_M+NZD ;9.L5O+$
MPCXSDF0$9QP#7G?BO]DO7;OQSXQO-#UK3HO"NJZ%>VFG:3=JX:RO;NXMYKCY
ME4CR&:V#A>2K2O@8P!]144 ?/%U^SMJGC[4].C\5Z/X6\.Z+:6-U93IX8EED
MN;Y9X#"R/(T,01 #NQALL%Z8KI=)\%?%0:=HGAO4/$FCV^BZ9- )M=TT2IJ6
MH6\+ K&T3+Y<+2!0LCJ[9!;:JY&WV*B@#G(--UW5="UVQUR73UDNI+F&T?3T
M?"6S B+S YYD /S8XSTKS3X:?!?Q)X<O;"\URZTHSVG@Z'PL%T]Y'5VBD8K-
M\Z*0"I&5YP<\GK7MU% 'R-\-/A)\1_"]_P#$?PKI3Z*+.ZLM,TN6^U.&X11B
MQ"23V[*I$V,E=AVX*_>Y(K2UG]C5Y[J>Y5M$U]+74K&\L=-UR.0VUQ'#ID=C
M(D^T$HQVEU90V..#S7U/10!XE\/_ -F+PSI_A&^TOQ9X7\+7BWFJR:HNF:9I
MRQV=F3&D:HK%0TK!4&97 )SC"@ !=<^ 5Y?>&/BYI%E=V-K'XPE@:P7:P2U2
M.SM[<*X ]821MSP17ME% 'R_XZ_9#/B/Q;XMNK;2/!M];>)KU;V36=<L6N;_
M $\E$258XBICF!"?+O90I8Y#@8/%W.D^+ WA[X6:3:;]-TCQO9ZDDCZ5=)<&
MTBOQ=.SR,HMU51DAUD<OA5V+N)'VI10!\MVW[*6O2^*/#>I7I\-/>:-KO]I3
M>(V\^?5=2@)E_=N6 6$CS%X5G!VX&P=>U\!_!/7])N/ 7]O3Z3/;^&+#4=+=
M+-I&%W#.(1&Y#*-K8C;<N2.1@GM[?10!\I0?L::C<>&-5M=<U72?$=_:ZK;'
M0(M2@=[6/2;4O]FLK@?>)Q++N=<_-M.&Q@^J_ _X.M\,CXBNI-)\-Z#)JTD>
MW3?#5MMA@1%(&Z=D5YF)).64!>@'4GUBB@#YO\ _L^>.--\*?#;PIXEU70)M
M%\$_Z3%=:8LPN+R=;>6&-&5@%C11,Q+ L7VCY5R:BUK]E.>\\)_"^*6T\.>)
M]4\'Z5)I-QIVO))]ANXY%BW.CJK-'(KPH0VQLJ74@9!'TK10!\S2_LMZM::-
MX5M(;?PIJ>G6']H-?>%I8)+'2&DNI(W29%B4F1X0C(/,7YA(S94UA:1^R-XL
M\.^$+71K2X\*37J6DMK;ZS;)<Z;>:0S7,\H>VE@^>1,3+^Y=E4,A^8AB*^MJ
M* /,]'^&^LZ;\0]?U"YN[34=!UO1+/3[IW=X[Q9H!,I8 +M*N)<YW @CH:XG
M3O@U\3[;X9Q?#N+Q;HVBZ)INBS:/8:]IUO(VHRCR##;R,C + R#:S&-V+%>-
MF:^@J* /E2W_ &2]:FE\47*6?A+PQ+K'@V^\-&'1S<3&6XF"A;B::10SC@Y!
M!(]6)KT;Q_\  6X\=N(Y-2ALX#X3FT#S%0LZ3M-;RI*!P"@,'()&<X]:]EHH
M \ \??!?QY\9/#4^G^,KSPJD=JUK/8Z9:V\MQ:W-Q#*LA>Y=U5PC[=OE("%R
M3N8X R]!_9;O+%;JZBL/"7A>:XUC2[W^SO#]H1#'#:.[G=<%%DF=RYP&553
M '+,?I.B@"E9/J+7E\+N&VCM%=1:/#*SR.FT;C(I4!3NR  6XP<CI5VBB@ H
MHHH **** "BBB@ HHHH _]E02P,$%     @ =SM96F:IOS',=   'GX  !@
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M03)[I!WSX.:W@^/>*#I%W(TX"1U4_\A6P5[W.ER'2>Q9P8%5R6EE)IKUJH3
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MF(_!HC&#C$CA?C,])9[ WA"-I_-+"<82UZ6>)GGM>)&^K,JTO;(;+H^ U>D
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MA6BR=3](Z!: #EPMT6@M483Q!D;*\(P0X/E2Z V":/Z-:>1EW (]E<MG$[>
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MEOAGO7AVAM<,_].-Q.A!O6TPDFK3<[?C"+5;>J$D 5]90^3 FZ$WN7:@[[<
M5Y3J.\1DH-=4"E'*(VQUSMB06NV&*SW&#&47*5+57QC5X@[J'W:DF?01>1WN
M(&("O?I]_CUCZMJ)6$_S\GM\LV*F]6IJ"XR9XPCCL^TYG@,%^"[ZBIO[;,8E
M\J6IEFWI:)S-MP<=@$Z$Z2U08M03=><;Q-@VW/F^R2JFN+HJ)0VXXH"[XU2C
M94<ZICC6*@1K9AF,OELBAPZ,1Y*C3UQ_</$^P"K P9"9_E6HF<98/]H(-1NO
M*;E0FW-1-QK&BZ3S4#[N@+G8.8OM)E0;:1_E'M3-^R@@VU8BZ97C#D0/,A(4
MA_Y,MEFR.'Y64U_A^B-E/NC$#6J_2DREK4ZXUDS8QM$*?K5R'UA9.1ET;"%%
M,QG[$$Z9(R#MOS#[:' G*PUWQ$<01"H]S*C6+_,OUJ)E8^S$I:@KMWU48%+4
MP^#"?&*)RGS66+8>3L2%R2?'=\?6VE5BLX=>.O#XRWBO*HI857WY7N/YQ>8Y
MD(S'">PF+]H!-N7B79&%S%JVCM8,^/*<D4Q#-%I^MWDMK*D(I2*J&RZ8 S<B
M)I'%7;:17LK42](O^\U.NYS:/+O:J *K.: VST(&H$E-J-_)92.#>"N&V41*
M0RZRN:/[\Z&,-[\A-H-N>YU>TU\$")4Y4)+G3^Q\J[#X%7N</_0PXW]6\$E>
M\71CYB_ <P'WI7,?@6TJFW=FS\%VWFG51HD]I*&)Y6%J!C4[TX-H,U %3B!4
M4LS'=$H<LF:X(WA +EOW>,0(-;JXL'YI%M#!^8R>D;_FB\D[E#8RWA2V>'_W
M^'SG@W2#K)C3@ >>A)(XP/5'DL9:I@>F]B7;1XQW8:[+IKR_:(&9A9LY<NP%
M33^ON!WC\_MRKE?4'4I2-2Y-)D:-*?JQ4]I)SY@Q11:^A+QB>,(8S;[44"9H
M9!/9(K>MR]=81OES:9Y'9KB-GH?$8[HGC2GM+=N82PDCW?&;)%[N?LJ'/GF'
MOPS]/45$5O2FJCI\^,=,*WT_PNL;3X:HL9 :Q(GI/LF'X.^K_Q+.MDY3]5U5
M&NK86;6>&'"L^?%&(2]*_1MKND7=FF 2RA=OQDM^3;DT!)^8U]0 P_8S;9Q-
M1FK\7_Y<9!#+AFN$LPG0VJY\3'+/.V(""P^]6&W<:X.05 Z3Y->6U^HKBKW#
MZGN^F\.D$[6R,@V6;*Z0O[^"<9J!3Q<5;5ZZ$TFY3OI.7IZ654/O#/H"#@EK
ME(#=N-DQJTX<F-60>S[";E1XM)TDX3S$:1)A+)"H!C_[%9I+YFID_-*.:3P"
MT_$&;/H::01KPFKCRE0R=_"*:B@UC\>PWCC<]]J2D+C/:R"2>X]]8B7X\1M'
MONQ[A^W3?@XZB5F35]D9">W#NI/O:ZV8/4N&3!.MN&G/)0I+:[(-?OU.C(BP
M-Y\K5QV)-P[OL3EQ"%KB=R#R:#&&1V[,UM;\/MZJJ*V+<TE3V5HWG:R.:1-?
M@RJ?'I%Z)'034AT?M'A5PRN3F#H$DQ86XV?5NYC$PE42"+F4/]N(#JR1&K+#
MKVLRKJ8HMSK$H"32E@CY!E>!*/YSB1>=FNS5J_B@_"[G6X#X:4[9&'TG/V_=
MA.M'<XMN987T>(S3HTL]JZO(Q0D3EJ>XH"Z#%TX[Y/X4OBU'7'N^B7+'NS=^
M"C^W6S!1O/D> 1H5NA,9=5^HO,&Y+3'59FOW:.(__'2EY/18UH3C?-7ND.3&
MMV630O!,DDN^6G%C.;UB4JC=A,JNRL/U(EAJ&\C>#7O;C,S/MC:D*0EC B6$
M>K#XX4X[H5T3^G=\EZ'AOGQ#6D46WB\^7"Q EIF7*B-2HIM/T=4BNV,18)Y"
M^7'#><7YRH9+5\/M4'$5!!LQD?6)2OX?[JQ0?($HOW>F9:7]L$HY%+>=S^ C
MT<_7;_70E!_B ;>U_ZN[\PQJ,NKV?6BB M*1C@A(KU($0FC21$! Z0&E]UX"
M)(!4Z0(""DI$I)?0.T&Z@-30>X+22P("$0)<WW/./7/OF?>><V;NS/UP/ZQO
MS\RS]UI[UOZMV?^U-SD.D4M@SR[%M(2Q08HT.M*7@G-@QU4F.UQHX[QU%/8W
MHLS?\KMCO:Z_0)U*0BH=KHF$0TE)^$;%F$6F@0O;PEC9W@BKP)>TZO\]]4/.
M^I63C+8R4BDA+V4VWQQHQ^?0MB]F;0$.N?<4 Z2);-;C^G]CO_IN63 ,G:.2
MZY;$[X_37@/RX?K+!JY_7'4X73AU6/*T^#[,_:P!IAOXV>A#E$\=)U>U= C&
MHB,K-?)20]S-#F:#FYY:*Z"*T)E-PD/ER/#-E8MK  EG!,@#'XJC,,8'5(F>
M) :_!3%M3*30^?\&10<J(3-/G:*@=D7X3?6XYZ@'Q]QA'-2K\1<%=WK#3W9C
MK@&Q3E@#PL5J^)K=+ E&G'+7IF[L37\G^ICO,-:)6\SCIVU@ZD'+7_RPJ5F[
MB( ):KS"*_8K>*5(:P<H27E)W45/-$/@K1)[6M> LJ;_5"1,0MY[.L*J4:(I
M-;-)1S1=H!QZM(M_X?!RAT7;@>=>"J;55/7^WQ#QD++^O!^]+3?I,@D;M6^T
M6U9$3(=G3T:(_@54H@T;^FN "SRF\X9,&XRK_TH6!94K75(1LVUHI\MR3F2D
M.N*A=# +V#?&RYTFX1UP%#T*LV^ <NLP'K.)WV8YL"<;"R;7@,=)@K9'W,_0
MWK=&5[Q];/BO)@.1LAU_D2$2(B4.V$*RSIX<K\T/S4,JY&OMCQ\LZ8_KKRF$
MSG*LY1XR0*7P.-PVP:_ !42/SX6M"39PR%+?XO7XRDO+S3<DJY/M_Y*P&Q7[
M_><S\JWP:."K+_B+'H7P-U"E4M5RYYSH,(_*?22T)=O'2%-%Z7F*ENO<]Q/$
M6#@YP1G_"6>L?_DIC'T;))?=E9TG.NXE [/IS3*1D)E:T1UN%,AVUOBN'_AZ
M*G2S&I^,(\$,='5&YI@F'("$7<* &=V<PBG4M ;Y6O1L':)?;XZO .X,CJ_S
M!:[1?TS+ 5S8R9#MGR!S'7R"_(1Z/+S8=$4J)V@U=1[]!LQV68M<5@+#J2.0
M(.@+[$&C)X&O:&<&R8I-;NM.]:#/UMYHYQ*S(>MBX84N/T(88+->X]B^;9K6
MX;SZ=ZFYMEO'H@N18'K3!&:9QQ^[?TPNBD!^<+2,A;W_3%W0?FO]D!JJAVV
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M7_Y><^)KIS'KBC8TB\X+&:*%N*E*?YT3G:^3E0<Z8SE9O?OD2JVA=@GG3 D
M(U\=8,9*>L)8N!RXW4-A(N%Q.]BJ]"+J(B&\/?P)(%>_$<0]%43[27;Z_#1'
M]9+\N*JS4-W)B3&F/A![+T6@?]K0^)_?ZZ ]Q/&DFO+KRZB5K+\>Z5P/BCI9
MC3%)QQ=TL5J=CV9O>':.?WXK;%FJ+#V^B=<R2<4Q;P6'WX*DKV)@%>>R[7#[
M"Z@H_9Q^]*$F,S"/+6H!63UESM2]]ATC3=NXH12K,#N8QY7CUG';I-W^(NR3
MMWU3F]FII-H/6U\E%LCG.UYHSR8<_:E9'8AN!LFU$R:(U:O\,>:$H1(SD,^/
M_OCE_5M%NYV[Y$KE9?BT"Q?\?:^XG,:"_$'%W1J-7SU%2ZHU,\;?EB-5!JS8
M.15,F[?A= 3%0I?6H-.KRF+G,U2W?;S80?J#=T3'[I2:/OLVN5SUB-[Y,!#!
MTJ?H<:G#9F5L7MIGZ@>6SH$\Z3J;>5&,!\^>];8\KS3P\/Q419CI5#0[!PH5
M)_I6OBEN;-(K1XZX?CI?6#8 7T82J#C.\>4#*R+1*\N0M,+JF%^V;-]''>^=
ML/!2IJIK9A1U82W7DT?R<GUX96F7W,UTF>AZ>P2*@7D=(;/M4$GL4TXF7='[
MZ)IB2-BH\*.)1W0ZR9.*=W[6R*QS-43E<L4WFKIX5B?F,J0](LFTE3) //D5
MHV7]%76AQ2&$H+=PM7'A,H*$8O1S,;*LX8?N 8^RH3-WW]A]D%PE/Z0^C=70
ML#VL<)T$.OV,KP8U;)JTDAWV7@/B0&PXZXQ2*==3'+FA!"5PZ@\X"+;&QGZ\
M4D'@Q[6?ZS>$%KIU5?;6>48&-POU^E%<X(Z:-#GD,>T;'\$??@X^:ORP?WJ>
MU&K_6)*9I]*'B_;D!$:W([W(.TE5$GVY"10@[(;V6K1[;YW)[=U*$!@6$AB\
M%Q*:8Q '(DY_Q#W3@&=L, \/9JPC##M3JZ;D7AIX3D4'*4A9:7PUYUL!357?
MR_;20VONA<F7O_LWP4;P#]8?.7(),KK"7TH%LT=3R0\U>Z+^1%DG6P6E(MDL
M(/,\S0D;>N+FKY\L[M"4.#X+*1=$3YUS?4L Z*[2<;_)N <,F7%,M#_/O  C
MU?(8N)X<+8NVJQ9 &O5(>J_4E@:.>Y3*Z:E^P-X[O84]_\?!ZU[CW?%Y"S(3
M#H4$0 _N93T*\:JEN;LW^F=>;#L* X]*[8.3V@Q(W30BE9--3^U@2)!BYIS?
M@JF6*]=3)^[O$02!&HDCBB+/^N'!'S\"A.7ZK@$TA[_AMRTA;AHHIZF X398
MY,($<) X9IA."?#S&A!?Z:(QY#KPZ;U)#*7TTO1!1;;)RF"XM8,!M3EXMY-8
M>G$Q+N-";?7,_5>*098/?#BUNXV#!UV- WWP\@F0CM7A-JHE.>8>,-QR52;>
M9;T;CV08+G:>U2A&[3\Q</-&@KMU/GX'*T2:P0N#6,,31:&":%$I53?1O7V/
MQD<OB3Y\!:!]9D4T;Q"5]+V(Y<PM-7X,WVQ:G1 ]9W]_^R,J^OF[W&C/BP;_
M:\!:'C5.;N!*KAGW!"J$ EJ^0D-LFU(O='N3G5'@>E_O-XE7E1RMGH\V)VO#
M2-T4X%W7@#>24-;9#0]CG39SL79YA(BJWA!LF_O]'<:NP;&0M7;PNA<-GG\@
M3'3Z2A0/!G([K5](-Z 0^PBR)59H]<\!QIZ2/QRMFPTV6/%^\9N0V=,(O)=,
M5EDV?'Y!KR]W]298M*C3GR5%GOE5ZM^MNNI="P?SKI[FF0[4Y*#]H$-6*?1D
M!T:+X^DUALCUL5(N^*NN7'E5@Q0]68Q@M<*>W>+TNP^U1>K_/+VWMF(M$<NO
MO'?'/ XI^:+]!9ILE@KYN2]WSV_ .^X2E9':W9$RI.U0'[./^RE%G!OB,<"X
MQOH1$46@!V7[71:4ZW'T%T:65&?\ZBVN>CC(/\LX]Q^:D[2 N(4NWLGF%(&I
M.D5V,H!]AC4WMO-T $O>A[B[?7XCE:G3-< _#TQO/"WM4ND>D!D'<JG_$,N[
M0 1<6S-M<#4<D_WDQU$=O23]M"8Q4Y03<T>.:-!J_5[@"/06UO(T%-^!1L2W
M/IH$,@9AX[131%6!CT6@)DTKG!TNW&FO/$!]GWY%_*E(M]^;(^*<(CK[85'Y
M#O-S((@T<B[S8T49],L-;<\PXU2+-:0H%(9M^ALY*N>%T:*SD-I=BR0+_6R7
M+X_%BCM:WTJ:K1-%YM'&\T4P[TXB9;!C>[]PU#V=Q.UZZ&7Q-<TH.\P87DOD
M=[+6\\Z9]0]0/3^.C3\.%T#?"E_BF%]T^M_W?O"X5VD\QVKM6:Y;(FY#@I[@
MQ"/<G>KK\1U<\3F3E[\Q:<Z^"V2?H"660RKVCY=)[4A?1WQSC "-X^TNU"!V
MF!]7@@K2%DFL7G'B-@9MTPT4/EY.?-UTM0/L,4C;)(D!@'\73\[2U)6PLX)I
M;_@=R'T7?@\OFYK6*1%H\YG:>%?=#[ZNM2N<SZX-O?E5_Q4_-B7*PQM.53\2
MI-.(SRC;;85'B6[6)U[8Z8;+N+.)=/,? 4>&*9,D;C&3)TB/S;-AQ@CWSSDR
M.Y(L*(?1G<SS%M]R/KJWDI\F%IB9WV)LDM P*EPG,^8G?_V6ND%Z+ G$.A,F
ML(PG'MH^"-@%<\NT4.JT4M?5C]SLC5AK_/W2M"%P&I>]%X>E[NVD!LF (7F'
MZ,S.'C"Q <G<5K(+V4G%AH<:2YUTS*O ?NS#YLLU(GZ?>[#<_USA]B\J-X7#
MN(W(7R>B@EH+-R]/:AZ9?[O2VW+[![)?*AO&&46WFYNJ-VI_?+7NI<GH6CS;
M+B;^Z\(CJ=-NZMW+)S=>#)Q9!3$F>E2\/\@:-DK<NSL08Z+<EKW,UCE^?/*9
M2N$_4S +4>Q>P&27QORD>FC614+@*HKP5R]$I1>O 8PT*)&<P/3P"$*=OM(U
MH!6Y[$S$9 FGL6K(R^F[9]P8BIZ O5 RZ'3=K>\06]6NTW6SO\6:V@LW"LU)
M'QVB LW?:TJVC;_!^/SE[;S_\__+2UQIMJN#ZV1O>)<IU/PFF:DTI:U<J;B2
M,N/M7W0FN7=FZ_L7E9I*^V 82Z\'MB+2I]< JS=!THF7D\NO3PF[_4"[?"YZ
M2.XSU._*FL,$-L<\L3=E%TOL00 B_&R)6^OV[ DM>I%E95*5.3W8.%9[<& (
M9L"C5#9:^M4<S]]CQ!=MV!,-7.<'M1R>2!/]Z;EP6%UVX[J;;? G9^QI=>S-
M<7\CWQ]:VW],<Z$"V-GX!OB;'(ZF:'4X'45,^O2TB8$  F3G2::&,#)@W+L&
M-!Q&R.@)70,>X]19^.NF\X]^O15?^F@?P[]LP*5N8QKVW8:H_C *2=0P(X[6
M 1I4?JM;UN]YP/S^AK;I.%$DS&"R8W[F.1;G5M;T!ZZKL)-%1P=^D3WL>Y5?
MY KBR%"->M:NNWU48-B>(,DZ)B;_LB#BH37UA<=#'03>=IN%B=N)U_Z$]X#4
MY\_LU%^J*J\$V49PLU<I<EG@Z4^S\/%B31@V4;$MYBKW[&'YK?G![Y?"(F4?
M76W3LV8<640%9OK[#-R4OY_+G;+CI/]R<%3#&/7PO;?;9VY .^0@.<^QS4Q'
M%,8@POUDY/Z.)+N+-XZ!CG$41G0Z!IH^BMOC1C3"<7<M&DR[K5QBWH>6ES*>
MWGUS\GV]X5T6!W5(C\37$HP#@Y_CNQ>45FN-0/IN+KI#F4.*);R-D8OH"=M=
MIA'OLLGX+#FRQC/1>M^.T"/AW4O0.95^/T6;"VGC\>=T.>L8[>^(/"CY6IN2
M"17X8#\M'_EN2$N-K8Y8GC20)V<1K[.N^XEZX.X*Q908;]LU(*NQ3CO,T>@6
MZ=5C^J6U,YE-3L,#__]9RIH^;W'34]AP8+%/JC['5#PL$W3D?NZK\XBX69P.
M?\1AH=C!I6J*[/"W#TZ7/;)=9Q'31"4 ?A'\UM37N6YJB7;\S%J8TMU4A;:W
MZB7%GG&\^8UI1VEVX#/='+-:4^"O GP[!9N;/J3+#L"^TH$^(%2QU F'O;[;
MK E.AK7@=)_7]U.2R#N"9C K9ID+2Z7 WY^I,PF>7NV*2E4%"*&=L'LM&=\G
M_1=?/NG?3/[&J>N7-#O>>2., 4[F8E#FQFL-R;DD:FNY6#$ZH>&^VLDK;MF<
M;(>C&RZS>PT6Q/LM1L[+>] >C2:R^P0ZN1M/0]8?@8J0"09T*HU]C!&&WRJ_
M_K'[CG3*B"L^21AC-"Z<,G6H"T,<U1[X=M(@&9SS! *G18I@]+V6WJV%[WLD
M?F="Z,1GX6K"@_6BMJOHO,*2Y!#A3WZ]'A?OBZL;G&Y&.+F[##[3XDOE)W7L
M,-JU;IUJD*NOX^(/4B(+;NJC$L '];'>*0^ <*<$9TV?<2!?\<<0-#7 \HV?
MY&I&4KN-8[377<KUQ4T]4S7WEX-6==V]X0P'!%5<XC?6_CPDV535[[6V.6O-
M?#/!4;4\G?6DVZGK#7$Q)]3S/3WGCLE%K:M#+[VH%UPD;FY$GB47JJ5FD"O&
M[W^<G5EAQ?X.\1?B>98/:YWE*R,P3EKVK6+?.N<Y9I;% V<$@E3,DB2/4EE>
MS9*:<$YZ?W0@JSM6RO%^YS4B)VX9%D\YSC?M'QYG 03Q9=V2F:Y-LM'QE$@6
M6\WEFEV5F8/*BZW<00V7BZDSKLYZKB=@"*;H\JY0NP?E$$OU-_"& 3<6T\7%
MEC]^L^SKA2')D98##L0+,4S=,K2D%VT^_4HU.FUMN4P"7Q)4_A4Y=-Z&_I,+
M;W72=O\+??2_M[Q,2R?J.4Y7'M[3P7C^4( )_6(@ZK5RMAB(\W7_N'-*<@7>
M='\:-6'3.=&IH*?<*VL1C50);&KC"IE!0UO(UT*N6*HP=0'A=[87]BS%/>S>
M!]J"7OU6*B$12RB4BPK0>_B)Q\3E/H=H -FQZ1;;(?5HZ7#9SH(3:U8,:&+&
M[0:]^.61=_@G@/N$635^6#,MLF-G8?!R^*NSY36 D[A!]+"RJO]E2^RK7?:$
MU>_CI%-&,:+C]+\9VM@N*O\\(W'.?W^/[\TS)7UAA=W>D!?9YY=/9AYN.1B%
M<X\ G"?,U/O&K3ZUPC)/ORXG23 :7&Q7"_TPX>2?;M5R^](='C\&%_]M>#Y^
M(V;DAZQW/6KH[>,.:\W;Y!@W(27;8PL[SGA'%$(]V/NVFM) ($%":=>Z!WT9
M;5S91TC?F=7]GK[?1 8:'@\C;K5/MGM6DO_<'V ;(3_"U>5C:25Z4/#0U73]
M:WIJNK*]=62KBH2$X'^4?_T':Q_ 9':LQ)0NXA.8DQHI[F9 GQ_3165F<$:]
M#6M!Z)=L1BJ^MQ9\IL,665$A=5-)]3-UKACHOB4D"&/]_BS;!&N^FU7$)L^I
M AQ\&SOW<"ISE+PA1#RQV,.RIU;:+_T'\9K?($(4'X4-,H@"P[L7]NN#5JBF
MB>!/7(A6G;SE)<L#>0X%R1^1!C+>[4Z] \GMR9/,[0EI1(C5?%GH%:OT++X&
MF#W[*.(9_B;)R6<C@O^R,(QUAU/L$AZ0J M9"%U6D.Y\_<QWY"XO==E&XS7
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MS@?LSR>"/"[%R6!/_IP21@G2A9G'S\MQ,I[62$13T1X^\51E2F;L]L[Y1F?
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MO]YE.F,D4OO^DYB:RISOLX,_,'PE]XMCT;M+J<KT63US>J4C;<I-XD.GDM<
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M#9\3-?^<T8J_!KAX,>)W4)K34)8O W9KV3BON-_!#2T!5-D_/)WJ@K7FGSI
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M,3!K,# T+FIP9^RZ=5A;7[<N&MRA0)'B6ER*2[!2K!0I%)>TQ4EQ"\6]N+1
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MF1DA4B7)S-I_\S!I<E&S:Y9*/CZ>!*QQ_4V,<R1G_@/9MBAWOFJX>1Y""96
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M6SZ0HXNQWM*5L\[<_ W4N:[F25G]%GT.KGL0/][C:7>>U=%'C!T2[PB8C-D
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M5$%;'_7ND[[M--$8OG6_<<]+N&N%2U$@Y\QQ=57-)L+GI*,Y4WJFP]-2@Z7
MPZD5H#&>\5&1""=B N#9K/17A';^>"7#=Q'BK?8D%H8;1]FF:'H\,!)ZWX)H
M.8*U3CT(Y$3CP$,H(0'J4+3_QHGQE>$"YXRPT.>,1Q[VDPEPF"A]+MXV<S?D
M[:).>?!4)EV7$')S?<G\:(T&:;<*7>Z![:P5<'=GXCZG3W O-'F^7<'I:B">
M\!+G^4$W/O!5R0^TG]KSSRL',)&$,B3;W'97EJMP849 UM,.:Q7LYZB\UC65
M'^3J[@#N&)3W==XIWI?X/D72#U8KG7E=4[R_9PO9-_5R=GU@2\]'>D<VLV\!
M#5/'!RR5=WK9L%?[2\7'B531V A<X1>EQ]N\0@G>#P[4NGNGZ):=Y7S:JN/^
MV,4D"W<8-^L$\6:;\H S'OVV5L&:6]DZ2_'U>0 ';23'\J!-MEACJ*4^P%SK
MA*NX:]X%S_/ MJ[>O'_*H$EJ*ESJ&1FK:/=@2]X1"T9WO',%A!3NZ##VL9#-
MP[C,N"Q8^5_'+<&&P4PX$1'K^!4K&-SKG#<UU9750,D-1Q$A/\9X?]LHVQCG
M"JE?0NE];>_SP\).!>K1#H@%%P+3ID7)/!;8+*AY)E.++J/MU^H?"?GT)5K9
M5!H33VP*+D\YZOR0@6X\G]6WMX AO\<ZCQAN 8/F>K$2<_[%=BEF&O:E#VX!
M?N=N4E5C9T,(=W<50-^"(O'-! -=='6'BA\\&3_$QOQ;T_EJ7^I8O  -"<N+
M@H\9UG(7)HP;%,=KF;X+5?!DG*KYT005+(C?F.TMP 3J9]<<0BZ'^A+H@= >
M6'LT&\RY1B31KF QX+E_YO0*E<6PBA<Y+FR;.88+_&C'Q4Y,<^>+)("+#"2_
MDUIC:^IHF4XPD9O,^G+PR;EAD*98ZAPVSD7!8!'\:UQ%F-LS^(][NSN =S60
MZ3K7T*KK^PF0!DXRX=IW.C-SV'_Y"*@#?!=_^0.?34;>1%"+&,L><#+\_Z36
M]*HPW$B[X42@79!M-K#-M[,*'6*6I!V_9),A4JOM/#.D_[CGE'88['K8S_8Z
MQP:A-R#U1S<*OM@RFY19@N[2HPX!QVY+>[%W9!^KOSY',&4%EKJ)AH<6;,(
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MD1T,4@[UD66!'2Y=K D/I]2WI;N3Q7US)$832^Y0]^7BR^@4HN9Z__;OJ#M
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M_0>4HCPC$-[_I(MI?ZU,HH(O_7 ,+0'KRW^\RT*QG&-?Z_<6\:5QWQUI%HG
M8XL8-U4E;]L=CG)KH_5C+"CK&708=WP@@B;?;6%V$31(7#DPL_=5YQD?+XH+
MJY]A*G(FY=NEVR#RAG\H3;[F6ZQ E6P5ER/%318$T*\=142R^M24&Q/>M/B&
MQ^^<XGU.!V5*("R3GX];X23W[Q0!?%(/8D489068CD%SE<F3NB%[Q6UQF.1R
M8NR[Z(H5&IR4I.C"?_8;S<K@.2L>7:\2?^R5.*3]!<^S.:Z1<5.,,?6=E!!&
M6;4PDKO'G/SX@1ZA=W+;*&[&/]M04WTT4SF_F+94U]&>*,4Q4^9^,:MBN K^
M8_G^]0C;>7@ P9J=/)F[,RD(;.P?%I%2WEF.F=DQ<%5GLB&:?OYLC)F="FJ9
M2NL8Y#V,X\8\0$($6JZ<+*\"2TEX\Z>)MLZ?(@XQ)RB&:>2$4C%C]P@@CH)L
M]?SM+O Q1K$A[18D=KISR29W!MB+[\2!LO=TO56<+YS>>Y@[WF&\71)1," %
MC),1J'@G$MXX6X76=!%6\WWA21=W#F,E^/9Z-"&U5I7D[=+W-91\?Q<!7R?Y
MH89+@9'#7Z:DGZL3I1/E63SR+S7X'@&>*1.VPJ_(R1II0@-^)_8H80/^?EP=
M@'%N1K C,8TK\Z<+8]]FIKPM=YI)"8)//M$9I)=@"<'#U(4)1+I7DROP_E4M
ML?VI]"R<EJ.V62.5 ?"&O#"HFVS(3 7Z"/ARY1^H?Y]=3\3=(Z8!UZR4@D+8
M&N?Y8\MEBQJF-0B]B/ D,I^O%'SK)>;0QV\GFT:SH3PJ43P#N:2BI@8G(9O]
M!C=+C3,]I5K>'&:FWP6EAB\&"]$SY"0RI!(# *_6?P8QSG6D6N14?^Q]O1$3
MUS]AT6 GSM@H^IJ4VC-\&IHY\@N5 K];)5+3]K?2C-!H:--4G@^LMX!RV42_
MH-XW8-6X?(V_;!7TNN^%G,%VX,IMOX$<]X*H%D:_$%B3ZE?K8&0H](XC_3G;
M_&UPGS-06/V>(_6R9WMBL\><%+PAV+0D JUW@Q2A,CQ\B;@<6CZ\@ 36_)CS
M;,,%C:7*U!X&;86&J+H"I,V?HBUFVXW@Z^9&79E]JC5SUS%Q[*? 4O;5\9EA
M,E-K5K5)]>X'CQ4PW6+N-@%EQ^SY:0./F(U><WV&=6PJAR!A86P(KMP7@Q!3
M-";2^C0[>RT%[%!FB(*=#P@M]Y6MJ1$BIAA*K5Y5O$$.YX!90\A2AY[$RP)[
MF$E.VU_!)^PG"01.0-DV1[ZK?=@EHI>T>RJJ7S6?8PKAEP">).449@(F4&'(
ML;X' L3I9(%5*=CX=*)AG'3*DKB$;C3R5@C4MH4MWP8V8 G^K2ZZ8 @][S,N
M3O<O6X%&O&F;<Z1-/KL@6,ZA]WQ/@,<@1AJDP)(4I +=[<+QLQ7HGJ"'PW\A
M-F$BAN['((BA/<7S'&E0)$-+PDG_X"P'K05M^,Y\O#V0&8V#9([C0,7.K(,;
M0TWFZ_V!0&"#5A3=V @?98]ACXH;L3CK1V%BB1[ M2<J'8[90,VW74D&&1]<
M>^M!H^B=[_5U\L1I]=*J2O)0HQ"MA0CH\K>U+H96*\U7"^CE+&[,:8?_'\_)
M33@%X!\9,'%-MZLX%!F"6RM\KHN+RC7ENKS\EDA['-R>8@JK!/6=<F/@XS+D
M ,@.S7%D=&P%PHW-3ZQ-Q8<RTZ-M+LXYN4^:V*YXP7=)&3BKV J]Z(C]_2!9
MQ=5M[$B1TNIK(N"[V;S,L^U9JN:N+X65SVI98?#H9&7KZ /7"YJGA3@E_URO
MS$VB0%2]3>;YZ)W,QP>V.>]0H1/Z3LC.V4ZUXU+Z[T"\=E-X(/4A$W>3%OW[
MUOKT?M*Q$BU_7I=(42+-TS)>5V\<\E*]N*_%N-Q$0Y)FTBAI),'@HM3UEUJ[
M))A6!=@G+97!^/NT@BU6>V/M"(82XR]RL=^<_?' S7?43@"<6I3Y &2;SWS
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M1YLJN;[YA7,670 7"/&2(AKJ^WW>\/N:2+Y[,<&A:( R*=S(S?GFD_?FN,6
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MJW(V0B'AIAAF;7,"N=K!CE?R*'4GIW_VRHF.QO'!.3LZG_V+JZL$3,WLY>V
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MJM>MEO0-DC^@A?.L<BYDX7$S;R4L(ZW^!*^!^,=N=-M#^QL#6-H7VE]5'I'
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MK]XTV+GD"#%%Y,.)8F&V!$K;;NP<.\!>Z]%0PK7/S><4':BBT+C@F".Q@L4
MFCSR9AU>+7\9&/V.M7O<!<W5<N95L<VG8T&BN?:'.'#OC?0"L/YCV]XMH)'R
MLU_V\H:)N>DH?Q5R/HO!<:K5=3-M@@RPQ2N7+3M$R1),E?# N:$FOWB?9>ZO
M:"R=^["'5S"?_C"#D5R?)*.CG9?AVZ@Y29O=>P&/\<J*1)[T1]==X:Z-42XD
M7UJ1L>B-PX,*GI$&4D^I2+"$$!T3:RI'-Y7B+2 "THQ[&-HNB;YL^3K;:$6(
MSSLQG*FI/50[@YVUUWK6V<;Z,9"0PZMEA?B2MNW<S8E6KMBWX%1#**_YX\C
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M/=0M(*%=.Y!HN2NZ,;6MJ3$CF@<9,;&^(+'5\+3)UV-...8NQ=T"*I7"&$'
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MQF_B:WJMZ$U--O;TI;)5KV.T%:(+TMZ\9R28+P([8F^L5\E#20QJ@&% ^^$
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MAN!>!(S"<[*2W.DV[1NON'&3NAGJC5:TYGQ^9[L--7M(;Q8=V$!_D[C37]A
M79IUG.8F<8S$T86J)HGZ#GW8%N=RS>G KZM7]2G]"UAH,.;.6>Y"E8O4 CBS
M*&)A :7Y-6/BGF)_(ZG'<V/?S4V6\9;KU)) ?^7%P;;B#3"+SG''HP2#*=A
MVD!G1=!B+77L$4&Z9O%C!KVKD ]?L 0'WAOTB@]]L!A=CJ$:$.==#0?^J^PJ
M.YMXIC[?N&[8B#&8L-CUCB8O+WU^98 +-B_RZ^H!2^Y@6>G>P@RJ3WBQE?\W
MOQGZJOGUPF=QHP^,[JP&B4PQ><!(F7-.\F-%[A(4-%@[ N14<*G(\O@68&]O
M9)_BE9$5H2&ZDQ(\WE+_P=/2I(O@8U?D#25N/:$BV!',P8#S^N)G$$2'78/U
MF3EMJTD@TG'M]7\HN6WO?(J7$N_7-)=,I-*94Y*!JNK@7MRP^1\LG_VD:/M]
M\.SQ\:Z+>F)['(-<9OT_6DQG9DY3_^#Q9CD C#W^BA/=Z&' [;M5CA>IU43'
MY\JOP-OC1ID=A#X_M+D^!!@[*337*G5<9XLI:F^*D>_YW7PMVL\^@J5.^E9;
M[=5W8/8]T:6MR)8(J.UGUU691SLO;-R7))L* HCG?@/9'6^X<@8FX<5!]Y'8
M^&HOD'KRB9Z)Q<:1TH>1-CY/H>.13N@S1Z(WMP"G_ C<WG Y,,I":L^EYHP5
M/#A;\YG1^WRTU5=D^Q=R@EKB%M JDG8GPL"^<*[+Z180F?W"#-&4'0%WXTAQ
MX"@*L.K+3KQ\5IQS;B'[%_@W;&?X<J-9$3E*6=I^"U"YCN>>NJ'3V53Q1_M_
M;IHZD1(1ZI> F@0[FZD]:UN)9GGC3J3)DU@E\?GTZ<1J$BA/Z#J[49<.A9]@
MQ$%*_M%6R'NL)'510^ 7KA:2[>#BJ_YK^"W 9U"F=NR_&26W /*,OK^!ZW4<
M)16@\J9%WJG#S?I0C'_6#W\YU\_ON3E^!"8C\EOO=^I1F%CW-@QMT$[D8(T'
M@Z2Q2S3F/[/MKK?%G9&2O10+%;P26K1_/@#,)"2'2'EYF3&V_\##8+$ Q]X4
M"^?!L2=$%>%(\A4<#Q>^!]=A9DI#33JGL^@Q4=_L/@J.*6&9E**WW(CWUY7P
M.A@K,F?YCE26]):2-:>$"K,EN0AJ*0@'FOR5%HJU+%-"PS650+5[@S7@&>;
M220/L[MH7C^]N2!V6",U6O7^FR;\<NES78+\L^\'F:._Q+\D?4E@O J<%2D$
M65%-MED@YZ68W#Z.V^BT-F:Y-+*_% )*ZQO"6A7;3%SUIA,UG <7@QU$/ WS
M#5H:<-O9]&<;GU)ZIC:<LOW5/, \"O+KZC>^7#N3WY^HR[G[5JM?IYQI!=C(
M1@W%2('(8V,A)&1'+HK QR_&2YWS4??^@ ??SW"NU;W7!'#HTA'L;9 %<:\'
M:*;T7R2K(_]Z1<"]2E#="[0]@C*GH^1MP]PKHEM,[ZC5Q])<LD=G@T37$CC
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M$E<*ET^=+-GP$'_L7R -N"F(/%^[>=IZID:GXE*DN X19/:*BR8W:NGY<3]
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M WW?QPA)L ?:4R@VX'YI<E\!)=XJ.2!%R0_?T.7["$OU2:P("NH%<2=_R'C
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M__3E-+H<BKR9=7N&O@<D_UYC5J& IOA8SBEHBEMRKU+JCQ02=>_DK@2Y6!^
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M0. O,_'_=N?\?P7]_RD(/+A3]O)R=8=^.)Q0U,>^!<Z4TM.9:OJZ9"K!5FF
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MM_;)&BEZ"HP*B+OO"$PM:&<2<O2D.S9M@ 70HY?-*&&MG9? /0QM#^+HJVZ
MH-6F%M=%(E8OS/GD3XCW'&"_Z0<;Q2\#LJ,%CX+L?XRNU&H1 ;F\\*PWQ>>)
M]UCHI;4NS1;/B_57?4].,63'V&&C/6PKL1+4H$3_,DD'0S:7XK;OH4_]?'Z=
M$!#LGDDB(]XN[CBH?L#XP?-&T^Z(Z:28I3GA@[>M"I5H4NJZ!_4P4<BB[9U<
MB/1GWVK##P_%U-@SAGJ9FV/N*&#MRZ?.BV<)_?7UD#9%OR-9?NK?+A::(^;9
M8:+[_%[C4+XC]PXLV_:Q4JBGKD,HHO8R_DU]=Z%I;T[QD4* 5V[GH8XCA^,[
M.3Q6M??DVJ-1[;1W"0U'"$UXTBEY?>W687& Q;H'M\W+U<B7A][OS5/*G\)V
M\KI#&%S81-:7>MA.J613I)^2%R%9M&XT\T8D?CR\V.#+-;_MMGS8$T09YD@E
M0&E0D@T7Q\VG!3N@)6U6P9JHTU<O5WP"^S0L\UD735HPY!]<A1ZLC5-+6CP;
M8DY43VC=)9AX%2WX]9=HPC5%8H=>F8:^WIH<!&)[B6*0)HGO+$#^"=/O\J-T
ME1-. .3JXOU49;@'$$9R>+(JQHT6,O5E)%: JCVA/:_)//W/++QWQ7.1.:HW
MW1.*!^_'Y<J9L">*:CL9),/#+]H+E +T84M>TL+*UWII8?B]ZL2%8IR?'>2S
MY]OCXDX,W-[?*GP%2\KT7$<TMO!" X0W?L,*C2?Q<J=G&CE=^1,R=1$/=:4S
MD.<Q_13HCI4$O]KO6]HR"4#AS'<NRY ]NH(+/+,4W"E5:TT&W,=>UDXT. <&
M-^;W .=0/0V,5C<RJ&T^*./AE66GC&5*5Q>95]TL2:4&4\:F/?'@%ZYL NF%
M4#LK#,OX*5&X4R/_XG84L5K(WR+/^ND0G]R2>LHNTF3:SP]R&R98/ /N: BB
MU[07I.JE9"KT%[P@@<<*%N<0G@SA,WJO^>P%%F0T[OXD \.8H-5P!0E8!6GC
M%U3"?[Z[C)^]F+!\61\4_$\"NK1OOC/8R[Q\<Q&V^Y4@'^R&K6WPN*/ =*%/
MJ(&7_W2T,;"[(W"I"MKE&2?<,-4REAS"KI>@T3VFZR.&(U_(QLJ+[LQW$M[/
M?]+:O134&_:[S/C(H,6BK_HV6\C?@*S-BYPV%:1IHC,A,J/L\\4.R[-]#Z#>
M.+JB1T2LWNKOID:H,WL_/]ID+G+ZQI6SDZFIOJW-L)%>EI8;G&Z>A&1+$O8N
M)G%9.G4,Z0DQETX;^4DVTB2UUR*J4.7J=0\@<H(R2N$4UH(-EX.^,$+BJG\4
M!YWH50*OEPHG&_(84P_/*,/"'1S83:%\P:HN7IFAB@E;I_*7=_CH+REFPP(8
MSTCZ);!.YX'AL,:ECK%I? 7_@6\VX-9?^?1-5)(R$Q8T)%\:<JU<ZL67]J)S
MOM(<PG.1N_!@GR'>I1/0[[0=4_%N=Y4$]>4[=#B$%7^IO8+"4@]8!\FI [[1
ML_6 9H$<H7X,ZT(NW]4C%MM%'GY]R/\ GJRLY($@KT#1=*/W2IFJF^-K,:ZE
M7$NVH2(<R102<D0)3++X.]L/29G/29DV5OJ?>/338F6KL<.&"\(BOTFR3GX5
MS&UB<H4V]&DXXMZE;,\P0#9'G'_+_J*(EV?I3)%B^J?NS<WM"?/-N^67X=F7
M:SKN1E5RSQ3>97\(&%2,]E1 \0W)K/13-<?"%)XD\I\)V?(MG9]Q/Z'M6Y*D
M_?GRC\0S*VU%-Z4Z7%E3['G4>VA*(^A6UD?Z/[Y:ZG3D;I+IEQ-]6/*A(W2Q
M>"&@9BK:34S1/2A'2W8^_E?C^5=%AZ9-K..&U!:AG7!BZ]>CA%UR:D8>SR Q
M"G$C/G59AFG*85Q ^1 H[HZ^?_'\M%F(KZR#N=?J9K+"L M84[Z1L\WKC9P:
MF_]@,F&4U3M9'P2*+Z=;.1<]$Y4ZY&:*_[J^9=6T/@D*$5+# TD)(+G9M:+/
M7G5Q)DX815,H8OA.*>I#54;8*'>6I!0\FV2'$8E%U>8\U3.)J'T4QD$\D=4"
M)^#I)*, #=(ZQ[)0A;Y#<"U"71!.[F$I_GGEEYXF+*,ZE63B[)PC35Q7J8<.
M,6.J<TGQ%KW]F:MN59GD7]?%B?"PNL/<=5U((ZZ16KB\MH(ZC0;OJ&\#IY=^
M*S^I3#T!9SL?%O1QX\=Q]4;9\^MYGZ9SLU/+CB4(;ZQ) 1WY MT?&ZJ64NI*
M]J\$) Z8 \.NI5][7>CE=GF3K=0S&.^J^)'73VU%+?O6/UKX^ Q# 3]C9<G)
M!;7'HMC:]7'5EWQ^V?><_DU8;FJ_?.G207)@H^G=.^.>K&!IZ(LS\;!S!RN-
MY#?=,#/H>K!E&44Y1E[I[Q>YEZ9_UU9:"'I["Q='56*7MSW_:?L]@ (22":O
M%^K#"VOMDK">P?";BWPLBW8V'LBA^ZJM'E#.CYO;A_W=:!ZZ%*IL0/R]@HKE
M^>: P-'II7'>]PWK8?["DYONF\<3TVT"OEK;'A&>.[O7RED[9$"88E9EJ-:%
M((OMJZB4D?+7U',.65.<FAD^] 6!0B:?"?!^&]ZRHC\O-059>/'EF<;^E58+
MO<X8GO(Q?1AC4=IO8RK'K9IQ$7V:P"@MTXPN'$*<GGT("*M5K$!(C@9$^!2^
MXNE;;\$CO!B"4*OCN9/O*<3R>R4P '[V1B'8C!=@CU#W *KC8I8V2 DJ15&V
MUA*X*J&PKG?9T:'Z)VN/^9VX/<-V*:\JP<LOJ,N&QM M[7D?F&S=(=X1:D$!
M+F'>>*YQ""TD22S^SJ3:Y#,U]>$Y].W:.^K:^L)M:-R9U#GEX4]@[G3M\:KK
MW?7RN9LX<RQ*0\H33J7\FZ)'J4H,C](#C05^I%_8+>K0ZPZ<S@L#"J\TAPB.
M/DG4T7.IEON[WBI"KCUC8.N.FX(-P^Q?C15NXEM](5>K^8:%ZW?#6XO)="'<
M*=L7T^.<#(: 9Z42+3>PF-+EK&0V.A]E-L_^)V^!%QZ>M1;N/IWG8,[DM.FU
M$N\IO&<-#U6M>.+XK;W9SPZEV.+Z'Z&GL2[MI_+A <@N5^A"#+S+#_2XZR<]
M&0=%*06\EX%A5 \5%7_'@,E8J?1K^/8E0*22MDJ61_2,D[R@36IEAXB=I%4[
M>)NT0&X6$':0T:]T?/<8/9[%JD(!1!_?,2RU'].E'U%(M\]O2N'P4.Q6.A-U
MJ\-H;\9JEN'N#6LL!J,R!<JD?2M;P[(REV_BWP"[RBU<0W=R3:"O.P60U"8J
M"EKF<0,,?)W+=V18/9NDD?DMX.)+1:V5"P_G+6M<P4'HI(NRV]EW&5YB[YN/
M51U8/>0TF?^.>7N64?N23[SZD6>$Y9E*Q[LE :F!YWB9-/B; RV !SJ ?]09
MA<F\GK; !/4"F4PZ*Y ;6BP2>L=_G0=X"CS#PSX,_2$XCZCBQ7%=!QBN=4UG
M769F>(%?M/V@YFVN.KYD94V<=_-C61[=CE[K_,.IE1&U0.\GCJ;)Z>52*FA!
M!PR]^;'2_[UV[KS1;LVCT)_G[Y *XG3$D:C2@5U<@M 1, X](TZ^I48'((XO
M+P[SUFOZI.B9TM:/Z"4FI;Y^$I)( I)P)W-FD2>8T[PJ3?_ZD*X)(S@F;S<*
M(L :1U$ Z2Y[)OKSS^A?YQK/6XWC\$3Y]KX\S,(+:*N;\V CN;6&+?WV%"4[
M1#@L24\7=:P5D5?7>:4R"'7(M#_-8>?>VW@@\B4?9WT$8M60AQ1-JET*]%9W
M^&3MP:28.^D2(M,2?#&^+]"8:CU=H$58I)&OH#8&Y,1J(,.#H>'A"@U6:6'-
M?*E'9%I[?%H]A7/=K.YYP=^Y_TRY^6P3 F*B*62@?VO/@S+X3/L7%/GP=O30
MOXI_SY@5M\3  _P"0(HDG03X^:?<B/6'^ ;35OV\?]\[HL_J:X=E\LDK:NP.
M"Q )_2T0FTDW-\&9&<6$(H=<Z1Q5XV>913_I&1FY/L9MV\5Z>Y^]C],.Y>A9
M4/E<D\E\'&_6NG[B-)!7#^3FN?LC,M(R6?];-*Z??OE7[<+9:;/K0G5;YI G
M[B>;L$=J#$.5M46).[$&0D\=M6EP$//J=88  ,X ;L?_K78L#L9IIR*^GYB,
M!ENS?[%UX[B]9ODW=\BSL6NM](_'MYOAN,D#P/;.?Q#AA2B";_3-6=9[32>D
M54,OB%)(\FB>1$]71!'C1=/4AJ<EP)NS\R+[X3R?]'%'(5MB(^=J<U"^[MB'
M,!!+U4)$C4V-E-!K 1]$%7U /N!VO!AP(6R&>EB+4DF!$W<8$$Q!KT')8/%/
M'@_&?AH5K*P$D=6VBR"IU?J>G>%\KWB7OB*;H2RY'CJ,C*S\=%A?]\-,5ID(
M(WSK2'):LW(VIL/A8Z(A*90>K .I]#FI7Y>Y]BE!2PXBI"%9#RM<PAU[Y*U'
M[=$>JYX\L!#2# G!/[V=+1GDZ]O>S'[&F^!':)>S'%!U?S;F$ TTD^<.1MNN
MJ\.=NOC=TD^R?42<U.?\1](/\E0?NZ7>B7CVLV >%P?GUPZ&"W_)%(;)WP,0
M9E7:3+HU&D'O.C7>XE$3_K/:3KD,^#^<L=!PBHR."N+)#ZK%?=7+L1;/0%^N
M(YHF_%=);IK?:G%TK</N ?4^6F;R/16#<&*/_>#NMEY@S3+'2G'0$L34!)9*
M&\-K1NVBDT)+:(R#FPU<L27,/4?AV?(O-PF9'NNWE^@O.D-S=O/?YVJZANG%
M)(ZXOR?[-E/KMQ6-DQ>.D31IQ2Y'(,U:6IGPLY)>697_FKL'N/^I*5"FY"!@
M-=KA@@3<2IL-13'SK9XI JYZB \149G"K,>ZQ0I;\J]'X0@C/@-A=;IX\3\6
M RYK7Q[V"L+_07Z_1-*HL=5,S[IIE/U/5$^!5"[9WHB_5B.U*N.[C($=OT^V
M;%@#9!2I[6&A960%-ZA:_?(ZT']C5LI4O NG@'!C:DSL0<9[ATBC!%2TXCW
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MLHW#"8,H'F'/#D8H9Z52KYWIZ(X]44H:VJ'$NH(M 1Y1D40Y.F09O3ILH<6
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MYHAEX9,!A==HS?4 4$V6_KT,^UV>#7AX+]"]%W#A^&S-P\X1Z*W4EYJ"]Q*
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M=_$-(4L'TK6*?^^%(>(R+4OR& NS?I/#S ^L;;/'XB= 8_7X@Q+<(TNIYXU
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MD79JT.*/*HW%)->)JB NHLX^&#5X27^FS+1>G[A#&B.T!7.&I>Y4+5"]_&+
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M-^-.4L%7 ,E%45Y>SE+<3]Y41F@,>7U?5")UZ'EXK&THJDQ0I1-=UZS:5SF
M1PZ7?(Q#>*,1#FRLRI H<Z>/W&P\N__)0B!27SJ%SUCQE:2?X'C&X!3R*=&0
MH#S0[//$S-)5G>;HKXXKPN_!NZH:C]:?89_"_+AU54PF89>2_/&$-#XALHVF
MN.7-!< 1?6!PF]*$7XKNQY6A3TPT7V\?Y]$A>6UM/>U@.%4&[,C6C.DXC"W[
MVA"P1>*!9,'KR;"=^[EJ=D,B(3)J=XBCIOBT\7#@4?C+ZBK7VDV9SAU&L7@K
MFA]+!?:/-=_07?\L6NS.1W')C8*9$/N&^*^%?,E=!HE,IN.^,-<[E"E]");;
MS%S&V(IZTF=]12L.\J&:+3Z.R=_NI;&[(H-'T(.*XV#G)GVUL5MQXD-)/G<I
M0DRH*.M*B)8K\_&Y\(@&Q2L6P_[M#;\>B[I'9>S]/>:%E%WR6DN<5)S57<)
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M!P840&]D\'J;=@DB5,F!A%\SY:'$MI)74?H_H1J+)^A"B)DKNXZ;*[73DGM
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M_W;RWT[^V\G_KYT$7WS_/P!02P,$%     @ =SM96B;OS8HI^P  %E ! !@
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MK&SL@D+"(M=%Y>1O*B@J*6O<U=32UM&]9_+0U,S<PM+*WL'1R=G%U<WOJ7]
M(#@H./)Y5'1,;%Q\6OK+C,RL5Z^S"XN*2]Z5OB_[4%M7W]#8U-S2V@OKZQ\8
M_/3YR_C$Y-3TS.SWN57XVOK&YM:/[1WDT?')Z=DYZN?%7^S" Q#@_;_'G]I%
MA[,+GY"0@)#D+W;AX0?^Y0(Z0J)KTL3TMXU)'OLP\,F$DS+>22VHZ2'CEWV
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MO19#=$VB32!L_YF27<G#::@+D "<8X;Z<<']%D+W'EQUJ9^O->W0]%J6DW[
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MT&[9^G?WMV\0+R=V6OA+5\"U@T]>9B>YRF/^/O%D@OX*D.[^BQ7^_SZ__H;
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MX*FHXL8FM[&!'TS?QSB4/+X/LC[B;JA&+J\=Q"!I>H/#.HI'_6A2T 8E/>_
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M_+,?X+R68V%/K--*@ML$,SF1.X1ZGGS #WZC<Y_DH_!<1Y?155J8@-6ND4M
MIU2Z*9)H(%E^UX-OHB_[61Y\>(LZVB#6\,NRT/["TVK**,*T0KD$^CJ  V3?
M>,>;K/N,<&:ZBP?H>JFB!H6U5L.H N^U=J7T!F!XVJ;,#9NM=WW?&<K;RPZ\
M_Z!!J9ST73C5EMD^PSC*[2$"?"_L*&.^E/OA5&6@!\/,R(D:I:1,T?,-V_KZ
MIKG W1 W2!Z/Q0VV@2:X+*F*?OZ\0L[MD]'7]Z]7B7MN62!%[@+JN)Z<D]/H
MXT#JXKA_N7XP!L?$K'XPYU&U(J;J>1#1^50[2]PS'O(,?#I!J046T+'OKY^)
MB4&ZK^"RX3^4L8!^*N'5O$I$C W2+O9UO1#*!,0T&OUE0?^B(JU[Y\/#:PF4
MLT,JE.Y;C9"?5V9D=N)1R_)9HFT;=BN[YZ"0V9V4QHS]A(R,JH/]ZJN.B4/U
M:]_0=/"1)Q.ZDP[3JAKO?K G%[8^ 9EGCQS-:4L--=>1D<V%1TH#5IR[&.<-
M*4 L&!5UM@:D9UU(DL8>@7']M%=QT^/-H">/CZ-GP;POJ&GN79BL5@]Z45E!
M>%'R1<O@[_5Z6  9JD6>RO8K7&5 UB(AG)?T2=)4M]V*P-/M\8H='DY5AM 2
M5-6$-A(2QM/5@LJ1BA?HNI1?L#<=_[Z8JJ!-Y_WPH_JC<*T@-KF-F,(/]X'?
MQVH]A/>F.H724?(3-G(SFX(//*6A5B'"R"#;9990FIQ.8300*=5[&#LW&NFE
MJE>YHYS\^D:TKGA#^:8NF:;[>QF"L0ZQ%Z!*8XO(:M1SNAX2Z_8U+(!O9IX%
M6B\%*T_A@ 1E#EK511_V1W^UH;%K:^R,9[:(^/E"Y]N'!<VTCH< 0Y/PR&.6
M0</80#LF=2&W3L%.3!]HJ(<G5RIF)8_#TM)(<J4.<^S3_5E-1ZA-9H&9@W9*
M5<N.=.YZBZ*F37-_AU)(8]/8H,=3&)-MI<"&(8-P^<3K_8"F+H?\W*\T?_<9
MHMWM7U=V4-?_Q-+^SWI&8 -\AF: I\0&9K]1]HKU?_]V?$]P2NK@P']^C*FR
M/D3CT[S-JY7:1-$TW15S"=MTA-A ()0&K?T>%&R>F-X3O,X<XEXE*;$4 BIT
M,$#HES'F7S<8EFE>2/BTHR1MJ8[/Z"BJ: 595.N_T.SJF0^1=5/<T_\@J#S>
MA,K?^>K<E\<V]91HPJ$16550;;W<.Z%Y,ZMJAY)1[*7CTQ=%Y?BE$>T1I)_D
MX\NKE&ZU#L99?"KY1O7D?--X,F7)5[&Z&LUU>0L-;$#]1-0-6%4.)!3N6'E4
MO54U*4>%Z+=$?]DO3K[;A$_'??;"DV/^EP?6$7?BIQ D^[*KE1SW48KRAK$F
M'!TDMI,;T[F%G:F=L.LO^HI_:@^;'*TJ#9B'1Z;D98C*%6:=.3CL0\.]#K>+
M>8X&;:2^UEMS9^?J=ITW-F"<KY:.CJ$HBJE\)N&SR1>JVQ6HU +##KY=A2CS
M'<B7LVH"S!!&$KF%%@/6@(\N:%"&3R:+)]!7("-N#4OG$4OO+3:8A]B;M3=.
M'8.K@0,TD1A"I%92F53BG('Z"LAH9[KIXPX5)Y^K@ OSTB+?47LI5:8D6PNG
MY V93DJT-RID9>P2!V=NX,8E'I0&/Y)V&M]B"9CFI?"3PX=F-!>FN+W44O.T
M["O]1>.CPJGSXMRK+YD363^+>&P=6K/'WJP)[OL8+"U[;!_>N0I1.)==<\@Q
M>REM$-AWG]$Q?M<\AF 2<U;L.,/8K#P8=_LN_0WE_L,OI44\2T_/J]VO,CKY
M?MA1RF,!L;(@VVLV?&K:O5D7IHG(?F^X=0MYT-T@G[2B#?N69P.@!;3*I0%8
MX5*O>[\<?+K1D+"*ON!N3I]?UA'L%,47C_RL[OHS9?33:LNZ\\3 8T1S<&V4
M:J.LWH>(&;V3R'V/<Y>-@@<-%M<-F>'+][U4H K#J" >RS26#/DNNGK=I(/6
MD573O_#5_3 1M R2I7>WBP+F!Q^Q?X C;C$:#3/[[!-6G5]@/EU/;KCB+=WD
M#$\=M;J075G>)UBA(0>#5F7L=@GNUR ZJEIH8MM5)82@^S$M^G>^,%'Z'JRI
M@R07F[?C9\>@+M!HY<!D524_H6HOOGY$XW)OZH[3U[UW665"5_,?$R1[.;Q>
M,UNS];"-^)B5:,EG1UMR6QQ#AQH.+>L;-B;NEI0<%&=6S#'D1#<W!7K5GXPI
MS'Q=YH>;I5OHHC-G5+7JG+TR_7.ZOY\,OIXNSI#_Q#5N8-\W5DM9VUD33)YB
M<OE5;#>% #,^1XI*]PN"7V(!-'-+@RO;JDI%J'+8M/EX EG,$.,$QS.G(,#H
MH1%#!(F2XGH8 UK_(V(O3_4;Q!+)/6_:,(5F@19NM[[0^[Z_FJ=+4.QIA2=$
M)G-SI8)X;0'>%E8==<]@X^.8,$(XY!"D4>J!;EO=!]VLC,]LNK2V[NJ8/$J)
M[J)4U45*\K#(E\:?YI"I*KU=0$6X')SFK#A%4'H]A.6_.GCD3%"M:D[_)_W;
MSF$9XH>"^E2"S$GZ$?>:@"2&D>,FCN# '0> R2N_)O[#/*5=4U6;2WTP%,-4
M%>ZZ,E]-98T#*5)7Q%+EZG[ A+&,0,QK=J:8*Z[7K_!KFX9IEO@5.5_^,/:7
M'[)WE3^CWYBP"9*?G#,5*L*<'52?Y71VE@[F_QULO5C^]8LH_H%_UINHO_'&
M*S0D$ O X3+"-+K4N=0&\A!)U%@0E%]GI2<1/Z2.)_R$M786D!X^EWF((;M<
M::.Z-V'8@BJ%4X1<=@_,35NZ9UKVK@7T23O6I+ZAEA'#V>>:BV_(Z);'VCCN
M^4M"_X4[2_;7*(Y/!!W[;=:?V?'>I/*:QV(!M?N/\G+A^2A=C#)$$=G6[2&/
MHW%S?:T!Z6"XTEJ]:=W-L=J+3P-!LHEP?2@15!8*V@2>, #1U':;8=6GXE+H
MBY2%KD]]61BRSZO-3X)XX#SQO7R9BGIWO-6>R]O=PP(B@L%Z-N-[IQ) N'-<
MM;C4-;V$D%=A Y_%/0LR)G^J1I#R7L[X([  >%[+>X5>L1CD]:E3@S"R8J1M
MNFAO^;NHNB 'W_B"2G1.E([W8"[*O9'5)X\8E0(G&D.3K+Y7U2Y%V6L"J>N'
M<F6.#HV21R2][K%N\&E'&/-KU*KV#RBD]=3>S)_[F7)%B!M<"+)^QDQ^[#K>
M ?IB ==PKCZ@H<8"QC20=E?'N(@,N& !,=[@0$P\3SP6<)ACB)&UN8I);H"M
MZ4#4UD;9+,&/37K/6 )F+AS&-$ ?EG4<6?PTQ#\?BSM>$V,=I-\()[1_@\1M
MHV;7RPQEKN 8J(%]^''.KC\G_,9CW)(WD\)/MI#I:MU]7T%1L0>0:'Q5_0K'
M#/1Q>BA!7X7J46 !ZD7G4D=*'OP8LN-5JK"A_6!HWRC#XGQ0;:]#HA6M0-*<
M$BUF*Z(JL3A 5-/FC\IFYB 5[B-&85<W14[-&FU @U;[+P//SKU[W&,NM3 0
M0^\=N)RC<<3;.F:C#K]'RS##^#PAY%:*'!9 :0/>WK\]J:KK9-NS+YAFL>\I
M$?8I4 ZH\%F\"&PJ6:2FY8*9&8;^$(*B.+N&U4NB<-.3\6763T;HZ@(W%Q90
M& /ONMS$<8S$,2R >@5Q>,4(9,("EF_FHYTZBM84XE4U5J1HP8;6$P[-'>.2
M3CG:+>/VFM<%)\?R:^X->FYP^U;<C2 YG,QORSXV\(-O]3&A-.$T#(/\LR!V
M@<8\GLF7UN&$+,9+I T4/R:+TEGC4L<Z'8TL,CSJ?Y60/ ]Z<?3M_=40.MD7
M5R3SJ]:DF=;5<;9"C4G%.I'#[I,L :3Q9#'ELJ+A"R](A-[]T8$EAXGRNUQB
MQI.;R+SP<K#_:1?UX.,S@WL</SV&LY]++U2DL=+=4W50SK/4\27%\XEQ1KI=
MVJ)>\\0<J ;9.Y9;HN9"0G+8Y'/$+$HF^)V/*L>7P2VNND>W?]XXX-ET^43X
MIS[D;(RYQ -+]34>CY:@C9 2>T;WSVKK[1S4'[WW1GX\ CNJT@8Q%?W!K16H
MP $6=>:T-=-Q](-IQ"+:O&5"\NG5V;Z'',-";:=OU'$$*RV,E:LN7__JS>GK
M!BH]N$%C 5PLR?QA ]*V@&:V:BNI.(+H!6G.+W@9]SP&$6NLC'_JS!31/SA*
M&ZT2">LZ,4+C< \R!T5F7US$ QN.>2[(\C$D4L<T98^A6Y-A&QCM3\"_7V-V
M=L;:9YWV6,!M61Q'W< \_G=8^4F"X>I97;X0"1/# CH]@*@1GM]O!]K=$?E3
MK_+@ !K6K*J"!6C2]$//1W"\F:W*\,'5LQ,.NW@,YS>29+3^F)U+=LGQ(Z:&
M8[JW>3WX*8OV5&>9POQ*F@-*HXNF6]E;Z#=2$5U[9C-=)]4ZQ<>/>JU4[^*J
M]3KTU30-96,)3PLWV1_"\A:(N'](+K%CF1\7)L22PO;:XW/=,1L>X*.=L"+1
M2X8)@>"9\9G&,(48D]:.VJYQR<K$_L?CDD_ 69^[R<.^M;UV^+H)Y+_.:H3'
M,4KC(9^9=:D%MEW" HPFG)"<>;3MT1BPZ;60U_W]T=3#F6QX\67"%!.*I;]!
MDLY_]P$W/UQJ5F,5QX#XH@T"X6=UA8/28@P["C>9X7>4HZ1H/W-/@;1P$!T&
MENT+?FH5G8XT[%,N>=Y"MVBIYRAG&'$;)GZ7D_;VUOMJ,#*O;M4CI*^3IR.E
M/YNI9*/5+>#%NQ+RA=O7DRWL6QZ]IB7C2Z736<RS3B9CXZ%6%T8-]653+63;
M1<IUF(V/FK5-P"<K#KOJ]J4>)PT,O>)W3!>Y?.6])Y,4S?OGB1-G>$F&5FN<
MCDY1&*!Z(F%1^_9C2#F>DA.;\<:K)H<(4M9U]N]_K-_! 2R !ZV,5%LJ0VP>
M#JBS(8;'[>9L0.?9T:5>KG):0M&F.E,+LE^'&._Q<!@'"?M^X"EX_P^G3]'O
MLS$T5)/G3WL+_SH/*I D!OJC %6-^8DC!FMRT-_O5EW]ONC23AH+>/L:1P9P
M-]VXR&3!A&H?V*U#BKPN =^M7,Z5]7F8VKVH,WSANGOVV8N_9$3?&(Z0J- B
M$0A@RO]#ZG5V%I8XM41TU##,7([C!LIV;K;#>T!?]=O_4/U6[T,&,1'..-HR
MA.[_IY7@?YT/(__@GQ8UO3.";QYA8BB_6]PJ2%G-T$*WK!%OLYEAK8@00G*@
M?Z+"G,6;Q T6UBV@OWD>*/_(NY,<"ZBQML4"QCOXTD?\R%R0N$F]NP1C;Z$J
M,_<R;!TL_'M//L/Q0I5VD:8RIS!!U"M;52?')J'180="_![(FQ5F(T/]U%T[
M/=OOJ"6N^SMG7[  G=9&6:88G98XN)TPX/KEG0/'=)57Z,3BQ[<(O535ZJ>M
M[/;95D-"KC0,<OI\P7>..'ZN/HPZ<&9A9E61L7 @%BU^(Z4/S_\U?C[Y=Q^
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M%^4P#X<"8\.IL/QXCO($2V0A4Y>\JX[[#8#4RXUAGAB;^QV(749E/Y?/+-A
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M?_!CAX_)-);4*?HA\/,"\^]R.!C9=^Z>GJ?MX 3RD(L_KNP?KZDKBQ5H"9]
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M2BK%4A!-+-7^QE\%EI,E\\?A\#US"VJ;R"CJ'.+BI;@!1<YB3$D;B4R'UUY
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M#P7DH0::+HA?OU/ZQ<_\+:*E.07]T*7^PHA7@PE\IIS3@A1]!YV(%&J^/2[
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M^M_B0I5V_Q43#*,T;A4$[]L;7="A6>[U><0!?B[:-Y3+Y7CO^X;S0^DY8Q4
MY#S?;TR>$]V7M:II)"XC^$Z; ALI;+%UY<65Z-8&%@)5[!;T@%J2I+I9>\C6
M7KS8F;ZBNLQQ;##=57XQNR,(4<KOB%S#L!9M8@AVJ%7WW4\^";\K_]60V+*Z
MUQV*CTJT.+UIXY2B4YMYLY4P%;%@.UZUXU;-)!F9-UTE3IR?O<;;GK31SVVU
M%)#@521)R!&JVZ?.#!?N\J?'OEM9_372X"V^E[>Z2^W+H@--.C/*_Z1!UNI5
MJ\YAY0SJA _ %"RD3K;X\-;\;_F-L8F/B\E]Z/MU1,QVVGG*QAJ9WY$9+ZU9
M7A;<!.JC 0T0,4GI]HMO^-W&@I!D)$CRR,H5_[<D_,+$RKG/!/<*O9YO/FBQ
M)>0A>/R_HJ\)'UXWQ!2M8(%1+<"D]Y@;P3>6Y:9R@TA^9EU- !^8^&:&A[]E
MT@#\5'_,;=4:R_[MBF-:_@%0_N$L<DJL84J,Z2BD?DK(PE]N+868-2V=[R3?
M-Y/ C-HSR0-%-%F:2\'=A)7C6>]C9\&6FXU?R%5LME:&AC9EIMJ,B&D[WEN"
MR7)S=J3#RD58I)D/4[!22 H<"'-3_9R@6-:3_B=HRP@QGV$?DNC(V,XV>QLE
M9@&^7A<<@\Y7DKC2AM-B.D2#RW>F&O=I1BK WD@R?@L,&W1U.)::U;N[)UBG
ML3:6X78J+C\C_A.US!H%V-N#@3OWQ;=OT.Z )&- "H>++XSM3%B78%7<B&=)
MTMAT'Z=(+N;VY);L#0QR'$Y^-?EK8OW_3*X?AFB@\YUH+UPG8;IEF^F\93<!
MDA"E^=#RHP 2>"_L)6?/!.TW*M%UL(("PJ+HQO](!LN3@>,[3R6$9EOIVK/L
M4.;*/2MV-2V?=AJR)]<((BE- \R?;WG$X-(&.(SZ$2YN,<OM=V'WW$843.)F
MEWU8>:>T,!0Y\K&T& 9AN=QZM5@J*_7/P[(QH0&_/Q\>7]+BK%[A8.\CJTD6
M(&QAF"-/-HIS\#0S28OI"$W/1K;.P]@?R\1+T!+OTW_VWM<_*>2IR/X>!;(+
MCDGW2E,]M&-)J?V91&9KUE5>B>D"8UY$?96"E^BCCKT?R8H_"%Q/0]U,"&:3
MRUF5W-F)%[&V.U%.S*VF!(E&=T1E7PV$."O]#B0J_6DH>6X,5K/ !IY+@P^[
MV9@F;6<;EZR?IPS-3M[/"Q?J#K(P5,'#C#4*]_V0-:X"MI,P"X<J-%:8&FJX
MEWMJWJ_>>4TY]$J=WHN@)4'SUWV>G'?U=*]4%8ERA2)SZU2W'6Q>*7UZS4 N
MDAEO\:!RVH*F-HEOS_09-,E )=8V25S(+%011S:%&R>N,,9P6)X&2X1L/OJ*
MIS$G2R9XE0S$F.IB2!8LATO4(PO-3)<?/%*M^PT9= [-5]EN#OU6I:U45X\N
MAM)7^R*TWE*$P^_UM%4JO\#PIMJ6C+2JM23U\3V_!H 8" E2=.E[&KA5(QD%
MRIL#?)O=Y/#-2:R!MB=);3V/S<]]7>;HM-4LB;%AYD\$'P+G#H"G@G9N-2!_
M7EM  R@N1E14ADUZ;B3[UF6V>#?2]]5*GX0%7]*9 NL(,EJ8>N,0:/$4<UDR
M A7F#MY]5TY%J<%P2OO%5KU:XS*]G>T=.]FQ0J2'=WRH?^TUH$'6N'2KR233
M\NW#I?DQ/K ^!"I*EIN@/Z,HU0OP3AY-S%.^#]64(?S*9R'S]D'%5:9[?SL_
MR;?6L5"8^ZHV";A84'Y!NPE#G@4JA2]8X!OKOXVTT7O\6  OP%E;_$;/$5W@
ME('ECLUE>MMQ6N;<:Y'F:B;1O1,:MIQ+%:FBPR#>]:RW:G$,<62A#_'!3"\<
MAMRU0Q1HQ..#:[#L.F@2OW4$J#I\ITI@-%D I4<_V2OW]?O4D,=31L6!UW?V
MW@K=#@#(?VV=E)6SFB"Y8=>N]Q<84]_MRP?+:5%OLK$%;<D !7>XFC_9WO7-
M6]F03O_MT\]^2];5MVC>P40M7/S^A0M#\'LWX(Y[X>2Q((MNTETN%I_0E#<"
MW.J[[49FA(9$U**A+'Z\6%.4IE-4:OL]]$KX6G/[]/&2T+9>W5S!U+Y89!*5
M8Y+YP@MSQ]WTQR@>!E+9@4XJQ+ .T021\KC*>)-$BB60'Z8<N@*=8W718E8+
MCT4TT)\0[I#U4:1^QYMS,C/\;O$?',;*,0*( ,8I^$H(V!H6F;ODWR7GB635
M?#63CWDN#=DMB9Q=;>R-_2E\$F3CJ<.5;$DU-/3<1S&7(M\?P3"IL,$*N@;X
M];*CHS?9C\B;K@$=5HU\N:0=6)6C^#,B4_^56K4+SC.U2[S*COT?E<_X\(2O
MJ'RYK@)G5TYW7EX#;K4G7@,4MYW.3_A?10&&;_BVI?HU(-<=>GE.Z]\E7.@_
M+KUP=1DUG1\@>@WX4WM>GA$0J:)XN,\WJF@2%Q:P0L_-]&+DMM@ *Y1=;,\[
M_),\(_IV#NQ4IR7IL3\)$#Z:^729LT-+?GZUB3Q11EJU^O[ CS#CU]&R%X>J
M(H-<,KTYE+(R"';:+6;!_C#(:9TOONP$/GSPR\JP-0G :TB32D"A58E)UI ?
M4[)Z&N$G-G^A%J?A7@FH2F/+R%5Y?T*>^J%/:\BLS'>?Z5S[TT,3KFC[L>9O
M,Q>/,%Q]J?M56WXX[373^Q40TCF/8?_7PZRC.94C/J6<B<Y*>G$Z>M< !J4Q
M6IS]5B18MUL$KO$E5D9;L^WSSNY(W_3A6]>06->9. JVGB/"*G\K>W8@_37
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M?:N5OF]R>)?',\*Y[>0,576_0!V-@4D$+7];"EU\_=LS<!M:Q;\FC.\WQHS
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MDV>?SC&8OD&8UN2[CU\K3O; "5X0,Q%V?QPJ+]SF,5H(S]<)F"!*@;S;5[Y
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MI/5>;<:7 8=IEDUB,W9[ CXMR]B0QOQQ!G^]@_&";/I" W2NOIP#Z)6'(AV
MNMV2NBS"TF\_/@T;2;8Y=*5_:SAZD!N?D3Z+/NW\O"\O= &\H5C5G;=E!5'#
MIK>0TYEPVA_O4Y:11#UA*@F#ES,/-/!%<BG\XKJ?)7?Q?,VH-4?H4V:U=SQ+
M/6?KOH* .O:'K@&AX+&=:H2YU527LC%&;=ZQ<8!#F\QDB_X'Y[YV39*Z5?,
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MSW/?>Q_OA_5EUIKUK]^_9M9Y+N:LZOIY7T:X@MZ ,9F FS13QM9AA>D?S\@
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M$@RQ$+/0UIK,<&E7+\3L,D1/?8+7U[5@1=T.X5!EK 9V=0A*97MVXT;,8>#
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M9Q@:L"^S[/%LP9FH,<.?[2V"1!POW!]' \_<8P?VU3+[4A5S>:UC,EUT.Q*
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M%XE^8C*<>&ZA3?;NI+2*9_&WPV6Y\*SZUSHQM3S9E#-S;22J?6SXF[VU'@/
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MEW)1SOTGU!MX3=#R6"_T_D+W0M]-B<[C31*I-8SDO,6.>]:3]XJ)R1=Z)@^
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M,C28\8J+$($J7% ??/DB._K0>=;?<J(H2'K9<R?=4LBX5IQBS/3N6*Q (!$
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M0E*^2,5??<Z^[WH!S?0,K[<13<LW!'E44;%PO8#JI.6EKA1AM1?PQFCOGFM
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ML>8/SPBO!P72.X>*+X$>"[!^^GB'X:S%!7.L="&NX)$/76G)(U][AW-;>HP
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M5KLSI.-. C2/M,MC-5]?LE.?&N<M4221B["/ +"PJ WA10UBB(5I9+?L_'%
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M/]Q1GN#:\K7S-O96F/*/U+S"?\-6NB@IX=WLUL:N:0*A1OZ4P+RXH']&#Z9
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MK24.L%>+:HI'7M<N](K_3E5T49UK_UQ3OXV_P[K'A%%W*P<S+@,[L #>@A;
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MDI=;$!16Q4HVJ(_4R!F<ZW6MKZN%./TDEYQV?G&IYW=CP[+B;;@V!M76S"-
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M(+S4M-:!.A 3 ]:KG39M+Q<H=J%(=DNS >9Y&U+-&I3'!@ZVK[.T4'_$O\O
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M51975-8ENO/O)YJQ)_X!4$L#!!0    ( '<[65JA? MJ)D,  &9*   8
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M(UXHM=JEUYT->GIE!W>#-<@T=#!!GP!@HL*K,@MD?2Q>L I^Y5[V693+VG-
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ML6@YD\++_(8;ZLPB3YH49Y7O2J *^$_*[I]"R0B8AWZV$G]0H&R655?"*29
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M(H:B'#-DL54M1WH<>>6,EV5O:OFRF]G3LG=Y(?8>"8:W\=,[(-S5]OL1D-D
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MBH)VR%9/^(QZUI^!PW0TY[=SN[8EJ'->WX+@"/)9#EOQ&P^BTS7F$M24\D^
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MSL8OU_>5W'H"*[[RS*F3+-YKB$,O7+K))P9\XHV>  :V1H;DGT@(VT_,KNN
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M! 8E-1IR)V]E> +>+EI*1MN=1&S__R8 4$L#!!0    ( '<[65I\KH@J;G,
M )F"   8    8F-Y8RTR,#(T,3(S,7@Q,&LP,#@N:G!GS+L'5%-/O"X:BB*]
M=R%*$14!$>DE-HH@(JATB I($VE2#8F @'0! 4$@TJ4&I$I)Z A(+Z&7()U
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M3$-'%JK\*_C;.VRY^);\3N"OX^-AC;8+&!CC^KS2B-2(#_8ZVFST-15@X1;
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M^?W5-!7:O/1/#691),,5\4"4\)=?F@PB)1NOR3$47OV[;N>M/YS7'HVAU&R
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MG?>0# DFJE(!/4>48?AA^V,J8$AZZY0^/@RUF+-PX< 0I%>!GPL+:2TQ]$\
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M"S;M[)I54+KN?P94'@N78R\^UX=A0ERI $G'L>'?DC:_>[<V"\4R!_,AGE0
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M)2.0?/YV#Z(?XNJV\3ZEZ[5OMMS])$NL'XKM2-T@/G8Q'SX^W@["<W>@>*$
M?_<.RHWG0OU[58UB;UA^+6*:LYI&C]X1XN"\2&XGRN7H]A&"Y;50G?1GPP)_
M+C^6KPX.)ICECUI=N)H3]8+'6!OPW\$;O<S*MML!!?X:W?;YUDR[^H+6A4^_
MP/S78*\ YTG4=+DC1K,P2JX)&,00ZL-L*-?QF&'J+0*S__)^EI\<5.$.4(K2
M8RF#CD"]69AF-VJ:D*V9^>IV@#L-V_N1 DXEA'Q0V6A!V-:3<[!+A-4LWGM7
MAK\&)1>*F"Z?QBW$^L=OPPK\$V"N[M-LW5V68;79B&]6] U-H[E[=I"BUN?8
MKNM40(?[QU-@,$7%WUV_^GW'Z&Z>199N1G5CG^/EACC7M?U 0HS&M8&XZ#0P
MJ1GX=+[WZLM*[B(FXEXC#%Z\'H0PARJ/)-G@H#6%#0Q6WU3MIG5-GF%J99;X
MCO =@AEB8;-K-SQGX9:>@*P D59$=K1S@3^KC?F)'(5QKO0"!>B?U'[KM]9H
MSF;B _$=;O1^?Y"3JB*NKB54JG5W!M9ERRJ''+7ALI9V9,JC''J>8)#K= DV
MDY.4XTPW"?B\UTOPS@G8D&%8F[?%][],A?UOXOQ9* #^P2KTTHS1#W_V#M/:
MVK:C53<M_^4Z3<E7'\^1C'A/:G#@#GB-;LL"C07![ %!^J7/2Y>]VUYSEI6?
MPU_-/!2Y,W .FNR_;/&MW98)76,.4)@R[_<6U?'J_1@'8B)]Q3%@V?%)%A.(
M&A0'R: AU'"B2:;8U=(GOZ8MV%W"@K-$5LOT]^*SRMQ#[D7V3Q [##Q<Z'7N
M<C\;D(V0;K+@-+IH4B(P>%'H0!\'FWS?G7X6#O"IDK;TW<CROZCQM=@4@R(D
MZ;NH +KIZ7\8VT#N^XN[[#8NHU/@3<Z9Q6]!MZ;*I2 9D$K$E=HB1 :+SW?V
M*)1]/%<G9G=&^2AD_/M/9$4<9L%(;,:DSC5@E$GW3^SO\M&CHO/M&%C[%NXF
MRV;I'&I"YB5E( U4YX@5'C!*^&=K;Y(R=:1E%@X!E?P@K^3OQ<2U(PX0[.JQ
M.(6@4LIJO+MD<N60S0[R($@H1I W^+?XI2A7+T\+* =2*#[L=G393-.,^2R\
M.&K<_67Z4;:L?Y&?AK-NRF.Y[!,J@&CBG_J88$=\[:_;4;!B%_8JSO!.]_YM
MY\S"2^_-9K.8\>6Q>.8[->C;PF.HT;<T\KU9S:TB\3700,H"%<"@85! TAXC
M0=P,N\/?)O*X)K\YN0%XDO<^ ?P4VB[*V8B+W][/D9F-E#KZ^!/<6;'VYJT.
M#:EDMJ.-JVWT1U:)T=;0GI.^?E.VFVCAT#-C;?_"'_]^@/]K\?DJPVV L38/
MP/AA4^!P?> 0[?"_O'$L \CP? OW3+<\"]_/%2*&9Q\_A#@[_4>YCHZ[,Y7/
MU%9@?$=1<O_=>IGD^Z]40+. B3G4 M$K[#[9UVJK27 HA[P>AMQ%3/NS,=3_
M4K,2(Q=N;Z[],1\T;/;$@DML%8; '10N].UW0;$P1\4*[R'^>[_(KON..KA!
MK#%N?W$B'Z?\B.#*EKVT9G% \!DR$WT0XS4UMQ/0:2"DM4M.\7%GW (#2"*>
MB]$!,AJW;Z2HFU]130 L1FC.H+=LRVSO$Z5(8DB", [8KL4YMO+01UW/;R[
M\?I/9<F[.^<"#TTX_F44_AU,'3^1M O\G^K!GTW(80_ZU5@$WY9G2#@I!">Z
M/O[>7%$[ADV?WYF7+O$C#C\*'D=^Q]\!"D-[D9=&-9X27:%##07QL//YA=9W
M"[^6E\$A[F&MK2(!"$]R\>WD,2C+YEZ6Y5!I'Q401$-V[8*]CI8. AW])>>X
M85]$3<Q=&@WI9*)_?O*>IC.('3_11[R_)!=YB4YBAON$ Y;O8;<\^+&$GX38
M4_?@_MMIDDAQ.$FF ARQAC7NH?/"]:\,!)@N$N6!(\T\[Q""Y"0YY!3.J^W&
MOKMT]^G:*;HJ[LO/$^^E:P;$DCWIFQ%79$MA352 0AO*K?G2%J@J(A+#W-C'
M>>8G(16*4MLVI;&.1^]P:0.&U3H+E!,IDFLUX3!7!+8X&//FN5^/[#>E5LJ0
M=12>G2 E6Y^*HG,<R42-WL;J."0$T72!$A#9MD>LY2.DX:5F>>E^H*FQ-N^:
M2/9__>_M8CRNTC@AV A;>" &]5%Q1M@(X'^!D-6ZM"_5-*]E-CC;*M8T2.&'
M8Z6I@ =G9E<43+G>L!2>@<E+)P[W7]^4G8!Y'B93<IT+Q'H"?%B+Y:>%')D8
M#P1+.'[__/[NQ7K@K8Q0\!=437PL1<8_R7I4EG+)"0WEKN'<KJJ.C>KHUJB]
MNU(R#G*$1<&K&2*T!*<LG6SI&O"/8R1\:Y%-*D&HN9-/$FSC4S>0^NGIB:@S
MY3M0Z=S?G0S/5H1C9&P@H.\N@;E=HY+)U:DR0AE\%_(_ :W->G67SSH<?R(!
M))RI=/SS[6GW2 U##.+#-)D*B"9I013*:M/\?TZFSGT0>Z-<&R0=GL]H8N8&
M27=\)'VM48*RO"(-)DAG!6LB9JR6'*.X]2V4#* _'PSK#C!*P*X?&46"Z[1"
M%W?#17GQ:Q%-TJ6$&1UT>X#=HR<(]^#?GY7U">Q+\1^U% CP(VF\RM"W-CQ$
M);)<5C9]5<-%XO+L$EC@U&P67L'^Z398@-(U_:)RA&] 1$TZ6ODA_G+B W#Z
MHX0%Q1[?=^L!!0E4P+DW(Y"[[UZ,4KC\BP^'V_0N)4KM]:B<5(XT'Q^%D*N:
M+A.UUM.E-TW-&E"1BI_XWH/8)@%H23WZ'4U^P6Y-3[ \K/7&F[(=Z"7("^Z[
M/,'NWX2'+D+W:PR74N.V*$Q%Y>W+QC3:%?9#RXV (F&SODEV0>)DSI+=NMS4
MX-$J;K![EP\4MM">COX(T1-7D(PKX3_M$-%[V8(HL$]X=6^G-TJMZB*-==D?
M+<YJ_.LT'OR&!R&V3OC!<^U?75JO &L"AYBFA:/%7^F#1\:$6 VN'OJ>@DH+
M,:^80J\#\81GXC-AV%\.QIZ<KXFY_CVG9A\HPZ@:^@4ZI 1)%=<4>&OS(::D
MZNU^ZO0+0'#"U@1*0W$PI.$X#&4/8B?YQF/>UBH2N9FG)@V]6N57SS'E@I34
MCC=L^X@&_EG$;BTY<M+AG+;147CV=0,E'4;O.BG\UI/Y, EH(KF<V0/YIK*]
MGB[" Y1IKFO!<^NFCR;36:2F4 $UMND+U4989HR->,LTZA/I8:F3:7%=H&%R
M3U75:*T'M@GX-:5+1SJ;' <5@SS'*V\GX=7O#1TZRVE8Y,SV..09^-QTMM-D
M<<*VBF>\AM\LA2:4S;)?BWP=FR?R1$5J+Q?[9,=G/W<V](9RS(_C T07*-QC
M$\X&E?6'D(SQH'@HT)^R_#PL'6/OC'7WOM1;^WA(.+N[++ &WH[U6W;'9N.K
MVGVAJN,DA8*@#(VVKM=:[]Y#%WM.=$=YO,_%C]GY7(@84- 1HP*ROG4M#,!7
MO\?_F6^4SYP2Z)Y  :%,_G)=8&$M.M)CW-E4Z'![U7T/1S^B65;--E-NQ=+^
M![+3,O-!8;X9=)?0<HHB<8/UJ("/=9W3M?$^BGL;./!&WZK-[/6^#@NI^LL&
MCL&Z-\W)-\-WF$,>/.V^)G)/!=2;C^AB9]N@ KA0K]GC@:SY%C7-M*,=9O+!
M;D4N5]:P'BF '9/'YX50KP?IX_6=9ZVXSE)(RS_*;PWB5V2S/G\!O5NJVEQ;
MD>YT4V&_F M5!G4F722X$I]!AY!,$5W3L,[Z RM6_8>6ZN\C@5[)7OF^12VM
M#%%D1?SCE(:U\!HWS1W#/#_?D3MHYHF;O3J[[:J(/B<*!XD'][9T7K"._,.'
M5>U9<O)2\%].W2O0%WHJ#(HWG,@7R7"2.&:!#B(W>ALFO%5)2.KPX-L_%*BJ
MO6,D$H!I%FK:760(_8Z3:FL6UJ_&2\S+U%QPB#;+/*[>G W-2#^XY7']\]?J
MENXMZ\).<&2Z61LH8GHM^K!6NF##=-69EKRF21M?=,FLQ0^(>PJ,FH9&LL?+
M0CD:($KU\+X(XUL?+KZ=.2;#F.1>@/3O_N:)F50<)#!TI8 YFOAS_9,,U4MK
MU)_]BLX*#O<DB$JO@J9+CF8F*%P0PQ&D$(&Y%;O,+K#0NB:0<D>C:NK>L83W
M1'3PX9 7PY4OJH?GD<;D!-";9H/E[N@FW<5X 8(UP:A+2,P]$?VGQT,+)ST9
M!U+["Y6@ EJU7XY E?T=6T3Y<<CO;<L6-G+&S1,RZ?0]22]OKNW&G>1[:,WU
MB)SDS0:L-NT>A1+Z"TD @EF9_ZCQA[G.%_"&6M;J_LO$HJPI1.1!/.$:O,-0
ME IH3U^(@?(I)2P:<<R6*EE&IM+9B5I8$2I4N\Y[:F\SK.]EQ#GK6I85+-PO
MVCA"IV"1\QC%%*5#4T&&O1()S%?@)>@ ?"\(5>U(]AA%'3"=AG;[YA!;U0YN
MW!+J=1]F1*2>I7.C$ZV%:65*O?/"Z;D@=]@;N1MOW6:$7\=^IHCS9NKMMQGO
M1!7*/BSR=0R!=M;IN(<W?+'?9_O>%V_TQ6S(8 1I3TXH!S_&Z\:]NYC 6]/S
M68[$<B:8"Z5[>O+[@PL:;8+ZLY#>HM8^NO.#NWIE199E.W#OMYLBDI&?B]:]
MI#&@R>L;I,MX5XQ?R(Y*FNRCWC1BMOD:%7"/]_BR8"=$#C=(N08F7 5'7R9&
M%^M>GO8?6"RD AP0)6W$L>+V7BK <Y^7//UE935H5/M\U'[<XO\7.R\7C=.O
M?F>!<_H;:>-]FCQ< Y\7E+"X-8LW?M+C;=9QU9F8$!;VQV(Q>I=B[^5YQEP/
MGF1*B?+SK2BM8\I&;'!NG?+E%^AC><PF1JS4"^>?^US7.UY%R+?TW]9Z+-]Y
M&<[A#,<99++K#TL,?2=4+C_#'0Q8!HFI&LNLT/\-?Z*.'H.S:+$2'!>/VW\W
M"2ZYZE0,+^M:\\UN_[DY\'#'M7&O^Q%>KYT4!<#!IKJ/](9@K_O=.]6R8LM=
MU*JS+GWMOP6^3L,IT[@R8P(= O_D#P4Y&=[KLT1E$=LI-RJ?&QAQ.-]Z\ROL
M[F_1"#S"ASEAXO-WX]GXN]H?<.PAP,K!< JK?X,1GS4AP@9?&"VD0+MYBNT)
M$(\G?F>3!A_U#_L N2A_0!SOFL6Z@@R,ZT=[[SJ["09(N+6'&4\T9WH23/[*
M!=Y@6(-OGQDB>L(H\C))!O<X?YG\OM,79W4UQ?W\O+[)N#5P1]1,:_P W>D^
MI=X.YM4PPAU;!#W>UQ9E^O+0SM&^V,Y#/NS-?IRZV:^O[1>3X&6BX&;I2[_V
M=CO<)]E;YY4)WWR68]4[ H]##UFU]3<KUI-.G*&,)Z%9WT4))6!6V$NY"Q!%
M@CMFX9RE:T/G/_]W2GKW5J3-T.FD]XO#P3&B0,G^1<;(E\' &R';)P9M<)P1
MF&EC_OIH#8J/T-VQP$$%5(DXC&(5MS*'+1L^WY=55>F^;X,.ACG(,+> A35>
MXF71%JCZ,8@!>Y)F3'&(@([\EVY0YOO4U%U]NW[U2UKO" 9$?G_O)89PI)A3
M ^R3HCI!P^4/VLOZ^OFZWR^)3>Q'\6#]P9_D$!(+O*J-)-X\5B.C:Q"^.#>S
M:50C^R)5E:5^.70:F2X?(J^;W'7+V>+<8*P;:C$=*N+.00!;C5$D_*MLQMXQ
M3CA)CCD\]+O^V50#V) K4K(=_NKQ^Z<?[_CE]AT7T*W_ZZ[!"E+2RL8&HHF_
MS:??'R#[S:.BV$?63H5N09% 7'+GA@ZD.VX7(OS].BW?H'"_/M6SV<[?5YZA
M^_S5XR9@67P+G VN4>Z&B1"X,0MM@Q%(&AM%13D^(W%#K7Q.'[U<<5^ > :W
M&<QY(>P4'*;%ZY_43;F(0X7#NTZUZXY"Y\$;2YC4/L&DOP)_]Z-2;CM16DYM
MJ_+.',Z%.K1XBC"J*B5.-9BEDGLOA#6(G@KP;4H]>DJH],97+2J'-5D%L?"=
MALTA9[Z6/;4W$,/Y(EYB;:LN]:;GB:\B"%=]DP.**3VV2E8J6:^C>))'Y).J
M509Y\? .N6A1#A05$&+MA!2L0=^PQS,;L("G7&^1LYD&4ZYH_&7QSC#;;,9^
M$8JMKJWSR.\L[371RW_2NWA(;Q8CM_T4IZW8-8Y>&DA49%?HW_>]^';0VI&G
M;$S6"URUUAG/1.(BIVMQ.5.4)L2&=GUD-"_71/WE&%$*9">N0WWVW3MEO(UP
M["1>NSMHB+8?7VING[V2K4V%7OC+:;;E+H4NUQTJX!.0!G(._VC=L5-+H&J<
M"J@4AF9(TC/;=<\!XG?B>^,C8300&GR4"G>7%E\ENBEL2GBV\$_)1L+ U0H@
M*Z5W.K\NE@I8S*<">)MTLP=23[FM!OCV9G<B]SAH!3R\[I:YSVQU9W$C"3.X
M^]M:ET:NN"ETR&?>_]T0&ULN(1Q3#Y)57T6.$1QQ1BT+##)2M3C'\-+J"X7=
MWXZ>K9!O&2FVNX(J^5NH $Y7Y>GR?-RN0<.8G(/SCJ/'5,+DRM?]V>$7&H44
M)L-29PJ('*?82 6PNBA-KWSQPZG/;HS>P'_X-;=_33PFZD3A*(\0OP07@G:B
M "2%[YNUZ>&-[AJ,FF%-V05A*;<*O>)T_[Q';P+#H$P$J59;AF^MT\KAV]L0
M>7F[*U^YWQDU%ETZ18M_IW0#SVO(8P0.FQ66CI)=BW6ETI,^]5QN^$OK>;]>
M-!XW/V]@%)$E&.(@?2/0K4&M[LD#U_15I-9FDC^LY=867;<1[G2@33MEZ[F5
MRHY71&R8-<<MO;]F.5U*/P#GZ#Z<\UP0J":_?T9X7SSC;^^T9ND#KJ("W.^O
M3JUY#'YM)@PN/V+_?+:F<-S%P*?AR^6%;IC0Y:L%M14S90)\[-4O.#.C  (;
MW?E!&!W7)="D2[O-"!7@LA!W-"\A=&<BM[:".Y;I,B_\?FR4FF<,$3U7?1FH
M2+I<*RI*+M#P*8BC_XT(7@ I'R+RT/F0M0+$$0P;%MA\;B72>S>,]\!IPU;4
MY)?S6(1S#U2J+AWI\F5MGA,6]O'M>=<E5.1[B/B9!V+')6]15@>?U'VZ7394
M:4H/]4?\$D)>.8O_$.=;&U!Y@AVFQ'U.L_GT[HV2L55M<7B!ZY:'[*$U<-H0
MJ!!ENZ;\.NUH8-%0QJSREU6?>L#0BGVL-51<\573?MDY'F.]E_^5'EM7_YIP
M/D"0IV8))MH4A+=KF\:&(3YHR/!5OL#M9JWJ_?D*(<_:OVIJI_#S8^7^$0YU
M%%H@1;;I].ODTV^A,=7;:8?UCX4ZEJ_J<C*-Y>2//!>#][_3RAU#7B* =9M3
M!LYTO*5-YNP#QDM96,Y1U*6,*%0.(5X??U%.*;G(TL7X\O2@\ZW?/*=<K-#G
M$,MF/!L*SVT^IF&1'POJ4/@I7&+_Z<<]GG/+69,(0W(6R17OV*8EB@H]TX'Q
MIJ-_,VZ/]+TU+UDN\)+N*\Q0-?7X(E(S?4R,K^LD! FI7, X8\S4C0GI3]#O
M]4]/_$#:"SOH+(@;H4RY=>$<ZI,8KJL,T_705&X;RP546EPCA)PRX<X3NHD&
MP8,?RE"XLSR$]SGP:S/TZQ25Q#U/WHVN#AM6'-'O?UL80K-4.:.5O#7<V=;T
MRXZO^7G\8-7%**3%0],BTXPDW^/7>925H1--T&)1^J,L27>VPC8C8= G3C^E
M+S)?9H-C_G9GSJEN@,T@$H2XLS5$@]4.\[!:1+<-ZPTGI+K@3\PXEXGM-1#Q
MI540CJ!IET0%B-X [9E[6H)J4;$073SPJ ''WFJ*9]T-:Q(/3.CW\[23#RZ\
M(0"'Q^G,LKU'O]QW7(]26UP*9;=+%]).T#-E0)]'*5+HYEW!5;O80V]<O"[>
M-!>#.K^I%*X;1_D[VP1JF&=\<RC"6*YPM(VNV9U27I;-E6I'"=A,61+:'WD&
MY?=XC0KS29U_1I_YX>A@-3JN>P%5#>] B9(4< Y9^;C]-@["S//$=6W%I-]W
MXC2"=E.:A=L:,H]*EC)ECY_7&*J;U-<]E)6Y[\G]F?GJ8#;B3_RT>'LB288<
MK,$0E.L/?](\=N@ZN2M[Z(^PW[_B*#C3Z'<WPVZZ%N0>:V;NS@[MGTA16\W.
MK\WETM8X2I6-F4F\^;#U)%YSP]H7])COF13-6-UW\=ME8CDI4A\8%4\<\,*M
M@:G;[41'R/5*W'$,2;?(8@OY=.Y*"634ONJ<9]Q7U0,,RJAF3DW32GOLC4.
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M(<3,9,FQAJ0G)UFB(S_..[<YZ-J23BV_"1+\]N9S6GDIH@<CI,VQ/E(0MYW
MI90&L/@IZO:VV=RLM_&3.5<+W/6;R]^TYBLX!FDNG,X#UVFG^8*PLXF3U\QU
M))=F+]7G7'C S*,G6+C$5%;0GM'5&&!:8[Z@P_X9W >TZ"PSYXMW??01"6$:
M'7<SLCJDZ!X7D0T0Q01B]C"<:1GX3/F5B:;:%;2B@+;J75)QQJT:OV9KX??5
MKIB,TMIF%]G;&8^ -X0]BF+!!FQ $(ZF848;ZE$"M]#Z\.WG?[WK?7:@U**L
MS%^\UT;C>D:SHHGAUIM6N@Q<;Y(EMHP3+AG^H0/7"[B9DX4-N3%\=N3E^ROA
M']U:AW>-$9,"I8)H%REE1*MFBE0./*?%Y=4T]K9?%'7#_-R15ZMMC9JTB_3]
M#%V:Z<N5VRSYT2W^\@EM%O:6+C3?<5@T/C8*%+7#FW:+^\M'/9HZN..CMX_%
M*3L-]W8MC6=4R(#K1;_!B+L)1*7Q%>1^\!4D-]P60_:>KPH(%R4G]!ME*[X@
M25Q_U.%X(9*;.VTK3;-&Z30!.!W=,:].PY<P/#A)!%1F.5S;:*1T5/O@A?WZ
MH--8N6P;YK,VP1+X&0HR0Z7F'>HBQ:6B;MR5< NF=N_3P06W*J<3(.5^3FK;
M1I,\VJYA._'D>%%/H;>'D]SEI2]>"VZC8"!#N)1A0+[V&)\GJI9Y;M1OO^?K
M$>GKQ67N6V^2_GZ+KYL2-OXX,W'K7IZ-G)V1EHT/7N+&<*):+$/?-RNJ+\42
M -<EC[$.DN>3"9"/;(#"Z0@!M8_"$V;1IA=+3I@M\0@PH92D;%!JFUY5,#KJ
MC-K6H\:?.A^2G9M51G,9W>1,AC@;0%A,'<_VC!%9_WAV&&J0L6<ZDK__^8!J
ML3@JFV<I]YDP* ;Q?@>9L#DTO=$E"E,G$%:P96/F8G.Q:JI;(GRG<ZER%-^I
M)?RU!C*$BB#C$MM.?\GP'[_X1FI?0D6ZPPEL/,VMP44GX<^G2R4_PNUV3]FP
M]K>?@,G3P2PQ.+ 6&2JFLY&5U[TGZDI+[JG"=P9<Y+55+_,+G*PC$T7.S>/4
M@M8MLP$0N8OJ.!.3F;-\95H_S'YR4V^R =DD9C%X)2F/#2APF]SDUSP@IUD0
MH! @HS#Y 2G^^@U:  ZOH>2U"<WH5BJ78D4 5_!QFZN0[P2N%2_I7C8@^24%
MA)\O+4T2_5STC#37PN>4Y6,?E/1$.=D0?%]I,\;I^^*[%/S*3'DG^)9/)B,S
M![Q0P'L<+ ;7H_RJTR)Z2U)-D?^]'V.%%*.+K%]^<F-)_:PHQI 78X8VIZ6M
M$#16\1"IPO7O^4)CCJ:*'NH_)5"%,M4MEH*TU[!9O$-B9 .W]"U1L!(6--+^
MP>0I\<:.2<J=:NLIR@J^-+YWO!"L1XMH4M0L.9]EZ_[D_[L3P/_^!;]',;8?
MA>O0+WE4;:=MG3742T$HHJQ&#::4Y_96%OPLT\GG)_7<"6*83?;RB+(!@BL^
M;  &Q'RLP9 X-]J;PP;48SIFD<DYHK.P05L(OMSV$$ K\+9XOMF56F L&P U
M#R= A*C'\9QD^X$EGK:7W+*Q,(G5,>[*81UX1[$8?^8_\WB$=.=8E"C))\5>
M:P 9% /N:PGJJM+%$;S_=CM?SQD7FJM<>G9(T:3Z;/:/\0,21PS=0QNMOLT*
MOA-^O]"EYLT&; ]&^!RBA\#MQ]&BB$$E78I(O/%T0TJ!J*=7@+KZ%>[KG,#+
MS]>E&4?CUZ:*[6@D8 ;\%_-(P^X(NT/M81GHL'<*5(GGBIF3A(7SNKKX^I2/
MYB^%3E>^[[R 4.?8L$!*%1O0[1"+X*-(E6OD5?@N#_<;Y$VWB"$/T^JHV6T3
M:%,$+I>O2Q"W_[N'6X+S*/S)SM6O.DM7UCT5[8Z"2HYXGXD4^\CSTB!LV\=(
MJ)PBJ=A;&A*B;&TQ=N0L&Q#)R46A!1:0C6SJ68I4*SF:^HY61\X'[?==L90;
MN5K>7.]]ZOQ!J]33NOJC:Q&9Y]:A"0C!<4PHDI\!I642H#(K;T-9"@_OW!QK
M; U,4ZZX#-"%*02DN<GN;+==@$1S#W[2'J[_?FR8;^]85-:86P^RIB^C#4FI
MH^JUW._KQOE1,NK7ER?,YG9D&56%Y^KBMUMR"4B_6;!<,+@QLR=/L)=U""D)
M,6IQ?GYO['--Z[.<1Z>W$8^\K+]%U?AEV8X\D^DP?0V28YPB#V$SC'1.]YB1
MDN("M>_*_##<-Z$:U'OK;O2"W"4X]J\/\*"I+(#[P,FY>J1GE"5O#*7L7DAQ
MZ/4I0:UEJ*C_N\,HH]Y!>46*KS,2>P$.8@.*'N.K&3)]+ .QS/-%;74LN6*.
M@6-*5 LC%WK!E&*6'&J!I<\AJ ;6G0VH24<23PR=+X&V0#XB\:\00#9@^!QY
MDB7$\:MRI^F<!E58Y]R2,.0 $.V3_N+0+!^^+1\X86@\JKJ^B=M_ZG(T'(Z^
M9'I@9^-]Y>[WB1FY^:5J.*R=E5&^H/RMYMIW?3N/>'C3Z9<I/O%T*[@?S9,B
MV&$GE4WPUNCVZ!:+OVI ;\@JTGAY5>GI&S>J$P6#!2?.^+3'5'^?L4XVC&X>
M,US<^M ;Z/.AV:*5T/:KB.X3/DE/G:A>Q":R5;=RJ?E'P)&&\'=F%^\.8^=R
M7D2!G_3-V&Z'0#[D4"MHEGR,1[_/NOQ/V!B2\D6_WW1[\F?(_OR:Z_]:";SA
M##=D ^)EV(#>6 O[M/4A6FAF/!NPZ=SV1W'F7TK^47&)%?H'JDC.RX4%QCGR
M)S;@W>YR*)6?X>B(H74G&[!SR$>.#>CDE'+<F?!Y<C0K[8^/\;UR\KG(*70@
M(V79@,1L_.LH-B#XWYT#< :U0+])R\87;X[M+C5@RTSK(QC_RO*?"/"7@M^J
M\9&<R)P\>\#FCU+@;H$"*-5';HB9\%^VAOAK:V#\2Q:0"";7P@TS?4G_+]S^
M"O!_0I+OY?!OD#B1D?^!T_"?7O_+2K^M ;&ZNUH82$_Y+Y?]K[B>9X"X_SYZ
M.O_?:S'^+?1_+E,TL+ZTHYF,8.ZQ;]7:;$!2!0W,!IS1^KWT+P7_NAJXP;J3
M?!VA!@L&_3: _\[8.86@C7^/L/]4'+<K#!:6:C (&\![E W( $3E22ZBR.,@
M/C;@6^E_%(/^4L(5\5]-0I7VWYG$WB&.OM6PQM@ OHXAAC9*^!(;,&;UF\3]
MD^05 /^%#A8@=C\W6]Z-$@:5%>^*V[^W"))#_ZHQ%F>>G9V<<"I KJK\=YGX
MCPA&3OW[P^?T..3 "3GPMNC_"(7N<$;__Q*]/X'?[,L#OT!&=A?>A&L1O/6[
M]XS%@:DQ'SXN+I6M*NE[NW#O/D72I%H,KD9NNM<6@1^2^=[B[T6+QQ).EGLW
MS<>"Y_LF6L\LGM'5+-B3A5[[=63XA)(MW0FNVDQ;).OU^(C4/#XX!B6]A:B6
M"ZCRB*("[H+E&-1)M!)K9%Z5F<=Q:;'G&1KY%I8CI-NP="_K11LY]*)\Q(N@
M=L3;!:=S'?!PHB?T/K@.AW6(GP?2SN.?MMDHOH9 JOL7M>_.<=F?U#XZSHQR
M$Z3;P\5I57C0S,<3-!QYK:N\U\>NMB^B#'NXY'ECHE:_#,_MZD]R1].T^3I0
MM:!5-H"BX4K[21$G+'4C15#[O&AW9R"PF\N7A9:_"BDED $*DP]HR(5MDB#=
M["+<A:R7A)"W);0+]CJ?S0IM'"UPEZQM)9_56+30VKK":;,?7(OIPLDA/H!J
M#0=>P6[2DGM#UT-53MV]5*6=4<^_K<3549W/D@[%U&O$84* T@P'Y/2&RW.6
MV%/G$5O>]M0S16NN>JU@8_O'.Y%Q9Z3VE#TVGXP*>[V]7QZ2JNSV<,^- ']3
MWPZ*UV0W+B%?F-93U%E"F\0V^JB.7GKJ(-FP#OWEP1YCKI6[D)JR]Y8>E^ :
MY$JJ)-F/68+0 HK#-4>'L'C%<H;*W:_[P^+#F&N/N"]'3!K^0)&[D'4<0HI!
M19 +G,B6VW8QN61J^C)8= %'[@+5;3/%D)QWC-D G[99@C%#O!7?6\G9^V_/
MRY'YDNK7A-V]S^YL/4M_V9I2*% 0\<((&$H72..%*;.Z?.M8#@R//]H%KJK1
MP5EL@.IS;#%K+I,VV;[@%/>K]2!"F9G $@0G-;@;@))F1)Y7VH4I>SHHA"GU
M\Q^W.4 U'&* F'%HV6\XP3:+,A@;T)$+3(&[A$&;'-'7-[1'OC ZWBZEWZI^
M1;8X=-WB\-7J\+E5V.'=SBF.2/QY6 0;P)5)&_6EBC%1L4.,PT@1(/T6F.CS
M\R1@JTQE$;F/LRV#+46G84.]TAX8+%)X[EM.MF=CYM6#&JOOWQ(<K:\V6:Q4
M<T)M/Q.%^99-@W+:P^QLK9E(./+%(['\B"'<I@V# T\LCAFU@-!E=8'W)6(2
MV0"\%,VNZ"=JMA$S [K2U+>CY/"\5>/'YD",?W?ZC3O%JEDGE*39 "$5NN47
M-J"GG,PQ#$T!+ ,,N0M<1V8#<NWP0XR];,#*9$O$SY&*@\T&7!OE]\"7,N]*
MLZ0F=.J1B6B%^O&RNMSCI@/-3@H]_%:#,.RE20OR;=:^#7(Q%B-\4_@XQR^*
MM!F^AKT2O-ZT_5$T7#MO5D.64;DB<*J *B%$CF0F@(,(7!S-<N!TQ@LF_II-
M%66BDHZ245@430C9V[Z>!J"MV;(!=V\Q3).)O6^KYF!\6&>&Y7/;)$$+C8^J
M/3?W;:C.?KH<\&*RE W \K-VT6CC9+ZQ&&;4=N[1$TK"G#D>I(.1PQID'(L;
MN;7RP9+S=J>9.1^!LY=P@V/APO@JD7FLQ_TE+ZO3H)G5Y/F4 -.A<DEJH@0_
MV8F^#S$TAQ:'18"V5I&]CQ"[Z_H[.)SQ^FS8(>X^!>DP/)@)"!%D5RT%S%!F
M _;5@VEGT9UZ4Y8#T%1S$D9WQ%X_MY)\GBI*.\VQ93E=ON0<AL8P&*_)&KQ'
MMR7=^IDSU#?T+C[]*_KUE^V%D?6]!_/%_S'N)18WB%(&WN4O-X>_'&P2W^X&
MBK^]O8WB]S-8W6!1RG8B>"$/(_*:90C#N(\S]N(KJ_=X3WOVE83D7U2?#]08
M\&^OY5^;:==BR9RF(D ;-@S3OU-F^X73B2%>#K]$_\ZOO_-U$D3,I&DL=5G8
MNI%+6H <6DY-SX3ZQ[CJ[_.M]_AY58 +]_5P>-^YG;)T1Y5.MUURI[ !#W^'
MQ?8W7G'&KLX9^QX4I?I.45S^/HU5SGR>SD*[D"*\G9UT8^1@,S@10W; )9B!
MXNIG]:08)N3Y2@(_EEFV[*>KJM;O _M6 NQ"EY<<\(]3 OYI'9>K=I>F@^-Q
M-,A?D2M3G)P@NC'&IN!NC!VWI2H9O*JR **% %/ L^!]]1C:"<O^$&;:E01Y
MJ#%TK5'HB\+60+0F,P$9M+:C.J\ IG(6MWU6[>V (E>GRGRL.0<F6RH2O&'3
M=IP#4Q\#,FAY"-EICI"'( Z2#5CBN])3=:S/U6;KO<<Q%*0>%'7$=##&I+I:
M\O[W;.Z16'-YEHPU%;';P.]D!.,3,$&<&#-XSJ&V *>W[VD\\.U7K$X<5_FH
MGDH#9U=Y_R9?VMUK5K3A0UZYZ6JXU^U.!YH&1]*%&::CG#U*D6%.GF@@P/+/
M1T1E28MQJTC(FGPKM;8?WWJCV0. Z3&.Y'"V%#;@E^=8S&X/F30_\#0;P$HU
M3@:397;QF= L #[:1-(T)KNBH:DLM;%JM (L%"K@-3W35S9U1_6INO=\A"2I
M50O7<.O0+KQ,EOCO C;9/IS.$1S0%&=6?8R'R-]%=2/S/JXFI^OMPBR0=HHE
M_FW)E355LY'X0@99^W-E:4GCQ\_H.I*O;WY2T?&F+0,N/.9/DI[]&TQ_T+&<
M 9F[L]9/+:\^!_BY?8$9C^"V*YNSAI KL5ES!O9O39M4((^/._AZN<F23[/V
MK9!;L4B1F^W'^U! <\,J6KZ^QDRUJ\H!^%NM_KZK CLSZ0*\,&/&D>15)@>5
M74GAB,%D"8?KXDP4)YO,AMW^?6Y.)S+3X!RQX_E"MLJA]!%$&@AZW+0K'+'W
MN.N9"5P^*2A_[!5/LX_1ER];ABL!NW1/9HQ 14"_2?FVE29WI\-N>*)^ELPK
M<#X5P#+\@JP/8HAG=UKJ<<0TN8 6N) I#(MP;IH(X_CT/ ^P6;_#FO_[P1O'
MW6:FBF+-1<%^P&F&<CSY.38A5I^5CNS-^R<!X C7?*BR/7$BUO(Z!;.J0C:!
MG?9DO:?9%2!#F6F^M7>,:$CCD.FF_.:>&VQ W1*G1@E#EEQ(&>J*D6>)X6I1
M)-'H:W)0_>@8@HA^NMO$ZEFOC1-#;X*YNSA;Q1]QP!FZ+ZL=],<B<>#Z;97:
MASWYLIP_\;V7\B4[@))J&!%C6\\S ; 0!I?NPP>>(3X7U72Q>T;"2%E9+R:+
MRG>1"&#9@).1\AP@UMR_I@'(UDP._1? 7[+_X),L16MWHT!Y-)!W:)[XH:3Z
MZ;"MYY![U."T.Q/G'/*DX4]XPDF^;I'%>^+RA?])4-B K6__(5B_M>= FVPC
M<'HQVNV%C%OGT"ESAPHF>B5W^=(TAKK"@)TK(41@LI+<>&3A[8B#S>ZV\8*_
MD@26,EMEG6ANX[ !F0+KO^RFG) %[^+"VL4%RFJ/QKXX5!%W[6=!T-_ ?)B@
M5G \N,$M]0U#98'&T%\X7L7+3WS8?\K3YJ;,FGQ$WE1/S"\O*BK6N3H89XZ_
M"#+@4I,$>D4:."J':A;%_<NS;YSD@A1 :2%2HVF@:MB'#R/'25;C+CJ%SW_(
MRBQ(414A4UI+0[.M>-<&2C+U&D4]$3\+;5P!Z'1+_>S,#NGGQLD6QE'FWU*.
M4Q-HM\D!6%2]42%%(C3J2FFT;"NYV),K3,CY*.#0]RA0*>(AC+O7E04F6R42
M;(^<::P,4ISA'N/U(F#4VMPH9(8S\S%#BVX>DB\W(=XW['L2&B'T8/_+Q>;!
MZ&VFUE807CH>Q]&R+IP +?0BS\/E*+C1(+$PT"GW[-75OG.:BGLENO_RO6<(
M&[!7E-9,0>*#XC3:R))M'K>3Q3X;%58? @4WWE@ Q.Y0?-KIRK Z3TK?ZO#"
M7,1%=+;+I)[VQ<76=[W+(-4]4PRM3N1"!4<(#8 B\ /CEK*?ST2J8ZIG2ZA#
M"I>[7]4*_0 GANSN[6Q \) 0K7*A"G675-AV[P+YR;,EWV<J7<<6,S]$;Y:.
M!8'H5C ':CK-:<$[FE#/!L@08D-&[R61QZ2^-U:*7I?DSO>L(* KF4\LM4)1
M<JR],,]>L_'8T08+J\_UPYI==5J2GXL_$0U_YM!/LJ8]'$CZ%(\A&XKB?&4!
M7'FD'*>>!Q$UEKMWB*4[9;(V@[%!!CID^ C01LD+7C"1KAC]4\.E<J&>#M)/
MW$+O'K$X$C5R(OJ,A-.%?WK^>;4%;:F(MM+MP_W<GA9=.?/-;'.]B#.Q.5V\
MT)V?:?=)]Q]_<_GBV\!' I8A!L!"2Q2?TG*O[Z\O[_><F0V(^& MNZE4?\32
ME)+9C<K U +[AKAIMSUHJ6R H/&O%/.LDHGMB2+C=.E.?JX%^N0XKAY)$L$(
MOKX*U\=WVSD0@E*R/W[:A%]3R^1UVSPS:$.M'ARZ"VK0BX.?I#PA$J"]X2]A
M\3UAM[*^W3IZR@Z=FUCSCN_N'<DMO3Z'*0PAIWMMAM<A+5^ EEI"B\P?U'PM
M]D/6!^(RNQ%VP"\B?_PP\=,'3E('97C3LBG<!+X>;Q4"*%77<+9*DICA=T/(
M=?U.NH(Z@)@>LS=F%773;9$CI>!.]+%DZF-:\G76P<S5W%\R19I$K=B U/32
M*:WJX3CSG<GO13$SP:>&?S^@_-MEH5FP62"D)_VFEB4Y/HHMFS/<@&A,>2PQ
M'9^#U->N3GY%]F6F@"717"5-+<DD>=Z7%-YI8JXOM^=TIO83UEZ+<VE,+<KD
M/?$.-'#"_!35V"QW>6+M1I@.;^ CS<%QI8:?4+HM:P2T%W'\VTSI?-R"<"1"
MQ[?(VN^&GY:Y^)XCL._6!2\#K$=QXN"K;( X0X[Y$*Y'1(I]>V!-9,;PN$[\
MFGCP(O_[K)P*F27)!0P/&@SQ%;4\ (M:ZL;4_RT*477[9J9>4CT=,.&0S2HY
MZR"[[(H)!L=A)-O"Z2(,@[;QU]6&& D8XA9Z+.R-3'MGH\KB>_.'O,>T^M '
M(3X2S%)S/_+S7VB&Y.\QP&ZYRQ3DU2&H_T&OC&?')!6Y7$TMZQNXJ=[1"$E#
MU\;3"D>*LYJ=3N[$N8;V"_QGB3*<JB#DG;U@I#]J6@#,0X9FSIS;P+^^A>8E
MNV2O^(H;TD!TLY&CCQOL2IZG B\!3+:K#W'6]AK\(BV.X]-P8J64_*9(0IZG
MU=A ^[MW?IWNM4YGN>^.YU&RJ=JTH2KX50JJ&R,(=QS9O#P6 ",1\F7SHZ-/
M8+YS<\6:D4V^MH%9^T87@&EN'N7=BE"LTN&FAMJ1'[I5/S:?96T@X7[*AZQE
M.JY&OIS %V9$TET8#K0, E#)=\57MH#F^?*;\[M1AD$8N2E:AO$B/;YC"0U9
M8P.FL 1HMUX:AE?;<"@E]UA(U*.$F-Q [[)U!7@MB82:P!R#ZQ,<$G?4GQ/#
M5(BX.$.2 R&CA['.B;\SS4+IL#->4<:6":*^<([:&&T.I9K=[IBV[I9N-5K_
MS#NLC/&_<G]2@3O_Q'+<*7G+)BN=%]3R\RKEX_S_04O.I;6$FH52'S8S<Q%B
M1@TE?6'&*7IO7$=Z=&L#K$S_EFXAO3/Y:9R2R9#8P-^J(F8FM*BWE[C;5:)$
MOH?/>2^37UYYB#.-:$(?W1F)WF/N2XVA32*)0ZD(A>?NS HY;ZNORQR?L*\\
M#J)_].N\J?YH0Q228\;NH4311UGCJ60POB\-B>>M&R593E>L'#VEBH+)'N8R
MOW\&WDJPK19!C(%E6%*=9%O\YUS%^6P#_15I5ZK_O&;C@XLO*OIDS/,;5I%2
M#3:8 -SL,_0A6N:O[6/F*M4A^:=]+UJ_4^TY<2EFO9D1(K0)G5JBWJ?,#?6!
MI.$2M&0D,$7OYOZ!H#<I5-L;W*(;]_-,J]]I;>10I<@3K11/:CEEN_=MR5S(
M/! #5$*%1[7*^;LO:/X K/D67YCH\CLC<?Z?GI@#[I8R-BM+K+@X[6.$NA/.
MW2,\HTL4?'S 1)%\AZ&U@:26D8=ZH=.W\144HT+Z68A<U9?M/3-##MX6*L8B
M41G3)AU?,;93L279L7SJ&"/SFP',=YAK$ <![0T<W(1L)@M5D=W??^2 >.:M
MO1'+-G$_D/SUR/L[;,!J=A&)8@ BUT0F2_-=&+?ZVM00D1\+?"%RM\VZFPW8
M;VF$Z,?49V(S!2 8T5F"_3/"=(!-U0]20IA8?:N\_WU6LN$69ZL'4>BGF(]9
M4N4IU?6S]S[>O%E36U?KE+=HW[E:+/FSG!Q-K2#KUE&25@B3O2\CPZ)['!TR
MI.T:8Y][6VHS2H!K0%:[1L%$^:H/?@I$+GJY;/;"8^)Q8,7)UO>MB1J9UY<@
M "NDV>&$X.'_RU'-\UYB)BOV1;''E,F-6;P%4.*(MC/MH=W([(%'*.^I@9"]
MEH]U)/CYSOV+=$76#)58GQ%Z.<=IY"KTR\D&G^]SJH%*L34EHPR]DF#2P9H1
M[:L>)QL&&FJMWT4IB%@W0(9/*. YILE&@R5:I?HPBIFDQU)O,,B3POZ26#2Z
MJE-/>_HCF.3G/H9R!BB,[_SU-^FOHLJR E[/INBM5JWA^2R]_V:KO#3)X_)!
MDSO?-YDEZ\Q/GG\@HQ!/E:&Q 7V0</\9 /<5L["7P05"LSI\]B-+^9XZ9A,C
M(8.!#^<EK1ZP ?4GOM;O]SM1_H\Y\;N+;/+R;)69+;:O]+<%TEW@VK1H@E8>
M7[>27MUH9'1 :E7IX.+.)[XWEZ.&WREM?4%(,"O1DC"B:XS^:4ID?C&BQN;Z
MI62UMGKO021 RVUAK0_'S8#5C5UCB%<J>N <4*O;.E_JHT&C7[DM--\I)7Q*
ME:C4#%3A.?+>,!L4;R"C^^2KA:"=[>/C3P+KTTTLFWLA$1*.RE+IM8\OR1PY
M$/]>N2($+3]2?Z<DM^]<[=M<!XQ:0XO5P-:!"(]Z1QY/^[63SM>4&B1)7^0B
M7VR[.;^6^J1BH_WF>D7!Y8<Q@&IML@/)D+Q-T(TGZ$"Q.VU-+59W%7"^@A>E
M)&>W&]_*P ,:N"T"5";2X^;?^2:@9.$:E(]880*0]WN0R\B3*[&#_L&LR.]'
ML 9K]T R<#VR+9:OVU*W+<=^A.>N>O-9)<>$S;EZ!6 4X,<-8<E,O)[X<KXA
MF9G47C172GU<<:INULMZ^-.FX=M_P/U=\5S6 RM^BQ6PP["V ?)(R$Y,0V;N
M[!>Z@9;,K2T3A=SAHMBC:^9J1=^-K;ZNG1G]\28"90:Y<'MH+'WB8;>*RP7'
M5\4 S0[NF;*B6+D7X>D"D7\ZN^1D)_#A]9NX\22!K ?6A5N[7&@WQK9<21M1
M-/ZUON98S 9D3Z_G2MR [<O@";.Q/8JG>N=W]M]0:4Z][(A(D,.< ;C4UC2-
MAA$;ZQO31F; K1+\HF[?^"1#_\6#*A4"S[Z> V-GKF6%&U#- O,>C2*KGLSO
MS4"]8'2+(.5&BV+UMRRD/GHDG$0&0)'71/"*8[\16 EBP+ D=X+7=4+X6)\#
MV  "I*@H3O3,_K0C*86B,!=N /#<80]-F?_-(]N[5Q_/5[03LPTM"%->XMB/
M'.*^-F-_EOH]>[&R,G^EZ]"CO!&;ZNB:7KL[3:2#Y$$V@ CJ6).F:9UK::H=
M,ZP$UYT.CT3IB&Q=;33MD^#:<-C]FC8Y,0P<" +"YG4$^LW=J)Z?(ATT95,^
M$ZL_^;>5XW-(7,0*9  PW4?GGH<4^L!(@XU_77MC0YIZZND%H<.QL*WJM\@K
MH+@=3,?:--:6=J?2]R+N^Y.:SU:3KL_;GAS3%TU/I[2TZ7<A:S+O;0*G[Q&L
ML1>WF,IVGMW;Z]Z>WE:JZ_ZN5_&T0<1C'6'#, =>BAM)E&X#-Z!%D)<(@V\)
MSSUQ0M^!"AKGTG57:JQNV_;QT&]6_S*.L&#<H4'H-HQC[RA/Z@+T$LVO+2\&
M2\D<[92O.! D^_F8Z4"47B]P*K,'*0H.' + C]5.WGP>XXNM4\V1CDA>#Q1X
M]_.(_L])6THKU9:BT8U3@LM.&C!][1H:R>>Z]9QCZ$N'7P%SXDCS3PH+B9CZ
M25( T5<<'C%N*0_3ZIT)ZJ(#@5UJ+1,-QE_775E[?]H#JFTXZ5048L3R".TC
ME @2HHW\T ER)G^N4)X@3>Z[+?^0BX_; NSQD39,%Z0UN="6[E# >$RJP7'%
MTTX9SFOV%,6<&9U:WF/2?*8K U&852PYB #$<G!J*<_<RA3Y+NWQXGH/CY+\
M6[JJ*,_<PPM<_4/+#IY)R2".83.FY&TG8 +S_'4L"9XA#:;$NCM^_N5^IGZH
M4R95:R*PPZ,<&[@JS\P(E'"RRI<.\?SH:%Q7MFYOAGI>Y<EL0P Y]@D3)!Q]
M]M."L=EXX^RL.U??4\?%1]%$DS?1U A:<AEK&%.;CA89W=+4:0L(*3'*>AFR
M?>#UDPB (]3G78="FED<N:^#Z4"LCF<# H5/]UKNH1CFQ^%U@(ZY(04NO-%E
M\\:\[\UCM#;=J$C*#FL<5-N85P6K_+7Q6</S?7[M]8%SXK5WFP$[1,.O2!&,
M/TX2=IP*ICATV>9!SSWW'"][Z%Y=#*3>%.K(F)8E+7OF"T2#ID!4\\91>.3K
MBW/S(0\^2H#]-)BZ08/OB3R7\\\(GOB\@%QXDJ\QYG:6EKT >9ZJ,<K0?VUP
MZR3N>H9"=@-':ULA1!1-'=,Y$-2! 1JR 7(0LF%^,=%S]*5:,9.&[U__&"4F
M')-A=U6=8XR/_/_]/\'_UG6YG:]=PO%@FE'SGJQ]FFAF<%'.R2W%N#;FH;,*
MG#G(3^6>[C#9')!PECZ)+0T,08L/WSQ>^7S@N$UM36L+&),_LS=C<0E\E%N#
M4I3F;^@0?K%E*,D@4_RT@@<Z)^AEGS@T0W?AXIZF"AX%.<V"8JMYU;N&::KN
MQ#,"%<5<U@62AO^#_R#+GOX_4$L#!!0    ( '<[65K,X9@ YG0  -Y\   8
M    8F-Y8RTR,#(T,3(S,7@Q,&LP,#DN:G!GW+MG6%/?M^\;>C>"($V("(B*
M"$JOL=%$B%CH$!$0, (" @%"@B!=1$% 18@40:1$I$1IH2,BO0D((?1.0EV0
M=OB=Y^R]S]GG?^\^][ZZSYU9(\^3M596UIAEC,]WSBSF'^84Z.@-(U,C$ LK
M",1R^ (QQT'70&RLK/]LAX7]<./@YN!@9^?@Y>+BY.;GY>?GX^7C$S@B=%3@
MB. 1/KZCQX\*'A,6$1'A!XN*'1<6$Q(6$?[G(BQLA]]AY^#AX. 1%N 3$/Y_
M7)@-($%N%C;6-#:64R!6018V019F"PAR>)\<+/^]@/Y'86$]O$=.+FX>7K[#
M$RJ/@EA9V-A8V=G^N>O#HV&'QT'L@AQ",A>O<!ZS=.8ZY2M\Z=GK;&[9JV6-
M(K?[R'*J#_PB>'B/BXJ)2\B?5CAS]IR:NH:FEK;.M>N&1L8FIC?NW+UG96UC
M:^?BZO;0W</SD?_3@, @9'!(Y/.HZ)C8N/CDE#>I:>EOW[W/R<W[E%_PN?#+
MM_**RBK\]Q_53<TMK6WM/SM^]0\,#@V/_!D=(TW/S,[-+RPN+5,VM[9W=O>
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M^>X0^R[)-#7!_F?\1>*\$9O(5)8X$#H#BX&6$1J)"6A)\OK'>@VR<8)R:HG
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MH#L/W%>SR=Z=36G]QF$E#MJUP^IR#F'Y<]%'=%<OLW[>%E\V-Z?*(+F:T:S
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M4SE9W$F[#^N!]IS%L;1"SX+ELY_@'M;\:2-IZ?Q_%!4FV4"1;7Y@EU<JVTG
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M_%0YJEJTK><(,GX,6H6$WQM*M\CJ7Y3S<'UIY>: >K?1K-)^S:F+RLGX7:\
MG%5(J#6=)AY!(AKQ8ULY=D!0\^<3-N.%#WG.4Y/>$E6D8!,*"GK"E8D+=9ET
MGX'.C0W_K"#8Q";^4R4!._'G8#[^3.&9_SDG_7MNFL8"9PS*/-T+D58#[4P0
M9\JT9A//-8T"G&??[X.LA-,6"R]:?OVL"2S3!H4W['*M/3IG5Q=O,0*5JA=
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M_/6+W-2_.&U,#SU7<>:^GYD<K@4IV+8-[*7-^&*GL^GPI;NW;W?GXW++8 /
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MSV)Q'"XC@FIZKMW/E,(TBU>"[F1>6WM^&09:+ CR?/MB)+^XU>[DJ8-;-X_
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MH\M&!MA[9[GHN4U6I#R)O9O)_)WU6WXB>T_#C<>W.B,DY\!/)]G;OT4[7/;
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M9["G1-46O<^KGADTO7W[?_P"X__;_Y.Q'T[\+U!+ P04    " !W.UE:=*%
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M=QHI]PRQL;Z@5$W4UZ\U1M^+&>1MK;XEY62SC+4<FD"Q'P.=0:U2#]^_1DB
M[A6_[1@_:YT.?R/P,[4-E?>%^R!CX67,$%&+G (B#TTCW>N'Z"(3.>XR-U3^
MJ&*/L$L/22@XBSM[_WYP?</+UW$%5!\%#&A/\NZ!GH0[<B7#92KF?TW'OT^U
MJ_T4"0=1\QG]6;G0$B#SDL9RN=;="..S(X&?J04::!Y?-[%&M;7FET7/ 6'5
M>1=I!50YM\+@+FPZAQ"(NI :)#C3OP0EK3-,L 93QWQ,UV'/#E32\ONB]//:
M\]5<E2B7@U0C5,Y:7^_>8Y(X3&V!A9@FO?OTWJHT8M.+ZOW; <&/ZY>WE6^2
MG1[8;CH0#C[T@5](Z'I;@KS8&V%Z!\\55"AP=X#< SJ'#R>-_U'2"MNN.+N/
M:+DUL6HK, XB60*6]S!_=6&L^(! WYAU"FJLDGX)%DNQ^BU>N#AW]B%,Q#TZ
M-]/D0 J/[F^Y;B@LFDJ)K6KI1 OI>1 /;@4P=6N-7U"AM#PL\F1:Y_/B6G81
M^!1B,?Q^[Q@H. :DOG;?SZXG[B(L$>44U ]YA9\JB<C&.P/2X0CMD3SN^]CI
M**=LII9N<^B-LE_UNUH)%.?2R DSU*WO]0HQ-[JL&,:W/M'/.83='#**5UBY
MX"!JPC%=<:]EYW HO=?K4P5]?:1CQ%S,2AN_C0O3,_Y_8OC_1 2Z*>H@S??9
M>%=[;9#>2.]CH$MWD2V#S0!92$;)7T1_.RQO- C4W,YHLXK<+.^!WD7M,U.\
MCH&:N'?(W_J50+0K(HCF4J+8E1;D9"=MMU'@P-!-]E #\07!?92')"@> X]O
MWAC?Y0+-@WC)VX=W([W^SD7@39=[Q)FVN%R*7GQGZN:-I(,&;H%RD!X4 \62
M=+*6Z7&K4)"\KSAD%*/W6-PEZXHT$*\][WFW=]'U9'ALW=;D @Y"K-U$^@9-
M87NH,NT3!I!()[)9:,"#/TMJOG<54I8<2Y^\D#OJ-Z_C?NYX$=> ^ #N'P,,
M^R"2-+IXCK03-92BQ[9T[@[WG%^[8)MS>,OU$KHGJEK?/C+VYWX&1/$W*1K_
M=GD('ALG+@$Z$S:=NYL%7RYJ\^Q^>]#_E^>#W]6FH['L5L57JBR,/$+Q.'#A
M/M,JT\:;#WZP>I6^( !^"DP@"2K=[!"GU\KVO6XDG87B9G[=?T64\()?V!54
M8%6M8CG;5MO=F,^-[+QR#/CY.ZQFZ_H8""^<*C$](R5E\;%W^+O'=/N;"2B^
M$,:\R\4&UQL)S9^ R[R+%*;,J74[<8R=7WO0OG6^]6^K<@V?[);!K^D'0G[9
M]:,NB.YVUA:P;VDH)?_T1/(*22A]AT5/][V4BW-:6-PFH=%7TA!0.#O)_[/:
MM:?=Y3; -1#$2!W4"<I XE^TRX-]Y2"J6TC\+/'/6YQ)@U#?1GAU6EHH<NZ)
M%5GUL\4)+I:C4?0XUR2ZIQF3B?3B2CP]WOA0N>2#B\^PXEY(]<.S<M?<7Z(4
MNR6DB\R_:"00AB:].Q"GCI[M8N/"FQN37Q/S,&K6^AL3YT5V[^9I<TYP,W=\
MM1A7ZX0F5<#%0/O7%%[0B[!%[Q,AE!]EE1)$]O>M9S)].1%\KT7R0TZ>/O]U
MIJX%XC45L!SIJS*-[CE(W@Y[.^'1:!_4QO]@SJVV> ?2E$QW#%SK0<#A' UM
MH,V;2(^EE1<RGL0RU)F/8]EZ+\E_K]0D]-WNSV>V1EXP?8-X2N$&@Y:XIO*I
MK"(D\7$5UO6H)!PTQ2?L8M@<U+H@6E>A9DOU]5_)W&2%MJ^W+XB:"^-/[RRP
MTMQ>"R$4:8V/R$ (X-Z#!7NX>876Q(,_*W_7YJHV5U)RLXK#XFP?&N[EUK"(
M<0 (6\18"+9O?2@=!M'K*S0).NT(!EW)?UDSDQ8=SRR6G#@_N33NX?;[T!^N
M>@PD#!S>H)P@WFCXLHM)'+=KV'K!^")MB<>@Z]+CP[OMA'8:$ J$*[<=O:BC
M[2W=)&DT)E9JU&(*P<#*GJ.>8=-KGU=.)%PVF&7N[)+5$R6?WMMPQZ.Y*3Y@
M!$EG]=;$J!M1\WG0&]\&DLLEI;NI$"W_:V]YO_8-WLOU$N5DT@8H-<1CH/O(
M@HP&#0]U$5];JOANUI(L>ZH:*EB_B+U6U,L[D.:;30\_O(CQI2G@#;>I 04.
M%1#?VS6;6'[Z:+U://6"I-AUXJ/Q,4#_Y!6RHWR3*Q']T10'38#5:=:24";Y
MCCG=S4\;<](4WA/\11R5'9X[\3ODCA%>FKC$BB7J>#RIIMW7G:(VBN "483Z
MQE1X %?2[I$;QYVC\8/1H6RSW'CCEHT6>.O'!YJK#U2^Q1H"E#0H+X4%ND%Z
M*#JR+KOT>/Z\N-3IZ1G9[#O,]@.J6W,MT>I34WL?]=<WL. YZYYW!KK4WF,
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MK:1%Y@/W\=9"A?OJ8FRWAG]^'[7%)J[]&=0:TVQK31!K6!I(W^R@:_W*>1^
MWD$(1OZ!I,+8*;)+"OZ.BDH4PS=.:]73_9U% D4R3\Y(Q5^ZYQEEGQLY2FX:
MH0@?.H!0O,N\>&O3&,6T[*A=R576AEVA ;_I*25]#)2*)X%);Q!P<.O0:"D_
M$^FQ$%LPCD464_3&*/2EL'EC;ZU<<I/;]+55;?9NYPK?3V(5&Y=6&B#X]MQ#
M+5JHO$'EC83A"GK+%SDD)XRS_PP.W6HYO#(N'X Y!H8%/IYO>?JY5/3AW,%W
MIG4O 5 -[Z_"3YVX3C$$$Y:X6"B7P*1%'MTT,7O<=(4@68=O0U7N0C\+<Y.+
MG'S)K>V<K%FX!;A,"G$X>D+E@^N1(I*KZK";:$$WGZC,9I61A][5"8K3/'K#
M3;.EF]F>:IYI87-%K^EW<.3BHZI0[%1:-Y0SM-(4-U&P! Y=S^YB4?(VZZE5
MZ&AY=EXW::O/^D_!WAHEY*@6ZTECPHC^!1ZD]S?=+O$SXUOJ;:9NLP<FU5&R
M#F_,-^E=KI3<.I-SGRON4?6%$:PQ-!"9.$JQ/7K:+NDS[G9[##]:>+/F?+;T
M=F7R"_FLN6XO*/YNK/[BIV,@'<)32>6F*)'L,ZHJ?HX%U''H!)A8F+E(]5>_
MOU-<1'=Q'?:8JGY4 @\F^7<ML&Y1=&76(8_:A1K1U_.C[VA[C-W@?[J]?>)M
M1Q1Q+JZO'=1U+B1G-Q_54K6;FJC=*)R0DUN6 $ZLQ#/-[TD;O:+F.ZZC\+UB
MKM&%*<S2R_Q-&:+')3"E['?(KX:"ID\L7B&27Z01MMU/7M3$<E[SI&K\_@&Z
M!Q]J_J8%&Z(EDHL2;'!F8BBM[LB\=-3=>5%)\;;.TR>G%E'"EV'PECBF$/N@
M0U.X VFA#YD,J3T&<!GN>A:+UEQK!B>'=]N,#(F;TS.NZ_DACL(K3VJ7'2C/
M]N.F!2^WU@.(KS:P;%C-$19EP 'W!%/P:4ILW6[\H/<'$';]::1WS^GZMF_C
MA3J.=>_E/YR7DC[/(-'_N:7FED;D7A=T"G<-I$$$!A!,(]F[D@2QFDV$F*LA
MI8XRI$.QIBL-WB'"_S:WXYB8G_V^!&D:LQ_"?A1*VPT20_1AV>LS'I #3&_F
M6&>S*%>)MF8S5\DDL%U8SIR<D/X;/?']%F!CS/\_E9NNX^K>X<RIJHZ9@/C;
MES IFL]?04"U<+#$:E#-[-,%\%$/3^N#9DC!?'?P&;(J9 X5I%9RHDVQA<Y>
MM<>(Q>(AM"D,*?U@L9J[RR;7=P-;#I%!S$+JV;&B\ <'@@F1JQT'BF^4'M^[
M#+.ZZ!^OPS,F>ZBM%R@!_TU8X/)S4YRXIQX@/NAJ=*O]^>V&^L=>/\,O L@4
M?)@&&O8.2;1>F'IH( +:J22+2]7VI88],W(TDMNO"#CE&3QMSB3[R863Q1WV
M?7+#C2]!]7-OP8Q954W,PLH"A7Y;4?_TU*!24]MN4 VUSC3D4 ;QV0FZL?VJ
MJNP]<UB0J)L)XS?J;.6KK*_GO8MW$94;YYF&G]K !I_-!L"[6JM//0\Q/P;L
M7+,.8ECYB6,_Y*]^H>4B%]-+_SYL= 1T_<1&/@$YO43HHT@=S+Q4<ZRYBS8;
M)Z2K-X3PQ#-#HS2[DJZEX[D- 50W!+50K=*#G1IRU&R7)GZ=. A-[YIQ''[D
MZN1"EVEHTZ23*6UK\./HU,30,5"/H3SZITCCZDTUOP09&GQ$7.I!R(W=^3BB
MI_5A32O;?%E1<_R!;N ./GBB#5%$[4(2KU8:X1"2HP82%)_&N+,UH<VC<&GA
MN]VEN=F;B?;+%R4EK*RTQ%DA5XFKE'0=V%$,C;J6I!Y28UGE7OUW*:GR<4*F
MA!96JMRJ2SVT;C82'=]6MNT\!O1X/NNE8HW5IR.,+'OF]*T'K:=5R%%MH$9%
MVH"4S&H"1EIR?+G)1P23*]NN UFD'^-QLWB]-E$@6.;_[O>>JN."LYE,8J2S
MOQ3]$T/,.!<_Z&%)0B=MU;FZ307N''[^>J-[_F6R?O)%";+$:<IG$$O$7@>-
MEZ*_G02?WX'-3[MZG%@\834A3N$VO5-&0UO+POD3$K_&P8E%;.70>(WHPN'E
M0MRB@3J6*$.-&<)2 ;AG/3B 3\:DF-677S-\-XT1\>SC+#U$C2&D7MB_G5B!
M=D!2_U+.@"E>'W2U1P*AP_6G[%]^KS[LB/"\Z+XCU809-9/-7&->21AW>'W]
MUZ\'%:\]N:-3]Z_-T._*4U=Q2O9K[::XU:8@<KCLK-O/>C?7B8&_TJ]2%;H-
M[LN]2@7^E2C\E_IBM.M_037%)ZFCZ!I([#'@-P>YVD#R6YCTB[J2H?RRTF>[
M0BO\3763D6I-KLRM)[?^%L=S::PN,"/Q+]!<[8*1I;=(EJO)<-LEF(#;[^W?
M*161J4>R>2/"=WQ>]#R&0/.^-L5,,L2>M(KFFBZE9<QCP*M\BV[&STV\=<*Y
MI^#1Y.7QVM<P;Z\+'-\^B:+F,XMRM\;HMC%Q4'<T'<7@Z(6>#='>ZD>KL59"
MJ['ZZ-R\JTO'Q.<1Q:OSSA5T0+=">LD:DOTAC88503F]O[=S_%:JC"QVIBBV
M%&P;NT<$M!-^-F<N)WPY-#@5E')IDF]9-OLAQ,;F$D21$D8#*)%P*/B#=#H(
MXK2.D"%RI?TIY7%;,Q!L<T8V<)2$2.8&/7MW_6KNH#;#ML5;9*>V =^OA5HR
MEIC7LSM@J= MI+D75=4H-F9ZLR5/6-!LP&Q8E9'Q/K\)P#XI?,=ZK.XZTU>H
M$ TV+7 @5&@=(0DM,W,1%NU$9730FU_SDJ-5'JCK#F>,;1V=!R8IQ?<2;HC(
MA/]\])R(H[+4$Y<(03T+'/!K=225]%VDX*\/RU5A,58*"=BLTFPUZ?VDA[HR
MTR>:8WDNR@8'5?A_0?JI3 OVD6&@<<S2G*G9IPFE .7;C9KA-16!O?;,G"L,
MP2^^,R7"#6E&.\#/DU!INW-!)B1(&H4M --B4%D*AES/5%"H[,X3$=?LD'FV
M*?UNB)5)8 $L)Y\ #1?1-#9A"5X.C7ZIBVOV7/G;3QZ\KU+2+)&$_N9U>Y"0
M?+O_5CH V,YLPCC@_ES=Z"0# 5)86^V4(>:W77-%^,C'NRG>"5[,9O@G$&%R
ME12^<1.*1Z,0"J2A)+B"S.&: 4>+L](M-^>'9M*^9]/O:>LF_I)>S9ROH\-'
M(2F\CPCI44F)NY8W>Q$&$QJ5K&NZA='KFW;"+&933G*LK>R",O+WA7SW9]#-
M0IN.4HXV66,ZY\_D)AJ*)[XT!N#UQ$8J2Q\139!-,) !D>;YKFW5I,V44<R,
M35.\N9+$T8K@9(5"[<E+'9\0'D:3JR6@_R$72$^PW]A;7'@TK4'^1!4C0:>M
M2I!AP6RP''4+/H&PQQ)=KQ+ZN;4'0]S$EI"@_)]"@G6J^ 6B95*7-5]D]C9.
MY\W@\V"#YZJ?17%J5SRGN7/9KV<5;!GPT-*;F9XP*;_# /IC)XAM?9PJ1PPL
M.LA82 @LA=6[])8Q??&::^%(D(@UE,H,N20&/P8^#L7^@7KY(V,MRR.3(W58
MTM?ARK>IWY7(#<W+%)2*R"1J%QF1V3H>U(,$98=PUFD&K$3.E(BP*M_3C7$[
M+0$0$Y)F?GB6GT70"7F3&LUOJ/X_!)-3U:XMR08LT?_V\GOGF]6$52LHN[AN
M>7D=XEU7Y&5^]TO'9*)>H]Y]A;EV4>K\_"F24*>* ,6*A$G<125.*\=%-E@&
M5)SQ3VOTM#-D#;CQM:<A;L-<XL0E1E3<PD<F'#:>%RR]\>CZ1*O-(IIG\EN9
M&XAR:W'<XF6Q]Z^X(F$K2Z_86;A,?W$1 _*1A8D0W-84K@?"&+KIW'TSDB:6
M^G/+/[YRP#,DNRN7FSNXV2]_ZA<O(^ZO04%%D^1VN^HP8E"OW3QC=I 2W/BI
M1/K2F?#D 62-#,5_W$"'.A_E_;A5"%\90=@0+)*I)>D7^OE_< WFJ'S7W%BG
MG?$Z+;0H9LS'YC7JMCD;Y.DY8&\A[AA@J@N*A;'N0  P:N5@VW2X-%OWX:XV
MSY]3>IAS\Y^3RU:>Q"6(>JR[_GC(M-%&F@Z:IB=\;5[^DW.4]F'*-4UAP$OI
M8ZUS9XA(L7N3D5$(&W^@3=HYI<;@W8-_&93_H_@W]Z;_Z>0QL;C003\VL6BZ
MJ40*#\I8$&XU6GSP<U)OX>YHJ3[O.#3/0%=0^ &T=1/V'M:0U&UN<)HZ:*"$
M;<COQ[8GA+;<X>3\/>/!\T=*]?PQ$(X5+B<C@(&1#!=X'I:5LO![3XUP,8=W
MBUUU%YE]9!USE&K 6-8'22=?7].D(A-W;$]GOJXP<+R,GNM"+L ]D6%NV#NQ
M ' 2V%!8/@9 6617#Y&I0\3U[N*<QP\]FPMCG@]HW7A#I%EC&A*#:8#!,L8(
M)M(S5?@UY%R7RFS9'TS>U@H-5Z)"9+H4E7E5_>?S,#N4$ZERF%1]XG]\58Y!
M'P/^L'TFT)_:/$3);H_]3U_$ZM'CT'_/_T;N[@I1$Q6V#L#_=/Q?\QT.Z8]*
MN$"Y#/H;E 7P!/@;VK?$OELQ^\A>?4@IO;]W2;=@3][D>D<\'5,\5]0OW$2>
M>(4?+C3,/5BMRSXA*KKG&+!805RR_Z6U$402:PT@UH>6ERV\BXP9_Y:R]IW[
MFO010&,T#6&DLC[H"5021$#/\-65(M<7(?OCI8TY$IRQ,?0!!^^KC@&R"BD'
M#%KB/^WQI6'4N3'[Q]C.-K^P%-3EO0WU")%2<"-3Z\2:T:L5V$3)P6"8B7"F
MPQKNU0U8(87KNY_<*ZP:5/1_P$C_44C64Z74RU!AY$:Q'^3 VM]MPNW<H3KR
ML^F2RM%3#J-CP'S3A_ZG-:B8\;[]$\AQKSF);&%9Y6JB\J5O*D6S]-O0H?8<
M:%]$'<&>5,+>MD8M,%"<B0,]15+-/^ 6'^H;:KW+_2 ^.3=M\X"5:W+STGRJ
M'^\1&G([!?8PFX:'XI&RY(:D+B(XLN=4_PBWQSMK*)@5S"\9=%XB[&FKU=7%
M"WM7BZSU+ZQ".+'XYV@./2:2LQGIQQ_LXH*PZZ]LQ0+]I!0-@:;&:KD(XT9F
MX<?>C'3W3M!)%/G0+V\E05DJL?@22'U?7V%0*E5ZPF.T51AY%OW*IR#F5T*
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MPAYDF=^?HK_GURVH[75*^"?*::R8:T@%/">[$4W26L1TPSAHF!P__W0ZL<T
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M]TRI0$[R,[;QQ67ZS9/%9& 9$J9YLJ-D2B<I+<*1$#A"3T1PO%9]7UX"E#Y
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MQ=2J368$KE*?&U;;;S?-&T(, _Q<$A*>;=STE!C,B(&W6[8FJ@T@6>B"XT<
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M>9S#\+>OWT0B?ORRXTY:^7I"?DLOQ_*[27N(^8ZJJL.'ZW>4\F;Z^SG5O#K
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MU_S:!.%]0YSFX[E;/EJV8.7EX4\^[C][<UELA!^C/'/QH5T$C9\NW$@&K=^
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MU TC0[6:L8+#%QAQ6G@"._[]3W<=O\Z#0A_,DCPKZ^<J,BME>=Q(*Y"T:3$
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M4MRIV:1WEH>%<V1H++;R$QFQ!8['!M:^6W<KFP.M+/CGK1;0:,B]BL[9E_;
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MYOZ@Y6"%Z$\!7K55#7>*.PGY<8V"#1CJ7J[=WC"AGG<_&-<*HBE<[']M9*<
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M Y$B"!V2WZS.T.,7D-HFCX;(J-8>MC@U6MWV0_/1%HD)?;"]:SU6BCD\5M^
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MPB[(5>Y_?VQ?X'V#KP1RIF^X'?D8<>7P)4;V;UZY34IM'NG=[2&Z21F<,NX
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MN.0ODW*J.O%8A=_ *-Y[3#RA9!-99X?_8]J_6/;_SK"P_Y9E_V'8_[)K 4"
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MZ"_J__BZSC#;EL!:OC,**,AX@7&%37$V%P]>RUU]$D0')_!S.J:BK0OG&+!
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M/<11 6*E#-!H$=S-&4H'_IR9_*@QU0&FW$<TK%@YG;N3+>QQZ3,,*IH%9VB
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MK\;FPGN[#@)<HO,/GCI!K9/]9_);FC\NME5S*W-1:(T0P/I"Y!0JH&L0*)$
M4+X9A@9$MSJL:Q^5L]?JIW>;W-0'#M#Z9EO*FL>=B21+44J%2- 3/+E@D+O2
M18!S':"$7L<L8X>J4ZT8OJ(G*4Y.[JG^-O&3BB_<1CE.!?_^^)3RXZHR#$06
MY AW#9>E1DI/B!(S+B.I81 DZT)"4>%!@&5D&LQQH7'FA.RH'%]YL;Z/HO7K
MWW&H5.GBI6L<F(X/#;!_A;"V]@X.<GEM\:(.&BPKY<F1D,:WL]\GAIVW&E1"
MQ=9<]FTY W"EC0WJLR!$^&[<D_5 8%\?ZGMM0O8%/U"WV2SV:&'T52HW]R</
M%TZ'!>G9(() 0V_8\!4(9MB5&$6"$)L=OK-3-RVIH_M^>9SNN;PTM+V5;6N#
M\2,E_B\U@&CF9G,S,4Z6%5%TQX\XX#/=B"S=E/$XE:]IFVOE%(_0;+:G6EWP
M6>M)%\SU#P1].*.7>FZ^%FJ^&PFU'X];F#NV0I%-7TJ4'P/[R.P]_1@W@%_W
MWLF:IL8[O_[.?=?I,?5Y?'D!&Q",";:I#(=0M7H7^ZUVMS-/EZ\U-=72MJ>N
M+^YM_&Y/GL8@SF@W]J+35SC+PBJF&=BIKP"_K\1D>-8UR^V-_ZGH8*&]P94"
M.<A+:G9 ,DB_+_2,VZ^*]1UY"1K@V%2Y8*>:>65\GRKM71[$F[:K--?;&]OK
MWW#LP1PX\)Z))_+1HR1$/YS4?Z=5SPA1!*_I #]M5<% ))7Z16G#BGH(R102
MQDY5:Y6FCUUG+-R%\^5#,F-R7K8$[L8![(,>?#C,U^DZ(RW'&:YA%"'-AQ/!
M :MK:T_:P!^>#RK,?J&_X12..<O5HT[Y%'B?V]62^!GXFR\+^DG4"8)Y2&72
M'U=Y*2-@0)OXN8[5<9 ]6=J]K6S6G7.^X&SK&35KY:_K2LS,JT^(G,U@JAY:
MV8*-6#3@Z4' >&2K1;8([&V&9#=5>$1;Z\9 /TM?91HSU8[=*E3&24KC/E]6
MQ$^QQP(7-I92RA_E4&2/HFKX(_W"\S&9>4/&)+#VA7;U,&]/E3<??=)G]3-B
M$8P+U\YQ!.=V05$4?X4LJ^.U+R-;ZTS=\>O^?$</,Q5,QS3W!0VZ<6G0AY.J
M_I91*Z@469A$^6F<Y>_3*&\(AEG_>DLEHM@YB*<0H:?I#+J<G&&N;C3^^:65
M^8/:-5;TVR]X=^$?@ Q_'IP:_+FYKV935ZZGS6!\@Y=G0R*QF[KU&6=,%X]]
M@=B;@JZ?@L T3M*!2=Z"^HC!2E$$Y$[9:94!2>504 B5A>9VKFOC6CIR,R3%
M&YJ@_H:ZTOFF$:WA$I2F/J(G(@0$)]TQHL89N1 "_G"<'D;!Z=R6N2#S8">W
M*_B!YX$SI@)&].MT/1;IBIXJ.2Y]:JS0T(M4D$\0TWT!2-@O\:KF4_="7\W3
M&%?2 TF7G+6F=S154^\)M[6*TUHV.YYL^/[(;^K $KUEDWP",.'*#7GR?XIM
M%/-*6V*DJXUB71@]B;F2/QK0%UCCM+8XV::>9#)I-A5S_DQRD+6S-JOR'?TO
M7YH:5L$#HVSP>)UIL0@B7(QR(G$]7F5?;WKT7*U*W-=3KH=VRX)QXL1U=VF0
M=(M)NH81@-3T>RC!>RM)S-5'"7M\=+.C":S6P*T>FKZK5(K QX-Q:V9*/P(^
MS$6]Q3V^@,0V'\=WU4U'@XE '[QQ_YY& N=$CTSXJUPK]MTL%E[8<]!T'N >
MX%X^;K>M?(=X9H?J@1(1SZ/^$'RX&%O-!!8  KC?!R2#"C/VJEEY"$H)2 ZX
M':4RBS^N.U1P). :GJKQ1.A><L8X'N^)9/JHY"$Q9P8:6J=HAH/3WL2V5$B!
M4H\5"X(N8;+Z;7#; A'^1"(R)^7.5)3NF(K)+47 DQ5HOV^+:DFIAJY];LPN
MT[]S>Y[SAJM#-"!Y3^Z(V D-R!FUS-6_V;SS4N"%T'>JYKO?)SD-Y;">CNYQ
M8>U:SK:-:\)/NVFDR=9=B1TS?'+<%@1-TQL#1>V+LM^FC!/\ZIRG6& -6WT>
MA453@;_N4E3@!S9O3^DQ\/5TF*,D7?@:N;Q4(]S?B47O;$BQ)X1H6'_@YHVP
MERIN:6<RU1Q9;JS^<*_B:M#UB:>M=J/GX9?'ID':,**L'&W[#+[:4^+%">8H
MC>05J=[,HUXL\1\C22GT0SK)\ES*@C'O$7EKRV4!B(8_=BGO61PX#@87U&BL
ME]B2PK^]L6%7[5_2/QPU<?9<V\DIKM%8+RV7G.?7GSJZ=>[&";6-&*(X%VZ:
M&G^]&]KP=SI#.QI$%)PK&+QV$];U.:GQ=R/7[F#LB,-7M719JZ_\2]9N,I(
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M(*J57^["U&#[/XDZCU7^:X?;'8*-!FQ]\6-%=?@ ;S49?+S^I9_^#]XX ]"
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MAZ0B;M:PN0:.:X!?<WMG%NLGA#4%-V.'A:J)'#7?F9]E+INM2>@W]2"N@VX
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M%*(^I'"25.,_7-"=:X "4_:L0$OU**$R1*F1QI>-TN\4-I(UW8]&AI3)D16
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M_ZB=UO&3&C10%$&D.?OA/5#VLKM;!EZ2_RA:8"/*S,'E=J)(5TXH6S)KPS#
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M<J#.=,Q=./_V?VSR?KBD?S.VSR!*S<Y&RY)?%Y2S*GTE_H02GG$;7KEHB=3
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MTM0GO#A=/JT0A1"==M)C+;IWKP$XXG84^\[YXI=F$>0Y+%Q,B!;L*R DR+"
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M<RN>?EBP#+JI]4G9*1-^4;..I\:G1D7/;@XKIL!N+ORE\J)&*],%#,+J\(C
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M=;GJ4".VKMST<8*'*\&:+P+J1KGF9/?@P2,Y=\='I'OU\BXD@^;[I]M;[F>
M#9U]3MST@D>,TPMJFMY'V";J*, >O<&A_7#US$3#6( 2&FHJ5LQ6D'+/LCA;
M#P93 %!LO*+9SELZ)U7ICJ"C,2A)Q:\@RDNZ*I;%,>(!3\\K;AC;;A1!Y%J
M#D$ETHVZ>'B9_*$+F38YLI)*+2B9OZGS_F53M<O!,R)I+>J!$<\KM6ML#\=/
MQUKT&YCD^1&:NJ-<2D(EOKI/A3ZY]@9T/P:P#6B-5#2S!_7[]1]%[+K(Z< ]
M<J?;6!_.FU2@4DP7%^/35UK7"G1,M*+)0HCR+=V*EBQ]<9.-W>:?C=>257_/
MU%+BI;FJ YD_!^B-_8X/G[\UD<)WM[&E:A_V1ZP!PR2KBJ L L<&SCM\E7G/
M;PY\\[X\W: FK03ZW05^++2P:L3UO<C2T=9^3"?TH^Y*4V;<X;Z?(*YLOF]
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MY2M7):Y=EY-74%125M&\JZ6MHZNG;_KPD9FYA:65PU/'9T[.+JX^OG[^ ;#
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M:!B5,_EYP)(4B%@T'UO6]=Q_O_]::5W@(GB^F =<=BSO8K5 8+*%&JZXFC^
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M47G5E@-%:JR.,C2H6Z_Z/%FU@HFI^;^<O_"7WUBLCOJ8&@WH/]@OLH$%W&M
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M<.9P%*<>V1&L;M2C."=6]0%N>#GI428G;\KO0[46])9]"Q_1(]:VC@1<?$,
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M^P@%$0^0J6J:""><+3V6/GH3EP2_4+)A1DSGNG2]NI.CZT?O0W!^A>M:_.(
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M:7XVI0 ;P?0O0Z%M8*&)/9 7MR$6PNRF8M80(M/O5[IA^N%IXZ7''E<_(:M
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MG'?7%)+;;_H$BX6U^M//7M#%YI.@>&BO_ZD,WC^U8FVMB&3>3NV\)4V[./W
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MOY>]>&;X8RHW< .WC*6/C&CL6;V'CR"(/'JI$KV^=U@UO_6*7E$H)TSNL]3
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MY2Z_MX?J,K<4XJLF_?EG(A'.TWD;%["CW3RW\,MJ.YV]VJXYYNOW975CA!*
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MW)>8W-*4 2^:#821#O@P&E GR;V47A?Z^33M?FUE):BRZ-K]7I+B3Y&*RU0
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MYR&[4A>QML;6%EL%N=0I2]ZFD\O<49%& XG8M#3=:S_6<IA:]^R_0Z41U+5
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M+17A!!L]^"@%W3!#%! :SLLS[EJ_)R?X-F"CG>8>IG"D34[#14Y^NNUASP6
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M[_(^,:F%-_UNJC_M-2.HH@%C_]:N9/];NU*^>"SSE\H&.B-R 1@U #OM B\
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M_[FWF'X$C+>]-A-\&TR_H34*T9$)6_M^ 2@ 654Y_'GG)YZ%/!W-"@G,E,[
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M3S1T2/=/0,?]%X"CF[8<9PP7@/XV9\3QL=\%(#\]/O?_T$ 3\DZT3!6]W)
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MRWW5<*Y3[&1WPKAI73KR$_@W ==;%G3$^9,OLX30HO7'D^B<MB? ]-QHO\+
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M9)-H!_J4ZQ$'9<> Z^-SUG&05Y"]CI/#;+*+T03_R#KNWJ^T&/%O_TF6R;\
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M(E ^7_(<M"2Z4V.M:-?3"W)X:2?*^ONN&2P48&?Q+L(.B<G9.UP"O9&;4WF
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MO,..'V^) 7;4DE(NUB,^SW*C]".5^,7CF](_^ISH1%]0__"?$U84<%QF&=F
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M]K9Y4$)+0B=JMO_*U]C<^]'F1^U4M8EY+R4^+L[=D_B-=CJD&CM2Z@98YC2
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M(04,ITS+RS5L;58<:PS:LJMT^9K<4-^S%ONF4TN^;$2I)KL=).$0_/E1?"#
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MJ0K,:#Q'+AZ0OP!Q0)FJ8@4OMV2@PER]6>?IY&T*V27VR;'<=R^^9A>2P\#
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MP/:T3-9#@UMK][_<YA;VO/?)ZKS@[<'=TE =!/8#,IAE\B\+D7AI!<YZ<WV
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M0!AN69PM^C/J_-X4X4G[SE1%>35$68>O"\NW-5_^)827L]6>@S;!\K  /F>
M^: "GHY=,D^"<"Y5!3, , 7*=1\H /KING*GS[$[?:'[PN6D7AN Q-GO7H9N
M73\X& #XGO4H!!/H$TF7 U$+J!KOY$/'@Y&$,09@6'ZH4WT;1N=KWK%]@7#F
MZS./-4$V(U(O>ODG5PN>50*(A(P'*UM:75,?&=F_JFB1G+SZQU@:_>L>GO\$
MUMN(XRCC,PD_>?)5!:[WJ3Q*!ORHW!FG9X9YA8E%M3$ N29P,V8XTO(HS;NF
M@VHQL@P:N%J@=L_IW,4CH#F:>:;S6?(25KAMU/2\,:S*-1_PT8;CW>N$^THL
MJUY>4CLJ^8J1K)533F^7YG?BCM\MTJVM]Z*BT30G;/X+SL/5"BE@(G&OA"W8
MQ@?D';K"+R2*QDYC=8^R@>42N"70/C9W$MKMO<D E,3>%@JV\23S9@@R (;B
MCD8&]#$#JB1?67IUZ(:F[%L4VE^:R3AY0@BQ*Z)7MG[^2%Q:@@$82JS.9 \D
MQ36]F!0G%MT?HA\R_2W>J ^IFK5_:'J]MBA1W6V/*<MJB.#8F4$OK!XV"-\T
M>(TJ7J#YV)I/WE#^_$8VPVD_4&EHW9.)@V5?U"*MN??@ECFUM4U<\4B>0K=N
MJ@Q_-M-+_3D?%/AL7%YJ9X\J<_]?ZTS^?W#XZR"=]KK@X/FWC2UTX@WEX_#%
M8ZUT;XUS:MM<$Y!9^Y>2.;L, $(0=JS2;P<YGP6BU2-,[\S@G,W9P\WU32)G
MY^]_(2;3:?R/E89DTO!*[]2?# L.^I!JI&'M/L&=AP@< =K3*Q^AN3^U_.?>
MZBW+JAV<1YJ+>1_1RY>JI!)V,0=?H,W!AL''TP.CV6X16O?X5CR!<FY6ZZ86
M. ;@81+$E  ZX^C=(_.E!<Q%<9EPOC[# #S8*>//R9Q6/+3>?)(!RR\L.Z<^
M\2 V^6@W64-Z#U3. (S3B)U^/0Q /6HD:OC0%>H:J2E[8>#(IF I<:,^9)MM
MEA)@K9R8[HCP_>PQ?>&2Z$#/4DT,R25E!W\0#8;](2C[:&'18%"*R5]3>]#W
M+\WEQXZ5LG^I;:O/%W<BW+[BWG^Q1<O@CTATWP*O,5I4,5T_:N&=/L^#<_\;
M9_*/N):FSW."FV1F+%W"6O6_//9_!\;TOP%02P,$%     @ =SM96@ \./)@
MD0  @90  !@   !B8WEC+3(P,C0Q,C,Q>#$P:S Q-2YJ<&?,NV50'='W)=JX
MN[L'$BP$=PL>@@4)'B"XZ\4MN$. 0'!-<+M<W)W@?G$($)R+7GSX_=_,FZJI
M^3#S/KW=O;_TD=JK3Y^]USI5_;SXO '@*\LKR0,(B " \'(!S\N +("$B/B?
M^\607VX4=!049&043#0T5'1L3&QL+$PL+!Q<0GP<7 )<+"Q\4GP"(F(2$A)L
M/#)R4F)R0F(2XO],@H#T,@89!0,%!8,8!PN'^/_:GKL  G0$(L1') 1& )$
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MYNS%!(N7#C2SVF=)(^L$']"Q)W/*'D]H\(("!.&#'V;%?'\=BM#F;JYBZ=7
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M)ZU#VT?[.[C;9MRC*/O>WP!!Y<[.13X+$:!.+<KKDBH'0JH?S4E;9F7K$3X
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MV#(/,PIVY> PM<QI;Z@WM[0%GU'K8J08I54,*B>SFT4<H?UQ5"):#$6T*N/
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MT5W^&C_9J8$)_Z(??6A8:,P 3O%[9D-9G#2[/2 0F!5K$,)LIM0?7[9 I["
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MBGLK^88]']%NQMY8?\[]@V& Q-=G(TX?7Q&>(-UW:Q/0!MI95HEZFEL LT0
M+I7J+=.MTNPQ71*7BUO39CE1 =!//A9U;J4KGF>6;E%$0<X* ^*_JG)GRV](
M=ZO".[0USOZL9X5 A3@(GR4RM@@C6,\YB*-_=KP)IN2^&O.UO@B23U2^^/-.
M&EWFP1&V3Y&\^;94[_#.:NO @DI@H UNE+>Y$:6ALSP0QX(&[R8_0%S=:N!
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M<MMQL /9M$Q@?F%*OLJK/]':KS76[,1)DK!SDX#3JIH BV^U%SG>)>!0)W#
M+1QS.N"#KI;<@8_'N1$<9EIE/6Z_A?6^6",TH;#D* LP]2P'5 "[D:D-2)I+
M_0P5_7> 285=X:O2=B97VX/KX_PD9JN?$?5V=]V?H@9%Y.S%P,MM'V&&V!M*
MW^JX6:NAE33\,J'DX(R+A4"\2[!/1JI\ C\]@!@K:'(2U>Z"L??JT(_RBE[B
M.-NY**?R%X3Q/7H>(A1MS#&+=(9 Q(WI=_4IJ7L,<!I"C6)I<(/(B["*'9@2
MA_G_DWT:.)<D2XVQE]$^:#\>>G8HKJ_(7#)K'YC5.E+V9NS33\'[S;3J;=K6
M:5"?JCUW$O7C2T X%07.!X2 B]0>+BMA']Z8J_75D>FV&FPMESMPX[R.@IVC
M@>.()V\'^L5?0%)CJCBDQ@L:3TJ9#+C^]_LQ/RV]'N;@0%^%/+VOC"9%-2U)
M>,+M=F6)SH,BGJ=<N5J!F-R9[WQ(7C+A7[07A.M/TX-UC7]OIU J/N#T;50)
M@XUX?)[83&RO(\,_ST@.IW[.C*M#N-HX.:O1]PQ\W#G7V?YNCR$<"#X4<]&)
M.5H?Z:$A&_+@Q^E47(;O=Y6_W^P_+;\-?#4P-B&()7 FBXE2K=3;YB7'K<\F
MTN^*<6^B^D#IN@6EA5L&F<$MDG];>VBV_VZQ8 "1!1,/3F[?5$;N!Y?O)S 2
MN9KF^P1%O*!,NY*^W0@3KHC<47+Q*-"7(\QZ-BG8)[KI(GM: /[V&WY$'F]W
M*5X/QU=RX.J[1[K9\9E$]E\2; Q^QL)<,6)F9[Q*BS^\\_MY?+VQV1E&"\<)
M.;'?9E&B6O4]WJ)$O+>SS>$O01E:ZE-X1_;5J=\W]R*U=[#WE:BA@:H4H16U
MP0JQ#)[R$_\O('2=07"<6/[$AN.M 7%=L#N=J/F []"YOG>^W)-8\H+#<.;C
M@E#>XBBB0:!J*O5JQZH::N4]A3_WV,+D@D8[,.#>C8=\:#"A?H/CGU8WNRN:
M=<Y\8X4XT:;O]A?P_DT0TM-")$0ORV>,VU"<&9\^%3'@9]M"B6?6:6?=:D "
MNB@H\^@6SX:P$<2(\21=Z$.I!_"'7A.)BA4.[J8DF/[XL9&@S!AU&CP1>C:;
M V%FP7+UYD_ERXH@\1)]"$#(7XF>2]PJK[+F;D8E]2+.P1G/7ODHE:%UKRYV
M8G/&QJX^00RP1.D '!M748A?U#?&0)A+#FH!;!S;5ID<%XF3"X-96"]0B))$
M3'G_RUJMIQ]Q4-OO#9$<H0$FA,X:N[[(34WD&2'5^FPF+BH._)-7NJ0CO5FK
MR8 /DI#AV(Q&/IRP5[+#5Z2%,SO7?,Z^$_/E9HPVT\3N9=8.YHZ?X8O%W;H;
M4+GB'!R:ET((M==OB+"=.KVGIFK3!GW5 >P"9W.^0[8AN,*>-ES*PAT#<#SF
M]\O($V6F[Y&@Z&MWA=VY@'Z-Q%@GF>5*.GR-YY9I&D)<*E>J6CSA3>L+7ZZ!
M_O8QO^L'^'2>G+$]TVYR8*W(9^@)FFFOMNV7^_XH4$RDL\W!=R-;&/##FK%L
M[I@^99MMH /<;76,3)ZT1?IXP@,!1#D8%/PU[]9UC:2EE8@?H)1>X*+:)+$Z
MO)('@S="O\5IOBN0G))=MD6$*BLDJGXG$,F#Q<PBG+Q2)"D5]/BB +^X5KAT
M:Q!.7ZBXIQ\,_E<3+/5[8LM\TLJ;+K89?,'J!SAZC\V<Q0'MNHZ-$+>M&.!&
M.54.#M6L>3[N@GPG?@Q97VO#6A(;FA1<OP4IX&8& 3,?KR3)C8/+V.J,D<=-
MI4A&I.5B8"!4.,;,V.2RI!23RYA']1)[\J:=\#3GND:@)"-#LS'Q@YG,#_.1
M,Z)_ZX^S\KKN)4J>.XYVJ7$0BC@; ]RT>5%^*?(C'H4C;B:_)CO84KQ(-M6;
M/'\6 >UG!XFC>Y;V4_ T3(['>MBO6^GNI-"4D 1=X:E^0+BA/,GU(2BXV)IF
M-M$Q$OI)^+7+Y,@7/'^SXN12?*(KA1O<4PUKA("P-HU#9R"<C;&*@::3^B.*
MBC\QLI)G[_W>MOMK81<Y[\01668]Y."@O%2W"8,D9_B(ROTFIT8T]!O&#P9-
MKADZ%&79N[]\"^_"?U2 ?^S>'WS%GG=]$Q;-U*>!T#/4^>+]H-3561,;Q0[1
MLN$K133)[V4_M-<))$+,$J]#N.4XZ;9=-@YIX[$LQF%NJQMBK/ A>2J5L2K?
M_TY&5%UG5L0'3PV^YM.M>_)Q[PDLSO"">516U37ID0*US!**47SADGB>K<JZ
M>9]B=]/Y1^+UQ<G;!?34W#=G3VE^S;\W#\.XD#R=+[4F^+3XIS5L?>D?N??H
MT7QH\:1([A &T<,LQ95RCX#E__GRE,__5/Y'9O_<IT@74:R!1Y[]>7R#\?A%
M,K<K%6\D"*D)=F<]*GGGONK?X38]M&+\0^CWN5(%Q_UKV@J6:2*6I4\89Q!5
MY]3'ND+J.H1:E+RJ*;L-K8;,GDHZY60+2M?M>CDZ"]W]B?55!5X$6/:[\BPL
MZ3W\X74T1'OTNS$_X6?EJL3/\-=..R;JZ<O/^Y7K?$]VVZU$9Y4[.B%+L^8)
M//'&&7\!]0XG"UM82@,SGHF]+68&*QN9[6T?]W!6(P /Q[""T[78OC7TDQVF
M4_&%:^:@.'^6%[+IFU+]GRPZ,W959+D<H]ZO^#!*5'_SE;\ ['L&<G^C*)W[
M  =M*YA3BH[CEY([H3'O[WX4OOQ/)WN?4=1^-S^D>:NAA+145EK7+NFS>DBT
M0L+%-P5A9#>58^?O%PVL_:AG[>Q_Z;#3_)S;5H<6B2'[91\;D39,74>S]!GU
M(RUHAIA;O&S_N@HP%H18OR3R39#=CQAZ]-KA+)W[6:=H1D<?WT^B,C_A63FX
M;(FY:'*%TX1\B$1MILN^J)P]#TI86;U7$"WNTS$EX3L![TA -U#,[I4V9V<L
MW!(UXB''C2I1@U$X-D\XFP39])VA/R)JF,VBU_X1^"^*[+9?;NQ:T?@R-GV<
M"HYX>DK#PMFN^4KR B\$ 60D7V0B-EM012=133;1I68SR(%M>K VXG?@D%2A
M'8QS[?^='33X"XBB1S>-4 7A3X)$MJ4)E9!>3K<_(.RW'&I];\FDD*2[ /?G
MQ]CQ]&$G5,RE)=10_!#K2#Y<!\[AK=%H#PL*D@=4*&E6!7VI6H<IPC>GKC;^
M:0<*+H=JZ^IU!F(:5/\4P0F5]M()ZB>&2C=KD<KT$_GEOP C\/29?:K.='XM
M1PT_$CX 9X)O+V3$#JB6)62/NO0.7QF&,GR$]@'AX^ Z1?4E3=,EVWAN-L/R
MJ2.9M#P]HA]J1,*$?),)_EC#(5L@"Y-!?!=@__)8I^6U(L^@OJ8N^+GG=T4-
M!ZF7!-.!MU_]XL%C_4T^LFA-ROEW'3G 5S>*) 2/;N&XJT)0AD\OPS=)E[I7
M\;EFOK5\Y_5A3&LRJG-_5O/$K)O]D[M)&Q!HVS&&FSPB&9VJT&K!N[#9GQ7^
M>8^9VS348A5AUG4/*A(M ,K6QB'1J]%78)+9%PDX\@VVL]%.N?)-E)_)! :D
M.,U)PF8IL+\O2FYY/A=^077]_GY"D%)%0GCU8CI\^6P':51>RC90[O?U_@>$
M]7OY-%C(FCQ+>*/0.'CJF9J84([2C3 =_D*K&T&ZN*V]DTF^A'^<A=T> TR-
M#C/FDD*=G40%R]*S_9]F^@/GJH6<XU:(8Q"KD<=(RYP*O-,^ @<>W],QJ,^"
MP]8<YX:*3@K1F!/HUL'ST:V%F8TW2+RW) ?[O%M8+CEGE*=B<@J&T3V?JQ:[
MBC QW<XM@OLM%TW-S,:]DA-.>A8CB2WP!NV?YNH1M8-MEMA\U*HALKHD\]>[
M+#D[NQ$I:6LMU('1NP]N9+D<&DO:3*D6R;PJ$DR@\._'W%RM%\__.Y80KV(=
MPVSV48V7E]8;M37%QYL<;-6!#@*2T% V\RLZ++H""PO(R;.R5T/B+0>*S>1&
MZ)I8(FY,:^T,O%+V?G@+ !&Q1)(JCVHT<E^%U<34[[X2-L3VM_Q\)/@2U7-%
M.^)>]=61VPH1U&U$?2EJMF7\?I3QO)Z2^;L-YT>:Y-=?+6L\7WRUB<_5EW5U
MJX9;Z76RMII5@QX=.^<A4B9;3,ISUQTZM1&,U&I,(AT.9]DI[0ZPRI[%FTK2
M#9OJ,)IIMC7U3>W52IJKA0[!')S/]Z"+6RR&]5'U6<+QGU5'4>*'H@M3Z088
M!/1=O6816Z>N4T[,N/S\"$$QR.YZF-_Q04A5VPQ0$3M-1:6?&,S0@U9]BN3N
M929J%7FNYNC0RTJ3NAH%7G5L 13%2Y%2]]K9&Z+47=* KA/_H1SLWJ[H6K5O
M$_;)!Y'3;<?=S!GWJ_OT/J!?E?]X7>!I0\_^XNR-ICKF?$*PH(@*%L!+I4;
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M&1Q+NR&#'L<E=@D6;R'X7'G1Y>8>BR\J074+[M*9Z1KX3Q[]4]F /YE"R5!
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M 7HJ%3:,ZM=DR00I#<.W1205HH"S>VF3$>#/NPCH;?Q&+;6'H[I'[!QYBFY
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M-28,569F#EU2-2,;FALJAW2VT6<;)XWQUJ1SD] ;Z>)_&RS0I.^V>1[0_2V
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M AT:'#_KWT7OOW_()C:,0)<N@V\*PFHC>M.2-="$]%\+-K,,=K"@MOBIY;G
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M]'>,7'N&Z8/1,#OK"3U ;HI4")7_FL-XGL>\UC=(-:-]9Z:.B5.PBTW2U1@
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MN9861%MO:]2R:=9HV"9<W^3QV&84 46U>F/W9WEGVO_42.0K''&NXFBZWI-
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MZ[#SG)\ZQQ=_,F"WV(;D 6U5$#LYH<SLF7((WAV(@U#P5K% #._G1@8XJ\:
M9LY:>"1A4MK*Z)Q.4":)ST]).W^5^D'\*J]'!G ASSJD76B$]ED\5%H56QP^
M]^>-[-#;"Q3(D3VCH7H4RP#'W(DG VJ_Y)[FXJB.GBG6X@<4O78N=8)B<L@
MQM6BA0_@&_+N+"EH,*>#%S.E]=NW=]J80!C6$3+@H921!C'$0T\@M017IC=J
M8YTB/<3+#AMKZCT-BAQZ?57QBZ^@NA[,OE/X (F6:O.AN+/)?8P,N+$FUGI$
M %*!R]W:WKNMA!\^P'6E'PU^ILB.K@UC=U)[FG(TR>L=>LY,_=.;"K4('F"'
M?"7DB8Z>5KB[*836B^A,!D@.VEU.6?P._CUZ$Z3628E\6 8+BJH3=C6?3: =
M5S9VD<GSWN2R7T"?B-A1[0X3:O<P3>4]^K%E<72XVE%;%Z%HW5%8:V<SD:1
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M!"R5--M1]Q31U$R?9=9UJ+!G"W9TN=W70,_Q_H&HK9'V=FE\Q?=8W<OTB%]
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M/(FI[ -XW6 (C+$ D@&,%GQ,G+V@7L02?/,3].085']C@2 ,N03]590%76P
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MC%K9(IB3#1V\Y47'TP)W9Q['O)9_]ZTF3=XW/Y?Y+A>T6/ K,"V $<6(YL'
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M'='&E&ZI,N>B*T/]_YL 4$L#!!0    ( '<[65KKXP]I[AT  )RQ   9
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MG*R 'HGW=A7;\>-:^KHG#%J"?2#T7,1Z3C%F^ZTGOI';=W\\+(1*ETF^@F?
M$V15+G)#62T</]9&44C=ZA]?^@.=J?R V8P5S8_E?V<Z3EG1^O-XR<I-$K;2
MY$NCP4D5I;Q";53DD98)[$%4&4Q#68I*C9N$ATC(%%0B'+=_5W"=':A[A@Q\
M#T^CI,O,K;J*1YAE"N8QKPR,8'R3<8!;+>&>HDKJ,]"W=&ZY)&Y[N/YT&NNT
MFYL%S5S&<((P[\/,\1NLM"QS4+UG($SQ@J,<A,8-7 "?1'F6V1-'QV\=E;#F
M2B_#P_R@EQ[TTO>JEWSNQO2K41=:7:HX,)%[[>>NM'9&I.5 ;00FQ8TJP0'%
ML1<2):7(E\O<E%5F.3R?E=*RK(PO-(OZ",16H1(0C1KD'%REKD#(-5YN1[JC
M8EV%KFV"M^?()*WTZ"=,:12(01"!"J1\6QKFUA='B3C3&6[K  5/E%0%8@.(
M3IV!)$;:8A4YT@SF/959PE+)()D[MM+/H,P3U3+/R KX=X7A+;Q.&A@#%B4T
M'WHFB \)IOB-"S6.X_#_%Z8663+Z<&[0"T2QE9N#O^S0/X<>UBO\P@'9X,D4
M;+%_[[3DU+XGJ#Q G?W$Q].UD7I+>:Z&,Z/DAZ&<PR8?R.12K@HK)Y[OC?:?
M.JEF(6@['03>GXSK(SKO ,/W);!NWP:J[Q9H10NP^-K LA>WRP3U(_?&OYY.
M)K]-3J9?&5O6$/TIT+):R'>!7O;&QHALB5!R$_ )+5LS5"7V0Y3$HT^RP&[*
M3]QH?NP_ZY@?7U2J.['XHFN^/7JU.^K++MP5-=?#%B8GD]/QFS#+%>C"^[9U
MNYNT=QQ*L'"#T9H=^MHB9RU@$3&%0"?:@;ZQJ.9S=#S1_JOM.KJ'\LT80!%S
ML(<7O2+G(]&LF)L/,)UB(J,%D@6&/9B7!2:<.+*"-R.IY/ "<7EFXSM(9HLH
M7VJ&EG#CN6=Y,R8^($:S5<\J<KDQEH21<XX?5> 5)!RCI] WR%0%?++=+"&-
M>*$0[GD_)>C>)K'A<8W0M'LY=:F51L5M!E_2X<$S?!O [#6'O/'_R)MBL*HN
M0JPJ>H%P9X!-%<?,Q'">.2**QQ[OR@H,8F41IHK*2Z4:$\$^RW_\H)W LE<2
MMR%HU>3)_>2+_4WBB_<915[A*+PS>:H+M7&L0 =&EA1O*.EQ=4#%"]S7J@&C
M,U4]J3HZ/H.SP;R_E"LZ<'D&AG4=Q+87UC'4<Y4I@U&. AY2W,>#NO?MF,"_
M@V=W?/+KH?CE[>DOD^/I>W#NQB?@YDVFTS>A<W??K>.]S;*.+<8-=BXW<Z5+
M8-K-%$!HR-G\'P5P62=?M"!ZO?:ONJ* *N$L4!;-C8P:BY(,6_KN,J\2\!0P
M''L)@ABS6&P^UIE.>'Z55@EI;M2X#64DS"X7H)(E_,@3(IU,>^^>KF;ORQY-
M*>%9VTEGRE! >VZ1(T;) G-?*(ZKS!+8K)-.4Q5C?@_HH01P!7LO2QO'F&&V
M,$.&LC.8\[:K>."6"1V,>@F\]*O-2(;19/B7PN.QS<^ZD+6X-)C]RSBL30K"
MF2Q]@!:7>[V74GZCS/2S6J.O$P/W:WNVY/8F;4_#YS,$ FCB.NL1H\N=8W*G
MJ!/>AD+4P/=+$GF,X: ,0B ]K7O@X3S@.0,!?C<.#TXYRZLT-QCJ!)%9Z*MR
M);:>[6QSQ#F6J\(;%^ZNI9E[!L4IMOIDC"] +*##5J,";VS%VR0EMM0VUVQN
MCU"L8_J=4G2<S"/IJ,YS2I99U; &'3-N)OE&7A8AA@!1>+%*Y(H!?!9H436
MD,:Y(XWAW\MR&09>-5*SL#KE0N>H -H/]X(82II$HR*A=;IY7(HXRP_>[CEJ
MZ71@>#F258%.+)9(6@I@:1_8FMAZME%L_<_3R=GD]/?)SZ-VC<$]W9YHH[;G
M#[+KV%($(1#*W1 7;W&\/A@*&),8-,M3RMM?R*0B%C<*6-<:K(5,D:&S#*$
M12,3T>KK8JU($CYP,AV5>*..R@VZ2<_%EMX6!>P E4A9+"2?@7P)QPQ&_*!
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MSG+N88EO'4F]JH+.PO5%0X@.K&HL0TV.Z0][;ADLA,HUT:GF<S+PJI1:]W7
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M''QS^I<\56SPU.U/Q@EL3^]01+H'.4LID*!9%BPV6+/4WO$FC$2#"KG^NA:
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M. >;,O-*LEIZK^GN$X*FTZHH;: )&YM1Q09: '&,GK6*V]?C048F")VPVA(
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M<2_U=OXXDJW)#O*$]%?*Z7QN @=+]V[*WSR>Y?$*?BS*-'GU7U!+ P04
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MD%)F#BB243CM- 42T[8TLH2'JGF1$P?]JT); Y^30!"(#%KPIH7A)-'2OD7
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MYQ/QT]O+GX;GH_?@W)U>@)LW'(W>Q,[=KEO'1]ME';M,(^Q<829*E\"TVRF
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M*#)'04F+C57I]T64]T64VU!$V=62X?LC6J65J)#81 #E N3O8B0E!D7&IO@
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MW#X7TE3 -65B8>_THLW35 [0RB0%4;;V^CL+"M;;&&V^:ZGJCLH"2F2X$V_
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M-$J1=23+4B93?,L*IU.9PHYOL 8_6KP.U+H(Z&*JDZG N76>%&9>&(),Y[3
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MW2F?E[.QRE&4H\;[LYQTO2J#BM$\G+<[[]_ 9H"1T2B;H1HF0^'/Q.1N@:8
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MQC#-QJ1\J1E:Y N$J9$<3;-Z3'Q C&:T'I?D9<&RR1-U/EJA$_9YR94$F:J
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MSQ_':6NR@SPA_8W2X'\TYXU5")]*>3\>9_$2?DR+6?+J_P%02P,$%     @
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MGP,Q^M\WY^-_B/.+,]C2\]]&XO7+X<4)[/O%8/3KZY>O_C$:B:LWSP;X\>=
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MW$]1@+MC$G+[7*%N427B3+$L8MG2.]QC21B7.4H5T,!6#F8+A=44:9PMQ0(
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MV2<)/K]'P])X=X,?6$F8@...::R16"3*KJ%4Q8CMS)M.*0_.\F"B4C7558+
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M^V#SVN!=Z\QD&#?$E$UJNV\ U6?!]D0\1_<U^P6>Y+*DSC"JRH2%UPJ7+98
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M:Q?(=6V)* <15DVYDCB4ZQUQ;-L +?'- !K+9>O:O*"51D/Z<#M-26H&_&]
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M]UF@\>70\<C5ZYS^^&XR^7ER<?W "TMJU=HN!K$/NKM%4X'UF)S1#,&@HJ'
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M-7@$PBRF.)Z1DC<N%6KS*7],US:S,T']L?A(43H*P:*(G"D>.1W#3645&@(
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MM-;1X,FS+J_UY^6U.@GVL"38=,<DV*1R@-J.#JKCVBWB.7H]UK\2@54!3@[
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M#3'U:^FU<RM 6I&(2U659-O<KTE_$#UOI' ,\U>Q=:$$K*,B>C^9$K*-X=6
M*= :\-(;NLLC[Z:1>H@QTUTR4J_Y1_9/62R =A"*SIC\:MRA78QC^M5C*-,H
M]D;A]<Q*Z6E94'B>6EE-8?G<7$<!BBTEU^K^&9<)"&&\R2I[DK0@)'.^HB0I
MYE!)>&.#2]/)LD[AFGJ>VYH+6 %<X4Z P*-1EJ8BLEFC(LA;PT+60202>S^
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MQI^*0SV>9O$*_BR*9?+R_P%02P,$%     @ =SM96I^,F9?4'0  5K$  !@
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MM&DO%SGG+RA1D'<Q9':]"<<"5N*%I'12C3 S.E);Z#QXP'$?)\ZI#D9U*ZP
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MPZ3,AQ<6V[&R[BJS?G+>RBN_7NRS*>M+J[FS?/RQH]CN<Y1=WCE025H=L8U
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M#-ZRFM1L5+CYAN%MX(9N,"^0; D%8P1(B=O_(?<=NUY7?U31Q*;\]TC9G7F
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M3*&3V+V54-DMD0X\^B9O!^R <DVZ=R):EB'$-_EC7-]LYE%Q62D'AUMW3:9
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M]+=$(9$7B-C2[>%%+J8ZB=BFY%UT]B>5[R98@(6U8IAGYGY"AHH@0)@L<:Y
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M>;#FAYSF%%D@@7CL6J3?^7A0Q7.5?G[,N'$PI3!A=WZ4$KC^7.A]=;=DE_*
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M%5Q,.+OB?8LN $_-'<Y'61;QJ!*EC*Q1SI!T(R2:)C23<OV@2F"3N/F(CY
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MD%T-G#F^6L<?/]GQG\UX7COO2*H0:8IT3LX@1+,F+5MF%AMX>_^X/E-SX,)
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M4G\FP9^?9!=X@^.RY!CQ30EO:R3BSUJ"?6\0=9GZ GKO_ZU*"9^G"JD!V)'
M =5L5/VE4D!K3?!9U@QSP:\HFH14P<<3G^3X$[#V'.))6&C2^U QK_$*/,-
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M@<'147]\L/1BH6WHKQC#>YX#_YKH?P%02P,$%     @ =SM96M 6<?!)!@
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MQ15D>AGQ/W=BIN8BL;1,G7XWU6/<V<'IC377UD+X.G3L;O?Y.&6^+Y*Y%?%
M.\/V:+0>4F(>KL9D)K1 712/F!97G&C7J'H19\IQI0['FPR^MC.M]@4RT5;
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MH=>Q^-?P47&MY7" WQ<U'.8WXM?#!?C^_1MVU7A#XW>SK("%@)^0%[9D>\'
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M&0=KO2J/S,N5IEQ0T=A>/:5>O=C';!VJLA^R3%A)]JSG(!RQ=08[FI3^+&3
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MF1INU)R9HK]/RL"31]O3<N+(.$3Y"VL']6Q.F2C4_4EGMW2!_'MT9L'"A'U
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M12TQ#<*OZH26C$(1<99(*M$*)!5C)SRMF?$5FKJDE6'-QQ45SN5/%?B!J^'
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M<7B)2W<31(LF,X:HV2EU_/=.'^'QIE*#V_YE0:Y4B'=FEAF,L3T-9+;Y4]9
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M/IQ@#GX#>]9; !-VS\B'[@8.V%'3JY]/&-^+;CN8*W3%,6*TT[DJSNC ZSS
MC3I1\O^ _7%)*_6Y(VT'C3&Z=&#2 #0$A\"RNS8#(52-4,KY(O1NFL;)$F,
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M,&<OQB!U:SI7^80P+?$U_=3B5M@Y*__79@*_,M'1>KT>PPX?7^97QX>XH7[
M:@=(+^;5;2/H>"-6)EQ\7LU%_%6GYN^+OQ'SO87VB]HH.XA!+6!F90.5+,#^
M$C#DMIT.N^HXGYA#HMIH0Q;]U^R>Z!H>SQPFJH*E,M<-1?.B?V#')[6P@2/.
MEIWKB$/74C%\X=@G2SY4%PA7Y]+/\#=G\@=(!2J]R;Q>:2,MG[G*A$FQ.0!*
M:L6][M$22$]/JOR$R3:I(8+WP(FP;(D=XH0M./P1'1ULW,_(H*@)OV344MN0
MD\]CZ<:IXAF0) &=XM:3ND^$4$_,0H[O^EQ_:,82%$.>-3.WSJHT\MZP-J5/
M3MC)"<GL?=XMZ3?:1<(@WNY5D1CJ?%R6QD6$&Z.ZEL1P''W7?0+]UOPNT40X
M)W]02Z(M^D#SN I*BG?.@2K;30K&SB'LL$["R8C4_L7,S_#N&5-#.;*Z_Z>N
M*8,L"^Q?SKN=1_>Z]7-[-NDZ*>@_$BYS;W+;I+56]GD=-]=#WR*_=A"X/;/$
M&>(+4)<NM3ZWC?HTYAB[--KA-]%12]I1/CI3"[H#?-Q^>6N7],FG]BNN6ZAC
MB=*FFQ%C)=V??@\Z3E7'CN30&MZ15$*%W737'IQ#5 3>SDG;@ULF7QHB5/)W
M.*N"LDWY%P1]MR2(W5IA90E<=8=/,)9"3 5X9]L@=A#5EG EJ)*1E,VPM_S&
M,;&^W_96>EBKNA#_KD/XY9,TN8PMP&]M4B+2W&S_67C@^352?JW;?*-,#8^X
M%2=0#*;.G8YFYI346NJ);'K) T1%=9H4TWI95@C=W67\;-$RJIM%H_4Y(!6X
MRV4A @=OM!W<&LW8/6'/88<E2*3$?$'^B_!Q> <]B]S47&=E%OT6IWBFF,9(
M;-M9,D?J4E_3ID>UK!7;;*3W'R:<'"Z]&2,T1KY\I$&R"X&JPM#4,WTK5[3"
M#4/&-%:AI6LN+\B]'12<X:U*&T0:RHN-K7U5;ME : >14SQ/#?D[4(PB!17G
M4#4J!@I0XYH^V.JVM@-CF!U.E[Q>P1EAW1TE7YV+5$8JGSH0SH23YQ]:@(8?
M>7$Q"DQRH-9B49/7($_*G(A?&@?-F^EM0\7>\&S+KSJFG/6K:Y9Z/#!Y[!]5
M\,V *AA0!0^X6E;9H5BMC7(8"$\^:PK;F?*M-F8KA["6&]1N8&6FTRSS+.*F
M'%R8CD80&0U:L.><Z.>U]W2TC@'[BJ2U=P+_3#!8>;W:<FV486#[V5=O,S8L
M619^!\M-1,6(&X'[+G;&[L,FBK/1OL#]XLVD+7 =KJ.X(YJ#[= D=9VX\&WF
M[+F1+8H7%P4YC'1UF+$AM:#W35#$P!H.[:UZB'K=>W*V9QD7"&>5%N<,8R_.
M0C;CRS$9D;%PP2%N4GD)K^"(Q&7;RF9T<>DY$ (N$'RL49"<#5]RYG$6Z!9K
MQAG;C>[S%W(B8'GEPXXCI!5/;9790DHGQE=QDNJIACYTB@ V)K&S)(#<+G&\
M&DL39V((DBGG35$B\@HIR)U)[T\OD@E)!(KH-WBV.<=#?^[((4V)VA"SO/9X
M>?U78ER0: +$"UKXT0GH<,?"6(>$IB5.\OQ#G\\O.K)QO$8$T@M5RPD*WLW9
MY.UXWO?O+EP@FZZ"WH=U;/RNQDB.L-<G&&C;'+=&[9Q1UEW=.95:L*C:VH]1
M1WN8:"JU@VB=5G .P6B88G)I)<JY%#7J6<6V6=OP7/;/BTVX%722F7D4B!-3
MK8W).M^)!\HSU-%.>%]@]9(W6H!25^F]91T6HPAG&HL7VUGGQ%TFE)DA3KI*
M65)+)U$*HZE2;?R8:Z<9'8FW9V:F0IC<.(EZ3E@SN/9DT7G&817&[7(MD<KX
M+Z\EXL=1ET<)0J0AKDIWUXRC[^"'<G\PEZ87?Z9.>V-5$DXK?G48VV?./4@<
M'^];?:>OKVL#Y1F5FN+!Q&PC!-I-8Y1-N3B.?F&63(P78.X#&=Y=$Y?P\MD\
M#"KR0@8N/#J5LG$5D:!0E]2-Q?3H,C*0S:"%<04C3)?3R4)N%5700KE+,#NM
M_. RU^<Z;P3LYV@T')9ID:SH$&$N+%ZGMLOY2NFK_;O22LF6_+_HD_\X(M)/
M<(6<*DV"4VZ@AN04?4/%Y&^8_;$V[@GY&3QH:V(C<PR-0.1]3'?R.BN=:D-O
MQ<'P)\*^95)S1=@C4!T.5<-I"OHN);RQ,W:*DTI6I\ADK0XNN@?(=BD,,MDT
M_"@CBD@U(ES]K_$"2:WPF-=PV[\IX>C.>(NG5H50'Q03K10R0S*CHLAC19,N
M,;7^EP1!%FOBJ,;1HE+OLN^Z)SSL1R.KZ_K(O@Q<,MK;0:9&M(24F%;\9J?X
M6_?(VV\\,-R<(SO'T7^O,?^#!-*54=R(<+(>X,@Z+,="9V6\F3]ZJNJ&SEK1
M';Q+W2VZ/3 >&N3?[!NVR91\Z85M2Z#!UH%<:. #U<@>T 0M$.,LO!LT*+;A
M(K<Z+*YD$KQ[YU@[D4_EY'/V,MQKKJ4R]Z[IV#;"\:W$S%3$,=4V<V\[/OQV
M:'9.D<TJ_BA<%N;CRF3E/L,KG[,6@C_],/8W<;DXP,L7-1.*4^C)B%&HAMO+
M.EXZ,98=Y\6I2/H;_'I>HT3J.EV_-E*5X8S,$ZV=&E[U^B=%2P@;1\UVHW68
MVJ?A/>)N6,050_.HCLM4<5E4V9B*WLPP%ZPH)?8(_<(X!CU5Y>$O<(/K*X+)
MLXR%87/>'37R$T:\&KO;@SD'LL'>+W3>A.J_.7&T2!1!TSI+(-/!\FC5C^R8
M1X+YB86L[J .,[37,RUU%A;"S[,TU2+G971+*$H!&31FYJ1BG+K2=(I^.5(+
M#_:8A[1CA>;8TH6$*E.88]2-8S[0A6\>!!(M:O21)R\S]DCS=:&7A']Q.,JX
M.!66W #$I[K>KK?@=;$*RF+'KC+Y:8G5.X@\5/>86UR6'Y@4ICHZ#$T,>/'\
M]0#$O(MR)_P?O+Y*TK9\0<3]Q#AZM$#,:2GKUF#QE24[4_#A<KJPI9/KC"B%
M?517PG[,8D9\;E:$*_8B,$/)468_[L=5#,'H_02CGP_!Z"$8_5BT:$V&/+C;
MKD./GB/<O7D#-OTV^U&MO;O$V7*]WJ8;:-Y2-)/>U*]C<R:.KMH>28 Y4D>$
MOK=9'.Z?=VE+) )OUPP>W,D!YCP$=S;<?%]#7<+RSBU&'3,L=# GI4NU&+F(
M,CG2C";ID <=%2%Q.VCN89]'DK;@S++3MM@*<C=WX^AGU._7T+QQ<Z\JH:<T
MCZ,?"X;308OB/^3PF_ZX9%5MUE+/:=.2?M[1+FHX2G$<EQ)C:)F\CT7AMC,L
M8H8V1J-R_)8=PDCT^%HI]A!4^K<(L1>F"FA(F!?HA3#XKO=U"S1TXY4$UDY3
MIE]3;YDR0,"<=FUQ;^\>X.[Y*6_[%8,=%*PQ&.-X/5'*YE62(\8'RR['Z^CH
M+JZ!\>7XUI)1^=,OQOYEBR:,UDA)+*4)FCTQRYYTXWLB**3=M6ML$I9WR]BI
MHXQ1#%1.4/Y,<DRY22JWT[HA9^*@:B2#N(9Z(54V5.C?>'TNC"YQV&6V/TJG
M[3NZT [PM/KJ)M>H;K@EY*HF!IH)[QC2-?NO::=94B[EJDCR0CDBQ:W6!3O1
MA^*RA+?WX9IF!G<O _?7"T->5CYN< #G=2J>SKC,T<<2'+F;#XPQ&5;%.T1I
MW.N?LC R'SMRVQFR^7_LX/+8F,H@8LNY"!*=G=]D <DDLC&Z,@3P+<)@UTC=
MO6MA;$3 '][%(GGS*?']LPZS&\C4^F7S%>Q!23Z"^2BT/!$/(A-J2Y*VZ%9F
M!?38)?-SK)$5C'[EAJ,(G2I.:U54HV 7G\IZ.^4*:=H&LM9+B[&7$F7OV2=2
MWRBNVM%1B=%I"NC&7Y>^/=6E"WDQ%%F0N65MN'A4I_'.#$%8SCLP>A>^;$ ;
M+YG?$^E_VT/V\G3\S5-9)O?/FU$D?C-^]N*6%(G4SI/QLZ\?$B'UQ68)"HNL
MX?,GG\J > JOW\?T/'\^_OJP"+N)Z6N6<ZX+?)5RMJ,I*Q<0D9/0< [(P<@+
M1NMU/R.Y]^WG$ _]J"CUAW,[G-O[/K?S&*.<Z#),$[1P.%TVGA*J796_LL<D
M&4[@HSV!.RES7_(1W!N3@'6#[620NXMQK_2V#U3E=PX[5:65%Q$G3*TG0F&$
MWD"R:%UD8A?#V<L1V2FRX1OT.P4Y^IR9 =:E,6#R7$K-O#1?-ZP*$FN/P57X
M0RHL$ WT],'9KM=Z"M'=RW!Q&W\1==?6*6X6HI($2N3ZP#U%]$>^>VD'AZ+4
M5]GF6.1:N3/*"[1.0VJR7'C]NVIX,1BJV9,F^E;2)Y@.]--]E^U0R4X'^@#W
M3Z\@M"X]NTV:TVVAG.PH[+E-G+./G&OB\9O=TN777.I>>'"?HTQ\H<*.0V/T
M4POD".C^;_A6&QDJ\2YAFT/<'')_V!T@>D/GX?.XO7:=1%@P(8*D$K54JMXG
M&X"I;-$^V;)._ KRJ*))0:@.<41[)>8IK8^H:>'HIIN;KM, 8MP/B/'% &(<
M0(P'JBK^3$+LT>N)CN+3Q7=0<H_: :#B5N%G5!'GO0P9\>R*0.C7JXAM'<U3
M#:U""*IMOE]-T#/#'JM2^/8:G2[<.5P"7;>/YLNW8KQ]ML"M], MFE\;'6,[
MZ"5G<8*'4MB 16^0A>' UZ\%%>P"\#T0\%[?"S\1O=?B7#_8]7L4 >DNL1#Z
MV5P2TA"M'J)>#\OEOO=H=2OD;'=_;Z":+]'^!X=H]7!NAW-[Q^=V"%8/!W (
M5G^&8'67)JQFNJU:UV,*-*UV@D1NBWP_A #WT_W-6RNR'.\QMKSO&/#9N>Z<
M<S<#^Z/,>F=F9DD\@H?&D.4[[AS19F'04>&5./B$#..='''D0F-G4'=4;S\0
M_BU^''V!A)8M'X4N:,.A<ZCVOB.,T?.99'#>ZJD<SY(XC-3A$M "\F; F.IE
MC ^ABX6+&[:H2+QI6Q7)U&RA2A$VI Y*GQWK%S77Z9.8F:S#X)I KI?/XM/#
MH:_+RD%;&<;K%(W%S:VM%Z(I-!W;<H_I(G8FO1[YC.=T^E+.8HF9+Y$S#K%^
M>[#V(\WU53*KPE14O\2F4U-(E,DP4TPGH=HE\9VYE&#6,<DXWI-?:1*723GJ
M*-1LW8)6+3@P-L<W5,FPC%YSK5%8TY\U=++/VN'W*\V:,2.BQO+N)0P6.9YH
M7#ZI&LEG-%ERO  I;ZFZK/D88V79$2.+E(LQUJ= EA"/,,6=L*18=!6G-?R\
M!,E7G=2K45!58$0TC7F:S"13OO"J=A98_+4L@SSZ3DY6TCGAU_&*-OU_I>G"
MY,5EG-F_EP:.>M'Q2DLQ%A1OG#*E]R%>8V^9+HUA.;PP:UPMI&B>@J0?>4M.
M, [+W-O%V(O9YDK_T*$O.-H*"U%L"O]V_57:2=RU68.8K2M)N[%KNR]+W(M*
MVQO4QK)> YO_IT@9JFVZ31'BNFOR&^_Z[BYB?$2U$6T=8]SK(/,U^U ';"\6
M\Q':T#J'-LW/%:33:E=\'+3FE07"4H4J4![B2C11(OLGR9Q[EQ!N97YO; 5;
MQQSW@E2U"B8'6!&ZLSWB>$V\*'P$Q]F(5 2:@B/]_@RFT-U>-V_+LJ8(N^6=
M0QU$]R%\>."W#W&Q<V40HFGRB$5;D 2_B%"S<)WR3A+7WV6>,P8-KI4$C@BR
MU?1JAZ^52-YO7C3TRJLVS;HM\9>R8__E #W;._3L_'2 G@W0L\$G_C""+E^R
M2WQ/0:DNZPK5LED-.E)<5XN\@"Z!:DU7%0+TJ9S12 #0JSB!?R.A+9H=96F]
M><12CY46J"YI S?CG.'#'A[V\.VK/I!;UY#'"VRU(ZJ%E,#C<7'L\M#(FARQ
M"UL-M2KOML7)$S?!^EFZ[=>QL_@D:V^O\9TA&CN<VB_KU&JE[\9-P\G\CJRV
ML[!0\[RZ>JO$QB^/8^M$JXL"@50\I>!/$Y.-(I--Z^6D0/-UI &OC>4J'8E;
M?80)/]6E5)J+9UB; "QX)#UG[BE)YW45+*4T(!C&>#0E)."8<5V-W DT+K6]
M\(U%0AYU%WK38E]'E!(VQWNT-^1U/(BCQRF.!G#(/8)#=A,LI![P 085 0_N
M:H7* 0L7R69!5<$C(GX(:) ]>^9M[%QF28I4(1T2NZ$2,2:2;)H75,<4H[09
M:E,; @ZHQ.SPLXZB6(I63O.R\BM"C9Q/F<0OPO?%JYR9*1HA!7EQ]9T<!H$'
M?Z\-.=*EW\ND;'3]P'RO[\6G.,+"K1/8MY:7[P+C5-&O4JCVW<%Y75^76F-9
M:T_[SD^_/F!EYV!*<\#E8&GX]4H#1%[T@TLZVYJ]%/^;;#@JZ*KGRK1YK]78
M?(B;H*8Y0&X=O*X<?1=/09R6.152&;(3!K7^05VC>U+K04+7&*35S )[8*CN
M^#M&?F'<#+1^^#POA/^&PH-KY!*5HH-PQ(@)U(^>M!=DT'&'LSF<S1W/IF(?
M-7J=4_U;O NK1,+8ER:KH3/*;5S"H..*P'$]6"G.</6B^,,9'<[H<$9O?4;1
MO-%K#]J*EZN2RY@6QE:%),@.'E-L\=]Y82ML!W7T7N'!'@[EHSR4@W/HGIQ#
MB,F.I09L4+#:\@OL@M7NHC]P5BY\7!<(IZK4@MR.B!]YT'F5%&*Y/B9OT_N<
MK6]GS"L3&%O\,]_D9Y.=*I5VF.I@6E#BLY?GT4Y6J!921$&3I'-;-'[9\TY<
M:_O>Z[9*4-V\9R>,/FTKQ-(_!PI63TC7OGCX'J[?8#%F1;R.TPXH(9<C?.,!
ML16$>(CNKFL]70KS<Z#GGAV,!K,/3U??5Q:@F<D[BAA%8LQS=2")A27=$(U>
M$Q=2A;E??_K#DQ>O<$_.DRE&YOZ-/8L9N8:=6\OJ]8.AVYAI"^"'T:?),A'T
M-B7QX#A^< 7/R:D+JE(A?F?OO$E/"?@/#:_M-@JY8[9VT/J&N0=VVILX3U')
M)&^G9TWP,Q0"[<51W"S3$FX"(<$7B4J(3F'?&2*ET&I9UDOE6RX_2/R"$.3D
MN2=,-Z50$5S"I?O1:_P9^QGAO=SG(#'(AC%).GJ1#T?D\UAH*VV)2ZG]B;!Y
M\F@E&6^,+%[VT(;B7HYA_H4:5-7[G:QO2G]0"YS7B= J=/LYOH"M64R8UNE!
M["=FCO25&H7F9?4SQ# *M@[$[DT.AQY=V&GQ!LO1N2KDC=Z)+"I#$@3US'-U
MV24<:%=#O'&G4CEQ)DJ[K%,)X$2_I :Q]1^,6>'B+!.2?3UES6D*B'8VGDX-
M[!:;PA <47K>PUEK/5(K,SN390]QJ_\[#'?XF3"!K/0&W+L3,+\#;5B4P>8C
M32_,[!#V&-PV#\I W!>.UBQ7>8&2A42?)#B1\"^H0)J9QC7\]R@Y#N_P29Y_
M<(6].Y(";8;N-,U+O(#ALZ,D.>Z$[2;+98X*& *I4/.;3O.:,[<#+N225+=H
M:4S%BA[27;@L;Z5X[S,CAQ,SG)A;GYB?N0"AUE=T2>_.?2(@7M6)O\C=.'CX
M[LG#]TX0F+0A$Y#F&)A6L0U"D?1-)"MVZJ:OCL(6]DNGARKT]0KBH?OH.AD[
M-.EVHJ7DV4Z&R8V3PJM4^DGZI>B4!/0"0V'#1@+T;Q:3*4&65JFUFV'U!BK^
M6R]T8\-]]>WYV9 /.>1#/GQ'\K]R4G2U@ON!NX<O368*2J]KV.E;/&\D>(4"
MJMM%Z97NQN^O>,K$I]=GH/2)YW%T@.Z/UV#]N,#/CF3PRD2]\2C%^DTMRQU"
MS#0UJKZ74H@ KZ\D0\P;NYW,1[@YN'S  DNGW6K]VK1NC943?J@,<V-J-@*5
ME ):(;\C] MF*DZWD*F'$],HU6[[SY=RIL,J##QCKDSC+>R)EL4X1&]:#Q6)
MK3$L#E!9J&!R:'?HH7>E[M5MBV'-^"JG( 8\;IIK>X082IAY#@).2!GZN#EN
MKKGCN9-0#OL:\+1CM;YR<-;=G[$WV'?7NQOVR"?WED-I('78Y26'<((7&T@E
M^&0!ED1Y:[JY+9<('=PC"C;4(K,=:Z,<[&.AH]U.?Q8KDSOZVA-V^Q4S%SGQ
MKH- RH27$=8M^4]..9 X_(;L7B]<\$HD6$>30Q+BHQ-,@Q?JIA-T+V)J!=OX
MGJ73F[9TVH'F[M,%DD?#JV+H,?G,+IR^AM;5>I& ]IOEG1/C""GL%'E9Y+08
ML^A(7&)'\3$J<:6AB"M&SB?YE0FXY_0=9>O&&T5'DV/];<^^&W5H]CZ0QPZE
M_Z+H&A'LGR:[&?W*9RX.MRO\@JH%8U7B<HH<M3GM1%)W\=M8U>"982 %*[YD
M=SG-^1JCELR2P)K#,;^RQ6=Q.M9(JCWB:SC+;9VW5I_L&+'?68N-!,U(,( J
MQB?9E65P'W6:YY;*[E%Z5'-&L ,89%S;:A.NO)V=%GW_B".)6'6OPGQ=]%:O
MU,7#S(ZE!APE<.GL26\/-"=0"569+ 'Q%43:B%.%<9VC*6U0E_*U$ZGWL45W
M9+QP@NI0Q%G>,K?0-QP7B'>JJ\Y-V ::*2MYZEB,^&OU^$L>:0#'[';O1[\1
M; J7 ,%8A90'7G!><UC;5CKG;%^<!*&M#6L+PX:JBZQS-&WL&9%BRR'DHG2?
M9$>W%;'SYTVI^'P?0K$AG&_D^!U\^;?UY9\/OOS!E__P??D_&H$'O&%8P"&Z
M\Y'<X*(3\MT"%"-RF-QQ*.\)0[QKH<RF^VY_AK%_2.*ZRL,C0I_L;CNK\<[R
MC4QI[:(ND)C8U]M\W\#5]$VWS3<^?WHS^_%L_,WS/35U_FS\HL=6#]NZ'M#2
M&JLLH\BPLS%.+S'#1RK^>E\;V?^X/_;LTMS?L;\PQ54R-?:T[VD9^^;@ADO[
MT%;A.KUAO^(X7)1/V<3V3G_YA^G4F/E\^V&Y#Z?[+A&>)OOYD1E?CM'(8?XW
M]Y7F9VWC#]<4+EN$0E(MCLIC4#1.]/<G]'MDZ:?,%[+/YHV:$UB/[!AS$J=I
M/1-R?MLE"O%@K8FR3JLPU"=H&>[1\>X.O.9QN^EZWO2T'>9V^745:?&CIUB'
MYOP5NB?LVIB>+.V;':5#F(BNI#U[=KKSHYKY2W*00%'2,@S[/T"?OO_O36MX
M( NZ96?+:NYG<Q_HP?_>KQV)J4U<]4-0]I;^J%T-Q)X*V=I:Y$>\<"['W*<:
M'.3V_>UN#'9\*5*[N8M)+OMYZNAW+JM\^J%K;Q,3KW[K[7"7T&+A2VZ#HQ%<
M%R#02_0FS\A=$:>2Y#T(YP>S?0_T8#=WM._(KVP%2<7U7[\GF])ZE60G^7P^
M".3#V]&', TX7G&+#.)P7YLG$I:%H,PMPA>B65R1U6!KQSH490-"\06+U*"F
MH/@^'+%N*!^+QF^;Y!8>T4*^SN#Y1;)R8%AI)*0^(BP"+._W[]^@=GQG]6CQ
MS$48W;Y]1=J[L#^':^.&)Q^13O."><29%3J?'_NDSH=RIU!XY=E^(E5OJ&9W
MZ:O[Z+?,$/%0*&Y)/XXSWKORE7_2IT$[O\0%(4U^<":K<_'\6*?M;^B$=+3T
MSA7-$.TKGBZB78IEL)! DR1U-(LDZ_E]!R(Z.HI^/-IKGS;VT_UL[!L+ JE>
MWR<&#A)_V(Q#NS TD=0WBIA*.'H*LQ##L5*:*L*5Q4.FR$!2\;#PV'LBJ6 N
MBJ,DTSB:9Q5HH2CRPJY,%J?H.#CN)/Z$ZTY.S$"//1S(X4!^^H&D@D.>V4B(
MJ)BAO)PU(+!9^N^$PH"&T,<VA[EI=K9(EUAKI+^L#<H$C0'?1U OIMD(?$^:
MA.0Q($&@FK@VRZL[_4(LP2Q?PI0J(2,5+(H_$%N3#7YR ,A1C8#B*ECRY H4
MVT'4#*)F$#6?+&JLJHL;&(ZJ2<U'.G#S>$K,5.*L6B9EJ32[%J&@_,[#&1S.
MX' &;W7=,RN<H]<O5X6)9QT\^VJ3MA.!M/S:GW/R3Y$'1K*WT"G-.56:M$3!
M:SS1HXB*PR[H1I[/DS21<AL=K=N4N=!#A62[L IPY2,7_72XD@=Q,(B#VVK_
M&!MAFG>LZXS*]#+F)+^3?'ZRRJ<?3.4*+(#M7A=%;Z@.SRWLY\RPQX\2,IO,
MT^:C0 IQXQ=Y&G( 6ODCGR+YG&1Q"#]W8#6T8+^6_AT+- S%>AZOD!A(%.Z)
MRM-I#;8Z#Q81;E1>N48PC)JV>FB7=\D-J3.#JL5E$2\_,UG!/M E<\VU4]UJ
M3F ]3@5OI#B4DMRMF>+=92Z0R)K:LF5R)4.?.1#$76)_R[AX(K2RY 6"*K#I
M#.QR[6G-O55QR)V-^9TMCXD(K?&34OO2>X\P[,!6R'#S0Q/HST9K6FW9A!GS
M')#?* 0"+V-DWED4>7VYX/=@ _)@8TH1_;#",.LT6<5915!WRC1'_Y&=WXEA
M#@@:E?C&.I[$Z%#'<W8^1UJ @B:+.S1")]K$+.)TK@KSQ&1F#LTBQP"".8YD
MW33Q48<@T]O1$1F<1VK>P.ETO:*'?02.Z!0FNY!UD+1_9SPT7D\N1N=)].K+
MC*/.<Q(28H0KZ=6BMM8(--!U-I1C(2X[AHO/>]"DUJ9MI?4@O)RW9[SLF<+N
MP92-G4D"EHK'\%YPM'^S5B]06C1ZXJ"5!'@/I$9C4D8=4] 8M]U!27:5)UC5
M6QV]X2@[AV:+JG1^VWDL!^J!V]XMC6OMJV_/GPS4 P/UP$-4);ONX!:QZ3CZ
M48%0A" -;NE>T4,9;=<*QJZ+XFZUA?+&=R:R)4WAW7Q["_2RMVGBK^$N-*1T
MOR"6GC8O^#+0&C>N1E?G+=2,^P705+=0%E"*4ZUWBU>F47\GJ!EX>^DIK'PA
M>L!!86#U=%-B<6HJNMX3GAX]_70$GAN0U\B6(74/QP*?M@_#_<P^*:$0T CN
MA[KWMB>]2;57F'E=PD;S>#A:E1:-Z>="'NW,TS'B=PF1-_,=(QV:G'BNH:;E
M>1*/)0^6!$\T$KWE\WF'RM/582'[S#:!Q!!6,!5PX1X?1V\D%N8UV#JC1X(%
M:XJL$G]Z++)GFB_=SBL7>5$1.U@E$X4UCB3&K:W R&")LLMQ]%- ^]5Z/Q5@
M90'7)%'!CZ_(1WB%+T)D0"@.LTM+#(=?=)MX7%@QX.U:%0DL@D?\C5/ [4DM
MO2Z6[,(DRTE=P(K74FY.IK?3-U$WK8F&FV&$/Q)L0'P5)RG[1J,53*X'K+=R
M5:7_UD9MWA[RLPF,EP;'6YGF'6N'BD53(M^<"OU6X 4W>AN<L2<JLKN5"UM%
MDF5!4S7N^6IGTK*'S[/T&N3-3#S8L++O8>&ELO"A,2[]QBH3[T.KSG00Z%.5
MFDVWE X*&F(C2"I(]0ZP#BW6-D7"/Y+Y5?S!6&Y*U16?G(*UNA$"R:;<(-Y'
M*I$SU9)8*.?6>9W.+"M@BO2$YC_U+)ERO54^MDD1$#CN4(05.VKI0[6*KKT!
M6B]+^!:DL7:\J=UWC++6JY6DH_-0&$LEH9M-E($ +4NZ1_+":4*5X(YMWH\;
MAD>7^AI%EG88U(Q+0BAC0UA-[P1>6M"M*#D$(_+<8&H :8.Z=E3C2<K?@;S%
MSJF;J_-NX1$$%PNIF9H#.D(9Z)4\TH"/LF8SO+I:[+#X_1/H7H\:^A(>0P](
MJU2J<^AL+X-T( ?XWQY!V@3-;[VA&V<F[SFZ"9?PQ9!4DM76A/.KE5H59,<F
M195AAR"<<[[MV[\3!E#<#RA/;2WO*ZGES?>B8OAT ^Y<;U<Y?^$&7J& KN07
ML-#'A[C2()G:M6=GL.?[JYY4<C&9/FEWP64$TTU_W1(,YBC<*RFF]1*%W)2Q
MH(BS!&L3?@/'G)P5U[\2Q())E-*CKS)T759\18@H:/I\JPCI;BN].;1V<^4N
MXG'T*Q=8=A^-O+IJ6V\!>Z#J3-EY#W'#O.:#ZT] UV1SM6OO_&,$&S=5Z#:Q
MIM41?.+N2*^L#=7D%C)EHAT2^PR/LMANG=$O>V2/K>E1PO=-_N &>?HX>FT%
M$W*_;!D<"33KIC$S,?2HKT0;HQ7FA8Z#W/?PSXS?J==P![-W#'.0G=ATAXF)
M"[(U. X#793R$ZL\R;953:*#G>7PZH*ZD(<50.V;G1=,KCFT:+5_N_:[K*BX
M=UWA2:;XU1'+>/::R:IX%V6S^*C:8@<I1M^V@].DN[ICLL4;T2<DEZC6.@L3
ML2SLA+/!W6AI8E[,H)SC-;>9!<#TBGJUK)L-4<P5]DF=4:):CJH1F"T%+&G@
MJV HOYJVU^?O\V6NQ.+$NLWV_DXO4LC^#I,M&OX$:U]-_B,D\"4\4\YCNTGU
M9J)\Q=U 1B2!0*/5)G;LMUKP7BUHK]V&\V=_Y^)>S-GOJ- VC.A[.XQ#LV.[
M_$DD69>P/6B+>'YICI"2&H$:3'":0+\U[,UBY8>]0'3$O,?XR-&/HUE=</DZ
MW'U@9]5@*X$!!R^K00#@95GF*293JSQ>U066T*7]"W9*G9%*#4V0,&(9KS);
M\!CVAH%G[ NX&@+*C)2?=]Y)MU_;&M@0I-U_D/;K(4@[!&D?C:B$_X\M_#LO
M/F!&#^ZYA".-@BWA&&>.?JH [C8*='N$%BXGUO8 "9!4)_6*15.#FH;4"I")
MWNLT!)%2N?&6CWRDX@XF#B]D-$:@3PLX(\[0/["+^!]>.1703G[VK "<M'\D
MK'<EA\?LW^T!HO(Q)566S1MC[5 ]I1)GPS8"Z[%9_<8K"S"P+PSI'@\*R+VG
M=(_?ML04P9Z3,X*!\"PE,XT#+X01Y:.#BBUY<S&> 6;?MOI2-C"0F4MHV!"R
M&53=&#,^X:NAMN5PF(?#O%>-#"ODI7&RY"!BFJC'1=GPX-RE6#CMND)N(_L$
M5SG#,\Y)G3%7^4M*=,17RK1'&A5#N27^AK\:V8I^6&@;1 A9II=Y+@* A%$/
M-FX[PJ='= SG:CA7G_M<S0S[*?G>!&MB7J?D>(&?VF*(4EX1'^6;=62/D=PG
M^O4LG]9TF<+WZ[B0>"<&1] 1"2JP)H6X@PC'J887V3>0U>0")XPJLPV[-R?9
ME2DK>EF1E!\0A53FTX3N>#J7_ .6%>VT2VWF"H8WHP$6T9K*I<HI[GR".AA_
M9,S'[[6A("%%/Z2<BLV/Z& LM7-6&'CC";V-O5PZ]$4"AB<"9O__]JYDMW$C
MB/Z*CF. &".'3 X!<G$R&X(<D@'F3(F4S $E&J0H1W^??K5U-Q=O8]D>IR]C
MC\RUU55=757OO:/<3H6_\%?//TV+_#WZ"_7&) 49W1'=I+TV(W3ZM>"C8(X$
M1<H4!"5GG9SU*78TH9ZSW]F@6:1L2>E7O"][FXIZ1-&ZU>UU[_+P0"29;S+?
M9+[?9;X:<@TBKFJ-KD!9?J>2&-(*QMW\SLZ75/7@,(+: *TLC NOJD-5X_-5
M6Z&X7 OQ)$4OJ)VU2&\CUO(H64*N%V6='RGYD;E02KH>Q;-H?)%+6^4E5_JD
MU5 JY+>%&,NCM'=J9&&-A]E"JOWTAOT>084<X\)-?G"ET\@$9N(O-3[7+CRZ
MDT8S!#BJ&<RK0:%>?'R"\G1J[]VDFO?XP6S$UHL/#7U[+MX-I)RB-K)E>6S
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M,# S+FIP9U!+ 0(4 Q0    ( '<[65I_&TZ#@80! *+  0 8
M  "  7:]"0!B8WEC+3(P,C0Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4    " !W
M.UE:)N_-BBG[   64 $ &               @ $M0@L 8F-Y8RTR,#(T,3(S
M,7@Q,&LP,#4N:G!G4$L! A0#%     @ =SM96@J,)6[!C   E)@  !@
M         ( !C#T, &)C>6,M,C R-#$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0
M   ( '<[65JA? MJ)D,  &9*   8              "  8/*# !B8WEC+3(P
M,C0Q,C,Q>#$P:S P-RYJ<&=02P$"% ,4    " !W.UE:?*Z(*FYS  "9@@
M&               @ '?#0T 8F-Y8RTR,#(T,3(S,7@Q,&LP,#@N:G!G4$L!
M A0#%     @ =SM96LSAF #F=   WGP  !@              ( !@X$- &)C
M>6,M,C R-#$R,S%X,3!K,# Y+FIP9U!+ 0(4 Q0    ( '<[65ITH4!0AG0
M (E\   8              "  9_V#0!B8WEC+3(P,C0Q,C,Q>#$P:S Q,"YJ
M<&=02P$"% ,4    " !W.UE:<<E0T#&@   5J@  &               @ %;
M:PX 8F-Y8RTR,#(T,3(S,7@Q,&LP,3$N:G!G4$L! A0#%     @ =SM96KE%
M/B#Q8P  ^&@  !@              ( !P@L/ &)C>6,M,C R-#$R,S%X,3!K
M,#$R+FIP9U!+ 0(4 Q0    ( '<[65J7X72DE&8  *5L   8
M  "  >EO#P!B8WEC+3(P,C0Q,C,Q>#$P:S Q,RYJ<&=02P$"% ,4    " !W
M.UE:$X5%&9-<  "S8@  &               @ &SU@\ 8F-Y8RTR,#(T,3(S
M,7@Q,&LP,30N:G!G4$L! A0#%     @ =SM96@ \./)@D0  @90  !@
M         ( !?#,0 &)C>6,M,C R-#$R,S%X,3!K,#$U+FIP9U!+ 0(4 Q0
M   ( '<[65K&J$=&;(0  +BP   8              "  1+%$ !B8WEC+3(P
M,C0Q,C,Q>#$P:S Q-BYJ<&=02P$"% ,4    " !W.UE:Z^,/:>X=  "<L0
M&0              @ &T21$ 8F-Y8RTR,#(T,3(S,7AE>#$P9#$P+FAT;5!+
M 0(4 Q0    ( '<[65HN#Q=./1L  'BA   9              "  =EG$0!B
M8WEC+3(P,C0Q,C,Q>&5X,3!D,3$N:'1M4$L! A0#%     @ =SM96N; ( %4
M&P  -J(  !D              ( !38,1 &)C>6,M,C R-#$R,S%X97@Q,&0Q
M,BYH=&U02P$"% ,4    " !W.UE:&^)S@R@=  "3L   &0
M@ '8GA$ 8F-Y8RTR,#(T,3(S,7AE>#$P9#$S+FAT;5!+ 0(4 Q0    ( '<[
M65I-M<IT.AT  )NQ   9              "  3>\$0!B8WEC+3(P,C0Q,C,Q
M>&5X,3!D,30N:'1M4$L! A0#%     @ =SM96BH^B-M$#   ?I,  !D
M         ( !J-D1 &)C>6,M,C R-#$R,S%X97@Q,&0S-BYH=&U02P$"% ,4
M    " !W.UE:^:Y/+\(6  # F@  &               @ $CYA$ 8F-Y8RTR
M,#(T,3(S,7AE>#$P9#<N:'1M4$L! A0#%     @ =SM96K*B#B@2%P  M)P
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M,S%D,2YH=&U02P$"% ,4    " !W.UE:$W9]0ID(  "G*@  &
M    @ $^A1( 8F-Y8RTR,#(T,3(S,7AE>#,Q9#(N:'1M4$L! A0#%     @
M=SM96M 6<?!)!@  =AP  !@              ( !#8X2 &)C>6,M,C R-#$R
M,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    ( '<[65H8$8$AO7X  *W9 P 7
M          "  8R4$@!B8WEC+3(P,C0Q,C,Q>&5X-&0V+FAT;5!+!08
.)0 E  T*  !^$Q,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>bcyc-20241231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcyc="http://www.bicycletherapeutics.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bcyc-20241231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_2q8U443nOk6gQC6m8b41-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:BakerBrothersAdvisorsLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_Q3Ip6DsZDUiZokIoW7oY_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_FinancialInstrumentAxis_us-gaap_OptionOnSecuritiesMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_cVgwDI4loUexIB3GNxcfVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_M9NqLknzNU-sMVpqCl-eFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_2llzQZ6_20K-zZTfy-CSow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_2uabg4H0sUy4TlBNK2BBbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_XPuSzU4R-ki_U9PggBrUeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_9_2021_To_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_IhORSIdihkWEmJuOaow7HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:IonisSharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-09</startDate>
            <endDate>2021-07-09</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0HyqUG8pkaNcopt1SdSjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dEcOv1S1kUyL15GIo0RjgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F8DiQa_QMka5iKKuHx7img">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EwM5Itcxx0ys92D7oHiEgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W-C5t6IG6UWyCMUiL7Gv7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wdRGjbbwREGbPju45P3i5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_StHDH1DIL0imMDDzyJOvmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_McmuDya3A0yjgIlscqnbsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_opu5bUpl2UC0TqjQ2ARQ8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CUy4QtZ-V0Cj2wqjpP3QOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_17g0OGLnwUulZtNoxhH01g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6cIYOfo-dUykEJArEMVFiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_23_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_1meCJkhmuUalIyW_wBy3UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="As_Of_7_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_8bqxGZ3cOEORs4A2Xq-g5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:IonisSharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-09</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kkvEbVaSgkafrtITcLkMkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Zt6VhwsXG0aIIZfDEMHd7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_v3o1BPc0-02UERuTDFMLWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_JmkuGODyoEa7uHAIThFJUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uYPMjaOR30-b-lalBWgACw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_a1Oi0t48FUudnS8WN5P3Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_WCDTG0m9xUCkxUKiJgwLbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Vi_9DbVLDEiUNj4B5lOvvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_P5YoMS1KNkutLYwlGkurgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_MAFub_g2y0GAD_IA8SQX-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zpq2bppWNkmyNQUoVWcEXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:PreIpoShareOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YameRw5flUWof726OmcJYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_QDfyXxUou0-hgJMM6cWXtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_E1--0LWw1EmKwIGcLWnwFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Iontov7wME-Mj-R-qqxvRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_NONBGaPxIUSKmSHZSQ1OaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_cpfcqvh4YUOX2BEX6A_K5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Lhc563hBmUO8945Z0wzLwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_ATqayKrwE0yk5TqZ6Qd3VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WvZe8laaPEeAxoXCnyr6Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_ThirdAmendedIonisMember_M_GcK9lsOUqu7PozYRvR_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:ThirdAmendedIonisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_axun9IhIKEiYQ2ka_ErQBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AmendedIonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QObiLon3H06DowS0D9UT9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_6B9ln8pBckaqlZDRFLAB3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qLy1Qlk7lUqL6zN6xMcMvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_DementiaDiscoveryFundCollaborationAgreementMember_LB_cYGPJt0-dBCSytUGDoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:DementiaDiscoveryFundCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yibznVR9GEqfsVp2Udu60g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_is22NBT1Jka8Gu-uasBItg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AstrazenecaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kkZvNCSDbEyvWrxvy0J0Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_4nF_ujCUWUWXOLzbDfjUZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B4rIlVudJkC7UiJJ14Ug0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CzvZPim0k0CUHrLZ3N9Ulw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_jYlsDtcKqkiYG1N-mRdO7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LZhexdWpm0qTV2Rf8LpgSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_cyshTxnH0kyrdYWVdqiIsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xx2lOaIKTUaBAJxmtahpDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nP9jA-aiYkONgvoroTyc9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PorQ7L3GZEWmg7J9b0BaFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_8msZM6Sha0iTRy5AvtsnvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_anAvD0bAqk2fupg6zYmu5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-28</startDate>
            <endDate>2024-05-28</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AM5bQ16iwE-vzlxN1fzJfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TWmLZerPx0-0_LBFph8ZLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_teqqpUcfr0ylhQrf7zeYbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_Emy5XN272EGkU-HVUNZzhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_FM8UcsJ6oE-QbWuVRXzXKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_QMFxV79NjE6OHW4kO9biSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_GB_wdbEmUAGK06mdxOOtgPJ8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DBNovfpDakCcvAVq5SANGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2JyJSn_aPkarPPFGcqtS1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNjPjZIFd06Z_lIP7g-WCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RLygLLyFe0W8BGYlL5x-bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gmBeuV6pUkqZOjdLGoLzMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_bcyc_TermLoanMember_us-gaap_TypeOfArrangementAxis_bcyc_LoanAndSecurityAgreementMember_65OBBumYj02j9k3Pn3oFYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_bMuDMhK8aEyJU12mzFiI9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_Ex-1F6jyfUO72vn1vcWu-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_X1BWRi7-lk2fvBqoP0fM9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcyc:InitialTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_VGLTprSZ00ajPx_iwKZOCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:ConsultancyServicesWithStoneSunnyIslesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_87Upa33xjkaMN_hOb2X7Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:ConsultancyServicesWithStoneSunnyIslesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_ypWL3awvzEqfgXwFXfo9UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:ConsultancyServicesWithStoneSunnyIslesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_fLJS0eBl9EOeJzgPO_7mZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ig3SHtuCIE-Ory8Hp3Mv3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcyc:EmployeeAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_9GER_6W-HkqnPxCUmp0fyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:UKPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_NRO15gR8R0C1PGFIWwvPqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:Plan401KMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_pS-QJkjLfUGnpbmjfIIQ7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:UKPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_arXRVu5ZWUSBIuONzGMp-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:Plan401KMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_-W-mugKxsU2yACc1ikbSBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:UKPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_PvHkFyAfO0qLp2QAqJ7T7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">bcyc:Plan401KMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_olYsF14wyEW_U0xeDnkzAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_xsjVq66pdkiUGagQ0I5-lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_D3g9RlG-o0yxRqde4Bnx9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_NmP2-XzDFUGGWP4ZizBE4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_9_30_2020_To_9_30_2020_OY1e7NwWCUq25fNFOMQDzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <startDate>2020-09-30</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ObVPQDakX0Kipqu1I4B_ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_2L8b9aOuvEGTIyzSbt8YAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_0G_PjFAo40GKFUdlMvcXrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_sWPs1iEFhUqaA2I4dkmTgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_KVWfPM5pcEK7pqypuPXWLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_5LReFI3s3U24XzqlQU2yZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bcyc:DeferredRevenueMaterialRightsOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_cyHRxQCIEESnLP8sT0_U6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_CLM3oWHaYEmA9xWRlsRxFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_l4IhOsVA_kaoaEarP7YyVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_-gMn9m7NtkmdLXLyH9rqdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_jkHOHVP16kyVT6B0B3UJYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_RdiH8PgdtkyqEjCC0xKdGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_YYJ26o4FAkKUoYNNZn4kKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgram4PerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_ISvkPDGZT0GtRplR-nMrEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UTg8-nc3xku3S4nBOYYTgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_tyLSGaCBcUCWHOiuJFWHhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AstrazenecaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_IbZb9vf99kediN_LZbIFuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisEvaluationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyIVXSsfEEW_9ZjaJ49EjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TZxfpEvZdUat_yMyIb9Zww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m2IV-GHD4EWsFxAP8z8-YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_VotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJXTy3J51UCZNJxJ1Ym8RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:VotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y61uWaX9NEaChNzvdxBdnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_y0EPkZSaVU-zndPzJODGAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcyc:BakerBrothersAdvisorsLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_IYGnT7YWfkykLNwOFediag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_V7TD4LyjyEOPQOb-5emQbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:InvestorsPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_jjLRXKu4UkmDU29qbwfUyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-17</instant>
        </period>
    </context>
    <context id="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_A4JYy9Ek902M2Ll6OJMTig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-17</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_llEDFF1MSUKzib9liGvGRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2025_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_3jebnT0paUKkYaQIJZSi9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_5QeHcJfW2U6x27_YDU1Ogw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_J_fXlQvUukSBnlagZHQH8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_MBs7tOGmkE641EB2R-K8nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_gQdGQPSVDUGV2TfhbI5-2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="As_Of_6_27_2022_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_4Vyzs47cNE-kgf6kZGnMbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-27</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_hWWYIZXzx0acMJRpjAgv5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gejPkuQhakeSpM_QZlP27Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_slT9uSBHsk6jvBbMvui31g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_7Bn4AO2XvkW3epaw1AM0Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IE3SmW-yQ0GAQXZrSOSVUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5MPhoYm4pEaBvoSPbVf8mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_RMsDq0ZFvE2Wx7B1y-0u5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s2IO880e1061sN4EIeiaUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_n-D9Cq5DWkCzJZg9ZJYbnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m2jh4dTe1k6tiJLwVhJUjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_4N9eS-gJjkuSY1TcnrqmKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b9GnNZBmAkmTdN5HqzSMxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_IrNimC9diUCVSYzfxLOnXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QJYt99nJFU-BQx9iYlyOVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_MD5oMOXiBEqT_oj0JeJMKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ExXLTtPGjESDM4D_A9YCDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qLo7iHGMOUW9rHUjaCEH5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_fd4h2ljJA02Or70KQeym_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tkd3FyxzzUqahEHsT-hpIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3zI24sd1-km1PKi1awanEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_Fpz4VUhMv0GEtQ7djr-DbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0q3pUAqe0kaGx2oDa6WY6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-20</instant>
        </period>
    </context>
    <context id="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_Kd_FmvXFs06iCWxDu-Ik9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcyc:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-20</instant>
        </period>
    </context>
    <context id="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_k7kwiL6Tv0Oaw0c1V1bDWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_hMqy_55tV0OU0RmfGW8IMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4FpKp43eMEOYJ8Be5CBt9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d2w1uOPLe0uqStZt99DW4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kKS5dyzsFEufpIX9K-WVUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_bG4-HMluqEmz8RSPzC0fGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:InducementPlan2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_UuY5gYBUFEyCVoKDAuW1eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:PreIpoShareOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_A43fKLk6X0Wn-S-Osq4rcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_qGTPrbV9lESEael4XrVLgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcyc:ShareBasedPaymentArrangementThreeYearVestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_78XxKxfYa0e6KIo8HByUpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcyc:ShareBasedPaymentArrangementThreeYearVestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_o8DXnIN9Gka0CBw_y9jx6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2019_To_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uDaWQIIw1kGEaQUSk3pBNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VqqK4Cb9V0iqlo_bcaxLfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsForExpansionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_1eSemPD_PUGZrSIfTiqkcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qPiuB9BUQEah87FFQEHHLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:SpecifiedTargetingArmMaterialRightArmProgramOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_kzAbTqHZN0CArARXFbOtYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationTwoPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fY6J4ndKWkuZNzesRX6wQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationTwoPerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_uRCFMRtOakyg2OeSksR3_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationOnePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_YDSCq1R7SUe1ir6yappJew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_qpxzdeztD02IVOBhBuyF0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0SmQ9UkaoEyo_zuVmF9T8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_r6MfE3ksRECQo64rWUZQ_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_H7vbLohDfUqZtqXKcd9CpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_IU-HPwKXJEOuf8TPozi9MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_Dj0LVN0iZ0u9fcBupRC2Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_z9unUt1Yik6ssQwliMMpIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_o4Ynp2Df5ky0p5ZF-8lSyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_vbS2D-byxUiv2iYUzl3WkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_uCp5g8aYYkiBWHoG8i9XIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_RWvBuWuwx0SypjAqYYDYow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="As_Of_9_7_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5spYzCTLIUOCuK3Eylw0Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="Duration_2_1_2024_To_2_29_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_F9BWe4BDkEGe1GncdURkdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_1_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_DRGyMBQk30C0HCqiKdLvbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_1IrDAG-GjkaODsojD2rcmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_1_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_mZK_WLmvd0u3bkPaVSH2lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="Duration_12_4_2024_To_12_4_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_goSmqlBU3UOCLW6hsHOXGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-04</startDate>
            <endDate>2024-12-04</endDate>
        </period>
    </context>
    <context id="As_Of_12_13_2016_-ccexalN_EuXuCJAskV6sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2016-12-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_a9Bb03tCQUq9DG0yh6RePg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_NYezOdO0N0G3gVUx6-pWmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_gUaCXINS2kCBhTYjLBFLvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_qWduzYXktEC6ieFWheazqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_10I2hU65G06H9LVN1JzgNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_Tw08wGHpiE2_uOJjC2Yifg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_DUUmLvrM0Ua-IV4gtEO4dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_m8NGtuG9hEuc-Q3am5BHDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_uoSoJfk0zkCYReunHXtq8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_TGvFsvJDaU-Z2goQUm6szg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_EDbD_nwgWEm3h1bnui3JPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_QCbJPntYS0mr7VXNm13-GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_SE-anRzrlEiUC4bJHOOjnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">bcyc:InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_SwAG22aJtUSKIsi9PCAZJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_p4p-FG55D0eRUEKCq8P6yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_4t0N24_S70mz2Zd2yTJ85A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-13</startDate>
            <endDate>2016-12-13</endDate>
        </period>
    </context>
    <context id="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_B_kz3AanWUGz-CXUrr44Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-13</startDate>
            <endDate>2016-12-13</endDate>
        </period>
    </context>
    <context id="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_T4B2SYwvKkiwF5Y-H5SnKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:SpecifiedTargetingArmMaterialRightArmProgramOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_NG89CENXf0WsYpj98IPH8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_HyrRNe-YbEC-tdg9gRuhvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_7SqqxQUnTU-2GwYuJp8WsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcyc:ShareOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_94phe6rJ4kWybY0cwUE7iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_eqvMYjbIIU-vjO_qsp7v0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_tnuYUMT7jkGkdVdgNaWQgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QqTrQCxSy0WuafIhqTZmRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WDczl612dESosUCoC72gug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5p4e8zASzk6UtchIaZHdrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ccXf6ptJGE-9qaLqRgb8FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsForExpansionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yFgBlbVotUajI_G7d99bBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_EZSaePc-y0-TinfVuSqYaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_Uq2YtHbmDEqFEAKHinp0mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UiXZnEQKrUaSVgTitUBvIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BdeUCV5wOkyMU6qL2DhWkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationOnePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BteqU8JwLEGuk_pXYeS0Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationOnePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5-nN-zX1y0-eX0PVinKM1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_AvjycYZCW0uI2cpw5iScdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_Jlm0mrvCf0W3IJVZZ2e3GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_SGS5MZDDqEWSBRcvMGqfGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInLexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2021_To_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_7_XmUdC8h0aJCYWeYcBvog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcyc:NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-06</startDate>
            <endDate>2021-12-06</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_NV57yxdHsUG-EvMIcuAkLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CancerResearchUkBtOneSevenOneEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcyc:IonisSharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-09</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bcyc:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PHabuvgaTkmQG0J2ns37DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_cqFl8FEbxkiSfD6iCj1uZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgram4PerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_D0rz7JpLrEi8DFIjkqRfAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_AjyoIuYKZEiR1VI--kfKQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qCp4Kues8ESQiRZdeh8N9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_9_2024_To_7_9_2024_ZJZfQXYoCEan2WXy8RfycA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <startDate>2024-07-09</startDate>
            <endDate>2024-07-09</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_DRfguGfVi0Or7GWsyp0CBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2024-07-09</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AstrazenecaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_30_2023_us-gaap_TypeOfArrangementAxis_bcyc_ThirdIonisAmendmentMember_wgyO8-AVfkC5eQxgiBeTrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:ThirdIonisAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_QA6y8ag3QEm7TEW69r2qZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AmendedIonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_4xrbU9mf7U-6_-7nZgiopA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisEvaluationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-09</startDate>
            <endDate>2021-07-09</endDate>
        </period>
    </context>
    <context id="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-09</startDate>
            <endDate>2021-07-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_95vuv8ocIUSRAGL9jhXDpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisEvaluationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_2TOiizb3YE6trqr0NK51Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TerminationIfSafetyOrRegulatoryIssueExistsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_l_SYxC8CcEy6vP73RrP97g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_k-g66Brr1Ea_7MONWi3pTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PVgTMTZKEkukeSrHzooTww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgram4PerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_ZNuFcicSUka_auEsj1BcvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentAndRegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rDEBgcbU2U6rfbdVzl6Apg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bsrGl4-r_kuiY-MRpYt5Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:MilestoneAcrossAllPotentialTargetProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xp4_gR1lU0ecKBaQ7hdhGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:AchievementOfSpecifiedLevelsOfNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_CompletionOfAllMilestonesForTargetsMember_WaiOPCwXwUCGOrGcdYAYvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcyc:CompletionOfAllMilestonesForTargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationProgramThreePerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_xgSdh5vtDES1WDH_f8Xs-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_RegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_m_fV9ESl1kiTO5YyS3qSDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:RegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_tki1umMlTE2iFkLuV5EjMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcyc:AchievementOfMilestoneAxis">bcyc:DevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_LwM9FXA8rkKkuLMtRDp7wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="As_Of_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VivFA-_htU2GU3D3QWHvWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:SpecifiedTargetingArmMaterialRightArmProgramOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationPerformanceOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_TSRQzXGT_UCdLkzF9xrWhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcyc:CollaborationPerformanceOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:IonisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-09</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_AgreementWithThirdPartyMember_cjzTWIaOY0KrEHYqPIpAew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:AgreementWithThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcyc:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761612</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_M_lugMOcstmECVEFUGtQg6XA">
        <measure>bcyc:M</measure>
    </unit>
    <unit id="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_Im4dTiIF5UiSe0qPdBr-ew">
        <measure>bcyc:segment</measure>
    </unit>
    <unit id="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">
        <measure>bcyc:item</measure>
    </unit>
    <unit id="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_jurisdiction_Wo3Cb55Vx0GOZokPR6rMjw">
        <measure>bcyc:jurisdiction</measure>
    </unit>
    <unit id="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">
        <measure>bcyc:installment</measure>
    </unit>
    <unit id="Unit_Standard_Vote_F2iWXsaSbUSm_tPiCaeIdA">
        <measure>bcyc:Vote</measure>
    </unit>
    <unit id="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_lDjarV2SKEKFeVF5ca6tnQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      id="Hidden_Cs-wGQgBv0KoBVquS-BRZw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_qzHYc8yUfk2FxdcgIRRDwA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_eeqXDGfmiUODYVi353xFTA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tc_82V5GHsWf0am4NT5Nc8s6A_2_1">0001761612</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tc_1kiYeAN46UC1mXVGrdqYOQ_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tc__9bPHJUmm0mgZiM8Y24DiQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5MPhoYm4pEaBvoSPbVf8mQ"
      decimals="-6"
      id="Hidden_KG5Qrpf6fkO6xb-NWzVFZA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IE3SmW-yQ0GAQXZrSOSVUQ"
      decimals="-6"
      id="Hidden_A2wJE6ZI3ECm9iej_OAGQg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:AssetsFairValueDisclosure>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Hidden_eLwDL01wNUSd9XxGg7qjIA">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:NoTradingSymbolFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ"
      id="Hidden_5e8aMSlzvkS657lOCk_QDg">true</dei:NoTradingSymbolFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_4nF_ujCUWUWXOLzbDfjUZw"
      id="Hidden_p8M7K2bjKEax4G-nyR6gbA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_12_31_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RLygLLyFe0W8BGYlL5x-bA"
      decimals="-5"
      id="Hidden_X5wnyztC8UGUEz3EZ1OAbA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">664900000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <bcyc:TermDepositMaturityPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4FpKp43eMEOYJ8Be5CBt9Q"
      id="Hidden_Vut1ulUKVEGQr75nUhokTQ">P30D</bcyc:TermDepositMaturityPeriod>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      id="Hidden_KW1rNIXqDU6mr2igGNJAXQ">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      id="Hidden_WTohRhZpUkiEgaVCaOLomQ">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Hidden_tsh7VRNlykaXUR1w5uepYg">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_VotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJXTy3J51UCZNJxJ1Ym8RQ"
      decimals="INF"
      id="Hidden_Lpo0wyq33EyQ4jsKrECq2Q"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">47569319</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y61uWaX9NEaChNzvdxBdnQ"
      decimals="INF"
      id="Hidden_isC1MjD3_kuhXs60-F47rw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">21492099</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_qGTPrbV9lESEael4XrVLgA"
      id="Hidden_8SmY0G3wPEWWtHANX-xYGQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <bcyc:MaterialRightsExerciseOrExpiryTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5-nN-zX1y0-eX0PVinKM1w"
      id="Hidden_7Ox68_7-tk2-gZ54jj6J7A">P4Y</bcyc:MaterialRightsExerciseOrExpiryTerm>
    <bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BdeUCV5wOkyMU6qL2DhWkg"
      id="Hidden_PuaulHhMWk2PS85VLrvMLw">P1Y</bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed>
    <bcyc:MaterialRightsExerciseOrExpiryTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BdeUCV5wOkyMU6qL2DhWkg"
      id="Hidden_CuyU_1zNJ0eAuH7pLi5zdQ">P4Y</bcyc:MaterialRightsExerciseOrExpiryTerm>
    <bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed
      contextRef="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_SwAG22aJtUSKIsi9PCAZJQ"
      id="Hidden_23cxoubFkkqKtXI7gxQnYw">P2Y</bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_89Xiz3lIwU210xUHlqxyBQ">http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_SQ4PzHGMvEedzinnZFOhqA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-5"
      id="Hidden_o8BOhRO22E6Ob_Qt--G_Gg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_lYaA-73yc0O8cmcTzPPaEg">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_Rcc02-kBPEezAjTVUU7wRQ">P4Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      id="Hidden_u8XOnpcF106LEEpbmUkWMA">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_bPio0aHPH02H3kETPh3RQQ">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_fXuiG5l0iU6QV8KHo7W_Vw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_suWSMoOh70GCzqZYX5RQrg">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_BQoM0Dyb-Eeeg1kuT14UPA">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_f0ZiEEh63EuO44tPSu-aaw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_hV1FDn89x0ixc65PaoTGBA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_utB0preXEUCAToayv86CJg">001-38916</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_rf1cBen0TkeKcOpq9Nn8uQ">BICYCLE THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tc_34dsv_L-ZEWljuiZ_AdLGg_1_0">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_TAEUaDzH-k2MuPJcBerZ-A">Blocks A &amp; B, Portway Building, Granta Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_01bpfWvS30OgYBIKQyRdBw">Great Abington, Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_uJ27db28_EuOWnhKDOdDcA">GB</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_eiwDq5XhjkSd9iyrEsHsqw">CB21 6GS</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_KXGyt6Dgu0yg5YUM9Ms6yg">+44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_UAroe5kui0-Fggwy5M4DBA">1223 261503</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ"
      id="Narr_R876U4qs1UieI-gfbiWmYQ">Ordinary shares, nominal value &#xa3;0.01 per share*</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg"
      id="Narr_8HajR58KkkKmQ9vfvAovHg">American Depositary Shares, each representing one ordinary share, nominal value &#xa3;0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg"
      id="Narr_jUFmn2ruiUKCKSOpvF6pVw">BCYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_-kMTEaQpQEG8PVXqm8eisQ"
      id="Narr_fsjm6WJ1B0CKAVWdukBtrg">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_55BF811nu0uTTF8ydtlIeg"
      id="Narr_q2AyrwhP40KYcjUkCoUKBg">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_18dz3XLPv0yBwspgSnURug">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_fwhYrTrJ_E2bU12nRYBoAw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_-D2ghJ5fO0Wazo5ZsALl2w">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_nsYQVS_rQkyRi235D7LoQA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr__5q8yLS6XUi0nKGgSKcuVA">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_NNh4DR4DWE2btiU6_CrH_A">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_WS9leNYseECmlAm7eZwzPA">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_UfUQFmhQ4kqfzqECpi8wvw">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_ZPJshysAcEansXO3YNDIRg">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_31N6BC-U20eKyJQhQjBy5A">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2024_Fpz4VUhMv0GEtQ7djr-DbQ"
      decimals="0"
      id="Narr_LAvXb8TZ1UuXNSb2eMF0Tw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">758541179</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_0q3pUAqe0kaGx2oDa6WY6A"
      decimals="INF"
      id="Narr_vN-XvvWHIkWZVhcqdvWnFg"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">47710256</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_20_2025_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_Kd_FmvXFs06iCWxDu-Ik9Q"
      decimals="INF"
      id="Narr_5rFqc0gkwkWUBLWn9kZRBA"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">21492099</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_9zojx7Xew0mMSuLPccLUBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, computer hardware and software, &lt;span style="white-space:pre-wrap;"&gt;and our critical data, which includes proprietary, confidential and sensitive data, including, without limitation, personal data (such as health-related data), intellectual property and trade secrets, referred to collectively as Information Assets.  Accordingly, we maintain certain risk assessment processes intended to identify cybersecurity threats, determine their likelihood of occurring, and assess potential material impact to our business.  Based on our assessment, &lt;/span&gt;we implement and maintain risk management processes designed to protect the confidentiality, integrity, and availability of our Information Assets and mitigate harm to our business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Risks from cybersecurity threats are among those that we address in our general risk management program. We rely on a multidisciplinary team (including personnel from our information security function, management and third-party service providers&lt;span style="white-space:pre-wrap;"&gt;, as needed, as described further below) to help identify, assess and manage our risks. We identify and assess such threats by, among other things, monitoring and evaluating the threat environment using various methods, including, for example, manual and automated tools, information security tools and platforms to alert us to potentially unwarranted activity on our networks, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, conducting scans of the threat environment, evaluating our and our industry&#x2019;s risk profile, evaluating threats reported to us, conducting threat assessments for internal and external threats, and conducting risk and vulnerability assessments to identify vulnerabilities.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Depending on the environment, we implement and maintain various technical, physical and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Assets. For example, the risk management and reduction measures we implement for certain of our Information Assets include: policies and procedures designed to address cybersecurity threats, including an incident response plan, vulnerability management, and disaster recovery/business continuity plans; incident detection and response solutions; internal and/or external audits to assess our exposure to cybersecurity threats; documented risk assessments; implementation of certain security standards/certifications; encryption of data; network security controls; data segregation; physical and electronic access controls; physical security; asset management, tracking and disposal; systems monitoring; employee security training; penetration testing; and cyber insurance. In addition to the above, management obtains a third-party review and formal certification of its information management system policies and procedures, which has been collated into an Information Security Management System (ISMS) which is maintained to ISO27001 standards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We work with third parties from time to time that assist us to identify, assess, and manage cybersecurity risks, including professional services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms and other vendors that help to identify, assess, or manage cybersecurity risks.&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;To operate our business, we utilize certain third-party service providers to perform a variety of functions, such as outsourced business critical functions including contract research organizations, or CROs, for managing clinical trials, professional services, SaaS platforms, managed services, property management, cloud-based infrastructure, data center facilities, content delivery to customers, encryption and authentication technology, corporate productivity services, and other functions. We generally engage reliable, reputable service providers that maintain cybersecurity programs.  Depending on the nature of the services provided, the sensitivity and quantity of information processed, and the identity of the service provider, our vendor management process may include reviewing the cybersecurity practices of such provider, contractually imposing obligations on the provider related to the services they provide and/or the information &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;they process, conducting security assessments, requiring their completion of written questionnaires regarding their services and data handling practices, and conducting periodic re-assessments during their engagement.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;For service providers that provide particularly critical services to us or process particularly sensitive information for us, we may also require that such providers possess at least one of the following certificates, reports, or procedures: SOC 2 Type 2; ISO 27001; annual penetration tests; and/or red/blue team tests.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including the risk factor titled: &lt;i style="font-style:italic;"&gt;Cyber-attacks, failures in or interruptions of, or other compromise of our information technology systems, or those of third parties with whom we work, or our data could result in adverse consequences that materially affect our business, including without limitation, regulatory investigations or actions, litigation, fines and penalties, information theft, data corruption, harm to our reputation and brand, significant disruption of our business operations and other adverse consequences&lt;/i&gt;. &lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_It_BIjO9X0-COpkmkpV6tw">we implement and maintain risk management processes designed to protect the confidentiality, integrity, and availability of our Information Assets and mitigate harm to our business.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_zo2kChfUD0qrjw1irNK28w">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_ihVcTU8llkyYA1wuT0neCw">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_sFqayYMYDkOngS8LPsWe-Q">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_v3On-tkYKEqN_6ydhPldxQ">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_hKvAQ1ld10yxQ6Dt4azAIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Governance&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Our cybersecurity risk management strategy relies on input from management, including our Vice President, Head of Computational &amp;amp; Structural Science, who reports directly to our Chief Technology Officer, and has over 10 years of experience in developing and implementing cybersecurity strategies for companies in the biopharmaceutical industry, as well as our Chief Financial Officer and Chief Legal Officer and General Counsel. We have also formed an Information Risk Assessment Committee, or IRAC, consisting of senior members of the finance, legal, operations and information technology functions, to oversee the management of information security as a whole, including integrating cybersecurity considerations into the company&#x2019;s overall risk management strategy, and for communicating key priorities to employees. The IRAC meets on a regular basis, generally quarterly, to discuss cybersecurity risk and to review our cybersecurity program. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our incident response team, which includes, but is not limited to, our Vice President, Head of Computational &amp;amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer&lt;span style="white-space:pre-wrap;"&gt;. In addition, our incident response processes include reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Management, including the IRAC, is also responsible for approving budgets, helping prepare for cybersecurity incidents, responding to cybersecurity incidents, approving cybersecurity policies and procedures, reviewing audit reports, and reporting to the board of directors.&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Our board of directors oversees our risk management strategy with respect to cybersecurity threats.  &lt;/span&gt;The board, through its Audit Committee, holds regular meetings, at least quarterly, to discuss issues including our cybersecurity threats. The meetings involve presentations and reports from our management, including our Vice President, Head of Computational &amp;amp; Structural Science, concerning our significant cybersecurity threats and risks and the processes we have implemented to address them. &lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_z6OCd-SyRUqdyUSUSOEnYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Our cybersecurity risk management strategy relies on input from management, including our Vice President, Head of Computational &amp;amp; Structural Science, who reports directly to our Chief Technology Officer, and has over 10 years of experience in developing and implementing cybersecurity strategies for companies in the biopharmaceutical industry, as well as our Chief Financial Officer and Chief Legal Officer and General Counsel. We have also formed an Information Risk Assessment Committee, or IRAC, consisting of senior members of the finance, legal, operations and information technology functions, to oversee the management of information security as a whole, including integrating cybersecurity considerations into the company&#x2019;s overall risk management strategy, and for communicating key priorities to employees. The IRAC meets on a regular basis, generally quarterly, to discuss cybersecurity risk and to review our cybersecurity program. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our incident response team, which includes, but is not limited to, our Vice President, Head of Computational &amp;amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer&lt;span style="white-space:pre-wrap;"&gt;. In addition, our incident response processes include reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Management, including the IRAC, is also responsible for approving budgets, helping prepare for cybersecurity incidents, responding to cybersecurity incidents, approving cybersecurity policies and procedures, reviewing audit reports, and reporting to the board of directors.&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_fXDg_gFqjEWW-A-hKAqC2w">Our cybersecurity risk management strategy relies on input from management, including our Vice President, Head of Computational &amp;amp; Structural Science, who reports directly to our Chief Technology Officer, and has over 10 years of experience in developing and implementing cybersecurity strategies for companies in the biopharmaceutical industry, as well as our Chief Financial Officer and Chief Legal Officer and General Counsel.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Group_EibKFks58U2M_3p3cA2tIg">Chief Technology OfficerVice President, Head of Computational &amp;amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_ApklqUHSfEGPWvElSi0gBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our incident response team, which includes, but is not limited to, our Vice President, Head of Computational &amp;amp; Structural Science, Chief Legal Officer and General Counsel and Chief Financial Officer&lt;span style="white-space:pre-wrap;"&gt;. In addition, our incident response processes include reporting to the Audit Committee of the board of directors for certain cybersecurity incidents.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Management, including the IRAC, is also responsible for approving budgets, helping prepare for cybersecurity incidents, responding to cybersecurity incidents, approving cybersecurity policies and procedures, reviewing audit reports, and reporting to the board of directors.&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_oeWrQm1xWEmV-1rfLPA17g">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_NT9neWo8n02R_lSYA1li_g">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_BpnZDfZsWU6rM-BMNFSLDQ">The board, through its Audit Committee, holds regular meetings, at least quarterly, to discuss issues including our cybersecurity threats. The meetings involve presentations and reports from our management</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_UxZMVXk3FUCcIAueZq0VkQ">Audit Committee</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg"
      id="Narr_e5TBDzWGQESUzP1nB09nGw">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg"
      id="Narr_jgvjAb5Eb0mGYXYtlUXp9Q">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg"
      id="Narr_DHt2946LgUy4cuWrZVclmQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_aCgOgGLk8EqMgqOMzKUcfg"
      id="Narr_-Y_2TrBPF0OdRw6aJ7Vr9g">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_3uyC1kn92kq1g7OPB2BWgg">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_mcaVUFOT40ujPMeVOd3iyw">876</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_qgulTrCGjkWxT0Uzjt_Iuw">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_zV_MJq5QuUGxLa9hv5zBIA">Cambridge, United Kingdom</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_TEPO02NCRUCMPKNRDeo3zw_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">879520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_4JQ0zOJ3CUuGkt5jH-qNpg_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">526423000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_6R3WCQx_0Ue56YrfHlQ8Rg_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">13432000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_tqa9W3w8L02hFSmdPPOwSw_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11406000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <bcyc:ResearchAndDevelopmentIncentivesReceivableCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_-8Q5UQr0pkO1U_8a5sOQkw_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">35653000</bcyc:ResearchAndDevelopmentIncentivesReceivableCurrent>
    <bcyc:ResearchAndDevelopmentIncentivesReceivableCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_sCTWW-Os00OxPQrp0iKimg_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">24039000</bcyc:ResearchAndDevelopmentIncentivesReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_44mVsT2ACUGk7fOorPl9Vw_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">928605000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_hW28rEwKREOgrat_QPtoxQ_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">561868000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_fG3O3ARjJ0y0bg8QmG4ZrQ_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9516000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_jRsCeSYLike7Q1qvvB-uiQ_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14515000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_UA54MpyS106rZSXw7fbE1w_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7673000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_lL8Hha4z2k6C_07ckY6HXg_10_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">13169000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_6NBNY0wxukihVNkofhd8RQ_11_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11074000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_sSm2IdHaG0alCl2E0d7YsQ_11_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5792000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_orSyzO6F3EKDy0wcSARtjA_12_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">956868000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_Db_RXM5Rd0GuTzBqtTXlvA_12_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">595344000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_1vGjzkGzD0ayINNNy5N7sw_15_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">15793000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_3qYCwBAZPkuqgtMjfE26gA_15_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">13050000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_7A0pG3Xg2Ead5-3M0OljQA_16_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">41246000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_B6ghhvq35028VHOkOBUj_g_16_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31509000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_gpz8di5J6ECjeEp6PcYBig_17_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10191000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_4RCVnC893k-Be89VPFxT3w_17_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">24978000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_sWXrY6AJlUaLHken547h9g_18_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">67230000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_U_96kKR1F0-b80nEtA1KiA_18_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">69537000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_7dxhMwTVZkCQjYKFzrNWEQ_19_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30698000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_7PaVTIU_sUOFMLGTR-wGJw_20_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3990000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_1HUtyWelIkO3P4rS0_KP6g_20_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9382000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_UsLzgMmM_EemZfpgtv4ScA_21_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">91467000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_mx87ZUQfmUC_jCj3vY83Eg_21_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">110216000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_Sl6Efpf7DU-VwxxQYdWoTw_22_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_A6MCfcOySESlmznAm9AT9w_22_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4579000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_ImeTtrHlBEu5vj7X8yBunw_23_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">163808000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_QFehG46fWkOJ0HkGO5MXBQ_23_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">224412000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="INF"
      id="Narr_pGuSZkx0tUaxbcu6OqQMgA"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="INF"
      id="Narr_tWtWbUyv2U6UKqL39fR2dQ"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="INF"
      id="Narr_OcBOm7VyCkWXToG-veamJQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">155876645</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="INF"
      id="Narr_ZIpKHPmLIkqJLp54sZ1g9g"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">59612613</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="INF"
      id="Narr_9tbUKZKU5UeNfrdJAwn6tg"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">69061418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="INF"
      id="Narr_HMrFlNJX10uf3TMmc7TK6w"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">69061418</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="INF"
      id="Narr_eZ-VX68cL0ap56pd3ufUXw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">42431766</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="INF"
      id="Narr_ZawGuXXiq0-TG9CN9HKpew"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">42431766</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_YM_It4MNs0ei2hxqh7prqg_26_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">890000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_JQ6cuw0zdEuqNiRcWhw8OQ_26_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">550000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_nf8N61aIHUCMv4MfX9Vy6w_27_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1472842000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_gg1FFKtFFU-_jDsMZLl8cw_27_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">883446000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_eeQZGN3S2Umjr-AxVyr4tw_28_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_DVG-Kj2onU-zygD8JMjzAw_28_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1304000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_exwNFRMaZ0KodHQ5fUdP8w_29_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-680791000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_uMfZOPD-n0SDfkCh7TWr_g_29_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-511760000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_AdkRNKyjE0m9K6KhQ4PqZQ_30_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">793060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_VA3YmlpGF0eBXJgGmMQovQ_30_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">370932000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_JpFHMsppaky9PC3Ievs4tw_31_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">956868000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_fI8jU41ykk-WcATcPDNB4g_31_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">595344000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_U_5tsnMbKU6izfmUbV31uA_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">35275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_GFrwoEDlK0W2XH2-f6ZqzQ_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_0zTWW2wotE6Nyup72CY_Wg_4_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_7D0xIk91JkezNOUDVVmxeg_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">172966000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_NtjaQrF61kS1A1VlqXFcOQ_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">156496000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_z3qGbYkGMUWhzdGZHPEwFA_6_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">81609000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_yntlJMgFekicTYVDw8z3vg_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">72181000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_sZLSyyaCn0erWTW88GLJzw_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">60426000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_6KnacaCNOUKCSQd6hIordQ_7_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">49507000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_ZPDh56JAcEOB7Kx5JN6XPA_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">245147000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_AOqZLdDjKkeXDBKGXIIrrA_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">216922000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_k-t6JhNuEUamFB-SwHvZoA_8_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">131116000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_cER7Y54lF0GubujtyaOGXQ_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-209872000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_EgojgkLfR0av8PeLko-X3A_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-189946000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_SiOgSwEbO0iB9ZLoxaYMaw_9_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-116653000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_3JJShh-ldkyBUr3E4IBuJg_11_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">34284000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_s1ArO5wG6Ey__JzUGEXiCA_11_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14002000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_N8zXLwcHZ0alFmcdDx1v4g_11_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5756000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_zgL-F9yYe0C90LG84v7PoA_12_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1730000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_r4hnJvcBKEOQj3QPGYjnJw_12_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3263000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_gEx-E7eHsUGKSTvu0mL0Iw_12_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3344000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_12jCDkLlBU2yHp56uo0q4A_13_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-954000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_lL2zAjF7a0Cy8RbX-k9RPg_14_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4476000</bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_AALqWln6QEyZrRtmVMfoFw_15_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">36076000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_xpWv84bpAkaKg18lzHIPBg_15_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10739000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_DylQ8giHA0evoz78BwT3_A_15_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2412000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_II0rJHLDskSRc36YVVOIvw_16_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-173796000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_kVAg-XxOd06qO6BT3ZgFZw_16_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-179207000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_xYS5lvwejkaEbZw3bt-3vA_16_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-114241000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_OLhNfOWiRE2fYcLjlvbupg_17_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4765000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_-mghNzYsqk6v5gy4B3AwUA_17_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1457000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_Is6rA3PLf0mDSWxhmeq26g_17_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1524000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_dTK4b-ML00qeJSI0wVpokQ_18_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169031000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_PhiAQOuix0yifdWucANaqA_18_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_AoIs33qW-kW4vzHufcG-3A_18_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112717000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="2"
      id="Tc_tN9_WG89zkOz2g1lqqzyIA_19_3"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-2.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="2"
      id="Tc_tN9_WG89zkOz2g1lqqzyIA_19_3_2"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-2.9</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="2"
      id="Tc_NldJMR8JsES9oQitIlw6og_19_6"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-5.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="2"
      id="Tc_NldJMR8JsES9oQitIlw6og_19_6_2"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-5.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="2"
      id="Tc_Oknb-ZIbL0ao1R1V--XKZw_19_9"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-3.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="2"
      id="Tc_Oknb-ZIbL0ao1R1V--XKZw_19_9_2"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-3.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="0"
      id="Tc_Mx-2zMKqxU-emRj-nxEwrQ_20_3"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">58207593</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="0"
      id="Tc_Mx-2zMKqxU-emRj-nxEwrQ_20_3_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">58207593</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="0"
      id="Tc_gsslnCc6T0OIQHJG9HcgXA_20_6"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">35592362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="0"
      id="Tc_gsslnCc6T0OIQHJG9HcgXA_20_6_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">35592362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="0"
      id="Tc_YUM9LdTjpEG9EkZHZAEHEw_20_9"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">29660659</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="0"
      id="Tc_YUM9LdTjpEG9EkZHZAEHEw_20_9_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">29660659</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_92hzwotLoUOhycE9Y7TvMg_23_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169031000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_eGNers5R8kuB4qHhIguerQ_23_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_UwOG43pZ0kWMXvyLTomjeg_23_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112717000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_3KPyFfWzT0qLBocxzK9z4g_25_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1423000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_q0VLbCWcTk-0p7aXtlkkqg_25_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1691000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_2_Xxv5TbWUqYp9vwfc_IgA_25_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3775000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_SZYZKvBV0kC-zSfDHS3mDg_26_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-167608000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_i1CaoAlZt0a-7XNo5PqHGg_26_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-182355000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_e2OE1c_d_U610wWW42fgrw_26_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-108942000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g"
      decimals="INF"
      id="Tc_UadjxvHA8kGgTPrfUzKVGA_5_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">29579364</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SYEHQ75UI0KWzSFJW0os_g"
      decimals="-3"
      id="Tc_33GOvKZNmUKwnuUuFRe4qA_5_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_17g0OGLnwUulZtNoxhH01g"
      decimals="-3"
      id="Tc_Nw-7Mhg3HkiBHAMVSTyk1w_5_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">567637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6cIYOfo-dUykEJArEMVFiw"
      decimals="-3"
      id="Tc_s4o7LTbYZkqT7BzvfYVgbQ_5_11"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-3388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CUy4QtZ-V0Cj2wqjpP3QOg"
      decimals="-3"
      id="Tc_VY7MzxBXzUiUi70TKLLmqw_5_14"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-218379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_7Bn4AO2XvkW3epaw1AM0Wg"
      decimals="-3"
      id="Tc_u2eHW47sF0G3XtiqN6YNvQ_5_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">346254000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ"
      decimals="INF"
      id="Tc_EJ7qvv9OGEuz-vh1pZ5l5g_6_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">78074</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ"
      decimals="-3"
      id="Tc_vA_npVpam0y-pEEGNzbPig_6_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw"
      decimals="-3"
      id="Tc_Bapl-rwA20Gpnu3sJ79HIQ_6_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">988000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_Ns25Wcfx9E-KNIfHjQJGMQ_6_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">989000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-5"
      id="Narr_aoD3YlMiskyBN2yDn0dckg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ"
      decimals="INF"
      id="Tc_1m4Gh4RiOUysm_DC14Iw8Q_7_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">181455</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ"
      decimals="-3"
      id="Tc_M7TgJkBumEyh5POJqXDgTg_7_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw"
      decimals="-3"
      id="Tc_FYDGlaXZBEubENykLANUbg_7_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5701000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_41BqrKGjy0K2vH__HN4J_w_7_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5703000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wRq4_Vs2hkCjXmNi9AT2NQ"
      decimals="INF"
      id="Tc_qKn_qULDs0uhzsCjN7d3hQ_8_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">35000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z64fzhQHdUSOJ5ErzJ4Csw"
      decimals="-3"
      id="Tc_t40pPaq3IUS6oS_FBY2s8w_9_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26779000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_9vpUSRE_JUqyk-mC443fnQ_9_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26779000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_teqqpUcfr0ylhQrf7zeYbA"
      decimals="-3"
      id="Tc_7QAECYfjr0-1ugdf_4y7iQ_10_11"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3775000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_I94TPNXOS0KqVz99lLa0aw_10_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3775000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNjPjZIFd06Z_lIP7g-WCw"
      decimals="-3"
      id="Tc_GBVpGupL3kSmm_1I6sdHeg_11_14"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_t4gh-f_K9U-QIz91lD8tYw_11_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112717000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m2IV-GHD4EWsFxAP8z8-YA"
      decimals="INF"
      id="Tc_x2s_Qqrn-kWXDPpJDxc6XA_12_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">29873893</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m2IV-GHD4EWsFxAP8z8-YA"
      decimals="-3"
      id="Tc_AEUJp48imkuJPxXJa-4bNA_12_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_McmuDya3A0yjgIlscqnbsQ"
      decimals="-3"
      id="Tc_cw5h1wcaCECWCeyrts4H5w_12_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">601105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_opu5bUpl2UC0TqjQ2ARQ8A"
      decimals="-3"
      id="Tc_E2pD-Qz8Y0SFKphzkiKsAg_12_11"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_StHDH1DIL0imMDDzyJOvmA"
      decimals="-3"
      id="Tc_7-KdiYcpRU-_U8_oRB4Ijg_12_14"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-331096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"
      decimals="-3"
      id="Tc_AYiJ_hLNPkOaK2SWs9OKNw_12_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">270783000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg"
      decimals="INF"
      id="Tc_7wVDd1xMqU6AqDBZbxNWwQ_13_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">54023</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw"
      decimals="-3"
      id="Tc_iroPJFsGzkShD6zMXMSQmg_13_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">681000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_gCZdjVCPFEugMw82Hl_pew_13_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">681000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_0pbPLS3uvkObg5DeJKMMhA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">16000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg"
      decimals="INF"
      id="Tc_qqbo-iMuJ06Bxaj9aUrswQ_14_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">12384706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg"
      decimals="-3"
      id="Tc__YRKY9Nq50yudGomal0lJg_14_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">162000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw"
      decimals="-3"
      id="Tc_L4HZSeH7fUqVxr0rcXiMuQ_14_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">249183000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_eAyhoCmnVEKn1f5kj9xzDA_14_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">249345000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg"
      decimals="INF"
      id="Tc_bUlhLMj-dES1Sv7J87-KcQ_15_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">119144</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8IjeLxjzokiDnVwikLrdbg"
      decimals="-3"
      id="Tc_o4jIEcV5_UWocOXeJytK1g_15_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_Y5f5d-YX5UCtYnUFDeJkiQ_15_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NFMSWtYfyESHVgS4Pvvvmw"
      decimals="-3"
      id="Tc_zxoOWwk7lUWFyN-3QxcBwA_16_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">32477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_1T4qPiL6MkaI6Fqwy5s_qg_16_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">32477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TWmLZerPx0-0_LBFph8ZLQ"
      decimals="-3"
      id="Tc_IG_mK6thQ0uL2f_PYyyu5g_17_11"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1691000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_wDzS4A2ms0Covk5fSkkSAw_17_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1691000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2JyJSn_aPkarPPFGcqtS1Q"
      decimals="-3"
      id="Tc_tIDuIzsLY02HNadC2Jjw-w_18_14"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_1gHi2wKdy0iw_X3FHXv2rg_18_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180664000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TZxfpEvZdUat_yMyIb9Zww"
      decimals="INF"
      id="Tc_jGeZ7r-sE0657VksgO2Kcg_19_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">42431766</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TZxfpEvZdUat_yMyIb9Zww"
      decimals="-3"
      id="Tc_0Wha9WvSDkWi5BnrVP6UQQ_19_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_W-C5t6IG6UWyCMUiL7Gv7g"
      decimals="-3"
      id="Tc_BjQA1zLUWUqa2kWS-ZVTKw_19_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">883446000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wdRGjbbwREGbPju45P3i5g"
      decimals="-3"
      id="Tc_AdohFCZPVUapRNDVo9TZlg_19_11"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EwM5Itcxx0ys92D7oHiEgw"
      decimals="-3"
      id="Tc_q96h7W6JxEyYue9kAL8ImQ_19_14"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-511760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_k6Oiw-0kLESQ0jlBIAvonw_19_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">370932000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ"
      decimals="INF"
      id="Tc_lFCNvkR2P0uhgISPpez2Ng_20_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">554596</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ"
      decimals="-3"
      id="Tc_NMLCIWDA3kSf8KS6iGC0Pg_20_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw"
      decimals="-3"
      id="Tc_MU3w8gZ-qUiFwlj8lDs6pg_20_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7519000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_ewdASPELyE2Fa4-oilIFTw_20_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7527000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_I1pTz_ZT6kaG6PIdyDQKBw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ"
      decimals="INF"
      id="Tc_ue84irKu9EOBc4OUJyKCLw_21_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">25933706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ"
      decimals="-3"
      id="Tc_LCBLRkzhd0ihF2wP-yx4iQ_21_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">331000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw"
      decimals="-3"
      id="Tc_tR2j2RML-0CFcnwodm7crg_21_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">543796000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_c4hynl_B5EasMl3iucWJYw_21_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">544127000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ"
      decimals="INF"
      id="Tc_P9D5Z_WI_E6JpJraIVlnag_22_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">141350</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PZuVNetcIkK4u4IvbJiSWQ"
      decimals="-3"
      id="Tc_-Vhre670_UCmLiY0ZnUeEg_22_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_UwMKA0K5BkSrWfwSNdilkA_22_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sX7r4McIVECLlGdtS0UhWw"
      decimals="-3"
      id="Tc_3MvGgunkS0SuUbbei9sajA_23_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">38081000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_VV2LPMqZG0CGgRdbHhLn5A_23_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">38081000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_AM5bQ16iwE-vzlxN1fzJfQ"
      decimals="-3"
      id="Tc_afXF6j4d-k6C5cZ6HDg81g_24_11"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1423000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_LMI4CbUD7EWSrhmCexvEaw_24_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1423000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DBNovfpDakCcvAVq5SANGw"
      decimals="-3"
      id="Tc_3tBlu2X00ECTKkHEEdj4Og_25_14"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169031000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_ZH-77hzPxkOes6nGyVCeqA_25_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169031000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyIVXSsfEEW_9ZjaJ49EjA"
      decimals="INF"
      id="Tc_ig4PgRpackSteTy1a6L1DA_26_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">69061418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dyIVXSsfEEW_9ZjaJ49EjA"
      decimals="-3"
      id="Tc_XdY-xUb26ES2Y4ZwvzmCNw_26_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">890000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dEcOv1S1kUyL15GIo0RjgQ"
      decimals="-3"
      id="Tc_r8saVKe6vkqfKsHmB2C1uw_26_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1472842000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_F8DiQa_QMka5iKKuHx7img"
      decimals="-3"
      id="Tc_oJ8TEVAFAka_86WINQg1Vg_26_11"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_n0HyqUG8pkaNcopt1SdSjQ"
      decimals="-3"
      id="Tc_nSJ3CXLPVk2d3k4OVxoAMA_26_14"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-680791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_aDsu4bCwikiqMA1Oh487_Q_26_17"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">793060000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_6xk1aku2SUuXOIF-1O_UWQ_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169031000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_bBm4UhPFKEG9wqxtuMYo6A_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180664000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc__sScb7edWEepi7_Dg2iQag_6_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112717000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_z4q1-3t8Bk-gtc5w0a4i9Q_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">38081000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_ChhkNgjdzEyLVIJMaz2o-w_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">32477000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_xqDr8j9Mj06uPtm4iGuf7g_8_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26779000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_GvpcXsZO8kK8RxOxgJOaPA_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7174000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_0u9Ttk9kmU6LbG6UU_BGOQ_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">6546000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_fSY2nOmQa0eYZEc_KO5Lkg_9_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3689000</us-gaap:DepreciationDepletionAndAmortization>
    <bcyc:NonCashInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_dHTNBgWF8E2yUnoOXCAvlw_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">211000</bcyc:NonCashInterestExpense>
    <bcyc:NonCashInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_MCJB7mAYkEGS8yXz6rI7fA_10_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">383000</bcyc:NonCashInterestExpense>
    <bcyc:NonCashInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_GNbM9FiHUECZg3Rl-lBAeQ_10_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">442000</bcyc:NonCashInterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_3GelHm8K70GaMzcr1NYkCQ_11_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-954000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_WT9sFKIXBEqwm_o98EZGhA_12_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4476000</bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_hgny9Wi7FUainjy-DYIZaQ_13_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-5226000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_QlrkP6WLpUmAbZ8xZQx65Q_13_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3306000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_BW46nZ0X0EWVFDhHlPohbg_13_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4976000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_Zfs3UmVv9EymnbQYxDrNCw_14_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1036000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_0ntefU7CVU2TNtqbe-3SJQ_14_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">661000</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_2TC-hsw4XU-6UvT-J-0ETw_16_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-2482000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_XKUW8YlHl0yCacK-QwBXeg_16_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1641000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_TezjvRLnFU-qu-q_lYrypg_17_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11947000</bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_4IB9v1oud0CP2ZPyUHkA8Q_17_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3684000</bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_1SIwvVVNZEaNfOJdVa0Q3g_17_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9707000</bcyc:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_UWZdXkwDeEqvItDubeiDfg_18_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2044000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_82McyKNIf0Szy3eRU2GE4w_18_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2072000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_K-FRssEG9EqbpzKA1jVr_g_18_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2020000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_ax9JK8hxI0SGYdAFN-wb2g_19_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4402000</bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_tKhKhyPk2kSESotWOdAaLQ_19_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4186000</bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_7jDRN27SD0-pj8Z_X5Fx-w_19_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-2698000</bcyc:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_piQbht4Lq0-ifgFazEbGlg_20_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3095000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_6ozHOFklhEe_5ePnv0gKVA_20_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8002000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_bLaeQqx5Vkm6Ko2KfiOVjA_20_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2561000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_vKMTL1miJ0ePw6yr_HoceA_21_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9698000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_NeecUq61wEmnFk2nhh5usA_21_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2398000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_5vNeL20xc02WaOcwhj4QKA_21_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12362000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_lZv1N3VrckOEewZFKhWsNQ_22_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4888000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_SfYm7Rq68UGAtH8K6FgxJA_22_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4109000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_eGE-aBklnUyxzNpjZxUfgw_22_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-2114000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_8caHU-QOjUGU-jiD9AeFeg_23_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-31952000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_EXPl3ALHeE6faj7WaHRCvA_23_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">68951000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_ioUR7Q13f0GVLNc-NEjtAw_23_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-2135000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_8y7Ye3Yn0kGfS6ctjjd7LQ_24_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">189000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_cg5r-KJq-Ua7MrY5Ue-I3w_24_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">509000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_sNaLVUY4ZU27gc-iot5Xhg_24_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">668000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_tNl33O1_UUGvZRpze5Ctag_25_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-164724000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_Yek0EluU5ky86fywnSYJzw_25_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-60628000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_HxT7YCAWI0C03xVBChC3XA_25_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-86111000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_OrVyUaAoCkCq21MT3X8gGA_27_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1235000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_w_5QqFFDaEawlEh9Id9-pQ_27_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2929000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_x2M5DIwsQ0CiitlrUxZJ4w_27_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">18987000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_REeC-hTYE0-si2KASMTIUg_28_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1235000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_ySMPax6EmkKyZCvlII4Z_w_28_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-2929000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_trKxMNsYZEmRbWNIN7AMKg_28_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-18987000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_vz1jVEH3dUGZGahHTLCEzA_30_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31863000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_Gah27WVyFUG8SV-EGqrkKw_31_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">544127000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_yvKkEumAc0m9fzM0SCLqNA_31_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">249345000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_wuEdgFKnHkGppB9jZk6Y1A_31_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5703000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_tWXf1FYIRk67jXSqXpAEyA_32_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7528000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_ACADALAGqUGh0wlIS6vlGQ_32_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">682000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_HIBa9b7xkkyyLk5nSOBxJg_32_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">989000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_Mx7M6Po0pU-fPIsWgk5DwA_33_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">42000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_iMDSRtkC_k2CQ7zT9Oc8hw_34_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">519750000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_4u3NjYoawUW5MVcsi0-cpA_34_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">250027000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_qdyrDut1tkGz3VpWiuuHlQ_34_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">6692000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_yZSCKKks7U-YIkKWezJ-dg_35_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-694000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_JRPGhwho-EGHlkhgoOBapQ_35_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1346000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_l3_Ks5u8-0qgBw3h4SDBMg_35_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1120000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_ICZ453GgrkO92rTdroYZJA_36_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">353097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_KNB7ydvi8k6fwrMdaSgd3w_36_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">187816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_odQV_fahlESBRe7sByt58A_36_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-99526000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_w2WIgF33ZUuGFPP08jvPOg_37_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">526970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"
      decimals="-3"
      id="Tc_vK68RPO6oUmHhpFOwiutvw_37_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">339154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_7Bn4AO2XvkW3epaw1AM0Wg"
      decimals="-3"
      id="Tc_Cbjhgh8dQkypxpu-Ji4C-g_37_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">438680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_Uh9sprQIb0WtmVUPX9uGPQ_38_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">880067000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_GiuNwWJ2aU2yEMpoqODSpQ_38_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">526970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"
      decimals="-3"
      id="Tc_cxaYMFS5LUKGWB-rM3nbPQ_38_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">339154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_dE-HrepswkWWTo5lXZomVg_40_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">879520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_BHbn4blXdECBRUb2WK-lEQ_40_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">526423000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"
      decimals="-3"
      id="Tc_wrLgLKtsjUGO1TZjkc2_3Q_40_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">339154000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_lMTPPbLdZkCFQewGXan4QQ_41_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">547000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_gkUbciRYCkuQosKnU0R1_w_41_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">547000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_hFguOFd7w0-CqKUAidMWBQ_42_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">880067000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_2gBj7j1oaU2c0A58XKxyZQ_42_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">526970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"
      decimals="-3"
      id="Tc_ysNz5FwGmkatz752BowP2g_42_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">339154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_vGJzJmqXTEi4AS-oi-Ja0g_44_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1373000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_buD9Mo9ae0GwBdLieUEn2g_44_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2753000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_xJHk_4f6vUGFXF4J8Tv5xA_44_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2793000</us-gaap:InterestPaidNet>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_IVp5M7d-wU6YCMYsoL1NaA_45_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">23000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_97v1F6R6XU-yecx-HI36ug_46_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">792000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_MO9n_pW6uEqOQQgaPrHfWA_46_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">562000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_VQhwDidIZUOegjwtsiVlNA_46_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2228000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_LVRxa0ijOkKmu7fo2CVbNg_47_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5785000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_Ig3KYGJ-10-bhTH5TQIMfw_47_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5595000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_2dPGDZIDq0SmeIiuOXSfcA_47_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3154000</us-gaap:OperatingLeasePayments>
    <bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_VVQusbQoO0e3lOB1bTUc4Q_48_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4000</bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid>
    <bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_mn1lFckw602zXeQYVGLq9A_48_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1744000</bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid>
    <bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_EiTqmOfUSkCOboQzZ4d0eA_48_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1564000</bcyc:IncreaseDecreaseCapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_K9tPMJeRsEm2rBaHAx7TuQ_49_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3898000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_nPzxb0ySsEKbGBPvzQ7Vng_49_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3120000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_rRvF8K_2y0uraa1LIiQvnA_50_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1102000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_-qAWikrN4UaJKCwpgtD9qA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;1. Nature of the business and basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Bicycle Therapeutics plc (collectively with its subsidiaries, the &#x201c;Company&#x201d;) is a clinical-stage pharmaceutical company developing a novel class of medicines, which the Company refers to as&#160;Bicycle&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; &#xae;&lt;/sup&gt; molecules, for diseases that are underserved by existing therapeutics.&#160;Bicycle molecules&#160;are a unique therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. The Company&#x2019;s initial internal programs are focused on oncology indications with high unmet medical need. The Company is evaluating zelenectide pevedotin, formerly BT8009, a Bicycle Toxin Conjugate (a &#x201c;BTC&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&#x201d;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; &lt;/sup&gt;molecule) targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing company-sponsored Phase II/III registrational trial, called Duravelo-2, BT5528, a BTC molecule targeting Ephrin type-A receptor 2 (&#x201c;EphA2&#x201d;), in an ongoing company-sponsored Phase I/II clinical trial, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (a &#x201c;Bicycle TICA&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&#x201d; molecule) targeting Nectin-4 and agonizing CD137, in an ongoing company-sponsored Phase I/II clinical trial. The Company&#x2019;s discovery pipeline in oncology includes&#160;next-generation BTC molecules and Bicycle&lt;i style="font-style:italic;"&gt; &lt;/i&gt;Radionuclide Conjugates (&#x201c;BRC&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&#x201d;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; &lt;/sup&gt;molecules). Beyond the Company&#x2019;s wholly owned oncology portfolio, the Company is collaborating with biopharmaceutical companies and organizations in therapeutic areas in which the Company believes its proprietary Bicycle screening platform can identify therapies to treat diseases with significant unmet medical need. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of Bicycle Therapeutics plc and its wholly owned subsidiaries, BicycleTx Limited, BicycleRD Limited and Bicycle Therapeutics&#160;Inc. All intercompany balances and transactions have been eliminated on consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;As of December 31, 2024, the Company had cash and cash equivalents of $879.5 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital. The Company has funded its operations with proceeds from the sale of its ordinary shares, American Depositary Shares (&#x201c;ADSs&#x201d;), including in its offerings pursuant to its at-the-market offering program (&#x201c;ATM&#x201d;), and non-voting ordinary shares, as well as proceeds received from its collaboration arrangements (Note&#160;9) and proceeds from a loan agreement with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;) (Note 6). The Company has incurred recurring losses since inception, including net losses of $169.0 million, $180.7 million, and $112.7 million for the&#160;years ended December&#160;31, 2024, 2023, and 2022, respectively. As of December&#160;31, 2024, the Company had an accumulated deficit of $680.8 million. The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash will be sufficient to fund its operating expenses and capital expenditure requirements through at least twelve&#160;months from the issuance date of these annual consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expects its expenses to increase substantially in connection with ongoing activities, particularly as the Company advances its clinical trials for its product candidates in development and preclinical activities. Accordingly, the Company will need to obtain additional funding in connection with continuing operations. If the Company is unable to raise funding when needed, or on attractive terms, it could be forced to delay, reduce or eliminate its research or drug development programs or any future commercialization efforts. There is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks common to companies in the biotechnology and pharmaceutical industries, including but not limited to, risks of delays in initiating or continuing research programs and clinical trials, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, if approved, dependence on key personnel and collaboration partners, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if the Company&#x2019;s research and development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_j9BIUOm9vkSQpTQXuRCezA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">879500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_q2aq-cNYmk-KiMUmgUKE2w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_RqU8899S3kaC2GhyOWFhrg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-5"
      id="Narr_fEX9F9HxckujokGIlrnvwg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112700000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_y3IzUzzOt0i8Ada46Wn_kw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-680800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_h5E56m3mTU23hOcIRe21Dw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of significant accounting policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and research and development incentives receivable, share-based compensation expense, valuation of right-of-use assets and liabilities, gain on extinguishment of research and development funding liability and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Significant risks and uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company currently operates in a period of economic uncertainty which has been significantly impacted by domestic and global monetary and fiscal policy, geopolitical conflicts such as the ongoing wars involving Ukraine and Israel, inflation and interest rates, and fluctuations in monetary exchange rates. While the Company has experienced limited financial impacts at this time, the Company continues to monitor these factors and events and the potential effects each may have on the Company&#x2019;s business, financial condition, results of operations and growth prospects. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency and currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The reporting currency of the Company is the U.S. Dollar (&#x201c;USD&#x201d;). The functional currency of Bicycle Therapeutics plc&#x2019;s wholly owned non-U.S. subsidiaries, BicycleTx Limited and BicycleRD Limited, is the British Pound Sterling, and the functional currency of its U.S. subsidiary, Bicycle Therapeutics Inc., is the USD. The functional currency of the Company&#x2019;s subsidiaries is the same as the local currency. Monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in general and administrative expense in the consolidated statements of operations and comprehensive loss as incurred. The Company recorded foreign exchange losses of $0.7 million, $0.6 million and $0.6 million for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company translates the assets and liabilities of its non-U.S. subsidiaries into USD at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a foreign currency translation adjustment, which is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;included in the consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive income (loss).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. The Company diversifies its cash and cash equivalents in multiple financial institutions and in money market funds that are primarily invested in U.S. Treasury securities that are backed by the U.S. government and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships and investments in money market funds invested in U.S. Treasury securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 and 2023, the Company had no accounts receivable. For the years ended December&#160;31, 2024, 2023, and 2022, the Company&#x2019;s revenue has primarily been generated from collaboration agreements with Bayer Consumer Care AG (&#x201c;Bayer&#x201d;), Novartis Pharma AG (&#x201c;Novartis&#x201d;), Ionis Pharmaceuticals, Inc. (&#x201c;Ionis&#x201d;), Genentech, Inc. (&#x201c;Genentech&#x201d;) and AstraZeneca AB (&#x201c;AstraZeneca&#x201d;) (Note 9).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company relies, and expects to continue to rely, on multiple vendors to manufacture clinical trial materials and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and restricted cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments that are readily convertible to known amounts of cash with original maturities of three&#160;months or less at date of purchase to be cash equivalents. The Company had cash equivalents of $664.9 million and $72.3 million at December&#160;31, 2024 and 2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 and 2023, the Company had $0.5 million of restricted cash related to a collateralized letter of credit in connection with the Company&#x2019;s lease for office and laboratory space in Cambridge, Massachusetts, which is included within other assets in the Company&#x2019;s consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders&#x2019; equity as a reduction of proceeds generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_p8M7K2bjKEax4G-nyR6gbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt; to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease term or useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for property and equipment not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. To date, there have been no significant asset retirements. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss may be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any material impairment losses on long-lived assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain of the Company&#x2019;s assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#160;&#x2014; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#160;&#x2014; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying values of cash, cash equivalents and restricted cash, research and development incentives receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. As of December 31, 2023, the carrying value of the debt approximated its fair value, which was determined using unobservable Level 3 inputs, including quoted interest rates from a lender for borrowings with similar terms. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;"&gt;Debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Debt issuance costs consist of certain third-party legal expenses and payments made to secure commitments under certain debt financing arrangements. These amounts are recorded as a reduction to the carrying value of the associated debt and are recognized as interest expense over the period of the financing arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment and geographic information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of a business for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company operates in two geographic regions: the United&#160;Kingdom and the United&#160;States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For additional segment information, see Note&#160;15, &#x201c;Segments and geographic information.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases are accounted for in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, &lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;(&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is or contains a lease at inception. Assets and liabilities related to operating leases are included in operating lease right of use (&#x201c;ROU&#x201d;) assets, other current liabilities, and operating lease liabilities in the Company&#x2019;s consolidated balance sheets. Assets and liabilities related to finance leases are included in property and equipment, net, accrued expenses and other current liabilities, and other long-term liabilities in the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets represent the Company&#x2019;s right to use and control an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The ROU asset also includes lease payments made before the lease commencement date and excludes any lease incentives. The Company identifies and assesses the following significant assumptions in recognizing the ROU assets and corresponding lease liabilities: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Expected lease term&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; The expected lease term includes both contractual lease periods and, when applicable, periods covered by an option to extend the lease when it is reasonably certain that the Company will exercise the extension option, or cancelable option periods when it is reasonably certain that the Company would not exercise such cancelation option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Incremental borrowing rate&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available on the commencement date in determining the present value of lease payments. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimates the incremental borrowing rate by comparing interest rates available in the market for similar borrowings and third-party quotations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Lease and non-lease components&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; The components of a lease shall be split into three categories, if applicable: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must then be allocated based on fair values to the lease components and non-lease components. The Company&#x2019;s operating leases for its facilities and finance leases for property and equipment may have both lease components and non-lease components for which the Company has elected to apply the practical expedient to account for each lease component and related non-lease component as one single component. The lease component results in a ROU asset being recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;For operating leases, lease expense for lease payments is considered operating lease cost and is recognized on a straight-line basis over the lease term. Variable payments for other operating costs, which may be billed based on both usage and as a percentage of the Company&#x2019;s share of total square footage, are considered variable lease cost and are recognized in the period in which the costs are incurred. For finance leases, amortization expense related to finance lease ROU assets is recognized on a straight-line basis over the earlier of the useful life of the ROU asset or the lease term and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;interest expense is recognized based on the effective interest method using the Company&#x2019;s incremental borrowing rate. Operating, variable and finance lease cost are recorded as a component of research and development expenses and general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The terms of these arrangements may include (i)&#160;performing research and development services using the Company&#x2019;s bicyclic peptide screening platform with the goal of identifying and/or optimizing compounds for further development and commercialization, (ii) the transfer of intellectual property rights (licenses), or (iii) options to obtain additional research and development services or licenses for additional targets, or to optimize product candidates, upon the payment of option fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; payments for research and development services and reimbursement of certain expenses incurred; fees upon the exercise of options to obtain additional services or licenses; payments based upon the achievement of defined collaboration objectives; future regulatory and sales-based milestone payments; and royalties on net sales of future products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC&#160;606&#x201d;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, and financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC&#160;606, it performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each performance obligation based on estimated relative standalone selling prices, and measuring progress towards the satisfaction of each performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Once a contract is determined to be within the scope of ASC&#160;606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations at contract inception. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. The promised goods or services in the Company&#x2019;s contracts with customers primarily consist of license rights to the Company&#x2019;s intellectual property, research and development services, options to acquire additional research and development services, and options to obtain additional licenses, such as a commercialization license for a potential product candidate. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources, and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the collaboration partner to develop the intellectual property on their own and whether the required expertise is readily available. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate variable consideration to include in the transaction price based on which method better predicts the amount of consideration expected to be received. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. The initial transaction price of a contract does not include amounts associated with customer option payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;After the transaction price is determined, it is allocated to the identified performance obligations based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, probabilities of technical and regulatory success and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an input method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of intellectual property:&lt;/i&gt; If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from portion of the transaction price allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, such as research and development services and a research license, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and development services:&lt;/i&gt; The promises under the Company&#x2019;s collaboration agreements may include research and development services to be performed by the Company on behalf of the customer. Payments or reimbursements resulting from the Company&#x2019;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Customer options:&lt;/i&gt; A customer&#x2019;s right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide, and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or at a discount. Optional future goods and services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. If optional future goods and services include a material right, they are accounted for as performance obligations. The Company determines an estimated standalone selling price of any material rights for the purpose of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;allocating the transaction price. The Company considers factors such as the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone payments:&lt;/i&gt; The Company&#x2019;s collaboration agreements may include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net loss in the period of adjustment. Milestone payments that may only be achieved after the exercise of a customer option are excluded from the initial determination of the transaction price. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt; For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company&#x2019;s collaboration agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company receives payments from customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional, such as when the Company has a contractual right to payment per the terms of the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For additional information regarding the Company&#x2019;s accounting for collaboration revenue, see Note&#160;9, &#x201c;Significant agreements.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, facilities costs, depreciation, materials and laboratory supplies, and external costs of outside vendors engaged to conduct preclinical development and clinical development activities, as well as costs to manufacture clinical trial materials. Facilities costs primarily include the allocation of rent and utilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized until the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company has entered into various research and development and manufacturing contracts, including contracts with respect to preclinical studies and clinical trials, with companies both inside and outside of the United&#160;States. These agreements are generally cancelable with 90&#160;days or less notice, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research and development and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development incentives and receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company, through its subsidiaries in the U.K., receives reimbursements of certain research and development expenditures as part of a U.K. government&#x2019;s research and development tax reliefs program. Under the Small and Medium-Sized Enterprises (&#x201c;SME&#x201d;) R&amp;amp;D Tax Relief program, the Company is able to surrender trading losses that arise from qualifying research and development expenses incurred by the Company&#x2019;s subsidiaries in the United&#160;Kingdom for a cash rebate of up to 33.35% of qualifying expenditure incurred prior to April 1, 2023, and up to 18.6% of qualifying expenditure incurred thereafter. Amendments to the U.K. R&amp;amp;D tax credit regime included in Finance Act 2024, which was enacted in February 2024, increased the cash rebate that may be claimed to 26.97% of qualifying expenditure, retroactively applied to qualifying expenditures incurred after April 1, 2023, if the Company qualifies as &#x201c;R&amp;amp;D intensive&#x201d; for an accounting period (broadly, a loss making SME whose relevant R&amp;amp;D expenditure represents, for accounting periods beginning on or after April 1, 2023, 40%, or, for accounting periods beginning on or after April 1, 2024, 30%, of its total expenditure for that accounting period). The Company was an R&amp;amp;D intensive SME for the years ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and development incentives as a reduction to research and development expenses in the consolidated statements of operations and comprehensive loss, as the research and development tax credits are not dependent on us generating future taxable income, the Company&#x2019;s ongoing tax status, or tax position. The research and development incentives receivable represent an amount due in connection with the above program. The Company recorded a reduction to research and development expense of $43.1 million for the year ended December 31, 2024, including the impact of an increase to U.K. R&amp;amp;D tax credit reimbursement rates enacted with Finance Act 2024 retroactively applied to qualifying expenditures incurred after April 1, 2023. The Company recorded a reduction to research and development expense of $23.5 million and $19.3&#160;million during the&#160;years ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with preparing, filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures all equity awards granted to employees and directors based on the fair value on the date of grant. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with only service-based vesting conditions using the straight-line method. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For share-based awards granted to non-employee consultants, the measurement date is the date of grant. The compensation expense is then recognized over the requisite service period, which is the vesting period of the respective award, without subsequent changes in the fair value of the award.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The fair value of each restricted share award is based on the fair value of the Company&#x2019;s shares, less any applicable purchase price. The fair value of each share option is estimated using the Black-Scholes option-pricing model, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;which requires inputs based on certain subjective assumptions, including the fair value of shares, the expected share price volatility, the expected term of the award, the risk-free interest rate and expected dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to 2022, due to a lack of company-specific historical volatility data, the Company&#x2019;s expected volatility was calculated based on reported volatility data for a representative group of publicly traded companies for which historical information was available. The historical volatility was calculated based on a period of time commensurate with the assumption used for the expected term. During 2022, the Company began to estimate its volatility by using a blend of its stock price history for the length of time it has market data for its stock and the historical volatility of similar public companies for the expected term of each grant. The Company continues to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its share-based awards. The Company uses the remaining contractual term for the expected life of non-employee awards. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll or service costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation as a component of other comprehensive loss in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential loss range is probable and reasonably estimable under the provisions of ASC Topic 450, &lt;i style="font-style:italic;"&gt;Contingencies&lt;/i&gt;. The Company expenses costs as incurred in relation to such loss contingencies as general and administrative expense within the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the (benefit from) provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that will more likely than not be realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period, including potential dilutive ordinary shares assuming the dilutive effect of ordinary share equivalents. In periods in which the Company reported a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures&lt;/i&gt;, which requires disclosure of incremental segment information on an interim and annual basis. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, and requires retrospective adoption to all prior periods presented in the consolidated financial statements. The adoption of ASU 2023-07 had no impact on the Company&#x2019;s reportable segments identified and additional required disclosures have been included in Note 15.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements not yet adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/i&gt;, which requires more detailed disclosures about specified categories of expenses included in certain expense captions presented on the face of the consolidated statements of operations and comprehensive loss, including employee compensation, depreciation and amortization. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to all prior periods presented. The Company is currently evaluating the impact of the adoption of ASU No. 2024-03 on its consolidated financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740) Improvements to Income Tax Disclosures&lt;/i&gt;, which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 is effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its consolidated financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_j9RJzY4qgkCIvIxiUghLDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and research and development incentives receivable, share-based compensation expense, valuation of right-of-use assets and liabilities, gain on extinguishment of research and development funding liability and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <bcyc:SignificantRisksAndUncertaintiesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_7BcIsmm0S0uxh-v_6glM0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Significant risks and uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company currently operates in a period of economic uncertainty which has been significantly impacted by domestic and global monetary and fiscal policy, geopolitical conflicts such as the ongoing wars involving Ukraine and Israel, inflation and interest rates, and fluctuations in monetary exchange rates. While the Company has experienced limited financial impacts at this time, the Company continues to monitor these factors and events and the potential effects each may have on the Company&#x2019;s business, financial condition, results of operations and growth prospects. &lt;/p&gt;</bcyc:SignificantRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_AhsD5Ybm-EytXKASIxtYbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency and currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The reporting currency of the Company is the U.S. Dollar (&#x201c;USD&#x201d;). The functional currency of Bicycle Therapeutics plc&#x2019;s wholly owned non-U.S. subsidiaries, BicycleTx Limited and BicycleRD Limited, is the British Pound Sterling, and the functional currency of its U.S. subsidiary, Bicycle Therapeutics Inc., is the USD. The functional currency of the Company&#x2019;s subsidiaries is the same as the local currency. Monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in general and administrative expense in the consolidated statements of operations and comprehensive loss as incurred. The Company recorded foreign exchange losses of $0.7 million, $0.6 million and $0.6 million for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company translates the assets and liabilities of its non-U.S. subsidiaries into USD at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a foreign currency translation adjustment, which is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;included in the consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive income (loss).&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_uRVNdsAb80OOcw5Ig3UFtA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_CkZzqzW8RkWYXOCBcb7FaQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-5"
      id="Narr_D0XfiWtVdUGp_MJxU5n4sQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_7oYyEoKqFEaq02l6a81Tlg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company deposits its cash in financial institutions in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. The Company diversifies its cash and cash equivalents in multiple financial institutions and in money market funds that are primarily invested in U.S. Treasury securities that are backed by the U.S. government and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships and investments in money market funds invested in U.S. Treasury securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 and 2023, the Company had no accounts receivable. For the years ended December&#160;31, 2024, 2023, and 2022, the Company&#x2019;s revenue has primarily been generated from collaboration agreements with Bayer Consumer Care AG (&#x201c;Bayer&#x201d;), Novartis Pharma AG (&#x201c;Novartis&#x201d;), Ionis Pharmaceuticals, Inc. (&#x201c;Ionis&#x201d;), Genentech, Inc. (&#x201c;Genentech&#x201d;) and AstraZeneca AB (&#x201c;AstraZeneca&#x201d;) (Note 9).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company relies, and expects to continue to rely, on multiple vendors to manufacture clinical trial materials and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Narr_dSJV7o_CDkuBlUGo--oz1g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Narr_cp1KmJAWSk6QFql8RROFJA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_uWoQccJLgk-RR5NpZ9G-Mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and restricted cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments that are readily convertible to known amounts of cash with original maturities of three&#160;months or less at date of purchase to be cash equivalents. The Company had cash equivalents of $664.9 million and $72.3 million at December&#160;31, 2024 and 2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 and 2023, the Company had $0.5 million of restricted cash related to a collateralized letter of credit in connection with the Company&#x2019;s lease for office and laboratory space in Cambridge, Massachusetts, which is included within other assets in the Company&#x2019;s consolidated balance sheet. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_eOxsQPNFNUW5htG-SqCshQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">664900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-5"
      id="Narr_Zw1EqSggmUW8nsqp7tMVkQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">72300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-5"
      id="Narr_AQQVIRQUfkm2FOsVScPM7w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">500000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_3u0zJeoV3kioY4ax5oe-ug"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">500000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_1HfjtNwyQUSYGUgUsOqWRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders&#x2019; equity as a reduction of proceeds generated as a result of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_DOTSTA1JHE6jzTT8YFGQIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_p8M7K2bjKEax4G-nyR6gbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt; to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease term or useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for property and equipment not yet placed into service are capitalized as construction-in-progress and depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. To date, there have been no significant asset retirements. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <bcyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_A4rOo4WOVkOReKwKDydyAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:34.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_p8M7K2bjKEax4G-nyR6gbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt; to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease term or useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CzvZPim0k0CUHrLZ3N9Ulw"
      id="Narr_KUkPDjU5zUmUmY7lsnDx2g">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xx2lOaIKTUaBAJxmtahpDA"
      id="Tc_dypJc4jlukOCY43A41TbzA_4_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kkZvNCSDbEyvWrxvy0J0Jg"
      id="Narr_IArfIt_Zr0ytUbutd4kZKA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_B4rIlVudJkC7UiJJ14Ug0g"
      id="Narr_1MdycqwAHU2ds5Kj-tFHoA">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_UfxqvYRgQ0aBDoMhPjxzdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss may be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any material impairment losses on long-lived assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_BQV8rCsiDECbXnjVCGHglQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain of the Company&#x2019;s assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#160;&#x2014; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#160;&#x2014; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying values of cash, cash equivalents and restricted cash, research and development incentives receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. As of December 31, 2023, the carrying value of the debt approximated its fair value, which was determined using unobservable Level 3 inputs, including quoted interest rates from a lender for borrowings with similar terms. &lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_z_LdgmJZjkKDsU1Lq3euIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;"&gt;Debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;Debt issuance costs consist of certain third-party legal expenses and payments made to secure commitments under certain debt financing arrangements. These amounts are recorded as a reduction to the carrying value of the associated debt and are recognized as interest expense over the period of the financing arrangement.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_K_0zFodpWke1LgFLhZdvXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment and geographic information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of a business for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company operates in two geographic regions: the United&#160;Kingdom and the United&#160;States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For additional segment information, see Note&#160;15, &#x201c;Segments and geographic information.&#x201d;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <bcyc:NumberOfGeographicRegionsInWhichOperating
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="INF"
      id="Narr_at9EyFuNf0G4DfjNXFQP4A"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfGeographicRegionsInWhichOperating>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_OEmndfTpBEqj1Dd1qgfgYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases are accounted for in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, &lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;(&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is or contains a lease at inception. Assets and liabilities related to operating leases are included in operating lease right of use (&#x201c;ROU&#x201d;) assets, other current liabilities, and operating lease liabilities in the Company&#x2019;s consolidated balance sheets. Assets and liabilities related to finance leases are included in property and equipment, net, accrued expenses and other current liabilities, and other long-term liabilities in the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets represent the Company&#x2019;s right to use and control an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The ROU asset also includes lease payments made before the lease commencement date and excludes any lease incentives. The Company identifies and assesses the following significant assumptions in recognizing the ROU assets and corresponding lease liabilities: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Expected lease term&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; The expected lease term includes both contractual lease periods and, when applicable, periods covered by an option to extend the lease when it is reasonably certain that the Company will exercise the extension option, or cancelable option periods when it is reasonably certain that the Company would not exercise such cancelation option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Incremental borrowing rate&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available on the commencement date in determining the present value of lease payments. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimates the incremental borrowing rate by comparing interest rates available in the market for similar borrowings and third-party quotations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Lease and non-lease components&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; The components of a lease shall be split into three categories, if applicable: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, maintenance, consumables, etc.) and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any related to non-components) must then be allocated based on fair values to the lease components and non-lease components. The Company&#x2019;s operating leases for its facilities and finance leases for property and equipment may have both lease components and non-lease components for which the Company has elected to apply the practical expedient to account for each lease component and related non-lease component as one single component. The lease component results in a ROU asset being recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;For operating leases, lease expense for lease payments is considered operating lease cost and is recognized on a straight-line basis over the lease term. Variable payments for other operating costs, which may be billed based on both usage and as a percentage of the Company&#x2019;s share of total square footage, are considered variable lease cost and are recognized in the period in which the costs are incurred. For finance leases, amortization expense related to finance lease ROU assets is recognized on a straight-line basis over the earlier of the useful life of the ROU asset or the lease term and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;interest expense is recognized based on the effective interest method using the Company&#x2019;s incremental borrowing rate. Operating, variable and finance lease cost are recorded as a component of research and development expenses and general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_j7GeSuWS4EazPLKwXQV5YA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s revenues are generated primarily through collaborative arrangements and license agreements with pharmaceutical companies. The terms of these arrangements may include (i)&#160;performing research and development services using the Company&#x2019;s bicyclic peptide screening platform with the goal of identifying and/or optimizing compounds for further development and commercialization, (ii) the transfer of intellectual property rights (licenses), or (iii) options to obtain additional research and development services or licenses for additional targets, or to optimize product candidates, upon the payment of option fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; payments for research and development services and reimbursement of certain expenses incurred; fees upon the exercise of options to obtain additional services or licenses; payments based upon the achievement of defined collaboration objectives; future regulatory and sales-based milestone payments; and royalties on net sales of future products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC&#160;606&#x201d;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, and financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC&#160;606, it performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each performance obligation based on estimated relative standalone selling prices, and measuring progress towards the satisfaction of each performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Once a contract is determined to be within the scope of ASC&#160;606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations at contract inception. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. The promised goods or services in the Company&#x2019;s contracts with customers primarily consist of license rights to the Company&#x2019;s intellectual property, research and development services, options to acquire additional research and development services, and options to obtain additional licenses, such as a commercialization license for a potential product candidate. Promised goods or services are considered distinct when: (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources, and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the collaboration partner to develop the intellectual property on their own and whether the required expertise is readily available. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of the potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate variable consideration to include in the transaction price based on which method better predicts the amount of consideration expected to be received. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. The initial transaction price of a contract does not include amounts associated with customer option payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;After the transaction price is determined, it is allocated to the identified performance obligations based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, probabilities of technical and regulatory success and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, based on the use of an input method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of intellectual property:&lt;/i&gt; If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the contract, the Company recognizes revenue from portion of the transaction price allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, such as research and development services and a research license, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and development services:&lt;/i&gt; The promises under the Company&#x2019;s collaboration agreements may include research and development services to be performed by the Company on behalf of the customer. Payments or reimbursements resulting from the Company&#x2019;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Customer options:&lt;/i&gt; A customer&#x2019;s right to choose, at its discretion, to make a payment for additional goods or services is generally considered an option. If the Company is not presently obligated to provide, and does not have a right to consideration for delivering additional goods or services, the item is considered an option. The Company evaluates the customer options for material rights, such as the ability to acquire additional goods or services for free or at a discount. Optional future goods and services that reflect their standalone selling prices do not provide the customer with a material right and, therefore, are not considered performance obligations and are accounted for as separate contracts. If optional future goods and services include a material right, they are accounted for as performance obligations. The Company determines an estimated standalone selling price of any material rights for the purpose of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;allocating the transaction price. The Company considers factors such as the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone payments:&lt;/i&gt; The Company&#x2019;s collaboration agreements may include development and regulatory milestones. The Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue and net loss in the period of adjustment. Milestone payments that may only be achieved after the exercise of a customer option are excluded from the initial determination of the transaction price. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt; For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognizes revenue at the later of: (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from the Company&#x2019;s collaboration agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company receives payments from customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional, such as when the Company has a contractual right to payment per the terms of the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For additional information regarding the Company&#x2019;s accounting for collaboration revenue, see Note&#160;9, &#x201c;Significant agreements.&#x201d;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_ekCYzrmLnUa1wOwKpQsfzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, travel, facilities costs, depreciation, materials and laboratory supplies, and external costs of outside vendors engaged to conduct preclinical development and clinical development activities, as well as costs to manufacture clinical trial materials. Facilities costs primarily include the allocation of rent and utilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized until the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <bcyc:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_Z9G0lXS6Z0CowCvLs1XG5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company has entered into various research and development and manufacturing contracts, including contracts with respect to preclinical studies and clinical trials, with companies both inside and outside of the United&#160;States. These agreements are generally cancelable with 90&#160;days or less notice, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research and development and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;</bcyc:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock>
    <bcyc:ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_mDOUbpUPREiF4fH7Z7cLjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development incentives and receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company, through its subsidiaries in the U.K., receives reimbursements of certain research and development expenditures as part of a U.K. government&#x2019;s research and development tax reliefs program. Under the Small and Medium-Sized Enterprises (&#x201c;SME&#x201d;) R&amp;amp;D Tax Relief program, the Company is able to surrender trading losses that arise from qualifying research and development expenses incurred by the Company&#x2019;s subsidiaries in the United&#160;Kingdom for a cash rebate of up to 33.35% of qualifying expenditure incurred prior to April 1, 2023, and up to 18.6% of qualifying expenditure incurred thereafter. Amendments to the U.K. R&amp;amp;D tax credit regime included in Finance Act 2024, which was enacted in February 2024, increased the cash rebate that may be claimed to 26.97% of qualifying expenditure, retroactively applied to qualifying expenditures incurred after April 1, 2023, if the Company qualifies as &#x201c;R&amp;amp;D intensive&#x201d; for an accounting period (broadly, a loss making SME whose relevant R&amp;amp;D expenditure represents, for accounting periods beginning on or after April 1, 2023, 40%, or, for accounting periods beginning on or after April 1, 2024, 30%, of its total expenditure for that accounting period). The Company was an R&amp;amp;D intensive SME for the years ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Management has assessed the Company&#x2019;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each period end, management estimates the reimbursement available to the Company based on available information at the time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes income from the research and development incentives when the relevant expenditure has been incurred, the associated conditions have been satisfied and there is reasonable assurance that the reimbursement will be received. The Company records these research and development incentives as a reduction to research and development expenses in the consolidated statements of operations and comprehensive loss, as the research and development tax credits are not dependent on us generating future taxable income, the Company&#x2019;s ongoing tax status, or tax position. The research and development incentives receivable represent an amount due in connection with the above program. The Company recorded a reduction to research and development expense of $43.1 million for the year ended December 31, 2024, including the impact of an increase to U.K. R&amp;amp;D tax credit reimbursement rates enacted with Finance Act 2024 retroactively applied to qualifying expenditures incurred after April 1, 2023. The Company recorded a reduction to research and development expense of $23.5 million and $19.3&#160;million during the&#160;years ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;</bcyc:ResearchAndDevelopmentIncentivesAndReceivablePolicyTextBlock>
    <bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses
      contextRef="Duration_3_31_2023_To_3_31_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredPriorToApril12023Member_1IrDAG-GjkaODsojD2rcmg"
      decimals="4"
      id="Narr_ywkV-ubSxE2yJHnQPGMYBw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.3335</bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses>
    <bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses
      contextRef="Duration_4_1_2023_To_4_1_2023_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_DRGyMBQk30C0HCqiKdLvbA"
      decimals="3"
      id="Narr_pMettojnVkWUYPsq8h42HQ"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.186</bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses>
    <bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses
      contextRef="Duration_2_1_2024_To_2_29_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12023Member_F9BWe4BDkEGe1GncdURkdA"
      decimals="4"
      id="Narr_jdz3HqdX20aeZrAXk4bapA"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.2697</bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses>
    <bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses
      contextRef="Duration_4_1_2024_To_4_1_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_mZK_WLmvd0u3bkPaVSH2lQ"
      decimals="2"
      id="Narr_0o0l-MksEUeon01v-sLoPg"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.40</bcyc:ResearchAndDevelopmentTaxReliefsProgramPercentageOfTaxCreditOnSurrenderableLosses>
    <bcyc:ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure
      contextRef="Duration_4_1_2024_To_4_1_2024_srt_StatementScenarioAxis_bcyc_CertainResearchAndDevelopmentExpendituresIncurredThereafterApril12024Member_mZK_WLmvd0u3bkPaVSH2lQ"
      decimals="2"
      id="Narr_PmHpCAesE06_Sz9Ty6kAzg"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.30</bcyc:ResearchAndDevelopmentPercentageOfTaxCreditOnTotalExpenditure>
    <bcyc:ReductionOfResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_ET6Dh-DVcEabpK_9O5aKOQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">43100000</bcyc:ReductionOfResearchAndDevelopmentExpense>
    <bcyc:ReductionOfResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_CIAQ2chcVU6-hakYDjvbWg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">23500000</bcyc:ReductionOfResearchAndDevelopmentExpense>
    <bcyc:ReductionOfResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-5"
      id="Narr_jk9Dw59NI0GKXIQyQ3dYJQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">19300000</bcyc:ReductionOfResearchAndDevelopmentExpense>
    <us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_BSNsdfOPL0-CGa99mg-bhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with preparing, filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_9hHiR1q1f06qsMYvMzOvPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures all equity awards granted to employees and directors based on the fair value on the date of grant. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with only service-based vesting conditions using the straight-line method. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For share-based awards granted to non-employee consultants, the measurement date is the date of grant. The compensation expense is then recognized over the requisite service period, which is the vesting period of the respective award, without subsequent changes in the fair value of the award.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The fair value of each restricted share award is based on the fair value of the Company&#x2019;s shares, less any applicable purchase price. The fair value of each share option is estimated using the Black-Scholes option-pricing model, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;which requires inputs based on certain subjective assumptions, including the fair value of shares, the expected share price volatility, the expected term of the award, the risk-free interest rate and expected dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to 2022, due to a lack of company-specific historical volatility data, the Company&#x2019;s expected volatility was calculated based on reported volatility data for a representative group of publicly traded companies for which historical information was available. The historical volatility was calculated based on a period of time commensurate with the assumption used for the expected term. During 2022, the Company began to estimate its volatility by using a blend of its stock price history for the length of time it has market data for its stock and the historical volatility of similar public companies for the expected term of each grant. The Company continues to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The Company uses the simplified method, under which the expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to the lack of historical exercise data and the plain nature of its share-based awards. The Company uses the remaining contractual term for the expected life of non-employee awards. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll or service costs are classified.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="2"
      id="Narr_dYLPBxsIKE2jri5I2g5nHw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_QsVm7HOFaEyle9eNwqLDrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; equity that result from transactions and economic events other than those with shareholders. The Company records unrealized gains and losses related to foreign currency translation as a component of other comprehensive loss in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_DCGB_oUWHkGDQ6TqnlsbuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential loss range is probable and reasonably estimable under the provisions of ASC Topic 450, &lt;i style="font-style:italic;"&gt;Contingencies&lt;/i&gt;. The Company expenses costs as incurred in relation to such loss contingencies as general and administrative expense within the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_uZEqd6HI_EiSBToZySOhng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the (benefit from) provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that will more likely than not be realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_KvhjuYsySU2gg5A9N_4Deg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares, including non-voting ordinary shares, outstanding for the period, including potential dilutive ordinary shares assuming the dilutive effect of ordinary share equivalents. In periods in which the Company reported a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_Dr5qV8-vJkipvs29bvOrag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently adopted accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures&lt;/i&gt;, which requires disclosure of incremental segment information on an interim and annual basis. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, and requires retrospective adoption to all prior periods presented in the consolidated financial statements. The adoption of ASU 2023-07 had no impact on the Company&#x2019;s reportable segments identified and additional required disclosures have been included in Note 15.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements not yet adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/i&gt;, which requires more detailed disclosures about specified categories of expenses included in certain expense captions presented on the face of the consolidated statements of operations and comprehensive loss, including employee compensation, depreciation and amortization. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to all prior periods presented. The Company is currently evaluating the impact of the adoption of ASU No. 2024-03 on its consolidated financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740) Improvements to Income Tax Disclosures&lt;/i&gt;, which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 is effective for annual periods beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. The Company is currently evaluating the potential impact of the adoption of ASU 2023-09 on its consolidated financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_5rd9voRKVESwpkaR3lydqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;3. Fair value of financial assets and liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, &lt;span style="-sec-ix-hidden:Hidden_X5wnyztC8UGUEz3EZ1OAbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2024&lt;/span&gt;&lt;/span&gt;, the Company had cash equivalents of $664.9 million consisting of money market funds that are primarily invested in U.S. Treasury securities, which are considered Level 1 assets. As of December 31, 2023, the Company had cash equivalents of $72.3 million, consisting of $22.1 million of money market funds and $50.2 million in &lt;span style="-sec-ix-hidden:Hidden_Vut1ulUKVEGQr75nUhokTQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;30-day&lt;/span&gt;&lt;/span&gt; term deposits which are considered Level 1 assets. As of December 31, 2024 and 2023, there were no other assets or liabilities measured at fair value on a recurring basis.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gejPkuQhakeSpM_QZlP27Q"
      decimals="-5"
      id="Narr_jXC6lsvfZEeuAIbVHC5qOw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">664900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_slT9uSBHsk6jvBbMvui31g"
      decimals="-5"
      id="Narr_4rbcbE26ukqpXS_-kRuH1w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">72300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gmBeuV6pUkqZOjdLGoLzMQ"
      decimals="-5"
      id="Narr_BLX1M1xr0EmoNva4BVQVVA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">22100000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:TimeDepositsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gmBeuV6pUkqZOjdLGoLzMQ"
      decimals="-5"
      id="Narr_sEbd7WDkzEqv3oRnRdvY2w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50200000</us-gaap:TimeDepositsAtCarryingValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5MPhoYm4pEaBvoSPbVf8mQ"
      decimals="-6"
      id="Narr_sZbYHVOncEuvSx7oijpGmQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_IE3SmW-yQ0GAQXZrSOSVUQ"
      decimals="-6"
      id="Narr_BIJtioe7_kmUoptroIlfQw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_pewttxbshEO_-9gZ3KijOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;4. Property and equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 28,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27,908&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,949)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,515&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense was $7.2 million, $6.5&#160;million and $3.7 million for the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. Depreciation and amortization expense for the years ended December 31, 2024, 2023 and 2022 included amortization expense of $0.1 million, zero and zero, respectively, related to property and equipment obtained under finance leases. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_pvkHlFs84ECq5ulwvz8j8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 28,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27,908&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,949)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,516&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,515&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_cyshTxnH0kyrdYWVdqiIsg"
      decimals="-3"
      id="Tc_g3OB9ZN6wUutx1maFmA71A_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14658000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_8msZM6Sha0iTRy5AvtsnvA"
      decimals="-3"
      id="Tc_r2E3a02biUmwmV9w1tQhVw_3_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">15554000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_jYlsDtcKqkiYG1N-mRdO7w"
      decimals="-3"
      id="Tc_VUnVF0hyrEOkYTPFSuOyrA_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10903000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nP9jA-aiYkONgvoroTyc9A"
      decimals="-3"
      id="Tc_3MaGi-rPeEKHQZNGQTQGwQ_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_6PtWJR1_jUG29cYcz9eufA_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1033000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_xx2lOaIKTUaBAJxmtahpDA"
      decimals="-3"
      id="Tc_GG-87_ALa0mwDblVuRcuqA_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_anAvD0bAqk2fupg6zYmu5g"
      decimals="-3"
      id="Tc_dBRssS5ir0moFDYRqYBXDA_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">532000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LZhexdWpm0qTV2Rf8LpgSA"
      decimals="-3"
      id="Tc_820Vw0GNKUenkqdzRrAN8Q_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1290000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PorQ7L3GZEWmg7J9b0BaFA"
      decimals="-3"
      id="Tc_SR6RX1C4mUCA8ZdctCRLpg_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_DCNQ4aNH4UW-JzsNuBuLIw_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">28465000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_C2L11pSAhE2wpjNdgmxPzQ_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">27908000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_w9AuVGY4yEisZQxQpVjV0w_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">18949000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_rhGnJCOpnUumaE98JwN5qA_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">13393000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_Or1LJJaP3UC2UlvjyooN2g_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9516000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_O2X5Ukb1FU6vcEK8EprO9A_10_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14515000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_U0BItUD_H0y_Szk8m1PKDw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_P_DwUyte60m8M_ZsgBO1Uw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">6500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-5"
      id="Narr_8kmD3fl_pkKj_11V1-jRlQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_mH-e50SGSEuotNUe3LsBAQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">100000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_-D-3paKqYU6klfgk9vx5lQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-5"
      id="Narr_0kRa3GzKAUy4W8oYNDSxgg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_uBtCVy1Gr0q-O47VsKkrGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;5. Accrued expenses and other current liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued employee compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,196&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KW1rNIXqDU6mr2igGNJAXQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_WTohRhZpUkiEgaVCaOLomQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 297&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 41,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 31,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In August 2024, the Company consolidated all discovery research activities to the Company&#x2019;s headquarters in Cambridge, U.K. As a result, during the year ended December 31, 2024, the Company recognized charges of $2.0 million in severance and other one-time termination benefits which are included in &lt;span style="-sec-ix-hidden:Hidden_tsh7VRNlykaXUR1w5uepYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;research&lt;/span&gt;&lt;/span&gt; and development expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss, of which $1.6 million were paid during the year ended December 31, 2024, and the remaining $0.4 million in unpaid benefits are included in accrued expenses and other current liabilities in the Company&#x2019;s consolidated balance sheet as of December 31, 2024.&lt;/p&gt;</bcyc:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <bcyc:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_zrHW8u09Y0u_eSDUpJtPmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued employee compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,196&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KW1rNIXqDU6mr2igGNJAXQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_WTohRhZpUkiEgaVCaOLomQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 297&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 41,246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 31,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_PQs20Ac_XEKCsRkH-_ZQOQ_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">16272000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_d082mTifPEqRgRhPAN4KxA_3_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">13394000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bcyc:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_Y3PfcummREmd1XWHwuWVbA_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14978000</bcyc:AccruedExternalResearchAndDevelopmentExpenses>
    <bcyc:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_-iyOpAnZWEGwSLJ_Tj9qkg_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11839000</bcyc:AccruedExternalResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_he2ES-aPtEKY-lCgBdqz8Q_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4196000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_SKL7cPDzf0uSAREigJEmpw_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1143000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_d2TopchPjE6FarcTSsn6vw_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5328000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_sVSaNs_l80OZy6R2S02QgA_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4876000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_1Q06UAKtJ0SZVXPcdJ5N6g_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">175000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_ToA6XmyNH0ejB_GuaaQxxw_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">297000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_AJ2ys4AcQkmDbcQQn07hVA_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">257000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_rtY6n9_ttUCfRaws8fNBew_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">41246000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_LmetBoZ8WkiKFI1VgR6P0Q_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31509000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_3bZ0WezC1ECTNMuaNEL3sQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_uMgTpcPpqEaXZ4fIbshszA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_8Wqsobo7mEeeVZFeP96TsQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">400000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_SpYyYCYWtESBU3_RzP9Phg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;6. Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On September 30, 2020, Bicycle Therapeutics plc and its subsidiaries (the &#x201c;Borrowers&#x201d;) entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules, as amended from time to time, which provided for aggregate maximum borrowings of up to $75.0 million, of which the Company had drawn down an aggregate of $30.0 million in 2021 and 2020. Payments on borrowings under the Loan Agreement were interest-only until April 1, 2025 and interest was paid at an annual rate of the &lt;i style="font-style:italic;"&gt;Wall Street Journal &lt;/i&gt;prime rate plus 4.55%, with a minimum annual rate of at least 8.05%, capped at a rate no greater than 9.05%, and the Loan Agreement included a 5.0% end-of-term charge payable upon maturity or repayment. The scheduled maturity date was July 1, 2025. On July 9, 2024, the Company repaid all amounts outstanding, including the outstanding borrowings of $30.0 million, accrued and unpaid interest of $0.1 million, an end-of-term charge of $1.5 million and a prepayment charge of $0.3 million, for a total aggregate payment of $31.9 million, and terminated the Loan Agreement. The Company recognized a loss on extinguishment of debt of $1.0 million during the year ended December 31, 2024 in connection with the repayment and termination of the Loan Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense associated with the Loan Agreement for the years ended December 31, 2024, 2023 and 2022 was $1.6 million, $3.1 million and $3.2 million, respectively. Upon termination of the Loan Agreement, all security interests granted to the secured parties thereunder were terminated and released.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Debt consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Term loan payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;End of term charge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (248)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Carrying value of term loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:29.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1.3pt;"&gt;&lt;td style="vertical-align:top;width:29.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_bcyc_TermLoanMember_us-gaap_TypeOfArrangementAxis_bcyc_LoanAndSecurityAgreementMember_65OBBumYj02j9k3Pn3oFYw"
      decimals="-5"
      id="Narr_jYt5gWmjm06pztUAJJqfTg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_NmP2-XzDFUGGWP4ZizBE4g"
      decimals="-5"
      id="Narr_Zqrm9KF-Y0uAxJznj4qIOA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_D3g9RlG-o0yxRqde4Bnx9Q"
      decimals="-5"
      id="Narr_uzoLQT8zUki2ETE2lO61qw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_xsjVq66pdkiUGagQ0I5-lQ"
      decimals="-5"
      id="Narr_0WNtuJIyUEaCW1c4a9B7xQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_9_30_2020_To_9_30_2020_OY1e7NwWCUq25fNFOMQDzQ"
      decimals="4"
      id="Narr_oMIf1gb9J0yrr40ckgs7Iw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.0455</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_olYsF14wyEW_U0xeDnkzAg"
      decimals="INF"
      id="Narr_FTEgfVVbEUKiJ9W09U7SPA"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.0805</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_NmP2-XzDFUGGWP4ZizBE4g"
      decimals="INF"
      id="Narr_LKta_S5gxUKc0U2pXBORzg"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.0905</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bcyc:DebtInstrumentEndOfTermChargeRate
      contextRef="As_Of_9_30_2020_DRfguGfVi0Or7GWsyp0CBw"
      decimals="3"
      id="Narr_nyiwKpjF-02CKfwatn4Qig"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.05</bcyc:DebtInstrumentEndOfTermChargeRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ"
      decimals="-5"
      id="Narr_WnwNY1t2gkep67F-aGUgkw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ"
      decimals="-5"
      id="Narr_PoNI65N5QEybLpsmd1fv8Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">100000</us-gaap:InterestPayableCurrent>
    <bcyc:DebtEndOfTermCharge
      contextRef="As_Of_7_9_2024_lqaCIZjxx0KlQPIbOZXWiQ"
      decimals="-5"
      id="Narr_Wjvd-OrWqU2rRh5a7lZUFA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1500000</bcyc:DebtEndOfTermCharge>
    <bcyc:DebtInstrumentPrepaymentCharges
      contextRef="Duration_7_9_2024_To_7_9_2024_ZJZfQXYoCEan2WXy8RfycA"
      decimals="-5"
      id="Narr_LOqQSu-750SFUWHPb3gjqw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">300000</bcyc:DebtInstrumentPrepaymentCharges>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_7_9_2024_To_7_9_2024_ZJZfQXYoCEan2WXy8RfycA"
      decimals="-5"
      id="Narr_w982B3koHU6tb7naA4kKKQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_KRaDIhn8nE-KAluNFxwSOw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_bMuDMhK8aEyJU12mzFiI9Q"
      decimals="-5"
      id="Narr_MgoVZ6R9lEmRCggxP8-vAA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1600000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_Ex-1F6jyfUO72vn1vcWu-w"
      decimals="-5"
      id="Narr_KXM5Zl-oQECJ2mZGx8O41Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3100000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_bcyc_InitialTermLoanMember_X1BWRi7-lk2fvBqoP0fM9A"
      decimals="-5"
      id="Narr_Ce4-y2xRTk6W138OBSpJBw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3200000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_MoofFSv1KUueGEjjy7g1IQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Debt consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Term loan payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;End of term charge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (248)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Carrying value of term loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_FVtIi79SkUC_DUzvSVgKJg_3_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <bcyc:DebtEndOfTermCharge
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_t_B4FXX2OUS169LrYjRBQw_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">946000</bcyc:DebtEndOfTermCharge>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_wMBCRk-JI0OUBA7hnNtdng_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">248000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_3BLLR4Zng0qsb-QnPFNFtQ_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30698000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_CBd-HkTby028OXsii2nJdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;7. Ordinary shares&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s ordinary shares are divided into two classes: (i) ordinary shares and (ii) non-voting ordinary shares. Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders. Holders of ADSs are not treated as holders of the Company&#x2019;s ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of the Company&#x2019;s ordinary shares, other than the rights that they have pursuant to the deposit agreement with the depositary. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The non-voting ordinary shares have the same rights and restrictions as the ordinary shares and otherwise rank &lt;i style="font-style:italic;"&gt;pari passu&lt;/i&gt; in all respects with the ordinary shares except for the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a holder of non-voting ordinary shares shall, in relation to the non-voting ordinary shares held, have no right to receive notice of, or to attend or vote at, any general meeting of shareholders save in relation to a variation of class rights of the non-voting ordinary shares;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the non-voting ordinary shares shall be re-designated as ordinary shares by the Company&#x2019;s board of directors, or a duly authorized committee or representative thereof, upon receipt of a re-designation notice and otherwise subject to the terms and conditions set out in the terms of issue. A holder of non-voting ordinary shares shall not be entitled to have any non-voting ordinary shares re-designated as ordinary shares where such re-designation would result in such holder thereof beneficially owning (for purposes of section 13(d) of the Exchange Act), when aggregated with &#x201c;affiliates&#x201d; and &#x201c;group&#x201d; members with whom such holder is required to aggregate beneficial ownership for the purposes of section 13(d) of the Exchange Act, in excess of 9.99% of any class of the Company&#x2019;s securities registered under the Exchange Act (which percentage may be increased or decreased on a holder-by-holder basis subject to the provisions set out in the terms of issue); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the non-voting ordinary shares shall be re-designated as ordinary shares automatically upon transfer of a non-voting ordinary share by its holder to any person that is not an &#x201c;affiliate&#x201d; or &#x201c;group&#x201d; member with whom such holder is required to aggregate beneficial ownership for purposes of section 13(d) of the Exchange Act. This automatic re-designation shall only be in respect of the non-voting ordinary shares that are subject to such transfer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 and 2023, the Company had not declared any dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31, 2024 and 2023, the Company&#x2019;s authorized capital share consisted of 155,876,645 and 59,612,613 ordinary shares, respectively, including ordinary shares and non-voting ordinary shares, with a nominal value of &#xa3;0.01 per share. Authorized share capital, or shares authorized, comprises (i) the currently issued and outstanding ordinary shares and non-voting ordinary shares, (ii) the remaining ordinary shares available for allotment under the existing authority granted to the Board at the annual general meeting held on May 16, 2024, (iii) ordinary shares issuable on the exercise of outstanding options and settlement of vested restricted share units (&#x201c;RSUs&#x201d;), and (iv) ordinary shares &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;reserved for issuance under the Bicycle Therapeutics plc 2024 Inducement Plan (the &#x201c;2024 Inducement Plan&#x201d;), the Bicycle Therapeutics plc 2020 Equity Incentive Plan (as amended from time to time, the &#x201c;2020 Plan&#x201d;), and/or the Bicycle Therapeutics plc 2019 Employee Share Purchase Plan (the &#x201c;ESPP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, there were 47,569,319 ordinary shares &lt;span style="-sec-ix-hidden:Hidden_Lpo0wyq33EyQ4jsKrECq2Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and outstanding and 21,492,099 non-voting ordinary shares &lt;span style="-sec-ix-hidden:Hidden_isC1MjD3_kuhXs60-F47rw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 23, 2024, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with purchasers named therein (the &#x201c;Investors&#x201d;). Pursuant to the Purchase Agreement, the Company sold 6,764,705 ADSs, representing the same number of ordinary shares, nominal value &#xa3;0.01 per share, and 19,169,001 non-voting ordinary shares, nominal value &#xa3;0.01 per share, each at a purchase price equal to $21.42 per share (the &#x201c;Private Placement&#x201d;). The Company completed the Private Placement on May 28, 2024. The transaction resulted in gross proceeds to the Company of $555.5 million, and after deducting commissions and offering expenses of $11.4 million, net proceeds to the Company of $544.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 17, 2023, the Company completed an underwritten public offering of its securities, pursuant to which the Company issued and sold 6,117,648 ADSs, representing the same number of ordinary shares, nominal value &#xa3;0.01 per share, which included 1,411,764 ADSs sold upon the underwriters&#x2019; full exercise of their option to purchase additional ADSs, and 4,705,882 non-voting ordinary shares, nominal value &#xa3;0.01 per share, at a public offering price of $21.25 per ADS or non-voting ordinary share, respectively. The transaction resulted in gross proceeds to the Company of $230.0 million, and after deducting underwriting discounts, commissions, and offering expenses of $14.9 million, net proceeds to the Company of $215.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On June 5, 2020, the Company entered into a Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and Oppenheimer &amp;amp; Co. Inc. (the &#x201c;Sales Agents&#x201d;) with respect to an ATM program pursuant to which the Company may offer and sell through the Sales Agents, from time to time at the Company&#x2019;s sole discretion, American Depositary Shares (&#x201c;ADSs&#x201d;), each ADS representing one ordinary share. No ADSs were issued or sold pursuant to the Sales Agreement during the year ended December 31, 2024. During the year ended December 31, 2023, the Company issued and sold 1,561,176 ADSs, representing the same number of ordinary shares for gross proceeds of $35.3 million, resulting in net proceeds of $34.2 million after deducting sales commissions and offering expenses of $1.1 million. During the year ended December 31, 2022, the Company issued and sold 181,455 ADSs, representing the same number of ordinary shares for gross proceeds of $5.9 million, resulting in net proceeds of $5.7 million after deducting sales commissions and offering expenses of $0.2 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bcyc:NumberOfVotePerShare
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="INF"
      id="Narr_YNijXuKWg0OipNcynWobgA"
      unitRef="Unit_Standard_Vote_F2iWXsaSbUSm_tPiCaeIdA">1</bcyc:NumberOfVotePerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="INF"
      id="Narr_DmJcFT8N2E2uu6-UPK7tFQ"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="INF"
      id="Narr_mU0M1rw7vk6ISTIugzyd8w"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="INF"
      id="Narr_REj3b3oIlUCm8SlJVjGueg"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">155876645</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="INF"
      id="Narr_NOUoR4rYLU-uX7ULycv37Q"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">59612613</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="INF"
      id="Narr_RIAxj2CuckeJEm18IMVEiQ"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="INF"
      id="Narr_AmI5j4n8tkyOv-r6Deq5eQ"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_VotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJXTy3J51UCZNJxJ1Ym8RQ"
      decimals="INF"
      id="Narr_-KJkurTXaEmp_ckZj1r8FQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">47569319</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y61uWaX9NEaChNzvdxBdnQ"
      decimals="INF"
      id="Narr_kGEOULlsl0GiwZxR8PmuIw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">21492099</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_IYGnT7YWfkykLNwOFediag"
      decimals="INF"
      id="Narr_znsXwMH2LEKdHC8TUu7XHw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">6764705</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_IYGnT7YWfkykLNwOFediag"
      decimals="2"
      id="Narr_Xpxhk5P5KUWuz7pJXlMqpw"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_V7TD4LyjyEOPQOb-5emQbg"
      decimals="INF"
      id="Narr_1rdMDHYfHkK8t28VgO5STg"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">19169001</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_5_23_2024_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_V7TD4LyjyEOPQOb-5emQbg"
      decimals="2"
      id="Narr_LUo5wExB00Oc_Ps-qBqMnA"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="As_Of_5_23_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_1meCJkhmuUalIyW_wBy3UA"
      decimals="2"
      id="Narr_racjQtVoXEmyYtkAzkzwJg"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">21.42</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw"
      decimals="-5"
      id="Narr_yHGwA2U7FUitPPxAQFyV8g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">555500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw"
      decimals="-5"
      id="Narr_lrKTMmdy00a2dk5eblQOEA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_5_28_2024_To_5_28_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_InvestorsPurchaseAgreementMember_tFP1WP-8iEaN0avvJibFQw"
      decimals="-5"
      id="Narr_6q_uuy3JekKID4nTDE-YtQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">544100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_M9NqLknzNU-sMVpqCl-eFw"
      decimals="INF"
      id="Narr_P6QBLRdHhUSf9Q_WrbZnIQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">6117648</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_jjLRXKu4UkmDU29qbwfUyg"
      decimals="INF"
      id="Narr_wEHLWSz2pECqfjBsXbvdbQ"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_FinancialInstrumentAxis_us-gaap_OptionOnSecuritiesMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_cVgwDI4loUexIB3GNxcfVg"
      decimals="INF"
      id="Narr_uHpfsnKzmEqCufuQXN7VRQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1411764</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_2llzQZ6_20K-zZTfy-CSow"
      decimals="INF"
      id="Narr_QU9Ch4xHREKSPN53Vr8KMA"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">4705882</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_A4JYy9Ek902M2Ll6OJMTig"
      decimals="INF"
      id="Narr_ixRD0U4upUKOOKpXiaRPbw"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="As_Of_7_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_jjLRXKu4UkmDU29qbwfUyg"
      decimals="2"
      id="Narr_XNF2AmaYJ0KTXL-XUByv1Q"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">21.25</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang"
      decimals="-5"
      id="Narr_zitLz3sakEipy2sk2MAb1A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">230000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang"
      decimals="-5"
      id="Narr_v-EdpVPLj0eg6o8_IaxTrQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_UnderwrittenPublicOfferingMember_kUFUcElRakWttWuD8n3ang"
      decimals="-5"
      id="Narr_7mgFEkKsg0iGN1ULId3ICQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">215100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_Q3Ip6DsZDUiZokIoW7oY_g"
      decimals="INF"
      id="Narr_LJ-gzEm1MEOGgrTPuQS6gA"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_2uabg4H0sUy4TlBNK2BBbg"
      decimals="INF"
      id="Narr_7nEN-wKvWk6gw9DP9Qzd_w"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1561176</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q"
      decimals="-5"
      id="Narr_04AAW9NKfkWTo21c6ZX1mQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">35300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q"
      decimals="-5"
      id="Narr_bRaQAvH3j0KEMPAZ-_Nz1Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">34200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_20VYTEL38kqWcYRlfezl4Q"
      decimals="-5"
      id="Narr_JikYKAhCJ0a-KfWIhBxpkQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_XPuSzU4R-ki_U9PggBrUeg"
      decimals="INF"
      id="Narr_HXOvmidqV0qj2UQXP4taCw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">181455</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ"
      decimals="-5"
      id="Narr_lfdKNYeNEky7U9NU1xjf8A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ"
      decimals="-5"
      id="Narr_jYvSwz9bM0KCS0PP4q2RWg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_bcyc_AtMarketOfferingMember_nmvIKmBSgESCx1XfyptQtQ"
      decimals="-5"
      id="Narr_rE6glOBXt0-FtmmWqu6Jmg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_u4U8_1IEzUSWWKSOSzsf-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;8. Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Employee incentive pool&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2024 Inducement Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In July 2024, the Company&#x2019;s board of directors approved the 2024 Inducement Plan. &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;The 2024 Inducement Plan allows for the granting of nonqualified share options, RSUs, and other equity awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company.&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;Share options granted under the 2024 Inducement Plan have a &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;10-year&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt; contractual life and generally vest over a &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;four-year&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt; service period with &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;25%&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt; of the award vesting on the first anniversary of the vesting commencement date and the balance thereafter in &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;36&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt; equal monthly installments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;white-space:pre-wrap;background:#ffffff;"&gt; The Company initially reserved &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;1,500,000&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt; of its ordinary shares, or the equivalent number of ADSs, for the issuance of awards under the 2024 Inducement Plan. As of December 31, 2024, there were &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;1,251,400&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt; shares available for future issuance under the 2024 Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, there were options to purchase 248,600 shares outstanding under the 2024 Inducement Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-weight:normal;"&gt;2020 Equity Incentive Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2020, the Company&#x2019;s shareholders first approved the 2020 Plan, under which the Company may grant market value options, market value stock appreciation rights or restricted shares, RSUs, performance RSUs and other share-based awards to the Company&#x2019;s employees. The Company&#x2019;s non-employee directors and consultants are eligible to receive awards under the 2020 Non-Employee Sub-Plan to the 2020 Plan. All awards under the 2020 Plan, including the 2020 Non-Employee Sub-Plan, will be set forth in award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms, change of control provisions and post-termination exercise limitations. In the event of a change of control of the Company, as defined in the 2020 Plan, any outstanding awards under the 2020 Plan will vest in full immediately prior to such change of control. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company initially reserved up to 4,773,557 ordinary shares for future issuance under the 2020 Plan, including shares subject to options that were granted under the Company&#x2019;s 2019 Share Option Plan (the &#x201c;2019 Plan&#x201d;) and that were granted pursuant to option contracts granted prior to the Company&#x2019;s IPO, in each case that expire, terminate, are forfeited or otherwise not issued from time to time, if any. On June 27, 2022, the Company&#x2019;s shareholders approved an amendment to the 2020 Plan (the &#x201c;Amendment&#x201d;) which increased the number of ordinary shares reserved for future issuance by 750,000 shares. Additionally, the number of ordinary shares reserved for issuance pursuant to the 2020 Plan will automatically increase on the first day of January of each year, initially commencing on January&#160;1, 2021 and continuing up to and including January 1, 2032, in an amount equal to 5% of the total number of the Company&#x2019;s ordinary shares outstanding on the last day of the preceding&#160;year, or a lesser number of shares determined by the Company&#x2019;s board of directors. Pursuant to this evergreen provision, on January 1, 2024, the number of shares reserved for issuance under the 2020 Plan was increased by 1,886,294 shares. As of December 31, 2024, there were 463,374 shares available for issuance under the 2020 Plan. The number of shares reserved for issuance under the 2020 Plan was increased by 2,378,465 shares effective January 1, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share options granted under the 2020 Plan have a 10-year contractual life, and generally vest over either a three-year service period in three equal annual installments for new non-employee director grants, or a four-year service period with 25% of the award vesting on the first anniversary of the vesting commencement date and the balance thereafter in 36 equal monthly installments for employees and consultants. Certain options granted to the Company&#x2019;s non-employee directors vest over a one-year service period in four equal quarterly installments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants RSUs to non-employee directors, consultants and certain employees under the 2020 Plan. Each RSU represents the right to receive one of the Company&#x2019;s ordinary shares upon vesting. RSUs granted to employees and consultants vest over a four-year service period with 25% of the award vesting on the first anniversary of the vesting commencement date and the remaining RSUs vesting in 12 equal quarterly installments. Certain RSUs granted to the Company&#x2019;s non-employee directors either vest over a &lt;span style="-sec-ix-hidden:Hidden_8SmY0G3wPEWWtHANX-xYGQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three-year&lt;/span&gt;&lt;/span&gt; service period in three equal annual installments for new non-employee director grants or over a one-year service period in four equal quarterly installments. The Company may also, in its sole discretion, provide for deferred settlement of RSUs granted to the Company&#x2019;s non-employee directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, there were options to purchase 6,211,123 shares and RSUs for 716,262 shares outstanding under the 2020 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2019 Share Option Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;&lt;span style="white-space:pre-wrap;"&gt;2019, the Company adopted the 2019 Plan, which became effective in conjunction with the IPO.  As of December 31, 2024, there were &lt;/span&gt;1,773,816 options to purchase ordinary shares outstanding under the 2019 Plan. In conjunction with the adoption of the 2020 Plan, all shares available for future issuance under the 2019 Plan as of June 29, 2020 became available for issuance under the 2020 Plan and the Company ceased making awards under the 2019 Plan. The 2020 Plan is the successor of the 2019 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Share options previously issued under the 2019 Plan have a 10-year contractual life, and generally either vest&#160;monthly over a three-year service period, or over a four-year service period with 25% of the award vesting on the first anniversary of the commencement date and the balance thereafter in 36 equal&#160;monthly installments. Certain awards &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;granted to the Company&#x2019;s non-employee directors were fully vested on the date of grant. The exercise price of share options issued under the 2019 Plan is not less than the fair value of ordinary shares as of the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Employee Share Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2019, the Company adopted the ESPP, which became effective in conjunction with the IPO. The Company initially reserved 215,000 ordinary shares for future issuance under this plan. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020 and each January 1 thereafter through January 1, 2029, by the lower of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31; (ii) 430,000 ordinary shares or (iii) such lesser number of shares as determined by the Compensation Committee. The number of shares reserved under the ESPP is subject to adjustment in the event of a split-up, share dividend or other change in the Company&#x2019;s capitalization. As of December 31, 2024, the total number of shares available for issuance under the ESPP was 1,577,671 shares. The number of shares reserved for issuance under the ESPP was increased by 430,000 shares effective January 1, 2025. As of December 31, 2024, there have been no offering periods to employees under ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 38,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 32,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the Company&#x2019;s option activity since December&#160;31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December 31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,469,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,438,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (554,596)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (604,561)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,748,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 22.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested and expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,748,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 22.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,359,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average grant-date fair value of share options granted during the&#160;years ended December&#160;31, 2024, 2023 and 2022 was $13.52 per share, $19.36 per share and $31.45 per share, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#x2019;s ordinary shares. The aggregate intrinsic value of share options exercised during the&#160;years ended December&#160;31, 2024, 2023 and 2022 was $5.1 million, $0.5 million and $1.5 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recorded share-based compensation expense for share options granted of $30.2 million, $27.0&#160;million and $21.9 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of share options granted to employees and directors:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 77.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 82.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 82.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2024, total unrecognized compensation expense related to the share options was $48.3&#160;million, which is expected to be recognized over a weighted average period of 2.4 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Restricted share units&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the Company&#x2019;s RSU activity under the 2020 Plan since December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 326,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 617,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested and settled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (141,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested and deferred&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (86,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 674,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested but subject to deferred settlement at December 31, 2024&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;The Company granted certain RSUs to the Company&#x2019;s non-employee directors which provided for deferred settlement of the RSUs to a specified date following the first to occur of (i) the date of the director&#x2019;s separation from service, (ii) the date of the director&#x2019;s disability, (iii) the date of the director&#x2019;s death or (iv) the date of a change in control event.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of RSUs that vested during the years ended December 31, 2024, 2023 and 2022 was $3.8 million, $3.0 million and $2.1 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Total share-based compensation expense for RSUs granted for the years ended December 31, 2024, 2023 and 2022 was $7.9 million, $5.5 million and $4.9 million, respectively. As of December 31, 2024, the total unrecognized compensation expense related to RSUs was $11.4 million, which is expected to be recognized over a weighted-average period of 2.4 years. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_a1Oi0t48FUudnS8WN5P3Bw"
      id="Narr_li7JlGQl_Uy_LegMMnWSXQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_E1--0LWw1EmKwIGcLWnwFA"
      id="Narr_raYQFuW0JEuJ1ExCAfiwBQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_MAFub_g2y0GAD_IA8SQX-A"
      decimals="2"
      id="Narr_m5vIkXhYwE6jBDs4Epg5xA"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_bG4-HMluqEmz8RSPzC0fGQ"
      decimals="INF"
      id="Narr_CC0gjSNMwUGUIdCJf4o1ug"
      unitRef="Unit_Standard_M_lugMOcstmECVEFUGtQg6XA">36</bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_7_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_MBs7tOGmkE641EB2R-K8nw"
      decimals="INF"
      id="Narr_XP1Re5DXnU-CudUFik6JUQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_J_fXlQvUukSBnlagZHQH8g"
      decimals="INF"
      id="Narr_rwy5nUnjjk-K0K62r-agRg"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1251400</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_InducementPlan2024Member_v3o1BPc0-02UERuTDFMLWg"
      decimals="INF"
      id="Narr_1Caf8exPLkytuhSkjPxJlQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">248600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_hWWYIZXzx0acMJRpjAgv5w"
      decimals="INF"
      id="Narr_fMsxM-e2VE2sOyMFGiqUzw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">4773557</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_27_2022_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_4Vyzs47cNE-kgf6kZGnMbw"
      decimals="INF"
      id="Narr_Rd_KfGf9mE2GtEa-xz-KTQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_o8DXnIN9Gka0CBw_y9jx6g"
      decimals="2"
      id="Narr_fF2WZEOhUUWfWj-hKNeMnQ"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.05</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_gQdGQPSVDUGV2TfhbI5-2w"
      decimals="INF"
      id="Narr_2kxUhQDcSkCBDrM5U9xftg"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1886294</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_5QeHcJfW2U6x27_YDU1Ogw"
      decimals="INF"
      id="Narr_vw1oTLI4dkud5W-BwK-FDw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">463374</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2025_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_3jebnT0paUKkYaQIJZSi9A"
      decimals="INF"
      id="Narr_nwp4YaFPbka4RlCaKGr62A"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">2378465</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Vi_9DbVLDEiUNj4B5lOvvQ"
      id="Narr_gQyFSHsma0-5eItKerRFDQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_Lhc563hBmUO8945Z0wzLwA"
      id="Narr_7Kh1MzmjlEyjQK0KsXY6bg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments
      contextRef="Duration_6_1_2020_To_6_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_78XxKxfYa0e6KIo8HByUpg"
      decimals="INF"
      id="Narr_KlbNzv8gnUm9YLY0UY_Edw"
      unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">3</bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_cpfcqvh4YUOX2BEX6A_K5g"
      id="Narr_UZ7NUbKWzkqlSCJjjYBO1w">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_QDfyXxUou0-hgJMM6cWXtA"
      decimals="2"
      id="Narr_7PgsaPEIUkKqi7VXz9sykw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_A43fKLk6X0Wn-S-Osq4rcQ"
      decimals="INF"
      id="Narr_Ck3Nb58gvke10OoP3fTzvQ"
      unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">36</bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kKS5dyzsFEufpIX9K-WVUQ"
      id="Narr_K39tgZduK0iOluR8fY1RHw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kKS5dyzsFEufpIX9K-WVUQ"
      decimals="INF"
      id="Narr_58uvwkyIm0y-WB9ivZ7U2w"
      unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">4</bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="INF"
      id="Narr_BROGknKEO0u8XxEa9KV-ng"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardsShareConversionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      id="Narr_Ui0BdifMukaA7zUExh2iww">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_YameRw5flUWof726OmcJYQ"
      decimals="2"
      id="Narr_nuDbwjPwQkyx19KdTSsdHw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d2w1uOPLe0uqStZt99DW4A"
      decimals="INF"
      id="Narr_20o5292hfECcpHiHb9Zt9g"
      unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">12</bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments>
    <bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_bcyc_ShareBasedPaymentArrangementThreeYearVestMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_qGTPrbV9lESEael4XrVLgA"
      decimals="INF"
      id="Narr_XxLEWOLGjU-uLeM7aaAQWQ"
      unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">3</bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualAnnualInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      id="Narr_nzQDe9trVUK2zsTsGDudSw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <bcyc:NumberOfQuarterlyInstallments
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_7SqqxQUnTU-2GwYuJp8WsQ"
      decimals="INF"
      id="Narr_CF-nAjfS2kKL6NYXL0YG2A"
      unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">4</bcyc:NumberOfQuarterlyInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_kkvEbVaSgkafrtITcLkMkQ"
      decimals="INF"
      id="Narr_Ao6VSqd5j02nFPUt5er61A"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">6211123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg"
      decimals="INF"
      id="Narr__kc9_MdZlEOyAjB06AqEVQ"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">716262</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Zt6VhwsXG0aIIZfDEMHd7w"
      decimals="INF"
      id="Narr_-O8FYm6XA06fTALwoc0OCw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1773816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_WCDTG0m9xUCkxUKiJgwLbw"
      id="Narr_sfZ9eVrrhU-71ip1jyGDow">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_Iontov7wME-Mj-R-qqxvRw"
      id="Narr_ekjU7gYbhkqconqTDBJ2hw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2019Member_NONBGaPxIUSKmSHZSQ1OaQ"
      id="Narr_CUeWA3k8EkWB4FNYZ6zjsQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zpq2bppWNkmyNQUoVWcEXg"
      decimals="2"
      id="Narr_HqS1Ot1K9U2p3k_r2ioYWg"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_bcyc_PreIpoShareOptionsAndRestrictedSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_UuY5gYBUFEyCVoKDAuW1eA"
      decimals="INF"
      id="Narr_SRKPS7U0-ketwf-bhMJZBg"
      unitRef="Unit_Standard_installment_IubmVw0B2kGZn1evdtcFsg">36</bcyc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uYPMjaOR30-b-lalBWgACw"
      decimals="INF"
      id="Narr_BNuGdqMCKkmT_rsDh1lxBg"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">215000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uDaWQIIw1kGEaQUSk3pBNw"
      decimals="INF"
      id="Narr_WKezOkiNGUeiB8ri_psgng"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.01</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_5_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_uYPMjaOR30-b-lalBWgACw"
      decimals="INF"
      id="Narr_xZzTrZSFzUCjIz_OlRtNuA"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_JmkuGODyoEa7uHAIThFJUQ"
      decimals="INF"
      id="Narr_VAgXyi-kM0WxxiEAT4UnTA"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">1577671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_llEDFF1MSUKzib9liGvGRg"
      decimals="INF"
      id="Narr_I94FshnqSUCGnJPsw7ftGw"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">430000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_XV1yR6EGv0icba-vozrO_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 15,581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 38,081&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 32,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 26,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_IrNimC9diUCVSYzfxLOnXA"
      decimals="-3"
      id="Tc_0GUlfNkZOEuXSTOlh4G2oA_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">19424000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ExXLTtPGjESDM4D_A9YCDw"
      decimals="-3"
      id="Tc_DFxX_-FCwUWyj5w5crXIRQ_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">15581000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_tkd3FyxzzUqahEHsT-hpIg"
      decimals="-3"
      id="Tc_6KrJtWMSH0ORuLeUU4VSdg_4_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_QJYt99nJFU-BQx9iYlyOVQ"
      decimals="-3"
      id="Tc_0uZTdfO7AEmhNCVxRdG2YQ_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">18657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qLo7iHGMOUW9rHUjaCEH5w"
      decimals="-3"
      id="Tc_WRFLQ69nGEyjyxRLsPX5Cw_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">16896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3zI24sd1-km1PKi1awanEA"
      decimals="-3"
      id="Tc_cBlcGcGwUEmUbkTZ9Kjk4Q_5_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">16385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_Oft1xit0AUO6Yu4mB6zH0A_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">38081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_eqmDkQdb3UOuFo4AlPrf8A_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">32477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_rBCAwCpwUky5isg_BznY_g_6_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_MeQtVHrEHUuYWo7kcmaJcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December 31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,469,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,438,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (554,596)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (604,561)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,748,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 22.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested and expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,748,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 22.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:54.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,359,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg"
      decimals="INF"
      id="Tc_bh4of0PupEupeB-VjAm4aA_6_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">7469527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg"
      decimals="2"
      id="Tc_dWnlBYXIPUqI3VwPb_PmJw_6_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">23.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg"
      id="Tc_wYa6poBIMkqE718vt6mlpQ_6_7">P6Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_EVDof6XzPkarxAJ2nipXeg"
      decimals="-3"
      id="Tc_N4VDy42YI0mK2z11Zy1oTQ_6_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">21920000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="INF"
      id="Tc_dEWDmUpQj0mzKqh4A502vw_7_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">2438356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="2"
      id="Tc_vr_7gJ1UakKSCXKpdW_Cbw_7_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">19.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="INF"
      id="Tc_Zw2HwXbDKUigXj_XeE4JMA_8_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">554596</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="2"
      id="Tc_3zIv9t9Y7EWPEcFnHcarww_8_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">13.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="INF"
      id="Tc_kTwZ5ZFf7UCQpHDyXjrOEQ_9_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">604561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="2"
      id="Tc_-UVVR4DX5UWfAUus3eDayQ_9_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">27.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="INF"
      id="Tc_qK2FFHL0ZUGZV4X1jzx1SA_10_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">8748726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="2"
      id="Tc_s1PNF8XFyk64_GgjfwNTRg_10_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">22.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      id="Tc_jdU5aKW6JUC6Sw1ikvyONA_10_7">P6Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="-3"
      id="Tc_-24VnK08-kagXgtoVyfBCw_10_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9559000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="INF"
      id="Tc_HKIbKIhcqUaopzbAem4zZw_11_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">8748726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="2"
      id="Tc_cfHChGncQEe_R2dyrVGTyQ_11_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">22.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      id="Tc_UP52BV4aVEyMsj8TlW_WrQ_11_7">P6Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="-3"
      id="Tc_zuxMZro92ECBqvBMtyfsoQ_11_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9559000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="INF"
      id="Tc_I2nQaqMWtUWuid3WacxnJA_12_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">5359049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="2"
      id="Tc_4NeneMjNSk-pkUYVkwT2Jw_12_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">21.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      id="Tc_pVuhtwBYC0ybiHiAULdU_w_12_7">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BxLLRYHYrUaj4YCw9eklpA"
      decimals="-3"
      id="Tc_UgvoOhVEokOrOW-lCsB5_Q_12_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9559000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="2"
      id="Narr__NFmXwZoi0OSlOqzTEcNww"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">13.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg"
      decimals="2"
      id="Narr_7oef8opr-UaGJ6CAMY0ieg"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">19.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ"
      decimals="2"
      id="Narr_kiJGQCblXUuxu_kSTlYMzg"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">31.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="-5"
      id="Narr_DmuO-TnAGU2yic7F6BpFZA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg"
      decimals="-5"
      id="Narr_EjjuyWEK_02irS0cj3wE6g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ"
      decimals="-5"
      id="Narr_Zceoknl8E0CBaz00ClLXHA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_cQpLrYmlS0GYV9yaM-cG4g"
      decimals="-5"
      id="Narr__ECWpdh9UUug5uKM-Cw3iw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_nUNVJQX8CEWH5QBmImctpg"
      decimals="-5"
      id="Narr__PO0nf-AIkeuijxfZNhCdQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">27000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_82hpgJrdxkGoapzRcBDyCQ"
      decimals="-5"
      id="Narr_FYZPMeZ6IkKwKbHBGhI9Mw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_FHs_KDfcKUOthDg8QHFOWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 77.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 82.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 82.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q"
      decimals="3"
      id="Tc_6_yJzi25LkySNzXU0Srn2g_4_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg"
      decimals="3"
      id="Tc_WJ09b9crXEK8mLXYZdFoRQ_4_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg"
      decimals="3"
      id="Tc_-1hh4tmv6kKM3SqGWmICrw_4_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q"
      decimals="3"
      id="Tc_b8-HY7tkMkaSBiwJjssCQg_5_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg"
      decimals="3"
      id="Tc_Fl31aRoU1EWoaq3fsTKFnQ_5_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg"
      decimals="3"
      id="Tc_yX38cIUg7k-1DJLDUklJlA_5_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q"
      id="Tc_68gMdExs_UqFwvHdQVMrpA_7_2">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_DDyOkNmLCEiqb8cRk6Fxhg"
      id="Tc_-V7dYAHvuU2G5vnA3cJzVQ_7_4">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_8WhZZufLg0mwlmG-A0s8tg"
      id="Tc_Dr0d2VAK8kuME3mcLUh7Yw_7_6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_ig3SHtuCIE-Ory8Hp3Mv3Q"
      decimals="-5"
      id="Narr_8B7QbVOGXkCBKNSGy-isQw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">48300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_bcyc_EmployeeAndDirectorMember_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_gQ10VJN0LUiMc8v2YKmo-Q"
      id="Narr_-T80r2p7bUiOKwBMiSPdww">P2Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_gndiCvCDNUWmWdnqmGlrFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 326,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 617,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested and settled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (141,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested and deferred&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (86,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 674,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.96&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested but subject to deferred settlement at December 31, 2024&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;The Company granted certain RSUs to the Company&#x2019;s non-employee directors which provided for deferred settlement of the RSUs to a specified date following the first to occur of (i) the date of the director&#x2019;s separation from service, (ii) the date of the director&#x2019;s disability, (iii) the date of the director&#x2019;s death or (iv) the date of a change in control event.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_P5YoMS1KNkutLYwlGkurgg"
      decimals="INF"
      id="Tc_287jUgfsoUWjkVw6JaEaFA_3_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">326848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_P5YoMS1KNkutLYwlGkurgg"
      decimals="2"
      id="Tc_pcmFtOB94EWeUF9JYDKsAQ_3_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">37.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="INF"
      id="Tc_1_f1lJQpikGdlpGwR39iHQ_4_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">617496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="2"
      id="Tc_KXwJHTb-a0GgIVEP0wQGMQ_4_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">18.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="INF"
      id="Tc_PP1BAjxl-E62N_3-6_Nj5A_5_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">-141350</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriod>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="2"
      id="Tc_weAp9lqxCk6hrQ_3HLoSVg_5_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">37.76</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndSettledInPeriodWeightedAverageGrantDateFairValue>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="INF"
      id="Tc_eNe8EpG1dECfsl9feiAfEg_6_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">-42000</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriod>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="2"
      id="Tc_ErbLgeMiSUaF87WYT0cdVw_6_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">18.07</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndDeferredInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="INF"
      id="Tc_N-vGzDGznke58vru1EZcsw_7_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">86732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="2"
      id="Tc_2NVKl-C1sEe4aVL-cLTZ7g_7_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">22.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg"
      decimals="INF"
      id="Tc_Hmh5zSYgE06mLdAP70KuNA_8_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">674262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg"
      decimals="2"
      id="Tc_VXWfTK3W2kC1DaivSj3cGQ_8_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">22.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="INF"
      id="Tc_ZT5B2wsmXUu87iVbDsB0EA_9_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">42000</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="2"
      id="Tc_LKH1Ven1D0G-aW4o1BHHXw_9_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">18.07</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageGrantDateFairValue>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg"
      decimals="INF"
      id="Tc_7DKEUgOig0CWksuqpxHgOw_10_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">716262</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingNumber>
    <bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg"
      decimals="2"
      id="Tc_X05sEIY73UuCYej9pzghLQ_10_5"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">22.67</bcyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="-5"
      id="Narr_5_YVaqRN9kWPU5MB12oiPw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_MD5oMOXiBEqT_oj0JeJMKQ"
      decimals="-5"
      id="Narr_dqZxlB57hEScAEwOqnaDlQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_fd4h2ljJA02Or70KQeym_A"
      decimals="-5"
      id="Narr_DBNcsWCgP02Se7upLs-Wew"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      decimals="-5"
      id="Narr_tqE2N1-toUKsUNHJMCphZA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_MD5oMOXiBEqT_oj0JeJMKQ"
      decimals="-5"
      id="Narr__5vl9gFkPkmLj7wMNtyAYQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_fd4h2ljJA02Or70KQeym_A"
      decimals="-5"
      id="Narr_qOjkF3xpH0a9yXrPY2yF1Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_ipJh-VLVvk-5P0ebyqQtqg"
      decimals="-5"
      id="Narr_ZqAdCPkgV0WHfBI-rXVxAQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_bcyc_ShareOptionPlan2020Member_6edrFfATH0yqjNfgOd-lJQ"
      id="Narr_lFmknT6kJUGaBg0z6v99lA">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_koEcBfr4r0eJ_a7AM2PB2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;9. Significant agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the revenue recognized from the Company&#x2019;s collaboration arrangements in the consolidated statements of operations and comprehensive loss (in&#160;thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Collaboration revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bayer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Novartis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,909&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Ionis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,734&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Genentech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dementia Discovery Fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total collaboration revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Bayer Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 4, 2023, the Company and Bayer entered into a collaboration and license agreement (the &#x201c;Bayer Collaboration Agreement&#x201d;), pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term up to a specified number of years per target program to generate radiopharmaceutical compounds incorporating optimized Bicycle constructs directed to two specified targets, under the oversight of a joint research committee. In addition, Bayer has a one-time right to expand the collaboration to include a third target program, and with respect to each of the up to three target programs, Bayer has an option, exercisable within a specified period of time following the effective date of the Bayer Collaboration Agreement, to generate, develop and commercialize non-radiopharmaceutical compounds directed to the applicable target, either itself or in collaboration with the Company. Bayer also has certain limited target substitution rights, in certain cases subject to specified additional payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For each collaboration program, Bayer may elect, at its sole discretion, to progress compounds arising from activities under the research programs into further preclinical development of potential products directed to the target of such collaboration program. On a target-by-target basis, if Bayer elects to progress development candidates directed to such target into further clinical development, Bayer will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products directed to the applicable target.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Bayer paid an upfront payment to the Company of $45.0 million in July 2023. All other payments under the Bayer Collaboration Agreement will be made in British Pound Sterling. If Bayer elects to expand the collaboration to include an additional target program, it will be required to make a one-time payment to the Company in connection with the selection of such target in the high single-digit millions. In addition, on a target-by-target basis, if Bayer elects to exercise its option to expand its rights with respect to such target to develop and commercialize non-radiopharmaceutical compounds directed to such target, Bayer will be required to pay to the Company, for each such target program for which it exercises such option, either a one-time option fee payment or quarterly payments of specified installment amounts for a specified maximum time period during which the Company is performing research activities, with the aggregate amounts receivable by the Company ranging from the high single-digit millions in the case of the one-time option fee payment, to the low single-digit millions in the case of the quarterly installments, in each case where the Company is performing specified research activities following the exercise of the option. Additionally, for each collaboration program, Bayer will reimburse the Company for certain expenses incurred in connection with specified research and discovery activities performed by a contract research organization (&#x201c;CRO&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On a target-by-target basis for the up to three targets, if Bayer elects to progress one or more candidate compounds into further development, Bayer will be required to pay a candidate selection fee for the first such compound progressed by Bayer directed to such target that incorporates a radionuclide, and for the first such compound directed to such target that does not incorporate a radionuclide (and for which Bayer has not paid the one-time option fee payment for non-radiopharmaceutical compounds), ranging from high single-digit millions to the mid single-digit millions. Upon declaring a candidate, Bayer will be responsible for all future development, manufacturing, and commercialization activities. On a target-by-target basis, if Bayer successfully conducts clinical development and achieves regulatory approval for compounds arising from the collaboration directed to such target in two indications, Bayer will be required &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;to pay to the Company development and regulatory/first commercial sale milestones of up to &#xa3;178.3 million for the first product directed to the applicable target to achieve such milestones (whether radiopharmaceutical or non-radiopharmaceutical), or &#xa3;534.9 million across all three potential target programs. In addition, if Bayer successfully commercializes products arising from the collaboration, Bayer will be required to pay to the Company, on a product-by-product basis, tiered royalties on net sales of products by Bayer, its affiliates or sublicensees at percentages ranging from the mid-single digits to the very low double digits, subject to standard reductions and offsets in certain circumstances, and a royalty floor. If Bayer commercializes diagnostic products directed to a target, royalties will be payable on such diagnostic products at a specified reduced percentage of the rates for therapeutic products. Royalties will be payable under the Bayer Collaboration Agreement on a product-by-product and country-by-country basis, commencing on the first commercial sale of each product, until the latest of (a) the expiration of the last valid claim of certain patents licensed by the Company to Bayer, (b) a specified number of years following first commercial sale of such product, and (c) expiration of all data and regulatory exclusivity for such product in the applicable country. On a target-by-target basis, Bayer will also owe the Company tiered sales milestones based on the achievement of specified levels of net sales of therapeutic products directed to such target totaling up to &#xa3;194.5 million in the aggregate per target, or &#xa3;583.5 million across all three potential target programs, and on diagnostic products directed to such target at a low double digit percentage of the therapeutic product milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Bayer Collaboration Agreement will remain in force on a product-by-product and country-by-country basis, unless earlier terminated by either party, until the expiration of the obligation for Bayer to make royalty payments to the Company for such product in such country, and will terminate in its entirety on the expiration of all such royalty terms in all countries. Either party may terminate the agreement upon 90 days&#x2019; written notice for the other party&#x2019;s uncured material breach (or 20 business days in the case of non-payment by Bayer), subject to extension of such cure period in certain circumstances, or upon the other party&#x2019;s insolvency. In addition, the Company has the right to terminate in the case of a patent challenge by or on behalf of Bayer (or any of its affiliates or sublicensees). In addition, Bayer may terminate the Bayer Collaboration Agreement (i) in its entirety or with respect to any product, collaboration program or target for any reason upon 60 or 90 days&#x2019; written notice to the Company (depending on whether such termination is prior to or following first commercial sale of a licensed product). The closing of the Bayer Collaboration Agreement was subject to the clearance of the transaction under the U.K. National Security and Investment Act 2021, which occurred on June 22, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounting Analysis&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;width:36pt;"&gt;&lt;/span&gt;At inception of the Bayer Collaboration Agreement, the Company identified the following performance obligations:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; combined performance obligations comprised of the license and the related research and development services during the research term associated with radiopharmaceutical compounds for the first and second targets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;A material right associated with certain limited substitution rights with respect to either the first or second target;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iv)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; material rights associated with the options to generate, develop, and commercialize non-radiopharmaceutical compounds for each of the first and second targets, for which each option includes an underlying option for research and development services and an option to progress non-radiopharmaceutical candidates directed to the first and second targets into further development; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(v)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;A material right related to the option to expand the collaboration to include a third target, which upon exercise includes research and development services during the research term associated with radiopharmaceutical compounds directed to the third target, as well as underlying options for: certain limited substitution rights; an option to progress a radiopharmaceutical candidate directed to the third target into further development; and an &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;option to generate, develop, and commercialize non-radiopharmaceutical compounds directed to the third target, inclusive of an underlying option for research and development services and an option to progress a non-radiopharmaceutical candidate into further development.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s participation in the joint research committee was assessed as immaterial in the context of the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the license granted at contract inception is not distinct from the research and development services as Bayer cannot obtain the benefit of the license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as they relate to constrained peptide technology that is not available in the marketplace. As a result, for each target, the license has been combined with the research and development services into a single performance obligation which is the combined performance obligation comprised of the license and related research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing whether the various options under the Bayer Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material rights identified above, the Company concluded that each of the options provided Bayer with a discount that it otherwise would not have received. The Company exercised judgment in concluding that certain development and commercialization rights associated with progressing product candidates into further development and commercialization represent options that are material rights, as Bayer cannot benefit from the development and commercialization rights until Bayer, in its sole discretion, elects to progress candidates into further development and pays the associated candidate selection fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction price was initially determined to be $47.5 million, consisting of the $45.0 million upfront fee and an estimated $2.5 million for the reimbursement of certain external CRO costs. The Company utilized the expected value method to determine the amount of variable consideration to be received. Additional payments to the Company upon Bayer&#x2019;s exercise of options are excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. The estimated $2.5 million in variable consideration was first allocated entirely to the first and second target combined performance obligations as the terms of the variable consideration relate specifically to the Company&#x2019;s efforts in satisfying the performance obligations and allocating the variable consideration entirely to those performance obligations is consistent with the allocation objective in ASC 606. The remaining transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the combined performance obligations for the first and second targets were based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling prices for the material rights were determined based on the fees that Bayer would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Bayer would exercise the options, inclusive of the probability of technical success. Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Material right associated with limited substitution rights for either the first or second target&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,691&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,703&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Material right for the option to expand the collaboration to include a third target and the underlying additional option rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is recognizing revenue related to amounts allocated to the first and second target combined performance obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of full-time equivalent efforts and external costs incurred to date as a percentage of total expected full-time equivalent efforts and external costs, which best reflects the progress towards satisfaction of the performance obligations. The amounts allocated to the material rights are recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. The first and second target combined performance obligations are expected to be satisfied over a period of approximately four years and the remaining material rights are expected to be exercised or expire within approximately seven years from contract inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;During the years ended December 31, 2024 and 2023, the Company recognized revenue of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$3.4&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1.2&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million, respectively, in connection with the Bayer Collaboration Agreement. The Company did &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;t recognize revenue in connection with the Bayer Collaboration Agreement during the year ended December 31, 2022. As of December 31, 2024 and 2023, the Company recorded deferred revenue of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$40.0&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$43.6&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million, respectively, in connection with the Bayer Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Novartis Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On March 27, 2023, the Company and Novartis entered into a collaboration and license agreement (the &#x201c;Novartis Collaboration Agreement&#x201d;), pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term of up to a specified number of years per target program to generate compounds incorporating optimized&#160;Bicycle&#160;constructs directed to two specified targets, under the oversight of a joint steering committee. The Company granted Novartis a non-exclusive, worldwide, royalty-free, sublicensable (subject to certain restrictions) license under the Company&#x2019;s intellectual property solely for Novartis to perform its research activities under each collaboration program during the research term (the &#x201c;Novartis Research License&#x201d;). For each collaboration program, Novartis may elect to progress compounds arising from activities under the research programs (&#x201c;Licensed Compounds&#x201d;) into further preclinical development of potential products directed to the target of such collaboration program. At a specified point, the Company will grant Novartis an exclusive, royalty-bearing, sublicensable, license under certain of the Company&#x2019;s intellectual property to develop, manufacture, and commercialize such Licensed Compound, subject to certain limitations. Novartis also has certain limited substitution rights for each target, and Novartis may extend the initial research term by one year by electing to make an additional payment. On a target-by-target basis, if Novartis elects to progress development candidates directed to such target into further clinical development, Novartis will be required to use commercially reasonable efforts to develop and seek regulatory approval in certain major markets for products containing Licensed Compounds directed to the applicable target. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Novartis paid a nonrefundable upfront payment to the Company of $50.0 million in April 2023. During the research term, upon achievement of a specified discovery milestone for the first target program, Novartis will make a one-time payment to the Company in the low single digit millions. On a target-by-target basis, if Novartis elects to progress one or more candidate compounds into further development and obtain an exclusive license for commercialization, Novartis will be required to pay a candidate selection fee for the first such Licensed Compound progressed by Novartis that incorporates a radionuclide, and for the first such Licensed Compound that does not incorporate a radionuclide, in each case in the mid-teen millions. Upon declaring a candidate, Novartis will be responsible for all future development, manufacturing, and commercialization activities. On a target-by-target basis, Novartis will be required to pay to the Company additional development and regulatory/first commercial sale milestones of up to $210.0 million for each of the first radionuclide product and non-radionuclide product directed to the applicable target upon the achievement of specified milestones, or $840.0 million in the aggregate if Novartis successfully achieves all such milestone events for both a radionuclide and a non-radionuclide product in each of the targets. In addition, the Company is eligible to receive tiered sales milestones based on the achievement of specified levels of net sales of such products totaling up to $200.0 million in the aggregate per product, or $800.0 million in the aggregate if Novartis successfully commercializes both a radionuclide and a non-radionuclide product in each of the target programs. In addition, (i) the Company is eligible to receive, on a therapeutic product-by-therapeutic product basis, tiered royalties on net sales of products by Novartis, its affiliates or sublicensees at percentages ranging from the high single digits to the very low double digits, subject to standard reductions and offsets in certain circumstances, and a royalty floor, and (ii) the Company is eligible to receive low single digit royalties on net sales of diagnostic products on a diagnostic product-&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;by-diagnostic product basis and a low single digit percentage of sublicensing income on diagnostic products. Royalties will be payable under the Novartis Collaboration Agreement on a product-by-product and country-by-country basis, commencing on the first commercial sale of each product in a country, until the latest of (a) the expiration of the last valid claim of certain patents licensed by Company to Novartis, (b) a specified number of years following first commercial sale of such product, and (c) expiration of all data and regulatory exclusivity for such product in the applicable country. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;"&gt;The Novartis Collaboration Agreement will remain in force on a product-by-product and country-by-country basis, unless earlier terminated by either party, until the expiration of the obligation for Novartis to make royalty payments to Company for such product in such country, and will terminate in its entirety on the expiration of all such royalty payment obligations in all countries. Either party may terminate the agreement upon 60 days&#x2019; written notice for the other party&#x2019;s uncured material breach, or upon the other party&#x2019;s insolvency. In addition, Novartis may terminate the Collaboration Agreement (i) in its entirety or on a product-by-product or target-by-target basis for any reason upon 90 days&#x2019; written notice to Company, and (ii) on a target-by-target basis on 30 days&#x2019; written notice if Novartis determines that a safety or regulatory issue exists which would have a material adverse effect on the development, manufacture, or commercialization of any product with respect to a given target. The Company may terminate the Novartis Collaboration Agreement, (a) on a target-by-target basis upon 30 days&#x2019; prior written notice if Novartis has not yet declared a development candidate for such target by the sixth anniversary of the commencement of research activities for such target and (b) if Novartis or any of its affiliates or sublicensees challenges the validity or enforceability of any of the patents in the Company&#x2019;s licensed intellectual property.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounting Analysis&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;Upon the execution of the Novartis Collaboration Agreement, the Company identified the following performance obligations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; combined performance obligations comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; material rights associated with certain limited substitution rights with respect to the first and second targets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; material rights associated with the option to progress development candidates that incorporate a radionuclide with respect to the first and second target; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iv)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; material rights associated with the option to progress development candidates that do not incorporate a radionuclide with respect to the first and second target.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The Company concluded that certain rights that require the payment of additional consideration, which approximates the standalone selling price of the underlying services to be provided, do not provide the customer with a material right and therefore, are not considered as performance obligations at the inception of the arrangement. The Company&#x2019;s participation in the joint steering committee was assessed as immaterial in the context of the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The Company has concluded that the Novartis Research License is not distinct from the research and development services as Novartis cannot obtain the benefit of the research license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as they relate to constrained peptide technology that is not available in the marketplace. As a result, for each target, the research license has been combined with the research and development services into a single performance obligation. The Company exercised judgment in concluding that Novartis&#x2019; rights to obtain certain research and development services associated with compounds that do not incorporate a radionuclide during the research term are not options that are material rights as they do not represent either options for additional goods or services or options for additional services that are at a discount that it would not have otherwise received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In assessing whether the various options under the Novartis Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material rights identified above the Company concluded that each of the options provided Novartis with a discount that it otherwise would not have received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The total transaction price was initially determined to be $50.0 million, consisting of the $50.0 million upfront fee. The Company utilizes the most likely amount method to determine the amount of variable consideration to be received. Variable consideration for development milestones not subject to option exercises was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved. Additional consideration to be paid to the Company upon the exercise of options by Novartis is excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the combined performance obligations for each of the targets were based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling prices for the material rights were determined based on the fees Novartis would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Novartis would exercise the options, inclusive of the probability of technical success. Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with limited substitution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with options to progress development candidates incorporating radionuclides&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with options to progress development candidates not incorporating radionuclides&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"&gt;In November 2024, the Company achieved a specified discovery milestone for the first target program and therefore updated its estimate of the variable consideration to include an additional $3.0 million, that is no longer constrained. The arrangement consideration was increased to $53.0 million. The Company allocated the additional $3.0 million to the performance obligations based on the relative estimated standalone selling prices of each performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The Company is recognizing revenue related to amounts allocated to the first and second target combined performance obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligations. The amounts allocated to the material rights are recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. The first and second target combined performance obligations are expected to be satisfied over a period of approximately three years and the remaining material rights are expected to be exercised or expire within approximately six years from contract execution. During the year ended December 31, 2024, the Company recognized revenue of $2.5 million upon the expiration of Novartis&#x2019; material rights for limited substitution rights for the first and second targets. The research and discovery activities for these targets are ongoing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;During the years ended December 31, 2024 and 2023, the Company recognized revenue of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$8.2&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1.9&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million in connection with the Novartis Collaboration Agreement. The Company did &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;t recognize revenue in connection with the Novartis Collaboration Agreement during the year ended December 31, 2022.&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; As of December 31, 2024 and 2023, the Company recorded deferred revenue of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$44.1&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$50.0&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million, respectively, in connection with the Novartis Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Ionis Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Ionis Evaluation and Option Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On December 31, 2020, the Company entered into an Evaluation and Option Agreement (the &#x201c;Evaluation and Option Agreement&#x201d;) with Ionis. Under the terms of the Evaluation and Option Agreement, Ionis had the option (the &#x201c;Ionis Option&#x201d;) to obtain an exclusive license to the Company&#x2019;s intellectual property for the purpose of continued research, development, manufacture and commercialization of products within a particular application of the Company&#x2019;s platform technology.  Ionis paid the Company a nonrefundable option fee of &lt;/span&gt;$3.0 million in January 2021 that was fully creditable against the upfront payment to be paid upon the execution of a license agreement. On July 9, 2021, the Ionis Option was exercised upon the parties&#x2019; entry into a collaboration and license agreement as contemplated by the Evaluation and Option Agreement. The Company determined that the Ionis Option exercise constituted a continuation of an existing arrangement. Therefore, the $3.0&lt;span style="white-space:pre-wrap;"&gt; million paid under the Evaluation and Option Agreement was included in the transaction price of the collaboration and license agreement.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Ionis Collaboration Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Following the exercise by Ionis of the Ionis Option granted pursuant to the Evaluation and Option Agreement, on July 9, 2021, the Company and Ionis entered into a collaboration and license agreement (the &#x201c;Ionis Collaboration Agreement&#x201d;). Pursuant to the Ionis Collaboration Agreement, the Company granted to Ionis a worldwide exclusive license under the Company&#x2019;s relevant technology to research, develop, manufacture and commercialize products incorporating Bicycle&lt;i style="font-style:italic;"&gt; &lt;/i&gt;peptides directed to the protein coded by the gene TFRC1 (transferrin receptor) (&#x201c;TfR1 Bicycle&lt;span style="white-space:pre-wrap;"&gt;&#x201d; molecules) intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans. Ionis will maintain exclusivity to all available targets unless it fails to achieve specified development diligence milestone deadlines.  If Ionis fails to achieve one or more development diligence milestone deadlines, the Company has the right to limit exclusivity to certain specific collaboration targets, subject to the payment by Ionis of a low-single-digit million dollar amount per target as specified in the Ionis Collaboration Agreement.  Each party was responsible for optimization of such TfR1 &lt;/span&gt;Bicycle molecules and other research and discovery activities related to TfR1 Bicycle&lt;span style="white-space:pre-wrap;"&gt; molecules, as specified by a research plan which was completed during the year ended December 31, 2024, and thereafter Ionis will be responsible for all future research, development, manufacture and commercialization activities.  The Company performed research and discovery activities including a baseline level of effort for a period of &lt;/span&gt;three years for no additional consideration. The parties will negotiate a commercially reasonable rate if additional research activities are agreed to be performed. The Company has retained certain rights, including the right to use TfR1 Bicycle molecules for all non-oligonucleotide therapeutic purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The activities under the Ionis Collaboration Agreement are governed by a joint steering committee (&#x201c;JSC&#x201d;) with an equal number of representatives from the Company and Ionis.  The JSC will oversee the performance of the research and development activities.  Upon first commercial sales of a licensed product, the JSC will have no further responsibilities or authority under the Ionis Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Under the Ionis Collaboration Agreement, Ionis made a non-refundable upfront payment of $31.0 million in addition to the $3.0 million already paid under the Option and Evaluation Agreement. Additionally, Ionis is obligated to reimburse the Company on a pass-through basis for expenses incurred in connection with research and discovery activities performed by a CRO. If Ionis is at risk of failing to achieve a specified development diligence milestone deadline, it can make up to three&lt;span style="white-space:pre-wrap;"&gt; separate payments of a mid-single-digit million dollar amount to extend the development diligence milestone deadlines.  On a collaboration target-by-collaboration target basis, Ionis will be required to make a low-single-digit million dollar payment upon acceptance of an investigational new drug application (&#x201c;IND&#x201d;) for the first product directed to such collaboration target (provided that Ionis will have a high single-digit &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;million dollar credit to be applied towards the IND acceptance fee for &lt;/span&gt;four collaboration targets, or for exclusivity payments for certain targets if specified development diligence milestones deadlines are not achieved), and Ionis will be required to make milestone payments upon the achievement of specified development and regulatory milestones of up to a low double-digit million dollar amount per collaboration target. In addition, the Company is eligible to receive up to a low double-digit million dollar amount in cumulative sales milestone payments. The Company is also entitled to receive tiered royalty payments on net sales at percentages in the low single digits, subject to certain standard reductions and offsets. Royalties will be payable, on a product-by-product and country-by-country basis, until the latest of the expiration of specified licensed patents covering such product in such country, ten years from first commercial sale of such product in such country, or expiration of marketing exclusivity for such product in such country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2021, the Company and Ionis entered into the first amendment to the Ionis Collaboration Agreement (the &#x201c;First Ionis Amendment&#x201d;) and Ionis paid the Company $1.6 million to perform additional research services utilizing its proprietary phage screening technology to identify and optimize new product candidates that target the TfR1 receptor. In April 2023, the Company and Ionis entered into the third amendment to the Ionis Collaboration Agreement (the &#x201c;Third Ionis Amendment&#x201d;) and Ionis paid the Company $0.8 million and the Company agreed to perform additional research services to continue to evaluate and optimize the new product candidates that target the TfR1 receptor for a period of one year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Either party may terminate the Ionis Collaboration Agreement for the uncured material breach of the other party or in the case of insolvency. Ionis may terminate the Ionis Collaboration Agreement for convenience on specified notice periods depending on the development stage of the applicable target, either in its entirety or on a target-by-target basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Ionis Share Purchase Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Concurrently with the execution of the Ionis Collaboration Agreement on July 9, 2021, the Company entered into the Ionis Share Purchase Agreement with Ionis, pursuant to which Ionis purchased 282,485 of the Company&#x2019;s ordinary shares (the &#x201c;Ionis Shares&#x201d;) at a price per share of $38.94, for an aggregate purchase price of approximately $11.0 million. The Share Purchase Agreement also provided that, subject to limited exceptions, Ionis could not sell any of the Ionis Shares until July 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company determined the fair value of the Ionis Shares to be $7.6 million, based on the closing price of the Company&#x2019;s ADSs of $31.11&lt;span style="white-space:pre-wrap;"&gt; per ADS on the date of the Ionis Share Purchase Agreement, less a discount for lack of marketability associated with resale restrictions applicable to the Ionis Shares. The Company concluded that the premium paid by Ionis under the Ionis Share Purchase Agreement represents additional consideration for the goods and services to be provided under the Ionis Collaboration Agreement.  As such, the total premium of &lt;/span&gt;$3.4 million was included in the transaction price under the Ionis Collaboration Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounting Analysis&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Upon execution of the Ionis Collaboration Agreement, the Company identified the following promises in the arrangement: (i) a worldwide exclusive license to research, develop, manufacture and commercialize products incorporating TfR1 Bicycle molecules intended for the delivery of oligonucleotide compounds directed to targets selected by Ionis for diagnostic, therapeutic, prophylactic and preventative uses in humans; (ii) research and discovery activities to customize and optimize such TfR1 Bicycle molecules; (iii) four material rights associated with options to obtain credits to be applied towards the IND acceptance fee for four&lt;span style="white-space:pre-wrap;"&gt; collaboration targets.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company&#x2019;s participation in the JSC was deemed immaterial in the context of the contract.  &lt;/span&gt;The Company concluded that the exclusive license to research, develop, manufacture and commercialize products was not distinct from the research and discovery services as Ionis cannot obtain the intended benefit of the license without the Company performing the agreed upon research and discovery services, including the optimization of such TfR1 Bicycle molecules. The services incorporated proprietary technology, unique skills and specialized expertise to optimize Bicycle molecules that were not available in the marketplace. As a result, the exclusive license to research, develop, manufacture and commercialize products was combined with the research and discovery activities into a single performance obligation. The Company concluded that the low-single-digit million dollar payments upon acceptance of an IND (and payment to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;extend the exclusive license to research, develop, manufacture and commercialize a product candidate for certain specific collaboration targets if Ionis fails to achieve specified development diligence milestone deadlines) is a customer option, as Ionis has the contractual right to choose to make the payment in exchange for the continued exclusive right to research, develop, manufacture and commercialize the product candidate, and the Company is not presently obligated to provide, and does not have a right to consideration, for the additional goods or services prior to Ionis&#x2019;s exercise of the option. In assessing whether the options under the Ionis Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon the option exercise and the standalone selling price of the underlying goods and services. For the material rights identified as performance obligations above, the Company concluded that each of the options to obtain credits provided Ionis with a discount that it otherwise would not have received without entering into the Ionis Collaboration Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The total transaction price was initially determined to be $38.0 million, consisting of the $31.0 million up front payment, the $3.0 million payment under the Option and Evaluation Agreement, that was credited against the total upfront payment payable pursuant to the Ionis Collaboration Agreement, the $3.4 million premium paid under the Ionis Share Purchase Agreement, and an estimated $0.6&lt;span style="white-space:pre-wrap;"&gt; million for the reimbursement of CRO costs. Additional variable consideration including development diligence milestone deadline extension payments, development and regulatory milestone payments, sales milestone payments and royalty payments was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling price of the Ionis combined licenses and research and discovery performance obligation was based on the nature of the licenses to be delivered, as well as the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling price for the material rights was determined based on the estimated value of the underlying goods and services, and the probability that Ionis would exercise the option. Based on the relative standalone selling price, the initial allocation of the transaction price to the separate performance obligations was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Combined licenses and research and discovery performance obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Four material rights associated with credits for IND Acceptance fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the year ended December 31, 2024, the Company updated its estimate of variable consideration for the reimbursement of CRO costs from $0.6 million to $0.4 million, and the transaction price decreased to $37.8 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company recognized revenue related to amounts allocated to the combined licenses and research and discovery performance obligation using a proportional performance model over the period of service using input-based measurements including total full-time equivalent effort and CRO costs incurred to date as a percentage of total full-time equivalent effort and CRO costs expected, which best reflects the progress towards satisfaction of the performance obligation. The amount allocated to the material rights is recorded as deferred revenue and the Company commences revenue recognition upon exercise of or upon expiry of the respective option. As of December 31, 2024, the combined licenses and research and discovery performance obligation was completed and all revenue allocated to the combined licenses and research and discovery performance obligation was recognized. The Company anticipates the material rights may be exercisable or may expire after approximately &lt;span style="-sec-ix-hidden:Hidden_7Ox68_7-tk2-gZ54jj6J7A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four&lt;/span&gt;&lt;/span&gt; to seven years from contract execution. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/span&gt;The Company concluded that the First Ionis Amendment was a separate contract, as the services were distinct from the Ionis Collaboration Agreement, and the price of the contract increased by an amount of consideration that reflects the Company&#x2019;s standalone selling price. The Company recognized $0.8 million associated with services for an initial six-month period as revenue as the underlying services were performed. The contract included an option to perform additional research services for an additional six months that did not contain a material right and the Company accounted for Ionis&#x2019; exercise of the option in October 2022 as a separate contract. The Company recognized $0.8 million associated with the services for the additional six-month period as revenue as the underlying services were performed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company concluded that the Third Ionis Amendment was a contract modification to the separate contract under the First Ionis Amendment, as the services were not distinct from the services provided under the First Ionis Amendment. The Company recognized $0.8 million associated with the services for the additional one-year period as revenue as the underlying services were performed. Revenue was recognized under the First Ionis Amendment and the Third Ionis Amendment using a proportional performance model over the period of service using input-based measurements of total full time equivalent efforts and external costs incurred to date as a percentage of total expected full time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2024, 2023 and 2022, the Company recognized $8.9 million, $10.7 million and $9.3 million in revenue, respectively, and as of December 31, 2024 and 2023, the Company recorded deferred revenue of $3.6 million and $12.5 million, respectively, in connection with the Ionis Collaboration Agreement, First and Third Ionis Amendments, and Ionis Evaluation and Option Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Genentech Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 21, 2020, the Company entered into a Discovery Collaboration and License Agreement, as amended from time to time (as amended, the &#x201c;Genentech Collaboration Agreement&#x201d;), with Genentech. The collaboration is focused on the discovery and development of Bicycle peptides directed to biological targets selected by Genentech and aimed at developing up to four potential development candidates against multiple immuno-oncology targets suitable for Genentech to advance into further development and commercialization. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Genentech Collaboration Agreement, the Company received a $30.0 million upfront, non-refundable payment. The initial discovery and optimization activities are focused on utilizing the Company&#x2019;s phage screening technology to identify product candidates aimed at two immuno-oncology targets (&#x201c;Genentech Collaboration Programs&#x201d;), which may also include additional discovery and optimization of Bicycle molecules&lt;i style="font-style:italic;"&gt; &lt;/i&gt;as a targeting element for each Genentech Collaboration Program (each a &#x201c;Targeting Arm&#x201d;). Genentech also had the option to nominate up to two additional immuno-oncology targets (each, an &#x201c;Expansion Option&#x201d;) as additional Genentech Collaboration Programs, which may also include an additional Targeting Arm for each Expansion Option. Genentech exercised the Expansion Options in October 2021 and June 2022, respectively. Genentech paid to the Company an expansion fee of $10.0 million for each Expansion Option. The Genentech Collaboration Agreement included rights, under certain limited circumstances, for Genentech to select an alternative target to be the subject of a Genentech Collaboration Program, in some cases subject to payment of an additional target selection fee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;If Genentech elects for the Company to perform discovery and optimization services for certain Targeting Arms, the Company will be entitled to receive an additional advance payment for the additional research services.  Genentech exercised its right to select a Targeting Arm for &lt;/span&gt;one of the initial Genentech Collaboration Programs at the inception of the arrangement, and for the first Expansion Option in October 2021, which entitled the Company to additional payments of $1.0&lt;span style="white-space:pre-wrap;"&gt; million each. If a Targeting Arm achieves specified criteria in accordance with the research plan, Genentech will be required to pay a further specified amount in the low single digit millions for each such Targeting Arm as consideration for the additional services to be provided.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company granted to Genentech a non-exclusive research license under the Company&#x2019;s intellectual property solely to enable Genentech to perform any activities under the agreement. The activities under the Genentech Collaboration Agreement are governed by a joint research committee (&#x201c;JRC&#x201d;) with representatives from each of the Company and Genentech. The JRC will oversee, review and recommend direction of each Genentech Collaboration Program, achievement of development criteria, and variations of or modifications to the research plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;After the Company performs the initial discovery and optimization activities in accordance with an agreed research plan and achieves specified criteria, Genentech will have the option to have the Company perform initial pre-clinical development and optimization activities in exchange for an additional specified milestone payment in the mid-single digit millions for each Genentech Collaboration Program (the &#x201c;LSR Go Option&#x201d;).  Upon completion of such initial pre-clinical development and optimization activities for each Genentech Collaboration Program, Genentech will have the option to obtain an exclusive license to exploit any compound developed under such Genentech Collaboration Program in exchange for an additional specified payment in the mid to high single digit millions for each of the initial &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;two Genentech Collaboration Programs and each of the two Expansion Option Genentech Collaboration Programs (the &#x201c;Dev Go Option&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On a Genentech Collaboration Program by Genentech Collaboration Program basis, if Genentech elects to obtain exclusive development and commercialization rights and pays the applicable LSR Go Option and Dev Go Option fees, Genentech will be required to make milestone payments to the Company upon the achievement of specified development, regulatory, and initial commercialization milestones for products arising from each collaboration program, totaling up to $200.0 million. Specifically, the Company is eligible for additional development milestones totaling up to $65.0 million, as well as regulatory milestones of up to $135.0 million for each collaboration program. In addition, the Company is also eligible to receive up to $200.0 million in sales milestone payments on a Genentech Collaboration Program-by-Genentech Collaboration Program basis. In addition, to the extent any of the product candidates covered by the licenses conveyed to Genentech are commercialized, the Company would be entitled to receive tiered royalty payments on net sales at percentages ranging from the mid-single to low double-digits, subject to certain standard reductions and offsets. Royalties will be payable, on a product by product and country by country basis, until the later of the expiration of specified licensed patents covering such product in such country, or ten years from first commercial sale of such product in such country. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounting Analysis&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the execution of the Genentech Collaboration Agreement, the Company has identified the following performance obligations: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Research license, and the related research and development and preclinical services through LSR Go for a first Genentech Collaboration Program (Genentech Collaboration Program #1); &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Research license, and the related research and development and preclinical services through LSR Go for a second Genentech Collaboration Program with a specified Targeting Arm (Genentech Collaboration Program #2); &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Material right associated with an option to a specified Targeting Arm for Genentech Collaboration Program #1;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(iv)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; material rights associated with the LSR Go Option for Genentech Collaboration Program #1 and Genentech Collaboration Program #2, which includes research services to be provided through the Dev Go Option and an option to receive an exclusive license; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(v)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Material rights associated with certain limited substitution rights with respect to a limited number of collaboration targets; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(vi)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; material rights related to each Genentech Expansion Option, which upon exercise include the services for an additional immuno-oncology target through the LSR Go Option, an LSR Go Option which includes the services to be provided through the Dev Go Option and an option to receive an exclusive license, limited substitution rights, and an option to select a specified Targeting Arm. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company concluded that certain substitution rights that require the payment of additional consideration, which approximate the standalone selling price of the underlying services to be provided, do not provide the customer with a material right and therefore, are not considered as performance obligations and are accounted for as separate contracts upon exercise, if ever.  The Company&#x2019;s participation in the JRC was assessed as immaterial in the context of the contract. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company has concluded that the research license is not distinct from the research and development services as Genentech cannot obtain the benefit of the research license without the Company performing the research and development services. The services incorporate proprietary technology and unique skills and specialized expertise, particularly as it relates to constrained peptide technology that is not available in the marketplace. As a result, for each &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;research program, the research license has been combined with the research and development services into a single performance obligation. In addition, the Company concluded that the Dev Go Option is not distinct or separately exercisable from the LSR Go Option, as the customer cannot benefit from the Dev Go Option unless and until the LSR Go Option is exercised. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In assessing whether the various options under the Genentech Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon the option exercise, the standalone selling price of the underlying goods, services, and additional options.  For the material rights identified above the Company concluded that each of the options provided Genentech with a discount that it otherwise would not have received. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The total transaction price was initially determined to be $31.0 million, consisting of the $30.0 million upfront fee and the additional $1.0&lt;span style="white-space:pre-wrap;"&gt; million for Genentech&#x2019;s selection of a new Targeting Arm at inception.  The Company utilizes the most likely amount method to determine the amount of research and development funding to be received. Additional consideration to be paid to the Company upon the exercise of options by Genentech and subsequent milestones are excluded from the transaction price as they relate to option fees and milestones that can only be achieved subsequent to the exercise of an option. In addition, other variable consideration for development milestones not subject to option exercises was fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. In March 2021, the Company achieved specified criteria in accordance with the research plan under the Genentech Collaboration Agreement and therefore updated its estimate of the variable consideration to include an additional &lt;/span&gt;$2.0 million, that is no longer constrained. The arrangement consideration was increased to $33.0 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. The estimated standalone selling prices for the Genentech Collaboration Programs was based on the nature of the services to be performed and estimates of the associated effort and costs of the services, adjusted for a reasonable profit margin for what would be expected to be realized under similar contracts. The estimated standalone selling price for the material rights was determined based on the fees Genentech would pay to exercise the options, the estimated value of the underlying goods and services, and the probability that Genentech would exercise the option and any underlying options.  &lt;/span&gt;Based on the relative standalone selling price, the allocation of the transaction price to the separate performance obligations is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Genentech Collaboration Program #1 Performance Obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Genentech Collaboration Program #2 Performance Obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,037&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Specified Targeting Arm Material Right Arm for Genentech Collaboration Program #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with the LSR Go Option for Collaboration Programs #1 and #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Material rights associated with limited substitution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights for Expansion Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,005&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue related to amounts allocated to the Genentech Collaboration Program #1 and #2 Performance Obligations as the underlying services are performed using a proportional performance model over the period of service using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and expected external costs, which best reflects the progress towards satisfaction of the performance obligation. The amount allocated to the material rights is recorded as deferred revenue and the Company will commence revenue recognition upon exercise of or upon expiry of the respective option. In June 2023, Genentech terminated Genentech Collaboration Program #2 and revenue of $6.0 million was recognized during the year ended December 31, 2023 related to the expiration of the material right associated with the LSR Go Option for Collaboration Program #2. The Company expects the remaining Genentech Collaboration Performance Program #1 performance obligations will be satisfied over the next &lt;span style="-sec-ix-hidden:Hidden_PuaulHhMWk2PS85VLrvMLw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to two years, and the remaining deferred revenue allocated to the LSR Go Option for Collaboration Program #1 will commence revenue recognition when the option is exercised or expires within approximately &lt;span style="-sec-ix-hidden:Hidden_CuyU_1zNJ0eAuH7pLi5zdQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four&lt;/span&gt;&lt;/span&gt; to five years from contract execution. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In October 2021 and June 2022, respectively, Genentech exercised the first and second Expansion Options to add additional Genentech Collaboration Programs (Genentech Collaboration Program #3 and Genentech Collaboration Program #4) and paid to the Company an expansion fee of $10.0 million for each option. For the first Expansion Option, Genentech also elected for the Company to perform discovery and optimization services for a Targeting Arm, and the Company received an additional payment of $1.0 million for additional research services. The Company concluded that the exercise of each Expansion Option, including the option to a specified Targeting Arm for the first Expansion Option, is accounted for as a continuation of an existing contract as the customer decided to purchase additional goods and services contemplated in the original contract. For the first Expansion Option, the additional arrangement consideration of $11.0 million received upon the option exercises and the $3.5 million originally allocated to the first Expansion Option material right is allocated to the underlying goods and services associated with the first Expansion Option on the same basis as the initial allocation of the Genentech Collaboration Agreement. In December 2022, the Targeting Arm associated with the first Expansion Option achieved specified criteria in accordance with the research plan under the Genentech Collaboration Agreement and therefore the Company updated its estimate of variable consideration to include an additional $2.0 million, that is no longer constrained. The Company allocated the additional $2.0 million entirely to the Genentech Collaboration Program #3 and Targeting Arm services as the terms of the variable consideration relate specifically to the Company&#x2019;s efforts in satisfying the performance obligation and allocating the variable consideration entirely to the performance obligation is consistent with the allocation objective in ASC 606. For the second Expansion Option, the additional arrangement consideration of $10.0 million received pursuant to the option exercise together with the $3.5 million originally allocated to the second Expansion Option material right is allocated to the underlying goods and services associated with the second Expansion option on the same basis as the initial allocation of the Genentech Collaboration Agreement. Other variable consideration for development milestones not subject to option exercises was fully constrained as a result of the uncertainty regarding whether any of the milestones will be achieved. The Company recognized the $8.4 million allocated to the Genentech Collaboration Program #3 and Targeting Arm services and is recognizing $5.3 million allocated to the Genentech Collaboration Program #4 services as the underlying services are performed using a proportional performance model over the period of service of approximately &lt;span style="-sec-ix-hidden:Hidden_23cxoubFkkqKtXI7gxQnYw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to three years for each program using input-based measurements of total full-time equivalent efforts and external costs incurred to date as a percentage of total full-time equivalent efforts and external costs expected, which best reflects the progress towards satisfaction of the performance obligations. The amount allocated to the material rights associated with an LSR Go Options for Genentech Collaboration Program #3 and Genentech Collaboration Program #4 of $7.4 million and $7.4 million, respectively, limited substitution material rights of $0.7 million and $0.7 million, respectively, and the material right associated with the option to select a Targeting Arm for Genentech Collaboration Program #4 of $0.1 million were recorded as deferred revenue. In January 2024, the JRC decided to discontinue research activities associated with Genentech Collaboration Program #3 and, as a result, the Company recognized revenue of $10.4 million during the year ended December 31, 2024, including $7.5 million related to the expiration of remaining material rights. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized revenue of $14.8 million, $12.0 million and $3.6 million, respectively, and as of December 31, 2024 and 2023, the Company recorded deferred revenue of 14.0 million and $29.1 million, respectively, in connection with the Genentech Collaboration Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Summary of Contract Assets and Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents changes in the balances of the Company&#x2019;s contract liabilities (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impact&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Bayer collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 43,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,393)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (561)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 39,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Novartis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 50,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 44,073&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Ionis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,881)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Genentech collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,840)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 135,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35,275)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,647)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 101,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impact&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bayer collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,160)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 43,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Novartis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,909)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 50,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Ionis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,489&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,734)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Genentech collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,969)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;AstraZeneca collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 61,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 135,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract assets represent research and development services which have been performed but have not yet been billed, and are reduced when they are subsequently billed. There were no contract assets at December 31, 2024 or 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Bayer, Novartis, Ionis, and Genentech deferred revenue balances include $31.9 million, $32.0 million, $3.6 million, and $13.5 million, respectively, allocated to material rights that will commence revenue recognition when the respective underlying options are exercised or when the options expires. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognized in the period from:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenue recognized based on proportional performance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenue recognized based on expiration of material rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenue recognized based on changes in transaction price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Cancer Research UK&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;BT1718&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On December 13, 2016, the Company entered into a Clinical Trial and License Agreement with Cancer Research Technology Limited (&#x201c;CRTL&#x201d;), a wholly owned subsidiary of Cancer Research UK that Cancer Research UK&#x2019;s commercial activities operate through, and Cancer Research UK (the &#x201c;BT1718 Cancer Research UK Agreement&#x201d;). Pursuant to the BT1718 Cancer Research UK Agreement, as amended in March 2017 and June 2018, Cancer Research UK&#x2019;s Centre for Drug Development sponsored and funded a Phase I/IIa clinical trial for BT1718, a BTC molecule, in patients with advanced solid tumors. The Company retained the right to continue the development of BT1718 during the clinical trial. Upon the completion of the Phase I/IIa clinical trial, the Company had the right to obtain a license to the results of the clinical trial upon the payment of a milestone, in cash and ordinary shares, with a combined value in the mid six-digit dollar amount. If such license was not acquired, or if it was acquired and the license was terminated and the Company decided to abandon development of all products that deliver cytotoxic payloads to the MT1 target antigen, CRTL could elect to receive an assignment and exclusive license to develop and commercialize the product on a revenue sharing basis (in which case the Company would receive tiered royalties of 70% to 90% of the net revenue depending on the stage of development when the license is granted). The BT1718 Cancer Research UK Agreement contained additional future milestone payments upon the achievement of development and regulatory milestones, payable in cash and shares, with an aggregate total value of $50.9 million, as well as royalty payments based on a single digit percentage on net sales of products developed. Cancer Research UK could terminate the arrangement for safety reasons or if it was determined that the objectives of the clinical trial will not be met and either party could terminate the arrangement upon an insolvency event, material breach of the terms of the contract, or upon a change in control (and the new controlling entity develops, sells or manufactures tobacco products or generates the majority of its profits from tobacco products or &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;is an affiliate of such party). The Company was required to reimburse Cancer Research UK for certain costs upon specified termination events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the costs incurred by Cancer Research UK was a research and development funding liability in accordance with ASC&#160;730, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;, as certain payments were not based solely on the results of the research and development having future economic benefit. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 4, 2024, the Company, CRTL and Cancer Research UK entered into an Expiry and Revenue Sharing Agreement (the &#x201c;BT1718 Expiration Agreement&#x201d;) pursuant to which (i) the Company did not exercise its option to obtain a license to the results of the clinical trial, (ii) CRTL did not elect to receive an assignment and exclusive license to develop and commercialize the product, (iii) the BT1718 Cancer Research UK Agreement will expire on December 4, 2024, and (iv) all rights and obligations (other than certain surviving provisions as outlined in the agreement) under the BT1718 Cancer Research UK Agreement expired and terminated as of December 4, 2024. Under the terms of the BT1718 Expiration Agreement, the Company agreed to pay to CRTL an upfront payment of &#xa3;50,000. The Company will also pay to CRTL specified royalty and other payments at percentages in the very low to low single digits related to specified products targeting the MT1 target antigen.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounted for the BT1718 Expiration Agreement by applying the concepts of ASC 470, &lt;i style="font-style:italic;"&gt;Debt&lt;/i&gt;. As all rights and obligations, including the Company&#x2019;s payment obligations, under the BT1718 Cancer Research UK Agreement expired and terminated, the Company concluded that the liability recorded under the BT1718 Cancer Research UK Agreement is extinguished as the Company has been legally released from being the primary obligor under the BT1718 Cancer Research UK Agreement. As such, the Company recognized a gain on extinguishment of the research and development funding liability of $4.5 million during the year ended December 31, 2024, which is recorded within other income, net, in the consolidated statements of operations and comprehensive loss. As of December 31, 2024 and 2023, the Company recorded a research and development funding liability of zero and $4.3 million, respectively, related to the BT1718 Cancer Research UK Agreement, which is recorded in other long-term liabilities in the consolidated balance sheets.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_jH_uEfo5lkiyFYhItrYfTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the revenue recognized from the Company&#x2019;s collaboration arrangements in the consolidated statements of operations and comprehensive loss (in&#160;thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Collaboration revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bayer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Novartis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,909&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Ionis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,734&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Genentech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dementia Discovery Fund&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,165&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total collaboration revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw"
      decimals="-3"
      id="Tc_hRCPME3KykmbJxyfhLjkGw_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3393000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw"
      decimals="-3"
      id="Tc_NmsOA9SdJ0yWjXQRbcseWg_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA"
      decimals="-3"
      id="Tc_5P6iK70Gg0Gx9PNFTyvj6Q_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ"
      decimals="-3"
      id="Tc_kB_UoMqMaUOhc8VGPkfXGA_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1909000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"
      decimals="-3"
      id="Tc_Pe1KJMH8yEeijWQ2HmTmSA_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8881000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g"
      decimals="-3"
      id="Tc_BUVHY3EO9UC9xYhGHudk_g_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10734000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_6B9ln8pBckaqlZDRFLAB3A"
      decimals="-3"
      id="Tc_Hcc0XZjZCEacU1r57G0H6A_8_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A"
      decimals="-3"
      id="Tc_JwyKxtt-eEKxQ9C3IaVEhg_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14840000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg"
      decimals="-3"
      id="Tc_xnLNEonYv0WPxBQdNSgnpA_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11969000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qLy1Qlk7lUqL6zN6xMcMvQ"
      decimals="-3"
      id="Tc_paxV88IVaUyznYnaQb_YWQ_9_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3565000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_DementiaDiscoveryFundCollaborationAgreementMember_LB_cYGPJt0-dBCSytUGDoA"
      decimals="-3"
      id="Tc_Ibt8OwxDKkG_nNdq447wWw_10_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ"
      decimals="-3"
      id="Tc_NtnMY0W9JUuIqN4XSU6R2A_11_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_is22NBT1Jka8Gu-uasBItg"
      decimals="-3"
      id="Tc_QcyvYpLrvUiQnMrE2B3U1A_11_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_0DePMDfJ1EayyLyWt-Q6nQ_12_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">35275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_S0gj-aDXeEqJit8Xistw2A_12_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_R7Uz8x_MeUmgrqNTGI3Amw_12_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A"
      decimals="INF"
      id="Narr_X4loeahQ60-QbvyXmAA1lQ"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ"
      decimals="INF"
      id="Narr_VN5tjHEf00esfvmjE9j5aA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">3</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg"
      decimals="-5"
      id="Narr_msS3A3WlU0Co_cYTL5rgMg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">45000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ"
      decimals="INF"
      id="Narr_UPeOeaN4c0KbTiJigoDNoQ"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">3</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment
      contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_ZNuFcicSUka_auEsj1BcvA"
      decimals="INF"
      id="Narr_l6mq0UkjrEO6_JQ5g6JvyA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">1</bcyc:CollaborationAndLicenseAgreementNumberOfCandidateCompoundsIntoFurtherDevelopment>
    <bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable
      contextRef="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentAndRegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rDEBgcbU2U6rfbdVzl6Apg"
      decimals="-5"
      id="Narr_0i2NDOlFHE2ccVzgK88d5Q"
      unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ">178300000</bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable
      contextRef="As_Of_5_4_2023_bcyc_AchievementOfMilestoneAxis_bcyc_MilestoneAcrossAllPotentialTargetProgramsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bsrGl4-r_kuiY-MRpYt5Sg"
      decimals="-5"
      id="Narr_G1GB_RdDYEakrbFvq2ZzTg"
      unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ">534900000</bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ"
      decimals="INF"
      id="Narr_huR3G1gtd06hy7HWTa09rw"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">3</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable
      contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ"
      decimals="-5"
      id="Narr_97gbRdUQaUKMXXMDYuj9KQ"
      unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ">194500000</bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A"
      decimals="-5"
      id="Narr_XoeOZGRs8kGew3ee8YnMHA"
      unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ">583500000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0-Og6mCXYUykfOlxR802qQ"
      decimals="INF"
      id="Narr_Hl6-S_BA1kWW7CDcJkibRA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">3</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg"
      id="Narr_ZMZlWTMgt0ejs-V-OHUgug">P90D</bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeForUncuredMaterialBreach>
    <bcyc:ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg"
      id="Narr_kI9ckzjyiEGQetSYkTG-gQ">P20D</bcyc:ThresholdBusinessDaysToTerminateAgreementUponNonPaymentByBayer>
    <bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer
      contextRef="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_k7kwiL6Tv0Oaw0c1V1bDWg"
      id="Narr_4g7wBmL-xEOnyfObTdOvuw">P60D</bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer>
    <bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer
      contextRef="Duration_5_4_2023_To_5_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_hMqy_55tV0OU0RmfGW8IMg"
      id="Narr_BkwcuWykQ0eqLryRRukUjA">P90D</bcyc:ThresholdPeriodToTerminateAgreementUponWrittenNoticeByBayer>
    <bcyc:NumberOfCombinedPerformanceObligations
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yFgBlbVotUajI_G7d99bBg"
      decimals="INF"
      id="Narr_1AzSpmZwlE2Tk_HPPSkB3A"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfCombinedPerformanceObligations>
    <bcyc:NumberOfMaterialRights
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_94phe6rJ4kWybY0cwUE7iw"
      decimals="INF"
      id="Narr_OUY5O_i-IUefO7g1_oXsYQ"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfMaterialRights>
    <bcyc:NumberOfMaterialRights
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_eqvMYjbIIU-vjO_qsp7v0A"
      decimals="INF"
      id="Narr_d6Dv1wjqOUiJkFPPrYPWIA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfMaterialRights>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A"
      decimals="-5"
      id="Narr_UJ0E6dqwr0eoDw3-Bqgafw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">47500000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg"
      decimals="-5"
      id="Narr_Oh9RAY1gaUiW80G-BgOOxQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">45000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations
      contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A"
      decimals="-5"
      id="Narr_Z_1Zf7ckBESsKLKvhcDLQQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2500000</bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations>
    <bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations
      contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A"
      decimals="-5"
      id="Narr_301clj6sz0ybiFGqwIiZyA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2500000</bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations>
    <bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw"
      id="Group_92GvSY0wwki8su7Fa3gl_g">Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Material right associated with limited substitution rights for either the first or second target&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,691&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,703&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Material right for the option to expand the collaboration to include a third target and the underlying additional option rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsRelatedToLicensesAndResearchAndDevelopmentServicesAssociatedWithRadiopharmaceuticalCompoundsDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_r6MfE3ksRECQo64rWUZQ_w"
      decimals="-3"
      id="Tc_UnlosqYBikCxf42PXGImuQ_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14976000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightAssociatedWithLimitedSubstitutionRightsForEitherFirstOrSecondTargetMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_IU-HPwKXJEOuf8TPozi9MQ"
      decimals="-3"
      id="Tc_70aUJBKFkUO83hMAnl2T1w_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1527000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressRadiopharmaceuticalCandidatesDirectedToFirstAndSecondTargetsIntoFurtherDevelopmentMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_qpxzdeztD02IVOBhBuyF0g"
      decimals="-3"
      id="Tc_LleZRmVTrkqzKQMC3E06Lg_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14691000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionToProgressNonRadiopharmaceuticalCompoundDirectedToFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_0SmQ9UkaoEyo_zuVmF9T8g"
      decimals="-3"
      id="Tc_LVZQ39w48EqEc0NHOFHjfw_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8703000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_5_4_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightForOptionToExpandCollaborationToIncludeThirdTargetAndUnderlyingAdditionalOptionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_H7vbLohDfUqZtqXKcd9CpQ"
      decimals="-3"
      id="Tc_R8XpHIMF2EufT69PfutHYw_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7603000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_uGzTeU_FIE-s30gmXsR64A"
      decimals="-3"
      id="Tc_HOUkRuzQKkOlPcut7-ltmA_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">47500000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg"
      id="Narr_uEPzRkKoiU-9hnfs4YpDMg">P4Y</bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed>
    <bcyc:MaterialRightsExerciseOrExpiryTerm
      contextRef="Duration_5_4_2023_To_5_4_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_4N94W5Gft0iXb4jI342zxg"
      id="Narr_QIpIktam1k2S75V05GhRgw">P7Y</bcyc:MaterialRightsExerciseOrExpiryTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw"
      decimals="-5"
      id="Narr_fDJ8L3tHmki1_6Kr-2OG3w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw"
      decimals="-5"
      id="Narr_hwkmCmbIN02x2LqKW5LKQA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_yibznVR9GEqfsVp2Udu60g"
      decimals="-5"
      id="Narr_u-FcWnCG3UWRv_ZxL-4O0Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_CLM3oWHaYEmA9xWRlsRxFw"
      decimals="-5"
      id="Narr_fG5pm3iWUU2WWWW6r_cM0g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">40000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q"
      decimals="-5"
      id="Narr_Ud59MTJ2xUqxAzQ4_r2A-g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">43600000</us-gaap:ContractWithCustomerLiability>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w"
      decimals="INF"
      id="Narr_xGEmcPczzEa1enUUII57RA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:AdditionalResearchTerm
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg"
      id="Narr_steJJ0lRREmlaJbu1uH1VQ">P1Y</bcyc:AdditionalResearchTerm>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg"
      decimals="-5"
      id="Narr_3h9LOsPatEqIAtZd0BH3fg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable
      contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w"
      decimals="-5"
      id="Narr_o1RjA6Ya4Ueoe80DnChxAg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">210000000</bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w"
      decimals="-5"
      id="Narr_QOmhVFzG30KR4Jan3QJatA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">840000000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable
      contextRef="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_AchievementOfSpecifiedLevelsOfNetSalesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xp4_gR1lU0ecKBaQ7hdhGA"
      decimals="-5"
      id="Narr_PwGxmIq6mUGTocHU-G-FZw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000000</bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable
      contextRef="As_Of_3_27_2023_srt_StatementScenarioAxis_bcyc_CompletionOfAllMilestonesForTargetsMember_WaiOPCwXwUCGOrGcdYAYvw"
      decimals="-5"
      id="Narr_uaFBKe3PLk-EPDTvnrV5Wg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">800000000</bcyc:CollaborationAgreementTieredSalesMilestonePaymentsReceivable>
    <bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationBasedOnOtherPartySUncuredMaterialBreachOrInsolvencyMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_l_SYxC8CcEy6vP73RrP97g"
      id="Narr_1I4DmEwSsUGmW2m57Ak3xA">P60D</bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement>
    <bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationInEntiretyOrProductByProductOrTargetByTargetBasisMember_k-g66Brr1Ea_7MONWi3pTQ"
      id="Narr_H8sSXrJRIE-LcaS8XQq7kg">P90D</bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement>
    <bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TerminationIfSafetyOrRegulatoryIssueExistsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_2TOiizb3YE6trqr0NK51Qw"
      id="Narr_2GAg-Vr8VUe8yt6T8cqFvg">P30D</bcyc:CollaborativeArrangementNoticeRequiredForTerminationOfAgreement>
    <bcyc:MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg"
      id="Narr__mFik9CYo0GVDK_ERxTHMA">P30D</bcyc:MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice>
    <bcyc:NumberOfCombinedPerformanceObligations
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_EZSaePc-y0-TinfVuSqYaQ"
      decimals="INF"
      id="Narr_UZ06X4YV7EGEmUJV5nBFnQ"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfCombinedPerformanceObligations>
    <bcyc:NumberOfMaterialRights
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WDczl612dESosUCoC72gug"
      decimals="INF"
      id="Narr_9YNFS76qzUC4bwCMaeBRRw"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfMaterialRights>
    <bcyc:NumberOfMaterialRights
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QqTrQCxSy0WuafIhqTZmRw"
      decimals="INF"
      id="Narr_A2OvpBTFbUSdpIhlM-3piA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfMaterialRights>
    <bcyc:NumberOfMaterialRights
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_tnuYUMT7jkGkdVdgNaWQgQ"
      decimals="INF"
      id="Narr_KXJiVQzfBEe0v-DIPAix7w"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfMaterialRights>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w"
      decimals="-5"
      id="Narr_QBJ30q7W-EqXX1nzRzdXpg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg"
      decimals="-5"
      id="Narr_qN2yl9t_E0GaIuo3FZKVWw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA"
      id="Group_h203v0VCx0G93Xq9xbC9ew">Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with limited substitution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with options to progress development candidates incorporating radionuclides&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:81.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with options to progress development candidates not incorporating radionuclides&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:81.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_vbS2D-byxUiv2iYUzl3WkQ"
      decimals="-3"
      id="Tc_-Ck_DXRS50iKTzGGx6v58Q_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">18008000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_o4Ynp2Df5ky0p5ZF-8lSyA"
      decimals="-3"
      id="Tc_KrL5ewlNMEu_UVQwQJpvzg_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2466000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_z9unUt1Yik6ssQwliMMpIw"
      decimals="-3"
      id="Tc_SFDMLCRrhUeIMS-sFd8O8w_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">19684000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_3_27_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_Dj0LVN0iZ0u9fcBupRC2Fg"
      decimals="-3"
      id="Tc_jxRiAFlOukqKL_YcOrhspw_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9842000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember__GuCf9ioqEeO4waxZs9t1w"
      decimals="-3"
      id="Tc_wdSgumeI6kuT0I6Odg_HJw_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:EstimatedVariableConsiderationNoLongerConstrained
      contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_AjyoIuYKZEiR1VI--kfKQQ"
      decimals="-5"
      id="Narr_2zwEvlIZAkK5XcT3bZHsAA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</bcyc:EstimatedVariableConsiderationNoLongerConstrained>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_YDSCq1R7SUe1ir6yappJew"
      decimals="-5"
      id="Narr_dYF5MZOp8k6l79_IJKTM5w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">53000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:EstimatedVariableConsiderationNoLongerConstrained
      contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_AjyoIuYKZEiR1VI--kfKQQ"
      decimals="-5"
      id="Narr_qDNkYu-HvEGFf-s8ma0Cdw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</bcyc:EstimatedVariableConsiderationNoLongerConstrained>
    <bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg"
      id="Narr_YQWg5MFcYEC6wKq6Nt9usQ">P3Y</bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed>
    <bcyc:MaterialRightsExerciseOrExpiryTerm
      contextRef="Duration_3_27_2023_To_3_27_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_OfevUU6QAUutxZwV2K0dbg"
      id="Narr_9Ke9DY6Ndk62e123ckmRFA">P6Y</bcyc:MaterialRightsExerciseOrExpiryTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_ExpirationOfTwoMaterialRightsAssociateWithLimitedSubstitutionRightsMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_WvZe8laaPEeAxoXCnyr6Mg"
      decimals="-5"
      id="Narr_PY6PDkDckUOrwzI6CljS5A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA"
      decimals="-5"
      id="Narr_FcF97NV59UiTO-XbTBvWUQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ"
      decimals="-5"
      id="Narr_VpE6_frq_k2OIgdOx3H98Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_QObiLon3H06DowS0D9UT9Q"
      decimals="-5"
      id="Narr_sVm9m3_obUSOkhPniT8vog"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_cyHRxQCIEESnLP8sT0_U6Q"
      decimals="-5"
      id="Narr_jyzm-j9rw0yHR31Q69RGGA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">44100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q"
      decimals="-5"
      id="Narr_OLqS_4w_rEqOKYp764AYNg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50000000</us-gaap:ContractWithCustomerLiability>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_95vuv8ocIUSRAGL9jhXDpw"
      decimals="-5"
      id="Narr_u1yqWJjrIki4QUFvdDhJrw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_IbZb9vf99kediN_LZbIFuQ"
      decimals="-5"
      id="Narr_7yTnU9EjF0u2Ff36TDazMA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</us-gaap:ContractWithCustomerLiability>
    <bcyc:PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng"
      id="Narr_NPia6DEWO0ata6-zftTlaA">P3Y</bcyc:PeriodForWhichResearchAndDiscoveryActivitiesWillBePerformedWithNoAdditionalConsideration>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng"
      decimals="-5"
      id="Narr_-cwk2t0ZHUqIwHSH0W5MNQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_4xrbU9mf7U-6_-7nZgiopA"
      decimals="-5"
      id="Narr_D-zsP3rea0-ZEu21AaKrGQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone
      contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA"
      decimals="INF"
      id="Narr_T3OJFPrPUkSqsVcUS6yrFQ"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">3</bcyc:NumberOfPaymentsOfMidSingleDigitMillionDollarFailingToAchieveSpecifiedDevelopmentDiligenceMilestone>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA"
      decimals="INF"
      id="Narr_WhxX1MyAlUCQyuTth82xTQ"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">4</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:NumberOfYearsOverWhichRoyaltyIsPayable
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng"
      id="Narr_A8BlED9zbkaDesQFmduRRg">P10Y</bcyc:NumberOfYearsOverWhichRoyaltyIsPayable>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_QA6y8ag3QEm7TEW69r2qZQ"
      decimals="-5"
      id="Narr_pT1Anu759kWO5Q0sovd8tg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1600000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_4_1_2023_To_4_30_2023_us-gaap_TypeOfArrangementAxis_bcyc_ThirdIonisAmendmentMember_wgyO8-AVfkC5eQxgiBeTrA"
      decimals="-5"
      id="Narr_tO3oWSkJWUyIPqtcgmNPwg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">800000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_IhORSIdihkWEmJuOaow7HQ"
      decimals="INF"
      id="Narr_kSgdefOn9E2amLbrJ9jw6g"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">282485</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg"
      decimals="2"
      id="Narr_bEtM9upU1E28oKg6ENXuqw"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">38.94</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_IhORSIdihkWEmJuOaow7HQ"
      decimals="-5"
      id="Narr_65ja8zHp20a1jtSC8pwF1Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bcyc:FairValueOfSharesHeld
      contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg"
      decimals="-5"
      id="Narr_-oYvlU_9gUK-fmpunYeOxg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7600000</bcyc:FairValueOfSharesHeld>
    <us-gaap:SharePrice
      contextRef="As_Of_7_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_8bqxGZ3cOEORs4A2Xq-g5Q"
      decimals="2"
      id="Narr_0pKXrVUVu0uE6eSJlW_d_Q"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">31.11</us-gaap:SharePrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg"
      decimals="-5"
      id="Narr_j0GyHqM09kWwsmevewiQrQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3400000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:NumberOfMaterialRightsAssociatedWithFuturePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"
      decimals="INF"
      id="Narr_WSSQoEwJnE667ETTgoWP1g"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">4</bcyc:NumberOfMaterialRightsAssociatedWithFuturePayments>
    <bcyc:CollaborationAgreementNumberOfTargets
      contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA"
      decimals="INF"
      id="Narr_U0MjLO3W4UeIyWWicOOEZw"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">4</bcyc:CollaborationAgreementNumberOfTargets>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA"
      decimals="-5"
      id="Narr_18HOPz-YLk-_dsPaBhqt1g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">38000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_brOJCFt6aEqWcSo0sPecng"
      decimals="-5"
      id="Narr_zpf5oG572kqkj2beDGdOzA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_7_9_2021_To_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisEvaluationAndOptionAgreementMember_4xrbU9mf7U-6_-7nZgiopA"
      decimals="-5"
      id="Narr_RdfOS6NAyUO0Z77WSFlX7A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_7_9_2021_us-gaap_SubsidiarySaleOfStockAxis_bcyc_IonisSharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_WrT1E0ny5UKIc23wIRECTg"
      decimals="-5"
      id="Narr_HN972QzvR02BTpII9kUsWA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3400000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations
      contextRef="As_Of_7_9_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_zU5eHHyIB0yOoW2LV-GahA"
      decimals="-5"
      id="Narr_aRaakE1VrU-cxJbisG7AIw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">600000</bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations>
    <bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"
      id="Group_w9JUx3SIA0G_PhvAAlmWVw">Based on the relative standalone selling price, the initial allocation of the transaction price to the separate performance obligations was as follows (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Combined licenses and research and discovery performance obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Four material rights associated with credits for IND Acceptance fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CombinedLicensesAndResearchAndDiscoveryPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_RWvBuWuwx0SypjAqYYDYow"
      decimals="-3"
      id="Tc_lPaYifzJ3EG28jVZvweJVQ_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">34100000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_9_7_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsAssociatedWithCreditsForIndAcceptanceFeesMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_uCp5g8aYYkiBWHoG8i9XIA"
      decimals="-3"
      id="Tc_ASEbVVPumEWBqgfUb1rQlA_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3900000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_9_7_2021_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_5spYzCTLIUOCuK3Eylw0Fg"
      decimals="-3"
      id="Tc__T88XyaOh0euySO6WvbtVw_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">38000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw"
      decimals="-5"
      id="Narr_F2iEtz5F9E-kWbeapCMM2g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">600000</bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations>
    <bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ"
      decimals="-5"
      id="Narr_tYCQUc1dXk-9w-dAycEfKA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">400000</bcyc:EstimatedAmountOfReimbursementPayableToContractResearchOrganizations>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ"
      decimals="-5"
      id="Narr_9_A8HjW_FEORtXneZyk0Vw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">37800000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:MaterialRightsExerciseOrExpiryTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_AvjycYZCW0uI2cpw5iScdQ"
      id="Narr_mm--kN8Y00iUEsB4SPwbWw">P7Y</bcyc:MaterialRightsExerciseOrExpiryTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_QA6y8ag3QEm7TEW69r2qZQ"
      decimals="-5"
      id="Narr_Qh2eGQN1O0GiYX4htUs88w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AmendedIonisCollaborationAgreementMember_axun9IhIKEiYQ2ka_ErQBg"
      decimals="-5"
      id="Narr_LoArq_3uEkypf_JZN3d8gw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_ThirdAmendedIonisMember_M_GcK9lsOUqu7PozYRvR_A"
      decimals="-5"
      id="Narr_dbBVBOpDSUCcAoXZh4_rhw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"
      decimals="-5"
      id="Narr_PSXUyrb5dECw2y154V7uOg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g"
      decimals="-5"
      id="Narr_bHrLi8MhCE-ebw2M_3VQ6A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_6B9ln8pBckaqlZDRFLAB3A"
      decimals="-5"
      id="Narr_YSoZOkGAIE6l2GrhcEQ3Hw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ"
      decimals="-5"
      id="Narr_A1rEWBxMikOb21s6_Ma8tQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw"
      decimals="-5"
      id="Narr_Z-AV5JUJcUmwBHA-_NMHLQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12500000</us-gaap:ContractWithCustomerLiability>
    <bcyc:NumberOfPotentialDevelopmentCandidates
      contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ"
      decimals="INF"
      id="Narr_6h7Rc05aGUi9P8dUAYzcFA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">4</bcyc:NumberOfPotentialDevelopmentCandidates>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w"
      decimals="-5"
      id="Narr_TNyeBlXQzESHLoAfM8kvdA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:NumberOfImmunoOncologyTargets
      contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ"
      decimals="INF"
      id="Narr_78rb96WL0Uyp4d8v4JJ8Ew"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfImmunoOncologyTargets>
    <bcyc:AdditionalNumberOfImmunoOncologyTargets
      contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ"
      decimals="INF"
      id="Narr_EOqbo-_b9kWLpuOqaQgUqA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:AdditionalNumberOfImmunoOncologyTargets>
    <bcyc:ExpansionFeePerAdditionalCollaborationProgram
      contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w"
      decimals="-5"
      id="Narr_PIJkPlvZjkKu_keCf0HA-w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10000000</bcyc:ExpansionFeePerAdditionalCollaborationProgram>
    <bcyc:NumberOfInitialCollaborationPrograms
      contextRef="As_Of_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VivFA-_htU2GU3D3QWHvWQ"
      decimals="INF"
      id="Narr_krrP3JuvCUeeidiNqm7qzw"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">1</bcyc:NumberOfInitialCollaborationPrograms>
    <bcyc:OptionFeeForDevelopmentAndExploitationRights
      contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_T4B2SYwvKkiwF5Y-H5SnKQ"
      decimals="-5"
      id="Narr_nWRdNhWxgUqTBZ0AgteXpg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000000</bcyc:OptionFeeForDevelopmentAndExploitationRights>
    <bcyc:NumberOfCollaborationPrograms
      contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UiXZnEQKrUaSVgTitUBvIQ"
      decimals="INF"
      id="Narr_mi6MQn2AHESZVqTTY8F4AQ"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfCollaborationPrograms>
    <bcyc:NumberOfExpansionOptionCollaborationProgramsDevGo
      contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ccXf6ptJGE-9qaLqRgb8FA"
      decimals="INF"
      id="Narr_OacxlxHdpUSWChUoiDJZoA"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfExpansionOptionCollaborationProgramsDevGo>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_LwM9FXA8rkKkuLMtRDp7wg"
      decimals="-5"
      id="Narr_pNS2Gn90sEStpfMyuhIvbA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_DevelopmentMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_tki1umMlTE2iFkLuV5EjMA"
      decimals="-5"
      id="Narr_XHoDv5RtekyECBoG-0Ks0Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">65000000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_2_21_2020_bcyc_AchievementOfMilestoneAxis_bcyc_RegulatoryMilestoneMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_m_fV9ESl1kiTO5YyS3qSDg"
      decimals="-5"
      id="Narr_CK9GvTSO8kS9Od5DF3INtg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">135000000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable
      contextRef="As_Of_2_21_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationPerformanceOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_TSRQzXGT_UCdLkzF9xrWhA"
      decimals="-5"
      id="Narr_RSojqaXkh0OgEPylL6q37A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000000</bcyc:CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable>
    <bcyc:NumberOfYearsOverWhichRoyaltyIsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_HyrRNe-YbEC-tdg9gRuhvQ"
      id="Narr_ALctHrZ5wEW1ObWDFjRzMw">P10Y</bcyc:NumberOfYearsOverWhichRoyaltyIsPayable>
    <bcyc:NumberOfCollaborationPrograms
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_Uq2YtHbmDEqFEAKHinp0mg"
      decimals="INF"
      id="Narr_AYIHzVq7_0GdK8derNgeAw"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfCollaborationPrograms>
    <bcyc:NumberOfExpansionOptionCollaborationProgramsDevGo
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_Uq2YtHbmDEqFEAKHinp0mg"
      decimals="INF"
      id="Narr_Sbh8z31DYk2dCMzs93N3_A"
      unitRef="Unit_Standard_item_gW4t-FQFSkC6w_1Wc152IQ">2</bcyc:NumberOfExpansionOptionCollaborationProgramsDevGo>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_vTosYm8TnUGQ6xXnzVZofQ"
      decimals="-5"
      id="Narr_4IPgN-lhdkWHWZntHonA2w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_2_21_2020_To_2_21_2020_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_5HYRdLVn40mYRAcYy2Rl0w"
      decimals="-5"
      id="Narr_yhySmwBCC0WFtGJuuvQLGg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30000000</bcyc:CollaborativeArrangementUpfrontCashPaymentReceived>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_2_21_2020_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VivFA-_htU2GU3D3QWHvWQ"
      decimals="-5"
      id="Narr_kfj9GXqSMEaSHB5owogCkg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_xgSdh5vtDES1WDH_f8Xs-A"
      decimals="-5"
      id="Narr_kuh01Rm43EG3mFb2YQZGDg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2000000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_xgSdh5vtDES1WDH_f8Xs-A"
      decimals="-5"
      id="Narr_mCqgc5VVUkS5Gj21Dh0pjw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">33000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A"
      id="Group_llnRfFzTJUSPQgI_JZqTUw">Based on the relative standalone selling price, the allocation of the transaction price to the separate performance obligations is as follows (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Allocation&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance Obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Genentech Collaboration Program #1 Performance Obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Genentech Collaboration Program #2 Performance Obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,037&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Specified Targeting Arm Material Right Arm for Genentech Collaboration Program #1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights associated with the LSR Go Option for Collaboration Programs #1 and #2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Material rights associated with limited substitution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Two material rights for Expansion Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,005&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:RevenuePerformanceObligationAllocationOfTransactionPriceTableTextBlock>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_uRCFMRtOakyg2OeSksR3_Q"
      decimals="-3"
      id="Tc_JGOq5tPQsU6ArzVNzyum7A_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4019000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationTwoPerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fY6J4ndKWkuZNzesRX6wQw"
      decimals="-3"
      id="Tc_okLB38mPLkaBRKgvC0DW9w_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8037000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qPiuB9BUQEah87FFQEHHLw"
      decimals="-3"
      id="Tc_V0AqDk6J-kyYtVYedsvQLg_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">352000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_1eSemPD_PUGZrSIfTiqkcQ"
      decimals="-3"
      id="Tc_6QfImL2FXU-IxyqbfOYTHQ_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12400000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_kzAbTqHZN0CArARXFbOtYw"
      decimals="-3"
      id="Tc_WOyh7gc6g0y9GkhvspiqdQ_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1187000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_TwoMaterialRightsForExpansionOptionsMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_VqqK4Cb9V0iqlo_bcaxLfw"
      decimals="-3"
      id="Tc_RGfcdFf8o0KPEqRI20y-Wg_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7005000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A"
      decimals="-3"
      id="Tc_z5LRzeAs_kSSESmeCbhvXQ_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">33000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_l4IhOsVA_kaoaEarP7YyVg"
      decimals="-5"
      id="Narr_nMtGtotx60WVkB3ttOclxw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">6000000</us-gaap:ContractWithCustomerLiability>
    <bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BteqU8JwLEGuk_pXYeS0Cw"
      id="Narr_Wo3wGId5FEi2_Y9qKoBbRw">P2Y</bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed>
    <bcyc:MaterialRightsExerciseOrExpiryTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationOnePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_BteqU8JwLEGuk_pXYeS0Cw"
      id="Narr_ttcqtLxxIkKSvWqIUH_g-g">P5Y</bcyc:MaterialRightsExerciseOrExpiryTerm>
    <bcyc:ExpansionFeePerAdditionalCollaborationProgram
      contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_D0rz7JpLrEi8DFIjkqRfAQ"
      decimals="-5"
      id="Narr_KbDhfBIUTUS1n6FlD8BD3A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10000000</bcyc:ExpansionFeePerAdditionalCollaborationProgram>
    <bcyc:ExpansionFeePerAdditionalCollaborationProgram
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PHabuvgaTkmQG0J2ns37DA"
      decimals="-5"
      id="Narr_2Egg-wlR7keThxuLvQ6hSg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10000000</bcyc:ExpansionFeePerAdditionalCollaborationProgram>
    <bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable
      contextRef="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA"
      decimals="-5"
      id="Narr_RS2SFQ7deE23l_qlOX84RA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000000</bcyc:CollaborationAgreementSalesMilestonePaymentsReceivable>
    <bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice
      contextRef="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA"
      decimals="-5"
      id="Narr_oLAjxK_1UU67Cqbc5GUmNg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11000000</bcyc:RevenueRecognitionAllocatedDeterminedTransactionPrice>
    <bcyc:CollaborationProgramAmountOfMaterialRights
      contextRef="As_Of_10_31_2021_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ZFcAgs_7JEGZPJCvTJhHmA"
      decimals="-5"
      id="Narr_rlXzsLuXe0aMehwkVpAlbQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3500000</bcyc:CollaborationProgramAmountOfMaterialRights>
    <bcyc:EstimatedVariableConsiderationNoLongerConstrained
      contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qCp4Kues8ESQiRZdeh8N9A"
      decimals="-5"
      id="Narr_hThZ_5EIQUC_ZhsabPkAbw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2000000</bcyc:EstimatedVariableConsiderationNoLongerConstrained>
    <bcyc:EstimatedVariableConsiderationNoLongerConstrained
      contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qCp4Kues8ESQiRZdeh8N9A"
      decimals="-5"
      id="Narr_KPo4mOXYmkSEFGD7CM1uHg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2000000</bcyc:EstimatedVariableConsiderationNoLongerConstrained>
    <bcyc:ExpansionFeePerAdditionalCollaborationProgram
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_cqFl8FEbxkiSfD6iCj1uZQ"
      decimals="-5"
      id="Narr_QKegQPeBdUGbJd9JXQZx5g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10000000</bcyc:ExpansionFeePerAdditionalCollaborationProgram>
    <bcyc:CollaborationProgramAmountOfMaterialRights
      contextRef="As_Of_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PVgTMTZKEkukeSrHzooTww"
      decimals="-5"
      id="Narr_rPpVR6mg0UyjEw-Xqstm7g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3500000</bcyc:CollaborationProgramAmountOfMaterialRights>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_PHabuvgaTkmQG0J2ns37DA"
      decimals="-5"
      id="Narr_T32i_15nBUu71qiO7rxVIA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_cqFl8FEbxkiSfD6iCj1uZQ"
      decimals="-5"
      id="Narr_v9dSTZB5V0W66dTg2sWgAw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed
      contextRef="Duration_12_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_p4p-FG55D0eRUEKCq8P6yg"
      id="Narr_lT3QwcqDQ0GmDYzlwptGwA">P3Y</bcyc:PeriodOverWhichPerformanceObligationsWillBePerformed>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_-gMn9m7NtkmdLXLyH9rqdQ"
      decimals="-5"
      id="Narr_rwXTpQ0SIkSwnERIpTh2VA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_jkHOHVP16kyVT6B0B3UJYg"
      decimals="-5"
      id="Narr_XqQeDyRczkqMeZKwJ2en4Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_RdiH8PgdtkyqEjCC0xKdGw"
      decimals="-5"
      id="Narr_RR-LjfT9OkW6oDy38ntifQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_RdiH8PgdtkyqEjCC0xKdGw"
      decimals="-5"
      id="Narr_zwtniAgEjEOu6iZmhKX4gA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgram4PerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_YYJ26o4FAkKUoYNNZn4kKw"
      decimals="-5"
      id="Narr_jfTbm8dpLE-Z9VyqW_ZxDQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_2L8b9aOuvEGTIyzSbt8YAA"
      decimals="-5"
      id="Narr_d6TAKxvGhUiZKe0aP1Skww"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CollaborationProgramThreePerformanceObligationMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_2L8b9aOuvEGTIyzSbt8YAA"
      decimals="-5"
      id="Narr_jp6q2N7alkSjRaJtuU27mw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A"
      decimals="-5"
      id="Narr_xaq-E5bLUUucXbEuy_hs4g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg"
      decimals="-5"
      id="Narr_rNYInLIoA0CQAnFsyr-jqA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg"
      decimals="-5"
      id="Narr_WapKFGXK1EedLSUb7pEEcw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_qLy1Qlk7lUqL6zN6xMcMvQ"
      decimals="-5"
      id="Narr_qLm3W6TeoU2SOTMlSxRJjA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A"
      decimals="-5"
      id="Narr_WYnykJwM-kSavM-sBWYqRQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg"
      decimals="-5"
      id="Narr_WRm-b3u0DUKBjM14IVMb4Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">29100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_p7V5nSJD402i8G1tr0lq9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents changes in the balances of the Company&#x2019;s contract liabilities (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impact&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Bayer collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 43,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,393)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (561)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 39,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Novartis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 50,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 44,073&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Ionis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,881)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Genentech collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,840)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 135,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35,275)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,647)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 101,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impact&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ending Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bayer collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,160)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 43,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Novartis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,909)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 50,008&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Ionis collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,489&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,734)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Genentech collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 39,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,969)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;AstraZeneca collaboration deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:37.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 61,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 135,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q"
      decimals="-3"
      id="Tc_zNiebIxv9k-kZeCIPNg5Tw_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">43618000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw"
      decimals="-3"
      id="Tc_8Bo8k1ajoEi-MlP-H7RfwA_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">296000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw"
      decimals="-3"
      id="Tc_ed6V_jUL-ECIxqt0YKlRjw_6_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3393000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_rLNYUS0D7E6DLs3lm0KsYw"
      decimals="-3"
      id="Tc_SN1569PEukeD_AxOM_BX9Q_6_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">561000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_CLM3oWHaYEmA9xWRlsRxFw"
      decimals="-3"
      id="Tc_8wxlkyqfQE6iXvpyE4uoJA_6_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">39960000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q"
      decimals="-3"
      id="Tc_WxcNoBShQkiaLqf-u2MiuQ_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50008000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA"
      decimals="-3"
      id="Tc_hVr2modrl0O1t3-Chy9JYA_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA"
      decimals="-3"
      id="Tc_cYwswef9DUmx_n5cZTihFg_7_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8161000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_qaKSx98hv0iv6sIv3VbyKA"
      decimals="-3"
      id="Tc_hIU4zkLqvUq8sC92GuiQxQ_7_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">774000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_cyHRxQCIEESnLP8sT0_U6Q"
      decimals="-3"
      id="Tc_VpM-HTxrxUalnECPY297YQ_7_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">44073000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw"
      decimals="-3"
      id="Tc_g5r8L-r4nUOGsiznym-FXg_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12464000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"
      decimals="-3"
      id="Tc_QTzyuaAOVUK0j3P-qQaYgw_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">90000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"
      decimals="-3"
      id="Tc_uXwOQE-LtE-EQ5-n0og0-w_8_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8881000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_0CU-ZuWViE6bRoG_LkOiuw"
      decimals="-3"
      id="Tc_MpAwKpPFbkSYVdEYf_VUvQ_8_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">86000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_mwh2s6n75k-AMje5WasMTQ"
      decimals="-3"
      id="Tc_-QGjamG2Lk6dpj4AsZ9Utg_8_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3587000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg"
      decimals="-3"
      id="Tc_oRgT6mQB5U-gySfW2z5cIA_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">29104000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A"
      decimals="-3"
      id="Tc_j7qgKc1diEi79oul9HQRBw_9_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14840000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_I3NXAQmKCEuhOp349MMp5A"
      decimals="-3"
      id="Tc_FHmkeiR8fEuG_mWu9i-9HA_9_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">226000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ETgG2Q9aGUWhoZTBUTPV7A"
      decimals="-3"
      id="Tc_NDY7KXvevE-nBWvaIBQvLQ_9_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14038000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_6aQyv6Vdxk2cH7imnFxPAw_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">135194000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_v3OvYpeduEeVN5-Y5gVvfA_10_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3386000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_dMMNL0QnmU-lsdPpEIVgnw_10_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">35275000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_4OWmwz1aXkmTotwFCA_kdA_10_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1647000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_BHbvleEXnkWXraCDdmPSMA_10_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">101658000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw"
      decimals="-3"
      id="Tc_A0goISth_Eu1gtIFPTOnuw_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">45000000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw"
      decimals="-3"
      id="Tc_y2bfPJ9tQk6qJiolTZsMOA_6_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1160000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_bTgEtOVB_Ey4qYUyDz75Zw"
      decimals="-3"
      id="Tc_MOfZHtB8m0iJB-pCThdrxQ_6_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">222000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_-kz5ucMN80iBDJiOm0Ay_Q"
      decimals="-3"
      id="Tc_QUgKXSEs3UimYQu0t8Ro8A_6_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">43618000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ"
      decimals="-3"
      id="Tc_DJ5mOS1CtEanMB3Quk4Klw_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50000000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ"
      decimals="-3"
      id="Tc_Y3B5-FBgdESgnuL08bFOdg_7_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1909000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_9rupyTWSbEmLT2Dihl-SnQ"
      decimals="-3"
      id="Tc_OxbunQfMgUmS2bq-mxBe3Q_7_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1917000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_xKonp4IczkaOo-hozfOu2Q"
      decimals="-3"
      id="Tc_dmoAro6KVEG1zGDl1u6t0g_7_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50008000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_ISvkPDGZT0GtRplR-nMrEw"
      decimals="-3"
      id="Tc_zt7Rfej4z0ivgpolvjmxuw_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">21489000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g"
      decimals="-3"
      id="Tc_tBE9Fmau-0GsAznA3Nplxw_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">960000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g"
      decimals="-3"
      id="Tc_WUkwX25hRE-OZSQnj7u3Jg_8_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10734000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_T8uYZbi-iUeisynfn1hs6g"
      decimals="-3"
      id="Tc_yE6Gwq4jc0SmxkDOxCxISQ_8_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-749000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_xLvfWtKy2k6LDATvmr6jnw"
      decimals="-3"
      id="Tc_0nU4a9P9kUGjmiunR8QQMw_8_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12464000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_UTg8-nc3xku3S4nBOYYTgw"
      decimals="-3"
      id="Tc_rPnxrqaIVEq-OpZSTWSPnA_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">39308000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg"
      decimals="-3"
      id="Tc_jOi55sEMhU6CrUacpRhMXA_9_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11969000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_fPd-40ojukuvNt5oz52qvg"
      decimals="-3"
      id="Tc_Qg7yP_XUbki5TwpmE0iu4g_9_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1765000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_9PUchNR8J06vVtnRoYFosg"
      decimals="-3"
      id="Tc_brgryS4kZkWX738FGFZjpA_9_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">29104000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_tyLSGaCBcUCWHOiuJFWHhg"
      decimals="-3"
      id="Tc_xh1JsSqYokiQM7z0x1ib1g_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1076000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ"
      decimals="-3"
      id="Tc_HAv9KlP9XESIREyCBaF9bQ_10_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1204000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_bcyc_AstrazenecaCollaborationAgreementMember_gNb8UZ0vpkiG9tlAZDEjIQ"
      decimals="-3"
      id="Tc_S6w-SqCfBEqnXYOmq_0Zdw_10_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-128000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"
      decimals="-3"
      id="Tc_u3-gaUqqa0qqF6jYQxxamA_11_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">61873000</us-gaap:ContractWithCustomerLiability>
    <bcyc:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_5sAA825Y0ECaxtCsfxIBmQ_11_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">95960000</bcyc:ContractWithCustomerLiabilityAdditions>
    <bcyc:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_g8CstDBle0-Z_RU_z7_iIg_11_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26976000</bcyc:ContractWithCustomerLiabilityDeductions>
    <bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_dpbo2BbVyUGqdqRjU4XuCg_11_12"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4337000</bcyc:ContractWithCustomerLiabilityForeignCurrencyAdjustment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_gpbA45zxzUSqjUWrW_eLxw_11_15"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">135194000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="0"
      id="Narr_5CPdAC1ZJ0a_nhd-9g9f_A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="0"
      id="Narr_LXA_SZyYhEC2pQJQvwRUPQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_BayerMember_5LReFI3s3U24XzqlQU2yZQ"
      decimals="-5"
      id="Narr_wN2CxmHn7EaYo0OUAFMByg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_NovartisCollaborationAgreementMember_0G_PjFAo40GKFUdlMvcXrw"
      decimals="-5"
      id="Narr_gRYrVi8yo0CwXWAcjusVkQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">32000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_IonisCollaborationAgreementMember_sWPs1iEFhUqaA2I4dkmTgg"
      decimals="-5"
      id="Narr_Mi8A_RFrZk2dFwLnVWhI6g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2024_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcyc_DeferredRevenueMaterialRightsOptionMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_KVWfPM5pcEK7pqypuPXWLw"
      decimals="-5"
      id="Narr_xkcXyIEEzU60Y7seJm_aHw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">13500000</us-gaap:ContractWithCustomerLiability>
    <bcyc:RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_Ush0bnPMnUCvyLFbLrtnog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognized in the period from:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenue recognized based on proportional performance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenue recognized based on expiration of material rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenue recognized based on changes in transaction price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:RevenueChangeInContractWithCustomerAssetAndLiabilityTableTextBlock>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_1h5YLU9390-c2C81FWncOQ_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">24266000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_DDJwLKY1SkyZgRSoI7Nv3A_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">19160000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_5PxkLlJpq0CG89DaqiTQxg_5_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">12358000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc__UEUbEo7bkKkDJPEeuMZ0A_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10576000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_0lt8LV82GkerqlzrEoctRA_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7816000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_SRt8cRdtDE-6DIp2XtYGyA_6_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1433000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_ySYpg3JgekuBAQs50LzpPQ_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">433000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice>
    <bcyc:ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_M2ZL6qQ_tkCD-FYU_6q4eQ_7_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">672000</bcyc:ContractWithCustomerLiabilityRevenueRecognizedChangesInTransactionPrice>
    <bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_iAogAmhmXkO5M8w_vQB68g_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">35275000</bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability>
    <bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_o7NDHCblPU2UI5FXGKsUmg_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26976000</bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability>
    <bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_-STWnxQfekmrrG3TmpDvRw_8_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14463000</bcyc:TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability>
    <bcyc:PercentageOfTieredRoyaltyOnNetRevenue
      contextRef="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_4t0N24_S70mz2Zd2yTJ85A"
      decimals="2"
      id="Narr_8aiD-VDJk0uh3ix1qa652w"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.70</bcyc:PercentageOfTieredRoyaltyOnNetRevenue>
    <bcyc:PercentageOfTieredRoyaltyOnNetRevenue
      contextRef="Duration_12_13_2016_To_12_13_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_B_kz3AanWUGz-CXUrr44Qg"
      decimals="2"
      id="Narr_KZ85mO-nH0y9URB_mlvexw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.90</bcyc:PercentageOfTieredRoyaltyOnNetRevenue>
    <bcyc:ResearchAndDevelopmentArrangementObligationToRepayOtherParties
      contextRef="As_Of_12_13_2016_-ccexalN_EuXuCJAskV6sA"
      decimals="-5"
      id="Narr_F_ZTLfvqBEaewQM98ic62w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">50900000</bcyc:ResearchAndDevelopmentArrangementObligationToRepayOtherParties>
    <bcyc:ResearchAndDevelopmentArrangementUpfrontCashPayment
      contextRef="Duration_12_4_2024_To_12_4_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_goSmqlBU3UOCLW6hsHOXGg"
      decimals="0"
      id="Narr_-hvGrs9SPkuh02mV9zmVxg"
      unitRef="Unit_Standard_GBP_rn0C-43M2kSvohnz-5f3XQ">50000</bcyc:ResearchAndDevelopmentArrangementUpfrontCashPayment>
    <bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_NV57yxdHsUG-EvMIcuAkLA"
      decimals="-5"
      id="Narr_thIyiiOY5US92SmDjGpKlA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4500000</bcyc:GainLossOnExtinguishmentOfResearchAndDevelopmentFundingLiability>
    <bcyc:ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties
      contextRef="As_Of_12_31_2023_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_CancerResearchUkBtOneSevenOneEightMember_a9Bb03tCQUq9DG0yh6RePg"
      decimals="-5"
      id="Narr_mbzsIeCDhka8kl56RR0m3Q"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4300000</bcyc:ResearchAndDevelopmentArrangementLiabilityToRepayOtherParties>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_kbxLzpIgi0G-RxnCMrMMrg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;10. Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of net loss before income tax provision are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United&#160;Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (182,980)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (116,275)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United&#160;States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (173,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (114,241)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the (benefit from) provision for income taxes are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current income tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,180)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (669)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current income tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,849)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred income tax (benefit) provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,772)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,454)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (865)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred income tax (benefit) provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,976)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total (benefit from) provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,524)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the (benefit from) provision for income taxes computed at the statutory income tax rate to the (benefit from) provision for income taxes as reflected in the financial statement is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(Benefit from) provision for income taxes at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increases (decreases) resulting from:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net losses surrendered for research credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impact of statutory rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impact of foreign exchange rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 81,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 66,555&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,035&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation &amp;amp; amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,742&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 111,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,201)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,389)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,201)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,389)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (99,672)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (80,274)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,891&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the years ended December 31, 2024, 2023 and 2022, the Company recorded an income tax benefit of $4.8 million, an income tax provision of $1.5 million and an income tax benefit of $1.5 million, respectively. The Company is subject to U.K. corporate taxation. Due to the nature of its business, the Company has generated losses since inception and therefore not paid U.K. corporation tax. The (benefit from) provision for income taxes included in the consolidated statements of operations and comprehensive loss represents the tax impact from operating activities in the United States, which has generated taxable income based on intercompany service arrangements. Deferred tax assets benefitted in the United States do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s income tax benefit recognized during the year ended December 31, 2024 is mainly the result of deferred tax assets in the United States that do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement, including incremental income tax benefits of approximately $3.5 million recognized during the year ended December 31, 2024 related to the completion of a U.S. research and development tax credit study. The Company&#x2019;s income tax provision recognized during the year ended December 31, 2023 is primarily related to the completion of an assessment, inclusive of an external tax analysis, during the year ended December 31, 2023, whereby the Company concluded that it is not required to capitalize certain research and development expenses incurred by its U.S. subsidiary associated with contractual research services performed on behalf of its U.K. subsidiary pursuant to an intercompany service arrangement because its U.S. subsidiary does not retain any ownership or rights in the underlying intellectual property resulting from the research services. The change in estimate &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;upon the completion of this analysis resulted in the recognition of an income tax provision of $2.4 million during the year ended December 31, 2023. The Company's income tax benefit recognized during the years ended December 31, 2022 is mainly the result of deferred tax assets benefitted in the U.S. that do not have a valuation allowance against them because of profits that will be generated by an intercompany service agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighed the evidence based on its objectivity. After consideration of the evidence, including the Company's history of cumulative net losses in the U.K., the Company has concluded that it is more likely than not that the Company will not realize the benefits of its U.K. deferred tax assets and accordingly the Company has provided a valuation allowance for the full amount of the net deferred tax assets in the U.K. The Company has considered its history of cumulative net profits in the United States and estimated future taxable income and has concluded that it is more likely than not that the Company will realize the benefits of its United States deferred tax assets and has not provided a valuation allowance against the net deferred tax assets in the United States. The valuation allowance increased in the year ended December 31, 2024 by $19.4 million due to the corresponding increase in U.K. deferred tax assets, primarily due to operating loss carryforwards generated during the year that were not surrendered for research credit utilization. The Company recorded a valuation allowance against all of its U.K. deferred tax assets as of December&#160;31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company intends to continue to maintain a full valuation allowance on its U.K. deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. The release of the valuation allowance would result in the recognition of certain deferred tax assets and an increase to the benefit for income taxes for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change on the basis of the level of profitability that the Company is able to actually achieve.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The (benefit from) provision for income taxes shown on the consolidated statements of operations differs from amounts that would result from applying the statutory tax rates to income before taxes primarily because of certain permanent expenses that were not deductible and U.K., U.S. federal and state research and development credits, as well as the application of valuation allowances against the U.K. deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had $326.0 million of U.K. operating loss carryforwards that have an indefinite life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes, in its consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. The Company had no uncertain tax positions during the years ended December 31, 2024 and 2023. There are no amounts of interest or penalties recognized in the consolidated statement of operations or accrued on the consolidated balance sheet for any period presented. The Company does not expect any material changes in these uncertain tax benefits within the next 12 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the United Kingdom, and in the United States for federal income taxes and in 11 jurisdictions for state income taxes. In the normal course of business, the Company is subject to examination by tax authorities in these jurisdictions. The 2023 and 2022 tax years remain open to examination by the HM Revenue &amp;amp; Customs. The statute of limitations for assessment with the Internal Revenue Service is generally three years from filing the tax return. As such, all years since 2021 in the U.S. remain open to examination. The Company is currently not under examination by jurisdictions for any tax years.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <bcyc:ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_9JXAqskntUqP3wtRdPYvqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of net loss before income tax provision are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United&#160;Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (182,980)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (116,275)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United&#160;States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (173,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (114,241)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bcyc:ScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxProvisionTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_2jeZkgFG80CrLNf69xdSMg_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-179610000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_gJQgu9ZbHEG80A9uEHuV0Q_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-182980000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_-xBHEjOaBkOZw93LPbecRQ_4_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-116275000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_Oj5HEhdbMU6tGShg2y-cVA_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5814000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_2egEJbXxQU-pUqHraBFgOw_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3773000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_v7D89GPS3Eie9cj3M1ufXA_5_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2034000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_3mPMn8xKmkmZ2NqjAjNlHQ_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-173796000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_vQ_UJFMM_kCC3h3nLBvd5A_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-179207000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_AX59XZmcqkaVfalr3ERb4A_6_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-114241000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_KdEj2ce0SUGfJvL21Itprg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the (benefit from) provision for income taxes are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current income tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,180)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (669)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current income tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,849)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred income tax (benefit) provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,772)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,454)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (865)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred income tax (benefit) provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,976)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total (benefit from) provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,524)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_u5whFZTKqEOqcCxSol3GpA_5_4"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">283000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_e4aXQWbD6k-c5QPjfqwBoQ_5_7"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1180000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_rohf023qQkyZnmuz0khmvQ_5_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2048000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_1b2GdkrS2U2gVkNMb_M3tA_6_4"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">178000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_1xwvjSd2bUyb8LG0EF5ucQ_6_7"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-669000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_hfPfdmavakWL6CzhDaJPzg_6_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1404000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_MnXLra4IXkWwHNbE4YeNXw_7_4"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">461000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_l2wUQ3feSkiWBd8Axzdm1Q_7_7"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1849000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_hr8WbpAPKkOW1KVr4wXxOA_7_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3452000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_sIQASnEcYEucSJTSquuO8g_9_4"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-3772000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_I2SBvL1qqkyA9_JidWwMOw_9_7"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2513000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_u10lJgF4C0aKXAewyHxy_Q_9_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4111000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_qBIzDxx0i0iF--OG6l2Tpg_10_4"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1454000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_BWVI5pe5AU6-gNZ-KLNkOQ_10_7"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">793000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_TwMrbI9lUkGgEoqjDZqVig_10_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-865000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc__g-nUbdnBUihKebxeDPaMA_11_4"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-5226000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_NFPvgPFtj0episaBF2sXYg_11_7"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3306000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_9rQhyiOwskeJbRbWf1wwVQ_11_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4976000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_ZbTjy0Osmk-9IoCXki3S_w_12_4"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4765000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_xdN8nf8KUUeLc8PdW0m0gw_12_7"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1457000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_bsalgRq-V02weu3lMuX7LA_12_10"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1524000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_gdCOARDkv0iFd-99v1eGdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(Benefit from) provision for income taxes at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increases (decreases) resulting from:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net losses surrendered for research credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impact of statutory rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impact of foreign exchange rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="3"
      id="Tc_43cEzrWnXkGg3ySrEJYa3w_4_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc_ZSmX18lBj0exuo98oc374A_4_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.235</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_EHTXiCSLt0uq2UmLzOk5qg_4_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.19</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="3"
      id="Tc_VFHWsJIaTEG_3Sf2V6xVSg_6_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc__wbYHSb-XUmTFU6tMk564Q_6_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_fJBSXh1xmkif8c3pZu-Vpg_6_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="3"
      id="Tc_bGVafrFGe0Cir7934vxm3Q_7_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.112</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc_qM1PrgaIYEen3FuBRZXhow_7_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.148</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_agHGiLlEhESnOVzL5Mtjpw_7_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.168</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="3"
      id="Tc_WEs3w7mce0iJvR0Avvklqw_8_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.142</bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit>
    <bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc_ucMWeB99VkuQh7LiRV6-sg_8_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.111</bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit>
    <bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_szFESx5APUyJUdFvRc74Sg_8_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.065</bcyc:EffectiveIncomeTaxRateReconciliationNetLossesSurrenderedForResearchCredit>
    <bcyc:EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc_DCivsPEMpkad_4EGm_wnmQ_9_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.027</bcyc:EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage>
    <bcyc:EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_weYZcbJYAESald6urcsUag_9_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.113</bcyc:EffectiveIncomeTaxRateReconciliationImpactOfStatutoryRateChangePercentage>
    <bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="3"
      id="Tc_ZeixxAG_X0id0MqG1077NQ_10_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.01</bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent>
    <bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc_brCUKnnhTUmy0QbfqLAahQ_10_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.001</bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent>
    <bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_6fIlYsffdU-Bg0CoQAfi5A_10_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.099</bcyc:EffectiveIncomeTaxRateReconciliationForeignExchangeRateDifferentialPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="3"
      id="Tc_8naiPfD110uSFqjoQ3_g4g_11_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc_slHNxSG_NEG83_RT7YlcTw_11_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_GU63a95DT0WK_ndwFc89cQ_11_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="3"
      id="Tc_EocaulyTZU2Pxk49fl970w_12_2"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.027</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="3"
      id="Tc_AalPjhtw6kKbtpRGc2vdiw_12_4"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="3"
      id="Tc_aRoa_K96V0qrnImB0M9zuA_12_6"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.013</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_2GrMTplUT0C3c35ZNCcH7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 81,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 66,555&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,035&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation &amp;amp; amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,742&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 111,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,201)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,389)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,201)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,389)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (99,672)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (80,274)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,891&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_6Y57PDBM0UOz_Z-xiho49A_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">81492000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_gR6S4Exdoka89BULVy6Xsg_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">66555000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_ONJlonS4306hPIaLlXNdOA_6_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3362000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <bcyc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_sl1bRujbXkSOLaINUuA_ag_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2641000</bcyc:DeferredTaxAssetsOperatingLeaseLiability>
    <bcyc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_f14dQpr5O0C7yqnAhmJ3zQ_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3680000</bcyc:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_uGFUU6hqLEaSvr8wKCW5XA_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">21035000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_Ywf4QotnTkOFLU56y-8KZw_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">15577000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <bcyc:DeferredTaxAssetDepreciationAndAmortization
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_BUgqSHr9mEmG_R9JcNFySw_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1508000</bcyc:DeferredTaxAssetDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_79mHoe6orE6WmwDnagNKwA_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1952000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_Bpu2NFNtwECgVGkPgROJ2g_10_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2742000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_-t5Yc_wmW0eC2UoH7L8Efw_11_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">111990000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_3uEhXiSmUEWl2CvIUoatmg_11_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">88554000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_6UZ6BNa-WkKlS-fEB-2Zdw_13_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2201000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_qGTrQMagOUWGvTurbHrJng_13_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3389000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_Tz2WxnixLky3wouvQAaw0A_14_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2201000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_zWWO6VnU6UeL4kYyogINKg_14_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3389000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_WIyXd33vuU-qScjzwF_rlg_15_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">99672000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_sd4tsAmzR0iVjFixUFAUVg_15_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">80274000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_LVq4AJ7goU2qdbVVC_J_RQ_16_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10117000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_A1VrcDwTp0G-d66ul7uV9w_16_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">4891000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_Qd4IuEplNUiiB7TCIPGYfQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-4800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_aytr3POz1kqRmf8BOP_7xw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-5"
      id="Narr_6NREiCwODk2owMWBzslohA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-1500000</us-gaap:IncomeTaxExpenseBenefit>
    <bcyc:IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_PpiD5hvFhUK34gOPc5HEwQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3500000</bcyc:IncrementalIncomeTaxBenefitOnCompletionOfResearchAndDevelopmentTaxCreditStudy>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-5"
      id="Narr_Pl6QfYxpL0-g7wlUuE-sow"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2400000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-5"
      id="Narr_-_kikkayqEyWiELYduyfOQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">19400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr__Sx-oX8S5ESMJhnrPYjLAg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">326000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-5"
      id="Narr_kpSi7USxAEuBjHKMxjZgwA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_t8nnLTSubkaW0aLmdFB2rw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_PF1GpkjdWUaDv8J9bl4wGg"
      decimals="-5"
      id="Narr_2LA40HCXuk6S5irr4LPlEw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-5"
      id="Narr_z1PP4Ecb_U21kcsOYWknwg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_9DQstctoF0aISeTa9Q6ozQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <bcyc:NumberOfJurisdictions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5p4e8zASzk6UtchIaZHdrQ"
      decimals="INF"
      id="Narr_Ta9ljMymL0CLYjHaXC_oJA"
      unitRef="Unit_Standard_jurisdiction_Wo3Cb55Vx0GOZokPR6rMjw">11</bcyc:NumberOfJurisdictions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_ASd2JGhsa0yCBJ0pIGlvrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;11. Commitments and contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Operating Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In January 2023, the Company entered into a lease agreement for office and laboratory space in Cambridge, Massachusetts. The lease has a contractual period of approximately three years, which, subject to certain conditions, may be extended for an additional two years at the Company&#x2019;s option. The Company concluded that the lease term is three &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;years, representing the non-cancelable lease period, as it is not reasonably certain that the lease will be extended. The annual rent is approximately $2.1 million in the first year of the lease and increases annually with the last year of the lease having annual rent of approximately $2.3 million. The annual rent is payable monthly in advance following a two-month rent-free period. In connection with the lease agreement, the Company has delivered to the landlord a security deposit in the form of a letter of credit of approximately $0.5 million. The Company recorded a right of use asset and lease liability of approximately $5.8 million, respectively, at the lease commencement date, based on the present value of future lease payments, discounted at 9.0%, the Company&#x2019;s estimated incremental borrowing rate at the commencement of the lease, over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 6, 2021 the Company entered into a lease of new office and laboratory space, in Cambridge, United Kingdom. The lease has a contractual period of 10 years, but may be cancelled by the Company on the fifth anniversary of the lease commencement date. The lease term is five years, representing the non-cancelable lease period, as it is not reasonably certain that the lease will not be cancelled. The Company has a contractual right to renew the lease for a further ten-year period, which also may be cancelled after five years. The annual rent is approximately $3.0 million, payable quarterly in advance beginning in June 2022, following a six-month rent-free period. There was no deposit paid in conjunction with the lease. The Company recorded a ROU asset of approximately $11.6 million and a lease liability of approximately $11.1 million at the lease commencement date, based on the present value of future lease payments, discounted at 6.9%, the Company&#x2019;s estimated incremental borrowing rate at the commencement of the lease, over the lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2017, the Company entered into a lease agreement for office and laboratory space in Building 900, Babraham Research Campus, Cambridge, U.K., which was renewed in December 2021 for five years through December 2026. The annual rent for the lease was approximately $0.6 million. Service charges were also payable based on floor area and are estimated to be approximately $0.2 million per year. In April 2023, the Company entered into a deed of surrender related to the lease, pursuant to which the lease was terminated effective immediately. As a result of the deed, the Company derecognized the lease liability and right of use asset associated with the lease. The Company also paid termination-related fees of $0.3 million in connection with the deed, which were recorded as a loss on lease termination and are included in operating expenses in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2017, Bicycle Therapeutics Inc. entered into a lease agreement for office and laboratory space in Lexington, Massachusetts, which commenced on January 1, 2018. In conjunction with the lease agreement, Bicycle Therapeutics Inc. paid a security deposit of $0.2 million. The deposit is recorded in other assets in the consolidated balance sheets. In March 2022, Bicycle Therapeutics Inc. notified the landlord of its intent to exercise its option to extend the lease, originally set to expire on December 31, 2022, for a successive period through December 31, 2027, which successive period was not included in the original lease term. The Company accounted for the change in lease term as a modification of the existing lease and remeasured the ROU asset and lease liability by calculating the present value of lease payments, discounted at 7.0%, the Company&#x2019;s incremental borrowing rate at the date of the modification of the lease, over the remaining lease term. In May 2022, the lease was extended. The payments for the extended lease are approximately $0.2 million for the remainder of 2022, $0.7 million in 2023, and increases annually pursuant to an escalation clause with the last year of the lease term having a per annum fixed rent obligation of $0.8 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Finance Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;width:36pt;"&gt;&lt;/span&gt;From time to time, the Company may enter into finance lease agreements for property and equipment. As of December 31, 2024, the Company recorded finance lease right-of-use assets of $1.0 million, which are included in &lt;span style="-sec-ix-hidden:Hidden_89Xiz3lIwU210xUHlqxyBQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;property and equipment&lt;/span&gt;&lt;/span&gt;, net, in the consolidated balance sheets. As of December 31, 2024, the Company recorded finance lease liabilities of $1.0 million, which are included in &lt;span style="-sec-ix-hidden:Hidden_SQ4PzHGMvEedzinnZFOhqA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;accrued&lt;/span&gt;&lt;/span&gt; expenses and other current liabilities and other long-term liabilities, as applicable, in the consolidated balance sheets. No finance lease right-of-use assets or &lt;span style="-sec-ix-hidden:Hidden_o8BOhRO22E6Ob_Qt--G_Gg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;liabilities&lt;/span&gt;&lt;/span&gt; were recorded as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the Company&#x2019;s lease expense are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,643&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average remaining operating lease term was &lt;span style="-sec-ix-hidden:Hidden_lYaA-73yc0O8cmcTzPPaEg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2.0&lt;/span&gt;&lt;/span&gt; years and 2.9 years as of December 31, 2024 and 2023, respectively, and the weighted average operating lease discount rate was 7.8% and 7.9% as of December 31, 2024 and 2023, respectively. The weighted average remaining finance lease term was &lt;span style="-sec-ix-hidden:Hidden_Rcc02-kBPEezAjTVUU7wRQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.7&lt;/span&gt;&lt;/span&gt; years as of December 31, 2024, and the weighted average finance lease discount rate was 9.5% as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the maturities of the Company&#x2019;s lease liabilities as of December 31, 2024 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,818&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (646)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (224)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_u8XOnpcF106LEEpbmUkWMA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,328)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (175)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into various agreements with contract research organizations to provide clinical trial services, contract manufacturing organizations to provide clinical trial materials and with vendors for preclinical research studies, synthetic chemistry and other services for operating purposes. These contracts are generally cancelable at any time upon less than 90&#160;days&#x2019; prior written notice. The Company is not contractually able to terminate for convenience and avoid any and all future obligations to these vendors. In some cases, the Company is contractually obligated to make certain minimum payments to the vendors, based on the timing of the termination notification and the exact terms of the agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;T&lt;span style="background:#ffffff;"&gt;he Company has also entered into separate agreements with third parties which provide for various future milestone payments upon the achievement of specified development, regulatory, commercial and sales-based milestones with an aggregate total value of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$166.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, as well as potential future royalty and other payments at percentages ranging from very low to low single digits.&lt;/span&gt; These additional milestone payments are contingent upon future events that are not considered probable of achievement as of December 31, 2024. As of December 31, 2024, the Company was unable to estimate the timing or likelihood of achieving these milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Legal proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company or its subsidiaries may become involved in various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. The Company is not currently subject to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of ASC 450, &lt;i style="font-style:italic;"&gt;Contingencies&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Indemnification obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has indemnification obligations towards members of its board of directors and officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. In addition, the Company has agreed to indemnify certain investors in limited circumstances. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <bcyc:LesseeOperatingLeaseContractualTerm
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw"
      id="Narr_iYonqfjMT0q1UL1bjN1Xcg">P3Y</bcyc:LesseeOperatingLeaseContractualTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg"
      id="Narr_DBMF7vfwL0CrLfYOrIL7-Q">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg"
      id="Narr_qjl5jbAot0eKyn11RRQiow">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bcyc:OperatingLeaseAnnualRent
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg"
      decimals="-5"
      id="Narr_--3OOdkJXkir1RAFnw7lmQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2100000</bcyc:OperatingLeaseAnnualRent>
    <us-gaap:PaymentsForRent
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw"
      decimals="-5"
      id="Narr_nPIvQlBYB0C87s3d_SXj8w"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2300000</us-gaap:PaymentsForRent>
    <bcyc:LesseeOperatingLeaseRentFreePeriod
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_gGN9tjDTXUqKWhHcwv7-sw"
      id="Narr_cbbOOGubDkypYk-uLYkN9w">P2M</bcyc:LesseeOperatingLeaseRentFreePeriod>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg"
      decimals="-5"
      id="Narr_76qVcDPFvE2JEjDQ5qGyvw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">500000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg"
      decimals="-5"
      id="Narr_U9GxDeemL0OJlwVcfmMpTQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_3rUnRasv50muSAdhaGVDOg"
      decimals="3"
      id="Narr_sHN__CmKhkSgKltJfafIVQ"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.09</us-gaap:LesseeOperatingLeaseDiscountRate>
    <bcyc:LesseeOperatingLeaseContractualTerm
      contextRef="Duration_12_6_2021_To_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_7_XmUdC8h0aJCYWeYcBvog"
      id="Narr_XwtcRAkPBEimRfdrpEePZQ">P10Y</bcyc:LesseeOperatingLeaseContractualTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      id="Narr_hqEX00ougEqxFWq2nUNbFA">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      id="Narr_RhA9Wod-wEWLbHeDAmJc6g">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      id="Narr_g-LDGDneREe4ogWdpCDvXg">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bcyc:OperatingLeaseAnnualRent
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      decimals="-5"
      id="Narr_Scr21G3CckO_TywS7ySuNQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3000000</bcyc:OperatingLeaseAnnualRent>
    <bcyc:LesseeOperatingLeaseRentFreePeriod
      contextRef="Duration_12_6_2021_To_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_7_XmUdC8h0aJCYWeYcBvog"
      id="Narr_-MVwU4fo2EmsTLscl0VemA">P6M</bcyc:LesseeOperatingLeaseRentFreePeriod>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      decimals="-5"
      id="Narr_ENns996UekGwjUjmYQpc7g"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      decimals="-5"
      id="Narr_Q96Z0sIgnEaSrv9eZcAjvQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      decimals="-5"
      id="Narr_pAhaWq9mFkC9Ec8GUx24Ow"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_6_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_NewOfficeAndLaboratorySpaceInCambridgeUnitedKingdomMember_x09-a5HAt0C-sNhA8wZsJw"
      decimals="3"
      id="Narr_5ENfumMNfUWpWBX5UbTv9Q"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.069</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w"
      id="Narr_ZlFOGbDJAE6FE-OQbaU4iQ">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <bcyc:OperatingLeaseAnnualRent
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w"
      decimals="-5"
      id="Narr_oNVGWBRnzEyhxTw58y8Ehw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">600000</bcyc:OperatingLeaseAnnualRent>
    <bcyc:OperatingLeaseAgreementEstimatedServiceCharges
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_U1LoYq8ockSLSEFJk9HT7w"
      decimals="-5"
      id="Narr__RMt6ukv_0izKwLvfILAfw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000</bcyc:OperatingLeaseAgreementEstimatedServiceCharges>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInBuilding900BabrahamResearchCampusCambridgeMember_fLJS0eBl9EOeJzgPO_7mZA"
      decimals="-5"
      id="Narr_NpG5v4o6vUWOR8ys0fp3WA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">300000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_9_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_ATqayKrwE0yk5TqZ6Qd3VA"
      decimals="-5"
      id="Narr_Dt5bM3DJ8kGRGQWRTbeMCQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_NG89CENXf0WsYpj98IPH8w"
      decimals="3"
      id="Narr_6fWAZXcLhUadBndMkHH9hA"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.07</us-gaap:LesseeOperatingLeaseDiscountRate>
    <bcyc:LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_SGS5MZDDqEWSBRcvMGqfGg"
      decimals="-5"
      id="Narr_j_m_3iwoPke1_lVV78fvdw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000</bcyc:LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember>
    <bcyc:LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_Jlm0mrvCf0W3IJVZZ2e3GQ"
      decimals="-5"
      id="Narr_rKj262Czu0eK4hYUYgsNdQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">700000</bcyc:LesseeOperatingLeaseLiabilityToBePaidRemainingThroughDecember>
    <bcyc:OperatingLeaseAnnualRent
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bcyc_OfficeAndLaboratorySpaceInLexingtonMassachusettsMember_NG89CENXf0WsYpj98IPH8w"
      decimals="-5"
      id="Narr_oSYfbA6paE6BZ9A1zEWDNg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">800000</bcyc:OperatingLeaseAnnualRent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_TOAKZzLB30ihy_hzT1j3Lw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-5"
      id="Narr_lhjqQqGqXECUwz0vPD7xMQ"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-5"
      id="Narr_5yIxaPLhVECaeG2X7EoHOw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_iWOZdHfoWkClhYm91SpugA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the Company&#x2019;s lease expense are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,643&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_h69muI7E5E-nkiN7Us5RTg_4_2"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5299000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_2Oqev_biBUij8EH-S9cBFA_4_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5408000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_E37o8pXTAEGirE98ZygdDA_4_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3790000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_fWOQmflCx02PMrvAVHkGeA_5_2"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2924000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_uTXvIk08gU-SQaPPP5MBng_5_5"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2777000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_CZwPg0r90UOy71ktHOQ_lw_5_8"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1643000</us-gaap:VariableLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_CmybGp6egESQA0aA7vI3QA_7_2"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">53000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_HXCAMv2m_UWSHF6jz1rPNQ_8_2"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">23000</us-gaap:FinanceLeaseInterestExpense>
    <bcyc:FinanceLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_1DD_TICX_Euyt1pg4__auQ_9_2"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">76000</bcyc:FinanceLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      id="Narr_DJugmSt9hU6Xxw-JOyFCQg">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="3"
      id="Narr_SKmccdSFGkeCGMoX8sA5Jw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.078</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="3"
      id="Narr_h2rN1qIanE2Qse2d2ibHaw"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.079</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="3"
      id="Narr_TOQuLnkh_0yzUoeehbmG6A"
      unitRef="Unit_Standard_pure_Knvdt-v-sEW_3jM3WYWd-g">0.095</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_80txg3OVC0i_oocQipLsMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the maturities of the Company&#x2019;s lease liabilities as of December 31, 2024 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,818&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (646)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (224)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_u8XOnpcF106LEEpbmUkWMA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,328)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (175)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long term lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_uUVlR9p3Z0md-goZ9jg3bQ_2_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5818000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_6RHmIkjmMkGTpmfgRIQIqg_2_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">256000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_YWp8lrpa6kOTW8aKQMttDA_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3325000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_OFnJzsF-QUaKMMeUBnkxGA_3_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">256000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_DcqLwWt1zU6-_JKxj3Ka2A_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">821000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_Pm46uzU1Vk-xRSpQ9Kq_qg_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">256000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_ThOOZDUVHE-xtygiusNMlg_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">256000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_E8PbViFhJ0mDND9VKPRbyA_6_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">192000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_FWTIqLlLe0Wi3Ki7rYW-lA_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">646000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_6u8mwBD6u0WjrPT349JA7Q_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">224000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_QBDxk7aTXk6zZqvUzMXQIQ_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9318000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_p61stqV6AUShAp-8yjG43Q_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">992000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_sapSwDlxNk6JBudS7yfVJA_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5328000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_Yh02fTIrFEOhQudh7ZeYAw_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">175000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_iG2r8ypWvEClG9Pro8L6wQ_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3990000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc_yFa8tXoOB0266TTlI2WhjQ_10_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">817000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <bcyc:MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Narr_vvOv2Q3TlUWyBhrD2XlAPA">P90D</bcyc:MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice>
    <bcyc:CollaborationAgreementFutureMilestoneContingentPaymentsPayable
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_bcyc_AgreementWithThirdPartyMember_cjzTWIaOY0KrEHYqPIpAew"
      decimals="-5"
      id="Narr_h5jAglAhw0Or8gT7q6cS_A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">166200000</bcyc:CollaborationAgreementFutureMilestoneContingentPaymentsPayable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_n_mli4MNJU6N_kIgTvQybg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;12. Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169,031)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (180,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (112,717)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average ordinary shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 58,207,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,592,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,660,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.08)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.80)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s potentially dilutive securities, which include options to purchase ordinary shares and restricted share units for ordinary shares, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of ordinary shares outstanding, which includes both ordinary shares and non-voting ordinary shares, used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potentially dilutive ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 716,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 326,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 187,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,748,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,469,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,898,888&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,464,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,796,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,086,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_zwAXgOZgpEmCzunjd5dINQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169,031)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (180,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (112,717)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average ordinary shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 58,207,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,592,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,660,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.08)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.80)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="-3"
      id="Tc_CjbwmaXD50aOTuaTdVErJQ_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169031000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="-3"
      id="Tc_mgMpr1udeEubUiodxr8dyw_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180664000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="-3"
      id="Tc_y_Md6kJqWkWnR4a5TaTalA_5_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112717000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="0"
      id="Tc_xpmLDKl_v0GeErm1A0IMPg_7_3"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">58207593</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="0"
      id="Tc_xpmLDKl_v0GeErm1A0IMPg_7_3_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">58207593</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="0"
      id="Tc_ZYAUe0NBl0q37huiz2HLgg_7_6"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">35592362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="0"
      id="Tc_ZYAUe0NBl0q37huiz2HLgg_7_6_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">35592362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="0"
      id="Tc_bvCaQSRccEWFLNRARyH7Mw_7_9"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">29660659</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="0"
      id="Tc_bvCaQSRccEWFLNRARyH7Mw_7_9_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">29660659</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="2"
      id="Tc_13dEY_wR6UWAW5u3s8L_1g_8_3"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-2.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="2"
      id="Tc_13dEY_wR6UWAW5u3s8L_1g_8_3_2"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-2.9</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="2"
      id="Tc_xNRtpy-pckePFATbLPf1CQ_8_6"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-5.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="2"
      id="Tc_xNRtpy-pckePFATbLPf1CQ_8_6_2"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-5.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="2"
      id="Tc_4ac3f-Yw5UuJCjuBB-DVXg_8_9"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-3.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="2"
      id="Tc_4ac3f-Yw5UuJCjuBB-DVXg_8_9_2"
      unitRef="Unit_Divide_USD_shares_47BQR4PI_0apTee5C9AwlQ">-3.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_n_QagbIRIU2mEmiqna4KbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 716,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 326,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 187,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:66.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,748,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,469,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,898,888&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,464,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,796,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,086,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_RMsDq0ZFvE2Wx7B1y-0u5w"
      decimals="INF"
      id="Tc_0Ow_ZhiZEE64d49OW1lNdA_3_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">716262</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_n-D9Cq5DWkCzJZg9ZJYbnA"
      decimals="INF"
      id="Tc_OOyVUr-mZE6iCxylsranBw_3_4"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">326848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_4N9eS-gJjkuSY1TcnrqmKQ"
      decimals="INF"
      id="Tc_W2N71mCudES-oCpK7ILYPA_3_6"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">187725</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s2IO880e1061sN4EIeiaUQ"
      decimals="INF"
      id="Tc_8KKF4Qvw50mD1wVpQjjaKA_4_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">8748726</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m2jh4dTe1k6tiJLwVhJUjw"
      decimals="INF"
      id="Tc_dZCdiJcCCUSc1sTySq7R5A_4_4"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">7469527</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_b9GnNZBmAkmTdN5HqzSMxQ"
      decimals="INF"
      id="Tc_wEoG5ITvvE-O6VfCJYdt_A_4_6"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">5898888</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="INF"
      id="Tc_q1lgWLINFkaxkfPqNl0Ygg_5_2"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">9464988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_QLN0RTdqmUqENF-uY2ActA"
      decimals="INF"
      id="Tc_rsd-pzfi6UG0xgalb-FWWw_5_4"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">7796375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_y6SwSmjQaEGrBFXV2OyQHA"
      decimals="INF"
      id="Tc_95w0XlfaLUePTHahm3-e4g_5_6"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">6086613</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_2w9nCYUNMUSY4Z9cxagtvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;13. Benefit plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company established a defined-contribution savings plan under Section&#160;401(k)&#160;of the Code (the &#x201c;401(k)&#160;Plan&#x201d;). The 401(k)&#160;Plan covers all U.S. employees and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of the Company&#x2019;s board of directors. During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company made contributions totaling $1.1 million, $0.8&#160;million and $0.5 million, respectively, to the 401(k)&#160;Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides a pension contribution plan for its employees in the United Kingdom, pursuant to which the Company may make contributions each&#160;year (&#x201c;U.K Plan&#x201d;). During the&#160;years ended December&#160;31, 2024, 2023 and 2022, the Company made contributions totaling $2.9&#160;million, $2.2&#160;million and $1.4 million, respectively, to the U.K. Plan.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_NRO15gR8R0C1PGFIWwvPqg"
      decimals="-5"
      id="Narr_EblZp2j34UCn6MUsmC0KFw"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_arXRVu5ZWUSBIuONzGMp-A"
      decimals="-5"
      id="Narr_wu8IEVj9tkyr8UhTJUpwHg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_Plan401KMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_PvHkFyAfO0qLp2QAqJ7T7g"
      decimals="-5"
      id="Narr_vpeS0hX0lkuSTzLucFWXWA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_9GER_6W-HkqnPxCUmp0fyA"
      decimals="-5"
      id="Narr_SUnwg72mX0-F1wSygQEoDA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_pS-QJkjLfUGnpbmjfIIQ7w"
      decimals="-5"
      id="Narr_8GcdW_yO1U2MRYJ7zAmMbg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">2200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_bcyc_UKPlanMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_-W-mugKxsU2yACc1ikbSBQ"
      decimals="-5"
      id="Narr_U-vGO0YKaEWC42s3VT0oPg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">1400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_Llt80H765kmxrevTpGaufw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;14. Related party transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Consulting Agreement with Stone Atlanta Estates LLC&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Chairman of the Company&#x2019;s board of directors is associated with Stone Atlanta Estates LLC, the successor-in-interest to Stone Sunny Isles Inc., which provided consultancy services to the Company totaling $0.3 million, $0.2 million and $0.2 million during each of the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Related Party Participation in Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Investors in the Private Placement included certain entities affiliated with Baker Bros. Advisors LP (the &#x201c;Baker Entities&#x201d;), an entity which may be deemed a beneficial owner of greater than 10% of the Company&#x2019;s voting securities. Felix J. Baker, one of the Company&#x2019;s directors, is a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP. In the Private Placement, the Baker Entities purchased an aggregate of 17,114,846 non-voting ordinary shares, nominal value &#xa3;0.01 per share, for an aggregate purchase price of $366.6 million. The Private Placement was approved in accordance with the Company&#x2019;s related person transaction policy by the Company&#x2019;s Related Parties Committee. See Note 11. &#x201c;Commitments and contingencies&#x201d; for additional information on indemnities provided to certain investors.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_VGLTprSZ00ajPx_iwKZOCQ"
      decimals="-5"
      id="Narr_8w1P9OmZs0ObrLzAMzO7HA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_87Upa33xjkaMN_hOb2X7Ag"
      decimals="-5"
      id="Narr_mrex0tOXzki1gmFMNYUrKA"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_bcyc_ConsultancyServicesWithStoneSunnyIslesIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_ypWL3awvzEqfgXwFXfo9UA"
      decimals="-5"
      id="Narr_WnLdE68emkSjKrQ8GcJ04A"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_y0EPkZSaVU-zndPzJODGAA"
      decimals="INF"
      id="Narr_BUTBuU2Rb0CB2KXEae1tag"
      unitRef="Unit_Standard_shares_ZfHiEWxC5UOtONkqzjIddw">17114846</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_y0EPkZSaVU-zndPzJODGAA"
      decimals="INF"
      id="Narr_o5CmUgrpD0q1xNny0kS88g"
      unitRef="Unit_Divide_GBP_shares_sIILkz7k6kW3qCybAJRIvA">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_bcyc_BakerBrothersAdvisorsLpMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_AffiliatedEntityMember_us-gaap_StatementClassOfStockAxis_bcyc_NonVotingOrdinarySharesMember_2q8U443nOk6gQC6m8b41-A"
      decimals="-5"
      id="Narr_e0ee5Pr-Y0SYQ9mIrgrdYg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">366600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_fIJW9jVTzkacxSgKdL7Dvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;15. Segments and geographic information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;). The CODM reviews consolidated operating results, manages the business on a consolidated basis and utilizes consolidated net loss from the consolidated statements of operations and comprehensive loss as the primary measure of segment profit or loss in making decisions surrounding allocating resources and assessing performance of the Company. The CODM is regularly provided detailed expense information, including expenses by program and expense category, and the CODM makes decisions surrounding capital and personnel allocation using this information on a consolidated basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents information about the Company&#x2019;s single operating segment, including significant segment expenses, for the years ended December 31, 2024, 2023 and 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collaboration revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant segment expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Zelenectide pevedotin (Nectin-4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 82,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;BT5528 (EphA2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;BT1718 (MT1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bicycle tumor-targeted immune cell agonists&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Discovery, platform and other expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Employee and contractor related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 58,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 31,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Facility expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Research and development incentives and government grants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,459)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,813)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 156,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 81,609&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel-related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,948&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional and consulting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other general and administrative costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Effect of foreign exchange rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 72,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 60,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 49,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total significant segment expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 245,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 216,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 131,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 40,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (169,031)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (180,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (112,717)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Other segment items include interest and other income, interest expense, loss on extinguishment of debt, gain on extinguishment of research and development funding liability and (benefit from) provision for income taxes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not regularly provide the CODM with detailed segment asset information other than what is included in the consolidated balance sheets. Please refer to the consolidated financial statements and the accompanying notes to the consolidated financial statements for segment asset information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company operates in two geographic regions: the United States and the United Kingdom. Information about the Company&#x2019;s long-lived assets, including operating lease ROU assets, held in different geographic regions is presented in the table below (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 17,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s collaboration revenue is attributed to the operations of the Company in the United Kingdom.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_SYKNwHkpw0yevzyxb3oepA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents information about the Company&#x2019;s single operating segment, including significant segment expenses, for the years ended December 31, 2024, 2023 and 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collaboration revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant segment expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Zelenectide pevedotin (Nectin-4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 82,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44,135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;BT5528 (EphA2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;BT1718 (MT1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bicycle tumor-targeted immune cell agonists&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Discovery, platform and other expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 37,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Employee and contractor related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 58,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 31,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 15,581&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Facility expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Research and development incentives and government grants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,459)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,813)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 172,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 156,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 81,609&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel-related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,948&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional and consulting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other general and administrative costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Effect of foreign exchange rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 72,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 60,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 49,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total significant segment expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 245,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 216,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 131,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment items&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 40,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (169,031)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (180,664)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (112,717)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Other segment items include interest and other income, interest expense, loss on extinguishment of debt, gain on extinguishment of research and development funding liability and (benefit from) provision for income taxes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_8ANx4ISMhEu_f6cytaDtgA_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">35275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_jz1PsxS8Y0qLBFNyLcfRsw_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">26976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_RxWiSjMhvUSMo_t90M_SGQ_4_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_gUaCXINS2kCBhTYjLBFLvQ"
      decimals="-3"
      id="Tc_0eI7I4REeEONbc01L5u1Iw_7_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">82705000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_DUUmLvrM0Ua-IV4gtEO4dw"
      decimals="-3"
      id="Tc_8sZhCW2WmkyLrF-mobulCg_7_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">44135000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT8009Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_EDbD_nwgWEm3h1bnui3JPw"
      decimals="-3"
      id="Tc_GKlH3FO3gE66AGy1gTyc3A_7_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11054000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_qWduzYXktEC6ieFWheazqQ"
      decimals="-3"
      id="Tc_VUxFpYUJGEexD-Psue-ThA_8_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9119000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_m8NGtuG9hEuc-Q3am5BHDQ"
      decimals="-3"
      id="Tc_kDlv7FNciUqYVgfkOcChPw_8_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9195000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramProductCandidateBicycleToxinConjugateMoleculeBT5528Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_QCbJPntYS0mr7VXNm13-GA"
      decimals="-3"
      id="Tc_kCGyyxXGeUiFo05fzCnoVg_8_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10702000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_NYezOdO0N0G3gVUx6-pWmw"
      decimals="-3"
      id="Tc_AFT3JeWMyUGUGMvm4gDDzg_9_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">250000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_Tw08wGHpiE2_uOJjC2Yifg"
      decimals="-3"
      id="Tc_iM2pbtifaECcliKsW0g9Mw_9_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">520000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_ProductCandidateBT1718SponsoredByCancerResearchUkCentreMember_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_TGvFsvJDaU-Z2goQUm6szg"
      decimals="-3"
      id="Tc__xT1mXyAW0arxmEYpjC6DQ_9_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">692000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_10I2hU65G06H9LVN1JzgNQ"
      decimals="-3"
      id="Tc_w-2gJPXNI02HR75ioYH9nw_10_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7840000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_uoSoJfk0zkCYReunHXtq8g"
      decimals="-3"
      id="Tc_mCt08ITHikmqTFmk47vutw_10_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">18878000</bcyc:ProjectSpecificCosts>
    <bcyc:ProjectSpecificCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_bcyc_InternalProgramBicycleTumorTargetedImmuneCellAgonistsBT7480Member_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_SE-anRzrlEiUC4bJHOOjnQ"
      decimals="-3"
      id="Tc_MReONNRQ0EOARBfTPtvEhQ_10_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">11268000</bcyc:ProjectSpecificCosts>
    <bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_3vFisiQ5ikyUh413QzJoMw_11_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">30043000</bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses>
    <bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_Pr6yEL7OGkiQIYWQ55RCEg_11_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">37295000</bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses>
    <bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_-zMLES90HEK6xJZR34sGQQ_11_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">21811000</bcyc:ResearchAndDevelopmentDiscoveryPlatformAndOtherExpenses>
    <bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_sgf4yikXu0OKeuM9ddh8Ug_12_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">58687000</bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses>
    <bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_P89Vxsn3606PR_GP3VESvg_12_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">46506000</bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses>
    <bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_zqB59uq8DU-Bga3BxelBpQ_12_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">31346000</bcyc:ResearchAndDevelopmentEmployeeAndContractorRelatedExpenses>
    <bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_Vo33iTx7tEalK8Keln20jQ_13_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">19424000</bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense>
    <bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_imnWWPmuQ0m18qO-NVdAlg_13_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">15581000</bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense>
    <bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_ULgaHr_tXUmY-ITAZVSRSw_13_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">10394000</bcyc:ResearchAndDevelopmentShareBasedPaymentArrangementExpense>
    <bcyc:FacilityExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_PrURAKUbj06wlroEfDyHUA_14_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8105000</bcyc:FacilityExpenses>
    <bcyc:FacilityExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_BjeRQSu8g02vK3IIJxlj_Q_14_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8845000</bcyc:FacilityExpenses>
    <bcyc:FacilityExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_NPV24KWpRkalehhyPk7V4g_14_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">5155000</bcyc:FacilityExpenses>
    <bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_Ch8rxCBH2EiVjhfziqb23Q_15_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">43207000</bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants>
    <bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_dsy4X4UrYEm7pqyXywDXzA_15_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">24459000</bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants>
    <bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_6ERsm16NpEejrNaw-1lghA_15_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">20813000</bcyc:ResearchAndDevelopmentTaxCreditsIncentivesAndGovernmentGrants>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_Lxl9wrdr6k6oyqtoxOqnqQ_16_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">172966000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_jlvf18-RfUCOIckA1Tft6A_16_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">156496000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_KVtydc5Do0i6kffGcmRjOA_16_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">81609000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_4azdw_UFAEuWvJVkpfJjwQ_18_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">23500000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_nVSe_zYkz0agfDc0DmqXDw_18_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">18985000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_CBzFp7Y5YEqUrA9Syr02cQ_18_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">13948000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_zFx_y23YFE-hOj7Cv4UZZQ_19_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">20258000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_Z5OfoZ0dGUi_CMSZqM7xJg_19_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14814000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_A6jZbFqYCU-xtuKyCGzqfw_19_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9836000</us-gaap:ProfessionalFees>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_RbegqlaTj0ics6BjrmMidQ_20_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9047000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_QNv2lgcF-USye7I_zNpP9g_20_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9137000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc__PrDa4A1XECu6L-Wj-xdPg_20_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">8783000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_pkQWO1F91EmY2m9EqQd50g_21_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">18657000</bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense>
    <bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_t_AvtFspfUKW6-fsmBDf5A_21_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">16896000</bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense>
    <bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_dHctzYtXg02_6kpRUloH0w_21_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">16385000</bcyc:GeneralAndAdministrativeShareBasedPaymentArrangementExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_M-ujDy6wtUaxET84NA9uyw_22_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-719000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_0HReeK26_Ue94inJXFrBMA_22_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-594000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_XKhSc2w9PUiY5YCZGEe_8w_22_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-555000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_VVM5FlN9OEyH16CTZJpv8g_23_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">72181000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_bqeBI6aepEqC3b8S6x6yxw_23_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">60426000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_OUv-k0p8fUCZceWjoW5Uwg_23_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">49507000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_-s0H6ePmbEu9sjAAQBQXCA_24_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">245147000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_JSLhdv1Wkk-_KoTFD4CWhA_24_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">216922000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_uZGSvXP4D0GtQ21Cb-u32A_24_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">131116000</us-gaap:OperatingExpenses>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_D3hWTFpx1UygzWGz7JxcPQ_25_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">40841000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_ycRn0qfpHEqGvueJcXkpOQ_25_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">9282000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_chqnIn8PWEKemMYQUGlv-g_25_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3936000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_XNF-T-2CAEqM1Np_FVOfLQ"
      decimals="-3"
      id="Tc_tVvJGFn7N0mW7kX7UJPTAg_26_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-169031000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_ZBMgbTJ7Z0iyJwra3MbvxQ"
      decimals="-3"
      id="Tc_oB19mQN75ke2WWXs3vORAA_26_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-180664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementBusinessSegmentsAxis_bcyc_SingleReportableSegmentMember_4fagn9uX2kWZpC8OKWul9g"
      decimals="-3"
      id="Tc_YDjen0LSCkSHTJ2mlbQz6A_26_9"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">-112717000</us-gaap:NetIncomeLoss>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      decimals="INF"
      id="Narr_rBISI5BhE0iLd3fwRRVAYw"
      unitRef="Unit_Standard_segment_Im4dTiIF5UiSe0qPdBr-ew">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Group_9M050xE47E2qkC-ZU25k0w">Information about the Company&#x2019;s long-lived assets, including operating lease ROU assets, held in different geographic regions is presented in the table below (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 17,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_Emy5XN272EGkU-HVUNZzhA"
      decimals="-3"
      id="Tc_Xl5Rl_QDsU-7091gdRq7wQ_3_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">3037000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_QMFxV79NjE6OHW4kO9biSA"
      decimals="-3"
      id="Tc_hJ4EkOVvoEiptlPH3noYSg_3_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7486000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_GB_FM8UcsJ6oE-QbWuVRXzXKA"
      decimals="-3"
      id="Tc_GzS8-529o0SRRbPWhaaZgw_4_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">14152000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_GB_wdbEmUAGK06mdxOOtgPJ8w"
      decimals="-3"
      id="Tc_-j2OTEZipkiN760umVITHQ_4_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">20198000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2024_rueqnm0cTUiY2v2od0MDqA"
      decimals="-3"
      id="Tc__cXx4ubPtE-lB4ZpwNBlcA_5_3"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">17189000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="As_Of_12_31_2023_5s-3rw-f8UOYZmNVpXbQhg"
      decimals="-3"
      id="Tc_hz6yQU0BPUC0DUJLvtmV7A_5_6"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">27684000</us-gaap:NoncurrentAssets>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_goPCHtX5H0ushLVPgUtHqQ"
      id="Tb_RRMvW6gVQUiJLu8204yslg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;16. Subsequent events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2025, Genentech provided the Company with a notice of termination for Genentech Collaboration Program #4, effective in March 2025, and the Company expects to recognize revenue of approximately $7.4 million of deferred revenue allocated to the material right associated with the LSR Go Option for Collaboration Program #4 in the first quarter of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_bcyc_GenentechMember_ObVPQDakX0Kipqu1I4B_ig"
      decimals="-5"
      id="Narr_aOo44z4Ssku8bwnOIXZAkg"
      unitRef="Unit_Standard_USD_AdbFks_By0OXtvDENytjjA">7400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
